PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	DeTure, MA; Di Noto, L; Purich, DL				DeTure, MA; Di Noto, L; Purich, DL			In vitro assembly of Alzheimer-like filaments - How a small cluster of charged residues in Tau and MAP2 controls filament morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; MICROTUBULE-BINDING REGION; PROTEIN-TAU; POLYMERIZATION; DEMENTIA; DISEASE; GENE; MUTATIONS; FRAGMENT; SITE	Although the microtubule-binding regions (MTBRs) of both Tau and MAP2 can undergo self-assembly into straight filaments (SFs) in vitro, only the Tau MTBR forms paired helical filaments (PHFs). Moreover, Tau appears to be the exclusive building block of the neuropathic filaments observed in Alzheimer's disease and certain frontotemporal dementias (FTDs). Despite significant conservation in the MTBR sequences, there are two persistently different stretches of amino acids (designated here as Module-A and Module-B) between Tau and MAP2 from a number of organisms. To evaluate the role of charged residues in these modules as potential morphology-specifying elements, we used site-directed mutagenesis to replace selected residues within the MAP2 MTBR by residues at corresponding positions in Tau. We then employed electron microscopy to determine the frequency of occurrence of SF and PHF morphology in filaments assembled from these mutant microtubule-binding regions. Our experimental results indicate that a very small number of residues are especially significant determinants of filament morphology; this inference is also supported by the observation that site-directed substitutions of individual Tau residues into MAP2 Module-B likewise result in the formation of PHF-like structures. Because the Module-B in Tau contains two naturally occurring FTD mutations, residues in this region may play a critical role in neuropathic filament assembly.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Purich, DL (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.							COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CROWTHER RA, 1991, P NATL ACAD SCI USA, V88, P2288, DOI 10.1073/pnas.88.6.2288; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DeTure MA, 1996, J BIOL CHEM, V271, P32702, DOI 10.1074/jbc.271.51.32702; Di Noto L, 1999, Mol Cell Biol Res Commun, V2, P71, DOI 10.1006/mcbr.1999.0153; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; Perez M, 1996, J NEUROCHEM, V67, P1183; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; TERRY RD, 1963, J NEUROPATH EXP NEUR, V22, P629, DOI 10.1097/00005072-196310000-00005; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Zhang EY, 1996, BIOCHEM BIOPH RES CO, V229, P176, DOI 10.1006/bbrc.1996.1776	23	14	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34755	34759		10.1074/jbc.M201201200	http://dx.doi.org/10.1074/jbc.M201201200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12023276	hybrid			2022-12-25	WOS:000178117000015
J	Mohrmann, K; Gerez, L; Oorschot, V; Klumperman, J; van der Sluijs, P				Mohrmann, K; Gerez, L; Oorschot, V; Klumperman, J; van der Sluijs, P			rab4 function in membrane recycling from early endosomes depends on a membrane to cytoplasm cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; GTPASES; RECEPTOR; VESICLES; PHOSPHORYLATION; LOCALIZATION; CELLUBREVIN; SECRETION; TRANSPORT	The monomeric GTPase rab4 is associated with early endosomes and regulates recycling. vesicle formation. Because the function of rab proteins in the biosynthetic pathway does not appear to depend on cycling between membranes and cytosol, we were interested to investigate whether or not this holds true for rab function in the endocytic pathway. We created a chimeric rab4 protein (NHrab4cbvn) in which the carboxyl-terminal prenylation motif was replaced by the transmembrane domain of cellubrevin. The chimeric protein was permanently attached to membranes, properly targeted to early endosomes, and bound guanine nucleotide to the same extent as wild type rab4. However, in transport assays we found that basolaterally endocytosed transferrin was less efficiently transported to the apical cell surface in Madin-Darby canine kidney cells transfected with NHrab4cbvn than in cells expressing wild type rab4. Hence, rab4 function requires ongoing cycles of association and dissociation from early endosomes. This cycle is altered during mitosis when rab4 accumulates in the cytoplasm through phosphorylation by a mitotic kinase. We show here, using a rab4 construct that is permanently hooked onto membranes, that the membrane-bound pool of rab4 is targeted by a mitotic kinase.	Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University	van der Sluijs, P (corresponding author), Univ Utrecht, Med Ctr, Dept Cell Biol, AZU Rm G02-525,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; Bielli A, 2001, BIOCHEM BIOPH RES CO, V281, P1141, DOI 10.1006/bbrc.2001.4468; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; Brennwald P, 2000, J CELL BIOL, V149, P1, DOI 10.1083/jcb.149.1.1; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWIT H, 2001, MOL BIOL CELL, V12, P3703; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; Gerez L, 2000, MOL BIOL CELL, V11, P2201, DOI 10.1091/mbc.11.7.2201; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Klumperman J, 1998, J CELL SCI, V111, P3411; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; McLauchlan H, 1998, CURR BIOL, V8, P34, DOI 10.1016/S0960-9822(98)70018-1; Mohrmann K, 2002, J BIOL CHEM, V277, P10474, DOI 10.1074/jbc.M111237200; Nagelkerken B, 2000, BIOCHEM J, V346, P593, DOI 10.1042/0264-6021:3460593; Nagelkerken B, 1997, ELECTROPHORESIS, V18, P2694, DOI 10.1002/elps.1150181427; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; OSSIG R, 1995, EMBO J, V14, P3645, DOI 10.1002/j.1460-2075.1995.tb00034.x; Pereira-Leal JB, 2000, J MOL BIOL, V301, P1077, DOI 10.1006/jmbi.2000.4010; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wu XF, 2001, J CELL SCI, V114, P1091; WU XS, 2002, NAT CELL BIOL, V4, P1; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	53	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32029	32035		10.1074/jbc.M203064200	http://dx.doi.org/10.1074/jbc.M203064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12036958	hybrid			2022-12-25	WOS:000177718700091
J	Engstrom, G; Xiao, KH; Yu, CA; Yu, L; Durham, B; Millett, F				Engstrom, G; Xiao, KH; Yu, CA; Yu, L; Durham, B; Millett, F			Photoinduced electron transfer between the Rieske iron-sulfur protein and cytochrome c(1) in the Rhodobacter sphaeroides cytochrome bc(1) complex - Effects of pH, temperature, and driving force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMING HYDROGEN-BONDS; DOMAIN MOVEMENT; BC1 COMPLEX; PROTON TRANSLOCATION; ENERGY TRANSDUCTION; 2FE-2S CLUSTER; BOVINE HEART; MITOCHONDRIAL; RESOLUTION; BINDING	Electron transfer from the Rieske iron-sulfur protein to cytochrome c(1) (cyt c(1)) in the Rhodobacter sphaeroides cytochrome bc(1) complex was studied using a ruthenium dimer complex, Ru2D. Laser flash photolysis of a solution containing reduced cyt bc(1), Ru2D, and a sacrificial electron acceptor results in oxidation of cyt c(1) within 1 mus, followed by electron transfer from the iron-sulfur center (2Fe-2S) to cyt c(1) with a rate constant of 80,000 s(-1). Experiments were carried out to evaluate whether the reaction was rate-limited by true electron transfer, proton gating, or conformational gating. The temperature dependence of the reaction yielded an enthalpy of activation of +17.6 kJ/mol, which is consistent with either rate-limiting conformational gating or electron transfer. The rate constant was nearly independent of pH over the range pH 7 to 9.5 where the redox potential of 2Fe-2S decreases significantly due to deprotonation of His-161. The rate constant was also not greatly affected by the Rieske iron-sulfur protein mutations Y156W, S154A, or S154A/Y156F, which decrease the redox potential of 2Fe-2S by 62, 109, and 159 mV, respectively. It is concluded that the electron transfer reaction from 2Fe-2S to cyt c(1) is controlled by conformational gating.	Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	University of Arkansas System; University of Arkansas Fayetteville; Oklahoma State University System; Oklahoma State University - Stillwater	Millett, F (corresponding author), Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA.	millett@comp.uark.edu	Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226	NCRR NIH HHS [1P20 RR 15569] Funding Source: Medline; NIGMS NIH HHS [GM 20488, GM 30721] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; Davidson VL, 1996, BIOCHEMISTRY-US, V35, P14035, DOI 10.1021/bi961577p; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DOWNARD AJ, 1991, INORG CHEM, V30, P2259, DOI 10.1021/ic00010a007; GEREN LM, 1995, J BIOL CHEM, V270, P2466, DOI 10.1074/jbc.270.6.2466; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; Guergova-Kuras M, 2000, BIOCHEMISTRY-US, V39, P7436, DOI 10.1021/bi992491+; HEACOCK DH, 1993, J BIOL CHEM, V268, P27171; HOFFMAN BM, 1987, J AM CHEM SOC, V109, P6237, DOI 10.1021/ja00255a003; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Izrailev S, 1999, BIOPHYS J, V77, P1753, DOI 10.1016/S0006-3495(99)77022-0; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MEINHARDT SW, 1982, FEBS LETT, V149, P223, DOI 10.1016/0014-5793(82)81105-8; MOELLER T, 1957, INORG SYN, V5, P185, DOI 10.1002/9780470132364.ch51; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Schroter T, 1998, EUR J BIOCHEM, V255, P100, DOI 10.1046/j.1432-1327.1998.2550100.x; SCOTT JR, 1994, J AM CHEM SOC, V116, P7356, DOI 10.1021/ja00095a045; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 2000, J BIOL CHEM, V275, P9587, DOI 10.1074/jbc.275.13.9587; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; Wang KF, 1996, BIOCHEMISTRY-US, V35, P15107, DOI 10.1021/bi9611117; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	46	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31072	31078		10.1074/jbc.M202594200	http://dx.doi.org/10.1074/jbc.M202594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12045199	hybrid			2022-12-25	WOS:000177579800086
J	Richard, D; Kundig, C; Ouellette, M				Richard, D; Kundig, C; Ouellette, M			A new type of high affinity folic acid transporter in the protozoan parasite Leishmania and deletion of its gene in methotrexate-resistant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTASE-THYMIDYLATE SYNTHASE; FOLATE-BINDING-PROTEIN; CHAIN DEHYDROGENASE GENE; DIHYDROFOLATE-REDUCTASE; P-GLYCOPROTEIN; MEMBRANE-TRANSPORT; DNA AMPLIFICATION; DRUG-RESISTANCE; KB CELLS; TARENTOLAE	The protozoan parasite Leishmania is a folate auxotroph and thus depends on the uptake of folate from the environment to meet its folate requirement. We show here that Leishmania contains several putative pteridine transporter genes. Some of these genes are deleted in methotrexate-resistant Leishmania cells where there is no measurable uptake of methotrexate. Transport studies suggest that Leishmania has more than one active folate transporter, and one of these, named FT5, corresponds to a very high affinity folate transporter (K-m 84 nm). The uptake of both folate and methotrexate was impaired in an FT5 null mutant at low substrate concentrations (50 nm), although transport properties at higher concentrations (1000 nm) were not statistically different between wild-type and the FT5 null mutant. Modulation of the expression of FT5 also changes the susceptibility of Leishmania cells to methotrexate. These results have permitted the characterization of a novel class of folate transporters and suggest that the parasite Leishmania has several gene products possibly transporting folates and related molecules under varying conditions.	CHUL, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; CHUL, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Div Microbiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University; Laval University	Ouellette, M (corresponding author), CHUQ, Ctr Rech Infectiol, Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Marc.Ouellette@crchul.ulaval.ca	Ouellette, Marc/K-8694-2017	Ouellette, Marc/0000-0002-6743-9646				Arrebola R, 1996, MOL BIOCHEM PARASIT, V79, P129, DOI 10.1016/0166-6851(96)02649-7; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P10053; ELLENBERGER TE, 1987, J BIOL CHEM, V262, P13501; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; GAMARRO F, 1994, BIOCHEM PHARMACOL, V47, P1939, DOI 10.1016/0006-2952(94)90067-1; GOTTESDIENER KM, 1994, MOL BIOCHEM PARASIT, V63, P143, DOI 10.1016/0166-6851(94)90017-5; GRONDIN K, 1993, NUCLEIC ACIDS RES, V21, P1895, DOI 10.1093/nar/21.8.1895; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; KAUR K, 1988, J BIOL CHEM, V263, P7020; KIDDER GW, 1958, J GEN MICROBIOL, V18, P621, DOI 10.1099/00221287-18-3-621; KUMAR HP, 1987, J BIOL CHEM, V262, P7171; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Kundig C, 1999, NUCLEIC ACIDS RES, V27, P3653, DOI 10.1093/nar/27.18.3653; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; LO RS, 1991, P ROY SOC B-BIOL SCI, V246, P161, DOI 10.1098/rspb.1991.0139; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; NARE B, 1997, PARASITOLOGY, V114, P101; OUELLETTE M, 1991, EMBO J, V10, P1009, DOI 10.1002/j.1460-2075.1991.tb08035.x; Ouellette M, 2002, INT J PARASITOL, V32, P385, DOI 10.1016/S0020-7519(01)00346-0; Ouellette M, 1998, ADV EXP MED BIOL, V456, P99; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 1993, NUCLEIC ACIDS RES, V21, P4305, DOI 10.1093/nar/21.18.4305; PAPADOPOULOU B, 1993, ADV EXP MED BIOL, V338, P559; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; PEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575, DOI 10.1128/AAC.31.10.1575; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Roy G, 2001, EXP PARASITOL, V97, P161, DOI 10.1006/expr.2001.4595; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SHANE B, 1975, J BIOL CHEM, V250, P2243; Sierra EE, 1999, SEMIN ONCOL, V26, P11; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; TRAGER W, 1969, J PROTOZOOL, V16, P372, DOI 10.1111/j.1550-7408.1969.tb02284.x; Wang JY, 1997, ARCH BIOCHEM BIOPHYS, V342, P197, DOI 10.1006/abbi.1997.0126; WASHTIEN WL, 1985, J BIOL CHEM, V260, P7809; WHITE TC, 1988, J BIOL CHEM, V263, P16977; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810	51	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29460	29467		10.1074/jbc.M204796200	http://dx.doi.org/10.1074/jbc.M204796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023977	hybrid			2022-12-25	WOS:000177509300016
J	Goti, D; Balazs, Z; Panzenboeck, U; Hrzenjak, A; Reicher, H; Wagner, E; Zechner, R; Malle, E; Sattler, W				Goti, D; Balazs, Z; Panzenboeck, U; Hrzenjak, A; Reicher, H; Wagner, E; Zechner, R; Malle, E; Sattler, W			Effects of lipoprotein lipase on uptake and transcytosis of low density lipoprotein (LDL) and LDL-associated alpha-tocopherol in a porcine in vitro blood-brain barrier model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; HEPARAN-SULFATE PROTEOGLYCANS; CAPILLARY ENDOTHELIAL-CELLS; HDL PARTICLE UPTAKE; SCAVENGER RECEPTOR; SELECTIVE UPTAKE; CHOLESTERYL ESTERS; VITAMIN-E; SR-BI; BINDING	During the present study the contribution of lipoprotein lipase (LPL) to low density lipoprotein (LDL) holoparticle and LDL-lipid (alpha-tocopherol (alphaTocH)) turnover in primary porcine brain capillary endothelial cells (BCECs) was investigated. The addition of increasing LPL concentrations to BCECs resulted in up to 11-fold higher LDL holoparticle cell association. LPL contributed to LDL holoparticle turnover, an effect that was substantially increased in response to LDL-receptor upregulation. The addition of LPL increased selective uptake of LDL-associated alphaTocH in BCECs up to 5-fold. LPL-dependent selective alphaTocH uptake was unaffected by the lipase inhibitor tetrahydrolipstatin but was substantially inhibited in cells where proteoglycan sulfation was inhibited by treatment with NaClO3. Thus, selective uptake of LDL-associated alphaTocH requires interaction of LPL with heparan-sulfate proteoglycans. Although high level adenoviral overexpression of scavenger receptor BI (SR-BI) in BCECs resulted in a 2-fold increase of selective LDL-alphaTocH uptake, SR-BI did not act in a cooperative manner with LPL. Although the addition of LPL to BCEC Transwell cultures significantly increased LDL holoparticle cell association and selective uptake of LDL-associated alphaTocH, holoparticle transcytosis across this porcine blood-brain barrier (BBB) model was unaffected by the presence of LPL. An important observation during transcytosis experiments was a substantial alphaTocH depletion of LDL particles that were resecreted into the basolateral compartment. The relevance of LPL-dependent alphaTocH uptake across the BBB was confirmed in LPL-deficient mice. The absence of LPL resulted in significantly lower cerebral alphaTocH concentrations than observed in control animals.	Graz Univ, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria; Graz Univ, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria	University of Graz; University of Graz	Sattler, W (corresponding author), Graz Univ, Inst Med Biochem & Mol Biol, Harrachgasse 21, A-8010 Graz, Austria.	wolfgang.sattler@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Panzenbock, Ute/0000-0002-0545-6758; Zechner, Rudolf/0000-0001-5483-1182				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENZEEV O, 1990, J LIPID RES, V31, P1307; BRECHER P, 1979, J LIPID RES, V20, P464; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; DEHOUCK B, 1994, J CELL BIOL, V126, P465, DOI 10.1083/jcb.126.2.465; DEVRIES HE, 1993, J NEUROCHEM, V61, P1813; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; EISENBERG S, 1984, J LIPID RES, V25, P1017; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Goldberg IJ, 1996, J LIPID RES, V37, P693; Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lucarelli M, 1997, FEBS LETT, V401, P53, DOI 10.1016/S0014-5793(96)01435-4; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Medh JD, 1996, J BIOL CHEM, V271, P17073, DOI 10.1074/jbc.271.29.17073; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MULDER M, 1993, J BIOL CHEM, V268, P9369; MULLER DPR, 1995, REDOX REP, V1, P239, DOI 10.1080/13510002.1995.11746993; NUNEZ M, 1995, BIOL NEONATE, V68, P119; Obunike JC, 2001, J BIOL CHEM, V276, P8934, DOI 10.1074/jbc.M008813200; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Panzenboeck U, 1997, J LIPID RES, V38, P239; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Rinninger F, 1998, J LIPID RES, V39, P1335; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Salinelli S, 1996, J BIOL CHEM, V271, P21906, DOI 10.1074/jbc.271.36.21906; Sattler W, 1996, BIOCHEM J, V318, P15, DOI 10.1042/bj3180015; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Schorsch F, 1997, FEBS LETT, V414, P507, DOI 10.1016/S0014-5793(97)01061-2; Seo T, 1997, J LIPID RES, V38, P765; Seo T, 2000, J BIOL CHEM, V275, P30355, DOI 10.1074/jbc.M910327199; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Swarnakar S, 1999, J BIOL CHEM, V274, P29733, DOI 10.1074/jbc.274.42.29733; Tewes B, 1997, DRUG TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER, P91; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Wicher I, 1996, J IMMUNOL METHODS, V192, P1, DOI 10.1016/0022-1759(95)00260-X; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	49	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28537	28544		10.1074/jbc.M203989200	http://dx.doi.org/10.1074/jbc.M203989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032155	hybrid			2022-12-25	WOS:000177342600026
J	Kinoshita, A; Whelan, CM; Berezovska, O; Hyman, BT				Kinoshita, A; Whelan, CM; Berezovska, O; Hyman, BT			The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SECRETASE; NUCLEAR TRANSLOCATION; INTRACELLULAR DOMAIN; NOTCH; PRESENILIN; FE65; MUTATIONS; CLEAVAGE; NEURONS; PROTEOLYSIS	The amyloid precursor protein (APP), a large glycoprotein highly expressed in neurons, is cleaved in its intramembranous domain by gamma secretase to generate amyloid-beta and a free carboxyl-terminal intracellular fragment (APP-CT), which has previously been suggested to interact with the adapter protein Fe65 and the histone acetyltransferase Tip60. An identical gamma secretase activity mediates cleavage of Notch, releasing an intracellular signaling domain that translocates to the nucleus. We examined the effect of an ectopically expressed 58-amino acid APP-CT fragment (APP-C58) on human H4 neuroglioma cells. We demonstrate by confocal microscopy and fluorescence resonance energy transfer analysis that APP-C58 translocates to the nucleus and forms a complex in the nucleus with the Tip60, independent of interactions with Fe65. APP-C58 transfected H4 cells undergo apoptosis within 48-72 h, marked by nuclear blebbing, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining, and blockade by a caspase inhibitor. When nuclear access of APP-C58 is prevented by fusing with a strong membrane-targeting farnesylation domain, apoptosis is blocked. APP-C58-induced apoptosis was markedly enhanced by co-transfection with wild type Tip60 and decreased by mutant Tip60 lacking histone acetyltransferase activity, suggesting that Tip60 mediates APP-CT-induced cell death. Thus, gamma secretase cleavage of APP may contribute to Alzheimer's disease-related neurodegencration in two ways: release of amyloid-beta and liberation of a bioactive carboxyl-terminal domain from membrane-bound APP.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hyman, BT (corresponding author), Dept Neurol, Alzheimers Unit, 114 16th St,CAGN 2009, Charlestown, MA 02129 USA.				NIA NIH HHS [P01 AG15379, AG12406] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012406, P01AG015379, R37AG012406] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Citron M, 2000, ANN NY ACAD SCI, V920, P192; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Daly J, 1999, PROG NEURO-PSYCHOPH, V23, P861, DOI 10.1016/S0278-5846(99)00046-9; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	29	114	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28530	28536		10.1074/jbc.M203372200	http://dx.doi.org/10.1074/jbc.M203372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032152	hybrid			2022-12-25	WOS:000177342600025
J	Marcinkeviciene, J; Kopcho, LM; Yang, T; Copeland, RA; Glass, BM; Combs, AP; Falahatpisheh, N; Thompson, L				Marcinkeviciene, J; Kopcho, LM; Yang, T; Copeland, RA; Glass, BM; Combs, AP; Falahatpisheh, N; Thompson, L			Novel inhibition of porcine pepsin by a substituted piperidine - Preference for one of the enzyme conformers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ASPARTIC PROTEINASE; RHIZOPUS-CHINENSIS; RENIN INHIBITORS; HIV-1 PROTEASE; PH-DEPENDENCE; ACTIVE-SITE; MECHANISM; PEPSTATIN; BINDING	Pepsin inhibition by 3-alkoxy-4-arylpiperidine (substituted piperidine; (3R,4R)-3-(4-bromobenzyloxy)-4-[4-(2-naphthalen-1-yl-2-oxo-ethoxy)phenyl]piperidine) has been studied using steady-state kinetic and pre-equilibrium. binding methods. Data were compared with pepstatin A, a well known competitive inhibitor of pepsin. Steady-state analysis reveals that the substituted piperidine likewise behaves as a competitive inhibitor. Pre-equilibrium binding studies indicate that the substituted piperidine can displace a fluorescently la e e statine inhibitor from the enzyme active site. Simulation of the stopped-flow fluorescence transients provided estimates of the K-d values of 1.4+/-0.2 muM and 39+/-2 nM for the piperidine and the fluorescently labeled statine, respectively. The effects of combinations of these two inhibitors resulted in a series of parallel lines when plotted by the method of Yonetani and Theorell (Yonetani, T., and Theorell, H. (1964) Arch. Biochem. Biophys. 106, 234-251), suggesting that the two inhibitors bind in a mutually exclusive fashion to pepsin. Fitting of the entire data set to the appropriate equation yielded an a factor of 8+/-1. The magnitude of this factor (infinity > alpha > 1) can be explained by a conformational distinction between the enzyme species that bind each inhibitor. The effects of pH on the inhibition constants for pepstatin A and the substituted piperidine also suggest that the inhibitors bind to distinct conformational forms of the enzyme. No inhibition by the piperidine was observed at acidic pH, while pepstatin A inhibition is maximal at low pH values. Inhibition by the piperidine was maximal when a group with pK 4.8+/-0.2 was deprotonated and another group with pK 5.9+/-0.2 was protonated. Most likely these two groups are the catalytic aspartates with perturbed ionization properties as a result of a significant and unique conformational change. Taken together, these data suggest. that the enzyme can readily interconvert between two conformers, one capable of binding substrate and pepstatin A and the other capable of binding the substituted piperidine.	Bristol Myers Squibb Pharmaceut Co, Dept Chem Enzymol, Wilmington, DE 19880 USA; Bristol Myers Squibb Pharmaceut Co, Dept Med Chem, Wilmington, DE 19880 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Marcinkeviciene, J (corresponding author), Bristol Myers Squibb Pharmaceut Co, Dept Chem Enzymol, Wilmington, DE 19880 USA.		Hu, Ruogu/B-2203-2008					BOTT R, 1982, BIOCHEMISTRY-US, V21, P6956, DOI 10.1021/bi00269a052; BUR D, 1999, Patent No. [09912532, 9912532]; Bursavich MG, 2001, ORG LETT, V3, P2317, DOI 10.1021/ol016092u; Bursawich M. G., 2000, J MED CHEM, V45, P541; CHOU TC, 1974, MOL PHARMACOL, V10, P235; Citron M, 2000, MOL MED TODAY, V6, P392, DOI 10.1016/S1357-4310(00)01759-7; Cleland W W, 1979, Methods Enzymol, V63, P103; Coates L, 2001, BIOCHEMISTRY-US, V40, P13149, DOI 10.1021/bi010626h; CORNISHBOWDEN AJ, 1969, BIOCHEM J, V113, P369, DOI 10.1042/bj1130369; ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628; FIREKE CA, 1987, BIOCHEMISTRY-US, V26, P4085; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Guller R, 1999, BIOORG MED CHEM LETT, V9, P1403, DOI 10.1016/S0960-894X(99)00196-1; Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t; HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001; HYLAND LJ, 1991, BIOCHEMISTRY-US, V30, P8454, DOI 10.1021/bi00098a024; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001; KATI WM, 1987, BIOCHEMISTRY-US, V26, P7621, DOI 10.1021/bi00398a014; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LIN YZ, 1992, J BIOL CHEM, V267, P18413; LOHRI B, 2000, Patent No. 00631713; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; Marcinkeviciene J, 2001, J BIOL CHEM, V276, P23790, DOI 10.1074/jbc.M101896200; MCGREGOR GA, 1981, NATURE, V291, P329; Northrop DB, 2001, ACCOUNTS CHEM RES, V34, P790, DOI 10.1021/ar000184m; Oefner C, 1999, CHEM BIOL, V6, P127, DOI 10.1016/S1074-5521(99)89004-8; Piana S, 2001, J AM CHEM SOC, V123, P8730, DOI 10.1021/ja003145e; RODRIGUEZ EJ, 1993, BIOCHEMISTRY-US, V32, P3557, DOI 10.1021/bi00065a006; Segel I.H, 1993, ENZYME KINETICS; Smith R, 1996, NAT STRUCT BIOL, V3, P946, DOI 10.1038/nsb1196-946; SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009; Vieira E, 1999, BIOORG MED CHEM LETT, V9, P1397, DOI 10.1016/S0960-894X(99)00195-X; Xie D, 1997, BIOCHEMISTRY-US, V36, P16166, DOI 10.1021/bi971550l; YONETANI T, 1964, ARCH BIOCHEM BIOPHYS, V106, P234	35	13	13	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28677	28682		10.1074/jbc.M203120200	http://dx.doi.org/10.1074/jbc.M203120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029090	hybrid			2022-12-25	WOS:000177342600044
J	Rubio, MA; Kim, SH; Campisi, J				Rubio, MA; Kim, SH; Campisi, J			Reversible manipulation of telomerase expression and telomere length - Implications for the ionizing radiation response and replicative senescence of human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN FIBROBLASTS; LIFE-SPAN; CELLULAR SENESCENCE; RETROVIRAL VECTORS; PREMATURE SENESCENCE; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; CRE RECOMBINASE; GENE-TRANSFER; IN-VIVO	Most human cells do not express telomerase and irreversibly arrest proliferation after a finite number of divisions (replicative senescence). Several lines of evidence suggest that replicative senescence is caused by short dysfunctional telomeres, which arise when DNA is replicated in the absence of adequate telomerase activity. We describe a method to reversibly bypass replicative senescence and generate mass cultures that have different average telomere lengths. A retrovirus carrying hTERT flanked by excision sites for Cre recombinase rendered normal human fibroblasts telomerase-positive and replicatively immortal. Superinfection with retroviruses carrying wild-type or mutant forms of TIN2, a negative regulator of telomere length, created telomerase-positive, immortal populations with varying average telomere lengths. Subsequent infection with a Cre-expressing retrovirus abolished telomerase activity, creating mortal cells with varying telomere lengths. Using these cell populations, we show that, after hTERT excision, cells senesce with shorter telomeres than parental cells. Moreover, long telomeres, but not telomerase, protected cells from the loss of division potential caused by ionizing radiation. Finally, although telomerase-negative cells with short telomeres senesced after fewer doublings than those with long telomeres, telomere length per se did not correlate with senescence. Our results support a role for telomere structure, rather than length, in replicative senescence.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,Mailstop 84-171, Berkeley, CA 94720 USA.	jcampisi@lbl.gov						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Campisi Judith, 1996, P121; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; de Lange T, 2001, SCIENCE, V292, P1075; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Evans SK, 2000, J CELL SCI, V113, P3357; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Gasser SM, 2000, SCIENCE, V288, P1377, DOI 10.1126/science.288.5470.1377; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hande P, 1999, GENOMICS, V56, P221, DOI 10.1006/geno.1998.5668; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Ludwig A, 2001, CANCER RES, V61, P3053; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; McIlrath J, 2001, CANCER RES, V61, P912; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang J, 2000, NATURE, V405, P755, DOI 10.1038/35015674; Wei S, 1999, CANCER RES, V59, P1539; Weng NP, 2000, J CLIN IMMUNOL, V20, P257; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	61	76	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28609	28617		10.1074/jbc.M203747200	http://dx.doi.org/10.1074/jbc.M203747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034742	hybrid			2022-12-25	WOS:000177342600035
J	Bishop, JD; Schumacher, JM				Bishop, JD; Schumacher, JM			Phosphorylation of the carboxyl terminus of inner centromere protein (INCENP) by the Aurora B kinase stimulates Aurora B kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS EMBRYOS; CYCLE-DEPENDENT EXPRESSION; CHROMOSOME SEGREGATION; MITOTIC SPINDLE; CYTOKINESIS; CENTROSOME; LOCALIZATION; DROSOPHILA; MIDBODY; AIR-2	How the events of mitosis are coordinated is not well understood. Intriguing mitotic regulators include the chromosomal passenger proteins. Loss of either of the passengers inner centromere protein (INCENP) or the Aurora B kinase results in chromosome segregation defects and failures in cytokinesis. Furthermore, INCENP and Aurora B have identical localization patterns during mitosis and directly bind each other in vitro. These results led to the hypothesis that INCENP is a direct substrate of Aurora B. Here we show that the Caenorhabditis elegans Aurora B kinase AIR-2 specifically phosphorylated the C. elegans INCENP ICP-1 at two adjacent serines within the carboxyl terminus. Furthermore, the full length and a carboxyl-terminal fragment of ICP-1 stimulated AIR-2 kinase activity. This increase in AIR-2 activity required that AIR-2 phosphorylate ICP-1 because mutation of both serines in the AIR-2 phosphorylation site of ICP-1 abolished the potentiation of AIR-2 kinase activity by ICP-1. Thus, ICP-1 is directly phosphorylated by AIR,2 and functions in a positive feedback loop that regulates AIR-2 kinase activity. Since the Aurora B phosphorylation site within INCENP and the functions of INCENP and Aurora B have been conserved among eukaryotes, the feedback loop we have identified is also likely to be evolutionarily conserved.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Genes & Dev Program, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Schumacher, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Schumacher, Jill/B-2932-2012		NATIONAL CANCER INSTITUTE [T32CA009299, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062181] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672, CA-16672, T32 CA09299] Funding Source: Medline; NIGMS NIH HHS [R01 GM062181, R01 GM062181-01, R01 GM062181-02, R01 GM062181-03, R01 GM62181-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; ANDREASSEN PR, 1991, J CELL SCI, V99, P523; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Rogers E, 2002, J CELL BIOL, V157, P219, DOI 10.1083/jcb.200110045; Roghi C, 1998, J CELL SCI, V111, P557; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	27	211	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27577	27580		10.1074/jbc.C200307200	http://dx.doi.org/10.1074/jbc.C200307200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12048181	Green Accepted, hybrid			2022-12-25	WOS:000177189800001
J	Kawada, M; Masuda, T; Ishizuka, M; Takeuchi, T				Kawada, M; Masuda, T; Ishizuka, M; Takeuchi, T			15-deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; IMMUNOSUPPRESSANT DEOXYSPERGUALIN; ANTITUMOR-ACTIVITY; AMINE OXIDASE; CELLS; RAPAMYCIN; SPERMIDINE	15-Deoxyspergualin (DSG) strongly inhibited growth of mouse EL-4 lymphoma cells in vitro and an vivo. It significantly prolonged the survival days of EL-4-transplanted mice. In vitro study revealed that its antiproliferative effect appeared only after 2 days of treatment. At that time, protein synthesis was significantly inhibited rather than DNA and RNA syntheses. Furthermore, DSG induced apoptosis without arresting the cell cycle. p70 S6 kinase (p70S6K), a key molecule in protein synthesis, was inhibited by 2 days of treatment of DSG. Akt, an upstream kinase of p70S6K, was also deactivated by 2 days of treatment of DSG. Hsp90 is reported to bind to and stabilize Akt kinase and also to bind to DSG. Yet DSG did not inhibit the binding of Hsp90 to Akt kinase. PI3-kinase, an activator of Akt, was not affected by DSG treatment. However, when we looked into phospholipid synthesis, we found that DSG inhibited phosphatidylcholine (PC) synthesis strongly rather than phosphatidylinositol even by 1 day of treatment. Moreover, DSG failed to inhibit Akt kinase activation and PC synthesis in DSG-less sensitive human K562 leukemia cells. These results demonstrate that DSG inhibits tumor cell growth through the inhibition of protein synthesis and induction of apoptosis, which is caused by the down-regulation of Akt kinase and p70S6K. It is also indicated that the down-regulation of Akt kinase by DSG should not depend on PI3-kinase and Hsp90. There might be possible involvement of PC in Akt kinase activity.	Microbial Chem Res Fdn, Inst Chemotherapy, Shizuoka 4100301, Japan		Ishizuka, M (corresponding author), Microbial Chem Res Fdn, Inst Chemotherapy, 18-24 Miyamoto, Shizuoka 4100301, Japan.			Kawada, Manabu/0000-0001-9348-4240				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Coffer PJ, 1998, BIOCHEM J, V329, P121; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; ERWIN BG, 1986, BIOCHEM J, V238, P581, DOI 10.1042/bj2380581; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HIBASAMI H, 1991, ANTICANCER RES, V11, P325; HIRATSUKA M, 1991, JPN J CANCER RES, V82, P1065, DOI 10.1111/j.1349-7006.1991.tb01758.x; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; IWASAWA H, 1982, J ANTIBIOT, V35, P1665, DOI 10.7164/antibiotics.35.1665; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kawada M, 2000, J ANTIBIOT, V53, P705, DOI 10.7164/antibiotics.53.705; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KUNIMOTO S, 1994, J ANTIBIOT, V47, P1130, DOI 10.7164/antibiotics.47.1130; KUNIMOTO S, 1989, J ANTIBIOT, V42, P116, DOI 10.7164/antibiotics.42.116; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; KURAMOCHI H, 1988, J ANTIBIOT, V41, P234, DOI 10.7164/antibiotics.41.234; MASUDA T, 1987, J ANTIBIOT, V40, P1612, DOI 10.7164/antibiotics.40.1612; NADEAU K, 1994, BIOCHEMISTRY-US, V33, P2561, DOI 10.1021/bi00175a027; NADLER SG, 1992, SCIENCE, V258, P484, DOI 10.1126/science.1411548; NEMOTO K, 1987, J ANTIBIOT, V40, P561, DOI 10.7164/antibiotics.40.561; NISHIKAWA K, 1991, J ANTIBIOT, V44, P1237, DOI 10.7164/antibiotics.44.1237; NISHIKAWA K, 1991, J ANTIBIOT, V44, P1101, DOI 10.7164/antibiotics.44.1101; Odaka C, 1998, IMMUNOLOGY, V95, P370; OIKAWA T, 1992, ANTI-CANCER DRUG, V3, P293, DOI 10.1097/00001813-199206000-00014; OIKAWA T, 1991, J ANTIBIOT TOKYO, V44, P1003; PESO LD, 1997, SCIENCE, V278, P687; PLOWMAN J, 1987, CANCER RES, V47, P685; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; TAKEUCHI T, 1981, J ANTIBIOT, V34, P1619, DOI 10.7164/antibiotics.34.1619; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; UMEDA Y, 1985, J ANTIBIOT, V38, P886, DOI 10.7164/antibiotics.38.886; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B	43	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27765	27771		10.1074/jbc.M200318200	http://dx.doi.org/10.1074/jbc.M200318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021268	hybrid			2022-12-25	WOS:000177189800025
J	Yang, DS; Tandon, A; Chen, FS; Yu, G; Yu, H; Arawaka, S; Hasegawa, H; Duthie, M; Schmidt, SD; Ramabhadran, TV; Nixon, RA; Mathews, PM; Gandy, SE; Mount, HTJ; St George-Hyslop, P; Fraser, PE				Yang, DS; Tandon, A; Chen, FS; Yu, G; Yu, H; Arawaka, S; Hasegawa, H; Duthie, M; Schmidt, SD; Ramabhadran, TV; Nixon, RA; Mathews, PM; Gandy, SE; Mount, HTJ; St George-Hyslop, P; Fraser, PE			Mature glycosylation and trafficking of nicastrin modulate its binding to presenilins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; INTRACELLULAR TRAFFICKING; SUBCELLULAR-LOCALIZATION; TERMINAL FRAGMENTS; MISSENSE MUTATIONS; EARLY-ONSET; WILD-TYPE; NOTCH	Nicastrin is an integral component of the high molecular weight presenilin complexes that control proteolytic processing of the amyloid precursor protein and Notch. We report here that nicastrin is most probably a type 1 transmembrane glycoprotein that is expressed at moderate levels in the brain and in cultured neurons. Immunofluorescence studies demonstrate that nicastrin is localized in the endoplasmic reticulum, Golgi, and a discrete population of vesicles. Glycosidase analyses reveal that endogenous nicastrin undergoes a conventional, trafficking-dependent maturation process. However, when highly expressed in transfected cells, there is a disproportionate accumulation of the endo-beta-N-acetylglucosaminidase H-sensitive, immature form, with no significant increase in the levels of the fully mature species. Immunoprecipitation revealed that presenilin-1 interacts preferentially with mature nicastrin, suggesting that correct trafficking and co-localization of the presenilin complex components are essential for activity. These findings demonstrate that trafficking and post-translational modifications of nicastrin are tightly regulated processes that accompany the assembly of the active presenilin complexes that execute gamma-secretase cleavage. These results also underscore the caveat that simple overexpression of nicastrin in transfected cells may result in the accumulation of large amounts of the immature protein, which is apparently unable to assemble into the active complexes capable of processing amyloid precursor protein and Notch.	Univ Toronto, Ctr Res Neurodegerat Dis, Toronto, ON M5S 3H2, Canada; New York Univ, Sch Med, Nathan Kline Inst, Orangeburg, NY 10962 USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Lab Med, Toronto, ON, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON, Canada; Univ Hlth Network, Toronto Western Hosp, Dept Med, Div Neurol, Toronto, ON M5S 1A8, Canada	University of Toronto; Nathan Kline Institute for Psychiatric Research; New York University; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fraser, PE (corresponding author), Univ Toronto, Ctr Res Neurodegerat Dis, 6 Queens Pk Crescent W,Tanz Neurosci Bldg, Toronto, ON M5S 3H2, Canada.	paul.fraser@utoronto.ca	Schmidt, Stephen/B-5398-2012; Mount, Howard/B-4097-2013; Schmidt, Stephen/AAC-6967-2019	Arawaka, Shigeki/0000-0002-1505-3012; Yu, Wai Haung/0000-0001-7186-6731; Mathews, Paul/0000-0003-1742-7687; St George-Hyslop, Peter/0000-0003-0796-7209				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Arduengo PM, 1998, J CELL SCI, V111, P3645; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Checler F, 2001, J NEUROCHEM, V76, P1621, DOI 10.1046/j.1471-4159.2001.00244.x; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fergani A, 2001, BIOCHEM BIOPH RES CO, V289, P678, DOI 10.1006/bbrc.2001.6030; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Levesque L, 1999, MOL MED, V5, P542, DOI 10.1007/BF03401981; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Mathews PM, 2000, MOL MED, V6, P878, DOI 10.1007/BF03401825; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Noll E, 2000, DEV BIOL, V227, P450, DOI 10.1006/dbio.2000.9925; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Satoh J, 2001, NEUROPATHOLOGY, V21, P115, DOI 10.1046/j.1440-1789.2001.00378.x; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; Wittenburg N, 2000, NATURE, V406, P306, DOI 10.1038/35018575; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yang DS, 1999, NEUROSCIENCE, V90, P1217, DOI 10.1016/S0306-4522(98)00561-2; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	55	136	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28135	28142		10.1074/jbc.M110871200	http://dx.doi.org/10.1074/jbc.M110871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032140	hybrid			2022-12-25	WOS:000177189800070
J	Mastrobattista, E; Koning, GA; van Bloois, L; Filipe, ACS; Jiskoot, W; Storm, G				Mastrobattista, E; Koning, GA; van Bloois, L; Filipe, ACS; Jiskoot, W; Storm, G			Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-ACTIVE PEPTIDES; N-TERMINAL PEPTIDES; GENE-TRANSFER; SYNTHETIC PEPTIDE; SPECTRAL BEHAVIOR; FUSION PEPTIDE; DESTABILIZATION; LIPOSOMES; OLIGONUCLEOTIDES	Antibody-directed liposomes (immunoliposomes) are frequently used for targeted drug delivery. However, delivery of large biotherapeutic molecules (i.e. peptides, proteins, or nucleic acids) with immunoliposomes is often hampered by an inefficient cytosolic release of entrapped macromolecules after target cell binding and subsequent endocytosis of immunoliposomes. To enhance cytosolic drug delivery from immunoliposomes present inside endosomes, a pH-dependent fusogenic peptide (diINF-7) resembling the NH2-terminal domain of influenza virus hemagglutinin HA-2 subunit was used. Functional characterization of this dimeric peptide showed its ability to induce fusion between liposome membranes and leakage of liposome-entrapped compounds when exposed to low pH. In a second series of experiments, diINF-7 peptides were encapsulated in immunoliposomes to enhance the endosomal escape of diphtheria toxin A chain (DTA), which inhibits protein synthesis when delivered into the cytosol of target cells. Immunoliposomes targeted to the internalizing epidermal growth factor receptor on the surface of ovarian carcinoma cells (OVCAR-3) and containing encapsulated DTA did not show any cytotoxicity toward OVCAR-3 cells. Cytotoxicity was only observed when diINF-7 peptides and DTA were co-encapsulated in the immunoliposomes. Thus, diINF-7 peptides entrapped inside liposomes can greatly enhance cytosolic delivery of liposomal macromolecules by pH-dependent destabilization of endosomal membranes after cellular uptake of liposomes.	Univ Utrecht, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands	Utrecht University	Storm, G (corresponding author), Univ Utrecht, Dept Pharmaceut, POB 80082, NL-3508 TB Utrecht, Netherlands.	g.storm@pharm.uu.nl	Mastrobattista, Enrico/O-6670-2016; Koning, Gerben A/K-2326-2012; Jiskoot, Wim/A-6877-2016; Storm, Gerrit/O-8696-2016	Mastrobattista, Enrico/0000-0002-6745-2015; Koning, Gerben A/0000-0003-3090-2403; Jiskoot, Wim/0000-0002-1012-3456; da Silva Filipe, Ana Cristina/0000-0002-9442-2903				Arigita C, 1999, PHARMACEUT RES, V16, P1534, DOI 10.1023/A:1015096302720; Bailey AL, 1997, BBA-BIOMEMBRANES, V1324, P232, DOI 10.1016/S0005-2736(96)00228-3; Baru M, 1998, J DRUG TARGET, V6, P191, DOI 10.3109/10611869808997893; Bohm G., 1997, CDNN CD SPECTRA DECO; Brasseur R, 2000, MOL MEMBR BIOL, V17, P31, DOI 10.1080/096876800294461; CARROLL SF, 1988, METHOD ENZYMOL, V165, P218; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; DUZGUNES N, 1992, J MEMBRANE BIOL, V128, P71, DOI 10.1007/BF00231872; DUZGUNES N, 1988, FEBS LETT, V227, P110, DOI 10.1016/0014-5793(88)80879-2; Fiske CH, 1925, J BIOL CHEM, V66, P375; Freulon I, 2001, BIOCHEM J, V354, P671, DOI 10.1042/0264-6021:3540671; Fujii G, 1999, ADV DRUG DELIVER REV, V38, P257, DOI 10.1016/S0169-409X(99)00032-0; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; HAMILTON TC, 1983, CANCER RES, V43, P5379; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Ishida T, 1999, FEBS LETT, V460, P129, DOI 10.1016/S0014-5793(99)01320-4; Kaneda Y, 2000, ADV DRUG DELIVER REV, V43, P197, DOI 10.1016/S0169-409X(00)00069-7; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; Kickler A, 1997, BIOCONJUGATE CHEM, V8, P213, DOI 10.1021/bc970009z; Laczko I, 1998, BIOCHEM BIOPH RES CO, V249, P213, DOI 10.1006/bbrc.1998.9109; Matsumoto T, 1999, BIOPHYS CHEM, V79, P153, DOI 10.1016/S0301-4622(99)00051-4; Mechtler K, 1997, NEW J CHEM, V21, P105; MEMOLI A, 1994, J PHARMACEUT BIOMED, V12, P307, DOI 10.1016/0731-7085(94)90004-3; Memoli A, 1999, J PHARMACEUT BIOMED, V19, P627, DOI 10.1016/S0731-7085(98)00229-5; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; OBERHAUSER B, 1995, DELIVERY STRATEGIES; OELTMANN TN, 1988, METHOD ENZYMOL, V165, P204; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pecheur EI, 1997, BIOCHEMISTRY-US, V36, P3773, DOI 10.1021/bi9622128; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Pichon C, 1997, ANTISENSE NUCLEIC A, V7, P335, DOI 10.1089/oli.1.1997.7.335; Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2; PLANK C, 1994, J BIOL CHEM, V269, P12918; PUYAL C, 1994, BBA-BIOMEMBRANES, V1195, P259, DOI 10.1016/0005-2736(94)90265-8; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; Schoen P, 1999, GENE THER, V6, P823, DOI 10.1038/sj.gt.3300919; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; Tong SG, 1996, BIOCHEMISTRY-US, V35, P4956, DOI 10.1021/bi9526903; Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847	45	149	167	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27135	27143		10.1074/jbc.M200429200	http://dx.doi.org/10.1074/jbc.M200429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021269	hybrid			2022-12-25	WOS:000177055900057
J	Yu, YL; Chiang, YJ; Yen, JJY				Yu, YL; Chiang, YJ; Yen, JJY			GATA factors are essential for transcription of the survival gene E4bp4 and the viability response of interleukin-3 in Ba/F3 hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-B LYMPHOCYTES; DNA-BINDING; ERYTHROID-DIFFERENTIATION; ENDOTHELIAL-CELLS; FACTOR EXPRESSION; ONE-COMPONENT; BZIP FAMILY; PROTEIN; APOPTOSIS; PHOSPHORYLATION	E4bp4, a member of the basic region/leucine zipper transcription factor superfamily, is up-regulated by the interleukin-3 (IL-3) signaling pathway and plays an important role in the anti-apoptotic response of IL-3. In this study, we demonstrated that E4bp4 is regulated by IL-3 mainly at the transcriptional level. Promoter analysis revealed that a GATA motif downstream of a major transcription initiation site is essential for E4bp4 expression in the IL-3-dependent Ba/F3 cell line. Gel shift assays demonstrated that both GATA-1 and GATA-2 proteins bind to the E4bp4 GATA site in vitro, and the chromatin immunoprecipitation assay further confirmed the in vivo binding of GATA-1 to the E4bp4 promoter. Overexpression of GATA-1 alone transactivates the E4bp4 reporter, whereas transactivation of the E4bp4 reporter by GATA-2 is dependent on the stimulation of IL-3. Last, we demonstrated that alteration of GATA-1 binding to the GATA site by stably overexpressing GATA-1 or a GATA-1 mutant containing only the DNA-binding domain not only modulates the expression of the E4bp4 gene but also influences apoptosis induced by IL-3 removal. Taken together, our results suggest that the GATA factors play an important role in transducing the survival signal of IL-3, and one of their cellular targets is E4bp4.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Grad Inst Life Sci, Natl Def Med Ctr, Taipei 115, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Defense Medical Center	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, No 128,Sec 2,Yen Jiou Yuan Rd, Taipei 115, Taiwan.		Yen, Jeffrey Jong-Young/Q-5134-2018	Yen, Jeffrey Jong-Young/0000-0001-6299-1995				Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen WS, 2001, MOL CELL BIOL, V21, P4636, DOI 10.1128/MCB.21.14.4636-4646.2001; Chtanova T, 2001, J IMMUNOL, V167, P3057, DOI 10.4049/jimmunol.167.6.3057; Chu CC, 1998, MOL IMMUNOL, V35, P487, DOI 10.1016/S0161-5890(98)00031-5; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KORNHAUSER JM, 1994, MOL BRAIN RES, V23, P100, DOI 10.1016/0169-328X(94)90216-X; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lai CK, 1999, J VIROL, V73, P3197, DOI 10.1128/JVI.73.4.3197-3209.1999; Lee SF, 1999, MOL CELL BIOL, V19, P7399; LEONARD M, 1993, BLOOD, V82, P1071; MARTIN DI, 1990, NATURE, V344, P4444; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; ORKIN SH, 1992, BLOOD, V80, P575; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Partington GA, 1999, NUCLEIC ACIDS RES, V27, P1168, DOI 10.1093/nar/27.4.1168; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; ZHANG W, 1995, MOL CELL BIOL, V15, P6055; ZON LI, 1993, BLOOD, V81, P3234	53	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27144	27153		10.1074/jbc.M200924200	http://dx.doi.org/10.1074/jbc.M200924200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023274	hybrid			2022-12-25	WOS:000177055900058
J	Flouriot, G; Brand, H; Seraphin, B; Gannon, F				Flouriot, G; Brand, H; Seraphin, B; Gannon, F			Natural trans-spliced mRNAs are generated from the human estrogen receptor-alpha (hER alpha) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROMOTER USAGE; BREAST-CANCER; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; RETINOIC ACID; ER-ALPHA; TRANSCRIPTS; ACTIVATION; ISOFORMS	The human estrogen receptor-alpha (heralpha) gene is a complex genomic unit exhibiting alternative splicing and promoter usage in a tissue-specific manner. During the investigation of new hERalpha mRNA variants by rapid amplification of 5' cDNA ends, we identified a cDNA in which the acceptor site of exon 1A, into which the different leader exons are normally alternatively spliced, was spliced accurately the 3' extremity of exon 1A (scrambled 1A-->1A hERalpha cDNA). Reverse transcription-PCR and S1 nuclease mapping analysis revealed that 1A-->1A hERalpha transcripts were not circular RNAs constituted by exon 1A only but corresponded to linear polyadenylated hERalpha RNAs composed of the eight coding exons of the hERalpha gene and characterized by a duplication of exon 1A. Genomic Southern blot experiments excluded the hypothesis of duplication of hERalpha exon 1A in the human genome. Therefore, these data suggested that 1A-->1A hERalpha transcripts were likely generated by trans-splicing. The production of such transcripts by trans-splicing of pre-mRNAs generated from a chimeric gene formed by a single hERalpha exon 1A, exon 2, and their flanking intronic regions was demonstrated in transient transfection experiments. Therefore, in addition to the alternative cis-splicing, the hERalpha gene is also subject to natural trans-splicing.	European Mol Biol Lab, D-69117 Heidelberg, Germany; CNRS, UMR 6026, F-35042 Rennes, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Flouriot, G (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Flouriot, Gilles/K-1833-2015; Gannon, Frank/G-1194-2015	Flouriot, Gilles/0000-0001-6250-4173; Seraphin, Bertrand/0000-0002-5168-1921				AUCHUS RJ, 1994, BAILLIERE CLIN ENDOC, V8, P433, DOI 10.1016/S0950-351X(05)80260-5; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; DANDEKAR T, 1990, NUCLEIC ACIDS RES, V18, P4719, DOI 10.1093/nar/18.16.4719; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Flouriot G, 1996, ANAL BIOCHEM, V237, P159, DOI 10.1006/abio.1996.0219; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P218, DOI 10.1159/000132325; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Griffin C, 1998, ENDOCRINOLOGY, V139, P4614, DOI 10.1210/en.139.11.4614; HENDERSON BE, 1988, CANCER RES, V48, P246; Hopp TA, 1998, J MAMMARY GLAND BIOL, V3, P73, DOI 10.1023/A:1018726418931; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; KEAVENEY M, 1991, J MOL ENDOCRINOL, V1, P25; Kos M, 2000, FEBS LETT, V477, P15, DOI 10.1016/S0014-5793(00)01750-6; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Malek O, 1997, P NATL ACAD SCI USA, V94, P553, DOI 10.1073/pnas.94.2.553; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Parker M., 1991, NUCL HORMONE RECEPTO; Pink JJ, 1996, NUCLEIC ACIDS RES, V24, P962, DOI 10.1093/nar/24.5.962; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; Service RF, 1998, SCIENCE, V279, P1631, DOI 10.1126/science.279.5357.1631; SHI YB, 1992, J BIOL CHEM, V267, P733; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; WATTS CKW, 1992, J STEROID BIOCHEM, V41, P529, DOI 10.1016/0960-0760(92)90378-V; Zaphiropoulos PG, 1997, MOL CELL BIOL, V17, P2985, DOI 10.1128/MCB.17.6.2985; Zaphiropoulos PG, 1996, P NATL ACAD SCI USA, V93, P6536, DOI 10.1073/pnas.93.13.6536; ZEINER M, 1994, BIOTECHNIQUES, V17, P1051; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	47	63	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26244	26251		10.1074/jbc.M203513200	http://dx.doi.org/10.1074/jbc.M203513200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011094	hybrid			2022-12-25	WOS:000176908700056
J	Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH				Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH			Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2 +/- cells	ONCOGENE			English	Article						tuberin; hamartin; glia; astrocytoma; tumor suppressor gene	NF1 TUMOR-SUPPRESSOR; MISSENSE MUTATIONS; ALLELIC LOSS; HAMARTIN; MICE; PROLIFERATION; PROTEIN; GROWTH; LESIONS; IDENTIFICATION	Tuberous sclerosis complex (TSC) is an autosomal dominant tumor predisposition syndrome characterized by benign proliferations (hamartomas). In the brain, individuals with TSC develop autism, mental retardation and seizures associated with focal cortical dysplasias, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs). We hypothesize that dysregulated astrocyte function due to mutations in they tumor suppressor genes, TSC1 and TSC2, may contribute to the pathogenesis of these brain abnormalities. In this report, we demonstrate that mice heterozygous for a targeted defect in either the Tsc1 or Tsc2 genes (Tsc1+/- and Tsc2+/- mice) exhibit a 1.5-fold increase in the number of astrocytes in vivo. Whereas increased astrocyte numbers in vivo were suggestive of a proliferative advantage, Tsc2+/- primary astrocyte cultures did not show a cell-autonomous growth advantage, anchorage-independent growth, increased saturation density, or increased fluid-phase endocytosis compared to wild type astrocytes. Tsc2 null mouse embryonic fibroblasts (MEFs) however, did exhibit increased saturation density compared to Tsc2 wild type controls. In both Tsc2+/- astrocytes and Tsc2 null mouse embryonic fibroblasts, p27-Kip1 expression was decreased compared to wild type cells, and was reversed by tuberin re-expression in Tsc2-/- MEFs. In contrast, no change in endocytosis was observed upon tuberin re-expression in Tsc2-/- MEFs. Collectively, these results suggest Tsc heterozygosity may provide a non-cell-autonomous growth advantage for astrocytes that may involve p27-Kip1 expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Apicelli, Anthony/AAB-8879-2021	Apicelli, Anthony/0000-0001-6791-8113; Gutmann, David/0000-0002-3127-5045; Burke, Stephen/0000-0002-8489-6953	NINDS NIH HHS [NS31535] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031535, R37NS031535] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Gutmann DH, 1997, ONCOGENE, V15, P1611, DOI 10.1038/sj.onc.1201314; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Henske EP, 1996, AM J HUM GENET, V59, P400; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lantuejoul S, 1997, HISTOPATHOLOGY, V30, P570, DOI 10.1046/j.1365-2559.1997.4600811.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Parry L, 2000, HUM GENET, V107, P350, DOI 10.1007/s004390000390; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1999, J MED GENET, V36, P285; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wolf HK, 1997, ACTA NEUROPATHOL, V93, P93, DOI 10.1007/s004010050587; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	46	58	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4050	4059		10.1038/sj.onc.1205435	http://dx.doi.org/10.1038/sj.onc.1205435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037687				2022-12-25	WOS:000175869900011
J	Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M				Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M			Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts	ONCOGENE			English	Article						cell adhesion; cell proliferation; angiogenesis; integrin; FGF; tyrosine kinase; FGF receptor	EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; IN-VITRO; ANGIOGENESIS; UROKINASE; PROTEIN; ACTIVATION; BINDING; INVITRO; ALPHA(V)BETA(3)	Substrate-bound FGF2 promotes endothelial cell adhesion by interacting With alpha(nu)beta(3) integrin. Here, endothelial GM7373 cells spread and organize focal adhesion plaques on immobilized FGF2, fibronectin (FN), and vitronectin (VN). alpha(nu)beta(3) integrin, paxillin, focal adhesion kinase, vinculin and pp60(src) localize in cell-substratum contact sites on FGF2, FN or VN. However, only immobilized FGF2 induces a long-lasting activation of extracellular signal-regulated kinases(1/2) (ERK1/2) and cell proliferation that was inhibited by the ERK1/2 inhibitor PD 098059 and the tyrosine kinase (TK) inhibitor tyrphostin 23, pointing to the engagement of FGF receptor (FGFR) at the basal side of the cell. To assess this hypothesis, GM7373 cells were transfected with a dominant negative TK--DeltaFGFR1 mutant (GM7373-DeltaFGFR1 cells) or with the full-length receptor (GM7373-FGFR1 cells). Both transfectants adhere and spread on FGF2 but GM7373-DeltaFGFR1 cells do not proliferate. Also, parental and GM7373-FGFR1 cells, but not GM7373-DeltaFGFR1 cells, undergo morphological changes and increased motility on FGF2-coated plastic. Finally, FGFR1, but not TK--DeltaFGFR1, localizes in cell adhesion contacts on immobilized FGF2. In conclusion, substrate-bound FGF2 induces endothelial cell proliferation, motility, and the recruitment of FGFR1 in cell-substratum contacts. This may contribute to the cross talk among intracellular signaling pathways activated by FGFR1 and alpha(nu)beta(3) integrin in endothelial cells.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Cagliari, Dept Cytomorphol, Cagliari, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Bari, Italy	University of Brescia; University of Cagliari; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.		Dell'Era, Patrizia/ABD-5848-2020; Rusnati, Marco/F-1168-2010; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/G-5294-2010; Dell'Era, Patrizia/N-6964-2019; Ria, Roberto/I-4263-2015	Rusnati, Marco/0000-0001-9968-5908; Dell'Era, Patrizia/0000-0001-6682-6321; Ennas, Maria Grazia/0000-0002-9448-715X; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871; Ria, Roberto/0000-0002-1515-0090				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BROADLEY KN, 1989, LAB INVEST, V61, P571; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CULP LA, 1976, BIOCHEMISTRY-US, V15, P4094, DOI 10.1021/bi00663a028; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DELROSSO M, 1992, EXP CELL RES, V203, P427; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giuliani R, 1999, J CELL SCI, V112, P2597; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LI Y, 1994, MOL CELL BIOL, V14, P7600; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1999, J CELL SCI, V112, P4213; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SMITH JC, 1982, NATURE, V296, P154, DOI 10.1038/296154a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; ZHANG WW, 1994, CANCER GENE THER, V1, P4	47	58	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3889	3897		10.1038/sj.onc.1205407	http://dx.doi.org/10.1038/sj.onc.1205407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032827				2022-12-25	WOS:000175847200008
J	Stubbs, MC; Hall, DJ				Stubbs, MC; Hall, DJ			The amino-terminus of the E2F-1 transcription factor inhibits DNA replication of autonomously replicating plasmids in mammalian cells	ONCOGENE			English	Article						S phase checkpoint; E2F-1; replication inhibition; elongation phase	ZINC-FINGER PROTEIN; S-PHASE; CORE ORIGIN; APOPTOSIS; INDUCTION; EXPRESSION; INITIATION; BINDING; DAMAGE; BRCA1	The E2F1 transcription factor plays a pivotal role in driving cells out of a quiescent state and into the S phase of the cell cycle, in part by transactivating genes needed for DNA replication including DHFR, thymidine kinase, and DNA Polymerase x. E2F1 has also been implicated in regulating an S phase checkpoint, however its role in this checkpoint is not well defined. To determine how E2F1 affects such a checkpoint, we utilized an in vivo replication assay employing a plasmid based SV40 origin of replication, transfected into cells expressing SV40 large T antigen. Here we show that expression of full length E2F1, or only its N terminus, represses replication from plasmids containing the SV40 origin, while N terminal deletions of E2F1 do not. E2F1 appears to inhibit the elongation phase of replication and not the initiation phase since it does not affect the replication of other cotransfected plasmids containing only the SV40 origin. Further, inhibition of replication is dependent on both the amino-terminus of the E2F1 protein and on a DNA sequence that is contained within the 3' end of the E2F1 cDNA. Additionally, both full-length E2F1, or just its N-terminus, form protein complexes with two portions of the 3' end of the E2F1 cDNA. These data provide a clue to the mechanism by which E2F1 regulates transit through the S phase checkpoint, by acting on a specific DNA sequence via its amino-terminal region, to inhibit elongation of DNA replication.	NIAMSD, Cartilage & Orthopaed Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hall, DJ (corresponding author), NIAMSD, Cartilage & Orthopaed Branch, NIH, MSC 5755,9000 Rockville Pk, Bethesda, MD 20892 USA.	halld@ep.niams.nih.gov		, Matthew/0000-0003-3771-7083	NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CHITTENDEN T, 1991, J VIROL, V65, P5944, DOI 10.1128/JVI.65.11.5944-5951.1991; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Deng CX, 2000, BIOESSAYS, V22, P728; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HARLOW F, 1988, ANTIBODIES LAB MANUA; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOrdan KL, 1996, BIOCHEMISTRY-US, V35, P12320, DOI 10.1021/bi9611927; Jordan-Sciutto KL, 1998, BIOCHEM CELL BIOL, V76, P37; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; LOGAN TJ, 1995, CANCER RES, V55, P2883; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stubbs MC, 1999, BIOCHEM BIOPH RES CO, V258, P77, DOI 10.1006/bbrc.1999.0603; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	44	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3715	3726		10.1038/sj.onc.1205473	http://dx.doi.org/10.1038/sj.onc.1205473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032840				2022-12-25	WOS:000175676000007
J	Foster, CJ; Lozano, G				Foster, CJ; Lozano, G			Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland	ONCOGENE			English	Article						proliferation; cell cycle; p53	TUMOR-SUPPRESSOR; S-PHASE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INK4A LOCUS; P53 PROTEIN; GENE; AMPLIFICATION; PRODUCT; ASSOCIATION	The protein encoded by the murine double minute 2 (Mdm2) gene inactivates the function of the tumor suppressor p53. The targeted expression of the mdm2 transgene (BLGmdm2) to the mammary epithelium disrupts the cell cycle, causing multiple rounds of DNA synthesis without proper cell division and consequently poor mammary gland development. These phenotypes in the mammary epithelia of the transgenic mice are not dependent on either p53 or the transcription factor E2F1, as mice null for these genes carrying the BLGmdm2 transgene exhibit similar defects to mice carrying the BLGmdm2 transgene alone. p19ARF, an alternative splice product of the INK4a/ARF locus, has been shown to interact directly with MDM2. Therefore, BLGmdm2 transgenic mice null for p19ARF were created to gain insight into the mechanism by which mdm2 overexpression disrupts the cell cycle. The BLGmdm2 phenotype in the absence of p19ARF was worse than BLGmdm2 mice and visible as early as day 15 of pregnancy. By day 5 of lactation the phenotype was very pronounced. Histological analysis of the mammary gland showed a decrease in ductal branching, smaller and fewer lobuloalveolar structures, and a decrease in luminal secretions. Multinucleated and enlarged cells were present due to continued replication in the absence of cytokinesis. Thus, the absence of p19ARF in this in vivo system enhanced the defect caused by mdm2 overexpression.	Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org		Vivian, Carolyn J./0000-0001-9598-0109	NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAO L, 1995, CANCER RES, V55, P2995; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MCCANN AH, 1995, BRIT J CANCER, V71, P981, DOI 10.1038/bjc.1995.189; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; STONE S, 1995, CANCER RES, V55, P2988; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	36	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3525	3531		10.1038/sj.onc.1205441	http://dx.doi.org/10.1038/sj.onc.1205441			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032854				2022-12-25	WOS:000175793700003
J	Schirmbeck, R; Kwissa, M; Fissolo, N; ElKholy, S; Riedl, P; Reimann, J				Schirmbeck, R; Kwissa, M; Fissolo, N; ElKholy, S; Riedl, P; Reimann, J			Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein-capturing, viral J-domain	FASEB JOURNAL			English	Article						stress protein; antigen expression; DNA-based vaccines	HEAT-SHOCK-PROTEIN; LARGE T-ANTIGEN; IN-VIVO; MOLECULAR CHAPERONES; FUSION PROTEINS; PEPTIDE; CELLS; GP96; HSP70; VIRUS	The N-terminal domain of large tumor antigens (T-Ag) of polyomaviruses forms a DnaJ-like structure with a conserved J domain that associates with constitutively expressed stress protein heat shock protein (hsp)73. Mutant (but not wild-type) SV40 T-Ag show stable, ATP-dependent binding to the stress protein hsp73 when expressed in cells from different vertebrate tissues. Intracellular T/hsp73 complexes accumulate to high steady-state levels. From this observation, we designed a vector system that supports stable expression of a large variety of hsp73-capturing, chimeric antigens containing an N-terminal, T-Ag-derived domain, and different C-terminal antigenic domains from unrelated antigens. Most antigenic domains tested could be stably expressed only in eukaryotic cells as fusion protein/hsp73 complexes. The N-terminal 77 residues representing the J domain of T-Ag were required for stable hsp73 binding and efficient expression of chimeric antigens. Hsp73-bound chimeric antigens expressed by DNA vaccines showed strikingly enhanced immunogenicity evident in humoral (antibody) and cellular cytolytic T lymphocytes (CTL) responses. The described system supports efficient expression of chimeric, polyvalent antigens and their codelivery with hsp73 as a "natural adjuvant" for enhanced immunogenicity for T and B cells.	Univ Ulm, Inst Med Microbiol & Immunol, D-89081 Ulm, Germany	Ulm University	Schirmbeck, R (corresponding author), Univ Ulm, Inst Med Microbiol & Immunol, Albert Einstein Allee 11, D-89081 Ulm, Germany.	reinhold.schirmbeck@medizin.uni-ulm.de	Fissolo, Nicolas/J-3067-2012	Fissolo, Nicolas/0000-0002-7701-9346; F. Elkholy, Dr. Shereen/0000-0002-2582-9021				ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Breloer M, 1999, J IMMUNOL, V162, P3141; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Chen CH, 2000, CANCER RES, V60, P1035; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; Cho BK, 2000, IMMUNITY, V12, P263, DOI 10.1016/S1074-7613(00)80179-X; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; FELDWEG AM, 1995, INT J CANCER, V63, P310, DOI 10.1002/ijc.2910630227; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Huang Q, 2000, J EXP MED, V191, P403, DOI 10.1084/jem.191.2.403; Ishii T, 1999, J IMMUNOL, V162, P1303; Kammerer R, 2002, J IMMUNOL, V168, P108, DOI 10.4049/jimmunol.168.1.108; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Kuhrober A, 1997, INT IMMUNOL, V9, P1203, DOI 10.1093/intimm/9.8.1203; KUHROBER A, 1996, J IMMUNOL, V156, P3687; Kwissa M, 2000, J MOL MED-JMM, V78, P495, DOI 10.1007/s001090000135; Kwissa M, 2000, VACCINE, V18, P2337, DOI 10.1016/S0264-410X(00)00030-X; Lammert E, 1996, EUR J IMMUNOL, V26, P875, DOI 10.1002/eji.1830260423; Liu DW, 2000, J VIROL, V74, P2888, DOI 10.1128/JVI.74.6.2888-2894.2000; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270; Pumpens P, 1999, FEBS LETT, V442, P1, DOI 10.1016/S0014-5793(98)01599-3; Roman E, 1997, IMMUNOLOGY, V90, P52, DOI 10.1046/j.1365-2567.1997.00136.x; Roman RC, 1996, DANCE MAG, V70, P88; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Schirmbeck R, 1999, EUR J IMMUNOL, V29, P1740, DOI 10.1002/(SICI)1521-4141(199905)29:05<1740::AID-IMMU1740>3.3.CO;2-O; SCHIRMBECK R, 1993, EUR J IMMUNOL, V23, P1528, DOI 10.1002/eji.1830230720; SCHIRMBECK R, 1994, EUR J IMMUNOL, V24, P1478, DOI 10.1002/eji.1830240704; Schirmbeck R, 1996, J IMMUNOL, V157, P3550; Schirmbeck R, 1997, EUR J IMMUNOL, V27, P2016, DOI 10.1002/eji.1830270828; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; Sondermann H, 2000, BIOL CHEM, V381, P1165, DOI 10.1515/BC.2000.144; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Suzue K, 1996, J IMMUNOL, V156, P873; Todryk S, 1999, J IMMUNOL, V163, P1398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; VONHOYNINGENHUENE V, 1992, VIROLOGY, V190, P155, DOI 10.1016/0042-6822(92)91201-5; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1	56	26	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1108	+		10.1096/fj.01-0993fje	http://dx.doi.org/10.1096/fj.01-0993fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039856				2022-12-25	WOS:000175973900008
J	Norambuena, L; Marchant, L; Berninsone, P; Hirschberg, CB; Silva, H; Orellana, A				Norambuena, L; Marchant, L; Berninsone, P; Hirschberg, CB; Silva, H; Orellana, A			Transport of UDP-galactose in plants - Identification and functional characterization of AtUTr1, an Arabidopsis thaliana UDP-galactose/UDP-glucose transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SUGAR TRANSPORTER; GOLGI-APPARATUS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; POLYSACCHARIDE BIOSYNTHESIS; MOLECULAR CHARACTERIZATION; N-ACETYLGALACTOSAMINE; ENDOPLASMIC-RETICULUM; GLYCOSYLATION; EXPRESSION	The synthesis of non-cellulosic polysaccharides and glycoproteins in the plant cell Golgi apparatus requires UDP-galactose as substrate. The topology of these reactions is not known, although the orientation of a plant galactosyltransferase involved in the biosynthesis of galactomannans in fenugreek is consistent with a requirement for UDP-galactose in the lumen of the Golgi cisternae. Here we provide evidence that sealed, right-sideout Golgi vesicles isolated from pea stems transport UDP-galactose into their lumen and transfer galactose, likely to polysaccharides and other acceptors. In addition, we identified and cloned AtUTr1, a gene from Arabidopsis thaliana that encodes a multitransmembrane hydrophobic protein similar to nucleotide sugar transporters. Northern analysis showed that AtUTr1 is indeed expressed in Arabidopsis. AtUTr1 is able to complement the phenotype of MDCK ricin-resistant cells; a mammalian cell line deficient in transport of UDP-galactose into the Golgi. In vitro assays using a Golgi-enriched vesicle fraction obtained from Saccharomyces cerevisiae expressing AtUTr1-MycHis is able to transport UDP-galactose but also UDP-glucose. AtUTr1-MycHis does not transport GDP-mannose, GDP-fucose, CMP-sialic acid, UDP-glucuronic acid, or UDP-xylose when expressed in S. cerevisiae. AtUTr1 is the first transporter described that is able to transport UDP-galactose and UDP-glucose. Thus AtUTr1 may play an important role in the synthesis of glycoconjugates in Arabidopsis that contain galactose and glucose.	Univ Chile, Dept Biol, Fac Sci, Santiago, Chile; Univ Chile, Millenium Inst Cell Biol & Biotechnol, Santiago, Chile; Boston Univ, Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Universidad de Chile; Universidad de Chile; Boston University	Orellana, A (corresponding author), Univ Chile, Dept Biol, Fac Sci, Las Palmeras 3425,Numoa,Casilla 653, Santiago, Chile.	aorellan@uchile.cl	Orellana, Ariel/AAE-4866-2021; Orellana, Ariel/E-2166-2014; Norambuena, Lorena/I-1248-2013; Silva, Herman P/C-7252-2012	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Norambuena, Lorena/0000-0002-6031-2394; Silva, Herman P/0000-0003-1007-7442; Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Baldwin TC, 2001, PLANT CELL, V13, P2283, DOI 10.1105/tpc.13.10.2283; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, J BIOL CHEM, V259, P4263; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Edwards ME, 1999, PLANT J, V19, P691, DOI 10.1046/j.1365-313x.1999.00566.x; Goto S, 2001, NAT CELL BIOL, V3, P816, DOI 10.1038/ncb0901-816; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Kainuma M, 2001, YEAST, V18, P533, DOI 10.1002/yea.708; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Munoz P, 1996, PLANT PHYSIOL, V112, P1585, DOI 10.1104/pp.112.4.1585; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Orellana A, 1997, PLANT PHYSIOL, V114, P99, DOI 10.1104/pp.114.1.99; Orellana A, 1999, ANAL BIOCHEM, V272, P224, DOI 10.1006/abio.1999.4159; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; Poster JB, 1996, J BIOL CHEM, V271, P3837; Reid JSG, 2000, CURR OPIN PLANT BIOL, V3, P512, DOI 10.1016/S1369-5266(00)00121-7; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; Segawa H, 2002, EUR J BIOCHEM, V269, P128, DOI 10.1046/j.0014-2956.2001.02632.x; Sun-Wada GH, 1998, J BIOCHEM, V123, P912; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Toma L, 1996, J BIOL CHEM, V271, P3897; Wulff C, 2000, PLANT PHYSIOL, V122, P867, DOI 10.1104/pp.122.3.867	38	71	82	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32923	32929		10.1074/jbc.M204081200	http://dx.doi.org/10.1074/jbc.M204081200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12042319	hybrid			2022-12-25	WOS:000177859000070
J	Abdel-Banat, BMA; Koga, D				Abdel-Banat, BMA; Koga, D			Alternative splicing of the primary transcript generates heterogeneity within the products of the gene for Bombyx mori chitinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE GROWTH-HORMONE; PRE-MESSENGER-RNA; MANDUCA-SEXTA; GENOMIC CLONE; ORGANIZATION; EXPRESSION; SILKWORM; SEQUENCE; EXON; IDENTIFICATION	The gene of chitinase in the silkworm, Bombyx mori, generates four mRNA products by alternative splicing. Nucleotide sequences of the entire gene for chitinase and respective cDNAs demonstrate that the pre-mRNA undergoes alternative splicing at both the 5' and 3' regions. At the 5' region, the pre-mRNA experienced differential splicing through two alternative 5'-intron consensus splicing sites. These products differ in the last amino acid of the signal peptide and the first amino acid of the mature N-terminal sequences: one with Cys(20)-Ala(21) and the other with Ser(20)-Asp(21). The product with Cys(20)-Ala(21) residues is one amino acid larger than the other with Ser(20)-Asp(21). At the 3' region the pre-mRNA of the chitinase gene undergoes alternative splicing in three different fashions. It is spliced either through retaining or excluding the upstream 121-bp direct repeat found at the 3' region of the coding sequences or through retaining or excluding of an insertion of 9 bp in a combinatorial manner. Retention or exclusion of the upstream 121-bp direct repeat results in a protein with a deduced amino acid sequence similar in size to the one retaining both direct repeats. However, exclusion of the insert of the 9 bp from the mRNA results in a protein with 22 extra amino acids. All of the mRNA products appear to be generated from a single gene as demonstrated by testing the 3' region of the genomic DNA and variant chitinase mRNA products. B. mori chitinase expression in the fifth instar larvae epidermal tissues appears to be developmentally regulated, but the phenomenon of alternative splicing of the pre-mRNA is not stage-dependent. Furthermore, the four mRNA products showed chitinase activity when expressed in Escherichia coli, which demonstrates the role of the alternative splicing process in generating multiple isoforms of the silkworm's chitinase.	Yamaguchi Univ, Fac Agr, Dept Biol Sci, Biochem Lab, Yamaguchi 7538515, Japan	Yamaguchi University	Koga, D (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Sci, Biochem Lab, Yamaguchi 7538515, Japan.	koga@agr.yamaguchi-u.ac.jp		Abdel-Banat, Babiker Mohamed Ahmed/0000-0001-8242-7988				Abdel-Banat BMA, 2001, INSECT BIOCHEM MOLEC, V31, P497, DOI 10.1016/S0965-1748(00)00160-0; ABDELBANAT BMA, 1999, INSECT BIOCHEM MOLEC, V29, P537; Bogo MR, 1998, CURR MICROBIOL, V37, P221, DOI 10.1007/s002849900368; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; Choi HK, 1997, INSECT BIOCHEM MOLEC, V27, P37, DOI 10.1016/S0965-1748(96)00066-5; COOKE NE, 1988, J BIOL CHEM, V263, P9001; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; FUHRMAN JA, 1995, PARASITOL TODAY, V11, P259, DOI 10.1016/0169-4758(95)80207-X; Garel A, 1997, INSECT BIOCHEM MOLEC, V27, P469, DOI 10.1016/S0965-1748(97)00022-2; GOPALAKRISHNAN B, 1995, INSECT BIOCHEM MOLEC, V25, P255, DOI 10.1016/0965-1748(94)00070-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Kim MG, 1998, INSECT BIOCHEM MOLEC, V28, P163, DOI 10.1016/S0965-1748(97)00112-4; KIMURA S, 1973, J INSECT PHYSIOL, V19, P115, DOI 10.1016/0022-1910(73)90227-8; KOGA D, 1989, INSECT BIOCHEM, V19, P123, DOI 10.1016/0020-1790(89)90082-6; KOGA D, 1983, INSECT BIOCHEM, V13, P295, DOI 10.1016/0020-1790(83)90052-5; Koga D, 1997, INSECT BIOCHEM MOLEC, V27, P757, DOI 10.1016/S0965-1748(97)00058-1; KOGA D, 1992, BIOSCI BIOTECH BIOCH, V56, P280, DOI 10.1271/bbb.56.280; Koga D, 1999, EXS, V87, P111; Kramer K.J., 1985, P75; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; Kramer KJ, 1997, INSECT BIOCHEM MOLEC, V27, P887, DOI 10.1016/S0965-1748(97)00078-7; Kramer KJ, 1996, ADV INSECT CONTROL T, P185; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Mikitani K, 2000, J BIOL CHEM, V275, P37725, DOI 10.1074/jbc.M005271200; OVERDIJK B, 1994, GLYCOBIOLOGY, V4, P797, DOI 10.1093/glycob/4.6.797; Pongjaroenkit S, 2001, INSECT BIOCHEM MOLEC, V31, P75, DOI 10.1016/S0965-1748(00)00107-7; Ranson H, 1998, P NATL ACAD SCI USA, V95, P14284, DOI 10.1073/pnas.95.24.14284; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; Tellam RL, 1996, PARASITOL TODAY, V12, P291, DOI 10.1016/0169-4758(96)80819-2; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865	40	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30524	30534		10.1074/jbc.M112422200	http://dx.doi.org/10.1074/jbc.M112422200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12045191	hybrid			2022-12-25	WOS:000177579800018
J	Canaan, S; Nielsen, R; Ghomashchi, F; Robinson, BH; Gelb, MH				Canaan, S; Nielsen, R; Ghomashchi, F; Robinson, BH; Gelb, MH			Unusual mode of binding of human group IIA secreted phospholipase A(2) to anionic interfaces as studied by continuous wave and time domain electron paramagnetic resonance spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXATION MAGNETIC-RESONANCE; CATALYSIS; SURFACE; MEMBRANES; BILAYERS; RESIDUES; DOCKING; ENZYMES; RELEASE; CELLS	Human group IIA phospholipase A(2) (hGIIA) is secreted from a number of cells during inflammation and is known to interact strongly with anionic membranes and to exhibit potent Gram-positive bactericidal activity. This protein contains 23 cationic residues, which are scattered over its entire surface, resulting in a high pI of 9.39. To understand the molecular basis for the selective binding of hGIIA to anionic membranes, 14 single-site, spin-labeled hGIIA proteins were analyzed in the presence and absence of vesicles of anionic phospholipid by time domain and continuous wave electron paramagnetic resonance (EPR) spin relaxant techniques. Surprisingly, for hGIIA bound to anionic vesicles, all of the spin labels were highly protected from water-soluble spin relaxants. Together with light scattering studies, these EPR results suggest the formation of a supramolecular aggregate involving clusters of hGIIA molecules bridging together multiple vesicles. This anomalous mode of binding of hGIIA to anionic phospholipid explains previous data in which charge reversal mutation of a few cationic residues on multiple faces of hGIIA leads to a comparable and modest reduction in affinity of the protein for anionic vesicles. In the presence of mixed micelles composed of 10% anionic phospholipids in Triton X-100 a monodisperse protein-lipid complex is formed. Under these conditions, the EPR methods were used to map the surface of hGIIA that constitutes the interfacial binding site (IBS). The IBS of hGIIA consists of the highly hydrophobic surface that surrounds the opening to the active site slot.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Robinson, BH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	robinson@chem.washington.edu; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, R23HL036235, R01HL036235, R37HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50040, HL 36235] Funding Source: Medline; NIEHS NIH HHS [P30 ES 07033] Funding Source: Medline; NIGMS NIH HHS [GM 065944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Foreman-Wykert AK, 2000, INFECT IMMUN, V68, P1259, DOI 10.1128/IAI.68.3.1259-1264.2000; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Lakshminarayanaiah N., 1984, EQUATIONS MEMBRANE B; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; MAILER C, 1985, REV SCI INSTRUM, V56, P1917, DOI 10.1063/1.1138445; MAILER C, 1991, J MAGN RESON, V91, P475, DOI 10.1016/0022-2364(91)90375-4; Mounier CM, 2000, EUR J BIOCHEM, V267, P4960, DOI 10.1046/j.1432-1327.2000.01523.x; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; ROBINSON BH, 1994, SCIENCE, V263, P490, DOI 10.1126/science.8290958; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; YAGER TD, 1979, INORG CHEM, V18, P725, DOI 10.1021/ic50193a039; YIN JJ, 1987, J MAGN RESON, V74, P82, DOI 10.1016/0022-2364(87)90081-3	36	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30984	30990		10.1074/jbc.M203649200	http://dx.doi.org/10.1074/jbc.M203649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12039961	hybrid			2022-12-25	WOS:000177579800075
J	Baek, MC; Krosky, PM; He, ZW; Coen, DM				Baek, MC; Krosky, PM; He, ZW; Coen, DM			Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase - Importance of the P+5 position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARICELLA-ZOSTER VIRUS; HERPES-SIMPLEX VIRUS; STABLE INHIBITOR PROTEIN; EPSTEIN-BARR-VIRUS; STRUCTURAL BASIS; HERPESVIRUSES ENCODE; SERINE THREONINE; TYROSINE KINASE; INFECTED-CELLS; SITES	Human cytomegalovirus UL97 is an unusual protein kinase that can phosphorylate nucleoside analogs such as ganciclovir but whose specificity for exogenous protein substrates has remained unknown. We found that purified, recombinant glutathione S-transferase-UL97 fusion protein can phosphorylate histone H2B. Phosphorylation was abrogated by substitution of glutamine for a conserved lysine in subdomain II and inhibited by a new antiviral drug, maribavir. Sequencing and mass spectrometric analyses of purified P-32-labeled tryptic peptides of H2B revealed that the sites of phosphorylation were, in order of extent, Ser-38, Ser-87, Ser-6, Ser-112, and Ser-124. Phosphorylation of synthetic peptides containing these sites, analyzed using a new, chimeric gel system, correlated with their phosphorylation in H2B. Phosphorylation of the Ser-38 peptide by UL97 occurred on Ser-38 and was specifically sensitive to maribavir, whereas phosphorylation of this peptide by cAMP-dependent protein kinase occurred on Ser-36. The extent of phosphorylation was greatest with peptides containing an Arg or Lys residue 5 positions downstream (P+5) from the Ser. Substitution with Ala at this position essentially eliminated activity. These results identify exogenous protein and peptide substrates of UL97, reveal an unusual dependence on the P+5 position, and may abet discovery of new inhibitors of UL97 and human cytomegalovirus replication.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Coen, DM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	Don_Coen@hms.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026077, T32AI007245] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI26077, T32 AI07245] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansari A, 1999, J VIROL, V73, P3284, DOI 10.1128/JVI.73.4.3284-3291.1999; BIRON KK, 2002, IN PRESS ANTIMICROB, V45; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; Chen MR, 2000, J VIROL, V74, P3093, DOI 10.1128/JVI.74.7.3093-3104.2000; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; DADD CA, 1993, BIOTECHNIQUES, V14, P266; Daikoku T, 1997, VIROLOGY, V235, P82, DOI 10.1006/viro.1997.8653; DEWIND N, 1992, J VIROL, V66, P5200, DOI 10.1128/JVI.66.9.5200-5209.1992; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1979, J BIOL CHEM, V254, P9728; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; He ZW, 1997, J VIROL, V71, P405, DOI 10.1128/JVI.71.1.405-411.1997; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kenyon TK, 2001, J VIROL, V75, P8854, DOI 10.1128/JVI.75.18.8854-8858.2001; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; MCGEOCH DJ, 1995, PROTEIN KINASE FACTS, V1, P391; Michel D, 1996, J VIROL, V70, P6340, DOI 10.1128/JVI.70.9.6340-6346.1996; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; Mocarski E.S., 2001, FIELDS VIROLOGY, V4th Edn, P2629; NG TI, 1992, VIROLOGY, V191, P9, DOI 10.1016/0042-6822(92)90161-H; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Prichard MN, 1999, J VIROL, V73, P5663, DOI 10.1128/JVI.73.7.5663-5670.1999; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; Roizman B., 1974, COMPREHENSIVE VIROLO, P229, DOI DOI 10.1007/978-1-4684-2703-5_4; SAMBROOK J, 1989, MOL CLONING LAB MANU, V18, P47; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SULLIVAN V, 1992, NATURE, V358, P162, DOI 10.1038/358162a0; Talarico CL, 1999, ANTIMICROB AGENTS CH, V43, P1941, DOI 10.1128/AAC.43.8.1941; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; vanZeijl M, 1997, VIROLOGY, V231, P72, DOI 10.1006/viro.1997.8523; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Wolf DG, 2001, P NATL ACAD SCI USA, V98, P1895, DOI 10.1073/pnas.98.4.1895; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	44	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29593	29599		10.1074/jbc.M202312200	http://dx.doi.org/10.1074/jbc.M202312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048183	hybrid			2022-12-25	WOS:000177509300033
J	Guo, ZY; Benten, WPM; Krucken, J; Wunderlich, F				Guo, ZY; Benten, WPM; Krucken, J; Wunderlich, F			Nongenomic testosterone calcium signaling - Genotropic actions in androgen receptor-free macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; PLASMODIUM-CHABAUDI MALARIA; ESTROGEN-INDUCED ACTIVATION; PROSTATE-CANCER CELLS; SURFACE-RECEPTORS; STEROID-HORMONES; CA2+ INFLUX; T-CELLS; INTRACELLULAR CALCIUM	Steroid hormones exert genotropic actions through members of the nuclear receptor family. Here, we have demonstrated genotropic actions of testosterone that are independent of intracellular androgen receptors (iAR). Through plasma membrane androgen receptors (mAR), testosterone induces a rapid rise in the intracellular free Ca2+ concentration of iAR-free murine RAW 264.7 macrophages. This nongenomic testosterone signaling, which is independent of both iAR and estrogen receptors, does not in itself activate either the mitogen-activated protein kinase (MAPK) families ERK1/2, p38, and JNK/SAPK, the stably and transiently transfected c-fos promoter, or NO production. In the context of lipopolysaccharide (LPS) signaling, however, testosterone attenuates LPS activation of the c-fos promoter and NO production, which is abolished by the intracellular Ca2+ chelator BAPTA. Testosterone also attenuates the LPS activation of p38 but not that of ERK1/2 and JNK/ SAPK, and this attenuation is abrogated by BAPTA. Moreover, the p38 inhibitor, SB 203580, largely reduces LPS activation of the c-fos promoter and NO production, and the remaining levels are no longer regulated by testosterone. This study is the first to provide information on genotropic actions of mAR-mediated nongenomic testosterone Ca2+ signaling by cross-talk with the LPS signaling pathway through p38 MAPK with impact on cell function.	Univ Dusseldorf, Div Mol Parasitol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Ctr Biol Med Res, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Wunderlich, F (corresponding author), Univ Dusseldorf, Div Mol Parasitol, Univ Str 1, D-40225 Dusseldorf, Germany.		Krücken, Jürgen/AAE-3133-2021; Krücken, Jürgen/B-6794-2009; Krücken, Jürgen/CAF-6903-2022	Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100; Krücken, Jürgen/0000-0002-2842-8100				Audy MC, 1996, EUR J ENDOCRINOL, V135, P367, DOI 10.1530/eje.0.1350367; Azenabor AA, 2001, BIOCHEM BIOPH RES CO, V281, P277, DOI 10.1006/bbrc.2001.4341; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benten WPM, 1997, FEBS LETT, V407, P211, DOI 10.1016/S0014-5793(97)00346-3; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Benten WPM, 1998, FEBS LETT, V422, P349, DOI 10.1016/S0014-5793(98)00039-8; BENTEN WPM, 1992, J ENDOCRINOL, V135, P407, DOI 10.1677/joe.0.1350407; Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669; BENTEN WPM, 1993, J ENDOCRINOL, V139, P487, DOI 10.1677/joe.0.1390487; Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Cato ACB, 1998, TRENDS ENDOCRIN MET, V9, P150, DOI 10.1016/S1043-2760(98)00039-3; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Chen CC, 1999, MOL PHARMACOL, V55, P481; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; COLLART MA, 1987, J IMMUNOL, V139, P949; de Jager T, 2001, J BIOL CHEM, V276, P27873, DOI 10.1074/jbc.M010984200; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Feng GJ, 1999, J IMMUNOL, V163, P6403; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Friedl R, 2000, LIFE SCI, V68, P417, DOI 10.1016/S0024-3205(00)00953-X; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Guo ZY, 2002, J BIOL CHEM, V277, P7044, DOI 10.1074/jbc.M109808200; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Krucken J, 1999, J BIOL CHEM, V274, P24383, DOI 10.1074/jbc.274.34.24383; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANTINHERMOSO RL, 1997, AM J PHYSIOL, V273, P119; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; Lyng FM, 2000, BIOL REPROD, V63, P736, DOI 10.1095/biolreprod63.3.736; Machelon V, 1996, J CELL BIOCHEM, V61, P619, DOI 10.1002/(SICI)1097-4644(19960616)61:4<619::AID-JCB16>3.0.CO;2-A; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Picard D, 1998, NATURE, V392, P437, DOI 10.1038/33014; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Wunderlich F, 2002, STEROIDS, V67, P535, DOI 10.1016/S0039-128X(01)00175-1; WUNDERLICH F, 1993, VACCINE, V11, P1097, DOI 10.1016/0264-410X(93)90068-9; WUNDERLICH F, 1991, PARASITE IMMUNOL, V13, P357, DOI 10.1111/j.1365-3024.1991.tb00289.x; WUNDERLICH F, 1988, INFECT IMMUN, V56, P2400, DOI 10.1128/IAI.56.9.2400-2406.1988; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	60	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29600	29607		10.1074/jbc.M202997200	http://dx.doi.org/10.1074/jbc.M202997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048191	hybrid			2022-12-25	WOS:000177509300034
J	Handschin, C; Podvinec, M; Amherd, R; Looser, R; Ourlin, JC; Meyer, UA				Handschin, C; Podvinec, M; Amherd, R; Looser, R; Ourlin, JC; Meyer, UA			Cholesterol and bile acids regulate xenosensor signaling in drug-mediated induction of cytochromes P450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; PREGNANE-X RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CHICKEN XENOBIOTIC RECEPTOR; HUMAN LIVER-MICROSOMES; RAT HEPATOCYTES; TRANSCRIPTIONAL ACTIVATION; ANTIEPILEPTIC DRUGS; HORMONE RECEPTORS; LITHOCHOLIC ACID	Cytochromes P450 (CYP) constitute the major enzymatic system for metabolism of xenobiotics. Here we demonstrate that transcriptional activation of CYPs by the drug-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and the chicken xenobiotic receptor (CXR) can be modulated by endogenous cholesterol and bile acids. Bile acids induce the chicken drug-activated CYP2H1 via CXR, whereas the hydroxylated metabolites of bile acids and oxysterols inhibit drug induction. The cholesterol-sensing liver X receptor competes with CXR, pregnane X receptor, or constitutive androstane receptor for regulation of drug-responsive enhancers from chicken CYP2H1, human CYP3A4, or human CYP2B6, respectively. Thus, not only cholesterol 7alpha-hydroxylase (CYP7A1), but also drug-inducible CYPs, are diametrically affected by these receptors. Our findings reveal new insights into the increasingly complex network of nuclear receptors regulating lipid homeostasis and drug metabolism.	Univ Basel, Biozentrum, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Div Pharmacol Neurobiol, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.		Handschin, Christoph/E-6886-2015	Handschin, Christoph/0000-0003-0603-1097; Podvinec, Michael/0000-0002-3267-2173				ANDERSSON M, 1994, BBA-LIPID LIPID MET, V1214, P79, DOI 10.1016/0005-2760(94)90012-4; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; Aynaci FM, 2001, J CHILD NEUROL, V16, P367; BACK P, 1987, PHARMACOL THERAPEUT, V33, P153, DOI 10.1016/0163-7258(87)90044-1; BLOUIN RA, 1993, ARCH BIOCHEM BIOPHYS, V303, P313, DOI 10.1006/abbi.1993.1289; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; Cancado ELR, 1998, AM J GASTROENTEROL, V93, P1510, DOI 10.1111/j.1572-0241.1998.00472.x; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; EIRIS JM, 1995, NEUROLOGY, V45, P1155, DOI 10.1212/WNL.45.6.1155; Fischer S, 1996, CLIN CHIM ACTA, V251, P173, DOI 10.1016/0009-8981(96)06305-X; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; Gan XD, 2001, J BIOL CHEM, V276, P48702, DOI 10.1074/jbc.M109402200; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2001, MOL PHARMACOL, V60, P681; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kocarek TA, 1998, MOL PHARMACOL, V54, P474, DOI 10.1124/mol.54.3.474; KOCAREK TA, 1993, TOXICOL APPL PHARM, V120, P298, DOI 10.1006/taap.1993.1115; Kocarek TA, 1998, BIOCHEM PHARMACOL, V55, P1435, DOI 10.1016/S0006-2952(97)00658-8; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Ourlin JC, 2002, BIOCHEM BIOPH RES CO, V291, P378, DOI 10.1006/bbrc.2002.6464; Penzak SR, 2000, SCAND J INFECT DIS, V32, P111; Plewka A, 1996, EXP TOXICOL PATHOL, V48, P249, DOI 10.1016/S0940-2993(96)80009-1; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Schwaninger M, 2000, J NEUROL, V247, P687, DOI 10.1007/s004150070111; Sehayek E, 2001, J LIPID RES, V42, P1250; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUDJANASUGIAMAN E, 1994, J LIPID RES, V35, P319; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; THOMAS KD, 1984, ISRAEL J MED SCI, V20, P240; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Verrotti A, 1997, J PAEDIATR CHILD H, V33, P242, DOI 10.1111/j.1440-1754.1997.tb01588.x; Watanabe M, 1996, MED SCI RES, V24, P257; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wietholtz H, 1996, J HEPATOL, V24, P713, DOI 10.1016/S0168-8278(96)80268-6; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yilmaz E, 2001, ACTA NEUROL BELG, V101, P217	59	54	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29561	29567		10.1074/jbc.M202739200	http://dx.doi.org/10.1074/jbc.M202739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12045201	Green Accepted, hybrid			2022-12-25	WOS:000177509300029
J	Kamura, T; Brower, CS; Conaway, RC; Conaway, JW				Kamura, T; Brower, CS; Conaway, RC; Conaway, JW			A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; F-BOX PROTEINS; CELL-CYCLE; DEPENDENT PROTEOLYSIS; COMPLEX; DEGRADATION; SCF; BINDING; SYSTEM	The multiprotein von Hippel-Lindau (VHL) tumor suppressor (CBCVHL, Cul2-Elongin BC-VHL) and SCF (Skp1-Cul1/Cdc53-F-box protein) complexes are members of structurally related families of E3 ubiquitin ligases that use a heterodimeric module composed of a member of the Cullin protein family and the RING finger protein Rbx1 (ROC1/Hrt1) to activate ubiquitylation of target proteins by the E2 ubiquitin-conjugating enzymes Ubc5 and Cdc34. VHL and F-box proteins function as the substrate recruitment subunits of CBCVHL and SCF complexes, respectively. In cells, many F-box proteins are short lived and are proposed to be ubiquitylated by an autocatalytic mechanism and destroyed by the proteasome following assembly into SCF complexes. In contrast, the VHL protein is stabilized by interaction with the Elongin B and C subunits of CBCVHL in cells. In this report, we have presented direct biochemical evidence that unlike the F-box protein Cdc4, which is ubiquitylated in vitro by Cdc34 in the context of the SCF, the VHL protein is protected from Ubc5-catalyzed ubiquitylation following assembly into the CBCVHL complex. CBCVHL is continuously required for negative regulation of hypoxia-inducible transcription factors in normoxic cells and of SCF complexes, many of which function only transiently during the cell cycle or in response to cellular signals. Our findings provide a molecular basis for the different modes of cellular regulation of VHL and F-box proteins and are consistent with the known roles of CBCVHL.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; CALTECH, Pasadena, CA 91125 USA	Stowers Institute for Medical Research; Kyushu University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Kansas; University of Kansas Medical Center; California Institute of Technology	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.			Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	37	51	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30388	30393		10.1074/jbc.M203344200	http://dx.doi.org/10.1074/jbc.M203344200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048197	hybrid, Green Accepted			2022-12-25	WOS:000177509300126
J	Lu, ZX; Murray, JT; Luo, WJ; Li, HL; Wu, XP; Xu, HX; Backer, JM; Chen, YG				Lu, ZX; Murray, JT; Luo, WJ; Li, HL; Wu, XP; Xu, HX; Backer, JM; Chen, YG			Transforming growth factor beta activates Smad2 in the absence of receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FYVE DOMAIN PROTEIN; MEDIATED ENDOCYTOSIS; DISTINCT ROLES; I RECEPTOR; SIGNAL; CLATHRIN; DYNAMIN; INTERNALIZATION; HRS	Like many other cell surface receptors, transforming growth factor beta (TGF-beta) receptors are internalized upon ligand stimulation. Given that the signaling-facilitating molecules Smad anchor for receptor activation (SARA) and Hrs are mainly localized in early endosomes, it was unclear whether receptor internalization is required for Smad2 activation. Using reversible biotin labeling, we directly monitored internalization of the TGF-beta type I receptor. Our data indicate that TGF-beta type I receptor is endocytosed via a clathrin-dependent mechanism and is effectively blocked by depletion of intracellular potassium or by expression of a mutant dynamin (K44A). However, blockage of receptor endocytosis by these two means has no effect on TGF-beta-mediated Smad2 activation. Furthermore, TGF-beta-induced Smad2 activation was unaffected by inhibition of hVPS34 activity with wortmannin or inhibitory anti-hVPS34 antibodies. Finally, we demonstrated that Smad2 interacted with cell surface receptors and that a SARA binding-deficient Smad2 mutant was phosphorylated by the receptors. Thus, our findings suggest that receptor endocytosis is dispersible for TGF-beta-mediated activation of Smad2 and that this activation can be mediated by both SARA-dependent and -independent mechanisms.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of California System; University of California Riverside; Yeshiva University; Albert Einstein College of Medicine; Rockefeller University	Chen, YG (corresponding author), Univ Calif Riverside, Div Biomed Sci, 1413 Webber Hall, Riverside, CA 92521 USA.	yeguang.chen@ucr.edu	Luo, Wenjie/ABF-8451-2020; Murray, James/AAC-6612-2019; Lu, ZX/G-4586-2010; Xu, Huaxi/AAV-7177-2021	Murray, James/0000-0002-6928-2347; 	NIA NIH HHS [P01 AG009464, AG09464] Funding Source: Medline; NIGMS NIH HHS [GM55692] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ehrlich M, 2001, J CELL SCI, V114, P1777; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Marmorstein AD, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P341; Massague J, 2000, GENE DEV, V14, P627; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pasche B, 1999, CANCER RES, V59, P5678; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	31	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29363	29368		10.1074/jbc.M203495200	http://dx.doi.org/10.1074/jbc.M203495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034739	hybrid			2022-12-25	WOS:000177509300004
J	Takemoto, CM; Yoon, YH; Fisher, DE				Takemoto, CM; Yoon, YH; Fisher, DE			The identification and functional characterization of a novel mast cell isoform of the microphthalmia-associated transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MUTANT MICE; IMPAIRED EXPRESSION; GENE-EXPRESSION; INVOLVEMENT; RECEPTOR; ZIPPER; LOCUS; MUTATIONS; KINASE	The microphthalmia-associated transcription factor (Mitf) is critical for mast cell development based on the severe mast cell deficiency seen in Mitf mutant mice. Mitf also is important for the development of melanocytes, osteoclasts, and retinal pigment epithelium. The lineage-restricted phenotypes of Mitf mutations correlate with tissue-restricted expression of Mitf, a feature due in part to the presence of several distinct Mitf isoforms. We report the identification and characterization of a novel mast cell isoform, Mitf-mc. This isoform arises from alternative splicing of a novel 5'-exon onto the common body of the gene and is predicted to encode a unique 43-amino acid sequence at its amino terminus. It is specifically expressed in mast cells. The mast cell isoform functions differently from the melanocyte isoform in its ability to activate cell type-specific Mitf gene targets. Mitf-me functions only on a mast cell target promoter and fails to activate a melanocyte target promoter despite binding to its E-box element. Moreover, Mitf-me heterodimerizes with a closely related transcription factor, Tfe3, and dominantly inhibits the ability of Tfe3 to transactivate a melanocyte-specific promoter. These studies identify a new isoform of Mitf with tissue-specific features that may underlie key aspects of the mast cell phenotype of Mitf mutations.	Johns Hopkins Univ, Div Pediat Hematol, Baltimore, MD 21205 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Johns Hopkins University; Harvard University; Dana-Farber Cancer Institute	Takemoto, CM (corresponding author), Johns Hopkins Univ, Div Pediat Hematol, 720 Rutland Ave, Baltimore, MD 21205 USA.	etakemot@jhmi.edu	Takemoto, Clifford M/Y-7558-2018		NHLBI NIH HHS [K08HL03700-05] Funding Source: Medline; NICHD NIH HHS [P30HD27799] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003700] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi S, 2000, J IMMUNOL, V164, P855, DOI 10.4049/jimmunol.164.2.855; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; Amiel J, 1998, CLIN DYSMORPHOL, V7, P17; Fuse N, 1999, J BIOCHEM-TOKYO, V126, P1043, DOI 10.1093/oxfordjournals.jbchem.a022548; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Hallsson JH, 2000, GENETICS, V155, P291; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; Jippo T, 1999, BLOOD, V93, P1942, DOI 10.1182/blood.V93.6.1942.406k08_1942_1950; Jippo T, 1997, BLOOD, V90, P2601, DOI 10.1182/blood.V90.7.2601.2601_2601_2608; Kim DK, 1998, BLOOD, V92, P1973, DOI 10.1182/blood.V92.6.1973.418k23_1973_1980; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; Oboki K, 2002, BIOCHEM BIOPH RES CO, V290, P1250, DOI 10.1006/bbrc.2002.6332; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIBAHARA S, 1992, PIGM CELL RES, P90; Smith SD, 2000, J MED GENET, V37, P446, DOI 10.1136/jmg.37.6.446; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; STEVENS J, 1982, PROC R SOC SER B-BIO, V215, P405, DOI 10.1098/rspb.1982.0050; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494	36	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30244	30252		10.1074/jbc.M201441200	http://dx.doi.org/10.1074/jbc.M201441200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039954	hybrid			2022-12-25	WOS:000177509300110
J	Fujita, N; Sato, S; Katayama, K; Tsuruo, T				Fujita, N; Sato, S; Katayama, K; Tsuruo, T			Akt-dependent phosphorylation of p27(Kip1) promotes binding to 14-3-3 and cytoplasmic localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; KINASE INHIBITOR P27(KIP1); CELL-CYCLE ARREST; COMPLEX-FORMATION; TUMOR-SUPPRESSOR; CDK INHIBITORS; P27; PROTEIN; PATHWAY; PROLIFERATION	In many human cancers, the cyclin-dependent kinase inhibitor P27(Kip1) is expressed at low or undetectable levels. The decreased p27(Kip1) expression allows cyclin-dependent kinase activity to cause cells to enter into S phase and correlates with poor patient survival. Inhibition of serine/threonine kinase Akt signaling by some pharmacological agents or by PTEN induces G, arrest, in part by up-regulating p27(Kip1). However, the role of Akt-dependent phosphorylation in p27(Kip1) regulation is not clear. Here, we show that Akt bound directly to and phosphorylated p27(Kip1). Screening p27(Kip1) phosphorylation sites identified the COOH-terminal Thr(198) residue as a novel site. Further analysis revealed that 14-3-3 proteins bound to p27(Kip1) through Thr(198) only when it was phosphorylated by Akt. Although Akt also phosphorylated p27(Kip1) at Ser(10) and Thr(187), these two sites were not involved in the binding to 14-3-3 proteins. p27(Kip1) phosphorylated at Thr(198) exists only in the cytoplasm. Therefore, Akt promotes cell-cycle progression through the mechanisms of phosphorylation-dependent 14-3-3 binding to p27(Kip1) and cytoplasmic localization.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Katayama, Kazuhiro/AAH-2914-2019	Katayama, Kazuhiro/0000-0003-4232-7661; Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zeng Y, 2000, BIOCHEM BIOPH RES CO, V274, P37, DOI 10.1006/bbrc.2000.3098; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	290	304	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28706	28713		10.1074/jbc.M203668200	http://dx.doi.org/10.1074/jbc.M203668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042314	hybrid			2022-12-25	WOS:000177342600048
J	Heinzer, AK; Kemp, S; Lu, JF; Watkins, PA; Smith, KD				Heinzer, AK; Kemp, S; Lu, JF; Watkins, PA; Smith, KD			Mouse very long-chain acyl-CoA synthetase in X-linked adrenoleukodystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID METABOLISM; PROTEIN-DEFICIENT MICE; HUMAN-SKIN FIBROBLASTS; RAT-LIVER PEROXISOMES; COENZYME-A SYNTHETASE; BETA-OXIDATION; CHILDHOOD ADRENOLEUKODYSTROPHY; SACCHAROMYCES-CEREVISIAE; TRANSPORT PROTEIN; CDNA CLONING	X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disorder characterized by accumulation of very long-chain fatty acids (VLCFA). This accumulation has been attributed to decreased VLCFA beta-oxidation and peroxisomal very long-chain acyl-CoA synthetase (VLCS) activity. The X-ALD gene, ABCD1, encodes a peroxisomal membrane ATP binding cassette transporter, ALDP, that is hypothesized to affect VLCS activity in peroxisomes by direct interaction with the VLCS enzyme. Recently, a VLCS gene that encodes a protein with significant sequence identity to known rat and human peroxisomal VLCS protein has been identified in mice. We find that the mouse VLCS gene (Vlcs) encodes an enzyme (Vlcs) with VLCS activity that localizes to peroxisomes and is expressed in X-ALD target tissues. We show that the expression of Vlcs in the peroxisomes of X-ALD mouse fibroblasts improves VLCFA beta-oxidation in these cells, implying a role for this enzyme in the biochemical abnormality of X-ALD. X-ALD mice, which accumulate VLCFA in tissues, show no change in the expression of Vlcs, the subcellular localization of Vlcs, or general peroxisomal VLCS activity. These observations imply that ALDP is not necessary for the proper expression or localization of Vlcs protein, and the control of VLCFA levels does not depend on the direct interaction of Vlcs and ALDP.	Johns Hopkins Univ, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21205 USA; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands; Fu Jen Catholic Univ, Sch Med, Hsinchuang, Taipei Hsien, Taiwan	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Fu Jen Catholic University	Smith, KD (corresponding author), Johns Hopkins Univ, Kennedy Krieger Inst, Rm 400A,707 N Broadway, Baltimore, MD 21205 USA.		Kemp, Stephan/A-3935-2008	Kemp, Stephan/0000-0003-2023-064X; Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD10981] Funding Source: Medline; NIGMS NIH HHS [2T32GM07814] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berger J, 1998, FEBS LETT, V425, P305, DOI 10.1016/S0014-5793(98)00255-5; Berger J, 1998, BIOCHEM BIOPH RES CO, V247, P255, DOI 10.1006/bbrc.1998.8770; Bezman L, 2001, ANN NEUROL, V49, P512, DOI 10.1002/ana.101; Braiterman LT, 1998, HUM MOL GENET, V7, P239, DOI 10.1093/hmg/7.2.239; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; Hogan B, 1994, MANIPULATING MOUSE E; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; MOSER HW, 2000, METABOLIC MOL BASES, V3, P3257; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Netik A, 1999, HUM MOL GENET, V8, P907, DOI 10.1093/hmg/8.5.907; Pujol A, 2002, HUM MOL GENET, V11, P499, DOI 10.1093/hmg/11.5.499; RIZZO WB, 1984, NEUROLOGY, V34, P163, DOI 10.1212/WNL.34.2.163; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; SHINNOH N, 1995, BIOCHEM BIOPH RES CO, V210, P830, DOI 10.1006/bbrc.1995.1733; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V254, P526, DOI 10.1016/0003-9861(87)90133-0; SINGH I, 1981, BIOCHEM BIOPH RES CO, V102, P1223, DOI 10.1016/S0006-291X(81)80142-8; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, ANN NEUROL, V46, P409, DOI 10.1002/1531-8249(199909)46:3<409::AID-ANA18>3.0.CO;2-9; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida Y, 1996, J BIOCHEM, V119, P565; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; WANDERS RJA, 1988, LANCET, V2, P170; WANDERS RJA, 1987, CLIN CHIM ACTA, V166, P255, DOI 10.1016/0009-8981(87)90428-1; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1996, J LIPID RES, V37, P2288; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; WATKINS PA, 1995, AM J HUM GENET, V57, P292; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Yamada T, 1999, NEUROLOGY, V52, P614, DOI 10.1212/WNL.52.3.614; Yamada T, 2000, CELL BIOCHEM BIOPHYS, V32, P239, DOI 10.1385/CBB:32:1-3:239	48	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28765	28773		10.1074/jbc.M203053200	http://dx.doi.org/10.1074/jbc.M203053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048192	hybrid			2022-12-25	WOS:000177342600055
J	Hyun, DH; Lee, M; Hattori, N; Kubo, SI; Mizuno, Y; Halliwell, B; Jenner, P				Hyun, DH; Lee, M; Hattori, N; Kubo, SI; Mizuno, Y; Halliwell, B; Jenner, P			Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; CU/ZN-SUPEROXIDE DISMUTASES; SUBSTANTIA-NIGRA; ALPHA-SYNUCLEIN; HYDROGEN-PEROXIDE; PROTEIN CARBONYLS; HUMAN BRAIN; UBIQUITIN; DNA; ACID	Mutations in Parkin (a ubiquitin protein ligase) are involved in autosomal recessive juvenile parkinsonism, but it is not known how they cause nigral cell death. We examined the effect of Parkin overexpression on cellular levels of oxidative damage, antioxidant defenses, nitric oxide production, and proteasomal enzyme activity. Increasing expression of Parkin by gene transfection in NT-2 and SK-N-MC cells led to increased proteasomal activity, decreased levels of protein carbonyls, 3-nitro-tyrosine-containing proteins, and a trend to a reduction in ubiquitinated protein levels. Transfection of these cells with DNA encoding three mutant Parkins associated with autosomal recessive juvenile parkinsonism (Del 3-5, T240R, and Q311X) gave smaller increases in proteasomal activity and led to elevated levels of protein carbonyls and lipid peroxidation. Turnover of the mutant proteins was slower than that of the wild-type protein, and both could be blocked by the proteasome inhibitor, lactacystin. A rise in levels of nitrated proteins and increased levels of NO(2) over bar/NO(3) over bar was also observed in cells transfected with mutant Parkins, apparently because of increased levels of neuronal nitric-oxide synthase. The presence of mutant Parkin in substantia nigra in juvenile parkinsonism may increase oxidative stress and nitric oxide production, sensitizing cells to death induced by other insults.	Kings Coll London, Wolfson Ctr Age Related Dis, GKT, Sch Biomed Sci, London SE1 1UL, England; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	University of London; King's College London; Juntendo University; National University of Singapore	Jenner, P (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, GKT, Sch Biomed Sci, London SE1 1UL, England.	div.pharm@kcl.ac.uk	Jenner, Peter G/M-3288-2013; Hattori, Nobutaka/ACR-0069-2022; Halliwell, Barry/C-8318-2009	Halliwell, Barry/0000-0002-3560-7123				Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; ANGULO A, 1995, J VIROL, V69, P3831, DOI 10.1128/JVI.69.6.3831-3837.1995; Beal MF, 1997, NEUROSCIENTIST, V3, P21, DOI 10.1177/107385849700300112; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BIEDLER JL, 1978, CANCER RES, V38, P3751; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; CHIRICO S, 1994, METHOD ENZYMOL, V233, P314; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Halliwell B, 1998, LANCET, V351, P1510, DOI 10.1016/S0140-6736(05)78898-X; Halliwell B., 1999, FREE RADICAL BIO MED, Vthird, P246; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; ISHIKAWA A, 1998, J NEUROL S3, V245; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kaur H, 1996, BIOCHEM J, V318, P21, DOI 10.1042/bj3180021; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kelner GS, 2000, J BIOL CHEM, V275, P580, DOI 10.1074/jbc.275.1.580; Khan J, 1998, BIOCHEM J, V332, P808; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klein C, 2000, ANN NEUROL, V48, P126, DOI 10.1002/1531-8249(200007)48:1<126::AID-ANA22>3.3.CO;2-B; Klein C, 2000, ANN NEUROL, V48, P65, DOI 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L; Korneev SA, 1999, J NEUROSCI, V19, P7711; Kruger R, 1999, J NEURAL TRANSM, V106, P159, DOI 10.1007/s007020050148; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lee M, 2001, J NEUROCHEM, V76, P957, DOI 10.1046/j.1471-4159.2001.00107.x; Lee M, 2001, J NEUROCHEM, V78, P209, DOI 10.1046/j.1471-4159.2001.00417.x; Lee MH, 2001, J NEUROCHEM, V78, P32, DOI 10.1046/j.1471-4159.2001.00416.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lyras L, 1998, J NEUROCHEM, V71, P302; Lyras L, 1997, J NEUROCHEM, V68, P2061; Lyras L, 1996, FREE RADICAL RES, V24, P397, DOI 10.3109/10715769609088038; McNaught KSP, 2000, BIOCHEM PHARMACOL, V60, P979, DOI 10.1016/S0006-2952(00)00415-9; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Mizuno Y, 2001, CURR OPIN NEUROL, V14, P477, DOI 10.1097/00019052-200108000-00008; Nisipeanu P, 1999, NEUROLOGY, V53, P1602, DOI 10.1212/WNL.53.7.1602; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; SIAN J, 1994, ANN NEUROL, V36, P356, DOI 10.1002/ana.410360306; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Takanashi M, 2001, PARKINSONISM RELAT D, V7, P311, DOI 10.1016/S1353-8020(00)00050-X; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V258, P168, DOI 10.1006/bbrc.1999.0564; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	61	139	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28572	28577		10.1074/jbc.M200666200	http://dx.doi.org/10.1074/jbc.M200666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034719	hybrid			2022-12-25	WOS:000177342600030
J	Li, ZQ; Hou, WS; Escalante-Torres, CR; Gelb, BD; Bromme, D				Li, ZQ; Hou, WS; Escalante-Torres, CR; Gelb, BD; Bromme, D			Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; COLLAGENOLYTIC ACTIVITY; SUBSTRATE-SPECIFICITY; OSTEOCLASTS; EXPRESSION; IDENTIFICATION; STABILITY; HEPARIN; REGION	Bone resorption in balance with bone formation is vital for the maintenance of the skeleton and is mediated by osteoclasts. Cathepsin K is the predominant protease in osteoclasts that degrades the bulk of the major bone forming organic component, type I collagen. Although the potent collagenase activity of cathepsin K is well known, its mechanism of action remains elusive. Here, we report a cathepsin K-specific complex with chondroitin sulfate, which is essential for the collagenolytic activity of the enzyme. The complex is an oligomer consisting of five cathepsin K and five chondroitin sulfate molecules. Only the complex exhibits potent triple helical collagen-degrading activity, whereas monomeric cathepsin K has no collagenase activity. The primary substrate specificity of cathepsin K is not altered by complex formation, suggesting that the protease-chondroitin sulfate complex primarily facilitates the destabilization and/or the specific binding of the triple helical collagen structure. Inhibition of complex formation leads to the loss of collagenolytic activity but does not impair the proteolytic activity of cathepsin K toward noncollagenous substrates. The physiological relevance of cathepsin K complexes is supported by the findings that (i) the content of chondroitin sulfate present in bone and accessible to cathepsin K activity is sufficient for complex formation and (ii) Y212C, a cathepsin K mutant that causes pyenodysostosis (a bone sclerosing disorder) and that has no collagenase activity but remains potent as a gelatinase, is unable to form complexes. These findings reveal a novel mechanism of bone collagen degradation and suggest that targeting cathepsin K complex formation would be an effective and specific treatment for diseases with excessive bone resorption such as osteoporosis.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bromme, D (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave 100 St, New York, NY 10029 USA.	Dieter.Bromme@mssm.edu			NIAMS NIH HHS [AR46182, AR 48669] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182, R01AR048669] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; Almeida PC, 1999, J BIOL CHEM, V274, P30433, DOI 10.1074/jbc.274.43.30433; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Chung L, 2000, PEPTIDES FOR THE NEW MILLENNIUM, P438; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GELB BD, 2001, METABOLIC MOL BASES, P3453; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Hou WS, 1999, J CLIN INVEST, V103, P731, DOI 10.1172/JCI653; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KomsaPenkova R, 1996, BBA-PROTEIN STRUCT M, V1297, P171, DOI 10.1016/S0167-4838(96)00092-1; KRANE SM, 1994, SCI AM MED, V3, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; MALLYA SK, 1992, J PROTEIN CHEM, V11, P99, DOI 10.1007/BF01025096; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; Meghji S, 2001, AM J PHYSIOL-ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; Smith AJ, 1997, HISTOCHEM J, V29, P1, DOI 10.1023/A:1026406932452; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669	34	138	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28669	28676		10.1074/jbc.M204004200	http://dx.doi.org/10.1074/jbc.M204004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039963	hybrid			2022-12-25	WOS:000177342600043
J	Matsumoto, H; Ma, WG; Daikoku, T; Zhao, XM; Paria, BC; Das, SK; Trzaskos, JM; Dey, SK				Matsumoto, H; Ma, WG; Daikoku, T; Zhao, XM; Paria, BC; Das, SK; Trzaskos, JM; Dey, SK			Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; MOUSE UTERUS; DEVELOPMENTAL EXPRESSION; VASCULAR-PERMEABILITY; PECAM-1 CD31; CELLS; GENE; VASCULOGENESIS; ANGIOPOIETIN-1	Increased vascular permeability and angiogenesis at the site of blastocyst apposition in the uterus are two hallmarks of the implantation process. The present investigation shows that although the proangiogenic vascular endothelial growth factor (VEGF) and its receptor, Flk-1, are primarily important for uterine vascular permeability and angiogenesis prior to and during the attachment phase of the implantation process, VEGF in complementation with the angiopoietins and their receptor, Tie-2, directs angiogenesis during decidualization following implantation. Mice with null mutation for the gene encoding cyclooxygenase-2 (COX-2), a rate-limiting enzyme in prostaglandin (PG) biosynthesis, show implantation and decidualization failure. Using reporter and mutant mice, we show here that COX-2-derived prostaglandins (PGs) are important for uterine vascular permeability and angiogenesis during implantation and decidualization, suggesting that one cause of the failure of these latter processes in Cox-2(-/-) mice is the deregulated vascular events in the absence of COX-2. The attenuation of uterine angiogenesis in these mice is primarily due to defective VEGF signaling and not due to the defective angiopoietin system.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pediat, Ralph L Smith Res Ctr, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Obstet & Gynecol, Ralph L Smith Res Ctr, Kansas City, KS 66160 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Wilmington, DE 19880 USA; Tohoku Univ, Grad Sch Agr Sci, Lab Anim Reprod, Sendai, Miyagi 9818555, Japan	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Bristol-Myers Squibb; Tohoku University	Dey, SK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, MCN-D4100, Nashville, TN 37232 USA.				NICHD NIH HHS [HD12304, HD33994, HD40193, HD29968, HD37394] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD040193, U01HD029968, R01HD012304, R01HD037394, R37HD012304] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; CHAKRABORTY I, 1995, J ENDOCRINOL, V147, P339, DOI 10.1677/joe.0.1470339; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Halder JB, 2000, GENESIS, V26, P213, DOI 10.1002/(SICI)1526-968X(200003)26:3<213::AID-GENE7>3.0.CO;2-M; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hogan B, 1994, MANIPULATING MOUSE E; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Ma W, 2001, MOL ENDOCRINOL, V15, P1983, DOI 10.1210/me.15.11.1983; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsumoto H, 2001, BIOL REPROD, V64, P1557, DOI 10.1095/biolreprod64.5.1557; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seno H, 2002, CANCER RES, V62, P506; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; Zachary I, 1998, INT J BIOCHEM CELL B, V30, P1169, DOI 10.1016/S1357-2725(98)00082-X	48	124	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29260	29267		10.1074/jbc.M203996200	http://dx.doi.org/10.1074/jbc.M203996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034746	hybrid			2022-12-25	WOS:000177342600115
J	Powell, AK; Fernig, DG; Turnbull, JE				Powell, AK; Fernig, DG; Turnbull, JE			Fibroblast growth factor receptors 1 and 2 interact differently with heparin/heparan sulfate - Implications for dynamic assembly of a ternary signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CELL-SURFACE; STRUCTURAL REQUIREMENTS; CRYSTAL-STRUCTURE; MOLECULAR-WEIGHT; LIGAND-BINDING; FACTOR FAMILY; BASIC FGF; PROTEOGLYCANS; AFFINITY	Heparan sulfate (HS) regulates the kinetics of fibroblast growth factor 2 (FGF2)-stimulated intracellular signaling and differentially activates cell proliferation of cells expressing different FGF receptors (FGFRs). Evidence suggests that HS interacts with both FGFs and FGFRs to form active ternary signaling complexes. Here we compare the interactions of two FGFRs with HS. We show that the ectodomains of FGFR1 IIIc and FGFR2 IIIc exhibit specific interactions with different characteristics for both heparin and porcine mucosal HS. These glycans are both known to activate FGF signaling via these receptors. FGFR2 interacts with a higher apparent affinity than FGFR1 despite both involving 6-O-, 2-O-, and N-sulfates. FGFR1 and FGFR2 bind heparin with mean association rate constants of 1.9 x 10(5) and 2.1 x 10(6) m-s(-1), respectively, and dissociation rate constants of 1.2 x 10(-2) and 2.7 x 10(-2) s(-1), respectively. These produced calculated affinities of 63 and 13 nm, respectively. Hence, FGFR1 and FGFR2 bind to heparin chains with markedly different kinetics and affinities. We propose a mechanistic model where the kinetic parameters of the HS/FGFR interaction are a key element regulating the formation of ternary complexes and the resulting FGF signaling outcomes.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Birmingham; University of Liverpool	Turnbull, JE (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.		Powell, Andrew/E-4491-2010; Malik, Sharali/F-7450-2010; Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293				Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BREKKE OH, 1995, IMMUNOL TODAY, V16, P85, DOI 10.1016/0167-5699(95)80094-8; Brickman YG, 1998, GLYCOBIOLOGY, V8, P463, DOI 10.1093/glycob/8.5.463; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carrasco B, 2001, BIOPHYS CHEM, V93, P181, DOI 10.1016/S0301-4622(01)00220-4; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; Conrad H. E., 1998, HEPARIN BINDING PROT; Delehedde M, 2000, J BIOL CHEM, V275, P33905, DOI 10.1074/jbc.M005949200; Delehedde M, 2001, J MAMMARY GLAND BIOL, V6, P253, DOI 10.1023/A:1011367423085; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; Fernig DG, 1992, GROWTH FACTORS, V7, P27, DOI 10.3109/08977199209023935; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; Hricovini M, 1997, CARBOHYD RES, V300, P69, DOI 10.1016/S0008-6215(97)00036-0; Hsu YR, 1999, BIOCHEMISTRY-US, V38, P2523, DOI 10.1021/bi9821317; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kinsella L, 1998, GLYCOCONJUGATE J, V15, P419, DOI 10.1023/A:1006986104865; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kwan CP, 2001, J BIOL CHEM, V276, P23421, DOI 10.1074/jbc.M010786200; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LaRochelle WJ, 1999, BIOCHEMISTRY-US, V38, P1765, DOI 10.1021/bi982092z; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LEE WT, 1984, J EXP MED, V159, P1790, DOI 10.1084/jem.159.6.1790; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; POWELL AK, 2001, THESIS U BIRMINGHAM; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stringer SE, 1999, J BIOL CHEM, V274, P25455, DOI 10.1074/jbc.274.36.25455; Uematsu F, 2000, BIOCHEM BIOPH RES CO, V272, P830, DOI 10.1006/bbrc.2000.2872; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Yates EA, 2000, CARBOHYD RES, V329, P239, DOI 10.1016/S0008-6215(00)00144-0; Yates EA, 1996, CARBOHYD RES, V294, P15; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	66	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28554	28563		10.1074/jbc.M111754200	http://dx.doi.org/10.1074/jbc.M111754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034712	hybrid			2022-12-25	WOS:000177342600028
J	Sasazuki, T; Sawada, T; Sakon, S; Kitamura, T; Kishi, T; Okazaki, T; Katano, M; Tanaka, M; Watanabe, M; Yagita, H; Okumura, K; Nakano, H				Sasazuki, T; Sawada, T; Sakon, S; Kitamura, T; Kishi, T; Okazaki, T; Katano, M; Tanaka, M; Watanabe, M; Yagita, H; Okumura, K; Nakano, H			Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; NF-KAPPA-B; MEDIATED EXPRESSION CLONING; C-FOS PROMOTER; TERNARY COMPLEX; KINASE; GENE; APOPTOSIS; RECEPTOR; LEUKEMIA	Tumor necrosis factor (TNF) is a multifunctional cytokine, which induces proliferation or death in a cell type-dependent manner. We previously showed that murine embryonic fibroblasts (MEFs) from TNF receptor-associated factor 2 (Traft) and Trat5 double-deficient (double knockout (DKO)) mice were highly susceptible to TNF-induced cell death. By functional cloning to rescue DKO MEFs from TNF-induced cell death, we have identified a novel gene, Bsac. BSAC is composed of N-terminal basic, SAP (SAF-A/B, Acinus, PIAS), and coiled-coil domains. BSAC is a nuclear protein, and overexpression of BSAC potently activates promoters containing A + T-rich sequences named CArG boxes. Domain mapping analysis revealed that both N-terminal basic and C-terminal proline-rich sequence are required for the transcriptional activity. Overexpression of BSAC in DKO MEFs partially inhibited TNF-induced cell death by suppressing activation of caspases. Interestingly, inhibition of TNF-induced cell death was not observed in DKO MEFs transfected with either N-terminal or C-terminal deletion mutant of BSAC, revealing an intimate correlation between transcriptional activity and antiapoptotic function. Recently, a human homologue of BSAC named MAL/MKL1 (megakaryocytic acute leukemia/megakaryoblastic leukemia-1) was identified as a fusion transcript generated by t(1,22) translocation in acute megakaryoblastic leukemia. Collectively, BSAC is a novel transcriptional activator with antiapoptotic function, which may be involved in the leukemogenesis.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Shibuya Ku, Tokyo 1510053, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Higashi Ku, Fukuoka 8128582, Japan; Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan	Juntendo University; Japan Science & Technology Agency (JST); Kyushu University; Kyushu University; Tokyo Medical & Dental University (TMDU); University of Tokyo	Nakano, H (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Kitamura, Toshio/AAA-2071-2021	OKAZAKI, TATSUMA/0000-0002-7110-3168; Nakano, Hiroyasu/0000-0003-4843-1427; Komazawa-Sakon, Sachiko/0000-0002-6244-1974				Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Chen CY, 1996, MOL CELL BIOL, V16, P6372; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kitamura T, 2000, METH MOL B, V134, P143; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Onishi M, 1996, EXP HEMATOL, V24, P324; REECY J, 1998, HEART DEV, P273; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4	27	83	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28853	28860		10.1074/jbc.M203190200	http://dx.doi.org/10.1074/jbc.M203190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12019265	hybrid			2022-12-25	WOS:000177342600068
J	Isawa, H; Yuda, M; Orito, Y; Chinzei, Y				Isawa, H; Yuda, M; Orito, Y; Chinzei, Y			A mosquito salivary protein inhibits activation of the plasma contact system by binding to factor XII and high molecular weight kininogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-INDEPENDENT ACCELERATION; HIGH-MR KININOGEN; ENDOTHELIAL-CELLS; ZINC IONS; PROLIXIN-S; RHODNIUS-PROLIXUS; ANIONIC SURFACE; DEXTRAN SULFATE; LIGHT CHAIN; PREKALLIKREIN	The salivary glands of female mosquitoes contain a variety of bioactive substances that assist their blood-feeding behavior. Here, we report a salivary protein of the malarial vector mosquito, Anopheles stephensi, that inhibits activation of the plasma contact system. This factor, named hamadarin, is a 16-kDa protein and a major component of the saliva of this mosquito. Assays using human plasma showed that hamadarin dose-dependently inhibits activation of the plasma contact system and subsequent release of bradykinin, a primary mediator of inflammatory reactions. Reconstitution experiments showed that hamadarin inhibits activation of the plasma contact system by inhibition of the reciprocal activation of factor XII and kallikrein. Direct binding assays demonstrated that this inhibitory effect is due to hamadarin binding to both factor XII and high molecular weight kininogen and interference in their association with the activating surface. The assays also showed that hamadarin binding to these proteins depends on Zn2+ ions, suggesting that hamadarin binds to these contact factors by recognizing their conformational change induced by Zn2+ binding. We propose that hamadarin may attenuate the host's acute inflammatory responses to the mosquito's bites by inhibition of bradykinin release and thus enable mosquitoes to take a blood meal efficiently and safely.	Mie Univ, Sch Med, Dept Med Zool, Tsu, Mie 5148507, Japan	Mie University	Yuda, M (corresponding author), Mie Univ, Sch Med, Dept Med Zool, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	m-yuda@doc.medic.mie-u.ac.jp						Arca B, 1999, P NATL ACAD SCI USA, V96, P1516, DOI 10.1073/pnas.96.4.1516; Bajaj SP, 1999, SEMIN THROMB HEMOST, V25, P407, DOI 10.1055/s-2007-994943; BERNARDO MM, 1993, J BIOL CHEM, V268, P12468; BERNARDO MM, 1993, J BIOL CHEM, V268, P12477; Citarella F, 1997, BRIT J HAEMATOL, V99, P197, DOI 10.1046/j.1365-2141.1997.3513165.x; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 1999, THROMB HAEMOSTASIS, V82, P1568; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Francischetti IMB, 1999, BIOCHEMISTRY-US, V38, P16678, DOI 10.1021/bi991231p; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Herwald H, 2001, EUR J BIOCHEM, V268, P396, DOI 10.1046/j.1432-1327.2001.01888.x; Isawa H, 2000, J BIOL CHEM, V275, P6636, DOI 10.1074/jbc.275.9.6636; JAMES AA, 1991, PARASITOL TODAY, V7, P267, DOI 10.1016/0169-4758(91)90092-3; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2001, THROMB HAEMOSTASIS, V85, P119; Kenneth KR, 1998, J BIOL CHEM, V273, P20802, DOI 10.1074/jbc.273.33.20802; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; Lin YZ, 2000, BIOCHEMISTRY-US, V39, P5104, DOI 10.1021/bi992048z; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; REDDIGARI SR, 1993, J BIOL CHEM, V268, P11982; RIBEIRO JMC, 1995, INFECT AGENT DIS, V4, P143; Rojkjaer R, 1997, EUR J BIOCHEM, V243, P160, DOI 10.1111/j.1432-1033.1997.0160a.x; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SAITO H, 1987, SEMIN THROMB HEMOST, V13, P36, DOI 10.1055/s-2007-1003474; SAMUEL M, 1992, J BIOL CHEM, V267, P19691; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; Schmaier AH, 1999, THROMB HAEMOSTASIS, V82, P226; SCHOUSBOE I, 1990, EUR J BIOCHEM, V193, P495, DOI 10.1111/j.1432-1033.1990.tb19364.x; SCHOUSBOE I, 1991, EUR J BIOCHEM, V197, P309, DOI 10.1111/j.1432-1033.1991.tb15912.x; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SCOTT CF, 1988, J LAB CLIN MED, V111, P708; SHIMADA T, 1987, J BIOCHEM-TOKYO, V102, P913, DOI 10.1093/oxfordjournals.jbchem.a122132; Sun JX, 1996, THROMB HAEMOSTASIS, V75, P573; TANKERSLEY DL, 1983, BLOOD, V62, P448; TAYEH MA, 1994, J BIOL CHEM, V269, P16318; Valenzuela JG, 1999, BIOCHEMISTRY-US, V38, P11209, DOI 10.1021/bi990761i; Waidhet-Kouadio P, 1998, BBA-GEN SUBJECTS, V1381, P227, DOI 10.1016/S0304-4165(98)00026-9; Yuda M, 1999, J EXP MED, V189, P1947, DOI 10.1084/jem.189.12.1947; Yuda M, 1997, EUR J BIOCHEM, V249, P337, DOI 10.1111/j.1432-1033.1997.00337.x; Yuda Masao, 1996, Medical Entomology and Zoology, V47, P263	46	60	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27651	27658		10.1074/jbc.M203505200	http://dx.doi.org/10.1074/jbc.M203505200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011093	hybrid			2022-12-25	WOS:000177189800012
J	Sawano, Y; Muramatsu, T; Hatano, K; Nagata, K; Tanokura, M				Sawano, Y; Muramatsu, T; Hatano, K; Nagata, K; Tanokura, M			Characterization of genomic sequence coding for bromelain inhibitors in pineapple and expression of its recombinant isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-PROTEINASE-INHIBITOR; PANCREATIC TRYPSIN-INHIBITOR; CIRCULAR-DICHROISM; GEL-ELECTROPHORESIS; SECONDARY STRUCTURE; STEM; CYSTATIN; DNA; VI; INTRONS	Bromelain inhibitor (BI) is a cysteine proteinase inhibitor isolated from pineapple stem (Reddy, M. N., Keim, P. S., Heinrikson, R. L., and Kezdy, F. J. (1975) J. Biol. Chem. 250, 1741-1750). It consists of eight isoinhibitors, and each isoinhibitor has a two-chain structure. In this study, the genomic DNA has been cloned and found to encode a precursor protein with 246 amino acids (M-r = similar to27,500) containing three isoinhibitor domains (BI-III, -VI, and -VII) that are 93% identical to one another in amino acid sequences. The gene structure indicated that these isoinhibitors are produced by removal of the N-terminal pre-peptide (19 residues), 3 interchain peptides (each 5 residues), 2 interdomain peptides (each 19 residues), and the C-terminal pro-peptide (18 residues). Moreover, all the amino acid sequences of bromelain isoinhibitors could be explained by removal of one or two amino acids from BI-III, -VI, and -VII with exopeptidases. A recombinant single-chain BI-VI with and without the interchain peptide showed the same and no bromelain inhibitory activity as compared with the native BI-VI, respectively. These results indicate that the interchain peptide plays an important role of the folding process of the mature isoinhibitors.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Fac Engn, Dept Biol Sci, Kiryu, Gumma 3768515, Japan; Univ Tokyo, Biotechnol Res Ctr, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; National Cancer Center - Japan; Gunma University; University of Tokyo	Tanokura, M (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.			Nagata, Koji/0000-0002-4704-0603; Tanokura, Masaru/0000-0001-5072-2480				Adler A J, 1973, Methods Enzymol, V27, P675; ATKINSON AH, 1993, PLANT CELL, V5, P203, DOI 10.1105/tpc.5.2.203; AUERSWALD EA, 1992, EUR J BIOCHEM, V209, P837, DOI 10.1111/j.1432-1033.1992.tb17355.x; BAEK JM, 1994, BIOSCI BIOTECH BIOCH, V58, P843, DOI 10.1271/bbb.58.843; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; HARRY JB, 1970, EUR J BIOCHEM, V16, P174, DOI 10.1111/j.1432-1033.1970.tb01069.x; HATANO K, 1995, EUR J BIOCHEM, V232, P335, DOI 10.1111/j.1432-1033.1995.335zz.x; Hatano K, 1998, J BIOCHEM-TOKYO, V124, P457, DOI 10.1093/oxfordjournals.jbchem.a022135; Hatano K, 1996, P JPN ACAD B-PHYS, V72, P104, DOI 10.2183/pjab.72.104; Hatano K, 1996, BIOCHEMISTRY-US, V35, P5379, DOI 10.1021/bi952754+; Heinrikson R L, 1976, Methods Enzymol, V45, P740; KAY E, 1974, J BIOL CHEM, V249, P797; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Nagata K, 2000, BIOCHEMISTRY-US, V39, P14753, DOI 10.1021/bi0006971; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rakwal R, 2001, GENE, V263, P189, DOI 10.1016/S0378-1119(00)00573-4; REDDY MN, 1975, J BIOL CHEM, V250, P1741; Reese M, 1996, P PAC S BIOC, P737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT MJ, 1987, J BIOL CHEM, V262, P5899; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Sreerama N, 1999, BIOCHEMISTRY-US, V38, P10814, DOI 10.1021/bi990516z; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL R, 1988, J BIOL CHEM, V263, P12661; WALDRON C, 1993, PLANT MOL BIOL, V23, P801, DOI 10.1007/BF00021535; WALSH TA, 1993, PLANT PHYSIOL, V103, P1227, DOI 10.1104/pp.103.4.1227; WERNER MH, 1992, BIOCHEMISTRY-US, V31, P999, DOI 10.1021/bi00119a008; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; ZHU H, 1993, NUCLEIC ACIDS RES, V21, P5279, DOI 10.1093/nar/21.22.5279	35	17	20	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28222	28227		10.1074/jbc.M202600200	http://dx.doi.org/10.1074/jbc.M202600200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12016215	hybrid			2022-12-25	WOS:000177189800080
J	Kim, YS; Randolph, TW; Stevens, FJ; Carpenter, JF				Kim, YS; Randolph, TW; Stevens, FJ; Carpenter, JF			Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein - Insights into transition states from pressure, temperature, and co-solute studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN DEPOSITS; CONGO RED; SURFACE-TENSION; STABILITY; DISEASE	The transition states for prenucleation assembly, nucleation, and growth of aggregates and amyloid fibrils were investigated for a dimeric immunoglobulin light chain variable domain, employing pressure, temperature, and solutes as variables. Pressure-induced aggregation was nucleation-dependent and first-order in protein concentration and could be seeded. The insoluble aggregates were mixtures of amyloid fibrils and amorphous aggregates. Activation volumes, activation surface areas, and activation waters of hydration were larger for aggregate growth than for prenucleation assembly or nucleation, although activation free energies were similar for the three processes. Activation free energies for each of the transition states were dominated by the unfavorable free energy of solvation of newly exposed surfaces. Equilibrium dissociation and unfolding of the dimer showed a much larger volume change than those required to form the transition states for the three processes. Thus, the transition states for these steps are similar to the native state, and their formation requires only small structural perturbations. Finally, the presence of Congo red during amyloid fibril formation shortened lag times and caused pressure insensitivity of nucleation, suggesting that this compound or its analogs may not be effective as inhibitors of amyloidosis.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Argonne National Laboratory	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, 4200 E 9th Ave, Denver, CO 80262 USA.	John.Carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509				Ashbaugh HS, 1996, J PHYS CHEM-US, V100, P1900, DOI 10.1021/jp952387b; Davis DP, 2000, IMMUNITY, V13, P433, DOI 10.1016/S1074-7613(00)00043-1; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Huang DB, 1997, MOL IMMUNOL, V34, P1291, DOI 10.1016/S0161-5890(98)00002-9; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kaplan B, 1997, CLIN EXP IMMUNOL, V110, P472, DOI 10.1046/j.1365-2249.1997.4421454.x; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kendrick BS, 1998, P NATL ACAD SCI USA, V95, P14142, DOI 10.1073/pnas.95.24.14142; Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Pace C N, 1986, Methods Enzymol, V131, P266; Piekarska B, 1996, BIOCHIMIE, V78, P183; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; Rudyk H, 2000, J GEN VIROL, V81, P1155, DOI 10.1099/0022-1317-81-4-1155; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; SMITH JM, 1956, CHEM ENG KINETICS, P41; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Stokes MB, 1997, MODERN PATHOL, V10, P1059; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; SUPRAN MK, 1971, J MILK FOOD TECHNOL, V34, P584, DOI 10.4315/0022-2747-34.12.584; VARGAFTIK NB, 1983, J PHYS CHEM REF DATA, V12, P817, DOI 10.1063/1.555688; Webb JN, 2001, P NATL ACAD SCI USA, V98, P7259, DOI 10.1073/pnas.131194798; Wetzel R, 1997, ADV PROTEIN CHEM, V50, P183, DOI 10.1016/S0065-3233(08)60322-8; Wetzel R, 1996, CELL, V86, P699, DOI 10.1016/S0092-8674(00)80143-9	36	51	51	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27240	27246		10.1074/jbc.M202492200	http://dx.doi.org/10.1074/jbc.M202492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023282	hybrid			2022-12-25	WOS:000177055900070
J	Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH				Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH			STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells	ONCOGENE			English	Article						transcription factor; STAT3; transformation response; matrix metalloproteinase; mouse skin cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; TRANSCRIPTION FACTORS; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; TRANSGENIC MICE; PROTEIN-KINASE; AP-1	STAT3, a member of signal transducers and activators of transcription (STATs) originally discovered as mediators in cytokine signaling pathways, plays an active role in oncogenesis. However, the function of STAT3 in signaling multistage carcinogenesis, especially in transformation of tumor-promotion sensitive epithelial cells has not been elucidated. The present study demonstrates that STAT3 is activated in interleukin-6 induced transformation in mouse skin epithelial cells. DNA binding and transcriptional activities of STAT3 were significantly increased by interleukin-6. This induced anchorage-independent transformation in tumor-promotion sensitive JB6 mouse skin P+ cells but not in the resistant variant P- cells. Two forms of dominant negative STAT3 (mutant of transcriptional domain, mF, or DNA-binding domain, mD) were stably transfected into P+ cells. Activation of STAT3 was abolished and importantly, interleukin-6 induced anchorage-independent growth was absent in both mutant STAT3 transfectants. To determine the genes targeted by STAT3, three matrix metalloproteinase proteins linked with carcinogenesis of epithelial cells were analysed. Both basal and interleukin-6 induced expression of collagenase I and stromelysin I, but not gelatinase A, were inhibited in the mutant STAT3 transfectants. Furthermore, transfection of a wild type STAT3 restored STAT3 transactivation and response to interleukin-6 induced transformation in mutant STAT3 transfectants, which up-regulated collagenase I and stromelysin I as well. Together, these results provide the first evidence that STAT3 activation is required in the progression of multistage carcinogenesis of mouse skin epithelial cells, and matrix metalloproteinases are actively involved in STAT3-mediated cell transformation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; NCI, Cytokine Mol Mech Sect, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; NCI, Lab Basic Res, NIH, Frederick, MD 21702 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44106 USA	City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cleveland Clinic Foundation	Li, JH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Halper S Bldg,H115,1500 Duarte Rd, Duarte, CA 91010 USA.			Li, Jian Jian/0000-0003-3694-9675; Yu, Cheng-Rong/0000-0001-7246-0362				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; BENEDETTI FD, 1990, MOL CELL BIOL CYTOKI, V1, P275; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin JB, 2000, CANCER RES, V60, P3971; Dokter WHA, 1996, LEUKEMIA, V10, P1308; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang CS, 1996, MOL CELL BIOL, V16, P6427; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAWANO M, 1989, CANCER SURV, V8, P905; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SIU X, 1999, BLOOD, V93, P2525; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Takeda K, 1998, J IMMUNOL, V161, P4652; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu CR, 1998, J LEUKOCYTE BIOL, V64, P245, DOI 10.1002/jlb.64.2.245; Yu CR, 1996, J IMMUNOL, V157, P126; Yu CR, 1999, J IMMUNOL, V162, P2785; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3949	3960		10.1038/sj.onc.1205499	http://dx.doi.org/10.1038/sj.onc.1205499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037677				2022-12-25	WOS:000175869900001
J	Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC				Neve, RM; Ylstra, B; Chang, CH; Albertson, DG; Benz, CC			ErbB2 activation of ESX gene expression	ONCOGENE			English	Article						ErbB2; ESX; breast cancer; Ets	ETS TRANSCRIPTION FACTOR; GENOMIC ORGANIZATION; ELF3; DIFFERENTIATION; AMPLICON; PROMOTER; TISSUES; CANCER; FAMILY; CELLS	Various members of the Ets multigene family exhibit diverse roles in development, cell differentiation, tissue-specific gene expression and human malignancy. In the search for Ets factors involved in mammary gland development and malignancy, ESX was found to be upregulated in a subset of breast tumours and cell lines. We report the transcriptional regulation of ESX in epithelial breast cancer cells. Transient reporter assays using the ESX promoter show that ESX transcription is regulated by ErbB receptor signalling. In cell lines and in 45 primary ductal breast cancers we show that ESX transcript expression significantly correlates with ErbB2 transcript levels. Moreover, expression of ErbB2 in cells upregulates ESX promoter activity while inhibition of ErbB2 or its downstream signaling pathways decrease both ESX promoter activity and endogenous ESX protein levels. These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Benz, CC (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.		Ylstra, Bauke/D-2906-2012	Ylstra, Bauke/0000-0001-9479-3010	NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 36773, P01 CA 44768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; NG AYN, 2002, IN PRESS GASTROENTER; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; RUDDERS S, 2000, J BIOL CHEM, V17, P17; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Shridhar V, 2001, CANCER RES, V61, P5895; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6	19	31	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3934	3938		10.1038/sj.onc.1205503	http://dx.doi.org/10.1038/sj.onc.1205503			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032832				2022-12-25	WOS:000175847200013
J	Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C				Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C			Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors	ONCOGENE			English	Article						DNA methylation; nonseminoma; seminoma; RLGS; genome scan	CARCINOMA IN-SITU; DNA METHYLATION; PATTERNS; EXPRESSION; CANCER; PATHOGENESIS; ORIGIN	The genetic nature of testicular germ cell tumors and the molecular mechanisms underlying the morphological and clinical differences between the two subtypes, seminomas and nonseminomas, remains unclear. Genetic studies show that both subtypes exhibit many of the same regional genomic disruptions, although the frequencies vary and few clear differences are found. We demonstrate significant epigenetic differences between seminomas and nonseminomas by restriction landmark genomic scanning. Seminomas show almost no CpG island methylation, in contrast to nonseminomas that show CpG island methylation at a level similar to other solid tumors. We find an average of 1.11% of CpG islands methylation in nonseminomas, but only 0.08% methylated in seminomas. Furthermore, we demonstrate that seminomas are more highly hypomethylated than nonseminomas throughout their genome. Since both subtypes are thought to arise from primordial germ cells, the epigenetic differences seen between these subtypes may reflect the normal developmental switch in primordial germ cells from an undermethylated genome to a normally methylated genome. We discuss these findings in relation to different developmental models for seminomatous and nonseminomatous testicular germ cell tumors.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Norwegian Radium Hosp, Dept Genet, Inst Canc Res, N-0310 Oslo, Norway	University System of Ohio; Ohio State University; University of Helsinki; University of Oslo	Smiraglia, DJ (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, 420 W 12th Ave,Room 470A, Columbus, OH 43210 USA.	Smiraglia.l@postbox.acs.ohio-state.edu	Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Smiraglia, Dominic/0000-0001-8852-1510; Lothe, Ragnhild A./0000-0002-1693-1032; Peltomaki, Paivi/0000-0001-8819-2980	NCI NIH HHS [T32 CA 09338-20, P30 CA 16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bestor TH, 1998, AM J HUM GENET, V62, P1269, DOI 10.1086/301891; Chaganti RSK, 1998, APMIS, V106, P80, DOI 10.1111/j.1699-0463.1998.tb01322.x; Coffigny H, 1999, CYTOGENET CELL GENET, V87, P175, DOI 10.1159/000015460; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Looijenga LHJ, 1998, APMIS, V106, P187, DOI 10.1111/j.1699-0463.1998.tb01335.x; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Murty VVVS, 1998, SEMIN ONCOL, V25, P133; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; PELTOMAKI P, 1991, BRIT J CANCER, V63, P851, DOI 10.1038/bjc.1991.189; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RajpertDeMeyts E, 1996, VIRCHOWS ARCH, V428, P133; ROTH M, 2000, SCAND J UROL NEPHR S, V205, P166; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trasler JM, 1998, SEMIN CELL DEV BIOL, V9, P467, DOI 10.1006/scdb.1998.0225	33	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3909	3916		10.1038/sj.onc.1205488	http://dx.doi.org/10.1038/sj.onc.1205488			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032829				2022-12-25	WOS:000175847200010
J	Brinkman, AB; Bell, SD; Lebbink, RJ; de Vos, WM; van der Oost, J				Brinkman, AB; Bell, SD; Lebbink, RJ; de Vos, WM; van der Oost, J			The Sulfolobus solfataricus Lrp-like protein LysM regulates lysine biosynthesis in response to lysine availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; ILVIH OPERON; THERMUS-THERMOPHILUS; PYROCOCCUS-FURIOSUS; ALPHA-AMINOADIPATE; PSEUDOMONAS-PUTIDA; GLOBAL REGULATOR; PROMOTER REGION; COMPLETE GENOME	Although the archaeal transcription apparatus resembles the eukaryal RNA polymerase II system, many bacterial-like regulators can be found in archaea. Particularly, all archaeal genomes sequenced to date contain genes encoding homologues of Lrp (leucine-responsive regulatory protein). Whereas Lrp-like proteins in bacteria are involved in regulation of amino acid metabolism, their physiological role in archaea is unknown. Although several archaeal Lrp-like proteins have been characterized recently, no target genes apart from their own coding genes have been discovered yet, and no ligands for these regulators have been identified so far. In this study, we show that the Lrp-like protein LysM from Sulfolobus solfataricus is involved in the regulation of lysine and possibly also arginine biosynthesis, encoded by the lys gene cluster. Exogenous lysine is the regulatory signal for lys gene expression and specifically serves as a ligand for LysM by altering its DNA binding affinity. LysM binds directly upstream of the TFB-responsive element of the intrinsically weak lysW promoter, and DNA binding is favored in the absence of lysine, when lysWXJK transcription is maximal. The combined an vivo and in vitro data are most compatible with a model in which the bacterial-like LysM activates the eukarya-like transcriptional machinery. As with transcriptional activation by Escherichia coli Lrp, activation by LysM is apparently dependent on a co-activator, which remains to be identified.	Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Hutchison MRC Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England	Wageningen University & Research	Brinkman, AB (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, POB 85060, NL-3508 AB Utrecht, Netherlands.	a.b.brinkman@med.uu.nl	van+der+Oost, John/Y-2548-2019; Lebbink, Robert Jan/GNH-5209-2022; Brinkman, Arie/V-1533-2018	Brinkman, Arie/0000-0002-9875-1835; Bell, Stephen/0000-0002-8474-6592; Lebbink, Robert Jan/0000-0002-1981-0420				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bell SD, 2000, J BIOL CHEM, V275, P12934, DOI 10.1074/jbc.275.17.12934; Bell SD, 2000, J BIOL CHEM, V275, P31624, DOI 10.1074/jbc.M005422200; Bell SD, 1999, P NATL ACAD SCI USA, V96, P13662, DOI 10.1073/pnas.96.24.13662; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Bensing BA, 1996, P NATL ACAD SCI USA, V93, P7794, DOI 10.1073/pnas.93.15.7794; Borovkov AY, 1997, BIOTECHNIQUES, V22, P812, DOI 10.2144/97225bm04; Brinkman AB, 2000, J BIOL CHEM, V275, P38160, DOI 10.1074/jbc.M005916200; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; Chen S, 2001, J MOL BIOL, V312, P625, DOI 10.1006/jmbi.2001.4955; Ciammaruconi A, 2001, J BACTERIOL, V183, P3866, DOI 10.1128/JB.183.13.3866-3874.2001; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Enoru-Eta J, 2000, J BACTERIOL, V182, P3661, DOI 10.1128/JB.182.13.3661-3672.2000; ERNSTING BR, 1993, J BACTERIOL, V175, P7160, DOI 10.1128/JB.175.22.7160-7169.1993; ERNSTING BR, 1992, J BACTERIOL, V174, P1109, DOI 10.1128/jb.174.4.1109-1118.1992; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Jafri S, 1999, J MOL BIOL, V288, P811, DOI 10.1006/jmbi.1999.2715; KANG WK, 1989, MOL GEN GENET, V217, P281, DOI 10.1007/BF02464894; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kobashi N, 1999, J BACTERIOL, V181, P1713, DOI 10.1128/JB.181.6.1713-1718.1999; Kosuge T, 1998, FEMS MICROBIOL LETT, V169, P361, DOI 10.1016/S0378-1097(98)00502-3; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; LEVINTHAL M, 1994, MOL GEN GENET, V242, P736, DOI 10.1007/BF00283429; LIN RT, 1992, J BACTERIOL, V174, P1948, DOI 10.1128/jb.174.6.1948-1955.1992; Littlefield O, 1999, P NATL ACAD SCI USA, V96, P13668, DOI 10.1073/pnas.96.24.13668; MADHUSUDHAN KT, 1995, J BACTERIOL, V177, P636, DOI 10.1128/jb.177.3.636-641.1995; Madhusudhan KT, 1997, J BACTERIOL, V179, P1992, DOI 10.1128/jb.179.6.1992-1997.1997; Magill CP, 2001, J BIOL CHEM, V276, P46693, DOI 10.1074/jbc.C100567200; MARASCO R, 1994, J BACTERIOL, V176, P5197, DOI 10.1128/JB.176.17.5197-5201.1994; Mathew E, 1996, J BACTERIOL, V178, P7234, DOI 10.1128/jb.178.24.7234-7240.1996; Miyazaki J, 2002, FEBS LETT, V512, P269, DOI 10.1016/S0014-5793(02)02290-1; Miyazaki J, 2001, J BACTERIOL, V183, P5067, DOI 10.1128/JB.183.17.5067-5073.2001; Napoli A, 1999, J BACTERIOL, V181, P1474, DOI 10.1128/JB.181.5.1474-1480.1999; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; Nishida H, 1999, GENOME RES, V9, P1175, DOI 10.1101/gr.9.12.1175; Paul L, 2001, J BACTERIOL, V183, P3910, DOI 10.1128/JB.183.13.3910-3918.2001; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; Qureshi SA, 1997, EMBO J, V16, P2927, DOI 10.1093/emboj/16.10.2927; REITER WD, 1987, NUCLEIC ACIDS RES, V15, P5581, DOI 10.1093/nar/15.14.5581; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; Roesch RL, 1998, MOL MICROBIOL, V27, P751, DOI 10.1046/j.1365-2958.1998.00720.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tolstrup N, 2000, EXTREMOPHILES, V4, P175, DOI 10.1007/s007920070032; Weyand NJ, 2001, MOL MICROBIOL, V39, P1504, DOI 10.1046/j.1365-2958.2001.02338.x; Zhi JZ, 1999, MOL MICROBIOL, V32, P29, DOI 10.1046/j.1365-2958.1999.01314.x; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	55	88	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29537	29549		10.1074/jbc.M203528200	http://dx.doi.org/10.1074/jbc.M203528200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042311	hybrid			2022-12-25	WOS:000177509300026
J	Rennefahrt, UEE; Illert, B; Kerkhoff, E; Troppmair, J; Rapp, UR				Rennefahrt, UEE; Illert, B; Kerkhoff, E; Troppmair, J; Rapp, UR			Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; ACTIN STRESS FIBERS; RHO-FAMILY PROTEINS; C-JUN ACTIVITY; MAP KINASES; CELLS; RAS; REQUIRES; GTPASES	The c-Jun N-terminal kinases (JNKs) (also known as stress-activated protein kinases or SAPKs), members of the mitogen-activated protein kinase (MAPK) family, regulate gene expression in response to a variety of physiological and unphysiological stimuli. Gene knockout experiments and the use of dominant interfering mutants have pointed to a role for JNKs in the processes of cell differentiation and survival as well as oncogenic transformation. Direct analysis of the transforming potential of JNKs has been hampered so far by the lack of constitutively active forms of these kinases. Recently, such mutants have become available by fusion of the MAPK with its direct upstream activator kinase. We have generated a constitutively active SAPKbeta-MKK7 hybrid protein and, using this constitutively active kinase, we are able to demonstrate the transforming potential of activated JNK, which is weaker than that of classical oncogenes such as Ras or Raf. The inducible expression of SAPKbeta-MKK7 caused morphological transformation of NIH 3T3 fibroblasts. Additionally, these cells formed small foci of transformed cells and grew anchorage-independent in soft agar. Furthermore, similar to oncogenic Ras and Raf, the expression of activated SAPKbeta resulted in the disassembly of F-actin stress fibers. Our data suggest that constitutive JNK activation elicits major aspects of cellular transformation but is unable to induce the complete set of changes which are required to establish the fully transformed phenotype.	Univ Wurzburg, Inst MSZ, D-97078 Wurzburg, Germany; Univ Wurzburg, Chirurg Klin & Poliklin, D-97080 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst MSZ, Versbacher Str 5, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de		Troppmair, Jakob/0000-0002-0611-3837				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Barr RK, 2002, J BIOL CHEM, V277, P10987, DOI 10.1074/jbc.M107565200; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Boettner B, 1999, Prog Mol Subcell Biol, V22, P135; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartkamp J, 1999, CANCER RES, V59, P2195; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kerkhoff E, 2002, BBA-MOL CELL RES, V1589, P151, DOI 10.1016/S0167-4889(02)00168-4; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Otto IM, 2000, CURR BIOL, V10, P345, DOI 10.1016/S0960-9822(00)00388-2; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ramesh N, 1999, TRENDS CELL BIOL, V9, P15, DOI 10.1016/S0962-8924(98)01411-1; RAO KMK, 1991, MUTAT RES, V256, P139, DOI 10.1016/0921-8734(91)90007-X; RAPP UR, 1994, ONCOGENE, V9, P3493; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1999, EUR J CANCER, V35, P1905, DOI 10.1016/S0959-8049(99)00293-2; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wellington A, 1999, DEVELOPMENT, V126, P5267; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao L, 2000, CANCER RES, V60, P400; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	63	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29510	29518		10.1074/jbc.M203010200	http://dx.doi.org/10.1074/jbc.M203010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039958	hybrid			2022-12-25	WOS:000177509300023
J	Takita, T; Inouye, K				Takita, T; Inouye, K			Transition state stabilization by the N-terminal anticodon-binding domain of lysyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; KINETIC-ANALYSIS; BACILLUS-STEAROTHERMOPHILUS; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; COMPLEX; AMINOACYLATION; COMMUNICATION; NUCLEOTIDES; RECOGNITION	Lysyl-tRNA synthetase from Bacillus stearothermophilus (B.s. LysRS) (EC 6.1.1.6) catalyzes aminoacylation of tRNA(Lys) with L-lysine, in which L-lysine was first activated with ATP to yield an enzyme (lysyladenylate complex), and then the lysine molecule was transferred from the complex to tRNA(Lys). B.s. LysRS is a homodimeric enzyme with a subunit that consists of two domains, an N-terminal tRNA anticodon-binding domain (TAB-ND: Ser(1)-Pro(144)) and a C-terminal Class II-specific catalytic domain (CAT-CD: Lys(151)-Lys(493)). CAT-CD alone retained catalytic activity, although at a low level; TAB-ND alone showed no activity. Size exclusion chromatography revealed that CAT-CD exists as a dimer, whereas TAB-ND was a monomer. The formation of a complex consisting of these domains was detected with the guidance of surface plasmon resonance. In accordance with this, the addition of TAB-ND to CAT-CD significantly enhanced both the L-lysine activation and the tRNA aminoacylation reactions. Kinetic analysis showed that deletion of TAB-ND resulted in a significant destabilization of the transition state of CAT-CD in the L-lysine activation reaction but had little effect on the ground state of substrate binding. A significant role of a cross-subunit interaction in the enzyme between TAB-ND and CAT-CD was proposed for the stabilization of the transition state in the L-lysine activation reaction.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan	Kyoto University	Takita, T (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan.	takita@kais.kyoto-u.ac.jp						Alexander RW, 1999, BIOCHEMISTRY-US, V38, P16359, DOI 10.1021/bi991948c; Augustine J, 1997, BIOCHEMISTRY-US, V36, P3473, DOI 10.1021/bi962395y; BOREL F, 1994, NUCLEIC ACIDS RES, V22, P2963, DOI 10.1093/nar/22.15.2963; CASSIO D, 1971, EUR J BIOCHEM, V20, P283, DOI 10.1111/j.1432-1033.1971.tb01393.x; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; Deinert K, 2001, J BIOL CHEM, V276, P6000, DOI 10.1074/jbc.M008682200; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; Eriani G, 1999, J MOL BIOL, V291, P761, DOI 10.1006/jmbi.1999.3012; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P818, DOI 10.1021/bi00649a014; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13644, DOI 10.1021/bi00212a032; FOURMY D, 1995, BIOCHEMISTRY-US, V34, P15681, DOI 10.1021/bi00048a012; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; GHOSH G, 1991, J BIOL CHEM, V266, P17136; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JASIN M, 1983, NATURE, V306, P441, DOI 10.1038/306441a0; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; LEATHERBARROW RJ, 1985, P NATL ACAD SCI USA, V82, P7840, DOI 10.1073/pnas.82.23.7840; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Onesti S, 2000, BIOCHEMISTRY-US, V39, P12853, DOI 10.1021/bi001487r; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; PUTZ J, 1993, EMBO J, V12, P2949, DOI 10.1002/j.1460-2075.1993.tb05957.x; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHMITT E, 1994, J MOL BIOL, V242, P566, DOI 10.1006/jmbi.1994.1601; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; Sherman JM, 1996, J MOL BIOL, V256, P818, DOI 10.1006/jmbi.1996.0128; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; Steer BA, 1999, P NATL ACAD SCI USA, V96, P13644, DOI 10.1073/pnas.96.24.13644; Takita T, 1998, J BIOCHEM-TOKYO, V123, P1218; Takita T, 1997, J BIOCHEM-TOKYO, V121, P244; Takita T, 1998, J BIOCHEM-TOKYO, V124, P45, DOI 10.1093/oxfordjournals.jbchem.a022095; Takita T, 2000, BIOSCI BIOTECH BIOCH, V64, P432, DOI 10.1271/bbb.64.432; Takita T, 1996, J BIOCHEM-TOKYO, V119, P680; Wang CC, 2000, J BIOL CHEM, V275, P17180, DOI 10.1074/jbc.M001057200	41	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29275	29282		10.1074/jbc.M200481200	http://dx.doi.org/10.1074/jbc.M200481200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12019264	hybrid			2022-12-25	WOS:000177342600117
J	Germaniuk, A; Liberek, K; Marszalek, J				Germaniuk, A; Liberek, K; Marszalek, J			A bichaperone (Hsp70-Hsp78) system restores mitochondrial DNA synthesis following thermal inactivation of Mip1p polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PROTEINS; HEAT-SHOCK; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONE; GENE-PRODUCT; YEAST; HSP70; HOMOLOG; NUCLEAR; REPLICATION	Mitochondrial DNA synthesis is a thermosensitive process in the yeast Saccharomyces cerevisiae. We found that restoration of mtDNA synthesis following heat treatment of cells is dependent on reactivation of the mtDNA polymerase Mip1p through the action of a mitochondrial bichaperone system consisting of the Hsp70 system and the Hsp78 oligomeric protein. mtDNA synthesis was inefficiently restored after heat shock in yeast lacking either functional component of the bichaperone system. Furthermore, the activity of purified Mip1p was also thermosensitive; however, the purified components of the mitochondrial bichaperone system (Ssc1p, Mdj1p, Mge1p, and Hsp78p) were able to protect its activity under moderate heat shock conditions as well as to reactivate thermally inactivated Mip1p. Interestingly, the reactivation of endogenous Mip1p contributed more significantly to the restoration of mtDNA synthesis than did import of newly synthesized Mip1p from the cytosol. These observations suggest an important link between function of mitochondrial chaperones and the propagation of mitochondrial genomes under ever-changing environmental conditions.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Marszalek, J (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.		Marszalek, Jaroslaw/F-5824-2011; Liberek, Krzysztof/F-5812-2011	Liberek, Krzysztof/0000-0002-7532-9279; Marszalek, Jaroslaw/0000-0002-6978-1189				Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; BISWAS TK, 1994, ACTA BIOCHIM POL, V42, P317; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; Duchniewicz M, 1999, MOL CELL BIOL, V19, P8201; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; FOURY F, 1989, J BIOL CHEM, V264, P20552; GENGA A, 1986, J BIOL CHEM, V261, P9328; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P13; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; HWANG DS, 1990, J BIOL CHEM, V265, P19244; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Kedzierska S, 1999, FEBS LETT, V446, P331, DOI 10.1016/S0014-5793(99)00154-4; Klanner C, 2000, FEBS LETT, V470, P365, DOI 10.1016/S0014-5793(00)01322-3; Konieczny I, 1999, GENET ENG P, V21, P95; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MOGK A, 2001, FRONTIERS MOL BIOL, V37, P1; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; VOOS W, 2001, FRONT MOL BIOL, V37, P61; Westermann B, 1996, MOL CELL BIOL, V16, P7063; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	41	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27801	27808		10.1074/jbc.M201756200	http://dx.doi.org/10.1074/jbc.M201756200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023279	hybrid			2022-12-25	WOS:000177189800029
J	Li, YK; Chin, LS; Levey, AI; Li, L				Li, YK; Chin, LS; Levey, AI; Li, L			Huntingtin-associated protein 1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate and functions in endosomal trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ZINC-FINGER DOMAIN; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; HRS INTERACTS; LOCALIZATION; SYNAPTOPHYSIN; EXOCYTOSIS; CLATHRIN; YEAST	Huntingtin-associated protein 1 (HAP1) is a novel protein of unknown function with a higher binding affinity for the mutant form of Huntington's disease protein huntingtin. Here we report that HAP1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a mammalian homologue of yeast vacuolar protein sorting protein Vps27p involved in the endosome-to-lysosome trafficking. This novel interaction was identified in a yeast two-hybrid screen using full-length Hrs as bait, and confirmed by in vitro binding assays and co-immunoprecipitation experiments. Deletion analysis reveals that the association of HAP1 with Hrs is mediated via a coiled-coil interaction between the central coiled-coil domains of both proteins. Immunofluorescence and subcellular fractionation studies show that HAP1 co-localizes with Hrs on early endosomes. Like Hrs, overexpression of HAP1 causes the formation of enlarged early endosomes, and inhibits the degradation of internalized epidermal growth factor receptors. Whereas overexpression of HAP1 does not affect either constitutive or ligand-induced receptor-mediated endocytosis, it potently blocks the trafficking of endocytosed epidermal growth factor receptors from early endosomes to late endosomes. These findings implicate, for the first time, the involvement of HAP1 in the regulation of vesicular trafficking from early endosomes to the late endocytic compartments.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University; Emory University	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Chin, Lih-Shen/0000-0002-0817-0368	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036320] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36320] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], ADV NEUROL; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bertaux F, 1998, FEBS LETT, V426, P229, DOI 10.1016/S0014-5793(98)00352-4; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Clague MJ, 2001, J CELL SCI, V114, P3075; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kwong J, 2000, J CELL SCI, V113, P2273; LAH JJ, 1993, J NEUROCYTOL, V22, P92, DOI 10.1007/BF01181573; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li SH, 1998, J NEUROCHEM, V71, P2178; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Martin EJ, 1999, J COMP NEUROL, V403, P421; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, BIOCHEM SOC T, V29, P472, DOI 10.1042/BST0290472; Raiborg C, 2001, J CELL SCI, V114, P2255; Sambrook J., 1989, MOL CLONING, pA1; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; TELLEZNAGEL I, 1974, J NEUROPATH EXP NEUR, V33, P308, DOI 10.1097/00005072-197404000-00008; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265	61	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28212	28221		10.1074/jbc.M111612200	http://dx.doi.org/10.1074/jbc.M111612200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021262	hybrid			2022-12-25	WOS:000177189800079
J	Neves, AR; Ventura, R; Mansour, N; Shearman, C; Gasson, MJ; Maycock, C; Ramos, A; Santos, H				Neves, AR; Ventura, R; Mansour, N; Shearman, C; Gasson, MJ; Maycock, C; Ramos, A; Santos, H			Is the glycolytic flux in Lactococcus lactis primarily controlled by the redox charge? Kinetics of NAD(+) and NADH pools determined in vivo by C-13 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; LACTATE-DEHYDROGENASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; STREPTOCOCCUS-CREMORIS; PYRUVATE METABOLISM; ACID; GENE; EXPRESSION; SEQUENCE; FERMENTATION	The involvement of nicotinamide adenine nucleotides (NAD(+), NADH) in the regulation of glycolysis in Lactococcus lactis was investigated by using C-13 and P-31 NMR to monitor in vivo the kinetics of the pools of NAD(+), NADH, ATP, inorganic phosphate (Pi), glycolytic intermediates, and end products derived from a pulse of glucose. Nicotinic acid specifically labeled on carbon 5 was synthesized and used in the growth medium as a precursor of pyridine nucleotides to allow for in vivo detection of C-13-labeled NAD(+) and NADH. The capacity of L. lactis MG1363 to regenerate NAD(+) was manipulated either by turning on NADH oxidase activity or by knocking out the gene encoding lactate dehydrogenase (LDH). An LDH- deficient strain was constructed by double crossover. Upon supply of glucose, NAD(+) was constant and maximal (similar to5 mm) in the parent strain (MG1363) but decreased abruptly in the LDH- strain both under aerobic and anaerobic conditions. NADH in MG1363 was always below the detection limit as long as glucose was available. The rate of glucose consumption under anaerobic conditions was 7-fold lower in the LDH- strain and NADH reached high levels (2.5 mm), reflecting severe limitation in regenerating NAD(+). However, under aerobic conditions the glycolytic flux was nearly as high as in MG1363 despite the accumulation of NADH up to 1.5 mm. Glyceraldehyde-3-phosphate dehydrogenase was able to support a high flux even in the presence of NADH concentrations much higher than those of the parent strain. We interpret the data as showing that the glycolytic flux in wild type L. lactis is not primarily controlled at the level of glyceraldehyde-3-phosphate dehydrogenate by NADH. The ATP/ADP/P-i content could play an important role.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Univ Nova Lisboa, Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal; Norwich Lab, Food Res Inst, Norwich NR4 7UA, Norfolk, England	Universidade Nova de Lisboa; Universidade Nova de Lisboa; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apt 127, P-2780 Oeiras, Portugal.	santos@itqb.unl.pt	Maycock, Christopher/H-9875-2012; Santos, Helena/B-9141-2011; Ventura, Rita/B-8011-2008; Maycock, Christopher/Z-3471-2019; Neves, Ana/B-9476-2008; Ramos, ver/B-2185-2010	Maycock, Christopher/0000-0002-6687-4435; Santos, Helena/0000-0002-8050-9485; Ventura, Rita/0000-0002-6854-7278; Maycock, Christopher/0000-0002-6687-4435; Neves, Ana/0000-0003-4896-9585; Ramos, Ana/0000-0003-3419-2226; Mansour, Nahla/0000-0002-8045-7531				Andersen HW, 2001, EUR J BIOCHEM, V268, P6379, DOI 10.1046/j.0014-2956.2001.02599.x; Andersen HW, 2001, J BACTERIOL, V183, P3458, DOI 10.1128/JB.183.11.3458-3467.2001; ANDERSEN KB, 1977, J BIOL CHEM, V252, P4151; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYSON TA, 1974, J ORG CHEM, V39, P1158, DOI 10.1021/jo00922a033; CocaignBousquet M, 1996, ANTON LEEUW INT J G, V70, P253, DOI 10.1007/BF00395936; CONDON S, 1987, FEMS MICROBIOL LETT, V46, P269, DOI 10.1111/j.1574-6968.1987.tb02465.x; de Felipe FL, 1998, J BACTERIOL, V180, P3804; de Graef MR, 1999, J BACTERIOL, V181, P2351, DOI 10.1128/JB.181.8.2351-2357.1999; de Vos WM, 1999, CURR OPIN MICROBIOL, V2, P289, DOI 10.1016/S1369-5274(99)80050-2; Even S, 1999, METAB ENG, V1, P198, DOI 10.1006/mben.1999.0120; Even S, 2001, J BACTERIOL, V183, P3817, DOI 10.1128/JB.183.13.3817-3824.2001; Garrigues C, 2001, METAB ENG, V3, P211, DOI 10.1006/mben.2001.0182; Garrigues C, 1997, J BACTERIOL, V179, P5282, DOI 10.1128/jb.179.17.5282-5287.1997; Gonzalez B, 1997, YEAST, V13, P1347, DOI 10.1002/(SICI)1097-0061(199711)13:14<1347::AID-YEA176>3.0.CO;2-O; GRIFFIN HG, 1992, GENE, V122, P193, DOI 10.1016/0378-1119(92)90049-U; HARRISON DE, 1970, APPL MICROBIOL, V19, P446, DOI 10.1128/AEM.19.3.446-450.1970; Hols P, 1999, J BACTERIOL, V181, P5521, DOI 10.1128/JB.181.17.5521-5526.1999; HUTSON SM, 1989, BIOCHEMISTRY-US, V28, P4325, DOI 10.1021/bi00436a030; JENSEN NB, 1999, THESIS TU DENMARK LY; KOEBMANN BJ, 2000, BTK2000 ANIMATING CE, P299; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Leonardo MR, 1996, J BACTERIOL, V178, P6013, DOI 10.1128/jb.178.20.6013-6018.1996; LLANOS RM, 1992, J BACTERIOL, V174, P6956, DOI 10.1128/JB.174.21.6956-6964.1992; LONDON J, 1966, J GEN MICROBIOL, V44, P241, DOI 10.1099/00221287-44-2-241; LONDON RE, 1988, PROG NUCL MAG RES SP, V20, P337, DOI 10.1016/0079-6565(88)80010-4; MASON PW, 1981, J BIOL CHEM, V256, P1861; Neves AR, 1999, BIOTECHNOL BIOENG, V64, P200, DOI 10.1002/(SICI)1097-0290(19990720)64:2&lt;200::AID-BIT9&gt;3.0.CO;2-K; Neves AR, 2000, EUR J BIOCHEM, V267, P3859, DOI 10.1046/j.1432-1327.2000.01424.x; Novak L, 2000, J BACTERIOL, V182, P1136, DOI 10.1128/JB.182.4.1136-1143.2000; PENFOUND T, 1996, ESCHERICHIA COLI SAL, P721; POOLMAN B, 1987, J BACTERIOL, V169, P5887, DOI 10.1128/jb.169.12.5887-5890.1987; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; POOLMAN B, 1987, J BACTERIOL, V169, P1460, DOI 10.1128/jb.169.4.1460-1468.1987; Ramos A, 2001, APPL ENVIRON MICROB, V67, P33, DOI 10.1128/AEM.67.1.33-41.2001; Ricci JCD, 2000, BIOCHEM BIOPH RES CO, V271, P244, DOI 10.1006/bbrc.2000.2603; SANTOS H, 1986, J MAGN RESON, V68, P345, DOI 10.1016/0022-2364(86)90251-9; SNOEP JI, 1992, THESIS U AMSTERDAM A; Tetaud E, 1999, BIOCHEM J, V338, P55, DOI 10.1042/0264-6021:3380055; Teusink B, 1998, TRENDS BIOCHEM SCI, V23, P162, DOI 10.1016/S0968-0004(98)01205-5; THOMAS TD, 1979, J BACTERIOL, V138, P109, DOI 10.1128/JB.138.1.109-117.1979; THOMAS TD, 1976, J BACTERIOL, V125, P1240, DOI 10.1128/JB.125.3.1240-1242.1976; THOMPSON J, 1984, J BACTERIOL, V158, P791, DOI 10.1128/JB.158.3.791-800.1984; UNKEFER CJ, 1983, SCIENCE, V222, P62, DOI 10.1126/science.6353573; VOGEL AI, 1989, VOGELS TXB PRACTICAL, P1062; WIMPENNY JW, 1972, J BACTERIOL, V11, P24, DOI 10.1128/JB.111.1.24-32.1972	48	108	112	1	23	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28088	28098		10.1074/jbc.M202573200	http://dx.doi.org/10.1074/jbc.M202573200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011086	Green Submitted, hybrid			2022-12-25	WOS:000177189800065
J	Stoll, SW; Kansra, S; Elder, JT				Stoll, SW; Kansra, S; Elder, JT			Metalloproteinases stimulate ErbB-dependent ERK signaling in human skin organ culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FACTOR-ALPHA; HUMAN KERATINOCYTES; GENE-EXPRESSION; MESSENGER-RNA; EGF RECEPTOR; CELL-LINE; BINDING; ACTIVATION; REQUIRES	To investigate the role of ERK signaling in human skin responses to wounding, organ cultures of human skin were maintained for 0.5-24 h in the presence of various inhibitors, followed by measurement of ERK phosphorylation or mRNA levels. The MEK inhibitor PD98059 produced near-complete (97-98%) inhibition of ERK phosphorylation, whereas inhibition of c-Fos, c-Jun, HB-EGF, AR, and VEGF mRNA by this compound was incomplete (41-65%). PD98059 was significantly more effective than either PD158780 or BB2516 as an inhibitor of ERK phosphorylation and of the rapid rise in c-Fos and c-Jun mRNA expression. In contrast, all three compounds inhibited the more delayed rise in HBEGF mRNA to the same extent. Exogenous epidermal growth factor abrogated the inhibition of ERK phosphorylation caused by BB2516. These data indicate that one or more metalloproteinases activate ErbB signaling in skin organ culture, that ErbB signaling plays an important but not exclusive role in the activation of ERK, and that non-ERK pathways contribute to gene expression in this system. Because metalloproteinase-mediated cleavage of the HB-EGF transmembrane precursor is known to be ERK-dependent, our data suggest that ERK activation resulting from initial trauma leads to metalloproteinase-mediated cleavage of HB-EGF, thereby triggering the ErbB signaling cascade.	Univ Michigan, Med Ctr, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Radiat Oncol Canc Biol, Ann Arbor, MI 48109 USA; Ann Arbor Vet Affairs Hlth Syst, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Elder, JT (corresponding author), Univ Michigan, Med Ctr, Dept Dermatol, 3312 CCGC,Box 0932,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	jelder@umich.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR048405] Funding Source: NIH RePORTER; NIAMS NIH HHS [R21 AR 48405] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BROWN RL, 1994, J SURG RES, V56, P562, DOI 10.1006/jsre.1994.1090; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; De Potter IY, 2001, EXP CELL RES, V271, P315, DOI 10.1006/excr.2001.5390; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Glaser KB, 1999, BIOCHEM PHARMACOL, V57, P291, DOI 10.1016/S0006-2952(98)00300-1; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JENSEN PJ, 1993, J CELL PHYSIOL, V155, P333, DOI 10.1002/jcp.1041550214; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; KLEIN SB, 1992, J CELL PHYSIOL, V151, P326, DOI 10.1002/jcp.1041510214; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; Marques MM, 1999, EXP CELL RES, V252, P432, DOI 10.1006/excr.1999.4634; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; NANNEY LB, 1990, J INVEST DERMATOL, V94, P624, DOI 10.1111/1523-1747.ep12876204; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rewcastle GW, 1998, J MED CHEM, V41, P742, DOI 10.1021/jm970641d; Sakai M, 2001, EXP NEPHROL, V9, P28; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Stoll SW, 1998, EXP DERMATOL, V7, P391, DOI 10.1111/j.1600-0625.1998.tb00339.x; Stoll SW, 2001, NEOPLASIA, V3, P339, DOI 10.1038/sj.neo.7900170; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; VARANI J, 1995, AM J PATHOL, V146, P210; VOORHEES JJ, 1972, ARCH DERMATOL, V105, P695, DOI 10.1001/archderm.105.5.695; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; Woolley K, 2000, BIOESSAYS, V22, P911; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	47	19	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26839	26845		10.1074/jbc.M201108200	http://dx.doi.org/10.1074/jbc.M201108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016209	hybrid			2022-12-25	WOS:000177055900019
J	Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK				Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK			Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells	ONCOGENE			English	Article						radiation; Erb-B; EGFR; Akt; p70 S6 kinase	GROWTH-FACTOR RECEPTOR; MESSENGER-RNA TRANSLATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MALIGNANT GLIOMA; IN-VIVO; INHIBITION; GENE; PROLIFERATION; TRANSDUCTION	In this study we have investigated the effects of low dose ionizing radiation (2 Gy) on p70 S6 kinase and Akt signaling with respect to Erb-B receptors in both the A431 squamous and the MDA-MB-231 mammary carcinoma cell lines. Ionizing radiation caused a 2-3-fold increase in p70 S6 kinase activity that was blocked pharmacologically using an EGFR inhibitor (AG1478) alone, or in combination with an Erb-B2 inhibitor (AG825). These results suggested that both EGFR and Erb-B2 receptors could initiate radiation-induced activation of p70 S6K. EGFR dependent Erb-B3 signaling also contributed to p70 S6 kinase activity through recruitment and activation of PI3K, which has been shown to regulate p70 S6 kinase activity. Furthermore, inhibition of the EGFR blocked IR stimulated increases in protein translation, a biologic consequence of p70 S6 kinase activation. We also report that ionizing radiation stimulated Akt activity that was partially independent of PI3K activity, but dependent on Erb-B2 function. Erb-B2 inhibition also correlated with enhanced apoptosis following IR exposure, suggesting an important role for Erb-B2 in cell survival. Together this work demonstrates that the Erb-B receptor tyrosine kinase network stimulates cytoprotective p70 S6 kinase and Akt activity in response to clinically relevant doses of ionizing radiation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA72955, R01 CA65896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto Tetsuo, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P714; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Huang SM, 1999, CANCER RES, V59, P1935; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KIM HH, 1994, J BIOL CHEM, V269, P24747; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu AX, 1998, CANCER RES, V58, P2973; Milas L, 2000, CLIN CANCER RES, V6, P701; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	44	136	142	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4032	4041		10.1038/sj.onc.1205500	http://dx.doi.org/10.1038/sj.onc.1205500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037685				2022-12-25	WOS:000175869900009
J	Tiwari, A; Salacinski, HJ; Punshon, G; Hamilton, G; Seifalian, AM				Tiwari, A; Salacinski, HJ; Punshon, G; Hamilton, G; Seifalian, AM			Development of a hybrid cardiovascular graft using a tissue engineering approach	FASEB JOURNAL			English	Article						hybrid graft; anticoagulant peptide; endothelial cells; spacer arm; covalent bonding; x-ray photoelectron spectroscopy	VASCULAR BYPASS GRAFTS; EXPANDED POLYTETRAFLUOROETHYLENE; CELL ATTACHMENT; EPTFE GRAFTS; IN-VITRO; ENDOTHELIALIZATION; ADHESION; SEQUENCE; DACRON; PTFE	Tissue engineering of endothelial cells (EC) and chemical engineering with anticoagulant moieties has been undertaken in order to improve prosthetic graft patency and thrombogenicity. This was done by covalently bonding a compliant poly(carbonate-urea) urethane graft (MyoLink(TM)) with arginine-glycine-aspartate (RGD) or/and heparin (Hep) to ascertain whether EC retention could be improved. The retention of these moieties and EC was assessed after exposure to pulsatile flow. We covalently bonded RGD, Hep, and RGD/Hep onto the luminal surface of MyoLink using spacer arm technology. Narrow-beam X-ray photoelectron spectroscopy was carried out to check the efficiency of the bonding. EC were radiolabeled and seeded onto native MyoLink and with 1) RGD-, 2) Hep-, and 3) RGD/Hep-bonded grafts and exposed to shear stress in a physiological flow circuit for 6 h, which reproduces femoral artery flow waveforms and pulsatility. Results were recorded on a gamma camera imaging system. Viability of cells was tested with a modified Alamar Blue assay (ABA) and scanning electron microscopy for morphological appearance of seeded cells. Experiments were repeated (n=6). RGD, Hep, and RGD/Hep were bonded together in a uniform distribution on the luminal surface of each graft type, and bioactivity of each moiety covalently bonded was very high. In the flow circuit, there was exponential cell retention for the first 60 min of flow for all the grafts, but after 6 h of exposure to pulsatile flow the RGD/Hep-bonded graft had a significantly better cell retention rate than native MyoLink (75.7%+/-2.3 vs. 60.5+/-10.1, P<0.05). ABA test showed that all the seeded cells postexposure to flow were viable, and significantly higher metabolic activity was recorded on a RGD/Hep-bonded graft than with MyoLink-seeded graft (P<0.01). Using RGD/Hep covalently bonded onto graft surfaces improves cell retention and provides an antithrombogenic surface for initial blood flow in vivo until full EC activity develops postseeding. This would allow the development and further improvement of hybrid grafts.	Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Univ Dept Surg, London NW3 2QG, England; UCL, Royal Free & Univ Coll Med Sch, Univ Dept Surg, Tissue Engn Ctr, London, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London	Seifalian, AM (corresponding author), Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Univ Dept Surg, Pond St, London NW3 2QG, England.	A.Seifalian@RFC.UCL.AC.UK	hamilton, george/K-4764-2013; Seifalian, Alexander M/I-6028-2013; Punshon, Geoffrey/K-5352-2013	Seifalian, Alexander M/0000-0002-1180-3322; Punshon, Geoffrey/0000-0001-9247-9546				ABBOTT WM, 1987, J VASC SURG, V5, P376, DOI 10.1067/mva.1987.avs0050376; BRANDLEY BK, 1988, ANAL BIOCHEM, V172, P270, DOI 10.1016/0003-2697(88)90442-3; Deutsch M, 1999, SURGERY, V126, P847, DOI 10.1016/S0039-6060(99)70025-5; Devine C, 2001, J VASC SURG, V33, P533, DOI 10.1067/mva.2001.113578; Giudiceandrea A, 1998, EUR J VASC ENDOVASC, V15, P147, DOI 10.1016/S1078-5884(98)80136-6; Giudiceandrea A, 2000, J ARTIF ORGANS, V3, P16; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Hynes RO, 1999, GUIDEBOOK EXTRACELLU, P422; HYNES RO, 1990, FIBRONECTIONS; JOHNSON WC, 1988, ARCH SURG-CHICAGO, V123, P434; KRIJGSMAN B, 2002, IN PRESS TISSUE ENG; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LIN HB, 1992, J BIOMAT SCI-POLYM E, V3, P217, DOI 10.1163/156856292X00132; LIN HB, 1994, J BIOMED MATER RES, V28, P329, DOI 10.1002/jbm.820280307; Netelenbos T, 2001, EXP HEMATOL, V29, P884, DOI 10.1016/S0301-472X(01)00653-1; Robinson BI, 1999, CARDIOVASC SURG, V7, P214, DOI 10.1016/S0967-2109(98)00126-4; RUBIN BG, 1992, J VASC SURG, V15, P683, DOI 10.1016/0741-5214(92)90016-2; Salacinski HJ, 2001, ARTIF ORGANS, V25, P974, DOI 10.1046/j.1525-1594.2001.06716.x; Salacinski HJ, 2001, MED BIOL ENG COMPUT, V39, P609, DOI 10.1007/BF02345431; Salacinski HJ, 2002, J BIOMED MATER RES, V59, P207; Salacinski HJ, 2000, EUR J VASC ENDOVASC, V20, P342, DOI 10.1053/ejvs.2000.1185; Seifalian AM, 2001, J BIOMED MATER RES, V55, P637, DOI 10.1002/1097-4636(20010615)55:4<637::AID-JBM1058>3.0.CO;2-Z; SEIFALIAN AM, 1999, TISSUE ENG PROSTHETI, V2, P45; Tai NR, 2000, BRIT J SURG, V87, P1516, DOI 10.1046/j.1365-2168.2000.01566.x; Tiwari A, 2001, EUR J VASC ENDOVASC, V21, P193, DOI 10.1053/ejvs.2001.1316; TIWARI A, 2002, IN PRESS CARDIOVASC; VOHRA RK, 1990, ARTIF ORGANS, V14, P41; Walluscheck KP, 1996, EUR J VASC ENDOVASC, V12, P321, DOI 10.1016/S1078-5884(96)80251-6; Walpoth BH, 1998, CIRCULATION, V98, pII319; ZILLA P, 1989, SURGERY, V105, P515	30	100	106	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6682/02/0016-0791	10.1096/fj.01-0826com	http://dx.doi.org/10.1096/fj.01-0826com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039860				2022-12-25	WOS:000176683900004
J	Canaff, L; Hendy, GN				Canaff, L; Hendy, GN			Human calcium-sensing receptor gene - Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; EXTRACELLULAR CA2+-SENSING RECEPTOR; PARATHYROID-HORMONE GENE; CHROMOGRANIN-A; IN-VIVO; SEVERE HYPERPARATHYROIDISM; DECREASED EXPRESSION; BENIGN HYPERCALCEMIA; SET-POINT	The calcium-sensing receptor (CASR), expressed in parathyroid chief cells, thyroid C-cells, and cells of the kidney tubule, is essential for maintenance of calcium homeostasis. Here we show parathyroid, thyroid, and kidney CASR mRNA levels increased 2-fold at 15 h after intraperitoneal injection of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) in rats. Human thyroid C-cell (TT) and kidney proximal tubule cell (HKC) CASR gene transcription increased similar to2-fold at 8 and 12 h after 1,25(OH)(2)D-3 treatment. The human CASR gene has two promoters yielding alternative transcripts containing either exon 1A or exon 1B 5'-untranslated region sequences that splice to exon 2 some 242 by before the ATG translation start site. Transcriptional start sites were identified in parathyroid gland and TT cells; that for promoter P1 lies 27 by downstream of a TATA box, whereas that for promoter P2, which lacks a TATA box, lies in a GC-rich region. In HKC cells, transcriptional activity of a P1 reporter gene construct was 11-fold and of P2 was 33-fold above basal levels. 10(-8) M 1,25(OH)(2)D-3 stimulated P1 activity 2-fold and P2 activity 2.5-fold. Vitamin D response elements (VDREs), in which half-sites (6 lip) are separated by three nucleotides, were identified in both promoters and shown to confer 1,25(OH)(2)D-3 responsiveness to a heterologous promoter. This responsiveness was lost when the VDREs were mutated. In electrophoretic mobility shift assays with either in vitro transcribed/translated vitamin D receptor and retinoid X receptor-a, or HKC nuclear extract, specific protein-DNA complexes were formed in the presence of 1,25(OH)(2)D-3 on oligonucleotides representing the P1 and P2 VDREs. In summary, functional VDREs have been identified in the CASR gene and provide the mechanism whereby 1,25(OH)(2)D up-regulates parathyroid, thyroid C-cell, and kidney CASR expression.	Royal Victoria Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University	Hendy, GN (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	geoffrey.hendy@mcgill.ca						Bapty BW, 1998, KIDNEY INT, V53, P583, DOI 10.1046/j.1523-1755.1998.00790.x; Bapty BW, 1998, AM J PHYSIOL-RENAL, V275, pF353, DOI 10.1152/ajprenal.1998.275.3.F353; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; BRINGHURST FR, 1998, WILLIAMS TXB ENDOCRI, P1155; Brown AJ, 1996, AM J PHYSIOL-RENAL, V270, pF454, DOI 10.1152/ajprenal.1996.270.3.F454; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Brown EM, 2001, PRINCIPLES PRACTICE, P478; Brown SB, 2000, J CLIN ENDOCR METAB, V85, P868, DOI 10.1210/jc.85.2.868; Canaff L, 1999, ENDOCRINOLOGY, V140, P3633, DOI 10.1210/en.140.8.3633; Canaff L, 2001, J BIOL CHEM, V276, P4070, DOI 10.1074/jbc.M009317200; Canaff L, 1998, ENDOCRINOLOGY, V139, P1184, DOI 10.1210/en.139.3.1184; Carey M, 2000, TRANSCRIPTIONAL REGU; Carling T, 2000, J CLIN ENDOCR METAB, V85, P2000, DOI 10.1210/jc.85.5.2000; Carling T, 2000, J CLIN ENDOCR METAB, V85, P2042, DOI 10.1210/jc.85.5.2042; Carling T, 2001, TRENDS ENDOCRIN MET, V12, P53, DOI 10.1016/S1043-2760(00)00345-3; CARLING T, 1995, NAT MED, V1, P1309, DOI 10.1038/nm1295-1309; Cetani F, 2000, J CLIN ENDOCR METAB, V85, P4789, DOI 10.1210/jc.85.12.4789; Cetani F, 1999, J BONE MINER RES, V14, P878, DOI 10.1359/jbmr.1999.14.6.878; Chikatsu N, 2000, J BIOL CHEM, V275, P7553, DOI 10.1074/jbc.275.11.7553; D'Souza-Li L, 2001, HUM MUTAT, V18, P411, DOI 10.1002/humu.1212; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; Degehardt S, 1998, KIDNEY INT, V53, P556, DOI 10.1046/j.1523-1755.1998.00802.x; DELMEZ JA, 1989, J CLIN INVEST, V83, P1349, DOI 10.1172/JCI114022; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DUNLAY R, 1989, KIDNEY INT, V36, P1093, DOI 10.1038/ki.1989.305; Farnebo F, 1998, SURGERY, V124, P1094, DOI 10.1067/msy.1998.91828; Farnebo F, 1997, J CLIN ENDOCR METAB, V82, P3481, DOI 10.1210/jc.82.10.3481; FERRARA J, 1994, J BIOL CHEM, V269, P2971; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; Hendy GN, 2002, PRINCIPLES BONE BIOL, P1017; HOOPES R, 1997, J AM SOC NEPHROL, V8, P563; HOSOKAWA Y, 1995, J CLIN ENDOCR METAB, V80, P3107, DOI 10.1210/jc.80.11.3107; Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523; JANICIC N, 1995, MAMM GENOME, V6, P798, DOI 10.1007/BF00539007; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; KWAN JTC, 1992, NEPHROL DIAL TRANSPL, V7, P829; LEDGER GA, 1994, J CLIN ENDOCR METAB, V79, P211, DOI 10.1210/jc.79.1.211; Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313; MALBERTI F, 1992, NEPHROL DIAL TRANSPL, V7, P822; MATSUMOTO T, 1987, AM J PHYSIOL, V253, pE503, DOI 10.1152/ajpendo.1987.253.5.E503; MOULAND AJ, 1991, ENDOCRINOLOGY, V128, P441, DOI 10.1210/endo-128-1-441; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Petrucci M, 2000, KIDNEY INT, V58, P38, DOI 10.1046/j.1523-1755.2000.00138.x; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rao DS, 2000, CLIN ENDOCRINOL, V53, P373, DOI 10.1046/j.1365-2265.2000.01081.x; ROGERS KV, 1995, ENDOCRINOLOGY, V136, P499, DOI 10.1210/en.136.2.499; SANDS JM, 1998, AM J PHYSIOL, V274, pE978; Scott P, 1999, J AM SOC NEPHROL, V10, P1007; Shiraishia K, 2001, AM J NEPHROL, V21, P507, DOI 10.1159/000046658; SILVER J, 1986, J CLIN INVEST, V78, P1296, DOI 10.1172/JCI112714; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; Soei YL, 1999, J BONE MINER RES, V14, pS447; Soliman E, 1997, ENDOCRINOLOGY, V138, P2596, DOI 10.1210/en.138.6.2596; THOMPSON DB, 1995, J CLIN ENDOCR METAB, V80, P3377, DOI 10.1210/jc.80.11.3377; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; TRECHSEL U, 1980, AM J PHYSIOL, V239, pE119, DOI 10.1152/ajpendo.1980.239.2.E119; WEISINGER JR, 1989, J BONE MINER RES, V4, P929; WU H, 1996, J BONE MINER RES, V11, pS488; Yamauchi M, 2001, CLIN ENDOCRINOL, V55, P373, DOI 10.1046/j.1365-2265.2001.01318.x; YAO J, 1998, BONE S, V23, pT265; Yao JL, 1998, J CLIN INVEST, V101, P2223, DOI 10.1172/JCI1164; Yokoyama K, 2002, CLIN NEPHROL, V57, P131; Yokoyama K, 2001, NEPHRON, V89, P315, DOI 10.1159/000046092; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	75	272	282	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30337	30350		10.1074/jbc.M201804200	http://dx.doi.org/10.1074/jbc.M201804200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12036954	hybrid			2022-12-25	WOS:000177509300120
J	Panin, VM; Shao, L; Lei, L; Moloney, DJ; Irvine, KD; Haltiwanger, RS				Panin, VM; Shao, L; Lei, L; Moloney, DJ; Irvine, KD; Haltiwanger, RS			Notch Ligands are substrates for protein O-fucosyltransferase-1 and fringe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED FUCOSE; SITE-DIRECTED MUTAGENESIS; GROWTH-FACTOR DOMAIN; HAMSTER OVARY CELLS; PLASMINOGEN-ACTIVATOR; DROSOPHILA; DELTA; SERRATE; MUTATIONS; GLYCOSYLTRANSFERASE	O-Fucose has been identified on epidermal growth factor-like (EGF) repeats of Notch, and elongation of O-fucose has been implicated in the modulation of Notch signaling by Fringe. O-Fucose modifications are also predicted to occur on Notch ligands based on the presence of the C(2)XXGG(S/T)C-3 consensus site (where S/T is the modified amino acid) in a number of the EGF repeats of these proteins. Here we establish that both mammalian and Drosophila Notch ligands are modified with O-fucose glycans, demonstrating that the consensus site was useful for making predictions. The presence of O-fucose on Notch ligands raised the question of whether Fringe, an O-fucose specific beta1,3-N-acetylglucosaminyltransferase, was capable of modifying O-fucose on the ligands. Indeed, O-fucose on mammalian Deltal and Jagged1 can be elongated with Manic Fringe in vivo, and Drosophila Delta and Serrate are substrates for Drosophila Fringe in vitro. These results raise the interesting possibility that alteration of O-fucose glycans on Notch ligands could play a role in the mechanism of Fringe action on Notch signaling. As an initial step to begin addressing the role of the O-fucose glycans on Notch ligands in Notch signaling, a number of mutations in predicted O-fucose glycosylation sites on Drosophila Serrate have been generated. Interestingly, analysis of these mutants has revealed that O-fucose modifications occur on some EGF repeats not predicted by the C(2)XXGGS/TC3 consensus site. A revised, broad consensus site, (CX3-5S)-X-2/TC3 (where X3-5 are any 3-5 amino acid residues), is proposed.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rutgers State University New Brunswick; Howard Hughes Medical Institute; Rutgers State University New Brunswick	Haltiwanger, RS (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126, R01GM054594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61126, R01 GM061126, GM54594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; BJOERN S, 1991, J BIOL CHEM, V266, P11051; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulman MP, 2000, NAT GENET, V24, P438, DOI 10.1038/74307; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; de Celis JF, 2000, DEVELOPMENT, V127, P1291; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; Gohlke M, 1996, J BIOL CHEM, V271, P7381, DOI 10.1074/jbc.271.13.7381; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Heritage ML, 2000, HUM MUTAT, V16, P408, DOI 10.1002/1098-1004(200011)16:5<408::AID-HUMU5>3.0.CO;2-9; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Jacobsen TL, 1998, DEVELOPMENT, V125, P4531; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; Ju BG, 2000, NATURE, V405, P191, DOI 10.1038/35012090; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Krantz ID, 1999, AM J MED GENET, V84, P56; Mer G, 1996, J MOL BIOL, V258, P158, DOI 10.1006/jmbi.1996.0240; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rini JM, 1999, CURR OPIN STRUC BIOL, V9, P578, DOI 10.1016/S0959-440X(99)00008-1; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Shimizu K, 2001, J BIOL CHEM, V276, P25753, DOI 10.1074/jbc.M103473200; THOMAS U, 1991, DEVELOPMENT, V111, P749; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002	53	138	144	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29945	29952		10.1074/jbc.M204445200	http://dx.doi.org/10.1074/jbc.M204445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12036964	hybrid			2022-12-25	WOS:000177509300075
J	Gioeli, D; Ficarro, SB; Kwiek, JJ; Aaronson, D; Hancock, M; Catling, AD; White, FM; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Weber, MJ				Gioeli, D; Ficarro, SB; Kwiek, JJ; Aaronson, D; Hancock, M; Catling, AD; White, FM; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Weber, MJ			Androgen receptor phosphorylation - Regulation and identification of the phosphorylation sites.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN PROGESTERONE-RECEPTOR; ACTIVATED PROTEIN-KINASE; MOUSE GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; CANCER CELLS; SIGNALING PATHWAY; MASS-SPECTROMETRY; SEQUENCE-ANALYSIS; GENE-EXPRESSION	Activation of signal transduction kinase cascades has been shown to alter androgen receptor (AR) activity. Although it has been suggested that changes in AR phosphorylation might be directly responsible, the basal and regulated phosphorylations of the AR have not been fully determined. We have identified the major sites of AR phosphorylation on ARs expressed in COS-1 cells using a combination of peptide mapping, Edman degradation, and mass spectrometry. We describe the identification of seven AR phosphorylation sites, show that the phosphopeptides seen with exogenously expressed ARs are highly similar to those seen with endogenous ARs in LN-CaP cells and show that specific agonists differentially regulate the phosphorylation state of endogenous ARs in LNCaP prostate cancer cells. Treatment of LNCaP cells with the synthetic androgen, R1881, elevates phosphorylation of serines 16, 81, 256, 308, 424, and 650. Ser-94 appears constitutively phosphorylated. Forskolin, epidermal growth factor, and phorbol 12-myristate 13-acetate increase the phosphorylation of Ser-650. The kinetics of phosphorylation of most sites in response to hormone or forskolin is temporally delayed, reaching a maximum at 2 h post-stimulation. The exception is Ser-81, which continues to display increasing phosphorylation at 6 h. These data provide a basis for analyzing mechanisms of crosstalk between growth factor signaling and androgen in prostate development, physiology, and cancer.	Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Dept Pathol, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Dept Chem, Hlth Sci Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Dept Pharmacol, Ctr Hlth Sci, Charlottesville, VA 22908 USA; Univ Virginia, Program Mol Med, Hlth Sci Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Weber, MJ (corresponding author), Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Charlottesville, VA 22908 USA.	MJW@Virginia.edu	Hunt, Donald F/I-6936-2012; Kwiek, Jesse/E-3449-2011	Hunt, Donald F/0000-0003-2815-6368; White, Forest/0000-0002-1545-1651; Kwiek, Jesse/0000-0003-4277-8315	NATIONAL CANCER INSTITUTE [P01CA076465, R37CA039076, R01CA039076, T32CA009109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09109, CA40042, CA76465, CA39076] Funding Source: Medline; NIDDK NIH HHS [T32 DK07320] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSSON PA, 1989, PROSTATE, V14, P71, DOI 10.1002/pros.2990140109; ANDREWS PE, 1992, CANCER RES, V52, P1525; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; BONKHOFF H, 1995, HUM PATHOL, V26, P167, DOI 10.1016/0046-8177(95)90033-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carson JP, 1999, CANCER RES, V59, P1449; CULIG Z, 1995, EUR UROL, V27, P45; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Gioeli D, 1999, CANCER RES, V59, P279; Gregory CW, 2001, CANCER RES, V61, P2892; HSU SC, 1995, J BIOL CHEM, V270, P3359, DOI 10.1074/jbc.270.7.3359; HU JM, 1994, MOL ENDOCRINOL, V8, P1709, DOI 10.1210/me.8.12.1709; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Pandian SS, 2001, BIOCHEM BIOPH RES CO, V283, P806, DOI 10.1006/bbrc.2001.4873; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; Webster JC, 1997, J BIOL CHEM, V272, P9287; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wen Y, 2000, CANCER RES, V60, P6841; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; Zhu ZX, 2001, BIOCHEM BIOPH RES CO, V284, P836, DOI 10.1006/bbrc.2001.5030	48	273	299	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29304	29314		10.1074/jbc.M204131200	http://dx.doi.org/10.1074/jbc.M204131200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12015328	hybrid			2022-12-25	WOS:000177342600120
J	Henderson, MJ; Russell, AJ; Hird, S; Munoz, M; Clancy, JL; Lehrbach, GM; Calanni, ST; Jans, DA; Sutherland, RL; Watts, CKW				Henderson, MJ; Russell, AJ; Hird, S; Munoz, M; Clancy, JL; Lehrbach, GM; Calanni, ST; Jans, DA; Sutherland, RL; Watts, CKW			EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; N-END RULE; CALCIUM-BINDING PROTEIN; UBIQUITIN LIGASE; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; 26S PROTEASOME; HUMAN HOMOLOG; POLY(A)-BINDING PROTEIN; RECOGNITION COMPONENT	The ubiquitin-protein ligase EDD encodes an orthologue of the hyperplastic discs tumor suppressor gene, which has a critical role in Drosophila development. Frequent allelic imbalance at the EDD chromosomal locus in human cancers suggests a role in tumorigenesis. In addition to a HECT (homologous to E6-AP carboxyl terminus) domain, the EDD protein contains a UBR1 zinc finger motif and ubiquitin-associated domain, each of which indicates involvement in ubiquitinylation pathways. This study shows that EDD interacts with importin alpha5 through consensus basic nuclear localization signals and is localized in cell nuclei. EDD also binds progesterone receptor (PR) and potentiates progestin-mediated gene transactivation. This activity is comparable with that of the coactivator SRC-1, but, in contrast, the interaction between EDD and PR does not appear to involve an LXXLL receptor-binding motif. EDD also binds calcium- and integrin-binding protein/DNA-dependent protein kinase-interacting protein, a potential target of ubiquitin-mediated proteolysis, and an altered association is found between EDD and calcium- and integrin-binding protein/DNA-dependent protein kinase-interacting protein in response to DNA damage. The data presented here demonstrate a role for EDD in PR signaling but also suggest a link to cancer through DNA damage response pathways.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Australian National University; John Curtin School of Medical Research; Monash University	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008; henderson, Michelle/G-6657-2012	Munoz, Marcia/0000-0001-7603-0351; Jans, David/0000-0001-5115-4745				Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Dennis AP, 2001, FRONT BIOSCI, V6, pD954, DOI 10.2741/Dennis; Deo RC, 2001, P NATL ACAD SCI USA, V98, P4414, DOI 10.1073/pnas.071552198; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Duncan PI, 2001, EXP CELL RES, V270, P78, DOI 10.1006/excr.2001.5333; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; GU J, 1995, ONCOGENE, V11, P2175; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Masuyama H, 1998, J CELL BIOCHEM, V71, P429, DOI 10.1002/(SICI)1097-4644(19981201)71:3<429::AID-JCB11>3.0.CO;2-P; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Richards S, 1996, GENETICS, V142, P1215; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; White R, 1998, ENDOCR-RELAT CANCER, V5, P1, DOI 10.1677/erc.0.0050001; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	68	84	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26468	26478		10.1074/jbc.M203527200	http://dx.doi.org/10.1074/jbc.M203527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011095	hybrid, Green Published			2022-12-25	WOS:000176908700085
J	Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ				Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ			Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer	ONCOGENE			English	Article						Fas; FADD; caspase 10; lung cancer; metastasis	APO-1/CD95 GENE; APOPTOSIS; DEATH; CARCINOMAS; RECEPTOR; RESISTANCE; MUTATIONS; MELANOMA	Many types of cancer cells are resistant to Fas-mediated apoptosis by several mechanisms, including the mutations of the genes involved in Fas-mediated apoptosis. In this study, to explore the possibility that the mutations of the genes involved in the proximal pathway of Fas-mediated apoptosis (Fas, FADD, caspase 8 and caspase 10) are involved in cancer metastasis, we have analysed somatic mutation and deletion of these genes in 80 non-small cell lung cancers (NSCLCs) with (n=43) and without (n=37) metastasis to the regional lymph nodes. We found 12 mutations (four Fas, four FADD, and four caspase 10 mutations) in 11 of 80 NSCLCs (13.8%). Interestingly, of these mutations, most mutations (10 out of 12) were detected in the NSCLCs with metastasis, and the frequency in the metastasis lesions (23%) was higher than that in the primary lesions of the NSCLCs without metastasis (5.4%). Furthermore, transfection study revealed that the tumor-derived mutants have decreased apoptosis inductions compared to the wild types. These data suggest that the inactivating mutations of the genes in the proximal pathway of Fas-mediated apoptosis may lead to a decreased cancer cell death and play a role in the metastasis of NSCLC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Thorac Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022	Park, Yong Gyu/0000-0002-8721-3230				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan ASK, 1996, LUNG CANCER-J IASLC, V15, P51, DOI 10.1016/0169-5002(96)00570-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOBZIK L, 1999, LUNG ROBBINS PATHOLO, P697; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATOLI G, 1995, ONCOGENE, V11, P1157; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Petersen S, 2000, BRIT J CANCER, V82, P65; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4	21	58	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4129	4136		10.1038/sj.onc.1205527	http://dx.doi.org/10.1038/sj.onc.1205527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037669				2022-12-25	WOS:000176186000007
J	Huang, STJ; Cidlowski, JA				Huang, STJ; Cidlowski, JA			Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes	FASEB JOURNAL			English	Article						Bcl-2 expression; glucocorticoids; cell shrinkage	PERMEABILITY TRANSITION PORE; MITOTIC CHROMOSOMAL BCL-2; PROTEIN-KINASE; CELL-DEATH; DEPENDENT DEGRADATION; SIGNALING PATHWAY; FAMILY PROTEINS; CYTOCHROME-C; BAX; SUPPRESSION	Glucocorticoids are known to induce apoptosis in lymphoid cells, and Bcl-2 overexpression can block the apoptosis-inducing action of glucocorticoids. Since phosphorylation of Bcl-2 is implicated in regulating Bcl-2 function, we considered the role of Bcl-2 phosphorylation in protecting lymphoid cells from glucocorticoid-induced cell death. Five stably transfected cell lines of WEHI 7.1 cells expressing either wild-type Bcl-2 or alanine mutants of Bcl-2 at amino acids threonine 56, serine 70, threonine 74, or serine 87 were created. Expression of the mutant Bcl-2 proteins was documented by flow cytometry and Western blot analysis. Mutation of Bcl-2 on T56 and S87 eliminated the ability of Bcl-2 to inhibit glucocorticoid-induced cell shrinkage, mitochondrial depolarization, DNA fragmentation, and cell death. Mutation of T74 only partially impaired the ability of Bcl-2 to block glucocorticoid-induced apoptosis whereas mutation of S70 in Bcl-2 did not alter its ability to block glucocorticoid-induced apoptosis.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), 111 TW Alexander Dr,Bldg 101,MD F3-07, Res Triangle Pk, NC 27709 USA.	cidlowski@niehs.nih.gov	Cidlowski, John A/G-2548-2019; Huang, Se-Te/F-6881-2013	Cidlowski, John A/0000-0003-1420-0516; 				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; COSSON P, 1993, RACHIS, V5, P5; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Fang GF, 1998, CANCER RES, V58, P3202; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Iida N, 1998, CARCINOGENESIS, V19, P1191, DOI 10.1093/carcin/19.7.1191; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IWATA M, 1994, INT IMMUNOL, V6, P431, DOI 10.1093/intimm/6.3.431; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1992, CANCER RES, V52, P5407; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murata M, 1997, CELL MOL LIFE SCI, V53, P737, DOI 10.1007/s000180050093; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; ORTI E, 1993, J BIOL CHEM, V268, P7779; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P139, DOI 10.1177/002215549904700203; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Wang ZH, 1999, ANTICANCER RES, V19, P5445; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277	46	33	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0825	10.1096/fj.01-0852com	http://dx.doi.org/10.1096/fj.01-0852com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039864				2022-12-25	WOS:000176683900008
J	Seo, YR; Sweeney, C; Smith, ML				Seo, YR; Sweeney, C; Smith, ML			Selenomethionine induction of DNA repair response in human fibroblasts	ONCOGENE			English	Article						cancer-chemoprevention; selenium; nutrition; DNA-repair	NUCLEOTIDE EXCISION-REPAIR; SELENIUM-COMPOUNDS; CANCER PREVENTION; MAMMARY-CANCER; TRIPHENYLSELENONIUM CHLORIDE; CHEMOPREVENTION; GROWTH; P53; SUPPLEMENTATION; SELENOPROTEINS	Selenium compounds have a long history in chemoprevention of mammary and colon cancers in rodent models. Selenium compounds are in current clinical trials, having shown promise in prevention of prostate and other human cancers. In human tissues, it has been estimated that each cell sustains approximately 10 000 potentially mutagenic (if not repaired) lesions per day due to endogenous DNA damage. Almost no studies have addressed the potential for selenium compounds to induce DNA repair, a potential mechanism for their cancer-preventive actions. We show that selenium in the form of selenomethionine induces a DNA repair response in normal human fibroblasts in vitro, and protects cells from DNA damage. We show a possible mechanism for the inducible DNA repair response, in which enhanced repair complex formation was observed in selenomethionine-treated cells.	Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Hematol Oncol Sect, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Smith, ML (corresponding author), Indiana Univ, Ctr Canc, Dept Microbiol, Walther Oncol Ctr,Sch Med, 1044 W Walnut,Room 155, Indianapolis, IN 46202 USA.	marlsmit@iupui.edu						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Ames BN, 1997, ENVIRON HEALTH PERSP, V105, P865, DOI 10.2307/3433296; Baines AT, 2000, CANCER LETT, V160, P193, DOI 10.1016/S0304-3835(00)00585-1; Berggren MM, 1999, BIOCHEM PHARMACOL, V57, P187, DOI 10.1016/S0006-2952(98)00283-4; Cheo DL, 1999, CANCER RES, V59, P771; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Combs G F Jr, 1997, Biomed Environ Sci, V10, P356; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Ip C, 1999, ANTICANCER RES, V19, P2875; IP C, 1981, CANCER RES, V41, P4386; Ip C, 1998, ANTICANCER RES, V18, P9; IP C, 1994, CARCINOGENESIS, V15, P187, DOI 10.1093/carcin/15.2.187; IP C, 1994, CARCINOGENESIS, V15, P2879, DOI 10.1093/carcin/15.12.2879; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LU JX, 1995, BIOCHEM PHARMACOL, V50, P213, DOI 10.1016/0006-2952(95)00119-K; Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02; Parshad R, 1996, BRIT J CANCER, V74, P1, DOI 10.1038/bjc.1996.307; Patterson BH, 1997, CANCER EPIDEM BIOMAR, V6, P63; Redman C, 1998, CANCER LETT, V125, P103, DOI 10.1016/S0304-3835(97)00497-7; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sinha R, 1996, CANCER LETT, V107, P277, DOI 10.1016/0304-3835(96)04373-X; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001	38	96	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3663	3669		10.1038/sj.onc.1205468	http://dx.doi.org/10.1038/sj.onc.1205468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032834				2022-12-25	WOS:000175676000001
J	Ozaki, M; Suzuki, S; Irani, K				Ozaki, M; Suzuki, S; Irani, K			Redox factor-1/APE suppresses oxidative stress by inhibiting activity of the rac1 GTPase	FASEB JOURNAL			English	Article						NA(D)PH oxidase; NF-kappa B; apoptosis; reactive oxygen species rac1	DNA-BINDING ACTIVITY; NF-KAPPA-B; APURINIC/APYRIMIDINIC ENDONUCLEASE; REPAIR ENZYME; FREE-RADICALS; IN-VIVO; EXPRESSION; ACTIVATION; APOPTOSIS; PROTEIN	Oxidative stress triggered by many environmental and clinical insults results in cellular injury and death. The small GTPase rac1 promotes oxidative stress via the production of reactive oxygen species (ROS). In turn, the homeostatic response to such stress includes up-regulation of the dual function reducing protein/DNA repair enzyme APE/redox factor-1(ref-1). In this report we explore the function and relationship between ref-1 and rac1 in the setting of oxidative stress triggered by re-oxygenation/reperfusion. In a model of mouse hepatic ischemia/reperfusion (I/R), recombinant adenoviral overexpression of ref-1 resulted in suppression of reperfusion-stimulated oxidative stress, NF-kappaB induction, apoptosis, and acute injury, whereas down-regulation of endogenous ref-1 by adenoviral expression of antisense ref-1 led to an increase in these reperfusion-induced parameters. Ref-1 also mitigated ROS production induced by adenoviral expression of an active form of rac1. Finally, overexpression of ref-1 in primary hepatocytes suppressed reoxygenation-stimulated rac1 activity. This work demonstrates a novel function of ref-1 in inhibition of rac1 activity, and rac1-mediated oxidative stress and injury.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Natl Childrens Med Res Ctr, Div Expt Surg, Tokyo 154, Japan	Johns Hopkins University; National Center for Child Health & Development - Japan	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.	Kirani@jhmi.edu	Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DUGUID JR, 1995, CANCER RES, V55, P6097; Embade N, 2000, MOL BIOL CELL, V11, P4347, DOI 10.1091/mbc.11.12.4347; Fung H, 1998, CANCER RES, V58, P189; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HASSELGREN PO, 1984, J SURG RES, V37, P409, DOI 10.1016/0022-4804(84)90207-5; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; HUANG Y, 1993, TOUGHENED PLASTICS, V1, P1; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Meira LB, 2001, CANCER RES, V61, P5552; MITOMO K, 1994, GENE, V145, P197; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; NAKAGAWARA A, 1981, J CLIN INVEST, V68, P1243, DOI 10.1172/JCI110370; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Schlossberg H, 1996, HEPATOLOGY, V23, P1546, DOI 10.1053/jhep.1996.v23.pm0008675176; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Webster KA, 1999, J CLIN INVEST, V104, P239; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	28	73	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					889	+		10.1096/fj.01-0664fje	http://dx.doi.org/10.1096/fj.01-0664fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039869				2022-12-25	WOS:000175425900031
J	Goncharova, EA; Goncharov, DA; Eszterhas, A; Hunter, DS; Glassberg, MK; Yeung, RS; Walker, CL; Noonan, D; Kwiatkowski, DJ; Chou, MM; Panettieri, RA; Krymskaya, VP				Goncharova, EA; Goncharov, DA; Eszterhas, A; Hunter, DS; Glassberg, MK; Yeung, RS; Walker, CL; Noonan, D; Kwiatkowski, DJ; Chou, MM; Panettieri, RA; Krymskaya, VP			Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation - A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; EKER RAT MODEL; MAMMALIAN PROTEIN; IN-VIVO; SCLEROSIS; PRODUCT; PROLIFERATION; GROWTH; DISEASE; LINE	Although the cellular functions of TSC2 and its protein product, tuberin, are not known, somatic mutations in the TSC2 tumor suppressor gene are associated with tumor development in lymphangioleiomyomatosis (LAM). We found that ribosomal protein S6 (S6), which exerts translational control of protein synthesis and is required for cell growth, is hyperphosphorylated in the smooth muscle-like cell lesions of LAM patients compared with smooth muscle cells from normal human blood vessels and trachea. Smooth muscle (SM) cells derived from these lesions (LAMD-SM) also exhibited S6 hyperphosphorylation, constitutive activation of p70 S6 kinase (p70S6K), and increased basal DNA synthesis. In parallel, TSC2-/- smooth muscle cells (ELT3) and TSC2-/- epithelial cells (ERC15) also exhibited hyperphosphorylation of S6, constitutive activation of p70S6K, and increased basal DNA synthesis. Re-introduction of wild type tuberin into LAMD-SM, ELT3, and ERC15 cells abolished phosphorylation of S6 and significantly inhibited p70S6K activity and DNA synthesis. Rapamycin, an immunosuppressant, inhibited hyperphosphorylation of S6, p70S6K activation, and DNA synthesis in LAMD-SM cells. Interestingly, the basal levels of phosphatidylinositol 3-kinase, Akt/protein kinase B, and p42/p44 MAPK activation were unchanged in LAMD-SM and ELT3 cells relative to levels in normal human tracheal and vascular SM. These data demonstrate that tuberin negatively regulates the activity of S6 and p70S6K specifically, and suggest a potential mechanism for abnormal cell growth in LAM.	Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Texas, MD Anderson Canc Ctr, Smithville, TX 78957 USA; Univ Miami, Div Pulm & Crit Care Med, Miami, FL 33101 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Brigham & Womens Hosp, Div Hematol, Genet Lab, Boston, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; University of Miami; University of Washington; University of Washington Seattle; University of Kentucky; Harvard University; Brigham & Women's Hospital	Krymskaya, VP (corresponding author), Univ Penn, Pulm Allergy & Crit Care Div, Dept Med, 421 Curie Blvd,847 BRB2-3, Philadelphia, PA 19104 USA.	krymskay@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019					Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Chu SC, 1999, CHEST, V115, P1041, DOI 10.1378/chest.115.4.1041; Costello LC, 2000, MAYO CLIN PROC, V75, P591, DOI 10.4065/75.6.591; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franz DN, 2001, AM J RESP CRIT CARE, V164, P661, DOI 10.1164/ajrccm.164.4.2011025; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; Halley D. J. J., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P63; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HOWE SR, 1995, AM J PATHOL, V146, P1568; Howe SR, 1996, CANCER RES, V56, P4049; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; KOBAYASHI T, 1995, NUCLEIC ACIDS RES, V23, P2608, DOI 10.1093/nar/23.14.2608; Kobayashi T, 1999, CANCER RES, V59, P1206; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Krymskaya VP, 1997, AM J PHYSIOL-LUNG C, V273, pL1220, DOI 10.1152/ajplung.1997.273.6.L1220; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Maheshwar MM, 1996, HUM MOL GENET, V5, P131, DOI 10.1093/hmg/5.1.131; Masuda-Robens J, 2001, METHOD ENZYMOL, V333, P45; Matsui K, 2000, AM J RESP CRIT CARE, V161, P1002, DOI 10.1164/ajrccm.161.3.9904009; Matsui K, 2000, ARCH PATHOL LAB MED, V124, P267; Matsumoto Y, 1999, AM J RESP CELL MOL, V21, P327, DOI 10.1165/ajrcmb.21.3.3693; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; NELLIST M, 1993, CELL, V75, P1305; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Ostrowski J, 2000, BRIT J CANCER, V82, P1041; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Seufferlein T, 1996, CANCER RES, V56, P3895; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Taveira-DaSilva AM, 2001, AM J RESP CRIT CARE, V164, P1072, DOI 10.1164/ajrccm.164.6.2102125; TAYLOR JR, 1990, NEW ENGL J MED, V323, P1254, DOI 10.1056/NEJM199011013231807; Tsuchiya H, 1996, CANCER RES, V56, P429; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; WALKER C, 1992, CARCINOGENESIS, V13, P25, DOI 10.1093/carcin/13.1.25; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Yu J, 2001, AM J RESP CRIT CARE, V164, P1537, DOI 10.1164/ajrccm.164.8.2104095	64	347	365	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30958	30967		10.1074/jbc.M202678200	http://dx.doi.org/10.1074/jbc.M202678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12045200	hybrid			2022-12-25	WOS:000177579800072
J	DeLisa, MP; Samuelson, P; Palmer, T; Georgiou, G				DeLisa, MP; Samuelson, P; Palmer, T; Georgiou, G			Genetic analysis of the twin arginine translocator secretion pathway in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; SEC-INDEPENDENT PROTEIN; ESCHERICHIA-COLI; SIGNAL PEPTIDE; MEMBRANE-PROTEINS; CELL BIOLOGY; EXPORT; SYSTEM; EXPRESSION; COMPONENTS	The twin arginine translocation (Tat) pathway of bacteria and plant chloroplasts mediates translocation of essentially folded proteins across the cytoplasmic membrane. The detailed understanding of the mechanism of protein targeting to the Tat pathway has been hampered by the lack of screening or selection systems suitable for genetic analysis. We report here the development of a highly quantitative protein reporter for genetic analysis of Tat-specific export. Specifically, export via the Tat pathway rescues green fluorescent protein (GFP) fused to an SsrA peptide from degradation by the cytoplasmic proteolytic ClpXP machinery. As a result, cellular fluorescence is determined by the amount of GFP in the periplasmic space. We used the GFP-SsrA reporter to isolate gain-of-function mutants of a Tat-specific leader peptide and for the genetic analysis of the "invariant" signature RR dipeptide motif. Flow cytometric screening of trimethylamine N-oxide reductase (TorA) leader peptide libraries resulted in isolation of six gain-of function mutants that conferred significantly higher steady-state levels of export relative to the wildtype TorA leader. All the gain-of-function mutations occurred within or near the (S/T)RRXFLK consensus motif, highlighting the significance of this region in interactions with the Tat export machinery. Randomization of the consensus RR dipeptide in the TorA leader revealed that a basic side chain (R/K) is required at the first position whereas the second position can also accept Gln and Asn in addition to basic amino acids. This result indicates that twin arginine translocation does not require the presence of an arginine dipeptide within the conserved sequence motif.	Univ Texas, Dept Chem Engn, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Georgiou, G (corresponding author), Univ Texas, Dept Chem Engn, Austin, TX 78712 USA.	gg@che.utexas.edu	DeLisa, Matthew/AAE-7361-2019	DeLisa, Matthew/0000-0003-3226-1566; Palmer, Tracy/0000-0001-9043-2592				Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Buchanan G, 2001, ARCH MICROBIOL, V177, P107, DOI 10.1007/s00203-001-0366-2; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Chen G, 2001, NAT BIOTECHNOL, V19, P537, DOI 10.1038/89281; CLINE K, 1992, J BIOL CHEM, V267, P2688; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; Daugherty PS, 2000, P NATL ACAD SCI USA, V97, P2029, DOI 10.1073/pnas.030527597; Feilmeier BJ, 2000, J BACTERIOL, V182, P4068, DOI 10.1128/JB.182.14.4068-4076.2000; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Georgiou G, 2001, ADV PROTEIN CHEM, V55, P293, DOI 10.1016/S0065-3233(01)55007-X; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SAMBROOK J, 2000, MOL CLONING LAB MANU; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Santini CL, 2001, J BIOL CHEM, V276, P8159, DOI 10.1074/jbc.C000833200; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 2001, TRENDS MICROBIOL, V9, P196, DOI 10.1016/S0966-842X(01)02017-0; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Simmons LC, 1996, NAT BIOTECHNOL, V14, P629, DOI 10.1038/nbt0596-629; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Stuart RA, 2000, NATURE, V406, P575, DOI 10.1038/35020668; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	41	113	119	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29825	29831		10.1074/jbc.M201956200	http://dx.doi.org/10.1074/jbc.M201956200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12021272	hybrid			2022-12-25	WOS:000177509300061
J	Gellon, L; Werner, M; Boiteux, S				Gellon, L; Werner, M; Boiteux, S			Ntg2p, a Saccharomyces cerevisiae DNA N-glycosylase/apurinic or apyrimidinic lyase involved in base excision repair of oxidative DNA damage, interacts with the DNA mismatch repair protein Mlh1p - Identification of a Mlh1p binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-III; ESCHERICHIA-COLI; OGG1 PROTEIN; REACTIVE OXYGEN; GENE DELETION; YEAST; SPECIFICITY; EXPRESSION; MUTATIONS; CLONING	Ntg2p is a DNA N-glycosylase/apurinic or apyrimidinic lyase involved in base excision repair of oxidatively damaged DNA in Saccharomyces cerevisiae. Using a yeast two-hybrid screen and a GST in vitro transcription and translation assay, the mismatch repair (MMR) protein Mlh1p was demonstrated to interact physically with Ntg2p. The Mlh1p binding site maps to amino acids residues 15-40 of Ntg2p. The Ntg2p binding site is localized in the C-terminal end (483-769) of Mlh1p. Overproduction of Ntg2p results in a mutator phenotype with enhanced frameshift reversion frequency, suggesting partial inhibition of the MMR pathway. In contrast, inactivation of NTG2 does not enhance mutagenesis, indicating that Ntg2p is not required for MMR. Site-directed mutagenesis of the Mlh1p binding domain of Ntg2p revealed three amino acids (Ser(24), Tyr(26), Phe(27)) that are absolutely required for Ntg2p-Mlh1p interaction. These residues are part of a motif found in Ntg2p (Arg(23)-Ser(24)-Lys(25)-Tyr(26)-Phe(27)), Exo1p (Arg(444)-Ser(445)-Lys(446)-Phe(447) Phe(448)), and Sgs1p (Lys(1383)-Ser(1384)-Lys(1385)-Phe(1386) Phe(1387)). In these three proteins, the motif is part of the domain that interacts with the C-terminal end of Mlh1p. Furthermore, S445A, F447A, and F448A mutants of Exo1p do not bind Mlh1p, but the wild type Exo1p does. Therefore, we propose that the R/K-S-R/K-Y/F-Y/F sequence could define a Mhl1 binding motif. The results also suggest that base excision repair and MMR can cooperate to prevent deleterious effects of oxidative DNA damage.	CEA, UMR217 CNRS, Lab Radiobiol DNA, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boiteux, S (corresponding author), CEA, UMR217 CNRS, Lab Radiobiol DNA, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.	boiteux@dsvidf.cea.fr	Werner, Michel/B-7316-2009	Werner, Michel/0000-0002-2965-5858; Gellon, Lionel/0000-0003-4981-581X				Alseth I, 1999, MOL CELL BIOL, V19, P3779; Ames B.N., 1993, DNA FREE RADICALS, P1; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bertrand P, 1998, P NATL ACAD SCI USA, V95, P14278, DOI 10.1073/pnas.95.24.14278; BOITEUX S, 1984, NUCLEIC ACIDS RES, V12, P5429, DOI 10.1093/nar/12.13.5429; Boiteux S, 2002, FREE RADICAL BIO MED, V32, P1244, DOI 10.1016/S0891-5849(02)00822-5; Bruner SD, 1998, CURR BIOL, V8, P393, DOI 10.1016/S0960-9822(98)70158-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chen C, 1999, MOL CELL BIOL, V19, P7801; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; D'Ham C, 1999, BIOCHEMISTRY-US, V38, P3335, DOI 10.1021/bi981982b; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Earley MC, 1998, P NATL ACAD SCI USA, V95, P15487, DOI 10.1073/pnas.95.26.15487; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; FEIG DI, 1994, CANCER RES, V54, pS1890; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gellon L, 2001, MOL GENET GENOMICS, V265, P1087, DOI 10.1007/s004380100507; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girard PM, 1997, BIOCHIMIE, V79, P559, DOI 10.1016/S0300-9084(97)82004-4; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Guibourt N, 2000, BIOCHEMISTRY-US, V39, P1716, DOI 10.1021/bi992262n; Hall MC, 2001, J MOL BIOL, V312, P637, DOI 10.1006/jmbi.2001.4958; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HARPER JW, 1993, CELL, V75, P805; Jackson AL, 1998, P NATL ACAD SCI USA, V95, P12468, DOI 10.1073/pnas.95.21.12468; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Karahalil B, 1998, NUCLEIC ACIDS RES, V26, P1228, DOI 10.1093/nar/26.5.1228; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maniatis T., 1982, MOL CLONING LAB MANU; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Miller J.H., 1972, EXPT MOL GENETICS; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; Pedrazzi G, 2001, NUCLEIC ACIDS RES, V29, P4378, DOI 10.1093/nar/29.21.4378; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Senturker S, 1998, NUCLEIC ACIDS RES, V26, P5270, DOI 10.1093/nar/26.23.5270; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; Swanson RL, 1999, MOL CELL BIOL, V19, P2929; Terato H, 1999, J BIOL CHEM, V274, P25144, DOI 10.1074/jbc.274.35.25144; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i	60	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29963	29972		10.1074/jbc.M202963200	http://dx.doi.org/10.1074/jbc.M202963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042306	hybrid			2022-12-25	WOS:000177509300077
J	Wyles, JP; McMaster, CR; Ridgway, ND				Wyles, JP; McMaster, CR; Ridgway, ND			Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PLECKSTRIN HOMOLOGY DOMAINS; SPHINGOMYELIN SYNTHESIS; GOLGI LOCALIZATION; SACCHAROMYCES-CEREVISIAE; LIGAND-BINDING; YEAST; TRANSPORT; 25-HYDROXYCHOLESTEROL; CHOLESTEROL	Oxysterol-binding protein (OSBP) is 1 of 12 related proteins implicated in the regulation of vesicle transport and sterol homeostasis. A yeast two-hybrid screen using full-length OSBP as bait was undertaken to identify partner proteins that would provide clues to the function of OSBP. This resulted in the cloning of vesicle-associated membrane protein-associated protein-A (VAP-A), a syntaxin-like protein implicated in endoplasmic reticulum (ER)/Golgi vesicle transport, and phospholipid regulation in mammalian cells and yeast, respectively. By using a combination of yeast two-hybrid, glutathione S-transferase pull-down and immunoprecipitation experiments, the VAP-A-binding region in OSBP was localized to amino acids 351-442. This region did not include the pleckstrin homology (PH) domain but overlapped with the N terminus of the oxysterol binding and OSBP homology domains. C- and N-terminal truncations or deletions of VAP prevented interaction with OSBP but did not affect VAP multimerization. Although the OSBP PH domain was not necessary for VAP-A binding in vitro, interaction with VAP-A was enhanced in cells by mutation of the conserved PH domain tryptophan (OSBP W174A) or deletion of the C-terminal half of the PH domain (OSBP Delta132-182). OSBP W174A retained oxysterol binding activity, association with phospholipid vesicles via the PH domain, and localized with VAP in unusual ER-associated structures. At 40 C, misfolded ts045-vesicular stomatitis virus G protein fused to green fluorescent protein was co-localized with VAP-A/OSBP W174A structures on the ER but was exported to the Golgi when folded normally at 32 C. A fluorescent ceramide analogue also accumulated in these ER inclusions, and export to the Golgi was partially inhibited as indicated by decreased Golgi staining and a 30% reduction in sphingomyelin synthesis. These studies show that OSBP binding to the ER and Golgi apparatus is regulated by its PH domain and VAP interactions, and the complex is involved at a stage of protein and ceramide transport from the ER.	Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	Ridgway, ND (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, 5849 Univ Ave, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776; Ridgway, Neale/0000-0002-0441-6228				Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; Beh CT, 2001, GENETICS, V157, P1117; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Foster LJ, 2000, TRAFFIC, V1, P512, DOI 10.1034/j.1600-0854.2000.010609.x; Fournier MV, 1999, CANCER RES, V59, P3748; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hauri HP, 2000, J CELL SCI, V113, P587; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; KANDUTSCH AA, 1981, J BIOL CHEM, V256, P3068; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205; Lagace TA, 1999, J LIPID RES, V40, P109; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lehto M, 2001, J LIPID RES, V42, P1203; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; MEER GV, 2000, BIOCHIM BIOPHYS ACTA, V1486, P145; Miyashita Y, 1997, J Atheroscler Thromb, V4, P73; Mohammadi A, 2001, J LIPID RES, V42, P1062; Moreira EF, 2001, J BIOL CHEM, V276, P18570, DOI 10.1074/jbc.M011259200; NIKAWA J, 1995, J BIOCHEM, V118, P39, DOI 10.1093/oxfordjournals.jbchem.a124889; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RIDGWAY ND, 1995, J LIPID RES, V36, P1345; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Shugrue CA, 1999, J CELL SCI, V112, P4547; SILVA A, 1993, J CELL BIOL, V120, P647; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Wang C, 2002, BIOCHEM J, V361, P461, DOI 10.1042/0264-6021:3610461; Weir ML, 1998, BIOCHEM J, V333, P247, DOI 10.1042/bj3330247; Weir ML, 2001, BIOCHEM BIOPH RES CO, V286, P616, DOI 10.1006/bbrc.2001.5437; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; Xu YQ, 2001, J BIOL CHEM, V276, P18407, DOI 10.1074/jbc.M101204200; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200	55	188	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29908	29918		10.1074/jbc.M201191200	http://dx.doi.org/10.1074/jbc.M201191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023275	hybrid			2022-12-25	WOS:000177509300071
J	Bastien, J; Adam-Stitah, S; Plassat, JL; Chambon, P; Rochette-Egly, C				Bastien, J; Adam-Stitah, S; Plassat, JL; Chambon, P; Rochette-Egly, C			The phosphorylation site located in the A region of retinoic X receptor alpha is required for the antiproliferative effect of retinoic acid (RA) and the activation of RA target genes in F9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; TERATOCARCINOMA STEM-CELLS; CYCLIN-DEPENDENT KINASES; RXR-ALPHA; RESPONSE ELEMENT; CDK INHIBITORS; FUNCTIONS AF-1; PPAR-GAMMA; DIFFERENTIATION; EXPRESSION	Mouse F9 embryocarcinoma cells constitute a well established cell autonomous model system for investigating retinoic acid (RA) signaling in vitro. RA induces the differentiation of F9 cells grown as monolayers into endodermal-like cells and decreases their rate of proliferation. Knock-out of the retinoic X receptor alpha (RXRalpha) gene abolishes endodermal differentiation and the induction of several endogenous RA-responsive genes. RXRa null cells are also drastically impaired in their antiproliferative response to RA. The role of the RXRa phosphorylation site located in the N-terminal A region (Ser(22)) has been investigated here by establishing cell lines re-expressing RXRa either wild type or mutated at the phosphorylation site (RXRalphaS22A) in a RXRalpha-null background. We show that Ser(22) is dispensable for RA-induced endodermal differentiation but is crucial for the expression of several IRA-responsive genes. Ser(22) is also indispensable for the antiproliferative effect of RA and necessary for the RA-induced down-regulation of p21(CIP) and p27(KIP) CKIs proteins that are known to be involved in the control of cell cycle progression.	Coll France, CNRS, INSERM, ULP,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), CU Strasbourg, IGBMC, BP 163, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr						Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Brocard J, 1996, BIOCHEM BIOPH RES CO, V229, P211, DOI 10.1006/bbrc.1996.1782; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chiba H, 1997, MOL CELL BIOL, V17, P3013, DOI 10.1128/MCB.17.6.3013; Chiba H, 1997, J CELL BIOL, V139, P735, DOI 10.1083/jcb.139.3.735; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Dirks PB, 1997, ONCOGENE, V15, P2037, DOI 10.1038/sj.onc.1201392; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Gudas Lorraine J., 1994, P443; Hayashi K, 2000, CANCER LETT, V151, P199, DOI 10.1016/S0304-3835(99)00422-X; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Mascrez B, 2001, DEVELOPMENT, V128, P2049; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Plassat JL, 2000, J CELL SCI, V113, P2887; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Ross SA, 2000, PHYSIOL REV, V80, P1021, DOI 10.1152/physrev.2000.80.3.1021; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Wan HS, 1999, CANCER RES, V59, P3518; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	61	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28683	28689		10.1074/jbc.M203623200	http://dx.doi.org/10.1074/jbc.M203623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032153	hybrid			2022-12-25	WOS:000177342600045
J	Chatellard-Causse, C; Blot, B; Cristina, N; Torch, S; Missotten, M; Sadoul, R				Chatellard-Causse, C; Blot, B; Cristina, N; Torch, S; Missotten, M; Sadoul, R			Alix (ALG-2-interacting protein X), a protein involved in apoptosis, binds to endophilins and induces cytoplasmic vacuolization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEINS; SH3 DOMAIN; ADAPTER PROTEIN; GENE ALG-3; IDENTIFICATION; SYNAPTOJANIN; PARTNERS; CLONING; AMPHIPHYSIN; ACTIVATION	ALG-2-interacting protein X (Alix), also known as AIP1, is a cytoplasmic protein ubiquitously expressed and concentrated in phagosomes and exosomes. Alix may regulate apoptosis since it binds apoptosis-linked gene 2 (ALG-2), a Ca2+-binding protein necessary for cell death, and also overexpression of its C-terminal half (Alix-CT) blocks death induced by several stimuli. This part of Alix contains a long proline-rich domain containing several potential SH3-binding sites. Using Alix as bait in a yeast two-hybrid system to screen a mouse brain library, we have found that SH3p4, SH3p8, and SH3p13, collectively known as endophilins, bind to Alix. Co-immunoprecipitations and overlay experiments allowed us to demonstrate that endophilins bind to Alix-CT through an SH3/proline-rich domain interaction. We have narrowed the region of Alix interacting with endophilins down to 14 amino acids containing a PXRPPPP consensus sequence, also present in synaptojanin and germinal center kinase-like kinase, allowing their interaction to endophilins. We further show that overexpression of Alix-CT, which blocks cell death, leads to cytoplasmic vacuolization into tubulo-vesicular structures delineated by Alix-CT. This vacuolization phenomenon is greatly enhanced upon co-expression with endophilins and may be part of the protecting mechanism afforded by Alix-CT.	Hop A Michallon, CHU Grenoble, INSERM, Lab Neurodegenerescence & Plast,UJF, F-38043 Grenoble 9, France; Serono Pharmaceut Res Inst, CH-1228 Plan Les Oates, Geneva, Switzerland	CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Sadoul, R (corresponding author), CHU Grenoble, Lab Neurodegenerescence & Plast, EMI 0108,Pavillon Neurol,BP 217, F-38043 Grenoble 9, France.		TORCH, sakina/N-7717-2013; TORCH, SAKINA/AAC-2994-2019	TORCH, Sakina/0000-0003-3691-4376; SADOUL, Remy/0000-0002-4763-0320				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Lacana E, 1997, J IMMUNOL, V158, P5129; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Xu WJ, 2001, J BACTERIOL, V183, P6917, DOI 10.1128/JB.183.23.6917-6923.2001	26	141	143	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29108	29115		10.1074/jbc.M204019200	http://dx.doi.org/10.1074/jbc.M204019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034747	hybrid			2022-12-25	WOS:000177342600099
J	De Smedt, V; Poulhe, R; Cayla, X; Dessauge, F; Karaiskou, A; Jessus, C; Ozon, R				De Smedt, V; Poulhe, R; Cayla, X; Dessauge, F; Karaiskou, A; Jessus, C; Ozon, R			Thr-161 phosphorylation of monomeric Cdc2 - Regulation by protein phosphatase 2C in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK-ACTIVATING KINASE; MEIOTIC MATURATION; CATALYTIC SUBUNIT; CELL-CYCLE; CAK; DEPHOSPHORYLATION; P40(MO15); P34(CDC2); ABSENCE	Fully grown Xenopus oocyte is arrested at prophase I of meiosis. Re-entry into meiosis depends on the activation of MPF (M-phase promoting factor or cyclin B.Cdc2 complex), triggered by progesterone. The prophase-arrested oocyte contains a store of Cdc2. Most of the protein is present as a monomer whereas a minor fraction, called pre-MPF, is found to be associated with cyclin B. Activation of Cdc2 depends on two key events: cyclin binding and an activating phosphorylation on Thr-161 residue located in the T-loop. To get new insights into the regulation of Thr-161 phosphorylation of Cdc2, monomeric Cdc2 was isolated from prophase oocytes. Based on its activation upon cyclin addition and detection by an antibody directed specifically against Cdc2 phosphorylated on Thr-161, we show for the first time that the prophase oocyte contains a significant amount of monomeric Cdc2 phosphorylated on Thr-161. PP2C, a Mg2+-dependent phosphatase, negatively controls Thr-161 phosphorylation of Cdc2. The unexpected presence of a population of free Cdc2 already phosphorylated on Thr-161 could contribute to the generation of the Cdc2 kinase activity threshold required to initiate MPF amplification.	Univ Paris 06, Dev Biol Lab, Inst Rech Agron, Unite Mixte Rech CNRS 7622, F-75252 Paris 05, France	INRAE; UDICE-French Research Universities; Sorbonne Universite	Jessus, C (corresponding author), Univ Paris 06, Dev Biol Lab, Inst Rech Agron, Unite Mixte Rech CNRS 7622, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr		Karaiskou, Anthi/0000-0002-1482-7899				BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng AY, 2000, J BIOL CHEM, V275, P34744, DOI 10.1074/jbc.M006210200; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Egan EA, 1998, MOL CELL BIOL, V18, P3659, DOI 10.1128/MCB.18.7.3659; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Fesquet D, 1997, ONCOGENE, V15, P1303, DOI 10.1038/sj.onc.1201300; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; Hochegger H, 2001, DEVELOPMENT, V128, P3795; JESSUS C, 1987, J CELL SCI, V87, P705; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Karaiskou A, 1999, J CELL SCI, V112, P3747; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOBAYASHI H, 1994, J BIOL CHEM, V269, P29153; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakajo N, 2000, GENE DEV, V14, P328; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; WU M, 1980, DEV BIOL, V79, P465, DOI 10.1016/0012-1606(80)90131-1	32	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28592	28600		10.1074/jbc.M202742200	http://dx.doi.org/10.1074/jbc.M202742200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036957	Green Published, hybrid			2022-12-25	WOS:000177342600033
J	Fosgerau, K; Breinholt, J; McCormack, JG; Westergaard, N				Fosgerau, K; Breinholt, J; McCormack, JG; Westergaard, N			Evidence against glycogen cycling of gluconeogenic substrates in various liver preparations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC GLUCOSE-PRODUCTION; DIABETES-MELLITUS; RAT-LIVER; PHOSPHORYLASE; INSULIN; INHIBITION; AUTOREGULATION; INACTIVATION; INCREASE; ETHANOL	The effect of inhibition of glycogen phosphorylase by 1,4-dideoxy-1,4-imino-D-arabinitol on rates of gluconeogenesis, gluconeogenic deposition into glycogen, and glycogen recycling was investigated in primary cultured hepatocytes, in perfused rat liver, and in fed or fasted rats in vivo clamped at high physiological levels of plasma lactate. 1,4-Dideoxy-1,4-imino-D-arabinitol did not alter the synthesis of glycerol-derived glucose in hepatocytes or lactate-derived glucose in perfused liver or fed or fasted rats in vivo. Thus, 1,4-dideoxy-1,4-imino-D-arabinitol inhibited hepatic glucose output in the perfused rat liver (0.77 +/- 0.19 versus 0.33 +/- 0.09, p < 0.05), whereas the rate of lactate-derived gluconeogenesis was unaltered (0.22 +/- 0.09 versus 0.18 +/- 0.08, p = not significant) (1,4-dideoxy-1,4-imino-D-arabinitol versus vehicle, mumol/min * g). Overall, the data suggest that 1,4-dideoxy-1,4-imino-D-arabinitol inhibited glycogen breakdown with no direct or indirect effects on the rates of gluconeogenesis. Total end point glycogen content (mumol of glycosyl units/g of wet liver) were similar in fed (235 19 versus 217 22, p = not significant) or fasted rats (10 +/- 2 versus 7 2, p = not significant) with or without 1,4-dideoxy-1,4-imino-D-arabinitol, respectively. The data demonstrate no glycogen cycling under the investigated conditions and no effect of 1,4-dideoxy-1,4-imino-D-arabinitol on gluconeogenic deposition into glycogen. Taken together, these data also suggest that inhibition of glycogen phosphorylase may prove beneficial in the treatment of type 2 diabetes.	Novo Nordisk AS, Pharmacol Res 2, DK-2760 Malov, Denmark; Novo Nordisk AS, MedChem Res, DK-2760 Malov, Denmark; Novo Nordisk AS, Hepat Biochem, DK-2760 Malov, Denmark; Novo Nordisk AS, Discovery Management, DK-2760 Malov, Denmark	Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk	Fosgerau, K (corresponding author), Novo Nordisk AS, Pharmacol Res 2, Novo Nordisk Pk,B8 1-03, DK-2760 Malov, Denmark.	kf@novonordisk.com	Westergaard, Niels/AAR-6449-2020	Westergaard, Niels/0000-0002-2663-8040				Andersen B, 1999, BIOCHEM J, V342, P545, DOI 10.1042/0264-6021:3420545; ANDERSEN L, 1993, CLIN CHEM, V39, P578; Bergans N, 2000, DIABETES, V49, P1419, DOI 10.2337/diabetes.49.9.1419; BOARD M, 1995, EUR J BIOCHEM, V228, P753, DOI 10.1111/j.1432-1033.1995.0753m.x; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; DEFRONZO RA, 1992, DIABETOLOGIA, V35, P389, DOI 10.1007/BF00401208; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Diraison F, 1998, DIABETOLOGIA, V41, P212, DOI 10.1007/s001250050892; Exton J H, 1975, Methods Enzymol, V39, P25; Fosgerau K, 2000, ARCH BIOCHEM BIOPHYS, V380, P274, DOI 10.1006/abbi.2000.1930; Fosgerau K, 2001, AM J PHYSIOL-ENDOC M, V281, pE375, DOI 10.1152/ajpendo.2001.281.2.E375; GRUNNET N, 1994, ARCH BIOCHEM BIOPHYS, V309, P18, DOI 10.1006/abbi.1994.1077; HAESLER E, 1995, CLIN PHYSIOL, V15, P581, DOI 10.1111/j.1475-097X.1995.tb00546.x; HANSEN SH, 2002, IN PRESS NMR BIOMED; Hellerstein MK, 1997, J CLIN INVEST, V100, P1305, DOI 10.1172/JCI119644; JAHOOR F, 1990, AM J PHYSIOL, V258, pE288, DOI 10.1152/ajpendo.1990.258.2.E288; JENSSEN T, 1990, J CLIN INVEST, V86, P489, DOI 10.1172/JCI114735; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KUBOTA M, 1992, P SOC EXP BIOL MED, V201, P114, DOI 10.3181/00379727-201-43488; KUNST A, 1984, METHOD ENZYMAT AN, V2, P154; MADSEN BN, 2001, ENZYMES, P366; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MARTIN JL, 1991, BIOCHEMISTRY-US, V30, P10101, DOI 10.1021/bi00106a006; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; Massillon D, 1995, AM J PHYSIOL-ENDOC M, V269, pE1037, DOI 10.1152/ajpendo.1995.269.6.E1037; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; McCormack JG, 2001, CURR PHARM DESIGN, V7, P1451, DOI 10.2174/1381612013397393; Mittelman S., 1998, CURR OPIN ENDOCRINOL, V5, P126; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; PUHAKAINEN I, 1991, DIABETES, V40, P1319, DOI 10.2337/diabetes.40.10.1319; Radziuk J, 2001, DIABETES-METAB RES, V17, P250, DOI 10.1002/dmrr.217; Shiota M, 1996, METABOLISM, V45, P481, DOI 10.1016/S0026-0495(96)90223-1; SHIOTA M, 1997, AM J PHYSIOL-ENDOC M, V273, pE866; TAPPY L, 1995, DIABETES METAB, V21, P233; Tayek JA, 1996, AM J PHYSIOL-ENDOC M, V270, pE709, DOI 10.1152/ajpendo.1996.270.4.E709; Treadway JL, 2001, EXPERT OPIN INV DRUG, V10, P439, DOI 10.1517/13543784.10.3.439; Trimmer JK, 2001, AM J PHYSIOL-ENDOC M, V280, pE657, DOI 10.1152/ajpendo.2001.280.4.E657; YKIJARVINEN H, 1994, DIABETES NUTR METAB, V7, P109	39	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28648	28655		10.1074/jbc.M201565200	http://dx.doi.org/10.1074/jbc.M201565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042303	hybrid			2022-12-25	WOS:000177342600040
J	Geymonat, M; Spanos, A; Smith, SJM; Wheatley, E; Rittinger, K; Johnston, LH; Sedgwick, SG				Geymonat, M; Spanos, A; Smith, SJM; Wheatley, E; Rittinger, K; Johnston, LH; Sedgwick, SG			Control of mitotic exit in budding yeast - In vitro regulation of Tem1 GTPase by Bub2 and Bfa1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; ACTIVATING PROTEIN; BINDING PROTEIN; FLUORESCENCE SPECTROSCOPY; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CHECKPOINT PATHWAY; PHOSPHATASE CDC14; SPINDLE POSITION; HYDROLYSIS	The elimination of mitotic kinase activity at the end of mitosis is essential for progression to the next stage of the eukaryotic cell cycle. In budding yeast, this process is controlled by a regulatory cascade called the mitotic exit network. Extensive genetic data indicate that mitotic exit network activity is determined by a GTP-binding protein, Tem1, and its putative regulators, Bub2, Bfa1, and Lte1. Here we describe the purification and in vitro activities of Tem1, Bub2, and Bfa1. We describe the nucleotide binding properties of Tem1 and characterize its intrinsic GTPase activity. The combination of Bfa1 and Bub2 acts as a two-component GTPase-activating protein for Tem1. In the absence of Bub2, Bfa1 inhibits the GTPase and GTP exchange activities of Tem1. This inhibition is elicited by either the N- or C-terminal regions of Bfa1, which also retain some ability to co-activate GTPase activity in the presence of Bub2. Although the C-terminal region of Bfa1 binds to Bub2, no interaction of the N-terminal half of Bfa1 with Bub2 was detected despite their combined GAP activity. Therefore, we propose that Bfa1 acts both as an adaptor to connect Bub2 and Tem1 and as an allosteric effector that facilitates this interaction.	Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Sedgwick, SG (corresponding author), Natl Inst Med Res, Div Yeast Genet, Mill Hill, London NW7 1AA, England.		Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435	Medical Research Council [MC_U117565398] Funding Source: Medline; MRC [MC_U117565398] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bloecher A, 2000, NAT CELL BIOL, V2, P556, DOI 10.1038/35019601; CHUANG TH, 1993, J BIOL CHEM, V268, P775; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Furge KA, 1999, J BIOL CHEM, V274, P11339, DOI 10.1074/jbc.274.16.11339; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HU F, 2001, CELL, V107, P1; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; Lee J, 1999, BBA-MOL CELL RES, V1449, P239, DOI 10.1016/S0167-4889(99)00015-4; Lee SE, 2001, J CELL SCI, V114, P2345; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; NEAL SE, 1988, J BIOL CHEM, V263, P19718; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2001, EMBO J, V20, P6359, DOI 10.1093/emboj/20.22.6359; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Song KW, 1996, J CELL BIOL, V133, P1307, DOI 10.1083/jcb.133.6.1307; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stroupe C, 2000, J MOL BIOL, V304, P585, DOI 10.1006/jmbi.2000.4236; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wang YC, 2000, CURR BIOL, V10, P1379, DOI 10.1016/S0960-9822(00)00779-X	42	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28439	28445		10.1074/jbc.M202540200	http://dx.doi.org/10.1074/jbc.M202540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048186	hybrid			2022-12-25	WOS:000177342600014
J	Hanasaki, K; Yamada, K; Yamamoto, S; Ishimoto, Y; Saiga, A; Ono, T; Ikeda, M; Notoya, M; Kamitani, S; Arita, H				Hanasaki, K; Yamada, K; Yamamoto, S; Ishimoto, Y; Saiga, A; Ono, T; Ikeda, M; Notoya, M; Kamitani, S; Arita, H			Potent modification of low density lipoprotein by group X secretory phospholipase A(2) is linked to macrophage foam cell formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; ATHEROSCLEROTIC LESIONS; ARACHIDONIC-ACID; APOLIPOPROTEIN-B; OXIDATIVE MODIFICATION; LIPID-PEROXIDATION; SCAVENGER RECEPTOR; CHOLESTERYL ESTER; OXIDIZED LDL; FATTY STREAK	The deposition of cholesterol ester within foam cells of the artery wall is fundamental to the pathogenesis of atherosclerosis. Modifications of low density lipoprotein (LDL), such as oxidation, are prerequisite events for the formation of foam cells. We demonstrate here that group X secretory phospholipase A(2) (sPLA(2)-X) may be involved in this process. sPLA(2)-X was found to induce potent hydrolysis of phosphatidylcholine in LDL leading to the production of large amounts of unsaturated fatty acids and lysophosphatidylcholine (lyso-PC), which contrasted with little, if any, lipolytic modification of LDL by the classic types of group IB and IIA secretory PLA(2)s. Treatment with sPLA(2)-X caused an increase in the negative charge of LDL with little modification of apolipoprotein B (apoB) in contrast to the excessive aggregation and fragmentation of apoB in oxidized LDL. The sPLA(2)-X-modified LDL was efficiently incorporated into macrophages to induce the accumulation of cellular cholesterol ester and the formation of non-membrane-bound lipid droplets in the cytoplasm, whereas the extensive accumulation of multilayered structures was found in the cytoplasm in oxidized LDL-treated macrophages. Immunohistochemical analysis revealed marked expression of sPLA(2)-X in foam cell lesions in the arterial intima of high fat-fed apolipoprotein E-deficient mice. These findings suggest that modification of LDL by sPLA(2)-X in the arterial vessels is one of the mechanisms responsible for the generation of atherogenic lipoprotein particles as well as the production of various lipid mediators, including unsaturated fatty acids and lyso-PC.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Sagisu 5-12-4, Osaka 5530002, Japan.			Kamitani, Shigeki/0000-0002-1268-4652				ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; AVIRAM M, 1992, BIOCHEM BIOPH RES CO, V185, P465, DOI 10.1016/S0006-291X(05)81008-3; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BOCAN TMA, 1986, AM J PATHOL, V123, P413; CHALVARDJIAN A, 1970, ANAL BIOCHEM, V36, P225, DOI 10.1016/0003-2697(70)90352-0; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Cyrus T, 2001, CIRCULATION, V103, P2277; deBeer FC, 1997, J LIPID RES, V38, P2232; Elinder LS, 1997, ARTERIOSCL THROM VAS, V17, P2257, DOI 10.1161/01.ATV.17.10.2257; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GUYTON JR, 1994, ARTERIOSCLER THROMB, V14, P1305, DOI 10.1161/01.ATV.14.8.1305; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; Hakala JK, 1999, ARTERIOSCL THROM VAS, V19, P1276, DOI 10.1161/01.ATV.19.5.1276; Hakala JK, 2001, ARTERIOSCL THROM VAS, V21, P1053, DOI 10.1161/01.ATV.21.6.1053; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hara S, 1997, ARTERIOSCL THROM VAS, V17, P1258, DOI 10.1161/01.ATV.17.7.1258; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hurt-Camejo E, 2001, CIRC RES, V89, P298, DOI 10.1161/hh1601.095598; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Itabe H, 2000, BBA-MOL CELL BIOL L, V1487, P233, DOI 10.1016/S1388-1981(00)00098-6; Jerome WG, 1998, J LIPID RES, V39, P1362; JEROME WG, 1985, AM J PATHOL, V119, P210; KLEINMAN Y, 1988, J LIPID RES, V29, P729; KLINKNER AM, 1995, J HISTOCHEM CYTOCHEM, V43, P1071, DOI 10.1177/43.10.7560885; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LEWIS JC, 1988, EXP MOL PATHOL, V48, P103, DOI 10.1016/0014-4800(88)90049-4; Lougheed M, 1999, ARTERIOSCL THROM VAS, V19, P1881, DOI 10.1161/01.ATV.19.8.1881; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; LUPU F, 1987, ATHEROSCLEROSIS, V67, P127, DOI 10.1016/0021-9150(87)90273-5; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; McNamara JR, 1996, J LIPID RES, V37, P1924; MENSCHIKOWSKI M, 1995, ANAL CELL PATHOL, V9, P113; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; NOBLE RP, 1968, J LIPID RES, V9, P693; ONO T, 1988, J BIOL CHEM, V263, P5732; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Romano M, 1998, ARTERIOSCL THROM VAS, V18, P519, DOI 10.1161/01.ATV.18.4.519; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saiga A, 2001, BBA-MOL CELL BIOL L, V1530, P67, DOI 10.1016/S1388-1981(00)00167-0; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Sartipy P, 2000, CIRC RES, V86, P707, DOI 10.1161/01.RES.86.6.707; Schiering A, 1999, ATHEROSCLEROSIS, V144, P73, DOI 10.1016/S0021-9150(99)00045-3; SHIO H, 1979, LAB INVEST, V41, P160; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; TOJO H, 1993, J LIPID RES, V34, P837; Tong H, 1998, J LIPID RES, V39, P1696; TRIBBLE DL, 1995, J LIPID RES, V36, P662; VADAS P, 1986, LAB INVEST, V55, P391; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; ZHANG HF, 1993, J BIOL CHEM, V268, P5535; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	77	135	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29116	29124		10.1074/jbc.M202867200	http://dx.doi.org/10.1074/jbc.M202867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021277	hybrid			2022-12-25	WOS:000177342600100
J	Hazama, A; Kozono, D; Guggino, WB; Agre, P; Yasui, M				Hazama, A; Kozono, D; Guggino, WB; Agre, P; Yasui, M			Ion permeation of AQP6 water channel protein - Single-channel recordings after Hg2+ activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; XENOPUS OOCYTES; AQUAPORIN-1; MEMBRANES; PERMEABILITY; CONDUCTANCE; KIDNEY	Aquaporin-6 (AQP6) has recently been identified as an intracellular vesicle water channel with anion permeability that is activated by low pH or HgCl2. Here we present direct evidence of AQP6 channel gating using patch clamp techniques. Cell-attached patch recordings of AQP6 expressed in Xenopus laevis oocytes indicated that AQP6 is a gated channel with intermediate conductance (49 picosiemens in 100 mm NaCl) induced by 10 pm HgCl2. Current-voltage relationships were linear, and open probability was fairly constant at any given voltage, indicating that Hg2+-induced AQP6 conductance is voltage-independent. The excised outside-out patch recording revealed rapid activation of AQP6 channels immediately after application of 10 muM HgCl2. Reduction of both Na+ and Cl- concentrations from 100 to 30 mm did not shift the reversal potential of the Hg2+-induced AQP6 current, suggesting that Na+ is as permeable as Cl-. The Na+ permeability of Hg2+-induced AQP6 current was further demonstrated by Na-22(+) influx measurements. Site-directed mutagenesis identified Cys-155 and Cys-190 residues as the sites of Hg2+ activation both for water permeability and ion conductance. The Hill coefficient from the concentration-response curve for Hg2+-induced conductance was 1.1 +/- 0.3. These data provide the first evidence of AQP6 channel gating at a single-channel level and suggest that each monomer contains the pore region for ions based on the number of Hg2+-binding sites and the kinetics of Hg2+-activation of the channel.	Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Yasui, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat & Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R01HL048268, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 2000, J AM SOC NEPHROL, V11, P764, DOI 10.1681/ASN.V114764; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Ma TH, 1996, GENOMICS, V35, P543, DOI 10.1006/geno.1996.0396; MACEY RI, 1984, AM J PHYSIOL, V246, P195; MITRA AK, 1994, BIOCHEMISTRY-US, V33, P12735, DOI 10.1021/bi00209a001; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; WEBER WM, 1995, BBA-BIOMEMBRANES, V1239, P201, DOI 10.1016/0005-2736(95)00151-R; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Yool AJ, 1996, SCIENCE, V273, P1216, DOI 10.1126/science.273.5279.1216	19	71	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29224	29230		10.1074/jbc.M204258200	http://dx.doi.org/10.1074/jbc.M204258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034750	hybrid			2022-12-25	WOS:000177342600111
J	Ohtsuka, T; Zhou, T				Ohtsuka, T; Zhou, T			Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; ICE/CED-3 FAMILY PROTEASES; FADD-DEPENDENT APOPTOSIS; TRAIL-INDUCED APOPTOSIS; CYTOTOXIC LIGAND TRAIL; SIGNALING PATHWAY; KAPPA-B; T-CELLS; INDEPENDENT PATHWAYS	Bisindolylmaleimide VIII (Bis VIII) has been previously shown to enhance Fas-mediated apoptosis through a protein kinase C-independent mechanism. In the present study, we examined the effect of Bis VIII on apoptosis induced by DR5 (TRAIL-R2), using an agonistic anti-human DR5 monoclonal antibody, TRA-8. Our results demonstrated that Bis VIII was able to enhance the apoptosis-inducing activity of TRA-8 both in vitro and in vivo. The combination of TRA-8 and Bis VIII led to a synergistic and sustained activation of the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase, which was mediated by MAPK kinase 4 and was caspase-8-dependent. The mitochondrial pathway is involved in the synergistic induction of apoptoosis by Bis VIII and TRA-8. Bis VIII alone induced the loss of mitochondrial membrane potential in a caspase-independent fashion without subsequent release of cytochrome c. However, in the presence of Bis VIII, TRA-8 induced more profound loss of mitochondrial membrane potential and release of cytochrome c. These results suggest that the enhanced and persistent activation of the JNK/p38 and the decreased mitochondrial membrane potential play a crucial role in synergistic induction of the death receptor-mediated apoptosis by Bis VIII. The unique ability of Bis VIII to enhance DR5-mediated apoptosis signal transduction discloses a potential utility of this compound in combination with anti-DR5 antibody in cancer therapy.	Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan	University of Alabama System; University of Alabama Birmingham; Daiichi Sankyo Company Limited	Zhou, T (corresponding author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 465 LHRB,701 19th St S, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [P50CA089019, P50CA083591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER; NCI NIH HHS [CA89019, CA83591] Funding Source: Medline; NIAMS NIH HHS [AR44982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; BIT RA, 1993, J MED CHEM, V36, P21, DOI 10.1021/jm00053a003; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bonavida B, 1999, INT J ONCOL, V15, P793; Cahill MA, 1996, ONCOGENE, V13, P2087; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dispersyn G, 1999, BBA-GEN SUBJECTS, V1428, P357, DOI 10.1016/S0304-4165(99)00073-2; Du J, 2000, J CELL BIOCHEM, V77, P333, DOI 10.1002/(SICI)1097-4644(20000501)77:2<333::AID-JCB15>3.0.CO;2-Q; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Faris M, 1998, J IMMUNOL, V160, P134; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2001, CANCER RES, V61, P1645; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	49	48	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29294	29303		10.1074/jbc.M203342200	http://dx.doi.org/10.1074/jbc.M203342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034736	hybrid			2022-12-25	WOS:000177342600119
J	Shen, TL; Han, DC; Guan, JL				Shen, TL; Han, DC; Guan, JL			Association of Grb7 with phosphoinositides and its role in the regulation of cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PLECKSTRIN HOMOLOGY DOMAINS; BRUTON TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; PH DOMAIN; STRUCTURAL BASIS; GROWTH-FACTOR; PROTEINS; BINDING	Grb7 is the prototype of a family of adaptor molecules that also include Grb10 and Grb14 that share a conserved molecular architecture including Src homology 2 (SH2) and pleckstrin homology (PH) domains. Grb7 has been implicated as a downstream mediator of integrin-FAK signal pathways in the regulation of cell migration, although the molecular mechanisms are still not well understood. In this paper, we investigated the potential role and mechanisms of PH domain in Grb7 in the regulation of cell migration. We found that the PH domain mediated Grb7 binding to phospholipids both in vitro and in intact cells. Furthermore, both Grb7 and its PH domain preferentially interacted with phosphatidylinositol phosphates showing strongest affinity to the D3- and D5-phosphoinositides. The PH domain interaction with phosphoinositides was shown to play a role in the stimulation of cell migration by Grb7. It was also shown to be necessary for Grb7 phosphorylation by FAR, although it was not required for Grb7 interaction with FAK or recruitment to the focal contacts. Last, we found that PI 3-kinase activity played a role in both Grb7 association with phosphoinositides and its stimulation of cell migration. In addition, both FAK binding to PI 3-kinase via its autophosphorylated Tyr(397) and integrin-mediated cell adhesion increased Grb7 association with phosphoinositides. Together, these results identified the Grb7 PH domain interaction with phosphoinositides and suggested a potential mechanism by which several signaling molecules including Grb7, FAK, and PI 3-kinase and their interactions cooperate to mediate signal transduction pathways in integrin-mediated cell migration.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu	Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NHLBI NIH HHS [HL64382] Funding Source: Medline; NIGMS NIH HHS [GM48050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CARY LA, 1999, FRONT BIOSCI, V4, P102; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ilic D, 1997, J CELL SCI, V110, P401; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; OOI J, 1995, ONCOGENE, V10, P1621; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	40	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29069	29077		10.1074/jbc.M203085200	http://dx.doi.org/10.1074/jbc.M203085200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021278	hybrid			2022-12-25	WOS:000177342600094
J	Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT				Sugars, JM; Cellek, S; Manifava, M; Coadwell, J; Ktistakis, NT			Hierarchy of membrane-targeting signals of phospholipase D1 involving lipid modification of a pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PX-DOMAIN; LOCALIZATION; BINDING; PROTEIN; ISOFORM; COMPLEX	The amino terminus of phospholipase D1 (PLD1) contains three potential membrane-interacting determinants: a phox homology (PX) domain, a pleckstrin homology (PH) domain and two adjacent cysteines at positions 240 and 241 within the PH domain that are fatty acylated in vivo. To understand how these determinants contribute to membrane localization, we have mutagenized critical residues of the PLD1 PH domain in the wild type or palmitate-free background in the intact protein, in a fragment that deletes the first 210 amino acids including the PX domain, and in the isolated PH domain. Mutants were expressed in COS-7 cells and examined for membrane residence, intracellular localization, palmitoylation, and catalytic activity. Our results are as follows. 1) Mutagenesis of critical residues of the PH domain results in redistribution of PLD1 from membranes to cytosol, independently of fatty acylation sites. Importantly, PH domain mutants in the wild type background showed greatly reduced fatty acylation, despite the presence of all relevant cysteines. 2) The isolated PH domain did not co-localize with PLD1 and was not palmitoylated. 3) The PX deletion mutant showed similar distribution and palmitoylation to the intact protein. Interestingly, PH domain mutants in this background showed significant palmitoylation and incomplete cytosolic redistribution. 4) PH domain mutants in the wild type or palmitate-free background maintained catalytic activity. We propose that membrane targeting of PLD1 involves a hierarchy of signals with a functional PH domain allowing fatty acylation leading to strong membrane binding. The PX domain may modulate function of the PH domain.	Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Ktistakis, NT (corresponding author), Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England.	nicholas.ktistakis@bbsrc.ac.uk		Cellek, Selim/0000-0002-4856-285X				BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hoer A, 2000, BBA-PROTEIN STRUCT M, V1481, P189, DOI 10.1016/S0167-4838(00)00108-4; Holbrook PG, 1999, FEBS LETT, V448, P269, DOI 10.1016/S0014-5793(99)00366-X; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Ktistakis NT, 1999, BIOCHEM SOC T, V27, P634, DOI 10.1042/bst0270634; Lemmon MA, 1999, BIOCHEM SOC T, V27, P617, DOI 10.1042/bst0270617; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; LSCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; Lucocq J, 2001, EUR J CELL BIOL, V80, P508, DOI 10.1078/0171-9335-00186; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Sugars JM, 1999, J BIOL CHEM, V274, P30023, DOI 10.1074/jbc.274.42.30023; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Xie Z, 2001, J BIOL CHEM, V276, P9383, DOI 10.1074/jbc.M009425200; XIE Z, 1998, J BIOL CHEM, V273, P34769; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29152	29161		10.1074/jbc.M112169200	http://dx.doi.org/10.1074/jbc.M112169200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021265	hybrid			2022-12-25	WOS:000177342600104
J	Falcon-Perez, JM; Starcevic, M; Gautam, R; Dell'Angelica, EC				Falcon-Perez, JM; Starcevic, M; Gautam, R; Dell'Angelica, EC			BLOC-1, a novel complex containing the pallidin and muted proteins involved in the biogenesis of melanosomes and platelet-dense granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERMANSKY-PUDLAK-SYNDROME; STORAGE POOL DEFICIENCY; PALE EAR EP; ACTIN CYTOSKELETON; AP-3 ADAPTER; MOUSE MODELS; MUTATION; CELLS; GENE; ENDOCYTOSIS	Recent studies have led to the identification of a group of genes required for normal biogenesis of lysosome-related organelles such as melanosomes and platelet-dense granules. Two of these genes, which are defective in the pallid and muted mutant mouse strains, encode small, coiled-coil-forming proteins that display no homology to each other or to any known protein: We report that these two proteins, pallidin and muted, are components of a novel protein complex. We raised antibodies that allow for detection of pallidin from a wide variety of mammalian cells. Endogenous pallidin was distributed in both soluble and peripheral membrane protein fractions. Size-exclusion chromatography and sedimentation velocity analyses indicated that the bulk of cytosolic pallidin is a component of an asymmetric protein complex with a molecular mass of similar to200 kDa. We named this complex BLOC-1 (for biogenesis of lysosome-related organelles complex 1). Steady-state pallidin protein levels were reduced in fibroblasts derived from muted and reduced pigmentation mice, suggesting that the genes defective in these two mutant strains could encode components of BLOC-1 that are required for pallidin stability. Co-immunoprecipitation and immunodepletion experiments using an antibody to muted confirmed that this protein is a subunit of BLOC-1. Yeast two-hybrid analyses revealed that pallidin is capable of self-association through a region that contains its two coiled-coil forming domains. Unlike AP-3-deficient pearl fibroblasts, which display defects in intracellular zinc storage, zinc distribution was not noticeably affected in pallid or muted fibroblasts. Interestingly, immunofluorescence and in vitro binding experiments demonstrated that pallidin/BLOC-1 is able to associate with actin filaments. We propose that BLOC-1 mediates the biogenesis of lysosome-related organelles by a mechanism that may involve self-assembly and interaction with the actin cytoskeleton.	Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roswell Park Cancer Institute	Dell'Angelica, EC (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.	Edellangelica@mednet.ucla.edu	Falcon-Perez, Juan M/F-5920-2011	Falcon-Perez, Juan M/0000-0003-3133-0670	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068117] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68117] Funding Source: Medline; NIGMS NIH HHS [GM07104] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013; Dell'Angelica EC, 2000, J BIOL CHEM, V275, P1300, DOI 10.1074/jbc.275.2.1300; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; ERWAY L, 1986, SCANNING ELECTRON MI, V4, P1681; Falcon-Perez JM, 2002, PIGM CELL RES, V15, P82, DOI 10.1034/j.1600-0749.2002.1r082.x; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Lanzetti L, 2001, EXP CELL RES, V271, P45, DOI 10.1006/excr.2001.5369; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; McGarry MP, 1999, P SOC EXP BIOL MED, V220, P162, DOI 10.1046/j.1525-1373.1999.d01-24.x; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; ROLFSEN RM, 1984, J HERED, V75, P158, DOI 10.1093/oxfordjournals.jhered.a109903; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Wu XF, 2000, CURR OPIN CELL BIOL, V12, P42, DOI 10.1016/S0955-0674(99)00055-1; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Yang W, 2000, J CELL SCI, V113, P4077; Zhang Q, 2002, HUM MOL GENET, V11, P697, DOI 10.1093/hmg/11.6.697; Zhen LJ, 1999, BLOOD, V94, P146, DOI 10.1182/blood.V94.1.146.413k39_146_155	45	135	142	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28191	28199		10.1074/jbc.M204011200	http://dx.doi.org/10.1074/jbc.M204011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12019270	hybrid			2022-12-25	WOS:000177189800077
J	Spinella, F; Rosano, L; Di Castro, V; Natali, PG; Bagnato, A				Spinella, F; Rosano, L; Di Castro, V; Natali, PG; Bagnato, A			Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA; FACTOR EXPRESSION; FACTOR-I; ACTIVATION; GENE; TRANSCRIPTION; MECHANISMS; PROTEIN; NEOVASCULARIZATION; ANGIOGENESIS	Angiogenesis is an essential prerequisite for tumor growth, invasion, and metastasis. In ovarian carcinoma cells, endothelin-1 (ET-1) stimulates the secretion of vascular endothelial growth factor (VEGF), a major mediator of tumor angiogenesis. In OVCA 433 and HEY ovarian carcinoma cell lines, ET-1 treatment increases VEGF mRNA expression and induces VEGF protein levels in a time- and dose-dependent fashion, and do so to a greater extent under hypoxic conditions. ET-1 also increases hypoxia-inducible factor-1alpha (HIP-1alpha) accumulation and activates the HIP-1 transcription complex under both normoxic and hypoxic conditions, suggesting a role for HIP-1 in the induction of VEGF expression. These effects are inhibited by the selective ETA receptor (ETAR) antagonist, BQ123. The ET-1-induced increase in HIP-1alpha protein levels is due to the enhanced HIP-1alpha stabilization. These results implicate HIP-1alpha in the induction of VEGF expression in ET-1-stimulated ovarian carcinoma cells, and provide a mechanism whereby ET-1 acting selectively through ETAR can interact with the HIP-1alpha-dependent machinery of angiogenesis. Our results suggest that new therapeutic strategies using specific ETAR antagonists could provide an additional approach to the treatment of ovarian carcinoma by inhibiting neovascularization as well as tumor cell growth.	Regina Elena Inst Canc Res, Lab Mol Pathol, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bagnato, A (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol, Via Messi Oro 156, I-00158 Rome, Italy.	bagnato@ifo.it	Bagnato, Anna/G-9747-2016; Di Castro, Valeriana/H-8873-2017; spinella, francesca/AAZ-8982-2020; Rosanò, Laura/B-2863-2018; Rosanò, Laura/I-9266-2012; ROSANO', Laura/AAK-1424-2020; Rosanò, Laura/AAB-7821-2019	Bagnato, Anna/0000-0002-7269-9522; Di Castro, Valeriana/0000-0002-1899-3683; Rosanò, Laura/0000-0002-9962-6411; ROSANO', Laura/0000-0002-9962-6411; Rosanò, Laura/0000-0002-3981-8593				Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; Birner P, 2001, CLIN CANCER RES, V7, P1661; Brahimi-Horn C, 2001, TRENDS CELL BIOL, V11, pS32, DOI 10.1016/S0962-8924(01)02126-2; Cruz A, 2001, J VASC RES, V38, P536, DOI 10.1159/000051089; DARREN ER, 2000, J BIOL CHEM, V275, P26765; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; Egidy G, 2000, AM J PATHOL, V157, P1863, DOI 10.1016/S0002-9440(10)64825-0; Feldser D, 1999, CANCER RES, V59, P3915; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Rosano L, 2001, CANCER RES, V61, P8340; RUBANJI GM, 1999, PHARMACOL REV, V46, P325; Ryan HE, 2000, CANCER RES, V60, P4010; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; SALANI D, 2002, CLIN SCI LOND, V102; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sodhi A, 2000, CANCER RES, V60, P4873; WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913; Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	38	186	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27850	27855		10.1074/jbc.M202421200	http://dx.doi.org/10.1074/jbc.M202421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023962	hybrid			2022-12-25	WOS:000177189800034
J	Yamada, M; Sato, N; Taniyama, C; Ohtani, K; Arai, K; Masai, H				Yamada, M; Sato, N; Taniyama, C; Ohtani, K; Arai, K; Masai, H			A 63-base pair DNA segment containing an Sp1 site but not a canonical E2F site can confer growth-dependent and E2F-mediated transcriptional stimulation of the human ASK gene encoding the regulatory subunit for human Cdc7-related kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-E GENE; SACCHAROMYCES-CEREVISIAE CDC7; S-PHASE ENTRY; CELL-CYCLE; PROTEIN-KINASE; REPLICATION ORIGINS; CHROMOSOMAL LOCALIZATION; G(1)/S TRANSITION; MAMMALIAN-CELLS; FISSION YEAST	Cdc7-Dbf4 kinase complexes, conserved widely in eukaryotes, play essential roles in initiation and progression of the S phase. Cdc7 kinase activity fluctuates during cell cycle, and this is mainly the result of oscillation of expression of the Dbf4 subunit. Therefore, it is crucial to understand the mechanisms of regulation of Dbf4 expression. We have isolated and characterized the promoter region of the human ASK gene encoding Dbf4-related regulatory subunit for human Cdc7 kinase. We have identified a 63-base pair ASK promoter segment, which is sufficient for mediating growth stimulation. This minimal promoter segment (MP), containing an Sp1 site but no canonical E2F site, can be activated by ectopic E2F expression as well. Within the 63-base pair region, the Sp1 site as well as other elements are essential for stimulation by growth signals and by E2F, whereas an AT-rich sequence proximal to the coding region may serve as an element required for suppression in quiescence. Gel shift assays in the presence of an antibody demonstrate the presence of E2F1 in the protein-DNA complexes generated on the MP segment. However, the complex formation on MP was not competed by a DHFR promoter fragment, known to bind to E2F, nor by a consensus E2F binding oligonucleotide. Gel shift assays with point mutant MP fragments indicate that a non-canonical E2F site in the middle of this segment is critical for generation of the E2F complex. Our results suggest that E2F regulates the ASK promoter through an atypical mode of recognition of the target site.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; Japan Sci & Technol, CREST, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Sato, Noriko/Y-7693-2019					ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; Chen X, 1999, MOL CELL BIOL, V19, P4695; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Geng Y, 1996, ONCOGENE, V12, P1173; Guo BQ, 2001, GENE, V264, P249, DOI 10.1016/S0378-1119(01)00332-8; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hess GF, 1998, GENE, V211, P133, DOI 10.1016/S0378-1119(98)00094-8; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITAGAWA M, 1995, ONCOGENE, V10, P229; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Lepke M, 1999, MOL GEN GENET, V262, P220, DOI 10.1007/s004380051078; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai Hisao, 1999, Frontiers in Bioscience, V4, pd834, DOI 10.2741/Masai; Nishikawa NS, 2000, NUCLEIC ACIDS RES, V28, P1525, DOI 10.1093/nar/28.7.1525; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Ogino K, 2001, J BIOL CHEM, V276, P31376, DOI 10.1074/jbc.M102197200; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rowles A, 1997, CURR OPIN GENET DEV, V7, P152, DOI 10.1016/S0959-437X(97)80123-2; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sclafani RA, 2000, J CELL SCI, V113, P2111; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Toone WM, 1997, ANNU REV MICROBIOL, V51, P125, DOI 10.1146/annurev.micro.51.1.125; TOYN JH, 1995, TRENDS BIOCHEM SCI, V20, P70, DOI 10.1016/S0968-0004(00)88960-4; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27668	27681		10.1074/jbc.M202884200	http://dx.doi.org/10.1074/jbc.M202884200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015319	hybrid			2022-12-25	WOS:000177189800014
J	Alfadhli, A; Steel, E; Finlay, L; Bachinger, HP; Barklis, E				Alfadhli, A; Steel, E; Finlay, L; Bachinger, HP; Barklis, E			Hantavirus nucleocapsid protein coiled-coil domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE MATRIX PROTEIN; C-TERMINAL DOMAIN; HEAT-SHOCK FACTOR; AMINO-ACID; OLIGOMERIZATION; ASSEMBLES; PROGRAM; VIRUS	The nucleocapsid (N) proteins of hantaviruses such as the Sin Nombre virus (SNV) bind to membranes and viral RNAs, associate with transcription and replication complexes, and oligomerize during the process of virus assembly. N proteins trimerize in vitro and in vivo, and associate via assembly domains at their amino- and carboxyl-terminal ends. Because structure prediction algorithms suggested that N protein residues 3-75 form two coiled-coil motifs separated by an intervening kink or turn sequence, we examined the properties of peptides representing SNV N protein residues 3-35, 43-75, and 3-75. Of the three peptides, N-(3-35) assembled coiled-coil oligomers only at high concentration and low temperature. In contrast, N-(43-75) efficiently trimerized at low concentration, implying that it carries a coiled-coil trigger sequence. Interestingly, while the longer peptide, N-(3-75), assembled dimers and/or trimers at high concentration, at low concentration it appeared to adopt an intramolecular helix-turn-helix conformation. These results suggest that N protein oligomerization involves the bundling of intramolecular antiparallel coils or a conformational switch from intra- to intermolecular coiled-coils.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Microbiol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Shriners Hosp Children, Res Unit, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Barklis, E (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.							Akey DL, 2001, BIOCHEMISTRY-US, V40, P6352, DOI 10.1021/bi002829w; Alfadhli A, 2001, J VIROL, V75, P2019, DOI 10.1128/JVI.75.4.2019-2023.2001; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Betz SF, 1997, BIOCHEMISTRY-US, V36, P2450, DOI 10.1021/bi961704h; Birkenbihl RP, 1998, J MOL BIOL, V280, P73, DOI 10.1006/jmbi.1998.1851; Bishop D. H. L., 1996, The Bunyaviridae., P19; CHIZHIKOV VE, 1995, J VIROL, V69, P8132, DOI 10.1128/JVI.69.12.8132-8136.1995; Ehrlich LS, 2001, BIOPHYS J, V81, P586, DOI 10.1016/S0006-3495(01)75725-6; FLOSSDORF J, 1980, MAKROMOL CHEM, V181, P715; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kaukinen P, 2001, J GEN VIROL, V82, P1845, DOI 10.1099/0022-1317-82-8-1845; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; *PROT SOL, 1998, DYN THEOR DAT INT GU, P1; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Ravkov EV, 2001, J VIROL, V75, P1808, DOI 10.1128/JVI.75.4.1808-1815.2001; SANTOS N, 1998, BIOPHYS J, V71, P1641; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmaljohn C. S., 1996, The Bunyaviridae., P63; Severson W, 1999, J BIOL CHEM, V274, P33732, DOI 10.1074/jbc.274.47.33732; Severson WE, 2001, J VIROL, V75, P2646, DOI 10.1128/JVI.75.6.2646-2652.2001; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xu XL, 2002, J VIROL, V76, P3301, DOI 10.1128/JVI.76.7.3301-3308.2002	30	56	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27103	27108		10.1074/jbc.M203395200	http://dx.doi.org/10.1074/jbc.M203395200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12019266	hybrid			2022-12-25	WOS:000177055900053
J	Erxleben, C; Everhart, AL; Romeo, C; Florance, H; Bauer, MB; Alcorta, DA; Rossie, S; Shipston, MJ; Armstrong, DL				Erxleben, C; Everhart, AL; Romeo, C; Florance, H; Bauer, MB; Alcorta, DA; Rossie, S; Shipston, MJ; Armstrong, DL			Interacting effects of N-terminal variation and strex exon splicing on slo potassium channel regulation by calcium, phosphorylation, and oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; LARGE-CONDUCTANCE; SMOOTH-MUSCLE; BETA-SUBUNIT; PROTEIN-PHOSPHORYLATION; XENOPUS-OOCYTES; BKCA CHANNEL; CA CHANNELS; MODULATION; CELLS	We have investigated the structural basis for the phenotype of a native rat Slo (rSlo) potassium channel (BKCa; KCNMA1) in a rat pituitary cell line, GH(4)C(1). Opposing regulation of these calcium- and voltage-activated potassium channels by cAMP- and cGMP-dependent protein kinases requires an alternatively spliced exon (strex) of 59 amino acids in the cytoplasmic C terminus of the pore-forming alpha subunit encoded by rslo. However, inclusion of this cysteine-rich exon produces a 10-fold increase in the sensitivity of the channels to inhibition by oxidation. Inclusion of the strex exon also increases channel sensitivity to stimulation by calcium, but responses in the physiological ranges of calcium and voltage require coassembly with beta(1) subunits. With strex present, however, beta(1) subunits only stimulated channels assembled from rSlo alpha subunits with a truncated N terminus beginning MDALI-. Thus N-terminal variation and strex exon splicing in rSlo interact to produce BKCa channels with a physiologically relevant phenotype.	NIEHS, Lab Signal Transduct F205, NIH, Res Triangle Pk, NC 27709 USA; Univ Edinburgh, Membrane Biol Grp, Edinburgh EH8 9XD, Midlothian, Scotland; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Edinburgh; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Armstrong, DL (corresponding author), NIEHS, Lab Signal Transduct F205, NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	armstro3@niehs.nih.gov	Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080043, Z01ES080043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Brenner R, 2000, J BIOL CHEM, V275, P6453, DOI 10.1074/jbc.275.9.6453; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Clark AG, 1999, J PHYSIOL-LONDON, V516, P45, DOI 10.1111/j.1469-7793.1999.045aa.x; Cox DH, 2000, J GEN PHYSIOL, V116, P411, DOI 10.1085/jgp.116.3.411; DiChiara TJ, 1997, J NEUROSCI, V17, P4942; Hall SK, 2000, J BIOL CHEM, V275, P3749, DOI 10.1074/jbc.275.6.3749; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Navaratnam DS, 1997, NEURON, V19, P1077, DOI 10.1016/S0896-6273(00)80398-0; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Schubert R, 2001, TRENDS PHARMACOL SCI, V22, P505, DOI 10.1016/S0165-6147(00)01775-2; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Shi JY, 2001, J GEN PHYSIOL, V118, P589, DOI 10.1085/jgp.118.5.589; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Shipston MJ, 2001, TRENDS CELL BIOL, V11, P353, DOI 10.1016/S0962-8924(01)02068-2; Shipston MJ, 1999, MOL ENDOCRINOL, V13, P1728, DOI 10.1210/me.13.10.1728; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Van Goor F, 2001, J NEUROSCI, V21, P5902, DOI 10.1523/JNEUROSCI.21-16-05902.2001; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Wang ZW, 1997, J GEN PHYSIOL, V110, P35, DOI 10.1085/jgp.110.1.35; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Zhang X, 2001, J GEN PHYSIOL, V118, P607, DOI 10.1085/jgp.118.5.607; Zhou XB, 2001, J BIOL CHEM, V276, P43239, DOI 10.1074/jbc.M104202200	44	54	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27045	27052		10.1074/jbc.M203087200	http://dx.doi.org/10.1074/jbc.M203087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016222	hybrid			2022-12-25	WOS:000177055900046
J	Kupershmidt, S; Yang, T; Chanthaphaychith, S; Wang, ZQ; Towbin, JA; Roden, DM				Kupershmidt, S; Yang, T; Chanthaphaychith, S; Wang, ZQ; Towbin, JA; Roden, DM			Defective human ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; POTASSIUM CHANNEL; PROTEIN TRAFFICKING; CARDIAC-ARRHYTHMIA; K+ CHANNELS; HUMAN HEART; HERG; EXPRESSION; MECHANISM; MUTATIONS	Mutations in the human Ether-h-go-go-Related gene (HERG), encoding the protein underlying the cardiac K+ current, I-Kr, cause chromosome 7-linked long QT syndrome (LQT2). In this study, we show that deletion of the C-terminal 147 amino acids (HERG(Delta147)) abolished I-Kr, whereas a larger, 159-amino acid deletion (HERG(Delta159)) identified in an LQT2 kindred did generate I-Kr, albeit with reduced amplitude compared with the wild type. The 12 amino acids present in HERG(Delta147) and absent in HERG(Delta159) include a potential endoplasmic reticulum. (ER) retention signal, RGR, which when mutated to LGL (HERG(Delta147-LGL)) restored I-Kr. Streptavidin selection of biotin-labeled surface proteins showed good expression of wild-type and HERG(Delta159) at the cell surface and low expression of HERG(Delta147-LGL) and HERG(Delta147). Additionally, a 100-amino acid peptide spanning the RGR triplet can rescue the defect in HERG,,147 when co-expressed as an ER-targeted minigene. Failure of HERG trafficking is known to cause LQT2, and this identified a molecular mechanism underlying this defect. Further, our data indicate that a key function of the C-terminal 104 amino acids is to mask the RGR ER retention signal, which becomes exposed when mutations truncate the HERG C terminus.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Baylor Coll Med, Grad Program Cardiovasc Sci, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Vanderbilt University; Vanderbilt University; Baylor College of Medicine; Baylor College of Medicine	Kupershmidt, S (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, 561A Preston Res Bldg, Nashville, TN 37232 USA.		Roden, Dan/ABD-5412-2021; Towbin, Jeffrey A./J-5595-2019; Kupershmidt, Sabina/AAO-5464-2021	Towbin, Jeffrey A./0000-0002-6585-714X; Kupershmidt, Sabina/0000-0002-8119-2723	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049989, R01HL051618, R01HL062570, P01HL046681] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62570, HL 51618, HL 46681, HL 49989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Baroudi G, 2001, CIRC RES, V88, pE78, DOI 10.1161/hh1201.093270; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Petersen CI, 2001, BIOPHYS J, V80, p6A; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Roden DM, 1999, J CARDIOVASC ELECTR, V10, P1664, DOI 10.1111/j.1540-8167.1999.tb00231.x; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang Zhiqing, 2001, Pediatric Research, V49, p34A; Yamashita F, 2001, J MOL CELL CARDIOL, V33, P197, DOI 10.1006/jmcc.2000.1300; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	31	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27442	27448		10.1074/jbc.M112375200	http://dx.doi.org/10.1074/jbc.M112375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021266	hybrid			2022-12-25	WOS:000177055900094
J	Mulder, LCF; Chakrabarti, LA; Muesing, MA				Mulder, LCF; Chakrabarti, LA; Muesing, MA			Interaction of HIV-1 integrase with DNA repair protein hRad18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; UBIQUITIN-CONJUGATING ENZYME; VIRUS TYPE-1 INTEGRASE; MU-TRANSPOSASE; YEAST RAD6; IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; MONOCLONAL-ANTIBODIES	We have previously shown that human immunodeficiency virus-1 (HIV-1) integrase is an unstable protein and a substrate for the N-end rule degradation pathway. This degradation pathway shares its ubiquitin-conjugating enzyme, Rad6, with the post-replication/translesion DNA repair pathway. Because DNA repair is thought to play an essential role in HIV-1 integration, we investigated whether other molecules of this DNA repair pathway could interact with integrase. We observed that co-expression of human Rad18 induced the accumulation of an otherwise unstable form of HIV-1 integrase. This accumulation occurred even though hRAD18 possesses a RING finger domain, a structure that is generally associated with E3 ubiquitin ligase function and protein degradation. Evidence for an interaction between integrase and hRad18 was obtained through reciprocal co-immunoprecipitation. Moreover we found that a 162-residue region of hRad18 (amino acids 65-226) was sufficient for both integrase stabilization and interaction. Finally, we observed that HIV-1 integrase co-localized with hRad18 in nuclear structures in a subpopulation of co-transfected cells. Taken together, these findings identify hRad18 as a novel interacting partner of HIV-1 integrase and suggest a role for post-replication/translesion DNA repair in the retroviral integration process.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA	Rockefeller University	Muesing, MA (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.			Chakrabarti, Lisa/0000-0002-1895-3630	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, R01AI047054] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI 47054-01, P30 AI 42848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Bukovsky A, 1996, J VIROL, V70, P6820, DOI 10.1128/JVI.70.10.6820-6825.1996; Burton BM, 2001, MOL CELL, V8, P449, DOI 10.1016/S1097-2765(01)00307-0; Daniel R, 2001, MOL CELL BIOL, V21, P1164, DOI 10.1128/MCB.21.4.1164-1172.2001; Daniel R, 2001, J VIROL, V75, P3121, DOI 10.1128/JVI.75.7.3121-3128.2001; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Gaken JA, 1996, J VIROL, V70, P3992; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Ha HC, 2001, P NATL ACAD SCI USA, V98, P3364, DOI 10.1073/pnas.051633498; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MADURA K, 1993, J BIOL CHEM, V268, P12046; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Nilsen BM, 1996, J VIROL, V70, P1580, DOI 10.1128/JVI.70.3.1580-1587.1996; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WISKERCHEN M, 1995, J VIROL, V69, P376, DOI 10.1128/JVI.69.1.376-386.1995; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	45	62	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27489	27493		10.1074/jbc.M203061200	http://dx.doi.org/10.1074/jbc.M203061200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016221	hybrid			2022-12-25	WOS:000177055900098
J	Sacchi, S; Lorenzi, S; Molla, G; Pilone, MS; Rossetti, C; Pollegioni, L				Sacchi, S; Lorenzi, S; Molla, G; Pilone, MS; Rossetti, C; Pollegioni, L			Engineering the substrate specificity of D-amino-acid oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE OXIDASE; SITE-DIRECTED MUTAGENESIS; RHODOTORULA-GRACILIS; BEEF KIDNEY; TRIGONOPSIS-VARIABILIS; AUTOMATED DOCKING; KINETIC MECHANISM; ESCHERICHIA-COLI; REDOX POTENTIALS; LACTATE OXIDASE	The high resolution crystal structure Of D-amino-acid oxidase (DAAO) from the yeast Rhodotorula gracilis provided us with the tool to engineer the substrate specificity of this flavo-oxidase. DAAO catalyzes the oxidative deamination Of D-amino acids, with the exception of D-aspartate and D-glutamate (which are oxidized by D-aspartate oxidase, DASPO). Following sequence homology, molecular modeling, and simulated annealing docking analyses, the active site residue Met-213 was mutated to arginine. The mutant enzyme showed properties close to those of DASPO (e.g. the oxidation of D-aspartate and the binding Of L-tartrate), and it was still active on D-alanine. The presence of an additional guanidinium group in the active site of the DAAO mutant allowed the binding (and thus the oxidation) Of D-aspartate, but it was also responsible for a lower catalytic activity on D-alanine. Similar results were also obtained when two additional arginines were simultaneously introduced in the active site of DAAO (M213R/Y238R mutant, yielding an architecture of the active site more similar to that obtained for the DASPO model), but the double mutant showed very low stability in solution. The decrease in maximal activity observed with these DAAO mutants could be due to alterations in the precise orbital alignment required for efficient catalysis, although even the change in the redox properties (more evident in the DAAO-benzoate complex) could play a role. The rational design approach was successful in producing an enzymatic activity with a new, broader substrate specificity, and this approach could also be used to develop DAAO variants suitable for use in biotechnological applications.	Univ Insubria, Dept Struct & Funct Biol, I-21100 Varese, Italy	University of Insubria	Pollegioni, L (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Via J H Dunant 3, I-21100 Varese, Italy.			SACCHI, SILVIA/0000-0002-2338-2561; POLLEGIONI, LOREDANO/0000-0003-1733-7243; ROSSETTI, CARLO/0000-0002-6806-2975; Molla, Gianluca/0000-0003-3688-3397				BURNS CL, 1984, BIOCHEM BIOPH RES CO, V125, P1039, DOI 10.1016/0006-291X(84)91388-3; CASALIN P, 1991, EUR J BIOCHEM, V197, P513, DOI 10.1111/j.1432-1033.1991.tb15939.x; Clark W.M., 1960, OXIDATION REDUCTION, P184; CURTI B, 1992, CHEM BIOCH FLAVOENZY, P69; FAOTTO L, 1995, BIOTECHNOL LETT, V17, P193, DOI 10.1007/BF00127987; Friedman M, 1999, J AGR FOOD CHEM, V47, P3457, DOI 10.1021/jf990080u; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harris CM, 1999, J BIOL CHEM, V274, P36233, DOI 10.1074/jbc.274.51.36233; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MINNAERT K, 1965, BIOCHIM BIOPHYS ACTA, V110, P42, DOI 10.1016/S0926-6593(65)80093-5; Molla G, 2000, J BIOL CHEM, V275, P24715, DOI 10.1074/jbc.M908193199; Molla G, 1998, PROTEIN EXPRES PURIF, V14, P289, DOI 10.1006/prep.1998.0956; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Negri A, 1999, BBA-PROTEIN STRUCT M, V1431, P212, DOI 10.1016/S0167-4838(99)00027-8; NEGRI A, 1987, J BIOL CHEM, V262, P10026; NEGRI A, 1992, J BIOL CHEM, V267, P11865; NEGRI A, 1988, J BIOL CHEM, V263, P13557; Pilone MS, 2000, CELL MOL LIFE SCI, V57, P1732, DOI 10.1007/PL00000655; Pilone MS, 2002, BIOCATAL BIOTRANSFOR, V20, P145, DOI 10.1080/10242420290020679; PILONESIMONETTA M, 1989, EUR J BIOCHEM, V180, P199, DOI 10.1111/j.1432-1033.1989.tb14634.x; Pollegioni L, 2000, EUR J BIOCHEM, V267, P6624, DOI 10.1046/j.1432-1327.2000.01757.x; POLLEGIONI L, 1992, BIOCHEM J, V286, P389, DOI 10.1042/bj2860389; POLLEGIONI L, 1994, J BIOL CHEM, V269, P31666; POLLEGIONI L, 1993, J BIOL CHEM, V268, P13850; POLLEGIONI L, 1992, BIOCHIM BIOPHYS ACTA, V1120, P11, DOI 10.1016/0167-4838(92)90418-D; Pollegioni L, 2001, FEBS LETT, V507, P323, DOI 10.1016/S0014-5793(01)02983-0; PORTER DJT, 1977, J BIOL CHEM, V252, P4464; Sacchi S, 1998, BIOTECHNOL TECH, V12, P149, DOI 10.1023/A:1008896602544; Sambrook J., 2002, MOL CLONING LAB MANU; TEDESCHI G, 1994, BBA-PROTEIN STRUCT M, V1207, P217, DOI 10.1016/0167-4838(94)00071-9; Umhau S, 2000, P NATL ACAD SCI USA, V97, P12463, DOI 10.1073/pnas.97.23.12463; Yorita K, 2000, P NATL ACAD SCI USA, V97, P13039, DOI 10.1073/pnas.250472297; Yorita K, 2000, P NATL ACAD SCI USA, V97, P2480, DOI 10.1073/pnas.040559797	38	71	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27510	27516		10.1074/jbc.M203946200	http://dx.doi.org/10.1074/jbc.M203946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021281	hybrid			2022-12-25	WOS:000177055900101
J	Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH				Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH			Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines	ONCOGENE			English	Article						syntenin; migration; invasion; breast cancer; gastric cancer	SUBTRACTIVE HYBRIDIZATION; EPHRIN LIGANDS; PDZ DOMAINS; NUDE-MICE; EXPRESSION; PROTEIN; CARCINOMA; RECEPTOR; BINDING; ESTABLISHMENT	Two human breast cancer cell lines of differing invasive and metastatic potential, MDA-MB-435 and MCF7, were examined using subtractive suppression hybridization in a search for any genes associated with metastasis. Of the 17 cDNAs identified as being differentially expressed genes, it was determined that syntenin was overexpressed in metastatic MDA-MB-435 cells. Expression analysis showed that the expression level of syntenin was well correlated with invasive and metastatic potential in various human breast and gastric cancer cell lines. Moreover, gastric tumor tissues exhibited a much higher syntenin mRNA expression than their normal counterparts. Syntenin-transfected MCF7 cells migrated more actively, and showed an increased invasion rate relative to vector-transfectants or parental MCF7 in vitro, without evidencing any effect on the adhesion to fibronectin, type I collagen and laminin. Similarly, the forced expression of syntenin to human gastric cancer cell line Az521 increased its migratory and invasive potential in vitro. Syntenin-expressing MCF7 cells were associated with the appearance of numerous cell surface extensions and with pseudopodia formation on collagen 1, suggesting that syntenin may be involved in the signaling cascade to actin-reorganization. Mutation study suggested that PDZ2 domain of syntenin could be an essential role in its stimulatory effect on the cell migration. This is the first demonstration that syntenin, a PDZ motif-containing protein, can be overexpressed during the metastatic progression of human breast and gastric cancer cells and that it can function as a meta stasis-inducing gene.	Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, Taejon 305600, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Seoul National University (SNU); Pusan National University	Lee, JH (corresponding author), Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, POB 115,Yuseong, Taejon 305600, South Korea.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byers RJ, 2000, INT J EXP PATHOL, V81, P391, DOI 10.1046/j.1365-2613.2000.00174.x; Cos S, 1998, CANCER RES, V58, P4383; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Davies EL, 1999, EUR J CANCER, V35, P902, DOI 10.1016/S0959-8049(99)00031-3; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK JG, 1990, CANCER RES, V50, P2773; PRICE JE, 1990, CANCER RES, V50, P717; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SHEIKH MS, 1994, INVAS METAST, V14, P329; SIMU G, 1978, CELL MOL BIOL, V23, P145; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOVER DM, 1994, CANCER RES, V54, P3092; Takai N, 2001, ONCOL REP, V8, P567; Talts JF, 1999, J CELL SCI, V112, P1855; Tang XX, 1999, CLIN CANCER RES, V5, P455; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; WHELAN SL, 1990, PATTERNS CANC 5 CONT; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yasoshima T, 1996, JPN J CANCER RES, V87, P153, DOI 10.1111/j.1349-7006.1996.tb03153.x; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	38	102	107	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4080	4088		10.1038/sj.onc.1205514	http://dx.doi.org/10.1038/sj.onc.1205514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037664				2022-12-25	WOS:000176186000002
J	Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M				Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M			Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway	ONCOGENE			English	Article						telomerase; TERT; EGF; MAP kinase	CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; GENE-EXPRESSION; C-MYC; TERMINAL DOMAIN; PROTEIN-KINASE; CELLS; PHOSPHORYLATION; JUN; TRANSDUCTION	Telomerase is a regulated enzyme and its activity is tightly associated with cell proliferation. The mechanisms of this association are unclear, but specific growth factors may regulate telomerase activity. The present study examines the effect of epidermal growth factor (EGF) on telomerase activity and identifies the signal transduction pathway involved in this process. EGF upregulated telomerase activity in EGF receptor-positive cells after the activation of telomerase reverse transcriptase (TERT) mRNA expression. This activation was rapid, peaked after 6 or 12 h and was not blocked by the concurrent exposure to cycloheximide, suggesting a direct effect of EGF on TERT transcription. Transient expression assays revealed that EGF activates the hTERT promoter and that the proximal core promoter is responsible for this regulation. The activation of hTERT mRNA expression by EGF was specifically blocked by MEK inhibitor, and in vitro kinase assays demonstrated that ERK is activated in response to EGF. Transient expression assays using mutant reporter plasmids revealed that an ETS motif located in the core promoter of hTERT is required for the EGF-induced transactivation of hTERT. Overexpression of wild type Ets in cells enhanced the EGF effect on hTERT transcription, while that of dominant negative Ets significantly repressed EGF action. These findings suggest that EGF activates telomerase through the direct activation of TERT transcription, in which the Ras/MEK/ERK pathway and Ets factor play major roles. Our data support the notion that growth factors directly regulate telomerase via specific signal transduction pathways.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9208641, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Kanazawa University; University of Tokyo; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.			Gotoh, Noriko/0000-0003-3733-260X				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; BORNAR AG, 1998, SCIENCE, V279, P349; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, J BIOL CHEMN, V267, P24798; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; Tsumuki H, 2000, RHEUMATOL INT, V19, P123, DOI 10.1007/s002960050115; Tu WW, 1999, BRIT J HAEMATOL, V104, P785, DOI 10.1046/j.1365-2141.1999.01272.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Z, 2000, CANCER RES, V60, P5376; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Yang XY, 2000, LIFE SCI, V66, P1545, DOI 10.1016/S0024-3205(00)00472-0	38	116	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4071	4079		10.1038/sj.onc.1205509	http://dx.doi.org/10.1038/sj.onc.1205509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037663	Green Submitted			2022-12-25	WOS:000176186000001
J	Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S				Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S			G-protein alpha olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells	ONCOGENE			English	Article						cAMP; PKA; rho GTPases; src; PI3 '-kinase; PTHrP; trefoil factors	HORMONE-RELATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER CELLS; SMALL GTPASE; TRANSFORMING ACTIVITY; KINASE ACTIVATION; COUPLED RECEPTORS; ADENYLYL CYCLASES; TREFOIL PEPTIDES; GENE-EXPRESSION	The heterotrimeric G-protein subunits Galpha and Gbetagamma are involved in cellular transformation and tumor development. Here, we report the expression of Galphaolf in human digestive and urogenital epithelial cells using RT-PCR and Western blot. When the constitutively activated form of GalphaolfQ214L (AGalphaolf) was stably transfected in canine kidney MDCKts.src and human colonic HCT-8/S11 epithelial cells, it induced cellular invasion in collagen gels. AGalphaolf-mediated invasion was abrogated by agonists of platelet activating factor receptors (PAF-R) and protease-activated receptors -1 (PAR-1), pharmacological inhibitors of P13'-Kinase (wortmannin), protein kinase C (Go6976 and GF109203X), Rho GTPase (C3T exoenzyme), but was independent of protein kinase A. Accordingly, the invasive phenotype induced by AGalphaolf in HCT-8/S11 cells was reversed by the RhoA antagonist RhoD (G26V). Although AGaolf protected MDCKts.src cells against serum starvation-mediated apoptosis via a Rho-independent pathway, both AGalphaolf and Rho inhibition by C3T induced neuroendocrine-like differentiation linked to extensive neurite outgrowth and parathyroid hormone-related protein expression in human prostatic LNCaP-AGalphaolf cells. Since prostate tumors with a larger neuroendocrine cell population display increased invasiveness, persistent activation of the G-protein alphaolf may exert convergent adverse effects on cellular invasion and survival in solid tumors during the neoplastic progression towards metastasis.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Hop Lariboisiere, CRC Bernard, F-75475 Paris 10, France; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Chiba University	Emami, S (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	emami@st-antoine.inserm.fr	Vakaet, Luc/A-6467-2010					Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Astesano A, 1999, J HISTOCHEM CYTOCHEM, V47, P289, DOI 10.1177/002215549904700303; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bolt MJG, 1998, GASTROENTEROLOGY, V115, P1494, DOI 10.1016/S0016-5085(98)70028-9; Bouvet M, 2001, J CLIN ENDOCR METAB, V86, P310, DOI 10.1210/jc.86.1.310; Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Cox ME, 1999, CANCER RES, V59, P3821; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Debruyne PR, 2001, MUTAT RES-FUND MOL M, V480, P359, DOI 10.1016/S0027-5107(01)00195-6; Deftos Leonard J., 2000, Cancer, V88, P3002; DEL PL, 1997, SCIENCE, V278, P687; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Escande B, 2001, SEMIN PERINATOL, V25, P76, DOI 10.1053/sper.2001.23194; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ferrand N, 1999, J MOL CELL CARDIOL, V31, P1137, DOI 10.1006/jmcc.1999.0945; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gujral A, 2001, CANCER RES, V61, P2282; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Jung YD, 1999, CANCER RES, V59, P4804; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Regnauld KL, 2002, AM J PHYSIOL-REG I, V282, pR870, DOI 10.1152/ajpregu.00374.2001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIUS RA, 1994, BRAIN RES, V643, P50, DOI 10.1016/0006-8993(94)90007-8; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shankar PP, 2000, BRAIN RES, V868, P230, DOI 10.1016/S0006-8993(00)02335-0; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Spada A, 1998, MOL CELL ENDOCRINOL, V142, P1, DOI 10.1016/S0303-7207(98)00116-6; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 2000, BIOCHEM BIOPH RES CO, V272, P513, DOI 10.1006/bbrc.2000.2804; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZIGMAN JM, 1993, ENDOCRINOLOGY, V133, P2508, DOI 10.1210/en.133.6.2508	85	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4020	4031		10.1038/sj.onc.1205498	http://dx.doi.org/10.1038/sj.onc.1205498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037684				2022-12-25	WOS:000175869900008
J	Hwang, DY; Chae, KR; Kang, TS; Hwang, JH; Lim, CH; Kang, HK; Goo, JS; Lee, MR; Lim, HJ; Min, SH; Cho, JY; Hong, JT; Song, CW; Paik, SG; Cho, JS; Kim, YK				Hwang, DY; Chae, KR; Kang, TS; Hwang, JH; Lim, CH; Kang, HK; Goo, JS; Lee, MR; Lim, HJ; Min, SH; Cho, JY; Hong, JT; Song, CW; Paik, SG; Cho, JS; Kim, YK			Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						AD; PS2; A beta-42; amyloid precursor protein	PRESENILIN-2 MUTATION N141I; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; GENE; EXPRESSION; BRAIN; CYCLOOXYGENASE-2; LOCALIZATION; APOPTOSIS; CLEAVAGE	Alzheimer's disease (AD) occurs when neurons in the memory and cognition regions of the brain are accompanied by an accumulation of the long amyloid beta-proteins of the 39 to 43 amino acids derived from the amyloid precursor protein (APP) by cleavage with beta- and gamma-secretase. An increased production of Abeta-42 by mutation of PS2 genes promotes caspase expression and is associated with the Cox-2 found in the brain of AD patients. To address this question in vivo, we expressed the human mutant PS2 (hPS2m) (N141I) as well as wild PS2 (hPS2w) as a control in transgenic (Tg) mice under control of the neuron-specific enolase (NSE) promoter. Water maze tests were used to demonstrate the behavioral defect; dot blot, Western blot, and immunohistochemical analyses were performed on the brain with the hPS2, Abeta-42, caspase- 3, and Cox-2 antibody. We concluded that 1) Tg mice showed a behavioral dysfunction in the water maze test, 2) levels of hPS2, Abeta-42, caspase-3, and Cox-2 expression were modulated in the brains of both Tg mice, 3) dense staining with antibody to hPS2, Abeta-42, caspase- 3, and Cox-2 was visible in the brains of Tg mice compared with age-matched control mice, and 4) distinguishable AD phenotypes between hPS2w- and hPS2m-Tg mice did not appear. These results suggest that an elevation of Abeta-42 by overexpression of hPS2 and mutation of hPS2m might induce the behavioral deficit and caspase- 3 and Cox-2 induction, which could be useful in the therapeutic testing of compounds to have considerable clinical effects.	Natl Inst Toxicol Res, Korea FDA, Div Lab Anim Resources, Seoul 122704, South Korea; Natl Inst Toxicol Res, Korea FDA, Div Neurotoxicol, Seoul 122704, South Korea; Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305704, South Korea	Chungbuk National University; Chungnam National University	Kim, YK (corresponding author), Natl Inst Toxicol Res, Korea FDA, Div Lab Anim Resources, 5 Nokbun Dong Eunpyng Ku, Seoul 122704, South Korea.	kimyongkyu@hanmail.net						Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Guenette SY, 1999, NEUROBIOL AGING, V20, P201, DOI 10.1016/S0197-4580(99)00042-1; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LETSCHER H, 1997, J BIOL CHEM, V272, P20655; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LI YM, 2000, NATURE, V405, P685; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; OYANA F, 1999, J NEUROCHEM, V71, P313; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; PerezTur J, 1995, NEUROREPORT, V7, P297; ROGAEV E, 1996, NATURE, V376, P775; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; van de Craen M, 1999, FEBS LETT, V445, P149, DOI 10.1016/S0014-5793(99)00108-8; VOGT BA, 1992, CEREB CORTEX, V2, P526, DOI 10.1093/cercor/2.6.526; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; WEST MJ, 1994, LANCET, V344, P526; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	35	107	112	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0805	10.1096/fj.01-0732com	http://dx.doi.org/10.1096/fj.01-0732com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039862				2022-12-25	WOS:000176683900006
J	Howard, SC; Budovskaya, YV; Chang, YW; Herman, PK				Howard, SC; Budovskaya, YV; Chang, YW; Herman, PK			The C-terminal domain of the largest subunit of RNA polymerase II is required for stationary phase entry and functionally interacts with the RaS/PKA signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; TRANSDUCTION PATHWAYS; MAMMALIAN MEDIATOR; ADENYLATE-CYCLASE; GENETIC-ANALYSIS; SHUTTLE VECTORS; BINDING PROTEIN; REPEAT DOMAIN	The Saccharomyces cerevisiae Ras proteins control cell growth by regulating the activity of the LAMP-dependent protein kinase (PKA). In this study, a genetic approach was used to identify cellular processes that were regulated by Ras/PKA signaling activity. Interestingly, we found that mutations affecting the C-terminal domain (CTD), of Rpb1p, the largest subunit of RNA polymerase II, were very sensitive to changes in Ras signaling activity. The Rpb1p CTD is a highly conserved, repetitive structure that is a key site of control during the production of a mature mRNA molecule. We found that mutations compromising the CTD were synthetically lethal with alterations that led to elevated levels of Ras/PKA signaling. Altogether, the data suggested that Ras/PKA activity was negatively regulating a protein that functioned in concert with the CTD during RNA pol II transcription. Consistent with this prediction, we found that elevated levels of Ras signaling caused growth and transcription defects that were very similar to those observed in mutants encoding an Rpb1p with a truncated CTD. In all, these data suggested that S. cerevisiae growth control and RNA pol II transcription might be coupled by using the Ras pathway to regulate CTD function.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Program Mol Cellular & Dev Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Herman, PK (corresponding author), Ohio State Univ, Dept Mol Genet, Rm 984,484 W 12th Ave, Columbus, OH 43210 USA.	herman.81@osu.edu	Budovskaya, Yelena/D-2254-2011	CHANG, YA-WEN/0000-0001-9656-3948				Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chang YW, 2001, GENETICS, V157, P17; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DENIS CL, 1991, J BIOL CHEM, V266, P17932; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GREENLEAF AL, 1993, P NATL ACAD SCI USA, V90, P10896, DOI 10.1073/pnas.90.23.10896; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Herman PK, 1997, EMBO J, V16, P6171, DOI 10.1093/emboj/16.20.6171; Hirose Y, 2000, GENE DEV, V14, P1415; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Howard SC, 2001, GENETICS, V159, P77; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kaiser C., 1994, METHODS YEAST GENETI; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lee YC, 1999, MOL CELL BIOL, V19, P2967; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meisels E, 1995, J BIOL CHEM, V270, P31255, DOI 10.1074/jbc.270.52.31255; Miller J.H., 1972, EXPT MOL GENETICS; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; Moore DD, 1995, GLOB MOB SURV; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Shenhar G, 2001, MOL CELL BIOL, V21, P1603, DOI 10.1128/MCB.21.5.1603-1612.2001; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Tadi D, 1999, YEAST, V15, P1733, DOI 10.1002/(SICI)1097-0061(199912)15:16<1733::AID-YEA490>3.0.CO;2-L; TAYLOR SS, 1993, PHILOS T ROY SOC B, V340, P315, DOI 10.1098/rstb.1993.0073; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WEST ML, 1995, GENETICS, V140, P1223; Zhang H, 2000, GENE DEV, V14, P2161, DOI 10.1101/gad.814700	83	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19488	19497		10.1074/jbc.M201878200	http://dx.doi.org/10.1074/jbc.M201878200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	12032176	hybrid			2022-12-25	WOS:000175894800035
J	Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D				Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D			Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model	ONCOGENE			English	Article						MnSOD; apoptosis; AP-1; p53; skin cancer	PROTEIN-KINASE-C; GENE-EXPRESSION; CYTOCHROME-C; ORNITHINE-DECARBOXYLASE; MALIGNANT PHENOTYPE; XANTHINE-OXIDASE; APOPTOSIS; OVEREXPRESSION; P53; SUPPRESSION	Previous studies in our laboratories demonstrated that overexpression of manganese superoxide dismutase (MnSOD) suppressed both the incidence and multiplicity of papillomas in a DMBA/TPA multi-stage skin carcinogenesis model. The activity of activator protein- 1 (AP-1), which is associated with tumor promotion, was reduced in MnSOD transgenic mice overexpressing MnSOD in the skin, suggesting that MnSOD may reduce tumor incidence by suppressing AP-1 activation. In the present study, we report that reduction of MnSOD by heterozygous knockout of the MnSOD gene (Sod2 -/+, MnSOD KO) increased the levels of oxidative damage proteins and the activity of AP-1 following TPA treatment. RNA levels of ornithine decarboxylase (ODC) were also increased, suggesting an increase in cell proliferation in the KO mice. Histological examination confirmed that the number of proliferating cells in DMBA/TPA-treated mouse skin were higher in the KO mice. Interestingly, histological examination also demonstrated greater numbers of apoptotic cells in the KO mice after DMBA/TPA treatment. Evidence of apoptosis, including DNA fragmentation, cytochrome e release from mitochondria, and caspase 3 activation were also observed by biochemical assays of the skin tissues. Apoptosis was associated with an increase in nuclear levels of p53 as determined by Western analysis. Quantitative immuno-gold ultrastructural analysis confirmed that p53 immunoreactive protein levels were increased to a greater level in the nuclei of epidermal cells from MnSOD KO mice compared to epidermal nuclei from wild type mice similarly treated. Moreover, p53 levels further increased in the mitochondria of DMBA/TPA treated mice, and this increase was much greater in the MnSOD KO than in the wild type mice, suggesting a link between MnSOD deficiency and mitochondrial-mediated apoptosis. Pathological examination reveals no difference in the incidence and frequency of papillomas comparing the KO mice and their wild type littermates. Taken together, these results suggest that: (1) MnSOD deficiency enhanced TPA-induced oxidative stress and AP-1 and p53 levels, consistent with the increase in both proliferation and apoptosis events in the MnSOD KO mice, and (2) increased apoptosis may negate increased proliferation in the MnSOD deficient mice during an early stage of tumor development.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Wisconsin, VA Hosp, Madison, WI 53705 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Kentucky; University of California System; University of California San Francisco; Mahidol University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	St Clair, D (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 73599-S1, CA 73599] Funding Source: Medline; NIA NIH HHS [AG 08938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL R, 1993, MOL CARCINOGEN, V8, P290, DOI 10.1002/mc.2940080412; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; BOWDEN GT, 1995, SKIN CANC MECH HUMAN, P99; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Donahue RJ, 2001, FASEB J, V15, P635, DOI 10.1096/fj.00-0262com; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Epperly MW, 2000, INT J CANCER, V90, P128, DOI 10.1002/1097-0215(20000620)90:3<128::AID-IJC2>3.0.CO;2-U; FISCHER SM, 1989, CANCER RES, V49, P6693; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keller JN, 1998, J NEUROSCI, V18, P687; Khajuria A, 1998, MOL CELL BIOCHEM, V189, P113, DOI 10.1023/A:1006877614411; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; LI JJ, 1995, ONCOGENE, V10, P1989; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McGarrity TJ, 2001, CANCER LETT, V163, P33, DOI 10.1016/S0304-3835(00)00663-7; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Nakamura Y, 1999, CANCER LETT, V140, P37, DOI 10.1016/S0304-3835(99)00048-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PENCE BC, 1987, CANCER RES, V47, P6388; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; REINERS JJ, 1987, CANCER RES, V47, P1775; REINERS JJ, 1991, CARCINOGENESIS, V12, P2337, DOI 10.1093/carcin/12.12.2337; RUGGERI BA, 1995, SKIN CANC MECH HUMAN, P339; SAFFORD SE, 1994, CANCER RES, V54, P4261; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; URANO M, 1995, CANCER RES, V55, P2490; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VERMA AK, 1986, CANCER RES, V46, P6149; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yan T, 1996, CANCER RES, V56, P2864; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	61	82	85	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3836	3846		10.1038/sj.onc.1205477	http://dx.doi.org/10.1038/sj.onc.1205477			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032821				2022-12-25	WOS:000175847200002
J	List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH				List, K; Haudenschild, CC; Szabo, R; Chen, WJ; Wahl, SM; Swaim, W; Engelholm, LH; Behrendt, N; Bugge, TH			Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis	ONCOGENE			English	Article						apoptosis; cell-surface proteolysis; skin; thymus; barrier function	HEPATOCYTE GROWTH-FACTOR; PROTEASE-ACTIVATED RECEPTOR-2; TRANSMEMBRANE SERINE-PROTEASE; FACTOR HGF ACTIVATOR; PLASMINOGEN-ACTIVATOR; STRATUM-CORNEUM; IN-VITRO; GENE; MUTATIONS; MICE	Matriptase/MT-SP1 is a novel tumor-associated type II transmembrane serine protease that is highly expressed in the epidermis, thymic stroma, and other epithelia. A null mutation was introduced into the Matriptase/MT-SP1 gene of mice to determine the role of Matriptase/MT-SP1 in epidermal development and neoplasia. Matriptase/MT-SP1-deficient mice developed to term but uniformly died within 48 h of birth. All epidermal surfaces of newborn mice were grossly abnormal with a dry, red, shiny, and wrinkled appearance. Matriptase/MT-SP1-deficiency caused striking malformations of the stratum corneum, characterized by dysmorphic and pleomorphic corneocytes and the absence of vesicular bodies in transitional layer cells. This aberrant skin development seriously compromised both inward and outward epidermal barrier function, leading to the rapid and fatal dehydration of Matriptase/MT-SP1-deficient pups. Loss of Matriptase/MT-SP1 also seriously affected hair follicle development resulting in generalized follicular hypoplasia, absence of erupted vibrissae, lack of vibrissal hair canal formation, ingrown vibrissae, and wholesale abortion of vibrissal follicles. Furthermore, Matriptase/MT-SP1-deficiency resulted in dramatically increased thymocyte apoptosis, and depletion of thymocytes. This study demonstrates that Matriptase/MT-SP1 has pleiotropic functions in the development of the epidermis, hair follicles, and cellular immune system.	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Cellular Imaging Core, NIH, Bethesda, MD 20892 USA; Finsen Lab, DK-2100 Copenhagen, Denmark; Amer Red Cross, Dept Expt Pathol, Rockville, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); American Red Cross	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Christian, Haudenschild C/D-1602-2009	Engelholm, Lars/0000-0002-6616-1232; Behrendt, Niels/0000-0003-1833-3922	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000046, ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699, Z01DE000046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANDREASEN PA, 1986, MOL CELL ENDOCRINOL, V45, P137, DOI 10.1016/0303-7207(86)90141-3; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Damiano BP, 1999, J PHARMACOL EXP THER, V288, P671; DAVIDSON P, 1952, J ANAT, V86, P342; DAVISSON MT, 1994, J HERED, V85, P134, DOI 10.1093/oxfordjournals.jhered.a111411; DeLaurenzi V, 1996, NAT GENET, V12, P52; Elias PM, 2001, J CELL BIOL, V153, P243, DOI 10.1083/jcb.153.2.243; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jensen PJ, 1999, J INVEST DERMATOL, V112, P240, DOI 10.1046/j.1523-1747.1999.00494.x; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; KAUFMANN MH, 1999, ANAT BASIS MOUSE DEV; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; KUBILUS J, 1979, AM J HUM GENET, V31, P50; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lee YR, 2001, J DERMATOL SCI, V25, P156, DOI 10.1016/S0923-1811(00)00124-9; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Luttun A, 2000, Curr Atheroscler Rep, V2, P407, DOI 10.1007/s11883-000-0079-z; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Manley NR, 2000, SEMIN IMMUNOL, V12, P421, DOI 10.1006/smim.2000.0263; MANN NS, 1994, P SOC EXP BIOL MED, V206, P114; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; RESKEKUNZ AB, 1979, J EXP MED, V149, P228, DOI 10.1084/jem.149.1.228; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SHAPIRO LJ, 1978, LANCET, V2, P756; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Williams O, 2001, TRENDS IMMUNOL, V22, P107, DOI 10.1016/S1471-4906(00)01797-X; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0; Yamazaki M, 1999, J INVEST DERM SYMP P, V4, P312, DOI 10.1038/sj.jidsp.5640236; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	60	271	280	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3765	3779		10.1038/sj.onc.1205502	http://dx.doi.org/10.1038/sj.onc.1205502			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032844				2022-12-25	WOS:000175676000011
J	Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T				Shiraishi, M; Sekiguchi, A; Terry, MJ; Oates, AJ; Miyamoto, Y; Chuu, YH; Munakata, M; Sekiya, T			A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes	ONCOGENE			English	Article						CpG island; DNA methylation; lung adenocarcinoma; methylated DNA binding domain column; chromatography; segregation of partly melted molecules	DE-NOVO METHYLATION; DNA METHYLATION; CHROMATIN-STRUCTURE; BINDING DOMAIN; FRAGMENTS; REPLICATION; EXPRESSION; RECEPTOR; REGIONS; COMPLEX	CpG island methylation is an important mechanism in gene silencing and is a key epigenetic event in cancer development. As yet, the number and identities of the genes that are inactivated in cancer cells has not been determined. In order to address this issue, we have performed a comprehensive isolation of CpG islands that are methylated in human lung adenocarcinomas. We have isolated approximately 200 CpG islands that are methylated in tumor DNA including those of known tumor-associated genes such as the HOXA5 gene. As the library contains the CpG islands of a number of known tumor suppressor genes it is highly likely that additional, previously unidentified tumor suppressor genes, will be present. On average, 1-2% of CpG islands were methylated specifically in tumors although this figure differed greatly between patients. This study provides an important resource in the search for genes inactivated in tumors and for the investigation of epigenetic dysregulation of gene expression by CpG island methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CROSS SH, 1994, NAT GENET, V6, P126; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; HASHIMOTOGOTOH T, 1993, GENE, V137, P211; Hughes J, 1999, HUM MOL GENET, V8, P543, DOI 10.1093/hmg/8.3.543; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 1995, P NATL ACAD SCI USA, V92, P4229, DOI 10.1073/pnas.92.10.4229; Shiraishi M, 1998, NUCLEIC ACIDS RES, V26, P5544, DOI 10.1093/nar/26.24.5544; Shiraishi M, 2001, P JPN ACAD B-PHYS, V77, P208, DOI 10.2183/pjab.77.208; Shiraishi M, 1999, BIOL CHEM, V380, P1127, DOI 10.1515/BC.1999.141; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 2000, GENE THER MOL BIOL, V5, P35; SHIRAISHI M, 2002, IN PRESS BIOL CHEM; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Thibonnier M, 1996, GENOMICS, V31, P327, DOI 10.1006/geno.1996.0055; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	39	33	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3804	3813		10.1038/sj.onc.1205454	http://dx.doi.org/10.1038/sj.onc.1205454			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032849				2022-12-25	WOS:000175676000016
J	Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH				Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH			Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma	ONCOGENE			English	Article						metastasis; lymphovascular invasion; tumor emboli; E-cadherin; sialyl-Lewis X/A; MUC1	POLYMERASE-CHAIN-REACTION; PERIPHERAL-BLOOD; RHOC GTPASE; CANCER; CELLS; EXPRESSION; MODEL; PROLIFERATION; METASTASIS; SELECTIN	Inflammatory breast carcinoma (IBC) is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a human-scid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2K(d)-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/alpha, beta-catenin axis which mediates tumor cell-tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the effects of palpation on MARY-X with the effects of palpation on a derived dominant-negative E-cadherin mutant (H-2K(d)-E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24(met)) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10-->30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10-100-fold (P<0.001) only in MARY-X. The mechanism of this effect was through an immediate post-palpation release of circulating tumor emboli detected 2-3 min after palpation (P<0.01) by human cytokeratin 19 RT-PCR of extracted RNA from 300 mul of murine blood. Although circulating human tumor cell-derived growth factors (IGF-I, IGF-II, TGF-alpha and TGF-beta) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P>0.1). Our findings support the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in IBC.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.	sbarsky@ucla.edu						Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 1999, CANCER RES, V59, P5079; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; Battaglia M, 1998, BONE MARROW TRANSPL, V22, P693, DOI 10.1038/sj.bmt.1701405; BISCHOFF J, 1995, BIOCHEM BIOPH RES CO, V210, P174, DOI 10.1006/bbrc.1995.1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; FUJIWARA T, 1993, CANCER RES, V53, P4129; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334; Kruger W, 1996, J CANCER RES CLIN, V122, P679, DOI 10.1007/BF01209032; LEVINE PH, 1985, JNCI-J NATL CANCER I, V74, P291; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1976, CANCER RES, V36, P889; MOORE DH, 1992, GYNECOL ONCOL, V47, P44, DOI 10.1016/0090-8258(92)90073-R; Mori M, 1996, INT J CANCER, V68, P739; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nguyen M, 1997, AM J PATHOL, V150, P1307; NISHIZAKI T, 1990, J SURG RES, V49, P92, DOI 10.1016/0022-4804(90)90116-J; Noun G, 1996, J IMMUNOL, V157, P2455; Rutz HP, 1999, MED HYPOTHESES, V53, P526, DOI 10.1054/mehy.1999.0805; Silverstein M. J., 1997, DUCTAL CARCINOMA SIT; Tomlinson JS, 2001, CANCER RES, V61, P5231; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wong IN, 1997, BRIT J CANCER, V76, P628, DOI 10.1038/bjc.1997.436; Wyld DK, 1998, INT J CANCER, V79, P288, DOI 10.1002/(SICI)1097-0215(19980619)79:3<288::AID-IJC14>3.0.CO;2-4; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhu AJ, 1996, J CELL SCI, V109, P3013	29	81	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3631	3643		10.1038/sj.onc.1205389	http://dx.doi.org/10.1038/sj.onc.1205389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032865				2022-12-25	WOS:000175793700014
J	Goncalves, J; Silva, F; Freitas-Vieira, A; Santa-Marta, M; Malho, R; Yang, XY; Gabuzda, D; Barbas, C				Goncalves, J; Silva, F; Freitas-Vieira, A; Santa-Marta, M; Malho, R; Yang, XY; Gabuzda, D; Barbas, C			Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-DEPENDENT REQUIREMENT; VIVO GENE DELIVERY; TYPE-1 VIF; IN-VIVO; SOR GENE; LENTIVIRAL VECTOR; HUMAN-ANTIBODIES; DNA-SYNTHESIS; LIFE-CYCLE	Human immunodeficiency virus type 1 (HIV-1)-encoded Vif protein is important for viral replication and infectivity. Vif is a cytoplasmic protein that acts during virus assembly by an unknown mechanism, enhancing viral infectivity. The action of Vif in producer cells is essential for the completion of proviral DNA synthesis following virus entry. Therefore, Vif is considered to be an important alternative therapeutic target for inhibition of viral infectivity at the level of viral assembly and reverse transcription. To gain insight into this process, we developed a Vif-specific single-chain antibody and expressed it intracellularly in the cytoplasm. This intrabody efficiently bound Vif protein and neutralized its infectivity-enhancing function. Intrabody-expressing cells were shown to be highly refractory to challenge with different strains of HIV-1 and HIV-1-infected cells. Inhibition of Vif by intrabody expression in the donor cell produced viral particles that do not complete reverse transcription in the recipient cell. The anti-Vif scFv was shown to be specific for Vif protein because its function was observed only in nonpermissive cells (H9, CEM, and U38). Moreover, transduction of peripheral blood mononuclear cells with an HIV-derived retroviral vector expressing Vif intrabody was shown to confer resistance to laboratory-adapted and primary HIV strains. This study provides biochemical evidence for the role of Vif in the HrV-1 lifecycle and validates Vif as a target for the control of HIV-1 infection.	Univ Lisbon, URIA Ctr Patogenese Mol, Fac Farm, P-1649019 Lisbon, Portugal; Univ Lisbon, Fac Ciencias Lisboa, Dept Plant Biol, P-1600 Lisbon, Portugal; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Universidade de Lisboa; Universidade de Lisboa; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute; Scripps Research Institute	Goncalves, J (corresponding author), Univ Lisbon, URIA Ctr Patogenese Mol, Fac Farm, Av Das Forcas Armadas, P-1649019 Lisbon, Portugal.		Malho, Rui/I-4503-2012; Silva, Frederico Aires/ABD-9602-2021; Goncalves, Joao/B-2013-2008; Santa-Marta, Mariana/L-2407-2013; iMed.ULisboa, M2B/B-5277-2014	Malho, Rui/0000-0001-5287-869X; Silva, Frederico Aires/0000-0002-3821-419X; Goncalves, Joao/0000-0002-1245-3715; Santa-Marta, Mariana/0000-0002-0243-4158; iMed.ULisboa, M2B/0000-0002-1245-3715	NIAID NIH HHS [AI 37470, AI 36186] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037470, R01AI036186] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akari H, 1999, J GEN VIROL, V80, P2945, DOI 10.1099/0022-1317-80-11-2945; ANDERSON NG, 1997, METHOD MOL BIOL, V88, P152; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; Bardy M, 2001, J GEN VIROL, V82, P2719, DOI 10.1099/0022-1317-82-11-2719; BORMAN AM, 1995, J VIROL, V69, P2058, DOI 10.1128/JVI.69.4.2058-2067.1995; Bour S, 2000, Adv Pharmacol, V48, P75; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; CATTANEO A, 1997, INTRACELLULAR ANTIBO; Chowdhury IH, 1996, J VIROL, V70, P5336, DOI 10.1128/JVI.70.8.5336-5345.1996; Dettenhofer M, 2000, J VIROL, V74, P8938, DOI 10.1128/JVI.74.19.8938-8945.2000; Duan L, 1997, GENE THER, V4, P533, DOI 10.1038/sj.gt.3300422; FAN LJ, 1992, VIROLOGY, V190, P19, DOI 10.1016/0042-6822(92)91188-Z; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Friedler A, 1999, J MOL BIOL, V289, P431, DOI 10.1006/jmbi.1999.2785; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Hassaine G, 2001, J BIOL CHEM, V276, P16885, DOI 10.1074/jbc.M009076200; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Henzler T, 2001, J GEN VIROL, V82, P561, DOI 10.1099/0022-1317-82-3-561; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Marasco WA, 2001, CURR TOP MICROBIOL, V260, P247; Marasco WA, 1999, J IMMUNOL METHODS, V231, P223, DOI 10.1016/S0022-1759(99)00159-3; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rader C, 2000, J BIOL CHEM, V275, P13668, DOI 10.1074/jbc.275.18.13668; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; Simon JHM, 1999, J VIROL, V73, P2667, DOI 10.1128/JVI.73.4.2667-2674.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; Steinberger P, 2000, J BIOL CHEM, V275, P36073, DOI 10.1074/jbc.M002765200; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Trono D, 1998, NAT MED, V4, P1368, DOI 10.1038/3953; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Worn A, 2000, J BIOL CHEM, V275, P2795, DOI 10.1074/jbc.275.4.2795; Yang SC, 2001, J BIOL CHEM, V276, P4889, DOI 10.1074/jbc.M004895200; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yang XY, 1999, J VIROL, V73, P3460, DOI 10.1128/JVI.73.4.3460-3466.1999; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	54	63	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32036	32045		10.1074/jbc.M201906200	http://dx.doi.org/10.1074/jbc.M201906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12039955	hybrid			2022-12-25	WOS:000177718700092
J	Cummings, RJ; Parinandi, NL; Zaiman, A; Wang, LX; Usatyuk, PV; Garcia, JGN; Natarajan, V				Cummings, RJ; Parinandi, NL; Zaiman, A; Wang, LX; Usatyuk, PV; Garcia, JGN; Natarajan, V			Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NECROSIS-FACTOR-ALPHA; ADP-RIBOSYLATION FACTOR; HUMAN ENDOTHELIAL-CELLS; KINASE-C-ALPHA; P38 MAP KINASE; GENE-EXPRESSION; A549 CELLS; SPHINGOSINE-1-PHOSPHATE; EDG-1	Sphingosine 1-phosphate (S1P), a potent bioactive sphingolipid, has been implicated in many critical cellular events, including a regulatory role in the pathogenesis of airway inflammation. We investigated the participation of SIP as an inflammatory mediator by assessing interleukin-8 (IL-8) secretion and phospholipase D (PLD) activation in human bronchial epithelial cells (Bear-2B). S1P(1), S1P(3), S1P(4), S1P(5), and weak S1P(2) receptors were detected in Beas-2B and primary human bronchial epithelial cells. S1P stimulated a rapid activation of PLD, which was nearly abolished by pertussis toxin (PTX) treatment, consistent with S1P receptor/G(i) protein coupling. S1P also markedly induced Beas-2B secretion of IL-8, a powerful neutrophil chemoattractant and activator, in a PTX-sensitive manner. This S1P-mediated response was dependent on transcription as indicated by a strong induction of IL-8 promoter-mediated luciferase activity in transfected Beas-2B cells and a complete inhibition by actinomycin D. Beas-2B exposure to 1-butanol, which converts the PLD-generated phosphatidic acid (PA) to phosphatidylbutanol by a transphosphatidylation reaction, significantly attenuated the SIP-induced IL-8 secretion, indicating the involvement of PLD-derived PA in the signaling pathway. Inhibition of 12-O-tetradecanoyl-phorbol-13-acetate-stimulated IL-8 production by 1-butanol further strengthened this observation. Blocking protein kinase C and Rho kinase also attenuated SIP-induced IL-8 secretion. Our data suggest that PLD-derived PA, protein kinase C, and Rho are important signaling components in SIP-mediated IL-8 secretion by human bronchial epithelial cells.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University	Natarajan, V (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Garcia, Joe GN/E-8862-2010; wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8755-2019		NHLBI NIH HHS [HL47671, HL71152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047671, R55HL047671, R01HL071152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcorn MJ, 2001, J VIROL, V75, P6450, DOI 10.1128/JVI.75.14.6450-6459.2001; Allen GL, 2000, AM J PHYSIOL-LUNG C, V278, pL253, DOI 10.1152/ajplung.2000.278.2.L253; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632; DESAI NN, 1992, J BIOL CHEM, V267, P23122; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280, DOI 10.1164/ajrccm.161.1.9904110; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hla T, 2000, ANN NY ACAD SCI, V905, P16; Igarashi Y, 1998, ACTA BIOCHIM POL, V45, P299, DOI 10.18388/abp.1998_4226; Im DS, 2001, BIOCHEMISTRY-US, V40, P14053, DOI 10.1021/bi011606i; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; Jbilo O, 1999, FEBS LETT, V448, P273, DOI 10.1016/S0014-5793(99)00380-4; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozawa O, 1997, ARCH BIOCHEM BIOPHYS, V345, P10, DOI 10.1006/abbi.1997.0232; Kozawa O, 1997, FEBS LETT, V418, P149, DOI 10.1016/S0014-5793(97)01366-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Meacci E, 2001, CELL SIGNAL, V13, P593, DOI 10.1016/S0898-6568(01)00177-2; Meacci E, 1999, J BIOL CHEM, V274, P18605, DOI 10.1074/jbc.274.26.18605; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; NATARAJAN V, 1993, J LAB CLIN MED, V121, P337; Natarajan V, 2001, AM J PHYSIOL-LUNG C, V281, pL435, DOI 10.1152/ajplung.2001.281.2.L435; Natarajan V, 1996, AM J PHYSIOL-LUNG C, V271, pL400, DOI 10.1152/ajplung.1996.271.3.L400; NATARAJAN V, 1994, AM J RESP CELL MOL, V11, P221, DOI 10.1165/ajrcmb.11.2.8049083; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; Orlati S, 2000, ARCH BIOCHEM BIOPHYS, V375, P69, DOI 10.1006/abbi.1999.1589; Plo I, 2000, BIOCHEM J, V351, P459, DOI 10.1042/0264-6021:3510459; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Racke K, 2000, PULM PHARMACOL THER, V13, P99, DOI 10.1006/pupt.2000.0241; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Watterson KR, 2002, J BIOL CHEM, V277, P5767, DOI 10.1074/jbc.M110647200; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; WU R, 1985, AM REV RESPIR DIS, V132, P311; Wyatt TA, 1999, AM J RESP CELL MOL, V21, P283, DOI 10.1165/ajrcmb.21.2.3636; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yatomi Y, 1997, J BIOCHEM, V121, P969; YEO EJ, 1994, J BIOL CHEM, V269, P27823	70	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30227	30235		10.1074/jbc.M111078200	http://dx.doi.org/10.1074/jbc.M111078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039947	hybrid			2022-12-25	WOS:000177509300108
J	Mitrasinovic, OM; Murphy, GM				Mitrasinovic, OM; Murphy, GM			Accelerated phagocytosis of amyloid-beta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CELL-LINE; SCAVENGER RECEPTOR; MURINE MICROGLIA; NITRIC-OXIDE; A-BETA; C-FMS; EXPRESSION; PROTEIN	Microglia surrounding Abeta plaques in Alzheimer's disease and in the APPV717F transgenic mouse model of Alzheimer's disease have enhanced immunoreactivity for the macrophage colony-stimulating factor receptor (M-CSFR), encoded by the proto-oncogene c-fins. Increased expression of M-CSFR on cultured microglia results in proliferation and release of pro-inflammatory cytokines and expression of inducible nitric-oxide synthase. We transfected mouse BV-2 and human SV-A3 microglia to overexpress M-CSFR and examined microglial phagocytosis of fluorescein-conjugated Abeta. Flow cytometry and laser confocal microscopy showed accelerated phagocytosis of Abeta in mouse and human microglia because of M-CSFR overexpression that was time-and concentration-dependent. In contrast, microglial uptake of 1-mum diameter polystyrene microspheres was not enhanced by M-CSFR overexpression. Microglial uptake of Abeta was blocked by cytochalasin D, which inhibits phagocytosis. M-CSFR overexpression increased the mRNA for macrophage scavenger receptor A, and fucoidan blocking of macrophage scavenger receptors inhibited uptake of Abeta. M-CSFR antibody blocking experiments demonstrated that increased Abeta uptake depended on the interaction of the M-CSFR with its ligand. These results suggest that overexpression of M-CSFR in APPV717F mice may prime microglia for phagocytosis of Abeta after immunization.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA	Stanford University	Mitrasinovic, OM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, MSLS P-104, Stanford, CA 94305 USA.				NIA NIH HHS [AG17824] Funding Source: Medline; NIMH NIH HHS [MH40041, MH57833] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040041, R01MH057833, P30MH040041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017824] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BORYCKI AG, 1995, EXP CELL RES, V218, P213, DOI 10.1006/excr.1995.1149; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; DU Y.S., 1997, P NATL ACAD SCI USA, V94, P5296; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Keshava N, 1999, J SOC GYNECOL INVEST, V6, P41, DOI 10.1016/S1071-5576(98)00041-0; Kopec KK, 1998, J NEUROCHEM, V71, P2123; Kopec KK, 2000, NITRIC OXIDE-BIOL CH, V4, P103, DOI 10.1006/niox.2000.0280; KOROTZER AR, 1995, EXP NEUROL, V134, P214, DOI 10.1006/exnr.1995.1051; Li R, 2000, J NEUROCHEM, V75, P1447, DOI 10.1046/j.1471-4159.2000.0751447.x; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; MIMURA N, 1976, NATURE, V261, P319, DOI 10.1038/261319a0; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; MOORE WA, 1986, HDB EXPT IMMUNOLOGY; Morelli L, 1999, NEUROSCI LETT, V262, P5, DOI 10.1016/S0304-3940(99)00023-3; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; *PE APPL BIOS, 1997, PE APPL BIOS US B, V2; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Webster SD, 2000, EXP NEUROL, V161, P127, DOI 10.1006/exnr.1999.7260; Webster SD, 2001, J IMMUNOL, V166, P7496, DOI 10.4049/jimmunol.166.12.7496	37	50	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29889	29896		10.1074/jbc.M200868200	http://dx.doi.org/10.1074/jbc.M200868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12032144	hybrid			2022-12-25	WOS:000177509300069
J	Chen, M; Won, DJ; Krajewski, S; Gottlieb, RA				Chen, M; Won, DJ; Krajewski, S; Gottlieb, RA			Calpain and mitochondria in ischemia/reperfusion injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR PROTON ATPASE; CYTOCHROME-C RELEASE; CELL-DEATH; ISCHEMIC MYOCARDIUM; DNA FRAGMENTATION; INFARCT SIZE; RABBIT CARDIOMYOCYTES; EXCHANGE INHIBITORS; NEURONAL APOPTOSIS; PROTEASE FAMILIES	Studies of ischemia/reperfusion (I/R) injury and preconditioning have shown that ion homeostasis, particularly calcium homeostasis, is critical to limiting tissue damage. However, the relationship between ion homeostasis and specific cell death pathways has not been investigated in the context of I/R. Previously we reported that calpain cleaved Bid in the absence of detectable caspase activation (1). In this study, we have shown that an inhibitor of the sodium/hydrogen exchanger prevented calpain activation after LIR. Calpain inhibitors prevented cleavage of Bid as well as the downstream indices of cell death, including DNA strand breaks, creatine kinase (CK) release, and infarction measured by triphenyl tetrazolium chloride (TTC) staining. In contrast, the broad spectrum caspase inhibitor IDN6734 was not protective in this model. To ascertain whether mitochondrial dysfunction downstream of these events was a required step, we utilized a peptide corresponding to residues 4-23 of Bcl-x(L) conjugated to the protein transduction domain of HIV TAT (TAT-BH4), which has been shown to protect mitochondria against Ca2+-induced DeltaPsi(m) loss (2). TAT-BH4 attenuated CK release and loss of TTC staining, demonstrating the role of mitochondria and a pro-apoptotic Bcl-2 family member in the process leading to cell death. We propose the following pathway. (i) Reperfusion results in sodium influx followed by calcium accumulation. (ii) This leads to calpain activation, which in turn leads to Bid cleavage. (iii) Bid targets the mitochondria, causing dysfunction and release of pro-apoptotic factors, resulting in DNA fragmentation and death of the cell. Ischemia/reperfusion initiates a cell death pathway that is independent of caspases but requires calpain and mitochondrial dysfunction.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Gottlieb, RA (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM220,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	robbieg@scripps.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60590] Funding Source: Medline; NINDS NIH HHS [NS 36821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Avkiran M, 2001, BASIC RES CARDIOL, V96, P306, DOI 10.1007/s003950170037; BASTIAANSE EML, 1994, FEBS LETT, V343, P151, DOI 10.1016/0014-5793(94)80308-0; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cesselli D, 2001, CIRC RES, V89, P279, DOI 10.1161/hh1501.094115; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Di Lisa F, 1998, BBA-BIOENERGETICS, V1366, P69, DOI 10.1016/S0005-2728(98)00121-2; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eigel BN, 2001, AM J PHYSIOL-HEART C, V281, pH2184, DOI 10.1152/ajpheart.2001.281.5.H2184; Elsasser A, 2001, BASIC RES CARDIOL, V96, P219, DOI 10.1007/s003950170052; Frankfurt OS, 2001, J HISTOCHEM CYTOCHEM, V49, P369, DOI 10.1177/002215540104900311; Gao G, 2000, J CELL BIOCHEM, V80, P53; GILPARRADO S, 2002, IN PRESS J BIOL CHEM; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; He HP, 2001, CIRC RES, V89, P461, DOI 10.1161/hh1701.096038; Holly TA, 1999, J MOL CELL CARDIOL, V31, P1709, DOI 10.1006/jmcc.1999.1006; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; Kajstura J, 1996, LAB INVEST, V74, P86; Karmazyn M, 2001, EXPERT OPIN INV DRUG, V10, P835, DOI 10.1517/13543784.10.5.835; Karwatowska-Prokopczuk E, 1998, CIRC RES, V82, P1139, DOI 10.1161/01.RES.82.11.1139; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Li HL, 2001, ANTIOXID REDOX SIGN, V3, P113, DOI 10.1089/152308601750100605; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Okamura T, 2000, CARDIOVASC RES, V45, P642, DOI 10.1016/S0008-6363(99)00271-0; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Urthaler F, 1997, CARDIOVASC RES, V35, P60, DOI 10.1016/S0008-6363(97)00099-0; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276	45	220	234	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29181	29186		10.1074/jbc.M204951200	http://dx.doi.org/10.1074/jbc.M204951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042324	hybrid			2022-12-25	WOS:000177342600107
J	Rozenfeld, R; Iturrioz, X; Maigret, B; Llorens-Cortes, C				Rozenfeld, R; Iturrioz, X; Maigret, B; Llorens-Cortes, C			Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; EXOPEPTIDASE SPECIFICITY; VASOPRESSIN RELEASE; MUTATIONAL ANALYSIS; CATALYTIC ACTIVITY; CONVERTING ENZYME; BP-1/6C3 ANTIGEN; ZINC PEPTIDASES; ANGIOTENSIN-III; CDNA CLONING	Aminopeptidase A is a zinc metalloenzyme involved in the formation of brain angiotensin III, which exerts a tonic stimulatory action on the central control of blood pressure. Thus, central inhibitors of aminopeptidase A constitute putative central antihypertensive agents. Mutagenic studies have been performed to investigate organization of the aminopeptidase A active site, with a view to designing such inhibitors. The structure of one monozinc aminopeptidase (leukotriene A(4) hydrolase) was recently resolved and used to construct a three-dimensional model of the aminopeptidase A ectodomain. This new model, highly consistent with the results of mutagenic studies, showed a critical structural interaction between two conserved residues, Arg-220 and Asp-227. Mutagenic replacement of either of these two residues disrupted maturation and subcellular localization and abolished the enzymatic activity of aminopeptidase A, confirming the critical structural role of these residues. In this study, we generated the first three-dimensional model of a strict aminopeptidase, aminopeptidase A. This model constitutes a new tool to probe further the active site of aminopeptidase A and to design new inhibitors of this enzyme.	Coll France, INSERM, Unite 36, F-75005 Paris, France; Univ Nancy 1, CNRS, UMR 7565, Chim Theor Lab, F-54506 Vandoeuvre Les Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Lorraine	Llorens-Cortes, C (corresponding author), Coll France, INSERM, Unite 36, 11 Pl Marcelin Berthelot, F-75005 Paris, France.		Iturrioz, Xavier/AAS-3555-2020; ITURRIOZ, Xavier/Q-4406-2017; Llorens-Cortes, Catherine/E-5839-2016; Llorens-Cortès, catherine/AAL-3893-2021	Iturrioz, Xavier/0000-0001-7143-8323; ITURRIOZ, Xavier/0000-0001-7143-8323; Llorens-Cortes, Catherine/0000-0002-7667-0401; Llorens-Cortès, catherine/0000-0002-7667-0401				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUVEL EN, 1994, J MED CHEM, V37, P1339, DOI 10.1021/jm00035a014; CHAUVEL EN, 1994, J MED CHEM, V37, P2950, DOI 10.1021/jm00044a016; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; Hesp JR, 1997, BIOCHEMISTRY-US, V36, P3000, DOI 10.1021/bi962401q; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Iturrioz X, 2000, BIOCHEMISTRY-US, V39, P3061, DOI 10.1021/bi9925726; Iturrioz X, 2001, BIOCHEMISTRY-US, V40, P14440, DOI 10.1021/bi011409j; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; Kull F, 2001, BIOCHEMISTRY-US, V40, P12695, DOI 10.1021/bi011348p; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; LEJCZAK B, 1993, J ENZYM INHIB, V7, P97, DOI 10.3109/14756369309040752; Li GS, 1998, J COMPUT CHEM, V19, P1675, DOI 10.1002/(SICI)1096-987X(19981130)19:15<1675::AID-JCC1>3.0.CO;2-K; LI L, 1993, GENOMICS, V17, P657, DOI 10.1006/geno.1993.1386; LODJA Z, 1980, HISTOCHEMISTRY, V67, P267; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; NAGATSU I, 1970, BIOCHIM BIOPHYS ACTA, V198, P255, DOI 10.1016/0005-2744(70)90058-6; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Papadopoulos T, 2001, BIOCHEMISTRY-US, V40, P9347, DOI 10.1021/bi010695w; Reaux A, 2001, TRENDS ENDOCRIN MET, V12, P157, DOI 10.1016/S1043-2760(01)00381-2; Reaux A, 1999, P NATL ACAD SCI USA, V96, P13415, DOI 10.1073/pnas.96.23.13415; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; SCHALK C, 1994, ARCH BIOCHEM BIOPHYS, V311, P42, DOI 10.1006/abbi.1994.1206; SONG LJ, 1994, AM J PHYSIOL-RENAL, V267, pF546, DOI 10.1152/ajprenal.1994.267.4.F546; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; TIEKU S, 1992, BIOCHEM PHARMACOL, V44, P1725, DOI 10.1016/0006-2952(92)90065-Q; Troyanovskaya M, 2000, AM J PHYSIOL-REG I, V278, pR413, DOI 10.1152/ajpregu.2000.278.2.R413; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; Vazeux G, 1997, BIOCHEM J, V327, P883, DOI 10.1042/bj3270883; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; WILK S, 1993, ADV NEUROIMMUNOL, V3, P195, DOI 10.1016/S0960-5428(05)80021-X; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3; Zini S, 1997, NEUROSCIENCE, V78, P1187, DOI 10.1016/S0306-4522(96)00660-4; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968	42	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29242	29252		10.1074/jbc.M204406200	http://dx.doi.org/10.1074/jbc.M204406200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042323	hybrid			2022-12-25	WOS:000177342600113
J	Chrestensen, CA; Sturgill, TW				Chrestensen, CA; Sturgill, TW			Characterization of the p90 ribosomal S6 kinase 2 carboxyl-terminal domain as a protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION MOTIFS; SIGNAL-REGULATED KINASE; MAP KINASE; DOCKING SITES; PHOSPHORYLATION SITES; STRUCTURAL BASIS; CREB KINASE; IN-VIVO; ACTIVATION; IDENTIFICATION	The carboxyl-terminal domain (CTD) of the p90 ribosomal S6 kinases (RSKs) is an important regulatory domain in RSK and a model for kinase regulation of FXXFXF(Y) motifs in AGC kinases. Its properties had not been studied. We reconstituted activation of the CTD in Escherichia coli by co-expression with active ERK2 mitogen-activated protein kinase (MAPK). GST-RSK2-(aa373-740) was phosphorylated in the P-loop (Thr(577)) by MAPK, accompanied by increased phosphorylation on the hydrophobic motif site, Ser(386). Activated GST-RSK2-(aa373-740) phosphorylates synthetic peptides based on Ser(386), The peptide RRQLFRGFSFVAK, which was termed CTDtide, was phosphorylated with K-m and V-max values of similar to140 muM and similar to1 mumol/min/mg, respectively. Residues Leu at p -5 and Arg at p -3 are important for substrate recognition, but a hydrophobic residue at p +4 is not. RSK2 CTD is a much more selective peptide kinase than MAPK-activated protein kinase 2. CTDtide was used to probe regulation of hemagglutinin-tagged RSK proteins immunopurified from epidermal growth factor-stimulated BHK-21 cells. K100A but not K451A RSK2 phosphorylates CTDtide, indicating a requirement for the CTD. RSK2-(aal-389) phosphorylates the S6 peptide, and this activity is inactivated by S386A mutation, but RSK2-(aa1-389) does not phosphorylate CTDtide. In contrast, RSK2-(aa373-740) containing only the CTD phosphorylates CTDtide robustly. Thus, CTDtide is phosphorylated by the CTD but not the NH2-terminal domain (NTD). Epidermal growth factor activates the CTD and NTD in parallel. Activity of the CTD for peptide phosphorylation correlates with Thr(577) phosphorylation. CTDtide activity is constrained in full-length RSK2. Interestingly, mutation of the conserved lysine in the ATP-binding site of the NTD completely eliminates S6 kinase activity, but a similar mutation of the CTD does not completely ablate kinase activity for intramolecular phosphorylation of Ser(386), even though it greatly reduces CTDtide activity. The standard lysine mutation used routinely to study kinase functions in vivo may be unsatisfactory when the substrate is intramolecular or in a tight complex.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Sturgill, TW (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 800735, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062890] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07320] Funding Source: Medline; NIGMS NIH HHS [GM62890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kemp B E, 1996, Adv Pharmacol, V36, P221, DOI 10.1016/S1054-3589(08)60584-0; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Poteet-Smith CE, 1999, J BIOL CHEM, V274, P22135, DOI 10.1074/jbc.274.32.22135; RAY LB, 1988, J BIOL CHEM, V263, P12721; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	44	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27733	27741		10.1074/jbc.M202663200	http://dx.doi.org/10.1074/jbc.M202663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12016217	hybrid			2022-12-25	WOS:000177189800021
J	Nakagawa, T; Kolodner, RD				Nakagawa, T; Kolodner, RD			The MER3 DNA helicase catalyzes the unwinding of Holliday junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEIOTIC CROSSING-OVER; SYNAPTONEMAL COMPLEX PROTEIN; SYNDROME GENE-PRODUCT; DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; MISMATCH REPAIR; BRANCH MIGRATION; MUTS HOMOLOG	The MER3 protein of Saccharomyces cerevisiae is required for crossover in meiosis and has been suggested to act at the initiation of homologous pairing and the resolution of Holliday junctions. The purified MER3 protein is a DNA helicase that translocates along singlestranded DNA in the 3' to 5' direction displacing annealed DNA fragments. Here, MER3 was found to be able to unwind various double-stranded DNA (dsDNA) substrates, including a 30-bp dsDNA with a 20-nucleotide 3'-overhang, a 30-bp dsDNA with a 20-nucleotide 5'-overhang, a 50-bp dsDNA with blunt ends, and a Holliday junction with 25-bp arms, each of which had a blunt end. Efficient unwinding of the 3'-overhang substrate appeared to initiate by the binding of MER3 to the 3' single-stranded tail in a reaction that required six or more unpaired bases. Unwinding of the blunt end and 5'-overhang substrates appeared to initiate at the blunt ends of these substrates. Unwinding of the Holliday junction was more efficient than the unwinding of the blunt and 5'-overhang substrates and was influenced by Mg2+ concentrations that cause changes in the structure of the junction. Possible roles for Holliday junction unwinding in meiotic crossover are discussed.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Ctr Canc, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.		Nakagawa, Takuro/A-1367-2017	Nakagawa, Takuro/0000-0003-3455-8224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026017, R37GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal S, 2000, CELL, V102, P245, DOI 10.1016/S0092-8674(00)00029-5; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Argueso JL, 2002, GENETICS, V160, P909; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; CLEGG RM, 1992, BIOCHEMISTRY-US, V31, P4846, DOI 10.1021/bi00135a016; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; DUCKETT DR, 1991, J MOL BIOL, V221, P147, DOI 10.1016/0022-2836(91)80211-C; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kneitz B, 2000, GENE DEV, V14, P1085; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; Nakagawa T, 1999, EMBO J, V18, P5714, DOI 10.1093/emboj/18.20.5714; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; Nakagawa T, 2002, MOL CELL BIOL, V22, P3281, DOI 10.1128/MCB.22.10.3281-3291.2002; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; Novak JE, 2001, GENETICS, V158, P1013; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729	55	29	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28019	28024		10.1074/jbc.M204165200	http://dx.doi.org/10.1074/jbc.M204165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12039965	hybrid			2022-12-25	WOS:000177189800056
J	Potapova, O; Grindley, NDF; Joyce, CM				Potapova, O; Grindley, NDF; Joyce, CM			The mutational specificity of the Dbh lesion bypass polymerase and its implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA-POLYMERASE; HUMAN DINB1 GENE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ERROR-PRONE; SULFOLOBUS-SOLFATARICUS; I KLENOW; NUCLEOTIDE INCORPORATION; INDUCED MUTAGENESIS; KINETIC MECHANISM	The Dbh polymerise of Sulfolobus solfataricus is a member of the recently described family of low fidelity DNA polymerases involved in bypass of DNA lesions. To investigate the enzymatic properties of Dbh, we characterized the errors made by this polymerase in vitro. Not only is Dbh much less accurate than the "classical" polymerises, but it showed a remarkable tendency to skip over a template pyrimidine positioned immediately 3' to a G residue, generating a single-base deletion. Single-turnover kinetic measurements suggest possible mechanisms. First, Dbh shows a bias in favor of dCTP, such that the rate of incorporation of dCTP opposite a template G is about 10-fold faster than for the other three dNTPs opposite their complementary partners. On a DNA substrate corresponding to a frameshift hotspot, the rate of frameshift insertion of dCTP opposite a template G that is one residue 5' to the expected templating position is approximately equal to the rate of the nonframeshifted C-dGTP insertion. We suspect that the unusual mutational specificity of Dbh (which is shared with other polymerases from the DinB branch of the bypass polymerase family) may be related to the type of DNA lesion(s) that it serves to bypass in vivo.	Yale Univ, Bass Ctr Mol & Struct Biol, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Bass Ctr Mol & Struct Biol, Dept Mol Biophys & Biochem, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Bull HJ, 2001, P NATL ACAD SCI USA, V98, P8334, DOI 10.1073/pnas.151009798; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Eckert KA, 1997, NUCLEIC ACIDS RES, V25, P1450, DOI 10.1093/nar/25.7.1450; Efrati E, 1997, J BIOL CHEM, V272, P2559; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; Gruz P, 2001, J BIOL CHEM, V276, P47394, DOI 10.1074/jbc.M107213200; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McKenzie GJ, 2001, CURR OPIN MICROBIOL, V4, P586, DOI 10.1016/S1369-5274(00)00255-1; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; Shen X, 2002, J BIOL CHEM, V277, P5265, DOI 10.1074/jbc.M109575200; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Wagner J, 2000, J BACTERIOL, V182, P4587, DOI 10.1128/JB.182.16.4587-4595.2000; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wagner J, 2000, EMBO REP, V1, P484; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0; Zillig W, 1998, EXTREMOPHILES, V2, P131, DOI 10.1007/s007920050052	50	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28157	28166		10.1074/jbc.M202607200	http://dx.doi.org/10.1074/jbc.M202607200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023283	hybrid			2022-12-25	WOS:000177189800073
J	Seshadri, V; Fox, PL; Mukhopadhyay, CK				Seshadri, V; Fox, PL; Mukhopadhyay, CK			Dual role of insulin in regulation of the acute phase reactant ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; INTACT HUMAN CERULOPLASMIN; LOW-DENSITY-LIPOPROTEIN; PLASMA-PROTEIN GENES; CELLULAR IRON UPTAKE; C-REACTIVE PROTEIN; BETA C/EBP-BETA; DIABETES-MELLITUS; TRANSCRIPTIONAL ACTIVATION; SERUM CERULOPLASMIN	Insulin is a potent negative regulator of the response of hepatic cells to pro-inflammatory cytokines, particularly, interleukin (IL)-6. The action of insulin is target-selective because it inhibits transcription of most but not all acute phase genes. We here show that ceruloplasmin (Cp), an acute phase reactant with important functions in iron homeostasis, is subject to a unique dual regulation by insulin. IL-6 increased Cp mRNA expression in HepG2 cells by similar to5-fold. Simultaneous treatment with insulin reduced this stimulation by half. Surprisingly, insulin by itself caused a 2-4-fold induction in Cp mRNA expression. The mechanism of induction by insulin was studied by transfecting into HepG2 cells chimeric constructs of the Cp 5'-flanking region driving luciferase. The activity of a 4800-bp segment of the Cp 5'-flanking region was increased 3-fold by insulin. Deletion and mutation analyses showed the requirement for a single hypoxia-responsive element in a 96-bp segment similar to3600 by upstream of the initiation site. The domains required for the two activities of insulin were distinct: The distal, hypoxia-responsive element-containing site was sufficient for Cp transactivation by insulin; in contrast, an 848-bp region adjacent to the initiation site was sufficient for IL-6 transactivation of Cp and for the inhibitory activity of insulin. The role of hypoxia-inducible factor-1 in the induction of Cp by insulin was shown by electrophoretic mobility shift assays and by the absence of insulin-stimulated Cp promoter activation in mouse Hepa c4 cells deficient in hypoxia-inducible factor-1 activity. Taken together these results show that insulin functions as a bidirectional, condition-dependent regulator of hepatic cell Cp expression. The unique regulation of Cp may reflect its dual roles in inflammation and iron homeostasis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India	Cleveland Clinic Foundation; Jawaharlal Nehru University, New Delhi	Fox, PL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxpl@ccf.org			NHLBI NIH HHS [HL67725, HL29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067725, P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agrawal A, 2001, J IMMUNOL, V166, P2378, DOI 10.4049/jimmunol.166.4.2378; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; ASAYAMA K, 1994, HORM METAB RES, V26, P313, DOI 10.1055/s-2007-1001693; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; AWADALLAH R, 1978, Z ERNAHRUNGSWISS, V17, P79, DOI 10.1007/BF02021114; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BEAUMIER DL, 1984, INFECT IMMUN, V46, P489, DOI 10.1128/IAI.46.2.489-494.1984; BINGLE CD, 1993, BIOCHEM J, V294, P473, DOI 10.1042/bj2940473; Campos SP, 1996, J BIOL CHEM, V271, P24418, DOI 10.1074/jbc.271.40.24418; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; CAMPOS SP, 1994, CYTOKINE, V6, P485, DOI 10.1016/1043-4666(94)90075-2; CHETA D, 1981, REV ROUM MED-MED INT, V19, P55; COLLIER A, 1990, DIABETIC MED, V7, P27, DOI 10.1111/j.1464-5491.1990.tb01302.x; CUNNINGHAM J, 1995, METABOLISM, V44, P996, DOI 10.1016/0026-0495(95)90095-0; Daffada AAI, 1999, FEBS LETT, V457, P214, DOI 10.1016/S0014-5793(99)01036-4; Daimon M, 1998, DIABETES CARE, V21, P1525, DOI 10.2337/diacare.21.9.1525; Daimon M, 2000, DIABETES CARE, V23, P559, DOI 10.2337/diacare.23.4.559; DEFEO P, 1993, DIABETES, V42, P995, DOI 10.2337/diabetes.42.7.995; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ESPINET C, 1993, BIOCHEM J, V293, P173, DOI 10.1042/bj2930173; Feldser D, 1999, CANCER RES, V59, P3915; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; JONES AF, 1988, DIABETES RES CLIN EX, V7, P89; JONSSON A, 1976, DIABETOLOGIA, V12, P245, DOI 10.1007/BF00422091; KUSHNER I, 1988, METHOD ENZYMOL, V163, P373; LAMB DJ, 1994, FEBS LETT, V338, P122, DOI 10.1016/0014-5793(94)80348-X; LEMAIGRE FP, 1994, FEBS LETT, V340, P221, DOI 10.1016/0014-5793(94)80142-8; MACKIEWICZ A, 1989, SCAND J IMMUNOL, V29, P265, DOI 10.1111/j.1365-3083.1989.tb01124.x; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; MCMILLAN DE, 1989, METABOLISM, V38, P1042, DOI 10.1016/0026-0495(89)90038-3; MILLER LL, 1990, HEPATOLOGY, V11, P635, DOI 10.1002/hep.1840110417; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; Mohan IK, 1998, FREE RADICAL BIO MED, V25, P757, DOI 10.1016/S0891-5849(98)00129-4; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Mukhopadhyay CK, 1997, P NATL ACAD SCI USA, V94, P11546, DOI 10.1073/pnas.94.21.11546; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; NOVELLI ELB, 1988, CAN J PHYSIOL PHARM, V66, P663, DOI 10.1139/y88-104; ORIORDAIN MG, 1995, AM J PHYSIOL-ENDOC M, V269, pE323, DOI 10.1152/ajpendo.1995.269.2.E323; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1966, J BIOL CHEM, V241, P5053; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Qian ZM, 2001, EXP BRAIN RES, V140, P369, DOI 10.1007/s002210100831; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P44, DOI 10.1210/jc.76.1.44; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; RYFFEL B, 1994, BLOOD, V83, P2093, DOI 10.1182/blood.V83.8.2093.bloodjournal8382093; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SERVICE FJ, 1993, J CLIN ENDOCR METAB, V76, P655, DOI 10.1210/jc.76.3.655; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; THOMPSON D, 1991, CYTOKINE, V3, P619, DOI 10.1016/1043-4666(91)90489-Z; Van Eden ME, 2000, ARCH BIOCHEM BIOPHYS, V381, P119, DOI 10.1006/abbi.2000.1952; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Xie JX, 2002, MOL BRAIN RES, V99, P12, DOI 10.1016/S0169-328X(01)00336-9; Yudkin JS, 2000, DIABETOLOGIA, V43, P1099, DOI 10.1007/s001250051500; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zundel W, 2000, GENE DEV, V14, P391	76	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27903	27911		10.1074/jbc.M203610200	http://dx.doi.org/10.1074/jbc.M203610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029093	hybrid			2022-12-25	WOS:000177189800041
J	Long, JC; DeLeon-Rangel, J; Vik, SB				Long, JC; DeLeon-Rangel, J; Vik, SB			Characterization of the first cytoplasmic loop of subunit a of the Escherichia coli ATP synthase by surface labeling, cross-linking, and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE HEART-MITOCHONDRIA; ALPHA-SUBUNIT; A-SUBUNIT; B-SUBUNIT; PROTON TRANSLOCATION; CYSTEINE RESIDUES; ROTARY MOTOR; H+-ATPASE; ROTATION; F1F0-ATPASE	The first cytoplasmic loop of subunit a of the Escherichia coli ATP synthase has been analyzed by eysteine substitution mutagenesis. 13 of the 26 residues tested were found to be accessible to the reaction with 3-(N-maleimidylpropionyl)-biocytin. The other 13 residues predominantly found in the central region of the polypeptide chain between the two transmembrane spans were more resistant to labeling by 3-(N-maleimidylpropionyl)-biocytin while in membrane vesicle preparations. This region of subunit a contains a conserved residue Glu-80, which when mutated to lysine resulted in a significant loss of ATP-driven proton translocation. Other substitutions including glutamine, alanine, and leucine were much less detrimental to function. Crosslinking studies with a photoactive cross-linking reagent were carried out. One mutant, K74C, was found to generate distinct cross-links to subunit b, and the cross-linking had little effect on proton translocation. The results indicate that the first transmembrane span (residues 40 - 64) of subunit a is probably near one or both of the b subunits and that a less accessible region of the first cytoplasmic loop (residues 75-90) is probably near the cytoplasmic surface, perhaps in contact with b subunits.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NIGMS NIH HHS [GM 40508, R01 GM040508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ARIS JP, 1983, J BIOL CHEM, V258, P4599; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boogerd FC, 1998, J BACTERIOL, V180, P5855, DOI 10.1128/JB.180.22.5855-5859.1998; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Caviston TL, 1998, FEBS LETT, V429, P201, DOI 10.1016/S0014-5793(98)00597-3; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; HARTZOG PE, 1993, J BACTERIOL, V175, P1337, DOI 10.1128/JB.175.5.1337-1343.1993; HATCH LP, 1995, J BIOL CHEM, V270, P29407, DOI 10.1074/jbc.270.49.29407; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HUMBERT R, 1983, J BACTERIOL, V153, P416, DOI 10.1128/JB.153.1.416-422.1983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1988, J BIOL CHEM, V263, P6599; VIK SB, 1994, J BIOL CHEM, V269, P30364; VIK SB, 1987, J BIOL CHEM, V262, P8340; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; von Ballmoos C, 2002, J BIOL CHEM, V277, P3504, DOI 10.1074/jbc.M110301200; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353	48	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27288	27293		10.1074/jbc.M202118200	http://dx.doi.org/10.1074/jbc.M202118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021273	hybrid			2022-12-25	WOS:000177055900076
J	Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M				Wang, ZO; Kyo, S; Maida, Y; Takakura, M; Tanaka, M; Yatabe, N; Kanaya, T; Nakamura, M; Koike, K; Hisamoto, K; Ohmichi, M; Inoue, M			Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells	ONCOGENE			English	Article						tamoxifen; telomerase; hTERT; endometrial cancer; breast cancer	ACTIVATED PROTEIN-KINASE; HUMAN ESTROGEN-RECEPTOR; PROMOTER-CONTEXT; IMMORTAL CELLS; PATHWAY; PHOSPHORYLATION; GROWTH	Tamoxifen is widely applied as an antiestrogenic agent for adjuvant therapy in the treatment of breast cancer, while its estrogen-agonistic activity occasionally causes proliferative disorders or carcinogenesis at other sites, such as the uterus. We reported that estrogen activates telomerase in breast and endometrial cancer cells. The present study examines the effects of tamoxifen on the gene expression of human telomerase reverse transcriptase (hTERT) in breast and endometrial cancer cells. Tamoxifen inhibited the cell growth of MCF-7 cells, as well as hTERT mRNA expression in the presence of estrogen (E2), antagonizing the E2 effects. In contrast, tamoxifen stimulated the growth of Ishikawa cells and activated hTERT mRNA expression in the absence or presence of E2, exhibiting estrogen-agonistic action. Transient expression assays revealed that these actions of tamoxifen are achieved by transcriptional regulation of the hTERT promoter. An estrogen responsive element (ERE) in the hTERT 5' regulatory region was partly responsible for both the E2-antagonistic and -agonistic actions of tamoxifen. Tamoxifen activated the MAP kinase cascade in Ishikawa cells, but not in MCF-7 cells, and the activation of hTERT mRNA expression was effectively blocked by MEK inhibitor, suggesting that the MAP kinase pathway is involved in the tamoxifen-induced activation of hTERT. These findings indicate that tamoxifen regulates hTERT expression in a cell-type specific manner. Tamoxifen-induced activation of hTERT may be one component of estrogen agonistic function of tamoxifen that is involved in endometrial carcinogenesis induced by this agent.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Takakura, Masahiro/E-1080-2011					Bergman L, 2000, LANCET, V356, P881, DOI 10.1016/S0140-6736(00)02677-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Colacurci N, 2000, PANMINERVA MED, V42, P45; Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Goldstein SR, 2000, EUR J CANCER, V36, pS54; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Ito H, 1998, CLIN CANCER RES, V4, P1603; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lasset C, 2001, LANCET, V357, P66, DOI 10.1016/S0140-6736(05)71563-4; Mandlekar S, 2000, CANCER RES, V60, P5995; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Schwartz LB, 1997, AM J OBSTET GYNECOL, V176, P129, DOI 10.1016/S0002-9378(97)80025-7; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Singer CA, 1999, J NEUROSCI, V19, P2455; Smith SMR, 2000, AM J SURG, V180, P249, DOI 10.1016/S0002-9610(00)00453-0; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sundaresan S, 1996, ENDOCRINOLOGY, V137, P304, DOI 10.1210/en.137.1.304; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Z, 2000, CANCER RES, V60, P5376; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479	36	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3517	3524		10.1038/sj.onc.1205463	http://dx.doi.org/10.1038/sj.onc.1205463			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032853				2022-12-25	WOS:000175793700002
J	Hickey, MJ; Sihota, E; Amrani, A; Santamaria, P; Zbytnuik, LD; Ng, ESM; Ho, W; Sharkey, KA; Kubes, P				Hickey, MJ; Sihota, E; Amrani, A; Santamaria, P; Zbytnuik, LD; Ng, ESM; Ho, W; Sharkey, KA; Kubes, P			Inducible nitric oxide synthase (iNOS) in endotoxemia: chimeric mice reveal different cellular sources in various tissues	FASEB JOURNAL			English	Article						leukocytes; chimera; lipopolysaccharide	DEFICIENT MICE; MESSENGER-RNA; SEPTIC SHOCK; L-ARGININE; LACKING; INFLAMMATION; MODULATION; EXPRESSION; INJURY; VIVO	The aim of these experiments was to determine the contribution of leukocyte-derived iNOS to total iNOS expression induced by lipopolysaccharide (LPS). By transferring bone marrow between iNOS(+/+) and iNOS(-/-) mice, we created chimeric mice in which iNOS expression was limited to either circulating leukocytes (leukocyte-iNOS mice) or parenchymal cells (parenchyma-iNOS mice). Analysis of congenic markers demonstrated that >95% of thymocytes in chimeric mice were of donor origin. Also, following LPS treatment, iNOS mRNA was detectable in blood from leukocyte-iNOS mice but not parenchyma-iNOS mice. Together these findings indicated that the host marrow had been replaced entirely by donor cells. In the lung, at least 50% of the LPS-induced iNOS mRNA was derived from leukocytes, and immunohistochemical analysis indicated that leukocytes were the main source of iNOS protein. In contrast in the liver, colon, and muscle, iNOS expression was derived predominantly from parenchymal cells. This divergence is potentially explained by the high level of leukocyte recruitment to the lung, relative to the other tissues. Plasma levels of NOS byproducts indicated that parenchymal iNOS was the dominant source of systemic iNOS activity. These findings indicate that in tissues other than the lung, parenchymal cells are the principal source of iNOS during endotoxemia.	Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, Clayton, Vic 3168, Australia; Univ Calgary, Immunol Grp, Calgary, AB, Canada; Univ Calgary, Neurosci Res Grp, Calgary, AB, Canada	Monash University; University of Calgary; University of Calgary	Hickey, MJ (corresponding author), Monash Univ, Monash Med Ctr, Dept Med, Ctr Inflammatory Dis, 246 Clayton Rd, Clayton, Vic 3168, Australia.	michael.hickey@med.monash.edu.au	Hickey, Michael J./A-5429-2012; Santamaria, Pere/ABF-6823-2021	Hickey, Michael J./0000-0003-2354-357X; Sharkey, Keith/0000-0001-9560-1711				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Comtois AS, 1999, AM J RESP CRIT CARE, V159, P1975, DOI 10.1164/ajrccm.159.6.9809020; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; Fierro IM, 1999, J LEUKOCYTE BIOL, V65, P508, DOI 10.1002/jlb.65.4.508; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; KOLLS J, 1994, P SOC EXP BIOL MED, V205, P220; Laubach VE, 1998, AM J PHYSIOL-HEART C, V275, pH2211, DOI 10.1152/ajpheart.1998.275.6.H2211; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; McCafferty DM, 2000, AM J PHYSIOL-GASTR L, V279, pG90, DOI 10.1152/ajpgi.2000.279.1.G90; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; McCaffery DM, 1999, GUT, V45, P864, DOI 10.1136/gut.45.6.864; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; Nicholson SC, 1999, SHOCK, V11, P253, DOI 10.1097/00024382-199904000-00005; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Peng HB, 1998, J IMMUNOL, V161, P1970; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; RIDINGS PC, 1995, AM J RESP CRIT CARE, V152, P247, DOI 10.1164/ajrccm.152.1.7541277; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; Schmidt D, 1999, J IMMUNOL, V162, P4627; Shears LL, 1997, J CLIN INVEST, V100, P2035, DOI 10.1172/JCI119736; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Tsukahara Y, 1998, WORLD J SURG, V22, P771, DOI 10.1007/s002689900468; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Wong J M, 1995, Adv Pharmacol, V34, P155	38	41	41	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1141	+		10.1096/fj.01-0764fje	http://dx.doi.org/10.1096/fj.01-0764fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039841				2022-12-25	WOS:000175973900005
J	Barna, T; Messiha, HL; Petosa, C; Bruce, NC; Scrutton, NS; Moody, PCE				Barna, T; Messiha, HL; Petosa, C; Bruce, NC; Scrutton, NS; Moody, PCE			Crystal structure of bacterial morphinone reductase and properties of the C191A mutant enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; PENTAERYTHRITOL TETRANITRATE REDUCTASE; ESTROGEN-BINDING PROTEIN; TRIMETHYLAMINE DEHYDROGENASE; MOLECULAR-CLONING; OVER-EXPRESSION; ACTIVE-SITE; SEQUENCE; GENE; REACTIVITY	The crystal structure of the NADH-dependent bacterial flavoenzyme morphinone reductase (MR) has been determined at 2.2-Angstrom resolution in complex with the oxidizing substrate codeinone. The structure reveals a dimeric enzyme comprising two 8-fold beta/alpha barrel domains, each bound to FMN, and a subunit folding topology and mode of flavin-binding similar to that found in Old Yellow Enzyme (OYE) and pentaerythritol tetranitrate (PETN) reductase. The subunit interface of MR is formed by interactions from an N-terminal beta strand and helices 2 and 8 of the barrel domain and is different to that seen in OYE. The active site structures of MR, OYE, and PETN reductase are highly conserved reflecting the ability of these enzymes to catalyze "generic" reactions such as the reduction of 2-cyclohexenone. A region of polypeptide presumed to define the reducing coenzyme specificity is identified by comparison of the MR structure (NADH-dependent) with that of PETN reductase (NADPH-dependent). The active site acid identified in OYE (Tyr-196) and conserved in PETN reductase (Tyr-186) is replaced by Cys-191 in MR. Mutagenesis studies have established that Cys-191 does not act as a crucial acid in the mechanism of reduction of the olefinic bond found in 2-cyclohexenone and codeinone.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England	University of Leicester; University of Cambridge	Bruce, NC (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk; pcem1@le.ac.uk	Moody, Peter/A-6832-2008; barna, terez/R-1357-2018	Moody, Peter/0000-0003-1762-9238; Petosa, Carlo/0000-0002-9975-1167				Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; BRUCE NC, 1995, TRENDS BIOTECHNOL, V13, P200, DOI 10.1016/S0167-7799(00)88946-5; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; FRENCH CE, 1995, BIO-TECHNOL, V13, P674, DOI 10.1038/nbt0795-674; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIM LW, 1986, J BIOL CHEM, V261, P5140; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MASSEY V, 1986, J BIOL CHEM, V261, P1215; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MELMON K, 1972, CLIN PHARM BASIC PRI; Moffat A.C, 1986, CLARKES ISOLATION ID, DOI DOI 10.1002/JPS.2600760520; Moody PCE, 1997, ACTA CRYSTALLOGR D, V53, P619, DOI 10.1107/S0907444997004046; MUH U, 1994, J BIOL CHEM, V269, P7982; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SCRUTTON DR, 1967, NATURE, V213, P950, DOI 10.1038/213950a0; SCRUTTON NS, 1994, BIOESSAYS, V16, P115, DOI 10.1002/bies.950160208; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STOTT K, 1993, J BIOL CHEM, V268, P6097; STRASSNER J, 1999, FLAVINS FLAVOPROTEIN, P655; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; WILLEY DL, 1993, BIOCHEM J, V290, P539, DOI 10.1042/bj2900539; Williams RE, 2001, BIOCHEM SOC SYMP, V68, P143; WILLIAMS RE, 1999, FLAVINS FLAVOPROTEIN, P663; YANG CC, 1995, EUR J BIOCHEM, V232, P264, DOI 10.1111/j.1432-1033.1995.tb20808.x	46	57	59	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30976	30983		10.1074/jbc.M202846200	http://dx.doi.org/10.1074/jbc.M202846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048188	hybrid			2022-12-25	WOS:000177579800074
J	Hellberg, A; Poole, J; Olsson, ML				Hellberg, A; Poole, J; Olsson, ML			Molecular basis of the globoside-deficient P-k blood group phenotype - Identification of four inactivating mutations in the UDP-N-acetylgalactosamine: Globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARVOVIRUS B19 INFECTION; ERYTHROCYTE-P; CLONING; EXPRESSION; GLYCOSYLTRANSFERASE; POPULATION; SYNTHASE; RECEPTOR; ANTIGEN; SYSTEM	The biochemistry and molecular genetics underlying the related carbohydrate blood group antigens P, P-k, and LKE in the GLOB collection and P1 in the P blood group system are complex and not fully understood. Individuals with the rare but clinically important erythrocyte phenotypes P-1(k) and P-2(k) lack the capability to synthesize P antigen identified as globoside, the cellular receptor for Parvo-B19 virus and some P-fimbriated Escherichia coli. As in the ABO system, naturally occurring antibodies, anti-P of the IgM and IgG class with hemolytic and cytotoxic capacity, are formed. To define the molecular basis of the P-k phenotype we analyzed the full coding region of a candidate gene reported in 1998 as a member of the 3-beta-galactosyltransferase family but later shown to possess UDP-N-acetylgalactosamine:globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase or globoside synthase activity. Homozygosity for different nonsense mutations (C-202 --> T and 538insA) resulting in premature stop codons was found in blood samples from two individuals of the P-2(k) phenotype. Two individuals with P-1(k) and P-2(k) phenotypes were homozygous for missense mutations causing amino acid substitutions (E266A or G271R) in a highly conserved region of the enzymatically active carboxyl-terminal domain in the transferase. We conclude that crucial mutations in the globoside synthase gene cause the P-k phenotype.	Univ Lund Hosp, Ctr Blood, Inst Lab Med, Dept Transfus Med, SE-22185 Lund, Sweden; Int Blood Grp Reference Lab, Bristol BS10 5ND, Avon, England	Lund University; Skane University Hospital	Olsson, ML (corresponding author), Univ Lund Hosp, Ctr Blood, Inst Lab Med, Dept Transfus Med, SE-22185 Lund, Sweden.	Martin_L.Olsson@transfumed.lu.se		Olsson, Martin L/0000-0003-1647-9610				Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BROWN KE, 1994, NEW ENGL J MED, V330, P1192, DOI 10.1056/NEJM199404283301704; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BROWN KE, 1995, BLOOD REV, V9, P176, DOI 10.1016/0268-960X(95)90023-3; CANTIN G, 1983, TRANSFUSION, V23, P350, DOI 10.1046/j.1537-2995.1983.23483276877.x; CEDERGREN B, 1973, HEREDITAS, V73, P27; COOLING LLW, 1995, J INFECT DIS, V172, P1198, DOI 10.1093/infdis/172.5.1198; DANIELS G, 1995, P BLOOD GROUPS HUMAN; DANIELS GL, 1995, VOX SANG, V69, P265, DOI 10.1111/j.1423-0410.1995.tb02611.x; Furukawa K, 2000, J BIOL CHEM, V275, P37752, DOI 10.1074/jbc.C000625200; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Heddle N M, 1989, Transfus Med Rev, V3, P219, DOI 10.1016/S0887-7963(89)70082-1; Irshaid NM, 2000, TRANSFUSION, V40, P69, DOI 10.1046/j.1537-2995.2000.40010069.x; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Keusch JJ, 2000, J BIOL CHEM, V275, P25315, DOI 10.1074/jbc.M002630200; KIJIMOTOOCHIAI S, 1977, P NATL ACAD SCI USA, V74, P5407, DOI 10.1073/pnas.74.12.5407; Koda Y, 1996, AM J HUM GENET, V59, P343; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; LINDSTROM K, 1992, GLYCOCONJUGATE J, V9, P325, DOI 10.1007/BF00731093; Marcus D M, 1989, Immunol Ser, V43, P701; MATSON GA, 1959, AM J HUM GENET, V11, P26; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1974, BIOCHEM BIOPH RES CO, V60, P1105, DOI 10.1016/0006-291X(74)90426-4; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Olsson ML, 2001, BLOOD, V98, P1585, DOI 10.1182/blood.V98.5.1585; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RCE RR, 1975, BLOOD GROUPS BLOOD, P139; SPITALNIK PF, 1995, TRANSFUS MED REV, V9, P110, DOI 10.1016/S0887-7963(05)80050-1; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	36	37	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29455	29459		10.1074/jbc.M203047200	http://dx.doi.org/10.1074/jbc.M203047200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023287	hybrid			2022-12-25	WOS:000177509300015
J	Xu, Y; Kohn, H; Widger, WR				Xu, Y; Kohn, H; Widger, WR			Mutations in the Rho transcription termination factor that affect RNA tracking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RHO; BINDING DOMAIN; PROTEIN; BICYCLOMYCIN; SITE; ATP; HELICASE; AFFINITY; INHIBITION; F1-ATPASE	Model studies have identified 16 conserved positively charged amino acids that form a positive strip pointing toward the center hole of Rho. Fourteen residues were individually changed to either an alanine or a glycine and one to a glutamate. Residues Arg(269), Arg(272), Lys(283), Arg(296), Lys(298), and Arg(299) form a subdomain (locus) located N-terminal to (above) the ATP hydrolysis domain (P-loop) and mutations in these residues led to either inactive Rho or to proteins displaying decreased k(cat) for poly(C)-dependent ATP hydrolysis, increased K-m for ribo(C)(10) activation, and decreased transcription termination efficiencies (57-77%) compared with wild-type Rho. Residues Arg(347), Lys(346), Lys(352), and Arg(353) form a subdomain (locus) C-terminal to (below) the ATP hydrolysis domain, and mutations in these residues also show a decreased k(cat) for poly(C)-dependent ATP hydrolysis, an increased K-m for ribo(C)(10) activation, and a 50-70% decrease in transcription termination, compared with wild-type Rho. Residues Arg(212) and Lys(336) surround the ATP hydrolysis domain, and mutations in these residues also altered the kinetic properties of Rho. We conclude that the secondary RNA-tracking site consists of amino acids whose putative orientation faces the central hole in Rho and in part reside in two clusters of positively charged residues located above and below the ATP hydrolysis domain.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	University of Houston System; University of Houston; University of North Carolina; University of North Carolina Chapel Hill	Widger, WR (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; INOKO H, 1977, P NATL ACAD SCI USA, V74, P1163; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kim DE, 2001, J BIOL CHEM, V276, P13902, DOI 10.1074/jbc.M011043200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Magyar A, 1999, J BIOL CHEM, V274, P7316, DOI 10.1074/jbc.274.11.7316; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Nowatzke WL, 1997, J BACTERIOL, V179, P5238, DOI 10.1128/jb.179.16.5238-5240.1997; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; Vincent F, 2001, J ORG CHEM, V66, P2251, DOI 10.1021/jo0013150; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9077, DOI 10.1021/bi000504+; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9067, DOI 10.1021/bi000503h; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Wei RR, 2001, J MOL BIOL, V314, P1007, DOI 10.1006/jmbi.2000.5207; Wei RR, 2001, J BIOL CHEM, V276, P28380, DOI 10.1074/jbc.M102444200; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	38	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30023	30030		10.1074/jbc.M111009200	http://dx.doi.org/10.1074/jbc.M111009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034708	Green Published, hybrid			2022-12-25	WOS:000177509300084
J	Kurata, HT; Soon, GS; Eldstrom, JR; Lu, GWK; Steele, DF; Fedida, D				Kurata, HT; Soon, GS; Eldstrom, JR; Lu, GWK; Steele, DF; Fedida, D			Amino-terminal determinants of U-type inactivation of voltage-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE INACTIVATION; SHAKER POTASSIUM CHANNELS; DELAYED RECTIFIER CURRENT; 3-DIMENSIONAL STRUCTURE; TETRAMERIZATION DOMAIN; SLOW INACTIVATION; TYROSINE KINASE; ALPHA-SUBUNITS; BETA-SUBUNIT; HUMAN HEART	The T1 domain is a cytosolic NH2-terminal domain present in all Kv (voltage-dependent potassium) channels, and is highly conserved between Kv channel subfamilies. Our characterization of a truncated form of Kv1.5 (Kv1.5DeltaN209) expressed in myocardium demonstrated that deletion of the NH2 terminus of Kv1.5 imparts a U-shaped inactivation-voltage relationship to the channel, and prompted us to investigate the NH2 terminus as a regulatory site for slow inactivation of Kv channels. We examined the macroscopic inactivation properties of several NH2-terminal deletion mutants of Kv1.5 expressed in HEK 293 cells, demonstrating that deletion of residues up to the T1 boundary (Kv1.5DeltaN19, Kv1.5DeltaN91, and Kv1.5DeltaN119) did not alter Kv1.5 inactivation, however, deletion mutants that disrupted the T1 structure consistently exhibited inactivation phenotypes resembling Kv1.5DeltaN209. Chimeric constructs between Kv1.5 and the NH2 termini of Kv1.1 and Kv1.3 preserved the inactivation kinetics observed in full-length Kv1.5, again suggesting that the Kv1 T1 domain influences slow inactivation. Furthermore, disruption of intersubunit T1 contacts by mutation of residues Glu(131) and Thr(132) to alanines resulted in channels exhibiting a U-shaped inactivation-voltage relationship. Fusion of the NH2 terminus of Kv2.1 to the transmembrane segments of Kv1.5 imparted a U-shaped inactivation-voltage relationship to Kv1.5, whereas fusion of the NH2 terminus of Kv1.5 to the transmembrane core of Kv2.1 decelerated Kv2.1 inactivation and abolished the U-shaped voltage dependence of inactivation normally observed in Kv2.1. These data suggest that intersubunit T1 domain interactions influence U-type inactivation in Kv1 channels, and suggest a generalized influence of the T1 domain on U-type inactivation between Kv channel subfamilies.	Univ British Columbia, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Fedida, D (corresponding author), Univ British Columbia, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.			Kurata, Harley/0000-0003-4357-4189				ATTALI B, 1993, J BIOL CHEM, V268, P24283; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Caprini M, 2001, J BIOL CHEM, V276, P21070, DOI 10.1074/jbc.M100487200; Chiara MD, 1999, J NEUROSCI, V19, P6865, DOI 10.1523/JNEUROSCI.19-16-06865.1999; Choe S, 1999, TRENDS BIOCHEM SCI, V24, P345, DOI 10.1016/S0968-0004(99)01440-1; Chung I, 1997, AM J PHYSIOL-CELL PH, V273, pC622, DOI 10.1152/ajpcell.1997.273.2.C622; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Elkes DA, 1997, NEURON, V19, P165, DOI 10.1016/S0896-6273(00)80356-6; FEDIDA D, 1993, CIRC RES, V73, P210, DOI 10.1161/01.RES.73.1.210; Fedida D, 1999, J PHYSIOL-LONDON, V515, P315, DOI 10.1111/j.1469-7793.1999.315ac.x; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Jiang M, 1997, J BIOL CHEM, V272, P24109, DOI 10.1074/jbc.272.39.24109; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; Johnstone DB, 1997, NEURON, V19, P151, DOI 10.1016/S0896-6273(00)80355-4; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Klemic KG, 2001, BIOPHYS J, V81, P814, DOI 10.1016/S0006-3495(01)75743-8; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kramer JW, 1998, AM J PHYSIOL-CELL PH, V274, pC1501, DOI 10.1152/ajpcell.1998.274.6.C1501; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kurata HT, 2001, J GEN PHYSIOL, V118, P315, DOI 10.1085/jgp.118.3.315; Levy DI, 1996, BIOPHYS J, V70, P798, DOI 10.1016/S0006-3495(96)79619-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Ogielska EM, 1998, J GEN PHYSIOL, V112, P243, DOI 10.1085/jgp.112.2.243; Olcese R, 1997, J GEN PHYSIOL, V110, P579, DOI 10.1085/jgp.110.5.579; PANYI G, 1995, BIOPHYS J, V69, P896, DOI 10.1016/S0006-3495(95)79963-5; PERSON WR, 1997, GENOMICS, V46, P24; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Zerr P, 1998, FEBS LETT, V431, P461, DOI 10.1016/S0014-5793(98)00814-X; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29045	29053		10.1074/jbc.M111470200	http://dx.doi.org/10.1074/jbc.M111470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021261	hybrid			2022-12-25	WOS:000177342600091
J	Mao, QC; Qiu, W; Weigl, KE; Lander, PA; Tabas, LB; Shepard, RL; Dantzig, AH; Deeley, RG; Cole, SPC				Mao, QC; Qiu, W; Weigl, KE; Lander, PA; Tabas, LB; Shepard, RL; Dantzig, AH; Deeley, RG; Cole, SPC			GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [I-125]LY475776 - Evidence of a major binding site in the COOH-proximal membrane spanning domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; HUMAN P-GLYCOPROTEIN; LEUKOTRIENE C-4; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; REDUCED GLUTATHIONE; DRUG-RESISTANCE; SULFONYLUREA RECEPTOR; VINCRISTINE TRANSPORT; ATPASE ACTIVITY	Substrates transported by the 190-kDa multidrug resistance protein 1 (MRP1) (AECC1) include endogenous organic anions such as the cysteinyl leukotriene C-4. In addition, MRP1 confers resistance against various anticancer drugs by reducing intracellular accumulation by co-export of drug with reduced GSH. We have examined the properties of LY475776, an intrinsically photoactivable AMPI-specific tricyclic isoxazole modulator that inhibits leukotriene C4 transport by this protein in a GSH-dependent manner. We show that [1251]LY475776 photolabeling of MRP1 requires GSH but is also supported by several non-reducing GSH derivatives and peptide analogs. Limited proteolysis revealed that [1251]LY475776 labeling was confined to the 75-kDa COOH-proximal half of MRP1. More extensive proteolysis generated two major I-125-labeled fragments of similar to56 and similar to41 kDa, and immunoblotting with regionally directed antibodies showed that these fragments correspond to amino acids similar to1045-1531 and similar to1150-1531, respectively. However, an similar to33-kDa COOH-terminal immunoreactive fragment was not labeled, inferring that the major [I-125]LY475776-labeling site resides approximately between amino acids 1150-1250. This region encompasses transmembrane (TM) segments 16 and 17 at the COOH-proximal end of the third membrane spanning domain of the protein. [1251]LY475776 labeling of mutant MRP1 molecules with substitutions of Trp(1246) in TM17 were reduced >80% compared with wild-type MRP1, confirming that TM17 is important for LY475776 binding. Finally, vanadate-induced trapping of ADP inhibited [125 I]LY475776 labeling, suggesting that ATP hydrolysis causes a conformational change in MRP1 that reduces the affinity of the protein for this inhibitor.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Queens University - Canada; Queens University - Canada; Eli Lilly	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Chen ZS, 2001, INT J CANCER, V93, P107, DOI 10.1002/ijc.1290; Chuman Y, 1998, CANCER LETT, V129, P69, DOI 10.1016/S0304-3835(98)00083-4; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Dantzig AH, 1999, J PHARMACOL EXP THER, V290, P854; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirrlinger J, 2001, J NEUROCHEM, V76, P627, DOI 10.1046/j.1471-4159.2001.00101.x; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Norman BH, 2002, BIOORG MED CHEM LETT, V12, P883, DOI 10.1016/S0960-894X(02)00051-3; Paulusma CC, 1999, BIOCHEM J, V338, P393, DOI 10.1042/0264-6021:3380393; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rappa G, 1997, CANCER RES, V57, P5232; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; SCHNEIDER E, 1995, BRIT J CANCER, V71, P38; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Vanhoefer U, 1996, CLIN CANCER RES, V2, P1961; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200	63	58	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28690	28699		10.1074/jbc.M202182200	http://dx.doi.org/10.1074/jbc.M202182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034727	hybrid			2022-12-25	WOS:000177342600046
J	Hori, N; Nakano, H; Takeuchi, T; Kato, H; Hamaguchi, S; Oshimura, M; Sato, K				Hori, N; Nakano, H; Takeuchi, T; Kato, H; Hamaguchi, S; Oshimura, M; Sato, K			A dyad oct-binding sequence functions as a maintenance sequence for the unmethylated state within the H19/Igf2-imprinted control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE H19 GENE; CELL-SPECIFIC DEMETHYLATION; ENHANCER-BLOCKING ACTIVITY; EMBRYONAL CARCINOMA-CELLS; DNA METHYLATION; IMPRINTED EXPRESSION; PATERNAL METHYLATION; H19/IGF2 LOCUS; CPG ISLAND; CTCF	DNA methylation of an imprinted control region (ICR) directs the allele-specific and reciprocal expression of the mouse H19 and the insulin-like growth factor 2 (Igf2) genes, mediated by controlling enhancer access. The ICR shows enhancer blocking activity through CTCF binding to an unmethylated sequence. The unmethylated state of the maternal ICR is maintained throughout development after establishment in the germ line; however, little is known of the molecular mechanisms that regulate DNA methylation. Hence, in this study we show that a dyad Oct-binding sequence (DOS) in the ICR mediates the demethylation of low-density methylation but not hypermethylation and is required to maintain the unmethylated state against the tendency for de novo methylation within the ICR in the embryonic carcinoma cell line P19. Furthermore, we also reveal that the unmethylated state of at least one CTCF-binding site within the ICR is under the control of DOS. Our results suggest that the ICR, as a CTCF-dependent insulator, requires DOS as well as CTCF-binding sites and that DOS maintains the maternal specific unmethylated state of the ICR at postimplantation stages.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, Yonago, Tottori 6830853, Japan; Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6830853, Japan	Tottori University; Tottori University	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol Biol, Nishimachi 86, Yonago, Tottori 6830853, Japan.							Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Drewell RA, 2000, DEVELOPMENT, V127, P3419; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Filippova GN, 2001, NAT GENET, V28, P335, DOI 10.1038/ng570; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Howell CY, 1998, MOL CELL BIOL, V18, P4149, DOI 10.1128/MCB.18.7.4149; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; Kaffer CR, 2000, GENE DEV, V14, P1908; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1997, GENOMIC IMPRINTING F, P1; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; SILKE J, 1995, FEBS LETT, V370, P170, DOI 10.1016/0014-5793(95)00830-3; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Ueda T, 2000, GENES CELLS, V5, P649, DOI 10.1046/j.1365-2443.2000.00351.x; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	35	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27960	27967		10.1074/jbc.M202280200	http://dx.doi.org/10.1074/jbc.M202280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029086	hybrid			2022-12-25	WOS:000177189800048
J	Zhao, GH; Ceci, P; Ilari, A; Giangiacomo, L; Laue, TM; Chiancone, E; Chasteen, ND				Zhao, GH; Ceci, P; Ilari, A; Giangiacomo, L; Laue, TM; Chiancone, E; Chasteen, ND			Iron and hydrogen peroxide detoxification properties of DNA-binding protein from starved cells - A ferritin-like DNA-binding protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-INNOCUA; OXIDATIVE STRESS; DODECAMERIC FERRITIN; SPLEEN FERRITIN; HORSE SPLEEN; DPS; PROTECTION; HYDROLYSIS; BACTERIOFERRITIN; SUPEROXIDE	The DNA-binding proteins from starved cells (Dps) are a family of proteins induced in microorganisms by oxidative or nutritional stress. Escherichia coli Dps, a structural analog of the 12-subunit Listeria innocua ferritin, binds and protects DNA against oxidative damage mediated by H2O2. Dps is shown to be a Fe-binding and storage protein where Fe(II) oxidation is most effectively accomplished by H2O2 rather than by O-2 as in ferritins. Two Fe2+ ions bind at each of the 12 putative dinuclear ferroxidase sites (P-Z) in the protein according to the equation, 2Fe(2+) + P-Z --> [(Fe(II)(2)-P](FS)(Z+2) + 2H(+). The ferroxidase site (FS) bound iron is then oxidized according to the equation, [(Fe(II)(2)-P](FS)(Z+2) + H2O2 + H2O --> [Fe(III)(2)O-2(OH)-P](FS)(Z-1) + 3H(+), where two Fe(II) are oxidized per H2O2 reduced, thus avoiding hydroxyl radical production through Fenton chemistry. Dps acquires a ferric core of similar to500 Fe(III) according to the mineralization equation, 2Fe(2+) + H2O2 + 2H(2)O --> 2Fe(III)OOH(core) + 4H(+), again with a 2 Fe(II)/H2O2 stoichiometry. The protein forms a similar ferric core with O-2 as the oxidant, albeit at a slower rate. In the absence of H2O2 and O-2, Dps forms a ferrous core of similar to400 Fe(II) by the reaction Fe2+ + H2O + Cl- --> Fe(II)OHCl(core) + H+. The ferrous core also undergoes oxidation with a stoichiometry of 2 Fe(II)/H2O2. Spin trapping experiments demonstrate that Dps greatly attenuates hydroxyl radical production during Fe(II) oxidation by H2O2. These results and an vitro DNA damage assays indicate that the protective effect of Dps on DNA most likely is exerted through a dual action, the physical association with DNA and the ability to nullify the toxic combination of Fe(II) and H2O2. In the latter process a hydrous ferric oxide mineral core is produced within the protein, thus avoiding oxidative damage mediated by Fenton chemistry.	Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Univ New Hampshire, Dept Biochem, Durham, NH 03824 USA; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, CS Biol Mol, I-00185 Rome, Italy	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; Sapienza University Rome	Chasteen, ND (corresponding author), Univ New Hampshire, Dept Chem, Parsons Hall, Durham, NH 03824 USA.		Laue, Tom/AAI-5136-2020; Ilari, Andrea/T-5501-2017; Ilari, Andrea/AAC-7670-2022	Laue, Tom/0000-0003-3571-9368; Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Ceci, Pierpaolo/0000-0001-7712-8430	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020194] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM20194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Chasteen ND, 1998, MET IONS BIOL SYST, V35, P479; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Frenkiel-Krispin D, 2001, EMBO J, V20, P1184, DOI 10.1093/emboj/20.5.1184; Grady JK, 2002, ANAL BIOCHEM, V302, P263, DOI 10.1006/abio.2001.5561; GRADY JK, 1998, THESIS U NEW HAMPSHI; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; HILTY S, 1994, J INORG BIOCHEM, V56, P173, DOI 10.1016/0162-0134(94)85004-6; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1986, J BACTERIOL, V166, P797; JACOBS DL, 1989, BIOCHEMISTRY-US, V28, P1650, DOI 10.1021/bi00430a033; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; MARUYAMA H, 1982, BIOCH PHYSL IRON, P491; MCKENZIE RA, 1989, ARCH BIOCHEM BIOPHYS, V272, P88, DOI 10.1016/0003-9861(89)90198-7; Nunoshiba T, 1999, J BIOL CHEM, V274, P34832, DOI 10.1074/jbc.274.49.34832; PENA MMO, 1995, ARCH MICROBIOL, V163, P337, DOI 10.1007/BF00404206; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; QUE L, 1990, PROG INORG CHEM, V38, P97; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; ROHRER JS, 1989, INORG CHEM, V28, P3393, DOI 10.1021/ic00316a031; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; SMITH AM, 1976, CRITICAL STABILITY C, V4, P1; Stefanini S, 1999, BIOCHEM J, V338, P71, DOI 10.1042/0264-6021:3380071; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Yang XO, 2000, BIOCHEMISTRY-US, V39, P4915, DOI 10.1021/bi992631f; Zhang H, 2000, FEBS LETT, V473, P58, DOI 10.1016/S0014-5793(00)01498-8; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j; Zhao ZW, 1997, J CHEM SOC DALTON, P3977, DOI 10.1039/a703675b	40	315	339	3	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27689	27696		10.1074/jbc.M202094200	http://dx.doi.org/10.1074/jbc.M202094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12016214	hybrid			2022-12-25	WOS:000177189800016
J	Cabart, P; Murphy, S				Cabart, P; Murphy, S			Assembly of human small nuclear RNA gene-specific transcription factor IIIB complex de novo on and off promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; POLYMERASE-III; HUMAN U6; IN-VIVO; CRYSTAL-STRUCTURE; HUMAN TFIIIB; DNA-BINDING; EFFICIENT TRANSCRIPTION; UPSTREAM PROMOTER; SNRNA GENES	In humans, transcription factor IIIB (TFIIIB)-alpha governs basal transcription from small nuclear RNA genes by RNA polymerase III (pol III). One of the components of this complex, BRFU/TFIIIB50, is specific for these promoters, whereas TATA-binding protein (TBP) and hB" are required for pol III transcription from both gene external and internal promoters. We show that hB" is specifically recruited to a promoter-bound (TBPBRFU)-B-. complex, which we have previously demonstrated as forming on TATA-containing templates. The N-terminal region of BRFU, containing a zinc ribbon domain, acts as a damper of hB" binding. TBP deactivates this negative mechanism through protein-protein contacts with both BRFU and hB", which may then promote their cooperative binding to form TFIIIB-alpha. In addition, we have identified a GC-rich sequence downstream from the TATA box (the BURE) which, depending on the strength of TATA box, can either enhance BRFU binding to the TBP(.)DNA complex or hB" association with the BRFU(.)TBP(.)DNA complex, and subsequently stimulate pol III transcription. Moreover, mutation of the BURE reduces pol III transcription and induces transcription by RNA polymerase 11 from the U2 gene promoter carrying a minimal TATA box.	Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, Oxford OX1 3RE, England	University of Oxford	Cabart, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Chem Pathol Unit, S Parks Rd, Oxford OX1 3RE, England.			Cabart, Pavel/0000-0003-0065-367X				BOYD DC, 1995, J MOL BIOL, V253, P677, DOI 10.1006/jmbi.1995.0582; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; Chong SS, 2001, J BIOL CHEM, V276, P20727, DOI 10.1074/jbc.M100088200; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARBER ME, 1994, MOL CELL BIOL, V14, P339, DOI 10.1128/MCB.14.1.339; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; Murphy S, 1997, NUCLEIC ACIDS RES, V25, P2068, DOI 10.1093/nar/25.11.2068; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Tsai FTF, 2000, EMBO J, V19, P25, DOI 10.1093/emboj/19.1.25; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200	42	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26831	26838		10.1074/jbc.M203119200	http://dx.doi.org/10.1074/jbc.M203119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016223	hybrid			2022-12-25	WOS:000177055900018
J	Kamikubo, Y; Okumura, Y; Loskutoff, DJ				Kamikubo, Y; Okumura, Y; Loskutoff, DJ			Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; AMINO-ACID-SEQUENCE; CELL-ADHESION; UROKINASE RECEPTOR; S-PROTEIN; FUNCTIONAL-CHARACTERIZATION; INTEGRIN ALPHA(V)BETA(3); BINDING-PROTEIN; CDNA CLONING; HUMAN-PLASMA	The NH2-terminal somatomedin B (SMB) domain (residues 1-44) of human vitronectin contains eight Cys residues organized into four disulfide bonds and is required for the binding of type 1 plasminogen activator inhibitor (PAI-1). In the present study, we map the four disulfide bonds in recombinant SMB (rSMB) and evaluate their functional importance. Active rSMB was purified from transformed Escherichia coli by immunoaffinity chromatography using a monoclonal antibody that recognizes a conformational epitope in SMB (monoclonal antibody 153). Plasmon surface resonance (BIA-core) and competitive enzyme-linked immunosorbent assays demonstrate that the purified rSMB domain and intact urea-activated vitronectin have similar PAI-1 binding activities. The individual disulfide linkages present in active rSMB were investigated by CNBr cleavage, partial reduction and S-alkylation, mass spectrometry, and protein sequencing. Two pairs of disulfide bonds at the NH2-terminal portion of active rSME were identified as Cys(5)-Cys(9) and Cys(19)-Cys(21). Selective reduction/S-alkylation of these two disulfide linkages caused the complete loss of PAI-1 binding activity. The other two pairs of disulfide bonds in the COOH-terminal portion of rSME were identified as CyS25-CyS31 and Cys(32)-CyS39 by protease-generated peptide mapping of partially reduced and S-alkylated rSMB. These results suggest a linear uncrossed pattern for the disulfide bond topology of rSMB that is distinct from the crossed pattern present in most small disulfide bond-rich proteins.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL 31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; Bures EJ, 1998, BIOCHEMISTRY-US, V37, P12172, DOI 10.1021/bi981082v; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Harrison PM, 1996, J MOL BIOL, V264, P603, DOI 10.1006/jmbi.1996.0664; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HUNTER MJ, 1995, PROTEIN SCI, V4, P2129, DOI 10.1002/pro.5560041019; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; Katsumi A, 2000, J BIOL CHEM, V275, P25585, DOI 10.1074/jbc.M002654200; KOST C, 1992, J BIOL CHEM, V267, P12098; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MIMURO J, 1989, J BIOL CHEM, V264, P936; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MURATA J, 1994, J BIOL CHEM, V269, P30479; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; Philips M, 2000, FIBRINOLYSIS PROTEOL, V14, P22, DOI 10.1054/fipr.2000.0047; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PODACK ER, 1979, J BIOL CHEM, V254, P9908; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Royle G, 2001, ANAL BIOCHEM, V296, P245, DOI 10.1006/abio.2001.5316; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Seiffert D, 1997, BIOCHIMIE, V79, P205, DOI 10.1016/S0300-9084(97)83507-9; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Standker L, 1996, EUR J BIOCHEM, V241, P557, DOI 10.1111/j.1432-1033.1996.00557.x; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; THIAGARAJAN P, 1988, THROMB HAEMOSTASIS, V60, P514; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; White CE, 1996, P NATL ACAD SCI USA, V93, P10177, DOI 10.1073/pnas.93.19.10177; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392; Wood MJ, 2000, NAT STRUCT BIOL, V7, P200; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YU HT, 1993, BIOCHEMISTRY-US, V32, P13123, DOI 10.1021/bi00211a022; ZHAO BG, 1992, J MOL BIOL, V227, P239, DOI 10.1016/0022-2836(92)90694-F	60	22	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27109	27119		10.1074/jbc.M200354200	http://dx.doi.org/10.1074/jbc.M200354200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12019263	hybrid			2022-12-25	WOS:000177055900054
J	Macol, CP; Tsuruta, H; Kantrowitz, ER				Macol, CP; Tsuruta, H; Kantrowitz, ER			Importance of domain closure for the catalysis and regulation of Escherichia coli aspartate transcarbamoylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; QUATERNARY STRUCTURE TRANSITION; HETEROTROPIC PROPERTIES; BISUBSTRATE ANALOG; ACTIVE-SITE; BINDING; PURIFICATION; SCATTERING; CHAIN; MUTAGENESIS	Two hybrid versions of Escherichia coli aspartate transcarbamoylase were studied to determine the influence of domain closure on the homotropic and heterotropic properties of the enzyme. Each hybrid holoenzyme had one wild-type and one inactive catalytic subunit. In the first case the inactive catalytic subunit had Arg-54 replaced by alanine. The holoenzyme with this mutation in all six catalytic chains exhibits a 17,000-fold reduction in activity, no loss in substrate affinity, and an R state structurally identical to that of the wild-type enzyme. In the second case, the inactive catalytic subunit had Arg-105 replaced by alanine. The holoenzyme with this mutation in all six catalytic chains exhibits a 1,100-fold reduction in activity, substantial loss in substrate affinity, and loss of the ability to be converted to the R state. Thus, the R54A substitution results in a holoenzyme that can undergo closure of the catalytic chain domains to form the high activity, high affinity active site and to undergo the allosteric transition, whereas the R105A substitution results in a holoenzyme that can neither undergo domain closure nor the allosteric transition. The hybrid holoenzyme with one wild-type and one R54A catalytic subunit exhibited the same maximal velocity per active site as the wild-type holoenzyme, reduced cooperativity, and normal heterotropic interactions. The hybrid with one wild-type and one R105A catalytic subunit exhibited significantly reduced maximal velocity per active site as compared with the wild-type holoenzyme, reduced cooperativity, and substantially reduced heterotropic interactions. Small angle x-ray scattered was used to verify that the R105A-containing hybrid could attain an R state structure. These results indicate the global nature of the conformational changes associated with the allosteric transition in the enzyme. If one catalytic subunit cannot undergo domain closure to create the active sites, then the entire molecule cannot attain the high activity, high activity R state.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41 RR 01209] Funding Source: Medline; NIGMS NIH HHS [GM 26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; DEMBOWSKI NJ, 1993, PROTEIN ENG, V6, P123, DOI 10.1093/protein/6.1.123; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FETLER L, 1995, J MOL BIOL, V251, P243, DOI 10.1006/jmbi.1995.0432; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GIBBONS I, 1974, P NATL ACAD SCI USA, V71, P4452, DOI 10.1073/pnas.71.11.4452; GIBBONS I, 1975, P NATL ACAD SCI USA, V72, P4298, DOI 10.1073/pnas.72.11.4298; HERVE G, 1985, J MOL BIOL, V185, P189, DOI 10.1016/0022-2836(85)90190-1; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; Macol C, 1999, PROTEIN SCI, V8, P1305, DOI 10.1110/ps.8.6.1305; Macol CP, 2001, NAT STRUCT BIOL, V8, P423, DOI 10.1038/87582; MANIATIS T, 1982, MOL CLONING LABORATO, P368; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; Sakash JB, 1998, BIOCHEMISTRY-US, V37, P281, DOI 10.1021/bi972102g; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1992, PROTEIN SCI, V1, P1435, DOI 10.1002/pro.5560011105; STEBBINS JW, 1989, J BIOL CHEM, V264, P14860; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; WALL KA, 1979, J BIOL CHEM, V254, P1910; WALL KA, 1979, J BIOL CHEM, V254, P1917	34	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26852	26857		10.1074/jbc.M203431200	http://dx.doi.org/10.1074/jbc.M203431200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016227	hybrid			2022-12-25	WOS:000177055900021
J	Oganesyan, V; Oganesyan, N; Terzyan, S; Qu, DF; Dauter, Z; Esmon, NL; Esmon, CT				Oganesyan, V; Oganesyan, N; Terzyan, S; Qu, DF; Dauter, Z; Esmon, NL; Esmon, CT			The crystal structure of the endothelial protein C receptor and a bound phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; BINDING; MECHANISMS; SYSTEM; THROMBOMODULIN; IDENTIFICATION; EXPRESSION; VESICLES; CELLS; MODE	The endothelial cell protein C receptor (EPCR) shares similar to20% sequence identity with the major histocompatibility complex class 1/CD1 family of molecules, accelerates the thrombin-thrombomodulin-dependent generation of activated protein C, a natural anticoagulant, binds to activated neutrophils, and can undergo translocation from the plasma membrane to the nucleus. Blocking protein C/activated protein C binding to the receptor inhibits not only protein C activation but the ability of the host to respond appropriately to bacterial challenge, exacerbating both the coagulant and inflammatory responses. To understand how EPCR accomplishes these multiple tasks, we solved the crystal structure of EPCR alone and in complex with the phospholipid binding domain of protein C. The structures were strikingly similar to CD1d. A tightly bound phospholipid resides in the groove typically involved in antigen presentation. The protein C binding site is outside this conserved groove and is distal. from the membrane-spanning domain. Extraction of the lipid resulted in loss of protein C binding, which could be restored by lipid reconstitution. CD1d augments the immune response by presenting glycolipid antigens. The EPCR structure is a model for how CD1d binds lipids and further suggests additional potential functions for EPCR in immune regulation, possibly including the anti-phospholipid syndrome.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Dept Crystallog, Oklahoma City, OK 73104 USA; NCI, SAIC, NIH, Frederick, MD 21702 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054502] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL54502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bevers EM, 1998, BIOL CHEM, V379, P973; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CHAM BE, 1976, J LIPID RES, V17, P176; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Esmon NL, 1997, THROMB HAEMOSTASIS, V78, P79; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Gu JM, 2000, BLOOD, V96, p814A; Hong SM, 1999, IMMUNOL REV, V169, P31, DOI 10.1111/j.1600-065X.1999.tb01304.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurosawa S, 2000, J IMMUNOL, V165, P4697, DOI 10.4049/jimmunol.165.8.4697; Liaw PCY, 2000, J BIOL CHEM, V275, P5447, DOI 10.1074/jbc.275.8.5447; Liaw PCY, 2001, J BIOL CHEM, V276, P8364, DOI 10.1074/jbc.M010572200; MANN KG, 1990, BLOOD, V76, P1; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; Shu F, 2000, FEBS LETT, V477, P208, DOI 10.1016/S0014-5793(00)01740-3; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	27	162	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24851	24854		10.1074/jbc.C200163200	http://dx.doi.org/10.1074/jbc.C200163200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12034704	hybrid			2022-12-25	WOS:000176747000003
J	Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF				Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF			Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter	ONCOGENE			English	Article						prostatic acid phosphatase; tissue-specific expression; promoter analysis; DNA injection	GENE-EXPRESSION; TRANSGENIC MICE; PRIMARY MYOBLASTS; ANTIGEN GENE; FACTOR-IX; ANDROGEN; CARCINOMA; THERAPY; PROTEIN; SPECIFICITY	Human prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen. The cellular form of PAcP functions as a neutral protein-tyrosine phosphatase, and is involved in regulating prostate cell growth. Although some information on the PAcP gene structure has been obtained, little is known regarding the cis- and traps-acting factors that regulate its expression. Due to the biological importance of PAcP, we investigated the regulation of its expression. A region upstream of the PAcP gene from -2899 to +87 base pairs was linked to the coding sequence of the chloramphenicol acetyltransferase (CAT) gene. Sequential deletions of the sequence between -2899 and -205 revealed that, in addition to the basic promoter, the region between -1258 and -779 represents a positive regulatory element. This -1258/-779 fragment could enhance the PAcP promoter activity in PC-3 and DU 145 human prostate cancer cells, but not in non-prostate cancer cells, including WI-38 lung diploid cells, A-431 epidermoid carcinoma cells, and HeLa cervix epitheloid carcinoma cells. Furthermore, this cis-element together with the promoter sequence could drive a high level of expression of green fluorescent protein (GFP) in PC-3 cells, but not in HeLa cells. The prostate-specific expression was further examined by injecting naked plasmid DNA into the prostate and the hamstring muscle of mice. The fluorescence pattern clearly showed that the level of GFP expression is consistently higher in prostate cells than in muscle cells of the intact animal. The data collectively indicate that region between -1258 and -779 is involved in governing the cell type-specific expression of the PAcP gene.	Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE USA; Univ Nebraska, Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA; Omaha VA Hosp, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA.	mlin@unmc.edu	Zelivianski, Stanislav/G-3043-2010		NCI NIH HHS [CA88184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; BANAS B, 1994, BBA-GENE STRUCT EXPR, V1217, P188, DOI 10.1016/0167-4781(94)90033-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes DE, 1998, PROSTATE, V35, P18, DOI 10.1002/(SICI)1097-0045(19980401)35:1<18::AID-PROS3>3.0.CO;2-D; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HENGGE UR, 1995, NAT GENET, V10, P161, DOI 10.1038/ng0695-161; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; PRIGOZY T, 1993, SOMAT CELL MOLEC GEN, V19, P111, DOI 10.1007/BF01233527; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROMAN M, 1992, SOMAT CELL MOLEC GEN, V18, P247, DOI 10.1007/BF01233861; Ruokonen M, 1996, BIOCHEM BIOPH RES CO, V218, P794, DOI 10.1006/bbrc.1996.0141; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFNER DL, 1995, LAB INVEST, V72, P283; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shan JD, 1997, ENDOCRINOLOGY, V138, P3764, DOI 10.1210/en.138.9.3764; SHARIEF FS, 1994, BIOCHEM MOL BIOL INT, V33, P561; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; VIRKKUNEN P, 1994, BIOCHEM BIOPH RES CO, V202, P49, DOI 10.1006/bbrc.1994.1892; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zelivianski S, 2000, BBA-GENE STRUCT EXPR, V1491, P123, DOI 10.1016/S0167-4781(00)00037-3; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200	38	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3696	3705		10.1038/sj.onc.1205471	http://dx.doi.org/10.1038/sj.onc.1205471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032838				2022-12-25	WOS:000175676000005
J	Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK				Wheeler, DL; Reddig, PJ; Dreckschmidt, NE; Leitges, M; Verma, AK			Protein kinase C delta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression	ONCOGENE			English	Article						tumor promotion; protein kinase C; transgenic mice; ornithine decarboxylase; skin carcinogenesis	PHORBOL ESTER; TRANSGENIC MICE; MOUSE SKIN; PROTEOLYTIC ACTIVATION; IRREVERSIBLE INHIBITOR; INDUCED APOPTOSIS; GENE-EXPRESSION; OKADAIC ACID; DBA/2 MICE; PROMOTION	Protein Kinase Cdelta (PKCdelta), a Call-independent, phospholipid-dependent serine/threonine kinase, is among the PKC isoforms expressed in mouse epidermis. We reported that FVB/N transgenic mice that overexpress (similar to eightfold) PKCdelta protein in basal epidermal cells are resistant to skin tumor formation by the 7,12-dimethylbenz(a)anthracene (DMBA)-initiation and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promotion protocol. However, despite being resistant to skin tumor promotion by TPA, PKCdelta transgenic mice elicited a 3-4-fold increase in TPA-induced epidermal ODC activity and putrescine levels than their wild-type littermates. PKCdelta was observed to be the key component of the TPA signal transduction pathways to the induction of mouse epidermal ODC activity. To determine if TPA-induced ODC activity and associated putrescine levels in PKCdelta transgenic mice contributed to PKCdelta-mediated suppression of skin tumor promotion by TPA, the irreversible inhibitor of ODC, alpha-difluoromethylornithine (DFMO), was used. PKCdelta transgenic mice and their wild-type littermates were initiated with 100 nmol DMBA and then promoted twice weekly with 5 nmol TPA. The experimental group was given 0.5% DFMO in their drinking water, while the control group was given tap water. After 25 weeks, the number of papillomas (> 2 mm) per mouse was counted. The DFMO treatment did not affect the skin tumor multiplicity of PKCdelta transgenic mice. These results indicate that PKCdelta-induced ODC activity is not involved in PKCdelta-mediated tumor suppression. Thus, the signaling pathways via PKCdelta to epidermal ODC induction and skin tumor suppression appear to be independent.	Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, Madison, WI 53792 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	University of Wisconsin System; University of Wisconsin Madison; University of North Carolina; University of North Carolina Chapel Hill; Max Planck Society	Verma, AK (corresponding author), Univ Wisconsin, Med Sch,Ctr Comprehens Canc, CSC, Dept Human Oncol, K4-532,, Madison, WI 53792 USA.	akverma@facstaff.wisc.edu	Leitges, Michael/AAN-1953-2021					ALDAZ CM, 1985, CANCER RES, V45, P2753; ARGYRIS TS, 1985, CRC CR REV TOXICOL, V14, P211, DOI 10.3109/10408448509037459; ASHENDEL CL, 1983, CANCER RES, V43, P4327; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DIGIOVANNI J, 1984, CARCINOGENESIS, V5, P1493, DOI 10.1093/carcin/5.11.1493; DRIEDGER PE, 1980, P NATL ACAD SCI-BIOL, V77, P567, DOI 10.1073/pnas.77.1.567; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FISCHER SM, 1988, CANCER RES, V48, P658; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GILMOUR SK, 1987, CANCER RES, V47, P1221; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HIRABAYASHI N, 1988, CARCINOGENESIS, V9, P2215, DOI 10.1093/carcin/9.12.2215; Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.0.CO;2-P; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; IMAMOTO A, 1992, CARCINOGENESIS, V13, P177, DOI 10.1093/carcin/13.2.177; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Jansen AP, 2001, CANCER RES, V61, P808; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOZA RA, 1991, CARCINOGENESIS, V12, P1619, DOI 10.1093/carcin/12.9.1619; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBrien TG, 1997, CANCER RES, V57, P2630; Otieno MA, 2000, CANCER RES, V60, P4391; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Rajesh D, 1999, MOL PHARMACOL, V56, P515, DOI 10.1124/mol.56.3.515; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Sawai H, 1997, J BIOL CHEM, V272, P2452; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VERMA AK, 1988, CANCER RES, V48, P1736; VERMA AK, 1992, CELLULAR AND MOLECULAR TARGETS FOR CHEMOPREVENTION, P207; VERMA AK, 1980, CARCINOGENESIS, V1, P271, DOI 10.1093/carcin/1.3.271; VERMA AK, 1986, CANCER RES, V46, P6149; VERMA AK, 1995, SKIN CANC MECH HUMAN, P383; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang HQ, 1999, J CELL SCI, V112, P3497; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	56	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3620	3630		10.1038/sj.onc.1205451	http://dx.doi.org/10.1038/sj.onc.1205451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032864				2022-12-25	WOS:000175793700013
J	Kunduzova, OR; Bianchi, P; Pizzinat, N; Escourrou, G; Seguelas, MH; Parini, A; Cambon, C				Kunduzova, OR; Bianchi, P; Pizzinat, N; Escourrou, G; Seguelas, MH; Parini, A; Cambon, C			Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion	FASEB JOURNAL			English	Article						monoamine oxidases; renal ischemia-reperfusion; pargyline; cell death; proliferation	HYDROGEN-PEROXIDE PRODUCTION; FREE-RADICAL PRODUCTION; LIPID-PEROXIDATION; KINASE ACTIVATION; PROTEIN-KINASES; STRESS; INJURY; REQUIREMENT; GENERATION; INHIBITION	Reactive oxygen species (ROS) contribute to the ischemia-reperfusion injury. In kidney, the intracellular sources of ROS during ischemia-reperfusion are still unclear. In the present study, we investigated the role of the catecholamine-degrading enzyme monoamine oxidases (MAOs) in hydrogen peroxide (H2O2) generation after reperfusion and their involvement in cell events leading to tissue injury and recovery. In a rat model of renal ischemia-reperfusion, we show concomitant MAO-dependent H2O2 production and lipid peroxidation in the early reperfusion period. Rat pretreatment with the irreversible MAO inhibitor pargyline resulted in the following: i) prevented H2O2 production and lipid peroxidation; ii) decreased tubular cell apoptosis and necrosis, measured by TUNEL staining and histomorphological criteria; and iii) increased tubular cell proliferation as determined by proliferating cell nuclear antigen expression. MAO inhibition also prevented Jun N-terminal kinase phosphorylation and promoted extracellular signal-regulated kinase activation, two mitogen-activated protein kinases described as a part of a "death" and "survival" pathway after ischemia-reperfusion. This work demonstrates the crucial role of MAOs in mediating the production of injurious ROS, which contribute to acute apoptotic and necrotic cell death induced by renal ischemia-reperfusion in vivo. Targeted inhibition of these oxidases could provide a new avenue for therapy to prevent renal damage and promote renal recovery after ischemia-reperfusion.	CHU Rangueil, Inst Louis Bugnard, INSERM, U388, F-31403 Toulouse 4, France; CHU Rangueil, Dept Pathol, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Cambon, C (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U388, IFR31,Bat L3, F-31403 Toulouse 4, France.	cambon@toulouse.inserm.fr		Kunduzova, Oksana/0000-0003-2503-6555; Parini, Angelo/0000-0002-9848-8838				Abe J, 2000, CIRC RES, V86, P607, DOI 10.1161/01.RES.86.6.607; ARUOMA OI, 1989, BIOCHEM J, V258, P617, DOI 10.1042/bj2580617; BEERI R, 1995, KIDNEY INT, V47, P1806, DOI 10.1038/ki.1995.249; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chatterjee PK, 2000, KIDNEY INT, V58, P658, DOI 10.1046/j.1523-1755.2000.00212.x; Chien CT, 2001, J AM SOC NEPHROL, V12, P973, DOI 10.1681/ASN.V125973; Chung H Y, 1999, J Nutr Health Aging, V3, P19; Ciccone CD, 1998, PHYS THER, V78, P313, DOI 10.1093/ptj/78.3.313; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; De Vecchi E, 1998, KIDNEY INT, V54, P857, DOI 10.1046/j.1523-1755.1998.00072.x; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; DiMari J, 1997, AM J PHYSIOL-RENAL, V272, pF292, DOI 10.1152/ajprenal.1997.272.3.F292; Elliott RM, 2000, FREE RADICAL BIO MED, V28, P1438, DOI 10.1016/S0891-5849(00)00271-9; Eschwege P, 1999, J UROLOGY, V162, P553, DOI 10.1016/S0022-5347(05)68626-0; FERNANDES MH, 1994, J NEURAL TRANSM-SUPP, P101; FERNANDEZ C, 1995, BRIT J CANCER, V72, P1194, DOI 10.1038/bjc.1995.485; Forbes JM, 2000, KIDNEY INT, V57, P2375, DOI 10.1046/j.1523-1755.2000.00097.x; FRANSSEN C, 1995, TRANSPLANT P, V27, P2880; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; Ishizuka S, 1999, BIOCHEM BIOPH RES CO, V254, P88, DOI 10.1006/bbrc.1998.9902; IWATA M, 1994, J AM SOC NEPHROL, V5, P1307; JOANNIDIS M, 1990, AM J PHYSIOL, V258, pF232, DOI 10.1152/ajprenal.1990.258.2.F232; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Malorni W, 1998, FEBS LETT, V426, P155, DOI 10.1016/S0014-5793(98)00315-9; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; NOHL H, 1993, FREE RADICAL RES COM, V18, P127, DOI 10.3109/10715769309147486; Offord E, 2000, Free Radic Res, V33 Suppl, pS5; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Pizzinat N, 1999, N-S ARCH PHARMACOL, V359, P428, DOI 10.1007/PL00005371; Pizzinat N, 1998, CURR OPIN NEPHROL HY, V7, P33, DOI 10.1097/00041552-199801000-00006; Pizzinat N, 1999, KIDNEY INT, V56, P1391, DOI 10.1046/j.1523-1755.1999.00673.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Safirstein R, 1998, SEMIN NEPHROL, V18, P519; SANDRI G, 1990, BIOCHIM BIOPHYS ACTA, V1035, P300, DOI 10.1016/0304-4165(90)90092-B; SCHUMER M, 1992, AM J PATHOL, V140, P831; SIMONSON SG, 1993, J CEREBR BLOOD F MET, V13, P125, DOI 10.1038/jcbfm.1993.15; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUZUKI T, 1995, PHARMACOLOGY, V50, P357, DOI 10.1159/000139304; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuji M, 2000, NEUROSCI LETT, V282, P41, DOI 10.1016/S0304-3940(00)00844-2; Vindis C, 2000, BIOCHEM BIOPH RES CO, V271, P181, DOI 10.1006/bbrc.2000.2524; Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x; Weight SC, 1996, BRIT J SURG, V83, P162, DOI 10.1002/bjs.1800830206; WERNER P, 1991, FEBS LETT, V280, P44, DOI 10.1016/0014-5793(91)80200-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; YU PH, 1986, RES COMMUN CHEM PATH, V51, P163; ZAGER RA, 1994, J AM SOC NEPHROL, V4, P1588	59	84	88	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1129	+		10.1096/fj.01-1008fje	http://dx.doi.org/10.1096/fj.01-1008fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039844				2022-12-25	WOS:000175973900003
J	De Genst, E; Areskoug, D; Decanniere, K; Muyldermans, S; Andersson, K				De Genst, E; Areskoug, D; Decanniere, K; Muyldermans, S; Andersson, K			Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; AMINO-ACIDS; FAB COMPLEX; IN-VITRO; ANTIBODY; BINDING; SEQUENCE; DISPLAY; ENERGY	We measured the influence of 14 mutations and 5 environmental variables (buffer perturbation) on the association and dissociation rate of a camel single domain antibody (cAb-Lys3) interacting with hen egg white lysozyme using a surface plasmon resonance-based biosensor. Based on this data set, we constructed quantitative predictive models for both kinetic (k(a) and k(d)) constants as for the affinity constant (K-d). Mutations, after parameterization by quantitative descriptors, and buffers were selected using multivariate experimental design. These models were able to predict the corresponding parameters of four new variants of cAb-Lys3. Moreover, the models provide insights to the important chemical aspects of the interacting residues, which are difficult to deduce from the crystal structure. Our approach provides useful physicochemical information of protein-protein interactions in general. The information obtained from this kind of analysis complements and goes beyond that of conventional methods like alanine scanning and substitution by closely related amino acids. The mathematical modeling may contribute to a rational approach in the optimization of bio-molecules of biotechnological interest.	Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium; Biacors AB, SE-75450 Uppsala, Sweden	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	De Genst, E (corresponding author), Free Univ Brussels VIB, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	edegenst@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575; Andersson, Karl/0000-0001-9141-9242				Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2; Andersson K, 2001, J MOL RECOGNIT, V14, P62, DOI 10.1002/1099-1352(200101/02)14:1<62::AID-JMR520>3.0.CO;2-T; BIACORE AB, 1998, BIAPPLICATIONS HDB; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Braden BC, 1998, IMMUNOL REV, V163, P45, DOI 10.1111/j.1600-065X.1998.tb01187.x; Burnett JC, 2001, PROTEINS, V42, P355, DOI 10.1002/1097-0134(20010215)42:3<355::AID-PROT60>3.0.CO;2-F; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; Choulier L, 2002, PROTEIN ENG, V15, P373, DOI 10.1093/protein/15.5.373; CHOWHURDY PS, 2002, NAT BIOTECHNOL, V17, P568; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P7981, DOI 10.1021/bi980148j; Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Dougan DA, 1998, PROTEIN ENG, V11, P65, DOI 10.1093/protein/11.1.65; Elcock AH, 2001, J MOL BIOL, V312, P885, DOI 10.1006/jmbi.2001.5009; Griffiths AD, 1998, CURR OPIN BIOTECH, V9, P102, DOI 10.1016/S0958-1669(98)80092-X; Gromiha MM, 1999, PROTEIN ENG, V12, P549, DOI 10.1093/protein/12.7.549; Haaland PD, 1989, EXPT DESIGN BIOTECHN; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HANSCH C, 1991, METHOD ENZYMOL, V202, P512; Hansch C., 1995, EXPLORING QSAR HYDRO; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; ITO W, 1993, J BIOL CHEM, V268, P16639; JACKSON T, 1992, PROTEIN ENG, V5, P343, DOI 10.1093/protein/5.4.343; Kabat EA, 1991, SEQUENCES PROTEINS I; Kurtzman AL, 2001, CURR OPIN BIOTECH, V12, P361, DOI 10.1016/S0958-1669(00)00228-7; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lee LP, 2001, PROTEIN SCI, V10, P362, DOI 10.1110/ps.40001; Lehmann M, 2001, CURR OPIN BIOTECH, V12, P371, DOI 10.1016/S0958-1669(00)00229-9; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Novotny J, 1997, J MOL BIOL, V268, P401, DOI 10.1006/jmbi.1997.0961; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rajpal A, 1998, PROTEIN SCI, V7, P1868, DOI 10.1002/pro.5560070903; Rognan D, 1999, J MED CHEM, V42, P4650, DOI 10.1021/jm9910775; ROVERO P, 1994, MOL IMMUNOL, V31, P549, DOI 10.1016/0161-5890(94)90042-6; Sandberg M, 1998, J MED CHEM, V41, P2481, DOI 10.1021/jm9700575; Taylor MG, 1998, PROTEIN SCI, V7, P1857, DOI 10.1002/pro.5560070902; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; Umetrics AB, 1999, MODDE 5 0 USER GUIDE; Vajda S, 1997, CURR OPIN STRUC BIOL, V7, P222, DOI 10.1016/S0959-440X(97)80029-2; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265	45	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29897	29907		10.1074/jbc.M202359200	http://dx.doi.org/10.1074/jbc.M202359200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048184	hybrid			2022-12-25	WOS:000177509300070
J	Fagerlund, R; Melen, K; Kinnunen, L; Julkunen, I				Fagerlund, R; Melen, K; Kinnunen, L; Julkunen, I			Arginine/lysine-rich nuclear localization signals mediate interactions between dimeric STATs and importin alpha 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MXB PROTEIN; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; BINDING; DOMAIN; GENE; ACTIVATION; BETA; DNA; TRANSLOCATION	Interferon stimulation results in tyrosine phosphorylation, dimerization, and nuclear import of STATs (signal transducers and activators of transcription). Proteins to be targeted into the nucleus usually contain nuclear localization signals (NLSs), which interact with importin alpha. Importin alpha binds to importin beta, which docks the protein complex to nuclear pores, and the complex translocates into the nucleus. Here we show that baculovirus-produced and -activated STAT1 homodimers and STAT1-STAT2 heterodimers directly interacted with importin alpha5 (NPI-1). This interaction was very stable and was dependent on lysines 410 and 413 of STAT1. Only STAT dimers that had two intact NLS elements, one in each monomer, were able to bind to importin alpha5. STAT-importin alpha5 complexes apparently consisted of two STAT and two importin a molecules. STAT NLS-dependent colocalization of importin alpha5 with STAT1 or STAT2 was seen in the nucleus of transfected cells. gamma-Activated sequence DNA elements efficiently inhibited STAT binding to importin alpha5 suggesting that the DNA and importin a binding sites are close to each other in STAT dimers. Our results demonstrate that specific NLSs in STATs mediate direct interactions of STAT dimers with importin alpha, which activates the nuclear import process.	Natl Publ Hlth Inst, Dept Microbiol, Lab Infect Dis Immunol, FIN-00300 Helsinki, Finland; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare	Fagerlund, R (corresponding author), Natl Publ Hlth Inst, Dept Microbiol, Lab Infect Dis Immunol, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Kinnunen, Leena/B-7059-2012	Kinnunen, Leena/0000-0001-8739-4812				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Cantell K, 1981, Methods Enzymol, V78, P29; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Mowen K, 1998, J BIOL CHEM, V273, P30073, DOI 10.1074/jbc.273.46.30073; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RONNI T, 1995, J IMMUNOL, V154, P2764; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sekimoto T, 1996, J BIOL CHEM, V271, P31017, DOI 10.1074/jbc.271.49.31017; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Summers M., 1986, TEX AGR EXP STN B, V1555, P1; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200	45	141	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30072	30078		10.1074/jbc.M202943200	http://dx.doi.org/10.1074/jbc.M202943200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048190	hybrid			2022-12-25	WOS:000177509300090
J	Gong, JS; Kobayashi, M; Hayashi, H; Zou, K; Sawamura, N; Fujita, SC; Yanagisawa, K; Michikawa, M				Gong, JS; Kobayashi, M; Hayashi, H; Zou, K; Sawamura, N; Fujita, SC; Yanagisawa, K; Michikawa, M			Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; HIGH-DENSITY-LIPOPROTEIN; CENTRAL-NERVOUS-SYSTEM; ALZHEIMER-DISEASE PATIENTS; HUMAN CEREBROSPINAL-FLUID; E EPSILON-4 ALLELE; CHOLESTEROL EFFLUX; CELLULAR CHOLESTEROL; DOMAIN INTERACTION; RAT ASTROCYTES	We have reported previously (Michikawa, M., Fan, Q.-W., Isobe, I., and Yanagisawa, K. (2000) J. Neurochem. 74, 1008-1016) that exogenously added recombinant human apolipoprotein E (apoE) promotes cholesterol release in an isoform-dependent manner. However, the molecular mechanism underlying this isoform-dependent promotion of cholesterol release remains undetermined. In this study, we demonstrate that the cholesterol release is mediated by endogenously synthesized and secreted apoE isoforms and clarify the mechanism underlying this apoE isoform-dependent cholesterol release using cultured astrocytes prepared from human apoE3 and apoE4 knock-in mice. Cholesterol and phospholipids were released into the culture media, resulting in the generation of two types of high density lipoprotein (HDL)-like particles; one was associated with apoE and the other with apoJ. The amount of cholesterol released into the culture media from the apoE3-expressing astrocytes was similar to2.5-fold greater than that from apoE4-expressing astrocytes. In contrast, the amount of apoE3 released in association with the HDL-like particles was similar to that of apoE4, and the sizes of the HDL-like particles released from apoE3- and apoE4-expressing astrocytes were similar. The molar ratios of cholesterol to apoE in the HDL fraction of the culture media of apoE3- and apoE4-expressing astrocytes were 250 +/- 6.0 and 119 +/- 5.1, respectively. These data indicate that apoE3 has an ability to generate similarly sized lipid particles with less number of apoE molecules, than apoE4, suggesting that apoE3-expressing astrocytes can supply more cholesterol to neurons than apoE4-expressing astrocytes. These findings provide a new insight into the issue concerning the putative alteration of apoE-related cholesterol metabolism in Alzheimer's disease.	Natl Inst Longev Sci, Dept Dementia Res, Aichi 4748522, Japan; Org Pharmaceut Safety & Res Japan, Tokyo 1000013, Japan; Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; JSPS, Tokyo 1028471, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Society for the Promotion of Science	Michikawa, M (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo Morioka, Aichi 4748522, Japan.		Sawamura, Naoya/K-1663-2018	Sawamura, Naoya/0000-0003-4753-1119				BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BORGHINI I, 1995, BBA-LIPID LIPID MET, V1255, P192, DOI 10.1016/0005-2760(94)00232-N; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Czyzewski K, 2001, ACTA NEUROBIOL EXP, V61, P21; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Fan QW, 2001, J AM AGING ASSOC, V24, P1, DOI 10.1007/s11357-001-0001-9; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; FORTE TM, 1993, J LIPID RES, V34, P317; GONG JS, 2002, IN PRESS J NEUROSCI; Hamanaka H, 2000, HUM MOL GENET, V9, P353, DOI 10.1093/hmg/9.3.353; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; Hayashi H, 2002, NEUROREPORT, V13, P383, DOI 10.1097/00001756-200203250-00004; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Isobe I, 1999, NEUROSCI LETT, V266, P129, DOI 10.1016/S0304-3940(99)00282-7; Isobe I, 2000, EXP NEUROL, V162, P51, DOI 10.1006/exnr.2000.7316; Ito J, 1999, J NEUROCHEM, V72, P2362, DOI 10.1046/j.1471-4159.1999.0722362.x; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Ji SR, 2002, J BIOL CHEM, V277, P6273, DOI 10.1074/jbc.M104146200; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; Kivipelto M, 2001, NEUROLOGY, V56, P1683, DOI 10.1212/WNL.56.12.1683; Koudinov AR, 2001, FASEB J, V15, P1858, DOI 10.1096/fj.00-0815fje; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MCCALL MR, 1988, J LIPID RES, V29, P1127; Mendez AJ, 1997, J LIPID RES, V38, P1807; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; Michikawa M, 1999, J NEUROCHEM, V72, P2278, DOI 10.1046/j.1471-4159.1999.0722278.x; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Mori T, 2001, J NEUROPATH EXP NEUR, V60, P778, DOI 10.1093/jnen/60.8.778; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Mulder M, 1998, ALZ DIS ASSOC DIS, V12, P198, DOI 10.1097/00002093-199809000-00012; Nakai M, 1996, NEUROSCI LETT, V211, P41, DOI 10.1016/0304-3940(96)12716-6; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; ROTH GS, 1995, TRENDS NEUROSCI, V18, P203, DOI 10.1016/0166-2236(95)93902-A; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; SEGREST JP, 1992, J LIPID RES, V33, P141; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	69	168	180	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29919	29926		10.1074/jbc.M203934200	http://dx.doi.org/10.1074/jbc.M203934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042316	hybrid			2022-12-25	WOS:000177509300072
J	Srinivasan, KN; Sivaraja, V; Huys, I; Sasaki, T; Cheng, B; Kumar, TKS; Sato, K; Tytgat, J; Yu, C; San, BCC; Ranganathan, S; Bowie, HJ; Kini, RM; Gopalakrishnakone, P				Srinivasan, KN; Sivaraja, V; Huys, I; Sasaki, T; Cheng, B; Kumar, TKS; Sato, K; Tytgat, J; Yu, C; San, BCC; Ranganathan, S; Bowie, HJ; Kini, RM; Gopalakrishnakone, P			kappa-hefutoxin1, a novel toxin from the scorpion Heterometrus fulvipes with unique structure and function - Importance of the functional diad in potassium channel selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; KAPPA-CONOTOXIN PVIIA; K+-CHANNELS; 3-DIMENSIONAL STRUCTURE; RYANODINE RECEPTORS; SECONDARY STRUCTURE; PROTEIN STRUCTURES; DENDROTOXIN-K; SNAKE TOXINS	An important and exciting challenge in the post-genomic era is to understand the functions of newly discovered proteins based on their structures. The main thrust is to find the common structural motifs that contribute to specific functions. Using this premise, here we report the purification, solution NMR, and functional characterization of a novel class of weak potassium channel toxins from the venom of the scorpion Heterometrus fulvipes. These toxins, kappa-hefutoxin1 and kappa-hefutoxin2, exhibit no homology to any known toxins. NMR studies indicate that kappa-hefutoxin1 adopts a unique three-dimensional fold of two parallel helices linked by two disulfide bridges without any beta-sheets. Based on the presence of the functional diad (Tyr(5)/Lys(19)) at a distance (6.0 +/- 1.0 Angstrom) comparable with other potassium channel toxins, we hypothesized its function as a potassium channel toxin. kappa-Hefutoxin 1 not only blocks the voltage-gated K+-channels, Kv1.3 and Kv1.2, but also slows the activation kinetics of Kv1.3 currents, a novel feature of kappa-hefutoxin 1, unlike other scorpion toxins, which are considered solely pore blockers. Alanine mutants (Y5A, K19A, and Y5A/K19A) failed to block the channels, indicating the importance of the functional diad.	Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, Singapore 117597, Singapore; DSO Natl Labs, Singapore 118230, Singapore; Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia; Fukuoka Womens Univ, Higashi Ku, Fukuoka 8138529, Japan; Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 119260, Singapore; Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Fac Med, Bioinformat Ctr, Singapore 119260, Singapore; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan; Catholic Univ Louvain, Toxicol Lab, B-3000 Louvain, Belgium; Natl Tsing Hua Univ, Dept Chem, Hsinchu, Taiwan	National University of Singapore; University of Adelaide; National University of Singapore; National University of Singapore; National University of Singapore; Universite Catholique Louvain; National Tsing Hua University	Gopalakrishnakone, P (corresponding author), Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, 4 Med Dr, Singapore 117597, Singapore.	antgopal@nus.edu.sg	Kumar, Suresh Thallapuranam/R-5606-2016; Tytgat, Jan/F-1560-2010; Kumar, Dr Suresh/HHZ-2615-2022; Huys, Isabelle/M-8673-2016; KUMAR, P. SURESH/AAT-8951-2020; Kini, Manjunatha/H-8029-2012	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; Kumar, Dr Suresh/0000-0002-2539-6553; KUMAR, P. SURESH/0000-0003-3222-2604; Tytgat, Jan/0000-0003-1778-6022; Kini, Manjunatha/0000-0002-6100-3251; Ranganathan, Shoba/0000-0002-8290-813X				Batista CVF, 2000, FEBS LETT, V486, P117, DOI 10.1016/S0014-5793(00)02253-5; BERNDT KD, 1993, J MOL BIOL, V234, P735, DOI 10.1006/jmbi.1993.1623; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BRIAN R, 1996, FEBS LETT, V383, P26; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dauplais M, 1995, BIOCHEMISTRY-US, V34, P16563, DOI 10.1021/bi00051a004; DEBIN JA, 1993, AM J PHYSIOL, V264, pC361, DOI 10.1152/ajpcell.1993.264.2.C361; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; GOPALAKRISHNAKONE P, 1995, LAB ANIM, V29, P456, DOI 10.1258/002367795780740050; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Gwee MCE, 1996, J TOXICOL-TOXIN REV, V15, P37, DOI 10.3109/15569549609080106; Hu SH, 1998, BIOCHEMISTRY-US, V37, P11425, DOI 10.1021/bi9806549; IlKim J, 1997, BIOCHEM BIOPH RES CO, V230, P133, DOI 10.1006/bbrc.1996.5900; JOHNSON BA, 1994, BIOCHEMISTRY-US, V33, P15061, DOI 10.1021/bi00254a015; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; LORET EP, 1991, BIOCHEMISTRY-US, V30, P633, DOI 10.1021/bi00217a007; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PILLET L, 1993, J BIOL CHEM, V268, P909; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6; RAMANAIAH M, 1990, BIOCHEM INT, V20, P301; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Savarin P, 1998, BIOCHEMISTRY-US, V37, P5407, DOI 10.1021/bi9730341; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; SUKUMAR M, 1995, PROTEIN SCI, V4, P1718, DOI 10.1002/pro.5560040907; Takahashi H, 2000, J MOL BIOL, V297, P771, DOI 10.1006/jmbi.2000.3609; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; VENKAIAH B, 1983, BIOCHEM INT, V7, P235; VENKATESWARLU D, 1977, INDIAN J EXP BIOL, V15, P1056; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886	47	112	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30040	30047		10.1074/jbc.M111258200	http://dx.doi.org/10.1074/jbc.M111258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034709	hybrid, Green Submitted			2022-12-25	WOS:000177509300086
J	Lim, D; Poole, K; Strynadka, NCJ				Lim, D; Poole, K; Strynadka, NCJ			Crystal structure of the MexR repressor of the mexRAB-oprM multidrug efflux operon of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-ANTIBIOTIC-RESISTANCE; CAP-DNA COMPLEX; ESCHERICHIA-COLI; EXPRESSION; SYSTEM; PUMPS; MARR; REGULATOR; GENE; OVEREXPRESSION	MexR is a member of the MarR family of bacterial transcriptional regulators and is the repressor for the MexAB-OprM operon, which encodes a tripartite multidrug efflux system in Pseudomonas aeruginosa. Mutations in MexR result in increased resistance to multiple antibiotics due to overexpression of this efflux system. We have determined the crystal structure of MexR to 2.1-Angstrom resolution in the absence of effector. The four copies of the MexR dimer in the asymmetric unit are observed in multiple conformations. Analysis of these conformational states in the context of a model of the MexR-DNA complex proposed in this study suggests that an effector-induced conformational change may inhibit DNA binding by reducing the spacing of the DNA binding domains. The inhibited conformation is exhibited by one of the four MexR dimers, which contains an ordered C-terminal tail from a neighboring monomer inserted between its DNA binding domains and which we propose may resemble the MexR-effector complex. Our results indicate that MexR may differ from the other described member of this family, MarR, in the nature of its effector, mode of DNA binding, and mechanism of regulation.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	University of British Columbia; Queens University - Canada	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca						Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067, DOI 10.1128/AAC.41.10.2067; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 1999, J BACTERIOL, V181, P4669, DOI 10.1128/JB.181.15.4669-4672.1999; Alekshun MN, 1999, TRENDS MICROBIOL, V7, P410, DOI 10.1016/S0966-842X(99)01589-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Evans K, 2001, J BACTERIOL, V183, P807, DOI 10.1128/JB.183.3.807-812.2001; Evans K, 1998, J BACTERIOL, V180, P5443, DOI 10.1128/JB.180.20.5443-5447.1998; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; GOTOH N, 1995, ANTIMICROB AGENTS CH, V39, P2567, DOI 10.1128/AAC.39.11.2567; Hancock REW, 1998, CLIN INFECT DIS, V27, pS93, DOI 10.1086/514909; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; Kohler T, 1999, CELL MOL LIFE SCI, V56, P771, DOI 10.1007/s000180050024; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li XZ, 1998, ANTIMICROB AGENTS CH, V42, P399; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x; Mine T, 1999, ANTIMICROB AGENTS CH, V43, P415, DOI 10.1128/AAC.43.2.415; Nikaido H, 1998, CLIN INFECT DIS, V27, pS32, DOI 10.1086/514920; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Pearson JP, 1999, J BACTERIOL, V181, P1203, DOI 10.1128/JB.181.4.1203-1210.1999; Poole K, 1996, ANTIMICROB AGENTS CH, V40, P2021, DOI 10.1128/AAC.40.9.2021; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; Poole K, 1996, MOL MICROBIOL, V21, P713, DOI 10.1046/j.1365-2958.1996.281397.x; Quinn JP, 1998, CLIN INFECT DIS, V27, pS117, DOI 10.1086/514912; Saito K, 1999, FEMS MICROBIOL LETT, V179, P67, DOI 10.1016/S0378-1097(99)00394-8; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Srikumar R, 1997, J BACTERIOL, V179, P7875, DOI 10.1128/jb.179.24.7875-7881.1997; Srikumar R, 1998, ANTIMICROB AGENTS CH, V42, P65, DOI 10.1128/AAC.42.1.65; Srikumar R, 2000, J BACTERIOL, V182, P1410, DOI 10.1128/JB.182.5.1410-1414.2000; SULAVIK MC, 1995, MOL MED, V1, P436, DOI 10.1007/BF03401581; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; YAP K, 1998, INTERHLX PROGRAM	44	104	109	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29253	29259		10.1074/jbc.M111381200	http://dx.doi.org/10.1074/jbc.M111381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034710	hybrid			2022-12-25	WOS:000177342600114
J	Nehrke, K; Melvin, JE				Nehrke, K; Melvin, JE			The NHX family of Na+-H+ exchangers in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TARGETED DISRUPTION; ANTIPORTER GENE; SODIUM; ISOFORM; YEAST; TOLERANCE; SECRETION; CELLS	Na+-H+ exchangers prevent cellular acidification by catalyzing the electroneutral exchange of extracellular sodium for an intracellular proton. To date, seven Na+-H+ exchangers have been identified in mammals, and although several members of this family have been extensively studied and characterized, it is clear that there are major gaps in our understanding with respect to the remaining family members. To initiate the study of Na+-H+ exchangers in a genomically defined and genetically tractable model system, we have cloned the complete cDNAs and analyzed splice site variation for nine putative homologs from the nematode Caenorhabditis elegans, which we have called NHX-1 through -9. The expression patterns and cellular distributions of the NHX proteins were determined using transcriptional and translational promoter-transgene fusion constructs to green fluorescent protein. Four of the putative exchangers were expressed at the cell surface, whereas five of the exchangers were associated with the membranes of intracellular organelles. Individual isoforms were expressed exclusively in the intestine, seam cells, hypodermal cells of the main body syncytium, and the excretory cell, all of which are polarized epithelial cells, suggesting a role for these proteins in epithelial membrane transport processes in the nematode. Other isoforms were found to express either ubiquitously or in a pan-neural pattern, suggesting a more conserved role in cell pH regulation or neuronal function. Finally, we show that recombinant NHX-4, the ubiquitous nematode Na+-H+ exchanger, mediates Na+-dependent pH recovery after intracellular acidification. NHX-4 has a K-a for Na+ of similar to32 mM, is not Cl--dependent, and is relatively insensitive to the amiloride analog EIPA.	Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Nehrke, K (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	keith_nehrke@urmc.rochester.edu		Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ahearn GA, 2001, J EXP ZOOL, V289, P232, DOI 10.1002/1097-010X(20010401/30)289:4<232::AID-JEZ4>3.0.CO;2-T; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Attaphitaya S, 1999, J BIOL CHEM, V274, P4383, DOI 10.1074/jbc.274.7.4383; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Nehrke K, 2000, AM J PHYSIOL-CELL PH, V279, pC2052, DOI 10.1152/ajpcell.2000.279.6.C2052; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; Nguyen HV, 2000, J PHYSIOL-LONDON, V523, P139, DOI 10.1111/j.1469-7793.2000.t01-2-00139.x; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Park K, 2001, J BIOL CHEM, V276, P27042, DOI 10.1074/jbc.M102901200; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006-3495(00)76468-X; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; TSE CM, 1993, J BIOL CHEM, V268, P11917; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WANG Z, 1993, J BIOL CHEM, V268, P11925; WASER M, 1992, J BIOL CHEM, V267, P5396	39	57	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29036	29044		10.1074/jbc.M203200200	http://dx.doi.org/10.1074/jbc.M203200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021279	hybrid			2022-12-25	WOS:000177342600090
J	Jacobsen, BM; Richer, JK; Schittone, SA; Horwitz, KB				Jacobsen, BM; Richer, JK; Schittone, SA; Horwitz, KB			New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORM-A; B-RECEPTORS; TRANSCRIPTIONAL AGONISTS; HORMONE RECEPTORS; MENSTRUAL-CYCLE; TRANSGENIC MICE; MESSENGER-RNA; MAMMARY-GLAND; EXPRESSION; PHOSPHORYLATION	All known progesterone target cells coexpress two functionally different progesterone receptor (PR) isoforms: 120-kDa B-receptors (PR-Bm) and N-terminally truncated, 94-kDa A-receptors (PR-A). Their ratio varies in normal and malignant tissues. In human breast cancer cells, homodimers of progesterone-occupied PR-A or PR-B regulate different gene subsets. To study PR homo- and heterodimers, we constructed breast cancer cell lines in which isoform expression is controlled by an inducible system. PR-negative cells or cells that stably express one or the other isoform were used to construct five sets of cells: (i) PR-negative control cells (Y iNull), (ii) inducible PR-A cells (Y iA), (iii) inducible PR-B cells (Y iB), (iv) stable PR-B plus inducible PR-A cells (B iA), and (v) stable PR-A plus inducible PR-B cells (A iB). Expression levels of each isoform and/or the PR-A/PR-B ratios could be tightly controlled by the dose of inducer as demonstrated by immunoblotting and transcription studies. Induced PRs underwent normal progestin-dependent phosphorylation and down-regulation and regulated exogenous promoters as well as endogenous gene expression. Transcription of exogenous promoters was dependent on the PR-A/PR-B ratio, whereas transcription of endogenous genes was more complex. Finally, we have described several genes that are regulated by induced PR-A even in the absence of ligand.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jacobsen, BM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA.			Jacobsen, Britta/0000-0001-8234-1690; Horwitz, Kathryn/0000-0001-7402-6455	NCI NIH HHS [CA26869, CA90073 F32] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026869, F32CA090073, R37CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbeitman MN, 2000, CELL, V101, P67, DOI 10.1016/S0092-8674(00)80624-8; Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; Bai WL, 1997, J BIOL CHEM, V272, P10457; Bamberger AM, 2000, HORM RES, V54, P32; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Camacho-Arroyo I, 2000, J NEURO-ONCOL, V49, P1, DOI 10.1023/A:1006412000726; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Fujimoto J, 1997, J STEROID BIOCHEM, V62, P449, DOI 10.1016/S0960-0760(97)00057-5; Galsgaard ED, 1999, J BIOL CHEM, V274, P18686, DOI 10.1074/jbc.274.26.18686; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; GRAHAM JD, 1995, CANCER RES, V55, P5063; GRAHAM ML, 1989, CANCER RES, V49, P3934; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; Horwitz K B, 1985, Recent Prog Horm Res, V41, P249; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; HORWITZ KB, 1985, DNA-J MOLEC CELL BIO, V4, P451, DOI 10.1089/dna.1985.4.451; HORWITZ KB, 1982, CELL, V28, P633, DOI 10.1016/0092-8674(82)90218-5; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Hu ZZ, 1999, J CLIN ENDOCR METAB, V84, P1153, DOI 10.1210/jc.84.3.1153; Hu ZZ, 1998, J BIOL CHEM, V273, P26225, DOI 10.1074/jbc.273.40.26225; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Mangal RK, 1997, J STEROID BIOCHEM, V63, P195, DOI 10.1016/S0960-0760(97)00119-2; Mani SK, 1996, MOL ENDOCRINOL, V10, P1728, DOI 10.1210/me.10.12.1728; McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; Mote PA, 2002, BREAST CANCER RES TR, V72, P163, DOI 10.1023/A:1014820500738; Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORMANDY CJ, 1992, DNA CELL BIOL, V11, P721, DOI 10.1089/dna.1992.11.721; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Revelli A, 1998, ENDOCR REV, V19, P3, DOI 10.1210/er.19.1.3; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Saez E, 2000, P NATL ACAD SCI USA, V97, P14512, DOI 10.1073/pnas.260499497; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; Thormeyer D, 1999, J STEROID BIOCHEM, V68, P163, DOI 10.1016/S0960-0760(99)00019-9; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577	57	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27793	27800		10.1074/jbc.M202584200	http://dx.doi.org/10.1074/jbc.M202584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021276	hybrid			2022-12-25	WOS:000177189800028
J	Pahlman, IL; Larsson, C; Averet, N; Bunoust, O; Boubekeur, S; Gustafsson, L; Rigoulet, M				Pahlman, IL; Larsson, C; Averet, N; Bunoust, O; Boubekeur, S; Gustafsson, L; Rigoulet, M			Kinetic regulation of the mitochondrial glycerol-3-phosphate dehydrogenase by the external NADH dehydrogenase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOSTAT CULTURES; PRODUCT FORMATION; CYTOSOLIC NADH; METABOLISM; TRANSHYDROGENASE; OXIDATION; GROWTH; YEASTS; GENES	In the yeast Saccharomyces cerevisiae, the two most important systems for conveying excess cytosolic NADH to the mitochondrial respiratory chain are external NADH dehydrogenase (Nde1p/Nde2p) and the glycerol-3-phosphate dehydrogenase shuttle. In the latter system, NADH is oxidized to NAD+ and dihydroxyacetone phosphate is reduced to glycerol 3-phosphate by the cytosolic Gpd1p; glycerol 3-phosphate gives two electrons to the respiratory chain via mitochondrial glycerol-3-phosphate dehydrogenase (Gut2p)-regenerating dihydroxyacetone phosphate. Both Nde1p/Nde2p and Gut2p are located in the inner mitochondrial membrane with catalytic sites facing the intermembranal space. In this study, we showed kinetic interactions between these two enzymes. First, deletion of either one of the external dehydrogenases caused an increase in the efficiency of the remaining enzyme. Second, the activation of NADH dehydrogenase inhibited the Gut2p in such a manner that, at a saturating concentration of NADH, glycerol 3-phosphate is not used as respiratory substrate. This effect was not a consequence of a direct action of NADH on Gut2p activity because both NADIR dehydrogenase and its substrate were needed for Gut2p inhibition. This kinetic regulation of the activity of an enzyme as a function of the rate of another having a similar physiological function may be allowed by their association into the same supramolecular complex in the inner membrane. The physiological consequences of this regulation are discussed.	Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Gothenburg, Lundberg Lab, Dept Cellular & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden; Chalmers, Dept Mol Biotechnol, Lundberg Lab, SE-40530 Gothenburg, Sweden	UDICE-French Research Universities; Universite de Bordeaux; University of Gothenburg; Chalmers University of Technology	Rigoulet, M (corresponding author), Univ Bordeaux 2, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	Michel.Rigoulet@ibgc.u-bordeaux2.fr		Larsson, Christer/0000-0002-0721-5405				Albers E, 1996, APPL ENVIRON MICROB, V62, P3187, DOI 10.1128/AEM.62.9.3187-3195.1996; Anderlund M, 1999, APPL ENVIRON MICROB, V65, P2333; Averet N, 1998, MOL CELL BIOCHEM, V184, P67, DOI 10.1023/A:1006830810440; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; BEAUVOIT B, 1993, EUR J BIOCHEM, V214, P163, DOI 10.1111/j.1432-1033.1993.tb17909.x; BERGMEYER HU, 1988, METHOD ENZYMAT AN, V6, P566; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BRUINENBERG PM, 1985, ARCH MICROBIOL, V142, P302, DOI 10.1007/BF00693408; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI, P14; Costenoble R, 2000, YEAST, V16, P1483, DOI 10.1002/1097-0061(200012)16:16<1483::AID-YEA642>3.0.CO;2-K; Grandier-Vazeille X, 2001, BIOCHEMISTRY-US, V40, P9758, DOI 10.1021/bi010277r; Guerin B, 1979, Methods Enzymol, V55, P149; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; LENAZ G, 1978, MOL CELL BIOCHEM, V22, P3; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; NORDSTROM K, 1968, J I BREWING, V74, P429, DOI 10.1002/j.2050-0416.1968.tb03154.x; Overkamp KM, 2000, J BACTERIOL, V182, P2823, DOI 10.1128/JB.182.10.2823-2830.2000; Pahlman IL, 2001, YEAST, V18, P611, DOI 10.1002/yea.709; RONNOW B, 1993, YEAST, V9, P1121, DOI 10.1002/yea.320091013; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; [No title captured]	22	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27991	27995		10.1074/jbc.M204079200	http://dx.doi.org/10.1074/jbc.M204079200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032156	hybrid			2022-12-25	WOS:000177189800052
J	Mackey, AD; Henderson, GN; Gregory, JF				Mackey, AD; Henderson, GN; Gregory, JF			Enzymatic hydrolysis of pyridoxine-5 '-beta-D-glucoside is catalyzed by intestinal lactase-phlorizin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY BETA-GLUCOSIDASE; PHLORIZIN HYDROLASE; METABOLIC UTILIZATION; VITAMIN-B-6 STATUS; PYRIDOXINE; RAT; BIOAVAILABILITY; GLUCOAMYLASE; PURIFICATION; MEMBRANE	An obligatory step in the mammalian nutritional utilization of pyridoxine-5'-beta-D-glucoside (PNG) is the intestinal hydrolysis of its beta-glucosidic bond that releases pyridoxine (PN). This laboratory previously reported the purification and partial characterization of a novel cytosolic enzyme, designated PNG hydrolase, which hydrolyzed PNG. An investigation of the subcellular distribution of intestinal PNG hydrolysis found substantial hydrolytic activity in the total membrane fraction, of which 40-50% was localized to brush border membrane. To investigate the possible role of a brush border beta-glucosidase in the hydrolysis of PNG, lactase phlorizin hydrolase (LPH) was purified from rat small intestinal mucosa. LPH hydrolyzed PNG with a K-m of 1.0 +/- 0.1 mm, a V-max of 0.11 +/- 0.01 mumol/min.mg protein, and a k(cat) of 1.0 s(-1). LPH-catalyzed PNG hydrolysis was inhibited by glucose, lactose, and cellobiose but not by PN. Specific blockage of the phlorizin hydrolase site of LPH using 2',4'-dintrophenyl-2-fluoro-2-deoxy-13-D-glucopyranoside did not reduce PNG hydrolysis. Evidence of transferase activity was also obtained. Reaction mixtures containing LPH, PNG, and lactose yielded the formation of another PN derivative that was identified as a pyridoxine disaccharide. These results indicate that LPH may play an important role in the bioavailability of PNG, but further characterization is needed to assess its physiological function.	Univ Florida, Inst Food & Agr Sci, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; Univ Florida, Coll Med, Dept Med, Div Endocrinol & Metab, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Gregory, JF (corresponding author), Univ Florida, Inst Food & Agr Sci, Dept Food Sci & Human Nutr, POB 110370, Gainesville, FL 32611 USA.	jfgy@ufl.edu		Gregory, Jesse/0000-0002-9976-2085	NCRR NIH HHS [RR 00082] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07667, DK 37481] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037481, T32DK007667] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDON MB, 1989, AM J CLIN NUTR, V50, P1050, DOI 10.1093/ajcn/50.5.1050; Arribas JCD, 2000, EUR J BIOCHEM, V267, P6996, DOI 10.1046/j.1432-1327.2000.01784.x; BANKS MA, 1994, J NUTR BIOCHEM, V5, P238, DOI 10.1016/0955-2863(94)90042-6; BANKS MA, 1994, J NUTR, V124, P406, DOI 10.1093/jn/124.3.406; BIRKENMEIER E, 1974, BIOCHIM BIOPHYS ACTA, V350, P100, DOI 10.1016/0005-2744(74)90207-1; Breitmeier D, 1997, ARCH BIOCHEM BIOPHYS, V346, P7, DOI 10.1006/abbi.1997.0274; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; Day AJ, 2000, FEBS LETT, V468, P166, DOI 10.1016/S0014-5793(00)01211-4; DUDLEY MA, 1992, J PEDIATR GASTR NUTR, V15, P260, DOI 10.1097/00005176-199210000-00006; FREUND JN, 1991, ENZYME, V45, P71, DOI 10.1159/000468868; GILBERT JA, 1992, J NUTR, V122, P1029, DOI 10.1093/jn/122.4.1029; GREGORY JF, 1991, J NUTR, V121, P177, DOI 10.1093/jn/121.2.177; Gregory JF, 1997, METHOD ENZYMOL, V280, P58; GREGORY JF, 1993, ACS SYM SER, V533, P113; Hansen CM, 1996, J NUTR, V126, P2512, DOI 10.1093/jn/126.10.2512; Harlow E, 1988, ANTIBODIES LABORATOR, P471; INK SL, 1986, J AGR FOOD CHEM, V34, P857, DOI 10.1021/jf00071a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McMahon LG, 1997, J BIOL CHEM, V272, P32025, DOI 10.1074/jbc.272.51.32025; MENARD MP, 1983, J NUTR, V113, P1434, DOI 10.1093/jn/113.7.1434; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NAKANO H, 1995, J NUTR, V125, P2751; Nakano H, 1997, J NUTR, V127, P1508, DOI 10.1093/jn/127.8.1508; RIVERASAGREDO A, 1992, EUR J BIOCHEM, V209, P415, DOI 10.1111/j.1432-1033.1992.tb17304.x; SCHLEGEL.S, 1972, BIOCHIM BIOPHYS ACTA, V258, P506, DOI 10.1016/0005-2744(72)90242-2; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; SKOVBJERG H, 1981, EUR J BIOCHEM, V114, P653, DOI 10.1111/j.1432-1033.1981.tb05193.x; TRUMBO PR, 1990, P SOC EXP BIOL MED, V195, P240; TRUMBO PR, 1988, J NUTR, V118, P1336, DOI 10.1093/jn/118.11.1336; TRUMBO PR, 1988, J NUTR, V118, P170, DOI 10.1093/jn/118.2.170; WACKER H, 1992, J BIOL CHEM, V267, P18744; Williams SJ, 2000, CARBOHYD RES, V327, P27, DOI 10.1016/S0008-6215(00)00041-0; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; ZHANG ZM, 1993, J NUTR, V123, P85, DOI 10.1093/jn/123.1.85	36	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26858	26864		10.1074/jbc.M201774200	http://dx.doi.org/10.1074/jbc.M201774200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023280	hybrid			2022-12-25	WOS:000177055900022
J	Pratico, D; Uryu, K; Sung, S; Tang, S; Trojanowski, JQ; Lee, VMY				Pratico, D; Uryu, K; Sung, S; Tang, S; Trojanowski, JQ; Lee, VMY			Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice	FASEB JOURNAL			English	Article						Alzheimer's disease; Tg2576 transgenic animal model; lipid peroxidation; isoprostanes; amyloid beta protein	ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; DRINKING-WATER; MOUSE MODEL; RISK; APOPTOSIS	Epidemiological studies have implicated aluminum (Al) exposure in the pathogenesis of Alzheimer's disease (AD); however, other studies have failed to confirm these results. Oxidative stress is a feature of AD, and Al can exacerbate oxidative events. This biological property has been suggested as a possible mechanism by which this metal could influence the onset and/or evolution of the disease. To test this hypothesis, we fed transgenic mice that over express human amyloid precursor protein (Tg2576) with a diet enriched in Al and measured isoprostane levels, sensitive and specific markers of in vivo oxidative stress, as well as amyloid beta peptide formation and deposition. Here, we show an increase in brain isoprostane levels that correlated with increased amyloid beta levels and accelerated plaque deposition in Tg2576 mice but not in wildtype (WT) littermates fed with high dietary Al. Significantly, these in vivo effects of Al were reversed by vitamin E, as judged by a reduction of isoprostane production, amyloid beta levels, and plaque deposition. These results indicate that dietary Al can modulate in vivo AD-like amyloidosis in Tg2576 by increasing brain oxidative stress.	Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Pratico, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, BRB2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020					Bondy SC, 1998, NEUROTOXICOLOGY, V19, P65; Campbell A, 2000, CELL MOL BIOL, V46, P721; Clark CM, 2000, NEURODEGENERATIVE DE, P95, DOI [DOI 10.1155/2016/258, 10.1155/2016/258]; Flaten TP, 2001, BRAIN RES BULL, V55, P187, DOI 10.1016/S0361-9230(01)00459-2; Ghribi O, 2001, BRAIN RES, V903, P66, DOI 10.1016/S0006-8993(01)02406-4; Guo GW, 2001, BRAIN RES, V888, P221, DOI 10.1016/S0006-8993(00)03057-2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; MCLACHLAN DRC, 1995, ENVIRONMETRICS, V6, P233, DOI 10.1002/env.3170060303; McLachlan DRC, 1996, NEUROLOGY, V46, P401, DOI 10.1212/WNL.46.2.401; Nourhashemi F, 2000, AM J CLIN NUTR, V71, p643S; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; Rondeau V, 2000, AM J EPIDEMIOL, V152, P59, DOI 10.1093/aje/152.1.59; SHARPE WE, 1985, ENV HLTH PERSPECT, V962, P196; Solomon B, 2001, BRAIN RES BULL, V55, P253, DOI 10.1016/S0361-9230(01)00466-X; Tsunoda M, 1999, ARCH TOXICOL, V73, P419, DOI 10.1007/s002040050630; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; WALTON J, 1995, NEUROTOXICOLOGY, V16, P187	23	210	218	4	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1138	+		10.1096/fj.02-0012fje	http://dx.doi.org/10.1096/fj.02-0012fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039845				2022-12-25	WOS:000175973900001
J	Diacovich, L; Peiru, S; Kurth, D; Rodriguez, E; Podesta, F; Khosla, C; Gramajo, H				Diacovich, L; Peiru, S; Kurth, D; Rodriguez, E; Podesta, F; Khosla, C; Gramajo, H			Kinetic and structural analysis of a new group of acyl-CoA carboxylases found in Streptomyces coelicolor A3(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ESCHERICHIA-COLI; CARRIER PROTEIN; BIOTIN; ACID; COMPLEX; PURIFICATION; POLYKETIDES; METABOLISM; EXPRESSION	Two acyl-CoA carboxylases from Streptomyces coelicolor have been successfully reconstituted from their purified components. Both complexes shared the same biotinylated alpha subunit, AccA2. The beta and the epsilon subunits were specific from each of the complexes; thus, for the propionyl-CoA carboxylase complex the beta and epsilon components are PccB and PccE, whereas for the acetyl-CoA carboxylase complex the components are AccB and AccE. The two complexes showed very low activity in the absence of the corresponding epsilon subunits; addition of PccE or AccE dramatically increased the specific activity of the enzymes. The kinetic properties of the two acyl-CoA carboxylases showed a clear difference in their substrate specificity. The acetyl-CoA carboxylase was able to carboxylate acetyl-, propionyl-, or butyryl-CoA with approximately the same specificity. The propionyl-CoA carboxylase could not recognize acetyl-CoA as a substrate, whereas the specificity constant for propionyl-CoA was 2-fold higher than for butyryl-CoA. For both enzymes the epsilon subunits were found to specifically interact with their carboxyltransferase component forming a beta-epsilon sub-complex; this appears to facilitate the further interaction of these subunits with the alpha component. The epsilon subunit has been found genetically linked to several carboxyltransferases of different Streptomyces species; we propose that this subunit reflects a distinctive characteristic of a new group of acyl-CoA carboxylases.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, CONICET, IBR,Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, CONICET, Ctr Estudios Fotosintet & Bioquim, RA-2000 Rosario, Argentina; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; National University of Rosario; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Stanford University	Gramajo, H (corresponding author), Fac Ciencias Bioquim, CONICET, IBR, Dept Microbiol, Suipaccha 531, RA-2080 Rosario, Santa Fe, Argentina.	gramajo@infovia.com.ar	Kurth, Daniel/AAG-4696-2019	Kurth, Daniel/0000-0001-8481-4359; Khosla, Chaitan/0000-0001-6529-495X; Diacovich, Lautaro/0000-0002-3339-0100; Podesta, Florencio/0000-0003-2719-6747	FIC NIH HHS [1R03 TW 05778-01] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005778] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALBERTS AW, 1972, ENZYMES, V6, P37; Blanchard CZ, 1998, J BIOL CHEM, V273, P19140, DOI 10.1074/jbc.273.30.19140; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramwell H, 1996, MICROBIOL-UK, V142, P649, DOI 10.1099/13500872-142-3-649; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; ERFLE JD, 1973, BIOCHIM BIOPHYS ACTA, V316, P143, DOI 10.1016/0005-2760(73)90004-0; HAASE FC, 1982, J BIOL CHEM, V257, P1994; HALENZ DR, 1962, J BIOL CHEM, V237, P2140; Haller T, 2000, BIOCHEMISTRY-US, V39, P4622, DOI 10.1021/bi992888d; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENRIKSON KP, 1979, J BIOL CHEM, V254, P5888; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; Janiyani K, 2001, J BIOL CHEM, V276, P29864, DOI 10.1074/jbc.M104102200; KAZIRO Y, 1961, J BIOL CHEM, V236, P1917; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kimura Y, 1998, ARCH MICROBIOL, V170, P179, DOI 10.1007/s002030050631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU EP, 1979, P NATL ACAD SCI USA, V76, P214, DOI 10.1073/pnas.76.1.214; LI SJ, 1993, J BACTERIOL, V175, P332, DOI 10.1128/JB.175.2.332-340.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; MEYER H, 1978, BIOCHEMISTRY-US, V17, P1822, DOI 10.1021/bi00603a003; NIKOLAU BJ, 1985, ANAL BIOCHEM, V149, P448, DOI 10.1016/0003-2697(85)90596-2; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; Rodriguez E, 2001, APPL ENVIRON MICROB, V67, P4166, DOI 10.1128/AEM.67.9.4166-4176.2001; Rodriguez E, 1999, MICROBIOL-SGM, V145, P3109, DOI 10.1099/00221287-145-11-3109; ROSENBERG LE, 1983, METABOLIC BASIS INHE, P474; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G	37	69	77	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31228	31236		10.1074/jbc.M203263200	http://dx.doi.org/10.1074/jbc.M203263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048195	hybrid			2022-12-25	WOS:000177579800104
J	Manning, SK; Woodrow, C; Zuniga, FA; Iserovich, P; Fischbarg, J; Louw, AI; Krishna, SR				Manning, SK; Woodrow, C; Zuniga, FA; Iserovich, P; Fischbarg, J; Louw, AI; Krishna, SR			Mutational analysis of the hexose transporter of Plasmodium falciparum and development of a three-dimensional model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATIVE GLUCOSE-TRANSPORTER; EXOFACIAL LIGAND-BINDING; SCANNING MUTAGENESIS; INFECTED ERYTHROCYTES; XENOPUS OOCYTES; GLUT1; SITE; EXPRESSION; POSITION; HELIX-7	Plasmodium falciparum infection kills more than 1 million children annually. Novel drug targets are urgently being sought as multidrug resistance limits the range of treatment options for this protozoan pathogen. PfHT1, the major hexose transporter of P. falciparum is a promising new target. We report detailed structure-function studies on PfHT1 using site-directed mutagenesis approaches on residues located in helix V (Q169N) and helix VII ((302)SGL --> AGT). Studies with hexose analogues in these mutants have established that hexose recognition and permeation are intimately linked to these helices. A "fructose filter" effect results from the Q169N mutation (abolishing fructose uptake but preserving affinity and transport of glucose, as reported in Woodrow, C. J., Burchmore, R. J. S., and Krishna, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97,9931-9936). Associated changes in competition for glucose uptake by C-2, C-3, and C-6 glucose analogues compared with native PfHT1 indicate subtle alterations in substrate interaction in this mutant. The K-m values for glucose uptake in helix VII mutants are also similar to native PfHT1. Hydrogen bonding to positions C-5 and C-6 in glucose analogues becomes relatively more important in these mutants compared with native PfHT1. To increase understanding of hexose permeation pathways in PfHT1, we have developed the first three-dimensional model for PfHT1. As predicted for GLUT1, the principal mammalian glucose transporter, PfHT1 contains a main and an auxiliary channel. After modeling, the Q169N mutation leads predominantly to local structural changes, including displacement of neighboring helix IV. The (302)SGL position in helix VII lies in the same plane as Gln-169 in helix V but is also adjacent to the main hexose permeation pathway, consistent with results from experiments mutating this triplet motif. Furthermore, there are obvious structural and functional differences between GLUT1 and PfHT1 that can now be explored in detail using the approaches presented here. The development of specific inhibitors for PfHT1 will also be aided by these insights.	St George Hosp, Sch Med, Dept Infect Dis, London SW17 0RE, England; Univ Pretoria, Dept Biochem, ZA-0002 Pretoria, South Africa; Columbia Univ, Dept Ophthalmol, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, Coll Phys & Surg, New York, NY 10032 USA	St Georges University London; University of Pretoria; Columbia University; Columbia University	Krishna, SR (corresponding author), St George Hosp, Sch Med, Dept Infect Dis, Cranmer Terrace, London SW17 0RE, England.		Louw, Abraham I/A-5726-2008; Zuniga, Felipe A/L-7885-2013; Zuniga, Felipe/Q-8035-2019	Woodrow, Charles/0000-0002-5134-7165; Louw, Abraham/0000-0002-8036-1513; Krishna, Sanjeev/0000-0003-0066-0634; Zuniga, Felipe A./0000-0003-0286-565X	NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08918] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arbuckle MI, 1996, BIOCHEMISTRY-US, V35, P16519, DOI 10.1021/bi962210n; Barrett MP, 1998, MOL BIOCHEM PARASIT, V91, P195, DOI 10.1016/S0166-6851(97)00192-8; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Kirk K, 1996, MOL BIOCHEM PARASIT, V82, P195, DOI 10.1016/0166-6851(96)02734-X; KRISHNA S, 1999, TRANSPORT TRAFFICKIN, V226, P126; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; Nosten F, 1996, CURR OPIN INFECT DIS, V9, P429, DOI 10.1097/00001432-199612000-00015; Pasquier C, 1999, PROTEIN ENG, V12, P381, DOI 10.1093/protein/12.5.381; Phillips RS, 2001, CLIN MICROBIOL REV, V14, P208, DOI 10.1128/CMR.14.1.208-226.2001; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Seatter MJ, 1997, BIOCHEMISTRY-US, V36, P6401, DOI 10.1021/bi970261u; TETAUD E, 1994, P NATL ACAD SCI USA, V91, P8278, DOI 10.1073/pnas.91.17.8278; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Woodrow CJ, 2000, P NATL ACAD SCI USA, V97, P9931, DOI 10.1073/pnas.170153097; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	22	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30942	30949		10.1074/jbc.M204337200	http://dx.doi.org/10.1074/jbc.M204337200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12042321	hybrid			2022-12-25	WOS:000177579800070
J	Weimar, JD; DiRusso, CC; Delio, R; Black, PN				Weimar, JD; DiRusso, CC; Delio, R; Black, PN			Functional role of fatty acyl-coenzyme A synthetase in the transmembrane movement and activation of exogenous long-chain fatty acids - Amino acid residues within the ATP/AMP signature motif of Escherichia coli FadD are required for enzyme activity and fatty acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA SYNTHETASE; OUTER-MEMBRANE; TRANSCRIPTION FACTOR; CATALYZED REACTIONS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN FADL; THIOESTERS; METABOLISM; BINDING	Fatty acyl-CoA synthetase (FACS, fatty acid:CoA ligase, AMP forming; EC 6.2.1.3) plays a central role in intermediary metabolism by catalyzing the formation of fatty acyl-CoA. In Escherichia coli this enzyme, encoded by the fadD gene, is required for the coupled import and activation of exogenous long-chain fatty acids. The E. coli FACS (FadD) contains two sequence elements, which comprise the ATP/AMP signature motif ((213)YTGGTTGVAKGA(224) and (356)GYGLTE(361)) placing it in the superfamily of adenylate-forming enzymes. A series of site-directed mutations were generated in the fadD gene within the ATP/AMP signature motif site to evaluate the role of this conserved region to enzyme function and to fatty acid transport. This approach revealed two major classes of fadD mutants with depressed enzyme activity: 1) those with 25-45% wild type activity (fadD(G216A), fadD(T217A), fadD(G219A), and fadD(K222A)) and 2) those with 10% or less wild-type activity (fadD(Y213A), fadD(T214A), and fadD(E361A)). Using anti-FadD sera, Western blots demonstrated the different mutant forms of FadD that were present and had localization patterns equivalent to the wild type. The defect in the first class was attributed to a reduced catalytic efficiency although several mutant forms also had a reduced affinity for ATP. The mutations resulting in these biochemical phenotypes reduced or essentially eliminated the transport of exogenous long-chain fatty acids. These data support the hypothesis that the FACS FadD functions in the vectorial movement of exogenous fatty acids across the plasma membrane by acting as a metabolic trap, which results in the formation of acyl-CoA esters.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College	Black, PN (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave,MC-8, Albany, NY 12208 USA.	blackp@mail.amc.edu	DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881				Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; Black PN, 2000, J BIOL CHEM, V275, P38547, DOI 10.1074/jbc.M006413200; BLACK PN, 1995, BIOCHEM J, V310, P389, DOI 10.1042/bj3100389; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLACK PN, 1992, J BIOL CHEM, V267, P25513; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; Chang KH, 1996, BIOCHEMISTRY-US, V35, P13478, DOI 10.1021/bi961284w; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Gargiulo CE, 1999, J LIPID RES, V40, P881; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Groot P H, 1976, Adv Lipid Res, V14, P75; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KLOSE M, 1993, J BIOL CHEM, V268, P25664; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; KUMAR GB, 1993, J BIOL CHEM, V268, P15469; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAI JCK, 1993, RES COMMUN CHEM PATH, V82, P331; Li ZN, 2001, J GEN VIROL, V82, P1085, DOI 10.1099/0022-1317-82-5-1085; MANGROO D, 1993, BIOCHEM CELL BIOL, V71, P51, DOI 10.1139/o93-008; Marra CA, 1999, LIPIDS, V34, P343, DOI 10.1007/s11745-999-0372-x; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; WATKINS JD, 1992, J BIOL CHEM, V267, P5686	46	102	111	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29369	29376		10.1074/jbc.M107022200	http://dx.doi.org/10.1074/jbc.M107022200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034706	hybrid			2022-12-25	WOS:000177509300005
J	Filipek, A; Jastrzebska, B; Nowotny, M; Kuznicki, J				Filipek, A; Jastrzebska, B; Nowotny, M; Kuznicki, J			CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES-TUMOR CELLS; ANNEXIN-II; CALCIUM; TARGET; EXPRESSION; NEURONS; COMPLEX; CYCLASE; MYOSIN; LINES	Recently, a human ortholog of mouse calcyclin (S100A6) -binding protein (CacyBP) called SIP (Siah-1-interacting protein) was shown to be a component of a novel ubiquitinylation pathway regulating beta-catenin degradation (Matsuzawa, S., and Reed, J. C. (2001) Mol. Cell 7, 915-926). In murine brain, CacyBP/SIP is expressed at a high level, but S100A6 is expressed at a very low level. Consequently we carried out experiments to determine if CacyBP/SIP binds to other S100 proteins in this tissue. Using CacyBP/SIP affinity chromatography, we found that S100B from the brain extract binds to CacyBP/SIP in a Ca2+-dependent manner. Using a nitrocellulose overlay assay with I-125-CacyBP/SIP and CacyBP/SIP affinity chromatography, we found that this protein binds purified S100A1, S100A6, S100A12, S100B, and S100P but not S100A4, calbindin D-9k, parvalbumin, and calmodulin. The interaction of S100 proteins with CacyBP/SIP occurs via its C-terminal fragment (residues 155-229). Co-immunoprecipitation of CacyBP/SIP with S100B from brain and with S100A6 from Ehrlich ascites tumor cells suggests that these interactions are physiologically relevant and that the ubiquitinylation complex involving CacyBP/SIP might be regulated by S100 proteins.	M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Filipek, A (corresponding author), M Nencki Inst Expt Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	anfil@nencki.gov.pl	Kuznicki, Jacek/AAW-9239-2020	Kuznicki, Jacek/0000-0001-6486-0657; Filipek, Anna/0000-0001-9484-9555				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barker N, 2000, BIOESSAYS, V22, P961; COX JA, 1985, J BIOL CHEM, V260, P2527; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; FILIPEK A, 1993, NEUROREPORT, V4, P383, DOI 10.1097/00001756-199304000-00010; Filipek A, 2002, J BIOL CHEM, V277, P21103, DOI 10.1074/jbc.M111010200; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; KUZNICKI J, 1989, BIOCHEM J, V263, P951; KUZNICKI J, 1987, BIOCHEM J, V247, P663, DOI 10.1042/bj2470663; KUZNICKI J, 1992, EXP CELL RES, V200, P425, DOI 10.1016/0014-4827(92)90191-A; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; Landar A, 1996, CELL CALCIUM, V20, P279, DOI 10.1016/S0143-4160(96)90033-0; Lloyd BH, 1998, ONCOGENE, V17, P465, DOI 10.1038/sj.onc.1201948; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Nowotny M, 2000, J BIOL CHEM, V275, P31178, DOI 10.1074/jbc.M001622200; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Santos JSD, 2000, BBA-MOL CELL RES, V1498, P181, DOI 10.1016/S0167-4889(00)00095-1; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Sitaramayya A, 2000, METHOD ENZYMOL, V315, P730; Sorci G, 2000, NEUROSCIENCE, V99, P773, DOI 10.1016/S0306-4522(00)00238-4; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; Sudo T, 1998, J BIOL CHEM, V273, P6351, DOI 10.1074/jbc.273.11.6351; Walikonis RS, 1998, J BIOL CHEM, V273, P9070, DOI 10.1074/jbc.273.15.9070; WETERMAN MAJ, 1992, CANCER RES, V52, P1291; Zhao XQ, 2000, BIOCHEM BIOPH RES CO, V267, P77, DOI 10.1006/bbrc.1999.1918; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9	35	119	135	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28848	28852		10.1074/jbc.M203602200	http://dx.doi.org/10.1074/jbc.M203602200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042313	hybrid			2022-12-25	WOS:000177342600067
J	Yalamanchili, RD; Stratmann, JW				Yalamanchili, RD; Stratmann, JW			Ultraviolet-B activates components of the systemin signaling pathway in Lycopersicon peruvianum suspension-cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIC-PROTEIN KINASE; GENE-EXPRESSION; GROWTH-FACTOR; HYDROGEN-PEROXIDE; UV-LIGHT; DEFENSE RESPONSES; CHITIN FRAGMENTS; SALICYLIC-ACID; JASMONIC ACID; H+-ATPASE	Among the early responses of Lycopersicon peruvianum suspension-cultured cells to the polypeptide wound signal systemin are the alkalinization of the culture medium and the activation of a 48-kDa mitogen-activated protein kinase (MAPK). Here. we report that both responses are induced in the cells by exposure to ultraviolet-B (UV-B) radiation. Suramin, an inhibitor of systemin receptor function, strongly inhibited the UV-B-induced medium alkalinization and MAPK activity. The UV-B response was also reduced when cells were initially treated with systemin or the systemin antagonist Ala-17-systemin, which competitively inhibits binding of systemin to the systemin receptor. Cells that were initially treated with either UV-B or systemin exhibited a strongly reduced response to a subsequent elicitation with systemin. The desensitization was transient, reaching a maximum at 30 - 60 min after the initial treatment. Several hours later, depending on the initial UV-B dose or systemin concentration, the cells regained their initial responsiveness. When cells were irradiated with low doses of UV-B and subsequently treated with systemin, the UV-B response reached levels higher than the response without UV-B treatment. The data provide evidence for an involvement of the systemin receptor and/or systemin-responsive signaling elements in the UV-B response.	Univ S Carolina, Inst Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Stratmann, JW (corresponding author), Univ S Carolina, Dept Biol Sci, Coker Life Sci Bldg, Columbia, SC 29208 USA.	johstrat@biol.sc.edu						Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; ARNOTT T, 1991, ENVIRON EXP BOT, V31, P209, DOI 10.1016/0098-8472(91)90072-V; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; ATKINSON MM, 1989, PLANT PHYSIOL, V91, P298, DOI 10.1104/pp.91.1.298; BALLARE CL, 1995, PHYSIOL PLANTARUM, V93, P584, DOI 10.1111/j.1399-3054.1995.tb05104.x; Ballare CL, 1996, PLANT PHYSIOL, V112, P161, DOI 10.1104/pp.112.1.161; Bergey DR, 1999, PLANT MOL BIOL, V40, P815, DOI 10.1023/A:1006247624823; Bergey DR, 1996, P NATL ACAD SCI USA, V93, P12053, DOI 10.1073/pnas.93.22.12053; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BREDERODE FT, 1991, PLANT MOL BIOL, V17, P1117, DOI 10.1007/BF00028729; Christie JM, 1996, PLANT CELL, V8, P1555, DOI 10.1105/tpc.8.9.1555; Conconi A, 1996, NATURE, V383, P826, DOI 10.1038/383826a0; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; Felix G, 1998, PLANT PHYSIOL, V117, P643, DOI 10.1104/pp.117.2.643; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; FELIX G, 1995, PLANT J, V7, P381, DOI 10.1046/j.1365-313X.1995.7030381.x; Frohnmeyer H, 1998, PLANT J, V13, P763, DOI 10.1046/j.1365-313X.1998.00074.x; GREEN R, 1995, PLANT CELL, V7, P203, DOI 10.1105/tpc.7.2.203; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Howe GA, 1996, PLANT CELL, V8, P2067, DOI 10.1105/tpc.8.11.2067; Jenkins GI, 1997, PLANT CELL ENVIRON, V20, P773, DOI 10.1046/j.1365-3040.1997.d01-105.x; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Logemann E, 2000, P NATL ACAD SCI USA, V97, P1903, DOI 10.1073/pnas.97.4.1903; Long JC, 1998, PLANT CELL, V10, P2077, DOI 10.1105/tpc.10.12.2077; Mackerness SAH, 1999, PLANT CELL ENVIRON, V22, P1413, DOI 10.1046/j.1365-3040.1999.00499.x; Mackerness SAH, 2001, FEBS LETT, V489, P237, DOI 10.1016/S0014-5793(01)02103-2; Meindl T, 1998, PLANT CELL, V10, P1561, DOI 10.1105/tpc.10.9.1561; Miles GP, 2002, PLANT CELL ENVIRON, V25, P521, DOI 10.1046/j.1365-3040.2002.00841.x; MILLER CC, 1994, J BIOL CHEM, V269, P3529; Moyen C, 1998, PLANT CELL ENVIRON, V21, P1101, DOI 10.1046/j.1365-3040.1998.00378.x; Narvaez-Vasquez J, 1999, PLANT CELL, V11, P2249, DOI 10.1105/tpc.11.11.2249; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; Orozco-Cardenas M, 1999, P NATL ACAD SCI USA, V96, P6553, DOI 10.1073/pnas.96.11.6553; Orozco-Cardenas ML, 2001, PLANT CELL, V13, P179, DOI 10.1105/tpc.13.1.179; PEARCE G, 1993, J BIOL CHEM, V268, P212; Rao MV, 1996, PLANT PHYSIOL, V110, P125, DOI 10.1104/pp.110.1.125; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Ryan CA, 2000, BBA-PROTEIN STRUCT M, V1477, P112, DOI 10.1016/S0167-4838(99)00269-1; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schaller A, 1999, PLANT CELL, V11, P263, DOI 10.1105/tpc.11.2.263; Schaller A, 1999, PLANT MOL BIOL, V40, P763, DOI 10.1023/A:1006279409687; Scheer JM, 1999, PLANT CELL, V11, P1525, DOI 10.1105/tpc.11.8.1525; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Stratmann J, 2000, P NATL ACAD SCI USA, V97, P8862, DOI 10.1073/pnas.97.16.8862; Stratmann JW, 1997, P NATL ACAD SCI USA, V94, P11085, DOI 10.1073/pnas.94.20.11085; Stratmann JW, 2000, PHOTOCHEM PHOTOBIOL, V71, P116, DOI 10.1562/0031-8655(2000)071&lt;0116:SIPUUR&gt;2.0.CO;2; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VERAESTRELLA R, 1994, PLANT PHYSIOL, V106, P97, DOI 10.1104/pp.106.1.97; YALPANI N, 1994, PLANTA, V193, P372, DOI 10.1007/BF00201815; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877	53	27	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28424	28430		10.1074/jbc.M203844200	http://dx.doi.org/10.1074/jbc.M203844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034744	hybrid			2022-12-25	WOS:000177342600012
J	Billings, PC; Whitbeck, JC; Adams, CS; Abrams, WR; Cohen, AJ; Engelsberg, BN; Howard, PS; Rosenbloom, J				Billings, PC; Whitbeck, JC; Adams, CS; Abrams, WR; Cohen, AJ; Engelsberg, BN; Howard, PS; Rosenbloom, J			The transforming growth factor-beta-inducibie matrix protein beta ig-h3 interacts with fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE; CELL-ADHESION; IN-VITRO; GENE; LOCALIZATION; INTEGRIN; IDENTIFICATION; CYTOSKELETON; CHONDROCYTES	Proper growth and development require the orderly synthesis and deposition of individual components of the extracellular matrix (ECM) into well ordered networks. Once formed, the ECM maintains tissue structure and houses resident cells. One ECM component, betaig-h3, is a highly conserved transforming growth factor-beta-inducible protein that has been hypothesized to function as a bifunctional linker between individual matrix components and resident cells. To gain insights into its physiological function, full-length betaig-h3 protein was produced using a baculovirus expression system and purified under native conditions. Human fibroblasts attached and spread on betaig-h3-coated plates and developed actin stress fibers. Purified betaig-h3 binds fibronectin (FN) and type I collagen (Col I) but does not bind gelatin. Using defined fragments of FN, we localized the betaig-h3 recognition region to the gelatin/collagen binding domain present in the N-terminal region of the FN molecule. Our results identify FN and Col I as two ligands of betaig-h3 in the ECM.	Univ Penn, Sch Med, Dept Orthoped Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA; Univ Penn, Sch Dent Med, Dept Anat & Histol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Billings, PC (corresponding author), Univ Penn, Sch Med, Dept Orthoped Surg, 424 Stemmler Hall, Philadelphia, PA 19104 USA.	pbilling@mail.med.upenn.edu	Abrams, William R/A-5782-2008; Adams, Christopher/Z-2537-2019	Adams, Christopher/0000-0003-2100-4417	NEI NIH HHS [EY12789] Funding Source: Medline; NHLBI NIH HHS [HL56401] Funding Source: Medline; NIDDK NIH HHS [DK48125] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012789] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056401] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aumailley M, 1998, J MOL MED-JMM, V76, P253, DOI 10.1007/s001090050215; Billings PC, 2000, AM J RESP CELL MOL, V22, P352, DOI 10.1165/ajrcmb.22.3.3732; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; BurtonWurster N, 1997, MATRIX BIOL, V15, P441, DOI 10.1016/S0945-053X(97)90018-4; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; COPLEN DE, 1994, IN VITRO CELL DEV-AN, V30A, P604, DOI 10.1007/BF02631259; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Fonseca C, 1999, SPRINGER SEMIN IMMUN, V21, P453, DOI 10.1007/BF00870305; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hynes RO, 1999, GUIDEBOOK EXTRACELLU, P422; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Klintworth GK, 1998, AM J PATHOL, V152, P743; Kosmehl H, 1996, VIRCHOWS ARCH, V429, P311; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MARTINEZ JR, 1995, DM-DIS MON, V41, P698, DOI 10.1016/S0011-5029(05)80007-0; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Pinzani M, 1999, SPRINGER SEMIN IMMUN, V21, P475, DOI 10.1007/BF00870306; Retta SF, 1999, METH MOL B, V96, P125; Romberger DJ, 1997, INT J BIOCHEM CELL B, V29, P939, DOI 10.1016/S1357-2725(96)00172-0; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; WEBER KT, 1995, HERZ, V20, P81; WILLIS SH, 1997, METHODS MOL MED HERP, V10, P131	32	107	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28003	28009		10.1074/jbc.M106837200	http://dx.doi.org/10.1074/jbc.M106837200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12034705	hybrid			2022-12-25	WOS:000177189800054
J	Chong, MMW; Thomas, HE; Kay, TWH				Chong, MMW; Thomas, HE; Kay, TWH			Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic beta cells to tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NONOBESE DIABETIC MOUSE; MICE LACKING SUPPRESSOR; INTERFERON-GAMMA; FACTOR-ALPHA; TYROSINE KINASE; GENE-EXPRESSION; MURINE ISLETS; IFN-GAMMA; PROTEIN	Suppressor of cytokine signaling-1 (SOCS-1) is a negative regulator of the Jak-STAT (signal transducer and activator of transcription cytokine) signaling pathway but may also regulate other pathways. At least in vitro, SOCS-1 inhibits the action of multiple cytokines. By studying the effects of SOCS-1 deficiency, we investigated whether SOCS-1 is involved in preventing cytokine-induced death of pancreatic islet cells, a potential mechanism of insulin deficiency in autoimmune diabetes. Tumor necrosis factor (TNF) + interferon-gamma (IFNgamma) was more potent at inducing cell death in SOCS-1-/- islets than in wild type. Individually, these cytokines did not induce cell death. The titration of the two cytokines suggested that this increased cell death was because of hypersensitivity to TNF. Interleukin-1 + IFNgamma induced the same level of cell death in SOCS-1-/- and wild-type islets, suggesting that the sensitivity of islets to IFNgamma or interleukin-1-mediated cytotoxicity is not affected by SOCS-1 deficiency. Additionally, SOCS-1-/- beta cells were responsive to lower concentrations of TNF measured by class I major histocompatibility complex up-regulation. The TNF + IFNgamma damage of islets was mediated by inducible nitric-oxide synthase (iNOS), and increased iNOS expression and nitric oxide production were found in SOCS-1-/- islets following cytokine treatment. A further analysis revealed that SOCS-1 deficiency results in augmented TNF signaling via the p38 mitogen-activated protein kinase pathway but not NFkappaB or c-Jun N-terminal kinase pathways. Increased p38 signaling may be responsible for the increased iNOS expression in SOCS-1-/- islets. Therefore, these findings provide evidence that physiological levels of SOCS-1 negatively regulate TNF signaling.	Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Kay, TWH (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	kay@wehi.edu.au	Chong, Mark/H-6684-2016	Chong, Mark/0000-0002-3701-7397				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Arnush M, 1998, J IMMUNOL, V160, P2684; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CAMPBELL IL, 1988, MOL ENDOCRINOL, V2, P101; Chong MMW, 2001, DIABETES, V50, P2744, DOI 10.2337/diabetes.50.12.2744; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; Dahlen E, 1998, J IMMUNOL, V160, P3585; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; Karlsen AE, 2001, P NATL ACAD SCI USA, V98, P12191, DOI 10.1073/pnas.211445998; Kay TWH, 2000, TRENDS ENDOCRIN MET, V11, P11, DOI 10.1016/S1043-2760(99)00210-6; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Liu M, 1995, TRANSPL P, V27, P3208; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsuda T, 2000, FEBS LETT, V472, P235, DOI 10.1016/S0014-5793(00)01444-7; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PUKEL C, 1988, DIABETES, V37, P133, DOI 10.2337/diabetes.37.1.133; RABINOVITCH A, 1995, J IMMUNOL, V154, P4874; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Sekine N, 2000, J CELL PHYSIOL, V184, P46, DOI 10.1002/(SICI)1097-4652(200007)184:1<46::AID-JCP5>3.0.CO;2-L; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stephens LA, 1999, ENDOCRINOLOGY, V140, P3219, DOI 10.1210/en.140.7.3219; TOYODA H, 1994, IMMUNOL LETT, V39, P283, DOI 10.1016/0165-2478(94)90170-8; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wishnok JS, 1996, METHOD ENZYMOL, V268, P130; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309	46	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27945	27952		10.1074/jbc.M110214200	http://dx.doi.org/10.1074/jbc.M110214200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032139	hybrid			2022-12-25	WOS:000177189800046
J	Palaniyar, N; Zhang, LQ; Kuzmenko, A; Ikegami, M; Wan, SJ; Wu, HX; Korfhagen, TR; Whitsett, JA; McCormack, FX				Palaniyar, N; Zhang, LQ; Kuzmenko, A; Ikegami, M; Wan, SJ; Wu, HX; Korfhagen, TR; Whitsett, JA; McCormack, FX			The role of pulmonary collectin N-terminal domains in surfactant structure, function, and homeostasis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-DEFICIENT MICE; COLLAGEN-LIKE REGION; GENE-TARGETED MICE; PROTEIN-A; IN-VIVO; II CELLS; LUNG; INHIBITION; INFECTION; MUTAGENESIS	The N-terminal domains of the lung collectins, surfactant proteins A (SP-A) and D (SP-D), are critical for surfactant phospholipid interactions and surfactant homeostasis, respectively. To further assess the importance of lung collectin N-terminal domains in surfactant structure and function, a chimeric SP-D/SP-A (D/A) gene was constructed by substituting nucleotides encoding amino acids Asn(1)-Ala(7) of rat SP-A with the corresponding N-terminal sequences from rat SP-D, Ala(1)-Asn(25). Recombinant D/A migrated as a 35-kDa band on reducing SDS-PAGE and as a ladder of disulfide-linked multimers under nonreducing conditions. The recombinant D/A bound and aggregated phosphatidylcholine containing vesicles as effectively as rat SP-A. Mice in which endogenous pulmonary collectins were replaced with D/A were developed by human SP-C promoter-driven overexpression of the D/A gene in SP-A(-/-) and SP-D-/- animals. Analysis of lavage fluid from SP-A(-/-) D/A mice revealed that glycosylated, oligomeric D/A was secreted into the air spaces at levels that were comparable with the authentic collectins and that the N-terminal interchange converted SP-A from a "bouquet" to a cruciform configuration. Transmission electron microscopy of surfactant from the SP-A(-/-,D/A) mice revealed atypical tubular myelin containing central "target-like" electron density. Surfactant isolated from SP-A(-/-,D/1) mice exhibited elevated surface tension both in the presence and absence of plasma inhibitors, but whole lung compliance of the SP-A(-/-,D/A) animals was not different from the SP-A(-/-) littermates. Lung-specific overexpression of D/A in the SPD-/- mouse resulted in hetero-oligomer formation with mouse SP-A and did not correct the air space dilation or phospholipidosis that occurs in the absence of SP-D. These studies indicate that the N terminus of SP-D 1) can functionally replace the N terminus of SP-A for lipid aggregation and tubular myelin formation, but not for surface tension lowering properties of SP-A, and 2) is not sufficient to reverse the structural and metabolic pulmonary defects in the SP-D-/- mouse.	Univ Cincinnati, Sch Med, Dept Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA; Childrens Hosp Res Fdn, Dept Pediat, Div Pulm Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	McCormack, FX (corresponding author), POB 670564, Cincinnati, OH 45267 USA.		McCormack, Francis X./ABE-8398-2020; Kuzmenko, Oleksandr/P-6059-2016	McCormack, Francis X./0000-0001-7168-9464; Palaniyar, Nades/0000-0002-2170-8548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058795, R01HL061612, P01HL061646, R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63329, HL 61646, HL 61612, HL 58795] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyama J, 1999, AM J RESP CELL MOL, V21, P193, DOI 10.1165/ajrcmb.21.2.3681; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; Ferguson JS, 1999, J IMMUNOL, V163, P312; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Gomes RFM, 2000, J APPL PHYSIOL, V89, P908, DOI 10.1152/jappl.2000.89.3.908; HALLER EM, 1992, J HISTOCHEM CYTOCHEM, V40, P1491, DOI 10.1177/40.10.1527372; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Ikegami M, 2000, J APPL PHYSIOL, V89, P644, DOI 10.1152/jappl.2000.89.2.644; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; Ikegami M, 2001, J BIOL CHEM, V276, P38542, DOI 10.1074/jbc.M102054200; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Poulain FR, 1999, AM J RESP CELL MOL, V20, P1049, DOI 10.1165/ajrcmb.20.5.3497; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SCHURCH S, 1989, J APPL PHYSIOL, V67, P2389, DOI 10.1152/jappl.1989.67.6.2389; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V56, P185, DOI 10.1016/0009-3084(90)90101-V; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; YUKITAKE K, 1995, PEDIATR RES, V37, P21, DOI 10.1203/00006450-199501000-00005; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200; Zhang M, 1998, BIOCHEMISTRY-US, V37, P16481, DOI 10.1021/bi9817966	45	39	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26971	26979		10.1074/jbc.M110080200	http://dx.doi.org/10.1074/jbc.M110080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015304	hybrid			2022-12-25	WOS:000177055900037
J	Qanungo, S; Basu, A; Das, M; Haldar, S				Qanungo, S; Basu, A; Das, M; Haldar, S			2-methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells	ONCOGENE			English	Article						apoptosis; mitochondria; 2-methoxyestradiol; pancreatic cancer	ENDOGENOUS MAMMALIAN METABOLITE; WILD-TYPE P53; ESTROGEN METABOLITE; CYTOCHROME-C; INHIBITS ANGIOGENESIS; BCL2 PHOSPHORYLATION; ACTIVATION; GROWTH; PATHWAY; ARREST	The antiproliferative action of 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite is specific for cancer cells and is mediated by the induction of programmed cell death or apoptosis. But the identity of the downstream effectors of apoptotic signaling induced by 2-ME is not known. In the present study, we explored the effect of 2-ME on apoptosis in a panel of human pancreatic cancer cell lines. We have identified two categories of pancreatic cancer cell lines, which are either sensitive to 2-ME such as MIA PaCa-2, CFPAC-1, PANC-1, or non-sensitive to 2-ME such as Hs 766T. The results presented here indicated that the cell lines responsive to 2-ME could undergo apoptosis either by G2-M arrest (PANC-1) with Bcl-X-L phosphorylation or by the accumulation of tetraploid cells in G1-S region (MIA PaCa-2) without Bcl-2/Bcl-X-L phosphorylation. Furthermore, 2-ME induced apoptosis in pancreatic cancer cells is mitochondria dependent as evident by the release of cytochrome c into the cytosol. 2-ME exposed cells exhibit Bid cleavage that is accompanied by the translocation of Bax into the mitochondria. Also 2-ME could induce phosphorylation of Bcl-X-L in G2-M arrested cells, thus indicating the involvement of various anti- and pro-apoptotic regulators in the signaling cascade. The dissection of differential response of pancreatic cancer cell lines holds promise for future therapeutic intervention.	Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System	Haldar, S (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, R456,Rammelkamp Bldg,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	Shaldar@metrohealth.org			NATIONAL CANCER INSTITUTE [R01CA077328] Funding Source: NIH RePORTER; NCI NIH HHS [CA77328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANDREAS G, 2000, CANCER RES, V60, P2163; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Basu A, 1998, INT J ONCOL, V13, P659; BASU A, 2002, IN PRESS NEOPLASIA, V4; Brady H J, 1999, Results Probl Cell Differ, V23, P127; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Denmeade S R, 1997, Adv Pharmacol, V41, P553, DOI 10.1016/S1054-3589(08)61072-8; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Huober JB, 2000, INT J RADIAT ONCOL, V48, P1127, DOI 10.1016/S0360-3016(00)00767-7; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; KARPINICH NO, 2002, IN PRESS J BIOL CHEM; KATOTAKA M, 1998, CANCER RES, V58, P4761; KHAN P, 1979, J CELL BIOL, V82, P1; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; Lottering ML, 1996, CANCER LETT, V110, P181, DOI 10.1016/S0304-3835(96)04489-8; MacCarthy-Morrogh L, 2000, CANCER RES, V60, P5441; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MARTUCCI CP, 1979, ENDOCRINOLOGY, V105, P1288, DOI 10.1210/endo-105-6-1288; MARTUCCI CP, 1983, CATECHOL ESTROGENS, P115; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schumacher G, 1999, CLIN CANCER RES, V5, P493; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; VANDERHEIDE MG, 2001, NATURE CELL BIOL, V1, pE209; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wassberg E, 1999, UPSALA J MED SCI, V104, P1; Wassberg E, 1999, AM J PATHOL, V154, P395, DOI 10.1016/S0002-9440(10)65286-8; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoubine MN, 1999, INT J ONCOL, V15, P639	60	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4149	4157		10.1038/sj.onc.1205508	http://dx.doi.org/10.1038/sj.onc.1205508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037671	Bronze			2022-12-25	WOS:000176186000009
J	Ermak, G; Harris, CD; Davies, KJA				Ermak, G; Harris, CD; Davies, KJA			The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress	FASEB JOURNAL			English	Article						calcium signaling; apoptosis; stress proteins and genes	SYNDROME CRITICAL REGION; DEPENDENT TRANSCRIPTIONAL PATHWAY; DOWN-SYNDROME; CARDIAC-HYPERTROPHY; MESSENGER-RNA; EXPRESSION; GENE; HOMOLOG; CELLS; OVEREXPRESSION	Although DSCR1 (Adapt78) has been associated with successful adaptation to oxidative stress and calcium stress and with devastating diseases such as Alzheimer's and Down syndrome, no rationale for these apparently contradictory findings has been tested. In fact, DSCR1 (Adapt78) has not yet been proved to provide protection against acute oxidative stress or calcium stress. We have addressed this question using cross-adaptation to H2O2 and the calcium ionophore A23187, stable DSCR1 (Adapt78) transfection and overexpression in hamster HA-1 cells, 'tet-off' regulated DSCR1 (Adapt78) isoform 1 transgene expression in human PC-12 cells, and DSCR1 (Adapt78) antisense oligonucleotides to test the ability of the DSCR1 (Adapt78) protein product calcipressin 1 (a calcineurin inhibitor) to protect against oxidative stress and calcium stress. Under all conditions, resistance to oxidative stress and calcium stress increased as a function of DSCR1 (Adapt78)/calcipressin 1 expression and decreased as gene/protein expression diminished. We conclude that cells may transiently use increased expression of the DSCR1 (Adapt78) gene product calcipressin 1 to provide short-term protection against acute oxidative stress and other calcium-mediated stresses, whereas chronic overexpression may be associated with Alzheimer disease progression.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA USA	University of Southern California; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003	NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER; NIA NIH HHS [AG16256] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crawford DR, 1997, SURGERY, V121, P581, DOI 10.1016/S0039-6060(97)90115-X; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V329, P137, DOI 10.1006/abbi.1996.0202; Crawford DR, 1996, ARCH BIOCHEM BIOPHYS, V325, P256, DOI 10.1006/abbi.1996.0032; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DAVIES KJA, 2000, IUBMB LIFE, V50, P35; Ermak G, 1996, CANCER RES, V56, P1037; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; Joseph JA, 1997, J NEUROCHEM, V69, P1252; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MATRSUDA T, 1998, NIPPON YAKURIGAKU S1, V112, pP24; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; WANG YF, 1996, MACROMOL REP A, V33, P1; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	41	109	110	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0814	10.1096/fj.01-0846com	http://dx.doi.org/10.1096/fj.01-0846com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039863				2022-12-25	WOS:000176683900007
J	Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E				Xiang, H; Fox, JA; Totpal, K; Aikawa, M; Dupree, K; Sinicropi, D; Lowe, J; Escandon, E			Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors	ONCOGENE			English	Article						Apo2L/TRAIL; CPT-11; SN-38; p21; DR4; DR5	APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; IONIZING-RADIATION; ANTITUMOR-ACTIVITY; COMPLEX-FORMATION; CANCER-CELLS; CASPASE 3; DEATH; INDUCTION; P53	Apo2L/TRAIL exhibits enhanced apoptotic activity in tumor xenograft models when used in combination with the topoisomerase 1 inhibitor CPT-11. To investigate the cellular mechanisms involved in this increased tumor-killing activity, a series of in vitro experiments were conducted using the human colon carcinoma cell line (HCT116). Apo2L/TRAIL induced a transient upregulation of DR5 mRNA, while CPT-11 increased both death and decoy receptor expression. Upregulation of decoy receptors by CPT-11 was partially inhibited by co-administration of Apo2L/TRAIL. CPT-11 treatment resulted in accumulation of cells at G(2)M-phase and correlated with a substantial increase in the protein levels of the cyclin-dependent kinase inhibitor p21. However, cells co-treated with CPT-11 and Apo2L/TRAIL, or pretreated with CPT-11 for up to 24 h followed by 2 h Apo2L/TRAIL, resulted in a caspase-dependent degradation of p21, reversal of G(2)-M phase arrest with a concomitant increase in apoptosis. The sequential treatment produced the greatest induction of DR5 and DR4, caspase-3-like cleavage/activation and p21 degradation, as well as increased apoptosis. These data indicate that the up-regulation of Apo2L/TRAIL ligand and its death receptors as well as cleavage of p21 protein in the Apo2L/TRAIL plus CPT-11 treatment contributes to the positive cooperation between these agents in enhancing tumor cell apoptosis.	Genentech Inc, Dept Clin & Expt Pharmacol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept BioAnalyt R&D, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Escandon, E (corresponding author), Genentech Inc, Dept Clin & Expt Pharmacol, 1 DNA Way, San Francisco, CA 94080 USA.							Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Choi SH, 1998, CANCER LETT, V124, P15, DOI 10.1016/S0304-3835(97)00428-X; Deptala A, 1999, INT J ONCOL, V15, P861; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farczadi E, 1999, NEOPLASMA, V46, P219; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HARPER JW, 1993, CELL, V75, P805; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; McDonald AC, 1998, BRIT J CANCER, V78, P745, DOI 10.1038/bjc.1998.571; Nagane M, 2000, CANCER RES, V60, P847; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; ROTHENBERG ML, 1993, J CLIN ONCOL, V11, P2194, DOI 10.1200/JCO.1993.11.11.2194; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sheikh MS, 1998, CANCER RES, V58, P1593; Sparreboom A, 1998, CLIN CANCER RES, V4, P2747; Strasser A, 1999, INT J CANCER, V81, P505, DOI 10.1002/(SICI)1097-0215(19990517)81:4<505::AID-IJC1>3.0.CO;2-J; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; TISHLER RB, 1993, CANCER RES, V53, P2212; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	42	46	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3611	3619		10.1038/sj.onc.1205449	http://dx.doi.org/10.1038/sj.onc.1205449			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032863				2022-12-25	WOS:000175793700012
J	Assil-Kishawi, I; Abou-Samra, AB				Assil-Kishawi, I; Abou-Samra, AB			Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND INTERACTION; HORMONE-RECEPTOR; PROTEIN-RECEPTOR; AGONIST-BINDING; AMINO-TERMINUS; XENOPUS-LAEVIS; HIGH-AFFINITY; PEPTIDE; CLONING; DOMAINS	Contact sites between the corticotropin-releasing factor receptor type 1 (CRFR1), the sauvagine (SVG) radio-ligands [Tyr(0),Gln(1)]SVG (I-125-YQS) and [Tyr(0),Gln(1), Leu(17)] SVG (I-125-YQLS) were examined. I-125-YQLS or I-125-YQS was cross-linked to CRFR1 using the chemical cross-linker, disuccinimidyl. suberate (DSS), which cross-links the epsilon amino groups of lysine residues that have a molecular distance of 11.4 Angstrom. DSS specifically and efficiently cross-linked I-125-YQLS and I-125-YQS to CRFR1. CRFR1 contains 5 putative extracellular lysine residues (Lys(110), Lys(111), Lys(113), Lys(257), and Lys(262)) that can cross-link to the 4 lysine residues (Lys(16), Lys(22), Lys(25), and Lys(27)) of the radioligands. Identification of the CNBr-cleaved fragments of CRFR1 cross-linked to I-125-YQLS or I-125-YQS established that the second extracellular loop of CRFR1 cross-links to Lys(16) of YQS. Additionally, site-directed mutagenesis (changing Lys to Arg in CRFR1 individually and in combination) revealed that Lys(257) in the second extracellular loop of CRFR1 is an important cross-linking site. In conclusion, it was shown that in SVG-bound CRFR1, Lys(257) of CRFR1 lies in close proximity (11.4 Angstrom) to Lys(16) of SVG.	Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Abou-Samra, AB (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Boston, MA 02114 USA.	samra@helix.mgh.harvard.edu	Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NIDDK NIH HHS [DK45020] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; ASSIL I, 2001, J PHYSL ENDOCRINOL M, V5, P10115; Assil IQ, 2001, PEPTIDES, V22, P1055, DOI 10.1016/S0196-9781(01)00424-7; Assil IQ, 2001, BIOCHEMISTRY-US, V40, P1187, DOI 10.1021/bi001758y; Beyermann M, 2000, J BIOL CHEM, V275, P5702, DOI 10.1074/jbc.275.8.5702; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; Dautzenberg FM, 1999, J NEUROCHEM, V73, P821, DOI 10.1046/j.1471-4159.1999.0730821.x; Dong MQ, 2000, ANN NY ACAD SCI, V921, P381; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Jin L, 2000, J BIOL CHEM, V275, P27238; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Myers DA, 1998, MOL CELL ENDOCRINOL, V144, P21, DOI 10.1016/S0303-7207(98)00157-9; Palchaudhuri MR, 1998, EUR J BIOCHEM, V258, P78, DOI 10.1046/j.1432-1327.1998.2580078.x; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Ruhmann A, 1996, P NATL ACAD SCI USA, V93, P10609, DOI 10.1073/pnas.93.20.10609; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; XIONG YT, 1995, ENDOCRINOLOGY, V136, P1828, DOI 10.1210/en.136.5.1828; Yu JX, 1996, ENDOCRINOLOGY, V137, P192, DOI 10.1210/en.137.1.192; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	26	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					32558	32561		10.1074/jbc.M204964200	http://dx.doi.org/10.1074/jbc.M204964200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12029097	hybrid			2022-12-25	WOS:000177859000023
J	Buchan, AMJ; Lin, CY; Choi, J; Barber, DL				Buchan, AMJ; Lin, CY; Choi, J; Barber, DL			Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RHO; LYSOPHOSPHATIDIC ACID; ACTIVATION; KINASE; THROMBIN; EXCHANGE; GTPASES; ADHESION; ANALOGS; GROWTH	Somatostatin regulates multiple biological functions by acting through a family of five G protein-coupled receptors, somatostatin receptors (SSTRs) 1-5. Although all five receptor subtypes inhibit adenylate cyclase activity and decrease intracellular cAMP levels, specific receptor subtypes also couple to additional signaling pathways. In CCL39 fibroblasts expressing either human SSTR1 or SSTR2, we demonstrate that activation of SSTR1 (but not SSTR2) attenuated both thrombin- and integrin-stimulated Rho-GTP complex formation. The reduction in Rho-GTP formation in the presence of somatostatin was associated with decreased translocation of Rho and LIM kinase to the plasma membrane and fewer focal contacts. Activation of Rho resulted in the formation of intracellular actin stress fibers and cell migration. In CCL39-R1 cells, somatostatin treatment prevented actin stress fiber assembly and attenuated thrombin-stimulated cell migration through Transwell membranes to basal levels. To show that native SSTR1 shares the ability to inhibit Rho activation, we demonstrated that somatostatin treatment of human umbilical vein endothelial cells attenuated thrombin-stimulated Rho-GTP accumulation. These data show for the first time that a G protein-coupled receptor, SSTR1, inhibits the activation of Rho, the assembly of focal adhesions and actin stress fibers, and cell migration.	Univ British Columbia, Dept Physiol, Vancouver, BC V6T 1Z3, Canada; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of British Columbia; University of California System; University of California San Francisco	Buchan, AMJ (corresponding author), Univ British Columbia, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	ambuchan@interchange.ubc.ca; barber@itsa.ucsf.edu		Buchan, Alison/0000-0003-3642-1328	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040259, R01DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058642] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32DE07204] Funding Source: Medline; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM58642] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647; Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Arnold R, 2000, DIGESTION, V62, P84, DOI 10.1159/000051861; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Averbukh E, 2000, Int J Exp Diabetes Res, V1, P39, DOI 10.1155/EDR.2000.39; BARBER DL, 1989, J BIOL CHEM, V264, P21038; Behr TM, 2001, Q J NUCL MED, V45, P189; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRUNS C, 1995, CIBA F SYMP, V190, P89; Bruns C, 2000, EUR J ENDOCRINOL, V143, pS3, DOI 10.1530/eje.0.143S003; Chen LC, 1999, BIOCHEM BIOPH RES CO, V258, P689, DOI 10.1006/bbrc.1999.0699; Csaba Z, 2001, NEUROPEPTIDES, V35, P1, DOI 10.1054/npep.2001.0848; Curtis SB, 2000, AM J PHYSIOL-HEART C, V278, pH1815, DOI 10.1152/ajpheart.2000.278.6.H1815; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Dib K, 2001, J IMMUNOL, V166, P6311, DOI 10.4049/jimmunol.166.10.6311; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HART MJ, 1998, SCIENCE, V280, P2074; HOU CF, 1994, J BIOL CHEM, V269, P10357; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jenkins SA, 2001, CHEMOTHERAPY, V47, P162, DOI 10.1159/000049168; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley A, 1999, CURR BIOL, V9, pR156, DOI 10.1016/S0960-9822(99)80100-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rivier JE, 2001, J MED CHEM, V44, P2238, DOI 10.1021/jm010037+; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer SP, 2000, J PHYSIOLOGY-PARIS, V94, P211, DOI 10.1016/S0928-4257(00)00215-1; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Stetak A, 2001, BIOCHEM BIOPH RES CO, V288, P564, DOI 10.1006/bbrc.2001.5811; Suich DJ, 2000, BIOORGAN MED CHEM, V8, P2229, DOI 10.1016/S0968-0896(00)00135-8; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	48	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28431	28438		10.1074/jbc.M201261200	http://dx.doi.org/10.1074/jbc.M201261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12045195	hybrid			2022-12-25	WOS:000177342600013
J	Clough, RR; Sidhu, RS; Bhullar, RP				Clough, RR; Sidhu, RS; Bhullar, RP			Calmodulin binds RalA and RalB and is required for the thrombin-induced activation of Ral in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; GTP-BINDING; SIGNALING CASCADE; PUTATIVE EFFECTOR; PHOSPHOLIPASE D1; EH DOMAIN; PROTEIN; INTERACTS; GTPASES; INVOLVEMENT	Ral GTPases may be involved in calcium/calmodulin-mediated intracellular signaling pathways. RalA and RalB are activated by calcium, and RalA binds calmodulin in vitro. It was examined whether RalA can bind calmodulin in vivo, whether RalB can bind calmodulin, and whether calmodulin is functionally involved in Ral activation. Yeast two-hybrid analyses demonstrated both Rals interact directly but differentially with calmodulin. Coimmunoprecipitation experiments determined that calmodulin and RalB form complexes in human platelets. In vitro pull-down experiments in platelets and in vitro binding assays showed endogenous Ral and calmodulin interact in a calcium-dependent manner. Truncated Ral constructs determined in vitro and in vivo that RalA has an additional calmodulin binding domain to that previously described, that although RalB binds calmodulin, its C-terminal region is involved in partially inhibiting this interaction, and that in vitro RalA and RalB have an N-terminal calcium-independent and a C-terminal calcium-dependent calmodulin binding domain. Functionally, in vitro Ral-GTP pull-down experiments determined that calmodulin is required for the thrombin-induced activation of Ral in human platelets. We propose that differential binding of calmodulin by RalA and RalB underlies possible functional differences between the two proteins and that calmodulin is involved in the regulation of the activation of Ral-GTPases.	Univ Manitoba, Dept Oral Biol, Winnipeg, MB R3E 0W2, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W2, Canada	University of Manitoba; University of Manitoba	Bhullar, RP (corresponding author), 744 Bannatyne Ave, Winnipeg, MB R3E 0W2, Canada.							Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FRECH M, 1990, J BIOL CHEM, V265, P6353; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Murai H, 1997, J BIOL CHEM, V272, P10483; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Park JB, 2001, EXP MOL MED, V33, P54, DOI 10.1038/emm.2001.10; Park JB, 1999, BIOCHEM BIOPH RES CO, V263, P765, DOI 10.1006/bbrc.1999.1463; Park SH, 1995, ONCOGENE, V11, P2349; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Shao HP, 2000, J BIOL CHEM, V275, P26914; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P13609; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang KL, 1999, J BIOL CHEM, V274, P14525, DOI 10.1074/jbc.274.21.14525; Wang KL, 1997, J BIOL CHEM, V272, P16002, DOI 10.1074/jbc.272.25.16002; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	55	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28972	28980		10.1074/jbc.M201504200	http://dx.doi.org/10.1074/jbc.M201504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034722	hybrid			2022-12-25	WOS:000177342600082
J	Eisses, JF; Kaplan, JH				Eisses, JF; Kaplan, JH			Molecular characterization of hCTR1, the human copper uptake protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; SACCHAROMYCES-CEREVISIAE; TRANSPORTING ATPASE; CANDIDATE GENE; MENKES DISEASE; ALPHA-SUBUNIT; YEAST; EXPRESSION; COMPLEMENTATION; NA,K-ATPASE	We have expressed hCTR1, the human copper transporter, in Sf9 cells using a baculovirus-mediated expression system, and we observed greatly enhanced copper uptake. Western blots showed that the protein is delivered to the plasma membrane, where it mediates saturable copper uptake with a K-m of similar to3.5 mum. We also expressed functional transporters where the N-linked glycosylation sites were substituted, and we provided evidence for the extracellular location of the amino terminus. Accessibility of amino-terminal FLAG epitope to antibody prior to permeabilization and of carboxyl-terminal FLAG only after permeabilization confirmed the extracellular location of the amino terminus and established the intracellular location of the carboxyl terminus. Tryptic digestion of hCTR1 occurred within the cytoplasmic loop and generated a 10-Da carboxyl-terminal peptide; cleavage was prevented by the presence of copper. hCTR1 mutants where Cys-161 and Cys-189, the two native cysteines, were replaced with serines also mediated copper uptake, indicating that neither cysteine residue was essential for transport. However, the mutants provided evidence that these residues may stabilize hCTR1 oligomerization. Western blots of hCTR1 in Sf9 cells showed expression levels 100-fold higher than in mammalian (HepG2) cells. The high level of functional expression and the low level of endogenous copper uptake will enable future structure-function analysis of this important protein.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Kaplan, JH (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	kaplanj@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Bartnikas TB, 2001, NAT STRUCT BIOL, V8, P733, DOI 10.1038/nsb0901-733; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Culotta V.C., 2001, METABOLIC MOL BASES, P3105; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG311, DOI 10.1152/ajpgi.1999.276.2.G311; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	26	148	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29162	29171		10.1074/jbc.M203652200	http://dx.doi.org/10.1074/jbc.M203652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034741	hybrid			2022-12-25	WOS:000177342600105
J	Li, BJ; Cong, F; Tan, CP; Wang, SX; Goff, SP				Li, BJ; Cong, F; Tan, CP; Wang, SX; Goff, SP			Aph2, a protein with a zf-DHHC motif, interacts with c-Abl and has pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; TYROSINE KINASE-ACTIVITY; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GENE-PRODUCT; DNA-DAMAGE; CELL-DEATH; B-CELL; V-ABL; REPEAT	c-Abl is a non-receptor tyrosine kinase implicated in DNA damage-induced cell death and in growth factor receptor signaling. To further understand the function and regulation of c-Abl, a yeast two-hybrid screen was performed to identify c-Abl-interacting proteins. Here we report the identification of Abl-philin 2 (Aph2), encoding a novel protein with a unique cysteine-rich motif (zf-DHHC) and a 53-amino acid stretch sharing homology with the creatine kinase family. The zf-DHHC domain is highly conserved from yeast to human. Two proteins containing this motif, Akr1p and Erf2p, have been characterized in Saccharomyces cerevisiae, both implicated in signaling pathways. Deletion analysis by two-hybrid assays revealed that the N-terminal portion of Aph2 interacts with the C terminus of c-Abl. Aph2 was demonstrated to interact with c-Abl by co-immunoprecipitation assays. Aph2 is expressed in most tissues tested and is localized in the cytoplasm, mainly in the endoplasmic reticulum (ER). The sequences required for ER location reside in the N terminus and the zfDHHC motif of Aph2. It has been reported that a portion of c-Abl is localized in the ER. We demonstrate here that Aph2 and c-Abl are co-localized in the ER region. Overexpression of Aph2 leads to apoptosis as justified by TUNEL assays, and the induction of apoptosis requires the N terminus. Co-expression of c-AbI and Aph2 had a synergistic effect on apoptosis induction and led to a decreased expression of both proteins, suggesting either that these two proteins are mutually down-regulated or that cells expressing both c-Abl and Aph2 rapidly disappeared from the culture. These results suggest that Aph2 may be involved in ER stress-induced apoptosis in which c-Abl plays an important role.	Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Columbia Univ, Coll Phys & Surg, Dept Biol, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Columbia University	Goff, SP (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, HHSC 1310C,701 W 168th St, New York, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				Agami R, 1999, NATURE, V399, P809; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; An DS, 1997, J VIROL, V71, P1397, DOI 10.1128/JVI.71.2.1397-1404.1997; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Givan SA, 1997, MOL BIOL CELL, V8, P1317, DOI 10.1091/mbc.8.7.1317; Gong JG, 1999, NATURE, V399, P806; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kao LR, 1996, MOL CELL BIOL, V16, P168; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; Putilina T, 1999, MOL CELL BIOCHEM, V195, P219, DOI 10.1023/A:1006932522197; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	33	44	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28870	28876		10.1074/jbc.M202388200	http://dx.doi.org/10.1074/jbc.M202388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12021275	hybrid			2022-12-25	WOS:000177342600070
J	Meyer, DA; Carta, M; Partridge, LD; Covey, DF; Valenzuela, CF				Meyer, DA; Carta, M; Partridge, LD; Covey, DF; Valenzuela, CF			Neurosteroids enhance spontaneous glutamate release in hippocampal neurons - Possible role of metabotropic sigma(1)-like receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; RAT FOREBRAIN SYNAPTOSOMES; TYPE-1 SIGMA-RECEPTOR; PREGNENOLONE SULFATE; ACETYLCHOLINE-RELEASE; DEHYDROEPIANDROSTERONE-SULFATE; NEUROACTIVE STEROIDS; TRANSMITTER RELEASE; INTRACELLULAR CA2+; MOLECULAR-CLONING	Pregnenolone sulfate (PREGS), one of the most abundantly produced neurosteroids in the mammalian brain, improves cognitive performance in rodents. The mechanism of this effect has been attributed to its allosteric modulatory actions on glutamate- and gamma-aminobutyric acid-gated ion channels. Here we report a novel effect of PREGS that could also mediate some of its actions in the nervous system. We found that PREGS induces a robust potentiation of the frequency but not the amplitude of miniature excitatory postsynaptic currents (mEPSCs) mediated by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors in cultured hippocampal neurons. PREGS also decreased paired pulse facilitation of autaptic EPSCs evoked by depolarization, indicating that it modulates glutamate release probability presynaptically. PREGS potentiation of mEPSCs was mimicked by dehydroepiandrosterone sulfate and (+)-pentazocine but not by (-)-pentazocine, the synthetic (-)-enantiomer of PREGS or the inactive steroid isopregnanolone. The a receptor antagonists, haloperidol and BD-1063, blocked the effect of PREGS on mEPSCs, as did pertussis toxin and the membrane-permeable Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (acetoxymethyl) ester. These results suggest that PREGS increases spontaneous glutamate release via activation of a presynaptic GO-coupled sigma receptor and an elevation in intracellular Ca2+ levels. We postulate that presynaptic actions of neurosteroids have a role in the maturation and/or maintenance of synaptic networks and the processing of information in the central nervous system.	Univ New Mexico, Dept Neurosci, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of New Mexico; University of New Mexico's Health Sciences Center; Washington University (WUSTL)	Valenzuela, CF (corresponding author), Univ New Mexico, Dept Neurosci, Hlth Sci Ctr, BMSB 145, Albuquerque, NM 87131 USA.			Partridge, Linda/0000-0001-9615-0094; Carta, Mario/0000-0003-1225-2742	NIAAA NIH HHS [AA12684] Funding Source: Medline; NIMH NIH HHS [MH63126] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH063126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012684] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; Barrot M, 1999, EUR J NEUROSCI, V11, P3757, DOI 10.1046/j.1460-9568.1999.00816.x; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; BOWLBY MR, 1993, MOL PHARMACOL, V43, P813; Brent PJ, 1997, J NEUROCHEM, V68, P2201; Brent PJ, 1996, NEUROSCI LETT, V211, P138, DOI 10.1016/0304-3940(96)12711-7; Costa ET, 2000, J BIOL CHEM, V275, P38268, DOI 10.1074/jbc.M004136200; Darnaudery M, 1998, J NEUROCHEM, V71, P2018; Darnaudery M, 2000, BRAIN RES, V852, P173, DOI 10.1016/S0006-8993(99)01964-2; Emptage NJ, 2001, NEURON, V29, P197, DOI 10.1016/S0896-6273(01)00190-8; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Guarneri P, 1998, EUR J NEUROSCI, V10, P1752, DOI 10.1046/j.1460-9568.1998.00191.x; Han MH, 2001, NEUROREPORT, V12, P2203, DOI 10.1097/00001756-200107200-00032; Hanner M, 1996, P NATL ACAD SCI USA, V93, P8072, DOI 10.1073/pnas.93.15.8072; Hayashi T, 2000, J PHARMACOL EXP THER, V293, P788; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; IRWIN RP, 1992, NEUROSCI LETT, V141, P30, DOI 10.1016/0304-3940(92)90327-4; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; Kimoto T, 2001, ENDOCRINOLOGY, V142, P3578, DOI 10.1210/en.142.8.3578; Lambert JJ, 1996, CELL MOL NEUROBIOL, V16, P155, DOI 10.1007/BF02088174; Li YX, 1998, J NEUROSCI, V18, P10231; Liere P, 2000, J CHROMATOGR B, V739, P301, DOI 10.1016/S0378-4347(99)00563-0; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Maurice T, 1999, JPN J PHARMACOL, V81, P125, DOI 10.1254/jjp.81.125; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Maurice T, 2001, BRIT J PHARMACOL, V134, P1731, DOI 10.1038/sj.bjp.0704355; Maurice T, 2001, BRAIN RES REV, V37, P116, DOI 10.1016/S0165-0173(01)00112-6; MCCANN DJ, 1990, EUR J PHARM-MOLEC PH, V188, P211, DOI 10.1016/0922-4106(90)90004-H; Mei JF, 2001, BIOCHEM PHARMACOL, V62, P349, DOI 10.1016/S0006-2952(01)00666-9; MENNERICK S, 1995, J PHYSIOL-LONDON, V488, P85, DOI 10.1113/jphysiol.1995.sp020948; Moebius FF, 1996, BIOCHEMISTRY-US, V35, P16871, DOI 10.1021/bi961996m; Moebius FF, 1997, TRENDS PHARMACOL SCI, V18, P67, DOI 10.1016/S0165-6147(96)01037-1; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Morin-Surun MP, 1999, P NATL ACAD SCI USA, V96, P8196, DOI 10.1073/pnas.96.14.8196; Nilsson KR, 1998, J MED CHEM, V41, P2604, DOI 10.1021/jm980148h; Park-Chung M, 1997, MOL PHARMACOL, V52, P1113, DOI 10.1124/mol.52.6.1113; Partridge LD, 2001, NEUROSCI LETT, V301, P103, DOI 10.1016/S0304-3940(01)01613-5; Perroy J, 2000, J NEUROSCI, V20, P7896; Rhodes ME, 1996, BRAIN RES, V733, P284, DOI 10.1016/0006-8993(96)00751-2; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Savic N, 1998, EUR J NEUROSCI, V10, P3379, DOI 10.1046/j.1460-9568.1998.00342.x; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; SEGAL MM, 1990, J NEUROPHYSIOL, V64, P1390, DOI 10.1152/jn.1990.64.5.1390; Seth P, 1997, BIOCHEM BIOPH RES CO, V241, P535, DOI 10.1006/bbrc.1997.7840; Seth P, 1998, J NEUROCHEM, V70, P922; Su TP, 2001, TRENDS PHARMACOL SCI, V22, P456, DOI 10.1016/S0165-6147(00)01740-5; SU TP, 1988, SCIENCE, V240, P219, DOI 10.1126/science.2832949; Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286, DOI 10.1152/jn.1999.82.3.1286; Teschemacher A, 1997, BRAIN RES, V772, P226, DOI 10.1016/S0006-8993(97)00872-X; Tokuyama S, 1999, NEUROSCI LETT, V268, P85, DOI 10.1016/S0304-3940(99)00387-0; Tokuyama S, 1997, NEUROSCI LETT, V233, P141, DOI 10.1016/S0304-3940(97)00657-5; Ueda H, 2001, NEUROSCI RES, V41, P33, DOI 10.1016/S0168-0102(01)00258-9; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vallee M, 2001, EUR J NEUROSCI, V14, P2003, DOI 10.1046/j.0953-816x.2001.01817.x; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Vilner BJ, 2000, J PHARMACOL EXP THER, V292, P900; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; WU FS, 1991, MOL PHARMACOL, V40, P333	60	110	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28725	28732		10.1074/jbc.M202592200	http://dx.doi.org/10.1074/jbc.M202592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042305	hybrid			2022-12-25	WOS:000177342600050
J	Qi, C; Chang, J; Zhu, YW; Yeldandi, AV; Rao, SM; Zhu, YJ				Qi, C; Chang, J; Zhu, YW; Yeldandi, AV; Rao, SM; Zhu, YJ			Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; GROWTH-FACTOR; CLONING; CBP; ACETYLTRANSFERASE; OLIGOMERIZATION; METHYLATION; COMPLEXES	In an attempt to isolate cofactors capable of influencing estrogen receptor alpha (ERalpha) transcriptional activity, we used yeast two-hybrid screening and identified protein arginine methyltransferase 2 (PRMT2) as a new ERalpha-binding protein. PRMT2 interacted directly with three ERa regions including AF-1, DNA binding domain, and hormone binding domain in a ligand-independent fashion. The ERalpha-interacting region on PRMT2 has been mapped to a region encompassing amino acids 133-275. PRMT2 also binds to ERbeta, PR, TRbeta, RARalpha, PPARgamma, and RXRalpha in a ligand-independent manner. PRMT2 enhanced both ERa AF-1 and AF-2 transcriptional activity, and the potential methyltransferase activity of PRMT2 appeared pivotal for its coactivator function. In addition, PRMT2 enhanced PR, PPARgamma, and RARalpha-mediated transactivation. Although PRMT2 was found to interact with two other coactivators, the steroid receptor coactivator-1 (SRC-1) and the peroxisome proliferator-activated receptor-interacting protein (PRIP), no synergistic enhancement of ERa transcriptional activity was observed when PRMT2 was coexpressed with either PRIP or SRC-1. In this respect PRMT2 differs from coactivators PRMT1 and CARM1 (coactivator-associated arginine methyltransferase). These results suggest that PRMT2 is a novel ERa coactivator.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Zhu, YJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	y-zhu2@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA088898, R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88898, CA 84472] Funding Source: Medline; NIEHS NIH HHS [K08 ES 00356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mayer BJ, 2001, J CELL SCI, V114, P1253; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QI C, 1999, CELL BIOCH BIOPHYS, V31, P1; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	43	132	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28624	28630		10.1074/jbc.M201053200	http://dx.doi.org/10.1074/jbc.M201053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039952	hybrid			2022-12-25	WOS:000177342600037
J	Veeraraghavan, S; Fagan, PA; Hu, HT; Lee, V; Harper, JF; Huang, B; Chazin, WJ				Veeraraghavan, S; Fagan, PA; Hu, HT; Lee, V; Harper, JF; Huang, B; Chazin, WJ			Structural independence of the two EF-hand domains of caltractin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; CALCIUM-BINDING; CHLAMYDOMONAS-REINHARDTII; FLAGELLAR EXCISION; PEPTIDE COMPLEX; YEAST CENTRIN; CENTRAL HELIX; HALF-BRIDGE; PROTEIN; CALMODULIN	Caltractin (centrin) is a member of the calmodulin subfamily of EF-hand Ca2+-binding proteins that is an essential component of microtubule-organizing centers in many organisms ranging from yeast and algae to humans. The protein contains two homologous EF-hand Ca2+-binding domains linked by a flexible tether; each domain is capable of binding two Ca2+ ions. In an effort to search for domain-specific functional properties of caltractin, the two isolated domains were subcloned and expressed in Escherichia coli. Ca2+ binding affinities and the Ca2+ dependence of biophysical properties of the isolated domains were monitored by UV, CD, and NMR spectroscopy. Comparisons to the corresponding results for the intact protein showed that the two domains function independently of each other in these assays. Titration of a peptide fragment from the yeast Kar1p protein to the isolated domains and intact caltractin shows that the two domains interact in a Ca2+-dependent manner, with the C-terminal domain binding much more strongly than the N-terminal domain. Measurements of the macroscopic Ca2+ binding constants show that only the N-terminal domain has sufficient apparent Ca2+ affinity in vitro (1-10 muM) to be classified as a traditional calcium sensor in signal transduction pathways. However, investigation of the microscopic Ca2+ binding events in the C-terminal domain by NMR spectroscopy revealed that the observed macroscopic binding constant likely results from binding to two sites with very different affinities, one in the micromolar range and the other in the millimolar range. Thus, the C-terminal domain appears to also be capable of sensing Ca2+ signals but is activated by the binding of a single ion.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA	Scripps Research Institute; Scripps Research Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University	Chazin, WJ (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.			Hu, Haitao/0000-0002-0312-1954	NCI NIH HHS [F32 CA-74421] Funding Source: Medline; NIGMS NIH HHS [R01 GM-40120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA074421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN SSL, 1999, MOL CHARACTERISTICS, V187; Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DRAKENBERG T, 1989, BIOCHEMISTRY-US, V28, P5946, DOI 10.1021/bi00440a035; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; HARPER JDI, 1999, CHLAMYDOMONAS CELL C, V189; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ivanovska I, 2001, GENETICS, V157, P503; Levy YY, 1996, CELL MOTIL CYTOSKEL, V33, P298; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; LINSE S, 1995, PROTEIN SCI, V4, P1038, DOI 10.1002/pro.5560040602; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; Marshall WF, 2000, CURR OPIN CELL BIOL, V12, P119, DOI 10.1016/S0955-0674(99)00065-4; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SANDERS MA, 1989, J CELL BIOL, V108, P1751, DOI 10.1083/jcb.108.5.1751; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; Tian DY, 1998, INT J ONCOL, V13, P1135; WEBER C, 1994, J BIOL CHEM, V269, P15795	29	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28564	28571		10.1074/jbc.M112232200	http://dx.doi.org/10.1074/jbc.M112232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034713	hybrid			2022-12-25	WOS:000177342600029
J	Claypool, SM; Dickinson, BL; Yoshida, M; Lencer, WI; Blumberg, RS				Claypool, SM; Dickinson, BL; Yoshida, M; Lencer, WI; Blumberg, RS			Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-RELATED RECEPTOR; MDCK CELLS; IMMUNOGLOBULIN-G; NEONATAL RAT; BIDIRECTIONAL TRANSCYTOSIS; INTESTINAL TRANSPORT; CRYSTAL-STRUCTURE; CYTOPLASMIC TAIL; IGG CATABOLISM; HUMAN PLACENTA	The major histocompatibility complex class I-related neonatal Fc receptor, FcRn, assembles as a heterodimer consisting of a heavy chain and beta(2)-microglobulin (beta(2)m), which is essential for FcRn function. We observed that, in Madin-Darby canine kidney (MDCK) cells, the function of human FCRn in mediating the bidirectional transport of IgG was significantly increased upon coexpression of the human isoform of beta(2)m. In MDCK cells, the presence of human beta(2)m endowed upon human FcRn an enhanced ability to exit the endoplasmic reticulum and acquire mature carbohydrate side-chain modifications at steady state, a faster kinetics of maturation, and augmented localization at the cell surface as a mature glycoprotein able to bind IgG. Although human FcRn with immature carbohydrate side-chain modifications was capable of exhibiting pH-dependent binding of IgG, only human FcRn with mature carbohydrate side-chain modifications was detected on the cell surface. These results show that human FcRn travels to the cell surface via the normal secretory pathway and that the appropriate expression and function of human FCRn in MDCK cells depends upon the co-expression of human beta(2)m.	Harvard Univ, Dept Med, Div Gastroenterol, Brigham & Womens Hosp,Sch Med,Program Immunol, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Ctr Digest Dis, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University	Blumberg, RS (corresponding author), Harvard Univ, Dept Med, Div Gastroenterol, Brigham & Womens Hosp,Sch Med,Program Immunol, 75 Francis St, Boston, MA 02115 USA.	rblumberg@partners.org		Lencer, Wayne/0000-0001-7346-2730; Claypool, Steven/0000-0001-5316-1623	NIDDK NIH HHS [R01 DK053056-03, DK51362, R37 DK044319, DK44319, R01 DK051362, R01 DK053056, R37 DK044319-13, R01 DK051362-02S1, DK53056] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053056, R01DK051362, R37DK044319, R01DK044319] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; Antohe F, 2001, HUM IMMUNOL, V62, P93, DOI 10.1016/S0198-8859(00)00244-5; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BERRYMAN M, 1995, J CELL SCI, V108, P2347; BRAMBELL FW, 1966, LANCET, V2, P1087, DOI 10.1016/S0140-6736(66)92190-8; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; Christianson GJ, 1997, J IMMUNOL, V159, P4781; Dickinson BL, 1999, J CLIN INVEST, V104, P903, DOI 10.1172/JCI6968; Ellinger I, 1999, EUR J IMMUNOL, V29, P733, DOI 10.1002/(SICI)1521-4141(199903)29:03<733::AID-IMMU733>3.0.CO;2-C; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; Harlow E., 1988, ANTIBODIES LAB MANUA; HUBER AH, 1993, J MOL BIOL, V230, P1077, DOI 10.1006/jmbi.1993.1220; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; KIM JK, 1994, EUR J IMMUNOL, V24, P2429, DOI 10.1002/eji.1830241025; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Kobayashi N, 2002, AM J PHYSIOL-RENAL, V282, pF358, DOI 10.1152/ajprenal.0164.2001; Kristoffersen E K, 1996, APMIS Suppl, V64, P5; Leung SM, 1999, MOL BIOL CELL, V10, P4369, DOI 10.1091/mbc.10.12.4369; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Martin WL, 1999, BIOCHEMISTRY-US, V38, P12639, DOI 10.1021/bi9913505; McCarthy KM, 2000, J CELL SCI, V113, P1277; McCarthy KM, 2001, J CELL SCI, V114, P1591; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; Ober RJ, 2001, INT IMMUNOL, V13, P1551, DOI 10.1093/intimm/13.12.1551; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; Praetor A, 1999, J CELL SCI, V112, P2291; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; Ramalingam TS, 2002, EMBO J, V21, P590, DOI 10.1093/emboj/21.4.590; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Rodionov DG, 2000, J BIOL CHEM, V275, P8279, DOI 10.1074/jbc.275.12.8279; Rodionov DG, 1999, J IMMUNOL, V162, P1488; Sanchez LM, 1999, BIOCHEMISTRY-US, V38, P9471, DOI 10.1021/bi9907330; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SMITHIES O, 1972, P NATL ACAD SCI USA, V69, P2914, DOI 10.1073/pnas.69.10.2914; Stefaner I, 1999, J BIOL CHEM, V274, P8998, DOI 10.1074/jbc.274.13.8998; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Vaughn DE, 1997, J MOL BIOL, V274, P597, DOI 10.1006/jmbi.1997.1388; Wang EI, 2000, TRAFFIC, V1, P480, DOI 10.1034/j.1600-0854.2000.010606.x; West AP, 2000, BIOCHEMISTRY-US, V39, P9698, DOI 10.1021/bi000749m; Wu Z, 2001, J BIOL CHEM, V276, P5240, DOI 10.1074/jbc.M006684200	52	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28038	28050		10.1074/jbc.M202367200	http://dx.doi.org/10.1074/jbc.M202367200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023961	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000177189800059
J	Volpi, S; Rabadan-Diehl, C; Cawley, N; Aguilera, G				Volpi, S; Rabadan-Diehl, C; Cawley, N; Aguilera, G			Transcriptional regulation of the pituitary vasopressin V1b receptor involves a GAGA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC STRESS; MESSENGER-RNA; DNA-BINDING; GENE; RAT; PROMOTER; BOX; INVOLVEMENT; ACTIVATION; SECRETION	The role of CT repeats (inverted GAGA box) in the rat vasopressin V1b receptor (V1bR) promoter in the transcriptional regulation of this gene was studied in H32 hypothalamic cells, which express endogenous V1bR. Transfection of a 2.5-kb V1bR fragment (2161 by upstream and 377 by downstream of the proximal transcriptional start point) into a luciferase vector (V1bRp2.5-Luc) results in promoter activity in these cells. The 670-by proximal promoter fragment containing the GAGA box showed maximal promoter activity, whereas deletion of the GAGA box abolished transcription. Drosophila GAGA-binding protein increased V1bR promoter activity by 11-fold when cotransfected with V1bRp2.5-Luc and increased endogenous V1bR expression. Electrophoretic mobility shift assay showed specific binding of pituitary nuclear extracts to radiolabeled GAGA oligonucleotides, which increased following restraint stress in rats, a condition associated with V1bR up-regulation. DNA-binding activity involved a protein complex because it was abolished by deoxycholate. Size-exclusion column chromatography showed a complex of 127 kDa, which dissociated into similar to70-kDa components after deoxycholate/Nonidet P-40 treatment. This study demonstrates that interactions of GAGA-binding proteins with the GAGA box of the V1bR promoter activate V1bR gene expression and provides a potential mechanism for physiological regulation of V1bR transcription.	NICHD, Sect Endocrine Physiol, DEB, NIH, Bethesda, MD 20892 USA; NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Volpi, S (corresponding author), NICHD, Sect Endocrine Physiol, DEB, NIH, Bldg 10,Rm 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.							AGUILERA G, 1994, FRONT NEUROENDOCRIN, V15, P321, DOI 10.1006/frne.1994.1013; Aguilera G, 2000, EXP PHYSIOL, V85, p19S, DOI 10.1111/j.1469-445X.2000.tb00004.x; AGUILERA G, 1994, J NEUROENDOCRINOL, V6, P299, DOI 10.1111/j.1365-2826.1994.tb00586.x; ANTONI FA, 1993, FRONT NEUROENDOCRIN, V14, P76, DOI 10.1006/frne.1993.1004; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; CHILDS GV, 1988, ENDOCRINOLOGY, V123, P2885, DOI 10.1210/endo-123-6-2885; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; GALLOPAYET N, 1986, ENDOCRINOLOGY, V119, P1042, DOI 10.1210/endo-119-3-1042; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; HAUGER RL, 1990, BRAIN RES, V532, P34, DOI 10.1016/0006-8993(90)91738-3; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; Leverrier S, 2000, BIOL CHEM, V381, P1031, DOI 10.1515/BC.2000.127; Li JW, 1998, NUCLEIC ACIDS RES, V26, P3018, DOI 10.1093/nar/26.12.3018; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MUGELE K, 1993, DNA CELL BIOL, V12, P119, DOI 10.1089/dna.1993.12.119; Nomura A, 2001, AM J PHYSIOL-ENDOC M, V280, pE780, DOI 10.1152/ajpendo.2001.280.5.E780; Rabadan-Diehl C, 2000, J NEUROENDOCRINOL, V12, P437; RabadanDiehl C, 1995, J NEUROENDOCRINOL, V7, P903, DOI 10.1111/j.1365-2826.1995.tb00734.x; Simar-Blanchet AE, 1998, MOL ENDOCRINOL, V12, P391, DOI 10.1210/me.12.3.391; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wyse BD, 2000, J MOL ENDOCRINOL, V25, P97, DOI 10.1677/jme.0.0250097	27	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27829	27838		10.1074/jbc.M201508200	http://dx.doi.org/10.1074/jbc.M201508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023277	hybrid			2022-12-25	WOS:000177189800032
J	Gu, JY; Park, JM; Song, EJ; Mizuguchi, G; Yoon, JH; Kim-Ha, J; Lee, KJ; Kim, YJ				Gu, JY; Park, JM; Song, EJ; Mizuguchi, G; Yoon, JH; Kim-Ha, J; Lee, KJ; Kim, YJ			Novel mediator proteins of the small Mediator complex in Drosophila SL2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; BINDING; YEAST; HOLOENZYME; GENES	The Mediator complex is generally required for transcriptional regulation in species ranging from yeast to human. Throughout evolution, the functional diversity of the Mediator complex has been enhanced to meet the increasing requirements for sophisticated gene regulation. It is likely that greater structural complexity is thus required to accomplish these new, complex regulatory functions. In this study, we took systematic steps to examine various types of Mediator complexes in Drosophila melanogaster. Such efforts led to the identification of three distinct forms of Mediator complexes. In exploring their compositional and functional heterogeneity, we found that the smallest complex (Cl) is highly enriched in a certain type of Drosophila cells and possesses novel Mediator proteins. The subunits shared among the three Mediator complexes (C1, C2, and C3) appear to form a stable modular structure that serves as a binding surface for transcriptional activator proteins. However, only C2 and C3 were able to support activated transcription in vitro. These findings suggest that different cell types may require distinct Mediator complexes, some of which may participate in nuclear processes other than the previously identified functions.	Yonsei Univ, Dept Biochem, Coll Sci,Natl Creat Res Initiat Ctr Genome Regula, Seodaemoon Ku, Seoul 120749, South Korea; Digital Genom Inc, Seoul 120749, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea; NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Sejong Univ, Dept Biol Mol, Seoul 143797, South Korea	Yonsei University; Ewha Womans University; Ewha Womans University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sejong University	Kim, YJ (corresponding author), Yonsei Univ, Dept Biochem, Coll Sci,Natl Creat Res Initiat Ctr Genome Regula, Seodaemoon Ku, Sinchondong 134, Seoul 120749, South Korea.			Song, Eun Joo/0000-0002-2420-6666; Lee, Kong-Joo/0000-0001-7972-6020				Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Fernandes M, 1995, NUCLEIC ACIDS RES, V23, P4799, DOI 10.1093/nar/23.23.4799; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Han SJ, 2001, J BIOL CHEM, V276, P37020, DOI 10.1074/jbc.M105596200; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Park JM, 2001, MOL CELL BIOL, V21, P2312, DOI 10.1128/MCB.21.7.2312-2323.2001; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Taatjes DJ, 2002, SCIENCE, V295, P1058, DOI 10.1126/science.1065249	28	17	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27154	27161		10.1074/jbc.M204144200	http://dx.doi.org/10.1074/jbc.M204144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021283	hybrid			2022-12-25	WOS:000177055900059
J	Thoden, JB; Henderson, JM; Fridovich-Keil, JL; Holden, HM				Thoden, JB; Henderson, JM; Fridovich-Keil, JL; Holden, HM			Structural analysis of the Y299C mutant of Escherichia coli UDP-galactose 4-epimerase - Teaching an old dog new tricks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE 4-EPIMERASE; N-ACETYLGLUCOSAMINE; BINDING; PURIFICATION; COFACTOR; PROGRAM; TIP30	UDP-galactose 4-epimerase catalyzes the interconversion of UDP-Gal and UDP-Glc during normal galactose metabolism. The mammalian form of the enzyme, unlike its Escherichia coli counterpart, can also interconvert UDP-GalNAc and UDP-GlcNAc. One key feature of the epimerase reaction mechanism is the rotation of a 4-ketopyranose intermediate in the active site. By comparing the high resolution x-ray structures of both the bacterial and human forms of the enzyme, it was previously postulated that the additional activity in the human epimerase was due to replacement of the structural equivalent of Tyr-299 in the E. coli enzyme with a cysteine residue, thereby leading to a larger active site volume. To test this hypothesis, the Y299C mutant form of the E. coli enzyme was prepared and its three-dimensional structure solved as described here. Additionally, the Y299C mutant protein was assayed for activity against both UDP-Gal and UDP-GalNAc. These studies have revealed that, indeed, this simple mutation did confer UDP-GalNAc/UDP-GlcNAc converting activity to the bacterial enzyme with minimal changes in its three-dimensional structure. Specifically, although the Y299C mutation in the bacterial enzyme resulted in a loss of epimerase activity with regard to UDP-Gal by almost 5-fold, it resulted in a gain of activity against UDP-GalNAc by more than 230-fold.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Emory Univ, Sch Med, Grad Program Nutr & Hlth Sci, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	University of Wisconsin System; University of Wisconsin Madison; Emory University; Emory University	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.	Hazel_Holden@biochem.wisc.edu			NIDDK NIH HHS [DK 07734, DK 47814, DK 46403] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403, R01DK047814, R29DK046403, R56DK047814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker ME, 1999, CURR BIOL, V9, pR471, DOI 10.1016/S0960-9822(99)80297-8; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, NEW ENGL J MED, V314, P1257; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V29, P26; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; PILLER F, 1983, J BIOL CHEM, V258, P774; ROUSSEL A, 1991, SILICON GRAPHICS GEO; SALO WL, 1968, BIOCHIM BIOPHYS ACTA, V151, P484, DOI 10.1016/0005-2744(68)90116-2; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Stammers DK, 2001, EMBO J, V20, P6619, DOI 10.1093/emboj/20.23.6619; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146	28	55	58	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27528	27534		10.1074/jbc.M204413200	http://dx.doi.org/10.1074/jbc.M204413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12019271	hybrid			2022-12-25	WOS:000177055900103
J	von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Gillissen, B; Starck, L; Graupner, V; Dorken, B; Daniel, PT			Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells	ONCOGENE			English	Article						proapoptotic genes; Bax; ceramide; mitochondria; DU 145 cells; HCT116 cells	CYTOCHROME-C RELEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ETOPOSIDE-INDUCED APOPTOSIS; DRUG-INDUCED APOPTOSIS; BCL-2 FAMILY MEMBERS; HUMAN-MELANOMA CELLS; GENE BAX; CANCER-CHEMOTHERAPY; CASPASE ACTIVATION; MEDIATED APOPTOSIS	The intracellular pathways leading to mitochondrial activation and subsequent cell death in the ceramide-mediated stress response have been intensively studied in recent years. Experimental evidence has been provided that ceramide-induced apoptosis is inhibited by overexpression of antiapoptotic proteins of the Bcl-2 family. However, the direct effect of proapoptotic gene products, e.g. Bax, on ceramide-induced death signalling has not yet been studied in detail. In the present work, we show by measurement of mitochondrial permeability transition, cytochrome c release, activation of caspase-3 and DNA fragmentation that ceramide-induced apoptosis is marginal in Bax-negative DU 145 cells. Reconstitution of Bax by generation of DU 145 cells stably expressing this proapoptotic factor, clearly enhanced ceramide-induced apoptosis at all levels of the mitochondrial signalling cascade. Using the broad-range caspase inhibitor zVAD-fmk and zDEVD-fmk, an inhibitor of caspase-3-like activities, we demonstrate that the ceramide-induced mitochondrial activation in Bax-transfected DU 145 cells is caspase-independent. On the other hand, apoptotic events located downstream of the mitochondria, e.g. DNA fragmentation, were shown to be caspase-dependent. This influence of Bax on ceramide-induced apoptosis was confirmed in another cellular system: whereas Bax-positive HCT116 wild type cells were very sensitive towards induction of cell death by C-2-ceramide, sensitivity of Bax knock-out HCT116 cells was significantly reduced. Thus, we conclude that Bax is a key activator of ceramide-mediated death pathways.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mde-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Engedal N, 2001, PROSTATE, V46, P289, DOI 10.1002/1097-0045(20010301)46:4<289::AID-PROS1035>3.0.CO;2-K; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Geilen CC, 1996, FEBS LETT, V378, P88, DOI 10.1016/0014-5793(95)01421-7; Geilen CC, 1997, ARCH DERMATOL RES, V289, P559, DOI 10.1007/s004030050240; Geilen GC, 1997, J BIOL CHEM, V272, P8997, DOI 10.1074/jbc.272.14.8997; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Jafrezou JP, 2001, FASEB J, V15, P123, DOI 10.1096/fj.00-0305com; Kim HJ, 2001, FEBS LETT, V505, P264, DOI 10.1016/S0014-5793(01)02836-8; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Y, 2000, APOPTOSIS, V5, P523, DOI 10.1023/A:1009637512917; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1999, INT J ONCOL, V15, P535; Malisan F, 1999, FEBS LETT, V452, P100, DOI 10.1016/S0014-5793(99)00543-8; Marcelli M, 2000, PROSTATE, V42, P260, DOI 10.1002/(SICI)1097-0045(20000301)42:4<260::AID-PROS3>3.0.CO;2-0; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; MIYASHITA T, 1993, BLOOD, V81, P151; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Peltenburg LTC, 2000, Q J NUCL MED, V44, P355; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Weinmann P, 1997, EUR J IMMUNOL, V27, P2466, DOI 10.1002/eji.1830270947; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	62	158	162	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4009	4019		10.1038/sj.onc.1205497	http://dx.doi.org/10.1038/sj.onc.1205497			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037683				2022-12-25	WOS:000175869900007
J	Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M				Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M			A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing	ONCOGENE			English	Article						tumour-associated; antigen; N-myc; leucine zipper	CYTOLYTIC T-LYMPHOCYTES; PRE-MESSENGER-RNA; SECONDARY STRUCTURE PREDICTION; SEROLOGICAL IDENTIFICATION; AUTOIMMUNE SERA; HUMAN-MELANOMA; CDNA CLONING; ANTIGENS; CANCER; LOCALIZATION	We describe here the definition and characterization of antigen CT-8/HOM-TES-85 encoded by a previously unknown gene and identified by serological expression screening using antibodies from a seminoma patient. Intriguingly, the leucine zipper region of CT-8/HOM-TES-85 shows an atypical amphipathy with clusters of hydrophobic residues that is exclusively shared by the N-myc proto-oncogene. CT-8/HOM-TES-85 gene is tightly silenced in normal tissues except for testis. However, it is frequently activated in human neoplasms of different types including lung cancer, ovarian cancer, melanoma and glioma. Endogenous as well as heterogeneously expressed CT-8/HOM-TES-85 targets predominantly, to the nucleus forming a distinctive speckled pattern of nuclear dots arranged in macromolecular structures. By co-localization studies these speckles were identified as loci of transcriptional activity and splicing, suggesting that CT-8/HOM-TES-85 may be involved in these processes. The aberrant expression of CT-8/HOM-TES-85 in human neoplasms might therefore be involved in cancer associated alterations of transcriptional or post-transcriptional processes and thus may disclose new mechanisms involved in the manifestation of the cancer phenotype.	Univ Mainz, Med Klin & Poliklin 3, D-55131 Mainz, Germany; Klinikum Bamberg, Abt Pathol, Bamberg, Germany; Stadtklin, Abt Gynakol, Baden, Switzerland; Univ Leipzig, Inst Humangenet, Leipzig, Germany; Univ Klinikun Saarlandes, Med Klin & Poliklin 1, Saarlandes, Germany	Johannes Gutenberg University of Mainz; Leipzig University; Universitatsklinikum des Saarlandes	Sahin, U (corresponding author), Univ Mainz, Med Klin 3, D-55131 Mainz, Germany.	Sahin@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; Bergsagel P L, 1992, Curr Top Microbiol Immunol, V182, P223; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; CHAN EKL, 1989, J AUTOIMMUN, V2, P321, DOI 10.1016/0896-8411(89)90159-5; Chen YT, 1999, CANCER J SCI AM, V5, P16; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GAUGLER B, 1995, J EXP MED, V79, P921; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P136, DOI 10.1007/BF02205562; Kim J, 2000, GENOME RES, V10, P1138, DOI 10.1101/gr.10.8.1138; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCCAULIFFE DP, 1989, J AUTOIMMUN, V2, P375, DOI 10.1016/0896-8411(89)90166-2; MEUWISSEN RJL, 1997, GENOMICS, V37, P101; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; RUBINFELD B, 1997, CANCER RES, V57, P462; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VENROOIJ WJ, 1989, CLIN EXP RHEUMATOL, V7, P635; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801	53	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3879	3888		10.1038/sj.onc.1205481	http://dx.doi.org/10.1038/sj.onc.1205481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032826				2022-12-25	WOS:000175847200007
J	Samuel, D; Liu, YJ; Cheng, CS; Lyu, PC				Samuel, D; Liu, YJ; Cheng, CS; Lyu, PC			Solution structure of plant nonspecific lipid transfer protein-2 from rice (Oryza sativa)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; BINDING; PURIFICATION; SITES; FOLD; GENE	The three-dimensional structure of rice nonspecific lipid transfer protein (nsLTP2) has been solved for the first time. The structure of nsLTP2 was obtained using 813 distance constraints, 30 hydrogen bond constraints, and 19 dihedral angle constraints. Fifteen of the 50 random simulated annealing structures satisfied all of the constraints and possessed good nonbonded contacts. The novel three-dimensional fold of rice nsLTP2 contains a triangular hydrophobic cavity formed by three prominent helices. The four disulfide bonds required for stabilization of the nsLTP2 structure show a different pattern of cysteine pairing compared with nsLTP1. The C terminus of the protein is very flexible and forms a cap over the hydrophobic cavity. Molecular modeling studies suggested that the hydrophobic cavity could accommodate large molecules with rigid structures, such as sterols. The positively charged residues on the molecular surface of nsLTP2 are structurally similar to other plant defense proteins.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Tsing Hua University	Lyu, PC (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan.	lslpc@life.nthu.edu.tw						Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; BRUNGER AT, 1992, XPLOR SOFTWARE MANUA; Buhot N, 2001, FEBS LETT, V509, P27, DOI 10.1016/S0014-5793(01)03116-7; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; DeSamblanx GW, 1997, J BIOL CHEM, V272, P1171, DOI 10.1074/jbc.272.2.1171; Douliez JP, 2001, EUR J BIOCHEM, V268, P1400, DOI 10.1046/j.1432-1327.2001.02007.x; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; DUNN MA, 1991, MOL GEN GENET, V229, P389, DOI 10.1007/BF00267460; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Goddard T. D., 1999, SPARKY; Han GW, 2001, J MOL BIOL, V308, P263, DOI 10.1006/jmbi.2001.4559; Jegou S, 2000, J AGR FOOD CHEM, V48, P5023, DOI 10.1021/jf000075m; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Liu YJ, 2002, BIOCHEM BIOPH RES CO, V294, P535, DOI 10.1016/S0006-291X(02)00509-0; McManus AM, 1999, J MOL BIOL, V293, P629, DOI 10.1006/jmbi.1999.3163; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Pato C, 2001, BIOCHEM PHARMACOL, V62, P555, DOI 10.1016/S0006-2952(01)00708-0; Poznanski J, 1999, EUR J BIOCHEM, V259, P692, DOI 10.1046/j.1432-1327.1999.00093.x; Sodano P, 1997, FEBS LETT, V416, P130, DOI 10.1016/S0014-5793(97)01185-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trevino MB, 1998, PLANT PHYSIOL, V116, P1461, DOI 10.1104/pp.116.4.1461; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; Wang YJ, 1997, J BIOMOL NMR, V10, P373, DOI 10.1023/A:1018315729609; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P176; YU YG, 1988, ARCH BIOCHEM BIOPHYS, V265, P466, DOI 10.1016/0003-9861(88)90151-8	28	86	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35267	35273		10.1074/jbc.M203113200	http://dx.doi.org/10.1074/jbc.M203113200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12011089	hybrid			2022-12-25	WOS:000178117000079
J	Vanhauwe, JF; Thomas, TO; Minshall, RD; Tiruppathi, C; Li, AL; Gilchrist, A; Yoon, E; Malik, AB; Hamm, HE				Vanhauwe, JF; Thomas, TO; Minshall, RD; Tiruppathi, C; Li, AL; Gilchrist, A; Yoon, E; Malik, AB; Hamm, HE			Thrombin receptors activate G(o) proteins in endothelial cells to regulate intracellular calcium and cell shape changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; POSSIBLE INVOLVEMENT; SIGNAL-TRANSDUCTION; PERTUSSIS TOXIN; G-ALPHA(O); PATHWAY; RELEASE; SYSTEM; PERMEABILITY; EXPRESSION	Thrombin receptors couple to G(i/o), G(q), and G(12/13) proteins to regulate a variety of signal transduction pathways that underlie the physiological role of endothelial cells in wound healing or inflammation. Whereas the involvement of G(i), G(q), G(12), or G(13) proteins in thrombin signaling has been investigated extensively, the role of G(o) proteins has largely been ignored. To determine whether Go proteins could contribute to thrombin-mediated signaling in endothelial cells, we have developed minigenes that encode an 11-amino acid C-terminal peptide of G(o), proteins. Previously, we have shown that use of the C-terminal minigenes can specifically block receptor activation of G protein families (1). In this study, we demonstrate that G(o) proteins are present in human microvascular endothelial cells (HMECs). Moreover, we show that thrombin receptors can stimulate [S-35]guanosine-5'-O-(3-thio)triphosphate binding to Go proteins when co-expressed in Sf9 membranes. The potential coupling of thrombin receptors to Go proteins was substantiated by transfection of the G(o1) minigene into HMECs, which led to a blockade of thrombin-stimulated release of [Ca2+](i) from intracellular stores. Transfection of the beta-adrenergic kinase C terminus blocked the [Ca2+](i) response to the same extent as with G(o1) minigene peptide, suggesting that this Go-mediated [Ca2+](i) transient was caused by Gbetagamma stimulation of PLCbeta. Transfection of a G(i1/2) minigene had no effect on thrombin-stimulated [Ca2+](i) signaling in HMEC, suggesting that Gbetagamma derived from G(o) but not Gi could activate PLCbeta. The involvement of G(o) proteins on events downstream from calcium signaling was further evidenced by investigating the effect of G(o1) minigenes on thrombin-stimulated stress fiber formation and endothelial barrier permeability. Both of these effects were sensitive to pertussis toxin treatment and could be blocked by transfection of G(o1) minigenes but not G(i1/2) minigenes. We conclude that the G(o) proteins play a role in thrombin signaling distinct from G(i1/2) proteins, which are mediated through their Gbetagamma subunits and involve coupling to calcium signaling and cytoskeletal rearrangements.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Vanderbilt University; Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 442 Robinson Res Bldg, Nashville, TN 37232 USA.		Gilchrist, Annette/I-4465-2014; Hamm, Heidi E/G-2374-2014	Gilchrist, Annette/0000-0003-2386-7646; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60678-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aengevaeren WR, 1999, ATHEROSCLEROSIS, V147, pS11, DOI 10.1016/S0021-9150(99)00250-6; Aschner JL, 1997, J CELL PHYSIOL, V173, P387, DOI 10.1002/(SICI)1097-4652(199712)173:3<387::AID-JCP11>3.0.CO;2-9; BAFFY G, 1994, J BIOL CHEM, V269, P8483; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Boulanger CM, 1997, J VASC RES, V34, P175, DOI 10.1159/000159221; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; FLAVAHAN NA, 1990, BLOOD VESSELS, V27, P218; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Gomez MD, 2000, J NEUROSCI, V20, P5254, DOI 10.1523/JNEUROSCI.20-14-05254.2000; Holtje M, 2000, J NEUROSCI, V20, P2131; HUANG CL, 1987, J BIOL CHEM, V262, P14134; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KAJIYAMA Y, 1990, BIOCHEM J, V270, P69, DOI 10.1042/bj2700069; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; MANOLOPOULOS VG, 1995, J CELL BIOCHEM, V57, P590, DOI 10.1002/jcb.240570403; Manolopoulos VG, 1997, BBA-MOL CELL RES, V1356, P321, DOI 10.1016/S0167-4889(97)00002-5; MANOLOPOULOS VG, 1995, BIOCHEM BIOPH RES CO, V208, P323, DOI 10.1006/bbrc.1995.1341; MARSEN TA, 1995, CIRC RES, V76, P987, DOI 10.1161/01.RES.76.6.987; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Murphy JT, 2001, J TRAUMA, V50, P213, DOI 10.1097/00005373-200102000-00005; OROURKE F, 1987, FEBS LETT, V214, P176, DOI 10.1016/0014-5793(87)80037-6; Rydholm HE, 1998, SCAND J CLIN LAB INV, V58, P347, DOI 10.1080/00365519850186535; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; vandenEijndenSchrauwen Y, 1997, ARTERIOSCL THROM VAS, V17, P2177, DOI 10.1161/01.ATV.17.10.2177; Vanhauwe JFM, 2000, PSYCHOPHARMACOLOGY, V150, P383, DOI 10.1007/s002130000418; Wu KK, 1996, ANNU REV MED, V47, P315	36	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34143	34149		10.1074/jbc.M204477200	http://dx.doi.org/10.1074/jbc.M204477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12039967	hybrid			2022-12-25	WOS:000177959100081
J	Chen, Y; Cai, JY; Murphy, TJ; Jones, DP				Chen, Y; Cai, JY; Murphy, TJ; Jones, DP			Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCATOR; MAMMALIAN THIOREDOXIN; CYTOCHROME-C; REDUCTASE; CLONING; DEATH; IDENTIFICATION; EXPRESSION; RELEASE	Oxidative damage to mitochondria is a central mechanism of apoptosis induced by many toxic chemicals. Thioredoxin family proteins share a conserved Cys-X-X-Cys motif at their active center and play important roles in control of cellular redox state and protection against oxidative damage. In addition to the well studied cytosolic and extracellular form (Trx1), rat and avian mitochondrial forms of thioredoxin (mtTrx) have been reported. In this study, we cloned the full-length human mtTrx cDNA and performed localization and functional studies in 143B human osteosarcoma cells. The coding sequence of human mtTrx consists of a region with homology to Trx1 as well as a putative mitochondrial localization signal (MLS) at its N terminus. In stably transfected cell lines, mtTrx had a mitochondrial localization as measured by subcellular fractionation studies and by confocal fluorescence microscopy. Deletion of the MLS rendered mtTrx to be solely expressed in the cytosolic fraction. On SDS-PAGE, transfected mtTrx had the same apparent molecular weight as the MLS truncated form, indicating that the leader sequence is cleaved during or after mitochondrial import. Treatment with the oxidant tert-butylhydroperoxide induced apoptosis in 143B cells. This oxidant-induced apoptosis was inhibited by overexpressing the full-length mtTrx in 143B cells. Thus, human mtTrx is a member of the thioredoxin family of proteins localized to mitochondria and may play important roles in protection against oxidant-induced apoptosis.	Emory Univ, Dept Biochem, Rollins Res Ctr 4131, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Jones, DP (corresponding author), Emory Univ, Dept Biochem, Rollins Res Ctr 4131, Atlanta, GA 30322 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011195, R01ES009047] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56107] Funding Source: Medline; NIEHS NIH HHS [ES11195, ES09047] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baker A, 1997, CANCER RES, V57, P5162; BODENSTEINLANG J, 1989, FEBS LETT, V258, P22, DOI 10.1016/0014-5793(89)81606-0; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; HEATH RL, 1976, ANAL BIOCHEM, V76, P184, DOI 10.1016/0003-2697(76)90277-3; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Miller S, 2001, CLIN SCI, V100, P543, DOI 10.1042/CS20000299; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5	32	137	146	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33242	33248		10.1074/jbc.M202026200	http://dx.doi.org/10.1074/jbc.M202026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12032145	hybrid			2022-12-25	WOS:000177859000109
J	Inoue, M; Fujii, Y; Furukawa, K; Okada, M; Okumura, K; Hayakawa, T; Furukawa, K; Sugiura, Y				Inoue, M; Fujii, Y; Furukawa, K; Okada, M; Okumura, K; Hayakawa, T; Furukawa, K; Sugiura, Y			Refractory skin injury in complex knock-out mice expressing only the GM3 ganglioside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SYNTHASE GENE; CELLS; DIFFERENTIATION; NEUROPEPTIDES; EXHIBIT; CLONING; FIBERS	We generated double knock-out mice lacking the GM2/GD2 and the GD3 synthase gene by mating single gene mutants, and we analyzed the abnormal phenotypes of the mutant mice expressing only the GM3 ganglioside. We observed a refractory skin lesion that appeared primarily on the face of the mutant mice at 25 weeks after birth or later. Frequent scratching of the wound sites was observed in mutant mice with the skin injury, suggesting that it is a triggering factor that exacerbates the injury. This was confirmed by isolating mice in special cages for metabolic study in which the skin injury developed more rapidly. Characteristic proliferation of nerve fibers was found in the epidermis and subepidermis at the injured sites of the mutants, probably a result of continuous skin injury. Peripheral nerve degeneration was observed in young mutant mice, suggesting that reduced sensory function induced over-scratching and the resulting skin lesion. The fact that sensory response to mechanical stimuli decreased while that to hot stimuli increased in the mutant mice supports this interpretation. Thus, only GM3-expressing mice displayed the important role of gangliosides in maintaining skin integrity via regulation of the peripheral nerves.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Anat 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 8528523, Japan	Nagoya University; Nagoya University; Nagoya University; Nagasaki University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp						DAY INM, 1990, BIOCHEM J, V268, P521, DOI 10.1042/bj2680521; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; EEDY DJ, 1993, BRIT J DERMATOL, V128, P597, DOI 10.1111/j.1365-2133.1993.tb00252.x; FERRARI G, 1993, J NEUROSCI, V13, P1879; Fukumoto S, 1997, GLYCOBIOLOGY, V7, P1111, DOI 10.1093/glycob/7.8.1111; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furukawa K, 2001, BBA-GEN SUBJECTS, V1525, P1, DOI 10.1016/S0304-4165(00)00185-9; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; GIANNETTI A, 1989, BRIT J DERMATOL, V121, P681, DOI 10.1111/j.1365-2133.1989.tb08209.x; Grewe M, 2000, J INVEST DERMATOL, V114, P1108, DOI 10.1046/j.1523-1747.2000.00974.x; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANDWERKER HO, 1987, EXP BRAIN RES, V65, P493; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hicks D, 1998, GEN PHARMACOL, V30, P265, DOI 10.1016/S0306-3623(97)00356-X; Kawai H, 2001, J BIOL CHEM, V276, P6885, DOI 10.1074/jbc.C000847200; MARTH JD, 1994, GLYCOCONJUGATE J, V11, P3, DOI 10.1007/BF00732424; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKASHIMA T, 1988, ANN OTO RHINOL LARYN, V97, P146, DOI 10.1177/000348948809700211; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; PINCELLI C, 1994, J INVEST DERMATOL, V103, P13, DOI 10.1111/1523-1747.ep12388914; Sato T, 1999, GLYCOCONJUGATE J, V16, P73, DOI 10.1023/A:1006957921382; SCHENGRUND CL, 1990, BRAIN RES BULL, V24, P131, DOI 10.1016/0361-9230(90)90297-D; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Sugiura H, 1997, ARCH DERMATOL RES, V289, P125, DOI 10.1007/s004030050167; SUZUKI K, 1967, J NEUROCHEM, V14, P917, DOI 10.1111/j.1471-4159.1967.tb09582.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; TOBIN D, 1992, J ALLERGY CLIN IMMUN, V90, P613, DOI 10.1016/0091-6749(92)90134-N; UNSICKER K, 1988, EXP CELL RES, V178, P377, DOI 10.1016/0014-4827(88)90407-7; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179; Wahlgren Carl-Fredrik, 1999, Journal of Dermatology (Tokyo), V26, P770; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; Zhao JM, 1999, J BIOL CHEM, V274, P13744, DOI 10.1074/jbc.274.20.13744	35	87	88	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29881	29888		10.1074/jbc.M201631200	http://dx.doi.org/10.1074/jbc.M201631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023957	hybrid			2022-12-25	WOS:000177509300068
J	Plafker, K; Macara, IG				Plafker, K; Macara, IG			Fluorescence resonance energy transfer biosensors that detect ran conformational changes and a Ran center dot GDP-importin-beta-RanBP1 complex in vitro and in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN IMPORT; GDP-BOUND FORM; LIVING CELLS; BINDING DOMAINS; FACTOR P97; TRANSPORT; RCC1; EXPORT; BETA; LOCALIZATION	The Ran GTPase plays a central role in nucleocytoplasmic transport. Association of Ran-GTP with transport carriers (karyopherins) triggers the loading/unloading of export or import cargo, respectively. The C-terminal tail of Ran-GTP is deployed in an extended conformation when associated with a Ran binding domain or importins. To monitor tail orientation, a Ran-GFP fusion was labeled with the fluorophore Alexa546. Fluorescence resonance energy transfer (FRET) occurs efficiently between the green fluorescent protein (GFP) and Alexa546 for Ran-GDP and Ran-GTP, suggesting that the tail is tethered in both states. However, Ran-GTP complexes with importin-beta, RariBP1, and Crm1 all show reduced FRET consistent with tail extension. Displacement of the C-terminal tail of Ran by karyopherins may be a general mechanism to facilitate RanBP1 binding. A Ran.GDP-RanBP1-importin-beta complex also displayed a low FRET signal. To detect this complex in vivo, a bipartite biosensor consisting of Ran-Alexa546 plus GST-GFP-RanBP1, was co-injected into the cytoplasm of cells. The Ran redistributed predominately to the nucleus, and RanBP1 remained cytoplasmic. Nonetheless, a robust cytoplasmic FRET signal was detectable, which suggests that a significant fraction of cytoplasmic Ran-GDP may exist in a ternary complex with RanBP1 and importins.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Macara, IG (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, POB 800577, Charlottesville, VA 22908 USA.							Askjaer P, 1999, MOL CELL BIOL, V19, P6276; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; Deane R, 1997, MOL CELL BIOL, V17, P5087, DOI 10.1128/MCB.17.9.5087; Englmeier L, 2001, EMBO REP, V2, P926, DOI 10.1093/embo-reports/kve200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Izaurralde E, 1998, RNA, V4, P351; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Lindsay ME, 2001, J CELL BIOL, V153, P1391, DOI 10.1083/jcb.153.7.1391; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mueller L, 1998, FEBS LETT, V427, P330, DOI 10.1016/S0014-5793(98)00459-1; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969	32	36	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30121	30127		10.1074/jbc.M203006200	http://dx.doi.org/10.1074/jbc.M203006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034733	hybrid			2022-12-25	WOS:000177509300095
J	Zhao, YW; Yue, LL; Gu, DS; Mazzone, T				Zhao, YW; Yue, LL; Gu, DS; Mazzone, T			Regulation of macrophage ApoE expression and processing by extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENE; CORONARY ATHEROSCLEROTIC PLAQUES; APOPROTEIN-E; CHOLESTEROL EFFLUX; LIPOPROTEIN-LIPASE; CELL-SURFACE; E SECRETION; FIBRONECTIN; ADHESION; MONOCYTES	Macrophage-derived apoE in the vessel wall has important effects on atherogenesis in vivo, making it important to understand factors that regulate its expression. Vessel wall macrophages are embedded in an extracellular matrix produced largely by arterial smooth muscle cells and endothelial cells. In this series of studies, we evaluated the influence of extracellular matrix on macrophage apoE expression. Subendothelial matrix, fibronectin, or collagen I stimulated macrophage apoE gene expression and apoE synthesis. Adhesion of macrophages to a polylysine substrate had no effect. An increase in apoE synthesis after plating on fibronectin could be observed by 2 h and was inhibited by blocking antibodies to the alpha(5)beta(1) integrin receptor for fibronectin. Fibronectin also regulated the post-translational processing of newly synthesized macrophage apoE by inhibiting its degradation. The increment in apoE resulting from suppressed degradation was retained in the cell-fibronectin monolayer in a pool that was resistant to release by exogenous high density lipoprotein subfraction 3. These observations establish a new pathway for the regulation of macrophage apoE expression in the vessel wall. The composition of the extracellular matrix changes after vessel wall injury and in response to locally produced cytokines and growth factors. The evolving composition of this matrix will, therefore, be important for regulating apoE expression and processing by vessel wall macrophages.	Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA	Rush University; Rush University	Mazzone, T (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Med, 1653 W Congress Pkwy, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL 59489, HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059489, R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assoian RK, 1996, J CLIN INVEST, V98, P2436, DOI 10.1172/JCI119059; BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DORY L, 1991, J LIPID RES, V32, P783; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; DUAN HW, 1995, J CLIN INVEST, V96, P915, DOI 10.1172/JCI118139; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; HUANG DY, 1995, EXP NEUROL, V136, P251, DOI 10.1006/exnr.1995.1101; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; Klezovitch O, 2000, J BIOL CHEM, V275, P18913, DOI 10.1074/jbc.M909644199; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lin CY, 1999, J LIPID RES, V40, P1618; Lin CY, 2001, J LIPID RES, V42, P1125; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; O'Blenes CAE, 2001, CIRC RES, V89, P26, DOI 10.1161/hh1301.093631; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; OBRIEN KD, 1994, AM J PATHOL, V144, P538; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SAXENA U, 1993, J BIOL CHEM, V268, P14812; Schmitz G, 1997, CURR OPIN LIPIDOL, V8, P287, DOI 10.1097/00041433-199710000-00008; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; WERB Z, 1993, J BIOL CHEM, V258, P10642; Wesley RB, 1998, ARTERIOSCL THROM VAS, V18, P432, DOI 10.1161/01.ATV.18.3.432; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759	37	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29477	29483		10.1074/jbc.M200219200	http://dx.doi.org/10.1074/jbc.M200219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034716	hybrid			2022-12-25	WOS:000177509300018
J	Feldman, DS; Zamah, AM; Pierce, KL; Miller, WE; Kelly, F; Rapacciuolo, A; Rockman, HA; Koch, WJ; Luttrell, LM				Feldman, DS; Zamah, AM; Pierce, KL; Miller, WE; Kelly, F; Rapacciuolo, A; Rockman, HA; Koch, WJ; Luttrell, LM			Selective inhibition of Heterotrimeric G(s) signaling - Targeting the receptor-G protein interface using a peptide minigene encoding the G alpha(s) carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; VIVO PRESSURE-OVERLOAD; TRIMERIC G-PROTEINS; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; IN-VIVO; CYTOPLASMIC DOMAINS; PHOSPHOLIPASE-C; ALPHA MUTANT; KINASE	The blockade of heptahelical receptor coupling to heterotrimeric G proteins by the expression of peptides derived from G protein Galpha subunits represents a novel means of simultaneously inhibiting signals arising from multiple receptors that share a common G protein pool. Here we examined the mechanism of action and functional consequences of expression of an 83-amino acid polypeptide derived from the carboxyl terminus of Ga. (GsCT). In membranes prepared from GsCT-expressing cells, the peptide blocked high affinity agonist binding to 132 adrenergic receptors (AR) and inhibited beta(2)AR-induced [S-35]GTPgammaS loading of Galpha(s). GsCT expression inhibited beta(2)AR- and dopamine D-1A receptor-mediated cAMP production, without affecting the cellular response to cholera toxin or forskolin, indicating that the peptide inhibited receptor-G. coupling without impairing G protein or adenylyl cyclase function. [S-35]GTPgammaS loading of Galpha(q/11) by alpha(1B)ARs and Galpha(i) by alpha(2A)ARs and G(q/11)- or G(i)-mediated phosphatidylinositol hydrolysis was unaffected, indicating that the inhibitory effects of GsCT were selective for G.. We next employed the GsCT construct to examine the complex role of G. in regulation of the ERK mitogen-activated protein kinase cascade, where activation of the cAMP-dependent protein kinase (PKA) pathway reportedly produces both stimulatory and inhibitory effects on heptahelical receptor-mediated ERK activation. For the beta(2)AR in HEK-293 cells, where PKA activity is required for ERK activation, expression of GsCT caused a net inhibition of ERK activation. In contrast, alpha(2A)AR-mediated ERK activation in COS-7 cells was enhanced by GsCT expression, consistent with the relief of a downstream inhibitory effect of PKA. ERK activation by the G(q/11)-coupled alpha(1B)AR was unaffected by GsCT. These findings suggest that peptide G protein inhibitors can provide insights into the complex interplay between G protein pools in cellular regulation.	Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC 27705 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University; Duke University	Luttrell, LM (corresponding author), Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, N3019 GRECC,508 Fulton St, Durham, NC 27705 USA.		Kelly, Frank J/C-6125-2009; Rapacciuolo, Antonio/AAR-8012-2020	Kelly, Frank J/0000-0003-2558-8392; Rapacciuolo, Antonio/0000-0002-4739-7004; Luttrell, Louis/0000-0003-2805-6949	NIDDK NIH HHS [DK55524] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Dorn GW, 1997, BIOCHEMISTRY-US, V36, P6415, DOI 10.1021/bi970080s; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; Esposito G, 2001, CIRCULATION, V103, P1453, DOI 10.1161/01.CIR.103.10.1453; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; Mazzoni MR, 2000, MOL PHARMACOL, V58, P226, DOI 10.1124/mol.58.1.226; Mischak H, 1996, MOL CELL BIOL, V16, P5409; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SEVARESE TM, 1992, BIOCHEM J, V283, P1; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	43	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28631	28640		10.1074/jbc.M204753200	http://dx.doi.org/10.1074/jbc.M204753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036966	hybrid			2022-12-25	WOS:000177342600038
J	Fukuda, M; Katayama, E; Mikoshiba, K				Fukuda, M; Katayama, E; Mikoshiba, K			The calcium-binding loops of the tandem C2 domains of synaptotagmin VII cooperatively mediate calcium-dependent oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE-CORE VESICLES; BETA-CELLS; FUNCTIONAL DIVERSITY; TRANSMITTER RELEASE; ANTIBODY INJECTION; SYNAPTIC VESICLE; EXOCYTOSIS; ISOFORMS; PROTEIN; FAMILY	Synaptotagmin VII (Syt VII), a proposed regulator for Ca2+-dependent exocytosis, showed a robust Ca2+-dependent oligomerization property via its two C2 domains (Fukuda, M., and Mikoshiba, K. (2001) J. Biol. Chem. 276, 27670-27676), but little is known about its structure or the critical residues directly involved in the oligomerization interface. In this study, site-directed mutagenesis and chimeric analysis between Syt I and Syt VII showed that three Asp residues in Ca2+-binding loop 1 or 3 (Asp-172, Asp-303, and Asp-357) are crucial to robust Ca2+-dependent oligomerization. Unlike Syt 1, however, the polybasic sequence in the 134 strands of the C2 structures (so-called "C2 effector domain") is not involved in the Ca2+-dependent oligomerization of Syt VII. The results also showed that the Ca2+-binding loops of the two C2 domains cooperatively mediate Syt VII oligomerization (i.e. the presence of redundant Ca2+-binding site(s)) as well as the importance of Ca2+-dependent oligomerization of Syt VII in Ca2+-regulated secretion. Expression of wild-type tandem C2 domains of Syt VII in PC12 cells inhibited Ca2+-dependent neuropeptide Y release, whereas mutant fragments lacking Ca2+-dependent oligomerization activity had no effect. Finally, rotary-shadowing electron microscopy showed that the Ca2+-dependent oligomer of Syt VII is "a large linear structure," not an irregular aggregate. By contrast, in the absence of Ca2+ Syt VII molecules were observed to form a globular structure. Based on these results, we suggest that the linear Ca2+-dependent oligomer may be aligned at the fusion site between vesicles and plasma membrane and modulate Ca2+-regulated exocytosis by opening or dilating fusion pores.	RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Biomol Imaging,Minato Ku, Tokyo 1088639, Japan; JST, PRESTO, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; RIKEN; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, Inst Phys & Chem Res, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				Bennett MR, 1999, PROG NEUROBIOL, V59, P243, DOI 10.1016/S0301-0082(99)00004-0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Craxton M, 2001, GENOMICS, V77, P43, DOI 10.1006/geno.2001.6619; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Gut A, 2001, J CELL SCI, V114, P1709; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; KATAYAMA E, 1995, BIOPHYS J, V68, P2419, DOI 10.1016/S0006-3495(95)80424-8; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizuta M, 1997, DIABETES, V46, P2002, DOI 10.2337/diabetes.46.12.2002; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002	49	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29315	29320		10.1074/jbc.M201697200	http://dx.doi.org/10.1074/jbc.M201697200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034723	hybrid			2022-12-25	WOS:000177342600121
J	Macias-Silva, M; Li, W; Leu, JI; Crissey, MAS; Taub, R				Macias-Silva, M; Li, W; Leu, JI; Crissey, MAS; Taub, R			Up-regulated transcriptional repressors SnoN and Ski bind Smad proteins to antagonize transforming growth factor-beta signals during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; DNA-SYNTHESIS; RAT-LIVER; CO-REPRESSOR; IN-VIVO; HEPATOCYTES; RECEPTOR; CELLS; PROTOONCOGENE; ACTIVATION	Transforming growth factor-beta (TGF-beta) functions as an antiproliferative factor for hepatocytes. However, for unexplained reasons, hepatocytes become resistant to TGF-beta signals and can proliferate despite the presence of TGF-beta during liver regeneration. TGF-beta is up-regulated during liver regeneration, although it is not known whether it is active or latent. TGF-beta activity may be examined by assessing Smad activation, a downstream signaling pathway. Smad pathway activation during liver regeneration induced by partial hepatectomy or CCl4 injury was examined by assessing the levels of phospho-Smad2 and Smad2-Smad4 complexes . We found that Smad proteins were slightly activated in quiescent liver, but that their activation was further enhanced in regenerating liver. Interestingly, TGF-beta/Smad pathway inhibitors (SnoN and Ski) were up-regulated during regeneration, and notably, SnoN was induced mainly in hepatocytes. SnoN and Ski are transcriptional repressors that may render some cells resistant to TGF-beta via binding Smad proteins. Complexes between SnoN, Ski, and the activated Smad proteins were detected from 2 to 120 h during the major proliferative phase in regenerating liver. Inhibitory complexes decreased after liver mass restitution (5-15 days), suggesting that persistently activated Smad proteins might participate in returning the liver to a quiescent state. Our data show that active TGF-beta/Smad signals are present during regeneration and suggest that SnoN/Ski induction might explain hepatocyte resistance to TGF-beta during the proliferative phase.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	University of Pennsylvania; Universidad Nacional Autonoma de Mexico	Taub, R (corresponding author), Bristol Myers Squibb Co, Rte 141 & Clay Rd,Expt Stn 400,Rm 2418, Wilmington, DE 19880 USA.	rebecca.taub@bms.com			NIDDK NIH HHS [DK49629] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049629] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; [Anonymous], GENOME BIOL; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Bouzahzah B, 2000, CANCER RES, V60, P4531; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BRAUN L, 1990, CELL GROWTH DIFFER, V1, P103; CARR BI, 1986, CANCER RES, V46, P2330; CHARI RS, 1995, AM J SURG, V169, P126, DOI 10.1016/S0002-9610(99)80120-2; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Date M, 1998, J HEPATOL, V28, P572, DOI 10.1016/S0168-8278(98)80280-8; Date M, 2000, GUT, V46, P719, DOI 10.1136/gut.46.5.719; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FUMAGALLI S, 1993, MELANOMA RES, V3, P23, DOI 10.1097/00008390-199304000-00004; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Grasl-Kraupp B, 1998, HEPATOLOGY, V28, P717, DOI 10.1002/hep.510280318; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STRAIN AJ, 1987, BIOCHEM BIOPH RES CO, V145, P436, DOI 10.1016/0006-291X(87)91340-4; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sugiyama A, 1997, BIOCHEM BIOPH RES CO, V238, P539, DOI 10.1006/bbrc.1997.7338; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Taub R, 1999, SEMIN LIVER DIS, V19, P117, DOI 10.1055/s-2007-1007104; Taub R, 1996, CLIN LAB MED, V16, P341, DOI 10.1016/S0272-2712(18)30273-7; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wrana JL, 1999, HEPATOLOGY, V29, P1909, DOI 10.1002/hep.510290641; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727	62	75	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28483	28490		10.1074/jbc.M202403200	http://dx.doi.org/10.1074/jbc.M202403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023281	hybrid			2022-12-25	WOS:000177342600019
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Shah, D; Scott, G; Burns, PA; Menichini, P; Abbondandolo, A; Gold, B; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Shah, D; Scott, G; Burns, PA; Menichini, P; Abbondandolo, A; Gold, B; Fronza, G			Influences of base excision repair defects on the lethality and mutagenicity induced by Me-lex, a sequence-selective N3-adenine methylating agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; APURINIC ENDONUCLEASE; MUTATIONAL SPECTRA; FUNCTIONAL ASSAY; SULFONATE ESTER; ABASIC SITES; DNA-DAMAGE; YEAST; ALKYLATION	Due to its minor groove selectivity, Me-lex preferentially generates N3-methyladenine (3-MeA) adducts in double-stranded DNA. We undertook a genetic approach in yeast to establish the influence of base excision repair (BER) defects on the processing of Me-lex lesions on plasmid DNA that harbors the p53 cDNA as target. We constructed a panel of isogenic strains containing a reporter gene to test p53 function and the following gene deletions: Deltamag1, Deltaapn1apn2, and Deltaapn1apn2mag1. When compared with the wild-type strain, a decrease in survival, was observed in Deltamag1, Deltaapn1apn2, and Deltaapn1apn2mag1. The Me-lex-induced mutation frequency increased in the following order: wild type < Deltamag1 < Deltaapn1apn2 = Deltaapn1apn2mag1. A total of 77 mutants (23 in wild type, 31 in Deltamag1, and 23 in Deltaapn1apn2) were sequenced. Eighty-one independent mutations (24 in wild type, 34 in Deltamag1, and 23 in Deltaapn1apn2) were detected. The majority of base pair substitutions were AT-targeted in all strains (14/23, 61% in wild type; 20/34, 59%, in Deltamag1; and 14123, 61%, in Deltaapn1apn2). The Mag1 deletion was associated with a significant decrease of GC > AT transitions when compared with both the wild-type and the AP endonuclease mutants. This is the first time that the impact of Mag1 and/or AP endonuclease defects on the mutational spectra caused by 3-MeA has been determined. The results suggest that 3-MeA is critical for Me-lex cytotoxicity and that its mutagenicity is slightly elevated in the absence of Mag1 glycosylase activity but significantly higher in the absence of AP endonuclease activity.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 69198 USA; Natl Canc Res Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Leeds; University of Genoa	Gold, B (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 69198 USA.	bgold@umnc.edu; gilberto.fronza@istge.it	Inga, Alberto/AAC-3815-2022; Campomenosi, Paola/C-9729-2011; Menichini, Paola/K-9422-2016; Monti, Paola/Y-1118-2019; Fronza, Gilberto/AAG-8735-2019; Ciribilli, Yari/K-2751-2018	Inga, Alberto/0000-0002-8767-1637; Campomenosi, Paola/0000-0002-8853-1134; Monti, Paola/0000-0002-1978-4998; Fronza, Gilberto/0000-0003-3722-553X; Ciribilli, Yari/0000-0001-9231-379X; Menichini, Paola/0000-0003-0057-6184	NCI NIH HHS [R01 CA 29088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; CHURCH KM, 1990, BIOCHEMISTRY-US, V29, P6827, DOI 10.1021/bi00481a011; Dinglay S, 1998, MUTAT RES-DNA REPAIR, V407, P109, DOI 10.1016/S0921-8777(97)00065-7; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FUJII T, 1989, NUCL ACIDS S SER, V8, pS17; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HENRYAMAR M, 1993, HEMATOL ONCOL CLIN N, V7, P369, DOI 10.1016/S0889-8588(18)30246-6; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; KARRAN P, 1980, J MOL BIOL, V140, P101, DOI 10.1016/0022-2836(80)90358-7; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; MARGISON GP, 1973, BIOCHIM BIOPHYS ACTA, V331, P349, DOI 10.1016/0005-2787(73)90021-X; MARSELOS M, 1991, CARCINOGENESIS, V12, P1751, DOI 10.1093/carcin/12.10.1751; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Shah D, 2001, BIOCHEMISTRY-US, V40, P1796, DOI 10.1021/bi0024658; Storici F, 1999, YEAST, V15, P271, DOI 10.1002/(SICI)1097-0061(19990315)15:4<271::AID-YEA371>3.0.CO;2-U; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; WEI X, 1993, P NATL ACAD SCI USA, V90, P2117, DOI 10.1073/pnas.90.6.2117; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138; ZHANG Y, 1993, BIOCHEMISTRY-US, V32, P7954, DOI 10.1021/bi00082a017	29	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28663	28668		10.1074/jbc.M203384200	http://dx.doi.org/10.1074/jbc.M203384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042310	hybrid			2022-12-25	WOS:000177342600042
J	Hayashi, T; Kaneda, T; Toyama, Y; Kumegawa, M; Hakeda, Y				Hayashi, T; Kaneda, T; Toyama, Y; Kumegawa, M; Hakeda, Y			Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS) - The possible counteracting role of SOCSs in IFN-beta-inhibited osteoclast formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TOLL-LIKE RECEPTOR-2; DENDRITIC CELLS; DIFFERENTIATION FACTOR; TYROSINE PHOSPHATASE; BONE-RESORPTION; TNF-ALPHA; TGF-BETA; GAMMA; LIPOPOLYSACCHARIDE	Bone resorption and the immune system are correlated with each other, and both are controlled by a variety of common cytokines produced in the bone micro-environments. Among these immune mediators, the involvement of type I interferons (IFNs) in osteoclastic bone resorption remains unknown. In this study, we investigated the participation of IFN-beta and suppressors of cytokine signaling (SOCS)-1 and -3 in osteoclastogenesis. Addition of exogenous IFN-beta to osteoclast progenitors (bone-derived monocytes/macrophages) inhibited their differentiation toward osteoclasts induced by the receptor activator of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor with/without transforming growth factor-beta, where inhibition was associated with down-regulation of the gene expressions of molecules related to osteoclast differentiation. In addition, RANKL induced the expression of IFN-beta; furthermore, neutralizing antibody against type I IFNs accelerated the osteoclast formation, indicating type I IFNs as potential intrinsic inhibitors. On the other hand, RANKL also induced the expression of SOCS-1 and -3, suppressors of the IFN signaling. Pretreatment with RANKL for a sufficient time for the induction of SOCSs attenuated phosphorylation of STAT-1 in response to IFN-beta in osteoclast progenitors, causing a decrease in the binding activity of nuclear extracts toward the interferon-stimulated response element. mRNA levels of STAT-1, STAT-2, and IFN-stimulated gene factor-3gamma, comprising IFN-stimulated gene factor-3, were not altered by RANKL. Thus, although the inhibitory cytokine such as IFN-beta is produced in response to RANKL, the inhibition of osteoclastogenesis may be rescued by the induction of signaling suppressors such as SOCSs.	Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1608582, Japan; Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol, Tokyo 1428501, Japan	Meikai University; Keio University; Hoshi University	Hakeda, Y (corresponding author), Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan.		Toyama, Yoshiaki/K-5743-2013					Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; BIZZARRI C, 1994, J BIOL CHEM, V269, P13817; Boisclair YR, 2000, J BIOL CHEM, V275, P3841, DOI 10.1074/jbc.275.6.3841; CHAMBERS TJ, 1985, J CLIN PATHOL, V38, P241, DOI 10.1136/jcp.38.3.241; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; FELIX R, 1990, J BONE MINER RES, V5, P781; Fox SW, 2000, J IMMUNOL, V165, P4957, DOI 10.4049/jimmunol.165.9.4957; Fox SW, 2000, BIOCHEM BIOPH RES CO, V276, P868, DOI 10.1006/bbrc.2000.3577; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; FULLER K, 1995, J IMMUNOL, V154, P6065; GESSANI S, 1994, J LEUKOCYTE BIOL, V56, P358, DOI 10.1002/jlb.56.3.358; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GOWEN M, 1986, J IMMUNOL, V136, P2478; Hamilton JA, 1996, J IMMUNOL, V156, P2553; Hong MH, 2000, J BONE MINER RES, V15, P911, DOI 10.1359/jbmr.2000.15.5.911; Horwood NJ, 2001, J IMMUNOL, V166, P4915, DOI 10.4049/jimmunol.166.8.4915; HUGHES TK, 1994, J INTERFERON RES, V14, P117, DOI 10.1089/jir.1994.14.117; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jimi E, 1999, J IMMUNOL, V163, P434; Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254; Kile BT, 2001, CELL MOL LIFE SCI, V58, P1627, DOI 10.1007/PL00000801; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Le Page C, 2000, Rev Immunogenet, V2, P374; Lehner M, 2001, BLOOD, V98, P736, DOI 10.1182/blood.V98.3.736; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; Mino T, 1998, ARTHRITIS RHEUM, V41, P2004, DOI 10.1002/1529-0131(199811)41:11<2004::AID-ART16>3.0.CO;2-Z; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicola NA, 2000, EXP HEMATOL, V28, P1105, DOI 10.1016/S0301-472X(00)00525-7; Parlato S, 2001, BLOOD, V98, P3022, DOI 10.1182/blood.V98.10.3022; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Rothfuchs AG, 2001, J IMMUNOL, V167, P6453, DOI 10.4049/jimmunol.167.11.6453; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; Scopes J, 2001, BONE, V29, P203, DOI 10.1016/S8756-3282(01)00500-2; Sick C, 1998, J BIOL CHEM, V273, P9749, DOI 10.1074/jbc.273.16.9749; Sing A, 2000, INFECT IMMUN, V68, P1600, DOI 10.1128/IAI.68.3.1600-1607.2000; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stoiber D, 1999, J IMMUNOL, V163, P2640; SUDA T, 1995, BONE S2, V17, P87; TAKAHASHI N, 1986, J IMMUNOL, V137, P3544; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Van Weyenbergh J, 2001, IMMUNOL LETT, V75, P117, DOI 10.1016/S0165-2478(00)00303-5; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; VIGNERY A, 1990, J BONE MINER RES, V5, P637; Wang XY, 2000, J VIROL, V74, P11566, DOI 10.1128/JVI.74.24.11566-11573.2000; Weiden M, 2000, J IMMUNOL, V165, P2028, DOI 10.4049/jimmunol.165.4.2028; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	64	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27880	27886		10.1074/jbc.M203836200	http://dx.doi.org/10.1074/jbc.M203836200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023971	hybrid			2022-12-25	WOS:000177189800038
J	Okada, K; Moe, PC; Blount, P				Okada, K; Moe, PC; Blount, P			Functional design of bacterial mechanosensitive channels - Comparisons and contrasts illuminated by random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; LARGE-CONDUCTANCE; GATING MECHANISM; ION-CHANNEL; MSCL; PROTEIN; IDENTIFICATION; MUTATIONS; TENSION	MscS and MscL are mechanosensitive channels found in bacterial plasma membranes that open large pores in response to membrane tension. These channels function to alleviate excess cell turgor invoked by rapid osmotic downshock. Although much is known of the structure and molecular mechanisms underlying MscL, genes correlating with MscS activity have only recently been identified. Previously, it was shown that eliminating the expression of Escherichia coli yggB removed a major portion of MscS activity. YggB is distinct from MscL by having no obvious structural similarity. Here we have reconstituted purified YggB in proteoliposomes and have successfully detected MscS channel activity, confirming that purified YggB protein encodes MscS activity. Additionally, to define functional regions of the channel protein, we have randomly mutagenized the structural gene and isolated a mutant that evokes a gain-of-function phenotype. Physiological experiments demonstrate that the mutated channel allows leakage of solutes from the cell, suggesting inappropriate channel opening. Interestingly, this mutation is analogous in position and character to mutations yielding a similar phenotype in MscL. Hence, although MscS and MscL mechanosensitive channels are structurally quite distinct, there may be analogies in their gating mechanisms.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60818] Funding Source: Medline; NIGMS NIH HHS [R01 GM061028, GM61028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Batiza AF, 2002, P NATL ACAD SCI USA, V99, P5643, DOI 10.1073/pnas.082092599; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; DAWSON RMC, 1968, DATA BIOCH RES, P501; Elmore DE, 2001, BIOPHYS J, V81, P1345, DOI 10.1016/S0006-3495(01)75791-8; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Innis MA, 1990, PCR PROTOCOLS GUIDE; Kloda A, 2001, EMBO J, V20, P1888, DOI 10.1093/emboj/20.8.1888; Kloda A, 2001, BIOPHYS J, V80, P229, DOI 10.1016/S0006-3495(01)76009-2; Kloda Anna, 2002, Archaea, V1, P35, DOI 10.1155/2002/419261; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Martinac B, 2001, CELL PHYSIOL BIOCHEM, V11, P61, DOI 10.1159/000047793; Maurer JA, 2000, J BIOL CHEM, V275, P22238, DOI 10.1074/jbc.M003056200; McLaggan D, 2002, MOL MICROBIOL, V43, P521, DOI 10.1046/j.1365-2958.2002.02764.x; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Moe PC, 2000, J BIOL CHEM, V275, P31121, DOI 10.1074/jbc.M002971200; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Oakley AJ, 1999, PROTEIN SCI, V8, P1915, DOI 10.1110/ps.8.10.1915; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Sukharev S, 1999, FASEB J, V13, pS55; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Touze T, 2001, MOL MICROBIOL, V42, P87, DOI 10.1046/j.1365-2958.2001.02591.x; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9	36	67	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27682	27688		10.1074/jbc.M202497200	http://dx.doi.org/10.1074/jbc.M202497200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015316	hybrid			2022-12-25	WOS:000177189800015
J	Furukawa-Hibi, Y; Yoshida-Araki, K; Ohta, T; Ikeda, K; Motoyama, N				Furukawa-Hibi, Y; Yoshida-Araki, K; Ohta, T; Ikeda, K; Motoyama, N			FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED PROTEIN GADD45; CAENORHABDITIS-ELEGANS; LIFE-SPAN; GENE; RESISTANCE; EXPRESSION; LONGEVITY; DAF-16; IRRADIATION; INHIBITION	Members of the FOXO family of mammalian forkhead transcription factors, including AFX, FKHRL1, and FKHR, are homologs of DAF-16, which regulates genes that contribute both to longevity and to resistance to various stresses (including oxidative stress) in Caenorhabditis elegans. We have generated mouse myoblastic C2C12 cell lines in which expression of a constitutively active form of AFX (AFX-TM) is inducible by Cre-mediated recombination at loxP sites. Here we show that forced expression of AFX-TM blocked cell cycle progression at the G(1) and G(2) phases and that FOXO family members regulated the expression of stress-inducible genes such as GADD45. AFX and FKHRL1 each directly activated the GADD45 promoter through interaction with FOXO binding motifs. Oxidative stress activated the GADD45 promoter in a FOXO-dependent manner, resulting in an increased abundance of GADD45 mRNA and protein as well as G(2) arrest. These responses were evident in cells in which the tumor suppressor protein p53 was inactivated. Our results suggest that the FOXO family of transcription factors plays an important role in the regulation of GADD45 in response to oxidative stress and thereby contributes to G(2)-M checkpoint.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Motoyama, N (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.							Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; FRIEDMAN DB, 1988, GENETICS, V118, P75; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Murakami S, 1996, GENETICS, V143, P1207; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takahashi S, 2001, CANCER RES, V61, P1187; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	30	201	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26729	26732		10.1074/jbc.C200256200	http://dx.doi.org/10.1074/jbc.C200256200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12048180	hybrid			2022-12-25	WOS:000177055900005
J	Saparbaev, M; Langouet, S; Privezentzev, CV; Guengerich, FP; Cai, HL; Elder, RH; Laval, J				Saparbaev, M; Langouet, S; Privezentzev, CV; Guengerich, FP; Cai, HL; Elder, RH; Laval, J			1,N-2-ethenoguanine, a mutagenic DNA adduct, is a primary substrate of Escherichia coli mismatch-specific uracil-DNA glycosylase and human alkylpurine-DNA-N-glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALKYLADENINE GLYCOSYLASE; RING FRAGMENTATION PRODUCT; 3-METHYLADENINE DNA; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; LIPID-PEROXIDATION; BASE EXCISION; HUMAN-CELLS; GENE MAPS; REPAIR	The promutagenic and genotoxic exocyclic DNA adduct 1 N-2-ethenoguanine (1,N-2-epsilonG) is a major product formed in DNA exposed to lipid peroxidation-derived aldehydes in vitro. Here, we report that two structurally unrelated proteins, the Escherichia coli mismatch-specific uracil-DNA glycosylase (MUG) and the human alkylpurine-DNA-N-glycosylase (ANPG), can release 1,N-2-epsilonG from defined oligonucleotides containing a single modified base. A comparison of the kinetic constants of the reaction indicates that the MUG protein removes the 1,N-2-epsilonG lesion more efficiently (k(cat)/K-m = 0.95 X 10(-3) min(-1) nM(-1)) than the ANPG protein (k(cat)/K-m = 0.1 X 10(-3) min(-1) nM(-1)). Additionally, while the nonconserved, N-terminal 73 amino acids of the ANPG protein are not required for activity on 1,N-6-ethenoadenine, hypoxanthine, or N-methylpurines, we show that they are essential for 1,N-2-epsilonG-DNA glycosylase activity. Both the MUG and ANPG proteins preferentially excise 1,N-2-epsilonG when it is opposite dC; however, unlike MUG, ANPG is unable to excise 1,N-2-EG when it is opposite dG. Using cell-free extracts from genetically modified E. coli and murine embryonic fibroblasts lacking MUG and mANPG activity, respectively, we show that the incision of the 1,N-2-epsilonG-containing duplex oligonucleotide has an absolute requirement for MUG or ANPG. Taken together these observations suggest a possible role for these proteins in counteracting the genotoxic effects of 1,N-2-epsilonG residues in vivo.	Inst Gustave Roussy, Ecole Normale Super Cachan, CNRS, Grp Reparat ADN,UMR 8532,Lab Biotechnol Pharmacol, F-94805 Villejuif, France; Univ Rennes 1, Fac Sci Pharmaceut & Biol, INSERM, U456, F-35043 Rennes, France; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA; Christie Hosp, Natl Hlth Serv Trust, Paterson Inst Canc Res, Canc Res United Kingdom Carcinogenesis Grp, Manchester M20 4BX, Lancs, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Vanderbilt University; Vanderbilt University; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Guengerich, FP (corresponding author), Inst Gustave Roussy, Ecole Normale Super Cachan, CNRS, Grp Reparat ADN,UMR 8532,Lab Biotechnol Pharmacol, F-94805 Villejuif, France.	guengerich@toxicology.mc.vanderbilt.edu	Saparbaev, Murat K/N-3225-2015; Langouet, Sophie A/I-2776-2015; Saparbaev, Murat/AAC-5478-2020	Saparbaev, Murat K/0000-0002-4630-1074; Saparbaev, Murat/0000-0002-4630-1074; Langouet, Sophie/0000-0002-0016-5425	NCI NIH HHS [R35 CA 44353] Funding Source: Medline; NIEHS NIH HHS [R01 ES 10375, P30 ES 00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010375, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Akasaka S, 1999, CHEM RES TOXICOL, V12, P501, DOI 10.1021/tx980259j; Asaeda A, 2000, BIOCHEMISTRY-US, V39, P1959, DOI 10.1021/bi9917075; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bartsch H, 1999, IARC SCI PUBL, P1; Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOLT HM, 1988, CRIT REV TOXICOL, V18, P299, DOI 10.3109/10408448809037469; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; Cullinan D, 2000, J MOL BIOL, V296, P851, DOI 10.1006/jmbi.1999.3490; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Guengerich F P, 1994, IARC Sci Publ, P57; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; Jurado J, 1998, BIOCHEMISTRY-US, V37, P7757, DOI 10.1021/bi972982z; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; Langouet S, 1997, BIOCHEMISTRY-US, V36, P6069, DOI 10.1021/bi962526v; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Marnett LJ, 1999, IARC SCI PUBL, P17; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; Morinello EJ, 2001, CHEM RES TOXICOL, V14, P327, DOI 10.1021/tx0002076; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; NAIR J, 1995, CARCINOGENESIS, V16, P613, DOI 10.1093/carcin/16.3.613; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; OESCH F, 1986, ROLE CYCLIC NUCLEIC, V70, P373; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; PENDLEBURY A, 1994, CARCINOGENESIS, V15, P2957, DOI 10.1093/carcin/15.12.2957; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Privezentzev CV, 2000, BIOCHEMISTRY-US, V39, P14263, DOI 10.1021/bi001337g; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; Saparbaev M, 1999, IARC SCI PUBL, P249; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Saparbaev M, 2000, NUCLEIC ACIDS RES, V28, P1332, DOI 10.1093/nar/28.6.1332; Shibutani S, 1996, BIOCHEMISTRY-US, V35, P14992, DOI 10.1021/bi961446o; SINGER B, 1984, CARCINOGENESIS, V5, P1165, DOI 10.1093/carcin/5.9.1165; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4	54	88	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26987	26993		10.1074/jbc.M111100200	http://dx.doi.org/10.1074/jbc.M111100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016206	hybrid			2022-12-25	WOS:000177055900039
J	Tam, C; Collinet, B; Lau, GKK; Raina, S; Missiakas, D				Tam, C; Collinet, B; Lau, GKK; Raina, S; Missiakas, D			Interaction of the conserved region 4.2 of sigma(E) with the RseA anti-sigma factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; CONTACT SITE; SUBUNIT; BINDING; IDENTIFICATION; INTERFACE; PROMOTER; PROTEIN; TARGET	Eo-E RNA polymerase transcribes a regulon of folding factors for the bacterial envelope and is induced by physical and chemical stresses. The RseA anti-sigma factor inhibits the activity of Esigma(E) RNA, polymerase. It is shown here that the N-terminal portion of sigma(E), residues 1-153, binds core RNA polymerase. RseA interacts with residues 154-191 of sigma(E), a site that is homologous to region 4, the sigma factor binding site for promoter DNA. Mutations that reduce transcription of Esigma(E) RNA polymerase map to sigma(E) residues 178, 181, and 183. Variant sigma(E) proteins with amino acid substitutions at residues 178, 181, or 183 do not associate with RseA. A regulatory mechanism is proposed whereby RseA binds to a C-terminal peptide of a-E and inhibits the transcription of Esigma(E) RNA polymerase by blocking promoter recognition.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland	University of Chicago; University of Geneva	Missiakas, D (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.	dmissiak@bad.uchicago.edu	Raina, Satish/AAU-9550-2021	Raina, Satish/0000-0003-3175-4932	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODY EN, 1995, FEMS MICROBIOL LETT, V128, P1; Campbell EA, 2000, J MOL BIOL, V300, P17, DOI 10.1006/jmbi.2000.3838; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Collinet B, 2000, J BIOL CHEM, V275, P33898, DOI 10.1074/jbc.M006214200; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Dove SL, 2001, J BACTERIOL, V183, P6413, DOI 10.1128/JB.183.21.6413-6421.2001; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; Jishage M, 1998, P NATL ACAD SCI USA, V95, P4953, DOI 10.1073/pnas.95.9.4953; Jishage M, 2001, J BACTERIOL, V183, P2952, DOI 10.1128/JB.183.9.2952-2956.2001; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; Landini P, 1999, J BACTERIOL, V181, P1524, DOI 10.1128/JB.181.5.1524-1529.1999; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; LONETTO MA, 1994, P NATL ACAD SCI USA, V91, P7573, DOI 10.1073/pnas.91.16.7573; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Minakhin L, 2001, J MOL BIOL, V306, P631, DOI 10.1006/jmbi.2001.4445; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; RAINA S, 1995, EMBO J, V14, P1043, DOI 10.1002/j.1460-2075.1995.tb07085.x; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; Urbauer JL, 2001, J BIOL CHEM, V276, P41128, DOI 10.1074/jbc.M106400200	29	17	19	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27282	27287		10.1074/jbc.M202881200	http://dx.doi.org/10.1074/jbc.M202881200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016219	hybrid			2022-12-25	WOS:000177055900075
J	Varnai, P; Lin, X; Lee, SB; Tuymetova, G; Bondeva, T; Spat, A; Rhee, SG; Hajnoczky, G; Balla, T				Varnai, P; Lin, X; Lee, SB; Tuymetova, G; Bondeva, T; Spat, A; Rhee, SG; Hajnoczky, G; Balla, T			Inositol lipid binding and membrane localization of isolated pleckstrin homology (PH) domains - Studies on the PH domains of phospholipase C delta(1) and p130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; CATALYTICALLY INACTIVE PROTEIN; ADRENERGIC-RECEPTOR KINASE; BRUTONS TYROSINE KINASE; PHOSPHOINOSITIDE-BINDING; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; STRUCTURAL BASIS; FYVE DOMAIN; 1,4,5-TRISPHOSPHATE RECEPTOR	The relationship between the ability of isolated pleckstrin homology (PH) domains to bind inositol lipids or soluble inositol phosphates in vitro and to localize to cellular membranes in live cells was examined by comparing the PH domains of phospholipase Cdelta(1) (PLCdelta(1)) and the recently cloned PLC-like protein p130 fused to the green fluorescent protein (GFP). The prominent membrane localization of PLCdelta(1)PH-GFP was paralleled with high affinity binding to inositol 1,4,5-trisphosphate (InsP(3)) as well as to phosphatidylinositol 4,5-bisphosphate-containing lipid vesicles or nitrocellulose membrane strips. In contrast, no membrane localization was observed with p130PH-GFP despite its InsP(3) and phosphatidylinositol 4,5-bisphosphate-binding properties being comparable with those of PLCdelta(1)PH-GFP. The N-terminal ligand binding domain of the type I InsP(3) receptor also failed to localize to the plasma membrane despite its 5-fold higher affinity to InsP(3) than the PH domains. By using a chimeric approach and cassette mutagenesis, the C-terminal alpha-helix and the short loop between the beta6-beta7 sheets of the PLCdelta(1)PH domain, in addition to its InsP(3)-binding region, were identified as critical components for membrane localization in intact cells. These data indicate that binding to the inositol phosphate head group is necessary but may not be sufficient for membrane localization of the PLCdelta(1)PH-GFP fusion protein, and motifs located within the C-terminal half of the PH domain provide auxiliary contacts with additional membrane components.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Sch Med, Dept Physiol, H-1444 Budapest, Hungary; Semmelweis Univ, Sch Med, Lab Cellular & Mol Physiol, H-1444 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Jefferson University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Semmelweis University; Semmelweis University	Balla, T (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Rm 6A35,Bldg 49,49 Convent Dr, Bethesda, MD 20892 USA.	tambal@box-t.nih.gov		Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051526, R01DK051526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059419] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51526] Funding Source: Medline; NIGMS NIH HHS [GM 59419] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRADFORD PG, 1986, J BIOL CHEM, V261, P5644; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Carman CV, 2000, J BIOL CHEM, V275, P10443, DOI 10.1074/jbc.275.14.10443; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Coso OA, 1996, J BIOL CHEM, V271, P3963; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kanematsu T, 2000, EUR J BIOCHEM, V267, P2731, DOI 10.1046/j.1432-1327.2000.01291.x; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; MAZZOTTI G, 1995, J HISTOCHEM CYTOCHEM, V43, P181, DOI 10.1177/43.2.7822774; MIKOSHIBA K, 1993, ANN NY ACAD SCI, V707, P178, DOI 10.1111/j.1749-6632.1993.tb38052.x; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Takeuchi H, 2000, BIOCHEM J, V349, P357, DOI 10.1042/0264-6021:3490357; Takeuchi H, 1999, CHEM PHYS LIPIDS, V98, P35, DOI 10.1016/S0009-3084(99)00016-X; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Uchiyama T, 2001, J BIOL CHEM, V276, P41343, DOI 10.1074/jbc.M103610200; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Yamamoto T, 1999, EUR J BIOCHEM, V265, P481, DOI 10.1046/j.1432-1327.1999.00786.x; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	62	99	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27412	27422		10.1074/jbc.M109672200	http://dx.doi.org/10.1074/jbc.M109672200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12019260	hybrid			2022-12-25	WOS:000177055900091
J	Simone, C; Bagella, L; Bellan, C; Giordano, A				Simone, C; Bagella, L; Bellan, C; Giordano, A			Physical interaction between pRb and cdk9/cyclinT2 complex	ONCOGENE			English	Article						cdk9; cyclin T2; pRb; phosphorylation	RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; CYCLIN-CDK COMPLEXES; P-TEFB KINASE; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HIV-1 TAT; IN-VITRO; FUNCTIONAL INACTIVATION; MUSCLE DIFFERENTIATION	Cyclin-dependent kinase 9 (cdk9) is a multifunctional kinase with roles in different cellular pathways such as transcriptional elongation, differentiation and apoptosis. Cdk9/cyclin T differs functionally from other cdk/cyclin complexes that regulate cell cycle progression, but maintains structural affinity with those complexes. In addition, previous reports have demonstrated that the cdk9 complex is able to phosphorylate p56/pRb in vitro. In this report we show in vitro and in vivo interaction between cdk9/cyclinT2 and the protein product of the retinoblastoma gene (pRb) in human cell lines. The interaction involves the region composed of residues 129-195 of cdk9, cyctinT2 (1-642 aa) and the C-terminal domain of pRb (835-928 aa). We located the minimal region of cdk9 phosphorylation on the C-terminus of pRb, by identifying the residues between 793 and 834. This region contains at least three proline-directed serines (sp), S795, S807 and S811, which have been reported to be phosphorylated in vivo and which could be targeted by the cdk9 complex. These data suggest that, in logarithmically growing cells, cdk9/cyclin T2 and pRb are located in a nuclear multiprotein complex probably involved in transduction of cellular signals to the basal transcription machinery and that one of these signals could be the cdk9 phosphorylation of pRb.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/L-3903-2013	BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; BAGELLA, Luigi/0000-0003-2815-037X				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; CORBEIL HB, 1995, ONCOGENE, V11, P909; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; De Luca P, 1998, J CELL BIOCHEM, V70, P281, DOI 10.1002/(SICI)1097-4644(19980801)70:2<281::AID-JCB13>3.0.CO;2-Q; DECAPRIO JA, 1998, CELL, V54, P257; DEFALCO G, 2002, IN PRESS CANC BIOL T; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LIS JT, 2000, GENE DEV, V11, P2633; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pan WJ, 2001, CANCER RES, V61, P2885; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Simone C., 2001, FRONT BIOSCI, V6, P1073; Stiegler P, 2001, CRIT REV EUKAR GENE, V11, P59; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4158	4165		10.1038/sj.onc.1205511	http://dx.doi.org/10.1038/sj.onc.1205511			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037672				2022-12-25	WOS:000176186000010
J	Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR				Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR			AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival	ONCOGENE			English	Article						AKT; HER-2/neu; overexpression; breast tumors; apoptosis; hypoxia	FACTOR-INDUCED APOPTOSIS; AKT/PROTEIN KINASE-B; KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; RECEPTOR; HEREGULIN; PHOSPHORYLATION; OVEREXPRESSION	Amplification or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/survival of HER-2/neu-overexpressing tumor cells have not been well defined. To determine if phosphatidylinositol 3-kinase/AKT signaling contributes to cell survival in HER-2/neu-positive breast cancers, we performed immunohistochemical analyses to evaluate expression of HER-2/neu and AKT in a series of 52 breast carcinomas. Elevated expression of HER-2/neu was found to correlate with overexpression of AKT2 protein and activation of AKT kinase. HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells. These observations suggest that AKT signaling augments resistance to stress-induced apoptosis in breast cancer cells over-expressing HER-2/neu.	Ventana Med Syst Inc, QDL, Westmont, IL 60559 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA	Roche Holding; Ventana Medical Systems, Inc.; Fox Chase Cancer Center; Cleveland Clinic Foundation	Bacus, SS (corresponding author), Ventana Med Syst Inc, QDL, 610 Oakmont Lane, Westmont, IL 60559 USA.	sbacus@ventanamed.com; D_Altomare@fccc.edu		Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, P30 CA006927, R01 CA077429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaoui-Jamali MA, 1997, BIOCHEM CELL BIOL, V75, P315, DOI 10.1139/bcb-75-4-315; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bacus S, 1997, ANAL QUANT CYTOL, V19, P316; Bacus S S, 2000, Breast Dis, V11, P63; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BACUS SS, 1992, CANCER RES, V52, P2580; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; BACUS SS, 1993, PATHOL ANNU, V28, P179; BACUS SS, 1994, COMPENDIUM COMPUTERI, P143; BACUS SS, 1996, MOL CARCINOG, V3, P350; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER G, 1979, J CELL PHYSIOL, V99, P101, DOI 10.1002/jcp.1040990112; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; HANCOCK MC, 1991, CANCER RES, V51, P4575; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Huang Y, 2000, CANCER RES, V60, P4426; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Shak S, 1999, SEMIN ONCOL, V26, P71; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	57	113	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3532	3540		10.1038/sj.onc.1205438	http://dx.doi.org/10.1038/sj.onc.1205438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032855				2022-12-25	WOS:000175793700004
J	Bowser, DN; Petrou, S; Panchal, RG; Smart, ML; Williams, DA				Bowser, DN; Petrou, S; Panchal, RG; Smart, ML; Williams, DA			Release of mitochondrial Ca2+ via the permeability transition activates endoplasmic reticulum Ca2+ uptake	FASEB JOURNAL			English	Article						mitochondrial permeability transition; targeted Ca2+ sensors (cameleons)	GREEN FLUORESCENT PROTEINS; RECEPTORS; CHANNEL	Regulatory interactions between the endoplasmic reticulum (ER) and the mitochondria in the control of intracellular free Ca2+ concentration ([Ca2+](I)), may be of importance in the control of many cell functions, and particularly those involved in initiating cell death. We used targeted Ca2+ sensors (cameleons) to investigate the movement of Ca2+ between the ER and mitochondria of intact cells and focused on the role of the mitochondrial permeability transition (MPT) in this interaction. We hypothesized that release of Ca2+ from mitochondria in response to a known MPT agonist (atractyloside) would cause release of ER Ca2+, perpetuating cellular Ca2+ overload, and cell death. Targeted cameleons (mitochondria and ER) were imaged with confocal microscopy 2-3 days following transient transfection of human embryonic kidney 293 cells. Opening of the MPT resulted in specific loss of mitochondrial Ca2+ (blocked by cyclosporin A), which was sequestered initially by ER. The ER subsequently released this Ca2+ load, leading to a global Ca2+ elevation, a response that was not observed when ER Ca2+-ATPases were blocked with cyclopiazonic acid. Thus, ER plays an important role in moderating changes in intracellular Ca2+ following MPT and may play a key role in cell death initiated by mitochondrial mechanisms.	Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia	University of Melbourne	Williams, DA (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.	davidaw@unimelb.edu.au	Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Panchal, Rekha/0000-0001-8621-9078; Bowser, David/0000-0002-8974-9442; Petrou, Steven/0000-0002-4960-6375				ANTONSSON B, 1997, SCIENCE; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Bowser D.N., 1999, FLUORESCENT LUMINESC, V2nd, P65; Bowser DN, 1998, BIOPHYS J, V75, P2004, DOI 10.1016/S0006-3495(98)77642-8; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Querfurth HW, 1998, BIOCHEM J, V334, P79, DOI 10.1042/bj3340079; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042	19	25	26	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1105	+		10.1096/fj.01-0828fje	http://dx.doi.org/10.1096/fj.01-0828fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039849				2022-12-25	WOS:000175973900015
J	Huisman, A; Vos, I; van Faassen, EE; Joles, JA; Grone, HJ; Martasek, P; van Zonneveld, AJ; Vanin, AF; Rabelink, TJ				Huisman, A; Vos, I; van Faassen, EE; Joles, JA; Grone, HJ; Martasek, P; van Zonneveld, AJ; Vanin, AF; Rabelink, TJ			Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: modulation of inducible nitric oxide synthase	FASEB JOURNAL			English	Article						renal transplantation; iNOS; superoxide	GENERATES SUPEROXIDE; ENDOTHELIAL FUNCTION; NADPH OXIDASE; FREE-RADICALS; L-ARGININE; RAT-BRAIN; IN-VIVO; INJURY; PEROXYNITRITE; NO	Oxidative stress contributes to the development of early transplant failure. As nitric oxide synthases (NOS) can act as sources of superoxide, we investigated the effect of the NOS cofactor tetrahydrobiopterin (BH4) on oxyradical production and early rejection in a rat kidney transplantation model. Allograft transplantation (Brown Norway to Lewis) showed more renal superoxide production and monocyte infiltration when compared with isografts (Lewis to Lewis). Administration of the stable BH4 precursor sepiapterin had no effect on superoxide production in the isografts (51 +/- 10 vs. 69 +/- 17 cps/10 mg protein), but led to a marked decrease in superoxide production in the allografts (116 +/- 11 vs. 60 +/- 6 cps/10 mg protein; P<0.05) and was accompanied by a reduction in periarterial macrophage infiltration (3.3 +/- 0.7 vs. 1.3 +/- 0.3 cells/vessel; P<0.05) and an increase in NO production (78 +/- 22 vs. 173 +/- 12 AU/g kidney) (P<0.01). In vitro experiments confirm that iNOS can produce superoxide mainly from the heme domain, whereas BH4 administration can reverse this superoxide production in the presence of adequate anti-oxidant defense. Our findings support the hypothesis that BH4 can be used to modulate the function of the inflammatory iNOS isoform and suggest a potential therapeutic role for sepiapterin in early allograft rejection.	Univ Med Ctr, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Hypertens & Nephrol, Utrecht, Netherlands; Univ Utrecht, Debye Inst, Sect Interface Phys, Utrecht, Netherlands; German Canc Inst, Dept Cellular & Mol Pathol, Heidelberg, Germany; Charles Univ, Fac Med 1, Dept Pediat, Prague, Czech Republic; Russian Acad Sci, Inst Chem Phys, Moscow, Russia; Univ Med Ctr, Dept Clin Chem, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Charles University Prague; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences; Utrecht University; Utrecht University Medical Center	Rabelink, TJ (corresponding author), Univ Med Ctr, Dept Vasc Med, F02-226,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	T.RABELINK@DIGD.AZU.NL	Shumaev, Konstantin/AAI-2362-2020; Huisman, Albert/A-2033-2008; Martásek, Pavel/G-6622-2017; Rabelink, Ton J./A-5316-2008; van Zonneveld, Anton Jan/D-8060-2018; Joles, Jaap/AAX-3249-2020; Anatoly, Vanin/I-1069-2016	Martásek, Pavel/0000-0001-6165-4444; Rabelink, Ton J./0000-0001-6780-5186; van Zonneveld, Anton Jan/0000-0002-1676-7738; Anatoly, Vanin/0000-0001-8392-4601				Adams MR, 1999, ATHEROSCLEROSIS, V146, P329, DOI 10.1016/S0021-9150(99)00157-4; Albrecht EWJA, 2000, TRANSPLANTATION, V70, P1610, DOI 10.1097/00007890-200012150-00013; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Attia DM, 2001, J AM SOC NEPHROL, V12, P2585, DOI 10.1681/ASN.V12122585; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bhattacharjee S, 2001, ARCH BIOCHEM BIOPHYS, V395, P69, DOI 10.1006/abbi.2001.2557; CARRUTHERS SG, 1983, CLIN CHEM, V29, P180; DANNENBERG AM, 1994, J LEUKOCYTE BIOL, V56, P436, DOI 10.1002/jlb.56.4.436; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; GROSS SS, 1992, J BIOL CHEM, V267, P25722; Hattori Y, 1997, BBA-MOL CELL RES, V1358, P61, DOI 10.1016/S0167-4889(97)00052-9; Heitzer T, 2000, DIABETOLOGIA, V43, P1435, DOI 10.1007/s001250051551; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kibbe M, 1999, CARDIOVASC RES, V43, P650, DOI 10.1016/S0008-6363(99)00130-3; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOJIMA S, 1995, FREE RADICAL RES, V23, P419, DOI 10.3109/10715769509065263; Koo DDH, 2001, KIDNEY INT, V60, P786, DOI 10.1046/j.1523-1755.2001.060002786.x; Laursen JB, 2001, CIRCULATION, V103, P1282; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MIESEL R, 1995, INFLAMMATION, V19, P347, DOI 10.1007/BF01534392; MIKOYAN VD, 1994, BIOFIZIKA+, V39, P919; Milstien S, 1999, BIOCHEM BIOPH RES CO, V263, P681, DOI 10.1006/bbrc.1999.1422; Mishra OP, 2000, NEUROCHEM RES, V25, P1559, DOI 10.1023/A:1026610301978; NICHOL CA, 1983, P NATL ACAD SCI-BIOL, V80, P1546, DOI 10.1073/pnas.80.6.1546; Pieper GM, 1997, J CARDIOVASC PHARM, V29, P8, DOI 10.1097/00005344-199701000-00002; Rimbach Gerald, 2000, Molecular Cell Biology Research Communications, V3, P238, DOI 10.1006/mcbr.2000.0219; SCHOTT K, 1991, BIOCHEM BIOPH RES CO, V176, P1430, DOI 10.1016/0006-291X(91)90446-E; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Sjakste N, 1999, BIOCHEM PHARMACOL, V58, P1955, DOI 10.1016/S0006-2952(99)00281-6; Stojanovic T, 1996, LAB INVEST, V74, P496; Stroes E, 1998, FEBS LETT, V438, P161, DOI 10.1016/S0014-5793(98)01292-7; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; Vanin AF, 2000, BBA-GEN SUBJECTS, V1474, P365, DOI 10.1016/S0304-4165(00)00033-7; Vanin AF, 1996, BBA-PROTEIN STRUCT M, V1295, P5, DOI 10.1016/0167-4838(95)00247-2; Vanin AF, 2001, FREE RADICAL BIO MED, V30, P813, DOI 10.1016/S0891-5849(01)00466-X; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Vos IHC, 2000, EUR J PHARMACOL, V391, P31, DOI 10.1016/S0014-2999(00)00021-2; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	50	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1135	+		10.1096/fj.01-0890fje	http://dx.doi.org/10.1096/fj.01-0890fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039851				2022-12-25	WOS:000175973900010
J	Okazaki, H; Osuga, JI; Tsukamoto, K; Isoo, N; Kitamine, T; Tamura, Y; Tomita, S; Sekiya, M; Yahagi, N; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Shimano, H; Kimura, S; Nagai, R; Yamada, N; Ishibashi, S				Okazaki, H; Osuga, JI; Tsukamoto, K; Isoo, N; Kitamine, T; Tamura, Y; Tomita, S; Sekiya, M; Yahagi, N; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Shimano, H; Kimura, S; Nagai, R; Yamada, N; Ishibashi, S			Elimination of cholesterol ester from macrophage foam cells by adenovirus-mediated gene transfer of hormone-sensitive lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; B SCAVENGER RECEPTOR; MESSENGER-RNA; ACYL-COENZYME; STEROL 27-HYDROXYLASE; TARGETED DISRUPTION; LDL RECEPTOR; PPAR-GAMMA; EXPRESSION; ATHEROSCLEROSIS	Cholesterol ester (CE)-laden foam cells are a hallmark of atherosclerosis. To determine whether stimulation of the hydrolysis of cytosolic CE can be used as a novel therapeutic modality of atherosclerosis, we overexpressed hormone-sensitive lipase (HSL) in THP-1 macrophage-like cells by adenovirus-mediated gene delivery, and we examined its effects on the cellular cholesterol trafficking. We show here that the overexpression of HSL robustly increased neutral CE hydrolase activity and completely eliminated CE in the cells that had been preloaded with CE by incubation with acetylated low density lipoprotein. In these cells, cholesterol efflux was stimulated in the absence or presence of high density lipoproteins, which might be at least partially explained by the increase in the expression of ABCA1 Importantly, these effects were achieved without the addition of acyl-CoA:cholesterol acyltransferase inhibitor, cAMP, or even high density lipoproteins. Furthermore, the uptake and degradation of acetylated low density lipoprotein was significantly reduced probably by decreased expression of scavenger receptor A and CD36. Notably, the cells with stimulated CE hydrolysis did not exhibit either buildup of free cholesterol or cytotoxicity. In conclusion, increased hydrolysis of CE by the overexpression of HSL leads to complete elimination of CE from THP-1 foam cells not only by increasing efflux but also by decreasing influx of cholesterol.	Jichi Med Sch, Div Endocrinol & Metab, Dept Med, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; University of Tokyo; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Div Endocrinol & Metab, Dept Med, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	ishibash@jichi.ac.jp	Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019; Yahagi, Naoya/D-2360-2014	Shimano, Hitoshi/0000-0002-5562-5572; Yahagi, Naoya/0000-0002-1823-1865				ACTON SL, 1994, J BIOL CHEM, V269, P21003; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; de Winther MPJ, 2000, J CLIN INVEST, V105, P1039, DOI 10.1172/JCI9919; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Escary JL, 1999, J LIPID RES, V40, P397; Escary JL, 1998, ARTERIOSCL THROM VAS, V18, P991, DOI 10.1161/01.ATV.18.6.991; Fazio S, 2001, J CLIN INVEST, V107, P163, DOI 10.1172/JCI10310; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Fu YC, 2000, J LIPID RES, V41, P2017; Ghosh S, 2000, PHYSIOL GENOMICS, V2, P1, DOI 10.1152/physiolgenomics.2000.2.1.1; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Graham A, 1996, ATHEROSCLEROSIS, V120, P135, DOI 10.1016/0021-9150(95)05695-5; Han JH, 1999, J LIPID RES, V40, P830; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEIDER JG, 1978, J LIPID RES, V19, P514; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; KHOO JC, 1993, J LIPID RES, V34, P1969; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRAEMER FB, 1993, J LIPID RES, V34, P663; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Perrey S, 2001, ATHEROSCLEROSIS, V154, P51, DOI 10.1016/S0021-9150(00)00457-3; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Reue K, 1997, ARTERIOSCL THROM VAS, V17, P3428, DOI 10.1161/01.ATV.17.12.3428; ROBERTS DCK, 1985, BIOCHEM J, V226, P319, DOI 10.1042/bj2260319; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; Shanahan CM, 2001, ATHEROSCLEROSIS, V154, P269, DOI 10.1016/S0021-9150(00)00473-1; SMALL CA, 1989, FEBS LETT, V247, P205, DOI 10.1016/0014-5793(89)81335-3; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yagyu H, 2000, J BIOL CHEM, V275, P21324, DOI 10.1074/jbc.M002541200; Ye XH, 1996, J BIOL CHEM, V271, P3639	50	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31893	31899		10.1074/jbc.M204016200	http://dx.doi.org/10.1074/jbc.M204016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12036961	hybrid			2022-12-25	WOS:000177718700075
J	Iwanaga, Y; Kasai, T; Kibler, K; Jeang, KT				Iwanaga, Y; Kasai, T; Kibler, K; Jeang, KT			Characterization of regions in hsMAD1 needed for binding hsMAD2 - A polymorphic change in an hsMAD1 leucine zipper affects MAD1-MAD2 interaction and spindle checkpoint function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHECKPOINT; PROMOTING COMPLEX; CENP-E; MAD2; CANCER; GENES; HBUB1; KINETOCHORES; MUTATION; ARREST	In eukaryotes, the mitotic spindle assembly checkpoint provides a monitor for the fidelity of chromosomal segregation. In this context, the mitotic arrest deficiency protein 2 (MAD2) censors chromosomal mis-segregation by monitoring microtubule attachment/tension, a role that requires its attachment to kinetochores. Studies in yeast have shown that binding of MAD1 to MAD2 is important for the checkpoint function of the latter. The interactions between human MAD1 (hsMAD1) and human MAD2 (hsMAD2) have, however, remained poorly characterized. Here we report that two leucine zipper domains (amino acids 501-522 and 557-571) in hsMAD1 are required for its contact with hsMAD2. Interestingly, in several cancer cell lines, we noted the frequent presence of a coding single nucleotide Arg to His polymorphism at codon 558 located within the second leucine zipper of hsMAD1. We found that hsMAD1H558 is less proficient than hsMAD1R558 in binding hsMAD2 and in enforcing mitotic arrest. We also document a first example of loss-of-heterozygosity for a spindle checkpoint gene (at the hsMAD1 558 locus) in a human breast cancer. Based on our findings, it is possible that hsMAD1H558 could be an at-risk polymorphism that contributes to attenuated spindle checkpoint function in human cells.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj73@nih.gov	Jeang, Kuan-Teh/A-2424-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; ALBERTS B, 1994, MOL BIOL CELL, P335; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell MS, 2001, J CELL SCI, V114, P953; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Elledge SJ, 1998, SCIENCE, V279, P999, DOI 10.1126/science.279.5353.999; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; HEIM S, 1995, CANC CYTOGENETICS, P1; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jin DY, 1999, GENOMICS, V55, P363, DOI 10.1006/geno.1998.5654; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Livingston DM, 2001, NATURE, V410, P536, DOI 10.1038/35069185; Meek DW, 2000, PATHOL BIOL, V48, P246; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Yamaguchi K, 1999, CANCER LETT, V139, P183, DOI 10.1016/S0304-3835(99)00035-X; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	43	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31005	31013		10.1074/jbc.M110666200	http://dx.doi.org/10.1074/jbc.M110666200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12042300	hybrid			2022-12-25	WOS:000177579800078
J	Barat, C; Tremblay, MJ				Barat, C; Tremblay, MJ			Engagement of CD43 enhances human immunodeficiency virus type 1 transcriptional activity and virus production that is induced upon TCR/CD3 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-TYROSINE KINASE; CAPACITATIVE CALCIUM-ENTRY; WISKOTT-ALDRICH SYNDROME; GENETIC-EVIDENCE; IMMUNOLOGICAL SYNAPSE; ALTERED GLYCOSYLATION; SIGNAL TRANSDUCTION	Human immunodeficiency virus type 1 (HIV-1) transcriptional activity is regulated by several cytokines and T cell activators. CD43 (sialophorin) is a sialoglycoprotein expressed on the surface of a wide variety of blood cells including T lymphocytes. Several studies have shown that CD43 ligation induces proliferation and activation of human T lymphocytes. We were thus interested in defining whether CD43-mediated signaling events can modulate the life cycle of HIV-1. We demonstrate here that CD43 cross-linking potentiates HIV-1 promoter-driven activity and virus production that is seen following the engagement of the T-cell receptor (TCR)-CD3 complex. This effect is independent of the CD28 co-stimulatory molecule and is mediated by both NF-kappaB and NFAT transcription factors. A number of signal transducers known to be involved in the TCR/CD3-dependent signal transduction pathway, including p56(lck), p36(lat), and SLP-76, as well as capacitative entry of calcium, are crucial for the noticed CD43 co-stimulatory effect. Calcium mobilization studies indicate that a synergy is occurring between CD43- and TCR/CD3-mediated signaling events leading to an augmented calcium release. These data suggest that CD43 can be seen as a co-stimulatory cell surface constituent that can modulate HIV-1 expression in T lymphocytes.	Ctr Hosp Univ Quebec, Lab Immuno Retrovirol Humaine, Ctr Rech Infectiol, Hop CHUL, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Med Biol, Fac Med, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), Ctr Hosp Univ Quebec, Lab Immuno Retrovirol Humaine, Ctr Rech Infectiol, Hop CHUL, RC709,2705 Boul Laurier,Ste Foy, Quebec City, PQ G1V 4G2, Canada.		Barat, Corinne/GWZ-4685-2022					ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; ASJO B, 1993, J VIROL, V67, P4395; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; Bagriacik EU, 2001, IMMUNOL CELL BIOL, V79, P303, DOI 10.1046/j.1440-1711.2001.01007.x; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barbeau B, 2001, J IMMUNOL, V167, P2700, DOI 10.4049/jimmunol.167.5.2700; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Brown TJ, 1996, J BIOL CHEM, V271, P27686, DOI 10.1074/jbc.271.44.27686; Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206; Carlow DA, 2001, J IMMUNOL, V166, P256, DOI 10.4049/jimmunol.166.1.256; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; Chang LJ, 1999, GENE THER, V6, P715, DOI 10.1038/sj.gt.3300895; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; COPELAND KFT, 1995, VIROLOGY, V209, P633, DOI 10.1006/viro.1995.1295; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Foger N, 2000, EUR J IMMUNOL, V30, P2888; Foger N, 2001, J CELL SCI, V114, P1169; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Gallego MD, 2001, AIDS, V15, P477, DOI 10.1097/00002030-200103090-00006; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; GRUTERS RA, 1991, EUR J IMMUNOL, V21, P167, DOI 10.1002/eji.1830210125; Gubina E, 2002, BLOOD, V99, P2518, DOI 10.1182/blood.V99.7.2518; Hamad M, 1996, DEV COMP IMMUNOL, V20, P77, DOI 10.1016/0145-305X(95)00037-T; He YW, 1999, J EXP MED, V190, P1903, DOI 10.1084/jem.190.12.1903; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HOHASHI N, 1995, INT IMMUNOL, V7, P1851, DOI 10.1093/intimm/7.11.1851; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; JONES AT, 1994, J IMMUNOL, V153, P3426; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Mitchell JS, 2002, J IMMUNOL, V168, P2737, DOI 10.4049/jimmunol.168.6.2737; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; PedrazaAlva G, 1996, J BIOL CHEM, V271, P27564, DOI 10.1074/jbc.271.44.27564; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Revy P, 2001, NAT IMMUNOL, V2, P925, DOI 10.1038/ni713; Robichaud GA, 2002, J BIOL CHEM, V277, P23733, DOI 10.1074/jbc.M201563200; Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Savage NDL, 2002, J IMMUNOL, V168, P3740, DOI 10.4049/jimmunol.168.8.3740; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; Stockl J, 1996, J EXP MED, V184, P1769, DOI 10.1084/jem.184.5.1769; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Thurman EC, 1998, INT IMMUNOL, V10, P691, DOI 10.1093/intimm/10.5.691; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; Trinh DP, 1999, BIOCHEM BIOPH RES CO, V256, P299, DOI 10.1006/bbrc.1999.0317; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; Viola A, 2001, TRENDS IMMUNOL, V22, P322, DOI 10.1016/S1471-4906(01)01938-X; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WILLARDGALLO KE, 1990, P NATL ACAD SCI USA, V87, P6713, DOI 10.1073/pnas.87.17.6713; WONG RCK, 1990, J IMMUNOL, V144, P1455; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	85	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28714	28724		10.1074/jbc.M111935200	http://dx.doi.org/10.1074/jbc.M111935200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12045189	hybrid			2022-12-25	WOS:000177342600049
J	Sine, SM; Wang, HL; Bren, N				Sine, SM; Wang, HL; Bren, N			Lysine scanning mutagenesis delineates structural model of the nicotinic receptor ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT INTERFACES; ALPHA-SUBUNIT; MOLECULAR DISSECTION; MYASTHENIC SYNDROME; DELTA-SUBUNIT; IDENTIFICATION; RESIDUES; SELECTIVITY; MUTATION	Nicotinic acetylcholine receptors (AChR) and their relatives mediate rapid chemical transmission throughout the nervous system, yet their atomic structures remain elusive. Here we use lysine scanning mutagenesis to determine the orientation of residue side chains toward core hydrophobic or surface hydrophilic environments and use this information to build a structural model of the ligand binding region of the AChR from adult human muscle. The resulting side-chain orientations allow assignment of residue equivalence between AChR subunits and an acetylcholine binding protein solved by x-ray crystallography, providing the foundation for homology modeling. The resulting structural model of the AChR provides a picture of the ACh binding site and predicts novel pairs of residues that stabilize subunit interfaces. The overall results suggest that lysine scanning can provide the basis for structural modeling of other members of the AChR superfamily as well as of other proteins with repeating structures delimiting a hydrophobic core.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, 200 First St SW, Rochester, MN 55905 USA.	sine@mayo.edu						BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bren N, 1997, J BIOL CHEM, V272, P30793, DOI 10.1074/jbc.272.49.30793; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; Fiser A, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P275; Fu DX, 1996, J BIOL CHEM, V271, P31479, DOI 10.1074/jbc.271.49.31479; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Novere N, 1999, BIOPHYS J, V76, P2329, DOI 10.1016/S0006-3495(99)77390-X; Leitolf H, 2000, J BIOL CHEM, V275, P27457; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Molles BE, 2002, J BIOL CHEM, V277, P5433, DOI 10.1074/jbc.M109232200; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; Ohno K, 1996, NEURON, V17, P157, DOI 10.1016/S0896-6273(00)80289-5; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Perutz M. F., 1990, MECH COOPERATIVITY A; PRINCE RJ, 1997, NICOTINIC ACETYLCHOL, P31; Quiram PA, 1999, J CLIN INVEST, V104, P1403, DOI 10.1172/JCI8179; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Wang D, 2000, J BIOL CHEM, V275, P28666, DOI 10.1074/jbc.M005441200; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Wright SN, 1998, MOL PHARMACOL, V54, P733	39	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29210	29223		10.1074/jbc.M203396200	http://dx.doi.org/10.1074/jbc.M203396200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12011092	hybrid			2022-12-25	WOS:000177342600110
J	Warmlander, S; Sponer, JE; Sponer, J; Leijon, M				Warmlander, S; Sponer, JE; Sponer, J; Leijon, M			The influence of the thymine C5 methyl group on spontaneous base pair breathing in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMINO PROTON-EXCHANGE; CRYSTALLIZING AGENT 2-METHYL-2,4-PENTANEDIOL; SEQUENCE-DIRECTED CURVATURE; NONEMPIRICAL AB-INITIO; CYTOSINE METHYLATION; ADENINE TRACT; B-DNA; UNUSUAL CONFORMATION; OPENING KINETICS; KINETOPLAST DNA	Sequences of four or more AT base pairs without a 5'-TA-3' step, so-called A-tracts, influence the global properties of DNA by causing curvature of the helix axis if phased with the helical repeat and also influence nucleosome packaging. Hence it is interesting to understand this phenomenon on the molecular level, and numerous studies have been devoted to investigations of dynamical and structural features of A-tract DNA. It was early observed that anomalously slow base pair-opening kinetics were a striking physical property unique to DNA A-tracts (Leroy, J. L., Charretier, E., Kochoyan, M., and Gueron, M. (1988) Biochemistry 27,8894-8898). Furthermore, a strong correlation between DNA curvature and anomalously slow base pair-opening dynamics was found. In the present work it is shown, using imino proton exchange measurements by NMR spectroscopy that the main contribution to the dampening of the base pair-opening fluctuations in A-tracts comes from the C5 methylation of the thymine base. Because the methyl group has been shown to have a very limited effect on the DNA curvature as well as the structure of the DNA helix, the thymine C5 methyl group stabilizes the helix directly. Empirical potential energy calculations show that methylation of the tract improves the stacking energy of a base pair with its neighbors in the tract by 3-4 kcal/mol.	Acad Sci Czech Republ, J Heyrovsky Inst Phys Chem, CR-18223 Prague 8, Czech Republic; Univ Stockholm, Arrhenius Lab, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic; Acad Sci Czech Republ, Natl Ctr Biomol Res, Brno 61265, Czech Republic	Czech Academy of Sciences; J. Heyrovsky Institute of Physical Chemistry of the Czech Academy of Sciences; Stockholm University; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Czech Academy of Sciences; Masaryk University Brno	Sponer, J (corresponding author), Acad Sci Czech Republ, J Heyrovsky Inst Phys Chem, Dolejskova 3, CR-18223 Prague 8, Czech Republic.		Sponer, Jiri/D-9467-2012; Sponer, Judit/D-9918-2012	Leijon, Mikael/0000-0001-8701-9887; Sponer, Jiri/0000-0001-6558-6186				BAUER C, 1984, J MAGN RESON, V58, P442, DOI 10.1016/0022-2364(84)90148-3; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Blomquist P, 1999, NUCLEIC ACIDS RES, V27, P517, DOI 10.1093/nar/27.2.517; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; Cao H, 1998, J MOL BIOL, V281, P253, DOI 10.1006/jmbi.1998.1925; CELDA B, 1989, BIOCHEMISTRY-US, V28, P1462, DOI 10.1021/bi00430a006; CHUPRINA VP, 1991, P NATL ACAD SCI USA, V88, P9087, DOI 10.1073/pnas.88.20.9087; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DIEKMANN S, 1992, J MOL BIOL, V225, P729, DOI 10.1016/0022-2836(92)90397-3; DIEKMANN S, 1987, P NATL ACAD SCI USA, V84, P8257, DOI 10.1073/pnas.84.23.8257; DIEKMANN S, 1989, EMBO J, V8, P1; Dlakic M, 1996, J BIOL CHEM, V271, P17911, DOI 10.1074/jbc.271.30.17911; Dornberger U, 1999, J BIOL CHEM, V274, P6957, DOI 10.1074/jbc.274.11.6957; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; FREDERICK CA, 1987, BIOPOLYMERS, V26, P145; Ganunis RM, 1996, BIOCHEMISTRY-US, V35, P13729, DOI 10.1021/bi961880q; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; GUERON M, 1990, STRUCTURE METHODS, V3, P113; GUPTA G, 1988, BIOCHEMISTRY-US, V27, P7909, DOI 10.1021/bi00420a049; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HAGERMAN PJ, 1990, BIOCHEMISTRY-US, V29, P1980, DOI 10.1021/bi00460a003; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HARAN TE, 1989, BIOCHEMISTRY-US, V28, P2763, DOI 10.1021/bi00433a003; HARVEY SC, 1995, J BIOMOL STRUCT DYN, V13, P301, DOI 10.1080/07391102.1995.10508841; HEINEMANN U, 1992, J BIOL CHEM, V267, P7332; Hobza P, 1999, CHEM REV, V99, P3247, DOI 10.1021/cr9800255; HODGESGARCIA Y, 1992, BIOCHEMISTRY-US, V31, P7595, DOI 10.1021/bi00148a022; HODGESGARCIA Y, 1995, J BIOL CHEM, V270, P197, DOI 10.1074/jbc.270.1.197; KATAHIRA M, 1988, NUCLEIC ACIDS RES, V16, P8619, DOI 10.1093/nar/16.17.8619; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; LEFEBVRE A, 1995, EUR J BIOCHEM, V229, P445, DOI 10.1111/j.1432-1033.1995.0445k.x; Leijon M, 1995, EUR J BIOCHEM, V234, P832, DOI 10.1111/j.1432-1033.1995.832_a.x; LEIJON M, 1992, NUCLEIC ACIDS RES, V20, P5339, DOI 10.1093/nar/20.20.5339; LEROY JL, 1988, BIOCHEMISTRY-US, V27, P8894, DOI 10.1021/bi00425a004; LYAMICHEV V, 1991, NUCLEIC ACIDS RES, V19, P4491, DOI 10.1093/nar/19.16.4491; Marcourt L, 1999, EUR J BIOCHEM, V265, P1032, DOI 10.1046/j.1432-1327.1999.00819.x; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MOE JG, 1990, NUCLEIC ACIDS RES, V18, P821, DOI 10.1093/nar/18.4.821; Mollegaard NE, 1997, NUCLEIC ACIDS RES, V25, P3497, DOI 10.1093/nar/25.17.3497; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PERRIN DD, 1979, BUFFERS PH METAL ION, P62; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PRICE MA, 1993, BIOCHEMISTRY-US, V32, P127, DOI 10.1021/bi00052a018; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rozenberg H, 1998, P NATL ACAD SCI USA, V95, P15194, DOI 10.1073/pnas.95.26.15194; Schatz T, 1997, J BIOMOL STRUCT DYN, V15, P265, DOI 10.1080/07391102.1997.10508191; Shimizu M, 2000, EMBO J, V19, P3358, DOI 10.1093/emboj/19.13.3358; SPONER J, 1993, J BIOMOL STRUCT DYN, V11, P277, DOI 10.1080/07391102.1993.10508726; Sponer J, 1997, BIOPHYS J, V73, P76, DOI 10.1016/S0006-3495(97)78049-4; Sponer J, 1996, J PHYS CHEM-US, V100, P5590, DOI 10.1021/jp953306e; Sponer J, 2000, NUCLEIC ACIDS RES, V28, P4893, DOI 10.1093/nar/28.24.4893; Sponer J, 2000, J BIOMOL STRUCT DYN, P383; SPONER J, 1993, J BIOMOL STRUCT DYN, V11, P27, DOI 10.1080/07391102.1993.10508707; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; UMEMOTO K, 1990, BIOCHEMISTRY-US, V29, P4714, DOI 10.1021/bi00471a028; Warmlander S, 2000, BIOCHEMISTRY-US, V39, P607, DOI 10.1021/bi991863b; Widlund HR, 1997, J MOL BIOL, V267, P807, DOI 10.1006/jmbi.1997.0916; Widlund HR, 1999, J BIOL CHEM, V274, P31847, DOI 10.1074/jbc.274.45.31847; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850	71	46	49	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28491	28497		10.1074/jbc.M202989200	http://dx.doi.org/10.1074/jbc.M202989200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029089	hybrid			2022-12-25	WOS:000177342600020
J	Wisniewski, M; Chen, Y; Balakrishnan, M; Palaniappan, C; Roques, BP; Fay, PJ; Bambara, RA				Wisniewski, M; Chen, Y; Balakrishnan, M; Palaniappan, C; Roques, BP; Fay, PJ; Bambara, RA			Substrate requirements for secondary cleavage by HIV-1 reverse transcriptase RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA STRAND TRANSFER; SITE-DIRECTED MUTAGENESIS; STRONG-STOP DNA; NUCLEOCAPSID PROTEIN; MINUS-STRAND; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; RIBONUCLEASE-H	During and after minus-strand DNA synthesis, human immunodeficiency virus 1 (HIV-1) reverse transcriptase (RT) degrades the RNA genome. To remove RNA left after polymerization, the RT aligns to cut 18 nucleotides in from the 5' RNA end. The enzyme then repositions, making a secondary cut 8 nucleotides from the RNA 5' end. Transfer of the minus strong stop DNA during viral replication requires cleavage of template RNA. Removal of the terminal RNA segment is a special case because the RNA-DNA hybrid forms a blunt end, shown previously to resist cleavage when tested in vitro. We show here that the structure of the substrate extending beyond the RNA 5' end is an important determinant of cleavage efficiency. A short single-stranded DNA extension greatly stimulated the secondary cleavage. Annealing an RNA segment to the DNA extension was even more stimulatory. Recessing the DNA from a blunt end by even one nucleotide caused the RT to reorient its binding, preventing secondary cleavage. The presence of the cap at the 5' end of the viral RNA did not improve the efficiency of secondary cleavage. However, NC protein greatly facilitated the secondary cut on the blunt-ended substrate, suggesting that NC compensates for the unfavorable substrate structure.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; U266 INSERM, URA D1500 CNRS, UER Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, F-75270 Paris 06, France	University of Rochester; University of Rochester; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NIDCR NIH HHS [T32 DE07207-09] Funding Source: Medline; PHS HHS [49573] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; Gao HQ, 2001, J VIROL, V75, P11874, DOI 10.1128/JVI.75.23.11874-11880.2001; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PETERS G, 1980, J VIROL, V35, P31, DOI 10.1128/JVI.35.1.31-40.1980; PETERS GG, 1980, J VIROL, V36, P692, DOI 10.1128/JVI.36.3.692-700.1980; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; SMITH JS, 1994, J VIROL, V68, P5721, DOI 10.1128/JVI.68.9.5721-5729.1994; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	42	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28400	28410		10.1074/jbc.M201645200	http://dx.doi.org/10.1074/jbc.M201645200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023278	hybrid			2022-12-25	WOS:000177342600009
J	Kim, YM; Hwang, S; Kim, YM; Pyun, BJ; Kim, TY; Lee, ST; Gho, YS; Kwon, YG				Kim, YM; Hwang, S; Kim, YM; Pyun, BJ; Kim, TY; Lee, ST; Gho, YS; Kwon, YG			Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-GROWTH; CELL PROLIFERATION; NITRIC-OXIDE; ANGIOGENESIS; KINASE; BINDING; MECHANISMS; MIGRATION; APOPTOSIS; RECEPTORS	Endostatin, a fragment of collagen XVIII, is a potent anti-angiogenic protein, but the molecular mechanism of its action is not yet clear. We examined the effects of endostatin on the biological and biochemical activities of vascular endothelial growth factor (VEGF). Endostatin blocked VEGF-induced tyrosine phosphorylation of KDR/Flk-1 and activation of ERK, p38 MAPK, and p125(FAK) in human umbilical vein endothelial cells. Endostatin also inhibited the binding of VEGF(165) to both endothelial cells and purified extracellular domain of KDR/Flk-1. Moreover, the binding of VEGF(121) to KDR/Flk-1 and VEGF(121)-stimulated ERK activation were blocked by endostatin. The direct interaction between endostatin and KDR/Flk-1 was confirmed by affinity chromatography. However, endostatin did not bind to VEGF. Our findings suggest that a direct interaction of endostatin with KDR/Flk-1 may be involved in the inhibitory function of endostatin toward VEGF actions and responsible for its potent anti-angiogenic and anti-tumor activities in vivo.	Kyung Hee Univ, Grad Sch East West Med Sci, Dept Oncol, Yongin 449701, South Korea; Kangweon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangweon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Catholic Univ, Catholic Res Inst Med Sci, Dept Dermatol, Seoul 137040, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Kyung Hee University; Kangwon National University; Kangwon National University; Catholic University of Korea; Yonsei University	Kwon, YG (corresponding author), Kyung Hee Univ, Grad Sch East West Med Sci, Dept Oncol, Yongin 449701, South Korea.			Lee, Seung-Taek/0000-0001-7300-9784				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Chang Z, 1999, AM J PATHOL, V155, P71, DOI 10.1016/S0002-9440(10)65101-2; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; JACKSON JR, 1997, FASEB J, V11, P4557; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kim YM, 2000, CANCER RES, V60, P5410; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Taddei L, 1999, BIOCHEM BIOPH RES CO, V263, P340, DOI 10.1006/bbrc.1999.1342; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	31	345	396	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27872	27879		10.1074/jbc.M202771200	http://dx.doi.org/10.1074/jbc.M202771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029087	hybrid			2022-12-25	WOS:000177189800037
J	Nielsen, LB; Bartels, ED; Bollano, E				Nielsen, LB; Bartels, ED; Bollano, E			Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN; TRANSGENIC MICE; LIPOPROTEIN SECRETION; NATRIURETIC PEPTIDES; ECHOCARDIOGRAPHY; EXPRESSION; RATS; CARDIOMYOPATHY; KNOCKOUT; DISEASE	The heart secretes apolipoprotein B (apoB) containing lipoproteins. Herein, we examined whether the overexpression of a human apoB transgene in the heart affects triglyceride accumulation and development of cardiac dysfunction in streptozotocin-treated diabetic mice. Blood glucose, plasma free fatty acids, and plasma triglycerides were similarly affected in diabetic wild type mice and diabetic apoB transgenic mice as compared with non-diabetic mice of the same genotype. After 12 weeks, heart triglycerides were increased by 48% in diabetic wild type mice. These mice displayed an increased expression of brain natriuretic peptide and deterioration of heart function on echocardiography. In diabetic apoB transgenic mice, heart, triglyceride levels were identical to those in non-diabetic wild type and apoB transgenic mice, and brain natriuretic peptide expression as well as echocardiographic indexes of heart function were only marginally affected or unaffected. The findings suggest that triglyceride accumulation in the heart is important for development of diabetic cardiomyopathy in mice, and that lipoprotein formation by cardiomyocytes plays an integrated role in cardiac lipid metabolism.	Univ Copenhagen, Rigshosp, Dept Clin Biochem KB3011, DK-2100 Copenhagen, Denmark; Sahlgrens Univ Hosp, Dept Cardiol, Wallenberg Lab, S-41345 Gothenburg, Sweden	Rigshospitalet; University of Copenhagen; Sahlgrenska University Hospital	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem KB3011, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.		Bollano, Entela/AAY-7176-2020; Bartels, Emil/AAY-3268-2020					Bartels ED, 2002, DIABETES, V51, P1233, DOI 10.2337/diabetes.51.4.1233; Bjorkegren J, 2001, J BIOL CHEM, V276, P38511, DOI 10.1074/jbc.M106839200; Bollano E, 2000, ENDOCRINOLOGY, V141, P2229, DOI 10.1210/en.141.6.2229; Boomsma F, 2001, CARDIOVASC RES, V51, P442, DOI 10.1016/S0008-6363(01)00195-X; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Finck BN, 2002, J CLIN INVEST, V109, P121, DOI 10.1172/JCI200214080; Frustaci A, 2000, CIRC RES, V87, P1123, DOI 10.1161/01.RES.87.12.1123; HEYLIGER CE, 1986, DIABETES, V35, P1152, DOI 10.2337/diabetes.35.10.1152; Heyliger CE, 1997, MOL CELL BIOCHEM, V176, P281, DOI 10.1023/A:1006817632484; Hoit BD, 1999, J CARD FAIL, V5, P324, DOI 10.1016/S1071-9164(99)91337-4; Joffe II, 1999, J AM COLL CARDIOL, V34, P2111, DOI 10.1016/S0735-1097(99)00436-2; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; Liao W, 1999, BIOCHEMISTRY-US, V38, P10215, DOI 10.1021/bi995082m; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Mathur SN, 1997, J LIPID RES, V38, P61; McCormick SPA, 1998, CURR OPIN LIPIDOL, V9, P103, DOI 10.1097/00041433-199804000-00005; Navasa M, 1998, J LIPID RES, V39, P1220; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; Nielsen LB, 1999, J MOL CELL CARDIOL, V31, P695, DOI 10.1006/jmcc.1998.0918; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Ruiz JI, 1997, J LIPID RES, V38, P1482; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Unger RH, 2000, INT J OBESITY, V24, pS28, DOI 10.1038/sj.ijo.0801498; Veniant MM, 1999, TRENDS CARDIOVAS MED, V9, P103, DOI 10.1016/S1050-1738(99)00011-0; Walther T, 2000, J MOL ENDOCRINOL, V24, P391, DOI 10.1677/jme.0.0240391; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	33	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27014	27020		10.1074/jbc.M203458200	http://dx.doi.org/10.1074/jbc.M203458200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015323	hybrid			2022-12-25	WOS:000177055900042
J	Schiemann, WP; Blobe, GC; Kalume, DE; Pandey, A; Lodish, HF				Schiemann, WP; Blobe, GC; Kalume, DE; Pandey, A; Lodish, HF			Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion - Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; HUMAN OVARIAN-CANCER; SIGNALING PATHWAYS; MASS-SPECTROMETRY; EXPRESSION; EMBRYO; GENE; FIBRONECTIN; RECEPTORS; BINDING	Fibulin-5 (FBLN-5; also known as DANCE or EVEC) is an integrin-binding extracellular matrix protein that mediates endothelial cell adhesion; it is also a calcium-dependent elastin-binding protein that scaffolds cells to elastic fibers, thereby preventing elastinopathy in the skin, lung, and vasculature. Transforming growth factor-P (TGF-beta) regulates the production of cytokines, growth factors, and extracellular matrix proteins by a variety of cell types and tissues. We show here that TGF-beta stimulates murine 3T3-L1 fibroblasts to synthesize FBLN-5 transcript and protein through a Smad3-independent pathway. Overexpression of FBLN-5 in 3T3-L1 cells increased DNA synthesis and enhanced basal and TGF-beta-stimulated activation of ERK1/ERK2 and p38 mitogen-activated protein kinase (MAPK). FBLN-5 overexpression also augmented the tumorigenicity of human HT1080 fibrosarcoma cells by increasing their DNA synthesis, migration toward fibronectin, and invasion through synthetic basement membranes. In stark contrast, FBLN-5 expression was down-regulated in the majority of metastatic human malignancies, particularly in cancers of the kidney, breast, ovary, and colon. Unlike its proliferative response in fibroblasts, FBLN-5 overexpression in mink lung Mv1Lu epithelial cells resulted in an antiproliferative response, reducing their DNA synthesis and cyclin A expression. Moreover, FBLN-5 synergizes with TGP-beta in stimulating AP-1 activity in Mv1Lu cells, an effect that was abrogated by overexpression of dominant-negative versions of either MKK1 or p38 MAPKalpha. Accordingly, both the stimulation and duration of ERK1/ERK2 and p38 MAPK by TGF-beta was enhanced in Mv1Lu cells expressing FBLN-5. Our findings identify FBLN-5 as a novel TGF-beta-inducible target gene that regulates cell growth and motility in a context-specific manner and affects protein kinase activation by TGF-beta. Our findings also indicate that aberrant FBLN-5 expression likely contributes to tumor development in humans.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA; Duke Univ, Sch Med, Dept Pharmacol, Durham, NC 27710 USA; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Duke University; Duke University; University of Southern Denmark; Massachusetts Institute of Technology (MIT)	Schiemann, WP (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Goodman Bldg,K1011,1400 Jackson St, Denver, CO 80206 USA.		Blobe, Gerard/AAJ-5945-2020; Pandey, Akhilesh/B-4127-2009; xu, huanfang/I-4315-2012	Blobe, Gerard/0000-0002-4274-8901; Pandey, Akhilesh/0000-0001-9943-6127; 	NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Gallagher WM, 1999, ONCOGENE, V18, P3608, DOI 10.1038/sj.onc.1202937; Gallagher WM, 2001, FEBS LETT, V489, P59, DOI 10.1016/S0014-5793(00)02389-9; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Ghaffari S, 1999, P NATL ACAD SCI USA, V96, P13186, DOI 10.1073/pnas.96.23.13186; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Kalume DE, 2000, J MASS SPECTROM, V35, P145, DOI 10.1002/(SICI)1096-9888(200002)35:2<145::AID-JMS922>3.0.CO;2-I; Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001; Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166; LECKACZERNIK B, 1995, MOL CELL BIOL, V15, P120, DOI 10.1128/MCB.15.1.120; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SPENCE SG, 1992, DEV BIOL, V151, P473, DOI 10.1016/0012-1606(92)90186-K; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003	39	132	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27367	27377		10.1074/jbc.M200148200	http://dx.doi.org/10.1074/jbc.M200148200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021267	hybrid			2022-12-25	WOS:000177055900086
J	Stoeckman, AK; Towle, HC				Stoeckman, AK; Towle, HC			The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; FATTY-ACID-SYNTHASE; PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR; TRANSCRIPTION FACTOR; RAT HEPATOCYTES; GLUCOSE REGULATION; DIFFERENTIATION FACTOR-1; PRIMARY CULTURE; INSULIN ACTION	A high carbohydrate diet up-regulates the transcription of enzymes of triglyceride biosynthesis (lipogenesis) in the mammalian liver. This treatment stimulates hepatic insulin signaling, leading to transcription of sterol regulatory element-binding protein-1c (SREBP-1c). SREBP-1c has been implicated as a major factor that up-regulates lipogenic genes in response to carbohydrate feeding. However, we presented evidence for another factor, carbohydrate response factor, which is also involved in this response, and we proposed a model wherein SREBP-1c and carbohydrate response factor are independent transcription factors that act in response to insulin and glucose, respectively. In this study, we examined the contribution of SREBP-1c to the expression of lipogenic genes in glucose- and insulin-treated primary rat hepatocytes using an inducible adenovirus system. We found that SREBP-1c overexpression leads to a modest induction of fatty acid synthase, S-14, and acetyl-CoA carboxylase mRNAs to 20% (fatty acid synthase), 10% (S-14), and 5% (acetyl-CoA carboxylase) of the induction seen by high glucose and insulin treatment. Restoring insulin to cells overexpressing SREBP-1c did not further increase these mRNA levels. In contrast, adenovirus-expressed SREBP-1c did not induce pyruvate kinase mRNA, suggesting that induction of this gene is SREBP-1c-independent. SREBP-1c does indeed play a role in the induction of lipogenic enzyme genes in response to insulin treatment, but it is not sufficient for the induction seen when hepatocytes are treated with insulin and high glucose.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Stoeckman, Angela/0000-0002-2009-0424				Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Cunningham BA, 1998, THYROID, V8, P815, DOI 10.1089/thy.1998.8.815; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Kaytor EN, 2000, MOL CELL BIOCHEM, V210, P13, DOI 10.1023/A:1007006429041; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; O'Callaghan BL, 2001, J BIOL CHEM, V276, P16033, DOI 10.1074/jbc.M101557200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rufo C, 2001, J BIOL CHEM, V276, P21969, DOI 10.1074/jbc.M100461200; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Stabile LP, 1998, J LIPID RES, V39, P1951; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Trinh K, 1999, DIABETES, V48, pA78; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298	44	141	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27029	27035		10.1074/jbc.M202638200	http://dx.doi.org/10.1074/jbc.M202638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016216	hybrid			2022-12-25	WOS:000177055900044
J	Wurster, AL; Rodgers, VL; White, MF; Rothstein, TL; Grusby, MJ				Wurster, AL; Rodgers, VL; White, MF; Rothstein, TL; Grusby, MJ			Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTIGEN-RECEPTOR ENGAGEMENT; CONSTITUTIVE ACTIVATION; NUCLEAR EXPRESSION; SURFACE IGM; IL-4; STAT6; DEATH; PROLIFERATION; BCL-X(L)	Apoptosis is an integral aspect of B lymphocyte development and homeostasis and is regulated by the engagement of antigen costimulatory and cytokine receptors. Although it is well established that interleukin 4 (IL-4) is a potent anti-apoptotic cytokine for B lymphocytes, little is known about the IL-4-induced molecular events regulating cell survival. Stat6 is rapidly activated after IL-4 stimulation, but its role in B lymphocyte apoptosis has not been explored. In this report we demonstrate that Stat6 is a critical signaling molecule for IL-4 in protecting primary B cells from passive and Fas-induced cell death. We show that expression of the Bcl-2 family member, Bcl-xL, is induced maximally by IL-4 and anti-IgML-4 in a Stat6-dependent manner. Additionally, we demonstrate that bcl-xL transcription is likely to be directly activated through a Stat6 binding site in the bcl-xL-flanking region. Finally, reconstitution of Stat6-deficient splenic B cells with Bcl-xL was able to protect those cells from Fas-induced cell death. These results suggest that the anti-apoptotic activity of IL-4 in B cells is mediated through the activation of Stat6 and subsequent transcription of Bcl-xL.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr, Boston, MA 02115 USA; Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Evans Mem Dept Clin Res, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	Grusby, MJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USA.	mgrusby@hsph.harvard.edu			NIAID NIH HHS [AI 40181, AI 40171] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, R01AI040171, R21AI040181, R01AI040181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BROOME HE, 1995, J IMMUNOL, V155, P2311; BRUNETTI M, 1995, BLOOD, V86, P4199, DOI 10.1182/blood.V86.11.4199.bloodjournal86114199; Catlett IM, 1999, J IMMUNOL, V163, P2378; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Delphin S, 1995, ANN NY ACAD SCI, V764, P123; Foote LC, 1996, J IMMUNOL, V157, P2749; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hoey T, 1999, Adv Immunol, V71, P145; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; ILLERA VA, 1993, J IMMUNOL, V151, P2965; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; Karras JG, 1996, J IMMUNOL, V157, P39; Kieslinger M, 2000, GENE DEV, V14, P232; Koizumi T, 1996, MOL IMMUNOL, V33, P1247, DOI 10.1016/S0161-5890(96)00084-3; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LIU JL, 1991, J IMMUNOL, V146, P1685; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PARRY SL, 1994, J IMMUNOL, V152, P2821; Paul WE, 1997, CIBA F SYMP, V204, P208; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Teague TK, 2000, J EXP MED, V191, P915, DOI 10.1084/jem.191.6.915; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Wurster AL, 2002, MOL CELL BIOL, V22, P117, DOI 10.1128/MCB.22.1.117-126.2002; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zamorano J, 1998, J IMMUNOL, V161, P859; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	52	115	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27169	27175		10.1074/jbc.M201207200	http://dx.doi.org/10.1074/jbc.M201207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023955	hybrid			2022-12-25	WOS:000177055900061
J	Kawamata, S; Du, CC; Li, KJ; Lavau, C				Kawamata, S; Du, CC; Li, KJ; Lavau, C			Overexpression of the Notch target genes Hes in vivo induces lymphoid and myeloid alterations	ONCOGENE			English	Article						Hes; Notch; B cells; hematopoiesis	DEVELOPING NERVOUS-SYSTEM; CELL-DEVELOPMENT; MOLECULAR CHARACTERIZATION; CHROMOSOMAL LOCUS; DROSOPHILA-HAIRY; LINEAGE DECISION; PRECURSOR CELLS; BONE-MARROW; DIFFERENTIATION; EXPRESSION	To examine the effects of Notch signaling on hematopoiesis, we transplanted mice with progenitors transduced with a constitutively active form of Notch1 (Notch1IC) or the Notch1 target genes Hes. Notch1IC-transduced cells induce T cell tumors and cannot generate B lymphocytes in vivo. Hes-transplanted mice remained healthy but cells transduced with Hes1 or Hes5 were partially impaired in their ability to differentiate into B cells. Both Hes1 and Hes5 were upregulated in the BM of Notch1IC mice and their ability to interfere with the transcriptional activity of E2A in a reporter assay was comparable to that of Notch1IC. This suggests that the inhibition of B cell development in the Notch1IC-transduced cells could be mediated by the interference of HES1/HES5 proteins with E2A. Hest1-, Hes5- and Notch1IC-transduced bone marrow cells cultured ex vivo in a colony forming assay in the presence of cytokines that promote myeloid differentiation remained very immature, indicating that the myeloid potential of these bone marrow cells was altered. Thymocytes overexpressing Hes1, Hes5 or Notch1IC matured normally into CD4 and CD8 single positive cells in vivo. Altogether our data suggest that Notch1IC induces T cell tumors independently of Hes genes but that its interference with lymphoid B and myeloid maturation is partly mediated by Hes1 and Hes5.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; SyStemix Inc, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Novartis	Lavau, C (corresponding author), Hop St Louis, CNRS UPR 9051, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Lavau, Catherine/Q-2928-2019; Du, Changchun/AAW-6540-2020	kawamata, shin/0000-0001-5148-1949; Lavau, Catherine/0000-0003-4800-1320				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1994, GENE THER, V1, P136; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Kim HK, 1998, MOL CELL BIOL, V18, P7166, DOI 10.1128/MCB.18.12.7166; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SCREPANTI I, 1989, J IMMUNOL, V142, P3378; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wilson A, 2001, J EXP MED, V194, P1003, DOI 10.1084/jem.194.7.1003; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294	43	99	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3855	3863		10.1038/sj.onc.1205487	http://dx.doi.org/10.1038/sj.onc.1205487			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032823				2022-12-25	WOS:000175847200004
J	Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M				Pandey, A; Dan, I; Kristiansen, TZ; Watanabe, NM; Voldby, J; Kajikawa, E; Khosravi-Far, R; Blagoev, B; Mann, M			Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain	ONCOGENE			English	Article						p2l-activated kinase; Ste20; CDC42; JNK; brain	ACTIVATED PROTEIN-KINASE; FAMILY; CELLS; APOPTOSIS; ACTIN; DEATH; RAS	The p21-activated kinase (PAK) family of protein kinases has recently attracted considerable attention as an effector of Rho family of small G proteins and as an upstream regulator of MAPK signalling pathways during cellular events such as re-arrangement of the cytoskeleton and apoptosis. We have cloned a novel human PAK family kinase that has been designated as PAK5. PAK5 contains a CDC42/Rac1 interactive binding (CRIB) motif at the N-terminus and a Ste20-like kinase domain at the C-terminus. PAK5 is structurally most related to PAK4 and PAK6 to make up the PAK-II subfamily. We have shown that PAK5 preferentially binds to CDC42 in the presence of GTP and that CRIB motif is essential for this interaction. PAK5 is a functional protein kinase but unlike PAK-I family kinases (PAKI, 2, and 3), the kinase activity of PAK5 does not seem to require the binding of CDC42. Overexpression of PAK5 activates the JNK kinase pathway but not p38 or ERK pathways. PAK5 transcript is predominantly expressed in brain as revealed by Northern blot and in situ hybridization. The expression pattern of PAK5 is distinct from that of PAK4 and PAK6, suggesting a functional division among PAK-11 subfamily kinases based on differential tissue distribution.	Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark; Harvard Med Ctr, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Sci,ERATO, JST,Kusumi Membrane Organizer Project,Chikusa Ku, Nagoya, Aichi 4648602, Japan	University of Southern Denmark; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Japan Science & Technology Agency (JST); Nagoya University	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.		Pandey, Akhilesh/B-4127-2009; Dan, Ippeita/F-9179-2011; Khosravi-Far, Roya/C-3789-2008; Mann, Matthias/A-3454-2013	Pandey, Akhilesh/0000-0001-9943-6127; Dan, Ippeita/0000-0002-1779-9205; Mann, Matthias/0000-0003-1292-4799; Blagoev, Blagoy/0000-0002-3596-0066	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	23	96	109	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3939	3948		10.1038/sj.onc.1205478	http://dx.doi.org/10.1038/sj.onc.1205478			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032833				2022-12-25	WOS:000175847200014
J	Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT				Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT			Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis	ONCOGENE			English	Article						small cell lung carcinoma (SCLC); microarray; subtractive hybridization; real-time PCR; gene expression	TUMOR-TRANSFORMING GENE; NEUROENDOCRINE CARCINOMA; BRONCHIAL EPITHELIUM; CANCER; PROTEINS; TISSUE; COMBINATION; MULTIPLE; REGIONS; FAMILY	To identify genes that are differentially over-expressed in Small Cell Lung Carcinoma (SCLC) we have used a combination of suppression subtractive hybridization and cDNA microarray to analyse the expression profiles of 2400 cDNAs clones. Genes that are over-expressed in SCLC were identified using 32 pairs of fluorescence-labeled cDNA samples representing various lung tumors and normal tissues. This comprehensive approach has resulted in the identification of 209 genes that are differentially over-expressed in SCLC. Quantitative real-time PCR was used to further validate the expression of 43 genes in SCLC tumors and various normal tissues. Discussed in this report are nine genes, which showed the most promising SCLC tumor to normal tissue differential expression profiles, including seven known and two novel genes. The large number of differentially expressed genes identified from this analysis and the characterization of these genes will provide valuable information in better understanding the biology of SCLC and help us in developing these gene products as potential targets for diagnostic as well as therapeutic usage.	Corixa Corp, Tumor Antigen Discovery, Seattle, WA 98104 USA; Rosetta Inpharm, Washington, WA 98034 USA	Corixa	Bangur, CS (corresponding author), Corixa Corp, Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.	bangur@corixa.com						Anbazhagan R, 1999, CANCER RES, V59, P5119; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FELD R, 2000, STAGING PROGNOSTIC F, P612; GIACCONE G, 1994, ANTICANCER RES, V14, P269; GINSBERG RJ, 1997, NONSMALL CELL LUNG C, P858; Girard L, 2000, CANCER RES, V60, P4894; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; GUINEE DG, 1994, AM J CLIN PATHOL, V102, P406, DOI 10.1093/ajcp/102.4.406; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; IHDE DC, 1997, SMALL CELL LUNG CARC, P911; JACKSONYORK GL, 1991, CANCER, V68, P374, DOI 10.1002/1097-0142(19910715)68:2<374::AID-CNCR2820680227>3.0.CO;2-2; KALEMKERIAN GP, 2000, GROWTH FACTORS, P181; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Nacht M, 1999, CANCER RES, V59, P5464; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Ono K, 2000, CANCER RES, V60, P5007; OSBORNE MA, 1994, J CELL BIOL, V125, P853, DOI 10.1083/jcb.125.4.853; OUD PS, 1989, CANCER, V64, P1304, DOI 10.1002/1097-0142(19890915)64:6<1304::AID-CNCR2820640623>3.0.CO;2-K; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; Sgroi DC, 1999, CANCER RES, V59, P5656; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tannoch VJ, 2000, ADV EXP MED BIOL, V465, P127; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Williams C L, 1997, Chest Surg Clin N Am, V7, P1; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Xia Y, 2000, CANCER RES, V60, P6303; Xu JC, 2000, CANCER RES, V60, P1677; YAMAGUCHI K, 1983, CANCER RES, V43, P3932; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	58	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3814	3825		10.1038/sj.onc.1205480	http://dx.doi.org/10.1038/sj.onc.1205480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032850				2022-12-25	WOS:000175676000017
J	Grouzmann, E; Monod, M; Landis, B; Wilk, S; Brakch, N; Nicoucar, K; Giger, R; Malis, D; Szalay-Quinodoz, I; Cavadas, C; Morel, DR; Lacroix, JS				Grouzmann, E; Monod, M; Landis, B; Wilk, S; Brakch, N; Nicoucar, K; Giger, R; Malis, D; Szalay-Quinodoz, I; Cavadas, C; Morel, DR; Lacroix, JS			Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa	FASEB JOURNAL			English	Article						DPPIV; chronic rhinosinusitis; substance P; NK1; non-adrenergic; non-cholinergic	GENE-RELATED PEPTIDE; NEUROKININ-A; GUINEA-PIG; AMINOPEPTIDASE-M; SPINAL-CORD; RELEASE; TACHYKININS; HISTAMINE; INCREASE; DIPEPTIDYL(AMINO)PEPTIDASE-IV	In this study, we have found that dipeptidylpeptidase IV (DPPIV) plays in vivo an active role in the modulation of the inflammatory response of chronic rhinosinusitis. Human nasal mucosa expresses DPPIV-like immunoreactivity in submucosal seromucus glands, leukocytes, and endothelial cells of blood vessels. DPPIV enzymatic activity in nasal tissue biopsies taken from patients suffering from chronic rhinosinusitis was correlated inversely with the density of inflammatory cells in the nasal mucosa, and the DPPIV activity rose when chronic rhinosinusitis was treated. By using a pig animal model, we have shown that the intranasal administration of recombinant DPPIV decreased the vasodilatation induced by exogenous substance P (SP), a proinflammatory peptide released by sensory nerves. In contrast, an inhibitor of DPPIV enhanced the vasodilatatory effect at low doses of SP. SP5-11 was 100- to 1000-fold less potent than SP as a vasodilator of the nasal mucosa. The vasodilatatory effect of SP was abolished by a NK1 receptor antagonist. In conclusion, these results suggest a new pathophysiological pathway for rhinitis based on clinical observations in humans, indicating the involvement of an enzyme to modulate non-adrenergic and non-cholinergicnon-cholinergic substrate that occurred during nasal dysfunctions.	CHU Vaudois, Div Hypertens, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Dermatol, CH-1011 Lausanne, Switzerland; Hop Cantonal Univ Geneva, Lab Rhinol Expt, Clin & Policlin Otorhinolaryngol & Chirurg Cervic, CH-1211 Geneva, Switzerland; CUNY Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Hop Cantonal Univ Geneva, Dept Clin Pathol, CH-1211 Geneva, Switzerland; Hop Cantonal Univ Geneva, Div Invest Anesthesiol, CH-1211 Geneva, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Geneva; University of Geneva	Grouzmann, E (corresponding author), CHU Vaudois, Div Hypertens, CH-1011 Lausanne, Switzerland.	Eric.Grouzmann@chuv.hospvd.ch	Cavadas, Claudia/K-8271-2014; Cavadas, Claudia/AAB-6904-2021	Cavadas, Claudia/0000-0001-8020-9266; Cavadas, Claudia/0000-0001-8020-9266				AHMAD S, 1992, J PHARMACOL EXP THER, V260, P1257; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; Beauvais A, 1997, INFECT IMMUN, V65, P3042, DOI 10.1128/IAI.65.8.3042-3047.1997; CHATELAIN C, 1995, EUR ARCH OTO-RHINO-L, V252, P83; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; ERJAVEC F, 1981, N-S ARCH PHARMACOL, V317, P67, DOI 10.1007/BF00506259; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; GEPPETTI P, 1991, J PHARMACOL EXP THER, V259, P759; HEYMANN E, 1978, FEBS LETT, V91, P360, DOI 10.1016/0014-5793(78)81210-1; Holzer P, 1998, GEN PHARMACOL, V30, P5, DOI 10.1016/S0306-3623(97)00078-5; HOPSUHAV.VK, 1969, HISTOCHEMISTRY, V17, P30, DOI 10.1007/BF00306327; HUA XY, 1986, NEUROSCIENCE, V19, P313, DOI 10.1016/0306-4522(86)90024-2; KENNY A, 1991, PPETIDASES INVOLVED, P47; KHALAF MR, 1987, J CLIN PATHOL, V40, P480, DOI 10.1136/jcp.40.5.480; Konno A, 1996, ANN OTO RHINOL LARYN, V105, P648, DOI 10.1177/000348949610500811; Lacroix JS, 1995, EUR ARCH OTO-RHINO-L, V252, P465, DOI 10.1007/BF02114752; LACROIX JS, 1989, ACTA PHYSIOL SCAND, V136, P1; LI JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P148, DOI 10.1006/abbi.1995.0020; LOJDA Z, 1977, HISTOCHEMISTRY, V54, P299, DOI 10.1007/BF00508273; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, P1; MACKAY IS, 1988, BRIT J DIS CHEST, V82, P1, DOI 10.1016/0007-0971(88)90002-2; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; MYGIND N, 1983, EUR J RESPIR DIS, V64, P16; NADEL JA, 1991, EUR RESPIR J, V4, P745; NAKATA Y, 1981, J NEUROCHEM, V37, P1529, DOI 10.1111/j.1471-4159.1981.tb06323.x; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; Ottosson A, 1997, CEPHALALGIA, V17, P166, DOI 10.1046/j.1468-2982.1997.1703166.x; PEDERSENBJERGAARD U, 1989, PEPTIDES, V10, P1147, DOI 10.1016/0196-9781(89)90006-5; PIEDIMONTE G, 1993, J APPL PHYSIOL, V74, P2462, DOI 10.1152/jappl.1993.74.5.2462; PIEDIMONTE G, 1993, J PHARMACOL EXP THER, V265, P36; Sakurada C, 1999, J PHARM SCI-US, V88, P1127, DOI 10.1021/js990149c; SCHARPE SL, 1991, CLIN CHIM ACTA, V195, P125, DOI 10.1016/0009-8981(91)90132-V; SHORE SA, 1988, AM REV RESPIR DIS, V137, P331, DOI 10.1164/ajrccm/137.2.331; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; STJARNE P, 1989, CELL TISSUE RES, V256, P439; TANI E, 1990, NEUROSCI LETT, V115, P171, DOI 10.1016/0304-3940(90)90450-N; THOMPSON JE, 1988, AM REV RESPIR DIS, V137, P337, DOI 10.1164/ajrccm/137.2.337; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x; UMENO E, 1989, J APPL PHYSIOL, V66, P2647, DOI 10.1152/jappl.1989.66.6.2647; Van der Velden VHJ, 1998, CLIN EXP ALLERGY, V28, P110; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; WANG LH, 1991, PEPTIDES, V12, P1357, DOI 10.1016/0196-9781(91)90220-J	42	52	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1132	+		10.1096/fj.01-0939fje	http://dx.doi.org/10.1096/fj.01-0939fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039843				2022-12-25	WOS:000175973900002
J	Veldman, RJ; Klappe, K; Hinrichs, J; Hummel, I; van der Schaaf, G; Sietsma, H; Kok, JW				Veldman, RJ; Klappe, K; Hinrichs, J; Hummel, I; van der Schaaf, G; Sietsma, H; Kok, JW			Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus	FASEB JOURNAL			English	Article						lactosylceramide; glucosylceramide; gangliosides; P-glycoprotein; brefeldin A	MDR2 P-GLYCOPROTEIN; SDZ PSC 833; PLASMA-MEMBRANE; BREFELDIN-A; IN-VITRO; GLYCOSPHINGOLIPID SYNTHESIS; GLUCOSYLCERAMIDE; CERAMIDE; SPHINGOMYELIN; TRANSPORT	Multidrug-resistant tumor cells display enhanced levels of glucosylceramide. In this study, we investigated how this relates to the overall sphingolipid composition of multidrug-resistant ovarian carcinoma cells and which mechanisms are responsible for adapted sphingolipid metabolism. We found in multidrug-resistant cells substantially lower levels of lactosylceramide and gangliosides in sharp contrast to glucosylceramide, galactosylceramide, and sphingomyelin levels. This indicates a block in the glycolipid biosynthetic pathway at the level of lactosylceramide formation, with concomitant accumulation of glucosylceramide. A series of observations exclude regulation at the enzyme level as the underlying mechanism. First, reduced lactosylceramide formation occurred only in intact resistant cells whereas cell-free activity of lactosylceramide synthase was higher compared with the parental cells. Second, the level of lactosylceramide synthase gene expression was equal in both phenotypes. Third, glucosylceramide synthase (mRNA and protein) expression and activity were equal or lower in resistant cells. Based on the kinetics of sphingolipid metabolism, the observation that brefeldin A does not restore lactosylceramide synthesis, and altered localization of lactosylceramide synthase fused to green fluorescent protein, we conclude that lactosylceramide biosynthesis is highly uncoupled from glucosylceramide biosynthesis in the Golgi apparatus of resistant cells.	Univ Groningen, Inst Drug Explorat, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen	Kok, JW (corresponding author), Univ Groningen, Inst Drug Explorat, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.w.kok@med.rug.nl						Babia T, 1998, EUR J BIOCHEM, V258, P233, DOI 10.1046/j.1432-1327.1998.2580233.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; Goulding CW, 2000, CANCER LETT, V149, P143, DOI 10.1016/S0304-3835(99)00353-5; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kok JW, 1999, FLUORESCENT LUMINESC, P136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Lucci A, 1998, ANTICANCER RES, V18, P475; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Maxzud MK, 2000, NEUROCHEM RES, V25, P145, DOI 10.1023/A:1007555903335; MAY GL, 1988, INT J CANCER, V42, P728, DOI 10.1002/ijc.2910420517; Raggers RJ, 1999, J CELL SCI, V112, P415; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sadeghlar F, 2000, FEBS LETT, V478, P9, DOI 10.1016/S0014-5793(00)01818-4; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; SENN HJ, 1989, EUR J BIOCHEM, V181, P657, DOI 10.1111/j.1432-1033.1989.tb14773.x; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Sietsma H, 1998, CANCER RES, V58, P4840; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Helvoort A, 1997, J CELL SCI, V110, P75; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; Yokoyama K, 1997, EUR J BIOCHEM, V249, P450, DOI 10.1111/j.1432-1033.1997.00450.x; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; ZIJLSTRA JG, 1990, MED ONCOL TUMOR PHAR, V7, P11, DOI 10.1007/BF03000485	43	78	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1111	+		10.1096/fj.01-0863fje	http://dx.doi.org/10.1096/fj.01-0863fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039850				2022-12-25	WOS:000175973900012
J	Napierala, M; Parniewski, P; Pluciennik, A; Wells, RD				Napierala, M; Parniewski, P; Pluciennik, A; Wells, RD			Long CTG-CAG repeat sequences markedly stimulate intramolecular recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; STRAND BREAK REPAIR; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; TRINUCLEOTIDE REPEAT; TRIPLET REPEAT; GENETIC INSTABILITIES; DNA-SEQUENCES; MYCOPLASMA-GALLISEPTICUM; SACCHAROMYCES-CEREVISIAE	Previous studies have shown that homologous recombination is a powerful mechanism for generation of massive instabilities of the myotonic dystrophy CTG.CAG sequences. However, the frequency of recombination between the CTG-CAG tracts has not been studied. Here we performed a systematic study on the frequency of recombination between these sequences using a genetic assay based on an intramolecular plasmid system in Escherichia coli. The rate of intramolecular recombination between long CTG-CAG tracts oriented as direct repeats was extraordinarily high; recombinants were found with a frequency exceeding 12%. Recombination occurred in both RecA(+) and RecA(-) cells but was similar to2-11 times higher in the recombination proficient strain. Long CTG-CAG tracts recombined similar to10 times more efficiently than non-repeating control sequences of similar length. The recombination frequency was 60-fold higher for a pair of (CTG.CAG)(165) tracts compared with a pair of (CTG-CAG)(17) sequences. The CTG-CAG sequences in orientation 11 (CTG repeats present on a lagging strand template) recombine similar to2-4 times more efficiently than tracts of identical length in the opposite orientation relative to the origin of replication. This orientation effect implies the involvement of DNA replication in the intramolecular recombination between CTG-CAG sequences. Thus, long CTG-CAG tracts are hot spots for genetic recombination.	Texas A&M Univ Syst, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA; Polish Acad Sci, Ctr Microbiol & Virol, PL-93232 Lodz, Poland	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Polish Academy of Sciences	Wells, RD (corresponding author), Texas A&M Univ Syst, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu			NIEHS NIH HHS [ES 11347] Funding Source: Medline; NIGMS NIH HHS [GM 52982] Funding Source: Medline; NINDS NIH HHS [NS 37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHMANN BJ, 1987, DERIVATIONS GENOTYPE; Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; Bi X, 1996, J MOL BIOL, V256, P849, DOI 10.1006/jmbi.1996.0131; Bi X, 1996, P NATL ACAD SCI USA, V93, P819, DOI 10.1073/pnas.93.2.819; BI X, 1995, J MOL BIOL, V247, P890, DOI 10.1006/jmbi.1995.0188; BI X, 1994, J MOL BIOL, V235, P414, DOI 10.1006/jmbi.1994.1002; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bzymek M, 2001, P NATL ACAD SCI USA, V98, P8319, DOI 10.1073/pnas.111008398; Bzymek M, 2001, GENETICS, V158, P527; Cemal CK, 1999, GENE, V236, P53, DOI 10.1016/S0378-1119(99)00273-5; CHIANG CS, 1988, PLASMID, V20, P207, DOI 10.1016/0147-619X(88)90027-3; Cox R, 1997, P NATL ACAD SCI USA, V94, P5237, DOI 10.1073/pnas.94.10.5237; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; De Bolle X, 2000, MOL MICROBIOL, V35, P211, DOI 10.1046/j.1365-2958.2000.01701.x; DROGE P, 1989, P NATL ACAD SCI USA, V86, P6062, DOI 10.1073/pnas.86.16.6062; Dutreix M, 1997, J MOL BIOL, V273, P105, DOI 10.1006/jmbi.1997.1293; ENNIS DG, 1987, GENETICS, V115, P11; Feschenko VV, 1998, J MOL BIOL, V276, P559, DOI 10.1006/jmbi.1997.1566; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Gendrel CG, 2000, GENE DEV, V14, P1261; Glew MD, 1998, INFECT IMMUN, V66, P5833, DOI 10.1128/IAI.66.12.5833-5841.1998; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; Inouye S, 1997, GENE, V189, P159, DOI 10.1016/S0378-1119(96)00753-6; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jakupciak JP, 2000, IUBMB LIFE, V50, P355, DOI 10.1080/152165400300089358; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; Jeffreys A, 1999, ELECTROPHORESIS, V20, P1665, DOI 10.1002/(SICI)1522-2683(19990101)20:8<1665::AID-ELPS1665>3.0.CO;2-L; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KITAMURA Y, 1990, MOL GEN GENET, V222, P185, DOI 10.1007/BF00633816; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LABAN A, 1981, MOL GEN GENET, V184, P200, DOI 10.1007/BF00272905; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LISKAY RM, 1986, P NATL ACAD SCI USA, V83, P1802, DOI 10.1073/pnas.83.6.1802; Liu L, 2000, INFECT IMMUN, V68, P871, DOI 10.1128/IAI.68.2.871-876.2000; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOVETT ST, 1993, GENETICS, V135, P631; LOVETT ST, 1994, MOL GEN GENET, V245, P294, DOI 10.1007/BF00290109; Lysnyansky I, 1999, J BACTERIOL, V181, P5734, DOI 10.1128/JB.181.18.5734-5741.1999; Lyu YL, 1999, J MOL BIOL, V285, P1485, DOI 10.1006/jmbi.1998.2419; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; MAHAN MJ, 1991, GENETICS, V129, P1021; MAHAN MJ, 1988, GENETICS, V120, P23; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Morag AS, 1999, J MOL BIOL, V289, P21, DOI 10.1006/jmbi.1999.2763; Morgan NV, 1999, AM J HUM GENET, V65, P1330, DOI 10.1086/302627; MURPHY KE, 1986, NUCLEIC ACIDS RES, V14, P7325, DOI 10.1093/nar/14.18.7325; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; PRADO F, 1995, GENETICS, V139, P109; Ren Z, 1999, J BACTERIOL, V181, P5865, DOI 10.1128/JB.181.18.5865-5870.1999; Richard GF, 1999, MOL GEN GENET, V261, P871, DOI 10.1007/s004380050031; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGALL A, 1988, SCIENCE, V241, P1314, DOI 10.1126/science.3045970; SKOWRONSKI J, 1984, J MOL BIOL, V177, P399, DOI 10.1016/0022-2836(84)90292-4; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; Suarez A, 1997, GENE, V196, P69, DOI 10.1016/S0378-1119(97)00197-2; TAKAHASHI NK, 1992, P NATL ACAD SCI USA, V89, P5912, DOI 10.1073/pnas.89.13.5912; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; van Belkum A, 1998, MICROBIOL MOL BIOL R, V62, P275, DOI 10.1128/MMBR.62.2.275-293.1998; Vogelstein B., 1998, GENETIC BASIS HUMAN; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; Watson MA, 1996, J MOL BIOL, V257, P317, DOI 10.1006/jmbi.1996.0165; Wells R.D., 1998, GENETIC INSTABILITIE; Yamamoto K, 1996, GENETICS, V143, P27; Young ET, 2000, GENETICS, V154, P1053	84	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34087	34100		10.1074/jbc.M202128200	http://dx.doi.org/10.1074/jbc.M202128200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12045198	hybrid			2022-12-25	WOS:000177959100075
J	Levin, MC; Marullo, S; Muntaner, O; Andersson, B; Magnusson, Y				Levin, MC; Marullo, S; Muntaner, O; Andersson, B; Magnusson, Y			The myocardium-protective Gly-49 variant of the beta(1)-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; HEART-FAILURE; ADRENERGIC-RECEPTOR; TRANSGENIC MICE; ACTIVATION; MUTATION; MUTANTS; PHOSPHORYLATION; OVEREXPRESSION; IDENTIFICATION	The beta(1)-adrenergic receptor (beta(1)AR) is a major mediator of catecholamine effects in human heart. Patients with heart failure who were hetero- or homozygous for the Gly-49 variant of the beta(1)AR (Gly-49-beta(1)AR) showed improved long-term survival as compared with those with the Ser-49 genotype. Here, the functional consequences of this polymorphism were studied in cells expressing either variant. The Gly-49-beta(1)AR demonstrated characteristic features of constitutively active receptors. In cells expressing the Gly-49-beta(1)AR, both basal and agonist-stimulated adenylyl cyclase activities were higher than in cells expressing the Ser-49 variant (Ser-49-beta(1)AR). The Gly-49-beta(1)AR was more sensitive to the inhibitory effect of the inverse agonist metoprolol and displayed increased affinity for agonists. Isoproterenol potency for adenylyl cyclase activation was higher on membranes expressing the Gly-49-beta(1)AR than on those expressing the Ser-49-beta(1)AR. After incubation with saturating concentrations of catecholamines or sustained stimulation, the Gly-49 variant showed a much higher desensitization, which largely prevailed over constitutive activity in terms of cAMP accumulation. The Gly-49-beta(1)AR also displayed a more profound agonist-promoted down-regulation than the Ser-49 variant. The stronger regulation of the Gly-49-beta(1)AR could explain the beneficial effect of the Gly-49 genotypes on survival, further supporting the concept that beta(1)AR desensitization is protective in heart failure.	Univ Gothenburg, Wallenberg Lab, SE-41345 Gothenburg, Sweden; Inst Cochin Genet Mol, Dept Cell Biol, F-70514 Paris, France	University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Magnusson, Y (corresponding author), Univ Gothenburg, Wallenberg Lab, SE-41345 Gothenburg, Sweden.		Marullo, Stefano/C-6142-2008	Marullo, Stefano/0000-0001-9604-9973; Levin, Malin/0000-0003-1069-5275				Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Borjesson M, 2000, EUR HEART J, V21, P1853, DOI 10.1053/euhj.1999.1994; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1990, CIRCULATION, V82, P112; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Engelhardt S, 2001, MOL PHARMACOL, V60, P712; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Hjalmarson A, 1999, LANCET, V353, P2001; Iwase M, 1996, CIRC RES, V78, P517, DOI 10.1161/01.RES.78.4.517; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Koehl P, 1999, P NATL ACAD SCI USA, V96, P12524, DOI 10.1073/pnas.96.22.12524; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; Lechat P, 1999, LANCET, V353, P9; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Magnusson Y., 1999, European Heart Journal, V20, P629; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; Maqbool A, 1999, LANCET, V353, P897, DOI 10.1016/S0140-6736(99)00549-8; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; NANTEL F, 1993, MOL PHARMACOL, V43, P548; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tesson F, 1999, J MOL CELL CARDIOL, V31, P1025, DOI 10.1006/jmcc.1999.0947	34	165	182	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30429	30435		10.1074/jbc.M200681200	http://dx.doi.org/10.1074/jbc.M200681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12034720	hybrid			2022-12-25	WOS:000177579800006
J	Menetrey, J; Flatau, G; Stura, EA; Charbonnier, JB; Gas, F; Teulon, JM; Le Du, MH; Boquet, P; Menez, A				Menetrey, J; Flatau, G; Stura, EA; Charbonnier, JB; Gas, F; Teulon, JM; Le Du, MH; Boquet, P; Menez, A			NAD binding induces conformational changes in Rho ADP-ribosylating Clostridium botulinum C3 exoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOTOXIN; CRYSTAL-STRUCTURE; TOXIN; NICOTINAMIDE; RECOGNITION; ACTIVATION; MECHANISM; DOMAIN; SITE	We have solved the crystal structures of Clostridium botulinum C3 exoenzyme free and complexed to NAD in the same crystal form, at 2.7 and 1.95 Angstrom, respectively. The asymmetric unit contains four molecules, which, in the free form, share the same conformation. Upon NAD binding, C3 underwent various conformational changes, whose amplitudes were differentially limited in the four molecules of the crystal unit. A major rearrangement concerns the loop that contains the functionally important ARTT motif (ADP-ribosyltransferase toxin turn-turn). The ARTT loop undergoes an ample swinging motion to adopt a conformation that covers the nicotinamide moiety of NAD. In particular, Gln-212, which belongs to the ARTT motif, flips over from a solvent-exposed environment to a buried conformation in the NAD binding pocket. Mutational experiments showed that Gln-212 is neither involved in NAD binding nor in the NAD-glycohydrolase activity of C3, whereas it plays a critical role in the ADP-ribosyl transfer to the substrate Rho. We observed additional NAD-induced movements, including a crab-claw motion of a subdomain that closes the NAD binding pocket. The data emphasized a remarkable NAD-induced plasticity of the C3 binding pocket and suggest that the NAD-induced ARTT loop conformation may be favored by the C3-NAD complex to bind to the substrate Rho. Our structural observations, together with a number of mutational experiments suggest that the mechanisms of Rho ADP-ribosylation by C3-NAD may he more complex than initially anticipated.	CE Saclay, Dept Ingn & Etudes Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Fac Med, INSERM, U452, F-06107 Nice 2, France; Serv Biochim Post Genom & Toxicol Nucl, Commissariat Energie Atom, Dept Ingn & Etudes Prot, F-30207 Bagnols Sur Ceze, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Menetrey, J (corresponding author), CE Saclay, Dept Ingn & Etudes Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France.	menetrey@cea.fr; andre.menez@cea.fr	Ménétrey, Julie/AAM-6408-2021; Charbonnier, Jean-Baptiste/A-3868-2009; Stura, Enrico A./A-2793-2010	Charbonnier, Jean-Baptiste/0000-0002-5219-1983; Stura, Enrico A./0000-0001-6718-2118				AKTORIES K, 1988, EUR J BIOCH, V172; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Han S, 2002, INT J MED MICROBIOL, V291, P523; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; HANS S, 2001, J MOL BIOL, V305, P95; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; MOODIE SL, 1993, NUCLEIC ACIDS RES, V21, P1369, DOI 10.1093/nar/21.6.1369; Moss J, 1990, ADP RIBOSYLATING TOX; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OPPENHEIMER NJ, 1994, MOL CELL BIOCHEM, V138, P245, DOI 10.1007/BF00928468; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PIZZA M, 1994, MOL MICROBIOL, V14, P51, DOI 10.1111/j.1365-2958.1994.tb01266.x; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Wilde C, 2002, J BIOL CHEM, V277, P14771, DOI 10.1074/jbc.M201072200; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Wilde C, 2001, TOXICON, V39, P1647, DOI 10.1016/S0041-0101(01)00152-0	26	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30950	30957		10.1074/jbc.M201844200	http://dx.doi.org/10.1074/jbc.M201844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12029083	hybrid			2022-12-25	WOS:000177579800071
J	Sanna, MG; Correia, JD; Luo, Y; Chuang, B; Paulson, LM; Nguyen, B; Deveraux, QL; Ulevitch, RJ				Sanna, MG; Correia, JD; Luo, Y; Chuang, B; Paulson, LM; Nguyen, B; Deveraux, QL; Ulevitch, RJ			ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; SIGNAL-TRANSDUCTION; CELL-DEATH; LINKED INHIBITOR; GROWTH-FACTOR; CYTOCHROME-C; KAPPA-B; IAP; KINASE; FAMILY	We have previously described a new aspect of the Inhibitor of Apoptosis (LAP) family of proteins anti-apoptotic activity that involves the TAK1/JNK1 signal transduction pathway (1, 2). Our findings suggest the existence of a novel mechanism that regulates the antiapoptotic activity of IAPs that is separate from caspase inhibition but instead involves TAK1-mediated activation of JNK1. In a search for proteins involved in the XIAP/TAK1/JNK1 signaling pathway we isolated by yeast two-hybrid screening a novel X chromosome-linked UP (XUP)-interacting protein that we called ILPIP (hILP-Interacting Protein). Whereas ILPIP moderately activates JNK family members when expressed alone, it strongly enhances XIAP-mediated activation of JNK1, JNK2, and JNK3. The expression of a catalytically inactive mutant of TAK1 blocked XIAP/ILPIP synergistic activation of JNK1 thereby implicating TAK1 in this signaling pathway. ILPIP moderately protects against interleukin-1beta converting enzyme- or Fas-induced apoptosis and significantly potentiates the anti-apoptotic activity of XUP. In vivo co-precipitation experiments show that both ILPIP and XUP interact with TAK1 and tumor necrosis factor receptor-associated factor 6. Finally, expression of ILPIP did not affect the ability of XIAP to inhibit caspase activation, further supporting the idea that XIAP protection against apoptosis is achieved by two separate mechanisms: one requiring JNK1 activation and a second involving caspase inhibition.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Rigel Inc, San Francisco, CA 94080 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Novartis	Ulevitch, RJ (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ulevitch@scripps.edu	Ulevitch, Richard J/Q-3393-2017		NIAID NIH HHS [AI 15136] Funding Source: Medline; NIGMS NIH HHS [GM 36796, GM 28485] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028485, R01GM028485] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen YR, 2000, INT J ONCOL, V16, P651; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 2000, METHOD ENZYMOL, V322, P154; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; HEDGE R, 2002, J BIOL CHEM, V277, P632; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nakamura S, 2001, J DERMATOL SCI, V25, P139, DOI 10.1016/S0923-1811(00)00123-7; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179	43	44	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30454	30462		10.1074/jbc.M203312200	http://dx.doi.org/10.1074/jbc.M203312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048196	hybrid			2022-12-25	WOS:000177579800009
J	Proenza, C; Tran, N; Angoli, D; Zahynacz, K; Balcar, P; Accili, EA				Proenza, C; Tran, N; Angoli, D; Zahynacz, K; Balcar, P; Accili, EA			Different roles for the cyclic nucleotide binding domain and amino terminus in assembly and expression of hyperpolarization-activated, cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNEL; PACEMAKER CHANNELS; FUNCTIONAL-CHARACTERIZATION; MOLECULAR MECHANISM; ION-CHANNEL; T1 DOMAIN; PROTEIN; SUBUNIT; AMP; IDENTIFICATION	In mammalian heart and brain, pacemaker currents are produced by hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, which probably exist as heteromeric assemblies of different subunit isoforms. To investigate the molecular domains that participate in assembly and membrane trafficking of HCN channels, we have used the yeast two-hybrid system, patch clamp electrophysiology, and confocal microscopy. We show here that the N termini of the HCN1 and HCN2 isoforms interacted and were essential for expression of functional homo- or heteromeric channels on the plasma membrane of Chinese hamster ovary cells. We also show that the cyclic nucleotide binding domain (CNBD) of HCN2 was required for the expression of functional homomeric channels. This expression was dependent on a 12-amino acid domain corresponding to the B-helix in the CNBD of the catabolite activator protein. However, co-expression with HCN1 of an HCN2 deletion mutant lacking the CNBD rescued surface immunofluorescence and currents, indicating that a CNBD need not be present in each subunit of a heteromeric HCN channel. Furthermore, neither CNBDs nor other COON-terminal domains of HCN1 and HCN2 interacted in yeast two-hybrid assays. Thus, interaction between NH2-terminal domains is important for HCN subunit assembly, whereas the CNBD is important for functional expression, but its absence from some subunits will still allow for the assembly of functional channels.	Simon Fraser Univ, Sch Kinesiol, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Accili, EA (corresponding author), Simon Fraser Univ, Sch Kinesiol, Ion Channel Lab, Burnaby, BC V5A 1S6, Canada.	eaaccili@sfu.ca		Proenza, Catherine/0000-0003-4324-6206				Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; Flucher BE, 2000, J CELL BIOL, V151, P467, DOI 10.1083/jcb.151.2.467; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grabner M, 1998, P NATL ACAD SCI USA, V95, P1903, DOI 10.1073/pnas.95.4.1903; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Marten I, 1997, P NATL ACAD SCI USA, V94, P3448, DOI 10.1073/pnas.94.7.3448; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Proenza C, 2000, J BIOL CHEM, V275, P23169, DOI 10.1074/jbc.M003389200; PROENZA C, 2001, J BIOL CHEM, V7, P5101; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Shi WM, 1999, CIRC RES, V85, pE1; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	38	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29634	29642		10.1074/jbc.M200504200	http://dx.doi.org/10.1074/jbc.M200504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034718	hybrid			2022-12-25	WOS:000177509300038
J	Ogawa, T; Bao, DH; Katoh, H; Shibata, M; Pakrasi, HB; Bhattacharyya-Pakrasi, M				Ogawa, T; Bao, DH; Katoh, H; Shibata, M; Pakrasi, HB; Bhattacharyya-Pakrasi, M			A two-component signal transduction pathway regulates manganese homeostasis in Synechocystis 6803, a photosynthetic organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE REGULATOR; GENES; SYSTEM; PHYTOCHROME; RESISTANCE; TRANSPORT; PROTEINS; IRON; IDENTIFICATION; CYANOBACTERIA	Elemental manganese is essential for the production of molecular oxygen by cyanobacteria, plants, and algae. In the cyanobacterium. Synechocystis sp. PCC 6803, transcription of the mntCAB operon, encoding a high affinity Mn transporter, occurs under Mn starvation (nM Mn) conditions but not in Mn-sufficient (muM Mn) growth medium. Using a strain in which the promoter of this operon directs the transcription of the luxAB reporter genes, we determined that inactivation of the slr0640 gene, which encodes a histidine kinase sensor protein component of a two-component signal transduction system, resulted in constitutive high levels of lux luminescence. Systematic targeted inactivation mutagenesis also identified slr1837 as the gene encoding the corresponding response regulator protein. We have named these two genes manS (manganese-sensor) and manR (manganese-regulator), respectively. A polyhistidine-tagged form of the ManS protein was localized in the Synechocystis 6803 cell membrane. Directed replacement of the conserved catalytic His-205 residue of this protein by Leu abolished its activity, although the mutated protein was present in cyanobacterial membrane. This mutant also showed suboptimal rates of Mn uptake under either Mn-starved or Mn-sufficient growth condition. These data suggest that the ManS/ManR two-component system plays a central role in the homeostasis of manganese in Synechocystis 6803 cells.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Nagoya Univ, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Washington University (WUSTL); Nagoya University	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.	Pakrasi@biology2.wustl.edu						AIBA H, 1981, J BIOL CHEM, V256, P1905; Aoki S, 1997, J BACTERIOL, V179, P5751, DOI 10.1128/jb.179.18.5751-5755.1997; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; BENDER CL, 1987, J BACTERIOL, V169, P470, DOI 10.1128/jb.169.2.470-474.1987; BROWN NL, 1992, PLASMID, V27, P41, DOI 10.1016/0147-619X(92)90005-U; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; CHELLY J, 1994, POLYM CHAIN REACTION; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; DASILVA JJR, 2001, BIOL CHEM ELEMENTS, P400; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; Foussard M, 2001, MICROBES INFECT, V3, P417, DOI 10.1016/S1286-4579(01)01390-9; Garcia-Dominguez M, 2000, J BACTERIOL, V182, P38, DOI 10.1128/JB.182.1.38-44.2000; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hirani TA, 2001, PLANT MOL BIOL, V45, P133, DOI 10.1023/A:1006425214168; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hughes O, 1999, PLANT PHYSIOL, V121, P1059; Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709; Jakubovics NS, 2000, MOL MICROBIOL, V38, P140, DOI 10.1046/j.1365-2958.2000.02122.x; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Katoh H, 2001, J BACTERIOL, V183, P2779, DOI 10.1128/JB.183.9.2779-2784.2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li H, 2000, J BACTERIOL, V182, P4268, DOI 10.1128/JB.182.15.4268-4277.2000; Lopez-Maury L, 2002, MOL MICROBIOL, V43, P247, DOI 10.1046/j.1365-2958.2002.02741.x; Mizuno T, 1996, DNA Res, V3, P407, DOI 10.1093/dnares/3.6.407; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; Pakrasi H, 2001, ADV PHOTOSYNTH, V11, P253; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Patzer SI, 2001, J BACTERIOL, V183, P4806, DOI 10.1128/JB.183.16.4806-4813.2001; Que Q, 2000, MOL MICROBIOL, V35, P1454, DOI 10.1046/j.1365-2958.2000.01811.x; SAMBROOK J, 1989, MOL CLONING LAB MANA; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; Shen JR, 1997, J BIOL CHEM, V272, P17821, DOI 10.1074/jbc.272.28.17821; Shibata M, 2001, P NATL ACAD SCI USA, V98, P11789, DOI 10.1073/pnas.191258298; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; VIOQUE A, 1992, NUCLEIC ACIDS RES, V20, P6331, DOI 10.1093/nar/20.23.6331; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Yocum CF, 1999, CURR OPIN CHEM BIOL, V3, P182, DOI 10.1016/S1367-5931(99)80031-3; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898	45	61	65	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28981	28986		10.1074/jbc.M204175200	http://dx.doi.org/10.1074/jbc.M204175200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039966	hybrid			2022-12-25	WOS:000177342600083
J	Sidenius, N; Andolfo, A; Fesce, R; Blasi, F				Sidenius, N; Andolfo, A; Fesce, R; Blasi, F			Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; LIGAND-BINDING; CELLULAR RECEPTOR; ADHESION; DOMAIN; CELLS; CHEMOTAXIS; REGION; UPAR; SITE	Adhesion of monocytes to the extracellular matrix is mediated by a direct high affinity interaction between cell-surface urokinase-type plasminogen activator (uPA) receptor (uPAR) and the extracellular matrix protein vitronectin. We demonstrate a tight connection between uPA-regulated uPAR oligomerization and high affinity binding to immobilized vitronectin. We find that binding of soluble uPAR (suPAR) to immobilized vitronectin is strictly ligand-dependent with a linear relationship between the observed binding and the concentration of ligand added. Nevertheless, a comparison of experimentally obtained binding curves to those generated using a simple equilibrium model suggests that the high affinity vitronectin-binding pro-uPA(.)suPAR complex contains two molecules of suPAR. In co-immunoprecipitation experiments, using different epitope-tagged suPAR molecules, suPAR/suPAR co-immunoprecipitation displayed a similar uPA dose dependence as that observed for vitronectin binding, demonstrating that the high affinity vitronectin-binding complex indeed contains oligomeric suPAR. Structurally, the kringle domain of uPA was found to be critical for the formation of the vitronectin-binding competent complex because the amino-terminal fragment, but not the growth factor-like domain, behaved as a full-length uPA. Our data represent the first demonstration of functional, ligand-induced uPAR oligomerization having extensive implications for glycosylphosphatidylinositol-anchored receptors in general, and for the biology of the uPA/uPAR system in particular.	Univ Vita Salute San Raffaele, Mol Genet Unit, DIBIT, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, Ctr Theoret Biol, DIBIT, I-20132 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University; Vita-Salute San Raffaele University	Sidenius, N (corresponding author), Univ Vita Salute San Raffaele, Mol Genet Unit, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.		Andolfo, Annapaola/B-2532-2013; Sidenius, Nicolai/M-9643-2015; fesce, riccardo/A-6317-2008	Andolfo, Annapaola/0000-0002-0566-2391; Sidenius, Nicolai/0000-0002-7825-7629; fesce, riccardo/0000-0001-9473-896X; Blasi, Francesco/0000-0001-9406-1784				ANDERSEN JK, 1984, J BIOCHEM BIOPH METH, V10, P203; APPELLA E, 1987, J BIOL CHEM, V262, P4437; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOYLE MDP, 1987, J IMMUNOL, V139, P169; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CHIAPPINELLI VA, 1985, J BIOL CHEM, V260, P6182; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Liang OD, 2001, J BIOL CHEM, V276, P28946, DOI 10.1074/jbc.M011437200; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380	34	82	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27982	27990		10.1074/jbc.M111736200	http://dx.doi.org/10.1074/jbc.M111736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12034711	hybrid			2022-12-25	WOS:000177189800051
J	Helledie, T; Grontved, L; Jensen, SS; Kiilerich, P; Rietveld, L; Albrektsen, T; Boysen, MS; Nohr, J; Larsen, LK; Fleckner, J; Stunnenberg, HG; Kristiansen, K; Mandrup, S				Helledie, T; Grontved, L; Jensen, SS; Kiilerich, P; Rietveld, L; Albrektsen, T; Boysen, MS; Nohr, J; Larsen, LK; Fleckner, J; Stunnenberg, HG; Kristiansen, K; Mandrup, S			The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; 9-CIS RETINOIC ACID; ALPHA PPAR-ALPHA; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL RESPONSE; BETA-OXIDATION; RAT; INHIBITOR; EXPRESSION	The acyl-CoA-binding protein (ACBP) is a 10-kDa intracellular protein that specifically binds acyl-CoA esters with high affinity and is structurally and functionally conserved from yeast to mammals. In vitro studies indicate that ACBP may regulate the availability of acylCoA esters for various metabolic and regulatory purposes. The protein is particularly abundant in cells with a high level of lipogenesis and de novo fatty acid synthesis and is significantly induced during adipocyte differentiation. However, the molecular mechanisms underlying the regulation of ACBP expression in mammalian cells have remained largely unknown. Here we report that ACBP is a novel peroxisome proliferator-activated receptor (PPAR)gamma target gene. The rat ACBP gene is directly activated by PPARgamma/retinoid X receptor a (RXRalpha) and PPARalpha/RXRalpha, but not by PPARdelta/RXRalpha, through a PPAR-response element in intron 1, which is functionally conserved in the human ACBP gene. The intronic PPAR-response element (PPRE) mediates induction by endogenous PPARgamma in murine adipocytes and confers responsiveness to the PPARgamma-selective ligand BRL49653. Finally, we have used chromatin immunoprecipitation to demonstrate that the intronic PPRE efficiently binds PPARgamma/RXRalpha in its natural chromatin context in adipocytes. Thus, the PPRE in intron 1 of the ACBP gene is a bona fide PPARgamma-rresponse element.	Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Nijmegen Ctr Mol Life Sci, Dept Mol Biol, NL-6525 GA Nijmegen, Netherlands; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of Southern Denmark; Radboud University Nijmegen; Novo Nordisk	Mandrup, S (corresponding author), Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.		Mandrup, Susanne/B-6693-2008; Kristiansen, Karsten/J-5148-2014; Kiilerich, Pia/B-9094-2015; Stunnenberg, Hendrik G./D-6875-2012	Kristiansen, Karsten/0000-0002-6024-0917; Kiilerich, Pia/0000-0001-5665-6074; Stunnenberg, Hendrik G./0000-0002-0066-1576; Grontved, Lars/0000-0002-6735-8483; Mandrup, Susanne/0000-0002-0961-5787				AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; BHUIYAN AKMJ, 1994, MOL CELL BIOCHEM, V139, P109, DOI 10.1007/BF01081733; BHUIYAN J, 1995, METABOLISM, V44, P1185, DOI 10.1016/0026-0495(95)90013-6; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Burgi B, 1999, J NEUROENDOCRINOL, V11, P85; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elholm M, 1996, GENE, V173, P233, DOI 10.1016/0378-1119(96)00213-2; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FYRST H, 1995, BIOCHEM J, V306, P793, DOI 10.1042/bj3060793; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gossett RE, 1998, ARCH BIOCHEM BIOPHYS, V350, P201, DOI 10.1006/abbi.1997.0521; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; Helledie T, 2000, J LIPID RES, V41, P1740; Jorgensen C, 2002, ANN NY ACAD SCI, V967, P431; Kerkhoff C, 1997, BBA-LIPID LIPID MET, V1346, P163, DOI 10.1016/S0005-2760(97)00030-1; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; KOLMER M, 1993, P NATL ACAD SCI USA, V90, P8439, DOI 10.1073/pnas.90.18.8439; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Kragelund BB, 1999, BBA-MOL CELL BIOL L, V1441, P150, DOI 10.1016/S1388-1981(99)00151-1; Kroll JB, 1996, GENE, V173, P239, DOI 10.1016/0378-1119(96)00214-4; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Mandrup S, 1998, J BIOL CHEM, V273, P23897, DOI 10.1074/jbc.273.37.23897; MANDRUP S, 1992, J MOL BIOL, V228, P1011, DOI 10.1016/0022-2836(92)90888-Q; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MATARESE V, 1988, J BIOL CHEM, V263, P14544; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; Rodriguez JC, 1998, BIOCHEM BIOPH RES CO, V242, P692, DOI 10.1006/bbrc.1997.8032; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; SKORVE J, 1995, XENOBIOTICA, V25, P1181, DOI 10.3109/00498259509046675; STERCHELE PF, 1994, BIOCHEM PHARMACOL, V48, P955, DOI 10.1016/0006-2952(94)90366-2; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Swinnen JV, 1996, DNA CELL BIOL, V15, P197, DOI 10.1089/dna.1996.15.197; Swinnen JV, 1996, MOL CELL ENDOCRINOL, V118, P65, DOI 10.1016/0303-7207(96)03767-7; Swinnen JV, 1998, J BIOL CHEM, V273, P19938, DOI 10.1074/jbc.273.32.19938; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1993, BIOCHIM BIOPHYS ACTA, V1177, P183, DOI 10.1016/0167-4889(93)90039-R	53	89	91	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26821	26830		10.1074/jbc.M111295200	http://dx.doi.org/10.1074/jbc.M111295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015306	hybrid, Green Published			2022-12-25	WOS:000177055900017
J	Inamdar, KV; Pouliot, JJ; Zhou, T; Lees-Miller, SP; Rasouli-Nia, A; Povirk, LF				Inamdar, KV; Pouliot, JJ; Zhou, T; Lees-Miller, SP; Rasouli-Nia, A; Povirk, LF			Conversion of phosphoglycolate to phosphate termini on 3 ' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR; DAMAGE; NEOCARZINOSTATIN; PURIFICATION; MECHANISMS; BLEOMYCIN; 3'-PHOSPHATASE; ENDONUCLEASE; RADIATION; PROTEIN	Mammalian cells contain potent activity for removal of 3'-phosphoglycolates from single-stranded oligomers and from 3' overhangs of DNA double strand breaks, but no specific enzyme has been implicated in such removal. Fractionated human whole-cell extracts contained an activity, which in the presence of EDTA, catalyzed removal of glycolate from phosphoglycolate at a single-stranded 3' terminus to leave a 3'-phosphate, reminiscent of the human tyrosyl-DNA phosphodiesterase hTdp1. Recombinant hTdp1, as well as Saccharomyces cerevisiae Tdp1, catalyzed similar removal of glycolate, although less efficiently than removal of tyrosine. Moreover, glycolate-removing activity could be immunodepleted from the fractionated extracts by antiserum to hTdpl. When a plasmid containing a double strand break with a 3'-phosphoglycolate on a 3-base 3' overhang was incubated in human cell extracts, phosphoglycolate processing proceeded rapidly for the first few minutes but then slowed dramatically, suggesting that the single-stranded overhangs gradually became sequestered and inaccessible to hTdp1. The results suggest a role for hTdp1 in repair of free radical-mediated DNA double strand breaks bearing terminally blocked 3' overhangs.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; NIMH, Mol Biol Lab, Bethesda, MD 20892 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Calgary; University of Alberta	Povirk, LF (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, POB 980230, Richmond, VA 23298 USA.	LPOVIRK@hsc.vcu.edu		Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA 40615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; Betti M, 2001, J BIOL CHEM, V276, P18038, DOI 10.1074/jbc.M010648200; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; Chen S, 2001, ANAL BIOCHEM, V289, P274, DOI 10.1006/abio.2000.4936; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Daza P, 1996, BIOL CHEM, V377, P775, DOI 10.1515/bchm3.1996.377.12.775; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; HABRAKEN Y, 1988, EUR J BIOCHEM, V171, P59, DOI 10.1111/j.1432-1033.1988.tb13758.x; HENNER WD, 1983, J BIOL CHEM, V258, P711; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Inamdar KV, 2002, RADIAT RES, V157, P306, DOI 10.1667/0033-7587(2002)157[0306:ROPDET]2.0.CO;2; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Mani RS, 2001, BIOCHEMISTRY-US, V40, P12967, DOI 10.1021/bi011383w; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; SANDIGURSKY M, 1993, RADIAT RES, V135, P229, DOI 10.2307/3578299; Suh D, 1997, NUCLEIC ACIDS RES, V25, P2495, DOI 10.1093/nar/25.12.2495; Van Houten B, 1998, MUTAT RES-FUND MOL M, V403, P171, DOI 10.1016/S0027-5107(98)00076-1; Vance JR, 2001, MOL CELL BIOL, V21, P7191, DOI 10.1128/MCB.21.21.7191-7198.2001; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	32	153	156	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27162	27168		10.1074/jbc.M204688200	http://dx.doi.org/10.1074/jbc.M204688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023295	hybrid			2022-12-25	WOS:000177055900060
J	Lovett, JL; Marchesini, N; Moreno, SNJ; Sibley, LD				Lovett, JL; Marchesini, N; Moreno, SNJ; Sibley, LD			Toxoplasma gondii microneme secretion involves intracellular Ca2+ release from inositol 1,4,5-triphosphate (IP3)/ryanodine-sensitive stores.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRYPANOSOMA-CRUZI; PHOSPHOLIPASE-C; CALCIUM-RELEASE; PROTEIN; INVASION; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE; RYANODINE; MOBILIZATION	Calcium-mediated microneme secretion in Toxoplasma gondii is stimulated by contact with host cells, resulting in the discharge of adhesins that mediate attachment. The intracellular source of calcium and the signaling pathway(s) triggering release have not been characterized, prompting our search for mediators of calcium signaling and microneme secretion in T. gondii. We identified two stimuli of microneme secretion, ryanodine and caffeine, which enhanced release of calcium from parasite intracellular stores. Ethanol, a previously characterized trigger of microneme secretion, stimulated an increase in parasite inositol 1,4,5-triphosphate, implying that this second messenger may mediate intracellular calcium release. Consistent with this observation, xestospongin C, an inositol 1,4,5-triphosphate receptor antagonist, inhibited microneme secretion and blocked parasite attachment and invasion of host cells. Collectively, these results suggest that T. gondii possess an intracellular calcium release channel with properties of the inositol 1,4,5-triphosphate/ryanodine receptor superfamily. Intracellular calcium channels, previously studied almost exclusively in multicellular animals, appear to also be critical to the control of parasite calcium during the initial steps of host cell entry.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	Washington University (WUSTL); University of Illinois System; University of Illinois Urbana-Champaign	Sibley, LD (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Box 8230, St Louis, MO 63110 USA.	sibley@borcim.wustl.edu	Lovett, Jennie/S-2996-2016; Sibley, L. David/C-4616-2008	Lovett, Jennie/0000-0002-3710-9400	NIAID NIH HHS [R01 AI034036, AI07172-19, AI43614] Funding Source: Medline; PHS HHS [34036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172, R01AI043614, R01AI034036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIREY JA, 1990, J BIOL CHEM, V265, P14187; Bahl A, 2002, NUCLEIC ACIDS RES, V30, P87, DOI 10.1093/nar/30.1.87; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; BUCK E, 1992, J BIOL CHEM, V267, P23560; CALVERT CM, 1995, J BIOL CHEM, V270, P7272, DOI 10.1074/jbc.270.13.7272; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Daly JW, 2000, J AUTONOM NERV SYST, V81, P44, DOI 10.1016/S0165-1838(00)00110-7; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; Fabczak H, 1999, PHOTOCHEM PHOTOBIOL, V69, P254, DOI 10.1111/j.1751-1097.1999.tb03283.x; Fourmaux MN, 1996, MOL BIOCHEM PARASIT, V83, P201, DOI 10.1016/S0166-6851(96)02773-9; Fukami K, 2001, SCIENCE, V292, P920, DOI 10.1126/science.1059042; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Garcia-Reguet N, 2000, CELL MICROBIOL, V2, P353, DOI 10.1046/j.1462-5822.2000.00064.x; Guse AH, 1999, CELL SIGNAL, V11, P309, DOI 10.1016/S0898-6568(99)00004-2; Kirkman LA, 2001, INFECT IMMUN, V69, P148, DOI 10.1128/IAI.69.1.148-153.2001; Kissmehl R, 1998, CELL CALCIUM, V24, P193, DOI 10.1016/S0143-4160(98)90128-2; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; Koyanagi M, 1998, FEBS LETT, V439, P66, DOI 10.1016/S0014-5793(98)01339-8; Marchesini N, 2002, MOL BIOCHEM PARASIT, V120, P83, DOI 10.1016/S0166-6851(01)00437-6; Masuda W, 1997, COMP BIOCHEM PHYS C, V118, P279, DOI 10.1016/S0742-8413(97)00173-4; Matsuoka T, 2000, J PHOTOCH PHOTOBIO B, V54, P131, DOI 10.1016/S1011-1344(00)00007-5; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; MORISAKI JH, 1995, J CELL SCI, V108, P2457; Passos APD, 1998, BIOCHEM BIOPH RES CO, V245, P155, DOI 10.1006/bbrc.1998.8338; Pingret L, 1996, J HISTOCHEM CYTOCHEM, V44, P1123, DOI 10.1177/44.10.8813077; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAHA S, 1994, MOL BIOCHEM PARASIT, V65, P63, DOI 10.1016/0166-6851(94)90115-5; Schaloske R, 2000, J BIOL CHEM, V275, P8404, DOI 10.1074/jbc.275.12.8404; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Sorrentino V, 2000, CURR OPIN GENET DEV, V10, P662, DOI 10.1016/S0959-437X(00)00139-8; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; THIEL G, 1990, EMBO J, V9, P1737, DOI 10.1002/j.1460-2075.1990.tb08297.x; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; Vieira MCF, 2000, MOL BIOCHEM PARASIT, V106, P157, DOI 10.1016/S0166-6851(99)00182-6; WAGNERMANN C, 1992, BRIT J PHARMACOL, V105, P903, DOI 10.1111/j.1476-5381.1992.tb09076.x; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; Zucchi R, 1997, PHARMACOL REV, V49, P1	48	120	127	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25870	25876		10.1074/jbc.M202553200	http://dx.doi.org/10.1074/jbc.M202553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011085	hybrid			2022-12-25	WOS:000176908700009
J	Masiello, D; Cheng, S; Bubley, GJ; Lu, ML; Balk, SP				Masiello, D; Cheng, S; Bubley, GJ; Lu, ML; Balk, SP			Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROSTATE-CANCER; LIGAND-BINDING DOMAIN; LNCAP CELLS; STEROID-RECEPTORS; AF2 DOMAINS; GENE; ACTIVATION; ANTIANDROGENS; COACTIVATOR; EXPRESSION	Prostate cancers (PCa) that relapse after androgen deprivation therapy invariably express high levels of androgen receptor (AR) and AR-regulated genes. Most do not respond to secondary hormonal therapies, including AR antagonists, and the mechanisms of AR activation in these clinically androgen-independent tumors are unclear. Bicalutamide, the most widely used AR antagonist, is a competitive antagonist shown previously to stabilize AR association with cytosolic heat shock protein complexes. This study found nuclear AR expression in bicalutamide-treated androgen-independent PCa and found that bicalutamide could stimulate AR nuclear translocation. Moreover, specific DNA binding by the bicalutamide-liganded AR was demonstrated in vivo using a VP16-AR fusion protein and was confirmed by chromatin immunoprecipitation showing binding to the prostate-specific antigen enhancer in LN-CaP PCa cells. Nonetheless, bicalutamide could not stimulate interactions between the AR N and C termini or recruitment of steroid receptor coactivator proteins (SRC-1 or -2), although SRC transfection augmented AR activity in the presence of dihydrotestosterone and inhibitory concentrations of bicalutamide. These results demonstrate that bicalutamide stimulates the assembly of a transcriptionally inactive AR on DNA and support altered coactivator (or corepressor) expression as a mechanism of bicalutamide-resistant androgen-independent PCa.	Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Urol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Balk, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.				NCI NIH HHS [R01CA65647] Funding Source: Medline; NIGMS NIH HHS [R29GM54713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Bubley GJ, 1996, HEMATOL ONCOL CLIN N, V10, P713, DOI 10.1016/S0889-8588(05)70363-4; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CHENG S, 2002, IN PRESS MOL ENDOCRI; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; COCKSHOTT ID, 1990, EUR UROL, V18, P10; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fenton MA, 1997, CLIN CANCER RES, V3, P1383; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; HOBISCH A, 1995, CANCER RES, V55, P3068; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1999, SEMIN ONCOL, V26, P407; Joyce R, 1998, J UROLOGY, V159, P149, DOI 10.1016/S0022-5347(01)64039-4; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reid P, 1999, INVEST NEW DRUG, V17, P271, DOI 10.1023/A:1006344807086; Scher HI, 1997, J CLIN ONCOL, V15, P2928, DOI 10.1200/JCO.1997.15.8.2928; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WONG CI, 1993, J BIOL CHEM, V268, P19004; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	44	187	222	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26321	26326		10.1074/jbc.M203310200	http://dx.doi.org/10.1074/jbc.M203310200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12015321	hybrid			2022-12-25	WOS:000176908700066
J	Marchalonis, JJ; Kaveri, S; Lacroix-Desmazes, S; Kazatchkine, MD				Marchalonis, JJ; Kaveri, S; Lacroix-Desmazes, S; Kazatchkine, MD			Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system	FASEB JOURNAL			English	Article						immune response; natural antibody repertoire; antigenic selection	ANTIGEN RECEPTOR; INNATE IMMUNITY; NORMAL IMMUNOGLOBULIN; MOLECULAR MIMICRY; LIGHT-CHAIN; ANTIBODIES; AUTOANTIBODIES; BINDING; PEPTIDE; HIV-1	The primordial combinatorial immune recognition repertoire arose in the evolution of jawed vertebrates similar to450 million years ago as a rapid genetic process independent of antigenic selection. We propose that it encompassed the entire repertoire of innate immunity involving molecules that had evolved over billions of years. The 'antigen-driven' compartment involving invasive pathogens operates in 'real time' showing inducibility and increases in affinity. Individuals within a species differ in their repertoires because of distinct antigenic challenges, genetics, or local environmental effects. The 'homeostatic' compartment that recognizes invariant cell and serum components should be conserved in all individuals of a species. The potential to recapitulate the entire recognition spectrum must be regenerated during the formation of new species. Evidence for the capacity of the combinatorial response to encompass the entire preexisting repertoire was obtained in studies of natural human IgG antibodies present in intravenous immunoglobulin. Since essential cellular recognition and regulatory elements are conserved throughout evolution, we propose that the natural antibodies of sharks, the most anciently emerged vertebrates to possess the combinatorial immune response, will resemble those of mammals in showing specificity for the conserved recognition/regulatory molecules. If verified, this hypothesis will establish the fundamental importance of natural antibodies not only in defense, but in regulation and functional homeostasis of the individual.	Univ Arizona, Arizona Hlth Sci Ctr, Coll Med, Tucson, AZ 85724 USA; Univ Paris 06, INSERM, U430, Paris, France	University of Arizona; University of Arizona Health Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Marchalonis, JJ (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	marchjj@email.arizona.edu		Lacroix-Desmazes, Sebastien/0000-0001-5625-8447				ADIB M, 1990, J IMMUNOL, V145, P3807; Adib-Conquy M, 1998, INT IMMUNOL, V10, P341, DOI 10.1093/intimm/10.3.341; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Avrameas A, 1998, P NATL ACAD SCI USA, V95, P5601, DOI 10.1073/pnas.95.10.5601; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baumgarth N, 1999, P NATL ACAD SCI USA, V96, P2250, DOI 10.1073/pnas.96.5.2250; Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; BHARDWAJ V, 1993, J IMMUNOL, V151, P5000; BHATTACHARJEE AK, 1977, J IMMUNOL, V120, P411; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Bouhlal H, 2001, J IMMUNOL, V166, P7606, DOI 10.4049/jimmunol.166.12.7606; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; Chen ZJ, 1998, EUR J IMMUNOL, V28, P989, DOI 10.1002/(SICI)1521-4141(199803)28:03<989::AID-IMMU989>3.0.CO;2-1; Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0; Dehghanpisheh K, 1997, SCAND J IMMUNOL, V45, P645, DOI 10.1046/j.1365-3083.1997.d01-439.x; Deng YJ, 2000, CLIN EXP IMMUNOL, V119, P69, DOI 10.1046/j.1365-2249.2000.01096.x; DIGHIERO G, 1983, BLOOD, V62, P264; Du Pasquier L., 1999, FUNDAMENTAL IMMUNOLO, P605; Fahmy TM, 2001, IMMUNITY, V14, P135, DOI 10.1016/S1074-7613(09)00099-5; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GARZA KM, 1995, J IMMUNOL, V155, P5444; GONZALEZ R, 1988, IMMUNOLOGY, V63, P31; GOOD RA, 1964, ADV IMMUNOL, V4, P1, DOI 10.1016/S0065-2776(08)60706-3; GREENBERG AS, 1995, NATURE, V374, P168, DOI 10.1038/374168a0; HARINDRANATH N, 1993, INT IMMUNOL, V5, P1523, DOI 10.1093/intimm/5.12.1523; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; HINDS KR, 1986, NATURE, V320, P546, DOI 10.1038/320546a0; HIORN K, 1998, CELL, V94, P463; HOHMAN VS, 1992, P NATL ACAD SCI USA, V89, P276, DOI 10.1073/pnas.89.1.276; HUREZ V, 1993, SCAND J IMMUNOL, V38, P190, DOI 10.1111/j.1365-3083.1993.tb01712.x; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; Hurez V, 1994, Ther Immunol, V1, P269; Janeway CA, 2001, P NATL ACAD SCI USA, V98, P7461, DOI 10.1073/pnas.131202998; JOHNSTON MFM, 1976, J IMMUNOL, V117, P1189; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAY MMB, 1975, P NATL ACAD SCI USA, V72, P3521, DOI 10.1073/pnas.72.9.3521; KAYMAZ H, 1993, J PROTEIN CHEM, V12, P659, DOI 10.1007/BF01024924; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Kohler H, 2000, IMMUNOLOGIST, V8, P91; Kraj P, 2001, J IMMUNOL, V166, P2251, DOI 10.4049/jimmunol.166.4.2251; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; LacroixDesmazes S, 1997, INT IMMUNOL, V9, P1175, DOI 10.1093/intimm/9.8.1175; Lake DF, 1999, INT IMMUNOL, V11, P745, DOI 10.1093/intimm/11.5.745; LAKE DF, 1994, P NATL ACAD SCI USA, V91, P10849, DOI 10.1073/pnas.91.23.10849; LESLIE GA, 1970, J IMMUNOL, V105, P1547; LI L, 1995, J IMMUNOL, V154, P3328; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Marchalonis JJ, 1997, CRIT REV IMMUNOL, V17, P497; Marchalonis JJ, 1998, J THEOR BIOL, V193, P429, DOI 10.1006/jtbi.1998.0711; Marchalonis JJ, 1998, IMMUNOL REV, V166, P103, DOI 10.1111/j.1600-065X.1998.tb01256.x; MARCHALONIS JJ, 1990, SCAND J IMMUNOL, V32, P13, DOI 10.1111/j.1365-3083.1990.tb02886.x; Marchalonis JJ, 1998, ADV IMMUNOL, V70, P417, DOI 10.1016/S0065-2776(08)60392-2; Marchalonis JJ, 2001, ADV EXP MED BIOL, V484, P13; Marchalonis JJ, 2001, J MOL RECOGNIT, V14, P110, DOI 10.1002/jmr.527; Marchalonis JJ, 2000, APPL BIOCHEM BIOTECH, V83, P31, DOI 10.1385/ABAB:83:1-3:31; MARCHALONIS JJ, 1993, DEV COMP IMMUNOL, V17, P41, DOI 10.1016/0145-305X(93)90014-H; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meister M, 2000, CURR TOP MICROBIOL, V248, P17; MUYDERMANS S, 1994, PROTEIN ENG, V7, P1129; Nuttall SD, 2001, MOL IMMUNOL, V38, P313, DOI 10.1016/S0161-5890(01)00057-8; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Pincus SH, 1998, J IMMUNOL, V160, P293; Plasterk R, 1998, NATURE, V394, P718, DOI 10.1038/29389; Prasad NKA, 1998, J IMMUNOL, V161, P3781; Putterman C, 2000, J IMMUNOL, V164, P2542, DOI 10.4049/jimmunol.164.5.2542; Ramsland PA, 1997, J COMPUT AID MOL DES, V11, P453, DOI 10.1023/A:1007932211514; Robey IF, 2000, J PROTEIN CHEM, V19, P9, DOI 10.1023/A:1007086608036; Rodman TC, 2001, EXP HEMATOL, V29, P1004, DOI 10.1016/S0301-472X(01)00678-6; ROSSI F, 1989, J IMMUNOL, V143, P4104; SASSO EH, 1992, J IMMUNOL, V149, P1230; Schluter SF, 1999, DEV COMP IMMUNOL, V23, P107; SILVESTRIS F, 1995, CLIN IMMUNOL IMMUNOP, V75, P197, DOI 10.1006/clin.1995.1072; STEWART J, 1992, IMMUNOL TODAY, V13, P396, DOI 10.1016/0167-5699(92)90088-O; SUSAL C, 1993, VOX SANG, V65, P10; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369; Vassilev TL, 1999, BLOOD, V93, P3624, DOI 10.1182/blood.V93.11.3624.411a28_3624_3631; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Williams RC, 1996, CLIN IMMUNOL IMMUNOP, V80, P194	83	49	50	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0842	10.1096/fj.01-0953hyp	http://dx.doi.org/10.1096/fj.01-0953hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039866				2022-12-25	WOS:000176683900010
J	Frigeri, A; Nicchia, GP; Repetto, S; Bado, M; Minetti, C; Svelto, M				Frigeri, A; Nicchia, GP; Repetto, S; Bado, M; Minetti, C; Svelto, M			Altered aquaporin-4 expression in human muscular dystrophies: a common feature?	FASEB JOURNAL			English	Article						AQP4; water channels; DMD	INSENSITIVE WATER CHANNEL; MUSCLE PLASMA-MEMBRANE; SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; MDX MOUSE; FREEZE-FRACTURE; EXTRACELLULAR-MATRIX; ORTHOGONAL ARRAYS; KNOCKOUT MICE; RAT-BRAIN	Duchenne Muscular Dystrophy (DMD) is a progressive lethal muscle disease that affects young boys. Dystrophin, absent in DMD and reduced in the milder form Becker Muscular Dystrophy (BMD), binds to several membrane-associated proteins known as dystrophin-associated proteins (DAPs). Once this critical structural link is disrupted, muscle fibers become more vulnerable to mechanical and osmotic stress. Recently, we have reported that the expression of aquaporin-4 (AQP4), a water-selective channel expressed in the sarcolemma of fast-twitch fibers and astrocyte end-feet, is drastically reduced in the muscle and brain of the mdx mouse, the animal model of DMD. In the present study, we analyzed the expression of AQP4 in several DMD/BMD patients of different ages with different mutations in the dystrophin gene. Immunofluorescence results indicate that, compared with healthy control children, AQP4 is reduced severely in all the DMD muscular biopsies analyzed and in 50% of the analyzed BMD. Western blot analysis revealed that the deficiency in sarcolemma AQP4 staining is due to a reduction in total AQP4 muscle protein content rather than to changes in immunoreactivity. Double-immunostaining experiments indicate that AQP4 reduction is independent of changes in the fiber myosin heavy chain composition. AQP4 and alpha-syntrophin analysis of BMD muscular biopsies revealed that the expression and stability of AQP4 in the sarcolemma does not always decrease when alpha-syntrophin is strongly reduced. Finally, limb-girdle muscular dystrophy biopsies and facioscapulohumeral muscular dystrophy revealed that AQP4 expression was not altered in these forms of muscular dystrophy. These experiments provide the first evidence of AQP4 reduction in a human pathology and show that this deficiency is an important feature of DMD/BMD.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, CEGBA, I-70126 Bari, Italy; Univ Genoa, Ist Giannina Gaslini, Serv Malattie Neuromuscolari, Genoa, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Genoa; IRCCS Istituto Giannina Gaslini	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014; Minetti, Carlo/K-4666-2018	Minetti, Carlo/0000-0002-0640-1804; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Culligan KG, 1998, INT J MOL MED, V2, P639; EMERY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Fitzsimons RB, 1999, CURR OPIN NEUROL, V12, P501, DOI 10.1097/00019052-199910000-00003; FRANCOOBREGON A, 1994, J PHYSIOL-LONDON, V481, P299, DOI 10.1113/jphysiol.1994.sp020440; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; Grichko VP, 2000, J APPL PHYSIOL, V88, P473, DOI 10.1152/jappl.2000.88.2.473; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Lidov HGW, 1996, BRAIN PATHOL, V6, P63, DOI 10.1111/j.1750-3639.1996.tb00783.x; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; MARSHALL PA, 1989, MUSCLE NERVE, V12, P528, DOI 10.1002/mus.880120703; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MCDONALD KS, 1992, J APPL PHYSIOL, V73, P1135, DOI 10.1152/jappl.1992.73.3.1135; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Ohlendieck K, 1996, EUR J CELL BIOL, V69, P1; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHOTLAND DL, 1981, ACTA NEUROPATHOL, V54, P189, DOI 10.1007/BF00687741; SCHOTLAND DL, 1977, SCIENCE, V196, P1005, DOI 10.1126/science.860127; SHIBUYA S, 1991, NEUROPATH APPL NEURO, V17, P335, DOI 10.1111/j.1365-2990.1991.tb00730.x; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; Verbavatz JM, 1997, J CELL SCI, V110, P2855; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	55	53	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1120	+		10.1096/fj.01-0797fje	http://dx.doi.org/10.1096/fj.01-0797fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039847				2022-12-25	WOS:000175973900016
J	Riedemann, NC; Guo, RF; Laudes, IJ; Keller, K; Sarma, VJ; Padgaonkar, V; Zetoune, FS; Ward, PA				Riedemann, NC; Guo, RF; Laudes, IJ; Keller, K; Sarma, VJ; Padgaonkar, V; Zetoune, FS; Ward, PA			C5a receptor and thymocyte apoptosis in sepsis	FASEB JOURNAL			English	Article						cecal ligation/puncture; caspases; thymus; complement	NON-MYELOID CELLS; POLYMICROBIAL SEPSIS; CECAL LIGATION; FAS LIGAND; ANAPHYLATOXIN; EXPRESSION; ENDOTOXIN; ANTI-C5A; RAT; ANTIBODIES	In sepsis, apoptosis occurs in many different organs. The mediators responsible for induction of apoptosis are not clearly known, although there are some suggestions that C5a and the C5a receptor (C5aR) might be directly linked to apoptosis. In the cecal ligation/puncture (CLP) model of sepsis in rats, apoptosis occurs early in a variety of organs, especially in the thymus. We demonstrate that thymocytes from normal rats show specific, saturable, and high affinity binding of I-125-labeled recombinant rat C5a. C5a binding to thymocytes was significantly increased 3 h after CLP and also when thymocytes from normal rats were first incubated in vitro with lipopolysaccharide (LPS) or IL-6. The expression of C5aR mRNA in thymocytes was markedly increased 3, 6, and 12 h after CLP and increased similarly when normal thymocytes were first exposed to LPS or IL-6 in vitro. Thymocytes obtained 2 or 3 h after CLP and exposed in vitro to C5a, but not normal thymocytes, underwent increased apoptosis, as demonstrated by annexin-V binding, coinciding with increased activation of caspases 3, 6, and 8. These data provide the first direct evidence that in the early onset of sepsis, increased expression of C5aR occurs in thymocytes, which increases their susceptibility to C5a-induced apoptosis.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010					Ayala A, 1999, SHOCK, V11, P211, DOI 10.1097/00024382-199903000-00010; Ayala A, 1999, IMMUNOLOGY, V97, P45; BARKE RA, 1994, ARCH SURG-CHICAGO, V129, P1256; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Floreani AA, 1998, J IMMUNOL, V160, P5073; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEI.IM, 1974, J IMMUNOL, V113, P1583; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; Izawa M, 1997, ENDOCR J, V44, P677, DOI 10.1507/endocrj.44.677; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Morris ID, 1997, TOXICOLOGY, V120, P19, DOI 10.1016/S0300-483X(97)03626-3; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Nataf S, 1999, J IMMUNOL, V162, P4018; SACKS T, 1978, J CLIN INVEST, V61, P1161, DOI 10.1172/JCI109031; Schieferdecker HL, 2000, J IMMUNOL, V164, P5453, DOI 10.4049/jimmunol.164.10.5453; SCHUMACHER WA, 1991, AGENTS ACTIONS, V34, P345, DOI 10.1007/BF01988727; SHIN HS, 1968, SCIENCE, V162, P361, DOI 10.1126/science.162.3851.361; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Tinsley KW, 2000, SHOCK, V13, P1, DOI 10.1097/00024382-200013010-00001; VILLA P, 1995, CLIN DIAGN LAB IMMUN, V2, P549, DOI 10.1128/CDLI.2.5.549-553.1995; WANG SD, 1994, J IMMUNOL, V152, P5014; WETSEL RA, 1995, IMMUNOL LETT, V44, P183, DOI 10.1016/0165-2478(94)00212-A; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	36	62	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					887	+		10.1096/fj.02-0033fje	http://dx.doi.org/10.1096/fj.02-0033fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039868	Green Submitted			2022-12-25	WOS:000175425900029
J	Moelling, K; Schad, K; Bosse, M; Zimmermann, S; Schweneker, M				Moelling, K; Schad, K; Bosse, M; Zimmermann, S; Schweneker, M			Regulation of Raf-Akt cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; BREAST-CANCER CELLS; NERVE GROWTH-FACTOR; MEK-ERK PATHWAY; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE; ONCOGENIC TRANSFORMATION; SUSTAINED ACTIVATION; PLASMA-MEMBRANE; SIGNAL	We have recently shown that the Ras-Raf-MEK-ERK and phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathways can cross-talk in the human breast cancer cell line MCF-7. High Raf activity induces growth arrest and differentiation in these cells, whereas high PI3K/Akt activity correlates with cell survival and proliferation. Here we show that the Raf-Akt cross-talk is regulated in a concentration- and ligand-dependent manner. High doses of insulin-like growth factor I (IGF-I) activate Akt quickly and strongly enough to suppress Raf kinase activity via phosphorylation of Ser-259, whereas low doses of IGF-I do not trigger this cross-talk but are still mitogenic. Phorbol 12-myristate 13-acetate, a differentiation-inducing stimulus, potently activates the Ras-Raf-MEK-ERK pathway but only weakly activates PI3K/Akt and does not trigger the cross-talk. Thus, the herein analyzed parameters such as ligand type, concentration, and time course may contribute to the cellular response of either proliferation or differentiation. This is highly relevant to understanding cellular transformation and may be of use in areas like tissue engineering.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30, CH-8028 Zurich, Switzerland.			Bosse, Magnus/0000-0002-3396-475X				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bartucci M, 2001, CANCER RES, V61, P6747; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen D, 1999, J IMMUNOL, V163, P5796; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; Guan KL, 2000, J BIOL CHEM, V275, P27354; JUN T, 1999, SCI STKE, V13, pPE1; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lovric J, 1996, ONCOGENE, V12, P1109; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	47	324	332	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31099	31106		10.1074/jbc.M111974200	http://dx.doi.org/10.1074/jbc.M111974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048182	hybrid			2022-12-25	WOS:000177579800089
J	Tepper, AWJW; Bubacco, L; Canters, GW				Tepper, AWJW; Bubacco, L; Canters, GW			Structural basis and mechanism of the inhibition of the type-3 copper protein tyrosinase from Streptomyces antibioticus by halide ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN BIOSYNTHESIS PATHWAY; CULTURED HUMAN MELANOCYTES; UNSTABLE O-QUINONES; ACTIVE-SITE; MAGNETIC-PROPERTIES; CRYSTAL-STRUCTURE; BINUCLEATING LIGANDS; HALF-MET; DICOPPER(II) COMPLEXES; ELECTRONIC-STRUCTURE	The inhibition of the type-3 copper enzyme tyrosinase by halide ions was studied by kinetic and paramagnetic H-1 NMR methods. All halides are inhibitors in the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) with apparent inhibition constants that follow the order I- < F- << Cl- < Br- at pH 6.80. The results show that the inhibition arises from the interaction of halide with both the oxidized (affinity F- > Cl- > Br- >> I-) and reduced (affinity I- > Br- > Cl- >> F-) enzyme. The paramagnetic H-1 NMR of the oxidized enzyme complexed with the halides is consistent with a direct interaction of halide with the type-3 site and shows that the (Cu-His(3))(2) coordination occurs in all halide-bound species. It is surmised that halides bridge both of the copper ions in the active site. Fluoride and chloride are shown to bind only to the low pH form of oxidized tyrosinase, explaining the strong pH dependence of the inhibition by these ions. We further show that p-toluic acid and the bidentate transition state analogue, Kojic acid, displace chloride from the oxidized active site, whereas the monodentate substrate analogue, p-nitrophenol, forms a ternary complex with the enzyme and the chloride ion. On the basis of the experimental results, a model is formulated for the inhibitor action and for the reaction of diphenols with the oxidized enzyme.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2333 CC Leiden, Netherlands; Univ Padua, Dept Biol, I-30121 Padua, Italy	Leiden University; Leiden University - Excl LUMC; University of Padua	Canters, GW (corresponding author), Leiden Univ, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.		Hu, Ruogu/B-2203-2008; Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208				ABDELMALEK Z, 1993, J CELL SCI, V106, P1323; Amendola V, 2001, COORDIN CHEM REV, V219, P821, DOI 10.1016/S0010-8545(01)00368-X; Amendola V, 2000, ANGEW CHEM INT EDIT, V39, P2917, DOI 10.1002/1521-3773(20000818)39:16<2917::AID-ANIE2917>3.3.CO;2-S; Amudha P, 1999, POLYHEDRON, V18, P1355, DOI 10.1016/S0277-5387(98)00401-X; Amudha P, 1998, INORG CHEM, V37, P4486, DOI 10.1021/ic9714955; Amudha P, 1999, POLYHEDRON, V18, P1363, DOI 10.1016/S0277-5387(99)00014-5; Berman SB, 1997, J NEUROCHEM, V69, P1185; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bertini I, 1998, COORDIN CHEM REV, V170, P283; BOYER PD, 1970, ENZYME KINETIC MECH, V2, P18; Bubacco L, 1999, FEBS LETT, V442, P215, DOI 10.1016/S0014-5793(98)01662-7; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; Calzolai L, 1997, J AM CHEM SOC, V119, P9341, DOI 10.1021/ja9715455; CANOVAS FG, 1982, J BIOL CHEM, V257, P8738; CASTRO I, 1992, J CHEM SOC DALTON, P1739, DOI 10.1039/dt9920001739; Cuff ME, 1998, J MOL BIOL, V278, P855, DOI 10.1006/jmbi.1998.1647; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; EICKMAN NC, 1979, P NATL ACAD SCI USA, V76, P2094, DOI 10.1073/pnas.76.5.2094; FABBRIZZI L, 1995, INORG CHIM ACTA, V238, P5, DOI 10.1016/0020-1693(95)04751-T; Fenoll LG, 2000, EUR J BIOCHEM, V267, P5865, DOI 10.1046/j.1432-1327.2000.01572.x; Fenoll LG, 2001, BBA-PROTEIN STRUCT M, V1548, P1, DOI 10.1016/S0167-4838(01)00207-2; Fuller BB, 2001, EXP CELL RES, V262, P197, DOI 10.1006/excr.2000.5092; Higashi Y, 2000, J NEUROCHEM, V75, P1771, DOI 10.1046/j.1471-4159.2000.0751771.x; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P5378, DOI 10.1021/ja00536a044; HIMMELWRIGHT RS, 1979, BIOCHEM BIOPH RES CO, V86, P628, DOI 10.1016/0006-291X(79)91759-5; HIMMELWRIGHT RS, 1978, BIOCHEM BIOPH RES CO, V84, P300, DOI 10.1016/0006-291X(78)90170-5; INUBUSHI T, 1983, J MAGN RESON, V51, P128, DOI 10.1016/0022-2364(83)90109-9; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; IWATA M, 1990, J INVEST DERMATOL, V95, P9, DOI 10.1111/1523-1747.ep12872677; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; LERCH K, 1972, EUR J BIOCHEM, V31, P427, DOI 10.1111/j.1432-1033.1972.tb02549.x; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; Malachowski MR, 1998, POLYHEDRON, V17, P1289, DOI 10.1016/S0277-5387(97)00380-X; MARTINEZ JH, 1985, BIOCHEM INT, V11, P729; MARTINEZ JH, 1986, COMP BIOCHEM PHYS B, V83, P633, DOI 10.1016/0305-0491(86)90309-3; Monzani E, 1998, INORG CHEM, V37, P553, DOI 10.1021/ic970996n; Monzani E, 1999, INORG CHEM, V38, P5359, DOI 10.1021/ic990397b; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; Oshio H, 1996, INORG CHEM, V35, P472, DOI 10.1021/ic950663v; Pena N, 2001, TALANTA, V55, P179, DOI 10.1016/S0039-9140(01)00414-3; PENAFIEL R, 1984, BIOCHIM BIOPHYS ACTA, V788, P327, DOI 10.1016/0167-4838(84)90045-1; PONS J, 1993, INORG CHIM ACTA, V208, P167, DOI 10.1016/S0020-1693(00)85117-8; Rodriguez M, 1999, INORG CHEM, V38, P2328, DOI 10.1021/ic9808504; RODRIGUEZLOPEZ JN, 1992, J BIOL CHEM, V267, P3801; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Streffer K, 2001, ANAL CHIM ACTA, V427, P201, DOI 10.1016/S0003-2670(00)01040-0; THOMPSON LK, 1995, INORG CHEM, V34, P2356, DOI 10.1021/ic00113a016; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; van Gastel M, 2000, FEBS LETT, V474, P228, DOI 10.1016/S0014-5793(00)01609-4; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; Wang B, 2000, BIOSENS BIOELECTRON, V15, P397, DOI 10.1016/S0956-5663(00)00096-8; WESTMORELAND TD, 1989, J AM CHEM SOC, V111, P6106, DOI 10.1021/ja00198a019; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; WILCOX DE, 1984, J AM CHEM SOC, V106, P2186, DOI 10.1021/ja00319a046; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Xu YM, 1997, MOL BRAIN RES, V45, P159, DOI 10.1016/S0169-328X(96)00308-7	60	44	45	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30436	30444		10.1074/jbc.M202461200	http://dx.doi.org/10.1074/jbc.M202461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048185	hybrid, Green Published			2022-12-25	WOS:000177579800007
J	Bracha, K; Lavy, M; Yalovsky, S				Bracha, K; Lavy, M; Yalovsky, S			The Arabidopsis AtSTE24 is a CAAX protease with broad substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; A-FACTOR; PLASMA-MEMBRANE; RAS PROTEINS; K-RAS; YEAST; PRENYLATION; METHYLATION; CELLS	Following prenylation, the proteins are subject to two prenyl-dependent modifications at their C-terminal end, which are required for their subcellular targeting. First, the three C-terminal residues of the CAAX box prenylation signaling motif are removed, which is followed by methylation of the free carboxyl group of the prenyl cysteine moiety. An Arabidopsis homologue of the yeast CAAX protease STE24 (AFC1) was cloned and expressed in rce1Delta ste24Delta mutant yeast to demonstrate functional complementation. The petunia calmodulin CaM53 is a prenylated protein terminating in a CTIL CAAX box. Coupled methylation proteolysis assays demonstrated the processing of CaM53 by AtSTE24. In addition, AtSTE24 promoted plasma membrane association of the GFP-RacU88402 fusion protein, which terminates with a CLLM CAAX box. Interestingly, a plant homologue of the second and major CAAX protease in yeast and animal cells, RCE1, was not identified despite the availability of vast amounts of sequence data. Taken together, these data suggest that AtSTE24 may process several prenylated proteins in plant cells, unlike its yeast homologue, which processes only a-mating factor, and its mammalian homologue, for which prenyl-CAAX substrates have not been established. Transient expression of GFP-AtSTE24 in leaf epidermal cells of Nicotiana benthamiana showed that AtSTE24 is exclusively localized in the endoplasmic reticulum, suggesting that prenylated proteins in plants are first targeted to the endoplasmic reticulum following their prenylation.	Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Yalovsky, S (corresponding author), Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel.							Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Boyartchuk VL, 1998, GENETICS, V150, P95; Caldelari D, 2001, PLANT PHYSIOL, V126, P1416, DOI 10.1104/pp.126.4.1416; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Crowell DN, 1998, PLANT PHYSIOL, V118, P115, DOI 10.1104/pp.118.1.115; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; Hong BM, 1999, PLANT PHYSIOL, V119, P1165, DOI 10.1104/pp.119.4.1165; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996; Rodriguez-Concepcion M, 1999, PLANT MOL BIOL, V39, P865, DOI 10.1023/A:1006170020836; Rodriguez-Concepcion M, 2000, PLANT J, V24, P775, DOI 10.1046/j.1365-313x.2000.00924.x; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Yalovsky S, 1999, TRENDS PLANT SCI, V4, P439, DOI 10.1016/S1360-1385(99)01492-2; Yalovsky S, 1997, MOL CELL BIOL, V17, P1986, DOI 10.1128/MCB.17.4.1986; YOUNG SG, 2000, PROTEIN LIPIDATION, V21, P156; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	34	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29856	29864		10.1074/jbc.M202916200	http://dx.doi.org/10.1074/jbc.M202916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039957	hybrid			2022-12-25	WOS:000177509300065
J	Conjard, A; Dugelay, S; Chauvin, MF; Durozard, D; Baverel, G; Martin, G				Conjard, A; Dugelay, S; Chauvin, MF; Durozard, D; Baverel, G; Martin, G			The anaplerotic substrate alanine stimulates acetate incorporation into glutamate and glutamine in rabbit kidney tubules - A C-13 NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; AMINO-ACIDS; ACETYL-COA; METABOLISM; GLUCONEOGENESIS; OXIDATION; PYRUVATE; MAMMALS; GLUCOSE; INVIVO	Although acetate, the main circulating volatile fatty acid in humans and animals, is metabolized at high rates by the renal tissue, little is known about the precise fate of its carbons and about the regulation of its renal metabolism. Therefore, we studied the metabolism of variously labeled [C-13]acetate and [C-14]acetate molecules and its regulation by alanine, which is also readily metabolized by the kidney, in isolated rabbit renal proximal tubules. With acetate as the sole substrate, 72% of the C-1 and 49% of the C-2 of acetate were released as CO2; with acetate plus alanine, the corresponding values were decreased to 49 and 25%. The only other important products formed from the acetate carbons were glutamine, and to a smaller extent, glutamate. By combining C-13 NNR and radioactive and enzymatic measurements with a novel model of acetate metabolism, fluxes through the enzymes involved were calculated. Thanks to its anaplerotic effect, alanine caused a stimulation of acetate removal and a large increase in fluxes through pyruvate carboxylase, citrate synthase, and the enzymes involved in glutamate and glutamine synthesis but not in flux through a-ketoglutarate dehydrogenase. We conclude that the anaplerotic substrate alanine not only accelerates the disposal of acetate but also prevents the wasting of the latter compound as CO2.	Hop Edouard Herriot, INSERM U 499, Ctr Etud Metab Spect Resonance Magnet, F-69374 Lyon 08, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Martin, G (corresponding author), Hop Edouard Herriot, INSERM U 499, Ctr Etud Metab Spect Resonance Magnet, Pavillon P,Pl Arsonval, F-69374 Lyon 08, France.			Duplany, Agnes/0000-0002-3485-1597				BALLARD FJ, 1972, AM J CLIN NUTR, V25, P773; BAVEREL G, 1979, BIOCHEM J, V184, P599, DOI 10.1042/bj1840599; BAVEREL G, 1978, KIDNEY INT, V14, P567, DOI 10.1038/ki.1978.165; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; CANIONI P, 1983, BIOCHEMISTRY-US, V22, P4974, DOI 10.1021/bi00290a015; Carvalho RA, 1999, MAGNET RESON MED, V42, P197, DOI 10.1002/(SICI)1522-2594(199907)42:1<197::AID-MRM26>3.0.CO;2-5; Chauvin MF, 1997, J BIOL CHEM, V272, P4705, DOI 10.1074/jbc.272.8.4705; CHAUVIN MF, 1994, J BIOL CHEM, V269, P26025; COHEN SA, 1989, MANUAL ADV TECHNIQUE, P1; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; DAVID F, 1994, ANAL BIOCHEM, V218, P143, DOI 10.1006/abio.1994.1153; Dugelay S, 1999, BIOCHEM J, V342, P555, DOI 10.1042/0264-6021:3420555; DUGELAY S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P191, DOI 10.1016/0304-4165(91)90251-B; Ferrier B, 1999, BIOCHEM J, V337, P543, DOI 10.1042/0264-6021:3370543; Gibala MJ, 2000, ACTA PHYSIOL SCAND, V168, P657, DOI 10.1046/j.1365-201x.2000.00717.x; HOHMANN B, 1969, PFLUG ARCH EUR J PHY, V312, P110, DOI 10.1007/BF00588536; HOWARTH OW, 1978, PROG NUCL MAG RES SP, V12, P1, DOI 10.1016/0079-6565(78)80001-6; JANICKI RH, 1969, AM J PHYSIOL, V216, P1107, DOI 10.1152/ajplegacy.1969.216.5.1107; Jans A W, 1989, NMR Biomed, V1, P171, DOI 10.1002/nbm.1940010404; JANS AWH, 1989, BIOCHEM J, V263, P231, DOI 10.1042/bj2630231; Jucker BM, 1998, J BIOL CHEM, V273, P12187, DOI 10.1074/jbc.273.20.12187; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KNOWLES SE, 1974, BIOCHEM J, V142, P401, DOI 10.1042/bj1420401; Krebs HA, 1932, H-S Z PHYSIOL CHEM, V210, P33, DOI 10.1515/bchm2.1932.210.1-2.33; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; Large V, 1997, AM J PHYSIOL-ENDOC M, V272, pE51, DOI 10.1152/ajpendo.1997.272.1.E51; Lietz T, 1997, ACTA BIOCHIM POL, V44, P323; LUNDQUIST F, 1962, J CLIN INVEST, V41, P955, DOI 10.1172/JCI104574; Panchal AR, 2000, AM J PHYSIOL-HEART C, V279, pH2390, DOI 10.1152/ajpheart.2000.279.5.H2390; POMARE EW, 1985, J CLIN INVEST, V75, P1448, DOI 10.1172/JCI111847; Pouteau E, 1996, AM J PHYSIOL-ENDOC M, V271, pE58, DOI 10.1152/ajpendo.1996.271.1.E58; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SIDOSSIS LS, 1995, J CLIN INVEST, V95, P278, DOI 10.1172/JCI117652; SKUTCHES CL, 1979, J CLIN INVEST, V64, P708, DOI 10.1172/JCI109513; Yang DW, 1996, AM J PHYSIOL-ENDOC M, V270, pE882, DOI 10.1152/ajpendo.1996.270.5.E882; ZHANG Y, 1994, J BIOL CHEM, V269, P11025	38	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29444	29454		10.1074/jbc.M111335200	http://dx.doi.org/10.1074/jbc.M111335200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12019262	hybrid			2022-12-25	WOS:000177509300014
J	Kim, O; Yang, JB; Qiu, Y				Kim, O; Yang, JB; Qiu, Y			Selective activation of small GTPase RhoA by tyrosine kinase Etk through its pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CELL-ADHESION; PROTEINS; CYTOSKELETON; LOCALIZATION; MORPHOLOGY; INVASION; CANCER; ACTIN; VAV	Etk/Bmx is a member of the Btk family tyrosine kinase, which contains an N-terminal pleckstrin homology domain. Etk has been shown to play a pivotal role in the regulation of various cellular processes including differentiation, apoptosis, and cell motility. Here we present evidence that Etk is a modulator of the small GTPase RhoA. Etk and RhoA both are translocated to the plasma membrane and can form a complex upon serum stimulation in C2C12 cells. Etk interacts with RhoA but not other closely related small GTPases such as Cdc42 and Rac1, suggesting a specific modulation of RhoA by Etk. Our results demonstrate that Etk activates RhoA and enhances Rho-mediated stress fiber formation and transcription activity in a pleckstrin homology domain-dependent manner. Furthermore, Etk disrupts the interaction between RhoA and Rho-GDI (guanine nucleotide dissociation inhibitor) and promotes the membrane translocation of RhoA. Our data suggest that Etk plays an important role in regulation of RhoA-mediated signaling.	Univ Maryland, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA; Univ Maryland, Dept Lab Med & Pathol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; del Peso L, 1997, ONCOGENE, V15, P3047; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kranenburg O, 1997, J CELL SCI, V110, P2417; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sander EE, 1999, EUR J CANCER, V35, P1905, DOI 10.1016/S0959-8049(99)00293-2; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; VAN AL, 1997, GENE DEV, V11, P2295; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Yoshioka K, 1999, CANCER RES, V59, P2004; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	28	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30066	30071		10.1074/jbc.M201713200	http://dx.doi.org/10.1074/jbc.M201713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023958	hybrid			2022-12-25	WOS:000177509300089
J	Numakawa, T; Yokomaku, D; Kiyosue, K; Adachi, N; Matsumoto, T; Numakawa, Y; Taguchi, T; Hatanaka, H; Yamada, M				Numakawa, T; Yokomaku, D; Kiyosue, K; Adachi, N; Matsumoto, T; Numakawa, Y; Taguchi, T; Hatanaka, H; Yamada, M			Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPAL-NEURONS; BDNF KNOCKOUT MICE; NEUROTROPHIC FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SYNAPTIC TRANSMISSION; INTRACELLULAR CA2+; NERVOUS-SYSTEM; RECEPTORS	We examined the possibility that basic fibroblast growth factor (bFGF) is involved in synaptic transmissions. We found that bFGF rapidly induced the release of glutamate and an increase in the intracellular Ca2+ concentration through voltage-dependent Ca2+ channels in cultured cerebral cortical neurons. bFGF also evoked a significant influx of Na+. Tetanustoxin inhibited the bFGF-induced glutamate release, revealing that bFGF triggered exocytosis. The mitogen-activated protein kinase (MAPK) pathway was required for these acute effects of bFGF. We also found that pretreatment with bFGF significantly enhanced high K+-elicited glutamate release also in a MAPK activation-dependent manner. Therefore, we propose that bFGF exerts promoting effects on excitatory neuronal transmission via activation of the MAPK pathway.	Osaka Univ, Inst Prot Res, Div Prot Biosynth, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, AIST, Neuron RG Div Human Life Technol, Osaka 5638577, Japan	Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Numakawa, T (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Biosynth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	t-numakawa@aist.go.jp	Kiyosue, Kazuyuki/AAH-5118-2020; Kiyosue, Kazuyuki/L-2857-2016	Kiyosue, Kazuyuki/0000-0001-9439-3295; Kiyosue, Kazuyuki/0000-0001-9439-3295; Adachi, Naoki/0000-0002-4850-1467				Abe K, 2000, DEV BRAIN RES, V122, P81, DOI 10.1016/S0165-3806(00)00054-7; Abe K, 2001, PHARMACOL RES, V43, P307, DOI 10.1006/phrs.2000.0794; ABE K, 1992, BRAIN RES, V593, P335, DOI 10.1016/0006-8993(92)91332-9; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Baron C, 1996, J NEUROCHEM, V66, P1005; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Boulanger L, 1999, NAT NEUROSCI, V2, P346, DOI 10.1038/7258; Boxer AL, 1999, J NEUROPHYSIOL, V82, P3367, DOI 10.1152/jn.1999.82.6.3367; Bradley J, 1999, BRAIN RES, V815, P140, DOI 10.1016/S0006-8993(98)01112-3; CHENG B, 1995, J NEUROCHEM, V65, P2525; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Dudek SM, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0002.2001; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Flint AC, 1999, P NATL ACAD SCI USA, V96, P12144, DOI 10.1073/pnas.96.21.12144; Gaspary HL, 1998, J NEUROPHYSIOL, V80, P270, DOI 10.1152/jn.1998.80.1.270; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Katsumori H, 1999, BRAIN RES, V819, P160, DOI 10.1016/S0006-8993(98)01352-3; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; KURINO M, 1995, J NEUROCHEM, V65, P1282; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Matsumoto T, 2001, J NEUROCHEM, V79, P522, DOI 10.1046/j.1471-4159.2001.00591.x; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; Numakawa T, 1999, BRAIN RES, V842, P431, DOI 10.1016/S0006-8993(99)01867-3; Numakawa T, 2002, J BIOL CHEM, V277, P6520, DOI 10.1074/jbc.M109139200; Numakawa T, 2001, J NEUROSCI RES, V66, P96, DOI 10.1002/jnr.1201; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pende M, 1997, J NEUROSCI, V17, P1291; Peterson DA, 1996, J NEUROSCI, V16, P886; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Stachowiak MK, 1997, MOL NEUROBIOL, V15, P257, DOI 10.1007/BF02740663; Takei N, 1998, J BIOL CHEM, V273, P27620, DOI 10.1074/jbc.273.42.27620; Tanaka T, 1996, BRAIN RES, V723, P190, DOI 10.1016/0006-8993(96)00245-4; TERLAU H, 1990, EUR J NEUROSCI, V2, P973, DOI 10.1111/j.1460-9568.1990.tb00009.x; UNSICKER K, 1991, ANN NY ACAD SCI, V638, P300; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yang F, 2001, NAT NEUROSCI, V4, P1071, DOI 10.1038/nn734; Yang F, 2001, NAT NEUROSCI, V4, P19, DOI 10.1038/82858	53	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28861	28869		10.1074/jbc.M202927200	http://dx.doi.org/10.1074/jbc.M202927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034732	hybrid			2022-12-25	WOS:000177342600069
J	Porter, GA; Makuck, RF; Rivkees, SA				Porter, GA; Makuck, RF; Rivkees, SA			Reduction in intracellular calcium levels inhibits myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; C2C12 MOUSE MYOTUBES; MYOSIN HEAVY-CHAIN; PROTEIN-KINASE-C; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; BETA-SPECTRIN; EXPRESSION; GENE; MYOGENESIS	In myocytes, calcium plays an important role in intracellular signaling and contraction. However, the ability of calcium to modulate the differentiation of striated muscle cells is poorly understood. To examine this issue we studied C2C12 cells, which is a myoblast cell line that differentiates in vitro. First, we observed that the L-type calcium channel blockers nifedipine and verapamil effectively inhibited electrically induced calcium transients. Next, C2C12 cells were exposed to these agents during conditions that induce myocyte differentiation. In the presence of nifedipine and verapamil, myoblasts failed to form myotubes. Dantrolene and thapsigargin, which decrease intracellular calcium by different mechanisms, also inhibited differentiation. In addition, nifedipine and verapamil inhibited the expression of myosin heavy chain and myogenin, two markers of skeletal myoblast differentiation. In contrast, levels of the transcriptional factor Myf5, which is expressed in undifferentiated myoblasts, did not decline. Calcium channel blockade also prevented the expression of a reporter driven by the skeletal muscle a-actin promoter. These data demonstrate that lowering intracellular calcium levels inhibits the differentiation of skeletal myoblasts into mature myotubes.	Yale Univ, Sch Med, Dept Pediat, Div Cardiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, Div Endocrinol, New Haven, CT 06520 USA	Yale University; Yale University	Porter, GA (corresponding author), Yale Univ, Sch Med, Dept Pediat, Div Cardiol, 333 Cedar St, New Haven, CT 06520 USA.		George A, Porter/E-7315-2013	George A, Porter/0000-0003-0726-9988	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058442] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58442] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; Bito H, 1998, CELL CALCIUM, V23, P143, DOI 10.1016/S0143-4160(98)90113-0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; Hermann S, 1998, CELL CALCIUM, V23, P135, DOI 10.1016/S0143-4160(98)90112-9; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; KUBO Y, 1991, J PHYSIOL-LONDON, V442, P743, DOI 10.1113/jphysiol.1991.sp018817; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; Lorenzon P, 2000, J PHYSIOL-LONDON, V525, P499, DOI 10.1111/j.1469-7793.2000.00499.x; Lorenzon P, 1997, EUR J NEUROSCI, V9, P800, DOI 10.1111/j.1460-9568.1997.tb01429.x; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V246, P287, DOI 10.1006/bbrc.1998.8600; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Temm-Grove CJ, 1999, EXP CELL RES, V247, P293, DOI 10.1006/excr.1998.4362; Vali S, 2000, J CELL PHYSIOL, V185, P184, DOI 10.1002/1097-4652(200011)185:2<184::AID-JCP3>3.0.CO;2-T; VARADI G, 1989, FEBS LETT, V250, P515, DOI 10.1016/0014-5793(89)80787-2; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287	31	101	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28942	28947		10.1074/jbc.M203961200	http://dx.doi.org/10.1074/jbc.M203961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042317	hybrid			2022-12-25	WOS:000177342600079
J	D'Atri, F; Nadalutti, F; Citi, S				D'Atri, F; Nadalutti, F; Citi, S			Evidence for a functional interaction between cingulin and ZO-1 in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTION PROTEIN ZO-1; TIGHT JUNCTION; MOUSE DEVELOPMENT; EPITHELIAL-CELLS; KINASE-C; DOMAINS; COMPLEX; LOCALIZATION; ORGANIZATION; IDENTIFICATION	Cingulin, a protein component of the submembrane plaque of tight junctions (TJ), contains globular and coiled-coil domains and interacts in vitro with several TJ and cytoskeletal proteins, including the PDZ protein ZO-1. Overexpression of Xenopus cingulin in transfected Xenopus A6 cells resulted in the disruption of endogenous ZO-1 localization, suggesting that cingulin functionally interacts with ZO-1. Glutathione S-transferase pull-down experiments showed that a conserved ZO-1 interaction motif (ZIM) at the NH2 terminus of cingulin is required for cingulin-ZO-1 interaction an vitro. An NH2-terminal region of cingulin, containing the ZIM, was sufficient, when fused to coiled-coil sequences, to target transfected cingulin to junctions. However, deletion of the ZIM did not abolish junctional localization of transfected cingulin in A6 cells, suggesting that cingulin can be recruited to TJ through multiple protein interactions. Interestingly, the ZIM was required for cingulin recruitment into ZO-1-containing adherens junctions of Rat-1 fibroblasts, indicating that cingulin junctional recruitment does not require the molecular context of TJ. Cingulin coiled-coil sequences enhanced the junctional accumulation of expressed cingulin head region in A6 cells, but purified recombinant cingulin did not form filaments under physiological conditions in vitro, suggesting that the cingulin coiled-coil domain acts primarily by promoting dimerization.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; Univ Padua, Dept Biol, I-35131 Padua, Italy	University of Geneva; University of Geneva; University of Padua	Citi, S (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Citi, Sandra/E-4514-2014	Citi, Sandra/0000-0002-6537-4818				Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Cardellini P, 1996, DEV DYNAM, V207, P104, DOI 10.1002/(SICI)1097-0177(199609)207:1<104::AID-AJA10>3.0.CO;2-0; Citi S, 2000, J STRUCT BIOL, V131, P135, DOI 10.1006/jsbi.2000.4284; CITI S, 1989, J CELL SCI, V93, P107; CITI S, 1986, J MOL BIOL, V188, P369, DOI 10.1016/0022-2836(86)90161-0; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CITI S, 2001, TIGHT JUNCTIONS, P231; Citi S, 2001, CELL CELL INTERACTIO, V256, P153; Cordenonsi M, 1999, J CELL BIOL, V147, P1569, DOI 10.1083/jcb.147.7.1569; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; D'Atri F, 2001, FEBS LETT, V507, P21, DOI 10.1016/S0014-5793(01)02936-2; Fesenko I, 2000, MECH DEVELOP, V96, P51, DOI 10.1016/S0925-4773(00)00368-3; FLEMING TP, 1993, DEVELOPMENT, V117, P1135; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Ryeom SW, 2000, MOL BIOL CELL, V11, P1687, DOI 10.1091/mbc.11.5.1687; Sheth B, 2000, MECH DEVELOP, V97, P93, DOI 10.1016/S0925-4773(00)00416-0; SMITH JC, 1991, METHOD CELL BIOL, V36, P635; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; YONEMURA S, 1995, J CELL SCI, V108, P127; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	31	48	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27757	27764		10.1074/jbc.M203717200	http://dx.doi.org/10.1074/jbc.M203717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023291	hybrid			2022-12-25	WOS:000177189800024
J	Yeap, BB; Voon, DC; Vivian, JP; McCulloch, RK; Thomson, AM; Giles, KM; Czyzyk-Krzeska, MF; Furneaux, H; Wilce, MCJ; Wilce, JA; Leedman, PJ				Yeap, BB; Voon, DC; Vivian, JP; McCulloch, RK; Thomson, AM; Giles, KM; Czyzyk-Krzeska, MF; Furneaux, H; Wilce, MCJ; Wilce, JA; Leedman, PJ			Novel binding of HuR and poly(C)-binding protein to a conserved UC-rich motif within the 3 '-untranslated region of the androgen receptor messenger RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MRNP STABILITY COMPLEX; BREAST-CANCER CELLS; POSTTRANSCRIPTIONAL REGULATION; MEDROXYPROGESTERONE ACETATE; PREDICTIVE VALUE; GENE-EXPRESSION; ELAV PROTEIN; IN-VITRO; ELEMENTS; IDENTIFICATION	The androgen receptor (AR) mediates androgen action and plays a central role in the proliferation of specific cancer cells. We demonstrated recently that AR mRNA stability is a major determinant of AR gene expression in prostate and breast cancer cells and that androgens differentially regulate AR mRNA decay dependent on cell type (Yeap, B. B., Kreuger, R. G., Leedman, P. J. (1999) Endocrinology 140,3282-3291). Here, we have identified a highly conserved UC-rich region in the 3-untranslated region of AR mRNA that contains a 5'-C(U)(n)C motif and a 3'-CCCUCCC poly(C)-binding protein motif. In transfection studies with LNCaP human prostate cancer cells, the AR UC-rich region reduced expression of a luciferase reporter gene. The AR UC-rich region was a target for cytoplasmic and nuclear RNA-binding proteins from human prostate and breast cancer cells as well as human testicular and breast cancer tissue. One of these proteins is Hull, a ubiquitously expressed member of the Elav/Hu family of RNA-binding proteins involved in the stabilization of several mRNAs. Poly(C)-binding protein-1 and -2 (CP1 and CP2), previously implicated in the control of mRNA turnover and translation, also bound avidly to the UC-rich region. Mutational analysis of the UC-rich region identified specific binding motifs for both HuR and the CPs. HuR and CP1 bound simultaneously to the UC-rich RNA and in a cooperative manner. Immunoprecipitation studies confirmed that each of these proteins associated with AR mRNA in prostate cancer cells. In summary, we have identified and characterized a novel complex of AR mRNA-binding proteins that target the highly conserved UC-rich region. The binding of HuR, CP1, and CP2 to AR mRNA suggests a role for each of these proteins in the post-transcriptional regulation of AR expression in cancer cells.	Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Dept Med, Perth, WA 6000, Australia; Univ Western Australia, Struct Biol Ctr, Perth, WA 6000, Australia; Univ Western Australia, Dept Pharmacol, Perth, WA 6000, Australia; Univ Western Australia, Dept Chem, Perth, WA 6000, Australia; Univ Western Australia, Dept Biochem, Perth, WA 6000, Australia; Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Univ Connecticut, Ctr Hlth, Dept Physiol, Vasc Biol Program, Farmington, CT 06030 USA	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University System of Ohio; University of Cincinnati; University of Connecticut	Leedman, PJ (corresponding author), Western Australian Inst Med Res, Lab Canc Med, 6th Floor,Med Res Fdn Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Leedman, Peter J/O-4044-2014; Wilce, Jacqueline/N-5018-2017	Wilce, Jacqueline/0000-0002-8344-2626; furneaux, henry/0000-0003-2212-1017; Voon, Dominic Chih-Cheng/0000-0002-2963-9305; Vivian, Julian/0000-0002-9400-4437				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; BIRRELL SN, 1995, J CLIN ONCOL, V13, P1572, DOI 10.1200/JCO.1995.13.7.1572; BOTHWELL ALM, 1991, J BIOL CHEM, V266, P24657; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gamarnik AV, 1997, RNA, V3, P882; Goktas S, 1999, SEMIN ONCOL, V26, P162; Jenster G, 1999, SEMIN ONCOL, V26, P407; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kiledjian M, 1999, METHODS, V17, P84, DOI 10.1006/meth.1998.0710; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Murray KE, 2001, RNA, V7, P1126, DOI 10.1017/S1355838201010044; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sheflin LG, 2001, ENDOCRINOLOGY, V142, P2361, DOI 10.1210/en.142.6.2361; SOREIDE JA, 1992, EUR J SURG ONCOL, V18, P112; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Szelei J, 1997, ENDOCRINOLOGY, V138, P1406, DOI 10.1210/en.138.4.1406; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	57	118	127	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27183	27192		10.1074/jbc.M202883200	http://dx.doi.org/10.1074/jbc.M202883200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011088	hybrid			2022-12-25	WOS:000177055900063
J	Bravo, A; Sanchez, J; Kouskoura, T; Crickmore, N				Bravo, A; Sanchez, J; Kouskoura, T; Crickmore, N			N-terminal activation is an essential early step in the mechanism of action of the Bacillus thuringiensis Cry1Ac insecticidal toxin.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL PROTEINS	A variant form of the Bacillus thuringiensis Cry1Ac toxin that is not cleaved at the N terminus during proteolytic activation with trypsin was found to be incapable of forming pores in Manduca sexta brush border membrane vesicles in vitro and had reduced insecticidal activity in vivo. Binding studies indicated an altered binding pattern of the mutant toxin in that bound toxin could not be fully displaced by a high molar excess of fully trypsin-activated toxin. These results suggest that proteolytic removal of the N-terminal peptide of Cry1Ac is an important step in toxin activation.	Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Crickmore, N (corresponding author), Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England.		Crickmore, Neil/H-7259-2012; de la Parra, Maria Alejandra Bravo/R-6740-2017	Crickmore, Neil/0000-0002-8448-0763; Bravo, Alejandra/0000-0002-7573-7475				Kouskoura T, 2001, CURR MICROBIOL, V43, P371, DOI 10.1007/s002840010318; LORENCE A, 1995, FEBS LETT, V360, P217, DOI 10.1016/0014-5793(95)00092-N; MARTENS JWM, 1995, J INVERTEBR PATHOL, V66, P249, DOI 10.1006/jipa.1995.1097; Morse RJ, 2001, STRUCTURE, V9, P409, DOI 10.1016/S0969-2126(01)00601-3; Park HW, 2000, APPL ENVIRON MICROB, V66, P4449, DOI 10.1128/AEM.66.10.4449-4455.2000; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Smedley DP, 1996, MICROBIOL-SGM, V142, P1617, DOI 10.1099/13500872-142-7-1617; Strizhov N, 1996, MOL GEN GENET, V253, P11, DOI 10.1007/s004380050290; VAECK M, 1987, NATURE, V328, P33, DOI 10.1038/328033a0; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3	10	45	56	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					23985	23987		10.1074/jbc.C200263200	http://dx.doi.org/10.1074/jbc.C200263200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	12019259	hybrid			2022-12-25	WOS:000176611800004
J	Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L				Claes, K; Vandesompele, J; Poppe, B; Dahan, K; Coene, I; De Paepe, A; Messiaen, L			Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5 ' end of the BRCA1 gene	ONCOGENE			English	Article						BRCA1; splice mutation; real time RT-PCR; breast cancer	OVARIAN-CANCER; MESSENGER-RNA; BREAST; IDENTIFICATION; EXPRESSION	We report two novel mutations in the splice sites of BRCA1 exon 5: IVS5+3A>G, a Belgian founder mutation, and IVS3-6T>G, identified in one family with a strong family history of breast cancer. Real-time RT-PCR showed that IVS3-6T>G leads to a fivefold increase of the BRCA1-Deltaex5 (isoform with an in frame skip of exon 5) ratio to the total BRCA1 expression level. lVS5+3A>G results in a 10-fold increase of the BRCA1-Delta22ntex5 ratio (isoform with an out of frame skip of the last 22 nucleotides of exon 5) and a twofold increase of the BRCA1-Deltaex5 ratio. These altered ratios are most likely to result from increased expression of the alternative transcripts, although we cannot completely rule out a small decrease of the total BRCA1 expression level due to highly variable BRCA1 levels in cultured cell lines. In order to explore the functional significance of the isoforms, we evaluated their prevalence in normal tissues and cancer cell lines. The BRCA1-Delta22ntex5 ratio was significantly higher in an ovarian cancer cell line compared to normal ovarian tissue. Our findings suggest that revealing the defects caused by some splice mutations requires accurate quantitative methods. We hypothesize that disruption of alternative transcript ratios of BRCA1 may be a dominant mechanism affecting predisposition to hereditary breast and/or ovarian cancer.	Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, B-9000 Ghent, Belgium; Clin Univ St Luc, Ctr Genet Humaine, B-1200 Brussels, Belgium	Ghent University; Ghent University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Messiaen, L (corresponding author), Ghent Univ Hosp, Dept Med Genet, Ctr Genet Med, OK5,Pintelaan 185, B-9000 Ghent, Belgium.	Ludwine.Messiaen@rug.ac.bc	Vandesompele, Jo/W-3411-2018; Claes, Kathleen/AFR-6830-2022	Vandesompele, Jo/0000-0001-6274-0184; Claes, Kathleen/0000-0003-0841-7372				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Claes K, 1999, DIS MARKERS, V15, P69, DOI 10.1155/1999/241046; EASTON DF, 1993, AM J HUM GENET, V52, P678; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ohno K, 1999, AM J HUM GENET, V65, P635, DOI 10.1086/302551; Pummi K, 2000, ARCH DERMATOL RES, V292, P422, DOI 10.1007/s004030000155; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vandenbroucke I I, 2001, Nucleic Acids Res, V29, pE68, DOI 10.1093/nar/29.13.e68; VANDESOMPELE, 2002, IN PRESS; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	23	29	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4171	4175		10.1038/sj.onc.1205520	http://dx.doi.org/10.1038/sj.onc.1205520			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037674				2022-12-25	WOS:000176186000012
J	Pias, EK; Aw, TY				Pias, EK; Aw, TY			Apoptosis in mitotic competent undifferentiated cells is induced by cellular redox imbalance independent of reactive oxygen species production	FASEB JOURNAL			English	Article						apoptosis in undifferentiated cells; GSH/GSSG status and apoptosis; mitochondrial apoptosis signaling; diamide; NADPH; pentose phosphate pathway	GLUTATHIONE; BCL-2; EXPRESSION; OXIDATION; THIOLS; INHIBITION; MODULATION; PATHWAYS; DIAMIDE; ROLES	Oxidants are known to induce cell apoptosis. Because oxidants also elicit redox imbalance, it is difficult to distinguish the direct effects of cellular redox from that of oxidants. This study tests the hypothesis that induction of redox imbalance independent of reactive oxygen species (ROS), can induce cell apoptosis in a mitotic competent, undifferentiated cell line, PC-12. Cells grown in standard DMEM containing 25 mM glucose were treated with diamide, a thiol oxidant, at a concentration that did not generate ROS. Diamide caused a rapid increase in oxidized glutathione (GSSG) and a loss of mitochondrial cytochrome c in 15-30 min, caspase-3 activation in 2 h, and apoptosis in 24 h. N-Acetyl cysteine attenuated GSSG elevation and diamide-induced apoptosis. Incubation of cells in 5 mM glucose or inhibition of the pentose phosphate pathway maintained GSSG elevation and accelerated cell apoptosis. Collectively, these results show that loss of redox balance is an upstream event that kinetically preceded mitochondrial apoptotic signaling. A sustained redox change was not critical or necessary for apoptotic progression, but its prolongation exacerbated apoptotic death. The potentiation of apoptosis by sustained redox imbalance was correlated with decreases in NADPH supply for GSSG reduction.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	taw@lsuhsc.edu		Hines, Erin Pias/0000-0002-2458-6267	NIDDK NIH HHS [DK 44510, R01 DK044510, R01 DK044510-09] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1994, J CLIN INVEST, V94, P2426, DOI 10.1172/JCI117610; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Constantini P., 1996, J BIOL CHEM, V271, P6746; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; GABBAY M, 2000, SHOCK, V14, P605; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hour TC, 1999, TOXICOL LETT, V110, P191, DOI 10.1016/S0378-4274(99)00158-7; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LeGrand TS, 1998, AM J PHYSIOL-GASTR L, V274, pG376, DOI 10.1152/ajpgi.1998.274.2.G376; Macho A, 1997, J IMMUNOL, V158, P4612; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SATO N, 1995, J IMMUNOL, V154, P3194; TAIN WN, 1999, AM J PHYSIOL, V276, P1121; Ueda S, 1998, J IMMUNOL, V161, P6689; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Wang TG, 2000, FASEB J, V14, P1567, DOI 10.1096/fj.14.11.1567; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wright SC, 1998, CANCER RES, V58, P5570; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701	34	70	75	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0781	10.1096/fj.01-0784com	http://dx.doi.org/10.1096/fj.01-0784com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039859				2022-12-25	WOS:000176683900003
J	de Kleijn, DPV; Smeets, MB; Kemmeren, PPCW; Lim, SK; van Middelaar, BJ; Velema, E; Schoneveld, A; Pasterkamp, G; Borst, C				de Kleijn, DPV; Smeets, MB; Kemmeren, PPCW; Lim, SK; van Middelaar, BJ; Velema, E; Schoneveld, A; Pasterkamp, G; Borst, C			Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring	FASEB JOURNAL			English	Article						artery; extracellular matrix; matrix metalloproteinase	MATRIX-METALLOPROTEINASE INHIBITION; ENDOTHELIAL-CELLS; CAROTID-ARTERY; BLOOD-FLOW; INTRAVASCULAR ULTRASOUND; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; YUCATAN MICROPIG; SMOOTH-MUSCLE; EXPRESSION	Collagen turnover and cell migration are fundamental aspects of arterial restructuring. To identify mRNAs involved in blood flow-induced arterial restructuring, we performed subtraction polymerase chain reaction and found expression of haptoglobin mRNA in adventitial fibroblasts of rabbit arteries. Haptoglobin is highly expressed in liver, but its arterial expression and function are unknown. In vitro studies revealed that stimulation of haptoglobin expression by lipopolysaccharides in mice fibroblasts stimulated migration of wild-type fibroblasts but had no effect on migration of haptoglobin knockout fibroblasts. In vivo studies showed that flow-induced arterial restructuring was delayed in haptoglobin knockout mice. This new function of haptoglobin might be explained by facilitating cell migration through accumulation of a temporary gelatin matrix because cell culture showed that haptoglobin is involved in the breakdown of gelatin. We conclude that haptoglobin is highly expressed in arterial tissue and is involved in arterial restructuring. This new haptoglobin function may also apply to other functional and pathological restructuring processes such as angiogenesis, tissue repair, and tumor cell invasion.	Univ Med Ctr G02 523, Expt Cardiol Lab, NL-3584 CX Utrecht, Netherlands; Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands; Natl Univ Singapore, NUMI, Cardiovasc Res Inst, Singapore 117548, Singapore	Utrecht University; Utrecht University Medical Center; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; National University of Singapore	de Kleijn, DPV (corresponding author), Univ Med Ctr G02 523, Expt Cardiol Lab, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	D.deKleijn@hli.azu.nl		Kemmeren, Patrick/0000-0003-2237-7354				Abbruzzese TA, 1998, SURGERY, V124, P328, DOI 10.1016/S0039-6060(98)70138-2; Baumann H, 2000, J BIOL CHEM, V275, P22014, DOI 10.1074/jbc.M002830200; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; CASSOT F, 1995, CIRCULATION, V92, P3122, DOI 10.1161/01.CIR.92.10.3122; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; de Smet BJGL, 2000, CIRCULATION, V101, P2962, DOI 10.1161/01.CIR.101.25.2962; DIMARIO C, 1995, AM J CARDIOL, V75, P772, DOI 10.1016/S0002-9149(99)80409-3; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; ElGhmati SM, 1996, J IMMUNOL, V156, P2542; Fernandez HA, 1999, J SURG RES, V82, P156, DOI 10.1006/jsre.1998.5534; FROHLANDER N, 1991, BIOCHEM BIOPH RES CO, V178, P343, DOI 10.1016/0006-291X(91)91820-3; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Godin D, 2000, CIRCULATION, V102, P2861; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Harmon KJ, 2000, AM J PATHOL, V156, P1741, DOI 10.1016/S0002-9440(10)65045-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; KARIM MA, 1995, CIRCULATION, V91, P2049, DOI 10.1161/01.CIR.91.7.2049; KATNIK I, 1995, EUR J CLIN CHEM CLIN, V33, P727; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Kumar A, 1997, ARTERIOSCL THROM VAS, V17, P2238, DOI 10.1161/01.ATV.17.10.2238; LANGILLE BL, 1989, AM J PHYSIOL, V256, pH931, DOI 10.1152/ajpheart.1989.256.4.H931; Lim SK, 1998, BLOOD, V92, P1870, DOI 10.1182/blood.V92.6.1870.418k38_1870_1877; Lim YK, 2000, KIDNEY INT, V58, P1033, DOI 10.1046/j.1523-1755.2000.00261.x; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; PASTERKAMP G, 1995, CIRCULATION, V91, P1444, DOI 10.1161/01.CIR.91.5.1444; Piva M, 1999, MOL HUM REPROD, V5, P71, DOI 10.1093/molehr/5.1.71; POST MJ, 1994, CIRCULATION, V89, P2816, DOI 10.1161/01.CIR.89.6.2816; Powell J T, 1991, Eur J Vasc Surg, V5, P145, DOI 10.1016/S0950-821X(05)80679-6; Puyraimond A, 1999, J CELL SCI, V112, P1283; REIJERKERK A, 2000, EUR J CANC, V36; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sierevogel MJ, 2001, CIRCULATION, V103, P302; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Wylie S, 1999, CLIN EXP METASTAS, V17, P111, DOI 10.1023/A:1006573417179	39	81	84	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1123	+		10.1096/fj.02-0019fje	http://dx.doi.org/10.1096/fj.02-0019fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039846				2022-12-25	WOS:000175973900006
J	Chen, Y; Peumans, WJ; Hause, B; Bras, J; Kumar, M; Proost, P; Barre, A; Rouge, P; Van Damme, EJM				Chen, Y; Peumans, WJ; Hause, B; Bras, J; Kumar, M; Proost, P; Barre, A; Rouge, P; Van Damme, EJM			Jasmonate methyl ester induces the synthesis of a cytoplasmic/nuclear chitooligosaccharide-binding lectin in tobacco leaves	FASEB JOURNAL			English	Article						chito-oligosaccharides; cytoplasmic/nuclear protein; jasmonate; plant lectin; stress response	HYDROPHOBIC CLUSTER-ANALYSIS; STORAGE PROTEIN GENES; SIGNAL-TRANSDUCTION; N-ACETYLGLUCOSAMINE; NUCLEAR-PORES; PHLOEM LECTIN; HIGHER-PLANTS; SALT STRESS; EXPRESSION; ACID	In contrast to animal lectins, no evidence has indicated the occurrence of plant lectins, which recognize and bind "endogenous" receptors and accordingly are involved in recognition mechanisms within the organism itself. Here we show that the plant hormone jasmonic acid methyl ester (JAME) induces in leaves of Nicotiana tabacum (var. Samsun NN) the expression of a lectin that is absent from untreated plants. The lectin specifically binds to oligomers of N-acetylglucosamine and is detected exclusively in the cytoplasm and the nucleus. Both the subcellular location and specificity indicate that the Nicotiana tabacum agglutinin (called Nictaba) may be involved in the regulation of gene expression in stressed plants through specific protein-carbohydrate interactions with regulatory cytoplasmic/nuclear glycoproteins. Searches in the databases revealed that many flowering plants contain sequences encoding putative homologues of the tobacco lectin, which suggest that Nictaba is the prototype of a widespread or possibly ubiquitous family of lectins with a specific endogenous role.	Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Lab Mol Immunol, Rega Inst, B-3001 Louvain, Belgium; Inst Plant Biochem, D-4050 Halle An Der Saale, Germany; CNRS, Inst Pharmacol & Biol Struct, UMR 5089, Toulouse, France	KU Leuven; KU Leuven; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Van Damme, EJM (corresponding author), Katholieke Univ Leuven, Lab Phytopathol & Plant Protect, Willem de Croylaan 42, B-3001 Louvain, Belgium.	Els.VanDamme@agr.kuleuven.ac.be	Rouge, Pierre/T-2059-2019; Van Damme, Els J/B-4410-2015; Proost, Paul/V-3052-2017; Van Damme, Els/U-3904-2019	Proost, Paul/0000-0002-0133-5545; Van Damme, Els/0000-0001-9848-766X; Barre, annick/0000-0002-1360-8491				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOSTWICK DE, 1994, PLANT MOL BIOL, V26, P887, DOI 10.1007/BF00028856; CLAES B, 1990, PLANT CELL, V2, P19, DOI 10.1105/tpc.2.1.19; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Dannenhoffer JM, 1997, PLANTA, V201, P405, DOI 10.1007/s004250050083; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Fabre C, 1998, BIOCHEM J, V329, P551, DOI 10.1042/bj3290551; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; Golecki B, 1999, PLANT CELL, V11, P127, DOI 10.1105/tpc.11.1.127; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; HEESEPECK A, 1995, PLANT CELL, V7, P1459, DOI 10.1105/tpc.7.9.1459; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; Hirano K, 2000, PLANT CELL PHYSIOL, V41, P258, DOI 10.1093/pcp/41.3.258; Kilpatrick D.C, 2000, HDB ANIMAL LECTINS P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MASON HS, 1990, PLANT CELL, V2, P569, DOI 10.1105/tpc.2.6.569; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; Moons A, 1997, PLANT CELL, V9, P2243, DOI 10.1105/tpc.9.12.2243; Peumans WJ, 2000, TRENDS GLYCOSCI GLYC, V12, P83, DOI 10.4052/tigg.12.83; READ SM, 1983, EUR J BIOCHEM, V134, P561, DOI 10.1111/j.1432-1033.1983.tb07603.x; REINBOTHE C, 1994, PLANT SCI, V104, P59, DOI 10.1016/0168-9452(94)90191-0; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANADI AR, 1994, J BIOL CHEM, V269, P5072; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shih CY, 1998, J PLANT PHYSIOL, V152, P358, DOI 10.1016/S0176-1617(98)80247-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Smith HMS, 1999, PLANT PHYSIOL, V119, P1157, DOI 10.1104/pp.119.4.1157; Sreerama N, 1999, PROTEIN SCI, V8, P370; STASWICK PE, 1991, PLANT PHYSIOL, V96, P130, DOI 10.1104/pp.96.1.130; Thornton TM, 1999, TRENDS PLANT SCI, V4, P424, DOI 10.1016/S1360-1385(99)01485-5; Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575, DOI 10.1016/S0735-2689(98)00365-7; Van Damme EJM, 1999, PLANT PHYSIOL, V119, P1547, DOI 10.1104/pp.119.4.1547; van der Holst PPG, 2001, CURR OPIN STRUC BIOL, V11, P608, DOI 10.1016/S0959-440X(00)00255-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG MB, 1994, PLANT MOL BIOL, V24, P159, DOI 10.1007/BF00040582; Wasternack C, 1998, J PLANT PHYSIOL, V152, P345, DOI 10.1016/S0176-1617(98)80149-1; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z; Yamaguchi T, 2000, TRENDS GLYCOSCI GLYC, V12, P113, DOI 10.4052/tigg.12.113; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang WL, 2000, PLANTA, V210, P970, DOI 10.1007/s004250050705	48	88	91	4	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					905	+		10.1096/fj.01-0598fje	http://dx.doi.org/10.1096/fj.01-0598fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039875				2022-12-25	WOS:000175425900022
J	Baillat, D; Begue, A; Stehelin, D; Aumercier, M				Baillat, D; Begue, A; Stehelin, D; Aumercier, M			ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MATRIX METALLOPROTEINASES; PROTEIN INTERACTIONS; AUTO-INHIBITION; EXPRESSION; DOMAIN; ACTIVATION; PHOSPHORYLATION; TRANSACTIVATION; SEQUENCES	Stromelysin-1 (matrix metalloproteinase-3) is a member of the matrix metalloproteinase family. Regulation of its gene expression is critical for tissue homeostasis. Patterns of increased co-expression of stromelysin-1 and ETS-1 genes have been observed in pathological processes. Stromelysin-1 promoter is transactivated by ETS proteins through two palindromic head to head ETS-binding sites, an unusual configuration among metalloproteinase promoters. By using surface plasmon resonance, electrophoretic mobility shift assay, and photo-cross-linking, we showed that full-length human ETS-1 (p51) binds cooperatively to the ETS-binding site palindrome of the human stromelysin-1 promoter, with facilitated binding of the second ETS-1 molecule to form an ETS-1.DNA.ETS-1 ternary complex. The study of N-terminal deletion mutants allowed us to conclude that cooperative binding implied autoinhibition counteraction, requiring the 245-330-residue region of the protein that is encoded by exon VII of the gene. This region was deleted in the natural p42 isoform of ETS-1, which was unable to bind cooperatively to the palindrome. Transient transfection experiments showed a good correlation between DNA binding and promoter transactivation for p51. In contrast, p42 showed a poorer transactivation, reinforcing the significance of cooperative binding for full transactivation. It is the first time that ETS-1 was shown to be able to counteract its own autoinhibition.	Inst Pasteur, CNRS UMR 8526, Inst Biol, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Aumercier, M (corresponding author), Inst Pasteur, CNRS UMR 8526, Inst Biol, BP 447,1 Rue Calmette, F-59021 Lille, France.	marc.aumercier@ibl.fr		Aumercier, Marc/0000-0002-0370-3452				Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; Cowley DO, 2000, GENE DEV, V14, P366; COWLEY DO, 2000, THESISU UTAH; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodge DR, 1996, ONCOGENE, V12, P11; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Liu ZW, 2001, INT J CANCER, V91, P638, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1102>3.0.CO;2-Y; Malemud Charles J., 1999, Frontiers in Bioscience, V4, pd762; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Naito T, 2000, J AM SOC NEPHROL, V11, P2243, DOI 10.1681/ASN.V11122243; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; OD AN, 1999, J CELL PHYSL, V178, P121; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Rekdal C, 2000, J BIOL CHEM, V275, P40288, DOI 10.1074/jbc.M006978200; SETH A, 1993, ONCOGENE, V8, P1783; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sternlicht MD, 1999, GUIDEBOOK EXTRACELLU, P505; Sun HB, 2001, BONE, V28, P303, DOI 10.1016/S8756-3282(00)00454-3; Tian G, 1999, MOL CELL BIOL, V19, P2946; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNERT N, 1994, CANCER RES, V54, P5683; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Yoshiyama Y, 2000, ACTA NEUROPATHOL, V99, P91, DOI 10.1007/PL00007428; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	60	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29386	29398		10.1074/jbc.M200088200	http://dx.doi.org/10.1074/jbc.M200088200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034715	hybrid			2022-12-25	WOS:000177509300007
J	Koizumi, S; Rosa, P; Willars, GB; Challiss, RAJ; Taverna, E; Francolini, M; Bootman, MD; Lipp, P; Inoue, K; Roder, J; Jeromin, A				Koizumi, S; Rosa, P; Willars, GB; Challiss, RAJ; Taverna, E; Francolini, M; Bootman, MD; Lipp, P; Inoue, K; Roder, J; Jeromin, A			Mechanisms underlying the neuronal calcium sensor-1-evoked enhancement of exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ SENSOR 1; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+-BINDING PROTEIN; CHROMAFFIN CELLS; BINDING-PROTEIN; CHANNELS; FREQUENIN; RELEASE; ELEMENTARY; MEMBRANE	Neuronal calcium sensor-1 (NCS-1) or the originally identified homologue frequenin belongs to a superfamily of EF-hand calcium binding proteins. Although NCS-1 is thought to enhance synaptic efficacy or exocytosis mainly by activating ion channel function, the detailed molecular basis for the enhancement is still a matter of debate. Here, mechanisms underlying the NCS-1-evoked enhancement of exocytosis were investigated using PC12 cells overexpressing NCS-1. NCS-1 was found to have a broad distribution in the cells being partially distributed in the cytosol and associated to vesicles and tubular-like structures. Biochemical and immunohistochemical studies indicated that NCS-1 partially colocalized with the light synaptic vesicle marker synaptophysin. When stimulated with UTP or bradykinin, agonists to phospholipase C-linked receptors, NCS-1 enhanced the agonist-mediated elementary and global Ca2+ signaling and increased the levels of downstream signals of phosphatidylinositol 4-kinase. NCS-1 enhanced the UTP-evoked exocytosis but not the depolarization-evoked Ca2+ responses or exocytosis, suggesting that the enhancement by NCS-1 should involve phospholipase C-linked receptor-mediated signals rather than the Ca2+ channels or exocytotic machinery per se. Taken together, NCS-1 enhances phosphoinositide turnover, resulting in enhancement of Ca2+ signaling and exocytosis. This is a novel regulatory mechanism of exocytosis that might involve the activation of phosphatidylinositol 4-kinase.	Natl Inst Hlth Sci, Sect Neuropharmacol, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan; Univ Milan, Dept Pharmacol, Inst Neurosci Cellular & Mol Pharmacol, I-20129 Milan, Italy; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	National Institute of Health Sciences - Japan; University of Milan; University of Leicester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Koizumi, S (corresponding author), Natl Inst Hlth Sci, Sect Neuropharmacol, Div Pharmacol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	skoizumi@nihs.go.jp	Bootman, Martin/AAB-3330-2019; Roder, John/G-6468-2013; taverna, elena/O-8180-2014; Challiss, R.A. John/A-9412-2008; Taverna, Elena/AFW-4935-2022; Koizumi, Schuichi/E-8568-2010	Bootman, Martin/0000-0002-6447-3451; taverna, elena/0000-0002-2430-4725; Koizumi, Schuichi/0000-0001-6184-3106; Rosa, Patrizia/0000-0002-2590-6955; FRANCOLINI, MAURA/0000-0002-3126-1575; Challiss, John/0000-0001-5506-2848				Allen RDM, 1997, TRANSPLANTATION, V63, P830, DOI 10.1097/00007890-199703270-00007; APPELL KC, 1989, BIOCHEM J, V263, P11, DOI 10.1042/bj2630011; Bartlett SE, 2000, J NEUROSCI RES, V62, P216, DOI 10.1002/1097-4547(20001015)62:2<216::AID-JNR6>3.0.CO;2-A; Bennett DL, 1998, BIOCHEM J, V329, P349; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Calegari F, 1999, J BIOL CHEM, V274, P22539, DOI 10.1074/jbc.274.32.22539; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CHALLISS RAJ, 1993, NEUROPROTOCOLS, V3, P135; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Iacovelli L, 1999, FASEB J, V13, P1; INOUE K, 1988, J BIOL CHEM, V263, P8157; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; KOIZUMI S, 1995, BRAIN RES, V673, P75, DOI 10.1016/0006-8993(94)01404-6; KOIZUMI S, 1995, BRIT J PHARMACOL, V115, P1502, DOI 10.1111/j.1476-5381.1995.tb16643.x; Koizumi S, 1998, BIOCHEM BIOPH RES CO, V244, P293, DOI 10.1006/bbrc.1998.8251; Koizumi S, 1999, J BIOL CHEM, V274, P33327, DOI 10.1074/jbc.274.47.33327; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Pan CY, 2002, J NEUROSCI, V22, P2427, DOI 10.1523/JNEUROSCI.22-07-02427.2002; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; Rowe J, 1999, J CELL SCI, V112, P1865; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; SMITH SJ, 1993, J PHYSIOL-LONDON, V472, P573, DOI 10.1113/jphysiol.1993.sp019963; Taylor SC, 2000, J NEUROCHEM, V75, P1583, DOI 10.1046/j.1471-4159.2000.0751583.x; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Thomas D, 2000, CELL CALCIUM, V28, P213, DOI 10.1054/ceca.2000.0152; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200	55	77	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30315	30324		10.1074/jbc.M201132200	http://dx.doi.org/10.1074/jbc.M201132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034721	hybrid, Green Published			2022-12-25	WOS:000177509300118
J	Zhao, P; Iezzi, S; Carver, E; Dressman, D; Girdley, T; Sartorelli, V; Hoffman, EP				Zhao, P; Iezzi, S; Carver, E; Dressman, D; Girdley, T; Sartorelli, V; Hoffman, EP			Slug is a novel downstream target of MyoD - Temporal profiling in muscle regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; SATELLITE CELLS; EXPRESSION; GENE; DIFFERENTIATION; WNT; ACTIVATION; MYOGENESIS; ENHANCER	Temporal expression profiling was utilized to define transcriptional regulatory pathways in vivo in a mouse muscle regeneration model. Potential downstream targets of MyoD were identified by temporal expression, promoter data base mining, and gel shift assays; Slug and calpain 6 were identified as novel MyoD targets. Slug, a member of the snail/slug family of zinc finger transcriptional repressors critical for mesoderm/ectoderm development, was further shown to be a downstream target by using promoter/reporter constructs and demonstration of defective muscle regeneration in Slug null mice.	Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; George Washington Univ, Genet Program, Washington, DC 20010 USA; Jackson Lab, Bar Harbor, ME 04609 USA; NIAMS, Muscle Gene Express Grp, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA	Children's National Health System; George Washington University; Jackson Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hoffman, EP (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.	ehoffman@cnmcresearch.org	Iezzi, Simona/AAA-3275-2021	Iezzi, Simona/0000-0002-7484-5861; Hoffman, Eric/0000-0001-6470-5139; Sartorelli, Vittorio/0000-0002-9284-3675	NHLBI NIH HHS [1-U01-HL66614] Funding Source: Medline; NICHD NIH HHS [R01-HD34883] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034883] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041126] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Becker JR, 2001, EXP CELL RES, V267, P135, DOI 10.1006/excr.2001.5249; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chen JCJ, 2001, DEV DYNAM, V221, P274, DOI 10.1002/dvdy.1138; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cohen ME, 1998, GENOMICS, V51, P468, DOI 10.1006/geno.1998.5367; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Coutelle O, 2001, DEV BIOL, V236, P136, DOI 10.1006/dbio.2001.0193; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GRAU Y, 1984, GENETICS, V108, P347; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hirsinger E, 1997, DEVELOPMENT, V124, P4605; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Launay T, 2001, J HISTOCHEM CYTOCHEM, V49, P887, DOI 10.1177/002215540104900709; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Marshall P, 2001, J BIOL CHEM, V276, P20719, DOI 10.1074/jbc.M102100200; Matsuo T, 2000, J BIOL CHEM, V275, P16560, DOI 10.1074/jbc.M001312200; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Montarras D, 2000, BIOL CELL, V92, P565, DOI 10.1016/S0248-4900(00)01110-2; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Polesskaya A, 2001, J BIOL CHEM, V276, P44502, DOI 10.1074/jbc.M106501200; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; Steinbach OC, 2000, BIOL CHEM, V381, P1013, DOI 10.1515/BC.2000.124; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Vallin J, 2001, J BIOL CHEM, V276, P30350, DOI 10.1074/jbc.M103167200; VANDEKLUNDERT FAJM, 1994, J BIOL CHEM, V269, P220; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; White JD, 2000, J HISTOCHEM CYTOCHEM, V48, P1531, DOI 10.1177/002215540004801110; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yablonka-Reuveni Z, 1999, DEV BIOL, V210, P440, DOI 10.1006/dbio.1999.9284; ZHOU JH, 1994, J BIOL CHEM, V269, P18563	53	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30091	30101		10.1074/jbc.M202668200	http://dx.doi.org/10.1074/jbc.M202668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023284	hybrid			2022-12-25	WOS:000177509300092
J	Zhao, Y; Goto, K; Saitoh, M; Yanase, T; Nomura, M; Okabe, T; Takayanagi, R; Nawata, H				Zhao, Y; Goto, K; Saitoh, M; Yanase, T; Nomura, M; Okabe, T; Takayanagi, R; Nawata, H			Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment - Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; AMINO-TERMINAL DOMAIN; HUMAN PROSTATE CELLS; TRANSCRIPTIONAL ACTIVATION; LIVING CELLS; SUBCELLULAR-LOCALIZATION; CYCLIN-E; IN-VIVO; RNA; GENE	In the androgen receptor (AR), most of its transactivation activity is mediated via the activation function-1 (AF-1). By employing yeast two-hybrid assay, we isolated a cDNA sequence encoding a protein binding to AR-AF-1. This protein, named ANT-1 (AR N-terminal domain transactivating protein-1), enhanced the ligand-independent autonomous AF-1 transactivation function of AR or glucocorticoid receptor but did not enhance that of estrogen receptor a. In contrast, the ANT-1 did not enhance any ligand-dependent AF-2 activities. Furthermore, the ligand-independent interaction between AR-AF-1 and ANT-1 was confirmed in vivo and in vitro. The ANT-1 sequence was identical to that of a protein that binds to U5 small nuclear ribonucleoprotein particle, a human homologue of yeast splicing factor Prp6p, involved in spliceosome. ANT-1 was compartmentalized into 20-40 coarse splicing factor compartment speckles against the background of the diffuse reticular distribution. AR colocalized with ANT-1 only in the diffusely distributed area, whereas the ANT-1 speckles were spatially distinct from but surrounded by the AR compartments. The active gene transcription has been shown to couple simultaneously with pre-mRNA processing at the periphery of the splicing factor compartment. The molecular interaction between two spatially distinct subnuclear compartments mediated by ANT-1 may therefore recruit AR into the transcription-splicing-coupling machinery.	Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3, Dept Med & Bioregulatory Sci,Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nawata, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3, Dept Med & Bioregulatory Sci,Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.			Zhao, Yue/0000-0001-8983-0024				Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Alen P, 1999, MOL CELL BIOL, V19, P6085; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Makarov EM, 2000, J MOL BIOL, V298, P567, DOI 10.1006/jmbi.2000.3685; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; Misteli T, 2000, J CELL SCI, V113, P1841; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nishikimi A, 1999, BBA-PROTEIN STRUCT M, V1435, P147, DOI 10.1016/S0167-4838(99)00203-4; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park JJ, 2000, CANCER RES, V60, P5946; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	65	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30031	30039		10.1074/jbc.M203811200	http://dx.doi.org/10.1074/jbc.M203811200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039962	hybrid			2022-12-25	WOS:000177509300085
J	You, M; Fischer, M; Deeg, MA; Crabb, DW				You, M; Fischer, M; Deeg, MA; Crabb, DW			Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLIC LIVER-DISEASE; ACETALDEHYDE ADDUCT; MAMMALIAN-CELLS; HEPATOMA-CELLS; BETA-OXIDATION; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PATHOGENESIS; CHOLESTEROL	Alcoholic fatty liver is the earliest and most common response of the liver to alcohol and may be a precursor of more severe forms of liver injury. The mechanism by which ethanol causes fatty liver and liver injury is complex. We found that in both rat H4IIEC3 and McA-RH7777 hepatoma cell lines, ethanol induced transcription of a sterol regulatory element-binding protein (SREBP)-regulated promoter via increased levels of mature SREBP-1 protein. This effect of ethanol was blocked by addition of sterols. This effect is likely mediated by acetaldehyde, because the effect was only seen in cell lines expressing alcohol dehydrogenase, and inhibition of ethanol oxidation by 4-methylpyrazole blocked the effect in the hepatoma cells. Furthermore, the aldehyde dehydrogenase inhibitor cyanamide enhanced the effect of ethanol in the hepatoma cells. Consistent with these in vitro findings, feeding mice a low fat diet with ethanol for 4 weeks resulted in a significant increase in steady-state levels of the mature (active) form of SREBP-1. Activation of SREBP-1 by ethanol feeding was associated with increased expression of hepatic lipogenic genes as well as the accumulation of triglyceride in the livers. These finding suggest that metabolism of ethanol increased hepatic lipogenesis by activating SREBP-1 and that this effect of ethanol may contribute to the development of alcoholic fatty liver.	Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	You, M (corresponding author), Vet Adm Res 151, 3rd Floor D-3035,1481 W 10th St, Indianapolis, IN 46202 USA.	miyou@iupui.edu	You, Min/I-4973-2012	You, Min/0000-0003-1977-3479	NIAAA NIH HHS [AA06463, AA07611] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007611, P60AA007611] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARAKAWA M, 1975, J NUTR, V105, P1500, DOI 10.1093/jn/105.12.1500; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carrasco MP, 2001, LIFE SCI, V68, P1295, DOI 10.1016/S0024-3205(00)01035-3; Crabb D W, 1993, Recent Dev Alcohol, V11, P207; Crabb David W., 1999, Keio Journal of Medicine, V48, P184; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; Crabb DW, 1995, ALCOHOL CLIN EXP RES, V19, P1414, DOI 10.1111/j.1530-0277.1995.tb01000.x; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Diehl AM, 2001, ALCOHOL CLIN EXP RES, V25, p8S, DOI 10.1111/j.1530-0277.2001.tb02368.x; Galli A, 1999, HEPATOLOGY, V29, P1164, DOI 10.1002/hep.510290420; Galli A, 2001, J BIOL CHEM, V276, P68, DOI 10.1074/jbc.M008791200; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GRUNNET N, 1986, ALCOHOL CLIN EXP RES, V10, pS64, DOI 10.1111/j.1530-0277.1986.tb05182.x; Grunnet N, 1987, Alcohol Alcohol Suppl, V1, P257; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; JOLY JG, 1973, J LIPID RES, V14, P337; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; Kotzka J, 2000, J LIPID RES, V41, P99; Kurose I, 1996, ALCOHOL CLIN EXP RES, V20, pA77, DOI 10.1111/j.1530-0277.1996.tb01736.x; Li CJ, 1997, HEPATOLOGY, V26, P650, DOI 10.1002/hep.510260317; LIEBER CS, 1989, HEPATOLOGY, V10, P501, DOI 10.1002/hep.1840100417; LIEBER CS, 1966, J CLIN INVEST, V45, P51, DOI 10.1172/JCI105323; LIN RC, 1989, HEPATOLOGY, V10, P807, DOI 10.1002/hep.1840100510; Lin RC, 1998, HEPATOLOGY, V27, P100, DOI 10.1002/hep.510270117; MURAMATSU M, 1981, JPN J PHARMACOL, V31, P931, DOI 10.1254/jjp.31.931; Nanji A. A., 1996, HEPATOLOGY TXB LIVER, P911; Naveau S, 1997, HEPATOLOGY, V25, P108, DOI 10.1002/hep.510250120; Nguyen VAT, 2000, BIOCHEM J, V349, P427, DOI 10.1042/0264-6021:3490427; RAO GA, 1985, LIPIDS, V20, P531, DOI 10.1007/BF02534894; Reddy MA, 1996, BIOCHEM PHARMACOL, V51, P661, DOI 10.1016/S0006-2952(95)02239-2; REDDY MA, 2000, BIOCHIM BIOPHYS ACTA, V149, P271; REINKE LA, 1987, P NATL ACAD SCI USA, V84, P9223, DOI 10.1073/pnas.84.24.9223; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; SALASPURO MP, 1981, HEPATOLOGY, V1, P33, DOI 10.1002/hep.1840010106; SEITZ HK, 1994, HEPATOLOGY, V20, P487; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Siler SQ, 1999, AM J CLIN NUTR, V70, P928; SMITH SL, 1989, J CLIN INVEST, V84, P337, DOI 10.1172/JCI114159; Spurway TD, 1997, BIOCHEM J, V323, P119, DOI 10.1042/bj3230119; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; TSUKAMOTO H, 1984, LIPIDS, V19, P419, DOI 10.1007/BF02537403; Tuma DJ, 1996, HEPATOLOGY, V23, P872, DOI 10.1002/hep.510230431; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yang SQ, 2001, AM J PHYSIOL-GASTR L, V281, pG382, DOI 10.1152/ajpgi.2001.281.2.G382; Zhu YY, 1996, HEPATOLOGY, V23, P115, DOI 10.1053/jhep.1996.v23.pm0008550030	49	375	394	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29342	29347		10.1074/jbc.M202411200	http://dx.doi.org/10.1074/jbc.M202411200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036955	hybrid			2022-12-25	WOS:000177342600124
J	Lee, D; Kim, HZ; Jeong, KW; Shim, YS; Horikawa, I; Barrett, JC; Choe, J				Lee, D; Kim, HZ; Jeong, KW; Shim, YS; Horikawa, I; Barrett, JC; Choe, J			Human papillomavirus E2 down-regulates the human telomerase reverse transcriptase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-CELLS; BOVINE PAPILLOMAVIRUS; CATALYTIC SUBUNIT; DNA-REPLICATION; GENE-PRODUCT; TUMOR-CELLS; HTERT GENE; TYPE-16 E6; C-MYC; PROTEIN	The transcriptional regulation of the human telomerase reverse transcriptase (hTERT) gene is a critical step in transformation and differentiation. Human papillomavirus E2 protein inhibits cell growth in HPV-infected cells and triggers apoptosis in HeLa cells. Because E2 induces cell growth suppression and senescence, we hypothesize that the protein may modulate cellular gene expression related to these processes. In this report, we demonstrate that E2 inhibits the hTERT promoter. The mapping of the E2-responsive region of hTERT reveals that Sp1 is important for E2-mediated repression of this promoter in 293T cells. Site-directed mutagenesis data on the hTERT promoter show that E2 does not abolish E-Box-mediated transcription and represses promoter activity via the Sp1 binding site. Furthermore, chromatin immunoprecipitation assays indicate that E2 is actively recruited to the hTERT promoter region. Our findings provide novel insights into the biological function of human papillomavirus E2.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; NCI, Lab Biosyst & Canc, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Korea Advanced Institute of Science & Technology (KAIST); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Choe, Joonho/F-3066-2011; Lee, Daeyoup/C-1653-2011	Lee, Daeyoup/0000-0003-2006-1823				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Horikawa I, 1999, CANCER RES, V59, P826; Howley P. M., 1996, FIELDS VIROLOGY; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; LUSKY M, 1993, J BIOL CHEM, V268, P15795; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Szatmari I, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.2.e3; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	49	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27748	27756		10.1074/jbc.M203706200	http://dx.doi.org/10.1074/jbc.M203706200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12019268	hybrid			2022-12-25	WOS:000177189800023
J	Wu, DY; Tkachuck, DC; Roberson, RS; Schubach, WH				Wu, DY; Tkachuck, DC; Roberson, RS; Schubach, WH			The human SNF5/INI1 protein facilitates the function of the growth arrest and DNA damage-inducible protein (GADD34) and modulates GADD34-bound protein phosphatase-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWI-SNF COMPLEX; HERPES-SIMPLEX VIRUS; MAMMALIAN-CELLS; REGULATORY SUBUNIT; NUCLEAR; GENE; TRANSCRIPTION; BINDING; FAMILY; HSNF5/INI1	The growth arrest and DNA damage-inducible protein (GADD34) mediates growth arrest and apoptosis in response to DNA damage, negative growth signals, and protein malfolding. GADD34 binds to protein phosphatase-1 (PP1) and can attenuate translational elongation of key transcriptional factors through dephosphorylation of eukaryotic initiation factor-2alpha. We reported previously that the human trithorax leukemia fusion protein (HRX) can bind to GADD34 and abrogate GADD34-mediated apoptosis in response to UV irradiation. We found that hSNF5/INI1, a component of the hSWI/SNF chromatin remodeling complex, also binds to GADD34 and can coexist with GADD34 and HRX fusion proteins as a trimolecular complexes in vivo. In the present report, we demonstrate that hSNF5/INI1 binds to GADD34 in part through the PP1 docking site within a domain homologous to herpes simplex virus-1 ICP34.5. We found that hSNF5/INI1 can bind PP1 independently and weakly stimulate its phosphatase activity in solution and in complex with GADD34. hSNF5/INI1 and PP1 do not compete for binding to GADD34 but rather form a stable heterotrimeric complex with GADD34. We also show that :Epstein-Barr nuclear protein 2, which binds hSNF5/INI1, can disrupt hSNF5/INI1 binding to GADD34 and partially reverse the GADD34-mediated growth suppression function in Ha-ras expressing HIH-3T3 (3T3-ras) cells. These results implicate hSNF5/INI1 in the function of GADD34 and suggest that hSNF5/INI1 may regulate PP1 activity in vivo.	Vet Adm Puget Sound Hlth Care Syst, Div Oncol, Dept Pathol, Seattle Div, Seattle, WA 98108 USA; Vet Adm Puget Sound Hlth Care Syst, Dept Med, Div Med Oncol, Seattle Div, Seattle, WA 98108 USA; Univ Washington, Med Ctr, Dept Med, Div Med Oncol, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wu, DY (corresponding author), Vet Adm Puget Sound Hlth Care Syst, Div Oncol, Dept Pathol, Seattle Div, 111-ONC,1660 S Columbian Way, Seattle, WA 98108 USA.				NCI NIH HHS [5K08CA71928-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA071928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Boyer LA, 2000, J BIOL CHEM, V275, P11545, DOI 10.1074/jbc.275.16.11545; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Cassady KA, 1998, J VIROL, V72, P7005; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG G, 2001, J VIROL, V75, P3686; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; GOW J, 1988, LEUKEMIA RES, V12, P805, DOI 10.1016/0145-2126(88)90033-1; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Hainaut P, 2000, B CANCER, V87, P11; Hardie D. G., 1993, PROTEIN PHOSPHORYLAT; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hasegawa T, 1999, BBA-GEN SUBJECTS, V1428, P161, DOI 10.1016/S0304-4165(99)00060-4; Hasegawa T, 2000, BIOCHEM BIOPH RES CO, V267, P593, DOI 10.1006/bbrc.1999.1991; Hasegawa T, 2000, BIOCHEM J, V352, P795, DOI 10.1042/0264-6021:3520795; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; Hollander MC, 2001, INT J CANCER, V96, P22, DOI 10.1002/1097-0215(20010220)96:1<22::AID-IJC3>3.0.CO;2-K; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Jagiello I, 2000, J CELL SCI, V113, P3761; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kempkes B, 1996, J GEN VIROL, V77, P227, DOI 10.1099/0022-1317-77-2-227; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; NOVCA I, 2001, J CELL BIOL, V153, P1011; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Samuel CE, 1997, INT J HEMATOL, V65, P227; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sood R, 2000, GENETICS, V154, P787; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	60	35	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27706	27715		10.1074/jbc.M200955200	http://dx.doi.org/10.1074/jbc.M200955200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12016208	hybrid			2022-12-25	WOS:000177189800018
J	Wu, JJP; Guidotti, G				Wu, JJP; Guidotti, G			Construction and characterization of a monomeric insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I DISULFIDES; SIGNAL TRANSDUCTION; STRUCTURAL REQUIREMENTS; DEPENDENT COVALENT; KINASE-ACTIVITY; SUBUNIT; ACTIVATION; COMPLEX; BONDS; IDENTIFICATION	A mutant insulin receptor was constructed by replacing cysteine residues Cys(524), Cys(682), Cys(683), and Cys(685) with serine. The mutant was expressed in COS7 and Chinese hamster ovary cells, did not form covalently linked dimers, and was present at the cell surface. There was half as much insulin binding activity at the cell surface in cells expressing the mutant compared with that in cells expressing the wild type receptor. The intracellular processing of the mutant receptor was affected, since its beta-subunit migrated more slowly than that of the wild type receptor on SDS-PAGE. The mutant was capable of insulin-dependent autophosphorylation and phosphorylation of insulin receptor substrate-1 in vivo and could be cross-linked into receptor dimers when membrane-bound. The amount of insulin-dependent autophosphorylation of the mutant receptor was half that of the wild type receptor. However, after solubilization the monomeric insulin receptor had minimal autophosphorylation activity, and, unlike the naturally occurring monomeric receptor tyrosine kinases, the solubilized monomeric insulin receptor did not dimerize in response to insulin binding as determined by sucrose density gradient centrifugation.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wu, JJP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIDDK NIH HHS [DK27626] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027626] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYER RA, 1983, J BIOL CHEM, V258, P4992; Baer K, 2001, BIOCHEMISTRY-US, V40, P14268, DOI 10.1021/bi015588g; BILAN PJ, 1994, BIOCHEM BIOPH RES CO, V205, P1891, DOI 10.1006/bbrc.1994.2891; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHIACCHIA KB, 1988, BIOCHEMISTRY-US, V27, P4894, DOI 10.1021/bi00413a046; CHIACCHIA KB, 1991, BIOCHEM BIOPH RES CO, V176, P1178, DOI 10.1016/0006-291X(91)90409-Z; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; FLORKE RR, 1990, EUR J BIOCHEM, V191, P473, DOI 10.1111/j.1432-1033.1990.tb19146.x; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; LEVITZKI A, 1981, NATURE, V289, P442, DOI 10.1038/289442a0; Lu KH, 1996, MOL BIOL CELL, V7, P679, DOI 10.1091/mbc.7.5.679; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; MASSAGUE J, 1982, J BIOL CHEM, V257, P6729; MORRISON BD, 1988, J BIOL CHEM, V263, P7806; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILDEN PA, 1989, BIOCHEMISTRY-US, V28, P785, DOI 10.1021/bi00428a056; [No title captured]	26	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27809	27817		10.1074/jbc.M200367200	http://dx.doi.org/10.1074/jbc.M200367200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023954	hybrid, Green Published			2022-12-25	WOS:000177189800030
J	Wu, N; Pai, EF				Wu, N; Pai, EF			Crystal structures of inhibitor complexes reveal an alternate binding mode in orotidine-5 '-monophosphate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OROTIDINE 5'-MONOPHOSPHATE DECARBOXYLASE; TRANSITION-STATE ANALOG; PROFICIENT ENZYME; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; MONOPHOSPHATE DECARBOXYLASE; 5'-PHOSPHATE DECARBOXYLASE; ACTIVE-SITE; X-RAY; MECHANISM; CATALYSIS	The crystal structures of the enzyme orotidine-5'-monophosphate decarboxylase from Methanobacterium thermoautotrophicum complexed with its product UMP and the inhibitors 6-hydroxyuridine 5'-phosphate (BMP), XMP, and CMP are reported. A mutant version of the protein, in which four residues of the flexible phosphate-binding loop (180)Gly-Gly(190) were removed and Arg(203) was replaced by alanine, was also analyzed. The XMP and CMP complexes reveal a ligand-binding mode that is distinct from the one identified previously with the aromatic rings located outside the binding pocket. A potential pathway for ligand binding is discussed.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Protein Engn Network, Ctr Excellence, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Pai, EF (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.		Hu, Ruogu/B-2203-2008; Pai, Emil F/D-2526-2013; Pai, Emil/R-8908-2019	Pai, Emil/0000-0002-1162-7242	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; Appleby TC, 2000, P NATL ACAD SCI USA, V97, P2005, DOI 10.1073/pnas.259441296; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1998, SPOCK; Feng WY, 2000, BIOCHEMISTRY-US, V39, P1778, DOI 10.1021/bi992553w; Harris P, 2000, BIOCHEMISTRY-US, V39, P4217, DOI 10.1021/bi992952r; Houk KN, 2001, CHEMBIOCHEM, V2, P113, DOI 10.1002/1439-7633(20010202)2:2<113::AID-CBIC113>3.3.CO;2-K; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller BG, 2000, BIOCHEMISTRY-US, V39, P8113, DOI 10.1021/bi000818x; Miller BG, 1999, J BIOL CHEM, V274, P23841, DOI 10.1074/jbc.274.34.23841; Miller BG, 2000, P NATL ACAD SCI USA, V97, P2011, DOI 10.1073/pnas.030409797; Miller BG, 2001, J BIOL CHEM, V276, P15174, DOI 10.1074/jbc.M011429200; Miller BG, 2001, BIOCHEMISTRY-US, V40, P6227, DOI 10.1021/bi0028993; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Rishavy MA, 2000, BIOCHEMISTRY-US, V39, P4569, DOI 10.1021/bi000376p; Rouhi AM, 2000, CHEM ENG NEWS, V78, P42, DOI 10.1021/cen-v078n011.p042; SAENGER W, 1973, ANGEW CHEM INT EDIT, V12, P591, DOI 10.1002/anie.197305911; Smiley JA, 1999, BIOORG CHEM, V27, P297, DOI 10.1006/bioo.1999.1140; Warshel A, 2001, CHEMBIOCHEM, V2, P109, DOI 10.1002/1439-7633(20010202)2:2<109::AID-CBIC109>3.0.CO;2-9; Wright DA, 1997, NUCLEIC ACIDS RES, V25, P2679, DOI 10.1093/nar/25.13.2679; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Wu N, 2002, BIOCHEMISTRY-US, V41, P4002, DOI 10.1021/bi015758p; Wu N, 2000, ACTA CRYSTALLOGR D, V56, P912, DOI 10.1107/S090744490000576X	27	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28080	28087		10.1074/jbc.M202362200	http://dx.doi.org/10.1074/jbc.M202362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011084	hybrid			2022-12-25	WOS:000177189800064
J	Hryb, DJ; Nakhla, AM; Kahn, SM; St George, J; Levy, NC; Romas, NA; Rosner, W				Hryb, DJ; Nakhla, AM; Kahn, SM; St George, J; Levy, NC; Romas, NA; Rosner, W			Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; ANDROGEN RECEPTOR; STEROID-HORMONES; BREAST-CANCER; SHBG GENE; PROTEIN; PLASMA; TESTOSTERONE; ACCUMULATION; CARCINOMA	Sex hormone-binding globulin (SHBG) is a plasma protein synthesized and secreted by the liver. Its initial description stemmed from its ability to bind estrogens and androgens and its capacity to regulate the free concentration of the steroids that bind to it. Additionally, it participates in signal transduction for certain steroid hormones at the cell membrane. It binds with high affinity to a specific membrane receptor (R-SHBG) in prostate stromal and epithelial cells, wherein the SHBG(.)R(SHBG) complex forms. An appropriate steroid binds to this complex and results in increases of intracellular cAMP. These two disparate functions of SHBG, regulation of the concentration of free steroids in plasma and signal transduction in selected tissues, raise the question of how its synthesis and secretion might be regulated so as to best perform these two disparate functions. In this paper we demonstrate that SHBG is produced in human prostate cancer cell lines (LNCaP, DU 145, and PC 3) as well as in cultured human prostate epithelial and stromal cells. In addition, in tissue sections of human prostate, we demonstrate the presence of SHBG (immunocytochemistry) and SHBG mRNA (in situ hybridization). These observations are consistent with the hypothesis that SHBG, destined to participate in signaling at the cell membrane, is locally regulated and produced.	Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Med, New York, NY 10019 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Urol, New York, NY 10019 USA; Columbia Univ, Coll Phys & Surg, New York, NY 10019 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University	Rosner, W (corresponding author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, Dept Med, New York, NY 10019 USA.			Levy-Carrick, Nomi/0000-0002-9576-2600				Avvakumov GV, 2001, J BIOL CHEM, V276, P34453, DOI 10.1074/jbc.M106274200; BORDIN S, 1980, P NATL ACAD SCI-BIOL, V77, P5678, DOI 10.1073/pnas.77.10.5678; COWAN RA, 1976, J ENDOCRINOL, V71, P121, DOI 10.1677/joe.0.0710121; DEJONG FH, 1991, CANCER RES, V51, P3445; DENNIS M, 1977, ACTA ENDOCRINOL-COP, V84, P207, DOI 10.1530/acta.0.0840207; Ding VDH, 1998, ENDOCRINOLOGY, V139, P213, DOI 10.1210/en.139.1.213; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Eaton NE, 1999, BRIT J CANCER, V80, P930, DOI 10.1038/sj.bjc.6690445; FISSORE F, 1994, STEROIDS, V59, P661, DOI 10.1016/0039-128X(94)90023-X; Fortunati N, 1999, J STEROID BIOCHEM, V69, P473, DOI 10.1016/S0960-0760(99)00068-0; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; GERSHAGEN S, 1989, NUCLEIC ACIDS RES, V17, P9245, DOI 10.1093/nar/17.22.9245; GRASSO M, 1990, CANCER, V66, P354, DOI 10.1002/1097-0142(19900715)66:2<354::AID-CNCR2820660225>3.0.CO;2-N; HAMMOND GL, 1987, FEBS LETT, V215, P100, DOI 10.1016/0014-5793(87)80121-7; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; Heikkila R, 1999, CANCER, V86, P312, DOI 10.1002/(SICI)1097-0142(19990715)86:2<312::AID-CNCR15>3.3.CO;2-Z; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JOSEPH DR, 1991, J STEROID BIOCHEM, V40, P771, DOI 10.1016/0960-0760(91)90302-L; JOSEPH DR, 1994, VITAM HORM, V49, P197; KABALIN JN, 1989, PROSTATE, V14, P251, DOI 10.1002/pros.2990140306; KHAN MS, 1982, J CLIN ENDOCR METAB, V54, P705, DOI 10.1210/jcem-54-4-705; KHAN MS, 1981, J CLIN ENDOCR METAB, V53, P448, DOI 10.1210/jcem-53-2-448; KRIEG M, 1977, ACTA ENDOCRINOL-COP, V86, P200, DOI 10.1530/acta.0.0860200; KRIEG M, 1984, PROGR CANCER RES THE, V31, P425; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lewis JG, 1999, STEROIDS, V64, P259, DOI 10.1016/S0039-128X(98)00119-6; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; MENDEL CM, 1992, J ANDROL, V13, P107; Nakhla AM, 1997, J BIOL CHEM, V272, P6838, DOI 10.1074/jbc.272.11.6838; NAKHLA AM, 1995, J CLIN ENDOCR METAB, V80, P2259, DOI 10.1210/jc.80.7.2259; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; Nakhla AM, 1999, STEROIDS, V64, P213, DOI 10.1016/S0039-128X(98)00084-1; NAKHLA AM, 1990, J CLIN ENDOCR METAB, V71, P398, DOI 10.1210/jcem-71-2-398; NAKHLA AM, 1994, STEROIDS, V59, P586, DOI 10.1016/0039-128X(94)90052-3; Noe G, 1999, J STEROID BIOCHEM, V68, P111, DOI 10.1016/S0960-0760(99)00026-6; PEEHL DM, 1995, WORLD J UROL, V13, P312; PORTO CS, 1991, ENDOCRINOLOGY, V129, P436, DOI 10.1210/endo-129-1-436; ROSNER W, 1984, J CLIN ENDOCR METAB, V59, P806, DOI 10.1210/jcem-59-4-806; Rosner W, 1998, STEROIDS, V63, P278, DOI 10.1016/S0039-128X(98)00017-8; ROSNER W, 1992, J ANDROL, V13, P101; ROSNER W, 1986, BINDING PROTEINS STE; ROSNER W, 1996, REPROD ENDOCRINOLOGY, P605; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; SINNECKER G, 1990, HORM METAB RES, V22, P47, DOI 10.1055/s-2007-1004847; Sinnecker G, 1988, Steroids, V52, P335, DOI 10.1016/0039-128X(88)90134-1; SULLIVAN PM, 1993, MOL ENDOCRINOL, V7, P702, DOI 10.1210/me.7.5.702; USUI T, 1983, UROL INT, V38, P16, DOI 10.1159/000280854	47	58	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26618	26622		10.1074/jbc.M202495200	http://dx.doi.org/10.1074/jbc.M202495200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12015315	hybrid			2022-12-25	WOS:000176908700103
J	Kubota, N; Terauchi, Y; Yamauchi, T; Kubota, T; Moroi, M; Matsui, J; Eto, K; Yamashita, T; Kamon, J; Satoh, H; Yano, W; Froguel, P; Nagai, R; Kimura, S; Kadowaki, T; Noda, T				Kubota, N; Terauchi, Y; Yamauchi, T; Kubota, T; Moroi, M; Matsui, J; Eto, K; Yamashita, T; Kamon, J; Satoh, H; Yano, W; Froguel, P; Nagai, R; Kimura, S; Kadowaki, T; Noda, T			Disruption of adiponectin causes insulin resistance and neointimal formation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN; OBESITY; MICE; EXPRESSION; ADIPOSE	The adipocyte-derived hormone adiponectin has been proposed to play important roles in the regulation of energy homeostasis and insulin sensitivity, and it has been reported to exhibit putative antiatherogenic properties in vitro. In this study we generated adiponectin-deficient mice to directly investigate whether adiponectin has a physiological protective role against diabetes and atherosclerosis in vivo. Heterozygous adiponectin-deficient (adipo(+/-)) mice showed mild insulin resistance, while homozygous adiponectin-deficient (adipo(-/-)) mice showed moderate insulin resistance with glucose intolerance despite body weight gain similar to that of wild-type mice. Moreover, adipo(-/-) mice showed 2-fold more neointimal formation in response to external vascular cuff injury than wild-type mice (p = 0.01). This study provides the first direct evidence that adiponectin plays a protective role against insulin resistance and atherosclerosis in vivo.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo 1138655, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Dis, Tokyo 1138655, Japan; Lille Pasteur Inst, F-59000 Lille, France; Lille Inst Biol, CNRS 8090, F-59000 Lille, France; Toho Univ, Ohashi Hosp, Sch Med, Dept Internal Med 3, Tokyo 1530044, Japan	University of Tokyo; Tohoku University; Japanese Foundation for Cancer Research; University of Tokyo; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Toho University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo 1138655, Japan.		Kubota, Naoto/N-7892-2015; FROGUEL, Philippe/O-6799-2017; Terauchi, Yasuo/AAO-4347-2020	FROGUEL, Philippe/0000-0003-2972-0784; Yano, Wataru/0000-0002-6866-8520	MRC [G0000477] Funding Source: UKRI; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Minowa O, 1999, SCIENCE, V285, P1408, DOI 10.1126/science.285.5432.1408; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; REAVEN GM, 1995, DIABETOLOGIA, V38, P3, DOI 10.1007/BF02369347; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	19	1077	1199	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25863	25866		10.1074/jbc.C200251200	http://dx.doi.org/10.1074/jbc.C200251200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12032136	hybrid			2022-12-25	WOS:000176908700007
J	Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K				Gounari, F; Signoretti, S; Bronson, R; Klein, L; Sellers, WR; Kum, J; Siermann, A; Taketo, MM; von Boehmer, H; Khazaie, K			Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia	ONCOGENE			English	Article						beta-catenin; prostate; neoplasia; metaplasia	COLORECTAL-CANCER; APC GENE; MAMMARY-GLAND; MICE; CELLS; EXPRESSION; MUTATIONS; POLYPOSIS; ACTIVATION; CARCINOMA	The present study documents that stabilization of beta-catenin is sufficient to induce lesions reminiscent of prostate intraepithelial neoplasia (PIN). Such lesions were present in all compound mutant mice and all prostate acini expressing stabilized beta-catenin. High grade PIN-like lesions resembling early human prostate cancer were detected as early as 10 weeks of age. Surprisingly, stabilization of beta-catenin in other secretory epithelia including salivary, preputial, harderian, and mammary glands induced extensive squamous metaplasia and keratinization associated with terminal differentiation of the target cells, but failed to cause neoplastic transformation. Epidermal hyperplasia, hair follicle cysts, and odontomas were also observed. The prostatic lesions exhibited upregulation of c-myc, increased rate of cellular proliferation, loss of the Na-K-Cl co-transporter NKCC1, and expression of androgen receptor. Basal cell markers such as p63 and keratin 5 were not expressed by the masses of PIN-like lesions, but were present in small foci of proliferating beta-catenin expressing basal cells. Our observations indicate that beta-catenin stabilization is a crucial event for the initiation of PIN-like lesions, but induces squamous metaplasia rather than tumorigenesis in secretory epithelia other than the prostate.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kyoto University	Khazaie, K (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Klein, Ludger/G-8785-2011	Klein, Ludger/0000-0003-2054-071X				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Davies G, 2000, J UROLOGY, V163, P985, DOI 10.1016/S0022-5347(05)67869-X; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hayward SW, 1996, ACTA ANAT, V155, P81; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; IOZZO RV, 1995, CANCER RES, V55, P3495; KHAZAIE K, 1994, P NATL ACAD SCI USA, V91, P7430, DOI 10.1073/pnas.91.16.7430; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; LAU W, 2001, NAT GENET, V28, P3; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; LUONGO C, 1994, CANCER RES, V54, P5947; MagiGalluzzi C, 1997, MODERN PATHOL, V10, P839; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Miyoshi K, 2001, GENOMICS, V71, P150, DOI 10.1006/geno.2000.6433; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULHOLLAND DJ, 2002, J BIOL CHEM, V20, P20; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; Rashid MG, 2001, CANCER RES, V61, P489; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sparks AB, 1998, CANCER RES, V58, P1130; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; SUNDBERG JP, 2000, COLON CANC STUDY SEC; SUZUKI H, 1994, JPN J CANCER RES, V85, P847, DOI 10.1111/j.1349-7006.1994.tb02957.x; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Watanabe M, 1996, JPN J CLIN ONCOL, V26, P77, DOI 10.1093/oxfordjournals.jjco.a023188; YANG F, 2002, J BIOL CHEM, V15, P15	47	88	92	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4099	4107		10.1038/sj.onc.1205562	http://dx.doi.org/10.1038/sj.onc.1205562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037666				2022-12-25	WOS:000176186000004
J	Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y				Lin, YM; Furukawa, Y; Tsunoda, T; Yue, CT; Yang, KC; Nakamura, Y			Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas	ONCOGENE			English	Article						colon cancer; adenoma-carcinoma sequence; cDNA microarray; expression profile	CDNA MICROARRAY; CANCER-CELLS; HYPOXIA; IDENTIFICATION; CARCINOGENESIS; RIBOSOME	Most colon cancers are thought to develop through the 'adenoma-to-carcinoma sequence' model. To elucidate the mechanisms underlying this pathway, we analysed gene-expression profiles of 20 colorectal tumors (nine adenomas and 11 differentiated adenocarcinomas) by means of a cDNA microarray representing 23 040 genes coupled with laser-capture micro dissection. A two-dimensional hierarchical clustering analysis of expression profiles of the 20 tumors correctly separated the carcinoma group from the adenoma group. Furthermore we identified 51 genes whose expression was commonly up-regulated, 376 that were commonly down-regulated in both types of tumors as opposed to normal colonic epithelium and 50 whose expression levels were significantly different between adenomas and carcinomas. On the basis of expression profiles of the 50 discriminating genes, we established a scoring system to separate adenomas from carcinomas. Application of this scoring system for evaluating five additional colorectal tumors correctly predicted their histological features. The genome-wide information reported here should contribute to a more profound understanding of colorectal tumorigenesis, particularly of adenoma-carcinoma progression, and provide indicators for developing novel strategies to diagnose, treat, and ultimately prevent colorectal carcinomas.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Taipei 11160, Taiwan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Shin Kong Wu Ho Su Memorial Hospital; RIKEN	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918				Afshari CA, 1999, CANCER RES, V59, P4759; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CHU FF, 1993, J BIOL CHEM, V268, P2571; Denko N, 2000, CLIN CANCER RES, V6, P480; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hoeren FU, 1998, GENETICS, V149, P479; Kallioniemi OP, 2001, ANN MED, V33, P142, DOI 10.3109/07853890109002069; Kitahara O, 2001, CANCER RES, V61, P3544; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Maguire BA, 2001, CELL, V104, P813, DOI 10.1016/S0092-8674(01)00278-1; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; Notterman DA, 2001, CANCER RES, V61, P3124; Ogiso Y, 1999, BIOCHEM BIOPH RES CO, V258, P448, DOI 10.1006/bbrc.1999.0635; Okabe H, 2001, CANCER RES, V61, P2129; Ono K, 2000, CANCER RES, V60, P5007; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815	22	157	172	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4120	4128		10.1038/sj.onc.1205518	http://dx.doi.org/10.1038/sj.onc.1205518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037668				2022-12-25	WOS:000176186000006
J	Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O				Yang, K; Lui, WO; Xie, YT; Zhang, AJ; Skytting, B; Mandahl, N; Larsson, C; Larsson, O			Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX; double fusion; double translocation	SYT; GENES; SSX; TRANSLOCATION; IDENTIFICATION; TRANSCRIPT; PROTEINS; VARIANT; TUMORS	The chromosomal translocation t(X;18)(p11.2;q11.2) is tightly linked to the tumorigenesis of synovial sarcoma. Through this translation the SYT gene on chromosome 18 is fused with a testis/cancer antigen gene on the X chromosome, generating either a SYT-SSX1, SYT-SSX2, or less often a SYT-SSX4 fusion gene. It has been anticipated that the individual synovial sarcoma carries only one of these variants, however, in this study we demonstrated that SYT-SSX1 and SYT-SSX2 coexist in a significant proportion of the cases. From 121 SYT-SSX positive primary tumors, co-expression of SYT-SSX1 and SYT-SSX2 was seen in 12 cases (10%), which were characterized in further detail both at the RNA, DNA and chromosomal level. In all 12 cases the SYT-SSX1 and SYT-SSX2 fusions resulted in identical SYT-SSX fusion transcripts. However, at the genomic level the translocations were different, and most likely occurred between variable intronic sites in the target genes. By interphase FISH analyses of 10 cases SYT-SSX2 translocations were found to be the most abundant in all but one of the cases, in which SYT-SSX1 was predominating. The findings reveal a new heterogenous feature of synovial sarcoma, accounting for approximately 10% of all cases, which may shed light on the molecular genetic mechanisms behind translocations in general, and on the etiology of synovial sarcoma in particular.	Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, CCK L801, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Stockholm Soder Hosp, SE-11883 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lund University; Skane University Hospital	Larsson, C (corresponding author), Karolinska Hosp, CCK R804, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden.	Catharina.Larsson@cmm.ki.se	Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Brodin B, 2001, GENE, V268, P173, DOI 10.1016/S0378-1119(01)00412-7; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Ladanyi M, 2000, HUM PATHOL, V31, P532, DOI 10.1053/hp.2000.6706; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nilsson G, 1999, CANCER RES, V59, P3180; O'Dwyer ME, 2000, CURR OPIN ONCOL, V12, P594, DOI 10.1097/00001622-200011000-00013; Panagopoulos I, 2001, GENE CHROMOSOME CANC, V31, P362, DOI 10.1002/gcc.1155; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sreekantaiah C, 1998, CYTOGENET CELL GENET, V82, P13, DOI 10.1159/000015056; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981	21	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4181	4190		10.1038/sj.onc.1205569	http://dx.doi.org/10.1038/sj.onc.1205569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037676				2022-12-25	WOS:000176186000014
J	Grabovsky, V; Dwir, O; Alon, R				Grabovsky, V; Dwir, O; Alon, R			Endothelial chemokines destabilize L-selectin-mediated lymphocyte rolling without inducing selectin shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NODE HOMING RECEPTOR; P-SELECTIN; CYTOPLASMIC DOMAIN; T-LYMPHOCYTES; SHEAR-FLOW; CHEMOTACTIC FACTORS; PHYSIOLOGICAL FLOW; LEUKOCYTE ADHESION; BINDING-PROPERTIES; BETA-2 INTEGRINS	Chemokines presented on specialized endothelial surfaces rapidly up-regulate leukocyte integrin avidity and firm arrest through G(i)-protein signaling. Here we describe a novel, G-protein-independent, down-regulatory activity of apical endothelial chemokines in destabilizing L-selectin-mediated leukocyte rolling. Unexpectedly, this anti-adhesive chemokine suppression of rolling does not involve L-selectin shedding. Destabilization of rolling is induced only by immobilized chemokines juxtaposed to L-selectin ligands and is an energy-dependent process. Chemokines are found to interfere with a subsecond stabilization of selectin tethers necessary for persistent rolling. This is a first indication that endothelial chemokines can attenuate in situ L-selectin adhesion to endothelial ligands at subsecond contacts. This negative feedback mechanism may underlie the jerky nature of rolling mediated by L-selectin in vivo.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				Alexander SR, 2000, J LEUKOCYTE BIOL, V67, P415, DOI 10.1002/jlb.67.3.415; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bruehl RE, 1997, J LEUKOCYTE BIOL, V61, P489, DOI 10.1002/jlb.61.4.489; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dwir O, 1998, CELL ADHES COMMUN, V6, P349, DOI 10.3109/15419069809010793; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Finger EB, 1996, J IMMUNOL, V157, P5085; Flaishon L, 2000, J EXP MED, V192, P1381, DOI 10.1084/jem.192.9.1381; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KAPLANSKI G, 1993, BIOPHYS J, V64, P1922, DOI 10.1016/S0006-3495(93)81563-7; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Li X, 1998, J EXP MED, V188, P1385, DOI 10.1084/jem.188.7.1385; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Puri KD, 1997, J IMMUNOL, V158, P405; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; Simon SI, 1999, J IMMUNOL, V163, P2891; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; Smith MJ, 1999, BIOPHYS J, V77, P3371, DOI 10.1016/S0006-3495(99)77169-9; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Stockton BM, 1998, IMMUNITY, V8, P373, DOI 10.1016/S1074-7613(00)80542-7; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Yoshida R, 1998, INT IMMUNOL, V10, P901, DOI 10.1093/intimm/10.7.901	59	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20640	20650		10.1074/jbc.M201763200	http://dx.doi.org/10.1074/jbc.M201763200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	12042326	hybrid			2022-12-25	WOS:000176204500071
J	Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC				Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC			Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway	ONCOGENE			English	Article						human lens epithelial cells; telomerase; cell growth; E2F; RB; p53; GCIP	EXPRESSION; CYCLE; E2F; P53; IMMORTALIZATION; INHIBITOR; PROTEIN; PROLIFERATION; INDUCTION; APOPTOSIS	Telomerase is a specialized reverse transcriptase that extends telomeres of eukaryotic chromosomes. The catalytic core of human telomerase is composed of an RNA template known as hTER (human telomerase RNA) and a protein subunit named hTERT (human telomerase reverse transcriptase). We have been studying other functions of the telomerase besides its major role in telomere maintenance. In our previous work, we have demonstrated that the hTERT can functionally interact with a rabbit TER to regulate expression of other genes and also attenuate the induced apoptosis. Here we report that overexpression of hTERT in a human lens epithelial cell fine accelerates growth of the transfected lens epithelial cells. Associated with the acceleration of cell growth, expression of p53, p21 and GCIP (Grap2 cyclin-D interacting protein) is downregulated in the hTERT-transfected cells. With the downregulation of p21 and GCIP, the retinoblastoma protein (RB) is completely hyperphosphorylated in the hTERT-transfected cells. As expected, in the presence of RB hyperphosphorylation, the E2F transactivity is upregulated. Inhibition of telomerase activity abolishes the observed growth acceleration and also the related molecular changes. Furthermore, expression of hTERT in telomerase-negative human lens epithelial cells derived from primary cultures also accelerates growth of the transfected cells. Taken together, our results suggest that hTERT, when overexpressed in human lens epithelial cells, accelerates cell growth rate through regulation of RB/E2F pathway and possibly other genes.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, Stratford, NJ 08084 USA; Univ Texas, Hlth Sci Ctr, Dept Med Biochem & Genet, Inst Biosci & Technol,Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Li, DWC (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	DWL168@att.net	Li, David/AAN-9205-2021	Liu, Mingyao/0000-0001-7339-5048; xiang, hua/0000-0003-0369-1225; Mao, Yingwei/0000-0001-7339-1565	NEI NIH HHS [EY 11372, EY 07003, EY 00484] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY000484, R29EY011372, R01EY000484] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHEN JD, 1992, ONCOGENE, V7, P1167; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gunes C, 2000, CANCER RES, V60, P2116; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Klingelhutz AJ, 1999, ANTICANCER RES, V19, P4823; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Magnenat L, 1999, MOL CELL BIOL, V19, P3457; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mata JE, 1997, TOXICOL APPL PHARM, V144, P189, DOI 10.1006/taap.1997.8103; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang S, 1999, MOL CELL BIOL, V19, P7447; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3784	3791		10.1038/sj.onc.1205455	http://dx.doi.org/10.1038/sj.onc.1205455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032846				2022-12-25	WOS:000175676000013
J	Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW				Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW			Phosphorylation regulates the stability of the regulatory CK2 beta subunit	ONCOGENE			English	Article						protein kinase CK2; ubiquitin; phosphorylation; proteasome	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; BETA-SUBUNIT; CYCLIN-E; DNA-DAMAGE; CELL-CYCLE; INDUCIBLE EXPRESSION; CK2 SUBUNITS; C-JUN; P53	Protein kinase CK2 is a protein serine/threonine kinase that exhibits elevated expression in a number of cancers and displays oncogenic activity in mice. The regulatory CK2beta subunit has a central role in assembly of functional tetrameric CK2 complexes where it participates in modulation of catalytic activity and substrate specificity. Since overexpression of CK2beta results in elevated levels of CK2 activity, we investigated the molecular mechanisms that control its degradation since perturbations in these pathways could contribute to elevated CK2 in cancer. In this study, we demonstrate that CK2beta is degraded by a proteasome-dependent pathway and that it is ubiquitinated. We have also investigated the role of phosphorylation and a putative destruction box in regulating its stability in cells. Importantly, replacement of three serine residues within the autophosphorylation site of CK2beta with glutamic acid residues resulted in a significant decrease in its degradation indicating that autophosphorylation is involved in regulating its stability. Notably, although the autophosphorylation site of CUP is remarkably conserved between species, this is the first functional role ascribed to this site. Furthermore, based on these results, we speculate that alterations in the phosphorylation or dephosphorylation of the regulatory CK2beta subunit could underlie the elevated expression of CK2 that is observed in cancer cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Canton, David/N-7463-2015; Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dick LR, 1997, J BIOL CHEM, V272, P182; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; Pham CD, 1999, ONCOGENE, V18, P4287, DOI 10.1038/sj.onc.1202804; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; Schwab M, 2001, NATURE, V413, P268, DOI 10.1038/35095157; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Vilk G, 2002, J CELL BIOCHEM, V84, P84, DOI 10.1002/jcb.1268; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; YOI OKO, 1993, EMBO J, V12, P1621; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	76	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3754	3764		10.1038/sj.onc.1205467	http://dx.doi.org/10.1038/sj.onc.1205467			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032843				2022-12-25	WOS:000175676000010
J	Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y				Shiraishi, M; Sekiguchi, A; Oates, AJ; Terry, MJ; Miyamoto, Y			HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas	ONCOGENE			English	Article						CpG island; DNA methylation; HOX gene	DNA METHYLATION; EXPRESSION; COMPLEX	CpG island methylation results in the silencing of the associated gene and is an important step in tumorigenesis. Following a comprehensive isolation of CpG islands that were methylated in human lung adenocarcinoma, we found that in cancer cells de novo CpG island methylation generally occurred in a sporadic manner. However, some methylated CpG islands appeared to cluster in discrete chromosomal regions. In this study, we have investigated the methylation status of CpG islands located at such chromosomal loci. We have found that many CpG islands at the HOXA and HOXD loci were methylated in human lung adenocarcinoma. The de novo methylation of these CpG islands was also observed in patient's DNA from noncancerous portions of lung tissue. These results indicate the presence of specific chromosomal regions that are susceptible to de novo methylation.	Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Shiraishi, M (corresponding author), Natl Canc Ctr, Res Inst, DNA Methylat & Genome Funct Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	mshirais@ncc.go.jp		Miyamoto, Yuji/0000-0003-3948-5044				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Flagiello D, 1996, FEBS LETT, V380, P103, DOI 10.1016/0014-5793(96)00017-8; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Golpon HA, 2001, AM J PATHOL, V158, P955, DOI 10.1016/S0002-9440(10)64042-4; Henke W, 1997, NUCLEIC ACIDS RES, V25, P3957, DOI 10.1093/nar/25.19.3957; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kappen C, 1996, AM J RESP CELL MOL, V15, P156, DOI 10.1165/ajrcmb.15.2.8703471; Lechner JF, 2001, RADIAT RES, V155, P235, DOI 10.1667/0033-7587(2001)155[0235:PCDTMA]2.0.CO;2; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shiraishi M, 1999, P NATL ACAD SCI USA, V96, P2913, DOI 10.1073/pnas.96.6.2913; SHIRAISHI M, 2002, IN PRESS ONCOGENE, V21; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TIBERIO C, 1994, INT J CANCER, V58, P608, DOI 10.1002/ijc.2910580426	19	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3659	3662		10.1038/sj.onc.1205453	http://dx.doi.org/10.1038/sj.onc.1205453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032868				2022-12-25	WOS:000175793700017
J	Kim, I; Ryu, YS; Kwak, HJ; Ahn, SY; Oh, JL; Yancopoulos, GD; Gale, NW; Koh, GY				Kim, I; Ryu, YS; Kwak, HJ; Ahn, SY; Oh, JL; Yancopoulos, GD; Gale, NW; Koh, GY			EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin-1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells	FASEB JOURNAL			English	Article						capillary mprphogenesis; p120-RasGAP; ERK1/2; Flk1; Tie2	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; SPECIFICITY; SURVIVAL; TIE2	Interaction between ephrinB2 and EphB4 in endothelial cells at the arterial-venous capillary interface is critical for proper embryonic capillary morphogenesis. However, the intracellular downstream signaling of ephrinB2-EphB in vascular endothelial cells is unknown. This study examined the effect of ephrinB2-induced activation of EphB kinases on vascular endothelial growth factor (VEGF)- and angiopoietin-1 (Ang1)-induced Ras/mitogen-activated protein kinase (MAPK) signaling cascades in human umbilical vein endothelial cells (HUVECs). Reverse transcriptase-polymer chain reaction results showed that HUVECs expressed three kinds of EphB kinases known to bind to ephrinB2: EphB2, EphB3, and EphB4. EphrinB2 not only increased the phosphorylation of EphB2 and EphB4 in a time-dependent manner but also increased recruitment of p120-Ras-GTPase-activating protein (p120-RasGAP) to EphB2 and EphB4. Accordingly, ephrinB2 inhibited VEGF- and Ang1-induced Ras-MAPK activities, whereas ephrinB2 did not alter VEGF-induced Flk phosphorylation or Ang1-induced Tie2 phosphorylation. Furthermore, ephrinB2 suppressed VEGF- and Ang1-induced proliferation and/or migration, which are mediated mainly through Ras/MAPK signaling cascades. From these results, we propose that ephrinB2-EphB, signaling through Ras/MAPK cascade, may be critical for proper morphogenesis of capillary endothelium through the arrest of endothelial cell proliferation and migration at the arterial-venous interface.	Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Pohang University of Science & Technology (POSTECH); Regeneron	Koh, GY (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Natl Creat Res Initiat Ctr Endothelial Cells, San 31, Pohang 790784, South Korea.	gykoh@postech.ac.kr	Kim, Injune/C-1710-2011; Koh, Gou Young/C-1615-2011	Kim, Injune/0000-0001-9244-815X; 				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Chae JK, 2000, ARTERIOSCL THROM VAS, V20, P2573, DOI 10.1161/01.ATV.20.12.2573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Holder N, 1999, DEVELOPMENT, V126, P2033; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wilkinson DG, 2000, INT REV CYTOL, V196, P177; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zhang XQ, 2001, BLOOD, V98, P1028, DOI 10.1182/blood.V98.4.1028	22	137	146	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1126	+		10.1096/fj.01-0805fje	http://dx.doi.org/10.1096/fj.01-0805fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039842				2022-12-25	WOS:000175973900004
J	Semov, A; Semova, N; Lacelle, C; Marcotte, R; Petroulakis, E; Proestou, G; Wang, E				Semov, A; Semova, N; Lacelle, C; Marcotte, R; Petroulakis, E; Proestou, G; Wang, E			Alterations in TNF- and IL-related gene expression in spaceflown WI38 human fibroblasts	FASEB JOURNAL			English	Article						cDNA microarray; spaceflight; aging; bone density; gene expression profile	PROTEIN-TYROSINE-PHOSPHATASE; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; CDNA MICROARRAYS; RECEPTOR; CELLS; OSTEOBLASTS; SPHINGOMYELINASE; SAMPLES; CLONING	Spaceflight, just like aging, causes profound changes in musculoskeletal parameters, which result in decreased bone density and muscular weakness. As these conditions decrease our ability to conduct long-term manned space missions, and increase bone frailty in the elderly, the identification of genes responsible for the apparition of these physiological changes will be of great benefit. Thus, we developed and implemented a new microarray approach to investigate the changes in normal WI38 human fibroblast gene expression that arise as a consequence of space flight. Using our microarray, we identified changes in the level of expression of 10 genes, belonging to either the tumor necrosis factor- (TNF) or interleukin- (IL) related gene families in fibroblasts when WI38 cells exposed to microgravity during the STS-93 Space Shuttle mission were compared with ground controls. The genes included two ligands from the TNF superfamily, TWEAK and TNFSF15; two TNF receptor-associated proteins, NSMAF and PTPN13; three TNF-inducible genes, ABC50, PTX3, and SCYA13; TNF-alpha converting enzyme, IL-1 receptor antagonist, and IL-15 receptor alpha chain. Most of these are involved in either the regulation of bone density, and as such the development of spaceflight osteopenia, or in the development of proinflammatory status.	Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada	University of Louisville; Lady Davis Institute; McGill University; McGill University	Wang, E (corresponding author), Univ Louisville, Sch Med, Dept Biochem & Mol Biol, 570 S Preston,Baxter Bldg Room 304, Louisville, KY 40202 USA.	eugenia.wang@louisville.edu						AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Akiyama H, 1996, J BIOTECHNOL, V47, P325, DOI 10.1016/0168-1656(96)01401-0; Alleva DG, 1997, J IMMUNOL, V159, P2941; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; Bertucci F, 1999, HUM MOL GENET, V8, P1715, DOI 10.1093/hmg/8.9.1715; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Carmeliet G, 2001, CRIT REV EUKAR GENE, V11, P131; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHAPES SK, 1992, J LEUKOCYTE BIOL, V52, P104, DOI 10.1002/jlb.52.1.104; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Doherty TJ, 2001, CURR OPIN CLIN NUTR, V4, P503, DOI 10.1097/00075197-200111000-00007; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Gerhold D, 1999, TRENDS BIOCHEM SCI, V24, P168, DOI 10.1016/S0968-0004(99)01382-1; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kumei Y, 1998, J APPL PHYSIOL, V85, P139, DOI 10.1152/jappl.1998.85.1.139; Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168-1656(96)01412-5; Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099; Langdahl BL, 2000, J BONE MINER RES, V15, P402, DOI 10.1359/jbmr.2000.15.3.402; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Martorana AM, 1999, BIOTECHNIQUES, V27, P136, DOI 10.2144/99271rr02; Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274; Richard M, 1998, GENOMICS, V53, P137, DOI 10.1006/geno.1998.5480; Rittweger J, 1999, J Gravit Physiol, V6, pP133; SARAS J, 1994, J BIOL CHEM, V269, P24082; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Semov A, 2002, ANAL BIOCHEM, V302, P38, DOI 10.1006/abio.2001.5515; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Taylor R L, 1993, J Br Interplanet Soc, V46, P97; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang E, 1999, FASEB J, V13, pS167; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Zhai YF, 1999, FASEB J, V13, P181, DOI 10.1096/fasebj.13.1.181; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	45	35	38	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					899	+		10.1096/fj.01-1002fje	http://dx.doi.org/10.1096/fj.01-1002fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039873				2022-12-25	WOS:000175425900026
J	Seong, YS; Kamijo, K; Lee, JS; Fernandez, E; Kuriyama, R; Miki, T; Lee, KS				Seong, YS; Kamijo, K; Lee, JS; Fernandez, E; Kuriyama, R; Miki, T; Lee, KS			A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of plk1 in u-2 OS cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; KINASE 1 PLK1; PROTEIN-KINASE; GAMMA-TUBULIN; MICE LACKING; LOCALIZATION; MITOSIS; PHOSPHORYLATION; MAD2; KINETOCHORES	Polo kinases play critical roles for proper M-phase progression. They are characterized by the presence of two regions of homology in the C-terminal non-catalytic domain, termed polo-box 1 (PB1) and polo-box 2 (PB2). Here we demonstrate that both PB1 and PB2 are required for targeting the catalytic activity of Plk1 to centrosomes, midbody, and kinetochores. Expression of either kinase-inactive PLK1/K82M or the C-terminal plk1DeltaN induced a pre-anaphase arrest with elevated Cdc2 and Plk1 activity. Prophase-arrested cells exhibited randomly oriented spindle structures, whereas metaphase cells exhibited aberrant bipolar spindles with Mad2 localization at kinetochores of misaligned chromosomes. Microtubule nucleation activity of centrosomes was not compromised. In vivo time-lapse studies revealed that expression of plk1DeltaN resulted irk repeated cycles of bipolar spindle formation and disruption, suggestive of a defect in spindle stability. A prolonged arrest frequently led to the generation of micronucleated cells in the absence of sisterchromatid separation and centrosome duplication, indicating that micronucleation is not a result of accumulated cytokinesis failures. Interestingly, bypass of the mitotic arrest by dominant-negative spindle checkpoint components led to a failure in completion of cytokinesis. We propose that, in mammalian cells, the polo-box-dependent Plk1 activity is required for proper metaphase/anaphase transition and for cytokinesis.	NCI, Ctr Canc Res, Lab Metab, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Basic Res Lab, NIH, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Minnesota System; University of Minnesota Twin Cities	Lee, KS (corresponding author), NCI, Ctr Canc Res, Lab Metab, NIH, 9000 Rockville Pike,Bldg 37,Rm 3D25, Bethesda, MD 20892 USA.	kyunglee@pop.nci.nih.gov	SEONG, YEON-SUN/B-2485-2016	SEONG, YEON-SUN/0000-0002-4743-8048				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Donaldson MM, 2001, J CELL BIOL, V153, P663, DOI 10.1083/jcb.153.4.663; ERRABOLU R, 1994, J CELL SCI, V107, P9; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; Ohta T, 2002, J CELL BIOL, V156, P87, DOI 10.1083/jcb.200108088; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Schott EJ, 1998, GENETICS, V148, P599; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Song S, 2000, MOL CELL BIOL, V20, P286, DOI 10.1128/MCB.20.1.286-298.2000; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001	42	184	189	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32282	32293		10.1074/jbc.M202602200	http://dx.doi.org/10.1074/jbc.M202602200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12034729	hybrid			2022-12-25	WOS:000177718700123
J	Baldwin, ET; Harris, MS; Yem, AW; Wolfe, CL; Vosters, AF; Curry, KA; Murray, RW; Bock, JH; Marshall, VP; Cialdella, JI; Merchant, MH; Choi, G; Deibel, MR				Baldwin, ET; Harris, MS; Yem, AW; Wolfe, CL; Vosters, AF; Curry, KA; Murray, RW; Bock, JH; Marshall, VP; Cialdella, JI; Merchant, MH; Choi, G; Deibel, MR			Crystal structure of type II peptide deformylase from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; N-TERMINAL METHIONINE; ESCHERICHIA-COLI; SPECTROPHOTOMETRIC ASSAY; POLYPEPTIDE DEFORMYLASE; SUBSTRATE RECOGNITION; ACTIVE-SITE; INHIBITION; IRON; CRYSTALLIZATION	The first crystal structure of Class II peptide deformylase has been determined. The enzyme from Staphylococcus aureus has been overexpressed and purified in Escherichia coli and the structure determined by x-ray crystallography to 1.9 Angstrom resolution. The purified iron-enriched form of S. aureus peptide deformylase enzyme retained high activity over many months. In contrast, the iron-enriched form of the E. coli enzyme is very labile. Comparison of the two structures details many differences; however, there is no structural explanation for the dramatic activity differences we observed. The protein structure of the S. aureus enzyme reveals a fold similar, but not identical to, the well characterized E. coli enzyme. The most striking deviation of the S. aureus from the E. coli structure is the unique conformation of the C-terminal amino acids. The distinctive C-terminal helix of the latter is replaced by a strand in S. aureus which wraps around the enzyme, terminating near the active site. Although there are no differences at the amino acid level near the active site metal ion, significant changes are noted in the peptide binding cleft which may play a role in the design of general peptide deformylase inhibitors.	Pharmacia, Dept Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA; Pharmacia, Dept Prot Sci, Kalamazoo, MI 49007 USA; Pharmacia, Dept Infect Dis Res, Kalamazoo, MI 49007 USA; Pharmacia, Dept Comp Aided Drug Discovery, Kalamazoo, MI 49007 USA; Human Genome Sci Inc, Dept Mol Biol, Rockville, MD 20850 USA	Pfizer; Pfizer; Pfizer; Pfizer; GlaxoSmithKline; Human Genome Sciences Inc	Baldwin, ET (corresponding author), Pharmacia, Dept Struct Analyt & Med Chem, 7255-209-102,301 Henrietta St, Kalamazoo, MI 49007 USA.	eric.t.baldwin@pharmacia.com	ID, IMCACAT/D-5867-2014	Baldwin, Eric/0000-0001-8186-2777				ADAMS JM, 1968, J MOL BIOL, V33, P571, DOI 10.1016/0022-2836(68)90307-0; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BALL LA, 1973, J MOL BIOL, V79, P531, DOI 10.1016/0022-2836(73)90404-X; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; BLUNDELL TL, 1994, NAT STRUCT BIOL, V1, P73, DOI 10.1038/nsb0294-73; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Chan MK, 1997, BIOCHEMISTRY-US, V36, P13904, DOI 10.1021/bi9711543; Chan MK, 1998, ABSTR PAP AM CHEM S, V216, pU232; Chang SC, 2001, CHEM COMMUN, P2396, DOI 10.1039/b106865m; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; Chen GJ, 1997, BIOCHEMISTRY-US, V36, P4278, DOI 10.1021/bi9618676; Clements JM, 2001, ANTIMICROB AGENTS CH, V45, P563, DOI 10.1128/AAC.45.2.563-570.2001; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DALBOGE H, 1990, FEBS LETT, V266, P1, DOI 10.1016/0014-5793(90)90001-B; Dardel F, 1998, J MOL BIOL, V280, P501, DOI 10.1006/jmbi.1998.1882; Dhanaraj V, 1996, Drug Des Discov, V13, P3; Durand DJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P297, DOI 10.1006/abbi.1999.1274; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Finzel BC, 1997, METHOD ENZYMOL, V277, P230, DOI 10.1016/S0076-6879(97)77014-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; Grant SK, 2001, BIOORG CHEM, V29, P211, DOI 10.1006/bioo.2001.1214; Green BG, 2000, ARCH BIOCHEM BIOPHYS, V375, P355, DOI 10.1006/abbi.1999.1673; Groche D, 1998, BIOCHEM BIOPH RES CO, V246, P342, DOI 10.1006/bbrc.1998.8616; GROCHE D, 1995, THESIS U HEIDELBERG; Hao B, 1999, BIOCHEMISTRY-US, V38, P4712, DOI 10.1021/bi982594c; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; HRUZA A, 2001, 22 ACS NAT M CHIC AU; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar A, 2002, STRUCTURE, V10, P357, DOI 10.1016/S0969-2126(02)00719-0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lazennec C, 1997, ANAL BIOCHEM, V244, P180, DOI 10.1006/abio.1996.9910; LIVINGSTON DM, 1969, BIOCHEMISTRY-US, V8, P435, DOI 10.1021/bi00829a059; Makarova KS, 1999, J MOL BIOL, V292, P11, DOI 10.1006/jmbi.1999.3059; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mazel D, 1997, J MOL BIOL, V266, P939, DOI 10.1006/jmbi.1996.0835; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; MEINNEL T, 1995, J BACTERIOL, V177, P1883, DOI 10.1128/jb.177.7.1883-1887.1995; Meinnel T, 1996, FEBS LETT, V385, P91, DOI 10.1016/0014-5793(96)00357-2; Meinnel T, 1996, J MOL BIOL, V262, P375, DOI 10.1006/jmbi.1996.0521; Meinnel T, 1999, BIOCHEMISTRY-US, V38, P4287, DOI 10.1021/bi982622r; Meinnel T, 1997, J MOL BIOL, V267, P749, DOI 10.1006/jmbi.1997.0904; MEINNEL T, 1993, J BACTERIOL, V175, P993, DOI 10.1128/JB.175.4.993-1000.1993; Meinnel T, 2000, PARASITOL TODAY, V16, P165, DOI 10.1016/S0169-4758(99)01627-0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; O'Connell JF, 1999, J BIOMOL NMR, V13, P311, DOI 10.1023/A:1008311502626; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pei D, 2001, Expert Opin Ther Targets, V5, P23, DOI 10.1517/14728222.5.1.23; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; Prescott J M, 1976, Methods Enzymol, V45, P530; Ragusa S, 1999, J MOL BIOL, V289, P1445, DOI 10.1006/jmbi.1999.2832; Ragusa S, 1998, J MOL BIOL, V280, P515, DOI 10.1006/jmbi.1998.1883; Rajagopalan PTR, 2000, BIOCHEMISTRY-US, V39, P779, DOI 10.1021/bi9919899; Rajagopalan PTR, 1997, BIOCHEMISTRY-US, V36, P13910, DOI 10.1021/bi971155v; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Scahill TA, 2001, J BIOMOL NMR, V19, P81, DOI 10.1023/A:1008367102421; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schmitt E, 1996, BIOCHIMIE, V78, P543, DOI 10.1016/S0300-9084(96)80001-0; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; TSO JY, 1982, J BIOL CHEM, V257, P3532; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Wei YM, 1997, ANAL BIOCHEM, V250, P29, DOI 10.1006/abio.1997.2194	81	40	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31163	31171		10.1074/jbc.M202750200	http://dx.doi.org/10.1074/jbc.M202750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12048187	hybrid			2022-12-25	WOS:000177579800096
J	Biberstine-Kinkade, KJ; Yu, LX; Stull, N; LeRoy, B; Bennett, S; Cross, A; Dinauer, MC				Biberstine-Kinkade, KJ; Yu, LX; Stull, N; LeRoy, B; Bennett, S; Cross, A; Dinauer, MC			Mutagenesis of p22(phox) histidine 94 - A histidine in this position is not required for flavocytochrome b(558) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CYTOCHROME-B; PHAGOCYTE NADPH OXIDASE; SUPEROXIDE-GENERATING SYSTEM; SRC HOMOLOGY-3 DOMAINS; CELL-FREE SYSTEM; LIGHT-CHAIN; HEME; BINDING; GP91(PHOX); ACTIVATION	The NADPH oxidase is a multicomponent enzyme that transfers electrons from NADPH to O-2 to generate superoxide (O-2(.-)), the precursor of microbicidal oxygen species that play an important role in host defense. Flavocytochrome b(558), a heterodimeric oxidoreductase comprised of gp91(phox) and p22(phox) subunits, contains two nonidentical, bis-histidine-ligated heme groups imbedded within the membrane. Four histidine residues that appear to serve as noncovalent axial heme ligands reside within the hydrophobic N terminus of gp91(phox), but the role of p22(phox) in heme binding is unclear. We compared biochemical and functional features of wild type flavocytochrome b(558) with those in cells co-expressing gp91(phox) with p22(phox) harboring amino acid substitutions at histidine 94, the only invariant histidine residue within the p22(phox) subunit. Substitution with leucine, tyrosine, or methionine did not affect heterodimer formation or flavocytochrome b(558) function. The heme spectrum in purified preparations of flavocytochrome b(558) containing the p22(phox) derivative was unaffected. In contrast, substitution of histidine 94 with arginine appeared to disrupt the intrinsic stability of p22(phox) and, secondarily, the stability of mature gp91(phox) and abrogated O-2(.-) production. These findings demonstrate that His(94) p22(phox) is not required for heme binding or function of flavocytochrome b(558) in the NADPH oxidase.	Indiana Univ, Sch Med, Dept Pediat Hematol Oncol, Herman B Wells Ctr Pediat Res,Riley Hosp Children, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Herman B Wells Ctr Pediat Res,Riley Hosp Children, Indianapolis, IN 46202 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Scripps Research Institute	Dinauer, MC (corresponding author), Wells Ctr Pediat Res, 1044 W Walnut St,R4,Rm 402A, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK049218] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL45635] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NIDDK NIH HHS [P30DK49218] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; Cross AR, 2000, BLOOD CELL MOL DIS, V26, P561, DOI 10.1006/bcmd.2000.0333; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; CROSS AR, 1994, J BIOL CHEM, V269, P21448; Davis AR, 1998, J LEUKOCYTE BIOL, V64, P114, DOI 10.1002/jlb.64.1.114; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; ESPOSTI MD, 1989, BIOCHIM BIOPHYS ACTA, V977, P249, DOI 10.1016/S0005-2728(89)80079-9; Foubert TR, 2001, J BIOL CHEM, V276, P38852, DOI 10.1074/jbc.M104373200; FUJII H, 1995, J BIOL CHEM, V270, P12685, DOI 10.1074/jbc.270.21.12685; HURST JK, 1991, J BIOL CHEM, V266, P1627; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; Maniatis T., 1982, MOL CLONING LAB MANU; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; YU LX, 1993, BIOCHIM BIOPHYS ACTA, V1178, P73, DOI 10.1016/0167-4889(93)90111-2; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Yu LX, 1999, BLOOD, V94, P2497, DOI 10.1182/blood.V94.7.2497.419k11_2497_2504; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	37	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30368	30374		10.1074/jbc.M203993200	http://dx.doi.org/10.1074/jbc.M203993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042318	hybrid			2022-12-25	WOS:000177509300123
J	Hrmova, M; Imai, T; Rutten, SJ; Fairweather, JK; Pelosi, L; Bulone, V; Driguez, H; Fincher, GB				Hrmova, M; Imai, T; Rutten, SJ; Fairweather, JK; Pelosi, L; Bulone, V; Driguez, H; Fincher, GB			Mutated barley (1,3)-beta-D-glucan endohydrolases synthesize crystalline (1,3)-beta-D-glucans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC AMINO-ACIDS; PACKING ANALYSIS; CDNA CLONE; IN-VITRO; SUBSTRATE; POLYSACCHARIDES; PURIFICATION; (1->3)-BETA-D-GLUCANS; (1->3)-BETA-GLUCAN; GLUCOSIDASE	Barley (1,3)-beta-D-glucan endohydrolases (EC 3.2.1.39), inactivated by site-directed mutagenesis of their catalytic nucleophiles, show autocondensation glucosynthetic activity with alpha-laminaribiosyl fluoride and heterocondensation glycosynthetic activity with a-laminaribiosyl fluoride and 4'-nitrophenyl beta-D-glucopyranoside. The native enzyme is a retaining endohydrolase of the family 17 group and catalyzes glycosyl transfer reactions at high substrate concentrations. Catalytic efficiencies (k(cat) K-m(-1)) of mutants E231G, E231S, and E231A as glycosynthases are 28.9, 0.9, and 0.5 x 10(-4) M-1 s(-1), respectively. Glycosynthase reactions appear to be processive and proceed with pH optima of 6-8 and yields of up to 75%. Insoluble products formed during the glycosynthase reaction appear as lamellar, hexagonal crystals when observed by electron microscopy. Methylation, NMR, and matrix-assisted laser desorption ionization time-of-flight analyses show that the reaction products are linear (1,3)-beta-D-glucans with a degree of polymerization of 30-34, whereas electron and x-ray diffraction patterns indicate that these (1,3)-beta-D-glucan chains adopt a parallel, triple helical conformation. The (1,3)-beta-D-glucan triple helices are orientated perpendicularly to the plane of the lamellar crystals. The barley (1,3)-beta-D-glucan glycosynthases have considerable potential for tailored and high efficiency synthesis of (1,3)-beta-D-linked oligo- and polysaccharides, some of which could have immunomodulating activity, or for the coupling of (1,3)-beta-D-linked glucosyl residues onto other oligosaccharides or glycoproteins.	Univ Adelaide, Dept Plant Sci, Glen Osmond, SA 5064, Australia; Ctr Rech Macromol Vegetales, UPR 38041, Grenoble 9, France	University of Adelaide; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Fincher, GB (corresponding author), Univ Adelaide, Dept Plant Sci, Waite Campus, Glen Osmond, SA 5064, Australia.	geof.fincher@adelaide.edu.au	Bulone, Vincent/C-8492-2019; 今井, 友也/M-1834-2019; Hrmova, Maria/AAH-3951-2020; Pelosi, Ludovic/M-6406-2014; Pelosi, Ludovic/AAB-9832-2020; Bulone, Vincent/D-7469-2013	Bulone, Vincent/0000-0003-2809-4160; 今井, 友也/0000-0001-7026-0287; Pelosi, Ludovic/0000-0002-4198-5681; Hrmova, Maria/0000-0002-3545-0605				Armand S, 1997, J BIOL CHEM, V272, P2709, DOI 10.1074/jbc.272.5.2709; Armand S, 1996, EUR J BIOCHEM, V236, P706, DOI 10.1111/j.1432-1033.1996.00706.x; BIELY P, 1980, EUR J BIOCHEM, V112, P375, DOI 10.1111/j.1432-1033.1980.tb07215.x; BULONE V, 1995, PLANT J, V8, P213, DOI 10.1046/j.1365-313X.1995.08020213.x; CHANZY H, 1985, POLYSACCHARIDES TOPI; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; CHUAH CT, 1983, MACROMOLECULES, V16, P1375, DOI 10.1021/ma00242a020; ContourGalcera MO, 1996, CARBOHYD RES, V281, P99, DOI 10.1016/0008-6215(95)00339-8; DESLANDES Y, 1980, MACROMOLECULES, V13, P1466, DOI 10.1021/ma60078a020; Estrada A, 1997, MICROBIOL IMMUNOL, V41, P991, DOI 10.1111/j.1348-0421.1997.tb01959.x; Falch BH, 2000, CARBOHYD RES, V329, P587, DOI 10.1016/S0008-6215(00)00222-6; Fort S, 2000, J AM CHEM SOC, V122, P5429, DOI 10.1021/ja9936520; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harada T., 1977, EXTRACELLULAR MICROB, V45, P265; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HRMOVA M, 1995, J BIOL CHEM, V270, P14556, DOI 10.1074/jbc.270.24.14556; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; Hrmova M, 1998, J CHEM SOC PERK T 1, P3571, DOI 10.1039/a804711a; JABRI E, 1989, CURR MICROBIOL, V19, P153, DOI 10.1007/BF01568934; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; Mackenzie LF, 1998, J AM CHEM SOC, V120, P5583, DOI 10.1021/ja980833d; MAEDA YY, 1971, NATURE, V229, P634, DOI 10.1038/229634a0; Malet C, 1998, FEBS LETT, V440, P208, DOI 10.1016/S0014-5793(98)01448-3; Mayer C, 2000, FEBS LETT, V466, P40, DOI 10.1016/S0014-5793(99)01751-2; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Nashiru O, 2001, ANGEW CHEM INT EDIT, V40, P417, DOI 10.1002/1521-3773(20010119)40:2<417::AID-ANIE417>3.0.CO;2-V; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohno N, 2000, BIOL PHARM BULL, V23, P866, DOI 10.1248/bpb.23.866; Parsiegla G, 2000, BIOCHEMISTRY-US, V39, P11238, DOI 10.1021/bi001139p; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Planas N, 2000, BBA-PROTEIN STRUCT M, V1543, P361, DOI 10.1016/S0167-4838(00)00231-4; ROBYT JF, 1967, ARCH BIOCHEM BIOPHYS, V122, P8, DOI 10.1016/0003-9861(67)90118-X; SAITO H, 1981, CHEM LETT, P571, DOI 10.1246/cl.1981.571; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAMUELS ML, 1991, STAT LIFE SCI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stewart RJ, 2001, PROTEIN ENG, V14, P245, DOI 10.1093/protein/14.4.245; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Trincone A, 2000, BIOORG MED CHEM LETT, V10, P365, DOI 10.1016/S0960-894X(99)00700-3; VARGHESE JN, 1994, P NATL ACAD SCI USA, V91, P2785, DOI 10.1073/pnas.91.7.2785; Wasser SP, 1999, CRIT REV IMMUNOL, V19, P65; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	48	82	86	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30102	30111		10.1074/jbc.M203971200	http://dx.doi.org/10.1074/jbc.M203971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023973	hybrid			2022-12-25	WOS:000177509300093
J	Basu, SS; Karbarz, MJ; Raetz, CRH				Basu, SS; Karbarz, MJ; Raetz, CRH			Expression cloning and characterization of the C28 acyltransferase of lipid A biosynthesis in Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; GENOME SEQUENCE; BACTERIAL LIPOPOLYSACCHARIDES; MASS-SPECTROMETRY; ACID; GENE; ENDOTOXINS; MUTANT; IDENTIFICATION	An unusual feature of lipid A from plant endosymbionts of the Rhizobiaceae family is the presence of a 27-hydroxyoctacosanoic acid (C28) moiety. An enzyme that incorporates this acyl chain is present in extracts of Rhizobium leguminosarum,Rhizobium etli, and Sinorhizobium meliloti but not Escherichia coli. The enzyme transfers 27-hydroxyoctacosanate from a specialized acyl carrier protein (AcpXL) to the precursor Kdo(2) ((3-deoxy-D-manno-octulosonic acid)(2))-lipid IVA. We now report the identification of five hybrid cosmids that direct the overexpression of this activity by screening similar to4000 lysates of individual colonies of an R. leguminosarum 3841 genomic DNA library in the host strain S. meliloti 1021. In these heterologous constructs, both the C28 acyltransferase and C28-AcpXL are overproduced. Sequencing of a 9-kb insert from cosmid pSSB-1, which is also present in the other cosmids, shows that acpXL and the lipid A acyltransferase gene (lpxXL) are close to each other but not contiguous. Nine other open reading frames around lpxXL were also sequenced. Four of them encode orthologues of fatty acid and/or polyketide biosynthetic enzymes. AcpXL purified from S. meliloti expressing pSSB-1 is fully acylated, mainly with 27-hydroxyoctacosanoate. Expression of lpxXL in E. coli behind a T7 promoter results in overproduction in vitro of the expected R. leguminosarum acyltransferase, which is C28-AcpXL-dependent and utilizes (3-deoxy-D-manno-octulosonic acid)(2)-lipid IVA as the acceptor. These findings confirm that lpxXL is the structural gene for the C28 acyltransferase. LpxXL is distantly related to the lauroyltransferase (LpxL) of E. coli lipid A biosynthesis, but highly significant LpxXL orthologues are present in Agrobacterium tumefaciens, Brucella melitensis, and all sequenced strains of Rhizobium, consistent with the occurrence of long secondary acyl chains in the lipid A molecules of these organisms.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008558, R37GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM-51796, R37 GM051796-06, GM-08558, R37 GM051796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Carty SM, 1999, J BIOL CHEM, V274, P9677, DOI 10.1074/jbc.274.14.9677; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COLONNAROMANO S, 1990, MOL GEN GENET, V223, P138, DOI 10.1007/BF00315806; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MILLER JR, 1972, EXPT MOL GENETIC; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Neumeister B, 1998, INFECT IMMUN, V66, P4151; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; QURESHI N, 1986, J MICROBIOL METH, V5, P65, DOI 10.1016/0167-7012(86)90002-3; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RASOOL O, 1992, INFECT IMMUN, V60, P1699, DOI 10.1128/IAI.60.4.1699-1702.1992; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; URBANIKSYPNIEWSKA T, 1989, ARCH MICROBIOL, V152, P527, DOI 10.1007/BF00425481; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Zahringer U, 1995, Prog Clin Biol Res, V392, P113; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93	61	41	43	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28959	28971		10.1074/jbc.M204525200	http://dx.doi.org/10.1074/jbc.M204525200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12019272	hybrid, Green Accepted			2022-12-25	WOS:000177342600081
J	Guerrero-Esteo, M; Sanchez-Elsner, T; Letamendia, A; Bernabeu, C				Guerrero-Esteo, M; Sanchez-Elsner, T; Letamendia, A; Bernabeu, C			Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING-PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TGF-BETA; CELLULAR-RESPONSES; SIGNALING RECEPTORS; HEART DEVELOPMENT; EXPRESSION; PHOSPHORYLATION; BETAGLYCAN	Endoglin is an auxiliary component of the transforming growth factor-beta (TGF-beta) receptor system, able to associate with the signaling receptor types I (TbetaRI) and II (TbetaRII) in the presence of ligand and to modulate the cellular responses to TGF-beta1. Endoglin cannot bind ligand on its own but requires the presence of the signaling receptors, supporting a critical role for the interaction between endoglin and TbetaRI or TbetaRII. This study shows that full-length endoglin interacts with both TbetaRI and TbetaRII, independently of their kinase activation state or the presence of exogenous TGF-beta1. Truncated constructs encoding either the extracellular or the cytoplasmic domains of endoglin demonstrated that the association with the signaling receptors occurs through both extracellular and cytoplasmic domains. However, a more specific mapping revealed that the endoglin/TbetaRI interaction was different from that of endoglin/TbetaRII. TbetaRII interacts with the amino acid region 437-558 of the extracellular domain of endoglin, whereas TbetaRI interacts not only with the region 437-558 but also with the protein region located between amino acid 437 and the N terminus. Both TbetaRI and TbetaRII interact with the cytoplasmic domain of endoglin, but TbetaRII only interacts when the kinase domain is inactive, whereas TbetaRII remains associated in its active and inactive forms. Upon association, TbetaRI and TbetaRII phosphorylate the endoglin cytoplasmic domain, and then TbetaRI, but not TbetaRII, kinase dissociates from the complex. Conversely, endoglin expression results in an altered phosphorylation state of TbetaRII, TbetaRI, and downstream Smad proteins as well as a modulation of TGF-beta signaling, as measured by the reporter gene expression. These results suggest that by interacting through its extracellular and cytoplasmic domains with the signaling receptors, endoglin might affect TGF-beta responses.	Consejo Super Invest Cientif, Ctr Invest Biol, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Bernabeu, C (corresponding author), Consejo Super Invest Cientif, Ctr Invest Biol, Velazquez 144, Madrid 28006, Spain.		Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Sanchez-Elsner, Tilman/0000-0003-1915-2410				Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Marchuk D A, 1998, Curr Opin Hematol, V5, P332, DOI 10.1097/00062752-199809000-00005; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Qu R, 1998, CELL TISSUE RES, V292, P333, DOI 10.1007/s004410051064; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; Vincent EB, 1998, DEV DYNAM, V213, P237, DOI 10.1002/(SICI)1097-0177(199811)213:3<237::AID-AJA1>3.0.CO;2-M; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Watanabe M, 1999, DEVELOPMENT, V126, P5621; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995	51	173	181	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29197	29209		10.1074/jbc.M111991200	http://dx.doi.org/10.1074/jbc.M111991200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12015308	Green Published, hybrid			2022-12-25	WOS:000177342600109
J	Leaman, DW; Chawla-Sarkar, M; Vyas, K; Reheman, M; Tamai, K; Toji, S; Borden, EC				Leaman, DW; Chawla-Sarkar, M; Vyas, K; Reheman, M; Tamai, K; Toji, S; Borden, EC			Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND; MELANOMA; PROTEIN; XIAP; MITOCHONDRIA; SMAC/DIABLO; RELEASE; KINASE; FAMILY; CELLS	In the course of gene array studies aimed at identifying IFN-stimulated genes associated with interferon 13 (IFN-beta)-induced apoptosis, we identified X-linked inhibitor of apoptosis-associated factor-1 (XAF1) as a novel IFN-stimulated gene. XAF1 mRNA was up-regulated by IFN-alpha and IFN-beta in all cells examined. However, IFNs induced high levels of XAF1 protein predominantly in cell lines sensitive to the proapoptotic effects of IFN-beta. In apoptosis-resistant cells including WM164 melanoma, WM35 melanoma, U937 pro-monocytic leukemia, an HT1080 fibrosarcoma cells, XAF1 mRNA was strongly up-regulated but XAF1 protein was up-regulated only weakly or not at all. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a critical mediator of IFN-beta-induced apoptosis, but most melanoma cell lines were resistant to recombinant TRAIL protein. For example, A375 melanoma cells were defective in TRAIL induction by IFN-beta and were resistant to TRAIL-induced apoptosis. However, IFN-beta pretreatment sensitized them to subsequent recombinant TRAIL-induced apoptosis. A375 cells expressing XAF1 constitutively were more sensitive to TRAIL-induced apoptosis compared with empty vector-transfected cells. The degree of sensitization by XAF1 was similar to that provided by IFN pretreatment and was correlated with the level of XAF1 expressed. Furthermore, the overexpression of the zinc-finger portion of XAF1 blocked IFN-dependent sensitization of A375 melanoma cells to the proapoptotic effects of TRAIL. These results suggested that IFN-dependent induction of XAF1 strongly influenced cellular sensitivity to the proapoptotic actions of TRAIL.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Cleveland Clin Taussig Canc Ctr, Cleveland, OH 44195 USA; Med & Biol Labs Co Ltd, Nagano 3960002, Japan	University System of Ohio; University of Toledo; Cleveland Clinic Foundation	Leaman, DW (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	dleaman@utnet.utoledo.edu	Vyas, Kavita/GRJ-4578-2022; Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911	NATIONAL CANCER INSTITUTE [R01CA090914, R01CA090837] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA90837, CA90914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; Borden EC, 1998, SEMIN ONCOL, V25, P3; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; CHAWLASARKAR M, IN PRESS J IMMUNOL; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Demaeyer E., 1988, INTERFERONS OTHER RE; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Leaman D W, 1998, Prog Mol Subcell Biol, V20, P101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; SEN GC, 1991, HORMONAL CONTROL GEN, P349; SILVERMAN RH, 1996, RIBONUCLEASES STRUCT, P515; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Zhang XD, 2001, CANCER RES, V61, P7339	31	142	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28504	28511		10.1074/jbc.M204851200	http://dx.doi.org/10.1074/jbc.M204851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029096	hybrid			2022-12-25	WOS:000177342600022
J	Ramos, M; Paradela, A; Vazquez, M; Marina, A; Vazquez, J; de Castro, JAL				Ramos, M; Paradela, A; Vazquez, M; Marina, A; Vazquez, J; de Castro, JAL			Differential association of HLA-B*2705 and B*2709 to ankylosing spondylitis correlates with limited peptide subsets but not with altered cell surface stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL ANCHOR; HLA-B27 SUBTYPES; MONOCLONAL-ANTIBODIES; MUTANTS MIMICKING; SUSCEPTIBILITY; EPITOPE; HLA; SPECIFICITY; ANTIGEN; IDENTIFICATION	In contrast to HLA-B*2705, B*2709 is weakly or not associated to ankylosing spondylitis. Both allotypes differ by a single D116H change. We compared the B*2705-and B*2709-bound peptide repertoires by mass spectrometry to quantify the effect of B*2709 polymorphism on peptide specificity. In addition, shared and differentially bound ligands were sequenced to define the structural features of the various peptide subsets. B*2705 shared 79% of its peptide repertoire with B*2709. Shared ligands accounted for 88% of the B*2709-bound repertoire. All B*2705 ligands not bound to B*2709 had G terminal basic or Tyr residues. Most B*2709-bound peptides had C-terminal aliphatic and Phe residues, but two showed C-terminal Arg or Tyr. The B*2709-bound repertoire included 12% of peptides not found in B*2705. These had aliphatic C-terminal residues, which are also favored in B*2705. However, these peptides bound weakly B*2705 in vitro, indicating distinct contribution of secondary anchor residues in both subtypes. Differences in peptide binding did not affect the ratio of native to beta(2)-microglobulin-free HLA-B27 heavy chain at the cell surface. Our results suggest that weaker association of B*2709 with ankylosing spondylitis is based on differential binding of a limited subset of natural ligands by this allotype.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Cantoblanco, E-28049 Madrid, Spain.	aldecastro@cbm.uam.es	Vazquez, Jesus/B-7697-2015; García, Miriam/HGD-0780-2022; Ramírez, Anabel Marina/ABG-7125-2021; Ramos, Manuel/F-5076-2016; GARCIA, MIRIAM NOHEMI N VAZQUEZ/G-8866-2017; Paradela, Alberto/H-2113-2015	Vazquez, Jesus/0000-0003-1461-5092; Ramírez, Anabel Marina/0000-0003-2927-6396; Ramos, Manuel/0000-0002-0404-7936; GARCIA, MIRIAM NOHEMI N VAZQUEZ/0000-0002-9810-884X; Paradela, Alberto/0000-0001-6837-7056				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boisgerault F, 1996, J CLIN INVEST, V98, P2764, DOI 10.1172/JCI119102; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; CALVO V, 1990, J IMMUNOL, V144, P4038; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; DELPORTO P, 1994, J IMMUNOL, V153, P3093; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garcia F, 1998, TISSUE ANTIGENS, V51, P1; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia-Peydro M, 1999, J IMMUNOL, V163, P2299; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Luckey CJ, 2001, J IMMUNOL, V167, P1212, DOI 10.4049/jimmunol.167.3.1212; MARCHIONNI L, 1999, 13 EUR HIST C EUR FE; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Olivieri I, 2002, ARTHRITIS RHEUM-US, V46, P553, DOI 10.1002/art.10127; Olivieri I, 2000, ANN RHEUM DIS, V59, P654; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PARHAM P, 1983, J BIOL CHEM, V258, P6179; Ren EC, 1997, TISSUE ANTIGENS, V49, P67, DOI 10.1111/j.1399-0039.1997.tb02713.x; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; Sesma L, 2002, J BIOL CHEM, V277, P16744, DOI 10.1074/jbc.M200371200; STAM NJ, 1986, J IMMUNOL, V137, P2299; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Tieng V, 1997, IMMUNOGENETICS, V47, P103, DOI 10.1007/s002510050334; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VILLADANGOS JA, 1994, J IMMUNOL, V152, P2317; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	42	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28749	28756		10.1074/jbc.M204155200	http://dx.doi.org/10.1074/jbc.M204155200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042320	hybrid			2022-12-25	WOS:000177342600053
J	Troyer, KP; Wightman, RM				Troyer, KP; Wightman, RM			Temporal separation of vesicle release from vesicle fusion during exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-MEDULLARY CELLS; ISOLATED SECRETORY GRANULES; NUCLEAR MAGNETIC-RESONANCE; BOVINE CHROMAFFIN CELLS; OSMOTIC-PRESSURE; MEMBRANE-FUSION; BEIGE MOUSE; TIME-COURSE; MAST-CELLS; CATECHOLAMINES	During exocytosis, vesicles in secretory cells fuse with the cellular membrane and release their contents in a Ca2+-dependent process. Release occurs initially through a fusion pore, and its rate is limited by the dissociation of the matrix-associated contents. To determine whether this dissociation is promoted by osmotic forces, we have examined the effects of elevated osmotic pressure on release and extrusion from vesicles at mast and chromaffin cells. The identity of the molecules released and the time course of extrusion were measured with fast scan cyclic voltammetry at carbon fiber micro-electrodes. In external solutions of high osmolarity, release events following entry of divalent ions (Ba2+ or Ca2+) were less frequent. However, the vesicles appeared to be fused to the membrane without extruding their contents, since the maximal observed concentrations of events were less than 7% of those evoked in isotonic media. Such an isolated, intermediate fusion state, which we term "kiss-and-hold," was confirmed by immunohistochemistry at chromaffin cells. Transient exposure of cells in the kiss and hold state to isotonic solutions evoked massive release. These results demonstrate that an osmotic gradient across the fusion pore is an important driving force for exocytotic extrusion of granule contents from secretory cells following fusion pore formation.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Wightman, RM (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	rmw@unc.edu						Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Amatore C, 2000, BIOCHIMIE, V82, P481, DOI 10.1016/S0300-9084(00)00213-3; Artalejo CR, 1998, CURR BIOL, V8, pR62, DOI 10.1016/S0960-9822(98)70036-3; Borges R, 1997, J BIOL CHEM, V272, P8325, DOI 10.1074/jbc.272.13.8325; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BRODWICK MS, 1992, J MEMBRANE BIOL, V126, P159; Chizmadzhev YA, 2000, BIOPHYS J, V78, P2241, DOI 10.1016/S0006-3495(00)76771-3; Cuchillo-Ibanez I, 1999, FEBS LETT, V459, P22, DOI 10.1016/S0014-5793(99)01115-1; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FINNEGAN JM, 1995, J BIOL CHEM, V270, P5353, DOI 10.1074/jbc.270.10.5353; HELLE KB, 1985, ACTA PHYSIOL SCAND, V123, P21, DOI 10.1111/j.1748-1716.1985.tb07556.x; HOLZ RW, 1986, J NEUROCHEM, V46, P1835; HOLZ RW, 1986, ANNU REV PHYSIOL, V48, P175; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; JANKOWSKI JA, 1994, J NEUROCHEM, V63, P1739; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; LESZCZYSZYN DJ, 1991, J NEUROCHEM, V56, P1855, DOI 10.1111/j.1471-4159.1991.tb03441.x; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Michael DJ, 1999, ANAL CHEM, V71, P3941, DOI 10.1021/ac990491+; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; NEHER E, 1995, NEUROPHARMACOLOGY, V34, P1423, DOI 10.1016/0028-3908(95)00144-U; Oheim M, 2000, EUR BIOPHYS J BIOPHY, V29, P67, DOI 10.1007/s002490050253; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; PIHEL K, 1994, ANAL CHEM, V66, P4532, DOI 10.1021/ac00096a021; Pihel K, 1996, BIOPHYS J, V71, P1633, DOI 10.1016/S0006-3495(96)79368-2; RABENSTEIN DL, 1987, BIOCHEMISTRY-US, V26, P6923, DOI 10.1021/bi00396a010; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Travis ER, 2000, P NATL ACAD SCI USA, V97, P162, DOI 10.1073/pnas.97.1.162; UVNAS B, 1984, ACTA PHYSIOL SCAND, V120, P99, DOI 10.1111/j.1748-1716.1984.tb07378.x; Uvnas B, 1991, J Physiol Pharmacol, V42, P211; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONRUDEN L, 1993, FEBS LETT, V336, P48, DOI 10.1016/0014-5793(93)81606-Z; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; WHITAKER M, 1987, J PHYSIOL-LONDON, V389, P527, DOI 10.1113/jphysiol.1987.sp016670; Wick PF, 1997, NEUROSCIENCE, V80, P847, DOI 10.1016/S0306-4522(97)00062-6; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; YOO SH, 1992, J BIOL CHEM, V267, P11236; Zimmerberg J, 1999, ADV DRUG DELIVER REV, V38, P197, DOI 10.1016/S0169-409X(99)00029-0; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	50	46	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29101	29107		10.1074/jbc.M202856200	http://dx.doi.org/10.1074/jbc.M202856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034731	Green Published, hybrid			2022-12-25	WOS:000177342600098
J	Vogel, A; Schilling, O; Niecke, M; Bettmer, J; Meyer-Klaucke, W				Vogel, A; Schilling, O; Niecke, M; Bettmer, J; Meyer-Klaucke, W			ElaC encodes a novel binuclear zinc phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; CRYSTAL-STRUCTURE; GLYOXALASE-II; BACILLUS-CEREUS; PROSTATE-CANCER; RESOLUTION; BINDING; PHOSPHATASE; HYDROLYSIS; HYDROLASE	ElaC is a widespread gene found in eubacteria, archaebacteria, and mammals with a highly conserved sequence. Two human ElaC variants were recently associated with cancer (Tavtigian, S. V., Simard, J., Teng, D. H., Abtin, V., Baumgard, M., Beck, A., Camp, N. J., Carillo, A. R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J. M., Frank, D., Frye, C., Ghaffari, S., Gupte, J. S., Hu, R., Iliev, D., Janecki, T., Kort, E. N., Laity, F, E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K. T., Reid, J. E., Richards, S., Schroeder, M., Smith, R., Snyder, S. C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A. M., Labrie, F., Skolnick, M. H., Neuhausen, S., Rommens, J., and Cannon-Albright, L. A. (2001) Nat. Genet. 27, 172-180; Yanaihara, N., Kohno, T., Takakura, S., Takei, M, Otsuka, A., Sunaga, N., Takahashi, M., Yamazaki, M., Tashiro, H., Fukuzumi, Y., Fujimori, Y., Hagiwara, K., Tanaka, T., and Yokota, J. (2001) Genomics 72, 169-179). Analysis of the primary sequence indicates homology to an arylsulfatase and predicts a metallo-beta-lactamase fold. At present, no ElaC gene product has been investigated. We cloned the Escherichia coli ElaC gene and purified the recombinant gene product. An enzymatic analysis showed that ElaC does not encode an arylsulfatase but rather encodes a phosphodiesterase that hydrolyzes bis(p-nitrophenyl)phosphate with a k(cat) of 59 s(-1) and K' of 4 mM. Kinetic analysis of the dimeric enzyme revealed positive cooperativity for the substrate bis(p-nitrophenyl)phosphate with a Hill coefficient of 1.6, whereas hydrolysis of the substrate thymidine-5'-p-nitrophenyl phosphate followed Michaelis-Menten kinetics. Furthermore, the enzyme is capable of binding two zinc or two iron ions. However, it displays phosphodiesterase activity only in the zinc form. The metal environment characterized by zinc K-edge x-ray absorption spectroscopy was modeled with two histidine residues, one carboxylate group, and 1.5 oxygen atoms. This corresponds to the coordination found in other metallo-beta-lactamase domain proteins. Phosphodiesterase activity is strongly dependent on the presence of zinc. These results identify the currently unassigned gene product ElaC to be a novel binuclear zinc phosphodiesterase.	European Mol Biol Lab Outstn Hamburg, D-22603 Hamburg, Germany; Univ Hamburg, Dept Expt Phys, D-22761 Hamburg, Germany; Johannes Gutenberg Univ Mainz, Dept Analyt Chem, D-55099 Mainz, Germany	European Molecular Biology Laboratory (EMBL); University of Hamburg; Johannes Gutenberg University of Mainz	Meyer-Klaucke, W (corresponding author), European Mol Biol Lab Outstn Hamburg, Notkestr 85, D-22603 Hamburg, Germany.	wolfram@embl-hamburg.de	Meyer-Klaucke, Wolfram/G-1148-2010; Schilling, O/AAC-8302-2019	Bettmer, Jorg/0000-0001-9923-9684; Schilling, Oliver/0000-0001-7678-7653				Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Aravind L, 1999, In Silico Biol, V1, P69; BARBEYRON T, 1995, MICROBIOL-UK, V141, P2897, DOI 10.1099/13500872-141-11-2897; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; Dotson SB, 1996, J BIOL CHEM, V271, P25754, DOI 10.1074/jbc.271.42.25754; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Garman E, 1999, STRUCT FOLD DES, V7, pR291, DOI 10.1016/S0969-2126(00)88335-5; George GN, 1998, NAT STRUCT BIOL, V5, P645, DOI 10.1038/1336; GROSSMANN D, 1990, NUCL INSTRUM METH B, V49, P495, DOI 10.1016/0168-583X(90)90299-A; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; MEYERKLAUCKE W, 2000, SYNCHROTRON RAD NEWS, V13, P17; Mijovilovich A, 2001, J SYNCHROTRON RADIAT, V8, P692, DOI 10.1107/S0909049500014540; O'Brien PJ, 2001, BIOCHEMISTRY-US, V40, P5691, DOI 10.1021/bi0028892; Park HI, 1999, ANGEW CHEM INT EDIT, V38, P2914, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2914::AID-ANIE2914>3.0.CO;2-P; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; PETTIFER RF, 1985, J APPL CRYSTALLOGR, V18, P404, DOI 10.1107/S0021889885010627; Rebbeck TR, 2000, AM J HUM GENET, V67, P1014, DOI 10.1086/303096; Roberton AM, 2000, METH MOL B, V125, P417; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Segel I.H, 1993, ENZYME KINETICS; Shim H, 1998, J BIOL CHEM, V273, P17445, DOI 10.1074/jbc.273.28.17445; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b; Yanaihara N, 2001, GENOMICS, V72, P169, DOI 10.1006/geno.2000.6454; Zang TM, 2001, J BIOL CHEM, V276, P4788, DOI 10.1074/jbc.M005090200; Zhao Y, 1997, PROTEIN SCI, V6, P2655	37	75	77	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29078	29085		10.1074/jbc.M112047200	http://dx.doi.org/10.1074/jbc.M112047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029081	hybrid			2022-12-25	WOS:000177342600095
J	Adib-Conquy, M; Cavaillon, JM				Adib-Conquy, M; Cavaillon, JM			Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; FACTOR-KAPPA-B; IFN-GAMMA; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; MOUSE MACROPHAGES; GENE-EXPRESSION; LIPOPOLYSACCHARIDE; CELLS; LPS	Endotoxin tolerance is characterized by a decreased production of proinflammatory cytokines by cultured leukocytes in response to lipopolysaccharide (LPS) following a first exposure to the same stimulus. Gamma interferon (IFNgamma) and granulocyte/monocyte colony-stimulating factor (GM-CSF) are immunostimulatory cytokines that prime monocytes and prevent endotoxin tolerance. In this study, we show that the deactivating effects of LPS, as well as the priming effects of IFNgamma and GM-CSF or their capacity to restore tumor necrosis factor (TNF) production by LPS-tolerized human monocytes are independent of the modulation of TLR2, TLR4, or MD-2. In monocytes pretreated with IFNgamma or GM-CSF, interleukin-1 receptor-associated kinase (IRAK) expression is up-regulated. After LPS stimulation, an increased IRAK kinase activity, a higher MyD88/IRAK association, and a stronger NF-kappaB activation are observed. In contrast, in LPS-tolerized monocytes, IRAK expression and kinase activity, IRAK/MyD88 association, and NF-kappaB activation are inhibited. Furthermore the prevention of tolerance by IFNgamma and GM-CSF was independent of IRAK kinase activity. Our results suggest that these cytokines prevent endotoxin tolerance induced by low but not by high doses of LPS by inhibiting IRAK degradation and by promoting its association with MyD88 after a second LPS stimulation, which in turn leads to NF-kappaB activation and TNF production.	Inst Pasteur, UP Cytokines & Inflammat, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Adib-Conquy, M (corresponding author), Inst Pasteur, UP Cytokines & Inflammat, 28 Rue Dr Roux, F-75724 Paris 15, France.							Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Blackwell TS, 1997, J LEUKOCYTE BIOL, V62, P885, DOI 10.1002/jlb.62.6.885; Bose S, 2001, BIOCHEM J, V353, P291, DOI 10.1042/0264-6021:3530291; Bundschuh DS, 1997, J IMMUNOL, V158, P2862; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cavaillon J-M., 1994, J ENDOTOXIN RES, V1, P21, DOI 10.1177/096805199400100105; CAVAILLON JM, 1995, TRENDS MICROBIOL, V3, P320, DOI 10.1016/S0966-842X(00)88963-5; deWit H, 1996, EXP HEMATOL, V24, P228; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Ertel W, 1997, BLOOD, V89, P1612, DOI 10.1182/blood.V89.5.1612.1612_1612_1620; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Flohe S, 1999, SHOCK, V12, P17, DOI 10.1097/00024382-199907000-00003; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; HAAS JG, 1990, EUR J IMMUNOL, V20, P1181, DOI 10.1002/eji.1830200535; HAYES MP, 1995, CYTOKINE, V7, P427, DOI 10.1006/cyto.1995.0058; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Martin M, 2001, J IMMUNOL, V167, P5278, DOI 10.4049/jimmunol.167.9.5278; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RANDELFRAUSTO M, 1999, INFECT DIS CLIN N AM, V13, P299; Randow F, 1997, J IMMUNOL, V158, P2911; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; TAKASUKA N, 1995, J IMMUNOL, V154, P4803; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; VANDEUREN M, 1994, J INFECT DIS, V169, P157, DOI 10.1093/infdis/169.1.157; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	43	118	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27927	27934		10.1074/jbc.M200705200	http://dx.doi.org/10.1074/jbc.M200705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032143	hybrid			2022-12-25	WOS:000177189800044
J	Ayala, JE; Streeper, RS; Svitek, CA; Goldman, JK; Oeser, JK; O'Brien, RM				Ayala, JE; Streeper, RS; Svitek, CA; Goldman, JK; Oeser, JK; O'Brien, RM			Accessory elements, flanking DNA sequence, and promoter context play key roles in determining the efficacy of insulin and phorbol ester signaling through the malic enzyme and collagenase-1 AP-1 motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 PROMOTER; GENE-EXPRESSION; TRANSCRIPTION FACTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE; BASAL EXPRESSION; RESPONSE ELEMENT; TRANSFERASE-PI; CYCLIC-AMP; MAP-KINASE; FACTOR-I	Insulin stimulates malic enzyme (ME)-chloramphenicol acetyltransferase (CAT) and collagenase-l-CAT fusion gene expression in H4IIE cells through identical activator protein-1 (AP-1) motifs. In contrast, insulin and phorbol esters only stimulate collagenase-l-CAT and not ME-CAT fusion gene expression in HeLa cells. The experiments in this article were designed to explore the molecular basis for this differential cell type- and gene-specific regulation. The results highlight the influence of three variables, namely promoter context, AP-1 flanking sequence, and accessory elements that modulate insulin and phorbol ester signaling through the AP-1 motif. Thus, fusion gene transfection and proteolytic clipping gel retardation assays suggest that the AP-1 flanking sequence affects the conformation of AP-1 binding to the collagenase-1 and ME AP-1 motifs such that it selectively binds the latter in a fully activated state. However, this influence of ME AP-1 flanking sequence is dependent on promoter context. Thus, the ME AP-1 motif will mediate both an insulin and phorbol ester response in HeLa cells when introduced into either the collagenase-1 promoter or a specific heterologous promoter. But even in the context of the collagenase-1 promoter, the effects of both insulin and phorbol esters, mediated through the ME AP-1 motif are dependent on accessory factors.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 761 PRB, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [5T 32 DK07563-12, P60DK20593, P60 DK20593, DK52820, DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R01DK052820, T32DK007563] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barroso I, 1999, J BIOL CHEM, V274, P17997, DOI 10.1074/jbc.274.25.17997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Choi BH, 1998, DNA CELL BIOL, V17, P951, DOI 10.1089/dna.1998.17.951; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GARCIAJIMENEZ C, 1993, ENDOCRINOLOGY, V132, P1537, DOI 10.1210/en.132.4.1537; Griffiths MR, 1998, BIOCHEM J, V335, P19, DOI 10.1042/bj3350019; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kotzka J, 2000, J LIPID RES, V41, P99; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAMOUNAS M, 1991, P NATL ACAD SCI USA, V88, P3530, DOI 10.1073/pnas.88.9.3530; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Miyazaki A, 1999, ENDOCRINOLOGY, V140, P4214, DOI 10.1210/en.140.9.4214; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OBRIEN RM, 2000, DIABETES MELLITUS FU, P291; Ortiz L, 1997, J BIOL CHEM, V272, P23334, DOI 10.1074/jbc.272.37.23334; Pan XL, 2001, ENDOCRINOLOGY, V142, P1635, DOI 10.1210/en.142.4.1635; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Solomon SS, 1997, ENDOCRINOLOGY, V138, P5052, DOI 10.1210/en.138.11.5052; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; Streeper RS, 1998, MOL ENDOCRINOL, V12, P1778, DOI 10.1210/me.12.11.1778; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tu ZH, 1997, BIOCHEM BIOPH RES CO, V238, P285, DOI 10.1006/bbrc.1997.7303; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	57	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27935	27944		10.1074/jbc.M203682200	http://dx.doi.org/10.1074/jbc.M203682200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032154	hybrid			2022-12-25	WOS:000177189800045
J	Kolodziej, SJ; Wagenknecht, T; Strickland, DK; Stoops, JK				Kolodziej, SJ; Wagenknecht, T; Strickland, DK; Stoops, JK			The three-dimensional structure of the human alpha(2)-macroglobulin dimer reveals its structural organization in the tetrameric native and chymotrypsin alpha(2)-macroglobulin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLAMINE TUNGSTATE STAIN; BUTVAR SUPPORT FILM; HUMAN ALPHA-2-MACROGLOBULIN; ELECTRON-MICROSCOPY; BAIT REGION; 3-DIMENSIONAL STRUCTURE; IMMUNOELECTRON MICROSCOPY; PROTEINASE ENTRAPMENT; ALPHA-MACROGLOBULINS; THIOL ESTERS	Three-dimensional electron microscopy reconstructions of the human alpha(2)-macroglobulin (alpha(2)M) dimer and chymotrypsin-transformed alpha(2)M reveal the structural, arrangement of the two dimers that comprise native and proteinase-transformed molecules. They consist of two side-by-side extended strands that have a clockwise and counterclockwise twist about their major axes in the native and transformed structures, respectively. This and other studies show that there are major contacts between the two strands at both ends of the molecule that evidently sequester the receptor binding domains. Upon proteinase cleavage of the bait domains and subsequent thiol ester cleavages, which occur near the central region of the molecule, the two strands separate by 40 Angstrom at both ends of the structure to expose the receptor binding domains and form the arm-like extensions of the transformed alpha(2)M. During the transformation of the structure, the strands untwist to expose the alpha(2)M central cavity to the proteinase. This extraordinary change in the architecture of alpha(2)M functions to completely engulf two molecules of chymotrypsin within its central cavity and to irreversibly encapsulate them.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth Sci, Albany, NY 12201 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Texas System; State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; American Red Cross	Stoops, JK (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA.	James.K.Stoops@uth.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784, R01HL042886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000276] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42886, HL54710, HL50784] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline; NIBIB NIH HHS [EB00276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Boisset N, 1996, J BIOL CHEM, V271, P25762, DOI 10.1074/jbc.271.42.25762; Bowen ME, 1998, J BIOL CHEM, V273, P1825, DOI 10.1074/jbc.273.3.1825; CREWS BC, 1987, BIOCHEMISTRY-US, V26, P5963, DOI 10.1021/bi00393a003; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; FIGLER NL, 1991, J STRUCT BIOL, V106, P237, DOI 10.1016/1047-8477(91)90073-6; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1985, NEW METHODOLOGIES ST, P36; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS P, 1990, BIOCHEMISTRY-US, V29, P7747, DOI 10.1021/bi00485a025; GETTINS PGW, 1994, FEBS LETT, V339, P276, DOI 10.1016/0014-5793(94)80430-3; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; HAVERBACK BJ, 1962, J CLIN INVEST, V41, P972, DOI 10.1172/JCI104576; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; KARKIC L, 1981, INT J PEPT PROT RES, V18, P416; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; Kolodziej SJ, 1998, J STRUCT BIOL, V123, P124, DOI 10.1006/jsbi.1998.4027; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; LAMARRE J, 1991, LAB INVEST, V65, P3; LIU D, 1987, BIOCHEMISTRY-US, V26, P5222; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mettenburg JM, 2002, J BIOL CHEM, V277, P13338, DOI 10.1074/jbc.M106792200; Qazi U, 2000, J STRUCT BIOL, V131, P19, DOI 10.1006/jsbi.2000.4269; Qazi U, 1998, J BIOL CHEM, V273, P8987, DOI 10.1074/jbc.273.15.8987; Qazi U, 1999, J BIOL CHEM, V274, P8137, DOI 10.1074/jbc.274.12.8137; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Shanbhag VP, 1996, ARCH BIOCHEM BIOPHYS, V333, P35, DOI 10.1006/abbi.1996.0361; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOFFLERMEILICKE M, 1988, METHOD ENZYMOL, V164, P503; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STOOPS JK, 1989, BIOCHEM BIOPH RES CO, V161, P216, DOI 10.1016/0006-291X(89)91583-0; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; VLAICU R, 1985, ATHEROSCLEROSIS, V55, P35, DOI 10.1016/0021-9150(85)90164-9; ZHOU ZH, 1995, NAT STRUCT BIOL, V2, P1026, DOI 10.1038/nsb1195-1026	42	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28031	28037		10.1074/jbc.M202714200	http://dx.doi.org/10.1074/jbc.M202714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015318	hybrid			2022-12-25	WOS:000177189800058
J	Olivares, M; Garcia-Perez, JL; Thomas, MC; Heras, SR; Lopez, MC				Olivares, M; Garcia-Perez, JL; Thomas, MC; Heras, SR; Lopez, MC			The non-LTR (long terminal repeat) retrotransposon L1Tc from Trypanosoma cruzi codes for a protein with RNase H activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; NUCLEASE ACTIVITY; ESCHERICHIA-COLI; RIBONUCLEASE-H; DNA-SYNTHESIS; DOMAIN; ELEMENTS; MUTAGENESIS; SPECIFICITY; DISEASE	The deduced amino acid sequence of the region downstream of the reverse transcriptase (RT) motif of the Trypanosoma cruzi L1Tc non-LTR retrotransposon shows a significant homology with the sequence coding for proteins with RNase H activity from different organisms and retroelements. The 25-kDa Hiss-tagged recombinant protein bearing only the L1Tc RNase H domain, named RHL1Tc, exhibits RNase H activity as measured on the [H-3]poly(rA)/poly(dT) hybrid used as substrate as well as on specific homologous and heterologous [(32)p]RNA/DNA hybrids. The mutation of the conserved aspartic acid at position 39 of the enzyme catalytic site, but not of the serine at position 56 (non-conservative amino acid), abolishes protein RNase H activity. The RNase H activity of the RHL1Tc protein is Mg2+-dependent, and it is also active in the presence of the Mn2+ ion. The optimal condition of RNase H activity is found at pH 8 and 37 degreesC, although it also has significant enzymatic activity at 19 degreesC and pH 6. However, it cannot be excluded that the RNase H activity level and its optimal conditions may be different from that of a protein containing both RT and RNase H domains.	Inst Parasitol & Biomed Lopez Neyra, Consejo Super Invest Cientif Calle Ventanill, Dept Biol Mol, Granada 18001, Spain; Hosp Univ San Cecilio, Unidad Invest Med, Serv Andaluz Salud, Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital Universitario San Cecilio	Lopez, MC (corresponding author), Inst Parasitol & Biomed Lopez Neyra, Consejo Super Invest Cientif Calle Ventanill, Dept Biol Mol, N11, Granada 18001, Spain.		Heras, Sara/C-3964-2017; Lopez, Manuel/Z-5641-2019; Thomas, María Carmen PhD/D-9065-2016	Heras, Sara/0000-0003-1677-7685; Lopez, Manuel Carlos/0000-0003-0002-3678; Thomas, M Carmen/0000-0003-3586-9657; Garcia-Perez, Jose Luis/0000-0002-8132-9849				Barroso-Deljesus A, 1999, ANTISENSE NUCLEIC A, V9, P433, DOI 10.1089/oli.1.1999.9.433; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; Berkhout B, 1999, J VIROL, V73, P2365, DOI 10.1128/JVI.73.3.2365-2375.1999; Boeke J. D., 1997, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROUCH R J, 1990, New Biologist, V2, P771; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; EVANS DB, 1994, J BIOL CHEM, V269, P21741; EVANS DB, 1991, J BIOL CHEM, V266, P20583; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Furano AV, 2000, PROG NUCLEIC ACID RE, V64, P255, DOI 10.1016/S0079-6603(00)64007-2; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; Kobil JH, 2000, BIOCHEM BIOPH RES CO, V270, P336, DOI 10.1006/bbrc.2000.2397; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; Martin F, 1996, TRENDS BIOCHEM SCI, V21, P283, DOI 10.1016/S0968-0004(96)80130-7; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; MCCLURE MA, 1993, REVERSE TRANSCRIPTAS, P425; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Olivares M, 1997, J BIOL CHEM, V272, P25224, DOI 10.1074/jbc.272.40.25224; Olivares M, 1999, J BIOL CHEM, V274, P23883, DOI 10.1074/jbc.274.34.23883; Olivares M, 2000, ELECTROPHORESIS, V21, P2973, DOI 10.1002/1522-2683(20000801)21:14&lt;2973::AID-ELPS2973&gt;3.0.CO;2-4; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; Tomilin NV, 1999, INT REV CYTOL, V186, P1; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	36	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28025	28030		10.1074/jbc.M202896200	http://dx.doi.org/10.1074/jbc.M202896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12039956	hybrid			2022-12-25	WOS:000177189800057
J	Meyer, RD; Dayanir, V; Majnoun, F; Rahimi, N				Meyer, RD; Dayanir, V; Majnoun, F; Rahimi, N			The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-RECEPTOR; KINASE-ACTIVITY; C-SRC; CELLS; KDR; ANGIOGENESIS; IDENTIFICATION; PROTEIN; FAMILY; SITES	Vascular endothelial growth factor receptor (VEGFR)-2 plays a critical role in vasculogenesis during embryonic development and pathological angiogenesis, but little is known about the molecular mechanisms governing its functions. Here we investigated the role of tyrosine 1212 on mouse VEGFR-2 autophosphorylation and its signal transduction relay in endothelial cells. Mutation of tyrosine 1212 on VEGFR-2 to phenylalanine severely impaired the ligand-dependent autophosphorylation of VEGFR-2 and its ability to associate with and activate Src. This mutation also reduced the VEGFR-2 ability to phosphorylate phospholipase Cgamma1 and mitogen-activated protein kinase (MAPK). Unlike mutation of tyrosine 1212 to phenylalanine, replacement of tyrosine 1212 with glutamic acid preserved the ligand-dependent activation of VEGFR-2 and activation of VEGFR-2-associated signaling proteins including Src, phospholipase Cgamma1, and MAPK. Further analysis showed that Src activation is not required for activation of VEGFR-2, since cells co-expressing wild type receptor with kinase dead Src or wild type Src displayed no apparent effect in the ligand-dependent autophosphorylation of VEGFR-2. Similarly, expression of wild type VEGFR-2 in fibroblast (SYF) cells obtained from the triple knockout Src family kinases showed normal ligand-dependent autophosphorylation. Collectively, these results suggest that phosphorylation of tyrosine 1212 of VEGFR-2 plays a crucial role in the activation of VEGFR-2 and subsequently VEGFR-2-mediated angiogenesis.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, 715 Albany St,Rm L921, Boston, MA 02118 USA.			Rahimi, Nader/0000-0002-6745-1725	NATIONAL EYE INSTITUTE [R01EY012997] Funding Source: NIH RePORTER; NEI NIH HHS [EY 012997] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; HORTON M, 1987, GENE, V77, P61; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; REITH AD, 1993, ONCOGENE, V8, P45; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SONYANG Z, 1993, CELL, V72, P767; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zisch AH, 2000, ONCOGENE, V19, P177, DOI 10.1038/sj.onc.1203304	33	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27081	27087		10.1074/jbc.M110544200	http://dx.doi.org/10.1074/jbc.M110544200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023952	hybrid			2022-12-25	WOS:000177055900050
J	Bettoun, DJ; Buck, DW; Lu, JF; Khalifa, B; Chin, WW; Nagpal, S				Bettoun, DJ; Buck, DW; Lu, JF; Khalifa, B; Chin, WW; Nagpal, S			A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; INHIBITION; 2A; DIFFERENTIATION; IDENTIFICATION; ACTIVATION; RAPAMYCIN; CARCINOMA; REGULATOR	We provide evidence of a cross-talk between nuclear receptor and Ser/Thr protein phosphatases and show that vitamin D receptor (VDR) interacts with the catalytic subunit of protein phosphatases, PP1c and PP2Ac, and induces their enzymatic activity in a ligand-dependent manner. PP1c specifically interacts with VDR but not retinoic acid receptor a and retinoid X receptor alpha in yeast. Although VDR-PP1c and VDR-PP2Ac interaction is ligand-independent in vivo, 1alpha,25-dihydroxy-vitamin D-3 induces VDR-associated phosphatase activity. Further, VDR modulation of PP1c/PP2Ac activity results in a rapid and specific dephosphorylation and inactivation of their substrate, p70 S6 kinase (p70(S6k)). Finally, we demonstrate that the endogenous VDR, PP1c or PP2Ac, and p70(S6k) are present in a ternary complex in vivo, and the interaction of p70(S6k) with the VDR-PP complex is modulated by the phosphorylation state of the kinase. Since p70(S6k) is essential for G(1)-S transition, our results provide a molecular basis of 1alpha,25-dihydroxyvitamin D-3-induced G(1) block in colon cancer cells.	Eli Lilly & Co, Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA	Eli Lilly	Nagpal, S (corresponding author), Eli Lilly & Co, Gene Regulat Bone & Inflammat Res, Indianapolis, IN 46285 USA.		Nagpal, Sunil/A-8007-2009					Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cross HS, 1996, ANTICANCER RES, V16, P2333; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Mangelsdorf David J., 1994, P319; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PETRISCH C, 2001, GENE DEV, V14, P3093; Prudencio J, 2001, J NATL CANCER I, V93, P745, DOI 10.1093/jnci/93.10.745; SHABAHANG M, 1993, CANCER RES, V53, P3712; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Templeton DJ, 2001, CURR BIOL, V11, pR596, DOI 10.1016/S0960-9822(01)00361-X; VANDEWALLE B, 1994, CANCER LETT, V86, P67, DOI 10.1016/0304-3835(94)90181-3; WALI RK, 1995, CANCER RES, V55, P3050; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	25	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24847	24850		10.1074/jbc.C200187200	http://dx.doi.org/10.1074/jbc.C200187200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12036952	hybrid			2022-12-25	WOS:000176747000002
J	Yamabhai, M; Anderson, RGW				Yamabhai, M; Anderson, RGW			Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; TRANSMEMBRANE DOMAIN; MDCK CELLS; MEMBRANE; VIRUS; ERYTHROBLASTOSIS; ASSOCIATION; MIGRATION; PROTEINS; SIGNAL	Previous studies have shown that similar to60% of the epidermal growth factor receptors (EGFRs) in quiescent fibroblasts are concentrated in the caveolae/raft fraction from purified plasma membranes. This high degree of localization suggests the EGFR contains targeting information for lipid domains. We have used mutagenesis to determine that the region of the receptor that controls targeting to caveolae/rafts resides in the juxtamembrane, second cysteine-rich region. A 60-amino acid-long sequence within this region that is continuous with the transmembrane domain was sufficient to target the transmembrane and cytoplasmic tails of both EGFR and the low density lipoprotein receptor to caveolae/rafts. Two N-linked sugars in this segment were not required for proper targeting, although unglycosylated wild-type receptors did not localize property. We conclude that, in contrast to signals for coated pit localization that are in the cytoplasmic tail, the targeting information for caveolae/rafts is on the extracellular side of the EGFR very close to the membrane.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER S, 1998, FRONT BIOSCI, V3, pD729; Barman S, 2000, J VIROL, V74, P6538, DOI 10.1128/JVI.74.14.6538-6545.2000; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	21	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24843	24846		10.1074/jbc.C200277200	http://dx.doi.org/10.1074/jbc.C200277200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12023273	hybrid			2022-12-25	WOS:000176747000001
J	Zwerner, JP; May, WA				Zwerner, JP; May, WA			Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines	ONCOGENE			English	Article						Ewing's sarcoma; Ewing family tumors; PDGF-C; EWS/FLI	TYROSINE KINASE; MONOCLONAL-ANTIBODY; ALPHA-RECEPTOR; BETA-RECEPTOR; HUMAN GLIOMA; LUNG-CANCER; V-SIS; SARCOMA; TRANSFORMATION; EXPRESSION	Nearly all cases of Ewing Family Tumors (EFT) harbor chimeric EWS/ETS transcription factors which are thought to aberrantly regulate transcriptional targets of phenotypic consequence. We have recently demonstrated that EWS/ETS proteins up-regulate platelet derived growth factor-C (PDGF-C), a novel transforming growth factor. To determine if PDGF-C signaling contributes to the malignant phenotype of EFT cell lines, we attempted to disrupt this presumed autocrine loop. AG1296, a PDGF receptor selective tyrosine kinase inhibitor, markedly inhibits anchorage-independent growth in an EFT cell line. To effect specific disruption, we have developed a dominant negative form of PDGF-C which is appropriately secreted and processed. This mutant has greatly reduced activity as a PDGF receptor agonist. When co-expressed with PDGF-C in a fibroblast transformation model, this dominant negative dramatically inhibits anchorage-independent growth. When this mutant is expressed in EFT cell lines, there is a similar reduction in anchorage-independent growth. This demonstrates that specific inhibition of PDGF-C signaling in EFT cell lines partially reverts their phenotype. These data support a significant role of PDGF-C in the biology of EFT. They also suggest that PDGF-C driven signaling may be a possible therapeutic target of more clinically relevant tyrosine kinase inhibitors.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	May, WA (corresponding author), 1824 6th Ave S,Room 569, Birmingham, AL 35242 USA.				NCI NIH HHS [CA 90666, R01 CA090666] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090666] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMANSON M, 1992, CANCER RES, V52, P3213; HOROWITZ ME, 1997, EWINGS SARCOMA FAMIL; KOVALENKO M, 1994, CANCER RES, V54, P6106; Krystal GW, 1997, CANCER RES, V57, P2203; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Look AT, 1995, ADV CANCER RES, V67, P25, DOI 10.1016/S0065-230X(08)60709-5; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERCOLA M, 1990, GENE DEV, V4, P2333, DOI 10.1101/gad.4.12b.2333; Nakayama Y, 1998, SURG NEUROL, V49, P181, DOI 10.1016/S0090-3019(97)00038-4; NANBERG E, 1993, J BIOL CHEM, V268, P18187; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Scotlandi K, 1998, CANCER RES, V58, P4127; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Sjoblom T, 2001, CANCER RES, V61, P5778; Sulzbacher I, 2000, MODERN PATHOL, V13, P632, DOI 10.1038/modpathol.3880109; Sundberg C, 1997, AM J PATHOL, V151, P479; Uutela M, 2001, CIRCULATION, V103, P2242; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; VIGNAUD JM, 1994, CANCER RES, V54, P5455; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	41	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3847	3854		10.1038/sj.onc.1205486	http://dx.doi.org/10.1038/sj.onc.1205486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032822				2022-12-25	WOS:000175847200003
J	Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M				Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M			Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappa B through an AKT/P70S6K/p38-MAPK pathway	ONCOGENE			English	Article						insulin signaling; differentiation; Ras-transformed; C2C12 cells	ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE DIFFERENTIATION; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; DOWN-REGULATION; PI 3-KINASE; IGF-II; K-RAS; MYOGENESIS	v-H-ras transformed C2C12 (C2Ras) myoblasts, over-expressing p21-Ras protein in the Ras-GTP active form, showed a differentiation-defective phenotype when cultured in low serum as compared with C2C12 myoblasts. Accordingly, the purpose of the present study was to delineate the signaling pathways that restore C2Ras myoblasts differentiation. Inhibition of p42/p44-MAPK with the chemical inhibitor PD98059, and activation of AKT/P70S6K and p38-MAPK with insulin, produced growth arrest (precluding the expression of PCNA, cyclin-D1 and retinoblastoma at the hyperphosphorylated state and inducing the expression of the cell cycle inhibitor p21(Cip)) and myogenesis (multinucleated myotubes formation and induction of creatine kinase, caveolin-3 and alpha-actin). Both events were accompanied by down-regulation of AP-1 and up-regulation of NF-kappaB transcriptional activities. Furthermore, inhibition of NF-kappaB transcriptional activity by the use of the proteasome inhibitor MG132 totally precluded differentiation by insulin + PD98059, demonstrating a direct role for NF-kappaB on C2Ras myogenesis. C2Ras myoblasts failed to restore differentiation when rapamycin or PD169316 were added in the presence of insulin + PD98059, indicating that the activation of both P70S6K and p38-MAPK was necessary to reach a fully differentiated phenotype. Finally, transient transfection of a constitutively active Myr-EGFP-AKT-HA construct (in the presence of PD98059) restored C2Ras myogenesis by its ability to activate P70S6K and p38-MAPK. A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis. Our results are delineating an AKT/P70S6K/p38-MAPK pathway involved in skeletal muscle differentiation.	Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid 28029, Spain	Complutense University of Madrid; Autonomous University of Madrid	Lorenzo, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain.	mlorenzo@farm.ucm.es	; Benito, Manuel/J-5637-2014	Cuadrado, Antonio/0000-0002-4039-7140; Benito, Manuel/0000-0002-7218-406X; Cuadrado, Antonio/0000-0002-3444-9012				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LYONS AB, 1992, CYTOMETRY, V13, P809; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mitin N, 2001, ONCOGENE, V20, P1276, DOI 10.1038/sj.onc.1204223; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V270, P947, DOI 10.1006/bbrc.2000.2522; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Noda Satoshi, 2000, Journal of Medical Investigation, V47, P47; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STRATTON MR, 1989, CANCER RES, V49, P6324; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; Suzuki J, 2000, ONCOGENE, V19, P1138, DOI 10.1038/sj.onc.1203402; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Zarich N, 2000, ONCOGENE, V19, P5872, DOI 10.1038/sj.onc.1203955; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	63	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3739	3753		10.1038/sj.onc.1205469	http://dx.doi.org/10.1038/sj.onc.1205469			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032842				2022-12-25	WOS:000175676000009
J	Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ				Bandyopadhyay, A; Zhu, Y; Malik, SN; Kreisberg, J; Brattain, MG; Sprague, EA; Luo, J; Lopez-Casillas, F; Sun, LZ			Extracellular domain of TGF beta type III receptor inhibits angiogenesis and tumor growth in human cancer cells	ONCOGENE			English	Article						TGF beta type III receptor; angiogenesis; metastasis; tumor growth	TRANSFORMING GROWTH-FACTOR-BETA-1; SUPPRESSES TUMORIGENICITY; IN-VIVO; BETAGLYCAN; EXPRESSION; PROTEOGLYCAN; METASTASIS; ANTIBODIES; MEMBRANE; STIMULATION	TGFbeta overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFbeta by the expression of a soluble TGFbeta type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFbeta appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA; Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Universidad Nacional Autonoma de Mexico	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	SUNL@UTHSCSA.EDU	, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R01CA079683, R01CA075253, R01CA072001, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA79683, CA75253, CA72001, CA50457] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chishima T, 1997, CANCER RES, V57, P2042; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Fajardo LF, 1996, LAB INVEST, V74, P600; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harlow E., 1988, ANTIBODIES LAB MANUA; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; JOSEPH A, 1995, J NATL CANCER I, V87, P372, DOI 10.1093/jnci/87.5.372; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PASSANITI A, 1992, LAB INVEST, V67, P519; PRICE JE, 1990, CANCER RES, V50, P717; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; UEKI N, 1993, JPN J CANCER RES, V84, P589, DOI 10.1111/j.1349-7006.1993.tb02017.x; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; Ye SC, 1999, CANCER RES, V59, P4725; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	43	69	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3541	3551		10.1038/sj.onc.1205439	http://dx.doi.org/10.1038/sj.onc.1205439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032856				2022-12-25	WOS:000175793700005
J	Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A				Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A			HMGA1 and HMGA2 protein expression in mouse spermatogenesis	ONCOGENE			English	Article						HMGA proteins; testis; spermatogenesis; fertility	IFN-BETA GENE; SERTOLI CELLS; HMGI(Y) PROTEINS; TRANSGENIC MICE; MESSENGER-RNA; DNA-BINDING; PROMOTER; RECEPTOR; I(Y); IDENTIFICATION	The high-mobility group A (HMGA) nonhistone chromosomal proteins HMGA1 and HMGA2 play a role in determining chromatin structure and in regulating the transcription of several genes. High levels of these proteins are characteristic of rapidly dividing cells in embryonic tissue and in tumors. The aim of this study was to determine the role of HMGA1 and HMGA2 throughout mouse spermatogenesis. Northern blot analysis and immunocytochemistry showed HMGA1 and HMGA2 expression during the progression from spermatocyte to spermatid. Interestingly, Western blot analysis with antibodies against the HMGA1 gene product revealed only the HMG1c isoform (27 kDa) in the testis; HMGA1a and HMGA1b were undetectable. These three isoforms are encoded by the HMGA1 gene through alternative splicing. Finally, few spermatids and complete absence of spermatozoa were observed in the testes of HMGA2-null mice, which suggests that the HMGA2 gene plays a critical role in male fertility.	Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy; Univ Roma Tor Vergata, Sezione Anat, Dipartimento Biol Cellulare & Sanita Publ, Rome, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Sannio, Fac Sci MM FF NN, Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; Magna Graecia University of Catanzaro; University of Sannio	Chieffi, P (corresponding author), Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Di Agostino, Silvia/S-8566-2019; Fedele, Monica/C-1417-2015; Barchi, Marco/Q-9378-2019; Tramontano, Donatella/AAS-1740-2020; Battista, Sabrina/AAY-2981-2020; Chiariotti, Lorenzo/AAC-5262-2022; Di Agostino, Silvia/H-1121-2018; Chieffi, Paolo/ABA-7892-2020; Pierantoni, Giovanna Maria/O-7527-2015	Fedele, Monica/0000-0002-9171-1312; Barchi, Marco/0000-0003-1104-6234; Battista, Sabrina/0000-0001-5899-9759; Di Agostino, Silvia/0000-0003-3730-1125; Pierantoni, Giovanna Maria/0000-0003-4078-8528; chieffi, paolo/0000-0001-8483-5635; Fusco, Alfredo/0000-0003-3332-5197; Tramontano, Donatella/0000-0002-9308-034X; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Albanesi C, 1996, DEVELOPMENT, V122, P1291; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOOCKFOR FR, 1991, ENDOCRINOLOGY, V129, P256, DOI 10.1210/endo-129-1-256; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; CHUBB C, 1985, ENDOCRINOLOGY, V117, P338, DOI 10.1210/endo-117-1-338; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DEKRETSER DM, 1995, BASIC ENDOCRINOLOGY, P2307; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; GERARD N, 1991, MOL CELL ENDOCRINOL, V82, pR13, DOI 10.1016/0303-7207(91)90019-O; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LEGER H, 1995, MOL CELL BIOL, V15, P3738; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; OKUDA Y, 1994, ENDOCRINE, V2, P1163; Pero R, 2001, AM J PATHOL, V159, P1225, DOI 10.1016/S0002-9440(10)62508-4; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J., 2002, MOL CLONING LAB MANU; Sette C, 1997, DEVELOPMENT, V124, P2267; Sharpe RM, 1994, REGULATION SPERMATOG, P1363; TAMIMI Y, 1993, CANCER RES, V53, P5512; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; vanWert JM, 1998, BIOL REPROD, V59, P704, DOI 10.1095/biolreprod59.3.704; WISNIEWSKI J, 1993, EUR J BIOCHEM, V212, P137, DOI 10.1111/j.1432-1033.1993.tb17643.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	85	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2002	21	22					3644	3650		10.1038/sj/onc/1205501	http://dx.doi.org/10.1038/sj/onc/1205501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032866				2022-12-25	WOS:000175793700015
J	Weng, S; Lauven, M; Schaefer, T; Polontchouk, L; Grover, R; Dhein, S				Weng, S; Lauven, M; Schaefer, T; Polontchouk, L; Grover, R; Dhein, S			Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation	FASEB JOURNAL			English	Article						connexin; intercellular coupling; radioligand binding; phosphorylation	NUCLEAR-MAGNETIC-RESONANCE; VENTRICULAR CELL PAIRS; GUINEA-PIG HEART; PHOSPHORYLATING CONDITIONS; PHOSPHOLIPASE-C; CONDUCTANCE; CHANNELS; CONNEXIN43; FIBRILLATION; PERMEABILITY	Antiarrhythmic peptides enhance gap junction current in pairs of cardiomyocytes and coupling in cardiac tissue. To elucidate the underlying mechanisms, we investigated the effects of the antiarrhythmic peptide AAP10 (GAG-4Hyp-PY-CONH2) on pairs of adult guinea pig ventricular cardiomyocytes and pairs of HeLa cells transfected with rat cardiac connexin 43 (Cx43). By using a double-cell voltage-clamp technique in pairs of cardiomyocytes, we found that under control conditions the gap junction conductance (gj) steadily decreased with time (by 0.292 +/- 0.130 nS/min). Use of 50 nmol/L AAP10 reversed this rundown and increased gj (by +0.290 +/- 0.231 nS/min, P<0.05). This effect of AAP10 could be significantly antagonized by bisindolylmaleimide I (BIM) and by the protein kinase C (PKC) subtype-specific inhibitor CGP54345 (PKC alpha). In HeLa-Cx43 cells, AAP10 exerted the same electrophysiological effect. In these cells, AAP10 activated PKC (determined by using ELISA) in CGP54345-sensitive manner and significantly enhanced incorporation of P-32 into Cx43 with dependence on PKC. If G-protein coupling was inhibited with 1 mM GDP-beta S, we found the effects of AAP10 on P-32 incorporation were also completely abolished. Next, we performed a radioligand binding study with C-14-AAP10 as radioligand and AAPnat as competitor. We found saturable binding of C-14-AAP10 to cardiac membrane preparations, which could be displaced with AAPnat. The K-d of AAP10 was 0.88 nmol/L. We conclude that 1) AAP10 increases gj both in adult cardiomyocytes and in transfected HeLa-Cx43 cells, 2) AAP10 exerts its effect via enhanced PKC-dependent phosphorylation of Cx43, 3) AAP10 activates PKC alpha, and 4) a membrane receptor exists for antiarrhythmic peptides in cardiomyocytes.	Univ Leipzig, Ctr Heart, Clin Cardiac Surg, D-04289 Leipzig, Germany; Univ Halle Wittenberg, Inst Pharmacol, D-06097 Halle An Der Saale, Saale, Germany; Univ Cologne, Inst Pharmacol, D-50931 Cologne, Germany	Heart Center Leipzig GMBH; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Martin Luther University Halle Wittenberg; University of Cologne	Dhein, S (corresponding author), Univ Leipzig, Ctr Heart, Clin Cardiac Surg, Strumpellstr 39, D-04289 Leipzig, Germany.	dhes@medizin.uni-leipzig.de						ALLEN DG, 1985, J PHYSIOL-LONDON, V361, P185, DOI 10.1113/jphysiol.1985.sp015640; AONUMA S, 1980, CHEM PHARM BULL, V28, P3332; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKAUSKAS FF, 1995, BIOPHYS J, V68, P2289, DOI 10.1016/S0006-3495(95)80411-X; Daleau P, 1998, J PHARMACOL EXP THER, V284, P1174; DHEIN S, 1994, N-S ARCH PHARMACOL, V350, P174; Dhein S, 1998, TRENDS PHARMACOL SCI, V19, P229, DOI 10.1016/S0165-6147(98)01192-4; Doble BW, 2000, CIRC RES, V86, P293, DOI 10.1161/01.RES.86.3.293; Grover R, 1998, PEPTIDES, V19, P1725, DOI 10.1016/S0196-9781(98)00129-6; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HRBOLICH JK, 1987, BIOCHEM J, V243, P457, DOI 10.1042/bj2430457; KAMEYAMA M, 1983, J PHYSIOL-LONDON, V336, P345, DOI 10.1113/jphysiol.1983.sp014585; Kjolbye AL, 2000, FASEB J, V14, pA698; KLEBER AG, 1987, CIRC RES, V61, P271, DOI 10.1161/01.RES.61.2.271; KOHAMA Y, 1987, CHEM PHARM BULL, V35, P3928; KUCERA GL, 1988, BIOCHEM BIOPH RES CO, V153, P417, DOI 10.1016/S0006-291X(88)81240-3; KWAK BR, 1995, MOL BIOL CELL, V6, P1707, DOI 10.1091/mbc.6.12.1707; KWAK BR, 1995, EXP CELL RES, V220, P456, DOI 10.1006/excr.1995.1337; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; LOEWENSTEIN WR, 1968, PERSPECT BIOL MED, V11, P260; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESNIL M, 1993, MOL CARCINOGEN, V7, P14, DOI 10.1002/mc.2940070103; METZGER P, 1985, J PHYSIOL-LONDON, V366, P177, DOI 10.1113/jphysiol.1985.sp015791; MORENO AP, 1994, CIRC RES, V74, P1050, DOI 10.1161/01.RES.74.6.1050; Muller A, 1999, AM J PHYSIOL-CELL PH, V276, pC980, DOI 10.1152/ajpcell.1999.276.4.C980; MUNSTER PN, 1993, PFLUG ARCH EUR J PHY, V423, P181, DOI 10.1007/BF00374392; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Nagy JI, 1997, EXP CELL RES, V236, P127, DOI 10.1006/excr.1997.3716; NOMA A, 1987, J PHYSIOL-LONDON, V382, P193, DOI 10.1113/jphysiol.1987.sp016363; Polontchouk L, 2001, J AM COLL CARDIOL, V38, P883, DOI 10.1016/S0735-1097(01)01443-7; SONTHEIMER H, 1995, NEUROMETH, V26, P37; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; SUGIURA H, 1990, CIRC RES, V66, P1095, DOI 10.1161/01.RES.66.4.1095; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Verrecchia F, 1999, J PHYSIOL-LONDON, V516, P447, DOI 10.1111/j.1469-7793.1999.0447v.x; Verrecchia F, 1997, AM J PHYSIOL-CELL PH, V272, pC875, DOI 10.1152/ajpcell.1997.272.3.C875; WEINGART R, 1986, J PHYSIOL-LONDON, V370, P267, DOI 10.1113/jphysiol.1986.sp015934; WIT AL, 1992, VENTRICULAR ARRHYTHM	43	80	88	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1114	+		10.1096/fj.01-0918fje	http://dx.doi.org/10.1096/fj.01-0918fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039852				2022-12-25	WOS:000175973900011
J	Iserovich, P; Wang, D; Ma, L; Yang, H; Zuniga, FA; Pascual, JM; Kuang, KY; De Vivo, DC; Fischbarg, J				Iserovich, P; Wang, D; Ma, L; Yang, H; Zuniga, FA; Pascual, JM; Kuang, KY; De Vivo, DC; Fischbarg, J			Changes in glucose transport and water permeability resulting from the T310I pathogenic mutation in Glut1 are consistent with two transport channels per monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; BLOOD-BRAIN-BARRIER; DEFICIENCY SYNDROME; FACILITATED DIFFUSION; PORE DIMENSIONS; BINDING-SITE; TRANSMEMBRANE; PROTEINS; MEMBRANE	We studied glucose and water passage across wild type (WT) glucose transporter Glut1 and its T310I pathogenic mutant, expressing them in Xenopus laevis oocytes. We found that the T310I mutation produced a 8-fold decrease in glucose transport (zero-trans influx, 13 +/- 2% compared with WT), accompanied by a 2.8-fold increase in the osmotic water permeability (P(f)280 +/- 40% compared with WT), and no change in the diffusional water permeability (P-d). The dependence of glucose and water transports on the amounts of mutant cRNA injected was identical exponential buildups (k = 19.7 ng), suggesting that they depend similarly on the quaternary structure. The E-a values for P-f were 16 +/- 0.4 (WT) and 11 +/- 1 kcal mol(-1) (T310I). We report for the first time that 10 mM D-glucose and L-glucose inhibit P-f by similar to45% in the WT but not in the T310I mutant. In addition, 10 mm maltose reduces P-f (15-20%) in both cases. However, 5 mM L-glucose increased the P-f of T310I, consistent with a cooperative effect. These experimental observations and an analysis of our three-dimensional model strongly suggest the presence of two channels per Glut1 monomer, one of which can be blocked by the mutation T310I.	Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fischbarg, J (corresponding author), Columbia Univ, Dept Physiol, Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Zuniga, Felipe/Q-8035-2019; Zuniga, Felipe A/L-7885-2013	Zuniga, Felipe A./0000-0003-0286-565X; Pascual, Juan/0000-0002-0843-8221	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001698, R01NS037949] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00645] Funding Source: Medline; NEI NIH HHS [EY 08918] Funding Source: Medline; NINDS NIH HHS [NS 01698, NS 37949] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Brockmann K, 2001, ANN NEUROL, V50, P476, DOI 10.1002/ana.1222; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3898, DOI 10.1021/bi00230a014; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; Ducarme P, 1996, J MOL MODEL, V2, P27, DOI 10.1007/s008940050018; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; ECHEVARRIA M, 1993, AM J PHYSIOL, V265, pC1349, DOI 10.1152/ajpcell.1993.265.5.C1349; EGGENA P, 1983, AM J PHYSIOL, V244, pC44, DOI 10.1152/ajpcell.1983.244.1.C44; FINKELSTEIN A, 1987, DISTINGUISHED LECT S, V4, P32; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamill S, 1999, BIOCHEMISTRY-US, V38, P16974, DOI 10.1021/bi9918792; HOLMAN GD, 1987, BIOCHIM BIOPHYS ACTA, V897, P395, DOI 10.1016/0005-2736(87)90437-8; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Hu XJ, 2000, BBA-BIOMEMBRANES, V1466, P306, DOI 10.1016/S0005-2736(00)00175-9; KITCHING JP, 1959, EXP BIOL, V37, P73; Klepper J, 1999, NEUROCHEM RES, V24, P587, DOI 10.1023/A:1022544131826; Klepper J, 2001, HUM MOL GENET, V10, P63, DOI 10.1093/hmg/10.1.63; Klepper J, 1999, PEDIATR RES, V46, P677, DOI 10.1203/00006450-199912000-00006; LAWACZECK R, 1984, BIOPHYS J, V45, P491, DOI 10.1016/S0006-3495(84)84184-3; LOIKE JD, 1993, J GEN PHYSIOL, V102, P897, DOI 10.1085/jgp.102.5.897; MACEY RI, 1984, AM J PHYSIOL, V246, P195; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Olsowski A, 1998, BIOCHEMISTRY-US, V37, P10738, DOI 10.1021/bi980440r; RENKIN EM, 1954, J GEN PHYSIOL, V38, P225; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Venkatesan P, 2000, BIOCHEMISTRY-US, V39, P10649, DOI 10.1021/bi0004394; VERA JC, 1989, MOL CELL BIOL, V9, P4187, DOI 10.1128/MCB.9.10.4187; Wang D, 2000, HUM MUTAT, V16, P224, DOI 10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.0.CO;2-P; WELLNER M, 1994, BIOCHEM J, V299, P813, DOI 10.1042/bj2990813; WIDDAS WF, 1991, CYTOBIOS, V66, P179; YE RG, 1989, BIOCHEMISTRY-US, V28, P824, DOI 10.1021/bi00428a062; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZOTTOLA RJ, 1995, BIOCHEMISTRY-US, V34, P9734, DOI 10.1021/bi00030a011; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	53	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30991	30997		10.1074/jbc.M202763200	http://dx.doi.org/10.1074/jbc.M202763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12032147	hybrid			2022-12-25	WOS:000177579800076
J	Anderson, LA; Perkins, ND				Anderson, LA; Perkins, ND			The large subunit of replication factor C interacts with the histone deacetylase, HDAC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACETYLTRANSFERASE HBO1; DNA-REPAIR; CHROMATIN; TRANSCRIPTION; PROTEINS; COMPLEX; ACETYLATION; ROLES; INHIBITION	Replication factor C (RFC) is a pentameric complex of five distinct subunits that functions as a clamp loader, facilitating the loading of proliferating cell nuclear antigen (PCNA) onto DNA during replication and repair. More recently the large subunit of RFC, RFC (p140), has been found to interact with the retinoblastoma (Rb) tumor suppressor and the CCAAT/enhancer-binding protein a (C/EBPalpha) transcription factor. We now report that RFC (p140) associates with histone deacetylase activity and interacts with histone deacetylase 1 (HDAC1). This complex is functional and when targeted to promoters as a Gal4 fusion, RFC (p140) is a strong, deacetylase-dependent repressor of transcription. Further analysis revealed that RFC (p140) contains two distinct transcriptional repression domains. Moreover, both of these domains interact separately with HDAC1.	Univ Dundee, Sch Life Sci, MSI WTB, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, MSI WTB, Div Gene Regulat & Express, Complex,Dow St, Dundee DD1 5EH, Scotland.							Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hong SH, 2001, J BIOL CHEM, V276, P28098, DOI 10.1074/jbc.M010912200; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Laj A, 1999, MOL CELL BIOL, V19, P6632; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang Y, 2000, GENE DEV, V14, P927; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	37	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29550	29554		10.1074/jbc.M200513200	http://dx.doi.org/10.1074/jbc.M200513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12045192	hybrid			2022-12-25	WOS:000177509300027
J	Kihara, A; Igarashi, Y				Kihara, A; Igarashi, Y			Identification and characterization of a Saccharomyces cerevasiae gene, RSB1, involved in sphingoid long-chain base release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STRESS; SERINE PALMITOYLTRANSFERASE; IMPROVED SOFTWARE; MEMBRANE-PROTEIN; SHUTTLE VECTORS; CEREVISIAE; YEAST; SPHINGOLIPIDS; GROWTH; METABOLISM	Sphingoid long-chain bases (LCBs) and long-chain base phosphates (LCBPs) act as signaling molecules in eukaryotic cells. Accumulation of LCBPs results in cell growth inhibition in yeast, although the mechanism is unknown. Here; we identified a novel yeast gene, RSB1 (resistance to sphingoid long-chain base), by screening a multicopy suppressor of the LCB-sensitive phenotype of the LCBP lyase mutant. RSB1 encodes a polypeptide of 354 amino acids with a molecular mass of 40.4 kDa. Rsb1p is predicted to be an integral membrane protein with seven transmembrane-spanning domains. We demonstrated that cells overproducing Rsb1p showed a decrease in accumulation of exogenously added sphingosine and dihydrosphingosine because of their increased release. This release was ATP-dependent, and a mutant of the predicted ATP binding motif had no activity. Substrate specificity analysis of Rsb1p demonstrated that it is active on LCBs but not on LCBPs or other hydrophobic compounds. These results suggest that Rsb1p is a transporter or flippase that translocates LCBs from the cytoplasmic side toward the extracytoplasmic side of the membrane.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.		KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim S, 2000, GENETICS, V156, P1519; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NESS F, 1995, GENETICS, V140, P945; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Soustre I, 1996, CURR GENET, V30, P121, DOI 10.1007/s002940050110; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WELLS GB, 1983, J BIOL CHEM, V258, P200; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	44	82	83	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30048	30054		10.1074/jbc.M203385200	http://dx.doi.org/10.1074/jbc.M203385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034738	hybrid			2022-12-25	WOS:000177509300087
J	Britto, PJ; Knipling, L; Wolff, J				Britto, PJ; Knipling, L; Wolff, J			The local electrostatic environment determines cysteine reactivity of tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; BINDING-SITE; IN-VIVO; PROTEIN; DISULFIDE; SULFUR; PALMITOYLATION; IDENTIFICATION; PEPTIDES; RESIDUES	Of the 20 cysteines of rat brain tubulin, some react rapidly with sulfhydryl reagents, and some react slowly. The fast reacting cysteines cannot be distinguished with [C-14]iodoacetamide, N-[C-14]ethylmaleimide, or IAE-DANS ([5-((((2-iodoacetyl)amino)ethyl) amino) naphthalene-l-sulfonic acid]), since modification to mole ratios much less than 1 cysteine/dimer always leads to labeling of 6-7 cysteine residues. These have been identified as Cys-305alpha, Cys-315alpha, Cys-316alpha, Cys-347alpha, Cys-376alpha, Cys-241beta, and Cys-356beta by mass spectroscopy and sequencing. This lack of specificity can be ascribed to reagents that are too reactive; only with the relatively inactive chloroacetamide could we identify Cys-347alpha as the most reactive cysteine of tubulin. Using the 3.5-Angstrom electron diffraction structure, it could be shown that the reactive cysteines were within 6.5 Angstrom of positively charged arginines and lysines or the positive edges of aromatic rings, presumably promoting dissociation of the thiol to the thiolate anion. By the same reasoning the inactivity of a number of less reactive cysteines could be ascribed to inhibition of modification by negatively charged local environments, even with some surface-exposed cysteines. We conclude that the local electrostatic environment of cysteine is an important, although not necessarily the only, determinant of its reactivity.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wolff, J (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.	janw@bdg8.niddk.nih.gov		Knipling, Leslie/0000-0002-2636-6460				BAI R, 1996, BIOCHEMISTRY-US, V28, P5606; Belanger C, 2001, FEBS LETT, V499, P59, DOI 10.1016/S0014-5793(01)02513-3; Bizzozero OA, 2001, BBA-PROTEIN STRUCT M, V1545, P278, DOI 10.1016/S0167-4838(00)00291-0; BROCKLEHURST K, 1973, BIOCHEM J, V133, P67, DOI 10.1042/bj1330067; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Chaudhuri AR, 2001, BIOCHEMISTRY-US, V40, P8834, DOI 10.1021/bi0101603; DENICOLASEOANE A, 1990, BIOCHIM BIOPHYS ACTA, V1040, P84, DOI 10.1016/0167-4838(90)90149-A; Dick S, 2002, BBA-PROTEIN STRUCT M, V1594, P219, DOI 10.1016/S0167-4838(01)00305-3; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FRIEDMAN M, 1973, CHEM BIOCH SULFHYRDR; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; Gupta ML, 2001, CELL MOTIL CYTOSKEL, V49, P67, DOI 10.1002/cm.1021; HANSON H, 1958, B SOC CHIM BIOL, V40, P1835; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; Knipling L, 1999, CELL MOTIL CYTOSKEL, V43, P63, DOI 10.1002/(SICI)1097-0169(1999)43:1<63::AID-CM7>3.0.CO;2-Z; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Legault J, 2000, CANCER RES, V60, P985; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MORGAN RS, 1978, INT J PEPT PROT RES, V11, P209; MULLER WEG, 1985, BASIC APPL HISTOCHEM, V29, P321; OBRIEN ET, 1986, J MED CHEM, V29, P1851, DOI 10.1021/jm00160a009; Ozols J, 1997, MOL BIOL CELL, V8, P637, DOI 10.1091/mbc.8.4.637; Pal D, 1998, J BIOMOL STRUCT DYN, V15, P1059, DOI 10.1080/07391102.1998.10509001; Pfeiffer E, 1996, CHEM-BIOL INTERACT, V102, P37, DOI 10.1016/0009-2797(96)03730-1; PRAKASH V, 1992, ARCH BIOCHEM BIOPHYS, V295, P137, DOI 10.1016/0003-9861(92)90499-M; RADKOWSKY AE, 1986, J AM CHEM SOC, V108, P4527, DOI 10.1021/ja00275a045; Ramachandran S, 2000, J MOL BIOL, V297, P733, DOI 10.1006/jmbi.2000.3605; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; Roychowdhury M, 2000, EUR J BIOCHEM, V267, P3469, DOI 10.1046/j.1432-1327.2000.01369.x; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Shan B, 1999, P NATL ACAD SCI USA, V96, P5686, DOI 10.1073/pnas.96.10.5686; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; STEENKAMP DJ, 1993, BIOCHEM J, V292, P295, DOI 10.1042/bj2920295; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VIGUERA AR, 1995, BIOCHEMISTRY-US, V34, P8771, DOI 10.1021/bi00027a028; WILSON L, 1970, BIOCHEMISTRY-US, V9, P4999, DOI 10.1021/bi00827a026; Wolff J, 1996, BIOCHEMISTRY-US, V35, P5910, DOI 10.1021/bi9527395; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; Wolff J, 2000, PROTEIN SCI, V9, P1357, DOI 10.1110/ps.9.7.1357; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Zambito AM, 2001, BIOCHEM BIOPH RES CO, V283, P42, DOI 10.1006/bbrc.2001.4735; Zambito AM, 1997, BIOCHEM BIOPH RES CO, V239, P650, DOI 10.1006/bbrc.1997.7525	46	90	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29018	29027		10.1074/jbc.M204263200	http://dx.doi.org/10.1074/jbc.M204263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023292	hybrid			2022-12-25	WOS:000177342600088
J	Christmas, P; Weber, BM; McKee, M; Brown, D; Soberman, RJ				Christmas, P; Weber, BM; McKee, M; Brown, D; Soberman, RJ			Membrane localization and topology of leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; INNER NUCLEAR-MEMBRANE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ALVEOLAR MACROPHAGES; PHOSPHOLIPASE A(2); GLUTATHIONE; ENVELOPE; IDENTIFICATION; TRANSLOCATION; EXPRESSION	Leukotriene C-4 (LTC4) synthase conjugates LTA(4) with GSH to form LTC4. Determining the site of LTC4 synthesis and the topology of LTC4 synthase may uncover unappreciated intracellular roles for LTC4, as well as how LTC4 is transferred to its export carrier, the multidrug resistance protein-1. We have determined the membrane localization of LTC4 synthase by immunoelectron microscopy. In contrast to the closely related five-lipoxygenase-activating protein, LTC4 synthase is distributed in the outer nuclear membrane and peripheral endoplasmic reticulum but is excluded from the inner nuclear membrane. We have combined immunofluorescence with differential membrane permeabilization to determine the topology of LTC4 synthase. The active site of LTC4 synthase is localized in the lumen of the nuclear envelope and endoplasmic reticulum. These results indicate that the synthesis of LTB4 and LTC4 occurs in different subcellular locations and suggests that LTC4 must be returned to the cytoplasmic side of the membrane for export by multidrug resistance protein-1. The differential localization of two very similar integral membrane proteins suggests that mechanisms other than size-dependent exclusion regulate their passage to the inner nuclear membrane.	Harvard Univ, Sch Med, Dept Med, Renal Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Program Membrane Biol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Charlestown, MA 02129 USA	Harvard University; Harvard University	Soberman, RJ (corresponding author), Bldg 149,Navy Yard,13th St, Charlestown, MA 02129 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061823] Funding Source: NIH RePORTER; NIDDK NIH HHS [1K01DK59991, 5P01DK-0384521] Funding Source: Medline; NIGMS NIH HHS [R01GM-061823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRAVOTTA D, 1990, J CELL BIOL, V111, P2983; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIR I, 1994, J BIOL CHEM, V269, P27807; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Rolls MM, 1999, J CELL BIOL, V146, P29, DOI 10.1083/jcb.146.1.29; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P587; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	31	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28902	28908		10.1074/jbc.M203074200	http://dx.doi.org/10.1074/jbc.M203074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023288	hybrid			2022-12-25	WOS:000177342600074
J	Nyakern-Meazza, M; Narayan, K; Schutt, CE; Lindberg, U				Nyakern-Meazza, M; Narayan, K; Schutt, CE; Lindberg, U			Tropomyosin and gelsolin cooperate in controlling the microfilament system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITES; MUSCLE THIN FILAMENT; F-ACTIN; PLASMA GELSOLIN; NONMUSCLE CELLS; CYTOSKELETAL CHANGES; REGULATORY PROTEIN; KINETIC-ANALYSIS; LEADING-EDGE; DYNAMICS	Tropomyosin has been shown to cause annealing of gelsolin-capped actin filaments. Here we show that tropomyosin is highly efficient in transforming even the smallest gelsolin-actin complexes into long actin filaments. At low concentrations of tropomyosin, the effect of tropomyosin depends on the length of the actin oligomer, and the cooperative nature of the process is a direct indication that tropomyosin induces a conformational change in the gelsolin-actin complexes, altering the structure at the actin (+) end such that capping by gelsolin is abolished. At increased concentrations of tropomyosin, heterodimers, trimers, and tetramers are converted to actin filaments. In addition, evidence is presented demonstrating that gelsolin, once removed from the (+) end of the actin, can reassociate with the newly formed tropomyosin-decorated actin filaments. Interestingly, the binding of gelsolin to the tropomyosin-actin filament complexes saturates at 2 gelsolin molecules per 14 actin and 2 tropomyosins, i.e. two gelsolins per tropomyosin-regulatory unit along the filament. These observations support the view that both tropomyosin and gelsolin are likely to have important functions in addition to those proposed earlier.	Stockholm Univ, Dept Cell Biol, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Princeton Univ, Dept Chem, Henry Hoyt Lab, Princeton, NJ 08544 USA	Stockholm University; Princeton University	Lindberg, U (corresponding author), Stockholm Univ, Dept Cell Biol, Wenner Gren Inst, SE-10691 Stockholm, Sweden.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044038] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44038] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESI JP, 1985, J BIOL CHEM, V260, P3276; ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arora PD, 1999, EXP CELL RES, V250, P155, DOI 10.1006/excr.1999.4521; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; BRYAN J, 1992, METHOD ENZYMOL, V215, P88; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Dabrowska R, 1996, BIOCHEM J, V315, P753, DOI 10.1042/bj3150753; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; DE LA CRUZ EM, 1994, BIOCHEMISTRY-US, V33, P14387, DOI 10.1021/bi00252a003; Dickinson RB, 2002, BIOPHYS J, V82, P605, DOI 10.1016/S0006-3495(02)75425-8; DISSMANN E, 1994, EUR J CELL BIOL, V63, P336; GONSIOR S, 1995, CELL MOTIL CYTOSKEL, V31, P196, DOI 10.1002/cm.970310303; Gunning P, 1998, BIOESSAYS, V20, P892, DOI 10.1002/(SICI)1521-1878(199811)20:11<892::AID-BIES4>3.3.CO;2-4; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; Hoglund A S, 1980, J Muscle Res Cell Motil, V1, P127, DOI 10.1007/BF00711795; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; JAMNEY PA, 1987, NATURE, V325, P362; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; Kinosian HJ, 1998, BIOPHYS J, V75, P3101, DOI 10.1016/S0006-3495(98)77751-3; KOEPF EK, 1992, FEBS LETT, V309, P56, DOI 10.1016/0014-5793(92)80738-3; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1976, J CELL BIOL, V68, P202, DOI 10.1083/jcb.68.2.202; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Maciver SK, 2000, FEBS LETT, V473, P71, DOI 10.1016/S0014-5793(00)01507-6; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; McGough A, 1998, CURR OPIN STRUC BIOL, V8, P166, DOI 10.1016/S0959-440X(98)80034-1; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Moraczewska J, 2000, BIOCHEMISTRY-US, V39, P6891, DOI 10.1021/bi000242b; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; Nyman T, 2002, J MOL BIOL, V317, P577, DOI 10.1006/jmbi.2002.5436; ONJI T, 1988, BIOCHEM BIOPH RES CO, V155, P91, DOI 10.1016/S0006-291X(88)81053-2; Ono S, 2002, J CELL BIOL, V156, P1065, DOI 10.1083/jcb.200110013; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-C; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Prochniewicz E, 1996, J MOL BIOL, V260, P756, DOI 10.1006/jmbi.1996.0435; Puius YA, 2000, BIOCHEMISTRY-US, V39, P5322, DOI 10.1021/bi992364d; Redowicz MJ, 2001, J MUSCLE RES CELL M, V22, P163; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Renoult C, 2001, EUR J BIOCHEM, V268, P6165, DOI 10.1046/j.0014-2956.2001.02574.x; Ressad F, 1998, J BIOL CHEM, V273, P20894, DOI 10.1074/jbc.273.33.20894; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; Schuler H, 1999, EUR J BIOCHEM, V265, P210, DOI 10.1046/j.1432-1327.1999.00716.x; Sheterline P, 1991, Acta Histochem Suppl, V41, P303; SMALL JV, 1978, NATURE, V272, P638, DOI 10.1038/272638a0; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUN HQ, 1994, J BIOL CHEM, V269, P9473; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693	80	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28774	28779		10.1074/jbc.M203360200	http://dx.doi.org/10.1074/jbc.M203360200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048198	hybrid			2022-12-25	WOS:000177342600056
J	Webster, CRL; Srinivasulu, U; Ananthanarayanan, M; Suchy, FJ; Anwer, MS				Webster, CRL; Srinivasulu, U; Ananthanarayanan, M; Suchy, FJ; Anwer, MS			Protein kinase B/Akt mediates cAMP- and cell swelling-stimulated Na+/taurocholate cotransport and Ntcp translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-KINASE LIPID PRODUCTS; SALT EXPORT PUMP; BILE-ACID UPTAKE; PHOSPHOINOSITIDE 3-KINASE; RAT-LIVER; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; INSULIN; EXPRESSION; AKT	Cyclic AMP and cell swelling stimulate hepatic Na+/TC cotransport and Ntcp translocation via the phosphoinositide 3-kinase signaling pathway. To determine the downstream target of the phosphoinositide 3-kinase action, we examined the role of protein kinase B (PYB)/Akt using SB203580 in hepatocytes as well as by transfection with a dominant negative (DN-PKB) or a constitutively active (CA-PKB) form of PKB in HuH-Ntcp cells. Both cAMP and cell swelling stimulated p38 mitogen-activated protein (MAP) kinase as well as PKB activity. Although 100 pm SB203580 inhibited cell swelling- and 8-chlorophenylthio-cAMP-induced activation of both p38 MAP kinase and PKB, 1 muM SB203580 inhibited activation of p38 MAP kinase, but not of PKB, in hepatocytes. 100 gm, but not 1 gm SB203580, inhibited cell swelling- and cAMP-induced increases in taurocholate (TC) uptake and Ntcp translocation in hepatocytes. TC uptake in HuH-Ntcp cells was more than 90% dependent on extracellular Na+. Cyclic AMP and cell swelling increased TC uptake by 50-100% and PKB activity 2-4-fold in HuH-Ntcp cells transfected with the empty vector and failed to increase PKB activity, TC uptake, and Ntcp translocation in DN-PKB-transfected HuH-Ntcp cells. Transfection with CA-PKB increased PKB activity, TC uptake, and Ntcp translocation in HuH-Ntcp cells compared with cells transfected with the empty vector. In contrast, transfection with DN-PKB did not affect basal PKB activity, TC uptake, or Ntcp translocation. Taken together, these results strongly suggest that cell swelling and cAW-mediated stimulation of hepatic Na+/TC cotransport and Ntcp translocation requires activation of PKB and is mediated at least in part via a phosphoinositide 3-kinase/PKB-signaling pathway.	Tufts Univ, Sch Vet Med, Dept Biomed Sci, North Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, Dept Clin Sci, North Grafton, MA 01536 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Tufts University; Tufts University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Anwer, MS (corresponding author), Tufts Univ, Sch Vet Med, Dept Biomed Sci, 200 Westboro Rd, North Grafton, MA 01536 USA.	sawkat.anwer@tufts.edu			NICHD NIH HHS [HD20632] Funding Source: Medline; NIDDK NIH HHS [DK-33436, DK-02721] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020632, R01HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033436, K08DK002721] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Anwer MS, 1998, CURR OPIN GASTROEN, V14, P182, DOI 10.1097/00001574-199805000-00002; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dranoff JA, 1999, HEPATOLOGY, V30, P223, DOI 10.1002/hep.510300136; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Gartung C, 1997, HEPATOLOGY, V25, P284; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kurz AK, 2001, GASTROENTEROLOGY, V121, P407, DOI 10.1053/gast.2001.26262; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Liu Y, 1997, AM J PHYSIOL-GASTR L, V272, pG46, DOI 10.1152/ajpgi.1997.272.1.G46; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meier PJ, 2000, NEWS PHYSIOL SCI, V15, P89; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Misra S, 1999, HEPATOLOGY, V30, p306A; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Simon FR, 1996, AM J PHYSIOL-GASTR L, V271, pG1043, DOI 10.1152/ajpgi.1996.271.6.G1043; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Trauner M, 1999, J HEPATOL, V31, P165, DOI 10.1016/S0168-8278(99)80179-2; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	39	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28578	28583		10.1074/jbc.M201937200	http://dx.doi.org/10.1074/jbc.M201937200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034724	hybrid			2022-12-25	WOS:000177342600031
J	Keeton, EK; Fletcher, TM; Baumann, CT; Hager, GL; Smith, CL				Keeton, EK; Fletcher, TM; Baumann, CT; Hager, GL; Smith, CL			Glucocorticoid receptor domain requirements for chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter in different nucleoprotein contexts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; TRANSACTIVATION DOMAIN; STEROID-RECEPTORS; NUCLEAR RECEPTORS; MMTV PROMOTER; IN-VITRO; PROGESTERONE-RECEPTOR; HORMONE RECEPTORS; GENE-EXPRESSION	The glucocorticoid receptor (GR) contains several activation domains, tau1 (AF-1), tau2, and AF-2, which were initially defined using transiently transfected reporter constructs. Using domain mutations in the context of full-length GR, this study defines those domains required for activation of the mouse mammary tumor virus (MMTV) promoter in two distinct nucleoprotein configurations. A transiently transfected MMTV template with a disorganized, accessible chromatin structure was largely dependent on the AF-2 domain for activation. In contrast, activation of an MMTV template in organized, replicated chromatin requires both domains but has a relatively larger dependence on the tau1 domain. Domain requirements for GR-induced chromatin remodeling of the latter template were also investigated. Mutation of the AF-2 helix 12 domain partially inhibits the induction of nuclease hypersensitivity, but the inhibition was relieved in the absence of tau1, suggesting the occurrence of an important interaction between the two domains. Further mutational analysis indicates that GR-induced chromatin remodeling requires the ligand-binding domain in the region of helix 3. Our study shows that the GR activation surfaces required for transcriptional modulation of a target promoter were determined in part by its chromatin structure. Within a particular cellular environment the GR appears to possess a significant degree of versatility in the mechanism by which it activates a target promoter.	NCI, Lab Receptor Biol& Gene Express, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; George Washington Univ, Dept Genet, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Smith, CL (corresponding author), NCI, Lab Receptor Biol& Gene Express, Ctr Canc Res, NIH, Bldg 41,Rm B608,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.	smithcat@exchange.nih.gov						Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BECKER P, 1984, EMBO J, V3, P2015, DOI 10.1002/j.1460-2075.1984.tb02084.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fletcher TM, 2002, MOL CELL BIOL, V22, P3255, DOI 10.1128/MCB.22.10.3255-3263.2002; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; Fragoso G, 1998, MOL CELL BIOL, V18, P3633, DOI 10.1128/MCB.18.6.3633; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jimenez-Lara AM, 1999, FASEB J, V13, P1073, DOI 10.1096/fasebj.13.9.1073; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Milhon J, 1997, MOL ENDOCRINOL, V11, P1795, DOI 10.1210/me.11.12.1795; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PADMANABHAN R, 1993, METHOD ENZYMOL, V218, P637; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHMITT J, 1993, NUCLEIC ACIDS RES, V21, P2673, DOI 10.1093/nar/21.11.2673; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	57	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28247	28255		10.1074/jbc.M203898200	http://dx.doi.org/10.1074/jbc.M203898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029095	hybrid			2022-12-25	WOS:000177189800083
J	Terry-Lorenzo, RT; Carmody, LC; Voltz, JW; Connor, JH; Li, S; Smith, FD; Milgram, SL; Colbran, RJ; Shenolikar, S				Terry-Lorenzo, RT; Carmody, LC; Voltz, JW; Connor, JH; Li, S; Smith, FD; Milgram, SL; Colbran, RJ; Shenolikar, S			The neuronal actin-binding proteins, neurabin I and neurabin II, recruit specific isoforms of protein phosphatase-1 catalytic subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR MYOSIN PHOSPHATASE; DENDRITIC SPINES; SUBCELLULAR-LOCALIZATION; POSTSYNAPTIC DENSITY; TARGETING SUBUNITS; REGULATORY SUBUNIT; DOPAMINE-RECEPTOR; SKELETAL-MUSCLE; SMOOTH-MUSCLE; NMDA RECEPTOR	Neurabins are protein phosphatase-1 (PP1) targeting subunits that are highly concentrated in dendritic spines and post-synaptic densities. Immunoprecipitation of neurabin I and neurabin II/spinophilin from rat brain extracts sedimented PPIgamma1 and PP1alpha but not PP1beta. In vitro studies showed that recombinant peptides representing central regions of neurabins also preferentially bound PP1gamma1 and PP1alpha from brain extracts and associated poorly with PP1beta. Analysis of PP1 binding to chimeric neurabins suggested that sequences flanking a conserved PP1-binding motif altered their selectivity for PP1beta and their activity as regulators of PP1 in vitro. Assays using recombinant PP1 catalytic subunits and a chimera of PP1 and protein phosphatase-2A indicated that the C-terminal sequences unique to the PP1 isoforms contributed to their recognition by neurabins. Collectively, the results from several different in vitro assays established the rank order of PP1 isoform selection by neurabins to be PP1gamma1 > PP1alpha > PP1beta. This PP1 isoform selectivity was confirmed by immunoprecipitation of neurabin I and II from brain extracts from wild type and mutant PP1gamma null mice. In the absence of PP1gamma1, both neurabins showed enhanced association with PP1alpha but not PP1beta. These studies identified some of the structural determinants in PP1 and neurabins that together contribute to preferential targeting of PP1gamma1 and PP1alpha to the mammalian synapse.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University; Vanderbilt University	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.		Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Carmody, Leigh/0000-0001-7941-2961; Connor, John/0000-0002-8867-7256	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038961, R01NS041063, R01NS037508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52054] Funding Source: Medline; NINDS NIH HHS [NS38961, NS37508, NS41063] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bennett D, 1999, BIOCHEMISTRY-US, V38, P16276, DOI 10.1021/bi9917028; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Brake WG, 2001, ENDOCRINOLOGY, V142, P1284, DOI 10.1210/en.142.3.1284; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; CHU YF, 1994, BBA-PROTEIN STRUCT M, V1208, P45, DOI 10.1016/0167-4838(94)90158-9; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; ENDO S, 1995, J NEUROCHEM, V64, P1833; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Keegan J, 2001, GENET RES, V77, P27, DOI 10.1017/S0016672300004870; Kim SE, 2000, TOHOKU J EXP MED, V191, P39, DOI 10.1620/tjem.191.39; Lin JW, 1998, J NEUROSCI, V18, P2017; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Muly EC, 2001, J COMP NEUROL, V440, P261, DOI 10.1002/cne.1384; Nairn A C, 1992, Curr Opin Neurobiol, V2, P296, DOI 10.1016/0959-4388(92)90118-5; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V194, P930, DOI 10.1006/bbrc.1993.1910; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Snyder GL, 1998, J NEUROSCI, V18, P10297; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, J NEUROCHEM, V68, P2119; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; Varmuza S, 1999, DEV BIOL, V205, P98, DOI 10.1006/dbio.1998.9100; VillaMoruzzi E, 1996, INT J BIOCHEM CELL B, V28, P13, DOI 10.1016/1357-2725(95)00119-0; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	65	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27716	27724		10.1074/jbc.M203365200	http://dx.doi.org/10.1074/jbc.M203365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12016225	hybrid			2022-12-25	WOS:000177189800019
J	Kawasaki, Y; Nakagawa, A; Nagaosa, K; Shiratsuchi, A; Nakanishi, Y				Kawasaki, Y; Nakagawa, A; Nagaosa, K; Shiratsuchi, A; Nakanishi, Y			Phosphatidylserine binding of class B scavenger receptor type I, a phagocytosis receptor of testicular Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HIGH-DENSITY-LIPOPROTEIN; ARREST-SPECIFIC GENE-6; APOPTOTIC CELLS; GERM-CELLS; RAT TESTIS; ANNEXIN-V; NONINVASIVE DETECTION; SPERMATOGENIC CELLS; PRIMARY CULTURE	Testicular Sertoli cells phagocytose apoptotic spermatogenic cells in a manner depending on the membrane phospholipid phosphatidylserine (PS) expressed at the surface of the latter cell type. Our previous studies have indicated that class B scavenger receptor type I (SR-BI) is responsible for the PS-mediated phagocytosis by Sertoli cells. We examined here whether SR-BI binds directly to PS. A cell line acquired the ability to bind to PS-exposing apoptotic cells and to incorporate PS-containing liposomes when it was forced to express SR-BI. Furthermore, the extracellular domain of rat SR-BI fused with human Fc (SRBIecd-Fc) bound to PS with a dissociation equilibrium constant of 2.4 x 10(-7) m in a cell-free solid-phase assay, whereas other phospholipids including phosphatidylethanolamine, phosphatidylinositol, and phosphatidylcholine were poor binding targets. The binding activity was enhanced when CaCl2 was included in the assay or when SRBIecd-Fc was pre-treated with N-glycanase. A portion of the extracellular domain spanning amino acid positions 33 and 191 (numbered with respect to the amino terminus) fused with Fc (SRBI33-191-Fc) showed activity and phospholipid specificity equivalent to those of SRBIecd-Fc. Finally, SRBI33-191-Fc bound to the surface of apoptotic cells with externalized PS, and the injection of SRBI33-191-Fc into the seminiferous tubules of live mice increased the number of apoptotic spermatogenic cells. These results allowed us to conclude that SR-BI is a phagocytosis-inducing PS receptor of Sertoli cells.	Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University	Nakanishi, Y (corresponding author), Kanazawa Univ, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	nakanaka@kenroku.kanazawa-u.ac.jp	Nakanishi, Yoshinobu/D-4602-2014; Nagaosa, Kaz/G-3857-2014; Shiratsuchi, Akiko/D-8391-2015	Nakanishi, Yoshinobu/0000-0002-8767-3587; Nagaosa, Kaz/0000-0002-1695-2562; Shiratsuchi, Akiko/0000-0002-7811-4409				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Allan D.J., 1987, P229; ALLAN DJ, 1992, CELL PROLIFERAT, V25, P241, DOI 10.1111/j.1365-2184.1992.tb01399.x; An XL, 2001, J BIOL CHEM, V276, P35778, DOI 10.1074/jbc.M101364200; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Braun RE, 1998, NAT GENET, V18, P202, DOI 10.1038/ng0398-202; BRINKWORTH MH, 1995, J REPROD FERTIL, V105, P25, DOI 10.1530/jrf.0.1050025; CALLARD GV, 1995, DEV GENET, V16, P140, DOI 10.1002/dvg.1020160207; CHEMES H, 1986, ENDOCRINOLOGY, V119, P1673, DOI 10.1210/endo-119-4-1673; Chimini G, 2001, CELL DEATH DIFFER, V8, P545, DOI 10.1038/sj.cdd.4400833; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Dumont EA, 2001, NAT MED, V7, P1352, DOI 10.1038/nm1201-1352; Dunkel L, 1997, CELL DEATH DIFFER, V4, P171, DOI 10.1038/sj.cdd.4400234; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Francavilla S, 2002, MOL HUM REPROD, V8, P213, DOI 10.1093/molehr/8.3.213; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; Graf GA, 1999, TRENDS CARDIOVAS MED, V9, P221, DOI 10.1016/S1050-1738(00)00031-1; Gumienny TL, 2001, CELL DEATH DIFFER, V8, P564, DOI 10.1038/sj.cdd.4400850; Hengartner MO, 2001, CELL, V104, P325, DOI 10.1016/S0092-8674(01)00219-7; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hikim APS, 1999, REV REPROD, V4, P38; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Horvitz HR, 1999, CANCER RES, V59, p1701S; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; IGARASHI K, 1995, J BIOCHEM-TOKYO, V117, P452, DOI 10.1093/jb/117.2.452; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622; Kaneko N, 1997, J MOL BIOL, V274, P16, DOI 10.1006/jmbi.1997.1375; Kataoka H, 2000, J BIOL CHEM, V275, P6573, DOI 10.1074/jbc.275.9.6573; KERR JB, 1992, J REPROD FERTIL, V95, P825, DOI 10.1530/jrf.0.0950825; Koji T, 2001, BIOL REPROD, V64, P946, DOI 10.1095/biolreprod64.3.946; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luo CW, 2001, J BIOL CHEM, V276, P6913, DOI 10.1074/jbc.M006954200; Maeda Y, 2002, CELL DEATH DIFFER, V9, P742, DOI 10.1038/sj.cdd.4401046; Martin Seamus J., 1996, P107; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MIETHING A, 1992, CELL TISSUE RES, V267, P583, DOI 10.1007/BF00319381; Mizuno K, 1996, CELL DEATH DIFFER, V3, P119; Mizutani T, 1997, BIOCHEM BIOPH RES CO, V234, P499, DOI 10.1006/bbrc.1997.6646; NAGAO Y, 1989, IN VITRO CELL DEV B, V25, P1088, DOI 10.1007/BF02621259; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347; Navazo MDP, 1996, J BIOL CHEM, V271, P15381, DOI 10.1074/jbc.271.26.15381; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Oka K, 1998, P NATL ACAD SCI USA, V95, P9535, DOI 10.1073/pnas.95.16.9535; Pearce SFA, 1998, J BIOL CHEM, V273, P34875, DOI 10.1074/jbc.273.52.34875; PINEAU C, 1991, CELL TISSUE RES, V264, P589, DOI 10.1007/BF00319048; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rosen A, 2001, NAT MED, V7, P664, DOI 10.1038/89034; RUSSELL LD, 1977, ANAT RECORD, V187, P347, DOI 10.1002/ar.1091870307; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Savill J, 1997, BRIT MED BULL, V53, P491; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Setty BNY, 2002, BLOOD, V99, P1564, DOI 10.1182/blood.V99.5.1564; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHIKONE T, 1994, BIOL REPROD, V51, P865, DOI 10.1095/biolreprod51.5.865; Shiratsuchi A, 1999, J BIOCHEM-TOKYO, V126, P1101, DOI 10.1093/oxfordjournals.jbchem.a022555; Shiratsuchi A, 1999, J BIOL CHEM, V274, P5901, DOI 10.1074/jbc.274.9.5901; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; Somersan S, 2001, J CELL BIOL, V155, P501, DOI 10.1083/jcb.200110066; Srivastava A, 2002, J BIOL CHEM, V277, P1855, DOI 10.1074/jbc.M105697200; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; VandenEijnde SM, 1997, CELL DEATH DIFFER, V4, P311, DOI 10.1038/sj.cdd.4400241; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Walport MJ, 2000, NAT GENET, V25, P135, DOI 10.1038/75963; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	92	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27559	27566		10.1074/jbc.M202879200	http://dx.doi.org/10.1074/jbc.M202879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016218	hybrid			2022-12-25	WOS:000177055900107
J	Jablonowski, D; Schaffrath, R				Jablonowski, D; Schaffrath, R			Saccharomyces cerevisiae RNA polymerase II is affected by Kluyveromyces lactis zymocin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE; CARBOXY-TERMINAL DOMAIN; CELL-WALL RECEPTOR; KILLER TOXIN; IN-VIVO; CTDK-I; YEAST; ELONGATOR; TRANSCRIPTION; HOLOENZYME	The G, arrest imposed by Kluyveromyces lactis zymocin on Saccharomyces cerevisiae cells requires a functional RNA polymerase II (pol II) Elongator complex. In studying a link between zymocin and pol II, progressively truncating the arboxyl-terminal domain (CTD) of pol II was found to result in zymocin hypersensitivity as did mutations in four different CTD kinase genes. Consistent with the notion that Elongator preferentially associates with hyperphosphorylated (II0) rather than hypophosphorylated (IIA) pol II, the II0/IIA ratio was imbalanced toward II0 on zymocin treatment and suggests zymocin affects pol II function, presumably in an Elongator-dependent manner. As judged from chromatin immunoprecipitations, zymocin-arrested cells were affected with regards to pol II binding to the ADH1 promotor and pol II transcription of the ADH1 gene. Thus, zymocin may interfere with pol II recycling, a scenario assumed to lead to down-regulation of pol II transcription and eventually causing the observed G(I) arrest.	Univ Halle Wittenberg, Inst Genet, D-06120 Halle An Der Saale, Saale, Germany	Martin Luther University Halle Wittenberg	Schaffrath, R (corresponding author), Univ Halle Wittenberg, Inst Genet, Weinbergweg 10, D-06120 Halle An Der Saale, Saale, Germany.	schaffrath@genetik.uni-halle.de						Ahmed A, 1999, CELL, V99, P283, DOI 10.1016/S0092-8674(00)81659-1; Archambault J, 1996, GENETICS, V142, P737; BUSSEY H, 1979, J BACTERIOL, V140, P888, DOI 10.1128/JB.140.3.888-892.1979; BUTLER AR, 1994, MOL CELL BIOL, V14, P6306, DOI 10.1128/MCB.14.9.6306; BUTLER AR, 1991, EUR J BIOCHEM, V199, P483, DOI 10.1111/j.1432-1033.1991.tb16147.x; BUTLER AR, 1991, YEAST, V7, P617, DOI 10.1002/yea.320070610; BUTLER AR, 1991, J GEN MICROBIOL, V137, P1749, DOI 10.1099/00221287-137-7-1749; DREBOT MA, 1993, MOL GEN GENET, V241, P327, DOI 10.1007/BF00284685; Eisfeld K, 2000, MOL MICROBIOL, V37, P926, DOI 10.1046/j.1365-2958.2000.02063.x; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Fichtner L, 2002, MOL MICROBIOL, V44, P865, DOI 10.1046/j.1365-2958.2002.02928.x; Fichtner L, 2002, MOL MICROBIOL, V43, P783, DOI 10.1046/j.1365-2958.2002.02794.x; Frohloff F, 2001, EMBO J, V20, P1993, DOI 10.1093/emboj/20.8.1993; Hawkes NA, 2002, J BIOL CHEM, V277, P3047, DOI 10.1074/jbc.M110445200; Jablonowski D, 2001, GENETICS, V159, P1479; Jablonowski D, 2001, MOL MICROBIOL, V42, P1095, DOI 10.1046/j.1365-2958.2001.02705.x; Jablonowski D, 2001, YEAST, V18, P1285, DOI 10.1002/yea.776; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Kirchberger J, 1999, BIOCHEM J, V341, P15, DOI 10.1042/0264-6021:3410015; Kishida M, 1996, BIOSCI BIOTECH BIOCH, V60, P798, DOI 10.1271/bbb.60.798; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LEE JM, 1991, GENE EXPRESSION, V1, P149; Li Y, 2001, J BIOL CHEM, V276, P29628, DOI 10.1074/jbc.C100274200; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Schaffrath R, 2000, FUNGAL GENET BIOL, V30, P173, DOI 10.1006/fgbi.2000.1221; SCHMITT M, 1988, J BACTERIOL, V170, P2192, DOI 10.1128/jb.170.5.2192-2196.1988; Schmitt MJ, 1996, MICROBIOL-SGM, V142, P2655, DOI 10.1099/00221287-142-9-2655; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STARK MJR, 1990, YEAST, V6, P1, DOI 10.1002/yea.320060102; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; Sugaya K, 2001, GENE, V274, P77, DOI 10.1016/S0378-1119(01)00615-1; TOKUNAGA M, 1989, NUCLEIC ACIDS RES, V17, P3435, DOI 10.1093/nar/17.9.3435; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WEST ML, 1995, GENETICS, V140, P1223; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704; Yao S, 2000, MOL CELL BIOL, V20, P7080, DOI 10.1128/MCB.20.19.7080-7087.2000; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	47	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26276	26280		10.1074/jbc.M203354200	http://dx.doi.org/10.1074/jbc.M203354200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12015322	hybrid			2022-12-25	WOS:000176908700060
J	Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T				Hatzi, E; Murphy, C; Zoephel, A; Rasmussen, H; Morbidelli, L; Ahorn, H; Kunisada, K; Tontsch, U; Klenk, M; Yamauchi-Takihara, K; Ziche, M; Rofstad, EK; Schweigerer, L; Fotsis, T			N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth	ONCOGENE			English	Article						N-myc; IL-6; STAT3; endothelial cell; neuroblastoma	DNA-BINDING; INTERLEUKIN-6; EXPRESSION; CELLS; ACTIVATION; GENE; INDUCTION; PROTEIN; STAT3; TRANSFORMATION	Angiogenesis is an indispensable prerequisite for the progression and metastasis of solid malignancies. Tumor angiogenesis appears to be governed by alterations of tumor suppressor or oncogenes operant in a broad range of tumors. We have addressed this issue in neuroblastoma, a malignancy characterized by the near-exclusive amplification and overexpression of the N-Myc oncogene. Here, we report that N-Myc overexpression results in down-regulation of interleukin-6 (IL-6) and that IL-6 is an inhibitor of endothelial cell proliferation and VEGF-induced rabbit corneal angiogenesis. STAT3 is instrumental for IL-6 activity as infection with adeno-viruses expressing a phosphorylation deficient STAT3 mutant renders endothelial cells insensitive to the antiproliferative action of IL-6. Finally, though IL-6 does not influence neuroblastoma cell growth, IL-6-expressing xenograft tumors in mice exhibit reduced neovascularization and suppressed growth. Our data shed new light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastomas.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Ioannina Biomed Res Inst, Ioannina, Greece; Boehringer Ingelheim Austria GmbH, Vienna, Austria; Norwegian Radium Hosp, Inst Canc Res, Dept Biophys, Oslo, Norway; Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Osaka Univ, Grad Sch Med, Dept Mol Med, Suita, Osaka, Japan; Univ Essen Gesamthsch, Kinderklin, Abt Hamatol Onkol & Endokrinol, Essen, Germany	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); Boehringer Ingelheim; University of Oslo; University of Siena; Osaka University; University of Duisburg Essen	Fotsis, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.	thfotsis@cc.uoi.gr	Morbidelli, Lucia/AAC-7858-2020; Murphy, Carol/ABE-4282-2021; Morbidelli, Lucia/K-4053-2016	Murphy, Carol/0000-0003-1353-8558; Morbidelli, Lucia/0000-0001-8148-7049				Ambrosino C, 1997, J BIOL CHEM, V272, P14883, DOI 10.1074/jbc.272.23.14883; Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Danielsen T, 1998, INT J CANCER, V76, P836, DOI 10.1002/(SICI)1097-0215(19980610)76:6<836::AID-IJC12>3.0.CO;2-0; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; GRADYLEOPARDI EF, 1986, CANCER RES, V46, P3196; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HILLER S, 1991, ONCOGENE, V6, P969; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mac SM, 2000, MOL CARCINOGEN, V29, P76, DOI 10.1002/1098-2744(200010)29:2<76::AID-MC4>3.0.CO;2-Y; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OHE Y, 1993, BRIT J CANCER, V67, P939, DOI 10.1038/bjc.1993.174; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Rofstad EK, 2000, CANCER RES, V60, P4932; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	40	49	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3552	3561		10.1038/sj.onc.1205440	http://dx.doi.org/10.1038/sj.onc.1205440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032857				2022-12-25	WOS:000175793700006
J	Piu, F; Magnani, M; Ader, ME				Piu, F; Magnani, M; Ader, ME			Dissection of the cytoplasmic domains of cytokine receptors involved in STAT and Ras dependent proliferation	ONCOGENE			English	Article						cytokine receptor; proliferation; STAT; Ras	COLONY-STIMULATING FACTOR; FACTOR G-CSF; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; THROMBOPOIETIN RECEPTOR; TYROSINE-PHOSPHORYLATION; MUSCARINIC RECEPTORS; HEMATOPOIETIC-CELLS; DISTINCT REGIONS; BETA-CHAIN	Cytokine receptors have different signaling requirements which ultimately lead to various physiological responses. In an effort to precisely characterize the molecular determinants involved in the proliferative response mediated by cytokines, we examine dose-dependent proliferation of the betac (GM-CSF, IL-3, IL-5) and homodimeric (G-CSF, TPO) cytokine receptors. Here we report that all cytokine receptors tested activate mostly STAT3 and STAT5. While STAT3 had a positive effect on betac cytokine receptor dependent proliferation, STAT5 was strongly inhibitory. Similarly, G-CSF and TPO lead to activation of STAT3 and STAT5 but, unlike the betac cytokine receptors, both stimulated cellular growth. On the other hand, Ras activation was necessary for all receptor mediated proliferation with the exception of G-CSF R. Truncated mutants of the receptors intracellular domains were used to delineate the functional domains involved in JAK/STAT and Ras activation linked to cellular growth. For instance, we revealed a critical role for the specific alpha subunit of the betac receptors in triggering receptor activation, STAT3 stimulation and proliferation, while Ras activation originates from the distal intracellular portion of the betac subunit. Finally, we showed that proximal STAT activation is the triggering event of G-CSF and TPO receptor function.	ACADIA Pharmaceut Inc, Signal Transduct Grp, San Diego, CA 92121 USA		Piu, F (corresponding author), ACADIA Pharmaceut Inc, Signal Transduct Grp, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	fpiu@acadia-pharm.com	Magnani, Mauro/A-1919-2008					Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; Downward J, 1996, CANCER SURV, V27, P87; Doyle SE, 1998, BLOOD, V92, P867; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Kasper B, 1999, INT J HEMATOL, V70, P241; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Porteu F, 1996, MOL CELL BIOL, V16, P2473; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; RONCO LV, 1994, J BIOL CHEM, V269, P277; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Silvennoinen O, 1997, APMIS, V105, P497, DOI 10.1111/j.1699-0463.1997.tb05047.x; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Ward AC, 1998, BIOCHEM BIOPH RES CO, V251, P117, DOI 10.1006/bbrc.1998.9441; Watanabe S, 1996, CURR OPIN GENET DEV, V6, P587, DOI 10.1016/S0959-437X(96)80088-8; WEISS M, 1993, BLOOD, V82, P3298; Wilks AF, 1996, CANCER SURV, V27, P139; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yoshimura A, 1998, Curr Opin Hematol, V5, P171, DOI 10.1097/00062752-199805000-00004	54	18	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3579	3591		10.1038/sj.onc.1205444	http://dx.doi.org/10.1038/sj.onc.1205444			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032860				2022-12-25	WOS:000175793700009
J	Fritz, G; Mittl, PRE; Vasak, M; Grutter, MG; Heizmann, CW				Fritz, G; Mittl, PRE; Vasak, M; Grutter, MG; Heizmann, CW			The crystal structure of metal-free human EF-hand protein S100A3 at 1.7-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; HUMAN PSORIASIN S100A7; N-15 NMR RELAXATION; RAT APO-S100B(BETA-BETA); 3-DIMENSIONAL STRUCTURE; BACKBONE DYNAMICS; ZINC-BINDING; ION-BINDING; FAMILY; CA2+	S100A3 is a unique member of the EF-hand superfamily of Ca2+-binding proteins. It binds Ca2+ with poor affinity (K-d = 4-35 mm) but Zn2+ with exceptionally high affinity (K-d = 4 nm). This high affinity for Zn2+ is attributed to the unusual high Cys content of S100A3. The protein is highly expressed in fast proliferating hair root cells and astrocytoma pointing toward a function in cell cycle control. We determined the crystal structure of the protein at 1.7 Angstrom The high resolution structure revealed a large distortion of the C-terminal canonical EF-hand, which most likely abolishes Ca2+ binding. The crystal structure of S100A3 allows the prediction of one putative Zn2+ binding site in the C terminus of each subunit of S100A3 involving Cys and His residues in the coordination of the metal ion. Zn2+ binding induces a large conformational change in S100A3 perturbing the hydrophobic interface between two S100A3 subunits, as shown by size exclusion chromatography and CD spectroscopy.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Fritz, G (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	gfritz@bioc.unizh.ch	Mittl, Peer/E-5352-2017; Fritz, Guenter/E-2933-2013	Fritz, Guenter/0000-0002-4571-8812				AKKE M, 1993, BIOCHEMISTRY-US, V32, P9832, DOI 10.1021/bi00088a039; Albertazzi E, 1998, DNA CELL BIOL, V17, P335, DOI 10.1089/dna.1998.17.335; Boni R, 1997, BRIT J DERMATOL, V137, P39, DOI 10.1046/j.1365-2133.1997.17651853.x; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; Brodersen DE, 1998, STRUCTURE, V6, P477, DOI 10.1016/S0969-2126(98)00049-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Camby I, 1999, BRAIN PATHOL, V9, P1; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1999, PROTEIN SCI, V8, P800; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; Fritz G, 1998, BBA-MOL CELL RES, V1448, P264, DOI 10.1016/S0167-4889(98)00138-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Inman KG, 2001, BIOCHEMISTRY-US, V40, P3439, DOI 10.1021/bi0027478; Ishikawa K, 2000, ACTA CRYSTALLOGR D, V56, P559, DOI 10.1107/S0907444900002833; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kizawa K, 1998, J INVEST DERMATOL, V111, P879, DOI 10.1046/j.1523-1747.1998.00385.x; KORDEL J, 1993, J MOL BIOL, V231, P711, DOI 10.1006/jmbi.1993.1322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lewit-Bentley A, 2000, CELL BIOL INT, V24, P799, DOI 10.1006/cbir.2000.0629; Maler L, 1999, J BIOMOL NMR, V13, P233, DOI 10.1023/A:1008315517955; Maler L, 2002, J MOL BIOL, V317, P279, DOI 10.1006/jmbi.2002.5421; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mittl PRE, 2002, ACTA CRYSTALLOGR D, V58, P1255, DOI 10.1107/S0907444902008430; Moroz OV, 2001, ACTA CRYSTALLOGR D, V57, P20, DOI 10.1107/S090744490001458X; Nishikawa T, 1997, J BIOL CHEM, V272, P23037, DOI 10.1074/jbc.272.37.23037; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PERRIN DD, 1971, BIOCHIM BIOPHYS ACTA, V230, P96, DOI 10.1016/0304-4165(71)90057-2; PHILIPPSEN A, 2001, DINO VISUALIZING STR; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Randazzo A, 2001, BIOCHEM BIOPH RES CO, V288, P462, DOI 10.1006/bbrc.2001.5793; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; SKELTON NJ, 1995, J MOL BIOL, V249, P441, DOI 10.1006/jmbi.1995.0308; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4	53	32	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 6	2002	277	36					33092	33098		10.1074/jbc.M200574200	http://dx.doi.org/10.1074/jbc.M200574200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591BC	12045193	hybrid			2022-12-25	WOS:000177859000090
J	Hamano, Y; Grunkemeyer, JA; Sudhakar, A; Zeisberg, M; Cosgrove, D; Morello, R; Lee, B; Sugimoto, H; Kalluri, R				Hamano, Y; Grunkemeyer, JA; Sudhakar, A; Zeisberg, M; Cosgrove, D; Morello, R; Lee, B; Sugimoto, H; Kalluri, R			Determinants of vascular permeability in the kidney glomerulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; BASEMENT-MEMBRANE; SLIT DIAPHRAGM; IV COLLAGEN; NEPHRIN LOCALIZES; PROTEIN TRACER; GENE; IDENTIFICATION; MUTATIONS; ALPHA-3(IV)	The human kidneys filter 70 liters of blood plasma every day. The hallmark of almost all kidney diseases, whether acquired or genetic, is the leakage of plasma proteins into the urine because of alterations in the glomerular filtration unit of the kidney. In this regard, the human mutations in nephrin, podocin, alpha-actinin-4, COL4A3, and COL4A5 genes expressed in the glomeruli have been implicated to cause alterations in glomerular filtration apparatus. Nevertheless, the expression of these proteins in relation to each other in mouse models for glomerular vascular leak is unknown. Additionally, within the glomerulus, the central question of whether the primary filtration barrier is the basement membrane or the epithelial slit diaphragm remains ambiguous. Therefore, in this study, we examined the localization and expression of glomerular epithelial slit diaphragm and glomerular basement membrane proteins implicated in glomerular vascular leak using mice deficient in either the alpha3 chain of type IV collagen, the major constituent of glomerular basement membrane, or LMX1B transcription factor, which regulates the expression of key glomerular type IV collagen genes COL4A3 and COL4A4 or nephrin, a glomerular epithelial slit diaphragm-associated protein. This study demonstrates that decreased expression of slit diaphragm protein, nephrin, correlates with a loss of glomerular filter integrity. Additionally, we demonstrate that defects induced by proteins of glomerular basement membrane lead to an insidious plasma protein leak, whereas the defects induced by proteins in the glomerular epithelia slit diaphragms lead to a precipitous plasma protein leak.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Matrix Biol,Dept Med,Div Gastroenterol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Program Matrix Biol, Boston, MA 02215 USA; Boys Town Natl Res Hosp, Gene Express Lab, Omaha, NE 68131 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Boys Town National Research Hospital; Baylor College of Medicine	Kalluri, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Matrix Biol,Dept Med,Div Gastroenterol, DANA 514,330 Brookline Ave, Boston, MA 02215 USA.	rkalluri@caregroup.harvard.edu	Wilson, Matthew H/K-3193-2013; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51711, DK 55001] Funding Source: Medline; Telethon [494/B] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ABRAHAMSON DR, 1987, AM J PHYSIOL, V253, pF783, DOI 10.1152/ajprenal.1987.253.5.F783; ANDERSON WA, 1972, J HISTOCHEM CYTOCHEM, V20, P672, DOI 10.1177/20.9.672; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Brandenberger R, 2001, J CELL BIOL, V154, P447, DOI 10.1083/jcb.200103069; BRENNER BM, 1991, KIDNEY, P2424; CAULFIEL.JP, 1974, J CELL BIOL, V63, P883, DOI 10.1083/jcb.63.3.883; CAULFIELD JP, 1975, J EXP MED, V142, P61, DOI 10.1084/jem.142.1.61; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; Cosgrove D, 2000, AM J PATHOL, V157, P1649, DOI 10.1016/S0002-9440(10)64802-X; Deen WM, 2001, AM J PHYSIOL-RENAL, V281, pF579; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; Farquhar MG, 1999, J AM SOC NEPHROL, V10, P2645; FARQUHAR MG, 1975, KIDNEY INT, V8, P197, DOI 10.1038/ki.1975.103; GRAHAM RC, 1966, J EXP MED, V124, P1123, DOI 10.1084/jem.124.6.1123; GRAHAM RC, 1968, J HISTOCHEM CYTOCHEM, V16, P275, DOI 10.1177/16.4.275; Holthofer H, 1999, AM J PATHOL, V155, P1681, DOI 10.1016/S0002-9440(10)65483-1; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; JONES DB, 1969, LAB INVEST, V21, P119; Kalluri R, 2000, J BIOL CHEM, V275, P12719, DOI 10.1074/jbc.275.17.12719; KANWAR YS, 1979, J CELL BIOL, V81, P137, DOI 10.1083/jcb.81.1.137; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Karnovsky M J, 1972, Adv Nephrol Necker Hosp, V2, P35; KARNOVSKY MJ, 1969, J HISTOCHEM CYTOCHEM, V17, P751, DOI 10.1177/17.11.751; Kashtan CE, 2001, J AM SOC NEPHROL, V12, P252, DOI 10.1681/ASN.V122252; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; LATTA H, 1970, J ULTRA MOL STRUCT R, V32, P526, DOI 10.1016/S0022-5320(70)80026-0; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; Lenkkeri U, 1999, AM J HUM GENET, V64, P51, DOI 10.1086/302182; MICHAEL AF, 1967, LAB INVEST, V17, P14; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; Morello R, 2001, NAT GENET, V27, P205, DOI 10.1038/84853; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; OLIVER C, 1972, J EXP MED, V136, P291, DOI 10.1084/jem.136.2.291; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SCHNEEBERGER EE, 1974, NEPHRON, V13, P7, DOI 10.1159/000180366; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; Topham PS, 1999, J CLIN INVEST, V104, P1559, DOI 10.1172/JCI7728; VENKATACHALAM MA, 1970, J EXP MED, V132, P1153, DOI 10.1084/jem.132.6.1153; VENKATACHALAM MA, 1969, J CELL BIOL, V42, P480, DOI 10.1083/jcb.42.2.480; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	51	94	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31154	31162		10.1074/jbc.M204806200	http://dx.doi.org/10.1074/jbc.M204806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12039968	hybrid			2022-12-25	WOS:000177579800095
J	Beck, M; Brickley, K; Wilkinson, HL; Sharma, S; Smith, M; Chazot, PL; Pollard, S; Stephenson, FA				Beck, M; Brickley, K; Wilkinson, HL; Sharma, S; Smith, M; Chazot, PL; Pollard, S; Stephenson, FA			Identification, molecular cloning, and characterization of a novel GABA(A) receptor-associated protein, GRIF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTIN-ASSOCIATED PROTEIN; PREDICTING COILED COILS; SUBCELLULAR-LOCALIZATION; ALPHA-SUBUNITS; BRAIN; GEPHYRIN; GABARAP; RAT	A novel 913-amino acid protein, gamma-aminobutyric acid type A (GABA(A)) receptor interacting factor-1 (GRIF-1), has been cloned and identified as a GABA(A) receptor-associated protein by virtue of its specific interaction with the GABA(A) receptor beta2 subunit intracellular loop in a yeast two-hybrid assay. GRIF-1 has no homology with proteins of known function, but it is the rat orthologue of the human ALS2CR3/KIAA0549 gene. GRIF-1 is expressed as two alternative splice forms, GRIF-1a and a C-terminally truncated form, GRIF-1b. GRIF-1 mRNA has a wide distribution with a major transcript size of 6.2 kb. GRIF-1a protein is only expressed in excitable tissues, i.e. brain, heart, and skeletal muscle major immunoreactive bands of M-r similar to 115 and 106 kDa and, in muscle and heart only, an additional 88-kDa species. When expressed in human embryonic kidney 293 cells, GRIF-1a yielded three immunoreactive bands with M-r similar to 115, 106, and 98 kDa. Co-expression of GRIF-1a and alpha1beta2gamma2 GABA(A) receptors in mammalian cells revealed some co-localization in the cell cytoplasm. Anti-FLAG-agarose specifically precipitated GRIF-1(FLAG) and GABAA receptor beta2 subunits from human embryonic kidney 293 cells co-transfected with GRIF-1a(FLAG) and beta2 subunit clones. Further, immobilized GRIF-1-(8-633) specifically precipitated in vitro GABA(A) receptor alpha1 and beta2 subunit immunoreactivities from detergent extracts of adult rat brain. The respective GABA(A) receptor beta2 subunit/GRIF-1 binding domains were mapped using the yeast two-hybrid reporter gene assays. A possible role for GRIF-1 as a GABA(A) receptor beta2 subunit trafficking factor is proposed.	Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	University of London; University College London; University of London School of Pharmacy	Stephenson, FA (corresponding author), Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, 29-39 Brunswick Sq, London WC1N 1AX, England.	anne.stephenson@amsl.ulsop.ac.uk	Smith, Miriam/J-4001-2015	Smith, Miriam/0000-0002-3184-0817				Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; BEDFORD FK, 2000, EUR J NEUROSCI S, V12; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Betz H, 1998, NAT NEUROSCI, V1, P541, DOI 10.1038/2777; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Connolly CN, 1996, P NATL ACAD SCI USA, V93, P9899, DOI 10.1073/pnas.93.18.9899; DUGGAN MJ, 1989, J NEUROCHEM, V53, P132, DOI 10.1111/j.1471-4159.1989.tb07304.x; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Gelfand MS, 1996, P NATL ACAD SCI USA, V93, P9061, DOI 10.1073/pnas.93.17.9061; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Hadano S, 2001, GENOMICS, V71, P200, DOI 10.1006/geno.2000.6392; Hanley JG, 1999, NATURE, V397, P66, DOI 10.1038/16258; Harlow E., 1999, USING ANTIBODIES LAB; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Kannenberg K, 1999, J BIOL CHEM, V274, P21257, DOI 10.1074/jbc.274.30.21257; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Li M, 1997, J BIOL CHEM, V272, P16564, DOI 10.1074/jbc.272.26.16564; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAMALAKI C, 1987, EMBO J, V6, P561, DOI 10.1002/j.1460-2075.1987.tb04791.x; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nusser Z, 1998, J NEUROSCI, V18, P1693; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; Pollard Simon, 1997, Biochemical Society Transactions, V25, p547S; Sambrook J, 2001, MOL CLONING LAB MANU; Sassoe-Pognetto M, 2000, EUR J NEUROSCI, V12, P2205, DOI 10.1046/j.1460-9568.2000.00106.x; Schaerer MT, 2001, J BIOL CHEM, V276, P26597, DOI 10.1074/jbc.M102534200; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; STEPHENSON FA, 1998, FRONT NEUROBIOL, V3, P65; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Tehrani MHJ, 1997, BRAIN RES, V776, P195, DOI 10.1016/S0006-8993(97)01037-8; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	45	88	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30079	30090		10.1074/jbc.M200438200	http://dx.doi.org/10.1074/jbc.M200438200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034717	hybrid			2022-12-25	WOS:000177509300091
J	Kimura, A; Mora, S; Shigematsu, S; Pessin, JE; Saltiel, AR				Kimura, A; Mora, S; Shigematsu, S; Pessin, JE; Saltiel, AR			The insulin receptor catalyzes the tyrosine phosphorylation of caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; STIMULATED GLUCOSE-UPTAKE; NITRIC-OXIDE SYNTHASE; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; GROWTH-FACTOR; LIPID RAFTS; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; RAT ADIPOCYTES	Our previous studies revealed that insulin stimulates the tyrosine phosphorylation of caveolin in 3T3L1 adipocytes. To explore the mechanisms involved in this event, we evaluated the association of the insulin receptor with caveolin. The receptor was detected in a Triton-insoluble low density fraction, co-sedimenting with caveolin and flotillin on sucrose density gradients. We also detected the receptor in caveolin-enriched rosette structures by immunohistochemical analysis of plasma membrane sheets from 3T3L1 adipocytes. Insulin stimulated the phosphorylation of caveolin-1 on Tyr(14). This effect of the hormone was not blocked by overexpression of mutant forms of the Cbl-associated protein that block the translocation of phospho-Cbl to the caveolin-enriched, lipid raft microdomains. Moreover, this phosphorylation event was also unaffected by inhibitors of the MAPK and phosphatidylinositol 3-kinase pathways. Although previous studies demonstrated that the Src family kinase Fyn was highly enriched in caveolae, an inhibitor of this kinase had no effect on insulin-stimulated caveolin phosphorylation. Interestingly, overexpression of a mutant form of caveolin that failed to interact with the insulin receptor did not undergo phosphorylation. Taken together, these data indicate that the insulin receptor directly catalyzes the tyrosine phosphorylation of caveolin.	Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Physiol, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa	Saltiel, AR (corresponding author), Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA.		Mora, Silvia/Y-3131-2019; Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Mora, Silvia/0000-0002-8473-1497	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK060591, R01DK059291, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60591, DK33823, DK59291] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; OKADA T, 1994, J BIOL CHEM, V269, P3568; Razani B, 2001, J BIOL CHEM, V276, P38121; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	51	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30153	30158		10.1074/jbc.M203375200	http://dx.doi.org/10.1074/jbc.M203375200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12036959	hybrid, Green Published			2022-12-25	WOS:000177509300099
J	Shen, ZJ; Nakamoto, T; Tsuji, K; Nifuji, A; Miyazono, K; Komori, T; Hirai, H; Noda, M				Shen, ZJ; Nakamoto, T; Tsuji, K; Nifuji, A; Miyazono, K; Komori, T; Hirai, H; Noda, M			Negative regulation of bone morphogenetic protein/Smad signaling by cas-interacting zinc finger protein in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GROWTH-FACTOR BETA-1; ENHANCES EXPRESSION; CRYSTAL-STRUCTURE; BINDING PROTEINS; DIFFERENTIATION; GENE; CBFA1; INDUCTION; DOMAIN	Bone morphogenetic protein (BMP) signaling regulates body axis determination, apoptosis, and differentiation of various types of cells including neuron, gut, and bone cells. However, the molecules involved in such BMP regulation of biological events have not been fully understood. Here, we examined the involvement of Cas-interacting zinc finger protein (CIZ) in the modulation of BMP2-induced osteoblastic cell differentiation. CIZ overexpression in osteoblastic MC3T3E1 cells suppressed BMP2-enhanced expression of alkaline phosphatase, osteocalcin, and type I collagen genes. Upstream analyses revealed that CIZ overexpression also suppressed BMP2-induced enhancement of the mRNA expression of Cbfa1, which is a critical transcription factor for osteoblastic differentiation. BMP-induced Smad1 and Smad5 activation of GCCG-mediated transcription was blocked in the presence of CIZ overexpression. CIZ overexpression alone in the absence of BMP2 moderately enhanced basal levels of Cbfa1 mRNA expression. CIZ overexpression also enhanced 1.8-kb Cbfa1 promoter activity in the absence of BMP2, whereas it suppressed the promoter activity in the presence of BMP2. Finally, CIZ overexpression suppressed the formation of mineralized nodules in osteoblastic cell cultures. These data indicate that CIZ is a novel type inhibitor of BMP/Smad signaling.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 101, Japan; Univ Tokyo, Dept Hematol & Oncol, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; Osaka Univ, Sch Med, Dept Mol Med, Osaka, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; University of Tokyo; Osaka University	Noda, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, 3-10 Kanda Sunugadai 2 Chome, Tokyo 101, Japan.	noda.mph@mri.tmd.ac.jp	Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380				Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto-Iwamoto M, 2000, J BONE MINER RES, V15, P1659, DOI 10.1359/jbmr.2000.15.9.1659; Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097-4644(20000901)78:3<476::AID-JCB12>3.0.CO;2-5; Furuya K, 2000, EXP CELL RES, V261, P329, DOI 10.1006/excr.2000.5051; GITELMAN SE, 1994, J CELL BIOL, V126, P1595, DOI 10.1083/jcb.126.6.1595; Gori F, 2001, J BIOL CHEM, V276, P46515, DOI 10.1074/jbc.M105757200; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hashimoto K, 1999, DEVELOPMENT, V126, P2771; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hollnagel A, 1997, J BONE MINER RES, V12, P1993, DOI 10.1359/jbmr.1997.12.12.1993; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Iemura S, 1999, J BIOL CHEM, V274, P26843, DOI 10.1074/jbc.274.38.26843; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; Kearns AE, 2001, J BIOL CHEM, V276, P42213, DOI 10.1074/jbc.M106163200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Macias D, 1997, DEVELOPMENT, V124, P1109; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Merino R, 1999, DEVELOPMENT, V126, P5515; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Narita T, 2000, DEVELOPMENT, V127, P981; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352; Pasco S, 2000, J BIOL CHEM, V275, P32999, DOI 10.1074/jbc.M005235200; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Wozney JM, 1998, EUR J ORAL SCI, V106, P160, DOI 10.1111/j.1600-0722.1998.tb02170.x; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	49	59	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29840	29846		10.1074/jbc.M203157200	http://dx.doi.org/10.1074/jbc.M203157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023967	hybrid			2022-12-25	WOS:000177509300063
J	Geyer, M; Yu, HF; Mandic, R; Linnemann, T; Zheng, YH; Fackler, OT; Peterlin, BM				Geyer, M; Yu, HF; Mandic, R; Linnemann, T; Zheng, YH; Fackler, OT; Peterlin, BM			Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CD4 DOWN-REGULATION; CELL-SURFACE CD4; HIV-1 NEF; T-CELLS; VACUOLAR (H+)-ATPASE; VIRAL INFECTIVITY; DILEUCINE MOTIF; SACCHAROMYCES-CEREVISIAE; VESICLE FORMATION	Nef is an accessory protein of human and simian immunodeficiency viruses (HIV and SIV) that is required for efficient viral infectivity and pathogenicity. It decreases the expression of CD4 on the surface of infected cells. V1H is the regulatory subunit H of the vacuolar membrane ATPase (V-ATPase). Previously, the interaction between Nef and V1H has been found to facilitate the internalization of CD4, suggesting that V1H could connect Nef to the endocytic machinery. In this study, we demonstrate that V1H binds to the C-terminal flexible loop in Nef from HIV-1 and to the medium chain (mu2) of the adaptor protein complex 2 (AP-2) in vitro and in vivo. The interaction sites of V1H and mu2 were mapped to a central region in V1H from positions 133 to 363, which contains 4 armadillo repeats, and to the N-terminal adaptin-binding domain in mu2 from positions 1 to 145. Fusing Nef to V1H reproduced the appropriate trafficking of Nef. This chimera internalized CD4 even in the absence of the C-terminal flexible loop in Nef. Finally, blocking the expression of V1H decreased the enhancement of virion infectivity by Nef. Thus, V1H can function as an adaptor for interactions between Nef and AP-2.	Univ Calif San Francisco, Mt Zion Canc Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Univ Marburg, Dept Otorhinolaryngol Head & Neck Surg, D-35037 Marburg, Germany; Univ Heidelberg, Dept Virol, Inst Hyg, D-69120 Heidelberg, Germany	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; Max Planck Society; Philipps University Marburg; Ruprecht Karls University Heidelberg	Peterlin, BM (corresponding author), Univ Calif San Francisco, Mt Zion Canc Res Ctr, Dept Med, Rm 226,Box 0703,2340 Sutter St, San Francisco, CA 94143 USA.		Zheng, Yong-Hui/AAP-4492-2021; Mandic, Robert/Y-4324-2019	Zheng, Yong-Hui/0000-0002-1098-7385; Mandic, Robert/0000-0003-2379-5515; Geyer, Matthias/0000-0002-7718-5002; Fackler, Oliver Till/0000-0003-2982-4209	NIAID NIH HHS [1R01AI38532-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038532] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Craig HM, 1998, P NATL ACAD SCI USA, V95, P11229, DOI 10.1073/pnas.95.19.11229; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 2001, J VIROL, V75, P6601, DOI 10.1128/JVI.75.14.6601-6608.2001; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fackler OT, 2001, CURR BIOL, V11, P1294, DOI 10.1016/S0960-9822(01)00373-6; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Geyer M, 2001, EMBO REP, V2, P580, DOI 10.1093/embo-reports/kve141; Geyer M, 2001, FEBS LETT, V496, P91, DOI 10.1016/S0014-5793(01)02394-8; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greenberg ME, 1997, EMBO J, V16, P6964, DOI 10.1093/emboj/16.23.6964; Gross I, 2000, EMBO J, V19, P103, DOI 10.1093/emboj/19.1.103; Grzesiek S, 1996, BIOCHEMISTRY-US, V35, P10256, DOI 10.1021/bi9611164; GUATELLI JC, 1990, J VIROL, V64, P4093, DOI 10.1128/JVI.64.9.4093-4098.1990; HARRIS MPG, 1994, J MOL BIOL, V241, P136; HO MN, 1993, J BIOL CHEM, V268, P18286; Janvier K, 2001, J VIROL, V75, P3971, DOI 10.1128/JVI.75.8.3971-3976.2001; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Klimkait T, 1998, ARCH VIROL, V143, P2109, DOI 10.1007/s007050050447; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; LIU Q, 1994, J BIOL CHEM, V269, P31592; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Mandic R, 2001, MOL BIOL CELL, V12, P463, DOI 10.1091/mbc.12.2.463; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Messmer D, 2000, J VIROL, V74, P2406, DOI 10.1128/JVI.74.5.2406-2413.2000; MILLER MD, 1995, J VIROL, V69, P579, DOI 10.1128/JVI.69.1.579-584.1995; MYERS M, 1993, J BIOL CHEM, V268, P9184; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Parnes J R, 1994, Semin Immunol, V6, P221, DOI 10.1006/smim.1994.1029; Petit C, 2001, VIROLOGY, V286, P225, DOI 10.1006/viro.2001.0984; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; ROBERTGUROFF M, 1990, J VIROL, V64, P3391, DOI 10.1128/JVI.64.7.3391-3398.1990; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rossi F, 1996, VIROLOGY, V217, P397, DOI 10.1006/viro.1996.0130; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Zheng YH, 2001, CURR BIOL, V11, P875, DOI 10.1016/S0960-9822(01)00237-8; Zhou ZM, 1999, J BIOL CHEM, V274, P15913, DOI 10.1074/jbc.274.22.15913; Zhou ZM, 1998, J BIOL CHEM, V273, P5878, DOI 10.1074/jbc.273.10.5878	62	87	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28521	28529		10.1074/jbc.M200522200	http://dx.doi.org/10.1074/jbc.M200522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032142	hybrid			2022-12-25	WOS:000177342600024
J	Gregori, C; Porteu, A; Mitchell, C; Kahn, A; Pichard, AL				Gregori, C; Porteu, A; Mitchell, C; Kahn, A; Pichard, AL			In vivo functional characterization of the aldolase B gene enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NUCLEAR FACTOR-I; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; LIVER-SPECIFIC TRANSCRIPTION; HORMONAL-REGULATION; BINDING-PROTEIN; FRUCTOSE INTOLERANCE; INTRONIC ENHANCER; MAMMALIAN-CELLS; TRANSGENIC MICE	A 400-bp intronic enhancer fragment in conjunction with the proximal promoter of the aldolase B gene provided correct tissue-specific expression in transgenic mice together with hormonal regulation in the liver. We investigated in vivo and in cultured cells the contribution of the intronic regulatory sequences and their interaction with the promoter elements in controlling aldolase B gene expression. Transgene activity was completely abolished by disruption of the two hepatocyte nuclear factor 1 (HNF1) binding sites in the enhancer, whereas mutation of one HNF1 site had no effect in the liver but strongly decreased activity in the kidney. Our data show that the HNF1 binding site(s) in the enhancer were key regulators of aldolase B transgene expression both in the liver and kidney. Deletion of the CCAAT/enhancer-binding protein site in the promoter completely abolished the enhancer function in HepG2 cells. These results suggest that expression of the aldolase B gene in the liver requires cooperative interactions between CCAAT/enhancer-binding protein and HNF1. Deletion of the HNF4 binding site in the enhancer suppressed expression in both liver and kidney in half of the transgenic lines, suggesting that this element might play a role in chromatin opening at the insertion site. We firmly establish that the endogenous aldolase B gene's first response to glucagon or cyclic AMP exposure was a transient increase in the expression in the liver, followed by a secondary decline in the transcription, as previously reported. This response was reproduced by all transgenes studied, indicating that neither HNF1 nor HNF4 binding sites in the enhancer were involved in this biphasic cyclic AMP response.	Inst Cochin Genet Mol, Dept Genet Dev & Pathol Mol, INSERM, CNRS, F-75014 Paris, France; Univ Paris 05, F-75014 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Pichard, AL (corresponding author), Inst Cochin Genet Mol, Dept Genet Dev & Pathol Mol, INSERM, CNRS, 24 Rue Faubourg St Jacques, F-75014 Paris, France.							Ali M, 1998, J MED GENET, V35, P353, DOI 10.1136/jmg.35.5.353; ANGRAND PO, 1994, CELL GROWTH DIFFER, V5, P957; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; COX TM, 1994, FASEB J, V8, P62, DOI 10.1096/fasebj.8.1.8299892; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Faust DM, 1996, MOL CELL BIOL, V16, P3125; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; Mitchell C, 2000, HUM MOL GENET, V9, P1597, DOI 10.1093/hmg/9.11.1597; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Soubt MK, 1998, MOL CELL BIOL, V18, P4698, DOI 10.1128/MCB.18.8.4698; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; VAULONT S, 1984, BIOCHEM BIOPH RES CO, V125, P135, DOI 10.1016/S0006-291X(84)80345-9; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WEBER A, 1984, J BIOL CHEM, V259, P1798; WU KJ, 1994, J BIOL CHEM, V269, P1177; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; You M, 2002, ARCH BIOCHEM BIOPHYS, V398, P79, DOI 10.1006/abbi.2001.2713; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	41	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28618	28623		10.1074/jbc.M204047200	http://dx.doi.org/10.1074/jbc.M204047200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034748	hybrid			2022-12-25	WOS:000177342600036
J	Niswender, CM; Ishihara, RW; Judge, LM; Zhang, C; Shokat, KM; McKnight, GS				Niswender, CM; Ishihara, RW; Judge, LM; Zhang, C; Shokat, KM; McKnight, GS			Protein engineering of protein kinase A catalytic subunits results in the acquisition of novel inhibitor sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNNATURAL NUCLEOTIDE SPECIFICITY; TYROSINE KINASE; V-SRC; EXPRESSION; GENE; ISOFORMS	Analysis of the role of specific protein kinases in signal transduction networks has relied heavily on ATP analog inhibitors. Currently used agents, however, often do not distinguish between kinase family members. Genetic approaches can also be used to inactivate a specific kinase, but these techniques do not afford the rapid kinetics possible with pharmacological inhibitors. To circumvent this problem, modification of the structure of a particular protein kinase can be performed to engineer a drug-target interaction of choice. We have used this method to create protein kinase A (PKA) catalytic subunits with modifications that confer sensitivity to novel ATP analog inhibitors. Mutation of methionine 120 to alanine or glycine in either the Calpha or Cbeta subunits of PKA induces sensitivity to a series of C-3 derivatized pyrazolo[3,4-d]pyrimidine-based inhibitors. Modification of threonine 183 enhances this inhibitor sensitivity. The IC50 values in cell culture of the most broadly effective agent, 1-NM, ranged from 25 to 200 nm depending upon the combination of modified amino acids and were significantly higher than the potencies observed with H-89. Despite their high sequence conservation, Cbeta enzymes with inhibitor-sensitive amino acids at position 120 showed a substantial loss of overall catalytic activity when used to induce reporter gene transcription in transfected cells. Conversion of position 46 (lysine to isoleucine) rescued the ability of position 120 mutated Cbeta enzymes to induce gene transcription. Application of this combined genetic and pharmacological approach should allow analysis of the specific roles of PKA isoforms in cell culture and in vivo.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	McKnight, GS (corresponding author), Univ Washington, Dept Pharmacol, K-540 HSB Box 357750, Seattle, WA 98195 USA.	mcknight@u.washington.edu			NIAID NIH HHS [AI44009] Funding Source: Medline; NIDDK NIH HHS [F32 DK10005-03] Funding Source: Medline; NIGMS NIH HHS [GM32875, 5T32 GM0266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop A, 2000, ANNU REV BIOPH BIOM, V29, P577, DOI 10.1146/annurev.biophys.29.1.577; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 2001, TRENDS CELL BIOL, V11, P167, DOI 10.1016/S0962-8924(01)01928-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Desseyn JL, 2000, P NATL ACAD SCI USA, V97, P6433, DOI 10.1073/pnas.97.12.6433; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANKS SK, 1991, METHODS ENZYMOL, V200, P38; HOWE DG, 2002, IN PRESS MOL CELL NE; Liu Y, 1998, BIOORGAN MED CHEM, V6, P1219, DOI 10.1016/S0968-0896(98)00099-6; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Liu Y, 2000, BIOCHEMISTRY-US, V39, P14400, DOI 10.1021/bi000437j; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; Reinton N, 2000, BIOL REPROD, V63, P607, DOI 10.1095/biolreprod63.2.607; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; UHLER MD, 1987, J BIOL CHEM, V262, P15202; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	24	36	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28916	28922		10.1074/jbc.M203327200	http://dx.doi.org/10.1074/jbc.M203327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034735	hybrid			2022-12-25	WOS:000177342600076
J	Zhang, H; Peters, KW; Sun, F; Marino, CR; Lang, JC; Burgoyne, RD; Frizzell, RA				Zhang, H; Peters, KW; Sun, F; Marino, CR; Lang, JC; Burgoyne, RD; Frizzell, RA			Cysteine string protein interacts with and modulates the maturation of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; EPITHELIAL SODIUM-CHANNEL; SYNTAXIN 1A; PLASMA-MEMBRANE; KINASE-A; CFTR; EXOCYTOSIS; EXPRESSION; DROSOPHILA; DOMAIN	The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-regulated chloride channel whose phosphorylation regulates both channel gating and its trafficking at the plasma membrane. Cysteine string proteins (Csps) are J-domain-containing, membrane-associated proteins that have been functionally implicated in regulated exocytosis. Therefore, we evaluated the possibility that Csp is involved in regulated CFTR trafficking. We found Csp expressed in mammalian epithelial cell lines, several of which express CFTR. In Calu-3 airway cells, immunofluorescence colocalized Csp with calnexin in the endoplasmic reticulum and with CFTR at the apical membrane domain. CFTR co-precipitated with Csp from Calu-3 cell lysates. Csp associated with both core-glycosylated immature and fully glycosylated mature CFTRs (bands B and C); however, in relation to the endogenous levels of the B and C bands expressed in Calu-3 cells, the Csp interaction with band B predominated. In vitro protein binding assays detected physical interactions of both mammalian Csp isoforms with the CFTR R-domain and the N terminus, having submicromolar affinities. In Xenopus oocytes expressing CFTR, Csp overexpression decreased the chloride current and membrane capacitance increases evoked by cAMP stimulation and decreased the levels of CFTR protein detected by immunoblot. In mammalian cells, the steady-state expression of CFTR band C was eliminated, and pulse-chase studies showed that Csp coexpression blocked the conversion of immature to mature CFTR and stabilized band B. These results demonstrate a primary role for Csp in CFTR protein maturation. The physical interaction of this Hsc70-binding protein with immature CFTR, its localization in the endoplasmic reticulum, and the decrease in production of mature CFTR observed during Csp overexpression reflect a role for Csp in CFTR biogenesis. The documented role of Csp in regulated exocytosis, its interaction with mature CFTR, and its coexpression with CFTR at the apical membrane domain of epithelial cells may reflect also a role for Csp in regulated CFTR trafficking at the plasma membrane.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Tennessee, Dept Med, Memphis, TN 38163 USA; Inst Europeen Chim & Biol, F-33607 Pessac, France; Univ Liverpool, Liverpool L69 3BX, Merseyside, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Health Science Center; University of Liverpool	Frizzell, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S362 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.		Lang, Jochen/B-1215-2010; Burgoyne, Robert/C-6706-2008; Lang, Jochen/F-5782-2014; Burgoyne, Robert D/P-6641-2019	Lang, Jochen/0000-0001-6847-5641; Burgoyne, Robert/0000-0002-9219-0387; Lang, Jochen/0000-0001-6847-5641; Burgoyne, Robert D/0000-0002-9219-0387	NIDDK NIH HHS [DK56490] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK056490] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADHURY N, 1998, AM J PHYSIOL, V278, pC257; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Brodsky JL, 2001, AM J PHYSIOL-LUNG C, V281, pL39, DOI 10.1152/ajplung.2001.281.1.L39; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Burgoyne RD, 1998, BIOESSAYS, V20, P328, DOI 10.1002/(SICI)1521-1878(199804)20:4<328::AID-BIES9>3.0.CO;2-L; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chamberlain LH, 1996, J BIOL CHEM, V271, P19514, DOI 10.1074/jbc.271.32.19514; Chamberlain LH, 1996, J BIOL CHEM, V271, P7320, DOI 10.1074/jbc.271.13.7320; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; Coppola T, 1996, FEBS LETT, V391, P269, DOI 10.1016/0014-5793(96)00750-8; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; GUDAROVA V, 2001, J BIOL CHEM, V276, P24891; Gundersen CB, 1996, LIFE SCI, V58, P2037, DOI 10.1016/0024-3205(96)00195-6; HOWARD M, 2000, AM J PHYSIOL, V279, pC373; Huang P, 2000, AM J PHYSIOL-CELL PH, V278, pC417, DOI 10.1152/ajpcell.2000.278.2.C417; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kuver R, 2000, GLYCOBIOLOGY, V10, P149, DOI 10.1093/glycob/10.2.149; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Mastrogiacomo A, 1998, BBA-MOL CELL RES, V1401, P239, DOI 10.1016/S0167-4889(97)00160-2; Mastrogiacomo A, 1998, FEBS LETT, V436, P85, DOI 10.1016/S0014-5793(98)01092-8; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nie ZP, 1999, J NEUROSCI, V19, P10270; PETERS KW, 1999, J PHYSL, V277, pC174; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Poage RE, 1999, J NEUROPHYSIOL, V82, P50, DOI 10.1152/jn.1999.82.1.50; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; QU B, 1997, J BIOENERG BIOMEMBER, V5, P483; Ranjan R, 1998, J NEUROSCI, V18, P956; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Strickland E, 1997, J BIOL CHEM, V272, P25421, DOI 10.1074/jbc.272.41.25421; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; TAKAGI M, 1996, ACTA ORTHOP SCAND S, V271, P1; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weber WM, 1999, PFLUG ARCH EUR J PHY, V438, P561, DOI 10.1007/s004240051076; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Yoo JS, 2002, J BIOL CHEM, V277, P11401, DOI 10.1074/jbc.M110263200; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	60	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28948	28958		10.1074/jbc.M111706200	http://dx.doi.org/10.1074/jbc.M111706200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039948	hybrid			2022-12-25	WOS:000177342600080
J	Beckel-Mitchener, AC; Miera, A; Keller, R; Perrone-Bizzozero, NI				Beckel-Mitchener, AC; Miera, A; Keller, R; Perrone-Bizzozero, NI			Poly(A) tail length-dependent stabilization of GAP-43 mRNA by the RNA-binding protein HuD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; NERVE GROWTH-FACTOR; MESSENGER-RNA; GENE-EXPRESSION; 3'-UNTRANSLATED REGION; NEURITE OUTGROWTH; PC12 CELLS; POSTTRANSCRIPTIONAL REGULATION; IN-VITRO; FUNCTIONAL-CHARACTERIZATION	The neuronal ELAV-like RNA-binding protein HuD binds to a regulatory element in the 3'-untranslated region of the growth-associated protein-43 (GAP-43) mRNA. Here we report that overexpression of HuD protein in PC12 cells stabilizes the GAP-43 mRNA by delaying the onset of mRNA degradation and that this process depends on the size of the poly(A) tail. Using a polysomebased in vitro mRNA decay assay, we found that addition of recombinant HuD protein to the system increased the half-life of full-length, capped, and polyadenylated GAP-43 mRNA and that this effect was caused in part by a decrease in the rate of deadenylation of the mRNA. This stabilization was specific for GAP-43 mRNA containing the HuD binding element in the 3'-untranslated region and a poly(A) tail of at least 150 A nucleotides. In correlation with the effect of HuD on GAP-43 mRNA stability, we found that HuD binds GAP-43 mRNAs with long tails (A150) with 10-fold higher affinity than to those with short tails (A30). We conclude that HuD stabilizes the GAP-43 mRNA through a mechanism that is dependent on the length of the poly(A) tail and involves changes in its affinity for the mRNA.	Univ New Mexico, Dept Neurosci, Sch Med, Albuquerque, NM 87131 USA	University of New Mexico	Perrone-Bizzozero, NI (corresponding author), Univ New Mexico, Dept Neurosci, Sch Med, Albuquerque, NM 87131 USA.				NIGMS NIH HHS [GM52576] Funding Source: Medline; NINDS NIH HHS [NS30255] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030255, R01NS030255] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; Anderson KD, 2000, J NEUROCHEM, V75, P1103, DOI 10.1046/j.1471-4159.2000.0751103.x; Anderson KD, 2001, EXP NEUROL, V168, P250, DOI 10.1006/exnr.2000.7599; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1990, METHOD ENZYMOL, V181, P203; Cantallops I, 1999, J NEUROBIOL, V41, P208, DOI 10.1002/(SICI)1097-4695(19991105)41:2<208::AID-NEU4>3.3.CO;2-M; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Chiaramello A, 1996, J BIOL CHEM, V271, P22035, DOI 10.1074/jbc.271.36.22035; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; Clayton GH, 1998, DEV BRAIN RES, V109, P271, DOI 10.1016/S0165-3806(98)00074-1; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; Kinney WR, 1996, MOL BRAIN RES, V38, P25, DOI 10.1016/0169-328X(95)00287-3; Kohn DT, 1996, MOL BRAIN RES, V36, P240, DOI 10.1016/0169-328X(95)00239-O; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; Namgung U, 2000, EUR J NEUROSCI, V12, P3124, DOI 10.1046/j.1460-9568.2000.00196.x; Namgung U, 1997, P NATL ACAD SCI USA, V94, P11675, DOI 10.1073/pnas.94.21.11675; NEDIVI E, 1992, J NEUROSCI, V12, P691; NEVE RL, 1995, METH NEUROSCI, V25, P163; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Okano HJ, 1997, J NEUROSCI, V17, P3024; Paillard L, 2002, J BIOL CHEM, V277, P3232, DOI 10.1074/jbc.M109362200; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perrone-Bizzozero N, 2002, J NEUROSCI RES, V68, P121, DOI 10.1002/jnr.10175; PERRONE-BIZZOZERO N I, 1991, Molecular and Cellular Neuroscience, V2, P402; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STARR RG, 1994, BRAIN RES, V638, P211, DOI 10.1016/0006-8993(94)90652-1; Tsai KC, 1997, J NEUROSCI, V17, P1950; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001	53	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27996	28002		10.1074/jbc.M201982200	http://dx.doi.org/10.1074/jbc.M201982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12034726	hybrid			2022-12-25	WOS:000177189800053
J	Cook, SP; Galve-Roperh, I; del Pozo, AM; Rodriguez-Crespo, I				Cook, SP; Galve-Roperh, I; del Pozo, AM; Rodriguez-Crespo, I			Direct calcium binding results in activation of brain serine racemase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE; ALANINE RACEMASE; NMDA-RECEPTORS; AMINO-ACIDS; GLUTAMATE RECEPTORS; PYRIDOXAL-PHOSPHATE; RAT-BRAIN; GLYCINE; INHIBITION; ENZYME	Serine racemase (SR) is a brain enzyme present in glial cells, where it isomerizes L-serine into D-serine that, in turn, diffuses and coactivates the N-methyl-D-aspartate receptor through the binding to the so-called "glycine site." We have developed a method for the slow expression of SR in a eukaryotic vector that permits the correct insertion of the prosthetic group into the active site, rendering functional SR with a K, toward L-serine of 4.8 mm. Divalent cations such as calcium or manganese were necessary for complete enzyme activity, whereas the presence of chelators such as EDTA completely inhibited the enzyme. Moreover, direct binding of calcium to SR was evidenced using Ca-45(2+). Gel filtration of the recombinant SR revealed the protein to be in a dimer-tetramer equilibrium. The addition of EDTA to a calcium-saturated serine racemase evokes a profound conformational change, as monitored by both fluorescence and circular dichroism techniques. Fluorescence titration allowed us to calculate a binding constant for calcium of 6.2 muM. Reagents that react with sulfhydryl groups, such as cystamine, were potent inhibitors of SR, in a clear reflection that one or more cysteine residues are important for enzyme activity. Additionally, 16 serine analogues were tested as a putative SR substrate or inhibitors. Significant inhibition was only observed for L-Ser-O-sulfate, L-cycloserine, and L-cysteine. Finally, activation of brain SR as a result of the changes in calcium concentration was studied in primary astrocytes. Treatment of astrocytes with the calcium ionophore A23187, as well as with compounds that augment the intracellular calcium levels such as glutamate or kainate led to an increase in the amount of D-serine present in the extracellular medium. These results suggest that there might be a glutamatergic-mediated regulation of SR activity by intracellular calcium concentration.	Univ Complutense Madrid, Fac CC Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Complutense University of Madrid	Rodriguez-Crespo, I (corresponding author), Univ Complutense Madrid, Fac CC Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	nacho@bbm1.ucm.es	Galve-Roperh, Ismael/AAG-2369-2020; Martinez-del-Pozo, Alvaro/L-8556-2014; Rodriguez-Crespo, J. Ignacio/M-1966-2018	Martinez-del-Pozo, Alvaro/0000-0003-0043-5939; Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X				Atlante A, 2001, FEBS LETT, V497, P1, DOI 10.1016/S0014-5793(01)02437-1; BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; BUELL MV, 1960, J AM CHEM SOC, V82, P6042, DOI 10.1021/ja01508a018; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Danysz W, 1998, PHARMACOL REV, V50, P597; De Miranda J, 2000, GENE, V256, P183, DOI 10.1016/S0378-1119(00)00356-5; DELPOZO AM, 1989, J BIOL CHEM, V264, P17784; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GALLI A, 1990, NEUROPHARMACOLOGY, V29, P145, DOI 10.1016/0028-3908(90)90054-U; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; HASHIMOTO A, 1995, NEUROSCIENCE, V66, P635, DOI 10.1016/0306-4522(94)00597-X; HASHIMOTO A, 1992, FEBS LETT, V296, P33, DOI 10.1016/0014-5793(92)80397-Y; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; LEJCZAK B, 1984, SYNTHESIS-STUTTGART, P577; Liu JQ, 1998, J BIOL CHEM, V273, P16678, DOI 10.1074/jbc.273.27.16678; Lo EH, 1998, NEUROSCIENCE, V83, P449, DOI 10.1016/S0306-4522(97)00434-X; MATSUI T, 1995, J NEUROCHEM, V65, P454; MATSUO Y, 1957, J AM CHEM SOC, V79, P2011, DOI 10.1021/ja01565a068; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Panizzutti R, 2001, P NATL ACAD SCI USA, V98, P5294, DOI 10.1073/pnas.091002298; Paudice P, 1998, EUR J NEUROSCI, V10, P2934, DOI 10.1046/j.1460-9568.1998.00302.x; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Plaitakis A, 2000, J NEUROL, V247, P25, DOI 10.1007/PL00007757; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; SZOKAN G, 1988, J CHROMATOGR, V444, P115, DOI 10.1016/S0021-9673(01)94014-2; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P721, DOI 10.1073/pnas.96.2.721; WROBLEWSKI JT, 1989, NEUROPHARMACOLOGY, V28, P447, DOI 10.1016/0028-3908(89)90077-4; Yasuda E, 2001, NEUROSCI LETT, V299, P162, DOI 10.1016/S0304-3940(01)01502-6	44	112	117	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27782	27792		10.1074/jbc.M111814200	http://dx.doi.org/10.1074/jbc.M111814200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021263	hybrid			2022-12-25	WOS:000177189800027
J	Furuhata, A; Nakamura, M; Osawa, T; Uchida, K				Furuhata, A; Nakamura, M; Osawa, T; Uchida, K			Thiolation of protein-bound carcinogenic aldehyde - An electrophilic acrolein-lysine adduct that covalently binds to thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; NITRIC-OXIDE; LIPID-PEROXIDATION; S-THIOLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; GLUTATHIONE; DISULFIDES; METABOLISM; PRODUCT; MODEL	Acrolein, a representative carcinogenic aldehyde that could be ubiquitously generated in biological systems under oxidative stress, shows facile reactivity with! the e-amino group of lysine to form N-epsilon-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) as the major product (Uchida, K., Kanematsu, M., Morimitsu, Y., Osawa, T., Noguchi, N., and Niki, E. (1998) J. Biol. Chem. 273,1605816066). In the present study, we determined the electrophilic potential of FDP-lysine and established a novel mechanism of protein thiolation in which the FDP-lysine generated in the acrolein-modified protein reacts with sulfhydryl groups to form thioether adducts. When a sulfhydryl enzyme, glyceraldehyde-3-phosphate dehydrogenase, was incubated with acrolein-modified bovine serum albumin in sodium phosphate buffer (pH 7.2) at 37degreesC, a significant loss of sulfhydryl groups, which was accompanied by the loss of enzyme activity and the formation of high molecular mass protein species (>200 kDa), was observed. The FDP-lysine adduct generated in the acrolein-modified protein was suggested to represent a thiol-reactive electrophile based on the following observations. (i) N-alpha-acetyl-FDP-lysine, prepared from the reaction of N-alpha-acetyl lysine with acrolein, was covalently bound to glyceraldehyde-3-phosphate dehydrogenase. (ii) The FDP-lysine derivative reacted with glutathione to form a GSH conjugate. (iii) The acrolein-modified bovine serum albumin significantly reacted with GSH to form a glutathiolated protein. Furthermore, the observation that the glutathiolated acrolein-modified protein showed decreased immunoreactivity with an anti-FDP-lysine monoclonal antibody suggested that the FDP-lysine residues in the acrolein-modified protein served as the binding site of GSH. These data suggest that thiolation of the protein-bound acrolein may be involved in redox alteration under oxidative stress, whereby oxidative stress generates the increased production of acrolein and its protein adducts that further potentiate oxidative stress via the depletion of GSH in the cells.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Lab Biomodeling, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	Nakamura, Mitsuhiro/I-1969-2014	Nakamura, Mitsuhiro/0000-0002-8679-2381; Uchida, Koji/0000-0003-3894-5299				ALAIZ M, 1995, CHEM PHYS LIPIDS, V75, P43, DOI 10.1016/0009-3084(94)02399-P; Baker A, 1998, CHEM RES TOXICOL, V11, P730, DOI 10.1021/tx970167e; Baker AG, 1999, J AM SOC MASS SPECTR, V10, P613, DOI 10.1016/S1044-0305(99)00029-X; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; COHEN SM, 1992, CANCER RES, V52, P3577; DANIELSON UH, 1987, BIOCHEM J, V247, P707, DOI 10.1042/bj2470707; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; IZARD C, 1977, MUTAT RES, V47, P115; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEISTER A, 1994, CANCER RES, V54, pS1969; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; SPITZ DR, 1991, FREE RADICAL BIO MED, V11, P415, DOI 10.1016/0891-5849(91)90159-Z; SPITZ DR, 1990, BIOCHEM J, V267, P453, DOI 10.1042/bj2670453; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; UCHIDA K, 1993, J BIOL CHEM, V268, P6388	36	84	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27919	27926		10.1074/jbc.M202794200	http://dx.doi.org/10.1074/jbc.M202794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032148	hybrid			2022-12-25	WOS:000177189800043
J	Cavanaugh, AH; Hirschler-Laszkiewicz, I; Hu, QY; Dundr, M; Smink, T; Misteli, T; Rothblum, LI				Cavanaugh, AH; Hirschler-Laszkiewicz, I; Hu, QY; Dundr, M; Smink, T; Misteli, T; Rothblum, LI			Rrn3 phosphorylation is a regulatory checkpoint for ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; TRANSCRIPTION FACTOR UBF; FACTOR-TIF-IA; SACCHAROMYCES-CEREVISIAE ENCODES; GROWTH-DEPENDENT REGULATION; GENE-TRANSCRIPTION; RDNA TRANSCRIPTION; DNA-TRANSCRIPTION; FACTOR SL1; INITIATION	Cycloheximide inhibits ribosomal DNA (rDNA) transcription in vivo. The mouse homologue of yeast Rrn3, a polymerase-associated transcription initiation factor, can complement extracts from cycloheximide-treated mammalian cells. Cycloheximide inhibits the phosphorylation of Rrn3 and causes its dissociation from RNA polymerase I. Rrn3 interacts with the rpa43 subunit of RNA polymerase 1, and treatment with cycloheximide inhibits the formation of a Rrn3.rpa43, complex in vivo. Rrn3 produced in Sf9 cells but not in bacteria interacts with rpa43 in vitro, and such interaction is dependent upon the phosphorylation state of Rrn3. Significantly, neither dephosphorylated Rrn3 nor Rrn3 produced in Escherichia coli can restore transcription by extracts from cycloheximide-treated cells. These results suggest that the phosphorylation. state of Rrn3 regulates rDNA transcription by determining the steady-state concentration of the Rrn3.RNA polymerase I complex within the nucleolus.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Danville, PA 17821 USA; NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rothblum, LI (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, 100 N Acad Ave, Danville, PA 17821 USA.	lrothblum@geisinger.edu						Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; BELL GI, 1977, J BIOL CHEM, V252, P3082; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Comai L, 2000, CELL GROWTH DIFFER, V11, P63; DETKE S, 1978, ARCH BIOCHEM BIOPHYS, V185, P333, DOI 10.1016/0003-9861(78)90175-3; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hannan KM, 1998, FRONT BIOSCI, V3, P376, DOI [10.2741/A282, DOI 10.2741/A282]; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Kuhn A, 1998, J MOL BIOL, V284, P1, DOI 10.1006/jmbi.1998.2164; LAMPERT A, 1974, BIOCHEM BIOPH RES CO, V58, P1030, DOI 10.1016/S0006-291X(74)80247-0; Le Panse S, 1999, J CELL SCI, V112, P2145; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16225; MATTHEWS JL, 1995, MOL CELL BIOL, V15, P3327; MIESFELD R, 1982, NUCLEIC ACIDS RES, V10, P3933, DOI 10.1093/nar/10.13.3933; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moorefield B, 2000, P NATL ACAD SCI USA, V97, P4724, DOI 10.1073/pnas.080063997; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; Siddiqi I, 2001, MOL CELL BIOL, V21, P2292, DOI 10.1128/MCB.21.7.2292-2297.2001; Sirri V, 1999, J CELL SCI, V112, P3259; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; YU F, 1972, P NATL ACAD SCI USA, V69, P2833, DOI 10.1073/pnas.69.10.2833; YU FL, 1971, P NATL ACAD SCI USA, V68, P2177, DOI 10.1073/pnas.68.9.2177; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	58	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27423	27432		10.1074/jbc.M201232200	http://dx.doi.org/10.1074/jbc.M201232200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015311	hybrid			2022-12-25	WOS:000177055900092
J	Fu, MG; Zhang, JF; Lin, YM; Zhu, XJ; Ehrengruber, MU; Chen, YQE				Fu, MG; Zhang, JF; Lin, YM; Zhu, XJ; Ehrengruber, MU; Chen, YQE			Early growth response factor-1 is a critical transcriptional mediator of peroxisome proliferator-activated receptor-gamma 1 gene expression in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PPAR-GAMMA; ENDOTHELIAL-CELLS; PROMOTER; ELEMENT; EGR-1; PPAR-GAMMA-2; ORGANIZATION; MODULATION; INDUCTION	To explore the molecular mechanisms of PPARgamma1 gene expression in vascular smooth muscle cells (VSMC), we hypothesized that early growth-response factor-1 (Egr-1) might be a transcriptional mediator of the growth factor- and cytokine-induced PPARgamma1 gene expression since a putative Egr-1 binding element was found in the human PPARgamma1 promoter. In this study, we document that overexpression of Egr-1 activates the human PPARgamma1 promoter in both VSMC and HepG2 cells. Using Northern blot analysis, we observed that growth factors and cytokines such as PDGF, bFGF, Ang 11, TNFalpha, and IL-1beta induce Egr-1 expression prior to PPARgamma1 up-regulation in human VSMC. In addition, overexpression of a constitutively active form of Egr-1 by adenoviral gene transfer in VSMC dramatically induced PPARgamma1 gene expression by 6-8-fold, and overexpression of NAB2, a potent negative feedback regulator of Egr-1, abrogated the growth factor- and cytokine-induced PPARgamma1 expression in VSMC. Furthermore, we demonstrate with gel mobility shift and transient transfection assays that the putative Egr-1 element in the human PPARgamma1 promoter specifically binds Egr-1 protein and becomes trans-activated by Egr-1. Taken together, our data demonstrate for the first time that Egr-1 is necessary and sufficient to activate human PPARgamma1 gene expression in VSMC.	Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Peking Univ, Hlth Sci Ctr, Cardiovasc Res Inst, Beijing 100083, Peoples R China	Morehouse School of Medicine; University of Zurich; Peking University	Chen, YQE (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, 720 Westview Dr SW, Atlanta, GA 30310 USA.	echen@msm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068878, UH1HL003676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER; NHLBI NIH HHS [5UH1 HL 03676-02, R01 HL 068878] Funding Source: Medline; NIGMS NIH HHS [S06 GM 08248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Ehrengruber MU, 2000, GENE, V258, P63, DOI 10.1016/S0378-1119(00)00445-5; Elberg G, 2000, J BIOL CHEM, V275, P27815; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fu MG, 2001, CIRC RES, V89, P1058, DOI 10.1161/hh2301.099642; Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Sugawara A, 2001, ENDOCRINOLOGY, V142, P3125, DOI 10.1210/en.142.7.3125; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Takata Y, 2001, J BIOL CHEM, V276, P12893, DOI 10.1074/jbc.M011655200; Takeda K, 2000, CIRCULATION, V102, P1834; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yamakawa K, 2000, BIOCHEM BIOPH RES CO, V271, P571, DOI 10.1006/bbrc.2000.2665; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	37	47	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26808	26814		10.1074/jbc.M203748200	http://dx.doi.org/10.1074/jbc.M203748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011097	hybrid			2022-12-25	WOS:000177055900015
J	San-Antonio, B; Iniguez, MA; Fresno, M				San-Antonio, B; Iniguez, MA; Fresno, M			Protein kinase C zeta phosphorylates nuclear factor of activated T cells and regulates its transactivating activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR NFAT1; SIGNAL-TRANSDUCTION; PKC-ZETA; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATASE CALCINEURIN; PHYSICAL ASSOCIATION; GENE-EXPRESSION; FAMILY	Although several isoforms of protein kinase C (PKC) have been implicated in T lymphocyte activation events, little is known about their mode of action. To address the role of PKCzeta in T cell activation, we have generated Jurkat T cell transfectants expressing either the wild type (J-PKCzeta) or "kinase-dead" mutant (J-PKCzeta(mut)) versions of this protein. Expression of PKCzeta but not PKCzeta(mut) increased transcriptional activation mediated by the NF-kappaB or nuclear factor of activated T cells (NFAT). PKCzeta cooperates with calcium ionophore and with NFAT1 or NFAT2 proteins to enhance transcriptional activation of a NFAT reporter construct. However, neither NFAT nuclear translocation nor DNA binding were in J-PKCzeta cells. Our results show that PKQ enhanced transcriptional activity mediated by Gal4-NFAT1 fusion proteins containing the N-terminal transactivation domain of human NFAT1. Interestingly, PKCzeta synergizes with calcineurin to induce transcriptional activation driven by the NFAT1 transactivation domain. Co-precipitation experiments showed physical interaction between PKCzeta and NFAT1 or NFAT2 isoforms. Even more, PKCzeta was able to phosphorylate recombinant glutathione S-transferase-NFAT1 (1-385) protein. These data reveal a new role of PKCzeta in T cells through the control of NFAT function by modulating the activity of its transactivation domain.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Cantoblanco, E-28049 Madrid, Spain.		Peña, Miguel Angel Iñiguez/J-8518-2012	Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Fresno Escudero, Manuel/0000-0002-9223-5477				Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Garcia-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2432, DOI 10.1002/1521-4141(2000)30:8<2432::AID-IMMU2432>3.0.CO;2-F; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZ J, 1995, EUR J IMMUNOL, V25, P2673, DOI 10.1002/eji.1830250941; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HO AM, 1994, J BIOL CHEM, V269, P28181; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Huang CS, 2000, MOL CARCINOGEN, V27, P65, DOI 10.1002/(SICI)1098-2744(200002)27:2<65::AID-MC2>3.0.CO;2-E; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; PARK JH, 1993, BLOOD, V82, P2470; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Standaert ML, 2001, BIOCHEMISTRY-US, V40, P249, DOI 10.1021/bi0018234; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	77	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27073	27080		10.1074/jbc.M106983200	http://dx.doi.org/10.1074/jbc.M106983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021260	hybrid			2022-12-25	WOS:000177055900049
J	Sweet, DH; Miller, DS; Pritchard, JB; Fujiwara, Y; Beier, DR; Nigam, SK				Sweet, DH; Miller, DS; Pritchard, JB; Fujiwara, Y; Beier, DR; Nigam, SK			Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOSCLEROSIS OC MUTATION; MOLECULAR-CLONING; RAT-LIVER; FUNCTIONAL-CHARACTERIZATION; EXPRESSION CLONING; EPITHELIAL-CELLS; LOCALIZATION; BRAIN; IDENTIFICATION; PROTEIN	To begin to develop in vivo model systems for the assessment of the contributions of specific organic anion transporter (OAT) family members to detoxification, development, and disease, we carried out a targeted disruption of the murine organic anion transporter 3 (Oat3) gene. Surviving Oat3(-/-) animals appear healthy, are fertile, and do not exhibit any gross morphological tissue abnormalities. No Oat3 mRNA expression was detected in kidney, liver, or choroid plexus (CP) of Oat3(-/-) mice. A distinct phenotype manifested by a substantial loss of organic anion transport capacity in kidney and CP was identified. Uptake sensitive to inhibition by bromosulfophthalein or probenecid was observed for taurocholate, estrone sulfate, and para-aminohippurate in renal slices from wild-type mice, whereas in Oat3(-/-) animals transport of these substances was greatly reduced. No discernable differences in uptake were observed between hepatic slices from wild-type and Oat(-/-) littermates, suggesting Oat3 does not play a major role in hepatic organic anion uptake. Cellular accumulation of fluorescein was reduced by similar to75% in CP from Oat3(-/-) mice. However, capillary accumulation of fluorescein-methotrexate was unchanged, indicating the effects of Oat3 loss are restricted to the entry step and that Oat3 is localized to the apical membrane of CP. These data indicate a key role for Oat3 in systemic detoxification and in control of the organic anion distribution in cerebrospinal fluid.	Univ Calif San Diego, Dept Pediat, Div Nephrol Hypertens, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Harvard Univ, Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol,Sch Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Pediat, Div Nephrol Hypertens, 9500 Gilman Dr 0693, La Jolla, CA 92093 USA.		Sweet, Douglas H/H-7914-2013	Sweet, Douglas H/0000-0002-8911-9184	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080060, ZIAES080048, ZIAES080031, Z01ES080031, Z01ES080054, Z01ES048014, Z01ES080048, ZIAES080060] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 40011] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; Bossuyt X, 1996, J PHARMACOL EXP THER, V276, P891; Brady KP, 1999, GENOMICS, V56, P254, DOI 10.1006/geno.1998.5722; Breen CM, 2002, AM J PHYSIOL-RENAL, V282, pF877, DOI 10.1152/ajprenal.00171.2001; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Cattori V, 2000, FEBS LETT, V474, P242, DOI 10.1016/S0014-5793(00)01596-9; Cattori V, 2001, PFLUG ARCH EUR J PHY, V443, P188, DOI 10.1007/s004240100697; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Cihlar T, 2000, ANAL BIOCHEM, V283, P49, DOI 10.1006/abio.2000.4633; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; Gao P, 1999, J HISTOCHEM CYTOCHEM, V47, P1255, DOI 10.1177/002215549904701005; Han YH, 2001, J PHARMACOL EXP THER, V296, P450; Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kobayashi Y, 2002, BIOCHEM BIOPH RES CO, V290, P482, DOI 10.1006/bbrc.2001.6180; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lopez-Nieto C. E., 1996, Journal of the American Society of Nephrology, V7, P1301; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Pavlova A, 2000, AM J PHYSIOL-RENAL, V278, pF635, DOI 10.1152/ajprenal.2000.278.4.F635; PRITCHARD JB, 1990, J PHARMACOL EXP THER, V255, P969; Pritchard JB, 1999, J BIOL CHEM, V274, P33382, DOI 10.1074/jbc.274.47.33382; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Rajan PD, 2000, CURR EYE RES, V20, P195, DOI 10.1076/0271-3683(200003)20:3;1-9;FT195; Reichel C, 1999, GASTROENTEROLOGY, V117, P688, DOI 10.1016/S0016-5085(99)70463-4; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Slitt AL, 2002, DRUG METAB DISPOS, V30, P212, DOI 10.1124/dmd.30.2.212; Sweet DH, 1999, AM J PHYSIOL-RENAL, V277, pF890, DOI 10.1152/ajprenal.1999.277.6.F890; Sweet DH, 2001, AM J PHYSIOL-RENAL, V281, pF197, DOI 10.1152/ajprenal.2001.281.2.F197; Sweet DH, 1999, AM J PHYSIOL-RENAL, V276, pF864, DOI 10.1152/ajprenal.1999.276.6.F864; Sweet DH, 1999, CELL BIOCHEM BIOPHYS, V31, P89, DOI 10.1007/BF02738157; Sweet DH, 2001, J BIOL CHEM, V276, P41611, DOI 10.1074/jbc.M108472200; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF216, DOI 10.1152/ajprenal.2000.279.2.F216; Villalobos AR, 1997, J PHARMACOL EXP THER, V282, P1109; Walters HC, 2000, AM J PHYSIOL-GASTR L, V279, pG1188, DOI 10.1152/ajpgi.2000.279.6.G1188	47	240	252	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26934	26943		10.1074/jbc.M203803200	http://dx.doi.org/10.1074/jbc.M203803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011098	hybrid			2022-12-25	WOS:000177055900032
J	Yu, Y; Flint, A; Dvorin, EL; Bischoff, J				Yu, Y; Flint, A; Dvorin, EL; Bischoff, J			AC133-2, a novel isoform of human AC133 stem cell antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTRUSIONS; HEMATOPOIETIC STEM; ENDOTHELIAL-CELLS; PROGENITOR CELLS; EPITHELIAL-CELLS; PROMININ; EXPRESSION; DIFFERENTIATION; PRECURSORS; PROTEIN	Human AC133 antigen, also called CD133, was recently identified as a hematopoietic stem cell marker. However, the molecular structure and function of this protein has remained unclear. Here we cloned and identified a novel isoform of AC133, which we named AC133-2. In comparison to the reported AC133 cDNA, which is referred to herein as AC133-1, a small exon of 27 nucleotides is deleted in AC133-2 by alternative mRNA splicing. Similar to the previously characterized AC133 antigen, recombinant AC133-2 expressed in 293 cells was glycosylated and transported to plasma membrane. AC133-2 mRNA was found predominant in a variety of human fetal tissue, adult tissues, and several carcinomas. In contrast, AC133-1 mRNA was more prominent in fetal brain and adult skeletal muscle but was not detected in fetal liver and kidney, adult pancreas,, kidney, and placenta, suggesting different roles for the two isoforms in fetal development and mature organ homeostasis. Here, we demonstrate that AC133-2 is the isoform. expressed on hematopoietic stem cells derived from fetal liver, bone marrow, and peripheral blood. The results indicate that AC133-2, not AC133-1, has been the cell surface antigen recognized by anti-AC133 monoclonal antibodies that are used for isolation of hematopoietic stem cells. To further investigate its expression in other stem cell populations, we found that AC133-2 co-expressed with beta(1) integrin in the basal layer of human neonatal epidermis. AC133-2(+)/beta(1) integrin(+) cells proliferated and differentiated in culture, which coincided with a loss of AC133-2 and gain in a terminal differentiation marker involucrin. Taken together, these results suggest that AC133-2 is expressed in multiple stem cell niches and may provide a means to isolate specific stem cell subpopulations from human tissues.	Childrens Hosp, Surg Res Lab, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Bischoff, J (corresponding author), Childrens Hosp, Surg Res Lab, Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.		BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Dvorin, Evan/0000-0001-5037-2783				BHARIA M, 2001, LEUKEMIA, V15, P1685; Boyer M, 2000, J VASC SURG, V31, P181, DOI 10.1016/S0741-5214(00)70080-2; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Corbeil D, 2001, TRAFFIC, V2, P82, DOI 10.1034/j.1600-0854.2001.020202.x; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; Gehling UM, 2000, BLOOD, V95, P3106; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Miraglia S, 1998, BLOOD, V91, P4390, DOI 10.1182/blood.V91.11.4390; OVEJERA AA, 1979, CANCER RES, V39, P3220; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Quirici N, 2001, BRIT J HAEMATOL, V115, P186, DOI 10.1046/j.1365-2141.2001.03077.x; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weigmann A, 1997, P NATL ACAD SCI USA, V94, P12425, DOI 10.1073/pnas.94.23.12425; WITHERS HR, 1967, RADIAT RES, V32, P227, DOI 10.2307/3572220; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012	21	132	163	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20711	20716		10.1074/jbc.M202349200	http://dx.doi.org/10.1074/jbc.M202349200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	12042327	hybrid			2022-12-25	WOS:000176204500079
J	Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K				Fishman, P; Madi, L; Bar-Yehuda, S; Barer, F; Del Valle, L; Khalili, K			Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells	ONCOGENE			English	Article						A3 adenosine receptor; IB-MECA; cAMP; Wnt pathway; GSK-3 beta	A3 ADENOSINE RECEPTOR; GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASE; BETA-CATENIN; PHOSPHORYLATION; TELOMERASE; ACTIVATION; INSULIN; MUSCLE; CAMP	The A3 adenosine receptor, A3AR, belongs to the family of Gi proteins, which upon induction, suppresses the formation of cAMP and its downstream effectors. Recent studies have indicated that activation of A3AR by its agonist, IB-MECA, results in growth inhibition of malignant cells. Here we demonstrate the ability of IB-MECA to decrease the levels of protein kinase A, a downstream effector of cAMP, and protein kinase B/Akt in melanoma cells. Examination of glycogen synthase kinase 3beta, GSK-3beta, whose phosphorylation is controlled by protein kinase A and B, showed a substantial decrease in the levels of its phosphorylated form and an increase in total GSK-3beta levels in IB-MECA treated melanoma cells. This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3beta in the cells. Evaluation of beta-catenin, a key component of Wnt signaling pathway which, upon phosphorylation by GSK-3beta rapidly ubiquitinates, showed a substantial decrease in its level after IB-MECA treatment. Accordingly, the level of beta-catenin responsive cell growth regulatory genes including c-myc and cyclin D1 was severely declined upon treatment of the cells with IB-MECA. These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists.	Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel; Can Fite Biopharma Ltd, Kiryat Matalon, Petach Tikva, Israel; Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishman, P (corresponding author), Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel.	pfishman@post.tau.ac.il	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				AUSUBEL F, 1989, CURRENT PROTOCOLS MO, P342; Bar-Yehuda S, 2001, NEOPLASIA, V3, P125, DOI 10.1038/sj.neo.7900138; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fishman P, 1998, CANCER RES, V58, P3181; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Fishman P, 2000, EUR J CANCER, V36, P1452, DOI 10.1016/S0959-8049(00)00130-1; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; McEwen DG, 2000, CURR BIOL, V10, pR562, DOI 10.1016/S0960-9822(00)00611-4; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; OHANA G, 2000, J CELLULAR PHYSL, V186, P19; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; STILES GL, 1990, CLIN RES, V38, P10; Zhao ZH, 2000, BBA-MOL BASIS DIS, V1500, P280, DOI 10.1016/S0925-4439(99)00111-8	27	92	99	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4060	4064		10.1038/sj.onc.1205531	http://dx.doi.org/10.1038/sj.onc.1205531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037688				2022-12-25	WOS:000175869900012
J	Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R				Im, HJ; Craig, TA; Pittelkow, MR; Kumar, R			Characterization of a novel hexameric repeat DNA sequence in the promoter of the immediate early gene, IEX-1, that mediates 1 alpha,25-dihydroxyvitamin D-3-associated IEX-1 gene repression	ONCOGENE			English	Article						immediate early gene; IEX-1; VDRE; transcriptional suppression	VITAMIN-D-RECEPTOR; TRANSFORMING-GROWTH-FACTOR; RETINOID-X-RECEPTOR; PROTEIN-KINASE-C; MEMBRANE CALCIUM-PUMP; EARLY RESPONSE GENE; FACTOR-BETA 2; 1,25-DIHYDROXYVITAMIN D-3; THYROID-HORMONE; DEFICIENCIES INCREASE	1alpha,25-Dihydroxyvitamin D-3(1alpha,25(OH)(2)D-3), the active metabolite of vitamin D-3, mediates anti-proliferative effects in cells by regulating the expression of 1alpha,25(OH)(2)D-3-responsive genes. The expression of the proliferation-promoting immediate Early gene X-1 (IEX-1) is reduced by 1alpha,25(OH)(2)D-3 through unknown mechanisms. Here we report the presence of a novel inhibitory hexameric repeat DNA response element in the promoter of the human IEX-1 gene that mediates 1alpha,25(OH)(2)D-3-associated IEX-1 gene repression. To localize a vitamin D sensitive DIVA response element we transfected the keratinocyte-like cell line, HaCaT, (referred as HaCaT) with a series of plasmids containing full-length and truncated IEX-1 promoter elements fused to the luciferase reporter gene in the absence or presence of 1alpha,25(OH)(2)D-3, and we performed electrophoretic gel mobility assays in the presence of receptors for 1alpha,25(OH)(2)D-3 (vitamin D receptor, VDR) and 9-cis-retinoic acid (RXRalpha). We mapped a negative response element between nt -405 and -391(15 bp) of the IEX-1 promoter (5'-TGAACC AGG GAGTCA-3') that mediates transcriptional inhibition in response to 1alpha,25(OH)(2)D-3 and which requires expression of both nuclear receptors for 1alpha,25(OH)(2)D-3 and 9-cis-retinoic acid. Our data indicate that the physiological repression of IEX-1 gene expression by 1alpha,25(OH)(2)D-3 is directly mediated by nuclear VDR/RXRalpha heterodimers through a specific transcriptional element.	Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Dermatol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Kumar, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	rkumar@mayo.edu		Kumar, Rajiv/0000-0003-3497-3057	NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR027032, R01AR027032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059505, R01DK058546, R01DK025409] Funding Source: NIH RePORTER; NCI NIH HHS [CA 015083] Funding Source: Medline; NIAMS NIH HHS [AR27032] Funding Source: Medline; NIDDK NIH HHS [DK58546, R01 DK025409, R01 DK058546, DK25409, DK59505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CAI Q, 1993, P NATL ACAD SCI USA, V90, P1345, DOI 10.1073/pnas.90.4.1345; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Craig TA, 1999, NAT BIOTECHNOL, V17, P1214, DOI 10.1038/70767; Craig TA, 1997, BIOCHEMISTRY-US, V36, P10482, DOI 10.1021/bi970561b; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Elstner E, 1996, CANCER RES, V56, P3570; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIULIANO AR, 1991, ARCH BIOCHEM BIOPHYS, V285, P261, DOI 10.1016/0003-9861(91)90358-P; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GROSS M, 1986, J BONE MINER RES, V1, P457; Haugen JD, 1996, BIOCHEM BIOPH RES CO, V229, P618, DOI 10.1006/bbrc.1996.1853; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; Herdick M, 2000, J MOL BIOL, V304, P793, DOI 10.1006/jmbi.2000.4267; IM HJ, 2002, J BIOL CHEM     0213; ITIN PH, 1994, ENDOCRINOLOGY, V135, P1793, DOI 10.1210/en.135.5.1793; James SY, 1996, J STEROID BIOCHEM, V58, P395, DOI 10.1016/0960-0760(96)00048-9; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Koszewski NJ, 2000, J STEROID BIOCHEM, V72, P125, DOI 10.1016/S0960-0760(00)00022-4; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KUMAR R, 1991, KIDNEY INT, V40, P1177, DOI 10.1038/ki.1991.332; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; Lutz W, 2000, BIOCHEM BIOPH RES CO, V271, P1, DOI 10.1006/bbrc.2000.2570; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; Mathiasen IS, 1999, CANCER RES, V59, P4848; Mehta RG, 1997, JNCI-J NATL CANCER I, V89, P212, DOI 10.1093/jnci/89.3.212; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; OCONNELL TD, 1995, BIOCHEM BIOPH RES CO, V213, P59, DOI 10.1006/bbrc.1995.2098; PEEHL DM, 1994, CANCER RES, V54, P805; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; Veenstra TD, 1998, BIOCHEMISTRY-US, V37, P5988, DOI 10.1021/bi972965+; Veenstra TD, 1998, NAT BIOTECHNOL, V16, P262, DOI 10.1038/nbt0398-262; Veenstra TD, 1998, J AM SOC MASS SPECTR, V9, P8, DOI 10.1016/S1044-0305(97)00229-8; WASSERMAN RH, 1992, GASTROENTEROLOGY, V102, P886, DOI 10.1016/0016-5085(92)90174-W; Wu YH, 1999, BIOCHEMISTRY-US, V38, P2654, DOI 10.1021/bi981944s; Wu YH, 1997, BIOCHEM BIOPH RES CO, V239, P734, DOI 10.1006/bbrc.1997.7544; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	64	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3706	3714		10.1038/sj.onc.1205450	http://dx.doi.org/10.1038/sj.onc.1205450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032839				2022-12-25	WOS:000175676000006
J	Wagner, KD; Wagner, N; Bondke, A; Nafz, B; Flemming, B; Theres, H; Scholz, H				Wagner, KD; Wagner, N; Bondke, A; Nafz, B; Flemming, B; Theres, H; Scholz, H			The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction	FASEB JOURNAL			English	Article						hypoxia; epicardium; cardiac ischemia; transcription factor; immunohistochemistry	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; GENE-PRODUCT; SUBNUCLEAR LOCALIZATION; SPLICE VARIANTS; PROTEIN; DNA; PECAM-1/CD31; FIBROBLASTS; MODULATION	Expression of the Wilms' tumor gene Wt1 in the epicardium is critical for normal heart development. Mouse embryos with inactivated Wt1 gene have extremely thin ventricles, which can result in heart failure and death. Here, we demonstrate that Wt1 can be activated in adult hearts by local ischemia. Wt1 mRNA was increased more than twofold in the left ventricular myocardium of rats between 1 day and 9 wk after infarction. Wt1 expression was localized by means of mRNA in situ hybridization and immunohistochemistry to vascular endothelial and vascular smooth muscle cells in the border zone of the infarcted tissue. A strikingly similar distribution was seen for vascular endothelial growth factor and two different cell proliferation markers in the coronary vessels of the ischemic heart. No Wt1 could be detected in the vasculature of the noninfarcted right ventricles. Wt1 expression in the coronary vessels of the ischemic heart was mimicked by exposure of rats to normobaric hypoxia (8% O-2) and 0.1% CO, respectively. These findings demonstrate that Wt1 is expressed in the vasculature of the heart in response to local ischemia and hypoxia. They suggest that Wt1 has a role in the growth of coronary vessels after myocardial infarction.	Humboldt Univ, Med Fak Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Med Fak Charite, Innere Med Klin 1, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scholz, H (corresponding author), Humboldt Univ, Med Fak Charite, Johannes Muller Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Wagner, Kay-Dietrich/E-6119-2016	Wagner, Kay-Dietrich/0000-0001-5483-7760; Wagner, Nicole/0000-0002-2746-0707				Algar EM, 1996, ONCOGENE, V12, P1005; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bohlender J, 1997, HYPERTENSION, V29, P428, DOI 10.1161/01.HYP.29.1.428; Braissant O, 1998, BIOCHEMICA, V1, P10; Carmona R, 2001, CELL TISSUE RES, V303, P173, DOI 10.1007/s004410000307; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DeLisser HM, 1997, AM J PATHOL, V151, P671; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Englert C, 1997, CANCER RES, V57, P1429; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Farrell MJ, 2001, INT REV CYTOL, V202, P99, DOI 10.1016/S0074-7696(01)02004-6; Ghatpande S, 1999, MOL CELL BIOCHEM, V196, P93, DOI 10.1023/A:1006974330613; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Matsunaga T, 2000, CIRCULATION, V102, P3098; Maurer U, 2001, J BIOL CHEM, V276, P3727, DOI 10.1074/jbc.M005292200; Menke AL, 1996, ONCOGENE, V12, P537; Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068; Moore AW, 1999, DEVELOPMENT, V126, P1845; Moore AW, 1998, MECH DEVELOP, V79, P169, DOI 10.1016/S0925-4773(98)00188-9; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; Perez-Pomares JM, 1998, DEV BIOL, V200, P57, DOI 10.1006/dbio.1998.8949; Pinter E, 1997, AM J PATHOL, V150, P1523; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1993, ADV EXP MED BIOL, V348, P23; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Scholz F, 1997, J SOLID STATE ELECTR, V1, P1, DOI 10.1007/s100080050017; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; SHARMA PM, 1992, CANCER RES, V52, P6407; SHEIBANI N, 1999, HISTOPATHOLOGY, V14, P185; Su H, 2000, P NATL ACAD SCI USA, V97, P13801, DOI 10.1073/pnas.250488097; Theres HP, 2000, CARDIOVASC DRUG THER, V14, P597, DOI 10.1023/A:1007846311040; Tio RA, 1999, HUM GENE THER, V10, P2953, DOI 10.1089/10430349950016366; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 1998, J MOL CELL CARDIOL, V30, P2341, DOI 10.1006/jmcc.1998.0794; Wenger RH, 2000, J EXP BIOL, V203, P1253	50	99	100	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1117	+		10.1096/fj.01-0986fje	http://dx.doi.org/10.1096/fj.01-0986fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039855				2022-12-25	WOS:000175973900013
J	Lloberas, NR; Torras, J; Herrero-Fresneda, I; Cruzado, JM; Riera, M; Hurtado, I; Grinyo, JM				Lloberas, NR; Torras, J; Herrero-Fresneda, I; Cruzado, JM; Riera, M; Hurtado, I; Grinyo, JM			Postischemic renal oxidative stress induces an inflammatory response through PAF and oxidized phospholipids: prevention by antioxidant treatment	FASEB JOURNAL			English	Article						PAF-like lipids; renal ischemia-reperfusion; oxygen free radicals; PMN leukocyte; vitamin C	PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; ISCHEMIA-REPERFUSION; VITAMIN-C; ENDOTHELIAL-CELLS; BLOOD-PLASMA; RECEPTOR; ANTAGONIST; NEUTROPHILS; ADHESION	Reperfusion injury is considered primarily an inflammatory response to oxidative stress. In vitro, oxygen free radicals induce the formation of oxidized phospholipids with platelet-activating factor (PAF) activity (PAF-like lipids). We examined the following: 1) whether PAF and PAF-like lipids are released during reperfusion; 2) the relationship between these phospholipids and oxidative damage on the one hand, and leukocyte recruitment in renal tissue on the other; and 3) whether antioxidant treatment influences the behavior of these phospholipids, the renal inflammatory response, and the outcome of postischemic acute renal failure. After 60 min of warm renal ischemia in rabbits, a release of PAF and, particularly, PAF-like lipids was seen in the first 15 min of reperfusion. In addition, the release of those phospholipids was associated with intense tissue DNA oxidation and with an increase in myeloperoxidase activity. Vitamin C was able to attenuate these postischemic oxidative changes, decrease PAF and PAF-like lipid levels, and, consequently, reduce myeloperoxidase activity. After 40 min of warm renal ischemia in rats, vitamin C treatment ameliorated renal function and structure. This is the first in vivo demonstration of the release of phospholipid oxidation products as part of an oxidative-inflammatory response after renal ischemia-reperfusion, with the release of phospholipid oxidation products significantly reduced by antioxidant treatment.	Univ Barcelona, Dept Med, Lab Expt Nephrol, Barcelona, Spain; Bellvitge Hosp, CSUB,Dept Med, Lab Expt Nephrol 4122, Med Unit,Nephrol Serv, E-08907 Barcelona, Spain	University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Grinyo, JM (corresponding author), Bellvitge Hosp, CSUB,Dept Med, Lab Expt Nephrol 4122, Med Unit,Nephrol Serv, Pavello Govern 4A Plta,Feixa Llarga S-N, E-08907 Barcelona, Spain.	jmgrinyo@medicina.ub.es	Torras, Joan/AAH-8131-2021					ARNOULD T, 1993, AM J PHYSIOL, V264, pC1102, DOI 10.1152/ajpcell.1993.264.5.C1102; BALLMER PE, 1994, J THORAC CARDIOV SUR, V108, P311; Balsa D, 1997, DRUG EXP CLIN RES, V23, P191; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Bunting M, 1997, J CLIN INVEST, V100, P565, DOI 10.1172/JCI119566; Carceller E, 1996, J MED CHEM, V39, P487, DOI 10.1021/jm950555i; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; DREYER WJ, 1989, CIRC RES, V65, P1751, DOI 10.1161/01.RES.65.6.1751; FERREIRA R, 1988, AM HEART J, V115, P307, DOI 10.1016/0002-8703(88)90475-9; FRANSSEN C, 1995, TRANSPLANT P, V27, P2880; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1991, AM J CLIN NUTR, V54, pS1113, DOI 10.1093/ajcn/54.6.1113s; Frey B, 2000, J LIPID RES, V41, P1145; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; Herrero I, 1999, NEPHROL DIAL TRANSPL, V14, P872, DOI 10.1093/ndt/14.4.872; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; IMAIZUMI TA, 1991, ATHEROSCLEROSIS, V87, P47, DOI 10.1016/0021-9150(91)90231-Q; KALUZNY MA, 1985, J LIPID RES, V26, P135; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LEHR HA, 1993, ARTERIOSCLER THROMB, V13, P1013, DOI 10.1161/01.ATV.13.7.1013; LEHR HA, 1994, P NATL ACAD SCI USA, V91, P7688, DOI 10.1073/pnas.91.16.7688; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LEHR HA, 1991, J CLIN INVEST, V88, P9, DOI 10.1172/JCI115309; Lloberas N, 2002, TRANSPLANT P, V34, P47, DOI 10.1016/S0041-1345(01)02660-4; LORANT DE, 1999, PROG INFLAM RES, P81; MA XL, 1992, J PHARMACOL EXP THER, V260, P1229; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; PARKS DA, 1983, SURGERY, V94, P428; PATEL KD, 1992, J BIOL CHEM, V267, P15168; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; PRESCOTT SM, 1993, ATHEROSCLER REV, V25, P59; Riera M, 1997, J PHARMACOL EXP THER, V280, P786; Riera M, 2001, TRANSPLANTATION, V72, P1217, DOI 10.1097/00007890-200110150-00006; SALARI H, 1990, CIRC SHOCK, V32, P189; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; TORRAS J, 1993, TRANSPLANT INT, V6, P236, DOI 10.1007/BF00337106; Weber C, 1996, CIRCULATION, V93, P1488, DOI 10.1161/01.CIR.93.8.1488; WHATLEY RE, 1996, HANDB LIP R, V8, P239; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, V2, P149	47	70	73	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					908	+		10.1096/fj.01-0880fje	http://dx.doi.org/10.1096/fj.01-0880fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039876				2022-12-25	WOS:000175425900028
J	McNally, JD; Wu, SB; Sturgeon, CM; Storey, KB				McNally, JD; Wu, SB; Sturgeon, CM; Storey, KB			Identification and characterization of a novel freezing-inducible gene, li16, in the wood frog Rana sylvatica	FASEB JOURNAL			English	Article						cryobiology; gene expression; protein expression; freeze tolerance; liver	DEPENDENT PROTEIN-KINASE; CRYOPROTECTANT SYNTHESIS; TOLERANT FROG; NITRIC-OXIDE; HEPATOCYTES; DEHYDRATION; RESPONSES; LIVER; CGMP; TRANSCRIPTION	The wood frog Rana sylvatica survives for weeks during winter hibernation with up to 65% body water frozen as ice. Natural freeze tolerance includes both seasonal and freeze-induced molecular adaptations that control ice formation, deal with long-term ischemia, regulate cell volume changes, and protect macromolecules. This report identifies and characterizes a novel freeze-inducible gene, li16, that codes for a protein of 115 amino acids. Northern blot analysis showed that li16 transcript levels rose quickly during freezing to reach levels 3.7-fold higher than control values after 24 h; immunoblotting showed a parallel 2.4-fold rise in Li16 protein. Regulatory influences on gene expression were assessed. Nuclear runoff assays confirmed that freezing initiated an increase in the rate of li16 transcription, and analysis of signal transduction pathways via in vitro incubation of liver slices implicated a cGMP-mediated pathway in li16 expression. Gene and protein expression in liver was also strongly stimulated by anoxia exposure, whereas the gene was less responsive to dehydration stress. The strong response of li16 to both freezing and anoxia, and the rapid down-regulation of the gene when oxygen was reintroduced, suggest that the Li16 protein may play a role in ischemia resistance during freezing.	Carleton Univ, Inst Biochem, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Dept Biol, Ottawa, ON K1S 5B6, Canada; Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada	Carleton University; Carleton University; Carleton University	Storey, KB (corresponding author), Carleton Univ, Inst Biochem, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada.	kenneth_storey@carleton.ca	Storey, Kenneth B/G-9883-2011	Storey, Kenneth/0000-0002-7363-1853				BALLS M, 1976, LONG TERM AMPHIBIAN; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; Cai Q, 1997, AM J PHYSIOL-REG I, V272, pR1480, DOI 10.1152/ajpregu.1997.272.5.R1480; Cai QY, 1997, GENE, V198, P305, DOI 10.1016/S0378-1119(97)00332-6; Cai QY, 1997, BBA-GENE STRUCT EXPR, V1353, P69, DOI 10.1016/S0167-4781(97)00057-2; CHURCHILL TA, 1993, AM J PHYSIOL, V265, pR1324, DOI 10.1152/ajpregu.1993.265.6.R1324; CHURCHILL TA, 1994, CAN J ZOOL, V72, P1420, DOI 10.1139/z94-188; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Gudi T, 1996, J BIOL CHEM, V271, P4597; HEMMINGS SJ, 1994, CAN J PHYSIOL PHARM, V72, P1552, DOI 10.1139/y94-223; HILLMAN SS, 1987, PHYSIOL ZOOL, V60, P608, DOI 10.1086/physzool.60.5.30156135; Holden CP, 1996, AM J PHYSIOL-REG I, V271, pR1205, DOI 10.1152/ajpregu.1996.271.5.R1205; Holden CP, 1997, J COMP PHYSIOL B, V167, P305, DOI 10.1007/s003600050078; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larade K, 2001, J EXP ZOOL, V290, P759, DOI 10.1002/jez.1126; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; MOMMSEN TP, 1992, GEN COMP ENDOCR, V87, P44, DOI 10.1016/0016-6480(92)90148-D; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Rakhit RD, 2000, AM J PHYSIOL-HEART C, V278, pH1211, DOI 10.1152/ajpheart.2000.278.4.H1211; RUBINSKY B, 1994, AM J PHYSIOL, V266, pR1771, DOI 10.1152/ajpregu.1994.266.6.R1771; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Sambrook J., 2002, MOL CLONING LAB MANU; STOREY JM, 1985, J COMP PHYSIOL B, V156, P191, DOI 10.1007/BF00695773; Storey JM, 1996, CRYOBIOLOGY, V33, P186, DOI 10.1006/cryo.1996.0019; STOREY KB, 1987, J COMP PHYSIOL B, V157, P373, DOI 10.1007/BF00693364; STOREY KB, 1992, ANNU REV PHYSIOL, V54, P619, DOI 10.1146/annurev.physiol.54.1.619; STOREY KB, 1986, COMP BIOCHEM PHYS A, V83, P613, DOI 10.1016/0300-9629(86)90699-7; Storey KB, 1996, ANNU REV ECOL SYST, V27, P365, DOI 10.1146/annurev.ecolsys.27.1.365; STOREY KB, 1994, AM J PHYSIOL, V266, pR1477, DOI 10.1152/ajpregu.1994.266.5.R1477; Storey KB, 1999, CLIN EXP PHARMACOL P, V26, P57, DOI 10.1046/j.1440-1681.1999.02990.x; STOREY KB, 2001, CELL MOL RESPONSES S, V2, P263	32	30	30	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					902	+		10.1096/fj.02-0017fje	http://dx.doi.org/10.1096/fj.02-0017fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039874				2022-12-25	WOS:000175425900025
J	Kim, YS; Lewandoski, M; Perantoni, AO; Kurebayashi, S; Nakanishi, G; Jetten, AM				Kim, YS; Lewandoski, M; Perantoni, AO; Kurebayashi, S; Nakanishi, G; Jetten, AM			Identification of Glis1, a novel Gli-related, Kruppel-like zinc finger protein containing transactivation and repressor functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LIMB DEVELOPMENT; HEDGEHOG-PATCHED-GLI; ZIC GENE FAMILY; SONIC-HEDGEHOG; TRANSCRIPTIONAL REPRESSOR; CUBITUS-INTERRUPTUS; DROSOPHILA EMBRYO; KINASE-IV; EXPRESSION; ACTIVATION	In this study, we describe the identification and characterization of a novel Kruppel-like protein named Gli-similar 1 (Glis1). The Glis1 gene encodes an 84.3-kDa proline-rich protein. Its five tandem zinc finger motifs exhibit highest homology with those of members of the Gli and Zic subfamilies of Kruppel-like proteins. Glis1 was mapped to mouse chromosome 4C6. Northern blot analysis showed that expression of the 3.3-kb Glisl mRNA is most abundant in placenta and adult kidney and expressed at lower levels in testis. Whole mount in situ hybridization on mouse embryos demonstrated that Glisl is expressed in a temporal and spatial manner during development; expression was most prominent in several defined structures of mesodermal lineage, including craniofacial regions, branchial arches, somites, vibrissal and hair follicles, limb buds, and myotomes. Confocal microscopic analysis showed that Glis1 is localized to the nucleus. The zinc finger region plays an important role in the nuclear localization of Glis1. Electrophoretic mobility shift assays demonstrated that Glis1 is able to bind oligonucleotides containing the Gli-binding site consensus sequence GACCACCCAC. Although monohybrid analysis showed that in several cell types Glis1 was unable to induce transcription of a reporter, deletion mutant analysis revealed the presence of a strong activation function at the carboxyl terminus of Glis1. The activation through this activation function was totally suppressed by a repressor domain at its amino terminus. Constitutively active Ca2+-dependent calmodulin kinase IV enhanced Glis1-mediated transcriptional activation about 4-fold and may be mediated by phosphorylation/activation of a co-activator. Our results suggest that Glis1 may play a critical role in the control of gene expression during specific stages of embryonic development.	NIEHS, Cell Biol Sect, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; NCI, Lab Canc & Dev Biol, NIH, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jetten, AM (corresponding author), NIEHS, Cell Biol Sect, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA.		Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445; Lewandoski, Mark/0000-0002-1066-3735	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100485, Z01ES100485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Aruga J, 1999, MECH DEVELOP, V89, P141, DOI 10.1016/S0925-4773(99)00220-8; Aruga J, 1998, J NEUROSCI, V18, P284; Aruga J, 1996, GENE, V172, P291, DOI 10.1016/0378-1119(96)00111-4; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; Bailey EC, 2000, E SCHERING RES FDN W, V29, P211; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Buscher D, 1998, DEV DYNAM, V211, P88; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Duan H, 2001, DEVELOPMENT, V128, P4489; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Furlong EEM, 2001, SCIENCE, V293, P1629, DOI 10.1126/science.1062660; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Green J, 1998, BRIT J DERMATOL, V139, P911; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARAMIS AG, 2001, CURRENT PROTOCOLS MO; He GP, 1999, J BIOL CHEM, V274, P14678, DOI 10.1074/jbc.274.21.14678; Hughes DC, 1997, GENOMICS, V39, P205, DOI 10.1006/geno.1996.4468; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kitaguchi T, 2000, DEVELOPMENT, V127, P4787; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuo JS, 1998, DEVELOPMENT, V125, P2867; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; Lamar E, 2001, DEVELOPMENT, V128, P1335; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; Lessing D, 1998, DEVELOPMENT, V125, P1469; Marcelle C, 1997, DEVELOPMENT, V124, P3955; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mizugishi K, 2001, J BIOL CHEM, V276, P2180, DOI 10.1074/jbc.M004430200; Mo R, 1997, DEVELOPMENT, V124, P113; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Nagai T, 1997, DEV BIOL, V182, P299, DOI 10.1006/dbio.1996.8449; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Poncelet DA, 1998, DNA CELL BIOL, V17, P931, DOI 10.1089/dna.1998.17.931; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Rohr KB, 1999, MECH DEVELOP, V85, P147, DOI 10.1016/S0925-4773(99)00044-1; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; VORTKAMP A, 1995, DNA CELL BIOL, V14, P629, DOI 10.1089/dna.1995.14.629; Walterhouse DO, 1999, ENVIRON HEALTH PERSP, V107, P167, DOI 10.2307/3434504; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496; ZHANG F, 2001, J BIOL CHEM, V12, P10139; Zulch A, 2001, MECH DEVELOP, V106, P159, DOI 10.1016/S0925-4773(01)00411-7	76	54	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30901	30913		10.1074/jbc.M203563200	http://dx.doi.org/10.1074/jbc.M203563200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12042312	hybrid			2022-12-25	WOS:000177579800065
J	Edmondson, DG; Davie, JK; Zhou, J; Mirnikjoo, B; Tatchell, K; Dent, SYR				Edmondson, DG; Davie, JK; Zhou, J; Mirnikjoo, B; Tatchell, K; Dent, SYR			Site-specific loss of acetylation upon phosphorylation of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; TETRAHYMENA-THERMOPHILA; BUDDING YEAST; LYSINE 9; IN-VIVO; ACETYLTRANSFERASE; CHROMATIN; METHYLATION; GROWTH	Post-translational modification of histones is a central aspect of gene regulation. Emerging data indicate that modification at one site can influence modification of a second site. As one example, histone H3 phosphorylation at serine 10 (Serb) facilitates acetylation of lysine 14 (Lys(14)) by Gcn5 in vitro (1, 2). In vivo, phosphorylation of H3 precedes acetylation at certain promoters. Whether H3 phosphorylation globally affects acetylation, or whether it affects all acetylation sites in H3 equally, is not known. We have taken a genetic approach to this question by mutating Ser(10) in H3 to fix either a negative or a neutral charge at this position, followed by analysis of the acetylation states of the mutant histones using site-specific antibodies. Surprisingly, we find that conversion of Ser(10) to glutamate (S10E) or aspartate (S10D) causes almost complete loss of H3 acetylation at lysine 9 (Lys(9)) in vivo. Acetylation of Lys(9) is also significantly reduced in cells bearing mutations in the Glc7 phosphatase that increase H3 phosphorylation levels. Mutation of Ser(10) in H3 and the concomitant loss of Lys(9) acetylation has minimal effects on expression of a Gcn5-dependent reporter gene. However, synergistic growth defects are observed upon loss of GCN5 in cells bearing H3 Ser(10) mutations that are reminiscent of delays in G(2)/M progression caused by combined loss of GCN5 and acetylation site mutations. Together these results demonstrate that H3 phosphorylation directly causes site-specific and opposite changes in acetylation levels of two residues within this histone, Lys(9) and Lys14, and they highlight the importance of these histone modifications to normal cell functions.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Dent, SYR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Dent, Sharon YR/F-1746-2011; Tatchell, Kelly/A-9643-2009	Dent, Sharon YR/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715	NIGMS NIH HHS [GM51189] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1980, CELL, V20, P609, DOI 10.1016/0092-8674(80)90307-4; ALLIS CD, 1984, EXP CELL RES, V153, P287, DOI 10.1016/0014-4827(84)90601-3; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Baker SH, 1997, GENETICS, V145, P615; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 2001, SCIENCE, V292, P64; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rose MD., 1990, METHODS YEAST GENETI; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; VANHOLDE KE, 1989, CHROMATIN MOL BIOL; Venturi GM, 2000, GENETICS, V155, P69; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WOLFFE A, 1992, CHROMATIN STRUCTURE; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155; ZHANG XY, 1983, NUCLEIC ACIDS RES, V11, P4287, DOI 10.1093/nar/11.13.4287	44	90	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29496	29502		10.1074/jbc.M200651200	http://dx.doi.org/10.1074/jbc.M200651200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039950	hybrid			2022-12-25	WOS:000177509300021
J	Leighton, BH; Seal, RP; Shimamoto, K; Amara, SG				Leighton, BH; Seal, RP; Shimamoto, K; Amara, SG			A hydrophobic domain in glutamate transporters forms an extracellular helix associated with the permeation pathway for substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; CYSTEINE ACCESSIBILITY METHOD; BINDING-SITE CREVICE; REENTRANT LOOP; MEMBRANE TOPOLOGY; CHLORIDE CHANNEL; GLT-1; RESIDUE; IDENTIFICATION; POTASSIUM	Recent work has shown that cysteine residues introduced into domain 10, a highly hydrophobic segment in the excitatory amino acid transporter 1, react readily when hydrophilic sulfhydryl-modifying reagents are applied extracellularly. To investigate the functional contributions of this region, we mutated each residue in domain 10 (Ala(446)-Gly(459)) to cysteine and assessed the transport kinetics and inhibitor sensitivities of the mutant carriers. Modification of the introduced sulfhydryl group with membrane-impermeant methanethiosulfonate derivatives inhibited substrate transport by all but one functional cysteine mutant. Substrates and/or nontransported inhibitors block thiol modification of most mutants within this region, implying that access to the domain becomes restricted as a consequence of the binding of substrates and substrate analogs. An examination of the temperature dependence of substrate protection for one mutant (I453C) indicates that substrates prevent modification at a step prior to the large conformational changes associated with translocation. When superimposed on a helical model, mutants with similar attributes are positioned in close proximity. Our data are consistent with a model in which domain 10 exists as an a-helix at an aqueous interface of the translocation pathway, which can be directly occluded by substrates and inhibitors at an early step in the transport cycle.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Howard Hughes Med Inst, Portland, OR 97201 USA; Univ Calif San Francisco, Ctr Med, Dept Physiol, San Francisco, CA USA; Univ Calif San Francisco, Ctr Med, Dept Neurol, San Francisco, CA USA; Suntory Inst Bioorgan Res, Osaka 6188503, Japan	Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Suntory Holdings Ltd	Amara, SG (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Seal, Rebecca/0000-0003-4955-703X; Amara, Susan/0000-0001-8914-1106	NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007595, R37DA007595] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07595] Funding Source: Medline; NIMH NIH HHS [F31 MH011673] Funding Source: Medline; NINDS NIH HHS [NS33273] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Borre L, 2002, J BIOL CHEM, V277, P13501, DOI 10.1074/jbc.M110861200; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Daniels GM, 1998, METHOD ENZYMOL, V296, P307; Eliasof S, 1998, J NEUROSCI, V18, P698; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Mitrovic AD, 1998, J BIOL CHEM, V273, P14698, DOI 10.1074/jbc.273.24.14698; Otis TS, 1998, J NEUROSCI, V18, P7099; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	38	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29847	29855		10.1074/jbc.M202508200	http://dx.doi.org/10.1074/jbc.M202508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12015317	hybrid			2022-12-25	WOS:000177509300064
J	Sato, K; Nagao, T; Kakumoto, M; Kimoto, M; Otsuki, T; Iwasaki, T; Tokmakov, AA; Owada, K; Fukami, Y				Sato, K; Nagao, T; Kakumoto, M; Kimoto, M; Otsuki, T; Iwasaki, T; Tokmakov, AA; Owada, K; Fukami, Y			Adaptor protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-GROWTH; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; STAT3 ACTIVATION; FAMILY KINASES; V-SRC; DOMAIN; TRANSFORMATION; GENE	The activity of c-Src protein-tyrosine kinase is upregulated under a number of receptor signaling pathways. However, the activation mechanism of c-Src under physiological conditions has remained unclear. We show here that the Shc adaptor protein is a novel direct activator of c-Src in epidermal growth factor receptor signaling in A431 human epidermoid carcinoma cells. Among the three Shc isoforms, P66 and P52, but not P46, were found to interact with and activate c-Src in vitro and in vivo. Activation of c-Src accompanied autophosphorylation of c-Src in the activation segment, but the carboxyl-terminal dephosphorylation was not observed. We have identified the interaction sites between Shc and c-Src and constructed a point mutant of She that abolishes the c-Src activation. Using this mutant, we have confirmed that the Shc-mediated c-Src activation triggers Stat-p21/WAF1/Cip1 pathway that has been implicated in the cell cycle arrest and apoptosis of epidermal growth factor-stimulated A431 cells.	Kobe Univ, Res Ctr Environm Genom, Kobe, Hyogo 6578501, Japan; Kobe Univ, Fac Sci, Dept Biol, Kobe, Hyogo 6578501, Japan; Kobe Univ, Grad Sch Sci & Technol, Kobe, Hyogo 6578501, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; Kyoto Pharmaceut Univ, Inst Mol & Cellular Biol Pharmaceut Sci, Kyoto 6078412, Japan	Kobe University; Kobe University; Kobe University; Kobe University; Kyoto Pharmaceutical University	Fukami, Y (corresponding author), Kobe Univ, Res Ctr Environm Genom, Kobe, Hyogo 6578501, Japan.							Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HRDIE G, 1995, PROTEIN KINASE FACTS; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sahara S, 1996, FEBS LETT, V384, P138, DOI 10.1016/0014-5793(96)00302-X; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; SUDOL M, 1993, ONCOGENE, V8, P823; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	51	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29568	29576		10.1074/jbc.M203179200	http://dx.doi.org/10.1074/jbc.M203179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048194	hybrid			2022-12-25	WOS:000177509300030
J	Sekulic, N; Shuvalova, L; Spangenberg, O; Konrad, M; Lavie, A				Sekulic, N; Shuvalova, L; Spangenberg, O; Konrad, M; Lavie, A			Structural characterization of the closed conformation of mouse guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDYLATE KINASE; ADENYLATE KINASE; DICTYOSTELIUM-DISCOIDEUM; PHOSPHORYL TRANSFER; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; CHROMATID DAMAGE; DOMAIN CLOSURE; CYTO-TOXICITY; DNA DAMAGE	Guanylate kinase (GMPK) is a nucleoside monophosphate kinase that catalyzes the reversible phosphoryl transfer from ATP to GMP to yield ADP and GDP. In addition to phosphorylating GMP, antiviral prodrugs such as acyclovir, ganciclovir, and carbovir and anticancer prodrugs such as the thiopurines are dependent on GMPK for their activation. Hence, structural information on mammalian GMPK could play a role in the design of improved antiviral and antineoplastic agents. Here we present the structure of the mouse enzyme in an abortive complex with the nucleotides ADP and GMP, refined at 2.1 Angstrom resolution with a final crystallographic R factor of 0.19 (R-free = 0.23). Guanylate kinase is a member of the nucleoside monophosphate (NMP) kinase family, a family of enzymes that despite having a low primary structure identity share a similar fold, which consists of three structurally distinct regions termed the CORE, LID, and NMP-binding regions. Previous studies on the yeast enzyme have shown that these parts move as rigid bodies upon substrate binding. It has been proposed that consecutive binding of substrates leads to "closing" of the active site bringing the NMP-binding and LID regions closer to each other and to the CORE region. Our structure, which is the first of any guanylate kinase with both substrates bound, supports this hypothesis. It also reveals the binding site of ATP and implicates arginines 44, 137, and 148 (in addition to the invariant P-loop lysine) as candidates for catalyzing the chemical step of the phosphoryl transfer.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Max Planck Inst Biophys Chem, Dept Mol Genet, D-37077 Gottingen, Germany	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Max Planck Society	Lavie, A (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, 1819 W Polk St, Chicago, IL 60612 USA.		Sekulic, Nikolina/F-8911-2013; Sekulic, Nikolina/N-5550-2016	Sekulic, Nikolina/0000-0001-7555-3222; Lavie, Arnon/0000-0001-5591-8722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046943] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46943-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702; Agarwal K C, 1978, Methods Enzymol, V51, P483; BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; Blaszczyk J, 2001, J MOL BIOL, V307, P247, DOI 10.1006/jmbi.2000.4427; BODELL WJ, 1991, MUTAGENESIS, V6, P175, DOI 10.1093/mutage/6.3.175; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; Brady WA, 1996, J BIOL CHEM, V271, P16734, DOI 10.1074/jbc.271.28.16734; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CHRISTIE NT, 1984, CANCER RES, V44, P3665; Cotton F.A., 1988, ADV INORG CHEM, P1386; DREUSICKE D, 1986, FEBS LETT, V208, P301, DOI 10.1016/0014-5793(86)81037-7; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; GENTRY D, 1993, J BIOL CHEM, V268, P14316; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; KONRAD M, 1992, J BIOL CHEM, V267, P25652; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar V, 2000, EUR J BIOCHEM, V267, P606, DOI 10.1046/j.1432-1327.2000.01045.x; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Li Y, 1996, J BIOL CHEM, V271, P28038, DOI 10.1074/jbc.271.45.28038; MAYBAUM J, 1981, EXP CELL RES, V135, P465, DOI 10.1016/0014-4827(81)90192-0; MAYBAUM J, 1983, CANCER RES, V43, P3852; MERRITT EA, 1994, ACTA CRYSTALLOGR, V24, P869; MILLER RL, 1977, BIOCHEM PHARMACOL, V26, P1573, DOI 10.1016/0006-2952(77)90071-5; MILLER WH, 1992, J BIOL CHEM, V267, P21220; MILLER WH, 1980, J BIOL CHEM, V255, P7204; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Ostermann N, 2000, J MOL BIOL, V304, P43, DOI 10.1006/jmbi.2000.4175; PAN BF, 1990, BIOCHEM PHARMACOL, V40, P1063; Perozzo R, 2000, J BIOL CHEM, V275, P16139, DOI 10.1074/jbc.M000509200; Prinz H, 1999, J BIOL CHEM, V274, P35337, DOI 10.1074/jbc.274.50.35337; Scheffzek K, 1996, BIOCHEMISTRY-US, V35, P9716, DOI 10.1021/bi960642s; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Sinev MA, 1996, BIOCHEMISTRY-US, V35, P6425, DOI 10.1021/bi952687j; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; Stolworthy TS, 2001, PROTEIN ENG, V14, P903, DOI 10.1093/protein/14.11.903; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2	41	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30236	30243		10.1074/jbc.M204668200	http://dx.doi.org/10.1074/jbc.M204668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12036965	hybrid, Green Published			2022-12-25	WOS:000177509300109
J	Akompong, T; Kadekoppala, M; Harrison, T; Oksman, A; Goldberg, DE; Fujioka, H; Samuel, BU; Sullivan, D; Haldar, K				Akompong, T; Kadekoppala, M; Harrison, T; Oksman, A; Goldberg, DE; Fujioka, H; Samuel, BU; Sullivan, D; Haldar, K			trans expression of a Plasmodium falciparum histidine-rich protein II (HRPII) reveals sorting of soluble proteins in the periphery of the host erythrocyte malarial food vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN DEGRADATION; PARASITE; SECRETION; HEMOZOIN; PATHWAY	The heme polymer hemozoin is produced in the food vacuole (fv) of the parasite after hemoglobin proteolysis and is the target of the drug chloroquine. A candidate heme polymerase, the histidine-rich protein II (HRPII), is proposed to be delivered to the fv by ingestion of the infected-red cell cytoplasm. Here we show that 97% of endogenous Plasmodium falciparum (Pf) HRPII (PfHR-PII) is secreted as soluble protein in the periphery of the red cell and avoids endocytosis by the parasite, and 3% remains membrane-bound within the parasite. Transfected cells release 90% of a soluble transgene PfHRPII-myc into the red cell periphery and contain 10% membrane bound within the parasite. Yet these cells show a minor reduction in hemozoin production and IC50 for chloroquine. They also show decreased transport of resident fv enzyme PfPlasmepsin 1, the endoplasmic reticulum (ER) marker PfBiP, and parasite-associated HRPII to fvs. Instead, all three proteins accumulate in the ER, although there is no defect in protein export from the parasite. The data suggest that novel mechanisms of sorting (i) soluble antigens like HRPII in the red cell cytoplasm and (ii) fv-bound membrane complexes in the ER regulate parasite digestive processes.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, W Harry Feinstone Dept Microbiol & Immunol, Baltimore, MD 21205 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Case Western Reserve University; Johns Hopkins University	Haldar, K (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.	k-haldar@northwestern.edu	Haldar, Kasturi/C-6685-2014		NHLBI NIH HHS [HL69630] Funding Source: Medline; NIAID NIH HHS [AI47798, AI26670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI026670, R01AI026670, R01AI047798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akompong T, 2000, ANTIMICROB AGENTS CH, V44, P88, DOI [10.1128/AAC.44.11.3107-3111.2000, 10.1128/AAC.44.1.88-96.2000]; Akompong T, 1999, MOL BIOCHEM PARASIT, V101, P71, DOI 10.1016/S0166-6851(99)00056-0; [Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Chen MM, 2001, MOL BIOCHEM PARASIT, V113, P1, DOI 10.1016/S0166-6851(00)00365-0; Cheresh P, 2002, J BIOL CHEM, V277, P16265, DOI 10.1074/jbc.M109331200; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; FITCH CD, 1987, J BIOL CHEM, V262, P15552; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Gething M J, 1990, Semin Cell Biol, V1, P65; Goldberg Daniel E., 1993, Seminars in Cell Biology, V4, P355, DOI 10.1006/scel.1993.1042; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; GRATZER WB, 1993, SEMIN HEMATOL, V30, P232; HALDAR K, 1985, J BIOL CHEM, V260, P4969; Holder Anthony A., 1996, P77; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; Kadekoppala M, 2001, MOL BIOCHEM PARASIT, V112, P211, DOI 10.1016/S0166-6851(00)00368-6; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; MORAN JS, 1989, JAMA-J AM MED ASSOC, V262, P245, DOI 10.1001/jama.262.2.245; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; Tormakangas K, 2001, PLANT CELL, V13, P2021, DOI 10.1105/tpc.13.9.2021; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tyas L, 1999, FEBS LETT, V454, P210, DOI 10.1016/S0014-5793(99)00805-4; VANDERJAGT DL, 1982, J PARASITOL, V68, P1068, DOI 10.2307/3281093; VanWye J, 1996, MOL BIOCHEM PARASIT, V83, P107, DOI 10.1016/S0166-6851(96)02759-4; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; WALSH JA, 1989, ANN NY ACAD SCI, V569, P1, DOI 10.1111/j.1749-6632.1989.tb27354.x; *WHO DIV CONTR TRO, 1996, WHOMAL961077; Wiser MF, 1997, P NATL ACAD SCI USA, V94, P9108, DOI 10.1073/pnas.94.17.9108	36	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28923	28933		10.1074/jbc.M201968200	http://dx.doi.org/10.1074/jbc.M201968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023959	hybrid			2022-12-25	WOS:000177342600077
J	Herbert, C; Jacquet, C; Borel, C; Esquerre-Tugaye, MT; Dumas, B				Herbert, C; Jacquet, C; Borel, C; Esquerre-Tugaye, MT; Dumas, B			A cis-acting sequence homologous to the yeast filamentation and invasion response element regulates expression of a pectinase gene from the bean pathogen Colletotrichum lindemuthianum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; ENDOPOLYGALACTURONASE GENE; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; GALACTURONIC ACID; BOTRYTIS-CINEREA; VIRULENCE; FUNGUS; TRANSFORMATION; PENETRATION	Phytopathogenic fungi secrete hydrolytic enzymes that degrade plant cell walls, notably pectinases. The signaling pathway(s) that control pectinase gene expression are currently unknown in filamentous fungi. Recently, the green fluorescent protein coding sequence was used as a reporter gene to study the expression of CLPG2, a gene encoding an endopolygalacturonase of the bean pathogen Colletotrichum lindemuthianum. CLPG2 is transcriptionally induced by pectin in the axenic culture of the fungus and during formation of the appressorium, an infection structure specialized in plant tissue penetration. In the present study, promoter deletion and mutagenesis, as well as gel shift mobility assays, allowed for the first time identification of cis-acting elements that bind protein factors and are essential for the regulation of a pectinase gene. We found that two different adjacent DNA motifs are combined to form an active element that shows a strong sequence homology with the yeast filamentation and invasion response element. The same element is required for the transcriptional activation of CLPG2 by pectin and during appressorium development. This study strongly suggests that the control of virulence genes of fungal plant pathogens, such as pectinases, involves the formation of a complex of transcriptional activators similar to those regulating the invasive growth in yeast.	Univ Toulouse 3, CNRS, UMR 5546, F-31326 Castanet Tolosan, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Dumas, B (corresponding author), Univ Toulouse 3, CNRS, UMR 5546, 24 Chemin Borde Rouge,BP Auzeville,Pole Biotechno, F-31326 Castanet Tolosan, France.		jacquet, Christophe/B-2563-2009; Dumas, Bernard/D-1751-2009	jacquet, Christophe/0000-0002-7377-5638; Dumas, Bernard/0000-0002-4138-3533				BANNEROT H, 1965, ANN AMELIOR PLANT, V15, P201; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BARTHE JP, 1981, PHYTOPATHOL Z, V100, P162; Centis S, 1997, MOL PLANT MICROBE IN, V10, P769, DOI 10.1094/MPMI.1997.10.6.769; Centis S, 1996, GENE, V170, P125, DOI 10.1016/0378-1119(95)00867-5; Chang YC, 2001, P NATL ACAD SCI USA, V98, P3258, DOI 10.1073/pnas.061031998; Di Pietro A, 2001, MOL MICROBIOL, V39, P1140, DOI 10.1111/j.1365-2958.2001.02307.x; Dumas B, 1999, APPL ENVIRON MICROB, V65, P1769; FraissinetTachet L, 1996, CURR MICROBIOL, V33, P49, DOI 10.1007/s002849900073; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; HARGREAVES J, 1992, MOL PLANT PATHOL, P79; Hugouvieux V, 1997, APPL ENVIRON MICROB, V63, P2287, DOI 10.1128/AEM.63.6.2287-2292.1997; HugouvieuxCottePattat N, 1996, ANNU REV MICROBIOL, V50, P213, DOI 10.1146/annurev.micro.50.1.213; Madhani HD, 1999, P NATL ACAD SCI USA, V96, P12530, DOI 10.1073/pnas.96.22.12530; Madhani HD, 1998, TRENDS CELL BIOL, V8, P348, DOI 10.1016/S0962-8924(98)01298-7; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Perfect SE, 1999, FUNGAL GENET BIOL, V27, P186, DOI 10.1006/fgbi.1999.1143; Prusky D, 2001, MOL PLANT MICROBE IN, V14, P1105, DOI 10.1094/MPMI.2001.14.9.1105; PUNT PJ, 1995, GENE, V158, P119, DOI 10.1016/0378-1119(95)00166-4; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; Rogers LM, 2000, P NATL ACAD SCI USA, V97, P9813, DOI 10.1073/pnas.160271497; Schweizer A, 2000, MOL MICROBIOL, V38, P435, DOI 10.1046/j.1365-2958.2000.02132.x; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Shieh MT, 1997, APPL ENVIRON MICROB, V63, P3548, DOI 10.1128/AEM.63.9.3548-3552.1997; ten Have A, 1998, MOL PLANT MICROBE IN, V11, P1009, DOI 10.1094/MPMI.1998.11.10.1009; Tonukari NJ, 2000, PLANT CELL, V12, P237, DOI 10.1105/tpc.12.2.237; Tucker SL, 2001, ANNU REV PHYTOPATHOL, V39, P385, DOI 10.1146/annurev.phyto.39.1.385; Vallim MA, 2000, MOL MICROBIOL, V36, P290, DOI 10.1046/j.1365-2958.2000.01874.x; Wubben JP, 2000, CURR GENET, V37, P152, DOI 10.1007/s002940050022; Yakoby N, 2001, MOL PLANT MICROBE IN, V14, P988, DOI 10.1094/MPMI.2001.14.8.988; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470	32	17	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29125	29131		10.1074/jbc.M201489200	http://dx.doi.org/10.1074/jbc.M201489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042302	hybrid			2022-12-25	WOS:000177342600101
J	Huang, H; Starodub, O; McIntosh, A; Kier, AB; Schroeder, F				Huang, H; Starodub, O; McIntosh, A; Kier, AB; Schroeder, F			Liver fatty acid-binding protein targets fatty acids to the nucleus - Real time confocal and multiphoton fluorescence imaging in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; RAT-LIVER; SUBCELLULAR-DISTRIBUTION; PHOSPHOLIPID CONTENT; LIPID-COMPOSITION; GENE-EXPRESSION; PPAR-ALPHA; TRANSPORT; LIGAND; FIBROBLASTS	Although unesterified long chain fatty acids interact with peroxisome proliferator-activated receptors to initiate transcription within the nucleus, almost nothing is known regarding factors regulating long chain fatty acid distribution to the nucleus of living cells. The possibility that the liver fatty acid-binding protein (LFABP) may function in this role was addressed in transfected L-cell fibroblasts overexpressing L-FABP using a series of fluorescent fatty acids differing in chain length and unsaturation. After 30 min of incubation, oxidation of BODIPY-, NBD-, and cis-parinaric acids was undetectable in L-cells. Likewise, L-cells very poorly esterified these fluorescent fatty acids in the following order: 0% BODIPY-C5, NBD-C6 (short chain length) < 0-3% NBD-C18, BODIPY-C16, cis-parinaric acid (long chain length) < 11% BODIPY-C12 (medium chain length). Real time confocal and multiphoton laser scanning microscopy (CLSM and MPLSM) showed that these fluorescent fatty acids were generally taken up in the following order: long chain (BODIPY-C16, NBD-C18) > medium chain (BODIPY-C12) much greater than short chain (BODIPY-C5, NBD-C6). The fluorescent fatty acids were imaged in the nucleus, primarily associated with the nuclear envelope, at levels about 2-3-fold lower than outside the nucleus. CLSM and MPLSM showed that L-FABP expression enhanced by 2-4-fold the initial rate and/or average maximal uptake of the long and medium chain but not the short chain fluorescent fatty acids in living cells. Furthermore, L-FABP expression increased the targeting of long and medium but not short chain fluorescent fatty acids to the nucleus by 2.9-4.4-fold and increased the proportion (i.e. nuclear:cytoplasm ratio) of medium and long chain but not short chain fatty acids by 2-3.6-fold. In summary, these results showed for the first time the presence of unesterified fatty acids in the nucleus of living cells and demonstrated that expression of a fatty acid-binding protein, L-FABP, specifically enhanced uptake and intracellular targeting of long and medium chain fatty acids to the nucleus.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fsehroeder@cvm.tamu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; BASSUK JA, 1987, P NATL ACAD SCI USA, V84, P7547, DOI 10.1073/pnas.84.21.7547; BORCHERS T, 1989, BIOCHIM BIOPHYS ACTA, V1002, P54, DOI 10.1016/0005-2760(89)90063-5; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; Burczynski FJ, 1997, CAN J PHYSIOL PHARM, V75, P1350, DOI 10.1139/cjpp-75-12-1350; BURNETT DA, 1979, GASTROENTEROLOGY, V77, P241; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DEUTSCH J, 1994, ANAL BIOCHEM, V220, P321, DOI 10.1006/abio.1994.1344; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; FAHIMI HD, 1990, HEPATOLOGY, V11, P859, DOI 10.1002/hep.1840110522; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Gorski J, 2000, MOL CELL BIOCHEM, V214, P57, DOI 10.1023/A:1007189503183; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Gorski J, 1996, LIFE SCI, V59, P2209, DOI 10.1016/S0024-3205(96)00578-4; Hamilton JA, 1998, J LIPID RES, V39, P467; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Heyliger CE, 1996, MOL CELL BIOCHEM, V155, P113; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; KEENAN TW, 1970, BIOCHIM BIOPHYS ACTA, V203, P547, DOI 10.1016/0005-2736(70)90191-4; Keler T, 1997, ADV EXP MED BIOL, V400, P517; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLEINIG H, 1970, J CELL BIOL, V46, P396, DOI 10.1083/jcb.46.2.396; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lawrence JW, 2000, J LIPID RES, V41, P1390; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; McArthur MJ, 1999, J LIPID RES, V40, P1371; Mizushina Y, 2000, BBA-MOL CELL BIOL L, V1486, P211, DOI 10.1016/S1388-1981(00)00065-2; Mizushina Y, 2000, J MOL BIOL, V304, P385, DOI 10.1006/jmbi.2000.4223; MORTON RE, 1982, LIPIDS, V17, P529, DOI 10.1007/BF02535380; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, ARCH BIOCHEM BIOPHYS, V335, P267, DOI 10.1006/abbi.1996.0507; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Murphy EJ, 2000, J LIPID RES, V41, P788; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; Nawrocki A, 1999, HORM METAB RES, V31, P252, DOI 10.1055/s-2007-978727; Palmer CNA, 1998, FEBS LETT, V431, P476, DOI 10.1016/S0014-5793(98)00818-7; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; PHELPSLUBY K, 1996, COMP BIOCH PHYSL B, V115, P295; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SHA RS, 1993, J BIOL CHEM, V268, P7885; SONG M, 1987, BASIC APPL HISTOCHEM, V31, P377; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; VINORES SA, 1984, P NATL ACAD SCI-BIOL, V81, P2092, DOI 10.1073/pnas.81.7.2092; Vork MM, 1997, PROSTAG LEUKOTR ESS, V57, P11, DOI 10.1016/S0952-3278(97)90486-5; Wahli W, 1999, ADV EXP MED BIOL, V447, P199; Weisiger RA, 1996, COMP BIOCHEM PHYS B, V115, P319, DOI 10.1016/S0305-0491(96)00179-4; Weisiger RA, 1996, HEPATOLOGY, V24, P1288; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Zendzian-Piotrowska M, 2000, HORM METAB RES, V32, P386, DOI 10.1055/s-2007-978659	75	127	128	4	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29139	29151		10.1074/jbc.M202923200	http://dx.doi.org/10.1074/jbc.M202923200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023965	hybrid			2022-12-25	WOS:000177342600103
J	Kato, A; Kawamata, N; Tamayose, K; Egashira, M; Miura, R; Fujimura, T; Murayama, K; Oshimi, K				Kato, A; Kawamata, N; Tamayose, K; Egashira, M; Miura, R; Fujimura, T; Murayama, K; Oshimi, K			Ancient ubiquitous protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin alpha subunits that plays a crucial role in the inside-out signaling of alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; CELL-LINE; DOMAIN; AFFINITY; BETA(3); GENE; INTEGRIN-ALPHA-IIB-BETA-3; BETA(3)-ENDONEXIN; ESTABLISHMENT; DEGRADATION	Modification of the cytoplasmic tails of the integrin alpha(IIb)beta(3) plays an important role in the signal transduction in platelets. We searched for proteins that bind to the alpha(IIb) cytoplasmic tail using the yeast two-hybrid assay with a cDNA library of the megakaryocyte-derived cell line and identified a protein, ancient ubiquitous protein I (Aup1), that is ubiquitously expressed in human cells. Observation of UT7/TPO cells expressing a red fluorescent protein-tagged Aup1 indicated its localization in the cytoplasm. Immunoprecipitation of UT7/TPO cells by an antibody for Aup1 revealed that similar to40% of alpha(IIB) is complexed with Aup1. Binding study with an alpha(IIb) cytoplasmic tail peptide and glutathione S-transferase-Aup1 fusion protein revealed a low affinity (K-d = 90 muM). Subsequent yeast two-hybrid assay indicated binding of Aup1 to cytoplasmic tails of other integrin alpha subunits. Binding study with the purified Aup1 and various glutathione S-transferase-alpha(IIb) cytoplasmic tail peptides revealed specific binding of Aup1 to the membrane-proximal sequence (KVGFFKR) that is conserved among the integrin a subunits and plays a crucial role in the alpha(IIb)beta(3) inside-out signaling. As Aup1 possesses domains related to signal transduction, these results suggest involvement of Aup1 in the integrin signaling.	Juntendo Univ, Sch Med, Div Hematol, Dept Internal Med,Bunkyo Ku, Tokyo 1130033, Japan; Juntendo Univ, Sch Med, Cent Lab Med Sci, Div Biochem Anal,Bunkyo Ku, Tokyo 1130033, Japan	Juntendo University; Juntendo University	Kato, A (corresponding author), Juntendo Univ, Sch Med, Div Hematol, Dept Internal Med,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1130033, Japan.	atkato@med.juntendo.ac.jp		Fujimura, Tsutomu/0000-0003-1744-7725				BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Fox JEB, 2001, THROMB HAEMOSTASIS, V86, P198; Hu RM, 2000, P NATL ACAD SCI USA, V97, P9543, DOI 10.1073/pnas.160270997; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Jang WH, 1996, GENOMICS, V36, P366, DOI 10.1006/geno.1996.0477; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Kato A, 1997, CRIT REV ONCOL HEMAT, V26, P1, DOI 10.1016/S1040-8428(97)00011-5; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Neuwald AF, 1997, CURR BIOL, V7, pR465; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SMYTH SS, 1993, BLOOD, V81, P2827; SMYTH SS, 1992, J BIOL CHEM, V267, P15568; SOLSKI PA, 1995, METHOD ENZYMOL, V250, P435; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691	36	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28934	28941		10.1074/jbc.M204340200	http://dx.doi.org/10.1074/jbc.M204340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042322	hybrid			2022-12-25	WOS:000177342600078
J	Raussens, V; Slupsky, CM; Ryan, RO; Sykes, BD				Raussens, V; Slupsky, CM; Ryan, RO; Sykes, BD			NMR structure and dynamics of a receptor-active apolipoprotein E peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; NUCLEAR-MAGNETIC-RESONANCE; N-TERMINAL DOMAIN; PROTEIN SECONDARY STRUCTURE; CELL-SURFACE RECEPTORS; LIGAND-BINDING DOMAIN; CYSTEINE-RICH REPEAT; LDL RECEPTOR; BACKBONE DYNAMICS; 3-DIMENSIONAL STRUCTURE	Apolipoprotein E (apoE) is important in lipid metabolism due to its interaction with members of the low density lipoprotein (LDL) receptor family. ApoE is able to interact with the LDL receptor only when it is bound to lipid particles. To address structural aspects of this phenomenon, a receptor-active apoE peptide, encompassing the receptor-binding region of the protein, was studied by NMR in the presence of the lipid-mimicking agent trifluoroethanol. In 50% trifluoroethanol, apoE-(126-183) forms a continuous amphipathic a-helix over residues Thr(130)-Glu(179). Detailed NAM relaxation analysis indicates a high degree of plasticity for the residues surrounding 149-159. This intrinsic flexibility imposes a curvature to the peptide that may be important in terms of interaction of apoE with various sized lipid particles and the LDL receptor. Residues 165-179 of apoE may act as a molecular switch whereby these residues are unstructured in the absence of lipids and prevent interaction with the LDL receptor. In the presence of lipids, these residues become helical resulting in a receptoractive conformation of the protein. Furthermore, the electrostatic characteristics and geometric features of apoE-(126-183) suggest that apoE binds to the LDL receptor by interacting with more than one of the receptor ligand-binding repeats.	Univ Alberta, Prot Engn Network Ctr Excellence, Heritage Med Res Ctr 713, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Heritage Med Res Ctr 713, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Prot Engn Network Ctr Excellence, Heritage Med Res Ctr 713, Edmonton, AB T6G 2S2, Canada.	brian.sykes@ualberta.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064159, R37HL064159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abseher R, 1998, PROTEINS, V31, P370; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BAX A, 1994, METHOD ENZYMOL, V239, P79; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Bieri S, 1998, BIOCHEMISTRY-US, V37, P10994, DOI 10.1021/bi980452c; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; BRUSCHWEILER R, 1995, J CHEM PHYS, V102, P3396, DOI 10.1063/1.469213; BRUSCHWEILER R, 1991, Journal of Biomolecular NMR, V1, P3, DOI 10.1007/BF01874565; Brutscher B, 1997, BIOCHEMISTRY-US, V36, P13043, DOI 10.1021/bi971538t; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Clayton D, 2000, FEBS LETT, V479, P118, DOI 10.1016/S0014-5793(00)01842-1; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; ESSER V, 1988, J BIOL CHEM, V263, P13282; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Gorler A, 2000, J BIOMOL NMR, V16, P147, DOI 10.1023/A:1008386726542; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Kumaran S, 1999, J PEPT RES, V53, P284, DOI 10.1034/j.1399-3011.1999.00027.x; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; MacRaild CA, 2001, BIOCHEMISTRY-US, V40, P5414, DOI 10.1021/bi002821m; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; North CL, 2000, BIOCHEMISTRY-US, V39, P2564, DOI 10.1021/bi992087a; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; PITAS RE, 1987, J BIOL CHEM, V262, P14352; RALL SC, 1986, METHOD ENZYMOL, V128, P273; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Raussens V, 2000, J BIOL CHEM, V275, P38329, DOI 10.1074/jbc.M005732200; Rozek A, 1999, BIOCHEMISTRY-US, V38, P14475, DOI 10.1021/bi982966h; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Saxena K, 1997, BIOCHEMISTRY-US, V36, P15940, DOI 10.1021/bi971579p; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC	84	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29172	29180		10.1074/jbc.M204043200	http://dx.doi.org/10.1074/jbc.M204043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036962	hybrid			2022-12-25	WOS:000177342600106
J	Ohya, T; Kawasaki, Y; Hiraga, SI; Kanbara, S; Nakajo, K; Nakashima, N; Suzuki, A; Sugino, A				Ohya, T; Kawasaki, Y; Hiraga, SI; Kanbara, S; Nakajo, K; Nakashima, N; Suzuki, A; Sugino, A			The DNA polymerase domain of pole is required for rapid, efficient, and highly accurate chromosomal DNA replication, telomere length maintenance, and normal cell senescence in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MCM PROTEIN; LIFE-SPAN; EPSILON; DELTA; CHECKPOINT; INTERACTS; GENES; COMPLEXES; HELICASE	Saccharomyces cerevisiae POL2 encodes the catalytic subunit of DNA polymerase epsilon. This study investigates the cellular functions performed by the polymerase domain of Pol2p and its role in DNA metabolism. The pol2-16 mutation has a deletion in the catalytic domain of DNA polymerase a that eliminates its polymerase and exonuclease activities. It is a viable mutant, which displays temperature sensitivity for growth and a defect in elongation step of chromosomal DNA replication even at permissive temperatures. This mutation is synthetic lethal in combination with temperature-sensitive mutants or the 3'- to 5'-exonuclease-deficient mutant of DNA polymerase delta in a haploid cell. These results suggest that the catalytic activity of DNA polymerase a participates in the same pathway as DNA polymerase delta, and this is consistent with the observation that DNA polymerases delta and epsilon colocalize in some punctate foci on yeast chromatids during S phase. The pol2-16 mutant senesces more rapidly than wild type strain and also has shorter telomeres. These results indicate that the DNA polymerase domain of Po12p is required for rapid, efficient, and highly accurate chromosomal DNA replication in yeast.	Osaka Univ, Dept Biochem & Mol Biol, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan	Osaka University	Sugino, A (corresponding author), Osaka Univ, Dept Biochem & Mol Biol, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	asugino@biken.osaka-u.ac.jp	Hiraga, Shin-ichiro/C-6596-2008	Hiraga, Shin-ichiro/0000-0002-8722-3869				Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Braguglia D, 1998, J MOL BIOL, V281, P631, DOI 10.1006/jmbi.1998.1973; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Falaschi A, 2000, TRENDS GENET, V16, P88, DOI 10.1016/S0168-9525(99)01917-4; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Frei C, 2000, GENE DEV, V14, P81; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kirchner JM, 2000, GENETICS, V155, P1623; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; McVey M, 2001, GENETICS, V157, P1531; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Morris DK, 1997, CURR BIOL, V7, P969, DOI 10.1016/S0960-9822(06)00416-7; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846; Park PU, 1999, MOL CELL BIOL, V19, P3848; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; Qi HY, 2000, GENE DEV, V14, P1777; Rose MD., 1990, METHODS YEAST GENETI; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	64	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28099	28108		10.1074/jbc.M111573200	http://dx.doi.org/10.1074/jbc.M111573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015307	hybrid			2022-12-25	WOS:000177189800066
J	Coste, H; Rodriguez, JC				Coste, H; Rodriguez, JC			Orphan nuclear hormone receptor Rev-erb alpha regulates the human apolipoprotein CIII promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; C-III EXPRESSION; TRIGLYCERIDE-RICH LIPOPROTEINS; ISCHEMIC-HEART-DISEASE; APOA-I GENE; A-I; INTESTINAL EXPRESSION; TRANSGENIC MICE; ROR-ALPHA; APOCIII ENHANCER	Apolipoprotein CIII (apoCIII) plays an important role in plasma triglyceride and remnant lipoprotein metabolism. Because hypertriglyceridemia is an independent risk factor in coronary artery disease and the presence in plasma of triglyceride-rich remnant lipoproteins is correlated with atherosclerosis, considerable research efforts have been focused on the identification of factors regulating apoCIII gene expression to decrease its production. Here we report that the orphan nuclear hormone receptor Rev-erbalpha regulates the human apoCIII gene promoter. In apoCIII expressing human hepatic HepG2 cells, transfection of Rev-erba specifically repressed apoCIII gene promoter activity. We determined by deletion and site-directed mutagenesis experiments that Rev-erba dependent repression is mainly due to an element present in the proximal promoter of the apoCIII gene. In contrast, we found no functional Rev-erba response elements in the convergently transcribed human apoAI gene or the common regulatory enhancer. The identified Rev-erba response element coincides with a RORalpha1 element, and in the present study we provide evidence that functional cross-talk between these orphan receptors modulates the apoCIII promoter. In vitro binding analysis showed that monomers of Rev-erba bound this element but not another upstream RORalpha1 response element. In addition, we showed that the closely related nuclear orphan receptor RVR also specifically repressed the human apoCIII gene. These studies underscore a novel physiological role for members of the Rev-erb family of nuclear receptors in the regulation of genes involved in triglyceride metabolism and the pathogenesis of atherosclerosis.	GlaxoSmithKline, F-91951 Les Ulis, France	GlaxoSmithKline	Coste, H (corresponding author), GlaxoSmithKline, 25 Ave Quebec, F-91951 Les Ulis, France.	hjcc6201@gsk.com; jcr0226@gsk.com						AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Adelmant G, 1996, P NATL ACAD SCI USA, V93, P3553, DOI 10.1073/pnas.93.8.3553; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; Bois-Joyeux B, 2000, DNA CELL BIOL, V19, P589, DOI 10.1089/104454900750019344; BONNELYE E, 1994, CELL GROWTH DIFFER, V5, P1357; Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; Clavey V, 1999, CELL PHYSIOL BIOCHEM, V9, P139, DOI 10.1159/000016311; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; Duez HM, 1998, CIRCULATION, V98, P449; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Esterbauer H, 1999, CLIN CHEM, V45, P331; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; Georgopoulos S, 2000, NUCLEIC ACIDS RES, V28, P4919, DOI 10.1093/nar/28.24.4919; Gervois P, 1999, MOL ENDOCRINOL, V13, P400, DOI 10.1210/me.13.3.400; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; Guo Q, 2001, BBA-MOL CELL BIOL L, V1533, P220, DOI 10.1016/S1388-1981(01)00156-1; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Haubenwallner S, 1995, J LIPID RES, V36, P2541; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hodis HN, 1999, CIRCULATION, V99, P2852, DOI 10.1161/01.CIR.99.22.2852; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JANUZZI JL, 1992, GENOMICS, V14, P1081, DOI 10.1016/S0888-7543(05)80133-8; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; Kan HY, 2000, J BIOL CHEM, V275, P30423, DOI 10.1074/jbc.M005641200; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KARATHANASIS SK, 1983, NATURE, V304, P371, DOI 10.1038/304371a0; Kassam A, 1999, J BIOL CHEM, V274, P22895, DOI 10.1074/jbc.274.32.22895; Krauss RM, 1998, AM J CARDIOL, V81, p13B, DOI 10.1016/S0002-9149(98)00032-0; Lawrence JW, 2001, TOXICOL APPL PHARM, V170, P113, DOI 10.1006/taap.2000.9098; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1990, DNA CELL BIOL, V9, P77, DOI 10.1089/dna.1990.9.77; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Marcoux C, 2001, METABOLISM, V50, P112, DOI 10.1053/meta.2001.19452; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; Miller M, 1998, J AM COLL CARDIOL, V31, P1252, DOI 10.1016/S0735-1097(98)00083-7; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Raspe E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; RETNAKARAN R, 1994, MOL ENDOCRINOL, V8, P1234, DOI 10.1210/me.8.9.1234; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Sauve FD, 2001, MOL CELL BIOL, V21, P343, DOI 10.1128/MCB.21.1.343-353.2001; Shachter NS, 2001, CURR OPIN LIPIDOL, V12, P297, DOI 10.1097/00041433-200106000-00009; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; STOCKS J, 1979, LANCET, V2, P667; STONE NJ, 1994, MED CLIN N AM, V78, P117, DOI 10.1016/S0025-7125(16)30179-1; Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; WALSH A, 1993, J LIPID RES, V34, P617; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; Winegar DA, 2001, J LIPID RES, V42, P1543; Zannis VI, 2001, CURR OPIN LIPIDOL, V12, P181, DOI 10.1097/00041433-200104000-00012	70	62	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27120	27129		10.1074/jbc.M203421200	http://dx.doi.org/10.1074/jbc.M203421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021280	Green Published, hybrid			2022-12-25	WOS:000177055900055
J	Robinson, NP; McCulloch, R; Conway, C; Browitt, A; Barry, JD				Robinson, NP; McCulloch, R; Conway, C; Browitt, A; Barry, JD			Inactivation of Mre11 does not affect VSG gene duplication mediated by homologous recombination in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SCHIZOSACCHAROMYCES-POMBE RAD32; DNA-DAMAGE RESPONSE; SACCHAROMYCES-CEREVISIAE; ANTIGENIC VARIATION; TELOMERE MAINTENANCE; PROTEIN COMPLEX; CHROMOSOMAL REARRANGEMENTS; MEIOTIC RECOMBINATION; AFRICAN TRYPANOSOMES	We demonstrate, by gene deletion analysis, that Mre11 has a critical role in maintaining genomic integrity in Trypanosoma brucei. mire11(-/-) null mutant strains exhibited retarded growth but no delay or disruption of cell cycle progression. They showed also a weak hyporecombination phenotype and the accumulation of gross chromosomal rearrangements, which did not involve sequence translocation, telomere loss, or formation of new telomeres. The trypanosome mre11(-/-) strains were hypersensitive to phleomycin, a mutagen causing DNA double strand breaks (DSBs) but, in contrast to mre11(-/-) null mutants in other organisms and T. brucei rad51(-/-) null mutants, displayed no hypersensitivity to methyl methanesulfonate, which causes point mutations and DSBs. Mre11 therefore is important for the repair of chromosomal damage and DSBs in trypanosomes, although in this organism the intersection of repair pathways appears to differ from that in other organisms. Mre11 inactivation appears not to affect VSG gene switching during antigenic variation of a laboratory strain, which is perhaps surprising given the importance of homologous recombination during this process.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Barry, JD (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Robinson, Nick/0000-0002-6094-1924				Alsford S, 2001, MOL BIOCHEM PARASIT, V113, P79, DOI 10.1016/S0166-6851(00)00388-1; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; Barry JD, 1997, PARASITOL TODAY, V13, P212, DOI 10.1016/S0169-4758(97)01039-9; Borst P, 1998, MOL BIOCHEM PARASIT, V91, P67, DOI 10.1016/S0166-6851(97)00184-9; BORST P, 1980, MOL BIOCHEM PARASIT, V1, P221, DOI 10.1016/0166-6851(80)90030-4; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1998, GENETICS, V150, P591; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; Cano MIN, 1999, P NATL ACAD SCI USA, V96, P3616, DOI 10.1073/pnas.96.7.3616; CAPBERN A, 1977, EXP PARASITOL, V42, P6, DOI 10.1016/0014-4894(77)90055-8; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Chin GM, 2001, GENE DEV, V15, P522, DOI 10.1101/gad.864101; Conway C, 2002, J BIOL CHEM, V277, P21269, DOI 10.1074/jbc.M200550200; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Ersfeld K, 1999, PARASITOL TODAY, V15, P58, DOI 10.1016/S0169-4758(98)01378-7; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Gallego ME, 2001, PLANT J, V25, P31, DOI 10.1046/j.1365-313x.2001.00928.x; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Horn D, 2000, EMBO J, V19, P2332, DOI 10.1093/emboj/19.10.2332; JOHZUKA K, 1995, GENETICS, V139, P1521; Kironmai KM, 1997, GENES CELLS, V2, P443; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LIU AYC, 1983, J MOL BIOL, V167, P57, DOI 10.1016/S0022-2836(83)80034-5; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; McCulloch R, 1999, GENE DEV, V13, P2875, DOI 10.1101/gad.13.21.2875; Melville SE, 2000, MOL BIOCHEM PARASIT, V111, P261, DOI 10.1016/S0166-6851(00)00316-9; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moreau S, 1999, MOL CELL BIOL, V19, P556; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Ritchie KB, 2000, GENETICS, V155, P475; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; SHAH JS, 1987, MOL BIOCHEM PARASIT, V24, P163, DOI 10.1016/0166-6851(87)90103-4; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SLOOF P, 1983, J MOL BIOL, V167, P1, DOI 10.1016/S0022-2836(83)80031-X; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAVASSOLI M, 1995, NUCLEIC ACIDS RES, V23, P383, DOI 10.1093/nar/23.3.383; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Wilson S, 1999, NUCLEIC ACIDS RES, V27, P2655, DOI 10.1093/nar/27.13.2655; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619	69	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26185	26193		10.1074/jbc.M203205200	http://dx.doi.org/10.1074/jbc.M203205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011090	hybrid			2022-12-25	WOS:000176908700048
J	Crochemore, C; Michaelidis, TM; Fischer, D; Loeffler, JP; Almeida, OFX				Crochemore, C; Michaelidis, TM; Fischer, D; Loeffler, JP; Almeida, OFX			Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation	FASEB JOURNAL			English	Article						corticosteroid; cell cycle arrest; apoptosis; HT-22 neural cell line	TUMOR-SUPPRESSOR P53; HIPPOCAMPAL GRANULE CELLS; RAT HEPATOMA-CELLS; GENE-EXPRESSION; CYCLE ARREST; DNA-DAMAGE; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; CORTICOSTEROID RECEPTORS; PROMOTER ACTIVITY	In analyzing the molecular mechanisms underlying glucocorticoid-induced apoptosis in neural cells, we observed that dexamethasone, by activating glucocorticoid receptors, causes arrest of HT-22 cells in the G(1) phase of the cell cycle; upon withdrawal of the agonist, cells resume proliferation. Our investigations revealed that glucocorticoid treatment, although having no effects on endogenous p53 protein stability, induces rapid translocation of p53 to the nucleus and enhances its transcriptional activity. Consistently, transfection studies with p53-responsive promoters revealed a substantial stimulation of the trans-activation potential of exogenous p53 by dexamethasone. Cells arrested in G(1) failed to show signs of apoptosis even after overexpression of p53. Although dexamethasone induced transcription of the proapoptotic gene bax, there was no increase of Bax protein levels. We conclude that glucocorticoid receptor-induced neural cell cycle arrest is associated with an increase in nuclear translocation and transcriptional activity of p53, and suggest that potentiation of p53 may serve as a brake on cell proliferation and may prime cells for differentiation or death induced by other signals.	Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Strasbourg, Fac Med, F-67000 Strasbourg, France	Max Planck Society; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.	osa@mpipsykl.mpg.de	Almeida, Osborne F.X. F/E-8402-2010; LOEFFLER, Jean-Philippe/AAS-4401-2020	Almeida, Osborne F.X. F/0000-0001-7331-6928; 				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Almeida OFX, 2000, FASEB J, V14, P779, DOI 10.1096/fasebj.14.5.779; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTHEL F, 1993, DNA CELL BIOL, V12, P553, DOI 10.1089/dna.1993.12.553; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BURNSTEIN KL, 1994, MOL ENDOCRINOL, V8, P1764, DOI 10.1210/me.8.12.1764; Cadepond F, 1997, ANNU REV MED, V48, P129; Campagne MV, 1998, J COMP NEUROL, V397, P181; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chapman MS, 1996, MOL ENDOCRINOL, V10, P967, DOI 10.1210/me.10.8.967; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CIDLOWSKI JA, 1977, NATURE, V266, P643, DOI 10.1038/266643a0; COLEMAN RE, 1992, BIOTHERAPY, V4, P37, DOI 10.1007/BF02171708; CORRELL PH, 1997, GENES FUNCTION, V1, P1; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1996, CANCER RES, V56, P5033; Glass CK, 2000, GENE DEV, V14, P121; Glick RD, 2000, J PEDIATR SURG, V35, P465, DOI 10.1016/S0022-3468(00)90216-1; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Hassan AHS, 1999, FASEB J, V13, P115, DOI 10.1096/fasebj.13.1.115; Hassan AHS, 1996, EXP NEUROL, V140, P43, DOI 10.1006/exnr.1996.0113; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jordan J, 1997, J NEUROSCI, V17, P1397; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; Meagher LC, 1996, J IMMUNOL, V156, P4422; MEYER JS, 1985, PHYSIOL REV, V65, P946, DOI 10.1152/physrev.1985.65.4.946; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; MIYASHITA T, 1995, CELL, V80, P293; Oldenburg NBE, 1997, ENDOCRINOLOGY, V138, P810, DOI 10.1210/en.138.2.810; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; RHEE K, 1995, CELL GROWTH DIFFER, V6, P691; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; ROSENFELD P, 1988, BRAIN RES, V470, P113; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER SS, 1994, EXP NEUROL, V130, P368, DOI 10.1006/exnr.1994.1216; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; Sousa N, 1999, NEUROSCIENCE, V89, P1079, DOI 10.1016/S0306-4522(98)00311-X; STEFFEN M, 1988, CANCER RES, V48, P7212; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TCHEKNEVA E, 1994, J IMMUNOL, V152, P5912; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WOOLLEY CS, 1991, BRAIN RES, V554, P312, DOI 10.1016/0006-8993(91)90207-C; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	85	57	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0761	10.1096/fj.01-0577com	http://dx.doi.org/10.1096/fj.01-0577com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039857				2022-12-25	WOS:000176683900001
J	Saadi, S; Wrenshall, LE; Platt, JL				Saadi, S; Wrenshall, LE; Platt, JL			Regional manifestations and control of the immune system	FASEB JOURNAL			English	Article						immunity; vascular endothelium; heparan sulfate proteoglycan; complement; antigen-presenting cells	VON-WILLEBRAND-FACTOR; INDUCED PLATELET-AGGREGATION; RENAL-ALLOGRAFT REJECTION; ENDOTHELIAL-CELLS; HEPARAN-SULFATE; REPERFUSION INJURY; INNATE IMMUNITY; EXTRACELLULAR-MATRIX; CARDIAC XENOGRAFTS; ADHESION MOLECULES	Although immune responses are generally considered to be systemic, local events such as interaction of complement products with blood vessels and with inflammatory cells play a pivotal role in determining the nature and manifestations of immune responses. This paper will discuss how blood vessel physiology and immunity influence one another to reach homeostasis upon exposure to an infectious agent. We review new insights into the mechanisms by which the microenvironment of tissues protects against microbial invasion yet facilitates migration of leukocytes and 'decides' whether immunity or tolerance ensues and whether, in the face of immunity, protective responses or tissue injury ensues. These 'decisions' are made based on interaction of components of normal tissues such as proteoglycans and injured tissues such as cell-associated cytokines with receptors on immune cells and blood vessels.	Mayo Clin, Dept Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Mol Biol & Biochem, Rochester, MN USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Mayo Clin, Dept Immunol, Rochester, MN USA; Mayo Clin, Dept Pediat, Rochester, MN USA	Mayo Clinic; Mayo Clinic; University of Washington; University of Washington Seattle; Mayo Clinic; Mayo Clinic	Platt, JL (corresponding author), Mayo Clin, Dept Surg, Rochester, MN 55905 USA.	Platt.jeffrey@mayo.edu	Platt, Jeffrey/AHB-0480-2022	Platt, Jeffrey/0000-0002-4915-0419				Ajzenberg N, 2000, BLOOD, V95, P3796; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binion DG, 1998, AM J PHYSIOL-GASTR L, V275, pG592, DOI 10.1152/ajpgi.1998.275.3.G592; BRAUER RB, 1995, TRANSPLANTATION, V59, P288, DOI 10.1097/00007890-199501270-00023; BRAUER RB, 1993, J IMMUNOL, V151, P7240; Bustos M, 1997, J CLIN INVEST, V100, P1150, DOI 10.1172/JCI119626; Bustos M, 2001, TRANSPLANTATION, V72, P509, DOI 10.1097/00007890-200108150-00025; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; Cybulsky AV, 2000, KIDNEY INT, V57, P1052, DOI 10.1046/j.1523-1755.2000.00932.x; DARDIK R, 1993, THROMB HAEMOSTASIS, V70, P522; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Engwerda CR, 2000, IMMUNOL TODAY, V21, P73, DOI 10.1016/S0167-5699(99)01549-2; Eppinger MJ, 1997, AM J PATHOL, V150, P1773; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; Gilat D, 1996, IMMUNOL TODAY, V17, P16, DOI 10.1016/0167-5699(96)80563-9; Goulet JL, 2001, J IMMUNOL, V167, P6631, DOI 10.4049/jimmunol.167.11.6631; Hammerberg C, 1998, J EXP MED, V187, P1133, DOI 10.1084/jem.187.7.1133; Haq M, 1998, J AM SOC NEPHROL, V9, P614; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HATTORI R, 1989, J BIOL CHEM, V264, P9053; HENSON PM, 1978, J IMMUNOL, V121, P851; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Irikura VM, 1999, INFECT IMMUN, V67, P1901; Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771; Kalady MF, 1998, MOL MED, V4, P629, DOI 10.1007/BF03401762; KANNO K, 1994, AM J PHYSIOL-HEART C, V267, pH2318, DOI 10.1152/ajpheart.1994.267.6.H2318; Kilgore KS, 1996, AM J PATHOL, V149, P953; Kirschfink M, 1997, J IMMUNOL, V158, P1324; KODAIRA Y, 2000, J IMMUNOL, V165, P1599; LABOW JM, 1997, J IMMUNOL, P159; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; LIDER O, 1989, J CLIN INVEST, V83, P752, DOI 10.1172/JCI113953; LOZADA C, 1995, P NATL ACAD SCI USA, V92, P8378, DOI 10.1073/pnas.92.18.8378; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; Moroi M, 1997, BLOOD, V90, P4413; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Nagayasu T, 2000, TRANSPLANTATION, V69, P475, DOI 10.1097/00007890-200002270-00003; NEMERSON Y, 1986, PROG ALLERGY, V11, P1; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Pratt JR, 1996, AM J PATHOL, V149, P2055; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; RHEINS LA, 1987, CELL IMMUNOL, V106, P33, DOI 10.1016/0008-8749(87)90147-X; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROBERTS HR, 1992, HOSP PRACT, V27, P97; Saadi S, 2000, CIRCULATION, V101, P1867, DOI 10.1161/01.CIR.101.15.1867; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; SAADI S, 1995, J EXP MED, V182, P1807, DOI 10.1084/jem.182.6.1807; SAKURABA M, 1989, J PERINAT MED, V17, P99, DOI 10.1515/jpme.1989.17.2.99; Schmid E, 1997, INFLAMMATION, V21, P325, DOI 10.1023/A:1027302017117; Selvan RS, 1998, J IMMUNOL, V161, P4388; Soslau G, 2001, J BIOL CHEM, V276, P21173, DOI 10.1074/jbc.M008249200; SOZZANI S, 1995, J IMMUNOL, V155, P3292; STEVENS RR, 1993, TRANSPLANT P, V25, P382; SUTTORP N, 1987, AM J PHYSIOL, V253, pC13, DOI 10.1152/ajpcell.1987.253.1.C13; Takano T, 2000, AM J PATHOL, V156, P2091, DOI 10.1016/S0002-9440(10)65080-8; TAPPY L, 1984, THROMB RES, V33, P117, DOI 10.1016/0049-3848(84)90172-5; Taylor PW, 1993, ACTIVATORS INHIBITOR, P37; Tedesco F, 1997, J EXP MED, V185, P1619, DOI 10.1084/jem.185.9.1619; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; VARANI J, 1989, AM J PATHOL, V135, P435; VERCELLOTTI GM, 1991, J IMMUNOL, V146, P730; Wang CZ, 1998, J ASIAN NAT PROD RES, V1, P1, DOI 10.1080/10286029808039839; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; Williams JP, 1999, J APPL PHYSIOL, V86, P938, DOI 10.1152/jappl.1999.86.3.938; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; WRENSHALL LE, 1991, J IMMUNOL, V147, P455; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; Yang D, 2000, J IMMUNOL, V165, P2694, DOI 10.4049/jimmunol.165.5.2694; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	77	87	88	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0849	10.1096/fj.01-0690hyp	http://dx.doi.org/10.1096/fj.01-0690hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039867				2022-12-25	WOS:000176683900011
J	Supp, DM; Wilson-Landy, K; Boyce, ST				Supp, DM; Wilson-Landy, K; Boyce, ST			Human dermal microvascular endothelial cells form vascular analogs in cultured skin substitutes after grafting to athymic mice	FASEB JOURNAL			English	Article						cultured skin substitute; endothelial cell; angiogenesis; tissue engineering	FULL-THICKNESS BURNS; HUMAN BLOOD-VESSEL; IN-VITRO; WOUND CLOSURE; GROWTH-FACTOR; KERATINOCYTES; TISSUE; MICROVESSELS; BIOPOLYMERS; ENGRAFTMENT	Cultured skin substitutes (CSS) consisting of autologous fibroblasts and keratinocytes combined with biopolymers are an adjunctive treatment for large excised burns. CSS containing two cell types are limited by anatomical deficiencies, including lack of a vascular plexus, leading to slower vascularization after grafting than split-thickness autograft. To address this limitation, CSS were prepared containing human keratinocytes, fibroblasts, and dermal microvascular endothelial cells (HDMEC) isolated from a single skin sample. After 16 days in culture, control CSS and CSS containing HDMEC (CSS+EC) were grafted to full-thickness wounds in athymic mice. In CSS+EC in vitro, HDMEC persisted in the dermal substitutes and formed multicellular aggregates. One wk after grafting, HDMEC in CSS+EC organized into multicellular structures, some containing lumens. By 4 wk after grafting, HDMEC were found in linear and circular organizations resembling vascular analogs associated with basement membrane deposition. In some cases, colocalization of HDMEC with mouse perivascular cells was observed. The results demonstrate HDMEC transplantation in a clinically relevant cultured skin model, persistence of HDMEC after grafting, and HDMEC organization into vascular analogs in vitro and in vivo. All cells were derived from the same donor tissue, indicating the feasibility of preparing CSS containing autologous HDMEC for grafting to patients.	Cincinnati Burns Hosp, Shriners Hosp Children, Dept Res, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Boyce, ST (corresponding author), Cincinnati Burns Hosp, Shriners Hosp Children, Dept Res, 3229 Burnet Ave, Cincinnati, OH 45229 USA.	boycest@uc.edu	Supp, Dorothy/ABQ-7999-2022	Supp, Dorothy/0000-0002-2429-6630	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050509] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM050509, R01 GM050509, R01 GM050509-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Boyce S T, 1996, Tissue Eng, V2, P255, DOI 10.1089/ten.1996.2.255; Boyce ST, 1996, J INVEST DERMATOL, V107, P82, DOI 10.1111/1523-1747.ep12298286; Boyce ST, 2002, ANN SURG, V235, P269, DOI 10.1097/00000658-200202000-00016; BOYCE ST, 1993, PLAST RECONSTR SURG, V91, P632, DOI 10.1097/00006534-199304000-00010; BOYCE ST, 1991, SURGERY, V110, P866; BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008; BOYCE ST, 1995, J INVEST DERMATOL, V104, P345, DOI 10.1111/1523-1747.ep12665374; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Boyce ST, 1999, J BURN CARE REHABIL, V20, P453, DOI 10.1097/00004630-199920060-00006; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; Boyce Steven T., 1998, V18, P365; Caruso DM, 1999, BURNS, V25, P771, DOI 10.1016/S0305-4179(99)00083-2; DAVISON PM, 1980, J INVEST DERMATOL, V75, P316, DOI 10.1111/1523-1747.ep12530941; HANSBROUGH JF, 1989, JAMA-J AM MED ASSOC, V262, P2125, DOI 10.1001/jama.262.15.2125; HEWETT PW, 1993, IN VITRO CELL DEV-AN, V29A, P823; Karasek M. A., 1989, J INVEST DERMATOL S, V93, p33S; KUROYANAGI Y, 1993, ANN PLAS SURG, V31, P340, DOI 10.1097/00000637-199310000-00011; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Supp AP, 1999, WOUND REPAIR REGEN, V7, P226, DOI 10.1046/j.1524-475X.1999.00226.x; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; SUPP SM, 2002, J BURN CARE REHABIL, V23, P10; Swope VB, 2001, J INVEST DERMATOL, V116, P650, DOI 10.1046/j.1523-1747.2001.01325.x; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005; Zacchi V, 1998, J BIOMED MATER RES, V40, P187, DOI 10.1002/(SICI)1097-4636(199805)40:2<187::AID-JBM3>3.0.CO;2-H; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	29	103	107	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0797	10.1096/fj.01-0868com	http://dx.doi.org/10.1096/fj.01-0868com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039861				2022-12-25	WOS:000176683900005
J	Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD				Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD			Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line	ONCOGENE			English	Article						ataxia-telangiectasia; gene silencing; epigenetics	DNA MISMATCH REPAIR; ATAXIA-TELANGIECTASIA HETEROZYGOTES; IONIZING-RADIATION; BREAST-CANCER; GENE-MUTATIONS; PROTEIN; HYPERMETHYLATION; INACTIVATION; EXPRESSION; PHENOTYPE	Recent findings suggest that DNA alkylating agents trigger cellular responses that overlap those activated after ionizing radiation. Moreover, activation of these responses is dependent upon a functional mismatch repair (MMR) system. These developments led us to test if MMR-deficient cells may be compromised in their ability to activate appropriate cellular signaling pathways after ionizing radiation. An initial experiment to address this notion was to determine the level of radiosensitivity of several MMR-deficient cell lines derived from patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC). While two of the three HNPCC lines investigated show levels of radiosensitivity consistent with that displayed by normal human fibroblasts, HCT-116 cells display moderate radio sensitivity compared to the other MMR-deficient lines. This increased sensitivity to ionizing radiation correlates with lowered levels of ATM expression in HCT-116. Analysis of genomic DNA from HCT-116 cells determined that these cells possess aberrant methylation of multiple CpG dinucleotides within the proximal promoter region of the ATM gene. The significance of this finding is underscored by our observations that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter methylation, promotes normal levels of ATM expression, and restores normal radiosensitivity. The proximal ATM promoter is a similar to520 bp region shared with the NPAT gene, and current evidence suggests that this region functions as a bi-directional promoter. We found that, unlike ATM, the methylation status of this intergenic region does not effect the expression of the NPAT gene. In sum, these observations indicate that the ATM gene is a novel target for epigentic silencing through inappropriate methylation of its proximal promoter region.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Brown, KD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Room 7101, New Orleans, LA 70112 USA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chen XG, 1997, MAMM GENOME, V8, P129, DOI 10.1007/s003359900371; Costello JF, 1996, CANCER RES, V56, P2405; Dork T, 2001, CANCER RES, V61, P7608; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Ejima Y, 2000, INT J CANCER, V86, P262, DOI 10.1002/(SICI)1097-0215(20000415)86:2<262::AID-IJC17>3.3.CO;2-9; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fritzell JA, 1997, CANCER RES, V57, P5143; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gnarra JR, 1998, J NATL CANCER I, V90, P1685, DOI 10.1093/jnci/90.22.1685; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hiraguri S, 1998, CANCER RES, V58, P1972; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Kane MF, 1997, CANCER RES, V57, P808; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; MORRELL D, 1986, J NATL CANCER I, V77, P89; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PANDITA TK, 1994, MUTAT RES-FUND MOL M, V310, P1, DOI 10.1016/0027-5107(94)90004-3; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xu Y, 1999, ADV IMMUNOL, V72, P179, DOI 10.1016/S0065-2776(08)60020-6; Yan T, 2001, CANCER RES, V61, P8290; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	48	78	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3864	3871		10.1038/sj.onc.1205485	http://dx.doi.org/10.1038/sj.onc.1205485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032824				2022-12-25	WOS:000175847200005
J	Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A				Vossio, S; Palescandolo, E; Pediconi, N; Moretti, F; Balsano, C; Levrero, M; Costanzo, A			DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest	ONCOGENE			English	Article						p53; p73; oncogenes; tumor suppressor; apoptosis; cell cycle	KINASE C-ABL; APOPTOTIC RESPONSE; P53 HOMOLOG; P73; RNA; FAMILY; DEATH; P63; EXPRESSION; DELTA-NP73	p53 and p73 genes are both activated in response to DNA damage to induce either cell cycle arrest or apoptosis, depending on the strength and the quality of the damaging stimulus. p53/p73 transcriptional activity must be tightly regulated to ensure that the appropriate biological response is achieved and to allow the cell to re-enter into the cell cycle after the damage has been repaired. In addition to multiple transcriptionally active (TA) isoforms, dominant negative (DN) variants, that lack the amino-terminal transactivation domain and function as trans-repressors of p53, p63 and p73, are expressed from a second internal promoter (P2-p73Pr). Here we show that, in response to a non apoptotic DNA damage induced by low doses of doxorubicin, p53 binds in vivo, as detected by a p53-specific chromatin immunoprecipitation assay, and activates the P2-p73 promoter. DN-p73alpha protein accumulates under the same conditions and exogenously expressed DN-p73alpha is able to counteract the p53-induced activation of the P2-p73Pr. These results suggest that DN-p73 may contribute to the autoregulatory loops responsible for the termination of p53/p73 responses in cells that do not undergo apoptosis. Accordingly, the activation of the P2-p73Pr is markedly enhanced in both p73-/- murine fibroblasts and in human cells in which p73 transcripts are selectively knocked-out by p73-specific small interfering RNAs.	Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, I-00161 Rome, Italy; Univ Aquila, Dip Med Interna, I-67100 Laquila, Italy; Univ Cagliari, Dip Sci Med Internist, Cagliari, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	Levrero, M (corresponding author), Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Policlin Umberto I, Viale Policlin 155, I-00161 Rome, Italy.	levmax@tin.it	Balsano, Clara/AAK-9870-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875				Agami R, 1999, NATURE, V399, P809; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Nishikura K, 2001, CELL, V107, P415, DOI 10.1016/S0092-8674(01)00581-5; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	27	67	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3796	3803		10.1038/sj.onc.1205465	http://dx.doi.org/10.1038/sj.onc.1205465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032848				2022-12-25	WOS:000175676000015
J	Canonaco, F; Schlattner, U; Pruett, PS; Wallimann, T; Sauer, U				Canonaco, F; Schlattner, U; Pruett, PS; Wallimann, T; Sauer, U			Functional expression of phosphagen kinase systems confers resistance to transient stresses in Saccharomyces cerevisiae by buffering the ATP pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; CREATINE-KINASE; H+-ATPASE; INTRACELLULAR PH; ARGININE KINASE; GROWTH; ENERGETICS; COMPARTMENTATION; RESPIRATION; ADAPTATION	Phosphagen kinase systems provide different advantages to tissues with high and fluctuating energy demands, in particular an efficient energy buffering system. In this study we show for the first time functional expression of two phosphagen kinase systems in Saccharomyces cerevisiae, which does not normally contain such systems. First, to establish the creatine kinase system, in addition to overexpressing creatine kinase isoenzymes, we had to install the biosynthesis pathway of creatine by co-overexpression of L-arginine:glycine amidinotransferase and guanidinoacetate methyltransferase. Although we could achieve considerable creatine kinase activity, together with more than 3 mm intracellular creatine, this was not sufficient to confer an obvious advantage to the yeast under the specific stress conditions examined here. Second, using arginine kinase, we successfully installed an intracellular phosphagen pool of about 5 mm phosphoarginine. Such arginine kinase-expressing yeast showed improved resistance under two stress challenges that drain cellular energy, which were transient pH reduction and starvation. Although transient starvation led to 50% reduced intracellular ATP concentrations in wild-type yeast, arginine kinase overexpression stabilized the ATP pool at the pre-stress level. Thus, our results demonstrate that temporal energy buffering is an intrinsic property of phosphagen kinases that can be transferred to phyloge-netically very distant organisms.	Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Florida State Univ, Kasha Lab Biophys, Tallahassee, FL 32306 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; State University System of Florida; Florida State University	Sauer, U (corresponding author), Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.	sauer@biotech.biol.ethz.ch	Wallimann, Theo/C-6047-2008; Sauer, Uwe/Y-3556-2019; Schlattner, Uwe/D-1267-2009	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911	NIGMS NIH HHS [R01 GM55837] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055837] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attfield PV, 1997, NAT BIOTECHNOL, V15, P1351, DOI 10.1038/nbt1297-1351; BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; BRINDLE K, 1990, BIOCHEMISTRY-US, V29, P3295, DOI 10.1021/bi00465a021; Dauner M, 2001, J BACTERIOL, V183, P7308, DOI 10.1128/JB.183.24.7308-7317.2001; ELLINGTON WR, 1989, J EXP BIOL, V143, P177; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Emmerling M, 2000, BIOTECHNOL BIOENG, V67, P623, DOI [10.1002/(SICI)1097-0290(20000305)67:5<623::AID-BIT13>3.0.CO;2-W, 10.1002/(SICI)1097-0290(20000305)67:5&lt;623::AID-BIT13&gt;3.0.CO;2-W]; Enfors SO, 2001, J BIOTECHNOL, V85, P175, DOI 10.1016/S0168-1656(00)00365-5; Farres J, 2002, TRANSGENIC RES, V11, P49, DOI 10.1023/A:1013957819596; Fernandes AR, 2001, YEAST, V18, P511; Greenhaff PL, 2001, J PHYSIOL-LONDON, V537, P657; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; Grieshaber M K, 1994, Rev Physiol Biochem Pharmacol, V125, P43, DOI 10.1007/BFb0030909; Hamilton CA, 2001, FEMS MICROBIOL LETT, V205, P231, DOI 10.1111/j.1574-6968.2001.tb10953.x; Hatano E, 1996, HEPATOLOGY, V24, P663, DOI 10.1002/hep.510240332; HAUF J, 1998, THESIS TH DARMSTADT; Holyoak CD, 1996, APPL ENVIRON MICROB, V62, P3158, DOI 10.1128/AEM.62.9.3158-3164.1996; HUMM A, 1994, FEBS LETT, V339, P101, DOI 10.1016/0014-5793(94)80394-3; IMAI T, 1995, APPL ENVIRON MICROB, V61, P3604, DOI 10.1128/AEM.61.10.3604-3608.1995; ISBRANDT D, 1995, BIOCHIM BIOPHYS ACTA, V1264, P264; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P336; MILLER K, 1993, AM J PHYSIOL, V265, pC1544, DOI 10.1152/ajpcell.1993.265.6.C1544; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; Mira de Orduna R, 2001, J AGR FOOD CHEM, V49, P549, DOI 10.1021/jf000522y; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Noguchi M, 2001, J EXP BIOL, V204, P1063; PANARETOU B, 1990, J GEN MICROBIOL, V136, P1763, DOI 10.1099/00221287-136-9-1763; Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495; RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sauer U, 2001, Adv Biochem Eng Biotechnol, V73, P129; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; SERRANO R, 1984, CURR TOP CELL REGUL, V23, P87; Snow RJ, 2001, MOL CELL BIOCHEM, V224, P169, DOI 10.1023/A:1011908606819; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; STRONG SJ, 1995, BBA-PROTEIN STRUCT M, V1246, P197, DOI 10.1016/0167-4838(94)00218-6; Theobald U, 1997, BIOTECHNOL BIOENG, V55, P305, DOI 10.1002/(SICI)1097-0290(19970720)55:2<305::AID-BIT8>3.0.CO;2-M; Tran QH, 1998, EUR J BIOCHEM, V251, P538, DOI 10.1046/j.1432-1327.1998.2510538.x; Viegas CA, 1998, APPL ENVIRON MICROB, V64, P779; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WINGE O, 1958, CHEM BIOL YEAST, P115; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107	43	36	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31303	31309		10.1074/jbc.M204052200	http://dx.doi.org/10.1074/jbc.M204052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12036963	hybrid			2022-12-25	WOS:000177718700005
J	Buschbeck, M; Eickhoff, J; Sommer, MN; Ullrich, A				Buschbeck, M; Eickhoff, J; Sommer, MN; Ullrich, A			Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; EPIDERMAL GROWTH-FACTOR; KINASE INTERACTION MOTIF; MAP KINASE; ACTIVATION; EXPRESSION; CELLS; TRANSDUCTION; CLONING; GENE	The duration and the magnitude of mitogen-activated protein kinase (MAPK) activation specifies signal identity and thus allows the regulation of diverse cellular functions by the same kinase cascade. A tight and finely tuned regulation of MAPK activity is therefore critical for the definition of a specific cellular response. We investigated the role of tyrosine-specific phosphatases (PTPs) in the regulation of ERK5. Although unique in its structure, ERK5 is activated in analogy to other MAPKs by dual phosphorylation of threonine and tyrosine residues in its activation motif. In this study we concentrated on whether and how PTP-SL, a kinase-interacting motif-containing PTP, might be involved in the down-regulation of the ERK5 signal. We found that both proteins interact directly with each other in vitro and in intact cells, resulting in mutual modulation of their enzymatic activities. PTP-SL is a substrate of ERK5 and independent of phosphorylation binding to the kinase enhances its catalytic phosphatase activity. On the other hand, interaction with PTP-SL not only down-regulates endogenous ERK5 activity but also effectively impedes the translocation of ERK5 to the nucleus. These findings indicate a direct regulatory influence of PTP-SL on the ERK5 pathway and corresponding downstream responses of the cell.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.		Buschbeck, Marcus/J-8204-2017	Buschbeck, Marcus/0000-0002-3218-4567				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Augustine KA, 2000, ANAT REC, V258, P221, DOI 10.1002/(SICI)1097-0185(20000301)258:3<221::AID-AR1>3.0.CO;2-W; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; Kawasaki E, 1996, BIOCHEM BIOPH RES CO, V227, P440, DOI 10.1006/bbrc.1996.1526; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laes JF, 2001, MAMM GENOME, V12, P199, DOI 10.1007/s003350010268; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; SHIOZUKA K, 1995, GENE, V162, P279, DOI 10.1016/0378-1119(95)00306-Q; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tarrega C, 2002, J BIOL CHEM, V277, P2629, DOI 10.1074/jbc.M108874200; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	51	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29503	29509		10.1074/jbc.M202149200	http://dx.doi.org/10.1074/jbc.M202149200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042304	hybrid			2022-12-25	WOS:000177509300022
J	Butcher, GQ; Dziema, H; Collamore, M; Burgoon, PW; Obrietan, K				Butcher, GQ; Dziema, H; Collamore, M; Burgoon, PW; Obrietan, K			The p42/44 mitogen-activated protein kinase pathway couples photic input to circadian clock entrainment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PHASE ADVANCES; ERK MAP KINASE; SUPRACHIASMATIC NUCLEUS; CREB PHOSPHORYLATION; BIOLOGICAL CLOCK; LIGHT; CASCADE; INVOLVEMENT; CALMODULIN; RHYTHMS	In mammals, the suprachiasmatic nuclei (SCN) of the hypothalamus function as the major biological clock. SCN-dependent rhythms of physiology and behavior are regulated by changes in the environmental light cycle. Currently, the second messenger signaling events that couple photic input to clock entrainment have yet to be well characterized. Recent work has revealed that photic stimulation during the night triggers rapid activation of the p42/44 mitogen activated protein kinase (MAPK) pathway in the SCN. The MAPK signal transduction pathway is a potent regulator of numerous classes of transcription factors and has been shown to play a role in certain forms of neuronal plasticity. These observations led us to examine the role of the MAPK pathway in clock entrainment. Here we report that pharmacological disruption of light-induced MAPK pathway activation in the SCN uncouples photic input from clock entrainment, as assessed by locomotor activity phase. In the absence of photic stimulation, transient disruption of MAPK signaling in the SCN did not alter clock-timing properties. We also report that signaling via the Ca2+/calmodulin kinase pathway functions upstream of the MAPK pathway, coupling light to activation of the MAPK pathway. Together these results delineate key intracellular signaling events that underlie light-induced clock entrainment.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University System of Ohio; Ohio State University; University of Illinois System; University of Illinois Urbana-Champaign	Obrietan, K (corresponding author), Ohio State Univ, Dept Neurosci, Graves Hall,Rm 4118,333 W 10th Ave, Columbus, OH 43210 USA.	obrietan.1@osu.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062335] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-62335] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Akashi M, 2000, GENE DEV, V14, P645; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Berman DE, 1998, J NEUROSCI, V18, P10037; Blum S, 1999, J NEUROSCI, V19, P3535; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; COLWELL CS, 1991, BRAIN RES, V554, P105, DOI 10.1016/0006-8993(91)90177-W; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ding JM, 1997, J NEUROSCI, V17, P667; Ding JM, 1998, NATURE, V394, P381, DOI 10.1038/28639; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferreyra GA, 1998, BRAIN RES, V797, P190, DOI 10.1016/S0006-8993(98)00376-X; Fukushima T, 1997, NEUROSCI LETT, V227, P45, DOI 10.1016/S0304-3940(97)00297-8; GOLOMBEK DA, 1995, NEUROSCI LETT, V192, P101, DOI 10.1016/0304-3940(95)99209-N; GOLOMBEK DA, 1994, NEUROREPORT, V5, P1638, DOI 10.1097/00001756-199408150-00024; Hayashi Y, 2001, FEBS LETT, V491, P71, DOI 10.1016/S0014-5793(01)02153-6; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; Mathur A, 1996, AM J PHYSIOL-REG I, V270, pR1031, DOI 10.1152/ajpregu.1996.270.5.R1031; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; Mintz EM, 1999, J NEUROSCI, V19, P5124; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; TUREK FW, 1985, ANNU REV PHYSIOL, V47, P49, DOI 10.1146/annurev.ph.47.030185.000405; Valjent E, 2000, J NEUROSCI, V20, P8701; Watt WC, 2001, J BIOL CHEM, V276, P2047, DOI 10.1074/jbc.M006703200; WEBER ET, 1995, NEUROSCI LETT, V197, P227, DOI 10.1016/0304-3940(95)11961-U; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Yokota S, 2001, J NEUROCHEM, V77, P618, DOI 10.1046/j.1471-4159.2001.00270.x; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	41	125	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29519	29525		10.1074/jbc.M203301200	http://dx.doi.org/10.1074/jbc.M203301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042309	hybrid			2022-12-25	WOS:000177509300024
J	Majumder, R; Weinreb, G; Zhai, X; Lentz, BR				Majumder, R; Weinreb, G; Zhai, X; Lentz, BR			Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; PLATELET PLASMA-MEMBRANE; COAGULATION FACTOR-XA; CATALYZED ACTIVATION; POLYACRYLAMIDE-GEL; THROMBIN; PROTEIN; VESICLES; BINDING; DOMAIN	Factor X-a (FXa) binding to factor V-a (FVa) on platelet-derived membranes containing surface-exposed phosphatidylserine (PS) forms the "prothrombinase complex" that is essential for efficient thrombin generation during blood coagulation. There are two naturally occurring isoforms of FVa, FVa1 and FVa2. These two isoforms differ by a 3-kDa polysaccharide chain (at Asn(2181) in human FVa1 (Kim, S. W., Ortel, T. L., Quinn-Allen, M. A., Yoo, L., Worfolk, L., Zhai, X., Lentz, B. R., and Kane, W. H. (1999) Biochemistry 38, 11448-11454)) and have different coagulant activities. We examined the interaction of the two bovine isoforms with active site-labeled FXa, finding no significant difference. A soluble form of PS (C6PS) bound to FVa1 and FVa2 with comparable affinities (K-d = 11-12 muM) and changes in FVa intrinsic fluorescence. At concentrations well below its critical micelle concentration, C6PS binding to bovine FVa2 enhanced its affinity for FXa in solution by nearly 3 orders of magnitude (K-d(eff) = 40-2 nm over a C6PS range of 30-400 mum) but had no effect on the affinity of FVa1 for FXa (K-d = 1 mum). This results in a soluble complex between FXa and FVa2, whose expected molecular weight was confirmed by calibrated native gel electrophoresis. This complex behaved as a normal Michaelis-Menten enzyme in its ability to produce thrombin from meizothrombin (apparent k(cat)/K-m = 10(9) M-1 s(-1)). The ability of soluble PS to trigger formation of a soluble prothrombinase complex suggests that exposure of PS molecules during platelet activation is likely the key event responsible for the assembly of an active membrane-bound complex.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lentz, BR (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Majumder, Rinku/J-7512-2019	majumder, Rinku/0000-0002-1727-7220	NHLBI NIH HHS [HL45916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045916] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banerjee M, 2002, BIOCHEMISTRY-US, V41, P950, DOI 10.1021/bi0116902; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ESMON CT, 1979, J BIOL CHEM, V254, P964; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Hoekema L, 1997, BIOCHEMISTRY-US, V36, P3331, DOI 10.1021/bi9623284; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JONES ME, 1985, THROMB RES, V39, P711, DOI 10.1016/0049-3848(85)90255-5; Kim SW, 1999, BIOCHEMISTRY-US, V38, P11448, DOI 10.1021/bi991275y; Koppaka V, 1997, BIOPHYS J, V73, P2638, DOI 10.1016/S0006-3495(97)78293-6; Koppaka V, 1996, BIOCHEMISTRY-US, V35, P7482, DOI 10.1021/bi952063d; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LENTZ BR, 1994, BIOCHEMISTRY-US, V33, P5460, DOI 10.1021/bi00184a015; MANN KG, 1990, BLOOD, V76, P1; MITRA P, 1994, ANAL BIOCHEM, V223, P327, DOI 10.1006/abio.1994.1594; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PERSSON E, 1993, J BIOL CHEM, V268, P22531; POWERS DD, 1993, J BIOL CHEM, V268, P3234; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1993, J BIOL CHEM, V268, P21130; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SCHICK PK, 1976, J CLIN INVEST, V57, P1221, DOI 10.1172/JCI108390; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; Srivastava A, 2002, J BIOL CHEM, V277, P1855, DOI 10.1074/jbc.M105697200; Srivastava A, 2001, BIOCHEMISTRY-US, V40, P8246, DOI 10.1021/bi010449k; Tanford C., 1973, HYDROPHOBIC EFFECT; Wu JR, 2002, BIOCHEMISTRY-US, V41, P935, DOI 10.1021/bi0116893; Zhai X, 2002, BIOCHEMISTRY-US, V41, P5675, DOI 10.1021/bi011844d	39	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29765	29773		10.1074/jbc.M200893200	http://dx.doi.org/10.1074/jbc.M200893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12045194	hybrid			2022-12-25	WOS:000177509300054
J	Wang, L; Manji, GA; Grenier, JM; Al-Garawi, A; Merriam, S; Lora, JM; Geddes, BJ; Briskin, M; DiStefano, PS; Bertin, J				Wang, L; Manji, GA; Grenier, JM; Al-Garawi, A; Merriam, S; Lora, JM; Geddes, BJ; Briskin, M; DiStefano, PS; Bertin, J			PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY-MEMBER; CASPASE ACTIVATION; APOPTOSIS; DOMAIN; MUTATION; INNATE; BCL10; NOD2; ASC	PYRIN-containing Apaf1-like proteins (PYPAFs) are members of the nucleotide-binding site/leucine-rich repeat (NBS/LRR) family of signal transduction proteins. We report here that PYPAF7 is a novel PYPAF protein that activates inflammatory signaling pathways. The expression of PYPAF7 is highly restricted to immune cells, and its gene maps to chromosome 19q13.4, a locus that contains a cluster of genes encoding numerous PYPAF family members. Co-expression of PYPAF7 with ASC results in the recruitment of PYPAF7 to distinct cytoplasmic loci and a potent synergistic activation of NF-kappaB. To identify other proteins involved in PYPAF7 and ASC signaling pathways, we performed a mammalian two-hybrid screen and identified pro-caspase-1 as a binding partner of ASC. Co-expression of PYPAF7 and ASC results in the synergistic activation of caspase-1 and a corresponding increase in secretion of interleukin-1beta. In addition, PYPAF1 induces caspase-1-dependent cytokine processing when co-expressed with ASC. These findings indicate that PYPAF family members participate in inflammatory signaling by regulating the activation of NF-kappaB and cytokine processing.	Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Bertin, J (corresponding author), Millennium Pharmaceut Inc, 75 Sidney St, Cambridge, MA 02139 USA.	bertin@mpi.com						Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Damiano JS, 2001, GENOMICS, V75, P77, DOI 10.1006/geno.2001.6579; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; Manji GA, 2001, J BIOL CHEM, V276, P16704, DOI 10.1074/jbc.M010179200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SRINIVASULA SM, 2002, IN PRESS J BIOL CHEM, V277; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Tong ZB, 2002, HUM REPROD, V17, P903, DOI 10.1093/humrep/17.4.903; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200	30	290	303	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29874	29880		10.1074/jbc.M203915200	http://dx.doi.org/10.1074/jbc.M203915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12019269	hybrid			2022-12-25	WOS:000177509300067
J	Barry, WT; Boudignon-Proudhon, C; Shock, DD; McFadden, A; Weiss, JM; Sondek, J; Parise, LV				Barry, WT; Boudignon-Proudhon, C; Shock, DD; McFadden, A; Weiss, JM; Sondek, J; Parise, LV			Molecular basis of CIB binding to the integrin alpha(IIb) cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-MYRISTOYL SWITCHES; PROTEIN; BETA(3); COMPLEX; INTERACTS; TAIL; IDENTIFICATION; RECOGNITION; CALMODULIN; ACTIVATION	Integrin adhesion receptors appear to be regulated by molecules that bind to their cytoplasmic domains. We previously identified a 22-kDa, EF-hand-containing protein, CIB, which binds to the alpha(IIb) cytoplasmic tail of the platelet integrin, alpha(IIB)beta(3). Here we describe regions within CIB and am, that interact with one another. CIB binding to alpha(IIb) cytoplasmic tail peptides, as measured by intrinsic tryptophan fluorescence, indicates a CIB-binding site within a hydrophobic, 15-amino acid, membrane-proximal region Of alpha(IIb). This region is analogous to the alpha-helical targets of other EF-hand-containing proteins, such as calcineurin B or calmodulin. A homology model of CIB based upon calcineurin B and recoverin indicated a conserved hydrophobic pocket within the C-terminal EF-hand motifs of CIB as a potential integrin-binding site. CIB engineered to contain alanine substitutions in the implicated regions retained wild type secondary structure as determined by circular dichroism, yet failed to bind alpha(IIb) in 11 of 12 cases, whereas CIB mutated within the N terminus retained binding activity. Thus, specific hydrophobic residues in the C terminus of CIB appear necessary for CIB binding to alpha(IIb). The identification of essential interacting regions within alpha(IIb) and CIB provides tools for further probing potential interrelated functions of these proteins.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Parise, LV (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, R01GM057391] Funding Source: NIH RePORTER; NHLBI NIH HHS [2-P01-HL-45100] Funding Source: Medline; NIGMS NIH HHS [GM62299, GM57391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guilbault G.G., 1973, PRACTICAL FLUORESCEN; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hwang PM, 2000, J MOL RECOGNIT, V13, P83, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<83::AID-JMR491>3.0.CO;2-A; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Leisner TM, 1999, J BIOL CHEM, V274, P12945, DOI 10.1074/jbc.274.18.12945; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Parise LV, 1999, CURR OPIN CELL BIOL, V11, P597, DOI 10.1016/S0955-0674(99)00018-6; Sarkar S, 1999, BIOCHEM J, V338, P677, DOI 10.1042/0264-6021:3380677; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Simon K. O., 1994, INTEGRINS MOL BIOL R, P49; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stabler SM, 1999, J CELL BIOL, V145, P1277, DOI 10.1083/jcb.145.6.1277; Tsuboi S, 2002, J BIOL CHEM, V277, P1919, DOI 10.1074/jbc.M110643200; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	29	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28877	28883		10.1074/jbc.M202983200	http://dx.doi.org/10.1074/jbc.M202983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023286	hybrid			2022-12-25	WOS:000177342600071
J	Li, XJ; Misik, AJ; Rieder, CV; Solaro, RJ; Lowen, A; Fliegel, L				Li, XJ; Misik, AJ; Rieder, CV; Solaro, RJ; Lowen, A; Fliegel, L			Thyroid hormone receptor alpha(1) regulates expression of the Na+/H+ exchanger (NHE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MESSENGER-RNA; RESPONSIVE ELEMENT; NA/H ANTIPORTER; RAT MYOCARDIUM; HEART-FAILURE; GENE; PROTEIN; ACID; ACTIVATION	In this paper we examine the role of thyroid hormone in regulating expression of the Na+/H+ exchanger. Thyroid hormone has been reported to regulate the activity of the Na+/H+ exchanger messenger RNA in some cell types. Treatment of cardiac myocytes with 3,5',3'-triiodothyronine results in an increased expression of Na+/H+ exchanger protein. Also, compared with euthyroid animals, hypothyroid rats express decreased amounts of the Na+/H+ exchanger protein. To examine the mechanisms involved in regulating expression of the Na+/H+ exchanger, we have characterized the regulation of a distal element of the NHE1 promoter by the thyroid hormone receptor. We have previously shown that a - 1085/- 800 nucleotide (nt) region of the promoter is a modular element with a -841/-800 nt activating element. Using electrophoretic mobility shift assay, we show that this element interacts with thyroid hormone receptor TRalpha(1), a nuclear hormone receptor. The addition of exogenous TRalpha increased transcriptional activity of the -841/-800 nt element of the Na+/H+ exchanger promoter. We show that TRalpha binds to a region on the -841/-800 nt element that is near, but not identical, to the previously identified chicken ovalbumin upstream promoter transcription factor-binding site. Our results are the first demonstration that thyroid hormone and the thyroid hormone receptor TRalpha, regulate expression of the Na+/H+ exchanger.	Univ Alberta, Fac Med, Dept Biochem, Canadian Inst Hlth Res,Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Illinois, Dept Physiol & Biophys, Coll Med, Chicago, IL 60612 USA	Institute for Work & Health; University of Alberta; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Fliegel, L (corresponding author), Univ Alberta, Fac Med, Dept Biochem, Canadian Inst Hlth Res,Membrane Prot Res Grp, 347 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	lfliegel@ualberta.ca						Azuma KK, 1996, AM J PHYSIOL-CELL PH, V270, pC585, DOI 10.1152/ajpcell.1996.270.2.C585; Besson P, 1998, AM J PHYSIOL-CELL PH, V274, pC831, DOI 10.1152/ajpcell.1998.274.3.C831; Cano A, 1999, AM J PHYSIOL-CELL PH, V276, pC102, DOI 10.1152/ajpcell.1999.276.1.C102; Chen L, 2001, J PHARMACOL EXP THER, V298, P469; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; DYCK JRB, 1995, CARDIOVASC RES, V29, P203, DOI 10.1016/S0008-6363(96)88571-3; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; Fernandez-Rachubinski F, 2001, EUR J BIOCHEM, V268, P620, DOI 10.1046/j.1432-1327.2001.01915.x; FernandezRachubinski FA, 1996, J BIOL CHEM, V271, P29502, DOI 10.1074/jbc.271.46.29502; Fliegel L, 2001, BASIC RES CARDIOL, V96, P301, DOI 10.1007/s003950170036; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Guo L, 2001, J BIOL CHEM, V276, P2797, DOI 10.1074/jbc.C000822200; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; Incerpi S, 1999, ENDOCRINOLOGY, V140, P683, DOI 10.1210/en.140.2.683; Karmazyn M, 2001, DRUGS, V61, P375, DOI 10.2165/00003495-200161030-00006; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; Kolyada AY, 1995, AM J PHYSIOL-CELL PH, V269, pC1408, DOI 10.1152/ajpcell.1995.269.6.C1408; Kusumoto K, 2001, AM J PHYSIOL-HEART C, V280, pH738, DOI 10.1152/ajpheart.2001.280.2.H738; MARTIN AF, 1982, CIRC RES, V50, P117, DOI 10.1161/01.RES.50.1.117; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Munoz A, 1997, EUR J ENDOCRINOL, V137, P433, DOI 10.1530/eje.0.1370433; MURTAZINA BR, 2001, EUR J BIOCHEM, V268, P1; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; QUEDNAU B, 1994, AM J PHYSIOL, V266, pC480, DOI 10.1152/ajpcell.1994.266.2.C480; RAO GN, 1992, J CELL PHYSIOL, V151, P361, DOI 10.1002/jcp.1041510217; Rieder CV, 2002, AM J PHYSIOL-HEART C, V283, pH273, DOI 10.1152/ajpheart.00042.2002; ROHRER D, 1988, J BIOL CHEM, V263, P6941; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; Shah M, 2000, AM J PHYSIOL-RENAL, V278, pF596, DOI 10.1152/ajprenal.2000.278.4.F596; Shahrara S, 1999, BIOL PHARM BULL, V22, P1027; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; WALKER P, 1980, PEDIATR RES, V14, P247, DOI 10.1203/00006450-198003000-00014; Wang HY, 1997, J BIOL CHEM, V272, P26545, DOI 10.1074/jbc.272.42.26545; Wolska BM, 1997, J MOL CELL CARDIOL, V29, P2653, DOI 10.1006/jmcc.1997.0495; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	39	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28656	28662		10.1074/jbc.M203221200	http://dx.doi.org/10.1074/jbc.M203221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039959	hybrid			2022-12-25	WOS:000177342600041
J	Lin, PJ; Jin, DY; Tie, JK; Presnell, SR; Straight, DL; Stafford, DW				Lin, PJ; Jin, DY; Tie, JK; Presnell, SR; Straight, DL; Stafford, DW			The putative vitamin K-dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYGLUTAMIC ACID PROTEINS; RECOGNITION SITE; FACTOR-IX; ENZYME-ACTIVITY; REGION; IDENTIFICATION; PROTHROMBIN; AFFINITIES; SUBSTRATE; HOMOLOGY	The vitamin K-dependent gamma-glutamyl carboxylase binds an 18-amino acid sequence usually attached as a propeptide to its substrates. Price and Williamson (Protein Sci. (1993) 2, 1997-1998) noticed that residues 495-513 of the carboxylase shares similarity with the propeptide. They suggested that this internal propeptide could bind intramolecularly to the propeptide binding site of carboxylase, thereby preventing carboxylation of substrates lacking a propeptide recognition sequence. To test Price's hypothesis, we created nine mutant enzyme species that have single or double mutations within this putative internal propeptide. The apparent K-d values of these mutant enzymes for human factor IX propeptide varied from 0.5- to 287-fold when compared with that of wild type enzyme. These results are consistent with the internal propeptide hypothesis but could also be explained by these residues participating in propeptide binding site per se. To distinguish between the two alternative hypotheses, we measured the dissociation rates of propeptides from each of the mutant enzymes. Changes in an internal propeptide should not affect the dissociation rates, but changes to a propeptide binding site may affect the dissociation rate. We found that dissociation rates varied in a manner consistent with the apparent Kd values measured above. Furthermore, kinetic studies using propeptide-containing substrates demonstrated a correlation between the affinity for propeptide and V-max. Taken together, our results indicated that these mutations affected the propeptide binding site rather than a competitive inhibitory internal propeptide sequence. These results agree with our previous observations, indicating that residues in this region are involved in propeptide binding.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.			Tie, Jian-Ke/0000-0002-8447-3408				CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; Furie B, 1999, BLOOD, V93, P1798, DOI 10.1182/blood.V93.6.1798.406k22_1798_1808; HELGELAND L, 1977, BIOCHIM BIOPHYS ACTA, V499, P181, DOI 10.1016/0304-4165(77)90001-0; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Mutucumarana VP, 2000, J BIOL CHEM, V275, P32572, DOI 10.1074/jbc.M006808200; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; PRICE PA, 1993, PROTEIN SCI, V2, P1987, DOI 10.1002/pro.5560021120; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRICE PA, 1988, ANNU REV NUTR, V8, P565, DOI 10.1146/annurev.nu.08.070188.003025; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; Stanley TB, 1999, BIOCHEMISTRY-US, V38, P15681, DOI 10.1021/bi991544k; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; SUTTIE JW, 1993, FASEB J, V7, P445, DOI 10.1096/fasebj.7.5.8462786; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; WU SM, 1990, J BIOL CHEM, V265, P13124	27	30	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28584	28591		10.1074/jbc.M202292200	http://dx.doi.org/10.1074/jbc.M202292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034728	Green Published, hybrid			2022-12-25	WOS:000177342600032
J	Schricker, R; Angermayr, M; Strobel, G; Klinke, S; Korber, D; Bandlow, W				Schricker, R; Angermayr, M; Strobel, G; Klinke, S; Korber, D; Bandlow, W			Redundant mitochondrial targeting signals in yeast adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GTP-AMP PHOSPHOTRANSFERASE; C HEME LYASE; INTERMEMBRANE SPACE; CYTOCHROME-C; PRECURSOR PROTEIN; IMPORT PATHWAY; INNER MEMBRANE; INVIVO; PRESEQUENCE	Yeast adenylate kinase (Aky2p, Adk1p) occurs simultaneously in cytoplasm and mitochondrial intermembrane space. It has no cleavable mitochondrial targeting sequence, and the signal for mitochondrial import and submitochondrial sorting is largely unknown. The extreme N terminus of Aky2p is able to direct cytoplasmic passengers to mitochondria. However, an Aky2 mutant lacking this sequence is imported with about the same efficiency as the wild type. To identify possible import-relevant information in the interior, parts of Aky2p were exchanged by homologous in vitro recombination for the respective segments of the purely cytoplasmic isozyme, Ura6p. Import studies revealed an internal region of about 40 amino acids, which was sufficient to direct the chimera to mitochondria but not for correct submitochondrial sorting. The respective Ura6p hybrid was arrested in the mitochondrial membrane at a position where it was inaccessible to protease but was released by alkaline extraction, suggesting that it had entered an import channel and passed the initial steps of recognition and uptake. Site-specific mutations within the presumptive address-specifying segment identified the amphipathic helix 5. A Ura6 mutant protein in which helix 5 had been replaced with the respective sequence from Aky2p was imported, and this address sequence cooperates with the N terminus in the respective double mutant in a synergistic fashion.	Univ Munich, Dept Biol 1, Bereich Genet, D-80638 Munich, Germany	University of Munich	Bandlow, W (corresponding author), Univ Munich, Dept Biol 1, Bereich Genet, Maria Ward Str 1A, D-80638 Munich, Germany.							ADES IZ, 1980, J BIOL CHEM, V255, P9925; Angermayr M, 2001, FEBS LETT, V508, P427, DOI 10.1016/S0014-5793(01)03122-2; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DIEDERICHS K, 1991, J MOL BIOL, V217, P541, DOI 10.1016/0022-2836(91)90756-V; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; DREUSICKE K, 1988, J MOL BIOL, V199, P359; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; FRANK R, 1986, EUR J BIOCHEM, V154, P205, DOI 10.1111/j.1432-1033.1986.tb09380.x; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HEIL A, 1974, EUR J BIOCHEM, V43, P131, DOI 10.1111/j.1432-1033.1974.tb03393.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; Klier H, 1996, BBA-BIOMEMBRANES, V1280, P251, DOI 10.1016/0005-2736(95)00304-5; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lithgow T, 1997, TRENDS BIOCHEM SCI, V22, P110, DOI 10.1016/S0968-0004(97)01007-4; MAGDOLEN V, 1987, CURR GENET, V12, P405, DOI 10.1007/BF00434817; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; NEUPERT W, 1997, ANNU REV BIOCHEM, V66, P861; Nobumoto M, 1998, J BIOCHEM, V123, P128; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; REID GA, 1982, J BIOL CHEM, V257, P3062; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Rost B, 1996, ANNU REV BIOPH BIOM, V25, P113, DOI 10.1146/annurev.bb.25.060196.000553; Sambrook J., 2002, MOL CLONING LAB MANU; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; Schricker R, 1995, J BIOL CHEM, V270, P31103, DOI 10.1074/jbc.270.52.31103; SCHRICKER R, 1992, GENE, V122, P111, DOI 10.1016/0378-1119(92)90038-Q; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; TOMASSELLI AG, 1986, EUR J BIOCHEM, V155, P111, DOI 10.1111/j.1432-1033.1986.tb09465.x; VERNER K, 1989, EMBO J, V8, P1491, DOI 10.1002/j.1460-2075.1989.tb03533.x; VESTWEBER D, 1989, NATURE, V341, P204; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	63	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28757	28764		10.1074/jbc.M201561200	http://dx.doi.org/10.1074/jbc.M201561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12045196	hybrid			2022-12-25	WOS:000177342600054
J	Gladwin, MT; Wang, XD; Reiter, CD; Yang, BK; Vivas, EX; Bonaventura, C; Schechter, AN				Gladwin, MT; Wang, XD; Reiter, CD; Yang, BK; Vivas, EX; Bonaventura, C; Schechter, AN			S-nitrosohemoglobin is unstable in the reductive erythrocyte environment and lacks O-2/NO-linked allosteric function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGIONAL BLOOD-FLOW; NITRIC-OXIDE; OXYGEN-BINDING; BIOCHEMICAL-CHARACTERIZATION; HUMAN HEMOGLOBINS; REDOX STATE; NITROSOTHIOLS; NITROSATION; GLUTATHIONE; INHIBITION	Our previous results run counter to the hypothesis that S-nitrosohemoglobin (SNO-Hb) serves as an in vivo reservoir for NO from which NO release is allosterically linked to oxygen release. We show here that SNO-Hb undergoes reductive decomposition in erythrocytes, whereas it is stable in purified solutions and in erythrocyte lysates treated with an oxidant such as ferricyanide. Using an extensively validated methodology that eliminates background nitrite and stabilizes erythrocyte S-nitrosothiols, we find the levels of SNO-Hb in the basal human circulation, including red cell membrane fractions, were 46 +/- 17 nM in human arterial erythrocytes and 69 +/- 11 nM in venous erythrocytes, incompatible with the postulated reservoir function of SNO-Hb. Moreover, we performed experiments on human red blood cells in which we elevated the levels of SNO-Hb to 10,000 times the normal in vivo levels. The elevated levels of intra-erythrocytic SNO-Hb fell rapidly, independent of oxygen tension and hemoglobin saturation. Most of the NO released during this process was oxidized to nitrate. A fraction (25%) was exported as S-nitrosothiol, but this fraction was not increased at low oxygen tensions that favor the deoxy (T-state) conformation of Hb. Results of these studies show that, within the redox-active erythrocyte environment, the beta-globin cysteine 93 is maintained in a reduced state, necessary for normal oxygen affinity, and incapable of oxygen-linked NO storage and delivery.	NIH, Warren G Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA; Duke Univ, Marine Freshwater Biomed Ctr, Beaufort, NC 28516 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Duke University	Gladwin, MT (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Crit Care Med, Bldg 10,Rm 7D43,10 Ctr Dr,MSC 1662, Bethesda, MD 20892 USA.	mgladwin@nih.gov	Vivas, Esther X./AAC-1008-2019	Vivas, Esther X./0000-0001-5740-2391; Schechter, Alan N/0000-0002-5235-9408	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025093, Z01DK025093] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL000190] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); CLINICAL CENTER		Bonaventura C, 1999, J BIOL CHEM, V274, P24742, DOI 10.1074/jbc.274.35.24742; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; Deem S, 2001, AM J RESP CRIT CARE, V163, P1164, DOI 10.1164/ajrccm.163.5.2007172; Ewing JF, 1998, FREE RADICAL BIO MED, V25, P621, DOI 10.1016/S0891-5849(98)00083-5; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAREL MC, 1986, J BIOL CHEM, V261, P4704; GAREL MC, 1984, MOL PHARMACOL, V26, P559; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gattoni M, 2001, ARCH BIOCHEM BIOPHYS, V386, P172, DOI 10.1006/abbi.2000.2185; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Gladwin MT, 2002, BRIT J HAEMATOL, V116, P436, DOI 10.1046/j.1365-2141.2002.03274.x; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Huang KT, 2001, P NATL ACAD SCI USA, V98, P11771, DOI 10.1073/pnas.201276698; HWANG C, 1995, METHOD ENZYMOL, V251, P212, DOI 10.1016/0076-6879(95)51123-7; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IMAI K, 1989, J BIOL CHEM, V264, P11174; IMAI K, 1982, ALLOSTERIC EFFECTS H, P39; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jourd'heuil D, 2000, BIOCHEM BIOPH RES CO, V273, P22, DOI 10.1006/bbrc.2000.2892; Kelm M, 1999, CARDIOVASC RES, V41, P765, DOI 10.1016/S0008-6363(98)00259-4; KISTER J, 1995, BBA-PROTEIN STRUCT M, V1246, P34, DOI 10.1016/0167-4838(94)00190-R; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; LUISI BF, 1986, NATURE, V320, P555, DOI 10.1038/320555a0; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Nedospasov A, 2000, P NATL ACAD SCI USA, V97, P13543, DOI 10.1073/pnas.250398197; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Rossi R, 2001, CIRC RES, V89; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; SHIH DTB, 1993, J MOL BIOL, V230, P1291; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	44	137	148	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27818	27828		10.1074/jbc.M203236200	http://dx.doi.org/10.1074/jbc.M203236200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023289	hybrid			2022-12-25	WOS:000177189800031
J	Desmoucelles, C; Pinson, B; Saint-Marc, C; Daignan-Fornier, B				Desmoucelles, C; Pinson, B; Saint-Marc, C; Daignan-Fornier, B			Screening the yeast "Disruptome" for mutants affecting resistance to the immunosuppressive drug, mycophenolic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; REGULATES TRANSCRIPTION ELONGATION; MAJOR FACILITATOR SUPERFAMILY; IMP DEHYDROGENASE GENE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE DEPLETION; PROTEOME ANALYSIS; SAGA COMPLEX; TRANSPORT; COMPONENTS	The immunosuppressive drug mycophenolic acid (MPA) is a potent and specific inhibitor of IMP dehydrogenase, the first committed step of GMP synthesis. A screen for yeast genes affecting MPA sensitivity, when overexpressed, allowed us to identify two genes, IMD2 and TPO1, encoding a homologue of IMP dehydrogenase and a vacuolar pump, respectively. In parallel, 4787 yeast strains, each carrying an identified knock-out mutation, were tested for growth in the presence of MPA, allowing identification of 100 new genes affecting MPA resistance when disrupted. Disturbance of several cellular processes, such as ergosterol biosynthesis, vacuole biogenesis, or glycosylation impaired the natural capacity of yeast to resist MPA, although most of the highly sensitive mutants affected the transcription machinery (19 mutants). Expression of TPO1 and/or IMD2 was strongly affected in 16 such transcription mutants suggesting that low expression of these genes could contribute to MPA sensitivity. Interestingly, the spM, spt8, and spt20 mutants behaved differently than other Spt-Ada-Gen5-acetyltransferase (SAGA) mutants. Indeed, in these three mutants, as in previously characterized transcription elongation mutants, IMD2 expression was only affected in the presence of MPA, thus suggesting a possible role for some SAGA subunits in transcription elongation.	CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Daignan-Fornier, B (corresponding author), CNRS, Inst Biochim & Genet Cellulaires, UMR 5095, 1 Rue Camille St Saens, F-33077 Bordeaux, France.			Pinson, Benoit/0000-0003-2936-9058				ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Calabrese D, 2000, MICROBIOL-UK, V146, P2743, DOI 10.1099/00221287-146-11-2743; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Costa PJ, 2000, GENETICS, V156, P535; DAIGNANFORNIER B, 1994, MOL GEN GENET, V243, P575, DOI 10.1007/BF00284206; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Digits JA, 1999, BIOCHEMISTRY-US, V38, P15388, DOI 10.1021/bi991558q; Dudley AM, 1999, GENETICS, V151, P1365; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P46237, DOI 10.1074/jbc.M103416200; Escobar-Henriques M, 2001, J BIOL CHEM, V276, P1523, DOI 10.1074/jbc.M007926200; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Farazi T, 1997, J BIOL CHEM, V272, P961, DOI 10.1074/jbc.272.2.961; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; Kohler GA, 1997, J BACTERIOL, V179, P2331; Lauder S, 1996, MOL CELL BIOL, V16, P6783; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; PRENDERGAST JA, 1995, YEAST, V11, P537, DOI 10.1002/yea.320110603; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; Shaw RJ, 2001, J BIOL CHEM, V276, P32905, DOI 10.1074/jbc.M105075200; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; SHERNAN F, 1986, METHODS YEAST GENETI; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Tomitori H, 1999, J BIOL CHEM, V274, P3265, DOI 10.1074/jbc.274.6.3265; Van Mullem V, 2002, J BIOL CHEM, V277, P10220, DOI 10.1074/jbc.M107207200; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	41	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27036	27044		10.1074/jbc.M111433200	http://dx.doi.org/10.1074/jbc.M111433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016207	hybrid			2022-12-25	WOS:000177055900045
J	Stauffer, AT; Rochat, MK; Dick, B; Frey, FJ; Odermatt, A				Stauffer, AT; Rochat, MK; Dick, B; Frey, FJ; Odermatt, A			Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID; EXPERIMENTAL CIRRHOSIS; SYSTEMIC HEMODYNAMICS; ASCITES FORMATION; SODIUM RETENTION; WATER-RETENTION; BLOOD-PRESSURE; NA+ RETENTION; RAT-KIDNEY	Inappropriate activation of the mineralocorticoid receptor (MR) results in renal sodium retention and potassium loss in patients with liver cirrhosis. Recent evidence suggested that this MR activation is, at least in part, a result of bile acid-dependent reduction in 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) activity, an enzyme preventing cortisol-dependent activation of MR by converting cortisol to cortisone. Here, we investigated the molecular mechanisms underlying bile acid-mediated MR activation. Analysis of urinary bile acids from 12 patients with biliary obstruction revealed highly elevated concentrations of chenodeoxycholic acid (CDCA), cholic acid (CA), and deoxycholic acid (DCA), with average concentrations of 50-80 muM. Although CDCA and DCA both mediated nuclear translocation of MR in the absence of 11betaHSD2 and steroids in transiently expressing HEK-293 cells, the transcriptional activity of MR was not stimulated. In contrast, CDCA and DCA both inhibited 11betaHSD2 with IC50 values of 22 and 38 muM, respectively and caused cortisol-dependent nuclear translocation and increased transcriptional activity of MR. LCA, the bile acid that most efficiently inhibited 11betaHSD2, was present at very low concentrations in cholestatic patients, whereas the weak inhibitor CA did not cause MR activation. In conclusion, these findings indicate that CDCA, and to a lesser extent DCA, by inhibiting 11betaHSD2, mediate cortisol-dependent nuclear translocation and transcriptional activation of MR and are responsible at least for a part of the sodium retention and potassium excretion observed in patients with biliary obstruction.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.			Odermatt, Alex/0000-0002-6820-2712				Ackermann D, 1999, HEPATOLOGY, V30, P623, DOI 10.1002/hep.510300303; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BUHLER H, 1994, STEROIDS, V59, P131, DOI 10.1016/0039-128X(94)90090-6; ELLIOTT WH, 1971, AM J MED, V51, P568, DOI 10.1016/0002-9343(71)90281-6; Escher G, 1998, GASTROENTEROLOGY, V114, P175, DOI 10.1016/S0016-5085(98)70645-6; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Ferrari P, 2001, HYPERTENSION, V38, P1330, DOI 10.1161/hy1101.096112; GOMEZSANCHEZ EP, 1992, AM J PHYSIOL, V263, pE1125; Heathcote EJ, 2000, HEPATOLOGY, V31, P1005, DOI 10.1053/he.2000.5984; HOLBROOK MM, 1980, J STEROID BIOCHEM, V13, P1355, DOI 10.1016/0022-4731(80)90097-7; HYLEMON PB, 1985, J BIOL CHEM, V260, P1015; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JIMENEZ W, 1985, HEPATOLOGY, V5, P245, DOI 10.1002/hep.1840050215; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; Kyossev Z, 1996, KIDNEY INT, V49, P271, DOI 10.1038/ki.1996.39; LATIF SA, 1994, STEROIDS, V59, P352, DOI 10.1016/0039-128X(94)90001-9; LEVY M, 1978, J LAB CLIN MED, V92, P560; LEVY M, 1978, J LAB CLIN MED, V91, P520; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; Martin PY, 1998, NEW ENGL J MED, V339, P533, DOI 10.1056/NEJM199808203390807; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; Morris DJ, 1996, ENDOCR RES, V22, P793, DOI 10.1080/07435809609043778; MYLES K, 1994, AM J PHYSIOL, V267, pE268, DOI 10.1152/ajpendo.1994.267.2.E268; NEALE G, 1971, GUT, V12, P145, DOI 10.1136/gut.12.2.145; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PERSCHEL FH, 1991, PFLUG ARCH EUR J PHY, V418, P538, DOI 10.1007/BF00370568; Ponz de Leon M, 1980, EUR J CLIN INVEST, V10, P261; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; SATOH K, 1993, NUCLEIC ACIDS RES, V21, P4429, DOI 10.1093/nar/21.18.4429; SCHRIER RW, 1988, NEW ENGL J MED, V319, P1127, DOI 10.1056/NEJM198810273191705; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Stewart PM, 1999, VITAM HORM, V57, P249; STIEHL A, 1977, CLIN GASTROENTEROL, V6, P45; WENSING G, 1990, HEPATOLOGY, V12, P13, DOI 10.1002/hep.1840120104; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Wilson RC, 2001, TRENDS ENDOCRIN MET, V12, P104, DOI 10.1016/S1043-2760(00)00356-8; Wu PS, 1999, STEROIDS, V64, P291, DOI 10.1016/S0039-128X(99)00005-7	43	39	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26286	26292		10.1074/jbc.M201556200	http://dx.doi.org/10.1074/jbc.M201556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12015312	hybrid			2022-12-25	WOS:000176908700062
J	Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ				Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ			Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation	ONCOGENE			English	Article						T-box; Tbx3; Myc; Ras; pl9ARF; p53	T-BOX GENES; FOOT MALFORMATION; MAMMARY SYNDROME; TYROSINE KINASE; P63 GENE; C-ABL; MUTATIONS; P19(ARF); MYC; EXPRESSION	Tbx3 is a member of the T-box family of transcription factors. Mutations in Tbx3 cause ulnar-mammary syndrome, an autosomal dominant disorder characterized by upper limb defects, apocrine-gland defects including mammary hypoplasia, and tooth, hair and genital defects. In cell culture, Tbx3 and its close relative Tbx2 are capable of immortalizing mouse embryo fibroblasts. We show that expression of Tbx3 together with Myc or oncogenic Ras (H-Ras(Val17)) leads to efficient transformation of mouse embryo fibroblasts. Oncogene cooperation by Tbx3 correlates with an ability of Tbx3 to suppress the induction of p19ARF and p53 that is typically caused by overexpression Myc and Ras, and to protect against Myc-induced apoptosis. Whereas Tbx3 is capable of interfering with apoptosis caused by excessive Myc levels, a Tbx3 mutant lacking its C-terminal repression domain shows no anti-apoptotic activity and fails to repress levels of p19ARF or p53. Consistent with an ability to suppress p53 pathway function, we find that Tbx3, but not a Tbx3 C-terminal mutant, efficiently blocks myogenic differentiation of C2C12 myoblasts. Our results support the idea that deregulation and/or excessive levels of Tbx3 may have oncogenic potential in vivo.	Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Hurlin, PJ (corresponding author), Oregon Hlth & Sci Univ, Shriners Hosp Children, 3101 Sam Jackson Pk Rd, Portland, OR 97201 USA.	pjh@shcc.org		Song, Youngsup/0000-0002-6268-5223				Agulnik SI, 1996, GENETICS, V144, P249; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bamshad M, 1999, AM J HUM GENET, V64, P1550, DOI 10.1086/302417; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gibson-Brown JJ, 1998, MECH DEVELOP, V74, P165, DOI 10.1016/S0925-4773(98)00056-2; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HURLIN PJ, 1987, CANCER RES, V47, P5752; Ianakiev P, 2000, AM J HUM GENET, V67, P59, DOI 10.1086/302972; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li QY, 1997, NAT GENET, V15, P21; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Schinke M, 2001, NAT GENET, V27, P238, DOI 10.1038/85784; SCHINZEL A, 1987, J MED GENET, V24, P778, DOI 10.1136/jmg.24.12.778; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	76	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3827	3835		10.1038/sj.onc.1205476	http://dx.doi.org/10.1038/sj.onc.1205476			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032820				2022-12-25	WOS:000175847200001
J	Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA				Sunesen, M; Stevnsner, T; Brosh, RM; Dianov, GL; Bohr, VA			Global genome repair of 8-oxoG in hamster cells requires a functional CSB gene product	ONCOGENE			English	Article						oxidative DNA damage; repair; DNA instability; Cockayne syndrome	BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; TRANSCRIPTION-COUPLED REPAIR; POLYMERASE-II TRANSCRIPTION; COCKAYNE-SYNDROME PATIENTS; RETRACTED ARTICLE. SEE; RNA-POLYMERASE; MITOCHONDRIAL REPAIR; FACTOR CSB/ERCC6; ACIDIC REGION	Cockayne syndrome (CS) is an autosomal recessive human disease characterized by UV-sensitivity as well as neurological and developmental abnormalities. Two complementation groups have been established, designated CS-A and CS-B. Traditionally, CSA and CSB have been ascribed a function in the transcription-coupled repair (TCR) pathway of nucleotide excision repair (NER) that efficiently removes bulky lesions from the transcribed strand of RNA polymerase 11 transcribed genes. To assess the role of the CSB protein in the repair of the highly mutagenic base lesion 7,8-dihydro-8-oxoguanine (8-oxoG), we have investigated the removal of this lesion using an in vitro incision approach with cell extracts as well as an in vivo approach with a modified protocol of the gene-specific repair assay, which allows the measurement of base lesion repair in intragenomic sequences. Our results demonstrate that the integrity of the CSB protein is pivotal for processes leading to incision at the site of 8-oxoG and that the global genome repair (GGR) of this lesion requires a functional CSB gene product in vivo.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	Stevnsner, Tinna/0000-0003-1007-0427				Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; Anson RM, 1999, METH MOL B, V113, P257; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1999, BIOCHIMIE, V81, P155, DOI 10.1016/S0300-9084(99)80048-0; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 1998, J BIOL CHEM, V273, P11844, DOI 10.1074/jbc.273.19.11844; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Grishko VI, 1997, MUTAT RES-DNA REPAIR, V384, P73, DOI 10.1016/S0921-8777(97)00017-7; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HTUN H, 1992, METHOD ENZYMOL, V212, P272; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; Kung HC, 1997, J BIOL CHEM, V272, P9227; Le Page F, 1999, BIOCHIMIE, V81, P147, DOI 10.1016/S0300-9084(99)80047-9; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LIN JJ, 1989, BIOCHEMISTRY-US, V28, P7979, DOI 10.1021/bi00446a002; Ljungman M, 1996, ONCOGENE, V13, P823; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MAYNE LV, 1982, CANCER RES, V42, P1473; Memisoglu A, 2000, MUTAT RES-FUND MOL M, V451, P39, DOI 10.1016/S0027-5107(00)00039-7; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; Sunesen M, 2000, NUCLEIC ACIDS RES, V28, P3151, DOI 10.1093/nar/28.16.3151; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; THORSLUND T, 2002, IN PRESS DNA REPAIR; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; Woods CG, 1998, ARCH DIS CHILD, V78, P178, DOI 10.1136/adc.78.2.178	57	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3571	3578		10.1038/sj.onc.1205443	http://dx.doi.org/10.1038/sj.onc.1205443			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032859				2022-12-25	WOS:000175793700008
J	Mak, PA; Laffitte, BA; Desrumaux, C; Joseph, SB; Curtiss, LK; Mangelsdorf, DJ; Tontonoz, P; Edwards, PA				Mak, PA; Laffitte, BA; Desrumaux, C; Joseph, SB; Curtiss, LK; Mangelsdorf, DJ; Tontonoz, P; Edwards, PA			Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages - A critical role for nuclear liver X receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC CONTROL REGION; MESSENGER-RNA LEVELS; TRANSGENIC MICE; LXR-ALPHA; C-I; CHOLESTEROL EFFLUX; CAUSES HYPERTRIGLYCERIDEMIA; CELLULAR CHOLESTEROL; OXYSTEROL RECEPTORS; LIPOPROTEIN-LIPASE	Lipid-loaded macrophage "foam cells" accumulate in the subendothelial space during the development of fatty streaks and atherosclerotic lesions. To better understand the consequences of such lipid loading, murine peritoneal macrophages were isolated and incubated with ligands for two nuclear receptors, liver X receptor (LXR) and retinoic acid receptor (RXR). Analysis of the expressed mRNAs using microarray technology led to the identification of four highly induced genes that encode apolipoproteins E, C-I, C-IV, and C-II. Northern blot analysis confirmed that the mRNA levels of these four genes were induced 2-14-fold in response to natural or synthetic ligands for LXR and/or RXR. The induction of all four mRNAs was greatly attenuated in peritoneal macrophages derived from LXRalpha/beta null mice. The two LXR response elements located within the multienhancers ME.1 and ME.2 were shown to be essential for the induction of apoC-II promoter-reporter genes by ligands for LXR and/or RXR. Finally, immunohistochemical studies demonstrate that apoC-II protein co-localizes with macrophages within murine arterial lesions. Taken together, these studies demonstrate that activated LXR induces the expression of the apoE/C-I/C-IV/C-II gene cluster in both human and murine macrophages. These results suggest an alternative mechanism by which lipids are removed from macrophage foam cells.	Univ Calif Los Angeles, Dept Biol Chem & Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Scripps Research Institute	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Desrumaux, Catherine/O-1925-2018	Mangelsdorf, David/0000-0002-4355-0796; Joseph, Sean/0000-0002-2602-8517	NHLBI NIH HHS [HL43815, HL35297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043815, R01HL035297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberti S, 2000, GENE, V243, P93, DOI 10.1016/S0378-1119(99)00555-7; ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; Allan CM, 1997, J BIOL CHEM, V272, P29113, DOI 10.1074/jbc.272.46.29113; Allan CM, 1996, J LIPID RES, V37, P1510; Attie AD, 2001, J LIPID RES, V42, P1717; BASU SK, 1982, J BIOL CHEM, V257, P9788; Boisvert WA, 1999, J LIPID RES, V40, P806; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Brunzell JD, 1995, METABOLIC BASIS INHE, P1913; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Edwards PA, 2002, J LIPID RES, V43, P2; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; FOJO SS, 1992, J INTERN MED, V231, P669, DOI 10.1111/j.1365-2796.1992.tb01256.x; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Grehan S, 2001, J INVEST DERMATOL, V116, P77, DOI 10.1046/j.1523-1747.2001.00213.x; Grehan S, 2001, J NEUROSCI, V21, P812, DOI 10.1523/JNEUROSCI.21-03-00812.2001; HOFFER MJV, 1993, GENOMICS, V17, P45, DOI 10.1006/geno.1993.1281; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; Jong MC, 1998, J CLIN INVEST, V101, P145, DOI 10.1172/JCI791; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; Lin CY, 1999, J LIPID RES, V40, P1618; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MAZZONE T, 1989, J LIPID RES, V30, P1055; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Pentikainen MO, 2002, ARTERIOSCL THROM VAS, V22, P211, DOI 10.1161/hq0102.101551; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; REUE KL, 1984, J BIOL CHEM, V259, P2100; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; SHACHTER NS, 1993, J LIPID RES, V34, P1699; Shachter NS, 2001, CURR OPIN LIPIDOL, V12, P297, DOI 10.1097/00041433-200106000-00009; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; VANECK MM, 1994, GENOMICS, V21, P110, DOI 10.1006/geno.1994.1231; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	52	197	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31900	31908		10.1074/jbc.M202993200	http://dx.doi.org/10.1074/jbc.M202993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12032151	hybrid			2022-12-25	WOS:000177718700076
J	Farzan, M; Babcock, GJ; Vasilieva, N; Wright, PL; Kiprilov, E; Mirzabekov, T; Choe, H				Farzan, M; Babcock, GJ; Vasilieva, N; Wright, PL; Kiprilov, E; Mirzabekov, T; Choe, H			The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; TETRASACCHARIDE SEQUENCE; SULFATED TYROSINES; N-TERMINUS; CCR5; 7-TRANSMEMBRANE; INFECTION; LIGAND; REGION	The chemokine receptor CXCR4 plays critical roles in development, immune function, and human immunodeficiency virus type 1 (HIV-1) entry. Here we demonstrate that, like the CC-chemokine receptors CCR5 and CCR2b, CXCR4 is posttranslationally modified by sulfation of its amino-terminal tyrosines. The sulfate group at tyrosine 21 contributes substantially to the ability of CXCR4 to bind its ligand, stromal derived factor la. Tyrosine sulfation plays a less significant role in CXCR4-dependent HIV-1 entry than in CCR5-dependent HIV-1 entry. In some cell lines, CXCR4 is efficiently modified by a chondroitin sulfate chain at serine 18, but neither HIV-1 entry nor stromal derived factor la binding was affected by loss of this glycosaminoglycan. These data demonstrate a functional role for tyrosine sulfate in the CXC-chemokine receptor family and underscore a general difference in HIV-1 utilization of CCR5 and CXCR4.	Harvard Univ, Childrens Hosp, Sch Med, Ina Sue Perlmutter Lab,Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Canc Immunol & AIDS, Div AIDS,Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Choe, H (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Ina Sue Perlmutter Lab,Dept Pediat, 300 Longwood Ave, Boston, MA 02115 USA.			Farzan, Michael/0000-0002-2990-5319	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048425, R01AI043891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43891, AI48425, R01 AI043891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babcock GJ, 2001, J BIOL CHEM, V276, P38433, DOI 10.1074/jbc.M106229200; Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; WU L, 1996, NATURE, V184, P179; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	28	174	184	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29484	29489		10.1074/jbc.M203361200	http://dx.doi.org/10.1074/jbc.M203361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034737	hybrid			2022-12-25	WOS:000177509300019
J	Psichari, E; Balmain, A; Plows, D; Zoumpourlis, V; Pintzas, A				Psichari, E; Balmain, A; Plows, D; Zoumpourlis, V; Pintzas, A			High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RHO; C-FOS GENE; TRANSCRIPTIONAL ACTIVATION; SKIN TUMORS; IN-VIVO; PATHWAYS; RAS; COMPLEX; PROLIFERATION; PROGRESSION	The serum response factor (SRF) regulates the transcription of target genes by binding to serum response elements in dimeric form and by interacting with ternary complex factors. In this study, we have analyzed the role of the serum response factor and mechanisms that regulate its activity in tumor progression utilizing a multistage model of mouse skin carcinogenesis. We demonstrate elevated SRF DNA binding activity only in the cell lines that have undergone an epithelial to mesenchymal transition and have increased actin stress fiber formation. Transient transfection experiments of activated or dominant negative forms of RhoA showed that the high activity of SRF and the induced formation of actin stress fibers in cells with spindle morphology were mediated by RhoA signaling. A dominant negative form of SRF inhibited RhoA-induced actin polymerization and stress fiber formation. The DNA binding activity of SRF in mesenchymal tumor cells was also correlated with elevated expression of SRF target genes, similar to SRF itself, actin, and vinculin. These observations suggest for the first time that SRF may play an important role in tumor progression, specifically at the transition to an invasive metastatic stage of carcinogenesis.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Lab Signal Mediated Gene Express, GR-11635 Athens, Greece; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	National Hellenic Research Foundation; University of California System; University of California San Francisco	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Lab Signal Mediated Gene Express, 48 Vas Constantinou Ave, GR-11635 Athens, Greece.	apint@eie.gr						Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; BALMAIN A, 1988, ADV CANCER RES, V51, P25; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS PA, 1991, ONCOGENE, V6, P2363; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Ding W, 2001, J CELL SCI, V114, P1011; Ducret C, 2000, ONCOGENE, V19, P5063, DOI 10.1038/sj.onc.1203892; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	39	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29490	29495		10.1074/jbc.M112368200	http://dx.doi.org/10.1074/jbc.M112368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039949	hybrid			2022-12-25	WOS:000177509300020
J	Santos, T; Carrasco, S; Jones, DR; Merida, I; Eguinoa, A				Santos, T; Carrasco, S; Jones, DR; Merida, I; Eguinoa, A			Dynamics of diacylglycerol kinase xi translocation in living T-cells - Study of the structural domain requirements for translocation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID BINDING; NUCLEAR-LOCALIZATION; MOLECULAR-CLONING; ACTIVATION; ZETA; RECEPTOR; PATHWAY; ALPHA; PHOSPHOINOSITIDES; STIMULATION	The diacylglycerol kinases (DGK) regulate diacylglycerol-based signals by phosphorylating this key lipid intermediate to phosphatidic acid. Here, we have investigated the spatial and temporal regulation of diacylglycerol kinase zeta (DGKzeta) in living Jurkat T-cells expressing a muscarinic type I receptor. Using real time confocal videomicroscopy, we show the rapid translocation of a green fluorescent protein-tagged enzyme from the cytosol to the plasma membrane following receptor stimulation. The generation of a panel of truncations, deletions, and point mutations of the enzyme allowed us to examine the requirements of the different structural motifs for both activity and receptor-regulated translocation. The data show that DGK has strict requirements for intact zinc fingers and the conserved catalytic domain for full enzymatic activity. Protein kinase C-driven myristoylated alanine-rich C kinase substrate domain phosphorylation and intact zinc fingers are in turn essential for plasma membrane translocation. DGKzeta does not translocate to the membrane following stimulation of the endogenous T-cell receptor, and our data demonstrate that the specificity in terms of receptor response is provided by the regulatory motifs present at the C-terminal domain of the protein. This is the first report that shows in vivo DGKzeta translocation in response to agonist stimulation and establishes the role of the different domains in enzymatic activity and the selectivity of the response to receptors.	Natl Biotechnol Ctr, Dept Immunol & Oncol, E-28049 Madrid, Spain		Merida, I (corresponding author), Natl Biotechnol Ctr, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	imerida@cnb.uam.es	Santos-Mendoza, Teresa/AAK-8528-2021; Merida, Isabel/A-9713-2014	Merida, Isabel/0000-0003-2762-6241; Santos, Teresa/0000-0003-3765-5863; Santos-Mendoza, Teresa/0000-0003-1015-5631				Andrade MA, 2001, J STRUCT BIOL, V134, P117, DOI 10.1006/jsbi.2001.4392; Arbuzova A, 1998, BBA-REV BIOMEMBRANES, V1376, P369, DOI 10.1016/S0304-4157(98)00011-2; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Burger KNJ, 2000, BIOCHEMISTRY-US, V39, P12485, DOI 10.1021/bi000971r; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Dalton KA, 1998, BIOCHEM J, V329, P637; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; Ebinu JO, 2000, BLOOD, V95, P3199; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Garcia-Garcia J, 1999, BIOCHEMISTRY-US, V38, P9667, DOI 10.1021/bi9905765; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Izquierdo M, 1996, J IMMUNOL, V157, P21; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Litosch I, 2000, BIOCHEMISTRY-US, V39, P7736, DOI 10.1021/bi000022y; Liu ZT, 2001, J BIOL CHEM, V276, P5900, DOI 10.1074/jbc.M007311200; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Pawelczyk T, 1999, EUR J BIOCHEM, V262, P291, DOI 10.1046/j.1432-1327.1999.00388.x; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	40	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30300	30309		10.1074/jbc.M200999200	http://dx.doi.org/10.1074/jbc.M200999200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12015310	hybrid			2022-12-25	WOS:000177509300116
J	Kashiwagi, T; Hara, K; Kohara, M; Iwahashi, J; Hamada, N; Honda-Yoshino, H; Toyoda, T				Kashiwagi, T; Hara, K; Kohara, M; Iwahashi, J; Hamada, N; Honda-Yoshino, H; Toyoda, T			Promoter/origin structure of the complementary strand of hepatitis C virus genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; RIBOSOME ENTRY SITE; DE-NOVO INITIATION; VIRAL-RNA; IN-VITRO; NS5B; REGION; NS3; IDENTIFICATION; REQUIREMENTS	Hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp). Sequences in the 3' termini of both the plus and minus strand of HCV genomic RNA harbor the activity of a replication origin and a transcription promoter. There are unique stem-loop structures in both termini of the viral RNA. We found that the complementary strand of the internal ribosome-binding site (IRES) showed strong template activity in vitro. The complementary strand RNA of the HCV genome works as a template for mRNA and viral genomic RNA. We analyzed the promoter/origin structure of the complementary sequence of IRES and found that the first and second stem-loops worked as negative and positive elements in RNA synthesis, respectively. The complementary strand of the second stem-loop of IRES was an important element also for binding to HCV RdRp.	Kurume Univ, Dept Virol, Sch Med, Kurume, Fukuoka 8300011, Japan; Tokyo Metropolitan Inst Med Biol, Dept Microbiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Kurume University	Toyoda, T (corresponding author), Kurume Univ, Dept Virol, Sch Med, 67 Asahimachi, Kurume, Fukuoka 8300011, Japan.	ttoyoda@med.kurume-u.ac.jp						Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Banerjee R, 2001, J VIROL, V75, P1708, DOI 10.1128/JVI.75.4.1708-1721.2001; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Cheng JC, 1999, J VIROL, V73, P7044, DOI 10.1128/JVI.73.8.7044-7049.1999; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Friebe P, 2001, J VIROL, V75, P12047, DOI 10.1128/JVI.75.24.12047-12057.2001; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; Hagedorn CH, 2000, CURR TOP MICROBIOL, V242, P225; Honda M, 1999, J VIROL, V73, P1165, DOI 10.1128/JVI.73.2.1165-1174.1999; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kashiwagi T, 2002, BIOCHEM BIOPH RES CO, V290, P1188, DOI 10.1006/bbrc.2001.6333; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129; Lesburg C A, 2000, Curr Opin Investig Drugs, V1, P289; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Lukavsky PJ, 2000, NAT STRUCT BIOL, V7, P1105; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MATSUURA Y, 1993, SEMIN VIROL, V4, P297, DOI 10.1006/smvy.1993.1026; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Reigadas S, 2001, EUR J BIOCHEM, V268, P5857, DOI 10.1046/j.0014-2956.2001.02532.x; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VANREGENMORTEL MHV, 2000, VIRUS TAXONOMY 7 REP, P872; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	46	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28700	28705		10.1074/jbc.M201251200	http://dx.doi.org/10.1074/jbc.M201251200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039953	hybrid			2022-12-25	WOS:000177342600047
J	Myllyharju, J; Kukkola, L; Winter, AD; Page, AP				Myllyharju, J; Kukkola, L; Winter, AD; Page, AP			The exoskeleton collagens in Caenorhabditis elegans are modified by prolyl 4-hydroxylases with unique combinations of subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; BETA-SUBUNIT; ENZYME TETRAMER; CLONING; MORPHOGENESIS; HOMOLOGS; ISOFORM; BINDING	The collagen prolyl 4-hydroxylases (P4Hs, EC 1.14.11.2) play a critical role in the synthesis of the extracellular matrix. The enzymes characterized from vertebrates and Drosophila are alpha(2)beta(2) tetramers, in which protein disulfide isomerase (PDI) serves as the beta subunit. Two conserved a subunit isoforms, PHY-1 and PHY-2, have been identified in Caenorhabditis elegans. We report here that three unique P4H forms are assembled from these polypeptides and the single 13 subunit PDI-2, both in a recombinant expression system and in vivo, namely a PHY-1/PHY-2/(PDI-2), mixed tetramer and PHY-1/PDI-2 and PHY-2/PDI-2 dimers. The mixed tetramer is the main P4H form in wild-type C. elegans but phy-2(-/-) and phy-1(-/-) (dpy-18) mutant nematodes can compensate for its absence by increasing the assembly of the PHY-1/PDI-2 and PHY-2/PDI-2 dimers, respectively. All three of the mixed tetramer-forming polypeptides PHY-1, PHY-2, and PDI-2 are coexpressed in the cuticle collagen-synthesizing hypodermal cells. The catalytic properties of the mixed tetramer are similar to those of other P4Hs, and analogues of 2-oxoglutarate were found to produce severe temperature-dependent effects on P4H mutant strains. Formation of the novel mixed tetramer was species-specific, and studies with hybrid recombinant PHY polypeptides showed that residues Gln(121)-Ala(271) and Asp(1)-Leu(122) in PHY-1 and PHY-2, respectively, are critical for its assembly.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Oulu, Collagen Res Unit, Bioctr, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Glasgow; University of Oulu; University of Oulu	Page, AP (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland.	a.page@udcf.gla.ac.uk						Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hill KL, 2000, GENETICS, V155, P1139; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Johnstone IL, 2000, TRENDS GENET, V16, P21, DOI 10.1016/S0168-9525(99)01857-0; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KRAMER JM, 1997, C ELEGANS, V2, P471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Page Antony P., 2001, P167, DOI 10.1079/9780851994239.0167; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000	33	34	42	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29187	29196		10.1074/jbc.M203824200	http://dx.doi.org/10.1074/jbc.M203824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036960	hybrid			2022-12-25	WOS:000177342600108
J	Naraba, H; Yokoyama, C; Tago, N; Murakami, M; Kudo, I; Fueki, M; Oh-Ishi, S; Tanabe, T				Naraba, H; Yokoyama, C; Tago, N; Murakami, M; Kudo, I; Fueki, M; Oh-Ishi, S; Tanabe, T			Transcriptional regulation of the membrane-associated prostaglandin E-2 synthase gene - Essential role of the transcription factor Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-RESPONSE GENE-1; FACTOR KAPPA-B; 5'-FLANKING REGION; ENDOTHELIAL-CELLS; THROMBOMODULIN GENE; UP-REGULATION; CYCLOOXYGENASE-2; EXPRESSION; INDUCTION; PROMOTER	Membrane-associated prostaglandin (PG) E-2 synthase (mPGES) is an inducible terminal enzyme in the biosynthetic pathway for prostaglandin E-2, which participates in many biological processes. In this study, we investigated the molecular mechanism controlling the inducible expression of mPGES. The mouse mPGES gene consisted of three exons, and its 5'-proximal promoter contained consensus motifs for the binding of several transcription factors. Transgenic expression in mice of the mouse mPGES promoter flanked by a reporter gene resulted in stimulus-dependent induction of the reporter in tissues where mPGES was intrinsically induced. Deletion and site-specific mutation analyses of the W-flanking region demonstrated that stimulus-inducible expression of mouse and human mPGES required tandem GC boxes adjacent to the initiation site. The stimulus-induced GC box binding activity was present in nuclear extracts of cells, in which the proximal GC box was essential for binding. An 80-kDa stimulus-inducible nuclear protein that bound to this GC box was identified as the transcription factor Egr-1 (for early growth response-1). These results suggest that Egr-1 is a key transcription factor in regulating the inducible expression of mPGES.	Natl Cardiovasc Ctr, Inst Res, Dept Pharmacol, Suita, Osaka 5658565, Japan; Showa Univ, Dept Hlth Chem, Sch Pharmaceut Sci, Shinagawa Ku, Tokyo 1428555, Japan; Kitasato Univ, Dept Pharmacol, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	National Cerebral & Cardiovascular Center - Japan; Showa University; Kitasato University	Tanabe, T (corresponding author), Natl Cardiovasc Ctr, Inst Res, Dept Pharmacol, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.							Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; Hatzinikolas G, 1998, J BIOL CHEM, V273, P29309, DOI 10.1074/jbc.273.45.29309; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Horie S, 2001, J BIOL CHEM, V276, P2440, DOI 10.1074/jbc.M004942200; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KOJIMA F, 2002, IN PRESS J RHEUMATOL; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Matsumoto H, 1998, EUR J PHARMACOL, V352, P47, DOI 10.1016/S0014-2999(98)00340-9; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Naraba H, 1998, J IMMUNOL, V160, P2974; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952-3278(90)90081-U; Ohkawara S, 2000, BBA-GENE STRUCT EXPR, V1494, P155, DOI 10.1016/S0167-4781(00)00212-8; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Soler M, 2000, CIRC RES, V87, P504; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Sugawara A, 2002, J BIOL CHEM, V277, P9676, DOI 10.1074/jbc.M104560200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; Thoren S, 2000, EUR J BIOCHEM, V267, P6428, DOI 10.1046/j.1432-1327.2000.01735.x; Ueno A, 2001, BIOCHEM PHARMACOL, V62, P157, DOI 10.1016/S0006-2952(01)00654-2; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	46	123	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28601	28608		10.1074/jbc.M203618200	http://dx.doi.org/10.1074/jbc.M203618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034740	hybrid			2022-12-25	WOS:000177342600034
J	Farrar, C; Clarke, S				Farrar, C; Clarke, S			Altered levels of S-adenosylmethionine and S-adenosylhomocysteine in the brains of L-isoaspartyl (D-aspartyl) O-methyltransferase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; CENTRAL-NERVOUS-SYSTEM; ADENOSYL-L-HOMOCYSTEINE; RAT-BRAIN; L-METHIONINE; PHOSPHOLIPID METHYLATION; ALZHEIMERS-DISEASE; DAMAGED PROTEINS; BETA-PEPTIDES; FOLIC-ACID	L-Isoaspartyl (D-aspartyl) O-methyltransferase (PCMT1) is a protein repair enzyme that initiates the conversion of abnormal D-aspartyl and L-isoaspartyl residues to the normal L-aspartyl form. In the course of this reaction, PCMT1 converts the methyl donor S-adenosylmethionine (AdoMet) to S-adenosylhomocysteine (AdoHcy). :Due to the high level of activity of this enzyme, particularly in the brain, it seemed of interest to investigate whether the lack of PCMT1 activity might alter the concentrations of these small molecules. AdoMet and AdoHcy were measured in mice lacking PCMT1 (Pcmt1-/-), as well as in their heterozygous (Pcmt1+/-) and wild type (Pemt1+/+) littermates. Higher levels of AdoMet and lower levels of AdoHcy were found in the brains of Pcmt1-/- mice, and to a lesser extent in Pemt1+/- mice, when compared with Pcmt1+/+ mice. In addition, these levels appear to be most significantly altered in the hippocampus of the Pcmt1-/- mice. The changes in the AdoMet/AdoHcy ratio could not be attributed to increases in the activities of methionine adenosyltransferase II or S-adenosylhomocysteine hydrolase in the brain tissue of these mice. Because changes in the AdoMet/AdoHcy ratio could potentially alter the overall excitatory state of the brain, this effect may play a role in the progressive epilepsy seen in the Pcmt1-/- mice.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), 640 Paul D Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000, R01AG015451] Funding Source: NIH RePORTER; NIA NIH HHS [AG15451, AG18000] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1975, NEUROPHARMACOLOGY, V14, P571, DOI 10.1016/0028-3908(75)90123-9; Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; BAUDRY M, 1973, J NEUROCHEM, V20, P13, DOI 10.1111/j.1471-4159.1973.tb12099.x; BHATTACHARYA A, 1979, P NATL ACAD SCI USA, V76, P4489, DOI 10.1073/pnas.76.9.4489; BILLINGSLEY ML, 1985, NEUROSCIENCE, V15, P159, DOI 10.1016/0306-4522(85)90130-7; BOIVIN D, 1995, BIOCHEM J, V309, P993, DOI 10.1042/bj3090993; BOIVIN D, 1993, J BIOL CHEM, V268, P2610; Bottiglieri T, 1996, NUTR REV, V54, P382, DOI 10.1111/j.1753-4887.1996.tb03851.x; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; FONLUPT P, 1980, CAN J PHYSIOL PHARM, V58, P493, DOI 10.1139/y80-082; FULLER RW, 1982, J PHARMACOL EXP THER, V223, P84; GEIGER T, 1987, J BIOL CHEM, V262, P785; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; HIRATA F, 1979, P NATL ACAD SCI USA, V76, P368, DOI 10.1073/pnas.76.1.368; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; HOFFMAN DR, 1980, J BIOL CHEM, V255, P822; HOMMES OR, 1979, FOLIC ACID NEUROLOGY, P285; Ikegaya Y, 2001, HIPPOCAMPUS, V11, P287, DOI 10.1002/hipo.1043; IQBAL M, 1976, J NEUROCHEM, V27, P605, DOI 10.1111/j.1471-4159.1976.tb12289.x; JOHNSON BA, 1985, BIOCHEMISTRY-US, V24, P2581, DOI 10.1021/bi00331a028; KAIJIMA M, 1984, EXP NEUROL, V86, P313, DOI 10.1016/0014-4886(84)90189-4; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Lindner H, 2001, EXP GERONTOL, V36, P1551, DOI 10.1016/S0531-5565(01)00140-1; Lowenson JD, 1999, METHOD ENZYMOL, V309, P89; Lowenson JD, 2001, J BIOL CHEM, V276, P20695, DOI 10.1074/jbc.M100987200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1986, J BIOL CHEM, V261, P1503; MCKEEVER M, 1995, CLIN SCI, V88, P73, DOI 10.1042/cs0880073; MIZOBUCHI M, 1994, J NEUROCHEM, V62, P322; Mudd SH, 2001, J INHERIT METAB DIS, V24, P448, DOI 10.1023/A:1010577512912; MURRAY ED, 1984, J BIOL CHEM, V259, P722; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; ORDONEZ LA, 1974, ARCH BIOCHEM BIOPHYS, V160, P372, DOI 10.1016/0003-9861(74)90410-X; POULTON JE, 1976, ARCH BIOCHEM BIOPHYS, V172, P135, DOI 10.1016/0003-9861(76)90058-8; REYNOLDS EH, 1973, LANCET, V1, P1376; REYNOLDS EH, 1991, ADV NEUROL, P44; SAIDO TC, 1987, J BIOCHEM-TOKYO, V102, P319, DOI 10.1093/oxfordjournals.jbchem.a122057; SCHATZ RA, 1983, J NEUROSCI RES, V10, P437, DOI 10.1002/jnr.490100410; SHAW GG, 1979, BIOCHEM PHARMACOL, V28, P1, DOI 10.1016/0006-2952(79)90261-2; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; SHIRASAWA T, 1995, NEUROSCI LETT, V188, P37, DOI 10.1016/0304-3940(95)11389-E; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; TASHIMA G, 1995, DEAMIDATION ISOASPAR, P167; TSVETNITSKY V, 1995, EUR J PHARMACOL, V282, P255, DOI 10.1016/0014-2999(95)00379-Y; UELAND PM, 1982, PHARMACOL REV, V34, P223; WARNER JR, 1976, J BACTERIOL, V125, P887, DOI 10.1128/JB.125.3.887-891.1976; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; Yamamoto A, 1998, J NEUROSCI, V18, P2063; ZAWAD JS, 1985, J NEUROCHEM, V44, P808, DOI 10.1111/j.1471-4159.1985.tb12887.x; Zhao WQ, 2001, EXP NEUROL, V171, P127, DOI 10.1006/exnr.2001.7726	55	33	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27856	27863		10.1074/jbc.M203911200	http://dx.doi.org/10.1074/jbc.M203911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023972	hybrid			2022-12-25	WOS:000177189800035
J	Sabatini, R; Meeuwenoord, N; van Boom, JH; Borst, P				Sabatini, R; Meeuwenoord, N; van Boom, JH; Borst, P			Site-specific interactions of JBP with base and sugar moieties in duplex J-DNA - Evidence for both major and minor groove contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSYL-HYDROXYMETHYLURACIL; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; BINDING-PROTEIN; KINETOPLASTID PROTOZOANS; TELOMERIC DNA; COMPLEX; SEQUENCE; GENE; TRANSCRIPTION	beta-D-Glucosyl-hydroxymethyluracil, also called base J, is an unusually modified DNA base conserved among Kinetoplastida. Base J is found predominantly in repetitive DNA and correlates with epigenetic silencing of telomeric variant surface glycoprotein genes. We have previously identified a J-binding protein (JBP) in Trypanosoma, Leishmania, and Crithidia, and we have shown that it is a structure-specific binding protein. Here we examine the molecular interactions that contribute to recognition of the glycosylated base in synthetic DNA substrates using modification interference, modification protection, DNA footprinting, and photocross-linking techniques. We find that the two primary requirements for J-DNA recognition include contacts at base J and a base immediately 5' of J (J-1). Methylation interference analysis indicates that the requirement of the base at position J-1 is due to a major groove contact independent of the sequence. DNA footprinting of the JBP(.)J-DNA complex with 1,10-phenanthroline-copper demonstrates that JBP contacts the minor groove at base J. Substitution of the thymine moiety of J with cytosine reduces the affinity for JBP similar to15-fold. These data indicate that the sole sequence dependence for JBP binding may lie in the thymine moiety of base J and that recognition requires only two specific base contacts, base J and J-1, within both the major and minor groove of the J-DNA duplex.	Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA; Leiden Inst Chem, Gorlaeus Labs, NL-2300 RA Leiden, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	University of Alabama System; University of Alabama Birmingham; Leiden University; Netherlands Cancer Institute; Netherlands Cancer Institute	Sabatini, R (corresponding author), Univ Alabama, Div Geog Med, Birmingham, AL 35294 USA.							BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; Borst P, 1997, MOL BIOCHEM PARASIT, V90, P1, DOI 10.1016/S0166-6851(97)00170-9; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BRUZIK JP, 1987, BIOCHEMISTRY-US, V26, P950, DOI 10.1021/bi00377a040; CHAING SY, 1996, J BIOL CHEM, V271, P23999; CHAING SY, 1994, BIOCHEMISTRY-US, V33, P7033; Cross M, 1999, EMBO J, V18, P6573, DOI 10.1093/emboj/18.22.6573; DEKORT M, 2000, THESIS U LEIDEN LEID; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; Gao YG, 1997, J AM CHEM SOC, V119, P1496, DOI 10.1021/ja963793r; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; HOGAN M, 1979, NATURE, V278, P521, DOI 10.1038/278521a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Maxam A M, 1980, Methods Enzymol, V65, P499; Mucke M, 2002, J BIOL CHEM, V277, P14288, DOI 10.1074/jbc.M109311200; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PAPAVASSILIOU AG, 1990, J BIOL CHEM, V265, P9402; PAPAVASSILIOU AG, 1995, BIOCHEM J, V305, P345, DOI 10.1042/bj3050345; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; SAATINI R, 2002, J BIOL CHEM, V277, P958; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; van Leeuwen F, 1998, MOL CELL BIOL, V18, P5643, DOI 10.1128/MCB.18.10.5643; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; van Leeuwen F, 2000, MOL BIOCHEM PARASIT, V109, P133, DOI 10.1016/S0166-6851(00)00247-4; vanLeeuwen F, 1996, NUCLEIC ACIDS RES, V24, P2476, DOI 10.1093/nar/24.13.2476; vanLeeuwen F, 1997, GENE DEV, V11, P3232, DOI 10.1101/gad.11.23.3232; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645	34	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28150	28156		10.1074/jbc.M201487200	http://dx.doi.org/10.1074/jbc.M201487200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029082	Green Published, hybrid			2022-12-25	WOS:000177189800072
J	Yamamoto, S; Oka, S; Inoue, M; Shimuta, M; Manabe, T; Takahashi, M; Miyamoto, M; Asano, M; Sakagami, J; Sudo, K; Iwakura, Y; Ono, K; Kawasaki, T				Yamamoto, S; Oka, S; Inoue, M; Shimuta, M; Manabe, T; Takahashi, M; Miyamoto, M; Asano, M; Sakagami, J; Sudo, K; Iwakura, Y; Ono, K; Kawasaki, T			Mice deficient in nervous system-specific carbohydrate epitope HNK-1 exhibit impaired synaptic plasticity and spatial learning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SULFOGLUCURONYL GLYCOLIPIDS; EXTRACELLULAR-MATRIX; CELL-ADHESION; PERISOMATIC INHIBITION; MOLECULAR-CLONING; GLUCURONOSYLTRANSFERASE; BIOSYNTHESIS; EXPRESSION; PROTEIN	The HNK-1 carbohydrate epitope, a sulfated glucuronic acid at the non-reducing terminus of glycans, is expressed characteristically on a series of cell adhesion molecules and is synthesized through a key enzyme, glucuronyltransferase (GlcAT-P). We generated mice with a targeted deletion of the GlcAT-P gene. The GlcAT-P -/- mice exhibited normal development of gross anatomical features, but the adult mutant mice exhibited reduced long term potentiation at the Schaffer collateral-CA1 synapses and a defect in spatial memory formation. This is the first evidence that the loss of a single non-reducing terminal carbohydrate residue attenuates brain higher functions.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, CREST Project, Japan Sci & Technol Corp, Kyoto 6068501, Japan; Kobe Univ, Fac Med, Dept Neurosci, Div Cell Biol & Neurophysiol, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Neuronal Network, Tokyo 1088639, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Pharmaceut Res Labs 1, Osaka 5328686, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Transgen Anim Sci, Kanazawa, Ishikawa 9208640, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Tokyo 1088639, Japan; Shimane Med Univ, Dept Anat, Izumo, Shimane 6938501, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kyoto University; Kobe University; University of Tokyo; Takeda Chemical Industries; Kanazawa University; University of Tokyo; Shimane University	Kawasaki, T (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Kyoto 6068501, Japan.	kawasaki@pharmsun.pharm.kyoto-u.ac.jp	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Miyamoto, Masaomi/0000-0003-4496-2685; Yamamoto, Shoji/0000-0002-8940-3257				CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Miura R, 2001, J NEUROCHEM, V76, P413, DOI 10.1046/j.1471-4159.2001.00042.x; MIYAMOTO M, 1986, PHYSIOL BEHAV, V38, P399, DOI 10.1016/0031-9384(86)90112-5; MOHAN PS, 1990, J NEUROCHEM, V54, P2024, DOI 10.1111/j.1471-4159.1990.tb04907.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nagase T, 2001, DEV GROWTH DIFFER, V43, P683; Nair SM, 1997, J NEUROCHEM, V68, P1286; Nakamura K, 2001, EUR J NEUROSCI, V13, P179, DOI 10.1046/j.0953-816X.2000.01366.x; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OKA S, 1992, J BIOL CHEM, V267, P22711; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Saghatelyan AK, 2001, MOL CELL NEUROSCI, V17, P226, DOI 10.1006/mcne.2000.0922; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; Yamamoto S, 2002, J BIOCHEM, V131, P337, DOI 10.1093/oxfordjournals.jbchem.a003108; YOSHIHARA Y, 1991, NEUROSCI RES, V10, P83, DOI 10.1016/0168-0102(91)90033-U	29	119	124	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27227	27231		10.1074/jbc.C200296200	http://dx.doi.org/10.1074/jbc.C200296200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12032138	hybrid			2022-12-25	WOS:000177055900068
J	Hewitson, KS; McNeill, LA; Riordan, MV; Tian, YM; Bullock, AN; Welford, RW; Elkins, JM; Oldham, NJ; Bhattacharya, S; Gleadle, JM; Ratcliffe, PJ; Pugh, CW; Schofield, CJ				Hewitson, KS; McNeill, LA; Riordan, MV; Tian, YM; Bullock, AN; Welford, RW; Elkins, JM; Oldham, NJ; Bhattacharya, S; Gleadle, JM; Ratcliffe, PJ; Pugh, CW; Schofield, CJ			Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; NUCLEAR-PROTEIN; FACTOR-I; DOMAINS; ALPHA; TRANSACTIVATION; JUMONJI; DESTRUCTION; COMPLEX; IRON	Activity of the hypoxia-inducible factor (HIF) complex is controlled by oxygen-dependent hydroxylation of prolyl and asparaginyl residues. Hydroxylation of specific prolyl residues by 2-oxoglutarate (2-OG)-dependent oxygenases mediates ubiquitinylation and proteasomal destruction of HIF-alpha. Hydroxylation of an asparagine residue in the C-terminal transactivation domain (CAD) of HIF-a abrogates interaction with p300, preventing transcriptional activation. Yeast two-hybrid assays recently identified factor inhibiting HIF (FIH) as a protein that associates with the CAD region of HIF-a. Since FIH contains certain motifs present in iron- and 2-OG-dependent oxygenases we investigated whether FIH was the HIF asparaginyl hydroxylase. Assays using recombinant FIH and HIF-a fragments revealed that FIH is the enzyme that hydroxylates the CAD asparagine residue, that the activity is directly inhibited by cobalt(II) and limited by hypoxia, and that the oxygen in the alcohol of the hydroxyasparagine residue is directly derived from dioxygen. Sequence analyses involving FIH link the 2-OG oxygenases with members of the cupin superfamily, including Zn(II)-utilizing phosphomannose isomerase, revealing structural and evolutionary links between these metal-binding proteins that share common motifs.	Oxford Ctr Mol Sci, Dyson Perrins Lab, Oxford OX1 3QY, England; Henry Wellcome Bldg Genom Med, Oxford OX3 7BN, England	University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Oxford Ctr Mol Sci, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	christopher.schofield@chem.ox.ac.uk	Gleadle, Jonathan M/K-4188-2012; Bhattacharya, Shoumo/F-4127-2010	Gleadle, Jonathan M/0000-0002-5215-7208; Bhattacharya, Shoumo/0000-0002-5571-0478; Elkins, Jon/0000-0003-2858-8929; Oldham, Neil/0000-0001-8024-4563; Schofield, Christopher/0000-0002-0290-6565; Ratcliffe, Peter/0000-0002-2853-806X				ARAVIND L, 2001, GENOME BIOL, V2, DOI DOI 10.1186/gb-2001-2-3-research0007; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chun YS, 2001, J CELL SCI, V114, P4051; Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dunwell JM, 2001, TRENDS BIOCHEM SCI, V26, P740, DOI 10.1016/S0968-0004(01)01981-8; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 2000, GENE DEV, V14, P1983; Toyoda M, 2000, BIOCHEM BIOPH RES CO, V274, P332, DOI 10.1006/bbrc.2000.3138; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WANG QP, 1991, J BIOL CHEM, V266, P14004; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wu M, 2000, BIOORG CHEM, V28, P261; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6	32	567	589	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26351	26355		10.1074/jbc.C200273200	http://dx.doi.org/10.1074/jbc.C200273200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12042299	hybrid			2022-12-25	WOS:000176908700070
J	Schulz, M; Eggert, M; Baniahmad, A; Dostert, A; Heinzel, T; Renkawitz, R				Schulz, M; Eggert, M; Baniahmad, A; Dostert, A; Heinzel, T; Renkawitz, R			RU486-induced glucocorticoid receptor agonism is controlled by the receptor N terminus and by corepressor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; THYROID-HORMONE; ACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVATION; PROGESTERONE-RECEPTOR; SIGNALING PATHWAYS; STEROID-RECEPTORS; GENE-EXPRESSION; CO-REPRESSOR; DNA-BINDING	Glucocorticoid-induced gene transcription has been shown to be mediated by coactivators bound to the glucocorticoid receptor (GR). The glucocorticoid antagonist RU486 interferes with the steroid-mediated activation and can also exhibit partial agonist activity, a response in which corepressors have been implicated. Here we have shown that deletion of the N terminus of GR totally abolishes the agonist activity of RU486. Furthermore, we have demonstrated that corepressors bind directly to the RU486-bound GR as determined by glutathione S-transferase pull-down, mammalian two-hybrid assay, and coimmunoprecipitation. Fine mapping of the interaction regions within GR and the corepressor NCoR reveals a complex interaction profile that involves a number of domains in each protein. Notably, the N and the C termini of GR are both involved in corepressor binding. Thus, the N terminus of GR is a major determinant for RU486-dependent NCoR interaction as well as for RU486-mediated agonist activity.	Univ Giessen, Genet Inst, D-35392 Giessen, Germany; Inst Biomed Res, D-60596 Frankfurt, Germany	Justus Liebig University Giessen	Renkawitz, R (corresponding author), Univ Giessen, Genet Inst, Heinrich Buff Ring 58-62, D-35392 Giessen, Germany.		Heinzel, Thorsten/B-1013-2015					Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BEATO M, 1987, J STEROID BIOCHEM, V27, P9, DOI 10.1016/0022-4731(87)90288-3; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Busch K, 2000, MOL ENDOCRINOL, V14, P201, DOI 10.1210/me.14.2.201; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; COLE TJ, 1995, STEROIDS, V60, P93, DOI 10.1016/0039-128X(94)00009-2; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Gast A, 1998, J STEROID BIOCHEM, V65, P117, DOI 10.1016/S0960-0760(97)00176-3; Giannoukos G, 2001, MOL ENDOCRINOL, V15, P255, DOI 10.1210/me.15.2.255; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Glass CK, 2000, GENE DEV, V14, P121; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Schulz M, 2001, BIOCHEM BIOPH RES CO, V280, P476, DOI 10.1006/bbrc.2000.4141; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	47	115	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26238	26243		10.1074/jbc.M203268200	http://dx.doi.org/10.1074/jbc.M203268200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011091	hybrid			2022-12-25	WOS:000176908700055
J	Meyer, TN; Schwesinger, C; Denker, BM				Meyer, TN; Schwesinger, C; Denker, BM			Zonula occludens-1 is a scaffolding protein for signaling molecules - G alpha(12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAC1 SMALL GTPASES; TIGHT JUNCTIONS; KINASE-C; CYTOPLASMIC DOMAIN; TYROSINE KINASE; BETA-CATENIN; ZO-1; EXPRESSION; INVOLVEMENT; BIOGENESIS	Zonula occludens proteins are multidomain proteins usually localized at sites of intercellular junctions, yet little is known about their role in regulating junctional properties. Multiple signaling proteins regulate the junctional complex, and several (including G proteins) have been co-localized with zonula occludens-1 (ZO-1) in the tight junction of epithelial cells. However, evidence for direct interactions between signaling proteins and tight junction proteins has been lacking. In these studies, we constructed Galpha-glutathione S-transferase (GST) fusion proteins and tested for interactions with [S-35]methionine-labeled in vitro translated ZO-1 and ZO-2. Only Galpha(12) directly interacted with in vitro translated ZO-1 and ZO-2. Using a series of ZO-1 domains expressed as GST fusion proteins and in vitro translated [S-35]methionine-labeled Galpha(12), we found that Galpha(12) and constitutively active (Q229L) alpha(12) (QLalpha(12)) bind to the Src homology 3 (SH3) domain of ZO-1. This binding was not detected with SH3 domains from other proteins. Inducible expression of wild-type alpha12 and QLalpha(12) in Madin-Darby canine kidney (MDCK) cells was established using the Tet-Off system. In Galpha(12)-expressing cells, we found that ZO-1 and Galpha(12) co-localize by confocal microscopy and co-immunoprecipitate. Galpha(12) from MDCK cell lysates bound to the GST-ZO-1-SH3 domain, and expression of QLalpha(12) in MDCK cells reversibly increased paracellular permeability. These studies indicated that ZO-1 directly interacts with Galpha(12) and that Galpha(12) regulates barrier function of MDCK cells.	Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Div Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Denker, BM (corresponding author), Brigham & Womens Hosp, Div Renal, Dept Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055223, R01GM055223] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balda MS, 2000, SEMIN CELL DEV BIOL, V11, P281, DOI 10.1006/scdb.2000.0177; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; Balda MS, 1996, FEBS LETT, V399, P326, DOI 10.1016/S0014-5793(96)01352-X; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; Ebnet K, 2000, J BIOL CHEM, V275, P27979; GONZALEZMARISCA.L, 1990, AM J PHYSIOL, V259, P978; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaplan DD, 2001, J BIOL CHEM, V276, P44037, DOI 10.1074/jbc.M106121200; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Meyer TN, 2001, J BIOL CHEM, V276, P22048, DOI 10.1074/jbc.M011477200; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Saha C, 2001, BIOCHEM BIOPH RES CO, V285, P250, DOI 10.1006/bbrc.2001.5154; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	33	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24855	24858		10.1074/jbc.C200240200	http://dx.doi.org/10.1074/jbc.C200240200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12023272	hybrid			2022-12-25	WOS:000176747000004
J	Kahana, O; Micksche, M; Witz, IP; Yron, I				Kahana, O; Micksche, M; Witz, IP; Yron, I			The focal adhesion kinase (P125(FAK)) is constitutively active in human malignant melanoma	ONCOGENE			English	Article						melanoma; anchorage independence; integrins; FAK; phosphorylation; cytoskeleton	DEPENDENT TYROSINE PHOSPHORYLATION; C-TERMINAL DOMAIN; PROTEIN-KINASE; CELL-LINES; SIGNAL-TRANSDUCTION; T-CELLS; EXPRESSION; GENE; SRC; OVEREXPRESSION	Malignant melanoma cells show high aggressiveness and metastatic potential. Tumor cells as they become more metastatic, gradually lose their dependence on both adhesion and serum. Thus, in the process of tumor progression cells undergo series of changes that allow them to adapt to different tissue milieu. This implies that during this process, points on the integrin pathway may become constitutively activated. In the present study we investigated the possible role of FAK, being one of the key members of the integrin-signaling pathway, in the multi-step progression towards a malignant phenotype in human melanoma. In our study we show that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation. Indeed, in all melanoma cells tested and not in nevus and neuroblastoma cells, we observed various degrees of constitutive activation of FAK. Our results also suggest that FAK constitutive activation is regulated at least in part by the cytoskeleton, implying that steps along the integrin signaling pathway involving FAK could be among the oncogenic mechanisms that operate in melanoma and may account for the highly aggressive, anchorage independent phenotype of this tumor.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Univ Vienna, Inst Canc Res, Dept Appl & Expt Oncol, Vienna, Austria	Tel Aviv University; Tel Aviv University; University of Vienna	Yron, I (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO;2-E; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Flinn HM, 1996, J CELL SCI, V109, P1133; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1983, J IMMUNOL, V131, P334; HYNES RO, 1992, CELL, V69, P1; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388	44	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					3969	3977		10.1038/sj.onc.1205472	http://dx.doi.org/10.1038/sj.onc.1205472			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037679				2022-12-25	WOS:000175869900003
J	Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS				Daosukho, C; Kiningham, K; Kasarskis, EJ; Ittarat, W; Clair, DKS			Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappa B dimerization	ONCOGENE			English	Article						NF-kappa B; tamoxifen; tumor control; MnSOD; tumor suppressor gene	MANGANESE SUPEROXIDE-DISMUTASE; BREAST-CANCER-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; SUBUNIT; OVEREXPRESSION; SUPPRESSION; ACTIVATION; INDUCTION; RECEPTOR	Manganese superoxide dismutase (MuSOD) has been shown to suppress the development of cancer. Tamoxifen (TAM), a nonsteroidal anti-estrogen that is widely used in chemotherapy, is known to be a modulator of antioxidant status. However, the mechanism by which TAM mediates antioxidant enzyme induction remains unclear. In this study we investigated TAM enhancement of MnSOD induction by TNF-alpha. The results show that co-treatment with TAM and TNF-alpha increases the MnSOD promoter/enhancer driven luciferase activity, MnSOD mRNA and protein levels. Interestingly, co-treatment with TAM and TNF-a drastically decreases the binding activity of the p50/p50 homodimer and increases that of the p50/p65 heterodimer compared to TNF-alpha alone. This change in DNA binding could not be attributed to a decrease in the level of p50, its precursor, p105, or its inhibitors. Furthermore, TAM did not enhance degradation of IkappaB-alpha. These results suggest that p50/p50 homodimer may act as an inhibitory complex of MnSOD expression. Modulation of the DNA binding activity in favor of the p50/p65 complex may enhance NF-kappaB mediated induction of MnSOD by TAM. These findings reveal a potential novel mechanism for the induction of the human MnSOD gene.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand	University of Kentucky; Mahidol University	Clair, DKS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 361 Hlth Sci Res Bldg, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL-03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059835, R29CA049797, R01CA049797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GOLDENBERG GJ, 1982, CANCER RES, V42, P5147; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; LI JJ, 1995, ONCOGENE, V10, P1989; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NEGRINI M, 1994, CANCER RES, V54, P1331; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; TAYLOR CM, 1984, CANCER RES, V44, P1409; THANGARAJU M, 1994, CANCER, V74, P78, DOI 10.1002/1097-0142(19940701)74:1<78::AID-CNCR2820740114>3.0.CO;2-L; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082	40	30	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3603	3610		10.1038/sj.onc.1205448	http://dx.doi.org/10.1038/sj.onc.1205448			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032862				2022-12-25	WOS:000175793700011
J	Zhu, XL; Wheeler, MT; Hadhazy, M; Lam, MYJ; McNally, EM				Zhu, XL; Wheeler, MT; Hadhazy, M; Lam, MYJ; McNally, EM			Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy	FASEB JOURNAL			English	Article						gene therapy; dystrophin; sarcoglycan	MDX MOUSE; GLYCOPROTEIN COMPLEX; GAMMA-SARCOGLYCAN; ANIMAL-MODELS; DILATED CARDIOMYOPATHY; DELTA-SARCOGLYCAN; MOLECULAR-BASIS; SMOOTH-MUSCLE; GENE; DUCHENNE	Dystrophin and its associated proteins, the sarcoglycans, are normally expressed in heart and skeletal muscle. Mutations that alter the expression of these membrane-associated proteins lead to muscular dystrophy (MD) and cardiomyopathy in humans. Because of the timing and nature of the accompanying cardiomyopathy, it has been suggested that cardiomyopathy develops as a secondary consequence of skeletal muscle dysfunction in the muscular dystrophies. To determine whether skeletal muscle dystrophy contributes to the development of sarcoglycan-mediated cardiomyopathy, we used mice lacking gamma-sarcoglycan and inserted a transgene that "rescued" sarcoglycan expression only in skeletal muscle. gamma-Sarcoglycan was expressed in skeletal muscle under the control of the skeletal muscle-specific myosin light chain 1/3 promoter. gamma-Sarcoglycan-null mice expressing this transgene fully restore gamma-sarcoglycan expression. Furthermore, the transgene-rescued mice lack the focal necrosis and membrane permeability defects that are a hallmark of MD. Despite correction of the skeletal muscle disease, focal degeneration and membrane permeability abnormalities persisted in cardiac muscle, and notably persisted in the right ventricle. Therefore, heart and skeletal muscle defects are independent processes in sarcoglycan-mediated muscular dystrophies and, as such, therapy should target both skeletal and cardiac muscle correction to prevent sudden death due to cardiomyopathy in the muscular dystrophies.	Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, 5841 S Maryland,MC 6088, Chicago, IL 60637 USA.	emcnally@medicine.bsd.uchicago.edu		Wheeler, Matthew/0000-0001-8721-3022; McNally, Elizabeth/0000-0002-1221-719X				Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; ANDERSON JE, 1987, ANAT REC, V219, P243, DOI 10.1002/ar.1092190305; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; Bonnemann Carsten G., 1996, Current Opinion in Pediatrics, V8, P569; Bonnemann CG, 1996, HUM MOL GENET, V5, P1953, DOI 10.1093/hmg/5.12.1953; Calvo F, 2000, NEUROMUSCULAR DISORD, V10, P560, DOI 10.1016/S0960-8966(00)00147-4; CONWAY RS, 1987, CARDIOVASC RES, V21, P796, DOI 10.1093/cvr/21.11.796; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; Cox GF, 1997, CURR OPIN CARDIOL, V12, P329; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Fadic R, 1996, NEW ENGL J MED, V334, P362, DOI 10.1056/NEJM199602083340604; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Hack AA, 2000, MICROSC RES TECHNIQ, V48, P167, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<167::AID-JEMT5>3.0.CO;2-T; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; Heydemann A, 2001, CURR OPIN CARDIOL, V16, P211, DOI 10.1097/00001573-200105000-00009; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOGAN B, 1994, MANIPULATING MOUSE E, P115; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; McNally EM, 1996, HUM MOL GENET, V5, P1841, DOI 10.1093/hmg/5.11.1841; McNally EM, 1996, NEW ENGL J MED, V334, P1610; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; Muntoni F, 1997, HEART, V78, P608, DOI 10.1136/hrt.78.6.608; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PERLOFF JK, 1967, AM J MED, V42, P179, DOI 10.1016/0002-9343(67)90017-4; PERLOFF JK, 1984, J AM COLL CARDIOL, V3, P1263, DOI 10.1016/S0735-1097(84)80186-2; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; Politano L, 1996, JAMA-J AM MED ASSOC, V275, P1335, DOI 10.1001/jama.275.17.1335; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Stedman Hansell, 2000, Human Gene Therapy, V11, P777; Straub V, 1999, J BIOL CHEM, V274, P27989, DOI 10.1074/jbc.274.39.27989; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; YAMAMOTO H, 1994, J BIOCHEM-TOKYO, V115, P162, DOI 10.1093/oxfordjournals.jbchem.a124294; Zatz M, 2000, CURR OPIN NEUROL, V13, P511, DOI 10.1097/00019052-200010000-00002; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	48	16	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2002	16	7					1096	+		10.1096/fj.01-0954fje	http://dx.doi.org/10.1096/fj.01-0954fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039854				2022-12-25	WOS:000175973900014
J	Maytum, R; Geeves, MA; Lehrer, SS				Maytum, R; Geeves, MA; Lehrer, SS			A modulatory role for the troponin T tail domain in thin filament regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN SUBFRAGMENT 1; TROPOMYOSIN-BINDING; ACTIN-TROPOMYOSIN; F-ACTIN; COOPERATIVE BINDING; CARDIAC TROPONIN; ATPASE ACTIVITY; MUSCLE; ACTIVATION; IDENTIFICATION	In striated muscle the force generating acto-myosin interaction is sterically regulated by the thin filament proteins tropomyosin and troponin (Tn), with the position of tropomyosin modulated by calcium binding to troponin. Troponin itself consists of three subunits, TnI, TnC, and TnT, widely characterized as being responsible for separate aspects of the regulatory process. TnI, the inhibitory unit is released from actin upon calcium binding to TnC, while TnT performs a structural role forming a globular head region with the regulatory TnI-TnC complex with a tail anchoring it within the thin filament. We have examined the properties of TnT and the TnT(1) tail fragment (residues 1-158) upon reconstituted actin-tropomyosin filaments. Their regulatory effects have been characterized in both myosin S1 ATPase and S1 kinetic and equilibrium binding experiments. We show that both inhibit the actin-tropomyosin-activated S1 ATPase with TnT1 producing a greater inhibitory effect. The S1 binding data show that this inhibition is not caused by the formation of the blocked B-state but by significant stabilization of the closed C-state with a 10-fold reduction in the C- to M-state equilibrium, K-T, for TnT(1). This suggests TnT has a modulatory as well as structural role, providing an explanation for its large number of alternative isoforms.	Univ Kent, Dept Biosci, Canterbury, Kent, England; Boston Biomed Res Inst, Muscle Res Grp, Watertown, MA 02472 USA	University of Kent; Boston Biomedical Research Institute	Maytum, R (corresponding author), Univ Kent, Dept Biosci, Canterbury, Kent, England.	r.m.maytum@ukc.ac.uk	Geeves, Michael/F-7583-2011; Lehrer, Sherwin/ABF-7282-2021	Geeves, Michael/0000-0002-9364-8898; Maytum, Robin/0000-0003-0395-403X				BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Cassell M, 1996, J BIOL CHEM, V271, P12867, DOI 10.1074/jbc.271.22.12867; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1975, BIOCHEMISTRY-US, V14, P2718, DOI 10.1021/bi00683a025; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; Geeves MA, 2000, BIOCHEMISTRY-US, V39, P9345, DOI 10.1021/bi0002232; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GREASER ML, 1973, J BIOL CHEM, V248, P2125; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HILL LE, 1992, J BIOL CHEM, V267, P16106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Maytum R, 2000, BIOCHEMISTRY-US, V39, P11913, DOI 10.1021/bi000977g; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2000, BIOPHYS J, V78, p365A; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NAKAMURA S, 1981, J BIOCHEM-TOKYO, V89, P1639, DOI 10.1093/oxfordjournals.jbchem.a133359; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; ONOYAMA Y, 1986, J BIOCHEM-TOKYO, V100, P517, DOI 10.1093/oxfordjournals.jbchem.a121742; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WILLIAMS DL, 1988, BIOCHEMISTRY-US, V27, P6987, DOI 10.1021/bi00418a048; Zhou X, 2000, BIOCHEMISTRY-US, V39, P1128, DOI 10.1021/bi992327m; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	51	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29774	29780		10.1074/jbc.M201761200	http://dx.doi.org/10.1074/jbc.M201761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12045197	hybrid			2022-12-25	WOS:000177509300055
J	Johnson, SE; Dorman, CM; Bolanowski, SA				Johnson, SE; Dorman, CM; Bolanowski, SA			Inhibition of myogenin expression by activated Raf is not responsible for the block to avian myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL MYOBLAST DIFFERENTIATION; PROTEIN-KINASE; MUSCLE DIFFERENTIATION; MECHANISM; GENE; REVEALS; CELLS; FIBROBLAST-GROWTH-FACTOR-2; TRANSFORMATION; PD-098059	Activated Raf is a potent inhibitor of skeletal muscle gene transcription and myocyte formation through stimulation of downstream MAPK. However, the molecular targets of elevated MAPK with regard to myogenic repression remain elusive. We examined the effects of activated Raf on myogenin gene expression in avian myoblasts. Overexpression of activated Raf in embryonic chick myoblasts prevented myogenin gene transcription and myocyte differentiation. Treatment with PD98059, an inhibitor of MAPK kinase (MEK), restored myogenin expression but did not reinstate the myogenic program. Using a panel of myogenin promoter deletion mutants, we were unable to identify a region within the proximal 829-bp promoter that confers responsiveness to MEK. Interestingly, our experiments identified MEF2A as a target of Raf-mediated inhibition in mouse myoblasts but not in avian myogenic cells. Embryonic myoblasts overexpressing activated Raf were unable to drive transcription from a minimal myogenin promoter reporter, containing a single E-box and MEF2 site, to levels comparable with controls. Unlike mouse myoblasts, forced expression of MEF2A did not synergistically enhance transcription from the myogenin promoter in chick myoblasts, indicating that additional molecular determinants of the block to myogenesis exist. Results of these experiments further exemplify specie differences in the mode of Raf-mediated inhibition of muscle differentiation.	Penn State Univ, Dept Poultry Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Johnson, SE (corresponding author), Penn State Univ, Dept Poultry Sci, 206 Henning, University Pk, PA 16802 USA.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dorman CM, 2000, J BIOL CHEM, V275, P27481; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fedorov YV, 2001, J CELL BIOL, V152, P1301, DOI 10.1083/jcb.152.6.1301; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; Vivian JL, 1999, DEV BIOL, V208, P44, DOI 10.1006/dbio.1998.9182; Wang XN, 2001, EXP CELL RES, V268, P294, DOI 10.1006/excr.2001.5292; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V15, P2521, DOI 10.1038/sj.onc.1201423; Winter B, 2000, J CELL SCI, V113, P4211	33	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28742	28748		10.1074/jbc.M203680200	http://dx.doi.org/10.1074/jbc.M203680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042315	hybrid			2022-12-25	WOS:000177342600052
J	Li, W; Liang, XP; Kellendonk, C; Poli, V; Taub, R				Li, W; Liang, XP; Kellendonk, C; Poli, V; Taub, R			STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; PARTIAL-HEPATECTOMY; SIGNAL TRANSDUCERS; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; BINDING PROTEIN; GROWTH-FACTOR; DNA-BINDING; CELL-LINES	STAT3 is rapidly induced during liver regeneration in an interleukin 6 (IL-6)-dependent fashion, and IL-6 is required for normal liver regeneration. We wanted to know whether STAT3 was also required for liver regeneration but disruption of the STAT3 gene during embryonic stages causes lethality. Therefore, an albumin promoter-driven Cre-loxP recombination system was used to create a STAT3 deletion in the adult mouse liver to study the role of STAT3 in liver regeneration. After partial hepatectomy, there was virtually no STAT3 RNA or protein induction in Alb(+) STAT3(fl/fl) livers. STAT3 DNA binding activity was also absent in Alb(+) STAT3(fl/fl) livers. Unlike in control livers, STAT1 was activated in STAT3 conditional-mutant livers posthepatectomy. Hepatocyte DNA synthesis at 40 h posthepatectomy in Alb+ STAT3(fl/fl) livers was reduced to approximately one-third of the control. Alb(+) STAT3(fl/fl) livers had abnormalities in immediate-early gene activation that largely correlated with but were not identical to those seen in IL-6-/-livers. G(1) phase cyclins including cyclins D1 and E had lower expression levels in Alb(+) STAT3(fl/fl) livers, indicating an abnormal G, to S phase transition. Therefore, STAT3 accounts for part of the DNA synthetic response of the hepatocytes during liver regeneration, which cannot be compensated for by induction of STAT1. Normal activation of the MAPK pathway in Alb(+) STAT3(fl/fl) livers reinforces the fact that at least part of the effect of IL-6 on hepatocyte proliferation is not mediated by STAT3. This study provides the first in vivo evidence that STAT3 promotes cell cycle progression and cell proliferation under physiological growth conditions.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Dipartimento Genet Biol & Biochem, I-10126 Turin, Italy	University of Pennsylvania; Columbia University; University of Dundee	Taub, R (corresponding author), Bristol Myers Squibb Co, Rt 141 Clay Rd,Expt Stn 400,Rm 2418, Wilmington, DE 19880 USA.		Poli, Valeria/A-9215-2012; Kellendonk, Christoph/O-7229-2018	Poli, Valeria/0000-0002-3739-3966; Kellendonk, Christoph/0000-0003-3302-2188	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058315, P30DK050306] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 58315, P30 DK50306] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; COFFER P, 1995, ONCOGENE, V10, P985; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Higgins GM, 1931, ARCH PATHOL, V12, P186; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kellendonk C, 2000, GENESIS, V26, P151, DOI 10.1002/(SICI)1526-968X(200002)26:2<151::AID-GENE17>3.0.CO;2-E; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mikita T, 1998, J IMMUNOL, V161, P1822; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Roselli HT, 1998, AM J PHYSIOL-GASTR L, V275, pG1472, DOI 10.1152/ajpgi.1998.275.6.G1472; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	47	254	271	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28411	28417		10.1074/jbc.M202807200	http://dx.doi.org/10.1074/jbc.M202807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032149	hybrid			2022-12-25	WOS:000177342600010
J	Schmidt, AE; Padmanabhan, K; Underwood, MC; Bode, W; Mather, T; Bajaj, SP				Schmidt, AE; Padmanabhan, K; Underwood, MC; Bode, W; Mather, T; Bajaj, SP			Thermodynamic linkage between the S1 site, the Na+ site, and the Ca2+ site in the protease domain of human activated protein C (APC) - Sodium ion in the APC crystal structure is coordinated to four carbonyl groups from two separate loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; THROMBIN-CATALYZED ACTIVATION; ENDOTHELIAL-CELL COFACTOR; MONO-VALENT CATIONS; HUMAN FACTOR-IX; CALCIUM-BINDING; FACTOR-X; SERINE PROTEASES; AMIDASE ACTIVITY; BOVINE PLASMA	The serine protease domain of activated protein C (APC) contains a Na+ and a Ca2+ site. However, the number and identity of the APC residues that coordinate to Na+ is not precisely known. Further, the functional link between the Na+ and the Ca2+ site is insufficiently defined, and their linkage to the substrate S1 site has not been studied. Here, we systematically investigate the functional significance of these two cation sites and their thermodynamic links to the S1 site. Kinetic data reveal that Na+ binds to the substrate-occupied APC with K-d values of similar to24 mM in the absence and similar to6 mM in the presence of Ca2+. Sodium-occupied APC has similar to100-fold increased catalytic efficiency (similar to4-fold decrease in K-m and similar to25-fold increase in k(cat)) in hydrolyzing S-2288 (H-D-Ile-Pro-Arg-p-nitroanilide) and Ca2+ further increases this k(cat) slightly (similar to1.2-fold). Ca2+ binds to the protease domain of APC with K-d values of similar to438 muM in the absence and similar to105 muM in the presence of Na+. Ca2+ binding to the protease domain of APC does not affect K-m but increases the k(cat) similar to10-fold, and Na+ further increases this k(cat) similar to3-fold and decreases the K-m value similar to3.7-fold. In agreement with the K-m data, sodium-occupied APC has similar to4-fold increased affinity in binding to p-aminobenzamidine (S1 probe). Crystallographically, the Ca2+ site in APC is similar to that in trypsin, and the Na+ site is similar to that in factor Xa but not thrombin. Collectively, the Na+ site is thermodynamically linked to the S1 site as well as to the protease domain Ca2+ site, whereas the Ca2+ site is only linked to the Na+ site. The significance of these findings is that under physiologic conditions, most of the APC will exist in Na2+-APC-Ca2+ form, which has 110-fold increased proteolytic activity.	St Louis Univ, Hlth Sci Ctr, Div Hematol & Oncol, Dept Pharmacol & Physiol Sci, St Louis, MO 63110 USA; St Louis Univ, Hlth Sci Ctr, Dept Internal Med, St Louis, MO 63110 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Oklahoma Med Res Fdn, Dept Cardiovasc Biol Res, Oklahoma City, OK 73104 USA	Saint Louis University; Saint Louis University; Michigan State University; Max Planck Society; Oklahoma Medical Research Foundation	Bajaj, SP (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Hematol & Oncol, Dept Pharmacol & Physiol Sci, 3635 Vista Ave,POB 15250, St Louis, MO 63110 USA.	Bajajps@slu.edu			NHLBI NIH HHS [HL70369, HL36365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL036365, R56HL036365, R01HL036365, R01HL070369] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1983, PREP BIOCHEM, V13, P191, DOI 10.1080/00327488308064248; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRUENGER AT, 1992, XPLOR VERSION 3 1; CASTELLINO FJ, 1995, TRENDS CARDIOVAS MED, V5, P55, DOI 10.1016/1050-1738(94)00031-X; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V14, P89, DOI 10.1016/0165-6147(93)90070-Z; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 2001, HEMOSTASIS THROMBOSI, P335; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FERSHT A, 1998, STRUCTURE MECH PROTE, P125; FOSTER D, 1984, P NATL ACAD SCI-BIOL, V81, P4766, DOI 10.1073/pnas.81.15.4766; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; HILL KAW, 1986, J BIOL CHEM, V261, P4991; HILL KAW, 1987, J BIOL CHEM, V262, P140; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG GL, 1984, P NATL ACAD SCI-BIOL, V81, P5653, DOI 10.1073/pnas.81.18.5653; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRICE PA, 1981, J BIOL CHEM, V256, P1172; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; STEINER SA, 1985, BIOCHEMISTRY-US, V24, P1136, DOI 10.1021/bi00326a011; STEINER SA, 1982, BIOCHEMISTRY-US, V21, P4609, DOI 10.1021/bi00262a015; STEINER SA, 1985, BIOCHEMISTRY-US, V24, P609, DOI 10.1021/bi00324a011; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1976, J BIOL CHEM, V251, P355; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	47	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28987	28995		10.1074/jbc.M201892200	http://dx.doi.org/10.1074/jbc.M201892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029084	hybrid			2022-12-25	WOS:000177342600084
J	Beaulieu, N; Morin, S; Chute, IC; Robert, MF; Nguyen, H; MacLeod, AR				Beaulieu, N; Morin, S; Chute, IC; Robert, MF; Nguyen, H; MacLeod, AR			An essential role for DNA methyltransferase DNMT3B in cancer cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; EPIGENETIC INACTIVATION; GENE; METHYLATION; HYPERMETHYLATION; ASSOCIATION; FAMILY; LUNG; P53; P21(WAF1/CIP1)	Abnormal methylation and associated silencing of tumor suppressor genes is a common feature of many types of cancers. The observation of persistent methylation in human cancer cells lacking the maintenance methyltransferase DNMT1 suggests the involvement of other DNA methyltransferases in gene silencing in cancer. To test this hypothesis, we have evaluated methylation and gene expression in cancer cells specifically depleted of DNMT3A or DNMT3B, de novo methyltransferases that are expressed in adult tissues. Here we have shown that depletion of DNMT3B, but not DNMT3A, induced apoptosis of human cancer cells but not normal cells. DNMT3B depletion reactivated methylation-silenced gene expression but did not induce global or juxtacentromeric satellite demethylation as did specific depletion of DNMT1. Furthermore, the effect of DNMT3B depletion was rescued by exogenous expression of either of the splice variants DNMT3B2 or DNMT3B3 but not DNMT1. These results indicate that DNMT3B has significant site selectivity that is distinct from DNMT1, regulates aberrant gene silencing, and is essential for cancer cell survival.	MethylGene Inc, Dept Mol Biol, Montreal, PQ, Canada	MethylGene Inc	MacLeod, AR (corresponding author), MethylGene Inc, Dept Mol Biol, Montreal, PQ, Canada.	macleodr@methylgene.com						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 2001, CANCER RES, V61, P3225; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Kawasaki T, 1996, INT J CANCER, V68, P501, DOI 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; KUKS F, 2001, EMBO J, V20, P2536; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; SZYF M, 1991, J BIOL CHEM, V266, P10027; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yeivin A, 1993, EXS, V64, P523; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	33	131	144	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28176	28181		10.1074/jbc.M204734200	http://dx.doi.org/10.1074/jbc.M204734200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015329	hybrid			2022-12-25	WOS:000177189800075
J	Li, DP; Zhu, HF; Liu, KF; Liu, X; Leggewie, G; Udvardi, M; Wang, DW				Li, DP; Zhu, HF; Liu, KF; Liu, X; Leggewie, G; Udvardi, M; Wang, DW			Purple acid Phosphatases of Arabidopsis thaliana - Comparative analysis and differential regulation by phosphate deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SPLICE VARIANT; STARVATION-INDUCED RIBONUCLEASE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; ALPHA-SUBUNIT; LUPINUS-ALBUS; SEQUENCE; IDENTIFICATION	Purple acid phosphatases (PAPs) are members of the metallo-phosphoesterase family. They are characterized by the presence of seven conserved amino acid residues involved in coordinating the dimetal nuclear center in their reactive site. We compared the 29 PAPs predicted for Arabidopsis thaliana in their varieties of potential metal-ligating residues. Although 24 members possessed sets of metal-ligating residues typical of known PAPs, 1 member lacked four of the seven residues. For the remaining four members, potential metal-ligating residues were generally more similar to those in metal-dependent exonucleases and related proteins. Evidence was obtained for the expression of the majority of the 29 PAPs. To facilitate future investigations, a scheme for naming Arabidopsis PAPs and a system for classifying the 29 PAPs are proposed. The cDNA sequences and the responses to phosphate deprivation of seven Arabidopsis PAPs (AtPAP7-AtPAP13) were characterized. For some AtPAPs analyzed, there were fully processed transcripts as well as splice variants. The splice variants of AtPAP10 were found to associate with polyribosomes and may be translated into a NH2-terminal truncated protein. Phylogenetic investigations showed that AtPAPs 7 and 8, together with similar enzymes from other plant species, formed the low molecular weight plant PAP group. Members of this group were more closely related to PAPs from mammalian cells. AtPAPs 9-13, together with kidney bean PAP, formed the high molecular weight PAP group. In phosphate deprivation experiments, gene transcription of AtPAP11 and AtPAP12 was induced and increased, respectively, whereas that of the remaining five AtPAPs was not affected by phosphate deprivation. The present work demonstrates that structure variation and expression regulation of plant PAPs are more complex than previously described and provides a framework for comprehensive molecular genetic and biochemical studies of all Arabidopsis PAPs in the future.	Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China; Max Planck Inst Mol Plant Physiol, D-14424 Potsdam, Germany	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Max Planck Society	Wang, DW (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China.	dwwang@genetics.ac.cn	Udvardi, Michael/GPX-4653-2022	Udvardi, Michael/0000-0001-9850-0828; wang, dao wen/0000-0002-6230-8735				Abel S, 2000, PLANT PHYSIOL, V122, P543, DOI 10.1104/pp.122.2.543; Baldwin JC, 2001, PLANT PHYSIOL, V125, P728, DOI 10.1104/pp.125.2.728; BARNBERGER C, 2001, FEBS LETT, V501, P121; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; Burleigh SM, 1998, GENE, V216, P47, DOI 10.1016/S0378-1119(98)00326-6; Chraibi A, 2001, CELL PHYSIOL BIOCHEM, V11, P115, DOI 10.1159/000047799; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; del Pozo JC, 1999, PLANT J, V19, P579, DOI 10.1046/j.1365-313X.1999.00562.x; DUFF SMG, 1991, P NATL ACAD SCI USA, V88, P9538, DOI 10.1073/pnas.88.21.9538; Durmus A, 1999, BBA-PROTEIN STRUCT M, V1434, P202, DOI 10.1016/S0167-4838(99)00176-4; Durmus A, 1999, EUR J BIOCHEM, V260, P709, DOI 10.1046/j.1432-1327.1999.00230.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969-2126(99)80100-2; Haran S, 2000, PLANT PHYSIOL, V124, P615, DOI 10.1104/pp.124.2.615; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hegeman CE, 2001, PLANT PHYSIOL, V126, P1598, DOI 10.1104/pp.126.4.1598; Hu YX, 2000, PLANT J, V24, P693, DOI 10.1046/j.1365-313x.2000.00915.x; Huang HB, 1997, P NATL ACAD SCI USA, V94, P3530, DOI 10.1073/pnas.94.8.3530; Imamura R, 1996, J BIOL CHEM, V271, P25423, DOI 10.1074/jbc.271.41.25423; Johnson JF, 1996, PLANT PHYSIOL, V112, P31, DOI 10.1104/pp.112.1.31; JOST W, 1991, EUR J BIOCHEM, V198, P1, DOI 10.1111/j.1432-1033.1991.tb15978.x; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLABUNDE T, 1995, FEBS LETT, V367, P56, DOI 10.1016/0014-5793(95)00536-I; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Klabunde T, 1997, STRUCT BOND, V89, P177; KOCK M, 1995, PLANT MOL BIOL, V27, P477, DOI 10.1007/BF00019315; Kone BC, 1998, J BIOL CHEM, V273, P2543, DOI 10.1074/jbc.273.5.2543; KOONIN EV, 1994, PROTEIN SCI, V3, P356; Lindqvist Y, 1999, J MOL BIOL, V291, P135, DOI 10.1006/jmbi.1999.2962; LOFFLER A, 1993, EUR J BIOCHEM, V214, P627, DOI 10.1111/j.1432-1033.1993.tb17962.x; LOHSE DL, 1995, STRUCTURE, V3, P987, DOI 10.1016/S0969-2126(01)00234-9; MALBOOBI MA, 1995, PLANT MOL BIOL, V28, P859, DOI 10.1007/BF00042071; Mertz P, 1997, J BIOL CHEM, V272, P21296, DOI 10.1074/jbc.272.34.21296; Miller SS, 2001, PLANT PHYSIOL, V127, P594, DOI 10.1104/pp.010097; Mou ZL, 2000, PLANT CELL, V12, P405, DOI 10.1105/tpc.12.3.405; Nakajima T, 1996, LIFE SCI, V58, P761, DOI 10.1016/0024-3205(95)02354-2; Nakazato H, 1998, PLANT PHYSIOL, V118, P1015, DOI 10.1104/pp.118.3.1015; Nei N., 2000, MOL EVOLUTION PHYLOG; NUTTLEMAN PR, 1990, J BIOL CHEM, V265, P12192; Palma DA, 2000, FEBS LETT, V486, P155, DOI 10.1016/S0014-5793(00)02266-3; Petracek ME, 1997, PLANT CELL, V9, P2291, DOI 10.1105/tpc.9.12.2291; Rubio V, 2001, GENE DEV, V15, P2122, DOI 10.1101/gad.204401; Schenk G, 2000, GENE, V255, P419, DOI 10.1016/S0378-1119(00)00305-X; Schenk G, 2000, GENE, V250, P117, DOI 10.1016/S0378-1119(00)00186-4; Schenk G, 1999, ACTA CRYSTALLOGR D, V55, P2051, DOI 10.1107/S0907444999012597; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; SIBILLE JC, 1987, J BIOL CHEM, V262, P59; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; TAKAHASHI T, 1992, J BIOL CHEM, V267, P12552; THEODOROU ME, 1992, J BIOL CHEM, V267, P21901; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trull MC, 1998, PLANTA, V206, P544, DOI 10.1007/s004250050431; Tsyguelnaia I, 1998, J MOL EVOL, V46, P612, DOI 10.1007/PL00013148; Uppenberg J, 1999, J MOL BIOL, V290, P201, DOI 10.1006/jmbi.1999.2896; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; Wasaki J, 1999, SOIL SCI PLANT NUTR, V45, P439, DOI 10.1080/00380768.1999.10409358; Zakhleniuk OV, 2001, PLANTA, V212, P529, DOI 10.1007/s004250000450; Zhang J, 1996, BIOCHEMISTRY-US, V35, P6276, DOI 10.1021/bi952954l; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	62	194	257	1	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27772	27781		10.1074/jbc.M204183200	http://dx.doi.org/10.1074/jbc.M204183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021284	hybrid			2022-12-25	WOS:000177189800026
J	Schroder, JM; Hasler, R; Grabowsky, J; Kahlke, B; Mallet, AI				Schroder, JM; Hasler, R; Grabowsky, J; Kahlke, B; Mallet, AI			Identification of diacylated ureas as a novel family of fungus-specific leukocyte-activating pathogen-associated molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC FACTORS; CANDIDA-ALBICANS; HUMAN-MONOCYTES; CHEMOATTRACTANTS; PEPTIDES; PROTEINS; RECOGNITION; DIACYLUREAS; NEUTROPHILS; COMPLEMENT	Polymorphonuclear leukocytes represent primary components of the host's innate immune defenses against fungal infection, suggesting involvement of fungal leukocyte attractants. We have found in various fungi, but not in bacteria or host cells, unstable lipid-like leukocyte chemoattractants, which also induced adherence and degranulation in human neutrophils. Purification from bakers' yeast and structural analyses by electrospray mass spectrometry, H-1 NMR spectroscopy, and chemical synthesis revealed these inflammatory mediators as diacylated ureas, a novel class of unstable lipoids. The N,N'-dipalmitoleyl urea appeared to be the most potent innate immune responses inducing compound eliciting half-maximum neutrophil chemotactic activity at 140 nM. The all-trans isomer, N,N'-dipalmitelaidyl urea, was found to be inactive with respect to stimulation of degranulation in neutrophils, which indicates a Delta(9) cis-double bond to be essential for bioactivity of these diacyl ureas. N,N'-Dipalmitoleyl urea elicited Ca2+ mobilization in neutrophils, which was found to be pertussis toxin-sensitive and sensitive toward a carboxylmethyltransferase inhibitor, indicating that these diacyl ureas activate leukocytes via a putative Galpha(i)-protein-coupled receptor. Their isolation exclusively from fungi suggests that these lipoids are fungus-specific pathogen-associated molecules that may alert the human innate immunity system to the presence of a fungal infection.	Univ Hosp Kiel, Dept Dermatol, Clin Res Unit Cutaneous Inflammat, D-24105 Kiel, Germany; Univ Greenwich, Sch Chem & Life Sci, London SE18 6PF, England	University of Kiel; Schleswig Holstein University Hospital; University of Greenwich	Schroder, JM (corresponding author), Univ Hosp Kiel, Dept Dermatol, Clin Res Unit Cutaneous Inflammat, Schittenhelmstr 7, D-24105 Kiel, Germany.	jschroeder@dermatology.uni-kiel.de	Schroeder, Jens M/B-3994-2009; Häsler, Robert/A-4908-2009	Häsler, Robert/0000-0003-4174-8229				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BRASCH J, 1992, ACTA DERM-VENEREOL, V72, P1; BRASCH J, 1991, MYCOSES, V34, P35, DOI 10.1111/j.1439-0507.1991.tb00616.x; Bulow M, 1996, MYCOSES, V39, P87, DOI 10.1111/j.1439-0507.1996.tb00511.x; Carlos Timothy M., 1994, Blood, V84, P2068; CARP H, 1982, J EXP MED, V155, P264, DOI 10.1084/jem.155.1.264; Clemons K V, 2001, Semin Respir Infect, V16, P60; Cole GT, 1996, CLIN INFECT DIS, V22, pS73, DOI 10.1093/clinids/22.Supplement_2.S73; CUTLER JE, 1977, INFECT IMMUN, V18, P568, DOI 10.1128/IAI.18.3.568-573.1977; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAHL MV, 1985, ARCH DERMATOL, V121, P70, DOI 10.1001/archderm.121.1.70; DAVIES RR, 1985, SABOURAUDIA, V23, P119; Edens HA, 1999, INFECT IMMUN, V67, P1063, DOI 10.1128/IAI.67.3.1063-1071.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haribabu B, 2000, IMMUNOL RES, V22, P271, DOI 10.1385/IR:22:2-3:271; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hazes B, 1996, J MOL BIOL, V258, P661, DOI 10.1006/jmbi.1996.0277; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holland SM, 1998, ANNU REV MED, V49, P185; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kahlke B, 1996, J INVEST DERMATOL, V107, P108, DOI 10.1111/1523-1747.ep12298332; Kennedy J, 2000, J LEUKOCYTE BIOL, V67, P725, DOI 10.1002/jlb.67.5.725; KURZER F, 1967, CHEM REV, V67, P107, DOI 10.1021/cr60246a001; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; LEWIS RA, 1981, J EXP MED, V154, P1243, DOI 10.1084/jem.154.4.1243; LONGLEY BJ, 1997, LEVERS HISTOPATHOLOG, P143; LOOS M, 1985, CURR TOP MICROBIOL, V121, P1; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Pappas, 1999, Curr Infect Dis Rep, V1, P245, DOI 10.1007/s11908-999-0026-2; PETERSEN U, 1983, METHODEN ORGANISCH E, V4, P392; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; ROMANI L, 1995, CURR OPIN IMMUNOL, V7, P517, DOI 10.1016/0952-7915(95)80097-2; SANNOMIYA P, 1990, P NATL ACAD SCI USA, V87, P66, DOI 10.1073/pnas.87.1.66; SCHIFFMANN E, 1975, J IMMUNOL, V114, P1831; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; Schroder JM, 1997, METHOD ENZYMOL, V288, P266; Schroder JM, 2000, CLIN DERMATOL, V18, P245, DOI 10.1016/S0738-081X(99)00117-0; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; Stoughton RW, 1939, J AM CHEM SOC, V61, P408, DOI 10.1021/ja01871a051; Stoughton RW, 1938, J ORG CHEM, V2, P514, DOI 10.1021/jo01229a004; TAGAMI H, 1982, ARCH DERMATOL RES, V272, P201, DOI 10.1007/BF00509048; Torosantucci A, 2000, J LEUKOCYTE BIOL, V68, P923; VOLPI M, 1985, P NATL ACAD SCI USA, V82, P2708, DOI 10.1073/pnas.82.9.2708; WALSH T J, 1992, Current Opinion in Oncology, V4, P647, DOI 10.1097/00001622-199208000-00008	46	13	14	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27887	27895		10.1074/jbc.M202998200	http://dx.doi.org/10.1074/jbc.M202998200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023966	hybrid			2022-12-25	WOS:000177189800039
J	Walker, JM; Tsivkovskii, R; Lutsenko, S				Walker, JM; Tsivkovskii, R; Lutsenko, S			Metallochaperone Atox1 transfers copper to the NH2-terminal domain of the Wilson's disease protein and regulates its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORTING ATPASE; IN-VITRO; CHAPERONE; TRAFFICKING; BINDING; ATP7B; ATX1; HOMEOSTASIS	Copper is essential for the growth and development of mammalian cells. The key role in the intracellular distribution of copper belongs to the recently discovered family of metallochaperones and to copper-transporting P-type ATPases. The mutations in the ATPase ATP7B, the Wilson's disease protein (WNDP), lead to intracellular accumulation of copper and severe hepatic and neurological abnormalities. Several of these mutations were shown to disrupt the protein-protein interactions between WNDP and the metallochaperone Atox1, suggesting that these interactions are important for normal copper homeostasis. To understand the functional consequences of the Atox1-WNDP interaction at the molecular level, we produced recombinant Atox1 and characterized its effects on WNDP. We demonstrate that Atox1 transfers copper to the purified amino-terminal domain of WNDP (N-WNDP) in a dose-dependent and saturable manner. A maximum of six copper atoms can be transferred to N-WNDP by the chaperone. Furthermore, the incubation of copper Atox1 with the full-length WNDP leads to the stimulation of the WNDP catalytic activity, providing strong evidence for the direct effect of Atox1 on the function of this transporter. Our data also suggest that Atox1 can regulate the copper occupancy of WNDP. The incubation with apo-Atox1 results in the removal of copper from the metalated N-WNDP and apparent down-regulation of WNDP activity. Interestingly, at least one copper atom remains tightly bound to N-WNDP even in the presence of excess apo-Atox1. We suggest that this incomplete reversibility reflects the functional non-equivalency of the metal-binding sites in WNDP and speculate about the intracellular consequences of the reversible Atox1-mediated copper transfer.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.				NHLBI NIH HHS [HL07781] Funding Source: Medline; NIDDK NIH HHS [DK55719] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055719] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Culotta VC, 1999, ADV EXP MED BIOL, V448, P247; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lockhart PJ, 2000, BBA-GENE STRUCT EXPR, V1490, P11, DOI 10.1016/S0167-4781(99)00230-4; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; Vanderwerf SM, 2001, J BIOL CHEM, V276, P36289, DOI 10.1074/jbc.M102055200	22	127	128	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27953	27959		10.1074/jbc.M203845200	http://dx.doi.org/10.1074/jbc.M203845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029094	hybrid			2022-12-25	WOS:000177189800047
J	Zhu, CC; Cook, LB; Hinkle, PM				Zhu, CC; Cook, LB; Hinkle, PM			Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; PROTEIN-COUPLED RECEPTORS; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; DELTA-OPIOID RECEPTOR; RAT PITUITARY-CELLS; HETEROMERIC COMPLEXES; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; GABA(B) RECEPTOR; GH CELLS	Dimerization and phosphorylation of thyrotropin-releasing hormone (TRH) receptors was characterized using HEK293 and pituitary GHFT cells expressing epitope-tagged receptors. TRH receptors tagged with FLAG and hemagglutinin epitopes were co-precipitated only if they were co-expressed, and 10-30% of receptors were isolated as hemagglutinin/FLAG-receptor dimers under basal conditions. The abundance of receptor dimers was increased when cells had been stimulated by TRH, indicating that TRH either stabilizes pre-existing dimers or increases dimer formation. TRH increased receptor dimerization and phosphorylation within 1 min in a dose-dependent manner. TRH increased phosphorylation of both receptor monomers and dimers, documented by incorporation of P-32 and an upshift in receptor mobility reversed by phosphatase treatment. The ability of TRH to increase receptor phosphorylation and dimerization did not depend on signal transduction, because it was not inhibited by the phospholipase C inhibitor U73122. Receptor phosphorylation required an agonist but was not blocked by the casein kinase 11 inhibitor apigenin, the protein kinase C inhibitor GF109203R, or expression of a dominant negative form of G protein-coupled receptor kinase 2. TRH receptors lacking most of the cytoplasmic carboxyl terminus formed dimers constitutively but failed to undergo agonist-induced dimerization and phosphorylation. TRH also increased phosphorylation and dimerization of TRH receptors expressed in GHFT pre-lactotroph cells.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Hinkle, PM (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	patricia_hinkle@urmc.rochester.edu		Cook, Laurie/0000-0002-1561-9047	NIDDK NIH HHS [DK19974] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CALZA L, 1992, NEUROSCIENCE, V51, P891, DOI 10.1016/0306-4522(92)90528-A; Cao J, 1998, J BIOL CHEM, V273, P32281, DOI 10.1074/jbc.273.48.32281; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Drmota T, 1998, J BIOL CHEM, V273, P24000, DOI 10.1074/jbc.273.37.24000; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Heuer H, 2000, J COMP NEUROL, V428, P319; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; HINKLE PM, 1989, ANN NY ACAD SCI, V553, P176; Horvat RD, 2001, MOL ENDOCRINOL, V15, P695, DOI 10.1210/me.15.5.695; IMAI A, 1985, J BIOL CHEM, V260, P536; Itadani H, 1998, BIOCHEM BIOPH RES CO, V250, P68, DOI 10.1006/bbrc.1998.9268; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KANYALOGLU AC, 2001, J BIOL CHEM, V276, P18066; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; Milligan G, 2001, J CELL SCI, V114, P1265; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; O'Dowd BF, 2000, MOL ENDOCRINOL, V14, P183, DOI 10.1210/me.14.1.183; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Petrou C, 1998, CELL SIGNAL, V10, P553, DOI 10.1016/S0898-6568(97)00190-3; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; PHILLIPS WJ, 1989, MOL PHARMACOL, V35, P533; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Romano C, 2001, MOL PHARMACOL, V59, P46, DOI 10.1124/mol.59.1.46; Salahpour A, 2000, TRENDS ENDOCRIN MET, V11, P163, DOI 10.1016/S1043-2760(00)00260-5; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; Yu R, 1998, MOL ENDOCRINOL, V12, P737, DOI 10.1210/me.12.5.737; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745; Yu R, 1998, THYROID, V8, P887, DOI 10.1089/thy.1998.8.887; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529	69	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28228	28237		10.1074/jbc.M204221200	http://dx.doi.org/10.1074/jbc.M204221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023974	hybrid			2022-12-25	WOS:000177189800081
J	Asahi, M; Kurzydlowski, K; Tada, M; MacLennan, DH				Asahi, M; Kurzydlowski, K; Tada, M; MacLennan, DH			Sarcolipin inhibits polymerization of phospholamban to induce superinhibition of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; FORMS; ATPASE; PHOSPHORYLATION; OVEREXPRESSION; CONTRACTILITY	Sarcolipin (SLN), a regulator of the sarco(endo)plasmic reticulum Ca2+-ATPase of fast-twitch skeletal muscle (SERCA1a), is also expressed in cardiac and slow-twitch skeletal muscles where phospholamban (PLN) and SERCA2a are expressed. Co-expression in HEK-293 cells of SLN tagged N-terminally with a FLAG epitope (NF-SLN), PLN, and SERCAs followed by measurement of the Ca2+ dependence of Ca2+ transport activity in isolated microsomal fractions showed that NF-SLN can reduce the apparent Ca2+ affinity of both SERCA1a (DeltaK(Ca) = -0.22 +/- 0.01 pCa units) and SERCA2a (DeltaK(Ca) = -0.37 +/- 0.04 pCa units). When SERCA1a or SERCA2a were co-expressed with both NF-SLN and PLN, inhibition was synergistic, reducing DeltaK(Ca) by about -1.0 pCa units. Co-immunoprecipitation showed that NF-SLN increased the binding of PLN to SERCA, whereas PLN did not increase the binding of NF-SLN to SERCA. Elevated Ca2+ dissociates both PLN and NF-SLN from their complexes with both SERCA1a and SERCA2a, but NF-SLN induced resistance to Ca2+ dissociation of the PLNSERCA complex. Co-immunoprecipitation of PLN and NF-SLN without SERCA showed that NF-SLN binds directly to PLN and that NF-SLN inhibits the formation of PLN pentamers. Thus the ability of NF-SLN to elevate the content of PLN monomers can account, at least in part, for the superinhibitory effects of NF-SLN in the presence of PLN.	Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, Toronto, ON M5G 1L6, Canada; Osaka Univ, Sch Med, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan	University of Toronto; Osaka University	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Charles H Best Inst, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Haghighi K, 2001, J BIOL CHEM, V276, P24145, DOI 10.1074/jbc.M102403200; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Hajjar RJ, 1998, P NATL ACAD SCI USA, V95, P5251, DOI 10.1073/pnas.95.9.5251; Hellstern S, 2001, J BIOL CHEM, V276, P30845, DOI 10.1074/jbc.M102495200; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mayer EJ, 2000, BIOCHEM BIOPH RES CO, V267, P40, DOI 10.1006/bbrc.1999.1920; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Tada M, 1989, Adv Exp Med Biol, V255, P79; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	24	85	87	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26725	26728		10.1074/jbc.C200269200	http://dx.doi.org/10.1074/jbc.C200269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12032137	hybrid			2022-12-25	WOS:000177055900004
J	Heckman, CA; Mehew, JW; Boxer, LM				Heckman, CA; Mehew, JW; Boxer, LM			NF-kappa B activates Bcl-2 expression in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; NF-kappa B	UP-REGULATES BCL-2; ANTISENSE OLIGONUCLEOTIDES ENHANCE; BREAST-CANCER CELLS; TRANSCRIPTION FACTOR; FOLLICULAR LYMPHOMA; RESPONSE ELEMENT; CREB PROTEINS; E-SELECTIN; T-CELLS; C-REL	The t(14;18) translocation, which is characteristic of follicular lymphoma, results in the overexpression of the bcl-2 gene dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy chain gene enhancers. Conflicting evidence exists on the effects of NF-kappaB expression on Bel-2 levels in different cell types. Lymphoma cells with the t(141;18) translocation show high levels of nuclear NF-kappaB proteins. We observed decreased levels of endogenous Bcl-2 when the IkappaBchi-super-repressor was expressed in a t(14;18) cell line. Deletion analysis of the bcl-2 promoter indicated that the repressive effect of the IkappaBalpha-super-repressor occurred through a region that contained no NF-kappaB consensus sequences. This highly active region contained a c-AMP response element (CRE) and several Sp1 binding sites. Chromatin immunoprecipitation assays with antibodies specific for the NF-kappaB and CREB/ATF family members, as well as Sp1, resulted in the isolation of this IkappaBalpha-super-repressor responsive region of the bcl-2 promoter. Mutation of the CRE and the two Sp1 sites in different combinations in bel-2 reporter constructs resulted in the loss of bcl-2 promoter repression by the IkappaBalpha-super-repressor. We therefore conclude that the activation of bcl-2 by NF-kappaB in t(14;18) lymphoma cells is mediated through the CRE and Sp1 binding sites.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CRAWFORD MJ, 2001, BIOCHEM BIOPH RES CO, V281, P1034; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Feng ZW, 1999, J BIOL CHEM, V274, P30341, DOI 10.1074/jbc.274.43.30341; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HEWITT SM, 1995, CANCER RES, V55, P5386; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Konopleva M, 2000, BLOOD, V95, P3929; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Munzert G, 2000, LEUKEMIA LYMPHOMA, V38, P395, DOI 10.3109/10428190009087031; Pepper C, 2001, LEUKEMIA LYMPHOMA, V42, P491, DOI 10.3109/10428190109064606; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SIF S, 1993, ONCOGENE, V8, P2501; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wacheck V, 2001, J MOL MED-JMM, V79, P587, DOI 10.1007/s001090100251; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	57	160	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3898	3908		10.1038/sj.onc.1205483	http://dx.doi.org/10.1038/sj.onc.1205483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032828				2022-12-25	WOS:000175847200009
J	Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH				Finkelstein, LD; Ney, PA; Liu, QP; Paulson, RF; Correll, PH			Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus	ONCOGENE			English	Article						erythroleukemia; receptor; tyrosine kinase; Stk; Fv2; signal transduction	MULTIFUNCTIONAL DOCKING SITE; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR; CELL-TRANSFORMATION; MET PROTOONCOGENE; POINT MUTATIONS; TRUNCATED FORM; TYROSINE; INDUCTION; GENE	During the initial stage of Friend virus-induced erythro-leukemia in mice, interaction of the viral protein gp55 with the erythropoietin receptor, and other host factors, drives the expansion of erythroid precursor cells. Recently, we demonstrated that the Friend virus susceptibility locus, Fv2, which is required for the expansion of infected cells, encodes a naturally occurring, N-terminally truncated form of the Stk receptor tyrosine kinase (Sf-Stk). Here we show that in vitro expression of Sf-Stk confers Friend virus sensitivity to erythroid progenitor cells from Fv2(rr) mice. Furthermore, our data reveal that Sf-Stk kinase activity and Y436, but not Y429, are required for Epo-independent colony formation following Friend virus infection. Introduction of a mutation that results in failure to bind Grb2 abrogates the ability of Sf-Stk to induce colonies in response to Friend virus, while the Grb2 binding site from EGFR restores this response. Consistent with the ability of Grb2 to recruit SOS and Gab1, the Ras/MAPK and PI3K pathways are activated by Sf-Stk, and both of these pathways are required for gp55-mediated erythroblast proliferation. These data clearly demonstrate a requirement for signaling through Sf-Stk in the Epo-independent expansion of Friend virus-infected cells, and suggest a pivotal role for Grb2 in this response.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; St Jude Children's Research Hospital	Correll, PH (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu			NCI NIH HHS [R01 CA084214-01, R01 CA084214-05, R01 CA084214-03, R01 CA084214-04, R01 CA084214, R01 CA084214-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL66471, R01 HL066471] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084214] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BONDURANT MC, 1985, J GEN VIROL, V66, P83, DOI 10.1099/0022-1317-66-1-83; CLARKE BJ, 1975, P NATL ACAD SCI USA, V72, P3556, DOI 10.1073/pnas.72.9.3556; Correll Pamela H., 1997, Genes and Function, V1, P69; DANDREA AD, 1992, CANCER SURV, V15, P19; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu QP, 1999, J IMMUNOL, V163, P6606; LONGATI P, 1994, ONCOGENE, V9, P49; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Yamamura Y, 1998, MOL CELL BIOL, V18, P1172, DOI 10.1128/MCB.18.3.1172; ZHEN Z, 1994, ONCOGENE, V9, P1691	38	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3562	3570		10.1038/sj.onc.1205442	http://dx.doi.org/10.1038/sj.onc.1205442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032858				2022-12-25	WOS:000175793700007
J	Gumbiowski, K; Panke, O; Junge, W; Engelbrecht, S				Gumbiowski, K; Panke, O; Junge, W; Engelbrecht, S			Rotation of the c subunit oligomer in EF0EF1 mutant cD61N	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; GAMMA-SUBUNIT; EPSILON-SUBUNIT; F-ATPASE; MOTOR; F0F1; F-1-ATPASE	ATP synthases (F0F1-ATPases) mechanically couple ion flow through the membrane-intrinsic portion, F-0, to ATP synthesis within the peripheral portion, F-1. The coupling most probably occurs through the rotation of a central rotor (subunits c(10)epsilongamma) relative to the stator (subunits ab(2)delta(alphabeta)(3)). The translocation of protons is conceived to involve the rotation of the ring of c subunits (the c oligomer) containing the essential acidic residue cD61 against subunits ab(2). In line with this notion, the mutants cD61N and cD61G have been previously reported to lack proton translocation. However, it has been surprising that the membrane-bound mutated holoenzyme hydrolyzed ATP but without translocating protons. Using detergent-solubilized and immobilized EF0F1 and by application of the microvideographic assay for rotation, we found that the c oligomer, which carried a fluorescent actin filament, rotates in the presence of ATP in the mutant cD61N just as in the wild type enzyme. This observation excluded slippage among subunit gamma, the central rotary shaft, and the c oligomer and suggested free rotation without proton pumping between the oligomer and subunit a in the membrane-bound enzyme.	Univ Osnabruck, FB Biol, Abt Biophys, D-49076 Osnabruck, Germany	University Osnabruck	Engelbrecht, S (corresponding author), Univ Osnabruck, FB Biol, Abt Biophys, Barbarastr 11, D-49076 Osnabruck, Germany.	engel@uos.de						Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dimroth P, 2000, BBA-BIOENERGETICS, V1458, P374, DOI 10.1016/S0005-2728(00)00088-8; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 2000, NAT STRUCT BIOL, V7, P1002, DOI 10.1038/80902; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; FILLINGAME RH, 1984, J BACTERIOL, V158, P1078, DOI 10.1128/JB.158.3.1078-1083.1984; GALANIS M, 1989, FEBS LETT, V249, P333, DOI 10.1016/0014-5793(89)80653-2; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; HOPPE J, 1982, FEBS LETT, V145, P21, DOI 10.1016/0014-5793(82)81198-8; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KRAUSE I, 1987, SILVER STAIN DRIED P; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; WISE JG, 1990, J BIOL CHEM, V265, P10403; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	35	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31287	31290		10.1074/jbc.M111678200	http://dx.doi.org/10.1074/jbc.M111678200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12045188	hybrid			2022-12-25	WOS:000177718700003
J	Gasmi, A; Bourcier, C; Aloui, Z; Srairi, N; Marchetti, S; Gimond, C; Wedge, SR; Hennequin, L; Pouyssegur, J				Gasmi, A; Bourcier, C; Aloui, Z; Srairi, N; Marchetti, S; Gimond, C; Wedge, SR; Hennequin, L; Pouyssegur, J			Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom - ICPP is angiogenic via vascular endothelial growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; DOMAIN; VEGF; TRANSDUCTION; MODULATION; MECHANISMS; INDUCE; KDR; ACT	The partial sequence of the increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom revealed a strong homology to vascular endothelial growth factor (VEGF)-A. We now report its complete amino acid sequence determined by Edman degradation and its biological effects on mouse and human vascular endothelial cells. ICPP is a homodimeric protein linked by cysteine disulfide bonds of 25115 Da revealed by mass spectrometry. Each monomer is composed of 110 amino acids including eight cysteine residues and a pyroglutamic acid at the N-terminal extremity. ICPP shares 52% sequence identity with human VEGF but lacks the heparin binding domain and Asn glycosylation site. Besides its strong capillary permeability activity, ICPP was found to be a potent in vitro angiogenic factor when added to mouse embryonic stem cells or human umbilical vein endothelial cells. ICPP was found to be as potent as human VEGF165 in activating p42/p44 MAPK, in reinitiation of DNA synthesis in human umbilical vein endothelial cells, and in promoting in vitro angiogenesis of mouse embryonic stem cells. All these biological actions, including capillary permeability in mice, were fully inhibited by 1 muM of a new specific VEGF receptor tyrosine kinase inhibitor (ZM317450) from AstraZeneca that belongs to the anilinocinnoline family of compounds. Indeed, up to a 30 times higher concentration of inhibitor did not affect platelet-derived growth factor, epidermal growth factor, FGF-2, insulin, alpha-thrombin, or fetal calf serum-induced p42/p44 MAPK and reinitiation of DNA synthesis. Therefore, we conclude that this venom-derived ICPP exerts its biological action (permeability and angiogenesis) through activation of VEGF receptor signaling (VEGF-R2 and possibly VEGF-R1).	Inst Pasteur, Lab Venins & Toxines, Tunis 1002, Tunisia; Ctr Antoine Lacassagne, CNRS UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France; AstraZeneca, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England	Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Antoine Lacassagne; AstraZeneca	Gasmi, A (corresponding author), Inst Pasteur, Lab Venins & Toxines, BP 74, Tunis 1002, Tunisia.	ammar.gasmi@pasteur.rns.tn; pouysseg@unice.fr	Marchetti, Sandrine/P-6479-2016	Marchetti, Sandrine/0000-0001-8326-5730; Gimond, Clotilde/0000-0003-1708-4629				BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Gasmi A, 2000, BIOCHEM BIOPH RES CO, V268, P69, DOI 10.1006/bbrc.2000.2078; GASPARINI G, 1995, J CLIN ONCOL, V13, P765, DOI 10.1200/JCO.1995.13.3.765; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Junqueira de Azevedo ILM, 2001, J BIOL CHEM, V276, P39836; KAWASAKI I, 1972, ANAL BIOCHEM, V48, P546, DOI 10.1016/0003-2697(72)90110-8; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Komori Y, 1999, BIOCHEMISTRY-US, V38, P11796, DOI 10.1021/bi990562z; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; L'allemain G, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Markland FS, 1998, TOXICON, V36, P1749, DOI 10.1016/S0041-0101(98)00126-3; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Mazure NM, 1996, CANCER RES, V56, P3436; MILES AA, 1955, BRIT J EXP PATHOL, V36, P71; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Saadeh PB, 2000, ENDOCRINOLOGY, V141, P2075, DOI 10.1210/en.141.6.2075; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; Waltenberger J, 1997, CIRCULATION, V96, P4083; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	39	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29992	29998		10.1074/jbc.M202202200	http://dx.doi.org/10.1074/jbc.M202202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12021274	hybrid			2022-12-25	WOS:000177509300080
J	Zhang, DY; Simmen, RCM; Michel, FJ; Zhao, G; Vale-Cruz, D; Simmen, FA				Zhang, DY; Simmen, RCM; Michel, FJ; Zhao, G; Vale-Cruz, D; Simmen, FA			Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEINS; LEUKOPROTEASE INHIBITOR; CYCLIN D1; TISSUE INHIBITOR; POTENT INHIBITOR; LYSYL OXIDASE; PHOSPHOLIPID SCRAMBLASE; INFLAMMATORY INJURY; PROMOTING ACTIVITY; MOLECULAR-CLONING	Secretory leukocyte protease inhibitor (SLPI) inhibits chymotrypsin, trypsin, elastase, and cathepsin G. This protein also exhibits proliferative effects, although little is known about the molecular mechanisms underlying this activity. We have generated SLPI-ablated epithelial sublines by stably transfecting the Ishikawa human endometrial cell line with an antisense human SLPI RNA expression vector. We demonstrate a positive correlation between cellular SLPI production and proliferation. We further show that Ishikawa sublines expressing low to undetectable SLPI have correspondingly increased and decreased expression, respectively, of transforming growth factor-beta1 and cyclin D1 genes, relative to parental cells. SLPI selectively increased cyclin D1 gene expression, with the effect occurring in part at the level of promoter activity. Cellular SLPI levels negatively influenced the anti-proliferative and pro-apoptotic insulin-like growth factor-binding protein-3 expression. We also identified lysyl oxidase, a phenotypic inhibitor of the ras oncogenic pathway and a tumor suppressor, as SLPI-repressed gene, whose expression is up-regulated by transforming growth factor-beta1. Our results suggest that SLPI acts at the node(s) of at least three major interacting growth inhibitory pathways. Because expression of SLPI is generally high in epithelial cells exhibiting abnormal proliferation such as in carcinomas, SLPI may define a novel pathway by which cellular growth is modulated.	Univ Florida, Interdisciplinary Concentrat Anim Mol & Cell Biol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Simmen, FA (corresponding author), Arkansas Childrens Hosp, Res Inst, Arkansas Childrens Nutr Ctr, Slot 512-20B,1120 Marshall St, Little Rock, AR 72202 USA.		Simmen, Frank A/J-9464-2012	Simmen, Frank/0000-0001-6842-7754	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021961, R29HD021961] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21961, R01 HD021961] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Ashcroft GS, 2000, NAT MED, V6, P1147, DOI 10.1038/80489; BADINGA L, 1994, MOL REPROD DEV, V38, P357, DOI 10.1002/mrd.1080380402; Badinga L, 1999, BIOL REPROD, V61, P380, DOI 10.1095/biolreprod61.2.380; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breier G, 2002, INT J CANCER, V97, P142, DOI 10.1002/ijc.1599; Chinoy MR, 2000, AM J PHYSIOL-LUNG C, V279, pL312, DOI 10.1152/ajplung.2000.279.2.L312; de Andrade CR, 2001, J PERIODONTOL, V72, P1726, DOI 10.1902/jop.2001.72.12.1726; Denison FC, 1999, J ENDOCRINOL, V161, P299, DOI 10.1677/joe.0.1610299; DEWATER R, 1986, AM REV RESPIR DIS, V133, P882; Ekholm EC, 2000, BONE, V27, P551, DOI 10.1016/S8756-3282(00)00359-8; Fanayan S, 2002, J BIOL CHEM, V277, P7255, DOI 10.1074/jbc.M108038200; Francart C, 1997, J MOL BIOL, V268, P666, DOI 10.1006/jmbi.1997.0983; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; GARVER RI, 1994, GENE THER, V1, P46; Gipson TS, 1999, J IMMUNOL, V162, P3653; GONZALEZ BY, 1994, DNA CELL BIOL, V13, P365, DOI 10.1089/dna.1994.13.365; Goselink HM, 1996, J EXP MED, V184, P1305, DOI 10.1084/jem.184.4.1305; GREEN ML, 1995, ENDOCRINOLOGY, V136, P3961, DOI 10.1210/en.136.9.3961; Grobmyer SR, 2000, CRIT CARE MED, V28, P1276, DOI 10.1097/00003246-200005000-00003; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HELMIG R, 1995, EUR J OBSTET GYN R B, V59, P95, DOI 10.1016/0028-2243(94)02023-8; Hiemstra PS, 1996, INFECT IMMUN, V64, P4520, DOI 10.1128/IAI.64.11.4520-4524.1996; Hinz M, 1999, MOL CELL BIOL, V19, P2690; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; Jaumann F, 2000, EUR RESPIR J, V15, P1052, DOI 10.1034/j.1399-3003.2000.01513.x; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kikuchi T, 2000, AM J RESP CELL MOL, V23, P364, DOI 10.1165/ajrcmb.23.3.3942; King AE, 2000, MOL HUM REPROD, V6, P191, DOI 10.1093/molehr/6.2.191; Lee CY, 1998, J REPROD FERTIL, V112, P369, DOI 10.1530/jrf.0.1120369; Lentsch AB, 1999, GASTROENTEROLOGY, V117, P953, DOI 10.1016/S0016-5085(99)70355-0; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Maruyama M, 1998, IN VIVO, V12, P535; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; Min SH, 2002, J BIOL CHEM, V277, P3647, DOI 10.1074/jbc.M100751200; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moriyama A, 1998, MOL HUM REPROD, V4, P946, DOI 10.1093/molehr/4.10.946; NISHIDA M, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P1103; Nystrom M, 1999, MEDIAT INFLAMM, V8, P147, DOI 10.1080/09629359990478; OHLSSON K, 1995, J ANDROL, V16, P64; Ohlsson S, 2001, MEDIAT INFLAMM, V10, P347, DOI 10.1080/09629350120102389; Park BJ, 2000, CANCER RES, V60, P3031; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rechler MM, 1998, TRENDS ENDOCRIN MET, V9, P176, DOI 10.1016/S1043-2760(98)00047-2; Reynolds RK, 1998, GYNECOL ONCOL, V70, P202, DOI 10.1006/gyno.1998.5089; RICE WG, 1990, SCIENCE, V249, P178, DOI 10.1126/science.2371565; Robertson MW, 1998, CANCER GENE THER, V5, P331; Semba RD, 1999, CLIN DIAGN LAB IMMUN, V6, P671, DOI 10.1128/CDLI.6.5.671-674.1999; Si-Tahar M, 2000, GASTROENTEROLOGY, V118, P1061, DOI 10.1016/S0016-5085(00)70359-3; Simmen RCM, 2002, DNA CELL BIOL, V21, P115, DOI 10.1089/104454902753604998; SIMMEN RCM, 1988, BIOL REPROD, V38, P551, DOI 10.1095/biolreprod38.3.551; Song XY, 1999, J EXP MED, V190, P535, DOI 10.1084/jem.190.4.535; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; Sumi Y, 2000, EXP CELL RES, V256, P203, DOI 10.1006/excr.2000.4815; Suzumori N, 1999, FERTIL STERIL, V72, P857, DOI 10.1016/S0015-0282(99)00381-7; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Tomee JFC, 1997, J INFECT DIS, V176, P740, DOI 10.1086/514098; Tseng CC, 2000, FEBS LETT, V475, P232, DOI 10.1016/S0014-5793(00)01700-2; Wahl SM, 1997, ORAL DIS S1, V3, pS64; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Zhang DY, 2002, ENDOCRINOLOGY, V143, P62, DOI 10.1210/en.143.1.62; Zhang XL, 2001, MOL CELL ENDOCRINOL, V181, P81, DOI 10.1016/S0303-7207(01)00536-6; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	75	68	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29999	30009		10.1074/jbc.M203503200	http://dx.doi.org/10.1074/jbc.M203503200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023969	hybrid			2022-12-25	WOS:000177509300081
J	Bouzidi, M; Tricaud, N; Giraud, P; Kordeli, E; Caillol, G; Deleuze, C; Couraud, F; Alcaraz, G				Bouzidi, M; Tricaud, N; Giraud, P; Kordeli, E; Caillol, G; Deleuze, C; Couraud, F; Alcaraz, G			Interaction of the Nav1.2a subunit of the voltage-dependent sodium channel with nodal Ankyrin(G) - In vitro mapping of the interacting domains and association in synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; ERYTHROCYTE ANKYRIN; BETA-1 SUBUNIT; DEVELOPING CNS; CELL-ADHESION; BINDING-SITE; RANVIER; ISOFORMS	Voltage-dependant sodium channels at the axon initial segment and nodes of Ranvier colocalize with the nodal isoforms of ankyrin(G) (Ank(G) node). Using fusion proteins derived from the intracellular regions of the Nav1.2a subunit and the Ank repeat domain of Ank(G) node, we mapped a major interaction site in the intracellular loop separating alpha subunit domains I-II. This 57-amino acid region binds the Ank repeat region with a K-D value of 69 nM. We identified another site in intracellular loop III-IV, and we mapped both Nav1.2a binding sites on the ankyrin repeat domain to the region encompassing repeats 12-22. The ankyrin repeat domain did not bind the beta(1) and beta(2) subunit cytoplasmic regions. We showed that in cultured embryonic motoneurons, expression of the beta(2) subunit is not necessary for the colocalization of Ank(G) node with functional sodium channels at the axon initial segment. Antibodies directed against the beta(1) subunit intracellular region, alpha subunit loop III-IV, and Ank(G) node could not co-immunoprecipitate Ank(G) node and sodium channels from Triton X-100 solubilisates of rat brain synaptosomes. Co-immunoprecipitation of sodium channel alpha subunit and of the 270- and 480-kDa Ank(G) node isoforms was obtained when solubilization conditions that maximize membrane protein extraction were used. However, we could not find conditions that allowed for co-immunoprecipitation of ankyrin with the sodium channel beta(1) subunit.	Univ Mediterranee, INSERM, U464, Inst Jean Roche, F-13916 Marseille 20, France; Univ Paris 06, CNRS, UMR 7592, F-75251 Paris, France; Univ Paris 07, CNRS, UMR 7592, F-75251 Paris 05, France; CNRS, UPR 902431, Neurobiol Lab, F-13402 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Alcaraz, G (corresponding author), Univ Mediterranee, INSERM, U464, Inst Jean Roche, Blvd Pierre Dramard, F-13916 Marseille 20, France.			Tricaud, Nicolas/0000-0002-1620-4046; Kordeli, Ekaterini/0000-0002-5115-2202				Alcaraz G, 1997, MOL BRAIN RES, V51, P143, DOI 10.1016/S0169-328X(97)00232-5; Alessandri-Haber N, 1999, J PHYSIOL-LONDON, V518, P203, DOI 10.1111/j.1469-7793.1999.0203r.x; ALESSANDRIHABER N, 1928, J PHYSL, V541, P25; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVRIES GH, 1978, BRAIN RES, V147, P339, DOI 10.1016/0006-8993(78)90844-2; Giraud P, 1998, MOL BRAIN RES, V56, P238, DOI 10.1016/S0169-328X(98)00067-9; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kaplan MR, 2001, NEURON, V30, P105, DOI 10.1016/S0896-6273(01)00266-5; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; Kazen-Gillespie KA, 2000, J BIOL CHEM, V275, P1079, DOI 10.1074/jbc.275.2.1079; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lambert S, 1997, J NEUROSCI, V17, P7025; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; Makita N, 1996, J NEUROSCI, V16, P7117; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; MATUS AI, 1978, PROC R SOC SER B-BIO, V203, P135, DOI 10.1098/rspb.1978.0097; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; Meadows L, 2001, J NEUROCHEM, V76, P1871, DOI 10.1046/j.1471-4159.2001.00192.x; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1999, J BIOL CHEM, V274, P35908, DOI 10.1074/jbc.274.50.35908; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; VABNICK I, 1996, J NEUROSCI, V165, P4916; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	49	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28996	29004		10.1074/jbc.M201760200	http://dx.doi.org/10.1074/jbc.M201760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036953	hybrid			2022-12-25	WOS:000177342600085
J	Qin, H; Shao, Q; Curtis, H; Galipeau, J; Belliveau, DJ; Wang, TQ; Alaoui-Jamali, MA; Laird, DW				Qin, H; Shao, Q; Curtis, H; Galipeau, J; Belliveau, DJ; Wang, TQ; Alaoui-Jamali, MA; Laird, DW			Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; MAMMARY-GLAND; EXPRESSION; PROTEINS; CANCER; CARCINOGENESIS; TRANSFECTION; SUPPRESSION; CX43; DIFFERENTIATION	The mechanism by which gap junction proteins, connexins, act as potent tumor suppressors remains poorly understood. In this study human breast tumor cells were found to exhibit diverse gap junction phenotypes including (a) undetectable Cx43 and no intercellular communication (HBL100); (b) low levels of Cx43 and sparse intercellular communication (MDA-MB-231); and (c) significant levels of Cx43 and moderate intercellular communication (Hs578T). Although retroviral delivery of Cx43 and Cx26 cDNAs to MDA-MB-231 cells did not achieve an expected substantial rescue of intercellular communication, overexpression of connexin genes did result in a dramatic suppression of tumor growth when connexin-expressing MDA-MB-231 cells were implanted into the mammary fat pad of nude mice. Subsequent immunolocalization studies on xenograph sections revealed only cytoplasmic stores of Cx43 and no detectable gap junctions. Moreover, DNA array and Western blot analysis demonstrated that overexpression of Cx43 or Cx26 in MDA-MB-231 cells down-regulated fibroblast growth factor receptor-3. Surprisingly, these results suggest that Cx43 and Cx26 induce their tumor-suppressing properties by a mechanism that is independent of significant gap junctional intercellular communication and possibly through the down-regulation of key genes involved in tumor growth. Moreover, our studies show that retroviruses are effective vehicles for delivering connexins to human breast tumor cells, facilitating potential gene therapy applications.	Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Pharmacol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Therapeut, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, McGill Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada	Western University (University of Western Ontario); Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Laird, DW (corresponding author), Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada.		Galipeau, Jacques/R-9909-2019; Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Galipeau, Jacques/0000-0002-9374-1996; Laird, Dale W/0000-0002-4568-3285; 				BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; Galipeau J, 1999, CANCER RES, V59, P2384; Goldberg GS, 1998, EXP CELL RES, V239, P82, DOI 10.1006/excr.1997.3872; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Huang RP, 1998, CANCER RES, V58, P5089; Jamieson S, 1998, J PATHOL, V184, P37, DOI 10.1002/(SICI)1096-9896(199801)184:1<37::AID-PATH966>3.0.CO;2-D; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 1996, J BIOENERG BIOMEMBR, V28, P311, DOI 10.1007/BF02110107; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Li GY, 1998, GENE, V209, P139, DOI 10.1016/S0378-1119(98)00039-0; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; MONAGHAN P, 1994, J HISTOCHEM CYTOCHEM, V42, P931, DOI 10.1177/42.7.8014476; Monaghan P, 1996, CELL BIOL INT, V20, P121, DOI 10.1006/cbir.1996.0016; Monaghan P, 1996, EXP CELL RES, V223, P29, DOI 10.1006/excr.1996.0055; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; POZZI A, 1995, EXP CELL RES, V220, P212, DOI 10.1006/excr.1995.1308; Qin H, 2001, CELL COMMUN ADHES, V8, P433, DOI 10.3109/15419060109080766; Saunders MM, 2001, CANCER RES, V61, P1765; Sawey MJ, 1996, MOL CARCINOGEN, V17, P49, DOI 10.1002/(SICI)1098-2744(199610)17:2<49::AID-MC1>3.3.CO;2-8; Sneyd J, 1998, BIOPHYS CHEM, V72, P101, DOI 10.1016/S0301-4622(98)00126-4; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Trosko JE, 2000, METHODS, V20, P245, DOI 10.1006/meth.1999.0941; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; Woodward TL, 1998, J CELL SCI, V111, P3529; Yamasaki H, 1999, NOVART FDN SYMP, V219, P241; Yamasaki H, 1999, CANCER DETECT PREV, V23, P273, DOI 10.1046/j.1525-1500.1999.99037.x; YAMASAKI H, 1991, ENVIRON HEALTH PERSP, V93, P191, DOI 10.2307/3431188; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	44	185	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29132	29138		10.1074/jbc.M200797200	http://dx.doi.org/10.1074/jbc.M200797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12042301	hybrid			2022-12-25	WOS:000177342600102
J	Cho, H; Hwang, JY; Kim, D; Shin, HS; Kim, Y; Earm, YE; Ho, WK				Cho, H; Hwang, JY; Kim, D; Shin, HS; Kim, Y; Earm, YE; Ho, WK			Acetylcholine-induced phosphatidylinositol 4,5-bisphosphate depletion does not cause short-term desensitization of G protein-gated inwardly rectifying K+ current in mouse atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DESENSITIZATION; ACTIVATION; RECEPTORS; CHANNELS; INHIBITION; HYDROLYSIS; BETA(1); PIP2	Depletion of phosphatidylinositol 4,5-bisphosphate (PIP2) induced by phenylephrine or endothelin causes the inhibition of acetylcholine-activated K+ current (I-KACh) in atrial myocytes. In the present study, we have investigated the hypothesis that muscarinic receptor induced PIP2 depletion also causes inhibition of I-KACh, resulting in desensitization. We confirmed the expression of G(q)-coupled muscarinic receptors in mouse atrial myocytes using reverse transcriptase-polymerase chain reaction. The involvement of M-1 and M-3 receptors in desensitization is examined using specific antagonists, 4-DAMP and pirenzepine, but they significantly reduced peak I-KACh, implying nonspecific M-2 blockade. When ACh-induced phosphoinositide depletion was specifically inhibited using PLCbeta1 knock-out mice, the extent of desensitization during 4 min was 47.5 +/- 3.2%, which was not different from that in wild type (46.8 +/- 2.1%). Phenylephrine-induced phosphoinositide hydrolysis and phenylephrine-induced inhibition of I-KACh were not affected by PLCbeta1 knock-out. To facilitate PIP2 depletion, replenishment of PIP2 was blocked by wortmannin. Wortmannin did not affect the desensitization and the recovery from desensitization. These results suggest that PIP2 depletion by acetylcholine does not contribute to short-term desensitization of I-KACh. The differential regulation of I-KACh by different phospholipase C-linked receptors may imply that receptor co-localization is required for PIP2 to act as a signaling molecule.	Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Natl Res Lab Cellular Signaling, Chongno Ku, Seoul 110799, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Korea Inst Sci & Technol, Natl Creat Res Initiat Ctr Calcium & Learning, Seoul 136791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Korea Institute of Science & Technology (KIST)	Cho, H (corresponding author), Seoul Natl Univ, Coll Med, Dept Physiol & Biophys, Chongno Ku, 28 Yonkeun Dong, Seoul 110799, South Korea.	wonkyung@snu.ac.kr	Kim, Daesoo/C-1625-2011; Ho, Won-Kyung/J-2798-2012	Kim, Daesoo/0000-0001-9915-1463; 				Aprigliano O, 1997, AM J PHYSIOL-HEART C, V272, pH2726, DOI 10.1152/ajpheart.1997.272.6.H2726; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Bunemann M, 1996, J PHYSIOL-LONDON, V494, P351; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Cho H, 2001, BRIT J PHARMACOL, V134, P1066, DOI 10.1038/sj.bjp.0704347; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Hong SG, 1996, AM J PHYSIOL-HEART C, V270, pH526, DOI 10.1152/ajpheart.1996.270.2.H526; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jan LY, 2000, NAT CELL BIOL, V2, pE165, DOI 10.1038/35023646; Kim D, 1997, NATURE, V389, P290, DOI 10.1038/38508; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Lanier LM, 2000, CURR BIOL, V10, pR655, DOI 10.1016/S0960-9822(00)00685-0; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; Logothetis DE, 1999, J PHYSIOL-LONDON, V520, P630, DOI 10.1111/j.1469-7793.1999.00630.x; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SHUI Z, 2001, J PHYSL P, V538, P14; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Wang HZ, 2001, MOL PHARMACOL, V59, P1029, DOI 10.1124/mol.59.5.1029; Wellner-Kienitz MC, 2001, J BIOL CHEM, V276, P37347, DOI 10.1074/jbc.M106234200; Wellner-Kienitz MC, 2000, CIRC RES, V86, P643, DOI 10.1161/01.RES.86.6.643; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Woodcock EA, 1997, J MOL CELL CARDIOL, V29, P3275, DOI 10.1006/jmcc.1997.0553; ZANG WJ, 1993, J PHYSIOL-LONDON, V464, P649, DOI 10.1113/jphysiol.1993.sp019656; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	32	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27742	27747		10.1074/jbc.M203660200	http://dx.doi.org/10.1074/jbc.M203660200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12019267	hybrid			2022-12-25	WOS:000177189800022
J	Jungas, T; Motta, I; Duffieux, F; Fanen, P; Stoven, V; Ojcius, DM				Jungas, T; Motta, I; Duffieux, F; Fanen, P; Stoven, V; Ojcius, DM			Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNASE-I; INTRACELLULAR PH; CHLORIDE CHANNEL; LUNG FIBROBLASTS; AIRWAY EPITHELIA; CAUTIONARY NOTE; GSH EXTRUSION; DEATH; TRANSPORT; CASPASES	Cystic fibrosis is characterized by chronic inflammation and an imbalance in the concentrations of alveolar and lung oxidants and antioxidants, which result in cell damage. Modifications in lung glutathione concentrations are recognized as a salient feature of inflammatory lung diseases such as cystic fibrosis, and glutathione plays a major role in protection against oxidative stress and is important in modulation of apoptosis. The cystic fibrosis transmembrane conductance regulator (CFTR) is permeable to Cl-, larger organic ions, and reduced and oxidized forms of glutathione, and the DeltaF508 CFTR mutation found in cystic fibrosis patients has been correlated with impaired glutathione transport in cystic fibrosis airway epithelia. Because intracellular glutathione protects against oxidative stress-induced apoptosis, we studied the susceptibility of epithelial cells (HeLa and IB3-1) expressing normal and mutant CFTR to apoptosis triggered by H2O2. We find that cells with normal CFTR are more sensitive to oxidative stress-induced apoptosis than cells expressing defective CFTR. In addition, sensitivity to apoptosis could be correlated with glutathione levels, because depletion of intracellular glutathione results in higher levels of apoptosis, and glutathione levels decreased faster in cells expressing normal CFTR than in cells with defective CFTR during incubation with H2O2. The pro-apoptotic BCL-2 family member, BAY, is also activated faster in cells expressing normal CFTR than in those with mutant CFTR under these conditions, and artificial glutathione depletion increases the extent of BAX activation. These results suggest that glutathione-dependent BAX activation in cells with normal CFTR represents an early step in oxidative stress-induced apoptosis of these cells.	Inst Pasteur, Lab Resonance Magnet Nucl Biomol, F-75724 Paris 15, France; Univ Paris 07, INSERM, Unite Biol Mol Gene, U277, F-75221 Paris, France; Inst Chim Subst Nat, UPR 2301, F-91198 Gif Sur Yvette, France; Hop Henri Mondor, INSERM, U 468, F-94010 Creteil, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ojcius, DM (corresponding author), Inst Pasteur, Lab Resonance Magnet Nucl Biomol, 25 Rue Dr Roux, F-75724 Paris 15, France.			Fanen, Pascale/0000-0002-3273-5349; Duffieux, Francis/0000-0003-4906-0314				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; Aoshiba K, 1999, AM J RESP CELL MOL, V21, P54, DOI 10.1165/ajrcmb.21.1.3411; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; CANNON CL, 1999, PEDIATR PULM, V19, P322; Celli A, 1998, AM J PHYSIOL-GASTR L, V275, pG749, DOI 10.1152/ajpgi.1998.275.4.G749; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Clain J, 2001, J BIOL CHEM, V276, P9045, DOI 10.1074/jbc.M008979200; Clarke LL, 1998, AM J PHYSIOL-GASTR L, V274, pG718, DOI 10.1152/ajpgi.1998.274.4.G718; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; Gallagher AM, 2001, AM J PHYSIOL-GASTR L, V281, pG681, DOI 10.1152/ajpgi.2001.281.3.G681; Gao L, 1999, AM J PHYSIOL-LUNG C, V277, pL113, DOI 10.1152/ajplung.1999.277.1.L113; Gao L, 2001, AM J PHYSIOL-LUNG C, V281, pL24, DOI 10.1152/ajplung.2001.281.1.L24; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Ho YS, 1997, MOL CARCINOGEN, V19, P101, DOI 10.1002/(SICI)1098-2744(199707)19:2<101::AID-MC5>3.0.CO;2-I; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Hultberg B, 1999, CLIN CHIM ACTA, V283, P21, DOI 10.1016/S0009-8981(99)00028-5; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim JA, 1999, BIOCHEM BIOPH RES CO, V261, P682, DOI 10.1006/bbrc.1999.1108; Konstan MW, 1997, PEDIATR PULM, V24, P137, DOI 10.1002/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3; LETHEM MI, 1990, EUR RESPIR J, V3, P19; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; Linsdell P, 1998, AM J PHYSIOL-CELL PH, V275, pC323, DOI 10.1152/ajpcell.1998.275.1.C323; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Maiuri L, 1997, FEBS LETT, V408, P225, DOI 10.1016/S0014-5793(97)00347-5; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Morcillo EJ, 1999, PHARMACOL RES, V40, P393, DOI 10.1006/phrs.1999.0549; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; MURTIE J, 1999, PEDIATR PULM, V19, P316; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakajima Y, 1999, LIFE SCI, V64, P2489, DOI 10.1016/S0024-3205(99)00206-4; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V284, P203, DOI 10.1006/bbrc.2001.4927; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ojcius DM, 1996, RES IMMUNOL, V147, P175, DOI 10.1016/0923-2494(96)83169-5; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman Q, 1999, CRIT REV TOXICOL, V29, P543, DOI 10.1080/10408449991349276; RANASINHA C, 1993, LANCET, V342, P199, DOI 10.1016/0140-6736(93)92297-7; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; vanKlaveren RJ, 1997, EUR RESPIR J, V10, P1392, DOI 10.1183/09031936.97.10061392; Velsor LW, 2001, AM J PHYSIOL-LUNG C, V281, pL31, DOI 10.1152/ajplung.2001.281.1.L31; WEBER A, 1999, PEDIATR PULM, V19, P309; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YASUDA M, 1995, ARCH HISTOL CYTOL, V58, P185, DOI 10.1679/aohc.58.185; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	67	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27912	27918		10.1074/jbc.M110288200	http://dx.doi.org/10.1074/jbc.M110288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023951	Green Published, hybrid			2022-12-25	WOS:000177189800042
J	Karlok, MA; Jang, SH; Jaehning, JA				Karlok, MA; Jang, SH; Jaehning, JA			Mutations in the yeast mitochondrial RNA polymerase specificity factor, Mtf1, verify an essential role in promoter utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIELD GEL-ELECTROPHORESIS; OPEN COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGMA-FACTORS; MOVING-PICTURES; DNA MOLECULES; SC-MTTFB	The yeast mitochondrial RNA polymerase (RNAP) is a two-subunit enzyme composed of a catalytic core (Rpo41) and a specificity factor (Mtf1) encoded by nuclear genes. Neither subunit on its own interacts with promoter DNA, but the combined holo-RNAP recognizes and selectively initiates from promoters related to the consensus sequence ATATAAGTA. To pursue the question of why Rpo41, which resembles the single polypeptide RNAPs from bacteriophage T7 and T3, requires a separate specificity factor, we analyzed a collection of Mtf1 point mutations that confer an in vivo petite phenotype. These mutant proteins are able to interact with Rpo41 and are capable of nearly wild type levels of initiation in vitro with a consensus promoter-containing template (14 S rRNA). However, the petite phenotype of two mutants can be explained by the fact that they exhibit dramatic transcriptional defects on non-consensus promoters. Y54F is incapable of transcribing the weak tRNA(Cys) promoter, and C192F cannot transcribe either tRNA(Cys) or the variant COX2 promoter from linear DNA templates. Transcription of the tRNA(Cys) promoter by both mutants was significantly corrected by addition of an initiating dinucleotide primer or by supercoiling the DNA template. These results establish the critical role of Mtf1 in promoter recognition and initiation of transcription.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Taegu Univ, Dept Mol Biol, Taegu 712714, South Korea	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jaehning, JA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave,B121, Denver, CO 80262 USA.				NIGMS NIH HHS [GM36692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bendich AJ, 1996, J MOL BIOL, V255, P564, DOI 10.1006/jmbi.1996.0048; BIAS TK, 1986, J BIOL CHEM, V261, P3927; BISWAS TK, 1990, P NATL ACAD SCI USA, V87, P9338, DOI 10.1073/pnas.87.23.9338; BISWAS TK, 1990, J BIOL CHEM, V265, P19053; Biswas TK, 1996, GENE, V170, P23, DOI 10.1016/0378-1119(95)00874-8; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; CAMERON VL, 1989, J BIOL CHEM, V264, P13391; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Chang CC, 1999, PLANT CELL, V11, P911, DOI 10.1105/tpc.11.5.911; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cho JH, 1998, MOL CELL BIOL, V18, P5712, DOI 10.1128/MCB.18.10.5712; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; Cliften PF, 1997, GENE DEV, V11, P2897, DOI 10.1101/gad.11.21.2897; Cliften PF, 2000, MOL CELL BIOL, V20, P7013, DOI 10.1128/MCB.20.18.7013-7023.2000; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; Grams J, 2002, J BIOL CHEM, V277, P16952, DOI 10.1074/jbc.M200662200; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Gruber TM, 2001, MOL CELL, V8, P21, DOI 10.1016/S1097-2765(01)00292-1; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Jacobs MA, 1996, CURR GENET, V30, P3, DOI 10.1007/s002940050093; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; JANG SH, 1994, TRANSCRIPTION, P171; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KELLY JL, 1986, J BIOL CHEM, V261, P348; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; Mangus D A, 1996, Methods Enzymol, V264, P57, DOI 10.1016/S0076-6879(96)64009-9; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; Nam SC, 2001, PROTEIN EXPRES PURIF, V21, P485, DOI 10.1006/prep.2000.1383; Newman SM, 1996, NUCLEIC ACIDS RES, V24, P386, DOI 10.1093/nar/24.2.386; OSINGA KA, 1982, NUCLEIC ACIDS RES, V10, P7993, DOI 10.1093/nar/10.24.7993; OSINGA KA, 1984, NUCLEIC ACIDS RES, V12, P1889, DOI 10.1093/nar/12.4.1889; Prieto-Martin A, 2001, FEBS LETT, V503, P51, DOI 10.1016/S0014-5793(01)02695-3; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; WETTSTEINEDWARDS J, 1986, J BIOL CHEM, V261, P2905; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214	53	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28143	28149		10.1074/jbc.M204123200	http://dx.doi.org/10.1074/jbc.M204123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12021282	hybrid			2022-12-25	WOS:000177189800071
J	Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Semenza, GL; Van Obberghen, E				Treins, C; Giorgetti-Peraldi, S; Murdaca, J; Semenza, GL; Van Obberghen, E			Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; INITIATION-FACTOR EIF2B; FACTOR MESSENGER-RNA; DNA-BINDING ACTIVITY; PROTEIN-KINASE-B; FACTOR EXPRESSION; FACTOR-I; GENE-EXPRESSION; GLIOMA-CELLS	Hypoxia-inducible factor 1 (HIF-1) is a transcription factor involved in normal mammalian development and in the pathogenesis of several disease states. It consists of two subunits, HIF-1alpha, which is degraded during normoxia, and HIF-1beta, which is constitutively expressed. Activated HIF-1 induces the expression of genes involved in angiogenesis, erythropoiesis, and glucose metabolism. We have previously reported that insulin stimulates vascular endothelial growth factor (VEGF) expression (1). In this study, we show that insulin activates HIF-1, leading to VEGF expression in retinal epithelial cells. Insulin activates HIF-1alpha protein expression in a dose-dependent manner with a maximum reached within 6 h. The expression of HIF-1alpha is correlated with the activation of HIF-1 DNA binding activity and the transactivation of a HIF-1-dependent reporter gene. Insulin does not appear to affect HIF-1alpha mRNA transcription but regulates HIF-1alpha protein expression through a translation-dependent pathway. The expression of an active form of protein kinase B and treatment of cells with specific inhibitors of phosphatidylinositol 3-kinase (PI3K), MAPK, and target of rapamycin (TOR) show that mainly PI3K and to a lesser extent TOR are required for insulin-induced HIF-1alpha expression. HIF-1 activity and VEGF expression are also dependent on PI3K- and TOR-dependent signaling. In conclusion, we show here that insulin regulates HIF-1 action through a PI3K/TOR-dependent pathway, resulting in increased VEGF expression.	Fac Med Nice, INSERM, U145, Inst Federatif Rech 50, F-06107 Nice 2, France; Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Johns Hopkins University	Giorgetti-Peraldi, S (corresponding author), Fac Med Nice, INSERM, U145, Inst Federatif Rech 50, F-06107 Nice 2, France.			Giorgetti-Peraldi, Sophie/0000-0002-2751-2618				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; Agardh Carl-David, 1992, Journal of Diabetes and its Complications, V6, P96, DOI 10.1016/1056-8727(92)90018-G; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Blancher C, 2001, CANCER RES, V61, P7349; BRINCHMANNHANSEN O, 1992, BRIT MED J, V304, P19, DOI 10.1136/bmj.304.6818.19; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Funatsu H, 2001, JPN J OPHTHALMOL, V45, P577, DOI 10.1016/S0021-5155(01)00420-8; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lawrence JC, 1997, ADV ENZYME REGUL, V37, P239, DOI 10.1016/S0065-2571(96)00016-7; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P3281; Maity A, 2000, CANCER RES, V60, P5879; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; MOSKALETS E, 1994, J DIABETES COMPLICAT, V8, P45, DOI 10.1016/1056-8727(94)90010-8; Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STEIN I, 1995, MOL CELL BIOL, V15, P5363; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Van Obberghen E, 2001, EUR J CLIN INVEST, V31, P966, DOI 10.1046/j.1365-2362.2001.00896.x; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang DG, 1999, CANCER RES, V59, P1464; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	57	437	465	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27975	27981		10.1074/jbc.M204152200	http://dx.doi.org/10.1074/jbc.M204152200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032158	hybrid			2022-12-25	WOS:000177189800050
J	Yamashita, T; Konishi, M; Miyake, A; Inui, K; Itoh, N				Yamashita, T; Konishi, M; Miyake, A; Inui, K; Itoh, N			Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT HYPOPHOSPHATEMIC RICKETS; TUMOR-INDUCED OSTEOMALACIA; OPOSSUM KIDNEY-CELLS; FACTOR RECEPTOR; RAT-KIDNEY; TRANSPORT; CLONING; FGF-23; DOMAIN; FGF23	The homeostasis of the plasma phosphate level is essential for many biological processes including skeletal mineralization. The reabsorption of phosphate in the kidney is a major determinant of the plasma levels of phosphate. Phosphatonin is a hormone-like factor that specifically inhibits phosphate uptake in renal proximal epithelial cells. Recent studies on tumor-induced osteomalacia suggested that phosphatonin was potentially identical to fibroblast growth factor (FGF)-23: However, as purified recombinant FGF-23 could not inhibit phosphate uptake in renal proximal epithelial cells, the mechanism of action of FGF-23 remains to be elucidated. Therefore, we examined the mechanism of action of FGF-23 in cultured renal proximal epithelial cells, opossum kidney cells. FGF-23 was found to require heparin-like molecules for its inhibitory activity on phosphate uptake. FGF-23 binds to the FGF receptor 3c, which is mainly expressed in opossum kidney cells, with high affinity. An inhibitor for tyrosine kinases of the FGF receptor, SU 5402, blocked the activity of FGF-23. FGF-23 activated the mitogen-activated protein kinase (MAPK) pathway, which is the major intracellular signaling pathway of FGF. Inhibitors of the MAPK pathway, PD98059 and 813203580, also blocked the activity of FGF-23. The present findings have revealed a novel MAPK-dependent mechanism of the regulation of phosphate uptake by FGF signaling.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan; Kyoto Univ Hosp, Dept Pharm, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Itoh, N (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; Cancilla B, 2001, KIDNEY INT, V60, P147, DOI 10.1046/j.1523-1755.2001.00781.x; CHASE LR, 1968, SCIENCE, V159, P545, DOI 10.1126/science.159.3814.545; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Hafdi Z, 1996, BIOCHEM J, V320, P615, DOI 10.1042/bj3200615; Konishi M, 2000, J BIOL CHEM, V275, P12119, DOI 10.1074/jbc.275.16.12119; Kumar R, 2000, BONE, V27, P333, DOI 10.1016/S8756-3282(00)00334-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Murer H, 1997, PFLUG ARCH EUR J PHY, V433, P379, DOI 10.1007/s004240050292; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756-3282(01)00660-3; Szebenyi G, 1999, INT REV CYTOL, V185, P45; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	21	139	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28265	28270		10.1074/jbc.M202527200	http://dx.doi.org/10.1074/jbc.M202527200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032146	hybrid			2022-12-25	WOS:000177189800085
J	Chikumi, H; Vazquez-Prado, J; Servitja, JM; Miyazaki, H; Gutkind, JS				Chikumi, H; Vazquez-Prado, J; Servitja, JM; Miyazaki, H; Gutkind, JS			Potent activation of RhoA by G alpha(q) and G(q)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; STRESS FIBER FORMATION; P115 RHOGEF; KINASE; ADHESION; GROWTH; FAMILY; RAS	Heterotrimeric G proteins of the G(i), G(s), and G(q) family control a wide array of physiological functions primarily by regulating the activity of key intracellular second messenger-generating systems. a subunits of the G(12) family, Galpha(12) and Galpha(13), however, can promote cellular responses that are independent of conventional second messengers but that result from the activation of small GTP-binding proteins of the Rho family and their downstream targets. These findings led to the identification of a novel family of guanine-nucleotide exchange factors (GEFs) that provides a direct link between Galpha(12/13) and Rho stimulation. Recent observations suggest that many cellular responses elicited by Galpha(q) and its coupled receptors also require the functional activity of Rho. However, available evidence suggests that Gaq may act on pathways downstream from Rho rather than by promoting Rho activation. These seemingly conflicting observations and the recent development of sensitive assays to assess the in vivo levels of active Rho prompted us to ask whether Gaq and its coupled receptors can stimulate endogenous Rho. Here we show that the expression of activated forms of Gaq and the stimulation of G(q)-coupled receptors or chimeric Galpha(q) molecules that respond to G(i)-linked receptors can promote a robust activation of endogenous Rho in HEK-293T cells. Interestingly, this response was not prevented by molecules interfering with the ability of G a,, to stimulate its linked RhoGEFs, together suggesting the existence of a novel molecular mechanism by which Gaq and the large family of G(q)-coupled receptors can regulate the activity of Rho and its downstream signaling pathways.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; VAZQUEZ-PRADO, JOSE/C-1630-2017	Gutkind, J. Silvio/0000-0002-5150-4482; VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; SERVITJA, JOAN-MARC/0000-0002-1241-8004	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHIKUMI H, 2002, J BIOL CHEM; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	24	138	138	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27130	27134		10.1074/jbc.M204715200	http://dx.doi.org/10.1074/jbc.M204715200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016230	hybrid			2022-12-25	WOS:000177055900056
J	Fehlner-Gardiner, C; Roshick, C; Carlson, JH; Hughes, S; Belland, RJ; Caldwell, HD; McClarty, G				Fehlner-Gardiner, C; Roshick, C; Carlson, JH; Hughes, S; Belland, RJ; Caldwell, HD; McClarty, G			Molecular basis defining human Chlamydia trachomatis tissue tropism - A possible role for tryptophan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNIT; BETA-2 SUBUNIT; FLEXIBLE LOOP; SALMONELLA-TYPHIMURIUM; ALPHA-2-BETA-2 COMPLEX; NUCLEOTIDE-SEQUENCE; INTERFERON-GAMMA	Here we report the cloning and sequencing of a region of the chlamydiae chromosome termed the "plasticity zone" from all the human serovars of C. trachomatis containing the tryptophan biosynthesis genes. Our results show that this region contains orthologues of the tryptophan repressor as well as the alpha and beta subunits of tryptophan synthase. Results from reverse transcription-PCR and Western blot analyses indicate that the trpBA genes are transcribed, and protein products are expressed. The TrpB sequences from all serovars are highly conserved. In comparison with other tryptophan synthase beta subunits, the chlamydial TrpB subunit retains all conserved amino acid residues required for beta reaction activity. In contrast, the chlamydial TrpA sequences display numerous mutations, which distinguish them from TrpA sequences of all other prokaryotes. All ocular serovars contain a deletion mutation resulting in a truncated TrpA protein, which lacks a reaction activity. The TrpA protein from the genital serovars retains conserved amino acids required for catalysis but has mutated several active site residues involved in substrate binding. Complementation analysis in Escherchia coli strains, with defined mutations in tryptophan biosynthesis, and in vitro enzyme activity data, with cloned TrpB and TrpA proteins, indicate these mutations result in a TrpA protein that is unable to utilize indole glycerol 3-phosphate as substrate. In contrast, the chlamydial TrpB protein can carry out the betareaction, which catalyzes the formation of tryptophan from indole and serine. The activity of the chlamydial Trp B protein differs from that of the well characterized E. coli and Salmonella TrpBs in displaying an absolute requirement for full-length TrpA. Taken together our data indicate that genital, but not ocular, serovars are capable of utilizing exogenous indole for the biosynthesis of tryptophan.	Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada; Hlth Canada, Natl Microbiol Lab, Winnipeg, MB R3E 0W3, Canada; NIAID, Rocky Mt Labs, Intracellular Parasites Lab, NIH, Hamilton, MT 59840 USA; NIAID, Rocky Mt Labs, Lab Human Bacterial Pathogenesis, NIH, Hamilton, MT 59840 USA	University of Manitoba; Health Canada; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	McClarty, G (corresponding author), Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada.	mcclart@cc.umanitoba.ca			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000672, Z01AI000845, Z01AI000672, ZIAAI000845] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN MK, 1963, GENETICS, V48, P1065; BALOWS A, 1991, PROKARYOTES, P1; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; BEATTY WL, 1994, MICROBIOL REV, V58, P686, DOI 10.1128/MMBR.58.4.686-699.1994; Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brunham RC, 1999, CHLAMYDIA, P211; BRZOVIC PS, 1992, J BIOL CHEM, V267, P13028; BRZOVIC PS, 1993, BIOCHEMISTRY-US, V32, P10404, DOI 10.1021/bi00090a016; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; Campbell LA, 2000, TRENDS MICROBIOL, V8, P255, DOI 10.1016/S0966-842X(00)01745-5; COLES AM, 1993, FEMS MICROBIOL LETT, V106, P193; CRAWFORD IP, 1975, BACTERIOL REV, V39, P87, DOI 10.1128/MMBR.39.2.87-120.1975; CRAWFORD IP, 1980, J MOL BIOL, V142, P489, DOI 10.1016/0022-2836(80)90259-4; CRAWFORD IP, 1958, P NATL ACAD SCI USA, V44, P1161, DOI 10.1073/pnas.44.12.1161; FLURI R, 1971, J BIOL CHEM, V246, P6620; GIBBS RS, 1987, AM J OBSTET GYNECOL, V156, P491, DOI 10.1016/0002-9378(87)90318-8; Grayston J T, 1997, Cardiologia, V42, P1145; HIGGINS W, 1980, J BIOL CHEM, V255, P512; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jones ML, 2001, MICROB PATHOGENESIS, V30, P299, DOI 10.1006/mpat.2001.0433; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; Kim SK, 2001, CURR OPIN IMMUNOL, V13, P429, DOI 10.1016/S0952-7915(00)00237-5; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Kuo CC, 1998, MOL MED TODAY, V4, P426, DOI 10.1016/S1357-4310(98)01351-3; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; LACY MJ, 1986, J IMMUNOL METHODS, V87, P169, DOI 10.1016/0022-1759(86)90527-2; LANE AN, 1983, EUR J BIOCHEM, V129, P571; Larsen B, 2001, CLIN INFECT DIS, V32, pE69, DOI 10.1086/318710; LIM WK, 1991, J BIOL CHEM, V266, P20205; Loomis WP, 2002, CURR OPIN MICROBIOL, V5, P87, DOI 10.1016/S1369-5274(02)00291-6; Mabey D, 1999, BRIT J OPHTHALMOL, V83, P1261, DOI 10.1136/bjo.83.11.1261; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; MILTON DL, 1986, J BIOL CHEM, V261, P6604; Morrison RP, 2000, INFECT IMMUN, V68, P6038, DOI 10.1128/IAI.68.10.6038-6040.2000; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NAGATA S, 1989, J BIOL CHEM, V264, P6288; NICHOLS BP, 1979, P NATL ACAD SCI USA, V76, P5244, DOI 10.1073/pnas.76.10.5244; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; ROSE JK, 1973, NATURE-NEW BIOL, V245, P133, DOI 10.1038/newbio245133a0; RUVINOV SB, 1992, FEBS LETT, V299, P197, DOI 10.1016/0014-5793(92)80246-D; Schachter J, 1999, CHLAMYDIA, P139; SCHACHTER J, 1989, PATHOL IMMUNOPATH R, V8, P206, DOI 10.1159/000157149; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Shaw AC, 2000, MICROBES INFECT, V2, P581, DOI 10.1016/S1286-4579(00)00368-3; Shirai M, 2000, NUCLEIC ACIDS RES, V28, P2311, DOI 10.1093/nar/28.12.2311; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; STEPHENS R, 1989, ANTIGENIC VARIATION; Stephens RS, 1999, CHLAMYDIA, P9; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TANIZAWA K, 1983, BIOCHEMISTRY-US, V22, P3594, DOI 10.1021/bi00284a009; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; YANOFSKY C, 1961, COLD SPRING HARB SYM, V26, P11, DOI 10.1101/SQB.1961.026.01.006; YANOFSKY C, 1972, J BIOL CHEM, V247, P4494; YANOFSKY C, 1960, BACTERIOL REV, V24, P221, DOI 10.1128/MMBR.24.2.221-245.1960; Yanofsky C, 2000, J BACTERIOL, V182, P1, DOI 10.1128/JB.182.1.1-8.2000	67	130	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26893	26903		10.1074/jbc.M203937200	http://dx.doi.org/10.1074/jbc.M203937200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011099	hybrid			2022-12-25	WOS:000177055900027
J	Gladysheva, IP; Sazonova, IY; Chowdhry, SA; Liu, L; Turner, RB; Reed, GL				Gladysheva, IP; Sazonova, IY; Chowdhry, SA; Liu, L; Turner, RB; Reed, GL			Chimerism reveals a role for the streptokinase beta-domain in nonproteolytic active site formation, substrate, and inhibitor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN BINDING REGION; RECOMBINANT STAPHYLOKINASE; MONOCLONAL-ANTIBODY; ACTIVATION; COMPLEX; MECHANISM; FIBRIN; ALPHA-2-ANTIPLASMIN; MICROPLASMIN; GENERATION	Streptokinase (SK) and staphylokinase form cofactorenzyme complexes that promote the degradation of fibrin thrombi by activating human plasminogen. The unique abilities of streptokinase to nonproteolytically activate plasminogen or to alter the interactions of plasmin with substrates and inhibitors may be the result of high affinity binding mediated by the streptokinase beta-domain. To examine this hypothesis, a chimeric streptokinase, SKbetaswap, was created by swapping the SK beta-domain with the homologous beta-domain of Streptococcus uberis Pg activator (SUPA or PauA, SK uberis), a streptokinase that cannot activate human plasminogen. SKbetaswap formed a tight complex with microplasminogen with an affinity comparable with streptokinase. The SKbetaswap-plasmin complex also activated human plasminogen with catalytic efficiencies (k(cat)/K-m = 16.8 versus 15.2 muM(-1) min(-1)) comparable with streptokinase. However, SKbetaswap was incapable of nonproteolytic active site generation and activated plasminogen by a staphylokinase mechanism. When compared with streptokinase complexes, SKbetaswap-plasmin and SKbetaswap-microplasmin complexes had altered affinities for low molecular weight substrates. The SKbetaswap-plasmin complex also was less resistant than the streptokinase-plasmin complex to inhibition by alpha(2)-antiplasmin and was readily inhibited by soybean trypsin inhibitor. Thus, in addition to mediating high affinity binding to plasmin(ogen), the streptokinase beta-domain is required for nonproteolytic active site generation and specifically modulates the interactions of the complex with substrates and inhibitors.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave,II-127, Boston, MA 02115 USA.		Gladysheva, Inna/AAU-9465-2020	Gladysheva, Inna/0000-0002-2501-9029	NHLBI NIH HHS [HL-57314, R01 HL058496] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057314] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIETH J, 1974, BIOCHIM BIOPHYS ACTA, V364, P97, DOI 10.1016/0005-2744(74)90136-3; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BUCK FF, 1968, J BIOL CHEM, V243, P3648; CASTELLINO FJ, 1984, SEMIN THROMB HEMOST, V10, P18, DOI 10.1055/s-2007-1004404; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; COLLEN D, 1993, EUR J BIOCHEM, V216, P307, DOI 10.1111/j.1432-1033.1993.tb18147.x; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; COLLEN D, 1993, J BIOL CHEM, V268, P8284; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GONIAS SL, 1988, BLOOD, V72, P1658; Gulba DC, 1996, ANN HEMATOL, V73, pS9; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jespers L, 1999, THROMB HAEMOSTASIS, V81, P479; Johnsen LB, 1999, INFECT IMMUN, V67, P1072, DOI 10.1128/IAI.67.3.1072-1078.1999; Johnsen LB, 2000, BIOCHEMISTRY-US, V39, P6440, DOI 10.1021/bi9922502; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LIJNEN HR, 1993, EUR J BIOCHEM, V211, P91, DOI 10.1111/j.1432-1033.1993.tb19873.x; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; LUKACOVA D, 1991, BIOCHEMISTRY-US, V30, P10164, DOI 10.1021/bi00106a013; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1973, BIOCHEM BIOPH RES CO, V51, P672, DOI 10.1016/0006-291X(73)91367-3; REDDY KNN, 1986, THROMB RES, V41, P671, DOI 10.1016/0049-3848(86)90364-6; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; REED GL, 1993, J IMMUNOL, V150, P4407; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.tb20441.x; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; Sazonova IY, 2001, J BIOL CHEM, V276, P12609, DOI 10.1074/jbc.M009265200; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; WOHL RC, 1980, J BIOL CHEM, V255, P2005; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	45	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26846	26851		10.1074/jbc.M202999200	http://dx.doi.org/10.1074/jbc.M202999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016220	hybrid			2022-12-25	WOS:000177055900020
J	Ho, CS; Marinescu, V; Steinhilb, ML; Gaut, JR; Turner, RS; Stuenkel, EL				Ho, CS; Marinescu, V; Steinhilb, ML; Gaut, JR; Turner, RS; Stuenkel, EL			Synergistic effects of Munc18a and X11 proteins on amyloid precursor protein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; SYNAPTIC VESICLE EXOCYTOSIS; ALZHEIMERS-DISEASE; BETA-PROTEIN; PDZ DOMAINS; CYTOPLASMIC DOMAIN; DISTINCT SITES; SECRETION; COMPLEX; FE65	X11 proteins have been shown to modulate metabolism of the amyloid precursor protein (APP) and to reduce the secretion of beta-amyloid peptides (Abeta) that are associated with Alzheimer's disease. Whereas X11alpha interacts with APP via its phosphotyrosine-binding domain, recent reports indicate that additional regulatory interactions involve the N terminus of X11. Here we report that the syntaxin-1alpha-binding protein Munc18a, which interacts with the Munc18a-interacting domain (MID) at the N terminus of X11, strongly regulates the actions of X11 on APP metabolism. When co-expressed with X11alpha, Munc18a potentiated the retention of APP and suppression of A13 secretion by X11alpha. As a result, the constitutive release of Abeta40 was nearly abolished. Experiments using N terminus deletion mutants of X11alpha/beta and the MID-deficient X11gamma revealed that the majority of the regulatory effect by Munc18a occurred independent of a direct interaction of Munc18a with X11, although the presence of X11 was required. Munc18a expression induced a small increase in beta-secretase activity, whereas it also intensified the reduction in AP40 secretion by X11alpha. These data indicate that Munc18a in concert with X11 acts to suppress gamma-secretase processing. We conclude that Munc18a acts through direct and indirect interactions with X11 proteins and powerfully regulates APP metabolism and Abeta secretion.	Univ Michigan, Med Ctr, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Inst Gerontol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Stuenkel, EL (corresponding author), 7804 Med Sci Bldg 2,1301 E Catherine St, Ann Arbor, MI 48109 USA.	esterm@umich.edu	Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935; Stuenkel, Edward/0000-0001-8225-5725	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG008671, P50 AG 08671] Funding Source: Medline; NINDS NIH HHS [NS 11103, NS 36277] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Hare JF, 2001, BIOCHEM BIOPH RES CO, V281, P1298, DOI 10.1006/bbrc.2001.4507; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Koo EH, 1996, J CELL SCI, V109, P991; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Nakajima Y, 2001, MOL BRAIN RES, V92, P27, DOI 10.1016/S0169-328X(01)00126-7; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 2001, NEUROSCIENCE, V104, P653, DOI 10.1016/S0306-4522(01)00124-5; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rowe J, 1999, J CELL SCI, V112, P1865; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	41	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27021	27028		10.1074/jbc.M201823200	http://dx.doi.org/10.1074/jbc.M201823200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016213	hybrid, Green Submitted			2022-12-25	WOS:000177055900043
J	Roh, MH; Liu, CJ; Laurinec, S; Margolis, B				Roh, MH; Liu, CJ; Laurinec, S; Margolis, B			The carboxyl terminus of zona occludens-3 binds and recruits a mammalian homologue of discs lost to tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADHESION MOLECULE; CELL-POLARITY; DROSOPHILA-MELANOGASTER; PDZ DOMAINS; OCCLUDIN; CRUMBS; ZO-1; EPITHELIA; STARDUST	Mammalian homologues of the Drosophila polarity proteins Stardust, Discs Lost, and Crumbs have been identified as Pals1, Pals1-associated tight junction protein (PATJ), and human Crumbs homologue 1 (CRB1), respectively. We have previously demonstrated that PATJ, Pals1, and CRB1 can form a tripartite tight junction complex in epithelial cells and that PATJ recruits Pals1 to tight junctions. Here, we observed that the Pals1/PATJ interaction was not crucial for the ultimate targeting of PATJ itself to tight junctions. This prompted us to examine if any of the 10 post-synaptic density-95/Discs Large/zona occludens-1 (PDZ) domains of PATJ could bind to the carboxyl termini of known tight junction constituents. We found that the 6(th) and 8(th) PDZ domains of PATJ can interact with the carboxyl termini of zona occludens-3 (ZO-3) and claudin 1, respectively. PATJ missing the 6(th) PDZ domain was found to mislocalize away from cell contacts. Surprisingly, deleting the 8(th) PDZ domain had little effect on PATJ localization. Finally, reciprocal co-immunoprecipitation experiments revealed that full-length ZO-3 can associate with PATJ. Hence, the PATJ/ZO-3 interaction is likely important for recruiting PATJ and its associated proteins to tight junctions.	Univ Michigan, Ctr Med, Howard Hughes Med Inst, Dept Biol Chem,Med Sch, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Ctr Med, Howard Hughes Med Inst, Dept Biol Chem,Med Sch, 4570 MSRB 2,Box 0650,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NIDDK NIH HHS [DK 58208] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07863, T32 GM 07544-24] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544, T32GM007863] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Grawe F, 1996, DEVELOPMENT, V122, P951; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Lapierre LA, 2000, ADV DRUG DELIVER REV, V41, P255, DOI 10.1016/S0169-409X(00)00045-4; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRAIGHT K, 2001, EMBO J, V12, P1329; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tepass U, 2001, ANNU REV GENET, V35, P747, DOI 10.1146/annurev.genet.35.102401.091415; TEPASS U, 1993, DEV BIOL, V159, P311, DOI 10.1006/dbio.1993.1243; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Tsukita S, 1998, GENES CELLS, V3, P569, DOI 10.1046/j.1365-2443.1998.00212.x; Vaccaro P, 2001, J BIOL CHEM, V276, P42122, DOI 10.1074/jbc.M104208200; Wei XR, 2001, MECH DEVELOP, V100, P217, DOI 10.1016/S0925-4773(00)00550-5; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	38	130	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27501	27509		10.1074/jbc.M201177200	http://dx.doi.org/10.1074/jbc.M201177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021270	hybrid			2022-12-25	WOS:000177055900100
J	You, ZZ; Kong, L; Newport, J				You, ZZ; Kong, L; Newport, J			The role of single-stranded DNA and polymerase alpha in establishing the ATR, Hus1 DNA replication checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; SCHIZOSACCHAROMYCES-POMBE; DAMAGE CHECKPOINT; FACTOR-C; PROTEIN COMPLEX; BUDDING YEAST; SLIDING CLAMP; IN-VIVO; CHK1; RAD1	Using a nucleus-free DNA replication system we have investigated the roles of Xenopus ATR (YATR) and Hus1 (Xhus1) as the DNA replication checkpoint sensors. Like XATR, Xhus1 is required for the checkpoint-dependent phosphorylation of Xchk1 and associates with chromatin in an initiation-dependent manner. While removal of replication protein A inhibits chromatin association of both XATR and Xhus1, removal of polymerase a only disrupts chromatin association of Xhus1. In addition, chromatin association of XATR and Xhus1 are independent of each other. Finally, like XATR, Xhus1 associates with chromatin in unperturbed S phase and dissociates from chromatin following completion of DNA replication.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newport, J (corresponding author), Univ Calif San Diego, Div Biol, Bonner Hall,4202,9500 Gilman Dr,, La Jolla, CA 92093 USA.		You, Zhongsheng/F-5404-2012	You, Zhongsheng/0000-0002-9719-8791	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044656] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 44656] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Brown EJ, 2000, GENE DEV, V14, P397; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu QH, 2000, GENE DEV, V14, P1448; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Melo JA, 2001, GENE DEV, V15, P2809; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shimada M, 1999, MOL BIOL CELL, V10, P3991, DOI 10.1091/mbc.10.12.3991; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Takai H, 2000, GENE DEV, V14, P1439; Tan SY, 2000, MOL CELL BIOL, V20, P7853, DOI 10.1128/MCB.20.21.7853-7866.2000; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Weiss RS, 2000, GENE DEV, V14, P1886; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	46	96	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27088	27093		10.1074/jbc.M204120200	http://dx.doi.org/10.1074/jbc.M204120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015327	hybrid			2022-12-25	WOS:000177055900051
J	Fiola, K; Perreault, JP				Fiola, K; Perreault, JP			Kinetic and binding analysis of the catalytic involvement of ribose moieties of a trans-acting delta ribozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS RIBOZYME; CRYSTAL-STRUCTURE; TRANSFER-RNA; CLEAVAGE; SPECIFICITY; HAMMERHEAD; HAIRPIN	We have identified ribose 2'-hydroxyl groups (2'-OHs) that are critical for the activity of a trans-cleaving S ribozyme derived from the antigenomic strand of the hepatitis 5 virus. Initially, an RNA-DNA mixed ribozyme composed of 26 deoxyribo- (specifically the nucleotides forming the P2 stem and the P4 stem-loop) and 31 ribonucleotides (those forming the catalytic center) was engineered. This mixed ribozyme catalyzed the cleavage of a small substrate with kinetic parameters virtually identical to those of the all-RNA ribozyme. The further substitution of deoxyribose for ribose residues permitted us to investigate the contribution of all 2'-OHs to catalysis. Determination of the kinetic parameters for the cleavage reaction of the resulting ribozymes revealed (i) 10 2'-OH groups appear to be important in supporting the formation of several hydrogen bonds within the catalytic core, 00 none of the important 2'-OHs seem to coordinate a magnesium cation, and (iii) 1 of the tested RNA-DNA mixed polymers appeared to stabilize the ribozyme-substrate transition-state complex, resulting in an improvement over the all-RNA counterpart. The contribution of the 2'-OHs to the catalytic mechanism is discussed, and differences with the crystal structure of a genomic 5 self-cleaved product are explained. Clearly, the 2'-OHs are essential components of the network of interactions involved in the formation of the catalytic center of the 5 ribozyme.	Univ Sherbrooke, Dept Biochim, RNA Grp, Grp ARN, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Perreault, JP (corresponding author), Univ Sherbrooke, Dept Biochim, RNA Grp, Grp ARN, Sherbrooke, PQ J1H 5N4, Canada.				Canadian Institutes of Health Research [44002] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Ananvoranich S, 2000, BIOCHEM BIOPH RES CO, V270, P600, DOI 10.1006/bbrc.2000.2465; Ananvoranich S, 1998, J BIOL CHEM, V273, P13182, DOI 10.1074/jbc.273.21.13182; Ananvoranich S, 2001, METHOD ENZYMOL, V341, P553, DOI 10.1016/S0076-6879(01)41176-1; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHOWRIRA BM, 1993, J BIOL CHEM, V268, P19458; Doherty EA, 2000, ANNU REV BIOCHEM, V69, P597, DOI 10.1146/annurev.biochem.69.1.597; EGLI M, 1993, BIOCHEMISTRY-US, V32, P3221, DOI 10.1021/bi00064a004; Fauzi H, 1998, ANAL CHIM ACTA, V365, P309, DOI 10.1016/S0003-2670(97)00598-9; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; Hertel KJ, 1996, EMBO J, V15, P3751, DOI 10.1002/j.1460-2075.1996.tb00745.x; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KUMAR PKR, 1994, BIOCHEMISTRY-US, V33, P583, DOI 10.1021/bi00168a025; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; Lafontaine DA, 1999, NUCLEIC ACIDS RES, V27, P3236, DOI 10.1093/nar/27.15.3236; Mercure S, 1998, BIOCHEMISTRY-US, V37, P16975, DOI 10.1021/bi9809775; Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; PAN T, 1993, RNA WORLD, P371; Pereira MJB, 2002, BIOCHEMISTRY-US, V41, P730, DOI 10.1021/bi011963t; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; Saenger W, 1984, PRINCIPLES NUCL ACID, P331; Sakamoto T, 1997, J BIOCHEM, V121, P1123; Sood VD, 2002, NUCLEIC ACIDS RES, V30, P1132, DOI 10.1093/nar/30.5.1132; Tanaka Y, 2002, NUCLEIC ACIDS RES, V30, P766, DOI 10.1093/nar/30.3.766; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; THILL G, 1993, BIOCHEMISTRY-US, V32, P4254, DOI 10.1021/bi00067a013; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; WICKHAM GS, 2002, CELL MOL LIFE SCI, V59, P112	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26508	26516		10.1074/jbc.M203468200	http://dx.doi.org/10.1074/jbc.M203468200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12015324	Green Accepted, hybrid			2022-12-25	WOS:000176908700090
J	Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ				Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ			Maspin sensitizes breast carcinoma cells to induced apoptosis	ONCOGENE			English	Article						tumor suppressor; serpin; staurosporine; caspases; maspin/PAI-1 chimera; PAI-1/maspin chimera; cell motility	TUMOR-NECROSIS-FACTOR; MAMMARY EPITHELIAL-CELLS; ALPHA-INDUCED APOPTOSIS; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; POLY(ADP-RIBOSE) POLYMERASE; THYMOSIN BETA-10; PROTEIN-KINASE; CANCER CELLS; SERPIN	Maspin, a novel serine protease inhibitor (serpin), suppresses the growth and metastasis of breast tumor in vivo. However, the underlying molecular mechanism is unclear. In the current study, we report the first evidence that endogenous maspin expression in mammary carcinoma cells MDA-MB-435 enhanced staurosporine (STS)-induced apoptosis as judged by the increased fragmentation of DNA, increased protcolytic inactivation of poly-[ADP-ribose]-polymerase (PARP), as well as the increased activation of caspase-8 and caspase-3. In parallel, recombinant maspin did not directly regulate the proteolytic activities of either caspase-3 or caspase-8 in vitro. Consistent with this result, maspin expressing normal mammary epithelial cells underwent more rapid STS-induced apoptosis as compared to breast carcinoma cells. Interestingly, maspin transfectant cells did not undergo spontaneous apoptosis in the absence of STS. Moreover, neither purified maspin protein added from outside nor endogenous maspin secreted to the cell culture media sensitized cells to STS-induced apoptosis. To investigate the structural determinants of maspin in its apoptosis-sensitizing effect, MDA-MB-435 cells were also transfected with maspin/PAI-1 and PAI-1/maspin chimeric constructs resulting from swapping the N-terminal and the C-terminal domains between maspin and PAI-1 (plasminogen activator inhibitor type 1). The resulting stable transfectant clones expressing maspin/PAI-1 and PAI-1/maspin, respectively, did not undergo spontaneous apoptosis, and were similarly inhibited as maspin transfectant cells in motility assay. Interestingly, however, expression of both maspin/PAI-1 and PAI-1/maspin in MDA-MB-435 cells failed to sensitize these cells to STS-induced apoptosis. Taken together, our evidence provides now insights into the complex molecular mechanisms of maspin that may suppress breast tumor progression not only at the step of invasion and motility, but also by regulating tumor cell apoptosis. The sensitizing effect of maspin on apoptosis is to be contrasted by the pro-survival effect of several other serpins.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Biliran H, 2001, CANCER RES, V61, P8676; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Bromme HJ, 1996, MOL CELL BIOCHEM, V164, P261; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lawrence DA, 1997, ADV EXP MED BIOL, V425, P99; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; McGowen R, 2000, CANCER RES, V60, P4771; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Schleef RR, 2000, J BIOL CHEM, V275, P26385, DOI 10.1074/jbc.C000389200; Seftor REB, 1998, CANCER RES, V58, P5681; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	45	107	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4089	4098		10.1038/sj.onc.1205507	http://dx.doi.org/10.1038/sj.onc.1205507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037665				2022-12-25	WOS:000176186000003
J	Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A				Simone, C; Stiegler, P; Bagella, L; Pucci, B; Bellan, C; De Falco, G; De Luca, A; Guanti, G; Puri, PL; Giordano, A			Activation of MyoD-dependent transcription by cdk9/cyclin T2	ONCOGENE			English	Article						cdk9; cyclins; MyoD; muscle differentiation; phosphorylation	RNA-POLYMERASE-II; P-TEFB KINASE; CARBOXY-TERMINAL DOMAIN; MUSCLE GENE-EXPRESSION; HELIX-LOOP-HELIX; CELL-CYCLE; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; MADS-BOX	Myogenic transcription is repressed in myoblasts by serum-activated cyclin-dependent kinases, such as cdk2 and cdk4. Serum withdrawal promotes muscle-specific gene expression at least in part by down-regulating the activity of these cdks. Unlike the other cdks, cdk9 is not serum- or cell cycle-regulated and is instead involved in the regulation of transcriptional elongation by phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase It. While ectopic expression of cdk2 together with its regulatory subunits (cyclins E and A) inhibits myogenic transcription, overproduction of cdk9 and its associated cyclin (cyclin T2a) strengthens MyoD-dependent transcription and stimulates myogenic differentiation in both MyoD-converted fibroblasts and C2C12 muscle cells. Conversely, inhibition of cdk9 activity by a dominant negative form (cdk9-dn) represses the myogenic program. Cdk9, cyclinT2 and MyoD can be detected in a multimeric complex in C2C12 cells, with the minimal cdk9-binding region of MyoD mapping within 101-161 aa of the bHLH region. Finally, cdk9 can phosphorylate MyoD in vitro, suggesting the possibility that cdk9/cycT2a regulation of muscle differentiation includes the direct enzymatic activity of the kinase on MyoD.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy; Univ Naples 2, Sch Med, Inst Topog Anat, I-80138 Naples, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena; Universita della Campania Vanvitelli; Sapienza University Rome; Salk Institute	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010; De Luca, Antonio/AAD-9562-2020; BELLAN, CRISTIANA/L-3903-2013; BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018	Giordano, Antonio/0000-0002-5959-016X; De Luca, Antonio/0000-0002-3905-6154; BELLAN, CRISTIANA/0000-0001-6119-9007; BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; BAGELLA, Luigi/0000-0003-2815-037X; Puri, Pier Lorenzo/0000-0003-4964-0095	Telethon [TCP00081] Funding Source: Medline	Telethon(Fondazione Telethon)		Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lis JT, 2000, GENE DEV, V14, P792; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MCLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SARTORELLI V, 2001, FRONT BIOSCI, V6, pD1073; SIMONE C, 2001, FRONT BIOSCI, V6, pD1024; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	100	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4137	4148		10.1038/sj.onc.1205493	http://dx.doi.org/10.1038/sj.onc.1205493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037670				2022-12-25	WOS:000176186000008
J	Beamish, H; Kedar, P; Kaneko, H; Chen, P; Fukao, T; Peng, C; Beresten, S; Gueven, N; Purdie, D; Lees-Miller, S; Ellis, N; Kondo, N; Lavin, MF				Beamish, H; Kedar, P; Kaneko, H; Chen, P; Fukao, T; Peng, C; Beresten, S; Gueven, N; Purdie, D; Lees-Miller, S; Ellis, N; Kondo, N; Lavin, MF			Functional link between BLM defective in Bloom's syndrome and the ataxia-telangiectasia-mutated protein, ATM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE RESPONSE; S-PHASE; SYNDROME CELLS; SYNDROME GENE; DEPENDENT PHOSPHORYLATION; IONIZING-RADIATION; CHECKPOINT PATHWAY; POSITIONAL CLONING; NUCLEAR-STRUCTURE	Chromosome aberrations, genomic instability, and cancer predisposition are hallmarks of a number of syndromes in which the defective genes recognize and/or repair DNA damage or are involved in some aspect of DNA processing. We report here direct interaction between BLM, mutated in Bloom's Syndrome (BS), and ATM, mutated is ataxia-telangiectasia, and we have mapped the sites of interaction. Full-length BLM cDNA corrected sister chromatid exchange (SCE) and radiosensitivity in BS cells. Mitotic phosphorylation of BLM was partially dependent on ATM, and phosphorylation sites on BLM were identified. A phosphospecific antibody against one of these sites (Thr-99) revealed radiation-induced phosphorylation, which was defective in ataxia-telangiectasia cells. Stable cell lines expressing phosphorylation site mutants failed to correct radiosensitivity in BS cells but corrected SCE. These mutants also sensitized normal control cells to radiation and increased radiation-induced chromosome aberrations but did not cause SCE numbers to increase. These data suggest that ATM and BLM function together in recognizing abnormal DNA structures by direct interaction and that these phosphorylation sites in BLM are important for radiosensitivity status but not for SCE frequency.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Brisbane, Qld 4029, Australia; NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008076, Japan; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Queensland, Dept Surg, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Pathol, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Gifu University; Memorial Sloan Kettering Cancer Center; University of Calgary; University of Queensland; University of Queensland	Lavin, MF (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Brisbane, Qld 4029, Australia.	martinL@qimr.edu.au	Peng, Cheng/G-4845-2010; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Lees-Miller, Susan/0000-0001-5809-2516; Peng, Cheng/0000-0003-2629-9437; Guven, Nuri/0000-0003-3782-767X	NCI NIH HHS [R01 CA085867, R01 CA085867-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; AURIAS A, 1985, CANCER GENET CYTOGEN, V16, P131, DOI 10.1016/0165-4608(85)90006-8; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHEBAB NH, 1999, P NATL ACAD SCI USA, V96, P13777; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, AM J HUM GENET, V57, P1019; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2001, ACTA ONCOL, V40, P686; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LONN U, 1990, CANCER RES, V50, P3141; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	49	101	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30515	30523		10.1074/jbc.M203801200	http://dx.doi.org/10.1074/jbc.M203801200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12034743	hybrid			2022-12-25	WOS:000177579800017
J	Bouton, C; Chauveau, MJ; Lazereg, S; Drapier, JC				Bouton, C; Chauveau, MJ; Lazereg, S; Drapier, JC			Recycling of RNA binding iron regulatory protein 1 into an aconitase after nitric oxide removal depends on mitochondrial ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL REGULATION; RESPONSIVE ELEMENTS; ABC TRANSPORTER; GENE-EXPRESSION; NO-SYNTHASE; CLUSTER; IDENTIFICATION; CELLS; TRANSCRIPTION; DEGRADATION	Iron regulatory proteins (IRPs) control iron metabolism by specifically interacting with iron-responsive elements (IREs) on mRNAs. Nitric oxide (NO) converts IRP-1 from a [4Fe-4S] aconitase to a trans-regulatory protein through Fe-S cluster disassembly. Here, we have focused on the fate of IRE binding IRP1 from murine macrophages when NO flux stops. We show that virtually all IRP-1 molecules from NO-producing cells dissociated from IRE and recovered aconitase activity after re-assembling a [4Fe-4S] cluster in vitro. The reverse change in IRP-1 activities also occurred in intact cells no longer exposed to NO and did not require de novo protein synthesis. Likewise, inhibition of mitochondrial aconitase via NO-induced Fe-S cluster disassembly was also reversed independently of protein translation after NO removal. Our results provide the first evidence of Fe-S cluster repair of NO-modified aconitases in mammalian cells. Moreover, we show that reverse change in IRP-1 activities and repair of mitochondrial aconitase activity depended on energized mitochondria. Finally, we demonstrate that IRP-1 activation by NO was accompanied by both a drastic decrease in ferritin levels and an increase in transferrin receptor mRNA levels. However, although ferritin expression was recovered upon IRP-1-IRE dissociation, expression of transferrin receptor mRNA continued to rise for several hours after stopping NO flux.	CNRS, Inst Chim Subst Nat, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Drapier, JC (corresponding author), CNRS, Inst Chim Subst Nat, Ave Terrasse, F-91190 Gif Sur Yvette, France.	Jean-Claude.Drapier@icsn.cnrs-gif.fr	Bouton, Cecile/J-8663-2013					Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; Bekri S, 2000, BLOOD, V96, P3256; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; Eisenstein RS, 2000, ANNU REV NUTR, V20, P627, DOI 10.1146/annurev.nutr.20.1.627; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gobert AP, 2000, INFECT IMMUN, V68, P4653, DOI 10.1128/IAI.68.8.4653-4657.2000; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; Kim S, 2000, J BIOL CHEM, V275, P6220, DOI 10.1074/jbc.275.9.6220; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; NASCIMENTO ALTO, 1995, CARCINOGENESIS, V16, P1335, DOI 10.1093/carcin/16.6.1335; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Recalcati S, 1998, BLOOD, V91, P1059, DOI 10.1182/blood.V91.3.1059.1059_1059_1066; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Savary S, 1997, GENOMICS, V41, P275, DOI 10.1006/geno.1997.4658; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Waddington SN, 2002, KIDNEY INT, V61, P876, DOI 10.1046/j.1523-1755.2002.00236.x; Wardrop SL, 2000, BIOCHEMISTRY-US, V39, P2748, DOI 10.1021/bi991099t; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7	46	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					31220	31227		10.1074/jbc.M203276200	http://dx.doi.org/10.1074/jbc.M203276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	12039960	hybrid			2022-12-25	WOS:000177579800103
J	Bitzer, M; Armeanu, S; Prinz, F; Ungerechts, G; Wybranietz, W; Spiegel, M; Bernlohr, C; Cecconi, F; Gregor, M; Neubert, WJ; Schulze-Osthoff, K; Lauer, UM				Bitzer, M; Armeanu, S; Prinz, F; Ungerechts, G; Wybranietz, W; Spiegel, M; Bernlohr, C; Cecconi, F; Gregor, M; Neubert, WJ; Schulze-Osthoff, K; Lauer, UM			Caspase-8 and Apaf-1-independent caspase-9 activation in Sendai virus-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; DEATH RECEPTORS; BCL-X; MITOCHONDRIA; PROCASPASE-9; CLEAVAGE; PATHWAYS; BINDING; APAF-1	Apoptotic cell death is of central importance in the pathogenesis of viral infections. Activation of a cascade of cysteine proteases, i.e. caspases, plays a key role in the effector phase of virus-induced apoptosis. However, little is known about pathways leading to the activation of initiator caspases in virus-infected host cells. Recently, we have shown that Sendai virus (SeV) infection triggers apoptotic cell death by activation of the effector caspase-3 and initiator caspase-8. We now investigated mechanisms leading to the activation of another initiator caspase, caspase-9. Unexpectedly we found that caspase-9 cleavage is not dependent on the presence of active caspases-3 or -8. Furthermore, the presence of caspase-9 in mouse embryonic fibroblast (MEF) cells was a prerequisite for Sendai virus-induced apoptotic cell death. Caspase-9 activation occurred without the release of cytochrome c from mitochondria and was not dependent on the presence of Apaf-1 or reactive oxygen intermediates. Our results therefore suggest an alternative mechanism for caspase-9 activation in virally infected cells beside the well characterized pathways via death receptors or mitochondrial cytochrome c release.	Univ Clin Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Max Planck Inst Biochem Mol Virol, D-82152 Martinsried, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Rome Tor Vergata; Max Planck Society; University of Munster	Bitzer, M (corresponding author), Univ Clin Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany.		Spiegel, Martin/H-7843-2019; Schulze-Osthoff, Klaus/N-9025-2013; Cecconi, Francesco/K-3969-2016	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Cecconi, Francesco/0000-0002-5614-4359				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Banki K, 1999, J IMMUNOL, V162, P1466; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Carthy CM, 1998, J VIROL, V72, P7669, DOI 10.1128/JVI.72.9.7669-7675.1998; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Devireddy LR, 1999, J VIROL, V73, P3778, DOI 10.1128/JVI.73.5.3778-3788.1999; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Everett H, 2001, VIROLOGY, V288, P1, DOI 10.1006/viro.2001.1081; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Fujita E, 2000, DEV BRAIN RES, V122, P135, DOI 10.1016/S0165-3806(00)00066-3; Galvan V, 1999, J VIROL, V73, P3219, DOI 10.1128/JVI.73.4.3219-3226.1999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; JAATTELA M, 1995, ONCOGENE, V10, P2297; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Leyrer S, 1998, J VIROL METHODS, V75, P47, DOI 10.1016/S0166-0934(98)00095-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Nava VE, 1998, J VIROL, V72, P452, DOI 10.1128/JVI.72.1.452-459.1998; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Palamara AT, 1996, BIOCHEM BIOPH RES CO, V228, P579, DOI 10.1006/bbrc.1996.1701; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SIGMUND M, 1988, J VIROL METHODS, V22, P231, DOI 10.1016/0166-0934(88)90105-X; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wybranietz WA, 1999, J GENE MED, V1, P265; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	66	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29817	29824		10.1074/jbc.M111898200	http://dx.doi.org/10.1074/jbc.M111898200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12021264	hybrid			2022-12-25	WOS:000177509300060
J	Park, SM; Jung, HY; Kim, TD; Park, JH; Yang, CH; Kim, J				Park, SM; Jung, HY; Kim, TD; Park, JH; Yang, CH; Kim, J			Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; A-BETA COMPONENT; ALZHEIMERS-DISEASE; CRYSTAL-STRUCTURE; CONFORMATIONAL PROPERTIES; H-1-NMR SPECTROSCOPY; QUATERNARY STRUCTURE; PARKINSONS-DISEASE; MOUSE HSP25; IN-VITRO	alpha-Synuclein, an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded. Recent studies have demonstrated that alpha-synuclein has chaperone activity both in vitro and in vivo, and that this activity is lost upon removing its C-terminal acidic tail. However, the detailed mechanism of the chaperone action of alpha-synuclein remains unknown. In this study, we investigated the molecular mechanism of the chaperone action of alpha-synuclein by analyzing the roles of its N-terminal and C-terminal domains. The N-terminal domain (residues 1-95) was found to bind to substrate proteins to form high molecular weight complexes, whereas the C-terminal acidic tail (residues 96-140) appears to be primarily involved in solubilizing the high molecular weight complexes. Because the substrate-binding domain and the solubilizing domain for chaperone function are well separated in a-synuclein, the N-terminal-binding domain can be substituted by other proteins or peptides. Interestingly, the resultant engineered chaperone proteins appeared to display differential efficiency and specificity in terms of the chaperone function, which depended upon the nature of the binding domain. This finding implies that the C-terminal acidic tail of alpha-synuclein can be fused with other proteins or peptides to engineer synthetic chaperones for specific purposes.	Yonsei Univ, Coll Med, Dept Microbiol, Seodaemoon Gu, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea; Seoul Natl Univ, Coll Nat Sci, Sch Chem, Seoul 151747, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Seoul National University (SNU)	Kim, J (corresponding author), Yonsei Univ, Coll Med, Dept Microbiol, Seodaemoon Gu, 134 Shinchon Dong, Seoul 120752, South Korea.		kim, doohun/AAC-4528-2019	Kim, Jongsun/0000-0002-3149-669X; Park, Jeon Han/0000-0001-9604-3205				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Hess J F, 1998, Mol Vis, V4, P29; Hook DWA, 1997, EUR J BIOCHEM, V247, P380, DOI 10.1111/j.1432-1033.1997.00380.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Iwai A, 2000, BBA-MOL BASIS DIS, V1502, P95, DOI 10.1016/S0925-4439(00)00036-3; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Ji HJ, 1997, CANCER RES, V57, P759; Kim J, 1997, MOL CELLS, V7, P78; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kumar LVS, 2000, J BIOL CHEM, V275, P22009, DOI 10.1074/jbc.M003307200; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Park SM, 2002, BIOCHEMISTRY-US, V41, P4137, DOI 10.1021/bi015961k; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; SCHUERTE JA, 1995, BIOCHEM BIOPH RES CO, V212, P900; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Szebeni A, 1999, PROTEIN SCI, V8, P905; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; Tanford C., 1961, PHYS CHEM MACROMOLEC; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	78	88	93	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28512	28520		10.1074/jbc.M111971200	http://dx.doi.org/10.1074/jbc.M111971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032141	hybrid			2022-12-25	WOS:000177342600023
J	Ellis, M; Sharma, DK; Hilley, JD; Coombs, GH; Mottram, JC				Ellis, M; Sharma, DK; Hilley, JD; Coombs, GH; Mottram, JC			Processing and trafficking of Leishmania mexicana GP63 - Analysis using GPI8 mutants deficient in glycosylphosphatidylinositol protein anchoring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM PROTEINS; PROMASTIGOTE SURFACE PROTEASE; CELL-FREE SYSTEM; TRYPANOSOMA-BRUCEI; MOLECULAR-CLONING; ACTIVE-SITE; IN-VITRO; ATTACHMENT; TRANSAMIDASE; MEMBRANE	GPI8 is a clan CD, family C13 cysteine protease and the catalytic core of the GPI-protein transamidase complex. In Leishmania mexicana, GPI8 is nonessential, and Deltagpi8 mutants lack the GPI-anchored metalloprotease GP63, which is the major surface protein of promastigotes. We have identified the active site histidine and cysteine residues of leishmanial GPI8 and generated Deltagpi8 lines expressing modified GPI8 proteins. This has allowed us to study the processing and trafficking of GP63 in wild type and Deltagpi8 mutants. We show using pulse-chase labeling that in Deltagpi8 non-GPI-anchored GP63 was glycosylated and secreted without further processing from the cell with a t(1/2) of 120 min. This secretion was prevented by growth of cells in the presence of tunicamycin, indicating that glycosylation is necessary for secretion of non-GPI-anchored proteins. In contrast, in wild type cells the majority of GP63 was rapidly glycosylated, GPI-anchored, and trafficked to the surface with defined processing intermediate forms. Tunicamycin inhibited glycosylation but did not prevent GPI anchor addition or trafficking. These results show that GPI-anchored and unanchored GP63 are trafficked via different pathways. In addition, the balance between GPI anchor addition and secretion of GP63 in Leishmania can vary depending on the activity of the GPI-protein transamidase, which has implications for the host-parasite interaction.	Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow	Mottram, JC (corresponding author), Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.			Mottram, Jeremy/0000-0001-5574-3766				Ali BRS, 2000, FEBS LETT, V483, P32, DOI 10.1016/S0014-5793(00)02073-1; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Bohme U, 2002, J CELL SCI, V115, P805; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; Denny PW, 2001, FEBS LETT, V491, P148, DOI 10.1016/S0014-5793(01)02172-X; Doering TL, 1997, BIOCHEM J, V328, P669; Eisenhaber B, 2001, PROTEIN ENG, V14, P17, DOI 10.1093/protein/14.1.17; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FIELD MC, 1994, J BIOL CHEM, V269, P10830; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Handman E, 2000, ADV PARASIT, V44, P1; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; Hiroi Y, 1998, FEBS LETT, V421, P252, DOI 10.1016/S0014-5793(97)01576-7; Ilg T, 1999, J BIOL CHEM, V274, P31410, DOI 10.1074/jbc.274.44.31410; IP HS, 1990, MOL BIOCHEM PARASIT, V40, P163, DOI 10.1016/0166-6851(90)90038-N; Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7; Lillico SG, 2002, FEMS MICROBIOL LETT, V211, P123, DOI 10.1111/j.1574-6968.2002.tb11213.x; MACDONALD MH, 1995, BBA-PROTEIN STRUCT M, V1253, P199, DOI 10.1016/0167-4838(95)00155-5; MAXWELL SE, 1995, J BIOL CHEM, V250, P536; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; McGwire BS, 2002, J BIOL CHEM, V277, P8802, DOI 10.1074/jbc.M109072200; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Nolan DP, 2000, J BIOL CHEM, V275, P4072, DOI 10.1074/jbc.275.6.4072; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; Ramalingam S, 1996, P NATL ACAD SCI USA, V93, P7528, DOI 10.1073/pnas.93.15.7528; Sharma DK, 2000, BIOCHEM J, V351, P717, DOI 10.1042/0264-6021:3510717; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Weise F, 2000, J CELL SCI, V113, P4587; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	49	36	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27968	27974		10.1074/jbc.M202047200	http://dx.doi.org/10.1074/jbc.M202047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029085	hybrid			2022-12-25	WOS:000177189800049
J	Lizcano, JM; Deak, M; Morrice, N; Kieloch, A; Hastie, CJ; Dong, LY; Schutkowski, M; Reimer, U; Alessi, DR				Lizcano, JM; Deak, M; Morrice, N; Kieloch, A; Hastie, CJ; Dong, LY; Schutkowski, M; Reimer, U; Alessi, DR			Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6) - Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC REGULATOR; PDK1; ACTIVATION; INSULIN; IDENTIFICATION; PKB/AKT	The AGC family of protein kinases, which includes isoforms of protein kinase B (also known as Akt), ribosomal S6 protein kinase (SW), and serum- and glucocorticoid-induced protein kinase (SGK) are activated in response to many extracellular signals and play key roles in regulating diverse cellular processes. They are activated by the phosphorylation of the T loop of their kinase domain by the 3-phosphoinositide-dependent protein kinase-1 and by phosphorylation of a residue located C-terminal to the kinase domain in a region termed the hydrophobic motif. Recent work has implicated the NIMA (never in mitosis, gene A)-related kinase-6 (NEK6) as the enzyme that phosphorylates the hydrophobic motif of S6K1 in vivo. Here we demonstrate that in addition to phosphorylating S6K1 and SGK1 at their hydrophobic motif, NEK6 also phosphorylates S6K1 at two other sites and phosphorylates SGK1 at one other site in vitro. Employing the Jerini pepSTAR method in combination with kinetic analysis of phosphorylation of variant peptides, we establish the key substrate specificity determinants for NEK6. Our analysis indicates that NEK6 has a strong preference for Leu 3 residues N-terminal to the site of phosphorylation. Its mutation to either Ile or Val severely reduced the efficacy with which NEK6-phosphorylated peptide substrates, and moreover, mutation of the equivalent Leu residue in S6K1 or SGK1 prevented phosphorylation of their hydrophobic motifs by NEK6 in vitro. However, these mutants of S6K1 or SGK1 still became phosphorylated at their hydrophobic motif following insulin-like growth factor-1 stimulation of transfected 293 cells. This study provides the first description of the basis for the substrate specificity of NEK6 and indicates that NEK6 is unlikely to be responsible for the IGF1-induced phosphorylation of the hydrophobic motif of S6K, SGK, and protein kinase B isoforms in vivo.	Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Univ Dundee, Div Signal Transduct Therapy Unit, Dundee DD1 5EH, Scotland; Jerini AG, Jerine Array Technol, D-10115 Berlin, Germany	University of Dundee; University of Dundee; Shire Pharmaceuticals Limited	Lizcano, JM (corresponding author), Univ Dundee, MRC, Prot Phosphorylat Unit, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	j.m.lizcano@dundee.ac.uk; j.m.lizcano@dundee.ac.uk	lizcano, jose m/AAK-3577-2020; Lizcano, Jose M/E-6080-2010	lizcano, jose m/0000-0002-3154-5383; Lizcano, Jose M/0000-0002-3154-5383; Reimer, Ulf/0000-0002-3375-6889; Schutkowski, MIke/0000-0003-0919-7076; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1994, J BIOL CHEM, V269, P6603; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T	36	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27839	27849		10.1074/jbc.M202042200	http://dx.doi.org/10.1074/jbc.M202042200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023960	hybrid			2022-12-25	WOS:000177189800033
J	Tanimura, S; Nomura, K; Ozaki, K; Tsujimoto, M; Kondo, T; Kohno, M				Tanimura, S; Nomura, K; Ozaki, K; Tsujimoto, M; Kondo, T; Kohno, M			Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; SUSTAINED ACTIVATION; TYROSINE KINASE; EPITHELIAL-CELLS; TUMOR-CELLS; PATHWAY; MIGRATION; EXPRESSION; RECEPTOR	We examined the signaling pathway by which hepatocyte growth factor (HGF) induces cell motility, with special focus on the role of extracellular signal-regulated kinase (ERK) in the nucleus. We used Madin-Darby canine kidney cells overexpressing ERK2 because of their prominent motility response to HGF. HGF stimulation of the cells induces not only a rapid, marked, and sustained activation and rapid nuclear accumulation of ERK1/2, but also a prolonged nuclear retention of the activated ERK1/2. Interruption of the ERK1/2 activation by PD98059 treatment of the cells 30 min after HGF stimulation abolishes the HGF-induced cell motility. Enforced cytoplasmic retention of the activated ERK1/2 by the expression of an inactive form of MKP-3 cytoplasmic phosphatase inhibits the cell motility response. Although epidermal growth factor stimulation of the cells induces the activation and nuclear accumulation of ERK1/2, it does not induce the prolonged nuclear retention of the activated ERK1/2, and fails to induce cell motility. In the nucleus, activated ERK1/2 continuously phosphorylate Elk-1, leading to the prolonged expression of c-fos, which results in the expression of several genes such as matrix metalloproteinase (mmp)-9; MMP-9 activity is :required for the induction of the cell motility response. Our results indicate that the sustained activity of ERK1/2 in the nucleus is required for the induction of HGF-induced cell motility.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Pharmaceut Sci, Lab Cell Regulat, Nagasaki 8528521, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Nagasaki Univ, Sch Med, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan	Nagasaki University; RIKEN; Nagasaki University	Kohno, M (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Pharmaceut Sci, Lab Cell Regulat, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	kohnom@net.nagasaki-u.ac.jp	Kohno, Michiaki/R-6532-2019	Kohno, Michiaki/0000-0002-7644-0059				ALBINI A, 1987, CANCER RES, V47, P3239; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GALARDY RE, 1994, CANCER RES, V54, P4715; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Hauck CR, 2001, CANCER RES, V61, P7079; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Iwasaki S, 1996, J BIOL CHEM, V271, P17360, DOI 10.1074/jbc.271.29.17360; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; OGATA Y, 1992, J BIOL CHEM, V267, P3581; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Spector M, 2000, EXP CELL RES, V258, P109, DOI 10.1006/excr.2000.4907; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xie H, 1998, J CELL SCI, V111, P615	55	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28256	28264		10.1074/jbc.M202866200	http://dx.doi.org/10.1074/jbc.M202866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12032150	hybrid			2022-12-25	WOS:000177189800084
J	Rodriguez-Pachon, JM; Martin, H; North, G; Rotger, R; Nombela, C; Molina, M				Rodriguez-Pachon, JM; Martin, H; North, G; Rotger, R; Nombela, C; Molina, M			A novel connection between the yeast Cdc42 GTPase and the Slt2-mediated cell integrity pathway identified through the effect of secreted Salmonella GTPase modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; PHEROMONE-RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; MAP KINASE; BINDING PROTEIN; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; SHO1-DEPENDENT ACTIVATION; SIGNALING COMPONENTS	Modulation of host cellular GTPases through the injection of the effector proteins SopE2 and SptP is essential for Salmonella typhimurium to enter into non-phagocytic cells. Here we show that expression of the guanine nucleotide exchange factor for Cdc42 SopE2 in Saccharomyces cerevisiae leads to the activation of Fus3 and Kss1 MAPKs, which operate in the mating and filamentation pathways, causing filamentous growth in haploid yeast cells. Furthermore, it promotes the activation of the cell integrity MAPK Slt2. Cdc42 activation by removal of its putative intrinsic GTPase-activating proteins (GAPs), Rga1, Rga2, and Bem3, also results in the phosphorylation of Kss1, Fus3, and Slt2 MAPKs. These data support the role of these GAP proteins as negative regulators of Cdc42, confirm the modulating effect of this GTPase on the filamentation and mating pathways and point to a novel connection between Cdc42 and the cell integrity pathway. Cdc42-induced activation of Slt2 occurs in a mating and filamentation pathway-dependent manner, but it does not require the function of Rho1, which is the GTPase that operates in the cell integrity pathway. Moreover, we report that Salmonella SptP can act as a GAP for Cdc42 in S. cerevisiae, down-regulating MAPK-mediated signaling. Thus, yeast provides a useful system to study the interaction of bacterial pathogenic proteins with eukaryotic signaling pathways. Furthermore, these proteins can be used as a tool to gain insight into the mechanisms that regulate MAPK-mediated signaling in eukaryotes.	Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Complutense University of Madrid	Molina, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, Plaza Ramon & Cajal S-N, E-28040 Madrid, Spain.	molmifa@farm.ucm.es	Molina, Maria/ABE-7186-2021; Martín, Humberto/Z-3423-2019; Rotger, Rafael/H-5525-2012; Brieva, Humberto Martin/E-9254-2016; Nombela Cano, César/H-2565-2015	Molina, Maria/0000-0003-0074-3309; Martín, Humberto/0000-0002-6736-3602; Brieva, Humberto Martin/0000-0002-6736-3602; Nombela Cano, César/0000-0003-0757-4034				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen GC, 1996, MOL CELL BIOL, V16, P1376; COMPANY M, 1988, MOL CELL BIOL, V8, P5299, DOI 10.1128/MCB.8.12.5299; Cullen PJ, 2000, GENETICS, V155, P1005; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Davis CR, 1998, J BIOL CHEM, V273, P849, DOI 10.1074/jbc.273.2.849; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; Lesser CF, 2001, EMBO J, V20, P1840, DOI 10.1093/emboj/20.8.1840; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAVARROGARCIA F, 1995, MOL CELL BIOL, V15, P2197; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PAWELRAMMINGEN U, 2000, MOL MICROBIOL, V36, P737; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tu H, 1999, MOL CELL BIOL, V19, P602; van Drogen F, 2000, CURR BIOL, V10, P630, DOI 10.1016/S0960-9822(00)00511-X; WILLIAMS ST, 1974, T BRIT MYCOL SOC, V63, P408, DOI 10.1016/S0007-1536(74)80193-2; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	62	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27094	27102		10.1074/jbc.M201527200	http://dx.doi.org/10.1074/jbc.M201527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016210	hybrid			2022-12-25	WOS:000177055900052
J	Taru, H; Kirino, Y; Suzuki, T				Taru, H; Kirino, Y; Suzuki, T			Differential roles of JIP scaffold proteins in the modulation of amyloid precursor protein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; BETA-SECRETASE; PHOSPHOTYROSINE INTERACTION; PHOSPHORYLATION; CLEAVAGE; FE65; IDENTIFICATION; APP	We previously found that the JNK-interacting proteins JIP1b and JIP2 associate with the cytoplasmic domain of the Alzheimer's amyloid precursor protein (APP) (Taru, H., Iijima, K., Hase, M., Kirino, Y., Yagi, Y., and Suzuki, T. (2002) J. Biol. Chem. 277, 20070-20078). This interaction involves the carboxyl-terminal phosphotyrosine interaction (PI) domain of JIP1b or JIP2 and the GYENPTY motif in the APP cytoplasmic domain. The expression of JIP1b stabilizes immature APP and suppresses the production of a secreted large extracellular amino-terminal domain of APP, the generation of a cleaved intracellular carboxyl-terminal fragment of APP, and the secretion of beta-amyloid 40 and 42. Deletion of the PI domain or alteration of PI amino acid residues prevents JIP1b from interacting with APP and affecting its metabolism, but deletion of the JNK-binding domain of JIP1b has no effect. JIP2, a weaker APP-binding protein, does not influence the processing of APP, although it is known that both JIP1b and JIP2 equally regulate the JNK signaling cascade. The present results suggest that JIP1b can directly modulate APP metabolism by interacting with the APP cytoplasmic domain, independent of its regulation of the JNK signaling cascade.	Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	Hokkaido University; University of Tokyo	Suzuki, T (corresponding author), Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Kita Ku, Kita-12,Nishi-6, Sapporo, Hokkaido 0600812, Japan.	tsuzuki@pharm.hokudai.ac.jp	Taru, Hidenori/B-7059-2009; Suzuki, Toshiharu/B-5342-2013					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Coffey ET, 2000, J NEUROSCI, V20, P7602; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Mills J, 1997, J NEUROSCI, V17, P9415; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	53	77	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27567	27574		10.1074/jbc.M203713200	http://dx.doi.org/10.1074/jbc.M203713200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023290	hybrid			2022-12-25	WOS:000177055900108
J	Kanzaki, M; Pessin, JE				Kanzaki, M; Pessin, JE			Caveolin-associated filamentous actin (Cav-actin) defines a novel F-actin structure in adipocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; KINASES C-ZETA; GLUCOSE-TRANSPORTER; SUBCELLULAR TRAFFICKING; PLASMA-MEMBRANE; RAT ADIPOCYTES; INSULIN; ACTIVATION; LAMBDA; TC10	Dynamic actin remodeling has been implicated in the translocation of the insulin-responsive glucose transporter 4 (GLUT4) to the plasma membrane in adipocytes. Here we show that fully differentiated 3T3L1 adipocytes have unique cortical filamentous actin structure, designated Cav-actin (caveolae-associated F-actin). During 3T3L1 adipocyte differentiation, rhodamine-phalloidin staining demonstrated the formation of a cortical actin cytoskeleton that is composed of small dot-like F-actin spikes lining the inside of the plasma membrane. Double labeling with a caveolin antibody indicated that these F-actin spikes emanate from organized rosette-like clusters of caveolae/lipid raft microdomains. In contrast, there was no obvious relationship between F-actin and caveolin localization and/or organization in 3T3L1 preadipocytes (fibroblasts). Treatments of differentiated adipocytes with latrunculin B, Clostridium difficile toxin B or a dominant-interfering TC10 mutant (TC10/T31N) disrupted the Cav-actin structure without significantly affecting the organization of clustered caveolae. Similarly, disruption of the clustered caveolae with methyl-beta-cyclodextrin also dispersed the Cav-actin structure. These data demonstrate that this novel Cav-actin, structure is organized through clustered caveolae but that the formation of caveolae-rosettes are not dependent upon F-actin.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Jeffrey-Pessin@uiowa.edu	Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955	NIDDK NIH HHS [DK59291, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059291, R01DK033823, R37DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, J BIOL CHEM, V276, P6065, DOI 10.1074/jbc.C000856200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Fujimoto T, 1998, J ELECTRON MICROSC, V47, P451, DOI 10.1093/oxfordjournals.jmicro.a023616; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KANZAKI M, 2002, IN PRESS MOL BIOL CE; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Khayat ZA, 2000, J CELL SCI, V113, P279; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VOLDSTEDLUND M, 1993, J MEMBRANE BIOL, V136, P63; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; YANG J, 1993, J BIOL CHEM, V268, P4600	37	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25867	25869		10.1074/jbc.C200292200	http://dx.doi.org/10.1074/jbc.C200292200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12039946	hybrid			2022-12-25	WOS:000176908700008
J	Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E				Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E			Antisense to Epstein Barr virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes	ONCOGENE			English	Article						EBV; LMP1; antisense oligodeoxynucleotides; EBV transforming genes; anti-apoptotic genes; B cell phenotype	LATENT MEMBRANE-PROTEIN; HUMAN EPITHELIAL-CELLS; GROWTH TRANSFORMATION; NUCLEAR PROTEIN-2; BCL-2 EXPRESSION; INDUCTION; LYMPHOMA; TUMORIGENICITY; IDENTIFICATION; INHIBITION	It is generally accepted that Epstein-Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, effectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might influence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or affect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not affect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modifications in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our findings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors.	Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Mattia, E (corresponding author), Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Chichiarelli, Silvia/F-1226-2011	Galletti, Roberta/0000-0001-8299-7649; MASCIARELLI, SILVIA/0000-0002-6738-6281; Chichiarelli, Silvia/0000-0002-5682-0353				BAICHWAL VR, 1988, ONCOGENE, V2, P461; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1993, ONCOGENE, V8, P1575; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Mattia E, 1997, ONCOGENE, V15, P489, DOI 10.1038/sj.onc.1201183; MILLER G, 1990, VIROLOGY, P1921; Nicholson LJ, 1997, ONCOGENE, V15, P275, DOI 10.1038/sj.onc.1201187; Noguchi T, 2001, BRIT J HAEMATOL, V114, P84, DOI 10.1046/j.1365-2141.2001.02887.x; PATARROYO M, 1986, INT J CANCER, V38, P539, DOI 10.1002/ijc.2910380414; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610	26	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4166	4170		10.1038/sj.onc.1205515	http://dx.doi.org/10.1038/sj.onc.1205515			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037673				2022-12-25	WOS:000176186000011
J	Segura, I; Serrano, A; De Buitrago, GG; Gonzalez, MA; Abad, JL; Claveria, C; Gomez, L; Bernad, A; Martinez-A, C; Riese, HH				Segura, I; Serrano, A; De Buitrago, GG; Gonzalez, MA; Abad, JL; Claveria, C; Gomez, L; Bernad, A; Martinez-A, C; Riese, HH			Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis	FASEB JOURNAL			English	Article						vasculogenesis; apoptosis; caspase inhibitors	HUMAN-ENDOTHELIAL-CELLS; CYTOCHROME-C; GROWTH; MECHANISMS; APOPTOSIS; PATHWAYS; PROTEIN; COMPLEX; DIFFERENTIATION; VASCULOGENESIS	Tissue remodeling during embryonic development and in the adult organism relies on a subtle balance between cell growth and apoptosis. As angiogenesis involves restructuring of preexisting endothelium, we examined the role of apoptosis in new vessel formation. We show that apoptosis occurs before capillary formation but not after vessels have assembled. Using the human umbilical vein endothelial cell (HUVEC) in vitro Matrigel angiogenesis model, we show that vascular-like structure formation requires apoptotic cell death through activation of a caspase-dependent mechanism and mitochondrial cytochrome c release. Vascular-like structure formation was further blocked by caspase inhibitors such as z-VAD or Ac-DEVD-CHO, using HUVEC and human lung microvascular endothelial cells. Overexpression of anti-apoptotic human Bcl-2 or baculovirus p35 genes in HUVEC altered endothelial cell rearrangement during in vitro angiogenesis, causing impaired vessel-like structure formation. Caspase inhibitors blocked VEGF- or bFGF-induced HUVEC angiogenesis on 2- or 3-D collagen gels, respectively, confirming that apoptosis was not the result of nonspecific cell death after seeding on the matrix. In an in vivo angiogenesis assay, caspase inhibitors blocked VEGF- dependent vascular formation at the alignment step, as demonstrated histologically. This evidence indicates that endothelial cell apoptosis may be relevant for precise vascular tissue rearrangement in in vitro and in vivo angiogenesis.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Martinez-A, C (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	cmartineza@cnb.uam.es	Bernad, Antonio/P-8573-2017; Gonzalez, Manuel A/A-3404-2013; Segura, Inmaculada/D-2878-2013; Segura, Inmaculada/AAA-7958-2020	Segura, Inmaculada/0000-0003-1849-5569; Serrano, Antonio/0000-0003-1993-640X; Bernad, Antonio/0000-0003-0620-9668				ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; BROOKS PC, 1994, CELL, V79, P1147; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang S, 2000, EXP CELL RES, V261, P91, DOI 10.1006/excr.2000.5044; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jones MK, 1999, NAT MED, V5, P1418; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; PASSANITI A, 1992, LAB INVEST, V67, P519; Pluda JM, 1997, SEMIN ONCOL, V24, P203; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Segura I, 2001, ANAL BIOCHEM, V296, P143, DOI 10.1006/abio.2001.5200; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	32	83	92	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0833	10.1096/fj.01-0819com	http://dx.doi.org/10.1096/fj.01-0819com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039865				2022-12-25	WOS:000176683900009
J	Reed, CC; Gauldie, J; Iozzo, RV				Reed, CC; Gauldie, J; Iozzo, RV			Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; colon carcinoma; squamous carcinoma	LEUCINE-RICH PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; DOWN-REGULATION; UP-REGULATION; EXPRESSION; CARCINOMA; CELLS; INHIBITION; REGULATORS	There is mounting evidence that decorin inhibits the growth of various tumor cell lines when either over-expressed in vitro or provided as a recombinant protein. The mechanism of action is primarily via a protracted inactivation of the epidermal growth factor receptor (EGFR) tyrosine kinase. In this study we explored the possibility of retarding the growth of tumor xenografts by decorin gene delivery into the growing neoplastic tissues. We demonstrate that transient transgene expression of replication-deficient adenovirus-containing decorin causes a significant growth inhibition of colon and squamous carcinoma tumor xenografts. These cytostatic effects were achieved with relatively low viral titers and correlated with a reduced proliferative index and an attenuation of the EGFR phosphorylation in vivo. Thus, decorin gene therapy helps in retarding the growth of human tumors in immunocompromised animals and could represent a new independent or adjunctive therapeutic modality against cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; McMaster University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Fischer JW, 2001, ARTERIOSCL THROM VAS, V21, P777, DOI 10.1161/01.ATV.21.5.777; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Shridhar V, 2001, CANCER RES, V61, P5895; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	38	123	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3688	3695		10.1038/sj.onc.1205470	http://dx.doi.org/10.1038/sj.onc.1205470			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032837				2022-12-25	WOS:000175676000004
J	Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA				Gemmill, RM; Bemis, LT; Lee, JP; Sozen, MA; Baron, A; Zeng, C; Erickson, PF; Hooper, JE; Drabkin, HA			The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway	ONCOGENE			English	Article						TRC8; VHL; renal cell carcinoma; JAB1/CSN-5; patched; RING-H2 finger	26S PROTEASOME; HUMAN HOMOLOG; RENAL-CARCINOMA; JAB1 INTERACTS; CNS MIDLINE; CELL-CYCLE; HIF-ALPHA; DROSOPHILA; PROTEIN; COMPLEX	VHL is part of an SCF related E3-ubiquitin ligase complex with 'gatekeeper' function in renal carcinoma. However, no mutations have been identified in VHL interacting proteins in wild type VHL tumors. We previously reported that the TRC8 gene was interrupted by a t(3;8) translocation in a family with hereditary renal and non-medullary thyroid cancer. TRC8 encodes a multi-membrane spanning protein containing a RING-H2 finger with in vitro ubiquitin ligase activity. We isolated the Drosophila homologue, DTrc8, and studied its function by genetic manipulations and a yeast 2-hybrid screen. Human and Drosophila TRC8 proteins localize to the endoplasmic reticulum. Loss of either DTrc8 or DVhl resulted in an identical ventral midline defect. Direct interaction between DTrc8 and DVhl was confirmed by GST-pulldown and co-immunoprecipitation experiments. CSN-5/JAB1 is a component of the COP9 signalosome, recently shown to regulate SCF function. We found that DTrc8 physically interacts with CSN-5 and that human JAB1 localization is dependent on VHL mutant status. Lastly, overexpression of DTrc8 inhibited growth consistent with its presumed role as a tumor suppressor gene. Thus, VHL, TRC8, and JAB1 appear to be linked both physically and functionally and all three may participate in the development of kidney cancer.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gemmill, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Box B-171,4200 E 9th Ave, Denver, CO 80262 USA.	robert.gemmill@uchsc.edu		Bemis, Lynne/0000-0001-9986-7154	NATIONAL CANCER INSTITUTE [R01CA076035, P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035, CA46934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	48	42	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3507	3516		10.1038/sj.onc.1205437	http://dx.doi.org/10.1038/sj.onc.1205437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032852				2022-12-25	WOS:000175793700001
J	Patrie, KM; Drescher, AJ; Welihinda, A; Mundel, P; Margolis, B				Patrie, KM; Drescher, AJ; Welihinda, A; Mundel, P; Margolis, B			Interaction of two actin-binding proteins, synaptopodin and alpha-actinin-4, with the tight junction protein MAGI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GUANYLATE-KINASE; TUMOR-SUPPRESSOR; PDZ DOMAIN; WW DOMAIN; GLOMERULAR PODOCYTES; SIGNALING PATHWAYS; EPITHELIAL-CELLS; BUNDLING PROTEIN; MEMBRANE	In an attempt to find podocyte-expressed proteins that may interact with the tight junction protein MAGI-1, we screened a glomerulus-enriched cDNA library with a probe consisting of both WW domains of MAGI-1. One of the isolated clones contained two WW domain-binding motifs and was identified as a portion of the actin-bundling protein synaptopodin. In vitro binding assays confirmed this interaction between MAGI-1 and synaptopodin and identified the second WW domain of MAGI-1 to be responsible for the interaction. MAGI-1 and synaptopodin can also interact in vivo, as they can be immunoprecipitated together from HEK293 cell lysates. Another actin-bundling protein that is found in glomerular podocytes and shown to be mutated in an inheritable form of glomerulosclerosis is alpha-actinin-4. We show that a-actinin-4 is also capable of binding to MAGI-1 in in vitro binding assays and that this interaction is mediated by the fifth PDZ domain of MAGI-1 binding to the C terminus of alpha-actinin-4. Exogenously expressed synaptopodin and alpha-actinin-4 were found to colocalize along with endogenous MAGI-1 at the tight junction of Madin-Darby canine kidney cells. The interaction and colocalization of MAGI-1 with two actin-bundling proteins suggest that MAGI-1 may play a role in actin cytoskeleton dynamics within polarized epithelial cells.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Margolis, B (corresponding author), Univ Michigan, Howard Hughes Med Inst, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu		Welihinda, Ajith/0000-0002-0049-0850	NIDDK NIH HHS [DK57683-01, 5F32DK09912-02, 2P50DK39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, F32DK009912, R01DK057683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; DRENCKHAHN D, 1988, LAB INVEST, V59, P673; Endlich K, 2001, CURR OPIN NEPHROL HY, V10, P331, DOI 10.1097/00041552-200105000-00006; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; LACHAPELLE M, 1991, VIRCHOWS ARCH B, V60, P105, DOI 10.1007/BF02899534; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; MUNDEL P, 1995, ANAT EMBRYOL, V192, P387; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Raats CJI, 2000, AM J PATHOL, V156, P1749, DOI 10.1016/S0002-9440(10)65046-8; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; RON D, 1992, BIOTECHNIQUES, V13, P866; Smoyer WE, 1997, AM J PHYSIOL-RENAL, V273, pF150, DOI 10.1152/ajprenal.1997.273.1.F150; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	38	106	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30183	30190		10.1074/jbc.M203072200	http://dx.doi.org/10.1074/jbc.M203072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042308	hybrid			2022-12-25	WOS:000177509300103
J	Pettersson, PL; Johansson, AS; Mannervik, B				Pettersson, PL; Johansson, AS; Mannervik, B			Transmutation of human glutathione transferase A2-2 with peroxidase activity into an efficient steroid isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN EVOLUTION; DESIGN; ENZYME; A1-1; SITE; SPECIFICITY; REDESIGN; FOLDS; ACID; P1-1	A major goal in protein engineering is the tailor-making of enzymes for specified chemical reactions. Successful attempts have frequently been based on directed molecular evolution involving libraries of random mutants in which variants with desired properties were identified. For the engineering of enzymes with novel functions, it would be of great value if the necessary changes of the active site could be predicted and implemented. Such attempts based on the comparison of similar structures with different substrate selectivities have previously met with limited success. However, the present work shows that the knowledge-based redesign restricted to substrate-binding residues in human glutathione transferase A2-2 can introduce high steroid double-bond isomerase activity into the enzyme originally characterized by glutathione peroxidase activity. Both the catalytic center activity (k(cat)) and catalytic efficiency (k(cat)/K-m) match the values of the naturally evolved glutathione transferase A3-3, the most active steroid isomerase known in human tissues. The substrate selectivity of the mutated glutathione transferase was changed 7000-fold by five point mutations. This example demonstrates the functional plasticity of the glutathione transferase scaffold as well as the potential of rational active-site directed mutagenesis as a complement to DNA shuffling and other stochastic methods for the redesign of proteins with novel functions.	Uppsala Univ, Dept Biochem, Biomed Ctr, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Dept Biochem, Biomed Ctr, Box 576, SE-75123 Uppsala, Sweden.			Jemth, Ann-Sofie/0000-0002-7550-1833				Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; Babbitt PC, 2000, P NATL ACAD SCI USA, V97, P10298, DOI 10.1073/pnas.97.19.10298; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CRONIN CN, 1987, J AM CHEM SOC, V109, P2222, DOI 10.1021/ja00241a072; Gustafsson A, 1999, J MOL BIOL, V288, P787, DOI 10.1006/jmbi.1999.2712; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hitchens TK, 2001, BIOCHEMISTRY-US, V40, P11660, DOI 10.1021/bi010909+; Johansson AS, 2002, J BIOL CHEM, V277, P16648, DOI 10.1074/jbc.M201062200; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Kraemer-Pecore CM, 2001, CURR OPIN CHEM BIOL, V5, P690, DOI 10.1016/S1367-5931(01)00267-8; Looger LL, 2001, J MOL BIOL, V307, P429, DOI 10.1006/jmbi.2000.4424; MANNERVIK B, 1991, CURRENT PROTOCOLS TO; Minshull J, 1999, CURR OPIN CHEM BIOL, V3, P284, DOI 10.1016/S1367-5931(99)80044-1; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stella L, 1999, PROTEINS, V37, P10, DOI 10.1002/(SICI)1097-0134(19991001)37:1<10::AID-PROT2>3.0.CO;2-0; Teichmann SA, 2001, TRENDS BIOTECHNOL, V19, P482, DOI 10.1016/S0167-7799(01)01813-3; THOMAS JL, 1989, J STEROID BIOCHEM, V33, P209, DOI 10.1016/0022-4731(89)90296-3; Thornburg LD, 2001, J AM CHEM SOC, V123, P9912, DOI 10.1021/ja016683f; Thornton JM, 1999, J MOL BIOL, V293, P333, DOI 10.1006/jmbi.1999.3054; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Watkins LM, 1997, J BIOL CHEM, V272, P25596, DOI 10.1074/jbc.272.41.25596; Wolf YI, 2000, J MOL BIOL, V299, P897, DOI 10.1006/jmbi.2000.3786; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	30	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30019	30022		10.1074/jbc.M204485200	http://dx.doi.org/10.1074/jbc.M204485200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12023294	hybrid			2022-12-25	WOS:000177509300083
J	Stewart, A; Ghosh, M; Spencer, DM; Leslie, CC				Stewart, A; Ghosh, M; Spencer, DM; Leslie, CC			Enzymatic properties of human cytosolic phospholipase A(2)gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MOUSE PERITONEAL-MACROPHAGES; LYSOPHOSPHOLIPASE ACTIVITY; P388D(1) MACROPHAGES; PANCREATIC-ISLETS; HYDROLYZING PHOSPHOLIPASE-A2; PHOSPHORYLATION SITES; REGULATORY FUNCTIONS; BROMOENOL LACTONE; MOLECULAR-CLONING	The enzymatic properties of cytosolic phospholipase A(2)gamma (cPLA(2)gamma), an isoform of 85-kDa group IV cPLA(2)alpha (cPLA(2)alpha) were studied in vitro and when the enzyme was expressed in cells. cPLA(2)gamma expressed in Sf9 cells is associated with membrane. Membranes isolated from [H-3]arachidonic acid-labeled Sf9 cells expressing cPLA(2)gamma, constitutively release [H-3]arachidonic acid. The membrane-associated activity is inhibited by the group IV PLA(2) inhibitor methylarachidonyl fluorophosphonate, but not effectively by the group VI PLA(2) inhibitor (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one. cPLA(2)gamma has higher lysophospholipase activity than PLA(2) activity. Purified His-cPLA(2)gamma does not exhibit phospholipase A(1) activity, but sequentially hydrolyzes fatty acid from the sn-2 and sn-1 positions of phosphatidylcholine. cPLA(2)gamma overexpressed in HEK293 cells is constitutively active in isolated membranes, releasing large amounts of oleic, arachidonic, palmitic, and stearic acids; however, basal fatty acid release from intact cells is not increased. cPLA(2)gamma overexpressed in lung fibroblasts from cPLA(2)alpha-deficient mice is activated by mouse serum resulting in release of arachidonic, oleic, and palmitic acids, whereas overexpression of cPLA(2)alpha results primarily in arachidonic acid release.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL034303, HL34303, HL61378] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 2000, ADV ENZYME REGUL, V40, P255, DOI 10.1016/S0065-2571(99)00031-X; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Loo RW, 1997, J BIOL CHEM, V272, P19214, DOI 10.1074/jbc.272.31.19214; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4	57	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29526	29536		10.1074/jbc.M204856200	http://dx.doi.org/10.1074/jbc.M204856200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12039969	hybrid			2022-12-25	WOS:000177509300025
J	Ghersi, G; Dong, H; Goldstein, LA; Yeh, Y; Hakkinen, L; Larjava, HS; Chen, WT				Ghersi, G; Dong, H; Goldstein, LA; Yeh, Y; Hakkinen, L; Larjava, HS; Chen, WT			Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE PROTEASE; MALIGNANT MELANOMA-CELLS; DIPEPTIDYL-PEPTIDASE; ACTIVATION PROTEIN; EXTRACELLULAR-MATRIX; STROMAL FIBROBLASTS; DPP-IV; EPITHELIAL CANCERS; MOLECULAR-CLONING; CARCINOMA-CELLS	The invasion of migratory cells through connective tissues involves metallo- and serine types of cell surface proteases. We show that formation of a novel protease complex, consisting of the membrane-bound prolyl peptidases seprase and dipeptidyl peptidase IV (DPPIV), at invadopodia of migratory fibroblasts is a prerequisite for cell invasion and migration on a collagenous matrix. Seprase and DPPIV form a complex on the cell surface that elicits both gelatin binding and gelatinase activities localized at invadopodia of cells migrating on collagenous fibers. The protease complex participates in the binding to gelatin and localized gelatin degradation, cellular migration, and monolayer wound closure. Serine protease inhibitors can block the gelatinase activity and the localized gelatin degradation by cells. Antibodies to the gelatin-binding domain of DPPIV reduce the cellular abilities of the proteases to degrade gelatin but do not affect cellular adhesion or spreading on type I collagen. Furthermore, expression of the seprase-DPPIV complex is restricted to migratory cells involved in wound closure in vitro and in connective tissue cells during closure of gingival wounds but not in differentiated tissue cells. Thus, we have identified cell surface proteolytic activities, which are non-metalloproteases, seprase and DPPIV, that are responsible for the tissue-invasive phenotype.	SUNY Stony Brook, Dept Med Med Oncol, Stony Brook, NY 11794 USA; Univ Palermo, Dept Cellular & Dev Biol, I-90138 Palermo, Italy; Univ British Columbia, Div Periodont, Vancouver, BC V6T 1Z3, Canada	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Palermo; University of British Columbia	Chen, WT (corresponding author), SUNY Stony Brook, Dept Med, Div Med Oncol, HSC T-15,Rm 053, Stony Brook, NY 11794 USA.		Dong, Huan/E-5146-2015; Hakkinen, Lari/B-2228-2016; Larjava, Hannu/GRO-4325-2022	Ghersi, Giulio/0000-0001-7250-9808	NCI NIH HHS [R01CA39077] Funding Source: Medline; NHLBI NIH HHS [R01HL33711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1979, J CELL BIOL, V81, P684, DOI 10.1083/jcb.81.3.684; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; GRINNELL F, 1994, J INVEST DERMATOL, V103, P155, DOI 10.1111/1523-1747.ep12392625; HANSKI C, 1988, EXP CELL RES, V178, P64, DOI 10.1016/0014-4827(88)90378-3; Hirai K, 1999, PATHOL INT, V49, P264, DOI 10.1046/j.1440-1827.1999.00859.x; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; Kaspari A, 1996, BBA-PROTEIN STRUCT M, V1293, P147, DOI 10.1016/0167-4838(95)00238-3; Kelly T, 1999, CLIN EXP METASTAS, V17, P57; Kelly T, 1998, MODERN PATHOL, V11, P855; Kelly T, 1998, CLIN EXP METASTAS, V16, P501, DOI 10.1023/A:1006538200886; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; LOSTER K, 1995, BIOCHEM BIOPH RES CO, V217, P341, DOI 10.1006/bbrc.1995.2782; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MONSKY WL, 1994, CANCER RES, V54, P5702; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; Pineiro-Sanchez ML, 1998, J BIOL CHEM, V273, P13366; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; SALO T, 1994, LAB INVEST, V70, P176; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; YOUNG PK, 1994, J INVEST DERMATOL, V103, P660, DOI 10.1111/1523-1747.ep12398424	36	143	156	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29231	29241		10.1074/jbc.M202770200	http://dx.doi.org/10.1074/jbc.M202770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023964	hybrid			2022-12-25	WOS:000177342600112
J	Kedishvili, NY; Chumakova, OV; Chetyrkin, SV; Belyaeva, OV; Lapshina, EA; Lin, DW; Matsumura, M; Nelson, PS				Kedishvili, NY; Chumakova, OV; Chetyrkin, SV; Belyaeva, OV; Lapshina, EA; Lin, DW; Matsumura, M; Nelson, PS			Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; BETA-CAROTENE 15,15'-DIOXYGENASE; RAT SMALL-INTESTINE; BINDING PROTEIN-II; ALL-TRANS-RETINOL; BETA,BETA-CAROTENE 15,15'-DIOXYGENASE; MOLECULAR-IDENTIFICATION; EXPRESSION; ACID; CLONING	All-trans-retinoic acid is a metabolite of vitamin A (all-trans-retinol) that functions as an activating ligand for a family of nuclear retinoic acid receptors. The intracellular levels of retinoic acid in tissues are tightly regulated, although the mechanisms underlying the control of retinoid metabolism at the level of specific enzymes are not completely understood. In this report we present the first characterization of the retinoid substrate specificity of a novel short-chain dehydrogenase/reductase (SDR) encoded by RalR1/PSDR1, a cDNA recently isolated from the human prostate (Lin, B., White, J.T., Ferguson, C., Wang, S., Vessella, R., Bumgarner, R., True, L. D., Hood, L., and Nelson, P. S. (2001) Cancer Res. 61, 1611-1618). We demonstrate that RalR1 exhibits an oxidoreductive catalytic activity toward retinoids, but not steroids, with at least an 800-fold lower apparent K. values for NADP(+) and NADPH versus NAD(+) and NADH as cofactors. The enzyme is similar to50-fold more efficient for the reduction of all-trans-retinal than for the oxidation of all-trans-retinol. Importantly, RalR1 reduces all-trans-retinal in the presence of a 10-fold molar excess of cellular retinol-binding protein type 1, which is believed to sequester all-trans-retinal from nonspecific enzymes. As shown by immunostaining of human prostate and LNCaP cells with monoclonal anti-RalR1 antibodies, the enzyme is highly expressed in the epithelial cell layer of human prostate and localizes to the endoplasmic reticulum. The enzymatic properties and expression pattern of RalR1 in prostate epithelium suggest that it might play a role in the regulation of retinoid homeostasis in human prostate.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA	University of Missouri System; University of Missouri Kansas City; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Kedishvili, NY (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd,103 BSB, Kansas City, MO 64110 USA.		Lapshina, Elena/AAC-5538-2019	Lapshina, Elena/0000-0001-5571-7787; Lapshina, Elena/0000-0002-2104-4024; Kedishvili, Natalia/0000-0001-6917-4891	NCI NIH HHS [CA75173] Funding Source: Medline; NIAAA NIH HHS [AA12153, AA00221, R01 AA012153-03, R01 AA012153] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA075173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ambroziak W, 1999, J BIOL CHEM, V274, P33366, DOI 10.1074/jbc.274.47.33366; Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Blaner William S., 1994, P229; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chetyrkin SV, 2001, ARCH BIOCHEM BIOPHYS, V386, P1, DOI 10.1006/abbi.2000.2203; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cook NR, 1999, CANCER, V86, P1783, DOI 10.1002/(SICI)1097-0142(19991101)86:9&lt;1783::AID-CNCR21&gt;3.0.CO;2-N; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; During A, 1998, BIOCHEM BIOPH RES CO, V249, P467, DOI 10.1006/bbrc.1998.9160; Gamble MV, 1999, J LIPID RES, V40, P2279; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KATO M, 1985, J BIOL CHEM, V260, P4832; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; Lin BY, 2001, CANCER RES, V61, P1611; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mangelsdorf David J., 1994, P319; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Pasquali D, 1999, J CLIN ENDOCR METAB, V84, P1463, DOI 10.1210/jc.84.4.1463; Pasquali D, 1996, J CLIN ENDOCR METAB, V81, P2186, DOI 10.1210/jc.81.6.2186; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; SCITA G, 1992, J NUTR BIOCHEM, V3, P118, DOI 10.1016/0955-2863(92)90103-P; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Wei RR, 1998, NUTR CANCER, V30, P53, DOI 10.1080/01635589809514640; Williams AW, 2000, J NUTR, V130, P728, DOI 10.1093/jn/130.4.728; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; YOST RW, 1988, J BIOL CHEM, V263, P18693; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	48	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28909	28915		10.1074/jbc.M202588200	http://dx.doi.org/10.1074/jbc.M202588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12036956	hybrid			2022-12-25	WOS:000177342600075
J	Joo, NS; Saenz, Y; Krouse, ME; Wine, JJ				Joo, NS; Saenz, Y; Krouse, ME; Wine, JJ			Mucus secretion from single submucosal glands of pig - Stimulation by carbachol and vasoactive intestinal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; TRACHEAL EPITHELIUM; CHLORIDE SECRETION; LIQUID SECRETION; ION-TRANSPORT; MUCOUS GLANDS; C-FIBERS; CELLS; DOGS; AIRWAYS	Secretion rates of >700 individual glands in isolated tracheal mucosa from 56 adult pigs were monitored optically. "Basal" secretion of 0.7 +/- 0.1 nl.min(-1) gland(-1) was observed 1-9 h post-harvest but was near zero on day 2. Secretion to carbachol (10 muM) peaked at 2-3 min and then declined to a sustained phase. Peak secretion was 12.4 +/- 1.1 nl.min(-1) gland(-1); sustained secretion was approximately one-third of peak secretion. Thapsigargin (1 muM) increased secretion from 0.1 +/- 0.05 to 0.7 +/- 0.2 nl.min(-1) gland(-1); thapsigargin did not cause contraction of the trachealis muscles. Isoproterenol and phenylephrine (10 muM each) were ineffective, but vasoactive intestinal peptide (1 muM) and forskolin (10 muM) each produced sustained secretion of 1.0 +/- 0.5 and 1.7 +/- 0.2 nl.min(-1) gland(-1), respectively. The density of actively secreting glands was 1.3/mm(2). Secretion to either carbachol or forskolin was inhibited (similar to50%) by either bumetanide or HCO(3) over bar removal and inhibited similar to90% by the combined treatments. Mucus secreted in response to carbachol or forskolin was acidic by similar to0.2 pH\units relative to the bath and remained acidic by similar to0.1 pH units after bumetanide. The strong secretory response to vasoactive intestinal peptide, the acidity of [CAMP](i)-stimulated mucus, and its inhibition by bumetanide were unexpected.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA; Ethicon EndoSurg Inc, Stanford, CA 94305 USA	Stanford University	Wine, JJ (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Bldg 420,Sierra Mall, Stanford, CA 94305 USA.	wine@stanford.edu			NHLBI NIH HHS [HL60288] Funding Source: Medline; NIDDK NIH HHS [DK51817] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 1999, AM J PHYSIOL-LUNG C, V277, pL694, DOI 10.1152/ajplung.1999.277.4.L694; BALLARD ST, 1995, AM J PHYSIOL-LUNG C, V268, pL526, DOI 10.1152/ajplung.1995.268.3.L526; BECQ F, 1993, FEBS LETT, V321, P73, DOI 10.1016/0014-5793(93)80624-4; BOUCHER RC, 1982, J APPL PHYSIOL, V52, P893, DOI 10.1152/jappl.1982.52.4.893; BURCH LH, 1995, AM J PHYSIOL, V26, pC511; CHAO P, 1988, PFLUG ARCH EUR J PHY, V411, P216, DOI 10.1007/BF00582318; Choi HK, 2000, J ANAT, V197, P361, DOI 10.1046/j.1469-7580.2000.19730361.x; Coakley R D, 2001, JOP, V2, P294; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; COLES SJ, 1984, CIBA F SYMP, V109, P40, DOI 10.1002/9780470720905.ch4; Crews A, 2001, J APPL PHYSIOL, V91, P797, DOI 10.1152/jappl.2001.91.2.797; DAVIS B, 1982, J APPL PHYSIOL, V53, P985, DOI 10.1152/jappl.1982.53.4.985; DAVIS B, 1982, J APPL PHYSIOL, V52, P1416, DOI 10.1152/jappl.1982.52.6.1416; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FINKBEINER WE, 1994, AM J PHYSIOL, V267, pL206, DOI 10.1152/ajplung.1994.267.2.L206; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Gaillard D, 2000, AM J PHYSIOL-LUNG C, V278, pL177, DOI 10.1152/ajplung.2000.278.1.L177; GASHI AA, 1989, AM J PHYSIOL, V251, pC223; GERMAN VF, 1982, J APPL PHYSIOL, V52, P1153, DOI 10.1152/jappl.1982.52.5.1153; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HAXHIU MA, 1990, RESP PHYSIOL, V82, P267, DOI 10.1016/0034-5687(90)90097-I; HAXHIU MA, 1991, J APPL PHYSIOL, V71, P1663, DOI 10.1152/jappl.1991.71.5.1663; Haxhiu MA, 2000, BRAIN RES, V883, P77, DOI 10.1016/S0006-8993(00)02890-0; HAXHIU MA, 1991, J APPL PHYSIOL, V71, P1669, DOI 10.1152/jappl.1991.71.5.1669; HEJAL R, 1993, J APPL PHYSIOL, V75, P2347, DOI 10.1152/jappl.1993.75.6.2347; Inglis SK, 1997, AM J PHYSIOL-LUNG C, V272, pL372, DOI 10.1152/ajplung.1997.272.2.L372; Inglis SK, 1998, AM J PHYSIOL-LUNG C, V274, pL762, DOI 10.1152/ajplung.1998.274.5.L762; Inglis SK, 1997, AM J PHYSIOL-LUNG C, V272, pL203, DOI 10.1152/ajplung.1997.272.2.L203; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; JOHNSON HG, 1983, INT J IMMUNOPHARMACO, V5, P391, DOI 10.1016/0192-0561(83)90013-9; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Linden A, 1997, PEPTIDES, V18, P843, DOI 10.1016/S0196-9781(97)00017-X; MEYRICK B, 1970, J ANAT, V107, P281; MEYRICK B, 1969, THORAX, V24, P729, DOI 10.1136/thx.24.6.729; Moon S, 1997, AM J PHYSIOL-LUNG C, V273, pL1208, DOI 10.1152/ajplung.1997.273.6.L1208; NADEL JA, 1991, RESPIRATION, V58, P3; NADEL JA, 1983, EUR J RESPIR DIS, V64, P322; PEATFIELD AC, 1983, AM REV RESPIR DIS, V128, P89, DOI 10.1164/arrd.1983.128.1.89; PEDERSEN M, 1983, EUR J RESPIR DIS, V64, P118; SCHULTZ HD, 1985, J APPL PHYSIOL, V58, P907, DOI 10.1152/jappl.1985.58.3.907; Sharma P, 1998, AM J RESP CELL MOL, V19, P30, DOI 10.1165/ajrcmb.19.1.3054; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHIMURA S, 1988, J APPL PHYSIOL, V65, P2537, DOI 10.1152/jappl.1988.65.6.2537; Singh M, 1997, AM J PHYSIOL-LUNG C, V272, pL690, DOI 10.1152/ajplung.1997.272.4.L690; Takahashi N, 2000, EUR J PHARMACOL, V410, P61, DOI 10.1016/S0014-2999(00)00840-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trout L, 1998, AM J PHYSIOL-LUNG C, V275, pL1095, DOI 10.1152/ajplung.1998.275.6.L1095; Trout L, 2001, AM J PHYSIOL-LUNG C, V281, pL639, DOI 10.1152/ajplung.2001.281.3.L639; Trout L, 1998, AM J PHYSIOL-LUNG C, V274, pL258, DOI 10.1152/ajplung.1998.274.2.L258; WANNER A, 1986, CLIN CHEST MED, V7, P247; Widdicombe JG, 1996, CLIN EXP ALLERGY, V26, P32, DOI 10.1111/j.1365-2222.1996.tb00656.x; Widdicombe JH, 2001, J ANAT, V198, P207, DOI 10.1046/j.1469-7580.2001.19820207.x; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; Wu DXY, 1998, AM J PHYSIOL-LUNG C, V274, pL388, DOI 10.1152/ajplung.1998.274.3.L388; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491; YU J, 1989, J APPL PHYSIOL, V67, P682, DOI 10.1152/jappl.1989.67.2.682	59	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28167	28175		10.1074/jbc.M202712200	http://dx.doi.org/10.1074/jbc.M202712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12011087	hybrid			2022-12-25	WOS:000177189800074
J	Sabarth, N; Lamer, S; Zimny-Arndt, U; Jungblut, PR; Meyer, TF; Bumann, D				Sabarth, N; Lamer, S; Zimny-Arndt, U; Jungblut, PR; Meyer, TF; Bumann, D			Identification of surface proteins of Helicobacter pylori by selective biotinylation, affinity purification, and two-dimensional gel electrophoresis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC EPITHELIAL-CELLS; NEUTROPHIL-ACTIVATING PROTEIN; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; OUTER-MEMBRANE; EXTRACELLULAR RELEASE; GNOTOBIOTIC PIGLETS; VACCINE CANDIDATES; CAGA PROTEIN; IV SECRETION	Helicobacter pylori is a widespread human pathogen that can cause gastric ulcers and cancer. To identify surface proteins that may play a role in pathogen-host interactions and represent potential targets for the control of this infection, we selectively biotinylated intact H. pylori with the hydrophilic reagent sulfosuccinimidyl-6-(biotinamido)-hexanoate and purified the labeled proteins by membrane isolation, solubilization, and affinity chromatography. After separation of 82 biotinylated proteins on two-dimensional gels, 18 were identified with comparison to proteome data and peptide mass fingerprinting. Among the identified proteins, 9 have previously been shown to be surface-exposed, 7 are associated with virulence, and 11 are highly immunogenic in infected patients. In conclusion, this generally applicable combined proteome approach facilitates the rapid identification of promising targets for the control of H. pylori and might be applicable to numerous other human pathogens although larger biotinylation reagents might be required in some cases to prevent permeation of porin channels in the outer membrane.	Max Planck Inst Infek Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Meyer, TF (corresponding author), Max Planck Inst Infek Biol, Mol Biol Abt, Schumannstr 21-22, D-10117 Berlin, Germany.		Sabarth, Nicolas/GQQ-0093-2022; Sabarth, Nicolas/GQP-7376-2022; Meyer, Thomas F. F/J-2485-2013; Jungblut, Peter R/A-1576-2011	Sabarth, Nicolas/0000-0003-3844-6297; Meyer, Thomas F. F/0000-0002-6120-8679; 				Alm RA, 2000, INFECT IMMUN, V68, P4155, DOI 10.1128/IAI.68.7.4155-4168.2000; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; Bina JE, 2000, ANTIMICROB AGENTS CH, V44, P248, DOI 10.1128/AAC.44.2.248-254.2000; BRADBURNE JA, 1993, APPL ENVIRON MICROB, V59, P663, DOI 10.1128/AEM.59.3.663-668.1993; Bumann D, 2002, INFECT IMMUN, V70, P3396, DOI 10.1128/IAI.70.7.3396-3403.2002; Cao P, 1998, INFECT IMMUN, V66, P2984, DOI 10.1128/IAI.66.6.2984-2986.1998; Chevalier C, 1999, MOL MICROBIOL, V31, P1359, DOI 10.1046/j.1365-2958.1999.01271.x; Cianciotto NP, 2001, INT J MED MICROBIOL, V291, P331, DOI 10.1078/1438-4221-00139; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Day WA, 2000, INFECT IMMUN, V68, P6337, DOI 10.1128/IAI.68.11.6337-6345.2000; DECKER J, 2001, INT J MED MICROBIOL, V291, pS31; DOIG P, 1995, J BACTERIOL, V177, P5447, DOI 10.1128/jb.177.19.5447-5452.1995; DOIG P, 1994, INFECT IMMUN, V62, P4526, DOI 10.1128/IAI.62.10.4526-4533.1994; DUNN BE, 1989, INFECT IMMUN, V57, P1825, DOI 10.1128/IAI.57.6.1825-1833.1989; Dunn BE, 1997, INFECT IMMUN, V65, P1181, DOI 10.1128/IAI.65.4.1181-1188.1997; Dunn BE, 1998, YALE J BIOL MED, V71, P63; EATON KA, 1989, INFECT IMMUN, V57, P1119, DOI 10.1128/IAI.57.4.1119-1125.1989; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; EHRMANN M, 1987, J BACTERIOL, V169, P3539, DOI 10.1128/jb.169.8.3539-3545.1987; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; Evans DJ, 2000, HELICOBACTER, V5, P183, DOI 10.1046/j.1523-5378.2000.00029.x; EXNER MM, 1995, INFECT IMMUN, V63, P1567, DOI 10.1128/IAI.63.4.1567-1572.1995; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Haas G, 2002, PROTEOMICS, V2, P313, DOI 10.1002/1615-9861(200203)2:3<313::AID-PROT313>3.0.CO;2-7; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Jungblut PR, 2000, MOL MICROBIOL, V36, P710, DOI 10.1046/j.1365-2958.2000.01896.x; Kimmel B, 2000, INFECT IMMUN, V68, P915, DOI 10.1128/IAI.68.2.915-920.2000; Lundstrom AM, 2001, MICROB PATHOGENESIS, V31, P243, DOI 10.1006/mpat.2001.0466; Marcus EA, 2001, HELICOBACTER, V6, P93, DOI 10.1046/j.1523-5378.2001.00014.x; Master S, 2001, J BACTERIOL, V183, P4033, DOI 10.1128/JB.183.13.4033-4039.2001; McAtee CP, 1998, CLIN DIAGN LAB IMMUN, V5, P537, DOI 10.1128/CDLI.5.4.537-542.1998; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; MURPHY GL, 1993, GENE, V129, P107, DOI 10.1016/0378-1119(93)90704-7; NAKAE T, 1976, J BIOL CHEM, V251, P2176; Namavar F, 1998, INFECT IMMUN, V66, P444, DOI 10.1128/IAI.66.2.444-447.1998; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; Nilsson CL, 2000, ANAL CHEM, V72, P2148, DOI 10.1021/ac9912754; Odenbreit S, 1996, J BACTERIOL, V178, P6960, DOI 10.1128/jb.178.23.6960-6967.1996; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Odenbreit S, 1999, MOL MICROBIOL, V31, P1537, DOI 10.1046/j.1365-2958.1999.01300.x; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Peck B, 1999, NUCLEIC ACIDS RES, V27, P3325, DOI 10.1093/nar/27.16.3325; Peck B, 2001, MICROBES INFECT, V3, P171, DOI 10.1016/S1286-4579(01)01377-6; Phadnis SH, 1996, INFECT IMMUN, V64, P905, DOI 10.1128/IAI.64.3.905-912.1996; Radcliff FJ, 1997, INFECT IMMUN, V65, P4668, DOI 10.1128/IAI.65.11.4668-4674.1997; Ramarao N, 2000, MOL MICROBIOL, V38, P103, DOI 10.1046/j.1365-2958.2000.02114.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Sharff A, 2001, EUR J BIOCHEM, V268, P5011, DOI 10.1046/j.0014-2956.2001.02442.x; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; St John G, 2001, P NATL ACAD SCI USA, V98, P9901; STAUDENMAIER H, 1989, J BACTERIOL, V171, P2626, DOI 10.1128/jb.171.5.2626-2633.1989; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Telford JL, 1997, CURR OPIN IMMUNOL, V9, P498, DOI 10.1016/S0952-7915(97)80101-X; Walker MM, 1998, ANN NY ACAD SCI, V859, P96, DOI 10.1111/j.1749-6632.1998.tb11114.x	57	121	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27896	27902		10.1074/jbc.M204473200	http://dx.doi.org/10.1074/jbc.M204473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023975	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000177189800040
J	Bjorkhem, I; Araya, Z; Rudling, M; Angelin, B; Einarsson, C; Wikvall, K				Bjorkhem, I; Araya, Z; Rudling, M; Angelin, B; Einarsson, C; Wikvall, K			Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver - No coordinate regulation of CYP7A1 and CYP27A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL 27-HYDROXYLASE GENE; HMG-COA REDUCTASE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MESSENGER-RNA; RAT HEPATOCYTES; EXPRESSION; BIOSYNTHESIS; RECEPTOR; CHOLESTYRAMINE; TRANSCRIPTION	It has been reported that there is a coordinate regulation of sterol 27-hydroxylase (CYP27A1) and cholesterol 7alpha-hydroxylase (CYP7A1) in rats. Thus, the levels of the mRNA corresponding to these two enzymes were found to change in the same direction in rat liver and in isolated rat hepatocytes. In contrast, other groups have not seen such regulation of CYP27A1 in rabbit liver or in rat liver when using an activity assay. In the present work, the effect of bile acid treatment on human CYP27A1/luciferase reporter activity was studied in a transient transfection assay in human liver-derived HepG2 cells. Neither the endogenous 27-hydroxylase activity nor the CYP27A1/luciferase reporter activity were down-regulated by treatment of HepG2 cells with chenodeoxycholic acid or taurochenodeoxycholic acid. We also measured CYP27A1 mRNA and CYP7A1 mRNA in liver of humans subjected to treatment with chenodeoxycholic acid, ursodeoxycholic acid, hydroxymethylglutaryl (HMG)-CoA reductase inhibitor and a combination of HMG-CoA reductase inhibitor and cholestyramine. There was a 60-fold variation in the levels of CYP7A1 mRNA but only a 5-fold variation in the levels of CYP27A1 mRNA. There was no correlation between the two mRNA species. It is concluded that, in humans, there is little or no coordinate regulation of CYP7A1 and CYP27A1 at the transcriptional level, and that CYP27A1 is not subject to a negative feedback control by bile acids. The results underline that marked species differences may exist in mechanisms for control of synthesis of bile acids and cholesterol homeostasis.	Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, S-75123 Uppsala, Sweden; Huddinge Univ Hosp, Dept Clin Lab Med & Technol, Div Clin Chem, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden	Uppsala University; Karolinska Institutet; Karolinska Institutet	Wikvall, K (corresponding author), Univ Uppsala, Dept Pharmaceut Biosci, Div Biochem, Box 578, S-75123 Uppsala, Sweden.			Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ANGELIN B, 1982, J CLIN INVEST, V70, P724, DOI 10.1172/JCI110668; ARAYA Z, 1995, BIOCHEM BIOPH RES CO, V216, P868, DOI 10.1006/bbrc.1995.2702; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; BJORKHEM I, 1973, EUR J BIOCHEM, V36, P201, DOI 10.1111/j.1432-1033.1973.tb02902.x; Bjorkhem I, 2001, CURR OPIN LIPIDOL, V12, P97, DOI 10.1097/00041433-200104000-00002; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; Duane WC, 1999, J LIPID RES, V40, P1194; LEITERSDORF E, 1993, J CLIN INVEST, V91, P2488, DOI 10.1172/JCI116484; LUND E, 1996, ARTERIOSCL THROM VAS, V16, P2073; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NILSELL K, 1983, GASTROENTEROLOGY, V85, P1248; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; Postlind H, 2000, BIOCHEM J, V347, P349, DOI 10.1042/0264-6021:3470349; Rao YP, 1999, J STEROID BIOCHEM, V70, P1, DOI 10.1016/S0960-0760(99)00099-0; REIHNER E, 1990, NEW ENGL J MED, V323, P224, DOI 10.1056/NEJM199007263230403; REIHNER E, 1989, GASTROENTEROLOGY, V97, P1498, DOI 10.1016/0016-5085(89)90395-8; RUDLING M, 1992, J LIPID RES, V33, P493; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarz M, 2001, J LIPID RES, V42, P1594; Segev H, 2001, ATHEROSCLEROSIS, V156, P339, DOI 10.1016/S0021-9150(00)00654-7; SHINKI T, 1992, J BIOL CHEM, V267, P13757; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; TWISK J, 1995, BIOCHEM J, V305, P505, DOI 10.1042/bj3050505; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Xu GR, 1999, J CLIN INVEST, V103, P89, DOI 10.1172/JCI4414	27	45	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26804	26807		10.1074/jbc.M202343200	http://dx.doi.org/10.1074/jbc.M202343200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011083	hybrid			2022-12-25	WOS:000177055900014
J	Garber, AC; Hu, JH; Renne, R				Garber, AC; Hu, JH; Renne, R			Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; ORIGIN RECOGNITION COMPLEX; LARGE T-ANTIGEN; GENE-EXPRESSION; SEQUENCE REQUIREMENTS; STABLE REPLICATION; HERPESVIRUS PAPIO; PLASMID ORIGIN; PROTEIN; ORIP	The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus is a multifunctional protein with important roles in both transcriptional regulation and episomal maintenance. LANA is also a DNA-binding protein and has been shown to specifically bind to a region within the terminal repeat. Here, we have performed a detailed analysis of the DNA-binding activity of LANA and show that it binds two sites separated by 22 bp. We used electrophoretic mobility shift assay to quantitatively analyze the binding sites and determined that the K-d of the high affinity site is 1.51 +/- 0.16 nM. Examination of the contribution of nucleotides near the ends of the site showed that the core binding site consists of 16 bp, 13 of which are conserved between both sites. Analysis of the affinity of each site alone and in tandem revealed that the binding to the second site is primarily due to cooperativity with the first site. Using deletion and point mutations, we show that both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. In addition, we show that the ability of LANA to carry out these functions is directly proportional to its affinity for the sites in this region. The affinities, spacing, and cooperative binding between the two sites is similar to that of the Epstein-Barr virus dyad symmetry element oriP, suggesting a requirement for such an element in latent replication of these related DNA tumor viruses.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Renne, R (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Div Hematol Oncol, BRB R301,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rfr3@po.cwru.edu			NATIONAL CANCER INSTITUTE [R01CA088763] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NCI NIH HHS [CA 88763-02] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07147] Funding Source: Medline; NIGMS NIH HHS [T32 GM007250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Ballestas ME, 2001, J VIROL, V75, P3250, DOI 10.1128/JVI.75.7.3250-3258.2001; Baumann M, 1999, EMBO J, V18, P6095, DOI 10.1093/emboj/18.21.6095; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; Cotter MA, 2001, VIROLOGY, V291, P241, DOI 10.1006/viro.2001.1202; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; DEYERLE KL, 1989, J VIROL, V63, P356, DOI 10.1128/JVI.63.1.356-365.1989; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Garber AC, 2001, J VIROL, V75, P7882, DOI 10.1128/JVI.75.17.7882-7892.2001; Glenn M, 1999, J VIROL, V73, P6953, DOI 10.1128/JVI.73.8.6953-6963.1999; GRUFFAT H, 1995, J VIROL, V69, P1878, DOI 10.1128/JVI.69.3.1878-1886.1995; HAASE SB, 1994, MOL CELL BIOL, V14, P2516, DOI 10.1128/MCB.14.4.2516; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698; Jeong J, 2001, J VIROL, V75, P1798, DOI 10.1128/JVI.75.4.1798-1807.2001; Kanda T, 2001, J CELL SCI, V114, P49; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Koons MD, 2001, J VIROL, V75, P10582, DOI 10.1128/JVI.75.22.10582-10592.2001; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; Kung SH, 1996, J VIROL, V70, P1738, DOI 10.1128/JVI.70.3.1738-1744.1996; Lagunoff M, 1997, VIROLOGY, V236, P147, DOI 10.1006/viro.1997.8713; Li R, 1999, J BIOL CHEM, V274, P30310, DOI 10.1074/jbc.274.42.30310; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Lim C, 2001, J BIOL CHEM, V276, P31016, DOI 10.1074/jbc.M102431200; LOEB DD, 1990, J VIROL, V64, P2876, DOI 10.1128/JVI.64.6.2876-2883.1990; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Marechal V, 1999, J VIROL, V73, P4385, DOI 10.1128/JVI.73.5.4385-4392.1999; Maxam A M, 1980, Methods Enzymol, V65, P499; MIDDLETON T, 1992, J VIROL, V66, P1795, DOI 10.1128/JVI.66.3.1795-1798.1992; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Piolot T, 2001, J VIROL, V75, P3948, DOI 10.1128/JVI.75.8.3948-3959.2001; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Ptashne M., 1992, A GENETIC SWITCH; Puglielli MT, 1996, J VIROL, V70, P5758, DOI 10.1128/JVI.70.9.5758-5768.1996; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Schwam DR, 2000, J VIROL, V74, P8532, DOI 10.1128/JVI.74.18.8532-8540.2000; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; Szekely L, 1999, J GEN VIROL, V80, P2889, DOI 10.1099/0022-1317-80-11-2889; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; Wu H, 2000, EMBO REP, V1, P140, DOI 10.1093/embo-reports/kvd026; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Yates JL, 2000, J VIROL, V74, P4512, DOI 10.1128/JVI.74.10.4512-4522.2000; Yates JL, 1996, VIROLOGY, V222, P1, DOI 10.1006/viro.1996.0392; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	83	141	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27401	27411		10.1074/jbc.M203489200	http://dx.doi.org/10.1074/jbc.M203489200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015325	hybrid			2022-12-25	WOS:000177055900090
J	Versteeg, HH; Sorensen, BB; Slofstra, SH; Van den Brande, JHM; Stam, JC; Henegouwen, PMPVE; Richel, DJ; Petersen, LC; Peppelenbosch, MP				Versteeg, HH; Sorensen, BB; Slofstra, SH; Van den Brande, JHM; Stam, JC; Henegouwen, PMPVE; Richel, DJ; Petersen, LC; Peppelenbosch, MP			VIIa/tissue factor interaction results in a tissue factor cytoplasmic domain-independent activation of protein synthesis, p70, and p90 S6 kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SIGNAL-TRANSDUCTION; CANINE KIDNEY-CELLS; FACTOR-VIIA; GENE-EXPRESSION; BLOOD-COAGULATION; UP-REGULATION; GROWTH-FACTOR; BINDING; INITIATION; INSULIN	FVIIa binding to tissue factor (TF) and subsequent signal transduction have now been implicated in a variety of pathophysiological processes, including cytokine production during sepsis, tumor angiogenesis and neoangiogenesis, and leukocyte diapedesis. The molecular details, however, by which FVIIa/TF affects gene expression and cellular physiology, remain obscure. Here we show that FVIIa induces a transient phosphorylation of p70/p85(S6K) and p90(RSK) in BHK cells stably transfected with either full-length TF or with a cytoplasmic domain-truncated TF but not in wild type BHK cells. Phosphorylation of these kinases was also observed in HaCaT cells, expressing endogenous TF. Phosphorylation of p70/p85(S6K) coincided with protein kinase B and GSK-3beta phosphorylation. Activation of p70/p85(S6K) was sensitive to inhibitors of phosphatidylinoitol 3-kinase and to rapamycin, whereas phosphorylation of p90RSK was sensitive to PD98059. FVIIa stimulation of p70/p85(S6K) and p90(RSK) correlated with phosphorylation of the eukaryotic initiation factor eIF-4E, up-regulation of protein levels of eEF1alpha and eEF2, and enhanced [S-35]methionine incorporation. These effects were not influenced by inhibitors of thrombin or FXa generation and were strictly dependent on the presence of the extracellular domain of TF, but they did not require the intracellular portion of TF. We propose that a TF cytoplasmic domain-independent stimulation of protein synthesis via activation of S6 kinase contributes to FVIIa effects in pathophysiology.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Oncol, NL-1105 AZ Amsterdam, Netherlands; Novo Nordisk AS, DK-2760 Malov, Denmark; Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Novo Nordisk	Peppelenbosch, MP (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		van Bergen en Henegouwen, Paul/B-8870-2011; Versteeg, Henri/G-1783-2018	van Bergen en Henegouwen, Paul/0000-0001-6050-9042; Versteeg, Henri/0000-0003-4294-175X; Peppelenbosch, Maikel/0000-0001-9112-6028				BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Cunningham MA, 1999, BLOOD, V94, P3413, DOI 10.1182/blood.V94.10.3413.422k24_3413_3420; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; Melis E, 2001, BIOCHEM BIOPH RES CO, V286, P580, DOI 10.1006/bbrc.2001.5425; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NOVAKHOFER I, 1985, J BIOL CHEM, V260, P314; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Petersen LC, 2000, THROMB HAEMOSTASIS, V83, P571; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Proud CG, 1997, BIOCHEM J, V328, P329; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; Rao LVM, 2001, TRENDS CARDIOVAS MED, V11, P14, DOI 10.1016/S1050-1738(01)00077-9; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Ruf W, 1999, THROMB HAEMOSTASIS, V82, P175; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Versteeg HH, 2001, THROMB HAEMOSTASIS, V86, P1353; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Wiiger MT, 2000, TRENDS CARDIOVAS MED, V10, P360, DOI 10.1016/S1050-1738(01)00074-3; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	37	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27065	27072		10.1074/jbc.M110325200	http://dx.doi.org/10.1074/jbc.M110325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12019261	hybrid			2022-12-25	WOS:000177055900048
J	Janciauskiene, S; Dominaitiene, R; Sternby, NH; Piitulainen, E; Eriksson, S				Janciauskiene, S; Dominaitiene, R; Sternby, NH; Piitulainen, E; Eriksson, S			Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; SERINE-PROTEASE INHIBITORS; ALPHA(1)-ANTITRYPSIN DEFICIENCY; CONFORMATIONAL DISEASE; LIVER-DISEASE; WEGENERS-GRANULOMATOSIS; PROTEINASE-INHIBITOR; BETA-SHEET; SERPINS; INSERTION	Globular inclusions of abnormal alpha1-antitrypsin (AAT) in the endoplasmic reticulum of hepatocytes are a characteristic feature of AAT deficiency of the PiZZ phenotype. Monoclonal antibodies, which contain constant specificity and affinity, are often used for the identification of Z-mutation carriers. A mouse monoclonal antibody (ATZ11) raised against PiZZ hepatocytic AAT was successfully used in enzyme-linked immunosorbent assays (ELISA) and in identification of Z-related AAT globular inclusions by immunohistochemical techniques. Using electrophoresis, Western blotting, and ELISA procedures, we have shown in the present study that this monoclonal antibody specifically detects a conformation-dependent neoepitope on both polymerized and elastase-complexed molecular forms of AAT. The antibody has no apparent affinity for native, latent, or cleaved forms of AAT. The antibody ATZ11 illustrates the structural resemblance between the polymerized form of AAT and its complex with elastase and provides evidence that Z-homozygotes beyond the native form may have at least one more circulating molecular form of AAT, i.e. its polymerized form. In addition, staining of endothelial cells with ATZ11 antibody in both M- and Z-AAT individuals shows that AAT attached to endothelial cells is in a polymerized form. The antibody can be a powerful tool for the study of the molecular profile of AAT, not only in Z-deficiency cases but also in other (patho)physiological conditions.	Malmo Univ Hosp, Dept Resp Med, S-20502 Malmo, Sweden; Malmo Univ Hosp, Dept Pathol, S-20502 Malmo, Sweden; Malmo Univ Hosp, Dept Internal Med, S-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Janciauskiene, S (corresponding author), Wallenberg Inst & Labs, Dept Med, UMAS, Ing 46, S-20502 Malmo, Sweden.	sabina.janciauskiene@medforsk.mas.lu.se	Longo, Kenneth A/A-5631-2010	Aldonyte, Ruta/0000-0002-9806-025X				ABBINK JJ, 1991, J IMMUNOL METHODS, V143, P197, DOI 10.1016/0022-1759(91)90045-H; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BOLMER S, 1986, AM J PATHOL, V123, P377; Borgmann S, 2001, CLIN IMMUNOL, V98, P244, DOI 10.1006/clim.2000.4962; CALLEA F, 1991, J HEPATOL, V12, P372, DOI 10.1016/0168-8278(91)90842-Y; Campbell EJ, 2000, RESP MED, V94, pS18, DOI 10.1053/rmed.2000.0854; CARLSON J, 1985, SCAND J GASTROENTERO, V20, P835, DOI 10.3109/00365528509088831; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1996, CHEST, V110, pS243, DOI 10.1378/chest.110.6_Supplement.243S; CARRELL RW, 1994, AM J RESP CRIT CARE, V150, pS171, DOI 10.1164/ajrccm/150.6_Pt_2.S171; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; ELDERING E, 1988, J BIOL CHEM, V263, P11776; Elliott PR, 2000, PROTEIN SCI, V9, P1274, DOI 10.1110/ps.9.7.1274; Elliott PR, 1998, AM J RESP CELL MOL, V18, P670, DOI 10.1165/ajrcmb.18.5.3065; Elzouki AN, 1997, J HEPATOL, V27, P42, DOI 10.1016/S0168-8278(97)80278-4; ELZOUKI ANY, 1994, J INTERN MED, V236, P543, DOI 10.1111/j.1365-2796.1994.tb00842.x; Eriksson S, 1996, CHEST, V110, pS237, DOI 10.1378/chest.110.6_Supplement.237S; Eriksson Sten, 1999, Journal of Hepatology, V30, P34; Esnault VLM, 1997, EXP CLIN IMMUNOGENET, V14, P206; Fischer HP, 2000, J HEPATOL, V33, P883, DOI 10.1016/S0168-8278(00)80119-1; FORSYTH KD, 1994, CLIN EXP IMMUNOL, V95, P277; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Janciauskiene S, 1996, SCAND J CLIN LAB INV, V56, P597, DOI 10.3109/00365519609090594; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; KALSHEKER N, 1990, THORAX, V45, P759, DOI 10.1136/thx.45.10.759; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Lomas DA, 2000, RESP MED, V94, pS3, DOI 10.1053/rmed.2000.0850; Lou JN, 1999, DIABETES, V48, P1773, DOI 10.2337/diabetes.48.9.1773; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; Mahadeva R, 1998, THORAX, V53, P501, DOI 10.1136/thx.53.6.501; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Moraga F, 2001, ARCH BIOCHEM BIOPHYS, V386, P221, DOI 10.1006/abbi.2000.2211; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; Nakatani K, 2001, J LEUKOCYTE BIOL, V69, P241; NUIJENS JH, 1987, IMMUNOLOGY, V61, P387; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; Perlmutter D H, 2000, Clin Liver Dis, V4, P387, DOI 10.1016/S1089-3261(05)70115-X; Perlmutter DH, 1998, SEMIN LIVER DIS, V18, P217, DOI 10.1055/s-2007-1007158; Picard V, 1999, J BIOL CHEM, V274, P4586, DOI 10.1074/jbc.274.8.4586; Reid P T, 2001, Curr Opin Investig Drugs, V2, P59; Saunders DN, 1998, J BIOL CHEM, V273, P10965, DOI 10.1074/jbc.273.18.10965; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Strandberg K, 2000, BIOCHEMISTRY-US, V39, P15713, DOI 10.1021/bi001640h; SUN JR, 1995, J BIOL CHEM, V270, P16089, DOI 10.1074/jbc.270.27.16089; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; TRAVIS J, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P313; WALLMARK A, 1984, P NATL ACAD SCI-BIOL, V81, P5690, DOI 10.1073/pnas.81.18.5690; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	61	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26540	26546		10.1074/jbc.M203832200	http://dx.doi.org/10.1074/jbc.M203832200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12023970	hybrid			2022-12-25	WOS:000176908700094
J	Sims, RJ; Weihe, EK; Zhu, L; O'Malley, S; Harriss, JV; Gottlieb, PD				Sims, RJ; Weihe, EK; Zhu, L; O'Malley, S; Harriss, JV; Gottlieb, PD			m-Bop, a repressor protein essential for cardiogenesis, interacts with skNAC, a heart- and muscle-specific transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-ASSOCIATED COMPLEX; ACUTE MYELOID-LEUKEMIA; FUSION PARTNER; HISTONE H3; N-COR; ETO; RECRUITMENT; COREPRESSOR; CHROMATIN; T(8-21)	The m-Bop protein encoded by the mouse Bop gene is strongly expressed in heart and skeletal muscle, and recent studies with Bop knockout mice have demonstrated that m-Bop is essential for cardiogenesis in vivo and can act as a HDAC-dependent repressor in vitro. In the present studies, m-Bop was observed to interact with skNAC, a reported transcriptional activator specific to heart and skeletal muscle. The amino-terminal S region of the split S-ET domain of m-Bop as well as the MYND domain were required for interaction with skNAC in both the two-hybrid system and in coimmunoprecipitation experiments from cultured mammalian cells. As shown previously for interaction of the MYND domain-containing transcriptional corepressor, BS69, with several viral and cellular oncoproteins, a PXLXP motif in skNAC was required for interaction with mBop. Similar kinetics of induction and localization of m-Bop and skNAC during the induction of myogenesis in cultured C2C12 cells suggests a possible associated role for these proteins during this process.	Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Gottlieb, PD (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.				NIAID NIH HHS [AI42047, AI47209] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI042047, R01AI047209] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Hwang I, 1997, J IMMUNOL, V158, P1165; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Munz B, 1999, J BIOL CHEM, V274, P13305, DOI 10.1074/jbc.274.19.13305; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Whitby MC, 2001, J MOL BIOL, V306, P703, DOI 10.1006/jmbi.2000.4407; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	24	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26524	26529		10.1074/jbc.M204121200	http://dx.doi.org/10.1074/jbc.M204121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	12011100	hybrid			2022-12-25	WOS:000176908700092
J	Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK				Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK			Effect of C-terminal deletion of P53 on heat induced CD95 expression and apoptosis in a rat histiocytoma	ONCOGENE			English	Article						deletion in p53; CD95; apoptosis; heat stress	FAS-INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; DEATH FACTOR; CELL-DEATH; GENES; SHOCK; INVOLVEMENT; GROWTH; SYSTEM; LIGAND	Tumor suppressor gene product p53 in its wild-type conformation, is an effector of apoptosis. A rat histiocytic tumor, AK-5 which has a rearranged and mutated p53 gene undergoes apoptosis upon heat shock through surface expression of CD95 receptor. DNA sequence analysis of p53 gene from tumor cells revealed a deletion of 'C' at nucleotide position 942 and an addition of 'A' at position 1055. Deletion of one nucleotide caused premature termination of p53 protein which resulted in shorter p53 protein with an altered sequence from amino acids 315 to 341. Altered p53 was unable to protect BC-8, a single cell clone of AK-5 cells from apoptosis upon heat shock. BC-8 cells transfected with a wild-type p53gene (3B4 cells) were resistant to heat induced apoptosis and did not show the expression CD95 death receptor. Inhibition of p53 expression by using antisense oligo induced apoptosis upon heat shock in 3134 cells. Similarly, inhibition of CD95 expression by antisense oligo inhibited heat induced apoptosis in BC-8 cells. In addition, cell cycle regulatory molecules, cdc2 and cdk2 are differentially regulated in a non-cell cycle dependent manner in these tumor cells. These results, in view of lack of heat shock response in BC-8 cells suggest a complex interaction between p53, CD95 and hsp70 which determines the fate of the cell. In the absence of functional p53, CD95 appears to be an effector of apoptosis in BC-8 cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Srinivas, UK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.							Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DESHPANDE G, 1990, FEBS LETT, V271, P199, DOI 10.1016/0014-5793(90)80405-8; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KHAR A, 1990, IN VITRO CELL DEV B, V26, P1024; Kim JM, 1999, ENDOCRINOLOGY, V140, P2307, DOI 10.1210/en.140.5.2307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murayama Y, 2000, HUM IMMUNOL, V61, P474, DOI 10.1016/S0198-8859(00)00100-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pardhasaradhi B. V. V., 1996, Indian Journal of Experimental Biology, V34, P945; RAFF M, 1992, NATURE, V343, P76; ROBINSON JP, 1988, CURRENT PROTOCOLS CY; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Sreedhar AS, 1999, FEBS LETT, V456, P339, DOI 10.1016/S0014-5793(99)00970-9; Sreedhar AS, 2000, FEBS LETT, V472, P271, DOI 10.1016/S0014-5793(00)01467-8; Swamynathan SK, 1996, DNA CELL BIOL, V15, P897, DOI 10.1089/dna.1996.15.897; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P539; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785; Zhou M, 1998, LEUKEMIA, V12, P1756, DOI 10.1038/sj.leu.2401198	40	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4042	4049		10.1038/sj.onc.1205504	http://dx.doi.org/10.1038/sj.onc.1205504			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037686				2022-12-25	WOS:000175869900010
J	Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH				Miyazono, F; Schneider, PM; Metzger, R; Warnecke-Eberz, U; Baldus, SE; Dienes, HP; Aikou, T; Hoelscher, AH			Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus	ONCOGENE			English	Article						mitochondrial DNA; D-Loop; mutation; Barrett's cancer; carcinogenesis	SOMATIC MUTATIONS; OXIDATIVE DAMAGE; GASTRIC TUMORS; NUCLEAR-DNA; CANCER; GENOME; P53; INSTABILITY; PROGRESSION; SEQUENCE	Mitochondrial DNA (mtDNA) is known for high mutation rates caused by lack of protective histones, inefficient DNA repair systems, and continuous exposure to mutagenic effects of oxygen radicals. We examined the frequency of mutations in the mtDNA D-Loop region in 20 patients with Barrett's carcinoma and associated Barrett's epithelium by automated DNA sequencing. Mutations were detected in eight of 20 (40%) patients in tumor and/or tumor-associated Barrett's epithelium. In six of eight positive cases, the mutations were detected only in the tumor, one of eight showed mutations in tumor and Barrett's epithelium, and one of eight only in Barrett's epithelium. The degree of dysplasia in Barrett's epithelium was classified low-grade in one and high grade in the two specimens. There was no association of mtDNA D-Loop mutations with histopathological stage of disease or tumor grading. We present the first study of frequent occurrence of mutations in the mtDNA D-Loop regions in adenocarcinomas in Barrett's esophagus. Furthermore, this study supports the hypothesis that oxidative damage might be a mechanism for the induction of adenocarcinoma in Barrett's esophagus. Since mutations were identified in tumor-associated dysplastic Barrett's epithelium, they also might become a marker for the malignant potential of Barrett's epithelium.	Univ Cologne, Dept Visceral & Vasc Surg, D-50931 Cologne, Germany; Univ Cologne, Inst Pathol, D-50931 Cologne, Germany; Kagoshima Univ, Sch Med, Dept Surg 1, Kagoshima 8908520, Japan	University of Cologne; University of Cologne; Kagoshima University	Schneider, PM (corresponding author), Univ Cologne, Dept Visceral & Vasc Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	Paul.Schneider@Medizin.Uni-Koeln.de		Warnecke-Eberz, Ute/0000-0002-2833-5633				Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Armstrong J, 2000, PEDIATR NEUROL, V23, P85, DOI 10.1016/S0887-8994(00)00158-2; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Chen XX, 2000, CARCINOGENESIS, V21, P257, DOI 10.1093/carcin/21.2.257; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; HEERDT BG, 1994, CANCER RES, V54, P3912; HERMANEK P, 1992, UICC TNM KLASSIFIKAT, P9; Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Miller KWP, 1996, INT J LEGAL MED, V109, P107, DOI 10.1007/BF01369668; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLYAEE M, 1995, GUT, V37, P168, DOI 10.1136/gut.37.2.168; Polkowski W, 1999, HISTOL HISTOPATHOL, V14, P927, DOI 10.14670/HH-14.927; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; Reid BJ, 1996, EUR J CANCER PREV, V5, P57, DOI 10.1097/00008469-199612002-00009; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; REIDDEL RH, 1985, BARRETTS ESOPHAGUS, P224; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Schneider PM, 1996, J THORAC CARDIOV SUR, V111, P323, DOI 10.1016/S0022-5223(96)70441-5; Schneider PM, 2000, CLIN CANCER RES, V6, P3153; Schrump DS, 1999, DIS ESOPHAGUS, V12, P181; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; Tamura G, 1999, EUR J CANCER, V35, P316, DOI 10.1016/S0959-8049(98)00360-8; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wetscher GJ, 1998, AM J SURG, V176, P569, DOI 10.1016/S0002-9610(98)00258-X; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; WILSON MR, 1995, BIOTECHNIQUES, V18, P662	36	61	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3780	3783		10.1038/sj.onc.1205532	http://dx.doi.org/10.1038/sj.onc.1205532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032845				2022-12-25	WOS:000175676000012
J	Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA				Joseph, T; Bryant, A; Frankel, P; Wooden, R; Kerkhoff, E; Rapp, UR; Foster, DA			Phospholipase D overcomes cell cycle arrest induced by high-intensity Raf signaling	ONCOGENE			English	Article						phospholipase D; Raf; cell cycle; survival signals	PROTEIN-KINASE-C; PHOSPHATIDIC-ACID; ACTIVATION; RECEPTOR; RALA; FIBROBLASTS; INVOLVEMENT; APOPTOSIS; CANCER; PROLIFERATION	Low level expression of an active Raf kinase results in a transformed phenotype; however, high intensity Raf signals block cell cycle progression. Phospholipase D (PLD) has been implicated in regulating cell cycle progression and PLD activity is elevated in Raf transformed cells. We report here that high intensity Raf signals reduce PLD activity and that elevated expression of either PLD1 or PLD2 prevents cell cycle arrest induced by high intensity Raf signals. Overexpression of either PLD1 or PLD2 also reversed increases in p21(Cip1) and protein kinase C delta (PKC delta) cleavage seen with high intensity Raf signals. These data indicate that PLD signaling provides a novel survival signal that overcomes cell cycle arrest induced by high intensity Raf signaling.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	City University of New York (CUNY) System; Hunter College (CUNY); University of Wurzburg	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edun			NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; ASKEW DS, 1991, ONCOGENE, V6, P1915; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; RAPP UR, 1987, ONCOGENES CANCER, P55; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; ZHONG M, 2002, IN PRESS ONCOGENE, V21; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	45	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3651	3658		10.1038/sj.onc.1205380	http://dx.doi.org/10.1038/sj.onc.1205380			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032867				2022-12-25	WOS:000175793700016
J	Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB				Su, ZZ; Kang, DC; Chen, YM; Pekarskaya, O; Chao, W; Volsky, DJ; Fisher, PB			Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH	ONCOGENE			English	Article						AIDS; gp120; Northern hybridization; reverse Northern hybridization; neuropathogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; NECROSIS-FACTOR-ALPHA; HUMAN GLIAL-CELLS; GROWTH ARREST; DIFFERENTIAL EXPRESSION; GLUTAMATE TRANSPORTERS; PRODUCTIVE INFECTION; TYPE-1 INFECTION; BRAIN-INJURY	Neurodegeneration and dementia are common complications of AIDS caused by human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system. HIV-1 target cells in the brain include microglia, infiltrating macrophages and astrocytes, but rarely neurons. Astrocytes play an important role in the maintenance of the synaptic micro-environment and in neuronal signal transmission. To investigate potential changes in cellular gene expression associated with HIV-1 infection of astrocytes, we employed an efficient and sensitive rapid subtraction hybridization approach, RaSH. Primary human astrocytes were isolated from abortus brain tissue and low-passage cells were infected with HIV-1. To identify genes that display both early and late expression modifications after HIV-1 infection and to avoid cloning genes displaying normal cell cycle fluctuations in astrocytes, RNAs were isolated and pooled from 6, 12, 24 h and 3 and 7 day uninfected and infected cells and used for RaSH. Temporal cDNA libraries were prepared from double-stranded cDNAs that were enzymatically digested into small fragments, ligated to adapters, PCR amplified, and hybridized by incubation of tester and driver PCR fragments. By subtracting temporal cDNAs derived from uninfected astrocytes from temporal cDNAs made from HIV-1 infected cells, genes displaying elevated expression in virus infected cells, termed astrocyte elevated genes (AEGs), were identified. Both known and novel AEGs, not reported in current DNA databases, are described that display early or late expression kinetics following HIV-1 infection or treatment with recombinant HIV-1 envelope glycoprotein (gp120). For selected AEGs, expression of their protein products was also tested by Western blotting and found to display elevated expression following HIV-1 infection. The comparable pattern of regulation of the AEGs following HIV-1 infection or gp120 treatment suggest that HIV-1 exposure of astrocytes, even in the absence of productive infection, can induce changes in cellular gene expression.	Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, St Lukes Roosevelt Hosp Ctr, Div Mol Virol, New York, NY 10019 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbfl@columbia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS31492, P01 NS031492] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1994, J NEUROPATH EXP NEUR, V53, P284, DOI 10.1097/00005072-199405000-00010; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Anderson CM, 2000, GLIA, V32, P1; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; Bencheikh M, 1999, J NEUROVIROL, V5, P115, DOI 10.3109/13550289909021993; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENOS DJ, 1994, ADV NEUROIMMUNOL, V4, P175, DOI 10.1016/S0960-5428(06)80254-8; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BOUSSADIA O, 1993, BIOCHIM BIOPHYS ACTA, V1172, P64, DOI 10.1016/0167-4781(93)90270-N; Brack-Werner R, 1999, AIDS, V13, P1, DOI 10.1097/00002030-199901140-00003; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Furukawa T, 1999, J HUM GENET, V44, P397, DOI 10.1007/s100380050186; Gabuzda D, 1999, J NEUROVIROL, V5, P643, DOI 10.3109/13550289909021293; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; GONDO H, 1987, J IMMUNOL, V139, P3840; Gonos ES, 1998, ANN NY ACAD SCI, V851, P466, DOI 10.1111/j.1749-6632.1998.tb09024.x; Gorry PR, 1999, J VIROL, V73, P352, DOI 10.1128/JVI.73.1.352-361.1999; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HONORE B, 1994, ELECTROPHORESIS, V15, P482, DOI 10.1002/elps.1150150166; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kawagoe H, 1997, CANCER RES, V57, P2516; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; Kort JJ, 1998, AIDS RES HUM RETROV, V14, P1329, DOI 10.1089/aid.1998.14.1329; Lee DK, 2001, MOL BRAIN RES, V86, P13, DOI 10.1016/S0169-328X(00)00242-4; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; Ludwig E, 1999, J VIROL, V73, P8279, DOI 10.1128/JVI.73.10.8279-8289.1999; MA MH, 1994, J VIROL, V68, P6824, DOI 10.1128/JVI.68.10.6824-6828.1994; Manji HK, 2000, BIOL PSYCHIAT, V48, P518, DOI 10.1016/S0006-3223(00)00929-X; Maragakis NJ, 2001, ARCH NEUROL-CHICAGO, V58, P365, DOI 10.1001/archneur.58.3.365; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NIQUET J, 1994, NEUROSCI LETT, V180, P13, DOI 10.1016/0304-3940(94)90902-4; O'Regan S, 2000, P NATL ACAD SCI USA, V97, P1835, DOI 10.1073/pnas.030339697; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Pope A., 1978, DYNAMIC PROPERTIES G, P13; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Prieto AL, 1999, BRAIN RES, V816, P646, DOI 10.1016/S0006-8993(98)01159-7; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Rubio ME, 1999, J NEUROCHEM, V73, P942, DOI 10.1046/j.1471-4159.1999.0730942.x; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAHABUDDIN N, 1994, AIDS RES HUM RETROV, V10, P1525; Sharma G, 2001, P NATL ACAD SCI USA, V98, P4148, DOI 10.1073/pnas.071540198; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shimizu N, 1999, J VIROL, V73, P5231, DOI 10.1128/JVI.73.6.5231-5239.1999; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Simm M, 2001, GENE, V269, P93, DOI 10.1016/S0378-1119(01)00456-5; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Szymocha R, 2000, J VIROL, V74, P6433, DOI 10.1128/JVI.74.14.6433-6441.2000; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; TSUKADA M, 1991, J GERONTOL, V46, pB213, DOI 10.1093/geronj/46.6.B213; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Yu N, 1998, P NATL ACAD SCI USA, V95, P2624, DOI 10.1073/pnas.95.5.2624	88	279	310	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3592	3602		10.1038/sj.onc.1205445	http://dx.doi.org/10.1038/sj.onc.1205445			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032861				2022-12-25	WOS:000175793700010
J	Levin, MK; Patel, SS				Levin, MK; Patel, SS			Helicase from hepatitis C virus, energetics of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; COLI REP HELICASE; RNA-STIMULATED ATPASE; NS3 PROTEIN; NONSTRUCTURAL PROTEIN-3; NUCLEOSIDE TRIPHOSPHATASE; INDUCED DIMERIZATION; ENZYMATIC-ACTIVITIES; CRYSTAL-STRUCTURES; KINETIC-ANALYSIS	The ability of a helicase to bind single-stranded nucleic acid is critical for nucleic acid unwinding. The helicase from the hepatitis C virus, NS3 protein, binds to the 3'-DNA or the RNA strand during unwinding. As a step to understand the mechanism of unwinding, DNA binding properties of the helicase domain of NS3 (NS3h) were investigated by fluorimetric binding equilibrium titrations. The global analysis of the binding data by a combinatorial approach was done using MATLAB. NS3h interactions with single-stranded DNA (ssDNA) are 300-1000-fold tighter relative to duplex DNA. The NS3h protein binds to ssDNA less than 15 nt in length with a stoichiometry of one protein per DNA. The minimal ssDNA binding site of NS3h helicase was determined to be 8 nucleotides with the microscopic K-d of 2-4 rim or an observed free energy of -50 kJ/mol. These NS3h-DNA interactions are highly sensitive to salt, and the K-d increases 4 times when the NaCl concentration is doubled. Multiple HCV helicase proteins bind to ssDNA >15 nucleotides in length, with an apparent occluded site of 8-11 nucleotides. The DNA binding data indicate that the interactions of multiple NS3h protein molecules with long ssDNA are both noncooperative and sequence-independent. We discuss the DNA binding properties of HCV helicase in relation to other superfamily 1 and 2 helicases. These studies provide the basis to investigate the DNA binding interactions with the unwinding substrate and their modulation by the ATPase activity of HCV helicase.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; Gwack Y, 1999, J VIROL, V73, P2909, DOI 10.1128/JVI.73.4.2909-2915.1999; HAN DS, 1995, J GEN VIROL, V76, P985, DOI 10.1099/0022-1317-76-4-985; Healy S, 1997, J BIOL CHEM, V272, P3411, DOI 10.1074/jbc.272.6.3411; Hesson T, 2000, BIOCHEMISTRY-US, V39, P2619, DOI 10.1021/bi992127a; Jezewska MJ, 2000, J BIOL CHEM, V275, P27865; Kadare G, 1997, J VIROL, V71, P2583; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; KOLYKHALOV AA, 1994, J VIROL, V68, P7525, DOI 10.1128/JVI.68.11.7525-7533.1994; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Mechanic LE, 1999, J BACTERIOL, V181, P2519, DOI 10.1128/JB.181.8.2519-2526.1999; Morgenstern KA, 1997, J VIROL, V71, P3767, DOI 10.1128/JVI.71.5.3767-3775.1997; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; PATEL SS, 2002, IN PRESS KINETIC ANA; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Record MT, 1998, ADV PROTEIN CHEM, V51, P281; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SECRIST JA, 1972, SCIENCE, V175, P646, DOI 10.1126/science.175.4022.646; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tackett AJ, 2001, NUCLEIC ACIDS RES, V29, P565, DOI 10.1093/nar/29.2.565; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TOLMAN GL, 1974, BIOCHEMISTRY-US, V13, P4869, DOI 10.1021/bi00721a001; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	46	56	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29377	29385		10.1074/jbc.M112315200	http://dx.doi.org/10.1074/jbc.M112315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034714	hybrid			2022-12-25	WOS:000177509300006
J	Park, JK; Wang, LX; Patel, HV; Roseman, S				Park, JK; Wang, LX; Patel, HV; Roseman, S			Molecular cloning and characterization of a unique beta-glucosidase from Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHITIN CATABOLISM; SEQUENCE; CLASSIFICATION; FURNISSII	We have recently reported the molecular cloning of a gene, gspK, in Vibrio cholerae that encodes a specific glucosamine kinase. We describe here the identification of bglA, a gene contiguous to gspK in a presumptive large chitin catabolic operon. BglA was molecularly cloned into Escherichia coli, and the protein BglA was overexpressed and purified to apparent homogeneity. BglA is 65 kDa (574 amino acids) with an N-terminal amino acid sequence predicted by the gene sequence, suggesting that the enzyme is cytoplasmic. The purified enzyme exhibited optimal activity with p-nitrophenyl beta-glucoside, cellobiose, and higher oligosaccharides of cellulose. No other glucosides or glycosides tested were hydrolyzed, including Glc-Glc disaccharides where the linkage is beta1-->2,beta1-->3, and beta1-->6, respectively. The predicted BglA sequence bears little similarity to other proteins in the data banks. The Henrissat algorithm places BglA sequence in Family, 9 of the glycosidases, suggesting it is an endoglucanase. However, the results summarized above suggested that BglA is an exoenzyme yielding Glc at each cleavage step. To resolve this apparent discrepancy, detailed kinetic studies were conducted with cellotetraose. Only exoglucanase activity was detected. The function of this enzyme in V. cholerae remains to be determined, especially because our strain of this organism does not utilize cellobiose.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Roseman, S (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 214,3400 N Charles St, Baltimore, MD 21218 USA.		Wang, Lai-Xi/E-8755-2019; Wang, Lai-Xi/E-8790-2019; wang, xl/Y-8251-2019	Wang, Lai-Xi/0000-0003-4293-5819; 	NIGMS NIH HHS [GM51215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1996, CURR PROT MOL BIOL, V1; CASTLE LA, 1992, J BACTERIOL, V174, P1478, DOI 10.1128/jb.174.5.1478-1486.1992; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Keyhani NO, 1999, BBA-GEN SUBJECTS, V1473, P108, DOI 10.1016/S0304-4165(99)00172-5; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; Morgan WTJ, 1934, BIOCHEM J, V28, P988, DOI 10.1042/bj0280988; Park JK, 2000, J BIOL CHEM, V275, P33077, DOI 10.1074/jbc.M001042200; Park JK, 2002, J BIOL CHEM, V277, P15573, DOI 10.1074/jbc.M107953200; Segel IH, 1976, BIOCH CALCULATIONS	14	26	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29555	29560		10.1074/jbc.M202978200	http://dx.doi.org/10.1074/jbc.M202978200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12042307	hybrid			2022-12-25	WOS:000177509300028
J	Illarionova, V; Eisenreich, W; Fischer, M; Haussmann, C; Romisch, W; Richter, G; Bacher, A				Illarionova, V; Eisenreich, W; Fischer, M; Haussmann, C; Romisch, W; Richter, G; Bacher, A			Biosynthesis of tetrahydrofolate - Stereochemistry of dihydroneopterin aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; CRYSTAL-STRUCTURE; CYCLOHYDROLASE-I; FOLIC-ACID; RESISTANCE; CHROMATOGRAPHY; CONSTRUCTION; PURIFICATION; RIBOFLAVIN	7,8-Dihydroneopterin aldolase catalyzes the formation of the tetrahydrofolate precursor, 6-hydroxymethyl-7,8-dihydropterin, and is a potential target for antimicrobial and anti-parasite chemotherapy. The last step of the enzyme-catalyzed reaction is believed to involve the protonation of an enol type intermediate. In order to study the stereochemical course of that reaction step, [1',2',3',6,7-C-13(5)] dihydroneopterin was treated with aldolase in deuterated buffer. The resulting, partially deuterated [6alpha,6,7-C-13(3)]6-hydroxymethyl-7,8-dihydropterin was converted to partially deuterated 6-(R)-[6,7,9,11-C-13(4)]5,10-methylenetetrahydropteroate by a sequence of three enzyme-catalyzed reactions followed by treatment with [C-13]formaldehyde. The product was analyzed by multinuclear NMR spectroscopy. The data show that the carbinol group of enzymatically formed 6-hydroxymethyl-dihydropterin contained H-2 predominantly in the pro-S position.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Eisenreich, W (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	wolfgang.eisenreich@ch.tum.de; gerald.richter@ch.tum.de	Fischer, Markus/AFT-1856-2022; Richter, Gerald/F-3642-2011; Fischer, Markus J./G-9477-2012; Eisenreich, Wolfgang/A-1258-2013	Fischer, Markus/0000-0001-7243-4199; Eisenreich, Wolfgang/0000-0002-9832-8279				Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; Appling DR, 1997, METHOD ENZYMOL, V281, P178; Auerbach G, 2000, P NATL ACAD SCI USA, V97, P13567, DOI 10.1073/pnas.240463497; Bermingham A, 2000, J BIOL CHEM, V275, P17962, DOI 10.1074/jbc.M000331200; BLAIR JA, 1970, ANAL BIOCHEM, V34, P376, DOI 10.1016/0003-2697(70)90122-3; Blaszczyk J, 2000, STRUCTURE, V8, P1049, DOI 10.1016/S0969-2126(00)00502-5; BLAU N, 1983, ANAL BIOCHEM, V128, P446, DOI 10.1016/0003-2697(83)90399-8; Bracher A, 1998, J BIOL CHEM, V273, P28132, DOI 10.1074/jbc.273.43.28132; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Detre KM, 2001, AM J EPIDEMIOL, V154, P221, DOI 10.1093/aje/154.3.221; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; Haussmann C, 1998, J BIOL CHEM, V273, P17418, DOI 10.1074/jbc.273.28.17418; Hennig M, 1998, NAT STRUCT BIOL, V5, P357, DOI 10.1038/nsb0598-357; Mathis J B, 1980, Methods Enzymol, V66, P556; MATHIS JB, 1970, J BIOL CHEM, V245, P3015; Nar H, 1996, BIOCHEM SOC T, V24, pS37, DOI 10.1042/bst024037s; REES L, 1983, CHEM BIOL PTERIDINES, P533; RICHEY DP, 1969, J BIOL CHEM, V244, P1582; RICHEY DP, 1970, BIOCHIM BIOPHYS ACTA, V222, P237, DOI 10.1016/0304-4165(70)90376-4; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; ROLAND S, 1979, J BIOL CHEM, V254, P337; SCHALHORN A, 1983, METHOD ENZYMAT AN, V3, P251; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SELHUB J, 1989, ANAL BIOCHEM, V182, P84, DOI 10.1016/0003-2697(89)90722-7; SINGER S, 1966, J GEN MICROBIOL, V42, P185, DOI 10.1099/00221287-42-2-185; Skold O, 2001, VET RES, V32, P261, DOI 10.1051/vetres:2001123; Skold O, 2000, DRUG RESIST UPDATE, V3, P155, DOI 10.1054/drup.2000.0146; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	31	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28841	28847		10.1074/jbc.M204046200	http://dx.doi.org/10.1074/jbc.M204046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039964	hybrid			2022-12-25	WOS:000177342600066
J	Yus-Najera, E; Santana-Castro, I; Villarroel, A				Yus-Najera, E; Santana-Castro, I; Villarroel, A			The identification and characterization of a noncontinuous calmodulin-binding site in noninactivating voltage-dependent KCNQ potassium channels.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; INACTIVATION; RECEPTORS; MECHANISM; MUTATION; SUBUNIT; DOMAINS	We show here that in a yeast two-hybrid assay calmodulin (CaM) interacts with the intracellular C-terminal region of several members of the KCNQ family of potassium channels. CaM co-immunoprecipitates with KCNQ2, KCNQ3, or KCNQ5 subunits better in the absence than in the presence of Ca2+. Moreover, in two-hybrid assays where it is possible to detect interactions with apo-CaM but not with Ca2+-bound calmodulin, we localized the CaM-binding site to a region that is predicted to contain two a-helices (A and B). These two helices encompass similar to85 amino acids, and in KCNQ2 they are separated by a dispensable stretch of similar to130 amino acids. Within this CaM-binding domain, we found an IQ-like CaM-binding motif in helix A and two overlapping consensus 1-5-10 CaM-binding motifs in helix B. Point mutations in helix A or B were capable of abolishing CaM binding in the two-hybrid assay. Moreover, glutathione S-transferase fusion proteins containing helices A and B were capable of binding to CaM, indicating that the interaction with KCNQ channels is direct. Full-length CaM (both N and C lobes) and a functional EF-1 hand were required for these interactions to occur. These observations suggest that apo-CaM is bound to neuronal KCNQ channels at low resting Ca2+ levels and that this interaction is disturbed when the [Ca2+] is raised. Thus, we propose that CaM acts as a mediator in the Ca2+-dependent modulation of KCNQ channels.	Consejo Super Invest, Inst Cajal, Madrid 28002, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Villarroel, A (corresponding author), Consejo Super Invest, Inst Cajal, Ave Dr Arce 37, Madrid 28002, Spain.	av@cajal.csic.es	Villarroel, Alvaro/H-5580-2015					Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Cruzblanca H, 1998, P NATL ACAD SCI USA, V95, P7151, DOI 10.1073/pnas.95.12.7151; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Gao TY, 2000, J BIOL CHEM, V275, P25436, DOI 10.1074/jbc.M003465200; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hisatsune C, 1997, J BIOL CHEM, V272, P20805, DOI 10.1074/jbc.272.33.20805; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; JOINER WJ, 2001, J BIOL CHEM, V31, P699; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Niethammer M, 1998, METHOD ENZYMOL, V293, P104; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Schmitt N, 2000, EMBO J, V19, P332, DOI 10.1093/emboj/19.3.332; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Schwake M, 2000, J BIOL CHEM, V275, P13343, DOI 10.1074/jbc.275.18.13343; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; Smith JS, 2001, J NEUROSCI, V21, P1096; VILLARROEL A, 1997, TRENDS GENET, V13, P164; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	39	158	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28545	28553		10.1074/jbc.M204130200	http://dx.doi.org/10.1074/jbc.M204130200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12032157	hybrid			2022-12-25	WOS:000177342600027
J	Gong, DM; Gong, ZZ; Guo, Y; Chen, XY; Zhu, JK				Gong, DM; Gong, ZZ; Guo, Y; Chen, XY; Zhu, JK			Biochemical and functional characterization of PKS11, a novel Arabidopsis protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT SALT TOLERANCE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE KINASE; SERINE THREONINE KINASES; PYRUVATE-KINASE; SACCHAROMYCES-CEREVISIAE; REGULATORY PROPERTIES; SELENASTRUM-MINUTUM; STRUCTURAL BASIS; CALCIUM-BINDING; ACTIVATION LOOP	The Arabidopsis SOS2 (Salt Overly Sensitive 2)-like protein kinases (PKS) are novel protein kinases that contain an SNF1-like catalytic domain with a putative activation loop and a regulatory domain with an FISL motif that binds calcium sensors. Very little biochemical and functional information is currently available on this family of kinases. Here we report on the expression of the PKS11 gene, activation and characterization of the gene product, and transgenic evaluation of its function in plants. PKS11 transcript was preferentially expressed in roots of Arabidopsis plants. Recombinant glutathione S-transferase fusion protein of PKS11 was inactive in substrate phosphorylation. However, the kinase can be highly activated by a threonine 161 to aspartate substitution (designated PKS11T161D) in the putative activation loop. Interestingly, PKS11 can also be activated by substitution of either a serine or tyrosine with aspartate within the activation loop. Deletion of the FISL motif also resulted in a slight activation of PKS11. PKS11T161D displayed an uncommon preference for Mn2+ over Mg2+ for substrate phosphorylation and autophosphorylation. The optimal pH and temperature values of PKS11T161D were determined to be 7.5 and 30 degreesC, respectively. The activated kinase showed substrate specificity, high affinity, and catalytic efficiency for a peptide substrate p3 and for ATP. AMP or ADP at concentrations from 10 muM to 1 mM did not activate PKS11T161D. Transgenic Arabidopsis plants expressing PKS11T161D were more resistant to high concentrations of glucose, suggesting the involvement of this protein kinase in sugar signaling in plants. These results provide insights into the function as well as regulation and biochemical properties of the PKS protein kinase.	Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University of Arizona	Zhu, JK (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Guo, Yan/X-1245-2019; Gong, Zhizhong/AAS-4796-2021; Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X; chen, xiuyin/0000-0002-1734-3267	NIGMS NIH HHS [R01GM59138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059138] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1994, J BIOL CHEM, V269, P31626; Barker JHA, 1996, PLANT PHYSIOL, V112, P1141, DOI 10.1104/pp.112.3.1141; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Chi AS, 2001, J BIOL CHEM, V276, P19974, DOI 10.1074/jbc.M011584200; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; FERRER A, 1985, BIOCHEM BIOPH RES CO, V132, P497, DOI 10.1016/0006-291X(85)91161-1; FURUICHI T, 2001, 12 ITN WORKSH PLANT, P63; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halford NG, 1998, PLANT MOL BIOL, V37, P735, DOI 10.1023/A:1006024231305; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; Hardie DG, 1999, ANNU REV PLANT PHYS, V50, P97, DOI 10.1146/annurev.arplant.50.1.97; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; IRELAND RJ, 1980, PLANT PHYSIOL, V65, P1188, DOI 10.1104/pp.65.6.1188; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; Knowles VL, 2001, J BIOL CHEM, V276, P20966, DOI 10.1074/jbc.M008878200; LIN M, 1989, ARCH BIOCHEM BIOPHYS, V269, P228, DOI 10.1016/0003-9861(89)90104-5; LIN M, 1989, ARCH BIOCHEM BIOPHYS, V269, P219, DOI 10.1016/0003-9861(89)90103-3; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; MACKINTOSH RW, 1992, EUR J BIOCHEM, V209, P923, DOI 10.1111/j.1432-1033.1992.tb17364.x; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MURANAKA T, 1994, MOL CELL BIOL, V14, P2958, DOI 10.1128/MCB.14.5.2958; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shah K, 2001, J BIOL CHEM, V276, P41263, DOI 10.1074/jbc.M102381200; Sheen J, 1999, CURR OPIN PLANT BIOL, V2, P410, DOI 10.1016/S1369-5266(99)00014-X; Shi HZ, 2000, P NATL ACAD SCI USA, V97, P6896, DOI 10.1073/pnas.120170197; Shi HZ, 2002, PLANT CELL, V14, P465, DOI 10.1105/tpc.010371; Smith CR, 2000, EUR J BIOCHEM, V267, P4477, DOI 10.1046/j.1432-1327.2000.01494.x; Stocchetto S, 1997, FEBS LETT, V414, P171, DOI 10.1016/S0014-5793(97)00980-0; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; Toroser D, 2000, PLANT PHYSIOL, V123, P403, DOI 10.1104/pp.123.1.403; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1986, ENZYMES, V17, P248; Wu SJ, 1996, PLANT CELL, V8, P617, DOI 10.1105/tpc.8.4.617; Zhang YH, 2001, PLANT J, V28, P431, DOI 10.1046/j.1365-313X.2001.01167.x; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200; Zhu JK, 1998, PLANT CELL, V10, P1181, DOI 10.1105/tpc.10.7.1181	50	56	67	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28340	28350		10.1074/jbc.M107719200	http://dx.doi.org/10.1074/jbc.M107719200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029080	hybrid			2022-12-25	WOS:000177189800092
J	Koipally, J; Georgopoulos, K				Koipally, J; Georgopoulos, K			A molecular dissection of the repression circuitry of Ikaros	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEXES; CHROMATIN REMODELING COMPLEXES; TRANSCRIPTION FACTOR; LYMPHOCYTE DEVELOPMENT; GENE; PROTEIN; FAMILY; AIOLOS; MUTATION; PARTNER	Ikaros is a key regulator of the hemo-lymphoid system in which it is presumed to function by both potentiating and repressing gene expression. Repression is mediated through two independent domains at the N and C terminus of the protein, both of which can independently recruit the corepressors Mi-2beta, Sin3A, and Sin3B and the Class I histone deacetylases 1 and 2; the N-terminal domain can also associate with the corepressor CtBP. Here we describe a detailed dissection of these two domains and identify the minimal repression modules and the corepressor requirements for their activity. Based on these studies, we describe mutations in a full-length Ikaros protein that abrogate interactions with each of the identified corepressors and abolish the protein's function as a repressor. Finally, we show that, barring CtBP, the Ikaros family members Aiolos, Helios, and Eos can associate with all of the identified corepressors of Ikaros including its newly identified interactors, Class II HDACs.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Georgopoulos, K (corresponding author), MGH E, CBRC, Bldg 149,13th St, Charlestown, MA 02129 USA.				NIAID NIH HHS [R01-AI380342-08] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Huang EY, 2000, GENE DEV, V14, P45; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Malik TH, 2001, EMBO J, V20, P1715, DOI 10.1093/emboj/20.7.1715; MOLNAR A, 1994, MOL CELL BIOL, V14, P785; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Perdomo J, 2000, J BIOL CHEM, V275, P38347, DOI 10.1074/jbc.M005457200; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200	29	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27697	27705		10.1074/jbc.M201694200	http://dx.doi.org/10.1074/jbc.M201694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015313	hybrid			2022-12-25	WOS:000177189800017
J	Mora, S; Durham, PL; Smith, JR; Russo, AF; Jeromin, A; Pessin, JE				Mora, S; Durham, PL; Smith, JR; Russo, AF; Jeromin, A; Pessin, JE			NCS-1 inhibits insulin-stimulated GLUT4 translocation in 3T3L1 adipocytes through a phosphatidylinositol 4-kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; GLUT4-CONTAINING VESICLES; MEMBRANE TRAFFICKING; PROTEIN; FREQUENIN; CALCIUM; SECRETION; 3-KINASE; AMINOPEPTIDASE; 4-KINASE	Expression of NCS-1 (neuronal calcium sensor-1, also termed frequenin) in 3T3L1 adipocytes strongly inhibited insulin-stimulated translocation of GLUT4 and insulin-responsive aminopeptidase. The effect of NCS-1 was specific for GLUT4 and the insulin-responsive aminopeptidase translocation as there was no effect on the trafficking of the cation-independent mannose 6-phosphate receptor or the GLUT1 glucose transporter isoform. Moreover, NCS-1 showed partial colocalization with GLUT4-EGFP in the perinuclear region. The inhibitory action of NCS-1 was independent of calcium sequestration since neither treatment with ionomycin nor endothelin-1, both of which elevated the intracellular calcium concentration, restored insulin-stimulated GLUT4 translocation. Furthermore, NCS-1 did not alter the insulin-stimulated protein kinase B (PKB/Akt) phosphorylation or the recruitment of Cbl to the plasma membrane. In contrast, expression of the NCS-1 effector phosphatidylinositol 4-kinase (PI 4-kinase) inhibited insulin-stimulated GLUT4 translocation, whereas co-transfection with an inactive PI 4-kinase mutant prevented the NCS-1-induced inhibition. These data demonstrate that PI 4-kinase functions to negatively regulate GLUT4 translocation through its interaction with NCS-1.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52246 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Iowa; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, 51 Newton Rd, Iowa City, IA 52242 USA.	Jeffrey-Pessin@uiowa.edu	Mora, Silvia/Y-3131-2019	Russo, Andrew/0000-0002-8156-5649; Mora, Silvia/0000-0002-8473-1497	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, P30DK025295, R01DK033823] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25969] Funding Source: Medline; NIDDK NIH HHS [DK 25295, DK 33823] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BURGOYNE R, 2001, BIOCHEM J, V15, P354; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Durham PL, 1999, J NEUROSCI, V19, P3423; Elmendorf JS, 1999, EXP CELL RES, V253, P55, DOI 10.1006/excr.1999.4675; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Haeseleer F, 2002, BIOCHEM BIOPH RES CO, V290, P615, DOI 10.1006/bbrc.2001.6228; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Hurley J B, 2001, Prog Brain Res, V131, P395; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1998, BIOCHEM J, V331, P829, DOI 10.1042/bj3310829; Kandror KV, 1999, J BIOL CHEM, V274, P25210, DOI 10.1074/jbc.274.36.25210; Kristiansen S, 1998, BIOCHEM J, V335, P351, DOI 10.1042/bj3350351; Martin S, 1997, J CELL SCI, V110, P2281; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; PERSHADSINGH HA, 1987, ENDOCRINOLOGY, V121, P1727, DOI 10.1210/endo-121-5-1727; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Ross SA, 1997, BIOCHEM BIOPH RES CO, V239, P247, DOI 10.1006/bbrc.1997.7459; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; Whitehead JP, 2001, J BIOL CHEM, V276, P27816, DOI 10.1074/jbc.M011590200; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	42	20	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27494	27500		10.1074/jbc.M203669200	http://dx.doi.org/10.1074/jbc.M203669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12011096	Green Published, hybrid			2022-12-25	WOS:000177055900099
J	Psaridi-Linardaki, L; Mamalaki, A; Remoundos, M; Tzartos, SJ				Psaridi-Linardaki, L; Mamalaki, A; Remoundos, M; Tzartos, SJ			Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris - Role of glycosylation in alpha-bungarotoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIN IMMUNOGENIC REGION; MONOCLONAL-ANTIBODIES; MYASTHENIA-GRAVIS; SYNTHETIC PEPTIDES; ASSEMBLY INTERMEDIATE; METHYLOTROPHIC YEASTS; TORPEDO-CALIFORNICA; PROTEIN EXPRESSION; ESCHERICHIA-COLI; RESIDUES	The N-terminal extracellular domain (amino acids 1-210; halpha-(1-210)) of the a subunit of the human muscle nicotinic acetylcholine receptor (AChR), bearing the binding sites for cholinergic ligands and the main immunogenic region, the major target for anti-AChR antibodies in patients with myasthenia gravis, was expressed in the yeast, Pichia pastorisr. The recombinant protein was water-soluble and glycosylated, and fast protein liquid chromatography analysis showed it to be a monomer. halpha-(1-210) bound 125 I-a-bungarotoxin with a high affinity (K-d = 5.1 +/- 2.4 nm), and this binding was blocked by unlabeled d-tubocurarine and gallamine (K(i)similar to7.5 mm). Interestingly, I-125-alpha-bungarotoxin binding was markedly impaired by in vitro deglycosylation of halpha-(1-210). Several monoclonal antibodies that show partial or strict conformation-dependent binding to the AChR were able to bind to ha-(1-210), as did antibodies from a large proportion of myasthenic patients. These results suggest that the extracellular domain of the human AChR alphasubunit expressed in P. pastoris has an apparently near native conformation. The correct folding of the recombinant protein, together with its relatively high expression yield, makes it; suitable for structural studies on the nicotinic acetylcholine receptor and for use as an autoantigen in myasthenia gravis studies.	Hellenic Pasteur Inst, Dept Biochem, Athens 11521, Greece; Univ Patras, Dept Pharm, Patras, Greece	University of Patras	Tzartos, SJ (corresponding author), Hellenic Pasteur Inst, Dept Biochem, 127 Vas Sofias Ave, Athens 11521, Greece.							Alexeev T, 1999, EUR J BIOCHEM, V259, P310, DOI 10.1046/j.1432-1327.1999.00041.x; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; ARONHEIM A, 1988, J BIOL CHEM, V263, P9933; BARKAS T, 1988, J BIOL CHEM, V263, P5916; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; CLAUDIO T, 1987, P NATL ACAD SCI USA, V84, P5967, DOI 10.1073/pnas.84.16.5967; CONROY WG, 1990, J BIOL CHEM, V265, P21642; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; FUJITA N, 1986, SCIENCE, V231, P1284, DOI 10.1126/science.3511531; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; Gellissen G, 2000, APPL MICROBIOL BIOT, V54, P741, DOI 10.1007/s002530000464; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; Green WN, 1998, J NEUROSCI, V18, P5555; GRIESMANN GE, 1990, J NEUROCHEM, V54, P1541, DOI 10.1111/j.1471-4159.1990.tb01202.x; Hollenberg CP, 1997, CURR OPIN BIOTECH, V8, P554, DOI 10.1016/S0958-1669(97)80028-6; Im SH, 2000, J IMMUNOL, V165, P3599, DOI 10.4049/jimmunol.165.7.3599; KAO PN, 1984, J BIOL CHEM, V259, P1662; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; Loutrari H, 1997, CLIN EXP IMMUNOL, V109, P538, DOI 10.1046/j.1365-2249.1997.4701367.x; LUKAS RJ, 1981, BIOCHEMISTRY-US, V20, P7373, DOI 10.1021/bi00529a008; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; RICKERT KW, 1995, CHEM BIOL, V2, P751, DOI 10.1016/1074-5521(95)90103-5; Schrattenholz A, 1998, J BIOL CHEM, V273, P32393, DOI 10.1074/jbc.273.49.32393; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; Tsouloufis T, 2000, INT IMMUNOL, V12, P1255, DOI 10.1093/intimm/12.9.1255; TZARTOS S, 1986, J NEUROIMMUNOL, V10, P235, DOI 10.1016/0165-5728(86)90105-0; TZARTOS S, 1983, FEBS LETT, V158, P116, DOI 10.1016/0014-5793(83)80688-7; TZARTOS SJ, 1990, J BIOL CHEM, V265, P21462; TZARTOS SJ, 1982, P NATL ACAD SCI-BIOL, V79, P188, DOI 10.1073/pnas.79.1.188; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; TZARTOS SJ, 1980, P NATL ACAD SCI-BIOL, V77, P755, DOI 10.1073/pnas.77.2.755; Tzartos SJ, 1998, IMMUNOL REV, V163, P89, DOI 10.1111/j.1600-065X.1998.tb01190.x; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; Vedvick T S, 1991, Curr Opin Biotechnol, V2, P742, DOI 10.1016/0958-1669(91)90045-7; Vincent A, 1998, NEUROCHEM INT, V32, P427, DOI 10.1016/S0197-0186(97)00118-6; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WILSON PT, 1988, BIOCHEMISTRY-US, V27, P6667, DOI 10.1021/bi00418a004; Yao Y, 2002, J BIOL CHEM, V277, P12613, DOI 10.1074/jbc.M108845200	49	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26980	26986		10.1074/jbc.M110731200	http://dx.doi.org/10.1074/jbc.M110731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12015305	hybrid			2022-12-25	WOS:000177055900038
J	Sorkina, T; Huang, FT; Beguinot, L; Sorkin, A				Sorkina, T; Huang, FT; Beguinot, L; Sorkin, A			Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; DOWN-REGULATION; SRC; PHOSPHORYLATION; ENDOCYTOSIS; BINDING; PROTEIN; TRANSFERRIN; FAMILY; AUTOPHOSPHORYLATION	Several inhibitors of epidermal growth factor receptor (EGFR) kinase and Src family kinases (SFK) were employed to study the role of these kinases in EGFR internalization through clathrin-coated pits. The EGFR kinase-specific compound PD158780 substantially diminished EGFR internalization. PP2, an inhibitor of SFK, had a moderate effect on EGFR internalization in several types of cells, including cells lacking SFK, indicating that the inhibition of endocytosis by PP2 is mediated by kinases other than SFK. In contrast, SU6656, a more specific inhibitor of SFK, did not affect EGFR internalization. To examine what stage of internalization requires receptor kinase activity, we established a quantitative assay based on three-dimensional fluorescence microscopy that measures co-localization of an EGF-rhodamine conjugate and a fluorescently tagged clathrin adaptor protein complex, AP-2. Interestingly, recruitment of EGFR into coated pits did not require physiological temperature because the maximal accumulation of EGFR in coated pits was observed at 4degreesC. Pretreatment of the cells with PD158780 prevented EGFR recruitment into coated pits, whereas the inhibitor did not block the internalization of receptors that had first been allowed to enter the coated pits at 4degreesC. These data demonstrate that the activation of receptor kinase is essential for the initial, coated pit recruitment step of endocytosis.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80111 USA; Hosp San Raffaele, Unit Oncol Mol, I-20100 Milan, Italy; Hosp San Raffaele, Inst Neurosci & Bioimmagini, I-20100 Milan, Italy	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80111 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NCI NIH HHS [CA 089151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bos M, 1997, CLIN CANCER RES, V3, P2099; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Dancey JE, 2001, ONCOLOGY-NY, V15, P748; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P5667, DOI 10.1021/bi00293a033; Ewald JA, 2001, EXP CELL RES, V268, P262, DOI 10.1006/excr.2001.5271; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HELIN K, 1991, J BIOL CHEM, V266, P8363; HILLMAN GM, 1982, BIOCHEMISTRY-US, V21, P1667, DOI 10.1021/bi00536a030; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LUND KA, 1990, J BIOL CHEM, V265, P15713; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; MORI S, 1994, J BIOL CHEM, V269, P4917; ONODA T, 1990, DRUG EXP CLIN RES, V16, P249; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SELVA E, 1993, J BIOL CHEM, V268, P2250; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085	50	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27433	27441		10.1074/jbc.M201595200	http://dx.doi.org/10.1074/jbc.M201595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12021271	hybrid			2022-12-25	WOS:000177055900093
J	Gianni, M; Kopf, E; Bastien, J; Oulad-Abdelghani, M; Garattini, E; Chambon, P; Rochette-Egly, C				Gianni, M; Kopf, E; Bastien, J; Oulad-Abdelghani, M; Garattini, E; Chambon, P; Rochette-Egly, C			Down-regulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation, and transcriptional activity of retinoic acid receptor gamma 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CLINICAL RESISTANCE; RAR-ALPHA; C-ABL; AKT; CELLS; INHIBITION; MECHANISM; CASCADES; PKB/AKT	Nuclear retinoic acid (RA) receptors (RARs) are phosphorylated at conserved serine residues located in their N-terminal domain. Phosphorylation of RARgamma2 at these residues is increased in response to RA subsequently to the activation of p38MAPK. We show here that this RA-induced phosphorylation of RARgamma2 resulted from the down-regulation of the phosphatidylinositol. 3-kinase (PI3K)/Akt pathway. By overexpressing Akt and by using agents that activated or inhibited the PI3K/Akt pathway, we also demonstrated that the RA-induced down-regulation of the PI3K/Akt pathway targeted not only the phosphorylation of RARgamma2 but also the turnover and transcriptional activity of the receptor. Altogether these data indicate that the PI3K/Akt pathway plays an important role in retinoic acid signaling.	Univ Strasbourg 1, CNRS,Coll France, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Ist Ric Farmacol Mario Negri, Mol Biol Lab, I-20157 Milan, Italy	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rochette-Egly, C (corresponding author), Univ Strasbourg 1, CNRS,Coll France, INSERM, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Garattini, Enrico/AAI-1998-2019; abdelghani, mustapha oulad/A-5986-2017; Gianni, Maurizio/ABG-6322-2020	abdelghani, mustapha oulad/0000-0002-8381-4397; Gianni, Maurizio/0000-0002-6945-708X; Garattini, Enrico/0000-0001-8983-886X				Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; Gambacorti-Passerini C, 2001, BRIT J HAEMATOL, V112, P972, DOI 10.1046/j.1365-2141.2001.02653.x; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Gianni' M, 2001, BLOOD, V97, P3234, DOI 10.1182/blood.V97.10.3234; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hochhaus A, 2001, SCIENCE, V293, P2163; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lawlor MA, 2001, J CELL SCI, V114, P2903; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Smith MA, 2001, CLIN CANCER RES, V7, P2955; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485	31	54	55	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24859	24862		10.1074/jbc.C200230200	http://dx.doi.org/10.1074/jbc.C200230200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	12032135	hybrid			2022-12-25	WOS:000176747000005
J	Semplici, F; Meggio, F; Pinna, LA; Oliviero, S				Semplici, F; Meggio, F; Pinna, LA; Oliviero, S			CK2-dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TrCP and enhances beta-catenin degradation	ONCOGENE			English	Article						CK2; UBC3; beta-TrCP; phosphorylation	PROTEIN-KINASE CK2; CELL-CYCLE GENE; CASEIN KINASE-2; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; BUDDING YEAST; S TRANSITION; VPU PROTEIN; SYSTEM; INHIBITOR	Protein kinase CK2 is a ubiquitous and pleiotropic Ser/Thr protein kinase involved in cell growth and transformation. Here we report the identification by yeast interaction trap of a CK2 interacting protein, UBC3B, which is highly homologous to the E2 ubiquitin conjugating enzyme UBC3/CDC34. UBC3B complements the yeast cdc34-2 cell cycle arrest mutant in S. cerevisiae and transfers ubiquitin to a target substrate in vitro. UBC3B is specifically phosphorylated by CK2 in vitro and in giro. We mapped by deletions and site directed mutagenesis the phosphorylation site to a serine residue within the C-terminal domain in position 233 of UBC3B and in the corresponding serine residue of UBC3. Following CK2-dependent phosphorylation both UBC3B and UBC3 bind to the F-box protein beta-TrCP, the substrate recognition subunit of an SCF (Skp1, Cul1, F-box) ubiquitin ligase. Furthermore, we observed that co-transfection of CK2alpha' together with UBC3B, but not with UBC3DeltaC, enhances the degradation of beta-catenin. Taken together these data suggest that CK2-dependent phosphorylation of UBC3 and UBC3B functions by regulating beta-TrCP substrate recognition.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy; Univ Padua, Dipartimento Chim Biol, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Studio Biomembrane, I-35100 Padua, Italy	University of Siena; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Allende CC, 1998, J CELL BIOCHEM, P129; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haas AL, 1997, FASEB J, V11, P1257; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MEGGIO F, 1981, J BIOL CHEM, V256, P1958; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; RAYAN A, 1985, CANCER RES, V45, P2277; Raymond F, 2000, J CELL SCI, V113, P1687; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Sun BG, 1997, BBA-GENE STRUCT EXPR, V1351, P231, DOI 10.1016/S0167-4781(96)00209-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105	60	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3978	3987		10.1038/sj.onc.1205574	http://dx.doi.org/10.1038/sj.onc.1205574			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037680				2022-12-25	WOS:000175869900004
J	Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V				Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V			NF-kappa B-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis	ONCOGENE			English	Article						NF-kappa B; TNF-alpha; MnSOD; apoptosis; cancer	MANGANESE SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; NUCLEAR-FACTOR; EPITHELIAL-CELLS; BCL-2 FAMILY; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; UP-REGULATION	NFkappaB is known to exert a cytoprotective action against TNF-alpha-induced apoptosis. To study the role of NF-kappaB in various TNF-alpha-treated epithelial cell lines, we generated stable transfectants overexpressing a mutated unresponsive form of the IkappaBalpha inhibitor (MT cells), As NF-kappaB prevented TNF-alpha-induced apoptosis in various epithelial cancer cell lines, we searched for NF-kappaB target gene products responsible for this difference of sensitivity. We observed an increased Bcl-X-L expression level in OVCAR-3 cells compared with OVCAR-3 cells expressing a mutated IkappaBalpha inhibitor (MT cells). Induction of the antioxidant enzyme MnSOD was detected only, in TNF-a-treated OVCAR, MCF7A/Z and HCT116 cells but not in MT cells. Moreover, reactive oxygen species were involved in TNF-a-induced apoptosis, as various antioxidants partially protected these cells from apoptosis. At last, transfection of the MnSOD cDNA in MT cells, which do not express this protein after TNF-alpha stimulation, partially restored resistance to TNF-alpha-induced cell death, as observed by clonogenic assays. However, transfection of the Bel-X-L cDNA did not induce any protective effect. Therefore, MnSOD expression is induced by NF-kappaB in epithelial cancer cells in response to TNF-alpha, and is at least partially responsible for their resistance to TNF-alpha-induced apoptosis, presumably through the clearance of death-inducing ROS.	Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium	University of Liege	Bours, V (corresponding author), Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, Sart Tilman, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bernard D, 2001, CANCER RES, V61, P2656; BEYAERT R, 1998, TUMOR NECROSIS FACTO, P335; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fiers W, 1988, Dev Biol Stand, V69, P143; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GIBBS LS, 1992, FREE RADICAL BIO MED, V12, P107, DOI 10.1016/0891-5849(92)90003-Y; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GWINNER W, 1995, KIDNEY INT, V48, P354, DOI 10.1038/ki.1995.303; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; JACOBY DB, 1994, FREE RADICAL BIO MED, V16, P821, DOI 10.1016/0891-5849(94)90198-8; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kifle Y, 1996, J NEUROCHEM, V66, P2128; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; LARSEN CJ, 1994, ANN GENET-PARIS, V37, P121; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LI JJ, 1995, ONCOGENE, V10, P1989; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; VAN AD, 1996, SCIENCE, V274, P787; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	105	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3917	3924		10.1038/sj.onc.1205489	http://dx.doi.org/10.1038/sj.onc.1205489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032830				2022-12-25	WOS:000175847200011
J	Bisson, SA; Ujack, EE; Robbins, SM				Bisson, SA; Ujack, EE; Robbins, SM			Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line	ONCOGENE			English	Article						E3-ubiquitin ligase; Src-family kinase; J-774; cells; Fc receptors	PHOSPHOTYROSINE-BINDING DOMAIN; GROWTH-FACTOR RECEPTOR; MEDIATED NEGATIVE REGULATION; SRC-FAMILY KINASES; FC-GAMMA-RI; TYROSINE KINASE; SH3 DOMAIN; PROTEIN PRODUCT; DOWN-REGULATION; IN-VIVO	The c-Cbl proto-oncogene acts as an E3 ubiquitin ligase via its RING finger domain to negatively regulate activated cellular signal transduction pathways. We have identified an aberrant Cbl-protein of approximately 95 kDa, which we have called p95Cbl, from the murine reticulum sarcoma cell-line, J-774. Cloning of the p95Cbl cDNA revealed that it contains a deletion resulting in the loss of 111 amino acids, eliminating two critical tyrosine residues in the linker region as well as the entire RING finger domain. p95Cbl displays a propensity for its interaction with the Src-family kinase Hck over cellular Cbl expressed in the same cells. Like its wildtype counterpart, p95Cbl is inducibly tyrosine phosphorylated in response to Fcgamma receptor engagement on hematopoietic cells, however this phosphorylation is sustained beyond that of cellular Cbl. NIH3T3 fibroblasts stably expressing p95Cbl acquire the typical refractile morphology associated with cellular transformation and form colonies in a focus-formation assay. The exogenously expressed mutant protein is constitutively phosphorylated in fibroblasts and partitions into the particulate fraction of cells, while cellular Cbl is exclusively cytoplasmic. p95Cbl is a novel, oncogenic mutant of the c-Cbl proto-oncogene, which might act in a dominant negative fashion to prolong normal cellular signaling responses by interfering with the down-regulation of activated signaling complexes through c-Cbl.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Robbins, SM (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	srobbins@ucalgary.ca		Robbins, Stephen/0000-0001-7475-1665				Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; COHN M, 1967, COLD SPRING HARB SYM, V32, P211, DOI 10.1101/SQB.1967.032.01.029; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Hirst JW, 1971, J IMMUNOL, V107, P926; Horita DA, 1998, J MOL BIOL, V278, P253, DOI 10.1006/jmbi.1998.1690; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAPLAN G, 1978, EXP CELL RES, V115, P53, DOI 10.1016/0014-4827(78)90401-9; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; PAIGE CJ, 1978, J IMMUNOL, V121, P641; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RALPH P, 1975, J IMMUNOL, V114, P898; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato N, 1999, J IMMUNOL, V163, P6123; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Scaife RM, 2000, J CELL SCI, V113, P215; SCHOLT G, 2000, J BIOL CHEM, V273, P14615; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	59	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3677	3687		10.1038/sj.onc.1205510	http://dx.doi.org/10.1038/sj.onc.1205510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032836				2022-12-25	WOS:000175676000003
J	Gupta, S; Afaq, F; Mukhtar, H				Gupta, S; Afaq, F; Mukhtar, H			Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells	ONCOGENE			English	Article						apigenin; prostate cancer; apoptosis; cell-cycle arrest; chemoprevention; nuclear factor-kappa B (NF-kappa B)	CANCER-CELLS; FLAVONOIDS; GROWTH; INHIBITION; ANTIGEN; GENE; CYCLOOXYGENASE; PROLIFERATION; EXPRESSION; REGULATORS	Apigenin, a common dietary flavonoid abundantly present in fruits and vegetables, may have the potential for prevention and therapy for prostate cancer. Here, we report for the first time that apigenin inhibits the growth of androgen-responsive human prostate carcinoma LNCaP cells and provide molecular understanding of this effect. The cell growth inhibition achieved by apigenin treatment resulted in a significant decrease in AR protein expression along with a decrease in intracellular and secreted forms of PSA. These effects were also observed in DHT-stimulated cells. Further, apigenin treatment of LNCaP cells resulted in G1 arrest in cell cycle progression which was associated with a marked decrease in the protein expression of cyclin D1, D2 and E and their activating partner cdk2, 4 and 6 with concomitant induction of WAFT/p21 and KIP1/p27. The induction of WAFT/p21 appears to be transcriptionally upregulated and is p53 dependent. In addition, apigenin inhibited the hyperphosphorylation of the pRb protein in these cells. Apigenin treatment also resulted in induction of apoptosis as determined by DNA fragmentation, PARP cleavage, fluorescence microscopy and flow cytometry. These effects were found to correlate with a shift in Bax/Bcl-2 ratio more towards apoptosis. Apigenin treatment also resulted in down-modulation of the constitutive expression. of NF-kappaB/p65. Taken together, these findings suggest that apigenin has strong potential for development as an agent for prevention against prostate cancer.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Inst Res, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland	Gupta, S (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	gxs44@po.cwru.edu		Gupta, Sanjay/0000-0002-9492-3249	NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 78809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmad N, 1999, ONCOGENE, V18, P1891, DOI 10.1038/sj.onc.1202493; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Birt DF, 1997, ANTICANCER RES, V17, P85; BIRT DF, 1998, CHEMOPREVENTION CANC, P1263; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; CHAUMONTET C, 1994, CARCINOGENESIS, V15, P2325, DOI 10.1093/carcin/15.10.2325; Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61; Duthie G, 2000, CURR OPIN LIPIDOL, V11, P43, DOI 10.1097/00041433-200002000-00007; Fotsis T, 1998, BAILLIERE CLIN ENDOC, V12, P649, DOI 10.1016/S0950-351X(98)80009-8; Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Herness EA, 2001, FRONT BIOSCI-LANDMRK, V6, pD1083, DOI 10.2741/Herness; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Kim HP, 1998, PROSTAG LEUKOTR ESS, V58, P17, DOI 10.1016/S0952-3278(98)90125-9; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; KUO ML, 1994, CANCER LETT, V87, P91, DOI 10.1016/0304-3835(94)90414-6; KUO ML, 1992, MUTAT RES, V270, P87, DOI 10.1016/0027-5107(92)90119-M; Lamb DJ, 2001, VITAM HORM, V62, P199, DOI 10.1016/S0083-6729(01)62005-3; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee JI, 1998, J CLIN PHARMACOL, V38, P981, DOI 10.1177/009127009803801101; Lepley DM, 1997, MOL CARCINOGEN, V19, P74, DOI 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L; Lepley DM, 1996, CARCINOGENESIS, V17, P2367, DOI 10.1093/carcin/17.11.2367; Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945; Masciullo V, 2000, INT J ONCOL, V17, P897; McVean M, 2000, CARCINOGENESIS, V21, P633, DOI 10.1093/carcin/21.4.633; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MIDDLETON E, 1984, TRENDS PHARMACOL SCI, V5, P335; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Mueller A, 1997, CANCER RES, V57, P5542; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Panes Julian, 1996, Microcirculation (Philadelphia), V3, P279, DOI 10.3109/10739689609148302; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sandhu C, 2000, CANCER DETECT PREV, V24, P107; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; Takahashi T, 1998, BIOSCI BIOTECH BIOCH, V62, P2199, DOI 10.1271/bbb.62.2199; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LG, 1997, CANCER RES, V57, P714; Wang WQ, 2000, MOL CARCINOGEN, V28, P102; WEI HC, 1990, CANCER RES, V50, P499; Yin F, 2001, ANTICANCER RES, V21, P413; Yin F, 1999, THYROID, V9, P369, DOI 10.1089/thy.1999.9.369; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	51	226	247	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3727	3738		10.1038/sj.onc.1205474	http://dx.doi.org/10.1038/sj.onc.1205474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032841				2022-12-25	WOS:000175676000008
J	Smith, AR; Visioli, F; Hagen, TM				Smith, AR; Visioli, F; Hagen, TM			Vitamin C matters: increased oxidative stress in cultured human aortic endothelial cells without supplemental ascorbic acid	FASEB JOURNAL			English	Article						vitamin C; human aortic endothelium; tissue culture; nitric oxide	NITRIC-OXIDE SYNTHESIS; PYRIDINE-NUCLEOTIDES; RESISTANCE VESSELS; HYDROGEN-PEROXIDE; ALPHA-TOCOPHEROL; S-NITROSOTHIOLS; FREE-RADICALS; HUMAN PLASMA; GLUTATHIONE; OXYGEN	Because standard culture media for human aortic endothelial cells (HAEC) do not contain vitamin C, we hypothesized that HAEC may be under significant oxidative insult compared with the situation in vivo. To assess parameters of oxidative stress, intracellular vitamin C, glutathione (GSH), GSH/GSSG, and NAD(P)H/NAD(P)(+) ratios, as well as oxidant appearance and oxidative damage, were measured in HAEC with or without vitamin C addition. The effect of vitamin C on eNOS activity was also determined. Results showed that HAEC without vitamin C treatment were essentially scorbutic. On addition of 100 muM vitamin C to the culture media, intracellular vitamin C levels increased and peaked at 6 h. A concomitant increase in the total GSH and the GSH/GSSG ratio was also observed; the NAD(P)H/NAD(P) + ratio increased more slowly over the 24-h time course. Significantly lower (P<0.05) oxidant appearance and steady-state oxidative damage were also observed following vitamin C repletion. Vitamin C treatment increased eNOS activity by 600%. Thus, HAEC are scorbutic under normal culture conditions and exhibit higher oxidative stress than vitamin C repleted cells. Vitamin C supplementation should be considered when using cultured cells, especially when experimental endpoints are related to cellular redox status and eNOS activity.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy	Oregon State University; Oregon State University; University of Milan	Hagen, TM (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	tory.hagen@orst.edu	Visioli, Francesco/AAE-8510-2020; Visioli, Francesco/J-9356-2013	Visioli, Francesco/0000-0002-1756-1723				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Aust AE, 1999, P SOC EXP BIOL MED, V222, P246, DOI 10.1046/j.1525-1373.1999.d01-141.x; Baker RA, 2001, J CARDIOVASC PHARM, V37, P333, DOI 10.1097/00005344-200103000-00012; Boulares AH, 2000, TOXICOL SCI, V55, P370, DOI 10.1093/toxsci/55.2.370; Brandes RP, 2000, P NATL ACAD SCI USA, V97, P9747, DOI 10.1073/pnas.97.17.9747; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burger MS, 2001, ENVIRON MOL MUTAGEN, V38, P1, DOI 10.1002/em.1044; Buyukafsar K, 1999, ACTA MED OKAYAMA, V53, P209; CANESTRARI F, 1994, ACTA HAEMATOL-BASEL, V91, P187; Carr A, 2000, FREE RADICAL BIO MED, V28, P1806, DOI 10.1016/S0891-5849(00)00225-2; Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349; Chepda T, 2001, IN VITRO CELL DEV-AN, V37, P26; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FURCHGOTT RF, 1987, BLOOD VESSELS, V24, P145; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; HAGEN TM, 1990, AM J PHYSIOL, V259, pG524; HALLIWELL B, 1999, PROOXIDANT EFFECTS A, P206; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; HENSCHKE PN, 1995, BIOCHEM J, V312, P485, DOI 10.1042/bj3120485; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Knowles RG, 1998, METH MOL B, V100, P67; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LUTGERINK JT, 1992, MUTAT RES, V275, P377, DOI 10.1016/0921-8734(92)90040-V; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; MASAKI H, 1995, BIOCHEM BIOPH RES CO, V206, P474, DOI 10.1006/bbrc.1995.1067; May JM, 2000, FREE RADICAL BIO MED, V28, P1421, DOI 10.1016/S0891-5849(00)00269-0; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; MICHELI V, 1993, CLIN CHIM ACTA, V220, P1, DOI 10.1016/0009-8981(93)90002-L; MONTGOMERY MR, 1991, J TOXICOL ENV HEALTH, V34, P115, DOI 10.1080/15287399109531552; Moon SK, 2001, AM J PHYSIOL-HEART C, V280, pH2779, DOI 10.1152/ajpheart.2001.280.6.H2779; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; Parmentier C, 1999, ELECTROPHORESIS, V20, P2938; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; Puskas F, 2000, FASEB J, V14, P1352, DOI 10.1096/fj.14.10.1352; REBOUCHE CJ, 1991, AM J CLIN NUTR, V54, pS1147, DOI 10.1093/ajcn/54.6.1147s; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Sogo N, 2000, BRIT J PHARMACOL, V131, P1236, DOI 10.1038/sj.bjp.0703700; Sogo N, 2000, CLIN PHARMACOL THER, V68, P75, DOI 10.1067/mcp.2000.107049; Taguchi H, 1998, INVEST OPHTH VIS SCI, V39, P358; Vanhoutte PM, 2001, J CLIN INVEST, V107, P23, DOI 10.1172/JCI11832; WAGNER TC, 1994, ANAL BIOCHEM, V222, P417, DOI 10.1006/abio.1994.1511; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Zhang ZQ, 2000, ANAL BIOCHEM, V285, P163, DOI 10.1006/abio.2000.4701; ZYCHLINSKI L, 1989, J BIOCHEM TOXICOL, V4, P251, DOI 10.1002/jbt.2570040408	58	61	69	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2002	16	7					1102	+		10.1096/fj.01-0825fje	http://dx.doi.org/10.1096/fj.01-0825fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	558NR	12039848				2022-12-25	WOS:000175973900007
J	Sachinidis, A; Skach, RA; Seul, C; Ko, Y; Hescheler, J; Ahn, HY; Fingerle, J				Sachinidis, A; Skach, RA; Seul, C; Ko, Y; Hescheler, J; Ahn, HY; Fingerle, J			Inhibition of the platelet-derived growth factor beta-receptor tyrosine-phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins	FASEB JOURNAL			English	Article						catechins; smooth muscle growth; PDGF-R beta; cardiovascular disease	CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASES; OXIDATIVE MODIFICATION; HUMAN GLIOBLASTOMA; FLAVONOID INTAKE; TEA FLAVONOIDS; ATHEROSCLEROSIS; PROLIFERATION; TRANSFORMATION; ANTIOXIDANTS	Abnormal proliferation of vascular smooth muscle cells (VSMC) as well as the platelet-derived growth factor (PDGF) plays an important role in the development of proliferative cardiovascular diseases. In this study, we show that treatment of rat and human aortic VSMC with 50 muM 2- (3,4-dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3,5,7-triol (catechin) and epicatechin (EC) fails to inhibit the PDGF-Rbeta-activated intracellular signal transduction pathway and VSMC growth. In contrast, 10-50 muM epigallocatechin-3 gallate (EGCG), epicatechin-3 gallate (ECG), and catechin-3 gallate (CG), which all have a galloyl group in the 3-position of the catechin structure, effectively inhibit tyrosine-phosphorylation of PDGF-R, PI 3'-K, and PLC-gamma1 as well as the PDGF-BB-induced increase in [Ca2+](i). The PDGF-BB-induced increase in DNA synthesis and cell number was inhibited by ECG, EGCG, and CG, but not by catechin and EC. Epigallocatechin (EGC) that has a galloyl group in the 2-position effectively inhibited VSMC growth without affecting the PDGF-Rbeta signal pathway. A reduction of 45% and 70% of the intimal and medial cell number in the S-phase, respectively, has been observed in the catheter-injured left carotid artery 7 days after treatment of Wistar Kyoto rats with 10 mg/day EGCG. These results suggest that the galloyl group in the 3-position of the catechin structure is essential for inhibiting the PDGF-Rbeta-mediated intracellular signal transduction pathway.	Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Med Univ, Poliklin, D-53111 Bonn, Germany; Chungbuk Natl Univ, Coll Med, Dept Pharmacol, Cheongju 361763, South Korea; Hoffmann La Roche AG, Preclin Pharma Res, Vasc & Metab Dis, CH-4070 Basel, Switzerland	University of Cologne; University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; Chungbuk National University; Roche Holding	Sachinidis, A (corresponding author), Univ Cologne, Ctr Physiol & Pathophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	A.Sachinidis@uni-koeln.de	Sachinidis, Agapios/AAD-4178-2020; Sachinidis, Agapios/AAM-7988-2020					Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLOWES AW, 1983, LAB INVEST, V49, P208; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; Duarte J, 2001, BRIT J PHARMACOL, V133, P117, DOI 10.1038/sj.bjp.0704064; Ferns GAA, 2000, INT J EXP PATHOL, V81, P63, DOI 10.1046/j.1365-2613.2000.00143.x; Geleijnse JM, 1999, ARCH INTERN MED, V159, P2170, DOI 10.1001/archinte.159.18.2170; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; Hu C, 2001, MOL CELL BIOCHEM, V218, P147, DOI 10.1023/A:1007220928446; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karim M, 2000, J NUTR, V130, p2105S, DOI 10.1093/jn/130.8.2105S; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Liang YC, 1999, J CELL BIOCHEM, V75, P1; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Lu LH, 1998, BRIT J PHARMACOL, V124, P1227, DOI 10.1038/sj.bjp.0701912; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIURA S, 1995, BIOL PHARM BULL, V18, P1; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1995, HYPERTENSION, V26, P771, DOI 10.1161/01.HYP.26.5.771; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Tijburg LBM, 1997, CRIT REV FOOD SCI, V37, P771, DOI 10.1080/10408399709527802	35	62	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					893	+		10.1096/fj.01-0799fje	http://dx.doi.org/10.1096/fj.01-0799fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039871				2022-12-25	WOS:000175425900023
J	Mai, JC; Shen, HM; Watkins, SC; Cheng, T; Robbins, PD				Mai, JC; Shen, HM; Watkins, SC; Cheng, T; Robbins, PD			Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; ANTENNAPEDIA HOMEOBOX PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS; HAMSTER OVARY CELLS; POLY-L-LYSINE; NF-KAPPA-B; INTRACELLULAR DELIVERY; IN-VIVO; MAMMALIAN-CELLS; HORSERADISH-PEROXIDASE	Protein transduction domains (PTDs), both naturally occurring and synthetic, have been increasingly utilized to deliver biologically active agents to a variety of cell types in vitro and in vivo. We report that in addition to previously characterized arginine-rich PTDs, including TAT, lysine homopolymers were able to mediate transduction of a wide variety of cell types, as measured by flow cytometric and enzymatic assays. The efficiency of PTD-mediated transduction was influenced by the cell type tested, although polylysine homopolymers demonstrate levels of internalization that consistently exceeded those of TAT and arginine homopolymers. Transduction of arginine/lysine-rich PTDs occurred at 4 degreesC and following depletion of cellular ATP pools, albeit generally at reduced levels. Although transduction was reduced in Chinese hamster ovary mutant lines deficient in either heparan sulfate or glycosaminoglycan synthesis, uptake was restored to wild-type levels by incubating target cells with dextran sulfate. The enhancement of transduction by dextran sulfate suggests that electrostatic interactions play an important first step in the process by which PTDs and their cargoes traverse the plasma membrane.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Canc, Dept Radiat Oncol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.		Mai, Jeffrey/F-1780-2011; Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Cheng, Tao/0000-0002-5925-2769	NIAMS NIH HHS [AR6-2225] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR062225] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Blanke SR, 1996, P NATL ACAD SCI USA, V93, P8437, DOI 10.1073/pnas.93.16.8437; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k; Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x; Drzeniek Z, 1999, BLOOD, V93, P2884; Dyer AP, 1997, J VIROL, V71, P191, DOI 10.1128/JVI.71.1.191-198.1997; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hakansson S, 2001, PROTEIN SCI, V10, P2138, DOI 10.1110/ps.23401; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Ho A, 2001, CANCER RES, V61, P474; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JOLIOT AH, 1991, NEW BIOL, V3, P1121; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; LEVINE TP, 1992, P NATL ACAD SCI USA, V89, P8342, DOI 10.1073/pnas.89.17.8342; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindberg M, 2001, FEBS LETT, V497, P39, DOI 10.1016/S0014-5793(01)02433-4; Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2; Mai JC, 2001, CANCER RES, V61, P7709; Matsushita M, 2001, J NEUROSCI, V21, P6000, DOI 10.1523/JNEUROSCI.21-16-06000.2001; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; MORAD N, 1984, BIOCHIM BIOPHYS ACTA, V801, P117, DOI 10.1016/0304-4165(84)90219-8; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Persson D, 2001, FEBS LETT, V505, P307, DOI 10.1016/S0014-5793(01)02843-5; PLANK C, 1994, J BIOL CHEM, V269, P12918; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; RYSER HJP, 1978, P NATL ACAD SCI USA, V75, P3867, DOI 10.1073/pnas.75.8.3867; RYSER HJP, 1965, SCIENCE, V150, P501, DOI 10.1126/science.150.3695.501; RYSER HJP, 1982, J CELL PHYSIOL, V113, P167, DOI 10.1002/jcp.1041130126; RYSER HJP, 1978, LIFE SCI, V22, P1253, DOI 10.1016/0024-3205(78)90094-2; RYSER HJP, 1980, CANCER, V45, P1207, DOI 10.1002/1097-0142(19800315)45:5+<1207::AID-CNCR2820451327>3.0.CO;2-M; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872; SHEN WC, 1979, MOL PHARMACOL, V16, P614; Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Yeung SN, 1999, GENE THER, V6, P1536, DOI 10.1038/sj.gt.3300980	64	124	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30208	30218		10.1074/jbc.M204202200	http://dx.doi.org/10.1074/jbc.M204202200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12034749	hybrid			2022-12-25	WOS:000177509300106
J	Rodriguez, AC				Rodriguez, AC			Studies of a positive supercoiling machine - Nucleotide hydrolysis and a multifunctional "latch" in the mechanism of reverse gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOLOBUS-ACIDOCALDARIUS; DNA TOPOISOMERASES; I TOPOISOMERASE; ATP; ARCHAEBACTERIA; HELICASE; CLEAVAGE; INVITRO; PROTEIN	Reverse gyrase, the only topoisomerase known to positively supercoil DNA, has an N-terminal ATPase domain that drives the activity of a topoisomerase domain. This study shows that the N-terminal domain represses topoisomerase activity in the absence of nucleotide, and nucleotide binding is sufficient to relieve the repression. A "latch" region in the N-terminal part was observed to close over the topoisomerase domain in the reverse gyrase crystal structure. Mutants lacking all or part of the latch relax DNA in the absence of nucleotide, indicating that this region mediates topoisomerase repression. The mutants also show altered DNA-dependent ATPase activity, suggesting that the latch may be involved in coupling nucleotide hydrolysis to supercoiling. It is not required for this process, however, because the mutants can still positively supercoil DNA. Nucleotide hydrolysis is essential to the specificity of reverse gyrase for increasing the linking number of DNA. Although with ATP the enzyme performs strand passage always toward increasing linking number, it can increase or decrease the linking number in the presence of a nonhydrolyzable ATP analog. This suggests that the mechanism of reverse gyrase is best described by a combination of recently proposed models.	MRC, Lab Mol Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rodriguez, AC (corresponding author), MRC, Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.							Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Declais AC, 2001, METHOD ENZYMOL, V334, P146; DELATOUR CB, 1990, J BACTERIOL, V172, P6803, DOI 10.1128/jb.172.12.6803-6808.1990; DELATOUR CB, 1991, J BACTERIOL, V173, P3921, DOI 10.1128/JB.173.12.3921-3923.1991; FORTERRE P, 1985, EMBO J, V4, P2123, DOI 10.1002/j.1460-2075.1985.tb03902.x; JAXEL C, 1989, EMBO J, V8, P3135, DOI 10.1002/j.1460-2075.1989.tb08466.x; Kaplan DL, 1999, J BIOL CHEM, V274, P6889, DOI 10.1074/jbc.274.11.6889; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; Krah R, 1997, J BIOL CHEM, V272, P13986, DOI 10.1074/jbc.272.21.13986; Li ZY, 2001, MOL CELL, V7, P301, DOI 10.1016/S1097-2765(01)00178-2; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MIRAMBEAU G, 1984, J MOL BIOL, V179, P559, DOI 10.1016/0022-2836(84)90080-9; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; NADAL M, 1988, BIOCHEMISTRY-US, V27, P9102, DOI 10.1021/bi00426a006; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; PRIESTLE JP, 1991, J APPL CRYSTALLOGR, V24, P946; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHIBATA T, 1987, J BIOL CHEM, V262, P10419; SLESAREV AI, 1990, J BIOMOL STRUCT DYN, V7, P935, DOI 10.1080/07391102.1990.10508533; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993	27	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29865	29873		10.1074/jbc.M202853200	http://dx.doi.org/10.1074/jbc.M202853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12048189	hybrid			2022-12-25	WOS:000177509300066
J	Baird, TR; Walsh, PN				Baird, TR; Walsh, PN			Activated platelets but not endothelial cells participate in the initiation of the consolidation phase of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; FACTOR-XI ACTIVATION; CRYSTAL-STRUCTURE; BINDING-SITE; FACTOR VIIA; FACTOR IXA; SURFACE; THROMBIN; COMPLEX; PROTHROMBIN	To address the question of whether initiation of the consolidation phase of coagulation occurs on platelets or on endothelium, we have examined the interaction of coagulation factor XI with human umbilical vein endothelial cells (HLTVEC) and with platelets. In microtiter wells factor XI binds to more sites in the absence of HUVEC (1.8 x 10(10) sites/well, K-D = 2.6 nm) than in their presence (1.3 x 10(10) sites/well, K-D = 12 nm) when high molecular weight kininogen (HK) and zinc are present. Binding was volume-dependent and abrogated by HUVEC or Chinese hamster ovary cells and was a function of nonspecific binding of HK to the artificial plastic surface. Factor XI did not bind to HLTVEC or to HEK293 cell monolayers anchored to microcarrier beads. Activation of HLTVEC resulted in von Willebrand's factor secretion, but factor XI binding was not observed. Only activated platelets supported factor XI binding in the presence of HK and zinc (K-D = 8 nm, B-max = 1319 sites/ cell). Activation of factor XI was observed in plasma in the presence of platelets activated by the thrombin receptor activation peptide but not with activated HLTVEC. These results support the concept that activated platelets, but not endothelial cells, expose a procoagulant surface for binding and activating factor XI, thereby initiating the consolidation phase of coagulation.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL64943, HL46213, HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, P01HL056914] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adler M, 2000, BIOCHEMISTRY-US, V39, P12534, DOI 10.1021/bi001477q; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; Cines DB, 1998, BLOOD, V91, P3527; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; KLEIN HG, 1977, NEW ENGL J MED, V296, P959, DOI 10.1056/NEJM197704282961702; LIPSCOMB MS, 1979, J CLIN INVEST, V63, P1006, DOI 10.1172/JCI109368; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; NAITO K, 1991, J BIOL CHEM, V266, P7353; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8903, DOI 10.1021/bi9525031; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; VROMAN L, 1967, THROMB DIATH HAEMOST, V18, P510, DOI 10.1055/s-0038-1655060; VROMAN L, 1969, J COLLOID INTERF SCI, V31, P188, DOI 10.1016/0021-9797(69)90325-7; Walsh P N, 1977, Br J Haematol, V36, P287; Walsh PN, 2001, THROMB HAEMOSTASIS, V86, P75	28	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28498	28503		10.1074/jbc.M203427200	http://dx.doi.org/10.1074/jbc.M203427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029092	hybrid			2022-12-25	WOS:000177342600021
J	Pessah, M; Marais, J; Prunier, C; Ferrand, N; Lallemand, F; Mauviel, A; Atfi, A				Pessah, M; Marais, J; Prunier, C; Ferrand, N; Lallemand, F; Mauviel, A; Atfi, A			c-Jun associates with the oncoprotein ski and suppresses Smad2 transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PROTEIN; ACTIVATION; COREPRESSOR; RESPONSES; DOMAIN; CELLS	The Smad proteins are key intracellular effectors of transforming growth factor-beta (TGF-beta) cytokines. The ability of Smads to modulate transcription results from a functional cooperativity with the coactivators p300/cAMP-response element-binding protein-binding protein (CBP), or the corepressors TGIF and Ski. The c-Jun N-terminal kinase (JNK) pathway, another downstream target activated by TGF-beta receptors, has also been suggested to inhibit TGF-beta signaling through interaction of c-Jun with Smad2 and Smad3. Here we show that c-Jun directly interacts with Ski to enhance the association of Ski with Smad2 in the basal state. Interestingly, TGF-beta signaling induces dissociation of c-Jun from Ski, thereby relieving active repression by c-Jun. Moreover, activation of JNK pathway suppressed the ability of TGF-beta to induce dissociation of c-Jun from ski. Thus, the formation of a c-Jun/Ski complex maintains the repressed state of Smad2-responsive genes in the absence of ligand and participates in negative feedback regulation of TGF-beta signaling by the JNK cascade.	Hop St Antoine, INSERM, U 482, F-75571 Paris 12, France; Hop St Louis, INSERM, U532, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Atfi, A (corresponding author), Hop St Antoine, INSERM, U 482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		MAUVIEL, Alain/F-6251-2013; Frottier, Celine Prunier/G-8259-2017	Frottier, Celine Prunier/0000-0002-7784-0273; Mauviel, Alain/0000-0002-0438-2793				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Frey RS, 1997, CANCER RES, V57, P628; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Reed JA, 2001, CANCER RES, V61, P8074; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1	28	39	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29094	29100		10.1074/jbc.M202831200	http://dx.doi.org/10.1074/jbc.M202831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034730	hybrid			2022-12-25	WOS:000177342600097
J	Stacey, M; Chang, GW; Sanos, SL; Chittenden, LR; Stubbs, L; Gordon, S; Lin, HH				Stacey, M; Chang, GW; Sanos, SL; Chittenden, LR; Stubbs, L; Gordon, S; Lin, HH			EMR4, a novel epidermal growth factor (EGF)-TM7 molecule up-regulated in activated mouse macrophages, binds to a putative cellular ligand on B lymphoma cell line A20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALPHA-LATROTOXIN RECEPTOR; 7-PASS TRANSMEMBRANE RECEPTOR; MESSENGER-RNA; EXTRACELLULAR DOMAIN; DIFFERENTIAL DISPLAY; POINT MUTATIONS; DENDRITIC CELLS; SECRETIN FAMILY; MARFAN-SYNDROME	A novel member of the EGF-TM7 family, mEMR4, was identified and characterized. The full-length mouse EMR4 cDNA encodes a predicted 689-amino acid protein containing two epidermal growth factor (EGF)-like modules, a mucin-like spacer domain, and a seven-transmembrane domain with a cytoplasmic tail. Genetic mapping established that mEMR4 is localized in the distal region of mouse chromosome 17 in close proximity to another EGF-TM7 gene, F4/80 (Emr1). Similar to F4/80, mEMR4 is predominantly expressed on resident macrophages. However, a much lower expression level was also detected in thioglycollate-elicited peritoneal neutrophils and bone marrow-derived dendritic cells. The expression of mEMR4 is up-regulated following macrophage activation in Biogel and thioglycollate-elicited peritoneal macrophages. Similarly, mEMR4 is over-expressed in TNF-alpha-treated resident peritoneal macrophages, whereas interleukin-4 and -10 dramatically reduce the expression. mEMR4 was found to undergo proteolytic processing within the extracellular stalk region resulting in two protein subunits associated noncovalently as a heterodimer. The proteolytic cleavage site was identified by N-terminal amino acid sequencing and located at the conserved GPCR (G protein-coupled receptor) proteolytic site in the extracellular region. Using multivalent biotinylated mEMR4-mFc fusion proteins as a probe, a putative cell surface ligand was identified on a B lymphoma cell line, A20, in a cell-binding assay. The mEMR4-ligand interaction is Ca2+-independent and is mediated predominantly by the second EGF-like module. mEMR4 is the first EGF-TM7 receptor known to mediate the cellular interaction between myeloid cells and B cells.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	University of Oxford; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Lin, HH (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		LIN, Hsi-Hsien/N-1488-2015	Stubbs, Lisa/0000-0002-9556-1972				Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Aust G, 1997, CANCER RES, V57, P1798; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Caminschi I, 2001, J IMMUNOL, V167, P3570, DOI 10.4049/jimmunol.167.7.3570; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Campbell ID, 1998, IMMUNOL REV, V163, P11; Carver EA, 1999, MAMM GENOME, V10, P1039, DOI 10.1007/s003359901157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Doyle J, 1996, GENOMICS, V35, P227, DOI 10.1006/geno.1996.0343; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Eichler W, 1997, TISSUE ANTIGENS, V50, P429, DOI 10.1111/j.1399-0039.1997.tb02897.x; FAUVE RM, 1983, J IMMUNOL METHODS, V64, P345, DOI 10.1016/0022-1759(83)90442-8; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; Gray JX, 1996, J IMMUNOL, V157, P5438; Hadjantonakis AK, 1997, GENOMICS, V45, P97, DOI 10.1006/geno.1997.4892; Hadjantonakis AK, 1998, MECH DEVELOP, V78, P91, DOI 10.1016/S0925-4773(98)00153-1; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hamann J, 1996, GENOMICS, V32, P144, DOI 10.1006/geno.1996.0092; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Hoang-Vu C, 1999, J CLIN ENDOCR METAB, V84, P1104, DOI 10.1210/jc.84.3.1104; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUME DA, 1983, J CELL PHYSIOL, V117, P189, DOI 10.1002/jcp.1041170209; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JOHNSTON RB, 1978, J EXP MED, V148, P115; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KENNEL SJ, 1993, J CELL SCI, V104, P373; KIM KJ, 1979, J IMMUNOL, V122, P549; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Lu BW, 1999, CURR BIOL, V9, P1247, DOI 10.1016/S0960-9822(99)80505-3; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McKnight AJ, 1996, IMMUNOL TODAY, V17, P283, DOI 10.1016/0167-5699(96)80546-9; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McKnight AJ, 1997, MAMM GENOME, V8, P946, DOI 10.1007/s003359900633; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Osterhoff C, 1997, DNA CELL BIOL, V16, P379, DOI 10.1089/dna.1997.16.379; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian YM, 1999, IMMUNOLOGY, V98, P303; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; Stacey M, 2001, J BIOL CHEM, V276, P18863, DOI 10.1074/jbc.M101147200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; TUCKER PW, 1979, SCIENCE, V206, P1299, DOI 10.1126/science.117548; TUCKER PW, 1979, SCIENCE, V206, P1303, DOI 10.1126/science.117549; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; WATSON S, 1994, GPROTEIN LINKED RECE; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957; Zendman AJW, 1999, FEBS LETT, V446, P292, DOI 10.1016/S0014-5793(99)00230-6	71	85	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29283	29293		10.1074/jbc.M204306200	http://dx.doi.org/10.1074/jbc.M204306200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023293	hybrid			2022-12-25	WOS:000177342600118
J	Zhong, Q; Chen, CF; Chen, PL; Lee, WH				Zhong, Q; Chen, CF; Chen, PL; Lee, WH			BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; RETRACTED ARTICLE. SEE; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; REPAIR; PROTEIN; DEFICIENT; P53; MICE; TUMORIGENESIS	BRCA1 is critical for the maintenance of genomic stability, in part through its interaction with the Rad50.Mre11.Nbs1 complex, which occupies a central role in DNA double strand break repair mediated by nonhomologous end joining (NHEJ) and homologous recombination. BRCA1 has been shown to be required for homology-directed recombination repair. However, the role of BRCA1 in NHEJ, a critical pathway for the repair of double strand breaks and genome stability in mammalian cells, remains elusive. Here, we established a pair of mouse embryonic fibroblasts (MEFs) derived from 9.5-day-old embryos with genotypes Brca1(+/+):p53(-/-) or Brca1(-/-):p53(-/-). The Brca1(-/-):p53(-/-) MEFs appear to be extremely sensitive to ionizing radiation. T e contribution of BRCA1 in NHEJ was evaluated in these cells using three different assay systems. First, transfection of a linearized plasmid in which expression of the reporter gene required precise end joining indicated that Brca1(-/-) MEFs display a moderate deficiency when compared with Brca1(+/+) cells. Second, using a retrovirus infection assay dependent on NHEJ, a 5-10-fold reduction in retroviral integration efficiency was observed in Brca1(-/-) MEFs when compared with the Brca1(+/+) MEFs. Third, Brca1(-/-) MEFs exhibited a 50-100-fold deficiency in microhomology-mediated end-joining activity of a defined chromosomal DNA double strand break introduced by a rare cutting endonuclease I-SceI. These results provide evidence that Brca1 has an essential role in microhomology-mediated end joining and suggest a novel molecular basis for its caretaker role in the maintenance of genome integrity.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Zhong, Q (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	leew@uthscsa.edu	Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X; Chen, Phang-Lang/0000-0002-0357-9017; Chen, Chi-Fen/0000-0002-6391-821X	NATIONAL CANCER INSTITUTE [R01CA085605, P50CA058183, P01CA081020, P01CA030195] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85605, CA 81020, CA30195, CA58183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lin YF, 1999, MOL CELL BIOL, V19, P8353; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lundberg R, 2001, J BIOL CHEM, V276, P9543, DOI 10.1074/jbc.M008634200; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Roth DB, 2000, NATURE, V404, P823, DOI 10.1038/35009180; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tomlinson GE, 1998, CANCER RES, V58, P3237; Tsukamoto Y, 1998, GENES CELLS, V3, P135, DOI 10.1046/j.1365-2443.1998.00180.x; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZHONG Q, 2002, IN PRESS CANC RES	45	118	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28641	28647		10.1074/jbc.M200748200	http://dx.doi.org/10.1074/jbc.M200748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12039951	hybrid			2022-12-25	WOS:000177342600039
J	Orlowski, RZ; Small, GW; Shi, YY				Orlowski, RZ; Small, GW; Shi, YY			Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; BREAST-CANCER; OKADAIC ACID; IN-VIVO; PEPTIDYL ALDEHYDES; CELL LINES; KAPPA-B; GROWTH; INDUCTION; PHOSPHATASE	The proteasome is emerging as a target for cancer therapy because small molecule inhibitors of its catalytic activity induce apoptosis in both in vitro and in vivo models of human malignancies and are proving to have efficacy in early clinical trials. To further elucidate the mechanism of action of these inhibitors, their impact on signaling through the p44/42 mitogen-activated protein kinase (MAPK) pathway was studied. Proteasome inhibition with either carbobenzoxy-leucyl-leucyl-phenylalaninal or lactacystin led to a loss of dually phosphorylated, activated p44/42 MAPK in A1N4-myc human mammary and MDA-MB-231 breast carcinoma cells in a dose- and time-dependent fashion. This correlated with an induction of the dual specificity MAPK phosphatases (MKP)-1 and -2, and blockade of MKP induction using either actinomycin D or Ro-31-8220 significantly decreased lass of activated p44/42 MAPK. Inhibition of p44/42 MAPK signaling by use of the MAPK kinase inhibitors PD 98059 or U0126, or by use of a dominant negative MAPK construct, enhanced proteasome inhibitor-mediated apoptosis. Conversely, activation of MAPK by epidermal growth factor, or use of a mutant MAPK resistant to MKP-mediated dephosphorylation, inhibited apoptosis. These studies support a role for inactivation of signaling through the p44/42 MAPK pathway in proteasome inhibitor-mediated apoptosis.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Orlowski, RZ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, 22-003,CB 7295,Mason Farm Rd, Chapel Hill, NC 27599 USA.			Orlowski, Robert/0000-0002-5723-4129; , George/0000-0002-7585-7258				Adams J, 1999, CANCER RES, V59, P2615; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bush KT, 1997, J BIOL CHEM, V272, P9086; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; CLARK R, 1988, CANCER RES, V48, P4689; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Cusack JC, 2001, CANCER RES, V61, P3535; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Goldberg AL, 1997, BIOL CHEM, V378, P131; Grimm L M, 1999, Results Probl Cell Differ, V23, P209; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hideshima T, 2001, CANCER RES, V61, P3071; Hirsch T, 1998, J IMMUNOL, V161, P35; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kudo Y, 2000, CLIN CANCER RES, V6, P916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Mao ML, 2000, BIOCHEM J, V352, P475, DOI 10.1042/0264-6021:3520475; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; Orlowski RZ, 1998, CANCER RES, V58, P4342; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEARGEANT LE, 1979, BIOCHEM J, V181, P247, DOI 10.1042/bj1810247; STINCHCOMBE TE, 2000, AM SOC HEMATOL, V96, pA516; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun JZ, 2001, CANCER RES, V61, P1280; SWARUP G, 1982, J BIOL CHEM, V257, P7298; Tanahashi N, 1999, MOL BIOL REP, V26, P3, DOI 10.1023/A:1006909522731; Tani E, 2001, FEBS LETT, V504, P53, DOI 10.1016/S0014-5793(01)02770-3; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Torres C, 2000, J CELL BIOCHEM, V80, P11; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	72	97	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					27864	27871		10.1074/jbc.M201519200	http://dx.doi.org/10.1074/jbc.M201519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023956	hybrid, Green Published			2022-12-25	WOS:000177189800036
J	Gomis-Ruth, FX; Bayes, A; Sotiropoulou, G; Pampalakis, G; Tsetsenis, T; Villegas, V; Aviles, FX; Coll, M				Gomis-Ruth, FX; Bayes, A; Sotiropoulou, G; Pampalakis, G; Tsetsenis, T; Villegas, V; Aviles, FX; Coll, M			The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NEUROPSIN MESSENGER-RNA; RAY CRYSTAL-STRUCTURE; AMINO-ACID-SEQUENCE; SERINE-PROTEASE; ZYME/PROTEASE M/NEUROSIN; CRYSTALLOGRAPHIC REFINEMENT; GENE FAMILY; ALZHEIMERS-DISEASE; MOLECULAR-CLONING	Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding primary tumors. Recent evidence suggests that hK6 may serve as a circulating tumor marker in ovarian cancers. In addition, it was described in the brain of Parkinson's disease and Alzheimer's disease patients, where it is implicated in amyloid precursor protein processing. It is thus a biomarker for these diseases. To examine the mechanism of activation of hK6, we have solved the structure of its proform, the first of a human kallikrein family member. The proenzyme displays a fold that exhibits chimeric features between those of trypsinogen and other family members. It lacks the characteristic "kallikrein loop" and forms the six disulfide bridges of trypsin. Pro-hK6 displays a completely closed specificity pocket and a unique conformation of the regions involved in structural rearrangements upon proteolytic cleavage activation. This points to a novel activation mechanism, which could be extrapolated to other human kallikreins.	CSIC, Inst Mol Biol, ES-08034 Barcelona, Spain; Univ Autonoma Barcelona, Unitat Ciencies, Dept Bioquim & Biol Mol, Inst Biotecnol & Biomed, Bellaterra 08193, Barcelona, Spain; Univ Patras, Sch Hlth Sci, Dept Pharm, Patras 26500, Greece	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Autonomous University of Barcelona; University of Patras	Gomis-Ruth, FX (corresponding author), CSIC, Inst Mol Biol, C-Jordi Girona 18-26, ES-08034 Barcelona, Spain.	xgrcri@ibmb.csic.es	Villegas, Sandra/D-8789-2011; Bayés, Àlex/H-2854-2015; Aviles, Francesc Xavier/F-3482-2019; Coll, Miquel/L-5999-2014; Villegas, Sandra/ABF-8206-2021; Avilés, Francesc Xavier/A-2664-2015	Villegas, Sandra/0000-0001-8644-4304; Bayés, Àlex/0000-0002-5265-6306; Aviles, Francesc Xavier/0000-0002-1399-6789; Coll, Miquel/0000-0003-4471-8674; Villegas, Sandra/0000-0001-8644-4304; Avilés, Francesc Xavier/0000-0002-1399-6789; Tsetsenis, Theodoros/0000-0002-4642-6539; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				AMFO K, 1995, ONCOGENE, V11, P351; Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bax B, 1997, STRUCTURE, V5, P1275, DOI 10.1016/S0969-2126(97)00280-3; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerf ME, 2000, METAB BRAIN DIS, V15, P315, DOI 10.1023/A:1011179426420; Chen ZL, 1998, J HISTOCHEM CYTOCHEM, V46, P313, DOI 10.1177/002215549804600304; CLEMENTS J, 1997, KININ SYSTEM, P71; CLEMENTS JA, 1994, MOL CELL ENDOCRINOL, V99, pC1, DOI 10.1016/0303-7207(94)90138-4; Diamandis EP, 2000, CLIN BIOCHEM, V33, P369, DOI 10.1016/S0009-9120(00)00145-4; Diamandis EP, 2002, CANCER RES, V62, P295; Diamandis EP, 2000, CLIN BIOCHEM, V33, P663, DOI 10.1016/S0009-9120(00)00185-5; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; EVANS BA, 1988, BIOCHEMISTRY-US, V27, P3124, DOI 10.1021/bi00409a003; EVANS BA, 1987, J BIOL CHEM, V262, P8027; Evans P. R., 1993, DATA COLLECTION PROC, P114; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FIEDLER F, 1979, BRADYKININ KALLIDIN, P103; FUJINAGA M, 1987, J MOL BIOL, V195, P373, DOI 10.1016/0022-2836(87)90658-9; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; Gomis-Ruth FX, 1998, EUR J BIOCHEM, V251, P839, DOI 10.1046/j.1432-1327.1998.2510839.x; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; HAREL M, 1991, BIOCHEMISTRY-US, V30, P5217, DOI 10.1021/bi00235a015; HARTLEY BS, 1964, NATURE, V201, P1284, DOI 10.1038/2011284a0; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JAMES MNG, 1978, CAN J BIOCHEM CELL B, V56, P396, DOI 10.1139/o78-062; Kishi A, 1999, J BIOL CHEM, V274, P4220, DOI 10.1074/jbc.274.7.4220; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kraut H, 1930, H-S Z PHYSIOL CHEM, V189, P97, DOI 10.1515/bchm2.1930.189.3-4.97; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Liu XL, 1996, CANCER RES, V56, P3371; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; MacDonald RJ, 1996, J BIOL CHEM, V271, P13684, DOI 10.1074/jbc.271.23.13684; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mitelman F., 1994, CATALOG CHROMOSOME A; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; NEURATH H, 1975, PROTEASES BIOL CONTR, V2, P51; NUSTAD K, 1978, GEN PHARMACOL-VASC S, V9, P1, DOI 10.1016/0306-3623(78)90049-6; Ogawa K, 2000, PSYCHIAT CLIN NEUROS, V54, P419, DOI 10.1046/j.1440-1819.2000.00731.x; Okui A, 2001, NEUROREPORT, V12, P1345, DOI 10.1097/00001756-200105250-00011; Ozen M, 2000, INT J ONCOL, V17, P113; Perez-Polo J R, 1972, Adv Exp Med Biol, V32, P91; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Petraki CD, 2001, J HISTOCHEM CYTOCHEM, V49, P1431, DOI 10.1177/002215540104901111; Quattrocchi CC, 2002, J BIOL CHEM, V277, P303, DOI 10.1074/jbc.M106996200; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; SCHACHTER M, 1979, PHARMACOL REV, V31, P1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Tanimoto H, 2001, TUMOR BIOL, V22, P11, DOI 10.1159/000030150; Timm DE, 1997, PROTEIN SCI, V6, P1418, DOI 10.1002/pro.5560060706; Tomizawa K, 1999, BRAIN RES, V824, P308, DOI 10.1016/S0006-8993(99)01238-X; Ventura S, 1999, J BIOL CHEM, V274, P19925, DOI 10.1074/jbc.274.28.19925; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yamaguchi N, 2002, J BIOL CHEM, V277, P6806, DOI 10.1074/jbc.M103645200; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; YOUNG CL, 1978, ATLAS PROTEIN SEQ S3, V5, P73; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 2001, CANCER RES, V61, P3425; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	79	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27273	27281		10.1074/jbc.M201534200	http://dx.doi.org/10.1074/jbc.M201534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016211	hybrid			2022-12-25	WOS:000177055900074
J	Schweitzer, JK; D'Souza-Schorey, C				Schweitzer, JK; D'Souza-Schorey, C			Localization and activation of the ARF6 GTPase during cleavage furrow ingression and cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR-6; EPITHELIAL-CELL MIGRATION; MEMBRANE TRAFFICKING; ACTIN CYTOSKELETON; PLASMA-MEMBRANE; TRANS-GOLGI; PROTEIN; FAMILY; REARRANGEMENTS; REQUIREMENT	The ARF6 GTPase mediates cell shape changes in interphase cells through its effects on membrane cycling and actin remodeling. In this study, we focus our attention on the dynamics of cell division and present evidence supporting a novel role for ARF6 during cleavage furrow ingression and cytokinesis. We demonstrate that endogenous ARF6 redistributes during mitosis and concentrates near the cleavage furrow during telophase. Constitutively activated ARF6 localizes to the plasma membrane at the site of cleavage furrow ingression and midbody formation, and dominant negative ARF6 remains cytoplasmic. By using a novel pull-down assay for ARF6-GTP, we find an abrupt, but transient, increase in ARF6-GTP levels as cells progress through cytokinesis. Whereas high levels of expression of a GTPase-defective ARF6 mutant induce aberrant phenotypes in cells at cytokinesis, cells expressing low levels of ARF6 mutants do not display a significant mitotic delay or cytokinesis defect, presumably due to compensatory or redundant mechanisms that allow cytokinesis to proceed when the ARF6 GTPase cycle is disrupted. Finally, actin accumulation and phospholipid metabolism kit the cleavage furrow are unchanged in cells expressing ARF6 mutants, suggesting that ARF6 may be involved in membrane remodeling during cytokinesis via effector pathways that are distinct from those operative in interphase cells.	Univ Notre Dame, Dept Sci Biol, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute	D'Souza-Schorey, C (corresponding author), Univ Notre Dame, Dept Sci Biol, Box 369,Galvin Life Sci Bldg, Notre Dame, IN 46556 USA.							Al-Awar O, 2000, MOL CELL BIOL, V20, P5998, DOI 10.1128/MCB.20.16.5998-6007.2000; Benard V, 2002, METHOD ENZYMOL, V345, P349; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Kartmann B, 2001, J CELL SCI, V114, P839; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KLEINMAN HK, 1998, CURRENT PROTOCOLS CE, V1; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; O'Halloran TJ, 2000, TRAFFIC, V1, P921, DOI 10.1034/j.1600-0854.2000.011201.x; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	31	89	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27210	27216		10.1074/jbc.M201569200	http://dx.doi.org/10.1074/jbc.M201569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12016212	hybrid			2022-12-25	WOS:000177055900066
J	Wilson-Sali, T; Hsieh, TS				Wilson-Sali, T; Hsieh, TS			Generation of double-stranded breaks in hypernegatively supercoiled DNA by Drosophila topoisomerase III beta, a type IA enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PHAGE SYSTEM; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; EUKARYOTIC CELLS; GENE-PRODUCT; HELICASE; INTERACTS; TOP3	Drosophila topoisomerase (topo) IIIbeta is a member of the type IA family of DNA topoisomerases, which generates a single-stranded break to form a covalent complex with the 5'-end of DNA. We show here that a purified preparation of topo IIIbeta is able to convert a hypernegatively supercoiled substrate into primarily nicked, but also linear, DNA at enzyme/DNA molar ratios of 5:1 or greater. Although the optimal temperature for the relaxation activity is between 37 and 45 degreesC, maximal cleavage occurs between 23 and 30 degreesC, a temperature range that is more physiologically relevant for fruit flies. The cleavage products require protease treatment to enter the gel, they are stable over time, they are reversible, and they are not observed with a Y332F active site mutant, which further supports the idea that topo IIIbeta possesses an endonucleolytic cleavage activity. This cleavage activity appears to be specific for highly unwound, or single strand-containing substrates. Southern blot analysis of the cleavage products demonstrates that the topo IIIbeta cleavage activity is concentrated primarily in highly A/T-rich regions. These results suggest that topo IIIbeta may function as a reversible endonuclease in vivo by recognizing and cleaving/rejoining DNA structures with single-stranded character.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Res Dr, Durham, NC 27710 USA.		Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAASE WA, 1974, BIOCHEMISTRY-US, V13, P4299, DOI 10.1021/bi00718a009; BAILIS AM, 1992, MOL CELL BIOL, V12, P4988, DOI 10.1128/MCB.12.11.4988; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Chakraverty RK, 2001, MOL CELL BIOL, V21, P7150, DOI 10.1128/MCB.21.21.7150-7162.2001; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kim YC, 2000, NUCLEIC ACIDS RES, V28, P2012, DOI 10.1093/nar/28.9.2012; Kobayashi M, 2001, BIOCHEM BIOPH RES CO, V287, P282, DOI 10.1006/bbrc.2001.5580; KREUZER KN, 1985, P NATL ACAD SCI USA, V82, P3345, DOI 10.1073/pnas.82.10.3345; KREUZER KN, 1986, J MOL BIOL, V188, P185, DOI 10.1016/0022-2836(86)90303-7; Kwan KY, 2001, P NATL ACAD SCI USA, V98, P5717, DOI 10.1073/pnas.101132498; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Mullen JR, 2001, GENETICS, V157, P103; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; Seki T, 1998, BBA-GENE STRUCT EXPR, V1396, P127, DOI 10.1016/S0167-4781(97)00192-9; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; Uematsu N, 1997, MUTAT RES-DNA REPAIR, V383, P223, DOI 10.1016/S0921-8777(97)00005-0; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wilson TM, 2000, J BIOL CHEM, V275, P1533, DOI 10.1074/jbc.275.3.1533; Wilson-Sali T, 2002, P NATL ACAD SCI USA, V99, P7974, DOI 10.1073/pnas.122007999; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Zhu Q, 2001, P NATL ACAD SCI USA, V98, P9766, DOI 10.1073/pnas.171579898	41	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					26865	26871		10.1074/jbc.M204641200	http://dx.doi.org/10.1074/jbc.M204641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	12023976	hybrid			2022-12-25	WOS:000177055900023
J	Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M				Araujo, FD; Pierce, AJ; Stark, JM; Jasin, M			Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks	ONCOGENE			English	Article						homologous recombination; DNA double-strand break repair; XRCC3; RAD51; polymorphism	DNA-REPAIR; CHROMOSOME STABILITY; GENES; POLYMORPHISMS	Polymorphisms in DNA repair genes, including double-strand break (DSB) repair genes, are postulated to confer increased cancer risk. A variant of the XRCC3 gene, which is involved in DSB repair, has been associated with increased risk of malignant skin melanoma and bladder cancer. We tested the hypothesis that this variant, Thr241Met, may affect cancer risk by disrupting a critical function of XRCC3, i.e., promoting homology-directed repair (HDR) of chromosomal DSBs. Using a quantitative fluorescence assay, we find that the variant XRCC3 protein is functionally active for HDR, complementing the HDR defects of an XRCC3 mutant cell line as well as the wild-type protein. We also examined cells expressing this variant for sensitivity to the interstrand cross-linking agent, mitomycin C (MMC), as HDR mutant cell lines, including the XRCC3 mutant, have been found to be hypersensitive to this DNA damaging agent. Cells expressing the variant protein were found to be no more sensitive than cells expressing the wild-type protein. These results suggest that the increased cancer risk associated with this variant may not be due to an intrinsic HDR defect.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org		Pierce, Andrew/0000-0001-9062-0307	NIGMS NIH HHS [GM54688] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Cui X, 1999, MUTAT RES-DNA REPAIR, V434, P75, DOI 10.1016/S0921-8777(99)00010-5; David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 2001, P NATL ACAD SCI USA, V98, P8440, DOI 10.1073/pnas.111005698; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; MIYAZAKI J, 1989, GENE, V79, P269; Moynahan ME, 2001, CANCER RES, V61, P4842; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Shen MR, 1998, CANCER RES, V58, P604; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Vogelstein B., 1998, GENETIC BASIS HUMAN; Winsey SL, 2000, CANCER RES, V60, P5612	20	95	96	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4176	4180		10.1038/sj.onc.1205539	http://dx.doi.org/10.1038/sj.onc.1205539			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037675				2022-12-25	WOS:000176186000013
J	Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB				Atanaskova, N; Keshamouni, VG; Krueger, JS; Schwartz, JA; Miller, F; Reddy, KB			MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance	ONCOGENE			English	Article						breast cancer; estrogen receptor; MAPK; cross-talk; anti-estrogens	ACTIVATED PROTEIN-KINASE; DEPENDENT TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; ER-ALPHA; PHOSPHORYLATION; ESTRADIOL; IDENTIFICATION; DOMAINS; CELLS; COACTIVATOR	The estrogen receptor alpha (ERalpha) signaling plays an essential role in breast cancer progression and endocrine therapy. Mitogen-activated protein kinase (MAPK/Erk1/2) has been implicated in ligand-independent activation of ER, resulting in the cross-talk between growth factor and ER mediated signaling. In this study, we examined the effect of the cross-talk on estradiol (E-2)-mediated signaling, tumor growth and its effect on anti-estrogen therapy. Our findings demonstrate that expression of constitutively activated mitogen activated kinase kinase (MEK1), an immediate upstream activator of MAPK in estrogen receptor positive MCF-7 breast cancer cells (MEK/MCF-7), showed an increase in ERalpha-driven transcriptional activation. In MEK/MCF-7 cells maximal transactivation levels were achieved in response to treatment with much lower E-2 concentrations (10(10) M E-2) when compared to MCF-7 control cells (10(8) M E-2) Furthermore, we have seen an increased association between ERalpha and its nuclear coactivators AIB1 or TIF2, in MEK/MCF-7 cells relative to those seen in MCF-7 control cells. In addition, in vivo studies show that mEK/MCF-7 cell tumors are similar tothreefold larger than those of MCF-7 cell, in the presence of E-2. Immunohistochemical staining demonstrates that progesterone receptor (PR) and pS2, two E-2-regulated gene products, are significantly increased in MEK/MCF-7 cell tumors compared to those of MCF-7 control tumors, suggesting that activation of ERalpha by MAPK enhances the expression of E-2-regulated genes and accelerates tumor growth. Remarkably, the antiestrogens tamoxifen and ICI 182,780, were shown both in vitro and in giro studies to efficiently antagonize the stimulatory effects of E-2 on ER regulated transactivation and tumor growth in MEK/MCF-7 as well as MCF-7 cell lines. Taken together, these data suggest that MAPK/ER cross-talk enhances ERalpha-mediated signaling and accelerates E-2-dependent tumor growth without diminishing sensitivity to the inhibitory effects of anti-estrogens.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	kreddy@med.wayne.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83964, CA 64248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; ElTanani MKK, 1997, J STEROID BIOCHEM, V60, P269, DOI 10.1016/S0960-0760(96)00226-9; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Kurokawa H, 2000, CANCER RES, V60, P5887; LAIDLAW IJ, 1995, ENDOCRINOLOGY, V136, P164, DOI 10.1210/en.136.1.164; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun M, 2001, CANCER RES, V61, P5985; Tari AM, 2000, INT J CANCER, V86, P295, DOI 10.1002/(SICI)1097-0215(20000415)86:2<295::AID-IJC22>3.0.CO;2-K; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; Welch DR, 2000, CANCER RES, V60, P1552; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	42	91	96	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4000	4008		10.1038/sj.onc.1205506	http://dx.doi.org/10.1038/sj.onc.1205506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037682				2022-12-25	WOS:000175869900006
J	Humar, R; Kiefer, FN; Berns, H; Resink, TJ; Battegay, EJ				Humar, R; Kiefer, FN; Berns, H; Resink, TJ; Battegay, EJ			Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling	FASEB JOURNAL			English	Article						microvessels; smooth muscle; endothelium; embryogenesis; neovascularization	ENDOTHELIAL GROWTH-FACTOR; RAS-TRANSFORMED-CELLS; CYCLIN D1 EXPRESSION; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-B; P70 S6 KINASE; IN-VITRO; MAMMALIAN TARGET; PHOSPHATIDYLINOSITOL 3-KINASE; FRAP-P70(S6K) PATHWAY	Angiogenesis and vascular cell proliferation are pivotal in physiological and pathological processes including atherogenesis, restenosis, wound healing, and cancer development. Here we show that mammalian target of rapamycin (mTOR) signaling plays a key role in hypoxia-triggered smooth muscle and endothelial proliferation and angiogenesis in vitro. Hypoxia significantly increased DNA synthesis and proliferative responses to platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in rat and human smooth muscle and endothelial cells. In an in vitro 3-dimensional model of angiogenesis, hypoxia increased PDGF- and FGF-stimulated sprout formation from rat and mouse aortas. Hypoxia did not modulate PDGF receptor mRNA, protein, or phosphorylation. PI3K activity was essential for cell proliferation under normoxic and hypoxic conditions. Activities of PI3K-downstream target PKB under hypoxia and normoxia were comparable. However, mTOR inhibition by rapamycin specifically abrogated hypoxia-mediated amplification of proliferation and angiogenesis, but was without effect on proliferation under normoxia. Accordingly, hypoxia-mediated amplification of proliferation was further augmented in mTOR-overexpressing endothelial cells. Thus, signaling via mTOR may represent a novel mechanism whereby hypoxia augments mitogen-stimulated vascular cell proliferation and angiogenesis.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Univ Med Outpatient Dept, CH-4031 Basel, Switzerland	University of Basel; University of Basel	Battegay, EJ (corresponding author), Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland.	ebattegay@uhbs.ch						Abizaid Alexandre, 2001, Curr Interv Cardiol Rep, V3, P1; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ALTMAN LK, 2001, NY TIMES        0106; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Barbe E., 1996, MEDITERR POLIT, V1, P25; Battegay EJ, 1996, TRENDS GLYCOSCI GLYC, V8, P231, DOI 10.4052/tigg.8.231; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BJORNHEDEN T, 1987, ARTERIOSCLEROSIS, V7, P238, DOI 10.1161/01.ATV.7.3.238; Bjornheden T, 1996, ARTERIOSCL THROM VAS, V16, P178, DOI 10.1161/01.ATV.16.1.178; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frid MG, 1998, CHEST, V114, p28S, DOI 10.1378/chest.114.1_Supplement.28S; Frid MG, 1997, CIRC RES, V81, P940; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Grewe M, 1999, CANCER RES, V59, P3581; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; MANNE V, 1995, ONCOGENE, V10, P1763; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ross MA, 2001, HEPATOLOGY, V34, P1135, DOI 10.1053/jhep.2001.29624; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SAKAKI T, 1995, NEUROSCI RES, V23, P289, DOI 10.1016/0168-0102(95)00954-X; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Spyridopoulos Ioakim, 1998, Frontiers in Bioscience, V3, pD269; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Thommen R, 1997, J CELL BIOCHEM, V64, P403; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhong H, 2000, CANCER RES, V60, P1541	54	328	354	2	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8							UNSP 0892-6638/02/0016-0771	10.1096/fj.01-0658com	http://dx.doi.org/10.1096/fj.01-0658com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12039858				2022-12-25	WOS:000176683900002
J	Trinei, M; Giorgio, M; Cicalese, A; Barozzi, S; Ventura, A; Migliaccio, E; Milia, E; Padura, IM; Raker, VA; Maccarana, M; Petronilli, V; Minucci, S; Bernardi, P; Lanfrancone, L; Pelicci, PG				Trinei, M; Giorgio, M; Cicalese, A; Barozzi, S; Ventura, A; Migliaccio, E; Milia, E; Padura, IM; Raker, VA; Maccarana, M; Petronilli, V; Minucci, S; Bernardi, P; Lanfrancone, L; Pelicci, PG			A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis	ONCOGENE			English	Article						Shc; p53; ageing; oxidative stress; apoptosis	P53-INDUCED APOPTOSIS; MITOCHONDRIAL-DNA; GROWTH ARREST; LIFE-SPAN; OXIDANTS; MEMBRANE; MODEL; MICE; SHC	Correlative evidence links stress, accumulation of oxidative cellular damage and ageing in lower organisms and in mammals. We investigated their mechanistic connections in p66Shc knockout mice, which are characterized by increased resistance to oxidative stress and extended hie span. We report that p66Shc acts as a downstream target of the tumour suppressor p53 and is indispensable for the ability of stress-activated p53 to induce elevation of intracellular oxidants, cytochrome c release and apoptosis. Other functions of p53 are not influenced by p66Shc expression. In basal conditions, p66Shc -/- and p53 -/- cells have reduced amounts of intracellular oxidants and oxidation-damaged DNA. We propose that steady-state levels of intracellular oxidants and oxidative damage are genetically determined and regulated by a stress-induced signal transduction pathway involving p53 and p66Shc.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; CNR, Unita Study Biomembranes, I-35100 Padua, Italy; FIRC, Inst Mol Oncol, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Giorgio, Marco/I-9425-2012; Franzeck, Fabian C/B-5055-2011; Bernardi, Paolo/C-3656-2008; Lanfrancone, Luisa/AAC-8671-2019; Minucci, Saverio/J-9669-2012; Petronilli, Valeria/C-3558-2015; Pelicci, Pier Giuseppe/AAL-6572-2020; Ventura, Andrea/F-1789-2011; maccarana, marco/AAB-4764-2021; Migliaccio, Enrica/AAQ-8880-2020	Giorgio, Marco/0000-0002-5842-6042; Bernardi, Paolo/0000-0001-9187-3736; Lanfrancone, Luisa/0000-0002-4523-3815; Petronilli, Valeria/0000-0003-4026-6404; Ventura, Andrea/0000-0003-4320-9907; Maccarana, Marco/0000-0003-3549-8921				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gniadecki R, 2000, J CELL BIOCHEM, V80, P216; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PURDIE CA, 1994, ONCOGENE, V9, P603; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	28	363	387	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3872	3878		10.1038/sj.onc.1205513	http://dx.doi.org/10.1038/sj.onc.1205513			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032825				2022-12-25	WOS:000175847200006
J	Slominski, A; Pisarchik, A; Semak, I; Sweatman, T; Wortsman, J; Szczesniewski, A; Slugocki, G; McNulty, J; Kauser, S; Tobin, DJ; Jing, C; Johansson, O				Slominski, A; Pisarchik, A; Semak, I; Sweatman, T; Wortsman, J; Szczesniewski, A; Slugocki, G; McNulty, J; Kauser, S; Tobin, DJ; Jing, C; Johansson, O			Serotoninergic and melatoninergic systems are fully expressed in human skin	FASEB JOURNAL			English	Article						serotonin; melatonin; tryptophan hydroxylase; arylalkylamine N-acetyltransferase; hydroxyindole-O-methyltransferase	CORTICOTROPIN-RELEASING HORMONE; PERFORMANCE LIQUID-CHROMATOGRAPHY; N-ACETYLTRANSFERASE; ENZYME-ACTIVITIES; ASSAY; ACETYLSEROTONIN; IDENTIFICATION; PROLIFERATION; MELANOGENESIS; SPECIFICITY	We investigated the cutaneous expression of genes and enzymes responsible for the multistep conversion of tryptophan to serotonin and further to melatonin. Samples tested were human skin, normal and pathologic (basal cell carcinoma and melanoma), cultured normal epidermal and follicular melanocytes, melanoma cell lines, normal neonatal and adult epidermal and follicular keratinocytes, squamous cell carcinoma cells, and fibroblasts from dermis and follicular papilla. The majority of the samples showed simultaneous expression of the genes for tryptophan hydroxylase, arylalkylamine N-acetyltransferase (AANAT), and hydroxyindole-O-methyltransferase (HIOMT). The products of AANAT activity were identified by RP-HPLC with fluorimetric detection in human skin and in cultured normal and malignant melanocytes and immortalized keratinocytes; HIOMT activity was detected in human skin, keratinocytes, and melanoma cells. N-acetylserotonin (NAS) was detected by RP-HPLC in human skin extracts. NAS identity was confirmed further by LC/MS in keratinocytes. In conclusion, we provide evidence that the human skin expresses intrinsic serotonin and melatonin biosynthetic pathways.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA; Belarusian State Univ, Dept Biochem, Minsk, BELARUS; So Illinois Univ, Dept Internal Med, Springfield, IL USA; Agilent Technol, Schaumburg, IL USA; Loyola Med Ctr, Dept Anat Cell Biol & Neurobiol, Maywood, IL USA; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England; Karolinska Inst, Expt Dermatol Unit, Dept Neurosci, Stockholm, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Belarusian State University; Southern Illinois University System; Southern Illinois University; Agilent Technologies; Loyola University Chicago; University of Bradford; Karolinska Institutet	Slominski, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol, 899 Madison Ave,Room 576M, Memphis, TN 38163 USA.	aslominski@utmem.edu	Semak, Igor/AAT-9273-2020; Tobin, Desmond/A-5228-2009	Semak, Igor/0000-0001-9430-8492; Pisarchik, Alexander/0000-0002-8991-919X; Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392				Abe M, 1999, EXP EYE RES, V68, P255, DOI 10.1006/exer.1998.0601; BEEVERS SJ, 1983, J NEUROCHEM, V40, P894, DOI 10.1111/j.1471-4159.1983.tb08066.x; Bos JD, 1997, SKIN IMMUNE SYSTEM S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buznikov GA, 2001, CELL TISSUE RES, V305, P177, DOI 10.1007/s004410100408; Coon SL, 2001, J BIOL CHEM, V276, P24097, DOI 10.1074/jbc.M011298200; Ebling FJG, 1990, HAIR HAIR DIS, P267; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; GRACE MS, 1993, J NEUROCHEM, V60, P990, DOI 10.1111/j.1471-4159.1993.tb03246.x; GRANDO SA, 1997, CUR OPIN DERMATOL, V4, P462; GUPTA D, 1988, PINEAL GLAND CANC; Itoh MT, 1999, MOL HUM REPROD, V5, P402, DOI 10.1093/molehr/5.5.402; Itoh MT, 1997, J CHROMATOGR B, V692, P217, DOI 10.1016/S0378-4347(96)00503-8; Johansson O, 1998, J INVEST DERMATOL, V111, P1010, DOI 10.1046/j.1523-1747.1998.00460.x; Karbownik M, 2001, INT J BIOCHEM CELL B, V33, P735, DOI 10.1016/S1357-2725(01)00059-0; Kema IP, 2000, J CHROMATOGR B, V747, P33, DOI 10.1016/S0378-4347(00)00341-8; Le Poole IC, 2000, IN VITRO CELL DEV-AN, V36, P309; MAGERL M, IN PRESS EXPT DERMAT; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; MCEWAN M, 1987, J INVEST DERMATOL, V89, P82, DOI 10.1111/1523-1747.ep12580425; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; NORDLUND JJ, 1988, PIGMENTARY SYSTEM PH; Pacak K, 2001, ENDOCR REV, V22, P502, DOI 10.1210/er.22.4.502; Pisarchik A, 2001, FASEB J, V15, P2754, DOI 10.1096/fj.01-0487fje; Quevedo ME, 2001, IN VITRO CELL DEV-AN, V37, P50; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; SCHULZ MK, 1995, RESTOR NEUROL NEUROS, V7, P127, DOI 10.3233/RNN-1994-7301; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2000, ENDOCR REV, V21, P457, DOI 10.1210/er.21.5.457; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 1996, INT J DERMATOL, V35, P849, DOI 10.1111/j.1365-4362.1996.tb05049.x; Slominski A, 2002, FEBS LETT, V511, P102, DOI 10.1016/S0014-5793(01)03319-1; Slominski A, 1999, IN VITRO CELL DEV-AN, V35, P564; Slominski A, 1998, CLIN DERMATOL, V16, P503, DOI 10.1016/S0738-081X(98)00023-6; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Stefulj J, 2001, J PINEAL RES, V30, P243, DOI 10.1034/j.1600-079X.2001.300408.x; SUGDEN D, 1987, METHOD ENZYMOL, V142, P590; THOMAS KB, 1990, ANAL BIOCHEM, V184, P228, DOI 10.1016/0003-2697(90)90673-W; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tsai SY, 1997, GLIA, V20, P243, DOI 10.1002/(SICI)1098-1136(199707)20:3<243::AID-GLIA8>3.0.CO;2-8; Yu H. L., 2020, ARXIV PREPRINT ARXIV	49	212	220	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					896	+		10.1096/fj.01-0952fje	http://dx.doi.org/10.1096/fj.01-0952fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039872				2022-12-25	WOS:000175425900024
J	Vidaltamayo, R; Sanchez-Soto, MC; Hiriart, M				Vidaltamayo, R; Sanchez-Soto, MC; Hiriart, M			Nerve growth factor increases sodium channel expression in pancreatic beta cells: implications for insulin secretion	FASEB JOURNAL			English	Article						NGF; sodium channel type III; RHPA; RT-PCR; electrical activity	B-CELLS; NGF; RAT; DBCAMP; CANINE; GENE; CDNA; FGF	The importance of nerve growth factor (NGF) modulation of pancreatic beta cells is demonstrated by the fact that these cells secrete and respond to this trophic factor. Among NGF effects on beta cells is an increase in Na+ and Ca2+ current densities. This study investigates the mechanisms involved in the NGF-induced increase in Na+ current and the implications of this effect for insulin secretion. The following results were obtained in single beta cells cultured with NGF for 5-7 days: 1) A steady-state level of mRNA coding for type III sodium channel subunit increased twofold compared with that for control cells. 2) The increase in Na+ current density was blocked either by cycloheximide or by actinomycin D, indicating that it is mediated by protein synthesis and mRNA transcription. 3) NGF treatment strengthened, by nearly fourfold, the beta-cell electrical activity; this effect is partially related to the increased Na+ current, because tetrodotoxin (TTX) decreased the duration of the depolarized plateau level. 4) Single beta cells secreted nearly two times more insulin in response to 5.6 or 15.6 mM glucose. This effect was inhibited by TTX, indicating that the enhanced Na+ current plays an important role. These data suggest that NGF could preserve an adequate expression of sodium channels and that impairment of NGF modulation could lead to deficient insulin secretion and diabetes mellitus.	Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biophys, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Hiriart, M (corresponding author), Natl Autonomous Univ Mexico, Inst Fisiol Celular, Dept Biophys, AP 70-253,Ciudad Univ, Mexico City 04510, DF, Mexico.	mhiriart@ifisiol.unam.mx	Vidaltamayo, Roman/A-3613-2014; Vidaltamayo, Roman/V-6035-2019; Hiriart, Marcia/A-3988-2008	Vidaltamayo, Roman/0000-0002-4747-0830; Vidaltamayo, Roman/0000-0002-4747-0830; Hiriart, Marcia/0000-0001-5711-8868				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DARCANGELO G, 1993, J CELL BIOL, V122, P915, DOI 10.1083/jcb.122.4.915; del Pliego MG, 2001, CELL TISSUE RES, V305, P365; EIZIRIK DL, 1991, ENDOCRINOLOGY, V128, P1611, DOI 10.1210/endo-128-3-1611; FARADJI V, 1990, ACTA NEUROL SCAND, V81, P402; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRIART M, 1991, ENDOCRINOLOGY, V128, P3193, DOI 10.1210/endo-128-6-3193; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HIRIART M, 1993, MOL CELL ENDOCRINOL, V93, P63, DOI 10.1016/0303-7207(93)90140-F; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P761, DOI 10.1210/en.136.2.761; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; Madsen OD, 1996, EUR J BIOCHEM, V242, P435, DOI 10.1111/j.1432-1033.1996.435rr.x; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; OSAWA S, 1986, PHYSIOL REV, V66, P887; PHILIPSON LH, 1993, DIABETES, V42, P1372, DOI 10.2337/diabetes.42.9.1372; Pierucci D, 2001, DIABETOLOGIA, V44, P1281, DOI 10.1007/s001250100650; PLANT TD, 1988, PFLUEGERS ARCH EUR J, V414, pS71; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; PRESSEL DM, 1990, J MEMBRANE BIOL, V116, P273, DOI 10.1007/BF01868466; Rosenbaum T, 1996, J MEMBRANE BIOL, V153, P53, DOI 10.1007/s002329900109; Rosenbaum T, 1998, P NATL ACAD SCI USA, V95, P7784, DOI 10.1073/pnas.95.13.7784; Rosenbaum T, 2001, DIABETES, V50, P1755, DOI 10.2337/diabetes.50.8.1755; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vidaltamayo R, 1996, ENDOCRINE, V4, P19, DOI 10.1007/BF02738870	26	28	32	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2002	16	6					891	+		10.1096/fj.01-0934fje	http://dx.doi.org/10.1096/fj.01-0934fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039870				2022-12-25	WOS:000175425900027
J	Steadman, BT; Schmidt, PH; Shanks, RA; Lapierre, LA; Goldenring, JR				Steadman, BT; Schmidt, PH; Shanks, RA; Lapierre, LA; Goldenring, JR			Transforming acidic coiled-coil-containing protein 4 interacts with centrosomal AKAP350 and the mitotic spindle apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA REGULATORY SUBUNIT; ANCHORING PROTEIN; KINASE-A; SCAFFOLD PROTEINS; BINDING-PROTEIN; NMDA RECEPTOR; GENE FAMILY; RII-ALPHA; CG-NAP; D-TACC	AKAP350 is a multiply spliced family of 350-450-kDa protein kinase A-anchoring proteins localized to the centrosomes and the Golgi apparatus. Using AKAP350A as bait in a yeast two-hybrid screen of a rabbit parietal cell library, we have identified a novel AKAP350-interacting protein, transforming acidic coiled-coil-containing protein 4 (TACC4). Two-hybrid binary assays demonstrate interaction of both TACC3 and TACC4 with AKAP350A and AKAP350B. Antibodies raised to a TACC4-specific peptide sequence colocalize TACC4 with AKAP350 at the centrosome in interphase Jurkat cells. Mitotic cell staining reveals translocation of TACC4 from the centrosome to the spindle apparatus with the majority of TACC4 at the spindle poles. Truncated TACC4 proteins lacking the AKAP350 minimal binding domain found in the carboxyl coiled-coil region of TACC4 could no longer target to the centrosome. Amino-truncated TACC4 proteins could no longer target to the spindle apparatus. Further, overexpression of TACC4 fusion proteins that retained spindle localization in mitotic cells resulted in an increased proportion of cells present in prometaphase. We propose that AKAP350 is responsible for sequestration of TACC4 to the centrosome in interphase, whereas a separate TACC4 domain results in functional localization of TACC4 to the spindle apparatus in mitotic cells.	Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Inst Mol Med & Genet, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Goldenring, JR (corresponding author), Vanderbilt Univ, Dept Surg, CC-2306 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jim.goldenring@vanderbilt.edu			NIDDK NIH HHS [DK48370, DK43405] Funding Source: Medline; NIGMS NIH HHS [GM19731] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370, R01DK043405, R29DK043405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019731] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Carlson CR, 2001, J CELL SCI, V114, P3243; CARR DW, 1991, J BIOL CHEM, V266, P14188; Charrasse S, 1998, J CELL SCI, V111, P1371; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Diviani D, 2001, J CELL SCI, V114, P1431; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 1999, FEBS LETT, V464, P174, DOI 10.1016/S0014-5793(99)01585-9; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Inaba K, 1998, J CELL SCI, V111, P1105; Keryer G, 1998, J BIOL CHEM, V273, P34594, DOI 10.1074/jbc.273.51.34594; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Lin JW, 1998, J NEUROSCI, V18, P2017; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	48	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30165	30176		10.1074/jbc.M201914200	http://dx.doi.org/10.1074/jbc.M201914200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12015314	hybrid			2022-12-25	WOS:000177509300101
J	Vieyra, D; Loewith, R; Scott, M; Bonnefin, P; Boisvert, FM; Cheema, P; Pastyryeva, S; Meijer, M; Johnston, RN; Bazett-Jones, DP; McMahon, S; Cole, MD; Young, D; Riabowol, K				Vieyra, D; Loewith, R; Scott, M; Bonnefin, P; Boisvert, FM; Cheema, P; Pastyryeva, S; Meijer, M; Johnston, RN; Bazett-Jones, DP; McMahon, S; Cole, MD; Young, D; Riabowol, K			Human ING1 proteins differentially regulate histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TUMOR-SUPPRESSOR; GENETIC ALTERATIONS; ESSENTIAL COFACTOR; BREAST-CANCER; DNA-REPAIR; C-MYC; P33(ING1); APOPTOSIS; CBP; COMPLEX	ING1 proteins are nuclear, growth inhibitory, and regulate apoptosis in different experimental systems. Here we show that similar to their yeast homologs, human ING1 proteins interact with proteins associated with histone acetyltransferase (HAT) activity, such as TRRAP, PCAF, CBP, and p300. Human ING1 immuno-complexes contain HAT activity, and overexpression of p33(ING1b), but not of p47(ING1a), induces hyperacetylation of histones H3 and H4, in vitro and in vivo at the single cell level. p47ING1a inhibits histone acetylation in vitro and in vivo and binds the histone deacetylase HDAC1. Finally, we present evidence indicating that p33ING1b affects the degree of physical association between proliferating cell nuclear antigen (PCNA) and p300, an association that has been proposed to link DNA repair to chromatin remodeling. Together with the finding that human ING1 proteins bind PCNA in a DNA damage-dependent manner, these data suggest that ING1 proteins provide a direct linkage between DNA repair, apoptosis, and chromatin remodeling via multiple HAT.ING1.PCNA protein complexes.	Univ Calgary, Dept Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biol Mol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Genome Prairie, Calgary, AB T2L 2K7, Canada; Hosp Sick Children, Programme Cell Biol, Toronto, ON M5G 1X8, Canada; Wistar Inst Anat & Biol, Mol Genet Program, Philadelphia, PA 19104 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Calgary; University of Calgary; University of Calgary; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); The Wistar Institute; Princeton University	Riabowol, K (corresponding author), 370 Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Loewith, Robbie J/S-6289-2016; Johnston, Randal/B-9247-2009; Scott, Michelle/C-7445-2013	Loewith, Robbie J/0000-0002-2482-603X; Scott, Michelle/0000-0001-6231-7714; Boisvert, Francois-Michel/0000-0001-8882-8619; McMahon, Steven/0000-0002-3405-1768				BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Boland D, 2000, HYBRIDOMA, V19, P161, DOI 10.1089/02724570050031202; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chen LS, 2001, CANCER RES, V61, P4345; Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258; Cheung KJ, 2001, CANCER RES, V61, P4974; Choy JS, 2001, J BIOL CHEM, V276, P43653, DOI 10.1074/jbc.M102531200; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gunduz M, 2000, CANCER RES, V60, P3143; Ha SH, 2002, CANCER RES, V62, P1275; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Helbing CC, 1997, CANCER RES, V57, P1255; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jager D, 1999, CANCER RES, V59, P6197; Kung AL, 2000, GENE DEV, V14, P272; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Leonard C, 2002, B CANCER, V89, P166; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; MA D, 1999, NAT GENET, V23, P373; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohmori M, 1999, AM J HEMATOL, V62, P118; RASHEED BKA, 1991, CANCER METAST REV, V10, P289; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Scott M, 2001, J CELL SCI, V114, P3455; Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176; Shinoura N, 1999, CANCER RES, V59, P5521; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Takahashi M, 2002, CANCER RES, V62, P2203; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	46	104	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29832	29839		10.1074/jbc.M200197200	http://dx.doi.org/10.1074/jbc.M200197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12015309	hybrid			2022-12-25	WOS:000177509300062
J	Allart, S; Martin, H; Detraves, C; Terrasson, J; Caput, D; Davrinche, C				Allart, S; Martin, H; Detraves, C; Terrasson, J; Caput, D; Davrinche, C			Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of Delta N-p73 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL NEURON DEATH; MURINE CYTOMEGALOVIRUS; P53; APOPTOSIS; INFECTION; PROTEINS; P73; NEUROBLASTOMA; TRANSCRIPTION; IE2	Intrauterine transmission of human cytomegalovirus (HCMV) to the fetus following primary infection in early and late pregnancy usually results in severe neurological handicaps and sensorineural hearing loss with typical migrational anomalies, optic atrophy, disturbed myelination, cerebella hypoplasia, microcephaly, hydrocephaly, and lissencephaly. Recently, evidences raised from the phenotype of p73-deficient mice show that an association may exist between the expression of the TP53 homologous gene and HCMV tropism in the brain, suggesting an implication of p73 in viral persistence. In this study, we demonstrated that HCMV-mediated inhibition of apoptosis only occurs in p73-expressing cells Upon infection, an accumulation of DeltaN-p73alpha isoform, was observed in HCMV-infected p73-positive cells. This phenomenon was shown to be responsible for the subsequent acquired resistance to apoptosis of infected cells. Inhibition of apoptosis in p73-positive cells by HCMV may thus contribute both to virus persistency and abnormal nervous cell survival. This finding provides the first molecular basis for HCMV-associated abnormal embryonic development and neurological defects in newborns.	Sanofi Synthelabo Rech, Mol & Funct Gen Dept, F-31676 Labege, France; CHU Purpan, INSERM, U395, F-31024 Toulouse, France	Sanofi-Aventis; Sanofi France; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Caput, D (corresponding author), Sanofi Synthelabo Rech, Mol & Funct Gen Dept, F-31676 Labege, France.			Detraves, Claire/0000-0003-4170-0786				Abina MA, 1998, GENE THER, V5, P497, DOI 10.1038/sj.gt.3300638; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; BRITT WJ, 1996, FIELDS VIROLOGY, V2, P2493; Cinatl J, 1998, CANCER RES, V58, P367; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; JAULT FM, 1995, J VIROL, V69, P6697, DOI 10.1128/JVI.69.11.6697-6704.1995; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kosugi I, 1998, ACTA NEUROPATHOL, V96, P239, DOI 10.1007/s004010050890; Kovacs A, 1996, AM J PATHOL, V149, P1531; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levrero M, 2000, J CELL SCI, V113, P1661; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MOCARSKI ES, 1996, FIELDS VIROLOGY, V2, P2447; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Muganda P, 1998, CELL MOL BIOL, V44, P321; Muralidhar S, 1996, J VIROL, V70, P8691, DOI 10.1128/JVI.70.12.8691-8700.1996; NIGRO G, 1995, MED PEDIATR ONCOL, V24, P200, DOI 10.1002/mpo.2950240311; Perez-Jimenez A, 1998, REV NEUROLOGIA, V26, P42; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Salvant BS, 1998, J VIROL, V72, P3729, DOI 10.1128/JVI.72.5.3729-3741.1998; Shinmura Y, 1997, AM J PATHOL, V151, P1331; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Wang J, 2001, J MOL MED, V78, P642, DOI 10.1007/s001090000157; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; ZHU H, 1995, J VIROL, V69, P7960, DOI 10.1128/JVI.69.12.7960-7970.1995	33	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29063	29068		10.1074/jbc.M201974200	http://dx.doi.org/10.1074/jbc.M201974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12034725	hybrid			2022-12-25	WOS:000177342600093
J	Gala, FA; Morrison, SL				Gala, FA; Morrison, SL			The role of constant region carbohydrate in the assembly and secretion of human IgD and IgA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCOSYLATION SITES; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; OVINE SUBMAXILLARY MUCIN; ASN-X-THR; AMINO-ACID; FUNCTIONAL-PROPERTIES; CORE-GLYCOSYLATION; OLIGOSACCHARIDE CHAINS; O-GLYCOSYLATION; HINGE REGION	immunoglobulins are glycoproteins, containing N-linked carbohydrates in the heavy chain constant regions of all isotypes and O-linked carbohydrates in the hinge regions of human IgA1 and IgD. A previous study showed that IgD synthesized in the presence of tunicamycin and lacking the three N-linked glycans on the heavy chain was not secreted (Shin, S. U., Wei, D. F., Amin, A. R., Thorbecke, G. J., and Morrison, S. L. (1992) Hum. Antibodies 3, 65-74). The contribution of each of the carbohydrates in the Fc of IgD to assembly and secretion was now analyzed by eliminating the carbohydrate addition sequence, Asn-X-Ser/Thr, through site-directed mutagenesis. Only the carbohydrate nearest the sole disulfide bond between heavy chains, which remained high mannose and appeared to be buried within the folded molecule, was found to be essential for secretion. When IgD lacked that glycan, assembly reached only the heavy/light chain half-molecule stage, and heavy chains were held inside the endoplasmic reticulum. Using benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside (BADG) to inhibit complete O-linked glycosylation, we found that IgA1 and IgD with incomplete hinge carbohydrates were assembled and secreted from cells. Thus, one N-linked glycan plays a structural role in IgD and is required for proper assembly and secretion, but the O-linked carbohydrates in the hinge of IgD and IgA1 are not required for folding and export.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Morrison, SL (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 405 Hilgard Ave, Los Angeles, CA 90095 USA.	sheriem@microbio.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029470, R01AI029470, R01AI039187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI 29470, AI39187] Funding Source: Medline; NIGMS NIH HHS [T32 GM08375] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B; BERG DT, 1993, BLOOD, V81, P1312; BREWER CF, 1986, J BIOL CHEM, V261, P7306; Chuang PD, 1997, J IMMUNOL, V158, P724; Coloma MJ, 1999, J IMMUNOL, V162, P2162; DANGL JL, 1982, CYTOMETRY, V2, P395; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DUBE S, 1988, J BIOL CHEM, V263, P17516; DWEK RA, 1995, BIOCHEM SOC T, V23, P1; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FRUTIGER S, 1988, J BIOL CHEM, V263, P8120; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hayes GR, 1997, BIOCHEMISTRY-US, V36, P5276, DOI 10.1021/bi962884y; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; HUNT LT, 1970, BIOCHEM BIOPH RES CO, V39, P757, DOI 10.1016/0006-291X(70)90270-6; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JEFFERIS R, 1995, IMMUNOL LETT, V44, P111, DOI 10.1016/0165-2478(94)00201-2; Kasturi L, 1997, BIOCHEM J, V323, P415, DOI 10.1042/bj3230415; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19271; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MELLIS SJ, 1983, J BIOL CHEM, V258, P1546; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; Novak J, 2000, MOL IMMUNOL, V37, P1047, DOI 10.1016/S0161-5890(01)00019-0; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; ROGENTINE GN, 1966, J CLIN INVEST, V45, P1467, DOI 10.1172/JCI105454; SCHAEFER HF, 1989, CHIMIA, V43, P1; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; SHIN S-U, 1992, Human Antibodies and Hybridomas, V3, P65; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1994, J BIOL CHEM, V269, P4979; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SIDMAN C, 1981, J BIOL CHEM, V256, P9374; STEVENSON SC, 1993, BIOCHEMISTRY-US, V32, P5121, DOI 10.1021/bi00070a021; TAKAHASHI N, 1982, P NATL ACAD SCI-BIOL, V79, P2850, DOI 10.1073/pnas.79.9.2850; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; WILLIAMS AM, 1991, J BIOL CHEM, V266, P17648; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; WRIGHT A, 1991, EMBO J, V10, P2717, DOI 10.1002/j.1460-2075.1991.tb07819.x; WYSS DF, 1993, BIOCHEMISTRY-US, V32, P10995, DOI 10.1021/bi00092a008; YAMASHITA Y, 1995, J NATL CANCER I, V87, P441, DOI 10.1093/jnci/87.6.441	55	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29005	29011		10.1074/jbc.M203258200	http://dx.doi.org/10.1074/jbc.M203258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12023968	hybrid			2022-12-25	WOS:000177342600086
J	McClatchy, DB; Knudsen, CR; Clark, BF; Kahn, RA; Hall, RA; Levey, AI				McClatchy, DB; Knudsen, CR; Clark, BF; Kahn, RA; Hall, RA; Levey, AI			Novel interaction between the M-4 muscarinic acetylcholine receptor and elongation factor 1A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; G-PROTEIN; GUANINE-NUCLEOTIDE; FACTOR 1-ALPHA; F-ACTIN; EXPRESSION; FACTOR-1-ALPHA; ACTIVATION; BINDING; PHOSPHORYLATION	The activation of the muscarinic acetylcholine receptor (mAChR) family, consisting of five subtypes (M-1-M-5), produces a variety of physiological effects throughout the central nervous system. However, the role of each individual subtype remains poorly understood. To further elucidate signal transduction pathways for specific subtypes, we used the most divergent portion of the subtypes, the intracellular third (i3) loop, as bait to identify interacting proteins. Using a brain pull-down assay, we identify elongation factor 1A2 (eEF1A2) as a specific binding partner to the i3 loop of M-4, and not to M-1 or M-2. In addition, we demonstrate a direct interaction between these proteins. In the rat striatum, the M4 mAChR colocalizes with eEF1A2 in the soma and neuropil. In PC12 cells, endogenous eEF1A2 co-immunoprecipitates with the endogenous M4 mAChR, but not with the endogenous M, mAChR. In our in vitro model, M4 dramatically accelerates nucleotide exchange of eEF1A2, a GTP-binding protein. This indicates the M, mAChR is a guanine exchange factor for eEF1A2. eEF1A2 is an essential GTP-binding protein for protein synthesis. Thus, our data suggest a novel role for M4 in the regulation of protein synthesis through its interaction with eEF1A2.	Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Dept Neurol, Atlanta, GA 30322 USA; Aarhus Univ, Inst Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University; Aarhus University; Emory University; Emory University	Levey, AI (corresponding author), Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Dept Neurol, Whitehead Biomed Res Bldg,Rm 505,615 Michael St, Atlanta, GA 30322 USA.	alevey@emory.edu	Levey, Allan/F-2104-2011; Kahn, Richard/ABD-2666-2020	Levey, Allan/0000-0002-3153-502X; Kahn, Richard/0000-0002-0259-0601; Knudsen, Charlotte/0000-0003-2356-4821; Hall, Randy/0000-0002-8318-8728	NINDS NIH HHS [NS43094-01, NS30454] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030454, F31NS043094] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berkeley JL, 2000, J NEUROCHEM, V75, P487, DOI 10.1046/j.1471-4159.2000.0750487.x; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BROWN LD, 1993, BRAIN RES, V612, P200, DOI 10.1016/0006-8993(93)91661-B; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Bymaster FP, 1999, LIFE SCI, V64, P527, DOI 10.1016/S0024-3205(98)00597-9; Calabresi P, 2000, TRENDS NEUROSCI, V23, P120, DOI 10.1016/S0166-2236(99)01501-5; Chambers DM, 1998, P NATL ACAD SCI USA, V95, P4463, DOI 10.1073/pnas.95.8.4463; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; Edmonds BT, 1998, J BIOL CHEM, V273, P10288, DOI 10.1074/jbc.273.17.10288; Eisenach JC, 1999, LIFE SCI, V64, P549, DOI 10.1016/S0024-3205(98)00600-6; FEIG S, 1993, J NEUROSCI, V13, P1010; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hellstrom-Lindahl E, 2000, EUR J PHARMACOL, V393, P255, DOI 10.1016/S0014-2999(00)00028-5; HERSCH SM, 1994, J NEUROSCI, V14, P3351; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Khalyfa A, 2001, J BIOL CHEM, V276, P22915, DOI 10.1074/jbc.M101011200; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE S, 1992, J BIOL CHEM, V267, P24064; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; NAGATA S, 1976, BIOCHEM BIOPH RES CO, V71, P933, DOI 10.1016/0006-291X(76)90745-2; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; OLESEN SP, 1988, CIRC RES, V62, P1059, DOI 10.1161/01.RES.62.6.1059; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; RICHARDSON RM, 1991, MOL PHARMACOL, V40, P908; Ruest LB, 2002, J BIOL CHEM, V277, P5418, DOI 10.1074/jbc.M110685200; Sanders J, 1996, J CELL SCI, V109, P1113; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SHIRAYAMA T, 1993, J PHARMACOL EXP THER, V265, P641; Stengel PW, 2000, J PHARMACOL EXP THER, V292, P877; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang WL, 2002, J NEUROSCI, V22, P1709, DOI 10.1523/JNEUROSCI.22-05-01709.2002	53	24	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29268	29274		10.1074/jbc.M203081200	http://dx.doi.org/10.1074/jbc.M203081200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12048193	hybrid			2022-12-25	WOS:000177342600116
J	Zeyda, M; Staffler, G; Horejsi, V; Waldhausl, W; Stulnig, TM				Zeyda, M; Staffler, G; Horejsi, V; Waldhausl, W; Stulnig, TM			LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLIPID-ENRICHED MICRODOMAINS; PROTEIN-TYROSINE KINASE; GPI-ANCHORED PROTEINS; MEMBRANE MICRODOMAINS; INDEPENDENT MECHANISM; POSITIVE SELECTION; FISH-OIL; ACTIVATION; RECEPTOR; TRANSDUCTION	Polyunsaturated fatty acids (PUFAs) suppress immune responses and inhibit T cell activation through largely unknown mechanisms. The displacement of signaling proteins from membrane lipid rafts has recently been suggested as underlying PUFA-mediated T cell inhibition. We show here that PUFA treatment specifically interferes with T cell signal transduction by blocking tyrosine phosphorylation of LAT (linker for activation of T cells) and phospholipase Cgamma1. A significant fraction of IAT was displaced from rafts by PUFA treatment along with other signaling proteins. However, retaining LAT alone in lipid rafts effectively restored phospholipase Cgamma1/calcium. signaling in PUFA-treated T cells. These data reveal LAT displacement from lipid rafts as a molecular mechanism by which PUFAs inhibit T cell signaling and underline the predominant importance of ILAT localization in rafts for efficient T cell activation.	Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria; Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	University of Vienna; University of Vienna; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Stulnig, TM (corresponding author), Univ Vienna, Dept Internal Med 3, Waehringer Guertel 18, A-1090 Vienna, Austria.		Horejsi, Vaclav/G-3113-2014	Horejsi, Vaclav/0000-0003-4925-0142; Zeyda, Maximilian/0000-0001-5000-1974; Stulnig, Thomas/0000-0003-3300-6161				Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BOROFSKY MA, 1992, IMMUNOL RES, V11, P154, DOI 10.1007/BF02918620; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdicka T, 1998, BIOCHEM BIOPH RES CO, V248, P356, DOI 10.1006/bbrc.1998.8857; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALDER PC, 1992, IMMUNOLOGY, V75, P108; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; James MJ, 1997, SEMIN ARTHRITIS RHEU, V27, P85, DOI 10.1016/S0049-0172(97)80009-1; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kosugi A, 1999, INT IMMUNOL, V11, P1395, DOI 10.1093/intimm/11.9.1395; Kosugi A, 2001, IMMUNOL LETT, V76, P133, DOI 10.1016/S0165-2478(01)00174-2; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rossetti RG, 1997, J LEUKOCYTE BIOL, V62, P438, DOI 10.1002/jlb.62.4.438; SANTOLI D, 1989, J IMMUNOL, V143, P1303; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2000, FASEB J, V14, P939, DOI 10.1096/fasebj.14.7.939; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Torgersen KM, 2001, CELL SIGNAL, V13, P213, DOI 10.1016/S0898-6568(01)00131-0; Van Laethem F, 2001, J EXP MED, V193, P803, DOI 10.1084/jem.193.7.803; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	50	136	149	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28418	28423		10.1074/jbc.M203343200	http://dx.doi.org/10.1074/jbc.M203343200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12029091	hybrid			2022-12-25	WOS:000177342600011
J	Scott, MP; Zappacosta, F; Kim, EY; Annan, RS; Miller, WT				Scott, MP; Zappacosta, F; Kim, EY; Annan, RS; Miller, WT			Identification of novel SH3 domain Ligands for the Src family kinase Hck - Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; TYROSINE KINASE; C-SRC; PROCESSIVE PHOSPHORYLATION; ACTIN POLYMERIZATION; CRYSTAL-STRUCTURE; BINDING-PROTEIN; ADAPTER PROTEIN; T-LYMPHOCYTES; THP-1 CELLS	The importance of the SH3 domain of Hck in kinase regulation, substrate phosphorylation, and ligand binding has been established. However, few in vivo ligands are known for the SH3 domain of Hck. In this study, we used mass spectrometry to identify similar to25 potential binding partners for the SH3 domain of Hck from the monocyte cell line U937. Two major interacting proteins were the actin binding proteins Wiskott-Aldrich syndrome protein (WASP) and WASP-interacting protein (WIP). We also focused on a novel interaction between Hck and ELMO1, an 84-kDa protein that was recently identified as the mammalian ortholog of the Caenorhabditis elegans gene, ced-12. In mammalian cells, ELMO1 interacts with Dock180 as a component of the CrkII/Dock180/Rac pathway responsible for phagocytosis and cell migration. Using purified proteins, we confirmed that WASP-interacting protein and ELMO1 interact directly with the SH3 domain of Hck. We also show that Hck and ELMO1 interact in intact cells and that ELMO1 is heavily tyrosine-phosphorylated in cells that co-express Hck, suggesting that it is a substrate of Hck. The binding of ELMO1 to Hck is specifically dependent on the interaction of a polyproline motif with the SH3 domain of Hck. Our results suggest that these proteins may be novel activators/effectors of Hck.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; GlaxoSmithKline, Dept Computat & Struct Sci, King Of Prussia, PA 19406 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; GlaxoSmithKline	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NATIONAL CANCER INSTITUTE [R29CA058530, R01CA058530] Funding Source: NIH RePORTER; NCI NIH HHS [CA58530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Banin S, 1999, MOL BIOL REP, V26, P173, DOI 10.1023/A:1006954206151; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chiaradonna F, 1999, EMBO J, V18, P3013, DOI 10.1093/emboj/18.11.3013; Cicmil M, 2000, J BIOL CHEM, V275, P27339; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Das BK, 1999, MOL CELL BIOL, V19, P6796; Dutcher SK, 2001, CURR OPIN CELL BIOL, V13, P49, DOI 10.1016/S0955-0674(00)00173-3; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Huang S, 2000, J STRUCT BIOL, V129, P233, DOI 10.1006/jsbi.2000.4247; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Judd BA, 2001, ONCOGENE, V20, P6291, DOI 10.1038/sj.onc.1204772; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kedzierska K, 2001, J LEUKOCYTE BIOL, V70, P322; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; King FJ, 1999, MOL CELL BIOL, V19, P2330; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kumar P, 2001, J BIOL CHEM, V276, P21039, DOI 10.1074/jbc.M009099200; Lang V, 1999, J IMMUNOL, V162, P7224; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; LIU XQ, 1993, ONCOGENE, V8, P1119; Lo YF, 2000, BREAST CANCER RES TR, V60, P259, DOI 10.1023/A:1006426400524; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Majeed M, 2001, J LEUKOCYTE BIOL, V70, P801; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mocsai A, 1999, J IMMUNOL, V162, P1120; N'Diaye EN, 1998, J IMMUNOL, V161, P4983; Nair KS, 2001, CELL IMMUNOL, V208, P96, DOI 10.1006/cimm.2001.1772; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ohta S, 1997, BIOCHEM BIOPH RES CO, V237, P307, DOI 10.1006/bbrc.1997.7113; Park C, 1998, MOL CELLS, V8, P518; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Ramesh N, 1999, TRENDS CELL BIOL, V9, P15, DOI 10.1016/S0962-8924(98)01411-1; Sanzenbacher R, 1999, J IMMUNOL, V163, P3143; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Trigwell S, 2000, BIOCHEM BIOPH RES CO, V278, P440, DOI 10.1006/bbrc.2000.3818; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Welch H, 1997, J BIOL CHEM, V272, P102; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	92	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28238	28246		10.1074/jbc.M202783200	http://dx.doi.org/10.1074/jbc.M202783200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12029088	hybrid			2022-12-25	WOS:000177189800082
J	Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y				Peng, YF; Mandai, K; Nakanishi, H; Ikeda, W; Asada, M; Momose, Y; Shibamoto, S; Yanagihara, K; Shiozaki, H; Monden, M; Takeichi, M; Takai, Y			Restoration of E-cadherin-based cell-cell adhesion by overexpression of nectin in HSC-39 cells, a human signet ring cell gastric cancer cell line	ONCOGENE			English	Article						nectin; afadin; cadherin; catenin; cell-cell adhesion	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; ALPHA-CATENIN; JUNCTIONAL COMPLEX; ADHERENS JUNCTION; EPITHELIAL-CELLS; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; ARMADILLO PROTEIN; STRUCTURAL BASIS	Nectin is an immunoglobulin-like adhesion molecule that comprises a family consisting of four members, nectin-1, -2, -3, and -4. Nectin is associated with the actin cytoskeleton through afadin, a nectin- and actin filament-binding protein. The nectin-afadin and cadherin-catenin systems are associated with each other and cooperatively form cell-cell adherens junctions in intact epithelial cells. HSC-39 cells, a human signet ring cell gastric cancer cell line, express E-cadherin but do not form cell-cell adhesion. The beta-catenin gene has been shown to be truncated at the N-terminal region including the alpha-catenin-binding domain in HSC-39 cells, but overexpression of normal beta-catenin failed to form cell-cell adhesion. HSC-39 cells expressed nectin-1, -2, and afadin, but not nectin-3. Overexpression of nectin-3 or -2 formed cell-cell adhesion and accumulation of E-cadherin, but not actin filaments, at the cell-cell adhesion sites. Overexpression of a truncated form of nectin-2 incapable of interacting with afadin failed to form cell-cell adhesion. However, the nectin-formed cell-cell adhesion was not so strong as that observed in epithelial cells, such as CaCo-2 cells. Co-expression of nectin-2 and normal beta-catenin did not form strong cell-cell adhesion. These results suggest that an unidentified mechanism, by which nectin and E-cadherin form the actin cytoskeleton-associated adherens junctions to form strong cell-cell adhesion, is impaired in HSC-39 cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Fac Med, Dept Surg & Clin Oncol, Suita, Osaka 5650871, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Biochem, Hirakata, Osaka 5730101, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan	Osaka University; Osaka University; Setsunan University; National Cancer Center - Japan; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Takeichi, Masatoshi/G-5903-2012; Ikeda, Wataru/V-8531-2019	Takeichi, Masatoshi/0000-0002-9931-3378; Ikeda, Wataru/0000-0002-6907-9058; Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ADAMSON ED, 1990, DEV BIOL, V138, P338, DOI 10.1016/0012-1606(90)90201-S; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; Kemler R, 1992, Semin Cell Biol, V3, P149; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M, 2000, J CELL SCI, V113, P2207; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; YANAGIHARA K, 1991, CANCER RES, V51, P381; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127	58	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4108	4119		10.1038/sj.onc.1205517	http://dx.doi.org/10.1038/sj.onc.1205517			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037667	Bronze			2022-12-25	WOS:000176186000005
J	Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS				Wu, WS; Xu, ZX; Ran, RX; Meng, F; Chang, KS			Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions	ONCOGENE			English	Article						PML; Nur77; transcriptional regulation; apoptosis	CREB BINDING-PROTEIN; RAR-ALPHA; ORPHAN RECEPTOR; GROWTH-FACTORS; NGFI-B; NUCLEAR; GENE; APOPTOSIS; NUR77; TRANSFORMATION	The promyelocytic leukemia protein PML is a tumor and growth suppressor and plays an important role in a multiple pathways of apoptosis and regulation of cell cycle progression. Our previous studies and others also documented a role of PML in transcriptional regulation through its association with transcription coactivator CBP and transcription corepressor HDAC. Here, we showed that PML is a potent transcriptional repressor of Nur77, an orphan receptor and a member of the steroid receptor superfamily of proteins. We found that PML represses Nur77-mediated transactivation through a physical and functional interaction between the two proteins. PML interacts with Nur-77 in vitro in a GST-pull down assay and in vivo by coimmunoprecipitation assay. PML/Nur77 colocalized in vivo in a double immunofluorescent staining and confocal microscopic analysis. Our study further showed that the coiled-coil domain of PML interacts with the DNA-binding domain of Nur77 (amino acids 267-332). Electrophoretic mobility shift assay demonstrated that PML interferes with Nur77 DNA binding in a dose-dependent manner. This study indicates that PML interacts with the DNA-binding domain of Nur77 and represses transcription by preventing it from binding to the target promoter. This study supports a role of PML/Nur77 interaction in regulating cell growth and apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chang, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kchang@mail.mdanderson.org	Wu, Wen-Shu/I-1258-2014	Wu, Wen-Shu/0000-0002-0225-2522	NCI NIH HHS [CA-11627, CA-55577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055577, R01CA011627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CALNAN BJ, 1995, IMMUNITY, V3, P273; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2633, DOI 10.1073/pnas.96.6.2633; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Duprez E, 1999, J CELL SCI, V112, P381; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VALLIAN S, 1998, ONCOGENE, V90, P3265; Wang ZG, 1998, SCIENCE, V279, P1547; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	48	29	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3925	3933		10.1038/sj.onc.1205491	http://dx.doi.org/10.1038/sj.onc.1205491			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032831				2022-12-25	WOS:000175847200012
J	van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG				van Engeland, M; Roemen, GMJM; Brink, M; Paachen, MMM; Weijenberg, MP; de Bruine, AP; Arends, JW; van den Brandt, PA; de Goeij, AFPM; Herman, JG			K-ras mutations and RASSF1A promoter methylation in colorectal cancer	ONCOGENE			English	Article						K-Ras; methylation; RASSF1A; silencing	TUMOR-SUPPRESSOR GENE; FREQUENT EPIGENETIC INACTIVATION; CPG ISLAND; HYPERMETHYLATION; 3P21.3; LUNG; CELL; BREAST; PROTEIN; OVARIAN	Human cancer is characterized by genetic and epigenetic alterations. In this study we provide evidence for the interruption of Ras signaling in sporadic colorectal cancer (CRC) by either genetic activation of the K-ras oncogene or epigenetic silencing of the putative tumor suppressor gene RASSF1A. Paraffin embedded tumor tissue samples from 222 sporadic CRC patients were analysed for K-ras codon 12 and codon 13 activating mutations and RASSF1A promoter hypermethylation. Overall, K-ras mutations were observed in 87 of 222 (39%) and RASSF1A methylation was observed in 45 of 222 (20%) of CRCs. Mutation of K-ras alone was detected in 76 of 222 (34%) CRCs. RASSF1A promoter methylation with wild-type K-ras was observed in 34 of 222 (15%) CRCs. In 101 of 222 (46%) CRCs neither K-ras mutations nor RASSF1A methylation was observed and 11 of 222 (5%) CRCs showed both K-ras mutations and RASSF1A methylation. These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test).	Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA; Univ Maastricht, Dept Pathol, NL-6200 MD Maastricht, Netherlands; Univ Maastricht, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; Maastricht University; Maastricht University	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 1650 Orleans St,Room 543, Baltimore, MD 21231 USA.	hermanji@jhmi.edu	van Engeland, Manon/A-7479-2009	van Engeland, Manon/0000-0002-7952-6843; van den Brandt, Piet/0000-0001-8781-8099				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2000, CANCER RES, V60, P129; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2001, CANCER RES, V61, P8659; Morrissey C, 2001, CANCER RES, V61, P7277; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sparks AB, 1998, CANCER RES, V58, P1130; VANDENBRANDT PA, 1990, J CLIN EPIDEMIOL, V43, P285, DOI 10.1016/0895-4356(90)90009-E; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	25	156	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3792	3795		10.1038/sj.onc.1205466	http://dx.doi.org/10.1038/sj.onc.1205466			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032847	Bronze, Green Submitted			2022-12-25	WOS:000175676000014
J	Miller, WH; Waxman, S				Miller, WH; Waxman, S			Differentiation induction as a treatment for hematologic malignancies	ONCOGENE			English	Review						differentiation therapy; acute promyelocytic leukemia; retinoids; arsenic trioxide; transcriptional repression	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; HISTONE DEACETYLASE; IN-VITRO; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; COMPLETE REMISSION		Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res & SMBD, Montreal, PQ H3T 1E2, Canada	Icahn School of Medicine at Mount Sinai; Lady Davis Institute; McGill University	Waxman, S (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.	Samuel.Wadman@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA059936, R01CA085748] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85748, R01 CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Chikayama S, 1998, HAEMATOLOGIA, V29, P115; COMIC M, 1994, LEUKEMIA, V8, P914; Cote S, 2000, BLOOD, V96, P3200, DOI 10.1182/blood.V96.9.3200.h8003200_3200_3208; CUNNINGHAM ML, 1994, EUR J BIOCHEM, V221, P285, DOI 10.1111/j.1432-1033.1994.tb18740.x; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dalla-Favera Riccardo, 1996, P139; Davis AF, 1997, J CELL BIOCHEM, V65, P308, DOI 10.1002/(SICI)1097-4644(19970601)65:3<308::AID-JCB2>3.0.CO;2-W; DAVISON K, 1999, AM ASS CANC RES, V40, P120; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; DELVA L, 1993, BLOOD, V82, P2175; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Douer D, 2001, BLOOD, V97, P73, DOI 10.1182/blood.V97.1.73; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FENAUX P, 1994, LEUKEMIA, V8, pS42; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; Ferrari A C, 1994, Cancer Chemother Biol Response Modif, V15, P337; Finch RA, 2000, BLOOD, V96, P2262; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GambacortiPasserini C, 1996, BLOOD, V88, P1411, DOI 10.1182/blood.V88.4.1411.bloodjournal8841411; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 2001, CURR TOP MICROBIOL, V254, P165; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HASSAN HT, 1991, EUR J CLIN PHARMACOL, V41, P531, DOI 10.1007/BF00314980; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Hozumi M, 1998, INT J HEMATOL, V68, P107; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YC, 1998, CLIN CANCER RES, V4, P2503; Huang Yicong, 1994, Molecular and Cellular Differentiation, V2, P83; Huang Yicong, 1995, Molecular and Cellular Differentiation, V3, P241; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2000, BLOOD, V96, p309A; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Makishima M, 1999, BIOCHEM PHARMACOL, V57, P521, DOI 10.1016/S0006-2952(98)00329-3; MANN KK, 2001, JOINT INT C APL DIFF, P44; MATUSHANSKY I, 2000, FRONT BIOSCI, V5, pD4848; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; Nervi C, 1998, BLOOD, V92, P2244; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Niitsu N, 1997, BIOCHEM BIOPH RES CO, V238, P100, DOI 10.1006/bbrc.1997.7250; Niitsu N, 1999, LEUKEMIA LYMPHOMA, V34, P261, DOI 10.3109/10428199909050951; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick S, 1999, BLOOD, V94, p61A; Novitzky N, 2000, AM J HEMATOL, V63, P212, DOI 10.1002/(SICI)1096-8652(200004)63:4<212::AID-AJH9>3.0.CO;2-D; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; RAZA A, 1993, AM J HEMATOL, V42, P147, DOI 10.1002/ajh.2830420202; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; ROWINSKY EK, 1992, LEUKEMIA, V6, P526; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Saba H I, 2001, Cancer Control, V8, P79; Sanz MA, 2000, BLOOD, V96, P1247; SCHER BM, 1982, CANCER RES, V42, P1300; SCHER W, 1983, CURRENT CONCEPTS ERY, P301; SCHWARTZ EL, 1983, CANCER RES, V43, P2725; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shiohara M, 2001, CANCER RES, V61, P3361; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STRAIR RK, 2001, JOINT INT C APL DIFF, P39; SUH N, 1999, CANCER RES, P336; Takeuchi M, 1998, LEUKEMIA LYMPHOMA, V31, P441, DOI 10.3109/10428199809057604; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Teofili L, 2001, BLOOD, V98, P495, DOI 10.1182/blood.V98.2.495; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; TRUMP DL, 2001, JOINT INT C APL DIFF, V47; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Wang JX, 1999, CANCER RES, V59, P2766; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; WAXMAN S, 1990, CANCER RES, V50, P3878; WAXMAN S, 2001, JOINT INT C APL DIFF, P22; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WITCHER M, 2001, JOINT INT C APL DIFF, P28; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	118	24	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3496	3506		10.1038/sj/onc/1205328	http://dx.doi.org/10.1038/sj/onc/1205328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032784				2022-12-25	WOS:000175633300019
J	Kim, CS; Lee, SH; Kim, RY; Kim, BJ; Li, SZ; Lee, IH; Lee, EJ; Lim, SK; Bae, YS; Lee, W; Baik, JH				Kim, CS; Lee, SH; Kim, RY; Kim, BJ; Li, SZ; Lee, IH; Lee, EJ; Lim, SK; Bae, YS; Lee, W; Baik, JH			Identification of domains directing specificity of coupling to G-proteins for the melanocortin MC3 and MC4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; MOLECULAR-CLONING; ACTIVATION; OBESITY; SELECTIVITY; MUTAGENESIS; EXPRESSION; PATHWAYS; RESIDUE; WEIGHT	The melanocortin receptors, MC3R and MC4R, are G protein-coupled receptors that are involved in regulating energy homeostasis. Using a luciferase reporter gene under the transcriptional control of a cAMP-responsive element (CRE), the coupling efficiency of the MC4R and MC3R to G-proteins was previously shown to be different. MC4R exhibited only 30-50% of the maximum activity induced by MC3R. To assess the role of the different MC3R and MC4R domains in G-protein coupling, several chimeric MC3R/MC4R receptors were constructed. The relative luciferase activities, which were assessed after transfecting the chimeric receptors into HEK 293T cells, showed that the i3 (3rd intracellular) loop domain has an essential role in the differential signaling of MC3R and MC4R. To reveal which amino acid residue was involved in the MC4R-specific signaling in the i3 loop, a series of mutant MC4Rs was constructed. Reporter gene analysis showed that single mutations of Arg(220) to Ala and Thr(232) to either Val or Ala increased the relative luciferase activities, which suggests that these specific amino acids, Arg(220) and Thr(232), in the i3 loop of MC4R play crucial roles in G-protein coupling and the subtype-specific signaling pathways. An examination of the inositol phosphate (IP) levels in the cells transfected with either MC3R or MC4R after being exposed to the melanocortin peptides revealed significant stimulation of IP production by MC3R but no detectable increase in IP production was observed by MC4R. Furthermore, none of the MC4R mutants displayed melanocortin peptide-stimulated IP production. Overall, this study demonstrated that MC3R and MC4R have distinct signaling in either the cAMP. or the inositol phospholipid-mediated pathway with different conformational requirements.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Med Res Ctr,Brain Korea Project Med Sci 21, Mol Biol Lab,Dept Pharmacol, Seoul 120752, South Korea	Ewha Womans University; Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Baik, JH (corresponding author), Yonsei Univ, Coll Med, Med Res Ctr,Brain Korea Project Med Sci 21, Mol Biol Lab,Dept Pharmacol, Seoul 120752, South Korea.		LEE, WEON TAE/AAQ-9088-2021; LEE, IN HYE/T-2714-2019	LEE, IN HYE/0000-0003-2334-3594; Lee, Weontae/0000-0003-2347-1262; Lee, Eun-Jin/0000-0001-5718-542X; Lee, Soohyun/0000-0003-1532-7041				Adan RAH, 2000, EUR J PHARMACOL, V405, P13, DOI 10.1016/S0014-2999(00)00537-9; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BAIK JH, 1996, METHODS NEUROSCI, V29, P75; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Cummings DE, 2000, NAT GENET, V26, P8, DOI 10.1038/79223; De Wied D, 1991, Methods Achiev Exp Pathol, V15, P167; DEWIED D, 1982, PHYSIOL REV, V62, P976, DOI 10.1152/physrev.1982.62.3.976; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KONDA Y, 1994, J BIOL CHEM, V269, P13162; KOZELL LB, 1994, J BIOL CHEM, V269, P30199; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lee EJ, 2001, EUR J BIOCHEM, V268, P582, DOI 10.1046/j.1432-1327.2001.01900.x; LEE NH, 1993, J BIOL CHEM, V268, P7949; Lembo PMC, 1997, MOL PHARMACOL, V52, P164, DOI 10.1124/mol.52.1.164; Li SJ, 1996, J NEUROSCI, V16, P5182; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Malmberg A, 2000, J NEUROCHEM, V75, P1283, DOI 10.1046/j.1471-4159.2000.751283.x; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Picetti R, 1997, CRIT REV NEUROBIOL, V11, P121, DOI 10.1615/CritRevNeurobiol.v11.i2-3.20; Raffin-Sanson ML, 2001, EUR J ENDOCRINOL, V144, P207, DOI 10.1530/eje.0.1440207; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SMITH EM, 1992, P NATL ACAD SCI USA, V89, P782, DOI 10.1073/pnas.89.2.782; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339	40	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31310	31317		10.1074/jbc.M112085200	http://dx.doi.org/10.1074/jbc.M112085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	12045190	Green Published, hybrid			2022-12-25	WOS:000177718700006
J	Tsuiji, M; Fujimori, M; Ohashi, Y; Higashi, N; Onami, TM; Hedrick, SM; Irimura, T				Tsuiji, M; Fujimori, M; Ohashi, Y; Higashi, N; Onami, TM; Hedrick, SM; Irimura, T			Molecular cloning and characterization of a novel mouse macrophage C-type lectin, mMGL2, which has a distinct carbohydrate specificity from mMGL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EPITOPE; CYSTEINE-RICH DOMAIN; ASIALOGLYCOPROTEIN RECEPTOR; MANNOSE RECEPTOR; SENSITIZATION PHASE; RECOGNITION DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; GENE-COMPLEX; HOST-DEFENSE	A novel mouse macrophage galactose-type C-type lectin 2 (mMGL2) was identified by BLAST analysis of expressed sequence tags. The sequence of mMGL2 is highly homologous to the mMGL, which should now be called mMGL1. The open reading frame of mMGL2 contains a sequence corresponding to a type 11 transmembrane protein with 332 amino acids having a single extracellular C-type lectin domain. The W-untranslated region included long terminal repeats of mouse early transposon. The Mgl2 gene was cloned from a 129/SvJ mouse genomic library and sequenced. The gene spans 7,136 base pairs and consists of 10 exons, which is similar to the genomic organization of mMGL1. The reverse transcriptase-PCR analysis indicates that mMGL2 is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner, also very similar to that of mMGL1. The mMGL2 mRNA was also detected in mMGL1-positive cells, which were sorted from thioglycollate-induced peritoneal cells with a mMGL1-specific monoclonal antibody, LOM-8.7. The soluble recombinant proteins of mMGL2 exhibited carbohydrate specificity for alpha- and beta-GalNAc-conjugated soluble polyacrylamides, whereas mMGL1 preferentially bound Lewis X-conjugated soluble polyacrylamides in solid phase assays. These two lectins may function cooperatively as recognition and endocytic molecules on macrophages and related cells.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of Tokyo; University of California System; University of California San Diego; University of California System; University of California San Diego	Irimura, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	irimura@mol.f.u-tokyo.ac.jp	Hedrick, Stephen M/E-9171-2010; Fujimori, Maiko/N-2883-2019; Tsuiji, Makoto/G-1411-2010	Tsuiji, Makoto/0000-0002-5607-4880; Hedrick, Stephen/0000-0002-6345-8751				Bider MD, 1998, FEBS LETT, V434, P37, DOI 10.1016/S0014-5793(98)00947-8; BLACKBURN CC, 1995, GENOMICS, V26, P308, DOI 10.1016/0888-7543(95)80215-8; Braun JR, 1996, J BIOL CHEM, V271, P21160, DOI 10.1074/jbc.271.35.21160; Brown MG, 1997, GENOMICS, V42, P16, DOI 10.1006/geno.1997.4721; Chun KH, 2000, INT IMMUNOL, V12, P1695, DOI 10.1093/intimm/12.12.1695; Chun KH, 2000, J LEUKOCYTE BIOL, V68, P471; COLLINS JC, 1984, HEPATOLOGY, V4, P80, DOI 10.1002/hep.1840040114; Denda-Nagai K, 2002, GLYCOBIOLOGY, V12, P443, DOI 10.1093/glycob/cwf061; Feizi T, 2000, IMMUNOL REV, V173, P79, DOI 10.1034/j.1600-065X.2000.917310.x; Higashi N, 2002, INT IMMUNOL, V14, P545, DOI 10.1093/intimm/dxf021; Higashi N, 2002, J BIOL CHEM, V277, P20686, DOI 10.1074/jbc.M202104200; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; Ichii S, 1997, J LEUKOCYTE BIOL, V62, P761, DOI 10.1002/jlb.62.6.761; Ichii S, 2000, CANCER IMMUNOL IMMUN, V49, P1, DOI 10.1007/s002620050021; Iida SI, 1999, J BIOL CHEM, V274, P10697, DOI 10.1074/jbc.274.16.10697; Imai Y, 1995, IMMUNOLOGY, V86, P591; KAWAKAMI K, 1994, JPN J CANCER RES, V85, P744, DOI 10.1111/j.1349-7006.1994.tb02423.x; Kimura T, 2000, MOL IMMUNOL, V37, P151, DOI 10.1016/S0161-5890(00)00027-4; KIMURA T, 1995, J BIOL CHEM, V270, P16056, DOI 10.1074/jbc.270.27.16056; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; LEWIS CE, 1992, MACROPHAGE NATURAL I, P1; Linehan SA, 2000, MICROBES INFECT, V2, P279, DOI 10.1016/S1286-4579(00)00300-2; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mager DL, 2000, J VIROL, V74, P7221, DOI 10.1128/JVI.74.16.7221-7229.2000; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; Mizuochi S, 1998, GLYCOCONJUGATE J, V15, P397, DOI 10.1023/A:1006930019886; Mizuochi S, 1997, GLYCOBIOLOGY, V7, P137, DOI 10.1093/glycob/7.1.137; Onami TM, 2002, MOL CELL BIOL, V22, P5173, DOI 10.1128/MCB.22.14.5173-5181.2002; OZAKI K, 1992, J BIOL CHEM, V267, P9229; Ruiz NI, 1996, GLYCOBIOLOGY, V6, P551, DOI 10.1093/glycob/6.5.551; SAKAMAKI T, 1995, J LEUKOCYTE BIOL, V57, P407, DOI 10.1002/jlb.57.3.407; Sato K, 1998, J IMMUNOL, V161, P6835; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Suzuki N, 1996, J IMMUNOL, V156, P128; Tanaka I, 2001, VIROLOGY, V280, P107, DOI 10.1006/viro.2000.0732; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Tsuiji M, 1999, IMMUNOGENETICS, V50, P67, DOI 10.1007/s002510050687; Valladeau J, 2001, J IMMUNOL, V167, P5767, DOI 10.4049/jimmunol.167.10.5767; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wragg S, 1999, J BIOL CHEM, V274, P35400, DOI 10.1074/jbc.274.50.35400; YAMAMOTO K, 1994, BIOCHEMISTRY-US, V33, P8159, DOI 10.1021/bi00192a021; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	44	98	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28892	28901		10.1074/jbc.M203774200	http://dx.doi.org/10.1074/jbc.M203774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12016228	hybrid			2022-12-25	WOS:000177342600073
J	Jones, LR; Cornea, RL; Chen, ZH				Jones, LR; Cornea, RL; Chen, ZH			Close proximity between residue 30 of phospholamban and cysteine 318 of the cardiac Ca2+ pump revealed by intermolecular thiol cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RESTRAINED MOLECULAR-DYNAMICS; RESONANCE ENERGY-TRANSFER; FACTOR EGF RECEPTOR; SWISS 3T3 CELLS; SIGNAL-TRANSDUCTION; EXTRACELLULAR DOMAIN; INTERFACE PEPTIDES; ERYTHROPOIETIN RECEPTOR; MONOCLONAL-ANTIBODIES	Phospholamban (PLB) is a 52-amino acid inhibitor of the Ca2+-ATPase in cardiac sarcoplasmic reticulum (SERCA2a), which acts by decreasing the apparent affinity of the enzyme for Ca2+. To localize binding sites of SERCA2a for PLB, we performed Cys-scanning mutagenesis of PLB, co-expressed the PLB mutants with SERCA2a in insect cell microsomes, and tested for cross-linking of the mutated PLB molecules to SERCA2a using 1,6-bismaleimidohexane, a 10-Angstrom-long, homobifunctional thiol cross-linking agent. Of several mutants tested, only PLB with a Cys replacement at position 30 (N30C-PLB) cross-linked to SERCA2a. Cross-linking occurred specifically and with high efficiency. The process was abolished by micromolar Ca2+ or by an anti-PLB monoclonal antibody and was inhibited 50% by phosphorylation of PLB by cAMP-dependent protein kinase. The SERCA2a inhibitors thapsigargin and cyclopiazonic acid also completely prevented cross-linking. The two essential requirements for cross-linking of N30C-PLB to SERCA2a were a Ca2+-free enzyme and, unexpectedly, a micromolar concentration of ATP or ADP, demonstrating that N30C-PLB cross-links preferentially to the nucleotide-bound, E2 state of SERCA2a. Sequencing of a purified proteolytic fragment in combination with SERCA2a mutagenesis identified Cys(318) of SERCA2a as the sole amino acid cross-linked to N30C-PLB. The proximity of residue 30 of PLB to Cys(318) of SERCA2a suggests that PLB may interfere with Ca2+ activation of SERCA2a by a protein interaction occurring near transmembrane helix M4.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Jones, LR (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, 1800 N Capitol Ave, Indianapolis, IN 46202 USA.			Cornea, Razvan/0000-0001-5739-0992	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, R37HL049428] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49428] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; Berezov A., 2001, BIAJOURNAL, V8, P4; CARRAWAY KL, 1990, BIOCHEMISTRY-US, V29, P8741, DOI 10.1021/bi00489a034; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cochran JR, 2001, TRENDS BIOCHEM SCI, V26, P304, DOI 10.1016/S0968-0004(01)01815-1; Crottet P, 1999, J BIOL CHEM, V274, P31445, DOI 10.1074/jbc.274.44.31445; Crouch MF, 2000, IMMUNOL CELL BIOL, V78, P408, DOI 10.1046/j.1440-1711.2000.00929.x; Crouch MF, 2001, J CELL BIOL, V152, P263, DOI 10.1083/jcb.152.2.263; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1988, ONCOGENE, V2, P273; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hirai H, 2001, NEUROSCI RES, V39, P261, DOI 10.1016/S0168-0102(00)00237-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Kamboj S, 1998, CURR BIOL, V8, pR719, DOI 10.1016/S0960-9822(98)70457-9; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Krawczyk C, 2001, J LEUKOCYTE BIOL, V69, P317; Kumagai T, 2001, P NATL ACAD SCI USA, V98, P5526, DOI 10.1073/pnas.071060598; Kwong E, 2000, NEUROREPORT, V11, P2703, DOI 10.1097/00001756-200008210-00019; Landgraf R, 2000, BIOCHEMISTRY-US, V39, P8503, DOI 10.1021/bi000953+; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Li H, 1997, PROTEIN SCI, V6, P956, DOI 10.1002/pro.5560060502; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; Nagy P, 1999, J CELL SCI, V112, P1733; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; Naismith JH, 1996, J MOL RECOGNIT, V9, P113, DOI 10.1002/(SICI)1099-1352(199603)9:2<113::AID-JMR253>3.0.CO;2-H; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Peczuh MW, 2000, CHEM REV, V100, P2479, DOI 10.1021/cr9900026; Prasanna V, 1998, BIOCHEMISTRY-US, V37, P6883, DOI 10.1021/bi9720989; Prevost JM, 2000, CYTOKINE, V12, P187, DOI 10.1006/cyto.1999.0527; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Sitrin RG, 2000, J IMMUNOL, V165, P3341, DOI 10.4049/jimmunol.165.6.3341; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tejero R, 1996, PROTEIN SCI, V5, P578; Tulloch PA, 1999, J STRUCT BIOL, V125, P11, DOI 10.1006/jsbi.1998.4066; TZAHAR E, 1997, EMBO J, V16, P1938; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; WELS W, 1992, CANCER RES, V52, P6310; WELS W, 1992, J STEROID BIOCHEM, V43, P1, DOI 10.1016/0960-0760(92)90180-Q; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; XU FJ, 1994, INT J CANCER, V59, P242, DOI 10.1002/ijc.2910590217; Yudt MR, 2001, STEROIDS, V66, P549, DOI 10.1016/S0039-128X(00)00224-5; Zhang HT, 1999, EXP MOL PATHOL, V67, P15, DOI 10.1006/exmp.1999.2266; Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7	70	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28319	28329		10.1074/jbc.M204085200	http://dx.doi.org/10.1074/jbc.M204085200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12015326	hybrid			2022-12-25	WOS:000177189800091
J	Mamidipudi, V; Li, XX; Wooten, MW				Mamidipudi, V; Li, XX; Wooten, MW			Identification of interleukin 1 receptor-associated kinase as a conserved component in the p75-neurotrophin receptor activation of nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; P75 NEUROTROPHIN RECEPTOR; INTERACTING PROTEIN P62; SIGNAL-TRANSDUCTION; PC12 CELLS; SURVIVAL; BINDING; DORSAL; DEATH	The neurotrophin nerve growth factor (NGF) supports neuronal survival by activating the transcription factor nuclear factor-kappaB (NF-kappaB). We report here, for the first time, the identification of p75-associated kinase that mediates NGF-driven NF-kappaB activation. Using coimmunoprecipitation, we demonstrate an NGF-dependent association of interleukin 1 receptor-associated kinase (IRAK) with the p75 neurotrophin receptor in PC 12 cells. Our results reveal that IRAK is recruited to the p75-NGF receptor leading to formation of a complex between IRAK, atypical protein kinase C interacting protein, p62, and TRAF6. Activation of NF-kappaB occurs predominantly through the p75 receptor, and TrkA activity suppresses NF-kappaB activation and retards IkappaBbeta degradation. In addition, we observe a requirement for the kinase activity of IRAK in mediating NGF-induced NF-kappaB activation, recruitment of the adapter protein p62 to the p75 receptor, and cell survival. Moreover, p75-IRAK-mediated kappaB activation and the recruitment of IKKbeta, but not IKKalpha, to the receptor require p62. Altogether, our data provide novel information regarding the proximal components involved in p75 receptor signaling and underscore the importance of the atypical PKC interacting protein p62 in this process.	Auburn Univ, Dept Sci Biol, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Auburn University System; Auburn University; Cleveland Clinic Foundation	Wooten, MW (corresponding author), Auburn Univ, Dept Sci Biol, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	Wootemw@auburn.edu			PHS HHS [33661] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buck H, 1996, J NEUROCHEM, V67, P345; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Cosgaya JM, 2001, J NEUROCHEM, V79, P391, DOI 10.1046/j.1471-4159.2001.00573.x; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Foehr ED, 2000, J NEUROSCI, V20, P7556; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAMNOUE M, 1999, MOL CELL NEUROSCI, V14, P28; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Ladiwala U, 1998, J NEUROSCI, V18, P1297; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Vig E, 2001, J BIOL CHEM, V276, P7859, DOI 10.1074/jbc.M010399200; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zapata JM, 2000, J BIOL CHEM, V275, P12102, DOI 10.1074/jbc.275.16.12102; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	61	61	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28010	28018		10.1074/jbc.M109730200	http://dx.doi.org/10.1074/jbc.M109730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12034707	hybrid			2022-12-25	WOS:000177189800055
J	Xu, YX; Wu, RF; Gu, Y; Yang, YS; Yang, MC; Nwariaku, FE; Terada, LS				Xu, YX; Wu, RF; Gu, Y; Yang, YS; Yang, MC; Nwariaku, FE; Terada, LS			Involvement of TRAF4 in oxidative activation of c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC OXIDASE COMPONENTS; RESPIRATORY BURST OXIDASE; ADAPTED ENDOTHELIAL-CELLS; ABL TYROSINE KINASE; KAPPA-B ACTIVATION; NADPH OXIDASE; PROTEIN-KINASE; NEUROTROPHIN RECEPTOR; BREAST-CARCINOMA; ADHESION KINASE	We previously found that the angiogenic factors TNFalpha and HIV-1 Tat activate an NAD(P)H oxidase in endothelial cells, which operates upstream of c-Jun N-terminal kinase (JNK), a MAPK involved in the determination of cell fate. To further understand oxidant-related signaling pathways, we screened lung and endothelial cell libraries for interaction partners of p47(phox) and recovered the orphan adapter TNF receptor-associated factor 4 (TRAF4). Domain analysis suggested a tail-to-tail interaction between the C terminus of p47(phox) and the conserved TRAF domain of TRAF4. In addition, TRAF4, like p47(phox), was recovered largely in the cytoskeleton/membrane fraction. Coexpression of p47(phox) and TRAF4 increased oxidant production and JNK activation, whereas each alone had minimal effect. In addition, a fusion between p47(phox) and the TRAF4 C terminus constitutively activated JNK, and this activation was decreased by the antioxidant N-acetyl cysteine. In contrast, overexpression of the p47(phox) binding domain of TRAF4 blocked endothelial cell JNK activation by TNFalpha and HIV-1 Tat, suggesting an uncoupling of p47(phox) from upstream signaling events. A secondary screen of endothelial cell proteins for TRAF4-interacting partners yielded a number of proteins known to control cell fate. We conclude that endothelial cell agonists such as TNFalpha and HIV-1 Tat initiate signals that enter basic signaling cassettes at the level of TRAF4 and an NAD(P)H oxidase. We speculate that endothelial cells may target endogenous oxidant production to specific sites critical to cytokine signaling as a mechanism for increasing signal specificity and decreasing toxicity of these reactive species.	Dallas VAMC, Dallas, TX 75216 USA; Univ Texas SW, Dept Internal Med, Dallas, TX 75216 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Dallas VAMC, Mail Code 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.			Terada, Lance/0000-0001-7441-9734	NHLBI NIH HHS [R01-HL61897, R01 HL061897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061897] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Asumalahti K, 2000, HUM MOL GENET, V9, P1533, DOI 10.1093/hmg/9.10.1533; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Dadgostar H, 2000, J BIOL CHEM, V275, P2539, DOI 10.1074/jbc.275.4.2539; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Gu Y, 2001, VIROLOGY, V286, P62, DOI 10.1006/viro.2001.0998; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Krajewska M, 1998, AM J PATHOL, V152, P1549; Ling L, 2000, J BIOL CHEM, V275, P23852, DOI 10.1074/jbc.M001095200; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manevich Y, 2001, AM J PHYSIOL-HEART C, V280, pH2126, DOI 10.1152/ajpheart.2001.280.5.H2126; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; Morozov I, 1998, J BIOL CHEM, V273, P15435, DOI 10.1074/jbc.273.25.15435; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Saltzman A, 1998, FEBS LETT, V425, P431, DOI 10.1016/S0014-5793(98)00287-7; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; Shiels H, 2000, AM J PATHOL, V157, P679, DOI 10.1016/S0002-9440(10)64578-6; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yang YS, 2001, AM J RESP CELL MOL, V24, P30, DOI 10.1165/ajrcmb.24.1.4050; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yonekura H, 1999, NUCLEIC ACIDS RES, V27, P2591, DOI 10.1093/nar/27.13.2591; Zapata JM, 2000, J BIOL CHEM, V275, P12102, DOI 10.1074/jbc.275.16.12102	58	67	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28051	28057		10.1074/jbc.M202665200	http://dx.doi.org/10.1074/jbc.M202665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12023963	hybrid			2022-12-25	WOS:000177189800060
J	Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P				Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P			Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages	ONCOGENE			English	Article						macrophage; proliferation; MAPK; fes; MCSF	PROTEIN PHOSPHATASE 2A; MAP-KINASE; TRANSFORMING ACTIVITY; TYROSINE KINASE; V-RAF; GROWTH; ACTIVATION; SPECIFICITY; FAMILY; PATHWAYS	We had previously shown that murine macrophages expressing v-Fes, the oncogenically activated counterpart of the c-Fes cytoplasmic tyrosine kinase, proliferate independently of Macrophage Colony-Stimulating Factor (MCSF) and that the Extracellular signal-Regulated Kinase (ERK) pathway mediates the mitogenic effect of v-Fes. In this study, the response of c-fes- and v-fes-overexpressing cells to MCSF was investigated. A critical modulation of the activation of Mitogen-activated ERK Kinase (MEK) and ERK based on the MCSF dose was characterized. ERK activation was increased by MCSF doses capable to elicit a mitogenic response (2-5 U/ml). On the contrary, MCSF doses as low as 0.05 U/ml markedly reduced ERK phosphorylation and nuclear content and moderately but significantly reduced cell proliferation. The reduction of MEK and ERK phosphorylation was very rapid, suggesting the involvement of cytosolic phosphatases. Among these, phospho-tyrosine protein phosphatases and phosphoserine/threonine protein phosphatase-2A were found involved. These findings represent the first observation that different doses of the same growth factor, MCSF in particular, can exert opposite effects on cell proliferation by switching on or off ERK signaling.	Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Vienna, Inst Microbiol & Genet, Vienna Bioctr, A-1090 Vienna, Austria	University of Florence; University of Vienna; Vienna Biocenter (VBC)	Dello Sbarba, P (corresponding author), Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	persio@unifi.it	Baccarini, Manuela/B-6481-2014; Dello Sbarba, Persio/AAX-9887-2020; Rovida, Elisabetta/F-3565-2015	Baccarini, Manuela/0000-0002-3033-391X; Rovida, Elisabetta/0000-0002-5949-3239				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUSCHER D, 1993, ONCOGENE, V8, P3323; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Rovida E, 2000, BLOOD, V95, P3959; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	28	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3670	3676		10.1038/sj.onc.1205409	http://dx.doi.org/10.1038/sj.onc.1205409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032835				2022-12-25	WOS:000175676000002
J	Hansel, A; Kuschel, L; Hehl, S; Lemke, C; Agricola, HJ; Hoshi, T; Heinemann, SH				Hansel, A; Kuschel, L; Hehl, S; Lemke, C; Agricola, HJ; Hoshi, T; Heinemann, SH			Mitochondrial targeting of the human peptide methionine sulfoxide reductase (MSRA), an enzyme-involved in the repair of oxidized proteins	FASEB JOURNAL			English	Article						methionine oxidation; reactive oxygen species; mitochondria; signal sequence; confocal microscopy; electron microscopy	CATALYTIC MECHANISM; EXPRESSION; IDENTIFICATION; OXIDATION; RESIDUES; GENE; CLONING; IMPORT; CA2+; LOCALIZATION	Peptide methionine sulfoxide reductase (MSRA) catalyzes the reduction of methionine sulfoxide to methionine. This widely expressed enzyme constitutes an important repair mechanism for oxidatively damaged proteins, which accumulate during the manifestation of certain degenerative diseases and aging processes. In addition, it is discussed to be involved in regulatory processes. Here we address the question of how the enzyme's diverse functions are reflected in its subcellular localization. Using fusions of the human version of MSRA with the enhanced green fluorescence protein expressed in various mammalian cell lines, we show a distinct localization at mitochondria. The N-terminal 23 amino acid residues contain the signal for this mitochondrial targeting. Activity tests showed that they are not required for enzyme function. Mitochondrial localization of native MSRA in mouse and rat liver slices was verified with an MSRA-specific antibody by using immunohistochemical methods. The protein was located in the mitochondrial matrix, as demonstrated by using pre-embedding immunostaining and electron microscopy. Mitochondria are the major source of reactive oxygen species (ROS). Therefore, MSRA has to be considered an important means for the general reduction of ROS release from mitochondria.	Univ Jena, Fac Med, D-07747 Jena, Germany; Univ Jena, Inst Anat 1, D-07743 Jena, Germany; Univ Jena, Inst Gen Zool & Anim Physiol, D-07743 Jena, Germany; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Pennsylvania	Heinemann, SH (corresponding author), Univ Jena, Fac Med, Drackendorfer Str 1, D-07747 Jena, Germany.	stefan.h.heinemann@uni-jena.de		Heinemann, Stefan H./0000-0002-4144-0251				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; CALDWELL P, 1978, P NATL ACAD SCI USA, V75, P5349, DOI 10.1073/pnas.75.11.5349; Ciorba MA, 1997, P NATL ACAD SCI USA, V94, P9932, DOI 10.1073/pnas.94.18.9932; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Hammen PK, 1996, J BIOL CHEM, V271, P21041, DOI 10.1074/jbc.271.35.21041; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Huang WH, 1999, GENE, V233, P233, DOI 10.1016/S0378-1119(99)00131-6; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kuschel L, 1999, FEBS LETT, V456, P17, DOI 10.1016/S0014-5793(99)00917-5; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P2095, DOI 10.1073/pnas.93.5.2095; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Moskovitz J, 1996, P NATL ACAD SCI USA, V93, P3205, DOI 10.1073/pnas.93.8.3205; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Sadanandom A, 2000, PLANT PHYSIOL, V123, P255, DOI 10.1104/pp.123.1.255; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Simpson PB, 2000, J BIOENERG BIOMEMBR, V32, P5, DOI 10.1023/A:1005552126516; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Taggart C, 2000, J BIOL CHEM, V275, P27258; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yermolaieva O, 2000, P NATL ACAD SCI USA, V97, P448, DOI 10.1073/pnas.97.1.448	34	92	101	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2002	16	6					911	+		10.1096/fj.01-0737fje	http://dx.doi.org/10.1096/fj.01-0737fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	549CA	12039877				2022-12-25	WOS:000175425900030
